@prefix afr: <http://purl.allotrope.org/ontologies/result#> .
@prefix bao: <http://www.bioassayontology.org/bao#> .
@prefix dc: <http://purl.org/dc/elements/1.1/> .
@prefix dcterms: <http://purl.org/dc/terms/> .
@prefix enm: <http://purl.enanomapper.org/onto/> .
@prefix fix: <http://purl.org/obo/owl/FIX#> .
@prefix foaf: <http://xmlns.com/foaf/0.1/> .
@prefix kb: <https://h2020-sbd4nano.github.io/sbd-data-landscape/> .
@prefix mesh: <http://purl.bioontology.org/ontology/MESH/> .
@prefix nci: <http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#> .
@prefix npo: <http://purl.bioontology.org/ontology/npo#> .
@prefix obo: <http://purl.obolibrary.org/obo/> .
@prefix opb: <http://bhi.washington.edu/OPB#> .
@prefix pubchem: <https://pubchem.ncbi.nlm.nih.gov/compound/> .
@prefix rcd: <http://purl.bioontology.org/ontology/RCD/> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix sbd: <https://www.sbd4nano.eu/rdf/#> .
@prefix sio: <http://semanticscience.org/resource/> .
@prefix skos: <http://www.w3.org/2004/02/skos/core#> .
@prefix sty: <http://purl.bioontology.org/ontology/STY/> .
@prefix void: <http://rdfs.org/ns/void#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://h2020-sbd4nano.github.io/sbd-data-landscape> a void:DatasetDescription ;
    dc:source <https://doi.org/10.1016/j.comtox.2018.12.002> ;
    dc:title "Computational models for the assessment of manufactured nanomaterials"@en ;
    foaf:page <https://www.sbd4nano.eu/> .

kb:Model_10 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "CORAL software"@en ;
            skos:narrower "Linear regression model"@en ] ;
    dcterms:source <http://doi.org/10.1016/j.chemosphere.2012.05.077> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_10/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_10/Endpoint> ;
    rdfs:comment "The aim of the present study is evaluation of the CORAL as a tool for the QSAR analysis of the toxicity of metal oxide nanoparticles. The obtained model is a linear regression, the interesting fact is how are selected and managed the descriptors to generate one variable form them for the linear regression. Developing different models with a different splitting of data into training and validation tests can be considered as a robustness evaluation methodology."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_11 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Multiple Linear Regression"@en,
                "Naive Bayes"@en,
                "Support vector machine classification"@en ] ;
    dcterms:source <http://doi.org/10.1039/c2ra21489j> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_11/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_11/Endpoint> ;
    rdfs:comment "The dataset from Weissleder et al., 2005, was checked and also compared with the data from Fourches, D. et al., 2010, converting the SMILES strings of the compounds into 3D structures with The Logistic regression was also included in the possible models, but it was not any of them selected for the final consensus model. The final consensus model also performed well in predicting the properties of the 14 nanoparticles which have significant cellular uptake (as defined by Weissleder et al.19) Briefly mention of the Mechanistic Interpretation of the results."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_12 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Decision Tree"@en ] ;
    dcterms:source <http://doi.org/10.1021/nn3010087> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_12/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_12/Endpoint> ;
    rdfs:comment "The main goal of the work was to demonstrate the theoretical approach about the toxicity of metal oxide nanoparticles through their bands position, hence their availability of reduction/oxidation reaction on cells, by experimental results (which was reasoned in extense way). At the end they also applied their data to generate a model, ( which display the toxicological impact of the descriptors), but it lets the model be in a second plane with not a deeply performance work neither checking about the reliability. It was used principal components analysis (PCA) to facilitate the interpretation of how individual assays contribute to the definition of the total toxicity profile and to understand how individual assays are related to each other."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_13 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Multiple Linear Regression"@en ] ;
    dcterms:source <http://doi.org/10.1021/ci3005308> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_13/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_13/Endpoint> ;
    rdfs:comment "The main objective of this paper was to explore the form, quality, and â€œcomplementarityâ€ of QSAR models developed using a variety of trial descriptor sets applied to different endpoints, rather than present a new model. However, with their study they generated a great quantity of models, and we chose one of them to classify it, since all of them were developed under the same methodology. From 80 decorator-nanotubes complexes (DNC), the 29 most toxic were selected based on cumulative index over all six endpoints measures in Zhou et al., 2008 Without an External validation, we cannot say if we are save of an overfitting case. Future mechanistic interpretation of the descriptors is suggested by the authors, because , as they admit, the topic was briefly discussed."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_14 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Support Vector Machine"@en ] ;
    dcterms:source <http://doi.org/10.1039/c3nr01533e> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_14/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_14/Endpoint> ;
    rdfs:comment "Data was normalized depending on source of data (i.e for HTS data was applied SSMD, standard mean difference). In order to arrive at a statistically reliable NP toxicity class definition, the normalized data were first analyzed via SOM based consensus clustering and by log-logistic doseâ€“response curve. SVM was selected after be compared with 5 models: NBC, LIR, LDA, LGR and qLGR Decision boundaries for the developed nano-SAR, at different acceptance levels of false negatives (FN, misclassification of a toxic NP as non-toxic) and false positives (FP, incorrect prediction of a non-toxic NP as toxic), were constructed using class probabilities. See section 4.6 Nano-SAR decision boundary. 0.632 estimator is a weighted average of re-substitution classification accuracy (Acc_resub) and bootstrapping classification accuracy (Acc_boot): Acc_0.632= 0.632*Acc_boot+0.368*Acc_resub There is a Mechanistic Interpretation based on external previous studies."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_15 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "NaÃ¯ve Bayesian Classifier"@en ] ;
    dcterms:source <http://doi.org/10.1002/smll.201201903> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_15/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_15/Endpoint> ;
    rdfs:comment "Consensus clustering by self-organizing maps (SOM) was also applied to obtain the previous classification of the data in order to define the end point. The accuracy result obtained by NBC (81.6%) was better than the obtained by H4 classification (78.1%). But, the acceptability of a particular nano-SAR endpoint (i.e., class definition) should not be dictated solely based on nano-SAR accuracy but also determined on the intended nano-SAR use. The H4 class definition was deemed to be a reasonable endpoint choice for a nano-SAR that reduces the level of false negative labelling. NaÃ¯ve Bayesian classifier (NBC), logistic regression (LGR), linear discriminate analysis (LDA) and nearest Neighbours (NN) were applied and compared. Finally NBC was selected as the best suitable building model. Mechanistic Interpretation of the final descriptors is briefly explained and referenced to previous studies."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_16 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "CORAL software"@en ;
            skos:narrower "Linear regression model"@en ] ;
    dcterms:source <http://doi.org/10.1016/j.chemosphere.2013.09.089> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_16/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_16/Endpoint> ;
    rdfs:comment "The obtained model is a linear regression, the interesting fact is how are selected and managed the descriptors to generate one variable form them for the linear regression. In this paper, the group also calculate a group of statistics from \" Ojha, P.K., Mitra, I., Das, R.N., Roy, K., 2011. Further exploring rm2 metrics for validation of QSPR models. Chemom. Intell. Lab. Syst. 107, 194â€“205 \" Since those statistics can not be compared with the majority of the classified models, we have decided only to mention that it was applied. It will be interesting to be careful about if the use of this statistics increase in the future classified models Developing different models with a different splitting of data into training and validation tests can be considered as a robustness evaluation methodology. The same work with an extension of the data set was developed in a posterior work: Toropova, A. P., Toropov, A. A., Benfenati, E., Puzyn, T., Leszczynska, D., & Leszczynski, J. (2014). Optimal descriptor as a translator of eclectic information into the prediction of membrane damage: The case of a group of ZnO and TiO2 nanoparticles. Ecotoxicology and Environmental Safety, 108, 203â€“209. http://doi.org/10.1016/j.ecoenv.2014.07.005"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_17a a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Instance Based Learner"@en,
                "k-Nearest Neighbour"@en ] ;
    dcterms:source <http://doi.org/10.2147/IJN.S40742> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_17a/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_17a/Endpoint> ;
    rdfs:comment "ABMiner software applied to develop the models. Variety of models, for different endpoints were developed, but only displayed the best ones that were presented. They implement a model base with a model query interface where you can vary the input parameters in order to predict your results for unsynthesized nanomaterials at: http://neiminer.i-a-i.com/nei_models (denied access) There is a lack of validation information( also values) and data set information of employed nanomaterials."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_17b a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Instance Based Learner"@en,
                "k-Nearest Neighbour"@en ] ;
    dcterms:source <http://doi.org/10.2147/IJN.S40742> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_17b/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_17b/Endpoint> ;
    rdfs:comment "ABMiner software applied to develop the models. Variety of models, for different endpoints were developed, but only displayed the best ones that were presented. They implement a model base with a model query interface where you can vary the input parameters in order to predict your results for unsynthesized nanomaterials at: http://neiminer.i-a-i.com/nei_models There is a lack of validation information( also values) and data set information of employed nanomaterials."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_18 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "CORAL software"@en ;
            skos:narrower "Linear regression model"@en ] ;
    dcterms:source <http://doi.org/10.1016/j.chemosphere.2013.03.012> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_18/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_18/Endpoint> ;
    rdfs:comment "The obtained model is a linear regression, the interesting fact is how are selected and managed the descriptors to generate one variable form them for the linear regression. In this paper, the group also calculate a group of statistics from \" Ojha, P.K., Mitra, I., Das, R.N., Roy, K., 2011. Further exploring rm2 metrics for validation of QSPR models. Chemom. Intell. Lab. Syst. 107, 194â€“205 \" Since those statistics can not be compared with the majority of the classified models, we have decided only to mention that it was applied. It will be interesting to be careful about if the use of this statistics increase in the future classified models Developing different models with a different splitting of data into training and validation tests can be considered as a robustness evaluation methodology."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_19a a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Regression Trees"@en ] ;
    dcterms:source <http://doi.org/10.1111/risa.12109> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19a/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19a/Endpoint> ;
    rdfs:comment "Coefficients and model performance statistics for stepwise linear regression models were performded and can be revised in Table 1 of the publication's Supplementary Material. Those results provide another perspective on input variable importance, however the amount of data excluded from these models reduces the confidence as compared to the RT and RF models. Mechanistic Interpretation was widely explained. Lack of validation techniques which could give more reliability to the model"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_19b a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Random Forest"@en ] ;
    dcterms:source <http://doi.org/10.1111/risa.12109> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19b/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19b/Endpoint> ;
    rdfs:comment "Coefficients and model performance statistics for stepwise linear regression models were performded and can be revised in Table 1 of the publication's Supplementary Material. Those results provide another perspective on input variable importance, however the amount of data excluded from these models reduces the confidence as compared to the RT and RF models. Mechanistic Interpretation was widely explained. Lack of validation techniques which could give more reliability to the model"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_19c a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Regression Trees"@en ] ;
    dcterms:source <http://doi.org/10.1111/risa.12109> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19c/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19c/Endpoint> ;
    rdfs:comment "Coefficients and model performance statistics for stepwise linear regression models were performded and can be revised in Table 1 of the publication's Supplementary Material. Those results provide another perspective on input variable importance, however the amount of data excluded from these models reduces the confidence as compared to the RT and RF models. Mechanistic Interpretation was widely explained. Lack of validation techniques which could give more reliability to the model"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_19d a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Random Forest"@en ] ;
    dcterms:source <http://doi.org/10.1111/risa.12109> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19d/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19d/Endpoint> ;
    rdfs:comment "Coefficients and model performance statistics for stepwise linear regression models were performded and can be revised in Table 1 of the publication's Supplementary Material. Those results provide another perspective on input variable importance, however the amount of data excluded from these models reduces the confidence as compared to the RT and RF models. Mechanistic Interpretation was widely explained. Lack of validation techniques which could give more reliability to the model"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_19e a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Regression Trees"@en ] ;
    dcterms:source <http://doi.org/10.1111/risa.12109> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19e/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19e/Endpoint> ;
    rdfs:comment "Coefficients and model performance statistics for stepwise linear regression models were performded and can be revised in Table 1 of the publication's Supplementary Material. Those results provide another perspective on input variable importance, however the amount of data excluded from these models reduces the confidence as compared to the RT and RF models. Mechanistic Interpretation was widely explained. Lack of validation techniques which could give more reliability to the model"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_19f a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Random Forest"@en ] ;
    dcterms:source <http://doi.org/10.1111/risa.12109> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19f/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19f/Endpoint> ;
    rdfs:comment "Coefficients and model performance statistics for stepwise linear regression models were performded and can be revised in Table 1 of the publication's Supplementary Material. Those results provide another perspective on input variable importance, however the amount of data excluded from these models reduces the confidence as compared to the RT and RF models. Mechanistic Interpretation was widely explained. Lack of validation techniques which could give more reliability to the model"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_19g a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Regression Trees"@en ] ;
    dcterms:source <http://doi.org/10.1111/risa.12109> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19g/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19g/Endpoint> ;
    rdfs:comment "Coefficients and model performance statistics for stepwise linear regression models were performded and can be revised in Table 1 of the publication's Supplementary Material. Those results provide another perspective on input variable importance, however the amount of data excluded from these models reduces the confidence as compared to the RT and RF models. Mechanistic Interpretation was widely explained. Lack of validation techniques which could give more reliability to the model"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_19h a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Random Forest"@en ] ;
    dcterms:source <http://doi.org/10.1111/risa.12109> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19h/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19h/Endpoint> ;
    rdfs:comment "Coefficients and model performance statistics for stepwise linear regression models were performded and can be revised in Table 1 of the publication's Supplementary Material. Those results provide another perspective on input variable importance, however the amount of data excluded from these models reduces the confidence as compared to the RT and RF models. Mechanistic Interpretation was widely explained. Lack of validation techniques which could give more reliability to the model"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_1a a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Multiple Linear Regression"@en ] ;
    dcterms:source <http://doi.org/10.1021/ie3006947> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_1a/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_1a/Endpoint> ;
    rdfs:comment "Proposed ANN vs the MLR. Lack in rigurosity of the external validation methodology, predictive power of the model and the treatment of the statistical obtained data."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_1b a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Multiplelayered Perceptron Neural Network"@en ] ;
    dcterms:source <http://doi.org/10.1021/ie3006947> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_1b/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_1b/Endpoint> ;
    rdfs:comment "Proposed ANN vs the MLR. Lack in rigurosity of the external validation methodology, predictive power of the model and the treatment of the statistical obtained data."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_20 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Latent Dirichlet Allocation"@en ] ;
    dcterms:source <http://doi.org/10.1016/j.envint.2014.08.009> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_20/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_20/Endpoint> ;
    rdfs:comment "New kind of model was presented, that differs from the normal QSARs since they take into account the experimental results that could affect on the physical measured properties for the model. One should notice here that they are focusing their study on uncoated nanoparticles, because it is important to evaluate and predict first the real ecotoxic effects of nanoparticles in their bare forms (uncoated) to gather a baseline reference. Then, future studies can be devoted to the influence of other factors such as the presence of coating agents, and light irradiation. Huge external data was expected to check the reliability of the model. Mechanistic Interpretation briefly explained. The same methodology and procedure with different set of NPs was applied by the same group in a posterior work: Horev-Azaria, L., Baldi, G., Beno, D., Bonacchi, D., Golla-Schindler, U., Kirkpatrick, J. C., â€¦ Korenstein, R. (2013). Predictive Toxicology of cobalt ferrite nanoparticles: Comparative in-vitro study of different cellular models using methods of knowledge discovery from data. Particle and Fibre Toxicology, 10(1). http://doi.org/10.1186/1743-8977-10-32"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_21 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Latent Dirichlet Allocation"@en ] ;
    dcterms:source <http://doi.org/10.1021/es503861x> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_21/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_21/Endpoint> ;
    rdfs:comment "An extension methodology form the previous reported paper in the table (Kleandrova, V. V, Luan, F., GonzÃ¡lez-DÃ­az, H., Ruso, J. M., Melo, A., Speck-Planche, A., & Cordeiro, M. N. D. S. (2014). Computational ecotoxicology: Simultaneous prediction of ecotoxic effects of nanoparticles under different experimental conditions. Environment International, 73, 288â€“294. ) Here, they increase the number of data, including several number of new NPs, some of them with coatings, also there are an increase of organisms. The most interesting difference is the new descriptor related with the coatings and the increase in the amount of input data and the external used data. Mechanistic Interpretation briefly explained."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_22 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "KNMINE software"@en ;
            skos:narrower "k-Nearest Neighbour"@en ] ;
    dcterms:source <http://doi.org/10.1039/c4ra07756c> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_22/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_22/Endpoint> ;
    rdfs:comment "It is very crucial that the developed model does not remain within the developers' group but is widely disseminated to the community so that it could immediately serve as an important source of information as it was initially designed to be. The proposed model was made publicly available online through Enalos InSilicoNano platform. Enalos InSilicoNano platform is a webservice that can host several validated and predictive models that can be utilized in the NPs design process"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_23a a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Random Forest"@en ] ;
    dcterms:source <http://doi.org/10.1039/c4nr03487b> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_23a/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_23a/Endpoint> ;
    rdfs:comment "The developed nano-QSAR models reveal the differences in the mechanisms of toxicity of metal oxide nanoparticles to bacteria and a human keratinocyte cell line, which belong to prokaryotic and eukaryotic systems, respectively. There is not a test for robustness, but, a cleaning process of the high correlated descriptors were developed before the model was built. Mechanistic interpretation of the different descriptors was explained and a comparison between both cases was presented."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_23b a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Random Forest"@en ] ;
    dcterms:source <http://doi.org/10.1039/c4nr03487b> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_23b/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_23b/Endpoint> ;
    rdfs:comment "The developed nano-QSAR models reveal the differences in the mechanisms of toxicity of metal oxide nanoparticles to bacteria and a human keratinocyte cell line, which belong to prokaryotic and eukaryotic systems, respectively. There is not a test for robustness, but, a cleaning process of the high correlated descriptors were developed before the model was built. Mechanistic interpretation of the different descriptors was explained and a comparison between both cases was presented."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_24a a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Multiple Linear Regression with Expectation Maximization"@en ] ;
    dcterms:source <http://doi.org/10.1021/nl303144k> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_24a/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_24a/Endpoint> ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_24b a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Bayesian Regularization Artificial Neural Network"@en ] ;
    dcterms:source <http://doi.org/10.1021/nl303144k> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_24b/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_24b/Endpoint> ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_24c a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Bayesian Regularization Artificial Neural Network"@en ] ;
    dcterms:source <http://doi.org/10.1021/nl303144k> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_24c/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_24c/Endpoint> ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_24d a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Multiple Linear Regression with Expectation Maximization"@en ] ;
    dcterms:source <http://doi.org/10.1021/nl303144k> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_24d/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_24d/Endpoint> ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_25a a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Decision Tree Boost"@en,
                "Decision Tree Forest"@en,
                "Ensable learning"@en ] ;
    dcterms:source <http://doi.org/10.1039/c4ra01274g> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_25a/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_25a/Endpoint> ;
    rdfs:comment "The statistical parameters given might bring confusion, since for example Q_F1^2 should be equal to R^2 if we look at the equation. Then, those values were not used in the discussion, and also the values to be compared with the previous studies were those which come from whole complete data"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_25b a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Decision Tree Boost"@en,
                "Decision Tree Forest"@en,
                "Ensable learning"@en ] ;
    dcterms:source <http://doi.org/10.1039/c4ra01274g> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_25b/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_25b/Endpoint> ;
    rdfs:comment "The statistical parameters given might bring confusion, since for example Q_F1^2 should be equal to R^2 if we look at the equation. Then, those values were not used in the discussion, and also the values to be compared with the previous studies were those which come from whole complete data"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_25c a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Decision Tree Boost"@en,
                "Decision Tree Forest"@en,
                "Ensable learning"@en ] ;
    dcterms:source <http://doi.org/10.1039/c4ra01274g> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_25c/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_25c/Endpoint> ;
    rdfs:comment "The statistical parameters given might bring confusion, since for example Q_F1^2 should be equal to R^2 if we look at the equation. Then, those values were not used in the discussion, and also the values to be compared with the previous studies were those which come from whole complete data"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_25d a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Decision Tree Boost"@en,
                "Decision Tree Forest"@en,
                "Ensable learning"@en ] ;
    dcterms:source <http://doi.org/10.1039/c4ra01274g> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_25d/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_25d/Endpoint> ;
    rdfs:comment "The statistical parameters given might bring confusion, since for example Q_F1^2 should be equal to R^2 if we look at the equation. Then, those values were not used in the discussion, and also the values to be compared with the previous studies were those which come from whole complete data"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_25e a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Decision Tree Boost"@en,
                "Decision Tree Forest"@en,
                "Ensable learning"@en ] ;
    dcterms:source <http://doi.org/10.1039/c4ra01274g> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_25e/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_25e/Endpoint> ;
    rdfs:comment "The statistical parameters given might bring confusion, since for example Q_F1^2 should be equal to R^2 if we look at the equation. Then, those values were not used in the discussion, and also the values to be compared with the previous studies were those which come from whole complete data"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_25f a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Decision Tree Boost"@en,
                "Decision Tree Forest"@en,
                "Ensable learning"@en ] ;
    dcterms:source <http://doi.org/10.1039/c4ra01274g> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_25f/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_25f/Endpoint> ;
    rdfs:comment "The statistical parameters given might bring confusion, since for example Q_F1^2 should be equal to R^2 if we look at the equation. Then, those values were not used in the discussion, and also the values to be compared with the previous studies were those which come from whole complete data"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_26 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Partial Least Squares"@en,
                "Stepwise Multiple Linear Regression"@en ] ;
    dcterms:source <http://doi.org/10.1016/j.tiv.2013.12.018> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_26/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_26/Endpoint> ;
    rdfs:comment "In this paper, the group also calculate a group of statistics from \" Ojha, P.K., Mitra, I., Das, R.N., Roy, K., 2011. Further exploring rm2 metrics for validation of QSPR models. Chemom. Intell. Lab. Syst. 107, 194â€“205 \" Since those statistics can not be compared with the majority of the classified models, we have decided only to mention that it was applied. It will be interesting to be careful about if the use of this statistics increase in the future classified models. Is in consonance with the guidelines of OECD WSAR model Development. There is a Mechanistic Interpretation"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_27 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Linear regression model"@en ] ;
    dcterms:source <http://doi.org/10.1016/j.chemosphere.2013.10.079> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_27/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_27/Endpoint> ;
    rdfs:comment "There are not structural or molecular descriptors, thus could be not considered as QSAR model. In this paper, the group also calculate a group of statistics from \" Ojha, P.K., Mitra, I., Das, R.N., Roy, K., 2011. Further exploring rm2 metrics for validation of QSPR models. Chemom. Intell. Lab. Syst. 107, 194â€“205 \" Since those statistics can not be compared with the majority of the classified models, we have decided only to mention that it was applied. It will be interesting to be careful about if the use of this statistics increase in the future classified models. It could be noticed that they also applied the same method to E. coli strain WP2 uvrA/pKM101 in a posterior paper: Toropova, A. P., Toropov, A. A., VeselinoviÄ‡, A. M., VeselinoviÄ‡, J. B., Benfenati, E., Leszczynska, D., & Leszczynski, J. (2016). Nano-QSAR: Model of mutagenecity of fullerene as a mathematical function of different conditions. Ecotoxicology and Environmental Safety, 124, 32â€“36. 10.1016/j.ecoenv.2015.09.038"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_28a a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "General Linear Model"@en ] ;
    dcterms:source <http://doi.org/10.1016/j.scitotenv.2013.09.006> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_28a/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_28a/Endpoint> ;
    rdfs:comment "It doesn't have a good statistical reliability: It is not clear if it used only 3 data points for building the model, which will be a poor set of data; there are not validation techniques, only the regression for the training data, which could be strong influenced by an overfitting. Comparison of the means for E. coli EC50 and D. magna LC50 among different treatments was performed using the one-way ANOVA followed by Dunnett t test (2-tailed posthoc) for multiple comparisons. The toxicity evaluation due free Ag ions was also included, which was greater the three NPs on E.Coli case. There is a Mechanistic Interpretation"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_28b a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "General Linear Model"@en ] ;
    dcterms:source <http://doi.org/10.1016/j.scitotenv.2013.09.006> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_28b/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_28b/Endpoint> ;
    rdfs:comment "It doesn't have a good statistical reliability: It is not clear if it used only 3 data points for building the model, which will be a poor set of data; there are not validation techniques, only the regression for the training data, which could be strong influenced by an overfitting. Comparison of the means for E. coli EC50 and D. magna LC50 among different treatments was performed using the one-way ANOVA followed by Dunnett t test (2-tailed posthoc) for multiple comparisons. The toxicity evaluation due free Ag ions was also included, which was greater the three NPs on E.Coli case. There is a Mechanistic Interpretation"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_29a a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Stepwise-MLR (Multiple Linear Regression)"@en ] ;
    dcterms:source <http://doi.org/10.1016/j.ecoenv.2014.05.026> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_29a/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_29a/Endpoint> ;
    rdfs:comment "In this paper, the group also calculate a group of statistics from \" Ojha, P.K., Mitra, I., Das, R.N., Roy, K., 2011. Further exploring rm2 metrics for validation of QSPR models. Chemom. Intell. Lab. Syst. 107, 194â€“205 \" Since those statistics can not be compared with the majority of the classified models, we have decided only to mention that it was applied. It will be interesting to be careful about if the use of this statistics increase in the future classified models. Statistical filled data was used to compare the performance and predictivity of the models against previous studies. Other statistic can be checked in the publication's Table 2 (for PLS) and the publication's Table S2 from Supplementary material (for stepwise-MLR). The Eq2 and Eq3 in the paper are models which include all the NPs in the training set (without external validation), which means that those one don't have as much reliability as the 10 randomized and splitted data of the other presented models. There is a Mechanistic Interpretation"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_29b a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Partial Least Squares"@en ] ;
    dcterms:source <http://doi.org/10.1016/j.ecoenv.2014.05.026> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_29b/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_29b/Endpoint> ;
    rdfs:comment "In this paper, the group also calculate a group of statistics from \" Ojha, P.K., Mitra, I., Das, R.N., Roy, K., 2011. Further exploring rm2 metrics for validation of QSPR models. Chemom. Intell. Lab. Syst. 107, 194â€“205 \" Since those statistics can not be compared with the majority of the classified models, we have decided only to mention that it was applied. It will be interesting to be careful about if the use of this statistics increase in the future classified models. Statistical filled data was used to compare the performance and predictivity of the models against previous studies. Other statistic can be checked in the publication's Table 2 (for PLS) and the publication's Table S2 from Supplementary material (for stepwise-MLR). The Eq2 and Eq3 in the paper are models which include all the NPs in the training set (without external validation), which means that those one don't have as much reliability as the 10 randomized and splitted data of the other presented models. There is a Mechanistic Interpretation"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_2a a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Linear Discrimination Analysis"@en,
                "Multiple Linear Regression"@en ] ;
    dcterms:source <http://doi.org/10.1111/j.1539-6924.2010.01438.x> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_2a/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_2a/Endpoint> ;
    rdfs:comment "This publication is focused in the methodology, more than in the final results, with huge future work specified in the text. Mechanistic Interpretation The presence or absence of Zeta potential as descriptor in both sets is argued."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_2b a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Linear Discrimination Analysis"@en,
                "Multiple Linear Regression"@en ] ;
    dcterms:source <http://doi.org/10.1111/j.1539-6924.2010.01438.x> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_2b/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_2b/Endpoint> ;
    rdfs:comment "This publication is focused in the methodology, more than in the final results, with huge future work specified in the text. Mechanistic Interpretation The presence or absence of Zeta potential as descriptor in both sets is argued."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_30 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "CORAL software"@en ;
            skos:narrower "Linear regression model"@en ] ;
    dcterms:source <http://doi.org/10.1007/s11051-014-2282-9> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_30/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_30/Endpoint> ;
    rdfs:comment "Really small data set, lack in reliability of the model. Developing different models with a different splitting of data into training and validation tests can be considered as a robustness evaluation methodology."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_31a a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Multiple Linear Regression"@en ] ;
    dcterms:source <http://doi.org/10.1016/j.jphotobiol.2013.11.023> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_31a/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_31a/Endpoint> ;
    rdfs:comment "Although the prediction set was used to compare the experimental and the calculated values of -logLC50, no statistical value was computed. The percentage of average error in the prediction set, was computed to include in this table."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_31b a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Multiple Linear Regression"@en ] ;
    dcterms:source <http://doi.org/10.1016/j.jphotobiol.2013.11.023> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_31b/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_31b/Endpoint> ;
    rdfs:comment "Although the prediction set was used to compare the experimental and the calculated values of -logLC50, no statistical value was computed. The percentage of average error in the prediction set, was computed to include in this table."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_32a a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "CORAL software"@en ;
            skos:narrower "Linear regression model"@en ] ;
    dcterms:source <http://doi.org/10.1080/1062936X.2014.984327> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_32a/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_32a/Endpoint> ;
    rdfs:comment "This is the case study 1 of the paper. As they explain in the introduction, could be not classified as QSPR/QSAR, due to the descriptors that they choose, which are not structural or physicochemical properties. In that particular case, it will be considered as QSPR. In this paper, the group also calculate a group of statistics from \" Ojha, P.K., Mitra, I., Das, R.N., Roy, K., 2011. Further exploring rm2 metrics for validation of QSPR models. Chemom. Intell. Lab. Syst. 107, 194â€“205 \" Since those statistics can not be compared with the majority of the classified models, we have decided only to mention that it was applied. It will be interesting to be careful about if the use of this statistics increase in the future classified models. Developing different models with a different splitting of data into training and validation tests can be considered as a robustness evaluation methodology."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_32b a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "CORAL software"@en ;
            skos:narrower "Linear regression model"@en ] ;
    dcterms:source <http://doi.org/10.1080/1062936X.2014.984327> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_32b/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_32b/Endpoint> ;
    rdfs:comment "This is the case study 2 of the paper. As they explain in the introduction, could be not classified as QSPR/QSAR, due to the descriptors that they choose, which are not structural or physicochemical properties. In this paper, the group also calculate a group of statistics from \" Ojha, P.K., Mitra, I., Das, R.N., Roy, K., 2011. Further exploring rm2 metrics for validation of QSPR models. Chemom. Intell. Lab. Syst. 107, 194â€“205 \" Since those statistics can not be compared with the majority of the classified models, we have decided only to mention that it was applied. It will be interesting to be careful about if the use of this statistics increase in the future classified models. Developing different models with a different splitting of data into training and validation tests can be considered as a robustness evaluation methodology. The same model was developed in posterior publication, with a different source of data, and AD was computed: Manganelli, S., Leone, C., Toropov, A. A., Toropova, A. P., & Benfenati, E. (2016). QSAR model for predicting Cellular viability of human embryonic kidney cells exposed to SiO2 nanoparticles. Chemosphere, 144, 995â€“1001. 10.1016/j.chemosphere.2015.09.086"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_33a a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Partial Least Squares"@en ] ;
    dcterms:source <http://doi.org/10.1016/j.biomaterials.2015.03.042> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_33a/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_33a/Endpoint> ;
    rdfs:comment "No external validation is provided, it is commented as future work, with more data. We should take into account the possible overfitting. ANOVA test was performed to confirm the statistically significance with p<0.05 . There is a Mechanistic Interpretation They are not nanomaterials according to EU definition"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_33b a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Partial Least Squares"@en ] ;
    dcterms:source <http://doi.org/10.1016/j.biomaterials.2015.03.042> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_33b/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_33b/Endpoint> ;
    rdfs:comment "No external validation is provided, it is commented as future work, with more data. We should take into account the possible overfitting. ANOVA test was performed to confirm the statistically significance with p<0.05 . There is a Mechanistic Interpretation They are not nanomaterials according to EU definition"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_33c a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Partial Least Squares"@en ] ;
    dcterms:source <http://doi.org/10.1016/j.biomaterials.2015.03.042> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_33c/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_33c/Endpoint> ;
    rdfs:comment "No external validation is provided, it is commented as future work, with more data. We should take into account the possible overfitting. ANOVA test was performed to confirm the statistically significance with p<0.05 . There is a Mechanistic Interpretation They are not nanomaterials according to EU definition"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_33d a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Partial Least Squares"@en ] ;
    dcterms:source <http://doi.org/10.1016/j.biomaterials.2015.03.042> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_33d/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_33d/Endpoint> ;
    rdfs:comment "No external validation is provided, it is commented as future work, with more data. We should take into account the possible overfitting. ANOVA test was performed to confirm the statistically significance with p<0.05 . There is a Mechanistic Interpretation They are not nanomaterials according to EU definition"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_33e a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Partial Least Squares"@en ] ;
    dcterms:source <http://doi.org/10.1016/j.biomaterials.2015.03.042> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_33e/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_33e/Endpoint> ;
    rdfs:comment "No external validation is provided, it is commented as future work, with more data. We should take into account the possible overfitting. ANOVA test was performed to confirm the statistically significance with p<0.05 . There is a Mechanistic Interpretation They are not nanomaterials according to EU definition"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_34a a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Random Forest"@en ] ;
    dcterms:source <http://doi.org/10.1039/c5ra11399g> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_34a/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_34a/Endpoint> ;
    rdfs:comment "They implement an additional criteria for quality evaluation and also a tool to elucidate underlying structure of nanotoxicity (Mechanistic Interpretation), which was the development of causal structures. For specific details see the publication's Figure 4. The conclusion was the following: In fact, there is no direct link between toxicity and any descriptor. It means there are only particular causal links and the developed models are the collection of the most important descriptors, which only represent the conditions for the emergence of particular cause of action. Correlation between target properties was evaluated via Ï•- coefficient. S_Ï• = 0.51which means that there is an average degree of association between two types of toxicity. There is a Mechanistic Interpretation"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_34b a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Random Forest"@en ] ;
    dcterms:source <http://doi.org/10.1039/c5ra11399g> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_34b/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_34b/Endpoint> ;
    rdfs:comment "They implement an additional criteria for quality evaluation and also a tool to elucidate underlying structure of nanotoxicity (Mechanistic Interpretation), which was the development of causal structures. For specific details see the publication's Figure 5. The conclusion was the following: In fact, there is no direct link between toxicity and any descriptor. It means there are only particular causal links and the developed models are the collection of the most important descriptors, which only represent the conditions for the emergence of particular cause of action. Correlation between target properties was evaluated via Ï•- coefficient. S_Ï• = 0.51which means that there is an average degree of association between two types of toxicity."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_35 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ] ;
    dcterms:source <http://doi.org/10.1007/s11051-015-3051-0> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_35/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_35/Endpoint> ;
    rdfs:comment "With whole data set: Spearman rank correlation by SigmaPlot v12.0 Hierarchical clustering algorithm with Euclidean distance measure and Wardlinkage rule by MATLAB Classification decision tree C4.5 with ten-fold cross-validation using WEKA software (v3.6.3) Decision tree (J48) (94% of accuracy) 68 different NPs were analyzed and studied, which can be seen at Online resource 1. The 4 types of Au NPs were selected after a clustering and classification analysis to be involved in the final model. Information about the classification decision tree was not clear (mistake at publication: the dendrogram was not published; and confusing cross-validation information), hence we decide to not classify it. There is not any robustness nor external validation. Then, an overfitting could be present, especially if we check the plot of the predicted vs. the measured EZ Metric (Online resource 3), we could see an agglomeration of data close to 0, which could be a noise data and give us a fake correlation idea."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_36 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Latent Dirichlet Allocation"@en ] ;
    dcterms:source <http://doi.org/10.2217/nnm.14.96> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_36/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_36/Endpoint> ;
    rdfs:comment "The methodology is related with the previous reported publication in the table (Kleandrova, V. V, Luan, F., GonzÃ¡lez-DÃ­az, H., Ruso, J. M., Melo, A., Speck-Planche, A., & Cordeiro, M. N. D. S. (2014). Computational ecotoxicology: Simultaneous prediction of ecotoxic effects of nanoparticles under different experimental conditions. Environment International, 73, 288â€“294. ) Physicochemical interpretations of the descriptors were provided"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_37 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Kriging estimation"@en ] ;
    dcterms:source <http://doi.org/10.3762/bjnano.6.160> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_37/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_37/Endpoint> ;
    rdfs:comment "External validation must be required to ensure the predictivity of the model. Neither there is any robustness evaluation technique. Even the lack in the reliability of the model, a new methodology is presented, which had not been applied in the previous classified papers. A brief mechanistic interpretation of the descriptors is presented."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_38a a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "QSARINS software"@en ;
            skos:narrower "Multiple Linear Regression"@en ] ;
    dcterms:source <http://doi.org/10.1080/1062936X.2015.1080186> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38a/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38a/Endpoint> ;
    rdfs:comment "Obtained data was analyzed and better results against the previous work were presented. Despite of the 11 split results give an idea of stability, and the increase of data increases the robustness of the model, the fact that \"the equation for the best model among the split models generated for each training set was newly calibrated on all of the available data for each dataset (full models).\" lets the final model without a proper external validation, which should be taken into account. Then, the \"external\" validation statistics were classified in the Robustness column."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_38b a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "QSARINS software"@en ;
            skos:narrower "Multiple Linear Regression"@en ] ;
    dcterms:source <http://doi.org/10.1080/1062936X.2015.1080186> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38b/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38b/Endpoint> ;
    rdfs:comment "Obtained data was analyzed and better results against the previous work were presented. Despite of the 11 split results give an idea of stability, and the increase of data increases the robustness of the model, the fact that \"the equation for the best model among the split models generated for each training set was newly calibrated on all of the available data for each dataset (full models).\" lets the final model without a proper external validation, which should be taken into account. Then, the \"external\" validation statistics were classified in the Robustness column."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_38c a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "QSARINS software"@en ;
            skos:narrower "Multiple Linear Regression"@en ] ;
    dcterms:source <http://doi.org/10.1080/1062936X.2015.1080186> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38c/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38c/Endpoint> ;
    rdfs:comment "Obtained data was analyzed and better results against the previous work were presented. Despite of the 11 split results give an idea of stability, and the increase of data increases the robustness of the model, the fact that \"the equation for the best model among the split models generated for each training set was newly calibrated on all of the available data for each dataset (full models).\" lets the final model without a proper external validation, which should be taken into account. Then, the \"external\" validation statistics were classified in the Robustness column."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_38d a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "Caret package of the Cran-R software"@en ;
            skos:narrower "Support Vector Machine linear"@en ] ;
    dcterms:source <http://doi.org/10.1080/1062936X.2015.1080186> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38d/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38d/Endpoint> ;
    rdfs:comment "Obtained data was analyzed and better results against the previous work were presented. Despite of the 11 split results give an idea of stability, and the increase of data increases the robustness of the model, the fact that all the data was used in the final model, hence letting the final model without an external validation, which should be taken into account."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_38e a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "Caret package of the Cran-R software"@en ;
            skos:narrower "Support Vector Machine linear"@en ] ;
    dcterms:source <http://doi.org/10.1080/1062936X.2015.1080186> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38e/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38e/Endpoint> ;
    rdfs:comment "Obtained data was analyzed and better results against the previous work were presented. Despite of the 11 split results give an idea of stability, and the increase of data increases the robustness of the model, the fact that all the data was used in the final model, hence letting the final model without an external validation, which should be taken into account."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_38f a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "Caret package of the Cran-R software"@en ;
            skos:narrower "Support Vector Machine linear"@en ] ;
    dcterms:source <http://doi.org/10.1080/1062936X.2015.1080186> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38f/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38f/Endpoint> ;
    rdfs:comment "Obtained data was analyzed and better results against the previous work were presented. Despite of the 11 split results give an idea of stability, and the increase of data increases the robustness of the model, the fact that all the data was used in the final model, hence letting the final model without an external validation, which should be taken into account."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_38g a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "Caret package of the Cran-R software"@en ;
            skos:narrower "Support Vector Machine radial"@en ] ;
    dcterms:source <http://doi.org/10.1080/1062936X.2015.1080186> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38g/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38g/Endpoint> ;
    rdfs:comment "Obtained data was analyzed and better results against the previous work were presented. Despite of the 11 split results give an idea of stability, and the increase of data increases the robustness of the model, the fact that all the data was used in the final model, hence letting the final model without an external validation, which should be taken into account."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_38h a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "Caret package of the Cran-R software"@en ;
            skos:narrower "Support Vector Machine radial"@en ] ;
    dcterms:source <http://doi.org/10.1080/1062936X.2015.1080186> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38h/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38h/Endpoint> ;
    rdfs:comment "Obtained data was analyzed and better results against the previous work were presented. Despite of the 11 split results give an idea of stability, and the increase of data increases the robustness of the model, the fact that all the data was used in the final model, hence letting the final model without an external validation, which should be taken into account."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_38i a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "Caret package of the Cran-R software"@en ;
            skos:narrower "Support Vector Machine radial"@en ] ;
    dcterms:source <http://doi.org/10.1080/1062936X.2015.1080186> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38i/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38i/Endpoint> ;
    rdfs:comment "Obtained data was analyzed and better results against the previous work were presented. Despite of the 11 split results give an idea of stability, and the increase of data increases the robustness of the model, the fact that all the data was used in the final model, hence letting the final model without an external validation, which should be taken into account."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_38j a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "MATLAB software"@en ;
            skos:narrower "Radial Basis Function Neural Networks"@en ] ;
    dcterms:source <http://doi.org/10.1080/1062936X.2015.1080186> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38j/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38j/Endpoint> ;
    rdfs:comment "Obtained data was analyzed and better results against the previous work were presented. Despite of the 11 split results give an idea of stability, and the increase of data increases the robustness of the model, the fact that all the data was used in the final model, hence letting the final model without an external validation, which should be taken into account."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_38k a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "MATLAB software"@en ;
            skos:narrower "Radial Basis Function Neural Networks"@en ] ;
    dcterms:source <http://doi.org/10.1080/1062936X.2015.1080186> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38k/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38k/Endpoint> ;
    rdfs:comment "Obtained data was analyzed and better results against the previous work were presented. Despite of the 11 split results give an idea of stability, and the increase of data increases the robustness of the model, the fact that all the data was used in the final model, hence letting the final model without an external validation, which should be taken into account."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_38l a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "MATLAB software"@en ;
            skos:narrower "Radial Basis Function Neural Networks"@en ] ;
    dcterms:source <http://doi.org/10.1080/1062936X.2015.1080186> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38l/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38l/Endpoint> ;
    rdfs:comment "Obtained data was analyzed and better results against the previous work were presented. Despite of the 11 split results give an idea of stability, and the increase of data increases the robustness of the model, the fact that all the data was used in the final model, hence letting the final model without an external validation, which should be taken into account."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_38m a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "MATLAB software"@en ;
            skos:narrower "General Regression Neural Networks"@en ] ;
    dcterms:source <http://doi.org/10.1080/1062936X.2015.1080186> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38m/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38m/Endpoint> ;
    rdfs:comment "Obtained data was analyzed and better results against the previous work were presented. Despite of the 11 split results give an idea of stability, and the increase of data increases the robustness of the model, the fact that all the data was used in the final model, hence letting the final model without an external validation, which should be taken into account."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_38n a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "MATLAB software"@en ;
            skos:narrower "General Regression Neural Networks"@en ] ;
    dcterms:source <http://doi.org/10.1080/1062936X.2015.1080186> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38n/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38n/Endpoint> ;
    rdfs:comment "Obtained data was analyzed and better results against the previous work were presented. Despite of the 11 split results give an idea of stability, and the increase of data increases the robustness of the model, the fact that all the data was used in the final model, hence letting the final model without an external validation, which should be taken into account."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_38o a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "MATLAB software"@en ;
            skos:narrower "General Regression Neural Networks"@en ] ;
    dcterms:source <http://doi.org/10.1080/1062936X.2015.1080186> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38o/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38o/Endpoint> ;
    rdfs:comment "Obtained data was analyzed and better results against the previous work were presented. Despite of the 11 split results give an idea of stability, and the increase of data increases the robustness of the model, the fact that all the data was used in the final model, hence letting the final model without an external validation, which should be taken into account."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_38p a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "WEKA software"@en ;
            skos:narrower "classification tree"@en ] ;
    dcterms:source <http://doi.org/10.1080/1062936X.2015.1080186> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38p/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38p/Endpoint> ;
    rdfs:comment "Obtained data was analyzed and better results against the previous work were presented."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_39 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Partial Least Squares"@en ] ;
    dcterms:source <http://doi.org/10.1016/j.proeng.2015.01.284> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_39/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_39/Endpoint> ;
    rdfs:comment "There is not an external validation procedure, and the data size is not enough to ensure the reliability of the model. Also the final regression function obtained from the PLS technique was not provided, which gives a confusing idea of the final used descriptors."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_3a a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "WinSVM (version 1.1.8) software"@en ;
            skos:narrower "Support vector machine classification"@en ] ;
    dcterms:source <http://doi.org/10.1021/nn1013484> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_3a/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_3a/Endpoint> ;
    rdfs:comment "Data was split into two classes: Z>=-0.40 and Z< -0.40 (Being Z the average activity). Clustering was performed. NPs with the same core were clustered together. They call external set the data which should be called test set, since when you use k-fold cross validation your tests set were be used as training set in other of the cycles, thus you have to consider it as an internal set. (additionally , for the training set an other 5-foldCV was applied, but only the better result was provided for the test set of such cycle of the \"external\" 5-fold-CV) The classification models were considered acceptable if: CCR_CV â‰¥ 0.6 and CCR_test â‰¥ 0.6 Where: CCR = 0.5*(Sensitivity+Specificity)"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_3b a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "k-Nearest Neighbour"@en ] ;
    dcterms:source <http://doi.org/10.1021/nn1013484> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_3b/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_3b/Endpoint> ;
    rdfs:comment "To enable model interpretation, they identified descriptors that occurred most frequently in kNN models with the highest prediction accuracy. The top-10 most frequently selected descriptors in each individual fold and the averaged frequency across five folds are listed in Supplementary Materials (SM_Tables S3 and S4). They call external set the data which should be called test set, since when you use k-fold cross validation your tests set were be used as training set in other of the cycles, thus you have to consider it as an internal set."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_40a a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "two dimensional hierarchical cluster analysis"@en ] ;
    dcterms:source <http://doi.org/10.1088/0957-4484/26/1/015701> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_40a/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_40a/Endpoint> ;
    rdfs:comment "Actually it could be interpreted as a filling gap of data procedure, but at a time is applying t-HCA it became a classification model. The obtained results were compared with a previous nano-QSAR model (source data) and also to the experimental results."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_40b a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "two dimensional hierarchical cluster analysis"@en ] ;
    dcterms:source <http://doi.org/10.1088/0957-4484/26/1/015701> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_40b/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_40b/Endpoint> ;
    rdfs:comment "Actually it could be interpreted as a filling gap of data procedure, but at a time is applying t-HCA it became a classification model. The obtained results were compared with a previous nano-QSAR model (source data) and also to the experimental results."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_41 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "CORAL software"@en ;
            skos:narrower "Linear regression model"@en ] ;
    dcterms:source <http://doi.org/10.1016/j.ecoenv.2014.10.003> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_41/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_41/Endpoint> ;
    rdfs:comment "Developing different models with a different splitting of data into training and validation tests can be considered as a robustness evaluation methodology."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_42 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "CORAL software"@en ;
            skos:narrower "Linear regression model"@en ] ;
    dcterms:source <http://doi.org/10.1007/s11356-014-3566-4> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_42/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_42/Endpoint> ;
    rdfs:comment "Developing different models with a different splitting of data into training and validation tests can be considered as a robustness evaluation methodology. The average of internal validation 0.5 (r^2) gives a moderate idea of an statistical significance, also the cross-validation correlation coefficient are not greater than 0.5 in average. It is important to notice that there is not a huge variability in the response data, which gives us a not good applicability of the model. If we check the source publication of the obtained data, we can observe that 7 over 24 NPs of the data set present a variability in the response versus the dose and the exposure time. Close to 1/3 of the data which presents variability could be hidden by the non variability response of the rest of the data."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_43 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "SPSS software"@en ;
            skos:narrower "Multiple Linear Regression"@en ] ;
    dcterms:source <https://www.researchgate.net/publication/282743802_Prediction_for_cellular_uptake_of_manufactured_nanoparticles_to_pancreatic_cancer_cells> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_43/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_43/Endpoint> ;
    rdfs:comment "There is a Mechanistic Interpretation. Good agreement with the OECD framework."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_44a a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Support Vector Regression"@en ] ;
    dcterms:source <http://doi.org/10.1039/c5nr01537e> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_44a/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_44a/Endpoint> ;
    rdfs:comment "The relative abundance of different protein corona were used as descriptors. Although they are not physicochemical descriptors it was concluded that protein corona encodes relevant biological information regarding cell association to the target NP. Not external validation test was applied, hence we cannot say that the obtained results will be totally reliable."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_44b a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Multiple Linear Regression"@en ] ;
    dcterms:source <http://doi.org/10.1039/c5nr01537e> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_44b/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_44b/Endpoint> ;
    rdfs:comment "The relative abundance of different protein corona were used as descriptors. Although they are not physicochemical descriptors it was concluded that protein corona encodes relevant biological information regarding cell association to the target NP. Not external validation test was applied, hence we cannot say that the obtained results will be totally reliable."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_45 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Linear regression model"@en ] ;
    dcterms:source <http://doi.org/10.1016/j.chemosphere.2014.10.067> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_45/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_45/Endpoint> ;
    rdfs:comment "There are not structural or molecular descriptors, thus could be not considered as QSAR model. In this paper, the group also calculate a group of statistics from \" Ojha, P.K., Mitra, I., Das, R.N., Roy, K., 2011. Further exploring rm2 metrics for validation of QSPR models. Chemom. Intell. Lab. Syst. 107, 194â€“205 \" Since those statistics can not be compared with the majority of the classified models, we have decided only to mention that it was applied. It will be interesting to be careful about if the use of this statistics increase in the future classified models. Developing different models with a different splitting of data into training and validation tests can be considered as a robustness evaluation methodology. The same work, with an other source of data, and almost the same descriptors with worst results were done in a posterior work of the same authors: Toropova, A. P., Toropov, A. A., Rallo, R., Leszczynska, D., & Leszczynski, J. (2016). Nano-QSAR: Genotoxicity of multi-walled carbon nanotubes. International Journal of Environmental Research, 10(1), 59â€“64."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_46 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "CORAL software"@en ;
            skos:narrower "Linear regression model"@en ] ;
    dcterms:source <http://doi.org/10.1016/j.chemosphere.2015.05.042> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_46/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_46/Endpoint> ;
    rdfs:comment "The presented model is a combination of two previous models which are already reported in the table ( Toropov, A. A., & Toropova, A. P. (2015). Quasi-QSAR for mutagenic potential of multi-walled carbon-nanotubes. Chemosphere, 124(1), 40â€“46. and Toropov, A. A., & Toropova, A. P. (2014). Optimal descriptor as a translator of eclectic data into endpoint prediction: Mutagenicity of fullerene as a mathematical function of conditions. Chemosphere, 104, 262â€“264. ) Developing different models with a different splitting of data into training and validation tests can be considered as a robustness evaluation methodology. The"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_47 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Multiple Linear Regression"@en ] ;
    dcterms:source <http://doi.org/10.3109/17435390.2014.930195> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_47/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_47/Endpoint> ;
    rdfs:comment "Good agreement with the OECD framework of QSAR model development. Not clearly described the obtained results from the Y-scrambling. If the correlation values don't decrease enough with the scrambling of the response variable, a chance correlation can no be discarded. It was discussed through the RMSE, but if a considerable correlation is on it, it could be blamed to a low variability in some of the descriptors and/or endpoint data. Good and extend Mechanistic interpretation."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_48 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "PLS Toolbox v5.8 software"@en ;
            skos:narrower "Partial Least Square Regression"@en ] ;
    dcterms:source <http://doi.org/10.1039/c5ra06198a> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_48/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_48/Endpoint> ;
    rdfs:comment "There is not an external validation procedure, and the data size is not enough to ensure the reliability of the model. Also the final regression function obtained from the PLS technique was not provided, which gives a confusing idea of the final used descriptors."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_49a a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Genetic Program-based decision Tree construction tool"@en ] ;
    dcterms:source <http://doi.org/10.3109/17435390.2016.1161857> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_49a/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_49a/Endpoint> ;
    rdfs:comment "The Model interpretation section ensures that the results are consistent with previous studies source publication and Liu and Rallo et al. 2013"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_49b a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Genetic Program-based decision Tree construction tool"@en ] ;
    dcterms:source <http://doi.org/10.3109/17435390.2016.1161857> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_49b/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_49b/Endpoint> ;
    rdfs:comment "The Model interpretation section ensures that the results are consistent with previous studies Fourches et al. 2010 (already reported in this table)"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_49c a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Genetic Program-based decision Tree construction tool"@en ] ;
    dcterms:source <http://doi.org/10.3109/17435390.2016.1161857> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_49c/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_49c/Endpoint> ;
    rdfs:comment "The Model interpretation section ensures that the results are consistent with previous studies Epa et al. 2012 (already reported in this table)"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_49d a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Genetic Program-based decision Tree construction tool"@en ] ;
    dcterms:source <http://doi.org/10.3109/17435390.2016.1161857> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_49d/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_49d/Endpoint> ;
    rdfs:comment "The Model interpretation section ensures that the results are consistent with previous studies source publication"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_49e a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Genetic Program-based decision Tree construction tool"@en ] ;
    dcterms:source <http://doi.org/10.3109/17435390.2016.1161861> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_49e/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_49e/Endpoint> ;
    rdfs:comment "The Model interpretation section ensures that the results are consistent with previous studies Bigdeli et al. 2015 and N. Oh and J. H. Park, 2014."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_4a a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Multiple Linear Regression"@en ] ;
    dcterms:source <http://doi.org/10.1016/j.jhazmat.2010.04.016> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_4a/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_4a/Endpoint> ;
    rdfs:comment "In this paper a linear regression model for few experimental results were developed, and a \"Quadratic model\" was also applied. The last one was not clearly explained, and an overfitting could be present. Due the some empty classification fields and the fact that the descriptors are not physicochemical or structural properties of the NP, it could be not considered as QSAR after all."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_4b a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Multiple Linear Regression"@en ] ;
    dcterms:source <http://doi.org/10.1016/j.jhazmat.2010.04.016> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_4b/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_4b/Endpoint> ;
    rdfs:comment "In this paper a linear regression model for few experimental results were developed, and a \"Quadratic model\" was also applied. The last one was not clearly explained, and an overfitting could be present. Due the some empty classification fields and the fact that the descriptors are not physicochemical or structural properties of the NP, it could be not considered as QSAR after all."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_5 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ] ;
    dcterms:source <http://doi.org/10.3109/17435390.2010.502980> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_5/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_5/Endpoint> ;
    rdfs:comment "This is more a theoretical model based on chemical theory rather than a QSAR that is based on observed data The model is built on data for 6 NPs and extrapolation is done for 64 NPs"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_50a a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Multiple Linear Regression with Expectation Maximization"@en ] ;
    dcterms:source <http://doi.org/10.1002/smll.201600597> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_50a/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_50a/Endpoint> ;
    rdfs:comment "There is not any robustness procedure. The final descriptors seem to be the same as the initial ones, but in MLREM cases having less than 15 weights indicates that there are some descriptors that were deleted within the modelling process."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_50b a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Bayesian Regularization Artificial Neural Network"@en ] ;
    dcterms:source <http://doi.org/10.1002/smll.201600597> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_50b/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_50b/Endpoint> ;
    rdfs:comment "There is not any robustness procedure. The final descriptors seem to be the same as the initial ones, but in MLREM cases having less than 15 weights indicates that there are some descriptors that were deleted within the modelling process."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_50c a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Multiple Linear Regression with Expectation Maximization"@en ] ;
    dcterms:source <http://doi.org/10.1002/smll.201600597> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_50c/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_50c/Endpoint> ;
    rdfs:comment "There is not any robustness procedure. The final descriptors seem to be the same as the initial ones, but in MLREM cases having less than 15 weights indicates that there are some descriptors that were deleted within the modelling process."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_50d a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Bayesian Regularization Artificial Neural Network"@en ] ;
    dcterms:source <http://doi.org/10.1002/smll.201600597> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_50d/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_50d/Endpoint> ;
    rdfs:comment "There is not any robustness procedure. The final descriptors seem to be the same as the initial ones, but in MLREM cases having less than 15 weights indicates that there are some descriptors that were deleted within the modelling process."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_50e a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Multiple Linear Regression with Expectation Maximization"@en ] ;
    dcterms:source <http://doi.org/10.1002/smll.201600597> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_50e/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_50e/Endpoint> ;
    rdfs:comment "There is not any robustness procedure. The final descriptors seem to be the same as the initial ones, but in MLREM cases having less than 15 weights indicates that there are some descriptors that were deleted within the modelling process."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_50f a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Bayesian Regularization Artificial Neural Network"@en ] ;
    dcterms:source <http://doi.org/10.1002/smll.201600597> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_50f/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_50f/Endpoint> ;
    rdfs:comment "There is not any robustness procedure. The final descriptors seem to be the same as the initial ones, but in MLREM cases having less than 15 weights indicates that there are some descriptors that were deleted within the modelling process."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_51a a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Random Forest"@en,
                "Support Vector Machine"@en,
                "k-Nearest Neighbour"@en ] ;
    dcterms:source <http://doi.org/10.3109/17435390.2015.1073397> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_51a/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_51a/Endpoint> ;
    rdfs:comment "The most important objective of this study was the prioritization of CNTs for experimental testing and their confirmation to demonstrate how computational screening incorporating similarity search and QSAR models can be used to facilitate the design of novel CNTs with the desired biological properties. To this end, they virtually screen an external compound collection consisting of 240 000 small molecules considered to be synthetically feasible and potentially attachable to the surface of CNTs by the developed QSAR models.Publication's Figure 2 illustrates the workflow of the process. Although it was reported as QSAR model, the endpoint suggests to label it as QSPR Despite of 5-fold cross validation is presented as external validation, actually all the data was used to develop the model, then, the statistical results have to be considered as goodness of fit, and robustness of the model. The real external validation was obtained with the final screened molecules."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_51b a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Random Forest"@en,
                "Support Vector Machine"@en,
                "k-Nearest Neighbour"@en ] ;
    dcterms:source <http://doi.org/10.3109/17435390.2015.1073397> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_51b/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_51b/Endpoint> ;
    rdfs:comment "The most important objective of this study was the prioritization of CNTs for experimental testing and their confirmation to demonstrate how computational screening incorporating similarity search and QSAR models can be used to facilitate the design of novel CNTs with the desired biological properties. To this end, they virtually screen an external compound collection consisting of 240 000 small molecules considered to be synthetically feasible and potentially attachable to the surface of CNTs by the developed QSAR models.Publication's Figure 2 illustrates the workflow of the process. Despite of 5-fold cross validation is presented as external validation, actually all the data was used to develop the model, then, the statistical results have to be considered as goodness of fit, and robustness of the model. The real external validation was obtained with the final screened molecules."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_52a a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "INForm v4.02 software"@en ;
            skos:narrower "Artificial Neural Network"@en ] ;
    dcterms:source <http://doi.org/10.1016/j.nano.2015.09.002> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_52a/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_52a/Endpoint> ;
    rdfs:comment "Good procedure, and the parameters of the Neural Network were provided, which allows to reproduce the model. The weakness of the model could come from the lack of a robustness evaluation. Mechanistic Interpretation. Despite of an used ANN and the abstract of the internally structure of the model, a good interpretation of the results due to fixing parameters to see the response of the other ones was done. Also the study for different descriptors around the size parameter was performed (Predictivity of cytotoxicity and size; Cytotoxicity with size as one of the descriptors; and finally with size as the only parameter. The following classifications in the table include the just mentioned cases)"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_52b a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "INForm v4.02 software"@en ;
            skos:narrower "Artificial Neural Network"@en ] ;
    dcterms:source <http://doi.org/10.1016/j.nano.2015.09.002> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_52b/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_52b/Endpoint> ;
    rdfs:comment "Good procedure, and the parameters of the Neural Network were provided, which allows to reproduce the model. The weakness of the model could come from the lack of a robustness evaluation. Mechanistic Interpretation. Despite of an used ANN and the abstract of the internally structure of the model, a good interpretation of the results due to fixing parameters to see the response of the other ones was done. Also the study for different descriptors around the size parameter was performed (Predictivity of cytotoxicity and size; Cytotoxicity with size as one of the descriptors; and finally with size as the only parameter. The following and the previous classifications in the table include the just mentioned cases)"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_52c a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "INForm v4.02 software"@en ;
            skos:narrower "Artificial Neural Network"@en ] ;
    dcterms:source <http://doi.org/10.1016/j.nano.2015.09.002> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_52c/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_52c/Endpoint> ;
    rdfs:comment "Good procedure, and the parameters of the Neural Network were provided, which allows to reproduce the model. The weakness of the model could come from the lack of a robustness evaluation. Mechanistic Interpretation. Despite of an used ANN and the abstract of the internally structure of the model, a good interpretation of the results due to fixing parameters to see the response of the other ones was done. Also the study for different descriptors around the size parameter was performed (Predictivity of cytotoxicity and size; Cytotoxicity with size as one of the descriptors; and finally with size as the only parameter. The previous classifications in the table include the just mentioned cases)"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_53a a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "WEKA software"@en ;
            skos:narrower "Functional Tree"@en ] ;
    dcterms:source <http://doi.org/10.1039/c6ra06159a> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53a/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53a/Endpoint> ;
    rdfs:comment "It is not clear if the 10-fold cross validation was applied during the development of the model of after of it, only in order to evaluate the \"predictivity\" and the robustness of the model. If it was done to obtain the final model, the data filling the external set validation ( \"NPs used as test set\" and also the \"Predictivity (External validation statistics)\") should be move to the test set and the external validation data could be interpreted as test test set and robustness properties. Specific-species give a better accuracy results than the global ones. There is a mechanistic Interpretation for the most relevant descriptors."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_53b a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "WEKA software"@en ;
            skos:narrower "C4.5 Decision Tree"@en ] ;
    dcterms:source <http://doi.org/10.1039/c6ra06159a> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53b/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53b/Endpoint> ;
    rdfs:comment "It is not clear if the 10-fold cross validation was applied during the development of the model of after of it, only in order to evaluate the \"predictivity\" and the robustness of the model. If it was done to obtain the final model, the data filling the external set validation ( \"NPs used as test set\" and also the \"Predictivity (External validation statistics)\") should be move to the test set and the external validation data could be interpreted as test test set and robustness properties. Specific-species give a better accuracy results than the global ones. There is a mechanistic Interpretation for the most relevant descriptors."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_53c a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "WEKA software"@en ;
            skos:narrower "Random Tree"@en ] ;
    dcterms:source <http://doi.org/10.1039/c6ra06159a> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53c/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53c/Endpoint> ;
    rdfs:comment "It is not clear if the 10-fold cross validation was applied during the development of the model of after of it, only in order to evaluate the \"predictivity\" and the robustness of the model. If it was done to obtain the final model, the data filling the external set validation ( \"NPs used as test set\" and also the \"Predictivity (External validation statistics)\") should be move to the test set and the external validation data could be interpreted as test test set and robustness properties. Specific-species give a better accuracy results than the global ones. There is a mechanistic Interpretation for the most relevant descriptors."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_53d a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "WEKA software"@en ;
            skos:narrower "Classification and Regression Tree"@en ] ;
    dcterms:source <http://doi.org/10.1039/c6ra06159a> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53d/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53d/Endpoint> ;
    rdfs:comment "It is not clear if the 10-fold cross validation was applied during the development of the model of after of it, only in order to evaluate the \"predictivity\" and the robustness of the model. If it was done to obtain the final model, the data filling the external set validation ( \"NPs used as test set\" and also the \"Predictivity (External validation statistics)\") should be move to the test set and the external validation data could be interpreted as test test set and robustness properties. Specific-species give a better accuracy results than the global ones. There is a mechanistic Interpretation for the most relevant descriptors."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_53e a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "WEKA software"@en ;
            skos:narrower "Functional Tree"@en ] ;
    dcterms:source <http://doi.org/10.1039/c6ra06159a> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53e/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53e/Endpoint> ;
    rdfs:comment "It is not clear if the 10-fold cross validation was applied during the development of the model of after of it, only in order to evaluate the \"predictivity\" and the robustness of the model. If it was done to obtain the final model, the data filling the external set validation ( \"NPs used as test set\" and also the \"Predictivity (External validation statistics)\") should be move to the test set and the external validation data could be interpreted as test test set and robustness properties. Specific-species give a better accuracy results than the global ones. There is a mechanistic Interpretation for the most relevant descriptors."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_53f a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "WEKA software"@en ;
            skos:narrower "C4.5 Decision Tree"@en ] ;
    dcterms:source <http://doi.org/10.1039/c6ra06159a> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53f/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53f/Endpoint> ;
    rdfs:comment "It is not clear if the 10-fold cross validation was applied during the development of the model of after of it, only in order to evaluate the \"predictivity\" and the robustness of the model. If it was done to obtain the final model, the data filling the external set validation ( \"NPs used as test set\" and also the \"Predictivity (External validation statistics)\") should be move to the test set and the external validation data could be interpreted as test test set and robustness properties. Specific-species give a better accuracy results than the global ones. There is a mechanistic Interpretation for the most relevant descriptors."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_53g a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "WEKA software"@en ;
            skos:narrower "Random Tree"@en ] ;
    dcterms:source <http://doi.org/10.1039/c6ra06159a> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53g/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53g/Endpoint> ;
    rdfs:comment "It is not clear if the 10-fold cross validation was applied during the development of the model of after of it, only in order to evaluate the \"predictivity\" and the robustness of the model. If it was done to obtain the final model, the data filling the external set validation ( \"NPs used as test set\" and also the \"Predictivity (External validation statistics)\") should be moved to the test set and the external validation data could be interpreted as internal test set with robustness properties. Specific-species give a better accuracy results than the global ones. There is a mechanistic Interpretation for the most relevant descriptors."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_53h a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "WEKA software"@en ;
            skos:narrower "Classification and Regression Tree"@en ] ;
    dcterms:source <http://doi.org/10.1039/c6ra06159a> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53h/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53h/Endpoint> ;
    rdfs:comment "It is not clear if the 10-fold cross validation was applied during the development of the model of after of it, only in order to evaluate the \"predictivity\" and the robustness of the model. If it was done to obtain the final model, the data filling the external set validation ( \"NPs used as test set\" and also the \"Predictivity (External validation statistics)\") should be move to the test set and the external validation data could be interpreted as test test set and robustness properties. Specific-species give a better accuracy results than the global ones. There is a mechanistic Interpretation for the most relevant descriptors."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_53i a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "WEKA software"@en ;
            skos:narrower "Functional Tree"@en ] ;
    dcterms:source <http://doi.org/10.1039/c6ra06159a> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53i/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53i/Endpoint> ;
    rdfs:comment "It is not clear if the 10-fold cross validation was applied during the development of the model of after of it, only in order to evaluate the \"predictivity\" and the robustness of the model. If it was done to obtain the final model, the data filling the external set validation ( \"NPs used as test set\" and also the \"Predictivity (External validation statistics)\") should be move to the test set and the external validation data could be interpreted as test test set and robustness properties. Specific-species give a better accuracy results than the global ones. There is a mechanistic Interpretation for the most relevant descriptors."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_53j a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "WEKA software"@en ;
            skos:narrower "C4.5 Decision Tree"@en ] ;
    dcterms:source <http://doi.org/10.1039/c6ra06159a> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53j/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53j/Endpoint> ;
    rdfs:comment "It is not clear if the 10-fold cross validation was applied during the development of the model of after of it, only in order to evaluate the \"predictivity\" and the robustness of the model. If it was done to obtain the final model, the data filling the external set validation ( \"NPs used as test set\" and also the \"Predictivity (External validation statistics)\") should be move to the test set and the external validation data could be interpreted as test test set and robustness properties. Specific-species give a better accuracy results than the global ones. There is a mechanistic Interpretation for the most relevant descriptors."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_53k a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "WEKA software"@en ;
            skos:narrower "Random Tree"@en ] ;
    dcterms:source <http://doi.org/10.1039/c6ra06159a> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53k/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53k/Endpoint> ;
    rdfs:comment "It is not clear if the 10-fold cross validation was applied during the development of the model of after of it, only in order to evaluate the \"predictivity\" and the robustness of the model. If it was done to obtain the final model, the data filling the external set validation ( \"NPs used as test set\" and also the \"Predictivity (External validation statistics)\") should be move to the test set and the external validation data could be interpreted as test test set and robustness properties. Specific-species give a better accuracy results than the global ones. There is a mechanistic Interpretation for the most relevant descriptors."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_53l a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "WEKA software"@en ;
            skos:narrower "Classification and Regression Tree"@en ] ;
    dcterms:source <http://doi.org/10.1039/c6ra06159a> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53l/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53l/Endpoint> ;
    rdfs:comment "It is not clear if the 10-fold cross validation was applied during the development of the model of after of it, only in order to evaluate the \"predictivity\" and the robustness of the model. If it was done to obtain the final model, the data filling the external set validation ( \"NPs used as test set\" and also the \"Predictivity (External validation statistics)\") should be move to the test set and the external validation data could be interpreted as test test set and robustness properties. Specific-species give a better accuracy results than the global ones. There is a mechanistic Interpretation for the most relevant descriptors."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_53m a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "WEKA software"@en ;
            skos:narrower "Functional Tree"@en ] ;
    dcterms:source <http://doi.org/10.1039/c6ra06159a> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53m/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53m/Endpoint> ;
    rdfs:comment "It is not clear if the 10-fold cross validation was applied during the development of the model of after of it, only in order to evaluate the \"predictivity\" and the robustness of the model. If it was done to obtain the final model, the data filling the external set validation ( \"NPs used as test set\" and also the \"Predictivity (External validation statistics)\") should be move to the test set and the external validation data could be interpreted as test test set and robustness properties. Specific-species give a better accuracy results than the global ones. There is a mechanistic Interpretation for the most relevant descriptors."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_53n a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "WEKA software"@en ;
            skos:narrower "C4.5 Decision Tree"@en ] ;
    dcterms:source <http://doi.org/10.1039/c6ra06159a> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53n/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53n/Endpoint> ;
    rdfs:comment "It is not clear if the 10-fold cross validation was applied during the development of the model of after of it, only in order to evaluate the \"predictivity\" and the robustness of the model. If it was done to obtain the final model, the data filling the external set validation ( \"NPs used as test set\" and also the \"Predictivity (External validation statistics)\") should be move to the test set and the external validation data could be interpreted as test test set and robustness properties. Specific-species give a better accuracy results than the global ones. There is a mechanistic Interpretation for the most relevant descriptors."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_53o a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "WEKA software"@en ;
            skos:narrower "Functional tree"@en ] ;
    dcterms:source <http://doi.org/10.1039/c6ra06159a> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53o/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53o/Endpoint> ;
    rdfs:comment "It is not clear if the 10-fold cross validation was applied during the development of the model of after of it, only in order to evaluate the \"predictivity\" and the robustness of the model. If it was done to obtain the final model, the data filling the external set validation ( \"NPs used as test set\" and also the \"Predictivity (External validation statistics)\") should be move to the test set and the external validation data could be interpreted as test test set and robustness properties. Specific-species give a better accuracy results than the global ones. There is a mechanistic Interpretation for the most relevant descriptors."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_53p a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "WEKA software"@en ;
            skos:narrower "C4.5 Decision Tree"@en ] ;
    dcterms:source <http://doi.org/10.1039/c6ra06159a> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53p/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53p/Endpoint> ;
    rdfs:comment "It is not clear if the 10-fold cross validation was applied during the development of the model of after of it, only in order to evaluate the \"predictivity\" and the robustness of the model. If it was done to obtain the final model, the data filling the external set validation ( \"NPs used as test set\" and also the \"Predictivity (External validation statistics)\") should be move to the test set and the external validation data could be interpreted as test test set and robustness properties. Specific-species give a better accuracy results than the global ones. There is a mechanistic Interpretation for the most relevant descriptors."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_53q a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "WEKA software"@en ;
            skos:narrower "Functional tree"@en ] ;
    dcterms:source <http://doi.org/10.1039/c6ra06159a> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53q/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53q/Endpoint> ;
    rdfs:comment "It is not clear if the 10-fold cross validation was applied during the development of the model of after of it, only in order to evaluate the \"predictivity\" and the robustness of the model. If it was done to obtain the final model, the data filling the external set validation ( \"NPs used as test set\" and also the \"Predictivity (External validation statistics)\") should be move to the test set and the external validation data could be interpreted as test test set and robustness properties. Specific-species give a better accuracy results than the global ones. There is a mechanistic Interpretation for the most relevant descriptors."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_53r a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "WEKA software"@en ;
            skos:narrower "C4.5 Decision Tree"@en ] ;
    dcterms:source <http://doi.org/10.1039/c6ra06159a> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53r/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53r/Endpoint> ;
    rdfs:comment "It is not clear if the 10-fold cross validation was applied during the development of the model of after of it, only in order to evaluate the \"predictivity\" and the robustness of the model. If it was done to obtain the final model, the data filling the external set validation ( \"NPs used as test set\" and also the \"Predictivity (External validation statistics)\") should be move to the test set and the external validation data could be interpreted as test test set and robustness properties. Specific-species give a better accuracy results than the global ones. There is a mechanistic Interpretation for the most relevant descriptors."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_53s a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "WEKA software"@en ;
            skos:narrower "C4.5 Decision Tree"@en ] ;
    dcterms:source <http://doi.org/10.1039/c6ra06159a> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53s/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53s/Endpoint> ;
    rdfs:comment "It is not clear if the 10-fold cross validation was applied during the development of the model of after of it, only in order to evaluate the \"predictivity\" and the robustness of the model. If it was done to obtain the final model, the data filling the external set validation ( \"NPs used as test set\" and also the \"Predictivity (External validation statistics)\") should be move to the test set and the external validation data could be interpreted as test test set and robustness properties. Specific-species give a better accuracy results than the global ones. There is a mechanistic Interpretation for the most relevant descriptors."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_54a a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Partial Least Squares"@en ] ;
    dcterms:source <http://doi.org/10.1016/j.ecoenv.2015.12.033> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_54a/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_54a/Endpoint> ;
    rdfs:comment "The nano-QTTR is not clearly well fitted with the meaning of QSAR, but it is interesting the idea of the model, as they explain, where will be possible to use in vitro data to develop a model of in vivo toxicity, hence reducing the number of experimental work with animals. There is a widespread Mechanistic Interpretation. More statistical results were provided related with Roy et al., 2012, as in a few previous classified papers where we decided to avoid that data since, there is not a good parameter to compare with the rest of classified publication in the table"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_54b a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Partial Least Squares"@en ] ;
    dcterms:source <http://doi.org/10.1016/j.ecoenv.2015.12.033> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_54b/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_54b/Endpoint> ;
    rdfs:comment "The nano-QTTR is not clearly well fitted with the meaning of QSAR, but it is interesting the idea of the model, as they explain, where will be possible to use in vitro data to develop a model of in vivo toxicity, hence reducing the number of experimental work with animals. There is a widespread Mechanistic Interpretation. More statistical results were provided related with Roy et al., 2012, as in a few previous classified papers where we decided to avoid that data since, there is not a good parameter to compare with the rest of classified publication in the table"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_55a a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "CORAL software"@en ;
            skos:narrower "Linear regression model"@en ] ;
    dcterms:source <http://doi.org/10.1039/c6ra01298a> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_55a/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_55a/Endpoint> ;
    rdfs:comment "Comparison with a previous work (source publication) was done, and a widespread Mechanistic Interpretation was performed ( see section 3.5 Mechanistic Interpretation). To do that it was applied a sensitivity analysis of the physicochemical descriptors: The R^2 value for the new reduced model on the training set was computed when the ith feature is excluded from the original model."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_55b a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "CORAL software"@en ;
            skos:narrower "Linear regression model"@en ] ;
    dcterms:source <http://doi.org/10.1039/c6ra01298a> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_55b/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_55b/Endpoint> ;
    rdfs:comment "Comparison with a previous work Sizochenko et al. 2014 (already reported in this table) was done, and a widespread Mechanistic Interpretation was performed ( see section 3.5 Mechanistic Interpretation). To do that it was applied a sensitivity analysis of the physicochemical descriptors: The R^2 value for the new reduced model on the training set was computed when the ith feature is excluded from the original model."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_55c a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "CORAL software"@en ;
            skos:narrower "Linear regression model"@en ] ;
    dcterms:source <http://doi.org/10.1039/c6ra01298a> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_55c/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_55c/Endpoint> ;
    rdfs:comment "Comparison with a previous work (source publication) was done, and a widespread Mechanistic Interpretation was performed ( see section 3.5 Mechanistic Interpretation). To do that it was applied a sensitivity analysis of the physicochemical descriptors: The R^2 value for the new reduced model on the training set was computed when the ith feature is excluded from the original model."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_55d a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "CORAL software"@en ;
            skos:narrower "Linear regression model"@en ] ;
    dcterms:source <http://doi.org/10.1039/c6ra01298a> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_55d/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_55d/Endpoint> ;
    rdfs:comment "Comparison with a previous work Sizochenko et al. 2014 (already reported in this table) was done, and a widespread Mechanistic Interpretation was performed ( see section 3.5 Mechanistic Interpretation). To do that it was applied a sensitivity analysis of the physicochemical descriptors: The R^2 value for the new reduced model on the training set was computed when the ith feature is excluded from the original model."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_56 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Multiple Linear Regression"@en ] ;
    dcterms:source <http://doi.org/10.1080/17435390.2016.1202352> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_56/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_56/Endpoint> ;
    rdfs:comment "A set of 51 NPs without bibliographic data was predicted and compare the obtained results with other papers. The final descriptors were explained in a Mechanistic interpretation of the model."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_57 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "CORAL software"@en ;
            skos:narrower "Linear regression model"@en ] ;
    dcterms:source <http://doi.org/10.1016/j.impact.2016.04.003> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_57/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_57/Endpoint> ;
    rdfs:comment "The obtained attributes from the publication's Table 2 are not consistent with the example presented in the table 4. It should be checked. In this paper, the group also calculate a group of statistics from \" Ojha, P.K., Mitra, I., Das, R.N., Roy, K., 2011. Further exploring rm2 metrics for validation of QSPR models. Chemom. Intell. Lab. Syst. 107, 194â€“205 \" Since those statistics can not be compared with the majority of the classified models, we have decided only to mention that it was applied. It will be interesting to be careful about if the use of this statistics increase in the future classified models. Developing different models with a different splitting of data into training and validation tests can be considered as a robustness evaluation methodology."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_58 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "kmine software"@en ;
            skos:narrower "classification tree"@en ] ;
    dcterms:source <http://doi.org/10.2174/1568026615666150506144536> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_58/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_58/Endpoint> ;
    rdfs:comment "The proposed model was made publicly available online through Enalos InSilicoNano platform. Enalos InSilicoNano platform is a webservice that can host several validated and predictive models that can be utilized in the NPs design process"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_59a a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Support Vector Regression"@en ] ;
    dcterms:source <http://doi.org/10.2174/1386207318666150306105525> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_59a/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_59a/Endpoint> ;
    rdfs:comment "Not external validation test was applied, hence we cannot say that the obtained results will be totally reliable."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_59b a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Multiple Linear Regression"@en ] ;
    dcterms:source <http://doi.org/10.2174/1386207318666150306105525> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_59b/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_59b/Endpoint> ;
    rdfs:comment "Not external validation test was applied, hence we cannot say that the obtained results will be totally reliable."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_6 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ] ;
    dcterms:source <http://doi.org/10.1002/smll.201002366> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_6/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_6/Endpoint> ;
    rdfs:comment "Strictly standardized mean difference (SSMD) and Maximum likelihood estimation(MLE) was used to identify and label measurable cytoToxic Effect (Active/Inactive)s, for the experimental results.(SI, Table S2 in the publication supplementary information). As they recognize: \"A significantly larger data set would be needed in order to expand the applicability domain and increase the confidence and the reliability of the results\" A widespread Mechanistic Interpretation is present, which improves the reliability of the model."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_60 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "Jetnet 3.0 software"@en ;
            skos:narrower "Artificial Neural Network"@en ] ;
    dcterms:source <http://doi.org/10.1021/jp000739v> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_60/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_60/Endpoint> ;
    rdfs:comment "The solubility decreases with increasing molar volume, increases with polar izability parameter, saturated surface area and average polar izability, and does not have a definite tendency with LUMO energy. The relation are chemically correct: the derivatives of the solubility with respect to the different molecular parameters are approximately constant for certain groups of solvents (not for alcohols, Figure 4 and 5 in the publication). Prediction is similar to other published studies. Ouliers are dut to chemical interactions between solven-fullerenes. In addition, authors create a model to predict the Hildreband parameters based on solubility determined in the study and other descriptors (to accept the values both solubility of both C60 and I2 should be similar)."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_61a a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "Generated the ADAPT (Aumotated Data and Pattern Recognition Tool) software"@en ;
            skos:narrower "Multiple Linear Regression"@en ] ;
    dcterms:source <http://doi.org/10.1021/ci000140s> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_61a/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_61a/Endpoint> ;
    rdfs:comment "Prediction rms decreased to 0.40 log if 1-phenylnaphthalene was removed from the set. Model was developed using standard tests of linear fitness and T-values greater than 4."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_61b a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "Generated the ADAPT (Aumotated Data and Pattern Recognition Tool) software"@en ;
            skos:narrower "Computational Neural Network"@en ] ;
    dcterms:source <http://doi.org/10.1021/ci000140s> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_61b/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_61b/Endpoint> ;
    rdfs:comment "Prediction rms decreased to 0.34 log units if trichloromethane was removed from the set. Model was developed using standard tests of linear fitness and T-values greater than 4. Descriptors tend to agree with basic solvation principles. Errors indicate a poor predictive model in that the external prediction set rms error was much higher than the training set."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_61c a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "Generated the ADAPT (Aumotated Data and Pattern Recognition Tool). software"@en ;
            skos:narrower "Computational Neural Network"@en ] ;
    dcterms:source <http://doi.org/10.1021/ci000140s> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_61c/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_61c/Endpoint> ;
    rdfs:comment "With the exception of trichloromethane, the remaining prediction set compounds fall within the range of the training and crossvalidation sets, indicating the formation of a predictive model. The Type IIA model represents a 15.3% improvement in the training set rms error, a 43.5% improvement in the cross-validation error, and a 33.7% improvement in the prediction set rms error over the Type II model (see above). Monte Carlos study was performed by randomizing the dependent variables and rennuning the models. From the results obtained, it is highly unlikely that a predictive model could be developed for the scrambled dependent variables using the methods and cutoffs employed. Errors indicate a poor predictive model in that the external prediction set rms error was much higher than the training set."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_62a a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Multiple Regression Analysis"@en ] ;
    dcterms:source <http://doi.org/10.1021/ci010003a> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_62a/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_62a/Endpoint> ;
    rdfs:comment "From the oririginal subset, the authors remove the solvent hexane, and the model generated is for n=6. Polarizibility parameter explained 99% of data. Small number of data."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_62b a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Multiple Regression Analysis"@en ] ;
    dcterms:source <http://doi.org/10.1021/ci010003a> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_62b/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_62b/Endpoint> ;
    rdfs:comment "In halogenated solvents, the solute-solvent interaction cannot be explained fully by polarizibility."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_62c a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Multiple Regression Analysis"@en ] ;
    dcterms:source <http://doi.org/10.1021/ci010003a> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_62c/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_62c/Endpoint> ;
    rdfs:comment "Polarizibility parameter explained 97,3% of data. Small number of data."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_62d a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Multiple Regression Analysis"@en ] ;
    dcterms:source <http://doi.org/10.1021/ci010003a> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_62d/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_62d/Endpoint> ;
    rdfs:comment "Being cyclic in nature, the structural parameter was able to explain a higher percentage of data variability. Small number of data."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_62e a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Multiple Regression Analysis"@en ] ;
    dcterms:source <http://doi.org/10.1021/ci010003a> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_62e/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_62e/Endpoint> ;
    rdfs:comment "Position of substutition played an important role in deciding the solubility. solubility of C60 depends on the structure of the solvent molecule. This observation is analogous to the situation in cycloalkanes.Small number of data."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_62f a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Multiple Regression Analysis"@en ] ;
    dcterms:source <http://doi.org/10.1021/ci010003a> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_62f/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_62f/Endpoint> ;
    rdfs:comment "The solubility of C60 in a cyclic solvent depends very much on the shape of the solvent molecule. Small number of data."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_62g a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Multiple Regression Analysis"@en ] ;
    dcterms:source <http://doi.org/10.1021/ci010003a> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_62g/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_62g/Endpoint> ;
    rdfs:comment "No regression model with a standard error less than 0.2 was obtained."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_62h a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Multiple Regression Analysis"@en ] ;
    dcterms:source <http://doi.org/10.1021/ci010003a> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_62h/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_62h/Endpoint> ;
    rdfs:comment "No regression model with a standard error less than 0.2 was obtained. Polarizability parameter (Î¦) and indicator parameter (IP) were sufficient to explain 91% of the data variability."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_62i a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Multiple Regression Analysis"@en ] ;
    dcterms:source <http://doi.org/10.1021/ci010003a> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_62i/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_62i/Endpoint> ;
    rdfs:comment "No regression model with a standard error less than 0.2 was obtained. As in the case of the individual Sets E and F, in the combined set also higher order Ï‡ terms correlated better with the solubility of C60."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_62j a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Multiple Regression Analysis"@en ] ;
    dcterms:source <http://doi.org/10.1021/ci010003a> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_62j/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_62j/Endpoint> ;
    rdfs:comment "The regression equation could be considered a three-parameter model for aliphatic solvents. A generalized equation was also made for aromatic solvent. Poor correlation was obtained, which was attributed to the limited set of data (only 25 solvents)."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_63a a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "crunc v. 4.0 software"@en ;
            skos:narrower "(Multiple Linear Regression)"@en ] ;
    dcterms:source <http://doi.org/10.1021/jp0023720> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_63a/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_63a/Endpoint> ;
    rdfs:comment "None of the iodoalkanes fit the correlation, methanol and others because of the extrem low solubility. Others because possible interactions C60-solvent. Compared to previous reports, to point out is the absence of a constant in the regression. It is possible to predict the solubility of the C60 fullerene in solvents in which it is so low that it could not so far be determined reliably. The present approach permits predictions of solubilities within 1 order of magnitude (2Ïƒ of the correlations) with much less effort. For aromatic solvents where the fullerene formed crystalline solvates, the enthalpy of incongruent melting and the temperature of maximum solubility were used to determine the â€œhypothetical solubilityâ€ of the unsolvated C60, which was then used in the statistical procedure instead of the solubility of the solvate. Increasing molar volume and solvent polarity (as measured by the Dimroth-Reichardt â€œgeneral polarityâ€ parameter, ET(30)) diminished the solubility of C60, whereas electron pair donation ability and polarizability enhanced solubility."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_63b a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "crunc v. 4.0 software"@en ;
            skos:narrower "(Multiple Linear Regression)"@en ] ;
    dcterms:source <http://doi.org/10.1021/jp0023720> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_63b/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_63b/Endpoint> ;
    rdfs:comment "Better performance when polarizability R and electron pari donicity are replaced by the polarity/polarizability parameter. Compared to previous reports, to point out is the absence of a constant in the regression. It is possible to predict the solubility of the C60 fullerene in solvents in which it is so low that it could not so far be determined reliably. The present approach permits predictions of solubilities within 1 order of magnitude (2Ïƒ of the correlations) with much less effort. For aromatic solvents where the fullerene formed crystalline solvates, the enthalpy of incongruent melting and the temperature of maximum solubility were used to determine the â€œhypothetical solubilityâ€ of the unsolvated C60, which was then used in the statistical procedure instead of the solubility of the solvate. Increasing molar volume and solvent polarity (as measured by the Dimroth-Reichardt â€œgeneral polarityâ€ parameter, ET(30)) diminished the solubility of C60, whereas electron pair donation ability and polarizability enhanced solubility."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_63c a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "crunc v. 4.0 software"@en ;
            skos:narrower "(Multiple Linear Regression)"@en ] ;
    dcterms:source <http://doi.org/10.1021/jp0023720> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_63c/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_63c/Endpoint> ;
    rdfs:comment "Outliers essentially the same as those defined above. Compared to previous reports, to point out is the absence of a constant in the regression. It is possible to predict the solubility of the C60 fullerene in solvents in which it is so low that it could not so far be determined reliably. The present approach permits predictions of solubilities within 1 order of magnitude (2Ïƒ of the correlations) with much less effort. For aromatic solvents where the fullerene formed crystalline solvates, the enthalpy of incongruent melting and the temperature of maximum solubility were used to determine the â€œhypothetical solubilityâ€ of the unsolvated C60, which was then used in the statistical procedure instead of the solubility of the solvate. Increasing molar volume and solvent polarity (as measured by the Dimroth-Reichardt â€œgeneral polarityâ€ parameter, ET(30)) diminished the solubility of C60, whereas electron pair donation ability and polarizability enhanced solubility."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_64a a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Multiple Linear Regression"@en ] ;
    dcterms:source <http://doi.org/10.1021/jp052223n> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_64a/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_64a/Endpoint> ;
    rdfs:comment "First model is generated, but six solvents are removed because outliers. Cyclopentane, diiodomethane, 1,1,1-trichloroethane, o-cresol, nitroethane and n-butylamine can react with fullerenes. Good predictive capability of the model."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_64b a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "Matlab/C software"@en ;
            skos:narrower "Least-Squares Support Vector Machine"@en ] ;
    dcterms:source <http://doi.org/10.1021/jp052223n> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_64b/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_64b/Endpoint> ;
    rdfs:comment "Performance of the LSSVM model is better thant that of the linear model described above. Results are most satisfactory than results obtained in the source publication."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_65 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Linear regression model"@en ] ;
    dcterms:source <http://doi.org/http://dx.doi.org/10.1016/j.cplett.2006.11.010> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_65/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_65/Endpoint> ;
    rdfs:comment "Rubustness is not assessed. Description of statistical characteristics is not provided. Monte Carlo method is used to calculate the values of the CW(Ik) that yield correlations coefficients that are as large as possible between YoungÂ´s modulus and the DWC for the training set. Three runs are done. Apart from the training and the validation set (named test set in the paper), the authors divide randoomly in four groups tranining and test (validation) sets and 4 other models are generated (Table 7 in the publication)."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_66 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Linear regression model"@en ] ;
    dcterms:source <http://doi.org/10.1016/j.cplett.2007.04.094> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_66/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_66/Endpoint> ;
    rdfs:comment "Not all descriptors are in both the training and test (validation) sets. Monte Carlo method is used to calculate the values of the CW(Ik) that yield correlations coefficients that are as large as possible between solubility and the DWC for the training set. Three runs are performed. Basic split into training and test (validation) sets is done by means of exchange some solvents from training into test set and vice-versa. Model generation by Monte Carlo optimization is again performed for each one of these 4 splits. Statistical characteristics are reproduced well."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_67 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Linear regression model"@en ] ;
    dcterms:source <http://doi.org/10.1016/j.cplett.2007.07.024> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_67/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_67/Endpoint> ;
    rdfs:comment "This paper describes exactly the same type of model than Toropov, A. A., Leszczynska, D., & Leszczynski, J. (2007). QSPR study on solubility of fullerene C60 in organic solvents using optimal descriptors calculated with SMILES. Chemical Physics Letters, 441(1-3), 119â€“122. but with using another data set. This is reliable model but with less accuracy that the nonlinear model developed in the source publication. (also the data source, which is based on quantum chemical descriptors. Larger numbers of SFk in the training set are related to higher statistical significance of the SFk for a given model. SFk is a fragment of SMILES."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_68a a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Multiple Linear Regression"@en ] ;
    dcterms:source <http://doi.org/10.1016/j.compbiolchem.2007.02.002> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_68a/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_68a/Endpoint> ;
    rdfs:comment "Small number of data values. Robustness is not assessed."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_68b a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Multiple Linear Regression"@en ] ;
    dcterms:source <http://doi.org/10.1016/j.compbiolchem.2007.02.002> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_68b/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_68b/Endpoint> ;
    rdfs:comment "Small number of data values. Robustness is not assessed."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_69 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Linear regression model"@en ] ;
    dcterms:source <http://doi.org/10.1016/j.cplett.2008.04.013> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_69/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_69/Endpoint> ;
    rdfs:comment "Two SMILES attributes (Sak) are absent in the training set (C1 and Br2). Therefore correlation weight values have been fixed as 1. Two outlayers are detected and removed from the analysis. Larger numbers of SAk in the training set are related to higher statistical significance of the SAk for a given model. Despite Q^2 is not defined as cross-validation correlation coefficient in the paper, the meaning has been extracted from other papers published by the same authors. Optimal descriptors calculated with two components SAk together with the global SMILES attributes (Nb and Ndb) are based on more information related to the molecular structure than the previous version of the descriptors on previous works. However, further increase of the detailing may leads to the overtraining (i.e. a situation when an excellent model for the training set is accompanied by a poor model for the test). Thus the proposed method has clear interpretations (each SMILES attribute is promoter of increase or decrease of the fuller- ene C60 solubility and this is defined by the correlation weight"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_7 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Multiple Linear Regression"@en ] ;
    dcterms:source <http://doi.org/10.1021/nn203303c> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_7/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_7/Endpoint> ;
    rdfs:comment "For visual presentation and a clear comparison of diverse nanomaterials, the five-dimensional information can be reduced to two-dimensional via principal component analysis of the five nanodescriptors. A two-dimensional plot of the two principal components (CP-1 versus CP-2) is shown in publication's Figure 4. The 16 nanomaterials can be roughly clustered in strong/medium/weak adsorption nanomaterials. The percentage of the explained variance should be reported for the components of the PCA, in order to evaluate the quality of the plot. The same model was fitted for a different set of NPs in a posterior work (almost the same authors were involved in) where also Artificial Neural Network was tested for the same descriptors. Reference: Chen, R., Zhang, Y., Monteiro-Riviere, N. A., & Riviere, J. E. (2016). Quantification of nanoparticle pesticide adsorption: computational approaches based on experimental data. Nanotoxicology, 10(8), 1118â€“1128. http://doi.org/10.1080/17435390.2016.1177745"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_70a a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "MATLAB software"@en ;
            skos:narrower "Genetic Algorithm-based Multivariate Linear Regression"@en ] ;
    dcterms:source <http://doi.org/10.1080/15363830701779315> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_70a/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_70a/Endpoint> ;
    rdfs:comment "From the first model generated using GA-MLR the authors remove 4 solvents of the datase because of of probable reaction between solvent-nanomaterial. The new model increased the accuracy and is the one included in goodness-of-fit. FFNN results are better in comparison with MLR equation. MLR equation has one variable less than the best previous reported linear models and is also more accurate."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_70b a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Three-layer Feed Forward Neural Network"@en ] ;
    dcterms:source <http://doi.org/10.1080/15363830701779315> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_70b/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_70b/Endpoint> ;
    rdfs:comment "From the first model generated using GA-MLR the authors remove 4 solvents of the datase because of of probable reaction between solvent-nanomaterial. The new model increased the accuracy and is the one included in goodness-of-fit. FFNN results are better in comparison with MLR equation. MLR equation has one variable less than the best previous reported linear models and is also more accurate."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_71 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Partial Least Squares regression"@en ] ;
    dcterms:source <http://doi.org/10.1016/j.bmc.2008.10.039> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_71/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_71/Endpoint> ;
    rdfs:comment "Novel fullerene derivatives with high inhibition effect can be designed by using this model. In last step Leapfrog de novo program and the 3D QSAR / CoMSIA contour maps have been used in order to generate a series of potent fullerenes. Since experimental and computed binding energies showed good correlation, both experimental binding affinities of structures (Table 1 in the publication) and estimated binding affinities (Table 2 in the publication) have been used to form the 3D QSAR models. Same model is also applied in Durdagi, S., Mavromoustakos, T., & Papadopoulos, M. G. (2008). 3D QSAR CoMFA/CoMSIA, molecular docking and molecular dynamics studies of fullerene-based HIV-1 PR inhibitors. Bioorganic and Medicinal Chemistry Letters, 18(23), 6283â€“6289. where their state it was first reported."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_72 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ] ;
    dcterms:source <http://doi.org/10.1007/s10910-008-9514-0> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_72/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_72/Endpoint> ;
    rdfs:comment "International Chemical Identifier can be used as elucidation of the molecular structure for the QSPR analysis of the solubility of fullerene C60 in organic solvents. The statistical quality of the InChI-based model for fullerene C60 solubility is better than the quality of SMILES-based model (source publication) of this parameter. Majority of the correlation weights (W(Ik) have similar values for the 3 splits (either promote or decrease solubility). Some others are unstable (e.g. h5, h7), probably because of a weak influence of relevant molecular phenomenon. The conclusion is that some optmimal descriptors can therefore hint that some mechanistic interpreations for the C60 solubility exists (tendencies can be modified). It should be also pointed out that for the first split of the three splits some descriptors are present (e.g. once), while for the other two not. This leads to signficant differences in between the three values. In the paper is stated that the model should describe substances must have InChI without rare (in the training set) attributes."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_73 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "CORAL software"@en ;
            skos:narrower "Linear regression model"@en ] ;
    dcterms:source <http://doi.org/10.1007/s11030-010-9245-6> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_73/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_73/Endpoint> ;
    rdfs:comment "Substance 5 is an outllier (model represented here is without this substance ). Chemical features of the ligand in this molecule are briefly discussed. Removing 5 improves model for the training set, but not the predicitivity ability of the model (validation set). The threshold is the parameter for separation of SMILES elements into two classes: rare and not rare. We have used Threshold=1. This value indicates that Sk that takes place in the training less than 1 time should be blocked, i.e., its correlation weight should be equal to zero. SMILES attributes, which are absent in the training set, have no influence on the model. SMILES attributes which are absent in the training set (i.e., attributes which take place only in the validation set) are not involved in the modeling process. If the correlation weight for the SMILES attribute SA in sequence of the runs of the optimization has values which all are larger than zero, then the attribute can be estimated as stable promoter of increase of the endpoint. Vice versa, if the correlationweight for the SA has in sequence of the runs of optimization values which all are smaller than zero, the attribute can be estimated as a stable promoter of decrease of the given endpoint. Finally, if a SMILES attribute in three runs of the optimization has both correlation weights: smaller and larger than zero values, one can estimate the attribute as an attribute of undefined role."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_74 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "BuildQSAR software"@en ;
            skos:narrower "Gnetic Algorithm and Multiple Linear Regression"@en ] ;
    dcterms:source <http://doi.org/10.1007/s11051-011-0238-x> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_74/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_74/Endpoint> ;
    rdfs:comment "Simple and transparent descriptors and mechanistically interpretable. Models with 1 to 5 descriptors are generated. The best is described with 4 descriptors. Although the X1sol descriptor alone displayed the statistically not so significant correlation, it still provides a main contribution to solubility (positive value). The presence of quantum- chemical descriptorâ€”HOMO energy confirmed the importance of nucleophilic properties of solvents for solubility of C60. Higher HOMO value for solvent results in the higher solubility of C60. (positive influence). Also HOMO-LUMO gap parameter might be used to build individual models for families of solvents (Figure 3 in the publication), despite the aim of the paper was to build general models. Surprisingly, the folding descriptor FDI showed certain correlation with solubility, asserting that the closer structure of solvent to linearity the higher solubility of C60 in this solvent is. The presence of nHAcc descriptor in the model confirms importance of H bonds. Original data was taken by the source publication from Beck MT, Mandi G (1997) Solubility of C60. Fuller Sci Technol 5:291â€“310"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_75a a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Partial Least Squares"@en ] ;
    dcterms:source <http://doi.org/10.1021/ci300482n> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_75a/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_75a/Endpoint> ;
    rdfs:comment "A traditional star plot represents a unique data point and is composed of a sequence of equiangular spokes. Each spoke represents a variable with the spoke length proportional to the magnitude of that variable in that data point. Modifying the definition of the traditional star plot, each star represents a variable, and the spokes are observations of that variable over a set of conditions.40 Spoke length is proportional to the normalized descriptor strength and provides a measure of descriptor importance. The spoke color indicates the correlation of the descriptor in the model with blue being positive (correlated) and red being negative (anticorrelated). One of the aims of the work was to obtain the critical descriptors to obtain the desired endpoint, which was also applied in a third analysis against experimental data with the obtained descriptors, but the obtained model was not applied in that analysis. An exaustive anaylis of the descriptors was done, which could be interpreted as an Mechanistic Interpretation."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_75b a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Partial Least Squares"@en ] ;
    dcterms:source <http://doi.org/10.1021/ci300482n> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_75b/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_75b/Endpoint> ;
    rdfs:comment "A traditional star plot represents a unique data point and is composed of a sequence of equiangular spokes. Each spoke represents a variable with the spoke length proportional to the magnitude of that variable in that data point. Modifying the definition of the traditional star plot, each star represents a variable, and the spokes are observations of that variable over a set of conditions.40 Spoke length is proportional to the normalized descriptor strength and provides a measure of descriptor importance. The spoke color indicates the correlation of the descriptor in the model with blue being positive (correlated) and red being negative (anticorrelated). One of the aims of the work was to obtain the critical descriptors to obtain the desired endpoint, which was also applied in a third analysis against experimental data with the obtained descriptors, but the obtained model was not applied in that analysis. An exaustive anaylis of the descriptors was done, which could be interpreted as an Mechanistic Interpretation."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_75c a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Partial Least Squares"@en ] ;
    dcterms:source <http://doi.org/10.1021/ci300482n> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_75c/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_75c/Endpoint> ;
    rdfs:comment "A traditional star plot represents a unique data point and is composed of a sequence of equiangular spokes. Each spoke represents a variable with the spoke length proportional to the magnitude of that variable in that data point. Modifying the definition of the traditional star plot, each star represents a variable, and the spokes are observations of that variable over a set of conditions.40 Spoke length is proportional to the normalized descriptor strength and provides a measure of descriptor importance. The spoke color indicates the correlation of the descriptor in the model with blue being positive (correlated) and red being negative (anticorrelated). One of the aims of the work was to obtain the critical descriptors to obtain the desired endpoint, which was also applied in a third analysis against experimental data with the obtained descriptors, but the obtained model was not applied in that analysis. An exaustive anaylis of the descriptors was done, which could be interpreted as an Mechanistic Interpretation."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_75d a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Partial Least Squares"@en ] ;
    dcterms:source <http://doi.org/10.1021/ci300482n> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_75d/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_75d/Endpoint> ;
    rdfs:comment "A traditional star plot represents a unique data point and is composed of a sequence of equiangular spokes. Each spoke represents a variable with the spoke length proportional to the magnitude of that variable in that data point. Modifying the definition of the traditional star plot, each star represents a variable, and the spokes are observations of that variable over a set of conditions.40 Spoke length is proportional to the normalized descriptor strength and provides a measure of descriptor importance. The spoke color indicates the correlation of the descriptor in the model with blue being positive (correlated) and red being negative (anticorrelated). One of the aims of the work was to obtain the critical descriptors to obtain the desired endpoint, which was also applied in a third analysis against experimental data with the obtained descriptors, but the obtained model was not applied in that analysis. An exaustive anaylis of the descriptors was done, which could be interpreted as an Mechanistic Interpretation."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_76 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "SPSS v15.0 MATLAB v7s software"@en ;
            skos:narrower "(Multiple Linear Regression)"@en ] ;
    dcterms:source <http://doi.org/10.1007/s10953-013-0062-2> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_76/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_76/Endpoint> ;
    rdfs:comment "A previous model was presented in the publication before the Applicability Domain, and the statistical result are compared. A little improvement was obtained after the outliers were excluded. The model was constructed based on some empirical parameters that were obtained using some experimental probes and these parameters can define some aspects of solvent interactions with the solute (here fullerene C60). Thus it could be said that the proposed model is a kind of LSER A good Mechanistic Interpretation was provided."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_77a a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Bayesian Regularization Artificial Neural Network"@en ] ;
    dcterms:source <http://doi.org/10.1021/mp3006402> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_77a/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_77a/Endpoint> ;
    rdfs:comment "The statistical parameters were not clearly reported for our classification, then the reported values were not obtained directly in the publication. Due to the lack of robustness validation and the lack of information about the final applied descriptors, those were not classified and the reliability of the model can not be ensured.."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_77b a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Bayesian Regularization Artificial Neural Network"@en ] ;
    dcterms:source <http://doi.org/10.1021/mp3006402> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_77b/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_77b/Endpoint> ;
    rdfs:comment "The statistical parameters were not clearly reported for our classification, then the reported values were not obtained directly in the publication. Due to the lack of robustness validation and the lack of information about the final applied descriptors, those were not classified and the reliability of the model can not be ensured.."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_77c a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Bayesian Regularization Artificial Neural Network"@en ] ;
    dcterms:source <http://doi.org/10.1021/mp3006402> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_77c/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_77c/Endpoint> ;
    rdfs:comment "The statistical parameters were not clearly reported for our classification, then the reported values were not obtained directly in the publication. Due to the lack of robustness validation and the lack of information about the final applied descriptors, those were not classified and the reliability of the model can not be ensured.."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_77d a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Bayesian Regularization Artificial Neural Network"@en ] ;
    dcterms:source <http://doi.org/10.1021/mp3006402> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_77d/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_77d/Endpoint> ;
    rdfs:comment "The statistical parameters were not clearly reported for our classification, then the reported values were not obtained directly in the publication. Due to the lack of robustness validation and the lack of information about the final applied descriptors, those were not classified and the reliability of the model can not be ensured.."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_78a a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Multiple Linear Regression"@en ] ;
    dcterms:source <http://doi.org/10.1007/s11051-013-2028-0> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_78a/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_78a/Endpoint> ;
    rdfs:comment "Compared the quality of the predictions of the log(Cmax) with three amidine solvents as an external test data, using model obtained. 1,1,3,3-tetramethylguan- idine (TMG), 1,5-diazabicyclo(4.3.0)non-5-ene (DBN) and 1,8-diazabicycloundec-7-ene (DBU) are consider as solvents which are incapable to disperse SWNTs, and correlated result were obtained after apply the built model. Statistical value were provided in the table 2 in the publication which could be understood as cross-validation value but it was not specified in the paper, thus it was considered as not be included in the table."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_78b a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Artificial Neural Network"@en ] ;
    dcterms:source <http://doi.org/10.1007/s11051-013-2028-0> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_78b/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_78b/Endpoint> ;
    rdfs:comment "Compared the quality of the predictions of the log(Cmax) with three amidine solvents as an external test data, using model obtained. 1,1,3,3-tetramethylguan- idine (TMG), 1,5-diazabicyclo(4.3.0)non-5-ene (DBN) and 1,8-diazabicycloundec-7-ene (DBU) are consider as solvents which are incapable to disperse SWNTs, and correlated result were obtained after apply the built model. Statistical value were provided in the table 2 in the publication which could be understood as cross-validation value but it was not specified in the paper, thus it was considered as not be included in the table."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_79 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Partial Least Squares"@en ] ;
    dcterms:source <http://doi.org/10.1080/1536383X.2012.702157> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_79/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_79/Endpoint> ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_8 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Decision Tree"@en ] ;
    dcterms:source <http://doi.org/10.1093/toxsci/kfr124> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_8/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_8/Endpoint> ;
    rdfs:comment "There are not structural or molecular descriptors, thus could be not considered as QSAR model. The data was treated also by a Naive Bayes model, getting 78.5% of accuracy (worst than the applied decision tree) \"In order to be able to discriminate between the direct toxicological effect of Co-NPs and their indirect effect due the release of Co-ions arising from the dissolution of the NPs, we determined the extent of release of Co-ions from Co-NPs\" Theoretical KDD (Knowledge Discovery from Data) was explained deeply . Deeply explained the Mechanistic Interpretation of the results. The same group, with the same methodology, develop the same model with a different set of NPs in a posterior work: Horev-Azaria, L., Baldi, G., Beno, D., Bonacchi, D., Golla-Schindler, U., Kirkpatrick, J. C., â€¦ Korenstein, R. (2013). Predictive Toxicology of cobalt ferrite nanoparticles: Comparative in-vitro study of different cellular models using methods of knowledge discovery from data. Particle and Fibre Toxicology, 10(1). http://doi.org/10.1186/1743-8977-10-32"@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_80a a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Multiple Linear Regression"@en ] ;
    dcterms:source <http://doi.org/10.1016/j.jiec.2013.08.011> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_80a/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_80a/Endpoint> ;
    rdfs:comment "The results of examination of the time on experimental adsorption data and fitting the data to conventional kinetic model show the suitability of pseudo-second order and intraparticle diffusion model. Evaluation of the experimental equilibrium data by Langmuir, Tempkin, Freundlich and Dubinin Radushkevich (D-R) isotherm explore that Langmuir is superior to other model for fitting the experimental data in term of higher correlation coefficient and lower error analysis."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_80b a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Least-Squares Support Vector Machine"@en ] ;
    dcterms:source <http://doi.org/10.1016/j.jiec.2013.08.011> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_80b/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_80b/Endpoint> ;
    rdfs:comment "The results of examination of the time on experimental adsorption data and fitting the data to conventional kinetic model show the suitability of pseudo-second order and intraparticle diffusion model. Evaluation of the experimental equilibrium data by Langmuir, Tempkin, Freundlich and Dubinin Radushkevich (D-R) isotherm explore that Langmuir is superior to other model for fitting the experimental data in term of higher correlation coefficient and lower error analysis."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_81 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Partial Least Square Regression"@en ] ;
    dcterms:source <http://doi.org/10.1021/nn406018q> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_81/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_81/Endpoint> ;
    rdfs:comment "The relative abundance of different protein corona were used as descriptors. Although they are not physicochemical descriptors it was concluded that protein corona encodes relevant biological information regarding cell association to the target NP. In addition to protein corona fingerprint, physicochemical parameter were sued to develop other models with the same procedure.Interestingly, a combined model that uses DLS, TEM, AS, and ZP along with the serum protein fingerprint predicts cell association with a Q^2_LOO of 0.86, which is only marginally more accurate than the model that uses the serum protein fingerprint alone, suggesting that the serum protein fingerprint encodes informa tion about the size, surface charge, and aggregation state of the nanoparticles. Hence, only the fingerprint descriptor model was classified in this table. A set f silver NPs was used yo test the model for Au NP, but it indicated that a model derived using Au NPs cannot be applied to accurately predict cell association of Ag. A mechanistic interpretation of the most relevant descriptors and general conclusion of the whole descriptors was developed in the publication."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_82 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "BuildQSAR software"@en ;
            skos:narrower "Genetic Algorithm and Multivariate Linear Regression"@en ] ;
    dcterms:source <http://doi.org/10.3390/nano5020778> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_82/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_82/Endpoint> ;
    rdfs:comment "r_m^2 statistical values presented in the publication, which were in doubt to be taken into account due this statistical values have not yet established in the whole community."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_83 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "R software"@en ;
            skos:narrower "Multiple Linear Regression"@en ] ;
    dcterms:source <http://doi.org/10.2174/1568026615666150506152808> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_83/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_83/Endpoint> ;
    rdfs:comment "Ag NPs data set was used to evaluate the predictivity of the model in other NPs. It was concluded that the model and the interaction is core specific. In orther to check if the methodology could be applied to generate a model for different core nanoparticles, the Ag NPs set was used, and relative good results were obtianed despite of the small size of the data set. Not external validation test was applied, hence we cannot say that the obtained results will be totally reliable. Close related with previous already reported publications in this table (C. D. Walkey et al., 2014 and Liu, R. et al., 2015) with a key difference in the way of how were treated the protein corona descriptors. The two fingerprint techniques have been compared by calculating the normalized mutual information index between the partitions obtained after clustering the nanoparticles represented in terms of each fingerprint approach. Clustering results indicate that the information conveyed by both fingerprints is essentially the same. In addition, the modelling approach proposed here for gold and silver nanoparticles outperforms models based only on relative abundances in terms of applicability, size and stability. There is a mechanistic interpretation for the final descriptors applied in the model."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_84 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Genetic Algorithm and Multivariate Linear Regression"@en ] ;
    dcterms:source <http://doi.org/10.1016/j.molliq.2015.01.028> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_84/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_84/Endpoint> ;
    rdfs:comment "In addition to the reported model an other model with different splitting compounds from the hierarchical clustering was performed ( it was known as Test set 2, while our reported model was the Test set 1). Also from the Genetic Algorithm procedure, different sets of descriptors for the Test set 1 were evaluated and the one which had the best performing was selected as the main model. Q^2_LGO: Leave-group-out corss-validation correlation coefficient was computed but the size of group was not reported, hence the value was ommited in this report. Also the modified r^2 ( (r_m)^2 ) was computed, after a revision of whole reported publications, it will be discussed if it will be reported or not. A widely explanation of Mechanistic Intepretation for each of the final descriptors was developed in the publication."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_85 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            bao:BAO_0090006 "QSARINS software"@en ;
            skos:narrower "Genetic Algorithm Multiple Linear Regression"@en ] ;
    dcterms:source <http://doi.org/10.1021/cm504406a> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_85/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_85/Endpoint> ;
    rdfs:comment "Consensus nano-QSPR model based on seven different splits of data was performed. The idea to perform a consensus model it was to face the small size of data set. The goodness-of-fit and prediction ability of the consensus model were estimated on a single training and test set (for split 2, where both of NPs , TiO2 and In2O3, are in training data set, which also had the best individual performance). For individual models (each splitting) cross-validation leave-one-out was computed. A good Mechanistic Interpretation is presented."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_86 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Partial Least Squares"@en ] ;
    dcterms:source <http://doi.org/10.1007/s10910-015-0581-8> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_86/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_86/Endpoint> ;
    rdfs:comment "AD was verified with leverage approach and Williams plot, but the resulting plot was not reported neither the leverage threshold nor about any detected outlier from data set. A Mechanistic Interpretation of the final descriptors is presented."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSPR"@en ] .

kb:Model_87a a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Multiple Linear Regression"@en ] ;
    dcterms:source <http://doi.org/10.1080/1062936X.2016.1197310> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87a/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87a/Endpoint> ;
    rdfs:comment "Multiple machine learning approaches compared in this publication, brief explanation of the different techniques are present. Mechanistic Interpretation of results was provided."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_87b a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "k-Nearest Neighbour"@en ] ;
    dcterms:source <http://doi.org/10.1080/1062936X.2016.1197310> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87b/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87b/Endpoint> ;
    rdfs:comment "Multiple machine learning approaches compared in this publication, brief explanation of the different techniques are present. Mechanistic Interpretation of results was provided."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_87c a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "General Regression Neural Network"@en ] ;
    dcterms:source <http://doi.org/10.1080/1062936X.2016.1197310> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87c/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87c/Endpoint> ;
    rdfs:comment "Multiple machine learning approaches compared in this publication, brief explanation of the different techniques are present. Mechanistic Interpretation of results was provided."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_87d a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Radial Basis Function Neural Networks"@en ] ;
    dcterms:source <http://doi.org/10.1080/1062936X.2016.1197310> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87d/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87d/Endpoint> ;
    rdfs:comment "Multiple machine learning approaches compared in this publication, brief explanation of the different techniques are present. Mechanistic Interpretation of results was provided."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_87e a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Counter Propagation Neural Network"@en ] ;
    dcterms:source <http://doi.org/10.1080/1062936X.2016.1197310> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87e/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87e/Endpoint> ;
    rdfs:comment "Multiple machine learning approaches compared in this publication, brief explanation of the different techniques are present. Mechanistic Interpretation of results was provided."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_87f a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Support Vector Machine radial"@en ] ;
    dcterms:source <http://doi.org/10.1080/1062936X.2016.1197310> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87f/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87f/Endpoint> ;
    rdfs:comment "Multiple machine learning approaches compared in this publication, brief explanation of the different techniques are present. Mechanistic Interpretation of results was provided."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_87g a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Support Vector Machine linear"@en ] ;
    dcterms:source <http://doi.org/10.1080/1062936X.2016.1197310> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87g/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87g/Endpoint> ;
    rdfs:comment "Multiple machine learning approaches compared in this publication, brief explanation of the different techniques are present. Mechanistic Interpretation of results was provided."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_87h a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Partial Least Squares"@en ] ;
    dcterms:source <http://doi.org/10.1080/1062936X.2016.1197310> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87h/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87h/Endpoint> ;
    rdfs:comment "Multiple machine learning approaches compared in this publication, brief explanation of the different techniques are present. Mechanistic Interpretation of results was provided."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_87i a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Projection Pursuit Regression"@en ] ;
    dcterms:source <http://doi.org/10.1080/1062936X.2016.1197310> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87i/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87i/Endpoint> ;
    rdfs:comment "Multiple machine learning approaches compared in this publication, brief explanation of the different techniques are present. Mechanistic Interpretation of results was provided."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_87j a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Multivariate adaptive regression splines (MARS or EARTH)"@en ] ;
    dcterms:source <http://doi.org/10.1080/1062936X.2016.1197310> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87j/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87j/Endpoint> ;
    rdfs:comment "Multiple machine learning approaches compared in this publication, brief explanation of the different techniques are present. Mechanistic Interpretation of results was provided."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_87k a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Random Forest using 6 descriptors"@en ] ;
    dcterms:source <http://doi.org/10.1080/1062936X.2016.1197310> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87k/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87k/Endpoint> ;
    rdfs:comment "Multiple machine learning approaches compared in this publication, brief explanation of the different techniques are present. Mechanistic Interpretation of results was provided."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_87l a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Random Forest using 6 descriptors"@en ] ;
    dcterms:source <http://doi.org/10.1080/1062936X.2016.1197310> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87l/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87l/Endpoint> ;
    rdfs:comment "Multiple machine learning approaches compared in this publication, brief explanation of the different techniques are present. Mechanistic Interpretation of results was provided."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

kb:Model_9 a sbd:Model,
        sbd:resource ;
    mesh:mapped_from [ a nci:C16275 ;
            skos:narrower "Multiple Linear Regression"@en ] ;
    dcterms:source <http://doi.org/10.1038/nnano.2011.10> ;
    dcterms:subject <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_9/Nanoparticle> ;
    bao:BAO_0090004 <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_9/Endpoint> ;
    rdfs:comment "All quantum-mechanical calculations were performed using the PM6 method as implemented in MOPAC 2009 (semi-empirical method). Because the size of the metal oxides nanoparticles we tested (15 - 90 nm) was too large even to perform calculations at the semi-empirical level it was necessary to simplify the molecular models used for calculations of the descriptors. Mechanistic Interpretation was proposed, which improves the reliability of the model. Consistent paper in all the QSAR fields, as well described in OECD document for Validation QSAR. Supplementary material is a great example of QSAR methodology."@en ;
    skos:narrower [ a mesh:D021281 ;
            rdfs:label "QSAR"@en ] .

<http://doi.org/10.1002/smll.201002366> a sio:SIO_000176 ;
    dcterms:issued 2011 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Yoram Cohen" ] ;
    dcterms:title "Classification NanoSAR Development for Cytotoxicity of Metal Oxide Nanoparticles" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "Y. Cohen" ],
        [ a foaf:Person ;
            foaf:name "R. Rallo" ],
        [ a foaf:Person ;
            foaf:name "S. George" ],
        [ a foaf:Person ;
            foaf:name "R. Liu" ],
        [ a foaf:Person ;
            foaf:name "A. E. Nel" ],
        [ a foaf:Person ;
            foaf:name "Z. Ji" ],
        [ a foaf:Person ;
            foaf:name "S. Nair" ] .

<http://doi.org/10.1002/smll.201201903> a sio:SIO_000176 ;
    dcterms:issued 2013 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Yoram Cohen" ] ;
    dcterms:title "Nano-SAR Development for Bioactivity of Nanoparticles with Considerations of Decision Boundaries" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "R. Weissleder" ],
        [ a foaf:Person ;
            foaf:name "R. Liu" ],
        [ a foaf:Person ;
            foaf:name "Y. Cohen" ],
        [ a foaf:Person ;
            foaf:name "R. Rallo" ],
        [ a foaf:Person ;
            foaf:name "S. Shaw" ],
        [ a foaf:Person ;
            foaf:name "C. Tassa" ] .

<http://doi.org/10.1007/s10910-008-9514-0> a sio:SIO_000176 ;
    dcterms:issued 2009 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Andrey A. Toropov" ] ;
    dcterms:title "Additive InChI-based optimal descriptors: QSPR modeling of fullerene C60 solubility in organic solvents" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "A. A. Toropov" ],
        [ a foaf:Person ;
            foaf:name "D. Leszczynska" ],
        [ a foaf:Person ;
            foaf:name "E. Benfenati" ],
        [ a foaf:Person ;
            foaf:name "J. Leszczynski" ],
        [ a foaf:Person ;
            foaf:name "A. P. Toropova" ] .

<http://doi.org/10.1007/s10910-015-0581-8> a sio:SIO_000176 ;
    dcterms:issued 2016 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Natalia Sizochenko" ] ;
    dcterms:title "Introduction of simplex-informational descriptors for QSPR analysis of fullerene derivatives" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "J. Leszczynski" ],
        [ a foaf:Person ;
            foaf:name "V. Kuzâ€™min" ],
        [ a foaf:Person ;
            foaf:name "L. Ognichenko" ],
        [ a foaf:Person ;
            foaf:name "N. Sizochenko" ] .

<http://doi.org/10.1007/s10953-013-0062-2> a sio:SIO_000176 ;
    dcterms:issued 2013 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "S. Yousefinejad" ] ;
    dcterms:title "New LSER Model Based on Solvent Empirical Parameters for the Prediction and Description of the Solubility of Buckminsterfullerene in Various Solvents" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "Z. Arianezhad" ],
        [ a foaf:Person ;
            foaf:name "F. Honarasa" ],
        [ a foaf:Person ;
            foaf:name "F. Abbasitabar" ],
        [ a foaf:Person ;
            foaf:name "S. Yousefinejad" ] .

<http://doi.org/10.1007/s11030-010-9245-6> a sio:SIO_000176 ;
    dcterms:issued 2011 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Alla A. Toropova" ] ;
    dcterms:title "CORAL: QSPR models for solubility of [C60] and [C70] fullerene derivatives" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "D. Leszczynska" ],
        [ a foaf:Person ;
            foaf:name "E. Benfenati" ],
        [ a foaf:Person ;
            foaf:name "A. P. Toropova" ],
        [ a foaf:Person ;
            foaf:name "J. Leszczynski" ],
        [ a foaf:Person ;
            foaf:name "G. Gini" ],
        [ a foaf:Person ;
            foaf:name "A. A. Toropov" ] .

<http://doi.org/10.1007/s11051-011-0238-x> a sio:SIO_000176 ;
    dcterms:issued 2011 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Bakhtiyor F. Rasulev" ] ;
    dcterms:title "Improved model for fullerene C60 solubility in organic solvents based on quantum-chemical and topological descriptors" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "T. Petrova" ],
        [ a foaf:Person ;
            foaf:name "B. F. Rasulev" ],
        [ a foaf:Person ;
            foaf:name "J. Leszczynski" ],
        [ a foaf:Person ;
            foaf:name "A. A. Toropov" ],
        [ a foaf:Person ;
            foaf:name "D. Leszczynska" ] .

<http://doi.org/10.1007/s11051-014-2282-9> a sio:SIO_000176 ;
    dcterms:issued 2014 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "A.A Toropov" ] ;
    dcterms:title "QSAR model for cytotoxicity of SiO2 nanoparticles on human lung fibroblasts" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "A. P. Toropova" ],
        [ a foaf:Person ;
            foaf:name "R. Korenstein" ],
        [ a foaf:Person ;
            foaf:name "A. A. Toropov" ],
        [ a foaf:Person ;
            foaf:name "E. Benfenati" ] .

<http://doi.org/10.1007/s11051-015-3051-0> a sio:SIO_000176 ;
    dcterms:issued 2015 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Stacey Harper" ] ;
    dcterms:title "Comparative hazard analysis and toxicological modeling of diverse nanomaterials using the embryonic zebrafish (EZ) metric of toxicity" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "R. Lins" ],
        [ a foaf:Person ;
            foaf:name "N. Baker" ],
        [ a foaf:Person ;
            foaf:name "B. Harper" ],
        [ a foaf:Person ;
            foaf:name "S. Chikkagoudar" ],
        [ a foaf:Person ;
            foaf:name "S. Harper" ],
        [ a foaf:Person ;
            foaf:name "K. Tang" ],
        [ a foaf:Person ;
            foaf:name "D. Thomas" ],
        [ a foaf:Person ;
            foaf:name "A. Heredia-Langner" ] .

<http://doi.org/10.1007/s11356-014-3566-4> a sio:SIO_000176 ;
    dcterms:issued 2015 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "A.A Toropov" ] ;
    dcterms:title "Optimal nano-descriptors as translators of eclectic data into prediction of the cell membrane damage by means of nano metal-oxides" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "R. Korenstein" ],
        [ a foaf:Person ;
            foaf:name "A. A. Toropov" ],
        [ a foaf:Person ;
            foaf:name "E. Benfenati" ],
        [ a foaf:Person ;
            foaf:name "J. Leszczynski" ],
        [ a foaf:Person ;
            foaf:name "A. P. Toropova" ],
        [ a foaf:Person ;
            foaf:name "D. Leszczynska" ] .

<http://doi.org/10.1016/j.bmc.2008.10.039> a sio:SIO_000176 ;
    dcterms:issued 2008 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Serdar Durdagi" ] ;
    dcterms:title "Computational design of novel fullerene analogues as potential HIV-1 PR inhibitors: Analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamics simulations" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "T. Mavromoustakos" ],
        [ a foaf:Person ;
            foaf:name "M. G. Papadopoulos" ],
        [ a foaf:Person ;
            foaf:name "N. Chronakis" ],
        [ a foaf:Person ;
            foaf:name "S. Durdagi" ] .

<http://doi.org/10.1016/j.chemosphere.2012.05.077> a sio:SIO_000176 ;
    dcterms:issued 2012 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "A.A Toropov" ] ;
    dcterms:title "Novel application of the CORAL software to model cytotoxicity of metal oxide nanoparticles to bacteria Escherichia coli" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "D. Leszczynska" ],
        [ a foaf:Person ;
            foaf:name "A. P. Toropova" ],
        [ a foaf:Person ;
            foaf:name "G. Gini" ],
        [ a foaf:Person ;
            foaf:name "J. Leszczynski" ],
        [ a foaf:Person ;
            foaf:name "A. A. Toropov" ],
        [ a foaf:Person ;
            foaf:name "E. Benfenati" ],
        [ a foaf:Person ;
            foaf:name "T. Puzyn" ] .

<http://doi.org/10.1016/j.chemosphere.2013.03.012> a sio:SIO_000176 ;
    dcterms:issued 2013 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "A.A Toropov" ] ;
    dcterms:title "QSAR as a random event: Modeling of nanoparticles uptake in PaCa2 cancer cells" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "D. Leszczynska" ],
        [ a foaf:Person ;
            foaf:name "T. Puzyn" ],
        [ a foaf:Person ;
            foaf:name "G. Gini" ],
        [ a foaf:Person ;
            foaf:name "A. A. Toropov" ],
        [ a foaf:Person ;
            foaf:name "E. Benfenati" ],
        [ a foaf:Person ;
            foaf:name "A. P. Toropova" ],
        [ a foaf:Person ;
            foaf:name "J. Leszczynski" ] .

<http://doi.org/10.1016/j.chemosphere.2013.09.089> a sio:SIO_000176 ;
    dcterms:issued 2013 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "A.A Toropov" ] ;
    dcterms:title "Optimal descriptor as a translator of eclectic information into the prediction of membrane damage by means of various TiO2 nanoparticles" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "A. P. Toropova" ],
        [ a foaf:Person ;
            foaf:name "A. A. Toropov" ] .

<http://doi.org/10.1016/j.chemosphere.2013.10.079> a sio:SIO_000176 ;
    dcterms:issued 2014 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "A.A Toropov" ] ;
    dcterms:title "Optimal descriptor as a translator of eclectic data into endpoint prediction: Mutagenicity of fullerene as a mathematical function of conditions" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "A. A. Toropov" ],
        [ a foaf:Person ;
            foaf:name "A. P. Toropova" ] .

<http://doi.org/10.1016/j.chemosphere.2014.10.067> a sio:SIO_000176 ;
    dcterms:issued 2015 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "A.A Toropov" ] ;
    dcterms:title "Quasi-QSAR for mutagenic potential of multi-walled carbon-nanotubes" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "A. A. Toropov" ],
        [ a foaf:Person ;
            foaf:name "A. P. Toropova" ] .

<http://doi.org/10.1016/j.chemosphere.2015.05.042> a sio:SIO_000176 ;
    dcterms:issued 2015 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "A.A Toropov" ] ;
    dcterms:title "Quasi-SMILES and nano-QFAR: United model for mutagenicity of fullerene and MWCNT under different conditions" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "A. A. Toropov" ],
        [ a foaf:Person ;
            foaf:name "A. P. Toropova" ] .

<http://doi.org/10.1016/j.cplett.2007.04.094> a sio:SIO_000176 ;
    dcterms:issued 2007 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Andrey A. Toropov" ] ;
    dcterms:title "QSPR study on solubility of fullerene C60 in organic solvents using optimal descriptors calculated with SMILES" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "A. A. Toropov" ],
        [ a foaf:Person ;
            foaf:name "D. Leszczynska" ],
        [ a foaf:Person ;
            foaf:name "J. Leszczynski" ] .

<http://doi.org/10.1016/j.cplett.2007.07.024> a sio:SIO_000176 ;
    dcterms:issued 2007 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Andrey A. Toropov" ] ;
    dcterms:title "Additive SMILES based optimal descriptors: QSPR modeling of fullerene C60 solubility in organic solvents" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "A. A. Toropov" ],
        [ a foaf:Person ;
            foaf:name "B. F. Rasulev" ],
        [ a foaf:Person ;
            foaf:name "D. Leszczynska" ],
        [ a foaf:Person ;
            foaf:name "J. Leszczynski" ] .

<http://doi.org/10.1016/j.cplett.2008.04.013> a sio:SIO_000176 ;
    dcterms:issued 2008 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Andrey A. Toropov" ] ;
    dcterms:title "Multiplicative SMILES-based optimal descriptors: QSPR modeling of fullerene C60 solubility in organic solvents" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "A. A. Toropov" ],
        [ a foaf:Person ;
            foaf:name "B. F. Rasulev" ],
        [ a foaf:Person ;
            foaf:name "J. Leszczynski" ],
        [ a foaf:Person ;
            foaf:name "D. Leszczynska" ] .

<http://doi.org/10.1016/j.ecoenv.2014.10.003> a sio:SIO_000176 ;
    dcterms:issued 2015 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "A.A Toropov" ] ;
    dcterms:title "Optimal descriptor as a translator of eclectic data into prediction of cytotoxicity for metal oxide nanoparticles under different conditions" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "D. Leszczynska" ],
        [ a foaf:Person ;
            foaf:name "A. A. Toropov" ],
        [ a foaf:Person ;
            foaf:name "J. Leszczynski" ],
        [ a foaf:Person ;
            foaf:name "R. Rallo" ],
        [ a foaf:Person ;
            foaf:name "A. P. Toropova" ] .

<http://doi.org/10.1016/j.envint.2014.08.009> a sio:SIO_000176 ;
    dcterms:issued 2014 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "A. Speck-Planche" ],
        [ a foaf:Person ;
            foaf:name "M.N.D.S. Cordeiro" ] ;
    dcterms:title "Computational ecotoxicology: Simultaneous prediction of ecotoxic effects of nanoparticles under different experimental conditions" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "V. V. Kleandrova" ],
        [ a foaf:Person ;
            foaf:name "M. N. D. S. Cordeiro" ],
        [ a foaf:Person ;
            foaf:name "F. Luan" ],
        [ a foaf:Person ;
            foaf:name "H. GonzÃ¡lez-DÃ­az" ],
        [ a foaf:Person ;
            foaf:name "J. M. Ruso" ],
        [ a foaf:Person ;
            foaf:name "A. Melo" ],
        [ a foaf:Person ;
            foaf:name "A. Speck-Planche" ] .

<http://doi.org/10.1016/j.impact.2016.04.003> a sio:SIO_000176 ;
    dcterms:issued 2016 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "A.P. Toropova" ] ;
    dcterms:title "Quasi-SMILES as a tool to utilize eclectic data for predicting the behavior of nanomaterials" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "S. Manganelli" ],
        [ a foaf:Person ;
            foaf:name "C. Leone" ],
        [ a foaf:Person ;
            foaf:name "R. Fanelli" ],
        [ a foaf:Person ;
            foaf:name "A. A. Toropov" ],
        [ a foaf:Person ;
            foaf:name "A. P. Toropova" ],
        [ a foaf:Person ;
            foaf:name "D. Baderna" ],
        [ a foaf:Person ;
            foaf:name "E. Benfenati" ] .

<http://doi.org/10.1016/j.molliq.2015.01.028> a sio:SIO_000176 ;
    dcterms:issued 2015 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Eslam Pourbasheer" ] ;
    dcterms:title "QSPR study on solubility of some fullerenes derivatives using the genetic algorithms â€” Multiple linear regression" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "J. S. Ardabili" ],
        [ a foaf:Person ;
            foaf:name "E. Pourbasheer" ],
        [ a foaf:Person ;
            foaf:name "M. R. Ganjali" ],
        [ a foaf:Person ;
            foaf:name "R. Aalizadeh" ] .

<http://doi.org/10.1016/j.proeng.2015.01.284> a sio:SIO_000176 ;
    dcterms:issued 2015 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Xue Z. Wang" ] ;
    dcterms:title "Structure-activity Relationship Models for Hazard Assessment and Risk Management of Engineered Nanomaterials" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "X. Z. Wang" ],
        [ a foaf:Person ;
            foaf:name "C. Y. Ma" ],
        [ a foaf:Person ;
            foaf:name "C. Oksel" ] .

<http://doi.org/10.1016/j.tiv.2013.12.018> a sio:SIO_000176 ;
    dcterms:issued 2014 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Kunal Roy" ] ;
    dcterms:title "Nano-quantitative structureâ€“activity relationship modeling using easily computable and interpretable descriptors for uptake of magnetofluorescent engineered nanoparticles in pancreatic cancer cells" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "S. Kar" ],
        [ a foaf:Person ;
            foaf:name "A. Gajewicz" ],
        [ a foaf:Person ;
            foaf:name "T. Puzyn" ],
        [ a foaf:Person ;
            foaf:name "K. Roy" ] .

<http://doi.org/10.1021/ci3005308> a sio:SIO_000176 ;
    dcterms:issued 2013 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Yufeng J. Tseng" ] ;
    dcterms:title "Dependence of QSAR Models on the Selection of Trial Descriptor Sets: A Demonstration Using Nanotoxicity Endpoints of Decorated Nanotubes" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "A. J. Hopfinger" ],
        [ a foaf:Person ;
            foaf:name "E. X. Esposito" ],
        [ a foaf:Person ;
            foaf:name "B.-H. Su" ],
        [ a foaf:Person ;
            foaf:name "Y. J. Tseng" ],
        [ a foaf:Person ;
            foaf:name "S.-Z. Chen" ],
        [ a foaf:Person ;
            foaf:name "C.-Y. Shao" ] .

<http://doi.org/10.1021/cm504406a> a sio:SIO_000176 ;
    dcterms:issued 2015 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Tomasz Puzyn" ] ;
    dcterms:title "Zeta Potential for Metal Oxide Nanoparticles: A Predictive Model Developed by a Nano-Quantitative Structureâ€“Property Relationship Approach" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "A. Mikolajczyk" ],
        [ a foaf:Person ;
            foaf:name "N. Schaeublin" ],
        [ a foaf:Person ;
            foaf:name "T. Puzyn" ],
        [ a foaf:Person ;
            foaf:name "A. Gajewicz" ],
        [ a foaf:Person ;
            foaf:name "B. Rasulev" ],
        [ a foaf:Person ;
            foaf:name "J. Leszczynski" ],
        [ a foaf:Person ;
            foaf:name "E. Maurer-Gardner" ],
        [ a foaf:Person ;
            foaf:name "S. Hussain" ] .

<http://doi.org/10.1021/es503861x> a sio:SIO_000176 ;
    dcterms:issued 2014 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "M.N.D.S. Cordeiro" ],
        [ a foaf:Person ;
            foaf:name "A. Speck-Planche" ] ;
    dcterms:title "Computational Tool for Risk Assessment of Nanomaterials: Novel QSTR-Perturbation Model for Simultaneous Prediction of Ecotoxicity and Cytotoxicity of Uncoated and Coated Nanoparticles under Multiple Experimental Conditions" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "H. GonzÃ¡lez-DÃ­az" ],
        [ a foaf:Person ;
            foaf:name "J. M. Ruso" ],
        [ a foaf:Person ;
            foaf:name "A. Speck-Planche" ],
        [ a foaf:Person ;
            foaf:name "V. V. Kleandrova" ],
        [ a foaf:Person ;
            foaf:name "M. N. D. S. Cordeiro" ],
        [ a foaf:Person ;
            foaf:name "F. Luan" ] .

<http://doi.org/10.1021/jp000739v> a sio:SIO_000176 ;
    dcterms:issued 2000 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "IstvÃ¡n. Z. Kiss" ] ;
    dcterms:title "Artificial Neural Network Approach to Predict the Solubility of C60 in Various Solvents" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "I. Z. Kiss" ],
        [ a foaf:Person ;
            foaf:name "G. MÃ¡ndi" ],
        [ a foaf:Person ;
            foaf:name "M. T. Beck" ] .

<http://doi.org/10.1021/nn203303c> a sio:SIO_000176 ;
    dcterms:issued 2011 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Jim E. Riviere" ] ;
    dcterms:title "Mapping the Surface Adsorption Forces of Nanomaterials in Biological Systems" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "X. Song" ],
        [ a foaf:Person ;
            foaf:name "B. Fadeel" ],
        [ a foaf:Person ;
            foaf:name "N. A. Monteiro-Riviere" ],
        [ a foaf:Person ;
            foaf:name "X. R. Xia" ],
        [ a foaf:Person ;
            foaf:name "S. Mathur" ],
        [ a foaf:Person ;
            foaf:name "J. E. Riviere" ],
        [ a foaf:Person ;
            foaf:name "S. J. Oldenberg" ],
        [ a foaf:Person ;
            foaf:name "L. Xiao" ] .

<http://doi.org/10.1021/nn3010087> a sio:SIO_000176 ;
    dcterms:issued 2012 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Andre E. Nel" ] ;
    dcterms:title "Use of Metal Oxide Nanoparticle Band Gap To Develop a Predictive Paradigm for Oxidative Stress and Acute Pulmonary Inflammation" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "Z. Ji" ],
        [ a foaf:Person ;
            foaf:name "A. E. Nel" ],
        [ a foaf:Person ;
            foaf:name "R. Damoiseaux" ],
        [ a foaf:Person ;
            foaf:name "Y. Cohen" ],
        [ a foaf:Person ;
            foaf:name "H. Zhang" ],
        [ a foaf:Person ;
            foaf:name "S. Lin" ],
        [ a foaf:Person ;
            foaf:name "C. Low-Kam" ],
        [ a foaf:Person ;
            foaf:name "X. Wang" ],
        [ a foaf:Person ;
            foaf:name "T. Xia" ],
        [ a foaf:Person ;
            foaf:name "Y.-P. Liao" ],
        [ a foaf:Person ;
            foaf:name "H. Meng" ],
        [ a foaf:Person ;
            foaf:name "D. Telesca" ],
        [ a foaf:Person ;
            foaf:name "L. Li" ],
        [ a foaf:Person ;
            foaf:name "S. Pokhrel" ],
        [ a foaf:Person ;
            foaf:name "R. Rallo" ],
        [ a foaf:Person ;
            foaf:name "J. I. Zink" ],
        [ a foaf:Person ;
            foaf:name "L. MÃ¤dler" ],
        [ a foaf:Person ;
            foaf:name "R. Liu" ],
        [ a foaf:Person ;
            foaf:name "M. Wang" ] .

<http://doi.org/10.1021/nn406018q> a sio:SIO_000176 ;
    dcterms:issued 2014 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Warren C. W. Chan" ] ;
    dcterms:title "Protein Corona Fingerprinting Predicts the Cellular Interaction of Gold and Silver Nanoparticles" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "R. Liu" ],
        [ a foaf:Person ;
            foaf:name "Y. Cohen" ],
        [ a foaf:Person ;
            foaf:name "A. Emili" ],
        [ a foaf:Person ;
            foaf:name "C. D. Walkey" ],
        [ a foaf:Person ;
            foaf:name "F. Song" ],
        [ a foaf:Person ;
            foaf:name "J. B. Olsen" ],
        [ a foaf:Person ;
            foaf:name "W. C. W. Chan" ],
        [ a foaf:Person ;
            foaf:name "D. W. H. Olsen" ],
        [ a foaf:Person ;
            foaf:name "H. Guo" ] .

<http://doi.org/10.1038/nnano.2011.10> a sio:SIO_000176 ;
    dcterms:issued 2011 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Jerzy Leszczynski" ] ;
    dcterms:title "Using nano-QSAR to predict the cytotoxicity of metal oxide nanoparticles" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "B. Rasulev" ],
        [ a foaf:Person ;
            foaf:name "A. Gajewicz" ],
        [ a foaf:Person ;
            foaf:name "X. Hu" ],
        [ a foaf:Person ;
            foaf:name "H.-M. Hwang" ],
        [ a foaf:Person ;
            foaf:name "T. Puzyn" ],
        [ a foaf:Person ;
            foaf:name "A. Toropov" ],
        [ a foaf:Person ;
            foaf:name "T. P. Dasari" ],
        [ a foaf:Person ;
            foaf:name "A. Michalkova" ],
        [ a foaf:Person ;
            foaf:name "J. Leszczynski" ],
        [ a foaf:Person ;
            foaf:name "D. Leszczynska" ] .

<http://doi.org/10.1039/c2ra21489j> a sio:SIO_000176 ;
    dcterms:issued 2012 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Chun Wei Yap" ] ;
    dcterms:title "Quantitative Nanostructureâ€“Activity Relationship modelling of nanoparticles" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "Y. T. Chau" ],
        [ a foaf:Person ;
            foaf:name "C. W. Yap" ] .

<http://doi.org/10.1039/c3nr01533e> a sio:SIO_000176 ;
    dcterms:issued 2013 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Yoram Cohen" ] ;
    dcterms:title "Development of structureâ€“activity relationship for metal oxide nanoparticles" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "C. H. Chang" ],
        [ a foaf:Person ;
            foaf:name "T. Xia" ],
        [ a foaf:Person ;
            foaf:name "Z. X. Ji" ],
        [ a foaf:Person ;
            foaf:name "H. Y. Zhang" ],
        [ a foaf:Person ;
            foaf:name "A. Nel" ],
        [ a foaf:Person ;
            foaf:name "R. Rallo" ],
        [ a foaf:Person ;
            foaf:name "R. Liu" ],
        [ a foaf:Person ;
            foaf:name "Y. Cohen" ] .

<http://doi.org/10.1039/c4ra07756c> a sio:SIO_000176 ;
    dcterms:issued 2014 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "A. Afantitis" ],
        [ a foaf:Person ;
            foaf:name "G. Melagraki" ] ;
    dcterms:title "Enalos InSilicoNano platform: an online decision support tool for the design and virtual screening of nanoparticles" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "A. Afantitis" ],
        [ a foaf:Person ;
            foaf:name "G. Melagraki" ] .

<http://doi.org/10.1039/c5ra06198a> a sio:SIO_000176 ;
    dcterms:issued 2015 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Mohammad Reza Hormozi-Nezhad" ] ;
    dcterms:title "Using nano-QSAR to determine the most responsible factor(s) in gold nanoparticle exocytosis" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "H. Parastar" ],
        [ a foaf:Person ;
            foaf:name "A. Bigdeli" ],
        [ a foaf:Person ;
            foaf:name "M. R. Hormozi-Nezhad" ] .

<http://doi.org/10.1080/1536383X.2012.702157> a sio:SIO_000176 ;
    dcterms:issued 2014 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Jahan B. Ghasemi" ] ;
    dcterms:title "An Alignment Independent 3D-QSAR Modeling of Dispersibility of Single-walled Carbon Nanotubes in Different Organic Solvents" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "M. Salahinejad" ],
        [ a foaf:Person ;
            foaf:name "J. B. Ghasemi" ],
        [ a foaf:Person ;
            foaf:name "M. K. Rofouei" ] .

<http://doi.org/10.1080/17435390.2016.1202352> a sio:SIO_000176 ;
    dcterms:issued 2016 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Fengchang Wu" ] ;
    dcterms:title "Predicting toxic potencies of metal oxide nanoparticles by means of nano-QSARs" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "Y. Qie" ],
        [ a foaf:Person ;
            foaf:name "Y. Mu" ],
        [ a foaf:Person ;
            foaf:name "F. Wu" ],
        [ a foaf:Person ;
            foaf:name "Q. Zhao" ],
        [ a foaf:Person ;
            foaf:name "J. P. Giesy" ],
        [ a foaf:Person ;
            foaf:name "B. Xing" ],
        [ a foaf:Person ;
            foaf:name "Y. Hu" ],
        [ a foaf:Person ;
            foaf:name "D. Hristozov" ],
        [ a foaf:Person ;
            foaf:name "C. Pang" ],
        [ a foaf:Person ;
            foaf:name "R. Ji" ],
        [ a foaf:Person ;
            foaf:name "Y. Zhou" ] .

<http://doi.org/10.1093/toxsci/kfr124> a sio:SIO_000176 ;
    dcterms:issued 2011 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Rafi Korenstein" ] ;
    dcterms:title "Predictive Toxicology of Cobalt Nanoparticles and Ions: Comparative In Vitro Study of Different Cellular Models Using Methods of Knowledge Discovery from Data" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "R. E. Unger" ],
        [ a foaf:Person ;
            foaf:name "C. Villiers" ],
        [ a foaf:Person ;
            foaf:name "C. J. Kirkpatrick" ],
        [ a foaf:Person ;
            foaf:name "F. Rossi" ],
        [ a foaf:Person ;
            foaf:name "D. Sommer" ],
        [ a foaf:Person ;
            foaf:name "O. Maimon" ],
        [ a foaf:Person ;
            foaf:name "L. Horev-Azaria" ],
        [ a foaf:Person ;
            foaf:name "U. Golla-Schindler" ],
        [ a foaf:Person ;
            foaf:name "C. Uboldi" ],
        [ a foaf:Person ;
            foaf:name "J. Ponti" ],
        [ a foaf:Person ;
            foaf:name "P. N. Marche" ],
        [ a foaf:Person ;
            foaf:name "R. Korenstein" ],
        [ a foaf:Person ;
            foaf:name "R. Romano" ] .

<http://doi.org/10.2174/1568026615666150506144536> a sio:SIO_000176 ;
    dcterms:issued 2015 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "G. Melagraki" ],
        [ a foaf:Person ;
            foaf:name "A. Afantitis" ] ;
    dcterms:title "A Risk Assessment Tool for the Virtual Screening of Metal Oxide Nanoparticles through Enalos InSilicoNano Platform" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "A. Afantitis" ],
        [ a foaf:Person ;
            foaf:name "G. Melagraki" ] .

<http://doi.org/10.2174/1568026615666150506152808> a sio:SIO_000176 ;
    dcterms:issued 2015 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Robert Rallo" ] ;
    dcterms:title "Predicting Cell Association of Surface-Modified Nanoparticles Using Protein Corona Structure - Activity Relationships (PCSAR)" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "A. Fernandez" ],
        [ a foaf:Person ;
            foaf:name "R. Rallo" ],
        [ a foaf:Person ;
            foaf:name "F. Giralt" ],
        [ a foaf:Person ;
            foaf:name "P. Kamath" ] .

<http://doi.org/10.2217/nnm.14.96> a sio:SIO_000176 ;
    dcterms:issued 2015 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "A. Speck-Planche" ] ;
    dcterms:title "Computational modeling in nanomedicine: prediction of multiple antibacterial profiles of nanoparticles using a quantitative structureâ€“activity relationship perturbation model" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "V. V. Kleandrova" ],
        [ a foaf:Person ;
            foaf:name "A. Speck-Planche" ],
        [ a foaf:Person ;
            foaf:name "F. Luan" ],
        [ a foaf:Person ;
            foaf:name "M. N. Ds Cordeiro" ] .

<http://doi.org/10.3109/17435390.2010.502980> a sio:SIO_000176 ;
    dcterms:issued 2011 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Enrico Burello" ] ;
    dcterms:title "A theoretical framework for predicting the oxidative stress potential of oxide nanoparticles" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "E. Burello" ],
        [ a foaf:Person ;
            foaf:name "A. P. Worth" ] .

<http://doi.org/10.3109/17435390.2014.930195> a sio:SIO_000176 ;
    dcterms:issued 2015 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Jerzy Leszczynski" ] ;
    dcterms:title "Towards understanding mechanisms governing cytotoxicity of metal oxides nanoparticles: Hints from nano-QSAR studies" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "J. Leszczynski" ],
        [ a foaf:Person ;
            foaf:name "A. Gajewicz" ],
        [ a foaf:Person ;
            foaf:name "N. Schaeublin" ],
        [ a foaf:Person ;
            foaf:name "S. Hussain" ],
        [ a foaf:Person ;
            foaf:name "D. Leszczynska" ],
        [ a foaf:Person ;
            foaf:name "T. Puzyn" ],
        [ a foaf:Person ;
            foaf:name "B. Rasulev" ] .

<http://doi.org/10.3109/17435390.2016.1161861> a sio:SIO_000176 ;
    dcterms:issued 2016 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Xue Z. Wang" ] ;
    dcterms:title "Accurate and interpretable nanoSAR models from genetic programming-based decision tree construction approaches" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "X. Z. Wang" ],
        [ a foaf:Person ;
            foaf:name "C. Y. Ma" ],
        [ a foaf:Person ;
            foaf:name "D. A. Winkler" ],
        [ a foaf:Person ;
            foaf:name "T. Wilkins" ],
        [ a foaf:Person ;
            foaf:name "C. Oksel" ] .

<http://doi.org/10.3390/nano5020778> a sio:SIO_000176 ;
    dcterms:issued 2015 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Hayriye Yilmaz" ] ;
    foaf:maker [ a foaf:Person ;
            foaf:name "H. R. B. L. J. M. t. D. o. S. W. C. N. i. O. S. b. Q. S.-A. R. A. Yilmaz" ] .

<http://doi.org/10.3762/bjnano.6.160> a sio:SIO_000176 ;
    dcterms:issued 2015 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Stacey Harper" ] ;
    dcterms:title "Influence of surface chemical properties on the toxicity of engineered zinc oxide nanoparticles to embryonic zebrafish" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "Z. Zhou" ],
        [ a foaf:Person ;
            foaf:name "Z. Zhou" ],
        [ a foaf:Person ;
            foaf:name "J. Son" ],
        [ a foaf:Person ;
            foaf:name "B. Harper" ],
        [ a foaf:Person ;
            foaf:name "S. Harper" ] .

<http://doi.org/http://dx.doi.org/10.1016/j.cplett.2006.11.010> a sio:SIO_000176 ;
    dcterms:issued 2006 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Andrey A. Toropov" ] ;
    dcterms:title "A new approach to the characterization of nanomaterials: Predicting Youngâ€™s modulus by correlation weighting of nanomaterials codes" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "J. Leszczynski" ],
        [ a foaf:Person ;
            foaf:name "A. A. Toropov" ] .

mesh:C0053349 rdfs:label "Beryyllium oxide" .

mesh:C0174148 rdfs:label "Barium oxide" .

mesh:C040225 rdfs:label "Disilver Oxide Ag2O" .

mesh:C042120 rdfs:label "Arsenic pentoxide" .

mesh:C569492 rdfs:label "cobalt ferrite (CoFe2O4)" .

npo:NPO_1150 rdfs:label "FeO" .

enm:ENM_9000248 rdfs:label "Cobalt nanoparticle" .

obo:CHEBI_23336 rdfs:label "Cobalt cations" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_10/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as log(1/EC50)"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Determined the cytotoxicity of the metal oxide nanoparticles in terms of EC50 (concentration which cytotoxicity reduces bacteria viability up to 50%) based on the curve fitting least squares procedure."@en ;
    skos:narrower mesh:D004926 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_10/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_10/Nanoparticle/Size> ;
    skos:narrower npo:NPO_1373,
        npo:NPO_1486,
        npo:NPO_1542,
        npo:NPO_1550,
        enm:ENM_0000118,
        obo:CHEBI_30187,
        pubchem:14776,
        pubchem:14794,
        pubchem:14805,
        pubchem:14829,
        pubchem:150906,
        pubchem:157925,
        pubchem:159375,
        pubchem:166955,
        pubchem:29131,
        pubchem:518712,
        pubchem:62762 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_10/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "15-90" ;
            sbd:lower_limit "15" ;
            sbd:upper_limit "90" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_11/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a npo:NPO_296 ;
            rdfs:label "Cellular uptake of extracellular material"@en ;
            rdfs:comment "measured as log(pM) /cell"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Cellular uptake is expressed as decadic logarithm of the concentration (pM) of NP per cell The cellular uptakes in PaCa2 for the 105 nanoparticles were ranged from 170 to 27 542 nanoparticles per cell. A total of 56 nanoparticles with cellular uptake of more than 5000 nanoparticles per cell were considered to have good/moderate (henceforth referred to as good for brevity) cellular uptake (positive class), while 49 nanoparticles with cellular uptake of less than 5000 nanoparticles per cellwere considered to have poor cellular uptake (negative class)"@en ;
    skos:narrower "Pancreatic human cancer cells (PaCa2)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_11/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "2-ammonio-3-(4-hydroxyphenyl)propanoate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:97914 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7923 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:72794 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:617 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78480 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8102 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78232 ],
        [ a npo:NPO_1962 ;
            skos:narrower "3-Methylidenedihydrofuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:3301 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:75498 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:70728 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:70334 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78479 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7719 ],
        [ a npo:NPO_1962 ;
            skos:narrower "3-Phenyldihydro-2Hpyran-2,6(3H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:17386 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8111 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:96196 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8265 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:76247 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12443 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:587821 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:750 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78218 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:75737 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:611 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:738 ],
        [ a npo:NPO_1962 ;
            skos:narrower "6-Nitro-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:74960 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1148 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:239163 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:220977 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:98484 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:424 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:2794246 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:994 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:587821 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:428 ],
        [ a npo:NPO_1962 ;
            skos:narrower "N-(2-Aminoethyl)-N'-(3-aminopropyl)butane-1,4-diamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:25160 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1,4,5, 8-Naphthalenetetracarboxylic acidanhydride"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69527 ],
        [ a npo:NPO_1962 ;
            skos:narrower "4 3,3-Dimethyldihydrofuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:16402 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:866 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5-Nitro-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5603 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Amino-3-(1Himidazol-4-yl)propanoic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:76074 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:513918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:25332 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:65729 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5610 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:85689 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:19990 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10946 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:79882 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5,6-Dihydro-1Hcyclopenta[c]furan-1,3(4H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:79743 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8359 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:205 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:67742 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5-amino-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:16217 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1182 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:15659773 ],
        [ a npo:NPO_1962 ;
            skos:narrower "6-Bromo-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:232 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12801 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:21631 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6385 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7894 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6558 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69339 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:602 ],
        [ a npo:NPO_1962 ;
            skos:narrower "4-Methyldihydro-2Hpyran-2,6(3H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7940 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:11089 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:513917 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:74918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:9845 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12019 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:681 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1045 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Tetrahydrofuro[3',4':3,4]cyclobuta[1,2-c]furan-1,3,4,6-tetrone"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69545 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:230976 ],
        [ a npo:NPO_1962 ;
            skos:narrower "7 3,4-Dimethylfuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:96580 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7908 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8926 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7922 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:88069 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:102679 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:20051 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8326 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12012 ],
        [ a npo:NPO_1962 ;
            skos:narrower "{Bis[2-(2,6-dioxomorpholin-4-yl)ethyl]amino}acetic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6811 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8060 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6810 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:866 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:95411 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:68986 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12475 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:876 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:2733254 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:86625 ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_11/Nanoparticle/Size> ;
    skos:narrower npo:NPO_729 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_11/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "38" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_12/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured by the area under the curve of dose-response on HTS assay"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "The multi-parameter fluorescence assay by HTS, which quantitatively assesses changes in ROS production (DCF and Mitoses red fluorescence), intracellular calcium flux (Fluo-4 fluorescence), mitochondrial membrane potential (JC-1 fluorescence), and surface membrane permeability (PI uptake) in BEAS-2B and RAW 264.7 cells. Established dose-response curves using nonparametric smoothing splines and summarized each trajectory with the area under the estimated dose-response curve. They related cytotoxicty (as measured by area under the curve) to conduction energy (Ec) and metal dissolution (dissolution in BEGM) in a regression tree model."@en ;
    skos:narrower "Human bronchial epithelial cells (BEAS-2B)",
        "Rat alveolar macrophage cells (RAW264.7)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_12/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_12/Nanoparticle/Size> ;
    skos:narrower npo:NPO_1373,
        npo:NPO_1486,
        npo:NPO_1542,
        npo:NPO_1548,
        npo:NPO_1550,
        enm:ENM_0000118,
        enm:ENM_9000254,
        obo:CHEBI_30187,
        pubchem:10855842,
        pubchem:14794,
        pubchem:14805,
        pubchem:14811,
        pubchem:14824,
        pubchem:14829,
        pubchem:150906,
        pubchem:157925,
        pubchem:159375,
        pubchem:159385,
        pubchem:159423,
        pubchem:160959,
        pubchem:166955,
        pubchem:29131,
        pubchem:62762,
        pubchem:73971 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_12/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "10-100" ;
            sbd:lower_limit "10" ;
            sbd:upper_limit "100" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_13/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as cellular viability by determining the mitochondrial dehydrogenasesâ€™ activity"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Also there was a study of immune response of macrophages and binding proteins to nanotubes as other endpoints, further, the sum over all the endpoints was been evaluated. To evaluate the acute cytotoxicity (Cell) of theDNClibrary in macrophages, Zhou et al., used the WST-1 assay. Cellular viability was measured by determining the mitochondrial dehydrogenasesâ€™ activity, in the presence and absence of the nanotubeâˆ’decorator complexes and expressed on a 0 to 100 scale (100 most â€œtoxicâ€). The immune response was measured by treating macrophages with DNC for 24 h in a solution of lipopolysaccharide"@en ;
    skos:narrower "THP-1 (human monocytic cell line) differenciate into Macrophages" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_13/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower pubchem:51147965 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:51148259 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5205930 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:47097636 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:51148276 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:303942 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:51148039 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:46744931 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:3496505 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:4528484 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:3393128 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:3618978 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:47099540 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:24101749 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:112762823 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:60407577 ] ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_461 ],
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_13/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_13/Nanoparticle/Size_2> ;
    skos:narrower "Decorator-nanotube complexes" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_13/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "30.0-50.0" ;
            sbd:lower_limit "30.0" ;
            sbd:upper_limit "50.0" ] ;
    skos:narrower obo:PATO_0001334 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_13/Nanoparticle/Size_2> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "130.0-370.0" ;
            sbd:lower_limit "130.0" ;
            sbd:upper_limit "370.0" ] ;
    skos:narrower obo:PATO_0000122 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_14/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured by the the curve of dose-response and consensus Self-Organizing Map clustering on SPS and HTS assay"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Toxicological responses of twenty-four metal oxide NPs (over a concentration range of 0.39â€“100 mg L^(-1)) on RAW 264.7 and BEAS-2B cell lines, using both single parameter screening (SPS) assays (MTS, ATP and LDH) and multi-parameter high-throughput screening (HTS) assays (Mito, Fluo4, JC1, and PI over exposure time of 1â€“24 h) Toxicity class definition derived based on both doseâ€“response analysis and consensus Self-Organizing Map clustering."@en ;
    skos:narrower "Human bronchial epithelial cells (BEAS-2B)",
        "Rat alveolar macrophage cells (RAW264.7)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_14/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_14/Nanoparticle/Size> ;
    skos:narrower npo:NPO_1373,
        npo:NPO_1486,
        npo:NPO_1542,
        npo:NPO_1548,
        npo:NPO_1550,
        enm:ENM_0000118,
        enm:ENM_9000254,
        obo:CHEBI_30187,
        pubchem:10855842,
        pubchem:14794,
        pubchem:14805,
        pubchem:14811,
        pubchem:14824,
        pubchem:14829,
        pubchem:150906,
        pubchem:157925,
        pubchem:159375,
        pubchem:159385,
        pubchem:159423,
        pubchem:160959,
        pubchem:166955,
        pubchem:29131,
        pubchem:62762,
        pubchem:73971 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_14/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "10-100" ;
            sbd:lower_limit "10" ;
            sbd:upper_limit "100" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_15/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as biological response by H4"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "The dataset provided measurements of biological response for four cell types (Endothelial cells (human aorta), Vascular smooth muscle cells (human coronary artery), Hepatocytes (human HepG2 cells), and Murine RAW 264.7 leukemic monocyte/macrophage cell), exposed to the NPs at four concentrations (0.01, 0.03, 0.1, and 0.3 mg/mL Fe), determined based on four different assays (Apo: apoptosis, Mito: mitochondrial potential, Red: reducing equivalents, and ATP: ATP content) With a certainty above 95%, NP induced response that is above that of the control. In the present work, SNR(Signal-to-Noise ratio) > 1.645 was identified as a hit for a given NP. A 5% chance of miss-identifying a non-hit as â€œhitâ€ for a given NP, would be equivalent to a miss-identification of 3.2 out of the 64 measurements in its HTS profile. Therefore, even if 5% uncertainty would be acceptable it would be more practical to set the threshold to or above the next higher integer value, i.e., N hit â‰¥ 4."@en ;
    skos:narrower "Endothelial cells (human aorta)",
        "Hepatocytes (human HepG2 cells)",
        "Murine RAW 264.7 leukemic monocyte/macrophage cell",
        "Vascular smooth muscle cells (human coronary artery)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_15/Nanoparticle> a npo:NPO_1384,
        npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "PVA :: Ethylene diamine, AminoSPARKâ„¢680"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: FITC, Glutamic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: L-arg7-COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amphiphilic polymer â€“ PEG :: NH2"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: Ethylene diamine, VT750"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: FITC"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: AminoSPARKâ„¢680"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Cy5.5"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Coating :: Surface modification"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: FITC, COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: FITC, COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: VT680"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: rhodamine, protamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: Ethylene diamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Cy7"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: PEG Ethylene diamine, AminoSPARKâ„¢680"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: VT680, protamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA, PEG :: NA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: L-arg8-COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: D-arg7-COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA, PEG :: Ethylene diamine, VT750"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Cy3.5"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Carboxymethyldextran :: NA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: FITC, succinimidyl iodoacetate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Arabino-galactan :: NA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Alexa Fluor 750"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Tat peptide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: glycine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Cy5.5, protamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: biotin"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amphiphilic polymer :: COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Cy5"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: protamine, rhodamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: Ethylene diamine, VT680"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Sucrose :: NA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: 15-mer peptide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA, PEG :: AngioSPARKâ„¢680- IVM"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Dextran :: NA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Alexa Fluor 488"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Cy5.5, tat"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: NH2"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: NA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: FITC, R-COOH"@en ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_15/Nanoparticle/Size> ;
    skos:narrower npo:NPO_1548,
        npo:NPO_1550 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_15/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "20-74" ;
            sbd:lower_limit "20" ;
            sbd:upper_limit "74" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_16/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "membrane damage measured as lactate dehydrogenase (LDH) release [units/L]"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Characterize the culture media by using Olympus Lactate Dehydrogenase reagents ( absorbance method at 340 nm). The release units was expressed in [units/L]"@en ;
    skos:narrower "Human Lung epithelial cell" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_16/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_16/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_16/Nanoparticle/Size_1>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_16/Nanoparticle/Size_2> ;
    skos:narrower npo:NPO_1486 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_16/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "125",
                "30",
                "45" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_16/Nanoparticle/Size_1> a obo:PATO_0000117 ;
    npo:contained_in obo:CHEBI_15377 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "101-967" ;
            sbd:lower_limit "101" ;
            sbd:upper_limit "967" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_16/Nanoparticle/Size_2> a obo:PATO_0000117 ;
    npo:contained_in npo:NPO_1846 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "961-3871" ;
            sbd:lower_limit "961" ;
            sbd:upper_limit "3871" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_17a/Endpoint> a sty:T001,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "Ecotoxicological endpoint" ;
            rdfs:comment "measured as 24 hours post fertilization (hpf) mortality (M)"@en ] ;
    bao:BAO_0095009 obo:OBI_0100026 ;
    rdfs:comment "The defined biological effect (Mortality, Delayed development, Spontaneous movement, Malformations, etc) is defined as the ratio of the number of zebrafish embryos having the effect over the total number of embryos tested. All endpoints were modelized but the most relevant result was classified in this table. For specific details see (in the publication) Table 1 and Table 2 to check all the endpoints on the modelling results"@en ;
    skos:narrower "Embryonic zebrafish" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_17a/Nanoparticle> a npo:NPO_1375,
        npo:NPO_1384,
        npo:NPO_1541,
        npo:NPO_707,
        npo:NPO_735 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_17b/Endpoint> a sty:T001,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "Ecotoxicological endpoint" ;
            rdfs:comment "measured as (M)Weightened EZ Metric score"@en ] ;
    bao:BAO_0095009 obo:OBI_0100026 ;
    rdfs:comment "The defined biological effect (Mortality, Delayed development, Spontaneous movement, Malformations, etc) is defined as the ratio of the number of zebrafish embryos having the effect over the total number of embryos tested. Weightened endpoints were added in one final endpoint (Weightened EZ Metric score)"@en ;
    skos:narrower "Embryonic zebrafish" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_17b/Nanoparticle> a npo:NPO_1375,
        npo:NPO_1384,
        npo:NPO_1541,
        npo:NPO_707,
        npo:NPO_735 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_18/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a npo:NPO_296 ;
            rdfs:label "Cellular uptake of extracellular material"@en ;
            rdfs:comment "measured as log(pM) /cell"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Cellular uptake is expressed as decadic logarithm of the concentration (pM) of NP per cell"@en ;
    skos:narrower "Pancreatic human cancer cells (PaCa2)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_18/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower pubchem:220977 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:96580 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:65729 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:15659773 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5,6-Dihydro-1Hcyclopenta[c]furan-1,3(4H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6558 ],
        [ a npo:NPO_1962 ;
            skos:narrower "6-Nitro-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "3-Phenyldihydro-2Hpyran-2,6(3H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78479 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12475 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7923 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:102679 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:97914 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:25332 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:3301 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5603 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8326 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-ammonio-3-(4-hydroxyphenyl)propanoate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:750 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:16217 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:68986 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:70728 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12443 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6385 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:19990 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:74918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8926 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:75737 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:866 ],
        [ a npo:NPO_1962 ;
            skos:narrower "6-Bromo-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:994 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:79882 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:513918 ],
        [ a npo:NPO_1962 ;
            skos:narrower "3-Methylidenedihydrofuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1,4,5, 8-Naphthalenetetracarboxylic acidanhydride"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8265 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7894 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7719 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:20051 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:70334 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:21631 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78232 ],
        [ a npo:NPO_1962 ;
            skos:narrower "7 3,4-Dimethylfuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:602 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Amino-3-(1Himidazol-4-yl)propanoic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:428 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:424 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7908 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:232 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1045 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6811 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:25160 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:85689 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12012 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:513917 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8102 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69545 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8060 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69339 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69527 ],
        [ a npo:NPO_1962 ;
            skos:narrower "4-Methyldihydro-2Hpyran-2,6(3H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:681 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:239163 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12019 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:11089 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5610 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:98484 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:617 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:67742 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10946 ],
        [ a npo:NPO_1962 ;
            skos:narrower "N-(2-Aminoethyl)-N'-(3-aminopropyl)butane-1,4-diamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Tetrahydrofuro[3',4':3,4]cyclobuta[1,2-c]furan-1,3,4,6-tetrone"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:205 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78480 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8359 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:876 ],
        [ a npo:NPO_1962 ;
            skos:narrower "4 3,3-Dimethyldihydrofuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:587821 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:96196 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:16402 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78218 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:88069 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5-Nitro-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:2794246 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:866 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:587821 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:75498 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8111 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7940 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:95411 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:738 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:76074 ],
        [ a npo:NPO_1962 ;
            skos:narrower "{Bis[2-(2,6-dioxomorpholin-4-yl)ethyl]amino}acetic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1182 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:611 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12801 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1148 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:79743 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5-amino-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7922 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:9845 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:72794 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:230976 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:86625 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:74960 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6810 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:2733254 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:76247 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:17386 ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_18/Nanoparticle/Size> ;
    skos:narrower npo:NPO_729 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_18/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "38" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19a/Endpoint> a sty:T001,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a obo:OAE_000056 ;
            rdfs:label "Lung inflamation AE"@en ;
            rdfs:comment "Immune response measured by polymorphonuclear neutrophils (PMNs)"@en ] ;
    bao:BAO_0095009 obo:OBI_0100026 ;
    rdfs:comment "The endpoints in the paper reflect several dimensions of immune response and cell membrane damage and death. These indicators were all measured in bronchoalveolar lavage (BAL) fluid extracted from the lungs of the mice or rats, and were reported as a counts per subject or fold of control measurements (the average indicator count or concentration in animal test subjects divided by the average count or concentration in control animals). Converted all toxicity results to fold of control format (ratio of the desired measure over a control measure), a form that many of the studies already reported."@en ;
    skos:narrower "Rodent's lung exposed via Instillation or Aspiration to CNTs." .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19a/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "Uncoated"@en ] ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_461 ],
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19a/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19a/Nanoparticle/Size_2> ;
    skos:narrower npo:NPO_606,
        "(with the presence of metal impurities)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19a/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "550-100000" ;
            sbd:lower_limit "550" ;
            sbd:upper_limit "100000" ] ;
    skos:narrower obo:PATO_0000122 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19a/Nanoparticle/Size_2> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "0.8-49" ;
            sbd:lower_limit "0.8" ;
            sbd:upper_limit "49" ] ;
    skos:narrower obo:PATO_0001334 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19b/Endpoint> a sty:T001,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a obo:OAE_000056 ;
            rdfs:label "Lung inflamation AE"@en ;
            rdfs:comment "Immune response measured by polymorphonuclear neutrophils (PMNs)"@en ] ;
    bao:BAO_0095009 obo:OBI_0100026 ;
    rdfs:comment "The endpoints in the paper reflect several dimensions of immune response and cell membrane damage and death. These indicators were all measured in bronchoalveolar lavage (BAL) fluid extracted from the lungs of the mice or rats, and were reported as a counts per subject or fold of control measurements (the average indicator count or concentration in animal test subjects divided by the average count or concentration in control animals). Converted all toxicity results to fold of control format (ratio of the desired measure over a control measure), a form that many of the studies already reported."@en ;
    skos:narrower "Rodent's lung exposed via Instillation or Aspiration to CNTs." .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19b/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "Uncoated"@en ] ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_461 ],
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19b/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19b/Nanoparticle/Size_2> ;
    skos:narrower npo:NPO_606,
        "(with the presence of metal impurities)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19b/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "550-100000" ;
            sbd:lower_limit "550" ;
            sbd:upper_limit "100000" ] ;
    skos:narrower obo:PATO_0000122 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19b/Nanoparticle/Size_2> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "0.8-49" ;
            sbd:lower_limit "0.8" ;
            sbd:upper_limit "49" ] ;
    skos:narrower obo:PATO_0001334 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19c/Endpoint> a sty:T001,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a obo:OAE_000056 ;
            rdfs:label "Lung inflamation AE"@en ;
            rdfs:comment "Immune response measured by macrophages (MAC)"@en ] ;
    bao:BAO_0095009 obo:OBI_0100026 ;
    rdfs:comment "The endpoints in the paper reflect several dimensions of immune response and cell membrane damage and death. These indicators were all measured in bronchoalveolar lavage (BAL) fluid extracted from the lungs of the mice or rats, and were reported as a counts per subject or fold of control measurements (the average indicator count or concentration in animal test subjects divided by the average count or concentration in control animals). Converted all toxicity results to fold of control format (ratio of the desired measure over a control measure), a form that many of the studies already reported."@en ;
    skos:narrower "Rodent's lung exposed via Instillation or Aspiration to CNTs." .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19c/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "Uncoated"@en ] ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_461 ],
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19c/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19c/Nanoparticle/Size_2> ;
    skos:narrower npo:NPO_606,
        "(with the presence of metal impurities)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19c/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "550-100000" ;
            sbd:lower_limit "550" ;
            sbd:upper_limit "100000" ] ;
    skos:narrower obo:PATO_0000122 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19c/Nanoparticle/Size_2> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "0.8-49" ;
            sbd:lower_limit "0.8" ;
            sbd:upper_limit "49" ] ;
    skos:narrower obo:PATO_0001334 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19d/Endpoint> a sty:T001,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a obo:OAE_000056 ;
            rdfs:label "Lung inflamation AE"@en ;
            rdfs:comment "Immune response measured by macrophages (MAC)"@en ] ;
    bao:BAO_0095009 obo:OBI_0100026 ;
    rdfs:comment "The endpoints in the paper reflect several dimensions of immune response and cell membrane damage and death. These indicators were all measured in bronchoalveolar lavage (BAL) fluid extracted from the lungs of the mice or rats, and were reported as a counts per subject or fold of control measurements (the average indicator count or concentration in animal test subjects divided by the average count or concentration in control animals). Converted all toxicity results to fold of control format (ratio of the desired measure over a control measure), a form that many of the studies already reported."@en ;
    skos:narrower "Rodent's lung exposed via Instillation or Aspiration to CNTs." .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19d/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "Uncoated"@en ] ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_461 ],
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19d/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19d/Nanoparticle/Size_2> ;
    skos:narrower npo:NPO_606,
        "(with the presence of metal impurities)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19d/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "550-100000" ;
            sbd:lower_limit "550" ;
            sbd:upper_limit "100000" ] ;
    skos:narrower obo:PATO_0000122 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19d/Nanoparticle/Size_2> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "0.8-49" ;
            sbd:lower_limit "0.8" ;
            sbd:upper_limit "49" ] ;
    skos:narrower obo:PATO_0001334 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19e/Endpoint> a sty:T001,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a obo:OAE_000056 ;
            rdfs:label "Lung inflamation AE"@en ;
            rdfs:comment "Cell membrane damage measured by lactate dehydrogenase (LDH) release"@en ] ;
    bao:BAO_0095009 obo:OBI_0100026 ;
    rdfs:comment "The endpoints in the paper reflect several dimensions of immune response and cell membrane damage and death. These indicators were all measured in bronchoalveolar lavage (BAL) fluid extracted from the lungs of the mice or rats, and were reported as a counts per subject or fold of control measurements (the average indicator count or concentration in animal test subjects divided by the average count or concentration in control animals). Converted all toxicity results to fold of control format (ratio of the desired measure over a control measure), a form that many of the studies already reported."@en ;
    skos:narrower "Rodent's lung exposed via Instillation or Aspiration to CNTs." .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19e/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "Uncoated"@en ] ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_461 ],
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19e/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19e/Nanoparticle/Size_2> ;
    skos:narrower npo:NPO_606,
        "(with the presence of metal impurities)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19e/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "550-100000" ;
            sbd:lower_limit "550" ;
            sbd:upper_limit "100000" ] ;
    skos:narrower obo:PATO_0000122 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19e/Nanoparticle/Size_2> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "0.8-49" ;
            sbd:lower_limit "0.8" ;
            sbd:upper_limit "49" ] ;
    skos:narrower obo:PATO_0001334 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19f/Endpoint> a sty:T001,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a obo:OAE_000056 ;
            rdfs:label "Lung inflamation AE"@en ;
            rdfs:comment "Cell membrane damage measured by lactate dehydrogenase (LDH) release"@en ] ;
    bao:BAO_0095009 obo:OBI_0100026 ;
    rdfs:comment "The endpoints in the paper reflect several dimensions of immune response and cell membrane damage and death. These indicators were all measured in bronchoalveolar lavage (BAL) fluid extracted from the lungs of the mice or rats, and were reported as a counts per subject or fold of control measurements (the average indicator count or concentration in animal test subjects divided by the average count or concentration in control animals). Converted all toxicity results to fold of control format (ratio of the desired measure over a control measure), a form that many of the studies already reported."@en ;
    skos:narrower "Rodent's lung exposed via Instillation or Aspiration to CNTs." .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19f/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "Uncoated"@en ] ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_461 ],
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19f/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19f/Nanoparticle/Size_2> ;
    skos:narrower npo:NPO_606,
        "(with the presence of metal impurities)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19f/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "550-100000" ;
            sbd:lower_limit "550" ;
            sbd:upper_limit "100000" ] ;
    skos:narrower obo:PATO_0000122 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19f/Nanoparticle/Size_2> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "0.8-49" ;
            sbd:lower_limit "0.8" ;
            sbd:upper_limit "49" ] ;
    skos:narrower obo:PATO_0001334 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19g/Endpoint> a sty:T001,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a obo:OAE_000056 ;
            rdfs:label "Lung inflamation AE"@en ;
            rdfs:comment "Cell death measured by total protein (TP)"@en ] ;
    bao:BAO_0095009 obo:OBI_0100026 ;
    rdfs:comment "The endpoints in the paper reflect several dimensions of immune response and cell membrane damage and death. These indicators were all measured in bronchoalveolar lavage (BAL) fluid extracted from the lungs of the mice or rats, and were reported as a counts per subject or fold of control measurements (the average indicator count or concentration in animal test subjects divided by the average count or concentration in control animals). Converted all toxicity results to fold of control format (ratio of the desired measure over a control measure), a form that many of the studies already reported."@en ;
    skos:narrower "Rodent's lung exposed via Instillation or Aspiration to CNTs." .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19g/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "Uncoated"@en ] ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_461 ],
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19g/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19g/Nanoparticle/Size_2> ;
    skos:narrower npo:NPO_606,
        "(with the presence of metal impurities)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19g/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "550-100000" ;
            sbd:lower_limit "550" ;
            sbd:upper_limit "100000" ] ;
    skos:narrower obo:PATO_0000122 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19g/Nanoparticle/Size_2> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "0.8-49" ;
            sbd:lower_limit "0.8" ;
            sbd:upper_limit "49" ] ;
    skos:narrower obo:PATO_0001334 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19h/Endpoint> a sty:T001,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a obo:OAE_000056 ;
            rdfs:label "Lung inflamation AE"@en ;
            rdfs:comment "Cell death measured by total protein (TP)"@en ] ;
    bao:BAO_0095009 obo:OBI_0100026 ;
    rdfs:comment "The endpoints in the paper reflect several dimensions of immune response and cell membrane damage and death. These indicators were all measured in bronchoalveolar lavage (BAL) fluid extracted from the lungs of the mice or rats, and were reported as a counts per subject or fold of control measurements (the average indicator count or concentration in animal test subjects divided by the average count or concentration in control animals). Converted all toxicity results to fold of control format (ratio of the desired measure over a control measure), a form that many of the studies already reported."@en ;
    skos:narrower "Rodent's lung exposed via Instillation or Aspiration to CNTs." .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19h/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "Uncoated"@en ] ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_461 ],
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19h/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19h/Nanoparticle/Size_2> ;
    skos:narrower npo:NPO_606,
        "(with the presence of metal impurities)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19h/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "550-100000" ;
            sbd:lower_limit "550" ;
            sbd:upper_limit "100000" ] ;
    skos:narrower obo:PATO_0000122 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_19h/Nanoparticle/Size_2> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "0.8-49" ;
            sbd:lower_limit "0.8" ;
            sbd:upper_limit "49" ] ;
    skos:narrower obo:PATO_0001334 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_1a/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a npo:NPO_296 ;
            rdfs:label "Cellular uptake of extracellular material"@en ;
            rdfs:comment "measured as log(pM) /cell"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Cellular uptake is expressed as decadic logarithm of the concentration (pM) of NP per cell"@en ;
    skos:narrower "Pancreatic human cancer cells (PaCa2)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_1a/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower pubchem:205 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6558 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:88069 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:68986 ],
        [ a npo:NPO_1962 ;
            skos:narrower "6-Bromo-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:21631 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:20051 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:239163 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:19990 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:866 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:102679 ],
        [ a npo:NPO_1962 ;
            skos:narrower "3-Methylidenedihydrofuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:13010 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:230976 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:866 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:65729 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:79743 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12801 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:70334 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69339 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:428 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:2794246 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:602 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:97914 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8102 ],
        [ a npo:NPO_1962 ;
            skos:narrower "4-Methyldihydro-2Hpyran-2,6(3H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1,4,5, 8-Naphthalenetetracarboxylic acidanhydride"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:86625 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6811 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:74960 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69545 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5603 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8060 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:513917 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69527 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:25160 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:424 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78480 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:513918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:72794 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5,6-Dihydro-1Hcyclopenta[c]furan-1,3(4H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "{Bis[2-(2,6-dioxomorpholin-4-yl)ethyl]amino}acetic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:2733254 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:25332 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12019 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6385 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:681 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7940 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7894 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8326 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:70728 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8265 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12443 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:220977 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:587821 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:232 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:9845 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12012 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7719 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78479 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:15659773 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:85689 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8359 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:17386 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:67742 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:95411 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1148 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:876 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:16217 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:750 ],
        [ a npo:NPO_1962 ;
            skos:narrower "6-Nitro-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "5-Nitro-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:96196 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5610 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:587821 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1045 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78232 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:617 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7923 ],
        [ a npo:NPO_1962 ;
            skos:narrower "N-(2-Aminoethyl)-N'-(3-aminopropyl)butane-1,4-diamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Amino-3-(1Himidazol-4-yl)propanoic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:79882 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:994 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:16402 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:738 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12475 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6810 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-ammonio-3-(4-hydroxyphenyl)propanoate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8926 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Tetrahydrofuro[3',4':3,4]cyclobuta[1,2-c]furan-1,3,4,6-tetrone"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:611 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:74918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:3301 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7908 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "5-amino-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7922 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10946 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:11089 ],
        [ a npo:NPO_1962 ;
            skos:narrower "3-Phenyldihydro-2Hpyran-2,6(3H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:76247 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:75498 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:87067 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:96580 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:76074 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1182 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:75737 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8111 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78218 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:98484 ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_1a/Nanoparticle/Size> ;
    skos:narrower npo:NPO_729 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_1a/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "38" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_1b/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a npo:NPO_296 ;
            rdfs:label "Cellular uptake of extracellular material"@en ;
            rdfs:comment "measured as log(pM) /cell"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Cellular uptake is expressed as decadic logarithm of the concentration (pM) of NP per cell"@en ;
    skos:narrower "Pancreatic human cancer cells (PaCa2)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_1b/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower pubchem:96580 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:876 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:25160 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:79743 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78479 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10946 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78232 ],
        [ a npo:NPO_1962 ;
            skos:narrower "3-Phenyldihydro-2Hpyran-2,6(3H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:3301 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1,4,5, 8-Naphthalenetetracarboxylic acidanhydride"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8265 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:994 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:232 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7922 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:2794246 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78480 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:88069 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7719 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:617 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:86625 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:68986 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:72794 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:20051 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7908 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12475 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:2733254 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:76074 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:98484 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69545 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:85689 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5-Nitro-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7940 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8060 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:21631 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6811 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:25332 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:428 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:866 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:75737 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:96196 ],
        [ a npo:NPO_1962 ;
            skos:narrower "4 3,3-Dimethyldihydrofuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12801 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69527 ],
        [ a npo:NPO_1962 ;
            skos:narrower "7 3,4-Dimethylfuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "5-amino-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:16217 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12012 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8359 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:97914 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:513918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7923 ],
        [ a npo:NPO_1962 ;
            skos:narrower "6-Nitro-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:424 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6558 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:74960 ],
        [ a npo:NPO_1962 ;
            skos:narrower "N-(2-Aminoethyl)-N'-(3-aminopropyl)butane-1,4-diamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8326 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:76247 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1045 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:9845 ],
        [ a npo:NPO_1962 ;
            skos:narrower "{Bis[2-(2,6-dioxomorpholin-4-yl)ethyl]amino}acetic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:602 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:239163 ],
        [ a npo:NPO_1962 ;
            skos:narrower "6-Bromo-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8111 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12443 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:611 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8102 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:587821 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:738 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:205 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1182 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69339 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7894 ],
        [ a npo:NPO_1962 ;
            skos:narrower "3-Methylidenedihydrofuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6810 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:17386 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:75498 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-ammonio-3-(4-hydroxyphenyl)propanoate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:102679 ],
        [ a npo:NPO_1962 ;
            skos:narrower "4-Methyldihydro-2Hpyran-2,6(3H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5603 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8926 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Tetrahydrofuro[3',4':3,4]cyclobuta[1,2-c]furan-1,3,4,6-tetrone"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:70334 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:230976 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:79882 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5,6-Dihydro-1Hcyclopenta[c]furan-1,3(4H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:513917 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1148 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:95411 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:74918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5610 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:15659773 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:19990 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:16402 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:866 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:750 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:70728 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6385 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:587821 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:67742 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Amino-3-(1Himidazol-4-yl)propanoic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12019 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:681 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78218 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:65729 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:220977 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:11089 ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_1b/Nanoparticle/Size> ;
    skos:narrower npo:NPO_729 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_1b/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "38" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_20/Endpoint> a sty:T001,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "Ecotoxicological endpoint" ;
            rdfs:comment "measured as binary classification into ecotoxic (\"1\") or non-ecotoxic (\"-1\") class which was obtained by different ecotoxic units (EC50, IC50, TC50 and LC50)"@en ] ;
    bao:BAO_0095009 obo:OBI_0100026 ;
    rdfs:comment "The nanoparticles/cases were considered as non-ecotoxic [Tox_i (c_j) = 1] when they exhibited high values of measures of ecotoxicity; otherwise, they were selected as ecotoxic [Tox_i (c_j ) = âˆ’1]. Tox_i(c_j) is a categorical variable that is used to classify nanoparticles as non-ecotoxic or ecotoxic, and the assignments for all the cases were realized by taking into account certain arbitrary (but rigorous) cutoff values of ecotoxicity. For specific details see (in the publication) Table 1."@en ;
    skos:narrower "Brassica napus",
        "Ceriodaphnia dubia (neonates)",
        "Chlorella sp.",
        "Chlorella vulgaris",
        "Cucumis sativus",
        "Danio rerio (adults)",
        "Danio rerio (embryos)",
        "Danio rerio (juvenile)",
        "Daphnia magna (juvenile)",
        "Daphnia magna (neonates)",
        "Daphnia pulex (adults)",
        "Desmodesmus subspicatus",
        "Lolium perenne",
        "Poecilia reticulata",
        "Pseudokirchneriella subcapitata",
        "Raphanus sativus",
        "Saccharomyces cerevisiae S288C",
        "Scenedesmus sp.",
        "Thamnocephalus platyurus",
        "Vibrio fischeri" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_20/Nanoparticle> a npo:NPO_1384,
        npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ],
        [ a npo:NPO_274 ;
            skos:narrower "irregular"@en ],
        [ a npo:NPO_274 ;
            skos:narrower npo:NPO_852 ],
        [ a npo:NPO_274 ;
            skos:narrower "strip"@en ],
        [ a npo:NPO_274 ;
            skos:narrower npo:NPO_850 ],
        [ a npo:NPO_274 ;
            skos:narrower npo:NPO_858 ],
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_20/Nanoparticle/Size> ;
    skos:narrower npo:NPO_103,
        npo:NPO_1486,
        npo:NPO_1542,
        npo:NPO_1548,
        npo:NPO_1550,
        npo:NPO_1892,
        obo:CHEBI_30187,
        obo:CHEBI_33888,
        pubchem:14805,
        pubchem:14829,
        pubchem:157925,
        pubchem:159385,
        pubchem:160959,
        pubchem:23926,
        pubchem:23980,
        pubchem:24261,
        pubchem:73971,
        pubchem:934 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_20/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "3-100" ;
            sbd:lower_limit "3" ;
            sbd:upper_limit "100" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_21/Endpoint> a sty:T001,
        sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002189 ;
            rdfs:label "Toxicity Assay"@en ;
            rdfs:comment "measured as binary classification into toxic (\"1\") or non-toxic (\"-1\") class which was obtained by different ecotoxic units (CC50, EC50, IC50, TC50 and LC50)"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285,
        obo:OBI_0100026 ;
    rdfs:comment "Classes were related with the toxic effect of a NP i in a defined experimental condition cj [TEi(cj)]. Thus, a case was chosen as nontoxic [TE_i (c_j) = 1] when it exhibited a high value of measured toxicity; otherwise, the compound was considered as toxic [TE_i (c_j)= âˆ’1]. All these assignments were realized according to cutoff values, which are represented in Table 1 in the publication"@en ;
    skos:narrower mesh:D000072283,
        "3T3 (M)",
        "BJ (H)",
        "BMSC (H)",
        "BMSC (M)",
        "BRL 3A (R)",
        "Brassica napus",
        "CaCo-2 (H)",
        "Caenorhabditis elegans (L1 juvenile)",
        "Ceriodaphnia dubia (neonates)",
        "Chlorella sp.",
        "Chlorella vulgaris",
        "Cucumis sativus",
        "Danio rerio (adults)",
        "Danio rerio (embryos)",
        "Danio rerio (juvenile)",
        "Daphnia magna (juvenile)",
        "Daphnia magna (neonates)",
        "Daphnia pulex (adults)",
        "Dendritic cells (M)",
        "Desmodesmus subspicatus",
        "H4IIE (R)",
        "HEK293 (H)",
        "HMM (H)",
        "HUVECs",
        "HepG2 (H)",
        "L929 (M)",
        "Lolium perenne",
        "MDCK (H)",
        "MDCK II (D)",
        "NCIH441 (H)",
        "NR8383 (R)",
        "Neuro-2A (M)",
        "PK-15 (P)",
        "Poecilia reticulata",
        "Precision-cut lung slices (R)",
        "Pseudokirchneriella subcapitata",
        "RAW264.7 (M)",
        "RBE4 (R)",
        "Raphanus sativus",
        "Saccharomyces cerevisiae",
        "Scenedesmus sp.",
        "TK6 (H)",
        "Tetrahymena thermophila",
        "Thamnocephalus platyurus",
        "Vero (Mon)",
        "Vibrio fischeri",
        "WISH (H)",
        "Xenopus laevis",
        "osteoblasts (R)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_21/Nanoparticle> a npo:NPO_1384,
        npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "N,N,N-trimethyl-3(1-propene) ammonium fragment"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:543502 ],
        [ a npo:NPO_1962 ;
            skos:narrower "undecylazide fragment"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1133 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6224 ],
        [ a npo:NPO_1962 ;
            skos:narrower "propylamonium fragment"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6917 ],
        [ a npo:NPO_1962 ;
            skos:narrower "PEG-Si(OMe)3"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5974 ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:222 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:439341 ] ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower "strip"@en ],
        [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ],
        [ a npo:NPO_274 ;
            skos:narrower "slice-shaped"@en ],
        [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ],
        [ a npo:NPO_274 ;
            skos:narrower "irregular"@en ],
        [ a npo:NPO_274 ;
            skos:narrower npo:NPO_850 ],
        [ a npo:NPO_274 ;
            skos:narrower npo:NPO_858 ],
        [ a npo:NPO_274 ;
            skos:narrower npo:NPO_852 ],
        [ a npo:NPO_274 ;
            skos:narrower npo:NPO_858 ],
        [ a npo:NPO_274 ;
            skos:narrower npo:NPO_461 ],
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_21/Nanoparticle/Size> ;
    skos:narrower mesh:C569492,
        npo:NPO_103,
        npo:NPO_1373,
        npo:NPO_1486,
        npo:NPO_1542,
        npo:NPO_1548,
        npo:NPO_1550,
        npo:NPO_1892,
        npo:NPO_401,
        obo:CHEBI_30187,
        obo:CHEBI_33888,
        pubchem:14802,
        pubchem:14805,
        pubchem:14824,
        pubchem:14829,
        pubchem:157925,
        pubchem:159375,
        pubchem:159385,
        pubchem:160959,
        pubchem:166955,
        pubchem:23926,
        pubchem:23942,
        pubchem:23980,
        pubchem:24261,
        pubchem:25087137,
        pubchem:4124403,
        pubchem:4226345,
        pubchem:6335514,
        pubchem:73971,
        pubchem:91574,
        pubchem:934,
        "Ca5(PO4)3(OH)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_21/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "1.6-123" ;
            sbd:lower_limit "1.6" ;
            sbd:upper_limit "123" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_22/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a npo:NPO_296 ;
            rdfs:label "Cellular uptake of extracellular material"@en ;
            rdfs:comment "measured as log(pM) /cell"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Cellular uptake is expressed as decadic logarithm of the concentration (pM) of NP per cell"@en ;
    skos:narrower "Pancreatic human cancer cells (PaCa2)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_22/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower pubchem:7922 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:750 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:513918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:866 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1045 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:65729 ],
        [ a npo:NPO_1962 ;
            skos:narrower "7 3,4-Dimethylfuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:428 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:79743 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5-amino-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78479 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:25160 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7908 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:19990 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78218 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:79882 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6810 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10946 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1,4,5, 8-Naphthalenetetracarboxylic acidanhydride"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8359 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:230976 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:513917 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1148 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:85689 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:738 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8326 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12801 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:95411 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12012 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Tetrahydrofuro[3',4':3,4]cyclobuta[1,2-c]furan-1,3,4,6-tetrone"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:866 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:21631 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:2794246 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:205 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:102679 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8060 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:70334 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7923 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:96196 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:74918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:239163 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8926 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:75737 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:11089 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5-Nitro-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:220977 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:587821 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:86625 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8111 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:15659773 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:88069 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:20051 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:74960 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7894 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8102 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6811 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8265 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5610 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78480 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12475 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78232 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:617 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7940 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6385 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69339 ],
        [ a npo:NPO_1962 ;
            skos:narrower "6-Nitro-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "5,6-Dihydro-1Hcyclopenta[c]furan-1,3(4H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1182 ],
        [ a npo:NPO_1962 ;
            skos:narrower "4 3,3-Dimethyldihydrofuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:611 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:97914 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:68986 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:994 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:3301 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:75498 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:72794 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:76247 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6558 ],
        [ a npo:NPO_1962 ;
            skos:narrower "4-Methyldihydro-2Hpyran-2,6(3H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:96580 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12443 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:25332 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:232 ],
        [ a npo:NPO_1962 ;
            skos:narrower "6-Bromo-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:681 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:70728 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Amino-3-(1Himidazol-4-yl)propanoic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:587821 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:424 ],
        [ a npo:NPO_1962 ;
            skos:narrower "{Bis[2-(2,6-dioxomorpholin-4-yl)ethyl]amino}acetic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12019 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69527 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:76074 ],
        [ a npo:NPO_1962 ;
            skos:narrower "3-Phenyldihydro-2Hpyran-2,6(3H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:9845 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:602 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:98484 ],
        [ a npo:NPO_1962 ;
            skos:narrower "3-Methylidenedihydrofuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-ammonio-3-(4-hydroxyphenyl)propanoate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "N-(2-Aminoethyl)-N'-(3-aminopropyl)butane-1,4-diamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:2733254 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:16217 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:16402 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5603 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69545 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:876 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:67742 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:17386 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7719 ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_22/Nanoparticle/Size> ;
    skos:narrower npo:NPO_729 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_22/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "38" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_23a/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as log(1/EC50)"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Originally measured in vitro effective concentration EC50 toxicity data (mol Lâˆ’1) were expressed as logarithms of the inverse molar concentration (log(1/EC50)) response variables, which represents the cytotoxicity that reduces bacteria viability up to 50%"@en ;
    skos:narrower mesh:D004926 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_23a/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_23a/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_23a/Nanoparticle/Size_2> ;
    skos:narrower npo:NPO_1373,
        npo:NPO_1486,
        npo:NPO_1542,
        npo:NPO_1550,
        enm:ENM_0000118,
        obo:CHEBI_30187,
        pubchem:14776,
        pubchem:14794,
        pubchem:14805,
        pubchem:14811,
        pubchem:150906,
        pubchem:157925,
        pubchem:159375,
        pubchem:166955,
        pubchem:29131,
        pubchem:518712,
        pubchem:62762 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_23a/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "15-150" ;
            sbd:lower_limit "15" ;
            sbd:upper_limit "150" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_23a/Nanoparticle/Size_2> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "180-2029" ;
            sbd:lower_limit "180" ;
            sbd:upper_limit "2029" ] ;
    skos:narrower npo:NPO_1967 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_23b/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as log(1/EC50)"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Originally measured in vitro effective concentration EC50 toxicity data (mol Lâˆ’1) were expressed as logarithms of the inverse molar concentration (log(1/EC50)) response variables, which represents the cytotoxicity that reduces bacteria viability up to 50%"@en ;
    skos:narrower mesh:D000084282 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_23b/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_23b/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_23b/Nanoparticle/Size_2> ;
    skos:narrower npo:NPO_1373,
        npo:NPO_1486,
        npo:NPO_1542,
        npo:NPO_1550,
        enm:ENM_0000118,
        obo:CHEBI_30187,
        pubchem:14776,
        pubchem:14794,
        pubchem:14805,
        pubchem:14811,
        pubchem:150906,
        pubchem:157925,
        pubchem:159375,
        pubchem:166955,
        pubchem:29131,
        pubchem:518712,
        pubchem:62762 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_23b/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "15-150" ;
            sbd:lower_limit "15" ;
            sbd:upper_limit "150" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_23b/Nanoparticle/Size_2> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "180-2029" ;
            sbd:lower_limit "180" ;
            sbd:upper_limit "2029" ] ;
    skos:narrower npo:NPO_1967 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_24a/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as biological activity by Dose-response curve of smooth muscle cell apoptosis (SMA)"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Biological activity was defined as the arithmetic mean of in vitro tests on four different cell lines, - Endothelial cells (human aorta) - Vascular smooth muscle cells (human coronary artery) - Hepatocytes (human HepG2 cells) - Murine RAW 264.7 leukemic monocyte/macrophage cell Using four doses, and four different assays of cellular physiology. The four assays measured (i) ATP content, (ii) Reducing equivalents, (iii) Caspase-mediated apoptosis, (iv) Mitochondrial membrane potential. Only the apoptosis assay (smooth muscle cell apoptosis, SMA) exhibited dose-response relationship."@en ;
    skos:narrower "Vascular smooth muscle cells (human coronary artery)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_24a/Nanoparticle> a npo:NPO_1384,
        npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "PVA :: 15-mer peptide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: Ethylene diamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Alexa Fluor 750"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: VT680, protamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Dextran :: NA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: Ethylene diamine, VT750"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: glycine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Sucrose :: NA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Cy7"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: FITC, COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Cy5.5, protamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: D-arg7-COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: PEG Ethylene diamine, AminoSPARKâ„¢680"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: FITC, R-COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amphiphilic polymer :: COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: NA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: biotin"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: AminoSPARKâ„¢680"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: L-arg7-COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Alexa Fluor 488"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: rhodamine, protamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: Ethylene diamine, AminoSPARKâ„¢680"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Cy5.5, tat"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Carboxymethyldextran :: NA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA, PEG :: Ethylene diamine, VT750"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Cy3.5"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: NH2"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amphiphilic polymer â€“ PEG :: NH2"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: VT680"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Arabino-galactan :: NA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Coating :: Surface modification"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: protamine, rhodamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: FITC, Glutamic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Cy5.5"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Cy5"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: FITC"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: FITC, succinimidyl iodoacetate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: FITC, COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: Ethylene diamine, VT680"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA, PEG :: NA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA, PEG :: AngioSPARKâ„¢680- IVM"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: L-arg8-COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Tat peptide"@en ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_24a/Nanoparticle/Size> ;
    skos:narrower npo:NPO_1548,
        npo:NPO_1550 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_24a/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "20-74" ;
            sbd:lower_limit "20" ;
            sbd:upper_limit "74" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_24b/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as biological activity by Dose-response curve of smooth muscle cell apoptosis (SMA)"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Biological activity was defined as the arithmetic mean of in vitro tests on four different cell lines, - Endothelial cells (human aorta) - Vascular smooth muscle cells (human coronary artery) - Hepatocytes (human HepG2 cells) - Murine RAW 264.7 leukemic monocyte/macrophage cell Using four doses, and four different assays of cellular physiology. The four assays measured (i) ATP content, (ii) Reducing equivalents, (iii) Caspase-mediated apoptosis, (iv) Mitochondrial membrane potential. Only the apoptosis assay (smooth muscle cell apoptosis, SMA) exhibited dose-response relationship."@en ;
    skos:narrower "Vascular smooth muscle cells (human coronary artery)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_24b/Nanoparticle> a npo:NPO_1384,
        npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "PVA :: Ethylene diamine, VT750"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Cy3.5"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: Ethylene diamine, AminoSPARKâ„¢680"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: FITC, COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: biotin"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: FITC"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: NA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Arabino-galactan :: NA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amphiphilic polymer :: COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: FITC, R-COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Carboxymethyldextran :: NA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amphiphilic polymer â€“ PEG :: NH2"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Coating :: Surface modification"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Cy5.5, protamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Alexa Fluor 488"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: FITC, Glutamic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Sucrose :: NA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: FITC, COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: protamine, rhodamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: FITC, succinimidyl iodoacetate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: 15-mer peptide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: glycine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: VT680, protamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: Ethylene diamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: D-arg7-COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA, PEG :: AngioSPARKâ„¢680- IVM"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Dextran :: NA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA, PEG :: NA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Cy5.5, tat"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Cy5"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: VT680"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: L-arg8-COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Tat peptide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: AminoSPARKâ„¢680"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: Ethylene diamine, VT680"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Cy5.5"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Cy7"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA, PEG :: Ethylene diamine, VT750"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: NH2"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: L-arg7-COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Alexa Fluor 750"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: PEG Ethylene diamine, AminoSPARKâ„¢680"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: rhodamine, protamine"@en ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_24b/Nanoparticle/Size> ;
    skos:narrower npo:NPO_1548,
        npo:NPO_1550 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_24b/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "20-74" ;
            sbd:lower_limit "20" ;
            sbd:upper_limit "74" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_24c/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a npo:NPO_296 ;
            rdfs:label "Cellular uptake of extracellular material"@en ;
            rdfs:comment "measured as log(pM) /cell"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Measured by well fluorescein isothiocyanate (FITC) concentrations. Experimental data were used as its log10 transform. In assessing whether both of the above assays contain useful biological information, the z-scored data were used where Z^NP =(Î¼NP-Î¼PBS)/ÏƒPBS, where Î¼ and Ïƒ are the mean and standard deviation of assay replicates, respectively, and the NP and PBS subscripts represent assays in the presence of PBS buffer controls. Assays where most of the dose-response curves fell within a z-score of Â±2 were considered to demonstrate negligible effect Of the five cell lines tested: - Human umbilical vein endothelial cells (HUVEC) - Primary resting human macrophages (RestMph) - Granulocyte macrophage colony stimulating factor-stimulated human macrophages (GMCSF_Mph) - Human macrophage-like cell line (U937) - Human pancreatic ductal adenocarcinoma cells (PaCa2) Only the pancreatic cancer (PaCa2) and human umbilical vein endothelial cell (HUVEC) lines showed significant variation in uptake of surface modified nanoparticles."@en ;
    skos:narrower "Human umbilical vein endothelial cells (HUVEC)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_24c/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower pubchem:70334 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:96196 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:79743 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:876 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:205 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:15659773 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:611 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6385 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7940 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8265 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5603 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:79882 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:67742 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-ammonio-3-(4-hydroxyphenyl)propanoate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69527 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78218 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:88069 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:16217 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12475 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:96580 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:3301 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Amino-3-(1Himidazol-4-yl)propanoic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:75498 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Tetrahydrofuro[3',4':3,4]cyclobuta[1,2-c]furan-1,3,4,6-tetrone"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:513917 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:68986 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:239163 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5-Nitro-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "4-Methyldihydro-2Hpyran-2,6(3H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "{Bis[2-(2,6-dioxomorpholin-4-yl)ethyl]amino}acetic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5610 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78232 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:230976 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1,4,5, 8-Naphthalenetetracarboxylic acidanhydride"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:587821 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:428 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:19990 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:20051 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1148 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7894 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12019 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69339 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:85689 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1045 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:74918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:2733254 ],
        [ a npo:NPO_1962 ;
            skos:narrower "N-(2-Aminoethyl)-N'-(3-aminopropyl)butane-1,4-diamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8359 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:424 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:65729 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:25332 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:11089 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:513918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:220977 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:9845 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:70728 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8102 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:102679 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7922 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:232 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:738 ],
        [ a npo:NPO_1962 ;
            skos:narrower "3-Methylidenedihydrofuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7908 ],
        [ a npo:NPO_1962 ;
            skos:narrower "4 3,3-Dimethyldihydrofuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:866 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:587821 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:2794246 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:98484 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6811 ],
        [ a npo:NPO_1962 ;
            skos:narrower "3-Phenyldihydro-2Hpyran-2,6(3H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "7 3,4-Dimethylfuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6558 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:994 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:21631 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:75737 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12801 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:25160 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78480 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:76074 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:97914 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:866 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5,6-Dihydro-1Hcyclopenta[c]furan-1,3(4H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69545 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7719 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:72794 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:16402 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:76247 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8111 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:86625 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1182 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12443 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5-amino-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:74960 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6810 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78479 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10946 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:681 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:602 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:95411 ],
        [ a npo:NPO_1962 ;
            skos:narrower "6-Bromo-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8326 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:750 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:17386 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12012 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7923 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8060 ],
        [ a npo:NPO_1962 ;
            skos:narrower "6-Nitro-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:617 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8926 ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_24c/Nanoparticle/Size> ;
    skos:narrower npo:NPO_729 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_24c/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "38" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_24d/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a npo:NPO_296 ;
            rdfs:label "Cellular uptake of extracellular material"@en ;
            rdfs:comment "measured as log(pM) /cell"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Measured by well fluorescein isothiocyanate (FITC) concentrations. Experimental data were used as its log10 transform. In assessing whether both of the above assays contain useful biological information, the z-scored data were used where Z^NP =(Î¼NP-Î¼PBS)/ÏƒPBS, where Î¼ and Ïƒ are the mean and standard deviation of assay replicates, respectively, and the NP and PBS subscripts represent assays in the presence of PBS buffer controls. Assays where most of the dose-response curves fell within a z-score of Â±2 were considered to demonstrate negligible effect Of the five cell lines tested: - Human umbilical vein endothelial cells (HUVEC) - Primary resting human macrophages (RestMph) - Granulocyte macrophage colony stimulating factor-stimulated human macrophages (GMCSF_Mph) - Human macrophage-like cell line (U937) - Human pancreatic ductal adenocarcinoma cells (PaCa2) Only the pancreatic cancer (PaCa2) and human umbilical vein endothelial cell (HUVEC) lines showed significant variation in uptake of surface modified nanoparticles."@en ;
    skos:narrower "Pancreatic human cancer cells (PaCa2)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_24d/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower pubchem:8326 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5610 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:76074 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:74960 ],
        [ a npo:NPO_1962 ;
            skos:narrower "N-(2-Aminoethyl)-N'-(3-aminopropyl)butane-1,4-diamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:20051 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:88069 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:96580 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:681 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12443 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:86625 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6810 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:19990 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:96196 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8265 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:25160 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:70728 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:9845 ],
        [ a npo:NPO_1962 ;
            skos:narrower "4-Methyldihydro-2Hpyran-2,6(3H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7894 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:513917 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7940 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:866 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69545 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:750 ],
        [ a npo:NPO_1962 ;
            skos:narrower "7 3,4-Dimethylfuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:98484 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:85689 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69527 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:79743 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:17386 ],
        [ a npo:NPO_1962 ;
            skos:narrower "3-Methylidenedihydrofuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:617 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:602 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:67742 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78218 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12019 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Tetrahydrofuro[3',4':3,4]cyclobuta[1,2-c]furan-1,3,4,6-tetrone"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Amino-3-(1Himidazol-4-yl)propanoic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:2733254 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:16402 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8060 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5-Nitro-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:611 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5603 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7923 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1182 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8102 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:587821 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:2794246 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:424 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:15659773 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:74918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:230976 ],
        [ a npo:NPO_1962 ;
            skos:narrower "3-Phenyldihydro-2Hpyran-2,6(3H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:79882 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8111 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:994 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:68986 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:205 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8926 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:866 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:876 ],
        [ a npo:NPO_1962 ;
            skos:narrower "4 3,3-Dimethyldihydrofuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:587821 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6811 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1045 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7719 ],
        [ a npo:NPO_1962 ;
            skos:narrower "6-Nitro-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1148 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:25332 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78479 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69339 ],
        [ a npo:NPO_1962 ;
            skos:narrower "6-Bromo-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:72794 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7922 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:11089 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12801 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78232 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78480 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-ammonio-3-(4-hydroxyphenyl)propanoate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:3301 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:16217 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:97914 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:428 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5-amino-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:239163 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:75498 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8359 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6558 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:102679 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:738 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:76247 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7908 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10946 ],
        [ a npo:NPO_1962 ;
            skos:narrower "{Bis[2-(2,6-dioxomorpholin-4-yl)ethyl]amino}acetic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12012 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:513918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6385 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:95411 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1,4,5, 8-Naphthalenetetracarboxylic acidanhydride"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:70334 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:65729 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5,6-Dihydro-1Hcyclopenta[c]furan-1,3(4H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:75737 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:21631 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:232 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12475 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:220977 ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_24d/Nanoparticle/Size> ;
    skos:narrower npo:NPO_729 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_24d/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "38" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_25a/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as biological activity by Dose-response curve of smooth muscle cell apoptosis (SMA)"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Biological activity was defined as the arithmetic mean of in vitro tests on four different cell lines,Using four doses, and four different assays of cellular physiology : (i) ATP content, (ii) Reducing equivalents, (iii) Caspase-mediated apoptosis, (iv) Mitochondrial membrane potential. Only the apoptosis assay (smooth muscle cell apoptosis, SMA) exhibited dose-response relationship."@en ;
    skos:narrower "Endothelial cells (human aorta)",
        "Hepatocytes (human HepG2 cells)",
        "Murine RAW 264.7 leukemic monocyte/macrophage cell",
        "Vascular smooth muscle cells (human coronary artery)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_25a/Nanoparticle> a npo:NPO_1384,
        npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "PVA :: Ethylene diamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA, PEG :: Ethylene diamine, VT750"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Sucrose :: NA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Alexa Fluor 488"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Cy5"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: Ethylene diamine, VT750"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: rhodamine, protamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: 15-mer peptide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: L-arg7-COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Dextran :: NA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: FITC, succinimidyl iodoacetate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: protamine, rhodamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Tat peptide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amphiphilic polymer â€“ PEG :: NH2"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Arabino-galactan :: NA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Cy3.5"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Coating :: Surface modification"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: FITC"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: Ethylene diamine, AminoSPARKâ„¢680"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: FITC, COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Cy5.5, protamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amphiphilic polymer :: COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: VT680"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: biotin"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: FITC, R-COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: VT680, protamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA, PEG :: AngioSPARKâ„¢680- IVM"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: L-arg8-COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Cy5.5, tat"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Cy7"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: AminoSPARKâ„¢680"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Alexa Fluor 750"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: Ethylene diamine, VT680"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: NA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA, PEG :: NA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: D-arg7-COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: PEG Ethylene diamine, AminoSPARKâ„¢680"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: FITC, Glutamic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: glycine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Cy5.5"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: NH2"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Carboxymethyldextran :: NA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: FITC, COOH"@en ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_25a/Nanoparticle/Size> ;
    skos:narrower npo:NPO_1548,
        npo:NPO_1550 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_25a/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "20-74" ;
            sbd:lower_limit "20" ;
            sbd:upper_limit "74" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_25b/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as biological activity by Dose-response curve of smooth muscle cell apoptosis (SMA)"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Biological activity was defined as the arithmetic mean of in vitro tests on four different cell lines,Using four doses, and four different assays of cellular physiology : (i) ATP content, (ii) Reducing equivalents, (iii) Caspase-mediated apoptosis, (iv) Mitochondrial membrane potential. Only the apoptosis assay (smooth muscle cell apoptosis, SMA) exhibited dose-response relationship."@en ;
    skos:narrower "Endothelial cells (human aorta)",
        "Hepatocytes (human HepG2 cells)",
        "Murine RAW 264.7 leukemic monocyte/macrophage cell",
        "Vascular smooth muscle cells (human coronary artery)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_25b/Nanoparticle> a npo:NPO_1384,
        npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: FITC, Glutamic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Cy5"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Alexa Fluor 750"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Arabino-galactan :: NA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Dextran :: NA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: FITC"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: NA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: VT680, protamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: FITC, R-COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: glycine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: AminoSPARKâ„¢680"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: Ethylene diamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: D-arg7-COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amphiphilic polymer â€“ PEG :: NH2"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Cy3.5"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: 15-mer peptide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: Ethylene diamine, VT680"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Sucrose :: NA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: biotin"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Cy5.5"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: rhodamine, protamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: NH2"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Tat peptide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Coating :: Surface modification"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: FITC, succinimidyl iodoacetate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: VT680"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: protamine, rhodamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Cy7"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: FITC, COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Cy5.5, tat"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: FITC, COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: L-arg7-COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA, PEG :: Ethylene diamine, VT750"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amphiphilic polymer :: COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: L-arg8-COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA, PEG :: AngioSPARKâ„¢680- IVM"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Alexa Fluor 488"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: Ethylene diamine, VT750"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Cy5.5, protamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: Ethylene diamine, AminoSPARKâ„¢680"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Carboxymethyldextran :: NA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA, PEG :: NA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: PEG Ethylene diamine, AminoSPARKâ„¢680"@en ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_25b/Nanoparticle/Size> ;
    skos:narrower npo:NPO_1548,
        npo:NPO_1550 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_25b/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "20-74" ;
            sbd:lower_limit "20" ;
            sbd:upper_limit "74" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_25c/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a npo:NPO_296 ;
            rdfs:label "Cellular uptake of extracellular material"@en ;
            rdfs:comment "measured as log(pM) /cell"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Cellular uptake is expressed as decadic logarithm of the concentration (pM) of NP per cell"@en ;
    skos:narrower "Pancreatic human cancer cells (PaCa2)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_25c/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower pubchem:97914 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:86625 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:866 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:76074 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:16402 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Amino-3-(1Himidazol-4-yl)propanoic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5610 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69545 ],
        [ a npo:NPO_1962 ;
            skos:narrower "4-Methyldihydro-2Hpyran-2,6(3H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "4 3,3-Dimethyldihydrofuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7894 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:513917 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:70728 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:750 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8111 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:866 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8326 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1,4,5, 8-Naphthalenetetracarboxylic acidanhydride"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:15659773 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12012 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:102679 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:876 ],
        [ a npo:NPO_1962 ;
            skos:narrower "7 3,4-Dimethylfuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "3-Phenyldihydro-2Hpyran-2,6(3H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1045 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7922 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:220977 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12443 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:16217 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:232 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:79882 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7719 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:76247 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:239163 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1148 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:25332 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7908 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1182 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:2733254 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7923 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12801 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:74960 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8060 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:98484 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:738 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:88069 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7940 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:20051 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:95411 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5,6-Dihydro-1Hcyclopenta[c]furan-1,3(4H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:617 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:65729 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6810 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:587821 ],
        [ a npo:NPO_1962 ;
            skos:narrower "6-Bromo-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78232 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8359 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:513918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:428 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:3301 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:75737 ],
        [ a npo:NPO_1962 ;
            skos:narrower "{Bis[2-(2,6-dioxomorpholin-4-yl)ethyl]amino}acetic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:70334 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:75498 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8265 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6385 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8102 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:85689 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78479 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Tetrahydrofuro[3',4':3,4]cyclobuta[1,2-c]furan-1,3,4,6-tetrone"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6558 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:9845 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12019 ],
        [ a npo:NPO_1962 ;
            skos:narrower "N-(2-Aminoethyl)-N'-(3-aminopropyl)butane-1,4-diamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:994 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:681 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78480 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:2794246 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5-Nitro-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "3-Methylidenedihydrofuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:602 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:424 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:611 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:25160 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10946 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:19990 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:79743 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:96196 ],
        [ a npo:NPO_1962 ;
            skos:narrower "6-Nitro-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69339 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:11089 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:17386 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:587821 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6811 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:21631 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:96580 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:68986 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5603 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12475 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:230976 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:205 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:74918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:67742 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5-amino-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-ammonio-3-(4-hydroxyphenyl)propanoate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8926 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:72794 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78218 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69527 ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_25c/Nanoparticle/Size> ;
    skos:narrower npo:NPO_729 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_25c/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "38" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_25d/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a npo:NPO_296 ;
            rdfs:label "Cellular uptake of extracellular material"@en ;
            rdfs:comment "measured as log(pM) /cell"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Cellular uptake is expressed as decadic logarithm of the concentration (pM) of NP per cell"@en ;
    skos:narrower "Pancreatic human cancer cells (PaCa2)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_25d/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower pubchem:6385 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:96580 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:17386 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5-amino-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "6-Bromo-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:67742 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:3301 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:587821 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:994 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:611 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12019 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:98484 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69339 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8359 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78479 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:424 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:25160 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1182 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8111 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:220977 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6811 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7923 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78480 ],
        [ a npo:NPO_1962 ;
            skos:narrower "{Bis[2-(2,6-dioxomorpholin-4-yl)ethyl]amino}acetic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Tetrahydrofuro[3',4':3,4]cyclobuta[1,2-c]furan-1,3,4,6-tetrone"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8102 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:2733254 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:86625 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:68986 ],
        [ a npo:NPO_1962 ;
            skos:narrower "N-(2-Aminoethyl)-N'-(3-aminopropyl)butane-1,4-diamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:21631 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:75498 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5,6-Dihydro-1Hcyclopenta[c]furan-1,3(4H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:79743 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:79882 ],
        [ a npo:NPO_1962 ;
            skos:narrower "4 3,3-Dimethyldihydrofuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:102679 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:513917 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:75737 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7719 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1045 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Amino-3-(1Himidazol-4-yl)propanoic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:74918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:239163 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10946 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:866 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12475 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7940 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:750 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5610 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:74960 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:72794 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7922 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7894 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12443 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:97914 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:513918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69527 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:76074 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1148 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:16217 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:587821 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:602 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5-Nitro-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69545 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:738 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8926 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:2794246 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:230976 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78218 ],
        [ a npo:NPO_1962 ;
            skos:narrower "3-Phenyldihydro-2Hpyran-2,6(3H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:70728 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-ammonio-3-(4-hydroxyphenyl)propanoate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:15659773 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8265 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6810 ],
        [ a npo:NPO_1962 ;
            skos:narrower "3-Methylidenedihydrofuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:9845 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6558 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:11089 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:65729 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:16402 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7908 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5603 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12012 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:76247 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12801 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:617 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:428 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:866 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:681 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8326 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:19990 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:70334 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:85689 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:205 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8060 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:88069 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:25332 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:20051 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:232 ],
        [ a npo:NPO_1962 ;
            skos:narrower "4-Methyldihydro-2Hpyran-2,6(3H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:95411 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1,4,5, 8-Naphthalenetetracarboxylic acidanhydride"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:96196 ],
        [ a npo:NPO_1962 ;
            skos:narrower "6-Nitro-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "7 3,4-Dimethylfuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:876 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78232 ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_25d/Nanoparticle/Size> ;
    skos:narrower npo:NPO_729 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_25d/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "38" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_25e/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as log(1/EC50)"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Determined the cytotoxicity of the metal oxide nanoparticles in terms of EC50 (concentration which cytotoxicity reduces bacteria viability up to 50%) based on the curve fitting least squares procedure. For experimental testing protocol see: Supplementary information (Section 1) from Puzyn et al. 2011 (already reported in this table)."@en ;
    skos:narrower mesh:D004926 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_25e/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_25e/Nanoparticle/Size> ;
    skos:narrower npo:NPO_1373,
        npo:NPO_1486,
        npo:NPO_1542,
        npo:NPO_1550,
        enm:ENM_0000118,
        obo:CHEBI_30187,
        pubchem:14776,
        pubchem:14794,
        pubchem:14805,
        pubchem:14829,
        pubchem:150906,
        pubchem:157925,
        pubchem:159375,
        pubchem:166955,
        pubchem:29131,
        pubchem:518712,
        pubchem:62762 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_25e/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "15-90" ;
            sbd:lower_limit "15" ;
            sbd:upper_limit "90" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_25f/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as cellular viability by determining the mitochondrial dehydrogenasesâ€™ activity"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Cellular viability was determined on the basis of the activity of the mitochondrial dehydrogenases in the presence and absence of the nanotubeâˆ’decorator complexes and expressed on a 0 to 100 scale (100 most â€œtoxicâ€) To evaluate the acute cytotoxicity (Cell) of theDNClibrary in macrophages, Zhou et al., used the WST-1 assay. Cellular viability was measured by determining the mitochondrial dehydrogenasesâ€™ activity. The immune response was measured by treating macrophages with DNC for 24 h in a solution of lipopolysaccharide"@en ;
    skos:narrower "THP-1 (human monocytic cell line) differenciate into Macrophages" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_25f/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_part [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:46744931 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5205930 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:3393128 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:51148039 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:47099540 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:3618978 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:4528484 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:47097636 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:3496505 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:303942 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:112762823 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:51147965 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:24101749 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:51148276 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:51148259 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:60407577 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ] ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_461 ],
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_25f/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_25f/Nanoparticle/Size_2> ;
    skos:narrower "Decorator-nanotube complexes" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_25f/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "30.0-50.0" ;
            sbd:lower_limit "30.0" ;
            sbd:upper_limit "50.0" ] ;
    skos:narrower obo:PATO_0001334 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_25f/Nanoparticle/Size_2> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "130.0-370.0" ;
            sbd:lower_limit "130.0" ;
            sbd:upper_limit "370.0" ] ;
    skos:narrower obo:PATO_0000122 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_26/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as Percentage of damaged cells by Propidium Iodide uptake of BEAS-2B"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Cellular uptake is expressed as decadic logarithm of the concentration (pM) of NP per cell"@en ;
    skos:narrower "Pancreatic human cancer cells (PaCa2)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_26/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower pubchem:98484 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:25332 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:74960 ],
        [ a npo:NPO_1962 ;
            skos:narrower "6-Nitro-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6385 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7908 ],
        [ a npo:NPO_1962 ;
            skos:narrower "3-Methylidenedihydrofuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:16217 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:232 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1148 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:9845 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:25160 ],
        [ a npo:NPO_1962 ;
            skos:narrower "4-Methyldihydro-2Hpyran-2,6(3H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "N-(2-Aminoethyl)-N'-(3-aminopropyl)butane-1,4-diamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69339 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:230976 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:876 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:20051 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:79882 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:424 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:72794 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:750 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:70334 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1182 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1,4,5, 8-Naphthalenetetracarboxylic acidanhydride"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:681 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6811 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8926 ],
        [ a npo:NPO_1962 ;
            skos:narrower "6-Bromo-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7719 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:65729 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12443 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:68986 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Amino-3-(1Himidazol-4-yl)propanoic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69527 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8060 ],
        [ a npo:NPO_1962 ;
            skos:narrower "4 3,3-Dimethyldihydrofuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12475 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78232 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:3301 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:96580 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:76074 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:866 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1045 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:587821 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78218 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:428 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5603 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8359 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5-Nitro-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:95411 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:76247 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:11089 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:102679 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:205 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:85689 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:67742 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6810 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:994 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8265 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:74918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:611 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:21631 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-ammonio-3-(4-hydroxyphenyl)propanoate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "{Bis[2-(2,6-dioxomorpholin-4-yl)ethyl]amino}acetic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:2733254 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:239163 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5,6-Dihydro-1Hcyclopenta[c]furan-1,3(4H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:2794246 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:16402 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78479 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:75737 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69545 ],
        [ a npo:NPO_1962 ;
            skos:narrower "7 3,4-Dimethylfuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8326 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:96196 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8102 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:17386 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:88069 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5-amino-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:70728 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7923 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8111 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6558 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:513918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:19990 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78480 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:220977 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7894 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:75498 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:617 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:602 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12012 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:79743 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12019 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5610 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Tetrahydrofuro[3',4':3,4]cyclobuta[1,2-c]furan-1,3,4,6-tetrone"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:15659773 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:738 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:513917 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7940 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12801 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:86625 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:587821 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7922 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:97914 ],
        [ a npo:NPO_1962 ;
            skos:narrower "3-Phenyldihydro-2Hpyran-2,6(3H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:866 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10946 ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_26/Nanoparticle/Size> ;
    skos:narrower npo:NPO_729 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_26/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "38" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_27/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a enm:ENM_0000042 ;
            rdfs:label "Mutagenicity"@en ;
            rdfs:comment "measured as the number of observed colonies"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "The mutagenecity of a substance is proportional to the number of observed colonies. Data on the bacterial reverse mutation test that was conducted using Salmonella typhimurium strain TA100 in the presence and absence of metabolic activation under dark conditions and irradiation are taken in the literature (Shinohara et al., 2009)."@en ;
    skos:narrower "Salmonella typhimurium TA100" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_27/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ],
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_27/Nanoparticle/Size> ;
    skos:narrower npo:NPO_730 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_27/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "<100.0" ;
            sbd:upper_limit "100.0" ] ;
    skos:narrower obo:PATO_0001334 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_28a/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as EC50"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Concentration of a drug, antibody or toxicant which induces a response halfway between the baseline and maximum after a specified exposure time."@en ;
    skos:narrower mesh:D004926 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_28a/Nanoparticle> a npo:NPO_1384,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "branched polyethyleneimine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6917 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:31348 ] ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ],
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_28a/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_28a/Nanoparticle/Size_2>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_28a/Nanoparticle/Size_3>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_28a/Nanoparticle/Size_4> ;
    skos:narrower npo:NPO_1892 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_28a/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    skos:narrower obo:PATO_0001334 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_28a/Nanoparticle/Size_2> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "5.4-14.6" ;
            sbd:lower_limit "5.4" ;
            sbd:upper_limit "14.6" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_28a/Nanoparticle/Size_3> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "42.0-70.0" ;
            sbd:lower_limit "42.0" ;
            sbd:upper_limit "70.0" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_28a/Nanoparticle/Size_4> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "48.0-96.0" ;
            sbd:lower_limit "48.0" ;
            sbd:upper_limit "96.0" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_28b/Endpoint> a sty:T001,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as LC50"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Non-renewable D.magna 48 h bioassay was performed following the standard USEPA guidelines, including the culture and main tenance of the daphnids (USEPA, 1987)"@en ;
    skos:narrower mesh:D004926 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_28b/Nanoparticle> a npo:NPO_1384,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "branched polyethyleneimine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:31348 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6917 ] ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ],
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_28b/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_28b/Nanoparticle/Size_2>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_28b/Nanoparticle/Size_3>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_28b/Nanoparticle/Size_4> ;
    skos:narrower npo:NPO_1892 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_28b/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    skos:narrower obo:PATO_0001334 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_28b/Nanoparticle/Size_2> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "5.4-14.6" ;
            sbd:lower_limit "5.4" ;
            sbd:upper_limit "14.6" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_28b/Nanoparticle/Size_3> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "42.0-70.0" ;
            sbd:lower_limit "42.0" ;
            sbd:upper_limit "70.0" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_28b/Nanoparticle/Size_4> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "48.0-96.0" ;
            sbd:lower_limit "48.0" ;
            sbd:upper_limit "96.0" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_29a/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as pEC50"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Negative logarithm of concentration of drug/toxic material for the 50 percent of its effect."@en ;
    skos:narrower mesh:D004926 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_29a/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_29a/Nanoparticle/Size> ;
    skos:narrower npo:NPO_1373,
        npo:NPO_1486,
        npo:NPO_1542,
        npo:NPO_1550,
        enm:ENM_0000118,
        obo:CHEBI_30187,
        pubchem:14776,
        pubchem:14794,
        pubchem:14805,
        pubchem:14829,
        pubchem:150906,
        pubchem:157925,
        pubchem:159375,
        pubchem:166955,
        pubchem:29131,
        pubchem:518712,
        pubchem:62762 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_29a/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "15-90" ;
            sbd:lower_limit "15" ;
            sbd:upper_limit "90" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_29b/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as pEC50"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Negative logarithm of concentration of drug/toxic material for the 50 percent of its effect."@en ;
    skos:narrower mesh:D004926 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_29b/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_29b/Nanoparticle/Size> ;
    skos:narrower npo:NPO_1373,
        npo:NPO_1486,
        npo:NPO_1542,
        npo:NPO_1550,
        enm:ENM_0000118,
        obo:CHEBI_30187,
        pubchem:14776,
        pubchem:14794,
        pubchem:14805,
        pubchem:14829,
        pubchem:150906,
        pubchem:157925,
        pubchem:159375,
        pubchem:166955,
        pubchem:29131,
        pubchem:518712,
        pubchem:62762 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_29b/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "15-90" ;
            sbd:lower_limit "15" ;
            sbd:upper_limit "90" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_2a/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "membrane damage measured as lactate dehydrogenase (LDH) release [units/L]"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Cell culture systems were cultured in F-12K medium (Kaighnâ€™s modification of Hamâ€™s F-12 medium) supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin. Cellular membrane damage was collected at 80â€“85% confluency. Tests for cellular membrane damage were done in triplicate. Characterize the culture media by using Olympus Lactate Dehydrogenase reagents ( absorbance method at 340 nm). The release [units/L] was classified in: y < 0,99 --> Dense cell membrane 0,99 < y < 1,09 --> Normal cell membrane 1,09 < y < 1,25 --> Leaky cell membrane 1,25 < y --> Disrupted cell membrane LDA classifies in Dense and Disrupted"@en ;
    skos:narrower rcd:X7A8D,
        "rat lung alveolar macrophages" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_2a/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_2a/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_2a/Nanoparticle/Size_1>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_2a/Nanoparticle/Size_2> ;
    skos:narrower npo:NPO_1486 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_2a/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "125",
                "30",
                "45" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_2a/Nanoparticle/Size_1> a obo:PATO_0000117 ;
    npo:contained_in obo:CHEBI_15377 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "101-967" ;
            sbd:lower_limit "101" ;
            sbd:upper_limit "967" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_2a/Nanoparticle/Size_2> a obo:PATO_0000117 ;
    npo:contained_in npo:NPO_1846 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "961-3871" ;
            sbd:lower_limit "961" ;
            sbd:upper_limit "3871" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_2b/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "membrane damage measured as lactate dehydrogenase (LDH) release [units/L]"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Cell culture systems were cultured in F-12K medium (Kaighnâ€™s modification of Hamâ€™s F-12 medium) supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin. Cellular membrane damage was collected at 80â€“85% confluency. Tests for cellular membrane damage were done in triplicate. Characterize the culture media by using Olympus Lactate Dehydrogenase reagents ( absorbance method at 340 nm). The release [units/L] was classified in: y < 0,99 --> Dense cell membrane 0,99 < y < 1,09 --> Normal cell membrane 1,09 < y < 1,25 --> Leaky cell membrane 1,25 < y --> Disrupted cell membrane LDA classifies in Dense and Disrupted"@en ;
    skos:narrower rcd:X7A8D,
        "rat lung alveolar macrophages" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_2b/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_2b/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_2b/Nanoparticle/Size_1>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_2b/Nanoparticle/Size_2>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_2b/Nanoparticle/Size_3> ;
    skos:narrower npo:NPO_1542 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_2b/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "1000",
                "1200",
                "1500",
                "50",
                "60",
                "70" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_2b/Nanoparticle/Size_1> a obo:PATO_0000117 ;
    npo:contained_in obo:CHEBI_15377 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "55-1283" ;
            sbd:lower_limit "55" ;
            sbd:upper_limit "1283" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_2b/Nanoparticle/Size_2> a obo:PATO_0000117 ;
    npo:contained_in npo:NPO_1846 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "158-2109" ;
            sbd:lower_limit "158" ;
            sbd:upper_limit "2109" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_2b/Nanoparticle/Size_3> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "107-1578" ;
            sbd:lower_limit "107" ;
            sbd:upper_limit "1578" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_30/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as Inhibition Ratio (IR%)"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "MTT [3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazoliumbromide] assay has been used as the endpoint for the QSAR analysis. HFLâ€I cell line was maintained in logarithmic phase of growth by subculturing at appropriate stages and in MEM with glutamine supplemented with 10% FBS and 1% penicillin streptomycin (Gibco, Invitrogen, NY, USA). The cell line was maintained at 37 Â°C in a 5% CO2 incubator. Appropriately assigned concentrations of SiO2 NPs were then added to the cell cultures at the stage of 80% confluency and incubated for 24 h. The exponentially growing HFLâ€I s (1 Ã— 105 per well) were seeded into 96â€well culture plates and incubated with various concentrations of SiO2 NPs (20 and 80 nm) for 48 h. Four hours before termination, the supernatants were replaced with 90 ml fresh medium and 10 ml MTT (1 mg mlâˆ’1 ) solution. After incubating for 4 h at 37 Â°C, the medium was aspirated and the formazan crystals were solubilised in acidified isopropanol. The reduction of absorbance was measured spectrophotometrically at 570 and 630 nm, and the Cellular viability was expressed as a percentage over the untreated control"@en ;
    skos:narrower "Human lung fibroblast" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_30/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_30/Nanoparticle/Size> ;
    skos:narrower npo:NPO_1373 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_30/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "20",
                "80" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_31a/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as -log(LC50)"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "The samples in Pyrex and quartz test tubes were exposed to sunlight for 30 min with agitation in a water bath at 150 r.p.m. Similarly, corresponding samples were exposed under dark conditions, by wrapping the test samples in the test tubes with aluminium foils (solar irradiation outdoors: irradiance: UVA range = 3.979â€“4.652 mW/cm2; UVB range = 3.1â€“3.7 MED/h, where an MED is defined as the minimum erythemal dose or the amount of UV radiation to produce barely perceptible erythema; 1 MED/h = 0.05833 W/m2)."@en ;
    skos:narrower mesh:D004926 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_31a/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_31a/Nanoparticle/Size> ;
    skos:narrower npo:NPO_1373,
        npo:NPO_1486,
        npo:NPO_1542,
        npo:NPO_1550,
        enm:ENM_0000118,
        obo:CHEBI_30187,
        pubchem:14776,
        pubchem:14794,
        pubchem:14805,
        pubchem:14829,
        pubchem:150906,
        pubchem:157925,
        pubchem:159375,
        pubchem:166955,
        pubchem:29131,
        pubchem:518712,
        pubchem:62762 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_31a/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "15-90" ;
            sbd:lower_limit "15" ;
            sbd:upper_limit "90" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_31b/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as -log(LC50)"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "The samples in Pyrex and quartz test tubes were exposed to sunlight for 30 min with agitation in a water bath at 150 r.p.m. Similarly, corresponding samples were exposed under dark conditions, by wrapping the test samples in the test tubes with aluminium foils (solar irradiation outdoors: irradiance: UVA range = 3.979â€“4.652 mW/cm2; UVB range = 3.1â€“3.7 MED/h, where an MED is defined as the minimum erythemal dose or the amount of UV radiation to produce barely perceptible erythema; 1 MED/h = 0.05833 W/m2)."@en ;
    skos:narrower mesh:D004926 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_31b/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_31b/Nanoparticle/Size> ;
    skos:narrower npo:NPO_1373,
        npo:NPO_1486,
        npo:NPO_1542,
        npo:NPO_1550,
        enm:ENM_0000118,
        obo:CHEBI_30187,
        pubchem:14776,
        pubchem:14794,
        pubchem:14805,
        pubchem:14829,
        pubchem:150906,
        pubchem:157925,
        pubchem:159375,
        pubchem:166955,
        pubchem:29131,
        pubchem:518712,
        pubchem:62762 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_31b/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "15-90" ;
            sbd:lower_limit "15" ;
            sbd:upper_limit "90" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_32a/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "Photocatalytic decolourization rate constants DRC (10^-5 /s) of methylene blue dye" ] ;
    rdfs:comment "The photocatalytic performance of each sample was tested by dye (methylene blue) decolourisation under simulated solar light illumination (mixture of UV and visible), with regular measurements of the dye concentration (determined by absorbance at 664 nm). (Goodall, 2010) The dye decolourisation rate is defined as d ln[C(t)/C0]/dt, where C0 is the initial dye concentration and C(t) is the dye concentration at time t."@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_32a/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_32b/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as perecentage of cellular viability"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "The effects of SiO2 nanoparticles on HK-2 and LLC-PK1 cells were determined by WST-1. The WST-1 assay evaluates cellular mitochondrial activity. It is based on cleavage of the tetrazolium salt to a soluble formazan dye by succinate-tetrazolium reductase, a mitochondrial enzyme that is active only in viable cells. % of cellular viability was calculated using the formula : (absorbance treated sample Ã— 100/absorbance control sample)"@en ;
    skos:narrower "Human kidney (HK-2) cells",
        "Porcine tubular LLC-PK_1 cells" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_32b/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ],
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_32b/Nanoparticle/Size> ;
    skos:narrower npo:NPO_1373 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_32b/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "100",
                "20" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_33a/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a obo:OBI_0001429 ;
            rdfs:label "Cell differentiation"@en ;
            rdfs:comment "measured by concentration of Arginase:iNOS"@en ] ;
    bao:BAO_0095009 obo:OBI_0100026 ;
    rdfs:comment "The library of materials used by Wang et al., was injected into SKH1-E mice and monitored for 7 days through in vivo fluorescence imaging. Histological analysis and ex vivo assays were performed on tissues collected 7 days post-injection, when the highest-level of MF presence is expected. The different evaluated endpoints are related with the differentiation of macrophages in M1 or M2. Cathepsin activity measured at 7 days was negatively correlated with TNF-a and positively correlated with arginase:iNOS, demonstrating that cathepsin is positively correlated with increased M2 MFs and negatively correlated with M1 MFs. High levels of IL-10 are commonly associated with M2 MFs and tumour progression, and high levels of TNF-a are commonly associated with M1 MFs and tumour suppression"@en ;
    skos:narrower obo:CL_0000235,
        "on 6-week-old female SKH-1 mice" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_33a/Nanoparticle> a npo:NPO_1375,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "3-butenylamine (Santa Cruz Biotechnology, Dallas, TX)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "malonamide (Fisher, Pittsburgh, PA)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2,4-dinitro-phenyl-hydroxylamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:91550 ],
        [ a npo:NPO_1962 ;
            skos:narrower "3-amino-1-propanesulfonic acid (Fisher, Pittsburgh, PA)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:16773849 ],
        [ a npo:NPO_1962 ;
            skos:narrower "and without functionalization"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Aminomethylphosphonic acid (Alfa Aesar,Ward Hill, MA)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:17749886 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-amino-4-oxocyclohexanecarboxylic and ethylene ketal"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "aminoacetaldehyde dimethyl acetal (Alfa Aesar, Ward Hill, MA)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5355751 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:3748064 ],
        [ a npo:NPO_1962 ;
            skos:narrower "tert-butyl 4- aminobutanoate (VWR, Radnor, PA)"@en ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_33a/Nanoparticle/Size> ;
    skos:narrower "p(NIPAm-co-AAc)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_33a/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "600" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_33b/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a obo:OBI_0001429 ;
            rdfs:label "Cell differentiation"@en ;
            rdfs:comment "measured by concentration of IL-10"@en ] ;
    bao:BAO_0095009 obo:OBI_0100026 ;
    rdfs:comment "The library of materials used by Wang et al., was injected into SKH1-E mice and monitored for 7 days through in vivo fluorescence imaging. Histological analysis and ex vivo assays were performed on tissues collected 7 days post-injection, when the highest-level of MF presence is expected. The different evaluated endpoints are related with the differentiation of macrophages in M1 or M2. Cathepsin activity measured at 7 days was negatively correlated with TNF-a and positively correlated with arginase:iNOS, demonstrating that cathepsin is positively correlated with increased M2 MFs and negatively correlated with M1 MFs. High levels of IL-10 are commonly associated with M2 MFs and tumour progression, and high levels of TNF-a are commonly associated with M1 MFs and tumour suppression"@en ;
    skos:narrower obo:CL_0000235,
        "on 6-week-old female SKH-1 mice" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_33b/Nanoparticle> a npo:NPO_1375,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "Aminomethylphosphonic acid (Alfa Aesar,Ward Hill, MA)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "tert-butyl 4- aminobutanoate (VWR, Radnor, PA)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "3-amino-1-propanesulfonic acid (Fisher, Pittsburgh, PA)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5355751 ],
        [ a npo:NPO_1962 ;
            skos:narrower "3-butenylamine (Santa Cruz Biotechnology, Dallas, TX)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2,4-dinitro-phenyl-hydroxylamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:17749886 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:16773849 ],
        [ a npo:NPO_1962 ;
            skos:narrower "malonamide (Fisher, Pittsburgh, PA)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:91550 ],
        [ a npo:NPO_1962 ;
            skos:narrower "and without functionalization"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-amino-4-oxocyclohexanecarboxylic and ethylene ketal"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:3748064 ],
        [ a npo:NPO_1962 ;
            skos:narrower "aminoacetaldehyde dimethyl acetal (Alfa Aesar, Ward Hill, MA)"@en ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_33b/Nanoparticle/Size> ;
    skos:narrower "p(NIPAm-co-AAc)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_33b/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "600" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_33c/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a obo:OBI_0001429 ;
            rdfs:label "Cell differentiation"@en ;
            rdfs:comment "measured by concentration of TNF-a"@en ] ;
    bao:BAO_0095009 obo:OBI_0100026 ;
    rdfs:comment "The library of materials used by Wang et al., was injected into SKH1-E mice and monitored for 7 days through in vivo fluorescence imaging. Histological analysis and ex vivo assays were performed on tissues collected 7 days post-injection, when the highest-level of MF presence is expected. The different evaluated endpoints are related with the differentiation of macrophages in M1 or M2. Cathepsin activity measured at 7 days was negatively correlated with TNF-a and positively correlated with arginase:iNOS, demonstrating that cathepsin is positively correlated with increased M2 MFs and negatively correlated with M1 MFs. High levels of IL-10 are commonly associated with M2 MFs and tumour progression, and high levels of TNF-a are commonly associated with M1 MFs and tumour suppression"@en ;
    skos:narrower obo:CL_0000235,
        "on 6-week-old female SKH-1 mice" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_33c/Nanoparticle> a npo:NPO_1375,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower pubchem:91550 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2,4-dinitro-phenyl-hydroxylamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:3748064 ],
        [ a npo:NPO_1962 ;
            skos:narrower "3-butenylamine (Santa Cruz Biotechnology, Dallas, TX)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "aminoacetaldehyde dimethyl acetal (Alfa Aesar, Ward Hill, MA)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "3-amino-1-propanesulfonic acid (Fisher, Pittsburgh, PA)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5355751 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-amino-4-oxocyclohexanecarboxylic and ethylene ketal"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "tert-butyl 4- aminobutanoate (VWR, Radnor, PA)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "and without functionalization"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Aminomethylphosphonic acid (Alfa Aesar,Ward Hill, MA)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "malonamide (Fisher, Pittsburgh, PA)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:17749886 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:16773849 ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_33c/Nanoparticle/Size> ;
    skos:narrower "p(NIPAm-co-AAc)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_33c/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "600" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_33d/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a obo:OBI_0001429 ;
            rdfs:label "Cell differentiation"@en ;
            rdfs:comment "measured by concentration of Cathepsin_3day"@en ] ;
    bao:BAO_0095009 obo:OBI_0100026 ;
    rdfs:comment "The library of materials used by Wang et al., was injected into SKH1-E mice and monitored for 7 days through in vivo fluorescence imaging. Histological analysis and ex vivo assays were performed on tissues collected 7 days post-injection, when the highest-level of MF presence is expected. The different evaluated endpoints are related with the differentiation of macrophages in M1 or M2. Cathepsin activity measured at 7 days was negatively correlated with TNF-a and positively correlated with arginase:iNOS, demonstrating that cathepsin is positively correlated with increased M2 MFs and negatively correlated with M1 MFs. High levels of IL-10 are commonly associated with M2 MFs and tumour progression, and high levels of TNF-a are commonly associated with M1 MFs and tumour suppression"@en ;
    skos:narrower obo:CL_0000235,
        "on 6-week-old female SKH-1 mice" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_33d/Nanoparticle> a npo:NPO_1375,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "3-butenylamine (Santa Cruz Biotechnology, Dallas, TX)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:3748064 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Aminomethylphosphonic acid (Alfa Aesar,Ward Hill, MA)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:91550 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-amino-4-oxocyclohexanecarboxylic and ethylene ketal"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:17749886 ],
        [ a npo:NPO_1962 ;
            skos:narrower "3-amino-1-propanesulfonic acid (Fisher, Pittsburgh, PA)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2,4-dinitro-phenyl-hydroxylamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "malonamide (Fisher, Pittsburgh, PA)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "and without functionalization"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "tert-butyl 4- aminobutanoate (VWR, Radnor, PA)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:16773849 ],
        [ a npo:NPO_1962 ;
            skos:narrower "aminoacetaldehyde dimethyl acetal (Alfa Aesar, Ward Hill, MA)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5355751 ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_33d/Nanoparticle/Size> ;
    skos:narrower "p(NIPAm-co-AAc)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_33d/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "600" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_33e/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a obo:OBI_0001429 ;
            rdfs:label "Cell differentiation"@en ;
            rdfs:comment "measured by concentration of Cathepsin_7day"@en ] ;
    bao:BAO_0095009 obo:OBI_0100026 ;
    rdfs:comment "The library of materials used by Wang et al., was injected into SKH1-E mice and monitored for 7 days through in vivo fluorescence imaging. Histological analysis and ex vivo assays were performed on tissues collected 7 days post-injection, when the highest-level of MF presence is expected. The different evaluated endpoints are related with the differentiation of macrophages in M1 or M2. Cathepsin activity measured at 7 days was negatively correlated with TNF-a and positively correlated with arginase:iNOS, demonstrating that cathepsin is positively correlated with increased M2 MFs and negatively correlated with M1 MFs. High levels of IL-10 are commonly associated with M2 MFs and tumour progression, and high levels of TNF-a are commonly associated with M1 MFs and tumour suppression"@en ;
    skos:narrower obo:CL_0000235,
        "on 6-week-old female SKH-1 mice" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_33e/Nanoparticle> a npo:NPO_1375,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower pubchem:16773849 ],
        [ a npo:NPO_1962 ;
            skos:narrower "aminoacetaldehyde dimethyl acetal (Alfa Aesar, Ward Hill, MA)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2,4-dinitro-phenyl-hydroxylamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "and without functionalization"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "tert-butyl 4- aminobutanoate (VWR, Radnor, PA)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:91550 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5355751 ],
        [ a npo:NPO_1962 ;
            skos:narrower "3-butenylamine (Santa Cruz Biotechnology, Dallas, TX)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:17749886 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Aminomethylphosphonic acid (Alfa Aesar,Ward Hill, MA)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:3748064 ],
        [ a npo:NPO_1962 ;
            skos:narrower "malonamide (Fisher, Pittsburgh, PA)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-amino-4-oxocyclohexanecarboxylic and ethylene ketal"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "3-amino-1-propanesulfonic acid (Fisher, Pittsburgh, PA)"@en ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_33e/Nanoparticle/Size> ;
    skos:narrower "p(NIPAm-co-AAc)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_33e/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "600" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_34a/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as binary classification in toxic(\"1\") or non-toxic (\"0\") tranformed from log(EC50)"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Originally measured data were characterized as slopes of the dose-response based on doses of nanoparticles (in Î¼g/mL) and responses (the decimal logarithm of EC50). In current study the final endpointsâ€™ data set was transformed to binary rank scale: slopes with negative values were marked as â€œ0â€, while positive slopes were marked as â€œ1â€. Thus, â€œ0â€ means non-toxic compound and â€œ1â€ means toxic compound in given conditions."@en ;
    skos:narrower "Human bronchial epithelial cells (BEAS-2B)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_34a/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_34a/Nanoparticle/Size> ;
    skos:narrower npo:NPO_1373,
        npo:NPO_1486,
        npo:NPO_1542,
        npo:NPO_1548,
        npo:NPO_1550,
        enm:ENM_0000118,
        enm:ENM_9000254,
        obo:CHEBI_30187,
        pubchem:10855842,
        pubchem:14794,
        pubchem:14805,
        pubchem:14811,
        pubchem:14824,
        pubchem:14829,
        pubchem:150906,
        pubchem:157925,
        pubchem:159375,
        pubchem:159385,
        pubchem:159423,
        pubchem:160959,
        pubchem:166955,
        pubchem:29131,
        pubchem:62762,
        pubchem:73971 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_34a/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "10-100" ;
            sbd:lower_limit "10" ;
            sbd:upper_limit "100" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_34b/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as binary classification in toxic(\"1\") or non-toxic (\"0\") tranformed from log(EC50)"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Originally measured data were characterized as slopes of the dose-response based on doses of nanoparticles (in Î¼g/mL) and responses (the decimal logarithm of EC50). In current study the final endpointsâ€™ data set was transformed to binary rank scale: slopes with negative values were marked as â€œ0â€, while positive slopes were marked as â€œ1â€. Thus, â€œ0â€ means non-toxic compound and â€œ1â€ means toxic compound in given conditions."@en ;
    skos:narrower "Rat alveolar macrophage cells (RAW264.7)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_34b/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_34b/Nanoparticle/Size> ;
    skos:narrower npo:NPO_1373,
        npo:NPO_1486,
        npo:NPO_1542,
        npo:NPO_1548,
        npo:NPO_1550,
        enm:ENM_0000118,
        enm:ENM_9000254,
        obo:CHEBI_30187,
        pubchem:10855842,
        pubchem:14794,
        pubchem:14805,
        pubchem:14811,
        pubchem:14824,
        pubchem:14829,
        pubchem:150906,
        pubchem:157925,
        pubchem:159375,
        pubchem:159385,
        pubchem:159423,
        pubchem:160959,
        pubchem:166955,
        pubchem:29131,
        pubchem:62762,
        pubchem:73971 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_34b/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "10-100" ;
            sbd:lower_limit "10" ;
            sbd:upper_limit "100" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_35/Endpoint> a sty:T001,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "Ecotoxicological endpoint" ;
            rdfs:comment "measured as Mod EZ Metric"@en ] ;
    bao:BAO_0095009 obo:OBI_0100026 ;
    rdfs:comment "Exposuresâ€™ concentrations were typically fivefold serial dilutions of nanomaterials ranging from approximately 250 parts per million (ppm) down to *16 parts per billion (ppb) prepared in fishwater. Control exposures comprised fishwater alone (without NPs). Embryos were incubated at 26 ÂºC under 14/10 light cycle and were evaluated visually at 24 hpf for viability, developmental progression, and spontaneous movement (earliest behaviour in zebrafish). At 120 hpf, behavioural endpoints (motility, tactile response) were thoroughly evaluated in vivo and larval morphology (body axis, eye, snout, jaw, otic vesicle, notochord, heart, brain, somite, fin, yolk sac, trunk, circulation, pigment, swim bladder) was evaluated visually and scored in a binary fashion (present or absent) (Harper et al., 2008a, b; Truong et al., 2011). To summarize the 21 measured toxicity endpoints for each dose applied to the embryonic zebrafish, we define the EZ Metric score to provide a relative comparison of nanomaterial-elicited effects Original EZ Metric responses were transformed by multiplying the score by 100 and adding 0.1 to avoid the discontinuity resulting from taking the natural logarithm of zero scores (denoted as Mod EZ Metric in publication's equation \"Eq. 3\")"@en ;
    skos:narrower "Zebrafish (Danio rerio) embryos" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_35/Nanoparticle> a npo:NPO_1384,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "TMAT: N,N,N-trimethylammoni-umethanethiol"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "MES: 2-mercaptoethanesulfonate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "MEE: 2-(2-mercaptoethoxy)ethanol"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "MEEE: 2,2,2-[mercaptoethoxy(ethoxy)]ethanol"@en ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_35/Nanoparticle/Size> ;
    skos:narrower npo:NPO_401 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_35/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "0.8",
                "10",
                "2" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_36/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as binary classification into antibacterial active (\"1\") or antibacterial inactive(\"-1\") class which was obtained by different antibacterial activities (MBC, MIC, Microb-Eff)"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "The NPs were tested against different bacteria, by considering several measures of antibacterial activity and diverse assay times. Diverse measures of antibacterial activity (m_e) MBC: Minimum bactericidal concentration MIC: Minimum inhibitory concentration Microb-Eff: Microbicidal effect 300 NPs/cases were assigned to 1 out of 2 possible groups related to their antibacterial activities in a specific condition c_j [AB_i (c_j)]. In this sense, AB_i (c_j) is a binary classification variable that accounts for the antibacterial activity of the NPs. Thus, the NPs/cases were considered as active [AB_i (c_j ) = 1], when they exhibited high antibacterial activities (low levels of growth inhibition); otherwise, they were selected as inactive [AB_i (c_j) = -1]"@en ;
    skos:narrower "34 different Bacteria" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_36/Nanoparticle> a npo:NPO_1384,
        npo:NPO_1541,
        npo:NPO_707 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_37/Endpoint> a sty:T001,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "Ecotoxicological endpoint" ;
            rdfs:comment "measured as percentage of Mortality"@en ] ;
    bao:BAO_0095009 obo:OBI_0100026 ;
    rdfs:comment "Wild-type 5D zebrafish (Danio rerio) embryos were obtained from group spawns of adult fish housed at the Sinnhuber Aquatic Research Laboratory at Oregon State University (Corvallis, OR). All NP dilutions and exposures were conducted in fish water (FW). The FW was prepared with 0.26 g/L Instant Ocean salts (Aquatic Ecosystem, Apopka, FL) combined with approximately 0.01g NaHCO3 pH buffer in reverse osmosis water (pH 7.0â€“7.4, conductivity 450â€“600 Î¼S) Despite assessing a suite of 19 different developmental, behavioural and morphological endpoints in addition to mortality in this study, mortality was the most common endpoint observed for all of the ZnO NP types tested"@en ;
    skos:narrower "Embryonic zebrafish" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_37/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower pubchem:445639 ],
        [ a npo:NPO_1962 ;
            skos:narrower "cyclohexanecaboxylic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6108 ],
        [ a npo:NPO_1962 ;
            skos:narrower "uncoated"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:243 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:379 ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_37/Nanoparticle/Size> ;
    skos:narrower npo:NPO_1542 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_37/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "4-70" ;
            sbd:lower_limit "4" ;
            sbd:upper_limit "70" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38a/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "membrane damage measured as lactate dehydrogenase (LDH) release [units/L]"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Cell culture systems were cultured in F-12K medium (Kaighnâ€™s modification of Hamâ€™s F-12 medium) supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin. Cellular membrane damage was collected at 80â€“85% confluency. Tests for cellular membrane damage were done in triplicate. Characterize the culture media by using Olympus Lactate Dehydrogenase reagents ( absorbance method at 340 nm). The release [units/L] was classified in: y < 0.99 --> Dense cell membrane 0.99 < y < 1.09 --> Normal cell membrane 1.09 < y < 1.25 --> Leaky cell membrane 1.25 < y --> Disrupted cell membrane In this paper they only used one cutoff value (i.e. LDH > 1.09) to distinguish between toxic (i.e. causing leaking or disruption of the membrane) and non-toxic effects due to exposure to TiO2 and ZnO NPs"@en ;
    skos:narrower rcd:X7A8D,
        "rat lung alveolar macrophages" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38a/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38a/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38a/Nanoparticle/Size_1>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38a/Nanoparticle/Size_2> ;
    skos:narrower npo:NPO_1486,
        npo:NPO_1542 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38a/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "125",
                "30",
                "45",
                "50",
                "60",
                "70" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38a/Nanoparticle/Size_1> a obo:PATO_0000117 ;
    npo:contained_in obo:CHEBI_15377 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "101-967" ;
            sbd:lower_limit "101" ;
            sbd:upper_limit "967" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38a/Nanoparticle/Size_2> a obo:PATO_0000117 ;
    npo:contained_in npo:NPO_1846 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "961-3871" ;
            sbd:lower_limit "961" ;
            sbd:upper_limit "3871" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38b/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "membrane damage measured as lactate dehydrogenase (LDH) release [units/L]"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Cell culture systems were cultured in F-12K medium (Kaighnâ€™s modification of Hamâ€™s F-12 medium) supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin. Cellular membrane damage was collected at 80â€“85% confluency. Tests for cellular membrane damage were done in triplicate. Characterize the culture media by using Olympus Lactate Dehydrogenase reagents ( absorbance method at 340 nm). The release [units/L] was classified in: y < 0.99 --> Dense cell membrane 0.99 < y < 1.09 --> Normal cell membrane 1.09 < y < 1.25 --> Leaky cell membrane 1.25 < y --> Disrupted cell membrane In this paper they only used one cutoff value (i.e. LDH > 1.09) to distinguish between toxic (i.e. causing leaking or disruption of the membrane) and non-toxic effects due to exposure to TiO2 and ZnO NPs"@en ;
    skos:narrower rcd:X7A8D,
        "rat lung alveolar macrophages" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38b/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38b/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38b/Nanoparticle/Size_1>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38b/Nanoparticle/Size_2> ;
    skos:narrower npo:NPO_1486 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38b/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "125",
                "30",
                "45" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38b/Nanoparticle/Size_1> a obo:PATO_0000117 ;
    npo:contained_in obo:CHEBI_15377 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "101-967" ;
            sbd:lower_limit "101" ;
            sbd:upper_limit "967" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38b/Nanoparticle/Size_2> a obo:PATO_0000117 ;
    npo:contained_in npo:NPO_1846 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "961-3871" ;
            sbd:lower_limit "961" ;
            sbd:upper_limit "3871" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38c/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "membrane damage measured as lactate dehydrogenase (LDH) release [units/L]"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Cell culture systems were cultured in F-12K medium (Kaighnâ€™s modification of Hamâ€™s F-12 medium) supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin. Cellular membrane damage was collected at 80â€“85% confluency. Tests for cellular membrane damage were done in triplicate. Characterize the culture media by using Olympus Lactate Dehydrogenase reagents ( absorbance method at 340 nm). The release [units/L] was classified in: y < 0.99 --> Dense cell membrane 0.99 < y < 1.09 --> Normal cell membrane 1.09 < y < 1.25 --> Leaky cell membrane 1.25 < y --> Disrupted cell membrane In this paper they only used one cutoff value (i.e. LDH > 1.09) to distinguish between toxic (i.e. causing leaking or disruption of the membrane) and non-toxic effects due to exposure to TiO2 and ZnO NPs"@en ;
    skos:narrower rcd:X7A8D,
        "rat lung alveolar macrophages" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38c/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38c/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38c/Nanoparticle/Size_1>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38c/Nanoparticle/Size_2> ;
    skos:narrower npo:NPO_1542 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38c/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "50",
                "60",
                "70" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38c/Nanoparticle/Size_1> a obo:PATO_0000117 ;
    npo:contained_in obo:CHEBI_15377 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "55-172" ;
            sbd:lower_limit "55" ;
            sbd:upper_limit "172" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38c/Nanoparticle/Size_2> a obo:PATO_0000117 ;
    npo:contained_in npo:NPO_1846 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "158-385" ;
            sbd:lower_limit "158" ;
            sbd:upper_limit "385" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38d/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "membrane damage measured as lactate dehydrogenase (LDH) release [units/L]"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Cell culture systems were cultured in F-12K medium (Kaighnâ€™s modification of Hamâ€™s F-12 medium) supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin. Cellular membrane damage was collected at 80â€“85% confluency. Tests for cellular membrane damage were done in triplicate. Characterize the culture media by using Olympus Lactate Dehydrogenase reagents ( absorbance method at 340 nm). The release [units/L] was classified in: y < 0.99 --> Dense cell membrane 0.99 < y < 1.09 --> Normal cell membrane 1.09 < y < 1.25 --> Leaky cell membrane 1.25 < y --> Disrupted cell membrane In this paper they only used one cutoff value (i.e. LDH > 1.09) to distinguish between toxic (i.e. causing leaking or disruption of the membrane) and non-toxic effects due to exposure to TiO2 and ZnO NPs"@en ;
    skos:narrower rcd:X7A8D,
        "rat lung alveolar macrophages" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38d/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38d/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38d/Nanoparticle/Size_1>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38d/Nanoparticle/Size_2> ;
    skos:narrower npo:NPO_1486,
        npo:NPO_1542 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38d/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "125",
                "30",
                "45",
                "50",
                "60",
                "70" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38d/Nanoparticle/Size_1> a obo:PATO_0000117 ;
    npo:contained_in obo:CHEBI_15377 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "101-967" ;
            sbd:lower_limit "101" ;
            sbd:upper_limit "967" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38d/Nanoparticle/Size_2> a obo:PATO_0000117 ;
    npo:contained_in npo:NPO_1846 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "961-3871" ;
            sbd:lower_limit "961" ;
            sbd:upper_limit "3871" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38e/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "membrane damage measured as lactate dehydrogenase (LDH) release [units/L]"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Cell culture systems were cultured in F-12K medium (Kaighnâ€™s modification of Hamâ€™s F-12 medium) supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin. Cellular membrane damage was collected at 80â€“85% confluency. Tests for cellular membrane damage were done in triplicate. Characterize the culture media by using Olympus Lactate Dehydrogenase reagents ( absorbance method at 340 nm). The release [units/L] was classified in: y < 0.99 --> Dense cell membrane 0.99 < y < 1.09 --> Normal cell membrane 1.09 < y < 1.25 --> Leaky cell membrane 1.25 < y --> Disrupted cell membrane In this paper they only used one cutoff value (i.e. LDH > 1.09) to distinguish between toxic (i.e. causing leaking or disruption of the membrane) and non-toxic effects due to exposure to TiO2 and ZnO NPs"@en ;
    skos:narrower rcd:X7A8D,
        "rat lung alveolar macrophages" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38e/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38e/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38e/Nanoparticle/Size_1>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38e/Nanoparticle/Size_2> ;
    skos:narrower npo:NPO_1486 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38e/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "125",
                "30",
                "45" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38e/Nanoparticle/Size_1> a obo:PATO_0000117 ;
    npo:contained_in obo:CHEBI_15377 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "101-967" ;
            sbd:lower_limit "101" ;
            sbd:upper_limit "967" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38e/Nanoparticle/Size_2> a obo:PATO_0000117 ;
    npo:contained_in npo:NPO_1846 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "961-3871" ;
            sbd:lower_limit "961" ;
            sbd:upper_limit "3871" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38f/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "membrane damage measured as lactate dehydrogenase (LDH) release [units/L]"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Cell culture systems were cultured in F-12K medium (Kaighnâ€™s modification of Hamâ€™s F-12 medium) supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin. Cellular membrane damage was collected at 80â€“85% confluency. Tests for cellular membrane damage were done in triplicate. Characterize the culture media by using Olympus Lactate Dehydrogenase reagents ( absorbance method at 340 nm). The release [units/L] was classified in: y < 0.99 --> Dense cell membrane 0.99 < y < 1.09 --> Normal cell membrane 1.09 < y < 1.25 --> Leaky cell membrane 1.25 < y --> Disrupted cell membrane In this paper they only used one cutoff value (i.e. LDH > 1.09) to distinguish between toxic (i.e. causing leaking or disruption of the membrane) and non-toxic effects due to exposure to TiO2 and ZnO NPs"@en ;
    skos:narrower rcd:X7A8D,
        "rat lung alveolar macrophages" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38f/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38f/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38f/Nanoparticle/Size_1>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38f/Nanoparticle/Size_2> ;
    skos:narrower npo:NPO_1542 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38f/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "50",
                "60",
                "70" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38f/Nanoparticle/Size_1> a obo:PATO_0000117 ;
    npo:contained_in obo:CHEBI_15377 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "55-172" ;
            sbd:lower_limit "55" ;
            sbd:upper_limit "172" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38f/Nanoparticle/Size_2> a obo:PATO_0000117 ;
    npo:contained_in npo:NPO_1846 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "158-385" ;
            sbd:lower_limit "158" ;
            sbd:upper_limit "385" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38g/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "membrane damage measured as lactate dehydrogenase (LDH) release [units/L]"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Cell culture systems were cultured in F-12K medium (Kaighnâ€™s modification of Hamâ€™s F-12 medium) supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin. Cellular membrane damage was collected at 80â€“85% confluency. Tests for cellular membrane damage were done in triplicate. Characterize the culture media by using Olympus Lactate Dehydrogenase reagents ( absorbance method at 340 nm). The release [units/L] was classified in: y < 0.99 --> Dense cell membrane 0.99 < y < 1.09 --> Normal cell membrane 1.09 < y < 1.25 --> Leaky cell membrane 1.25 < y --> Disrupted cell membrane In this paper they only used one cutoff value (i.e. LDH > 1.09) to distinguish between toxic (i.e. causing leaking or disruption of the membrane) and non-toxic effects due to exposure to TiO2 and ZnO NPs"@en ;
    skos:narrower rcd:X7A8D,
        "rat lung alveolar macrophages" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38g/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38g/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38g/Nanoparticle/Size_1>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38g/Nanoparticle/Size_2> ;
    skos:narrower npo:NPO_1486,
        npo:NPO_1542 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38g/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "125",
                "30",
                "45",
                "50",
                "60",
                "70" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38g/Nanoparticle/Size_1> a obo:PATO_0000117 ;
    npo:contained_in obo:CHEBI_15377 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "101-967" ;
            sbd:lower_limit "101" ;
            sbd:upper_limit "967" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38g/Nanoparticle/Size_2> a obo:PATO_0000117 ;
    npo:contained_in npo:NPO_1846 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "961-3871" ;
            sbd:lower_limit "961" ;
            sbd:upper_limit "3871" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38h/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "membrane damage measured as lactate dehydrogenase (LDH) release [units/L]"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Cell culture systems were cultured in F-12K medium (Kaighnâ€™s modification of Hamâ€™s F-12 medium) supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin. Cellular membrane damage was collected at 80â€“85% confluency. Tests for cellular membrane damage were done in triplicate. Characterize the culture media by using Olympus Lactate Dehydrogenase reagents ( absorbance method at 340 nm). The release [units/L] was classified in: y < 0.99 --> Dense cell membrane 0.99 < y < 1.09 --> Normal cell membrane 1.09 < y < 1.25 --> Leaky cell membrane 1.25 < y --> Disrupted cell membrane In this paper they only used one cutoff value (i.e. LDH > 1.09) to distinguish between toxic (i.e. causing leaking or disruption of the membrane) and non-toxic effects due to exposure to TiO2 and ZnO NPs"@en ;
    skos:narrower rcd:X7A8D,
        "rat lung alveolar macrophages" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38h/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38h/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38h/Nanoparticle/Size_1>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38h/Nanoparticle/Size_2> ;
    skos:narrower npo:NPO_1486 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38h/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "125",
                "30",
                "45" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38h/Nanoparticle/Size_1> a obo:PATO_0000117 ;
    npo:contained_in obo:CHEBI_15377 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "101-967" ;
            sbd:lower_limit "101" ;
            sbd:upper_limit "967" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38h/Nanoparticle/Size_2> a obo:PATO_0000117 ;
    npo:contained_in npo:NPO_1846 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "961-3871" ;
            sbd:lower_limit "961" ;
            sbd:upper_limit "3871" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38i/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "membrane damage measured as lactate dehydrogenase (LDH) release [units/L]"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Cell culture systems were cultured in F-12K medium (Kaighnâ€™s modification of Hamâ€™s F-12 medium) supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin. Cellular membrane damage was collected at 80â€“85% confluency. Tests for cellular membrane damage were done in triplicate. Characterize the culture media by using Olympus Lactate Dehydrogenase reagents ( absorbance method at 340 nm). The release [units/L] was classified in: y < 0.99 --> Dense cell membrane 0.99 < y < 1.09 --> Normal cell membrane 1.09 < y < 1.25 --> Leaky cell membrane 1.25 < y --> Disrupted cell membrane In this paper they only used one cutoff value (i.e. LDH > 1.09) to distinguish between toxic (i.e. causing leaking or disruption of the membrane) and non-toxic effects due to exposure to TiO2 and ZnO NPs"@en ;
    skos:narrower rcd:X7A8D,
        "rat lung alveolar macrophages" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38i/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38i/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38i/Nanoparticle/Size_1>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38i/Nanoparticle/Size_2> ;
    skos:narrower npo:NPO_1542 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38i/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "50",
                "60",
                "70" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38i/Nanoparticle/Size_1> a obo:PATO_0000117 ;
    npo:contained_in obo:CHEBI_15377 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "55-172" ;
            sbd:lower_limit "55" ;
            sbd:upper_limit "172" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38i/Nanoparticle/Size_2> a obo:PATO_0000117 ;
    npo:contained_in npo:NPO_1846 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "158-385" ;
            sbd:lower_limit "158" ;
            sbd:upper_limit "385" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38j/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "membrane damage measured as lactate dehydrogenase (LDH) release [units/L]"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Cell culture systems were cultured in F-12K medium (Kaighnâ€™s modification of Hamâ€™s F-12 medium) supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin. Cellular membrane damage was collected at 80â€“85% confluency. Tests for cellular membrane damage were done in triplicate. Characterize the culture media by using Olympus Lactate Dehydrogenase reagents ( absorbance method at 340 nm). The release [units/L] was classified in: y < 0.99 --> Dense cell membrane 0.99 < y < 1.09 --> Normal cell membrane 1.09 < y < 1.25 --> Leaky cell membrane 1.25 < y --> Disrupted cell membrane In this paper they only used one cutoff value (i.e. LDH > 1.09) to distinguish between toxic (i.e. causing leaking or disruption of the membrane) and non-toxic effects due to exposure to TiO2 and ZnO NPs"@en ;
    skos:narrower rcd:X7A8D,
        "rat lung alveolar macrophages" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38j/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38j/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38j/Nanoparticle/Size_1>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38j/Nanoparticle/Size_2> ;
    skos:narrower npo:NPO_1486,
        npo:NPO_1542 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38j/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "125",
                "30",
                "45",
                "50",
                "60",
                "70" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38j/Nanoparticle/Size_1> a obo:PATO_0000117 ;
    npo:contained_in obo:CHEBI_15377 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "101-967" ;
            sbd:lower_limit "101" ;
            sbd:upper_limit "967" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38j/Nanoparticle/Size_2> a obo:PATO_0000117 ;
    npo:contained_in npo:NPO_1846 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "961-3871" ;
            sbd:lower_limit "961" ;
            sbd:upper_limit "3871" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38k/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "membrane damage measured as lactate dehydrogenase (LDH) release [units/L]"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Cell culture systems were cultured in F-12K medium (Kaighnâ€™s modification of Hamâ€™s F-12 medium) supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin. Cellular membrane damage was collected at 80â€“85% confluency. Tests for cellular membrane damage were done in triplicate. Characterize the culture media by using Olympus Lactate Dehydrogenase reagents ( absorbance method at 340 nm). The release [units/L] was classified in: y < 0.99 --> Dense cell membrane 0.99 < y < 1.09 --> Normal cell membrane 1.09 < y < 1.25 --> Leaky cell membrane 1.25 < y --> Disrupted cell membrane In this paper they only used one cutoff value (i.e. LDH > 1.09) to distinguish between toxic (i.e. causing leaking or disruption of the membrane) and non-toxic effects due to exposure to TiO2 and ZnO NPs"@en ;
    skos:narrower rcd:X7A8D,
        "rat lung alveolar macrophages" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38k/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38k/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38k/Nanoparticle/Size_1>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38k/Nanoparticle/Size_2> ;
    skos:narrower npo:NPO_1486 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38k/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "125",
                "30",
                "45" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38k/Nanoparticle/Size_1> a obo:PATO_0000117 ;
    npo:contained_in obo:CHEBI_15377 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "101-967" ;
            sbd:lower_limit "101" ;
            sbd:upper_limit "967" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38k/Nanoparticle/Size_2> a obo:PATO_0000117 ;
    npo:contained_in npo:NPO_1846 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "961-3871" ;
            sbd:lower_limit "961" ;
            sbd:upper_limit "3871" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38l/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "membrane damage measured as lactate dehydrogenase (LDH) release [units/L]"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Cell culture systems were cultured in F-12K medium (Kaighnâ€™s modification of Hamâ€™s F-12 medium) supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin. Cellular membrane damage was collected at 80â€“85% confluency. Tests for cellular membrane damage were done in triplicate. Characterize the culture media by using Olympus Lactate Dehydrogenase reagents ( absorbance method at 340 nm). The release [units/L] was classified in: y < 0.99 --> Dense cell membrane 0.99 < y < 1.09 --> Normal cell membrane 1.09 < y < 1.25 --> Leaky cell membrane 1.25 < y --> Disrupted cell membrane In this paper they only used one cutoff value (i.e. LDH > 1.09) to distinguish between toxic (i.e. causing leaking or disruption of the membrane) and non-toxic effects due to exposure to TiO2 and ZnO NPs"@en ;
    skos:narrower rcd:X7A8D,
        "rat lung alveolar macrophages" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38l/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38l/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38l/Nanoparticle/Size_1>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38l/Nanoparticle/Size_2> ;
    skos:narrower npo:NPO_1542 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38l/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "50",
                "60",
                "70" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38l/Nanoparticle/Size_1> a obo:PATO_0000117 ;
    npo:contained_in obo:CHEBI_15377 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "55-172" ;
            sbd:lower_limit "55" ;
            sbd:upper_limit "172" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38l/Nanoparticle/Size_2> a obo:PATO_0000117 ;
    npo:contained_in npo:NPO_1846 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "158-385" ;
            sbd:lower_limit "158" ;
            sbd:upper_limit "385" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38m/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "membrane damage measured as lactate dehydrogenase (LDH) release [units/L]"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Cell culture systems were cultured in F-12K medium (Kaighnâ€™s modification of Hamâ€™s F-12 medium) supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin. Cellular membrane damage was collected at 80â€“85% confluency. Tests for cellular membrane damage were done in triplicate. Characterize the culture media by using Olympus Lactate Dehydrogenase reagents ( absorbance method at 340 nm). The release [units/L] was classified in: y < 0.99 --> Dense cell membrane 0.99 < y < 1.09 --> Normal cell membrane 1.09 < y < 1.25 --> Leaky cell membrane 1.25 < y --> Disrupted cell membrane In this paper they only used one cutoff value (i.e. LDH > 1.09) to distinguish between toxic (i.e. causing leaking or disruption of the membrane) and non-toxic effects due to exposure to TiO2 and ZnO NPs"@en ;
    skos:narrower rcd:X7A8D,
        "rat lung alveolar macrophages" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38m/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38m/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38m/Nanoparticle/Size_1>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38m/Nanoparticle/Size_2> ;
    skos:narrower npo:NPO_1486,
        npo:NPO_1542 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38m/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "125",
                "30",
                "45",
                "50",
                "60",
                "70" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38m/Nanoparticle/Size_1> a obo:PATO_0000117 ;
    npo:contained_in obo:CHEBI_15377 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "101-967" ;
            sbd:lower_limit "101" ;
            sbd:upper_limit "967" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38m/Nanoparticle/Size_2> a obo:PATO_0000117 ;
    npo:contained_in npo:NPO_1846 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "961-3871" ;
            sbd:lower_limit "961" ;
            sbd:upper_limit "3871" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38n/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "membrane damage measured as lactate dehydrogenase (LDH) release [units/L]"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Cell culture systems were cultured in F-12K medium (Kaighnâ€™s modification of Hamâ€™s F-12 medium) supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin. Cellular membrane damage was collected at 80â€“85% confluency. Tests for cellular membrane damage were done in triplicate. Characterize the culture media by using Olympus Lactate Dehydrogenase reagents ( absorbance method at 340 nm). The release [units/L] was classified in: y < 0.99 --> Dense cell membrane 0.99 < y < 1.09 --> Normal cell membrane 1.09 < y < 1.25 --> Leaky cell membrane 1.25 < y --> Disrupted cell membrane In this paper they only used one cutoff value (i.e. LDH > 1.09) to distinguish between toxic (i.e. causing leaking or disruption of the membrane) and non-toxic effects due to exposure to TiO2 and ZnO NPs"@en ;
    skos:narrower rcd:X7A8D,
        "rat lung alveolar macrophages" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38n/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38n/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38n/Nanoparticle/Size_1>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38n/Nanoparticle/Size_2> ;
    skos:narrower npo:NPO_1486 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38n/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "125",
                "30",
                "45" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38n/Nanoparticle/Size_1> a obo:PATO_0000117 ;
    npo:contained_in obo:CHEBI_15377 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "101-967" ;
            sbd:lower_limit "101" ;
            sbd:upper_limit "967" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38n/Nanoparticle/Size_2> a obo:PATO_0000117 ;
    npo:contained_in npo:NPO_1846 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "961-3871" ;
            sbd:lower_limit "961" ;
            sbd:upper_limit "3871" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38o/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "membrane damage measured as lactate dehydrogenase (LDH) release [units/L]"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Cell culture systems were cultured in F-12K medium (Kaighnâ€™s modification of Hamâ€™s F-12 medium) supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin. Cellular membrane damage was collected at 80â€“85% confluency. Tests for cellular membrane damage were done in triplicate. Characterize the culture media by using Olympus Lactate Dehydrogenase reagents ( absorbance method at 340 nm). The release [units/L] was classified in: y < 0.99 --> Dense cell membrane 0.99 < y < 1.09 --> Normal cell membrane 1.09 < y < 1.25 --> Leaky cell membrane 1.25 < y --> Disrupted cell membrane In this paper they only used one cutoff value (i.e. LDH > 1.09) to distinguish between toxic (i.e. causing leaking or disruption of the membrane) and non-toxic effects due to exposure to TiO2 and ZnO NPs"@en ;
    skos:narrower rcd:X7A8D,
        "rat lung alveolar macrophages" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38o/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38o/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38o/Nanoparticle/Size_1>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38o/Nanoparticle/Size_2> ;
    skos:narrower npo:NPO_1542 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38o/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "50",
                "60",
                "70" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38o/Nanoparticle/Size_1> a obo:PATO_0000117 ;
    npo:contained_in obo:CHEBI_15377 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "55-172" ;
            sbd:lower_limit "55" ;
            sbd:upper_limit "172" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38o/Nanoparticle/Size_2> a obo:PATO_0000117 ;
    npo:contained_in npo:NPO_1846 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "158-385" ;
            sbd:lower_limit "158" ;
            sbd:upper_limit "385" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38p/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "membrane damage measured as lactate dehydrogenase (LDH) release [units/L]"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Cell culture systems were cultured in F-12K medium (Kaighnâ€™s modification of Hamâ€™s F-12 medium) supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin. Cellular membrane damage was collected at 80â€“85% confluency. Tests for cellular membrane damage were done in triplicate. Characterize the culture media by using Olympus Lactate Dehydrogenase reagents ( absorbance method at 340 nm). The release [units/L] was classified in: y < 0.99 --> Dense cell membrane 0.99 < y < 1.09 --> Normal cell membrane 1.09 < y < 1.25 --> Leaky cell membrane 1.25 < y --> Disrupted cell membrane In this paper they only used one cutoff value (i.e. LDH > 1.09) to distinguish between toxic (i.e. causing leaking or disruption of the membrane) and non-toxic effects due to exposure to TiO2 and ZnO NPs"@en ;
    skos:narrower rcd:X7A8D,
        "rat lung alveolar macrophages" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38p/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38p/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38p/Nanoparticle/Size_1>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38p/Nanoparticle/Size_2> ;
    skos:narrower npo:NPO_1486,
        npo:NPO_1542 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38p/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "125",
                "30",
                "45",
                "50",
                "60",
                "70" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38p/Nanoparticle/Size_1> a obo:PATO_0000117 ;
    npo:contained_in obo:CHEBI_15377 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "101-967" ;
            sbd:lower_limit "101" ;
            sbd:upper_limit "967" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_38p/Nanoparticle/Size_2> a obo:PATO_0000117 ;
    npo:contained_in npo:NPO_1846 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "961-3871" ;
            sbd:lower_limit "961" ;
            sbd:upper_limit "3871" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_39/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as cellular viability by determining the mitochondrial dehydrogenasesâ€™ activity"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Initially, 6 different toxicity assay at different doses expositions were analyzed, but due to the bad performance of the model applied to different endpoints at a time, they decide to focus the study on a single toxicity assay. Cellular viability was assessed in A549 human lung epithelial cells exposed to NPs (24 h; 1-100 Î¼g/ml) in terms of mitochondrial function, using a commercially available assay (MTT). The basis of this assay viable cell-mediated conversion of colourless, water soluble (3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide; MTT) to an insoluble formazan that can be measured spectrophotometrically (Î»=570 nm). Conversion of the formazan to MTT is dependent on NAD(P)H reductase enzymes, and hence is related to the metabolic activity of the cells. The mitochondrial impact of the NP panel was explored in more detail using a flow cytometry-based assessment of mitochondrial membrane potential using the fluorescent dye, DiOC6, to detect collapse of this potential. Traditionally, this test is used as an early marker of apoptosis and is conducted in parallel with a test for secondary necrosis (PI in this case). This test was conducted in a different, but equally relevant, cell type (THP-1 human monocyte-like cells) because the assay is better-suited to non-adherent cells that remain in suspension."@en ;
    skos:narrower mesh:D000072283 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_39/Nanoparticle> a npo:NPO_1384,
        npo:NPO_1541,
        npo:NPO_707 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_3a/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured by different biological activities"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Biological activity was defined as the arithmetic mean of in vitro tests on four different cell lines,Using four doses, and four different assays of cellular physiology. The four assays measured (i) ATP content, (ii) Reducing equivalents, (iii) Caspase-mediated apoptosis, (iv) Mitochondrial membrane potential. Biological activity profiles were recorded for the following concentrations of MNPs: 0.01, 0.03, 0.1, and 0.3 mg/mL for all iron-based MNPs; and 3, 10, 30, and 100 nM for the three quantum dot-based MNPs Vector of 64 measurements reduced to one value, Zmean. Classifying the endpoint in class 1 (Zmean â‰¥ -0.40) or class 0 (Zmean < -0.40)"@en ;
    skos:narrower "Endothelial cells (human aorta)",
        "Hepatocytes (human HepG2 cells)",
        "Murine RAW 264.7 leukemic monocyte/macrophage cell",
        "Vascular smooth muscle cells (human coronary artery)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_3a/Nanoparticle> a npo:NPO_1384,
        npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "PVA :: 15-mer peptide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA, PEG :: NA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: NA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: PEG Ethylene diamine, AminoSPARKâ„¢680"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: VT680"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: Ethylene diamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Dextran :: NA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: protamine, rhodamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA, PEG :: Ethylene diamine, VT750"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: glycine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: AminoSPARKâ„¢680"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: FITC, R-COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA, PEG :: AngioSPARKâ„¢680- IVM"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Cy5.5"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Alexa Fluor 750"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: VT680, protamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Cy5.5, tat"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Arabino-galactan :: NA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Alexa Fluor 488"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Coating :: Surface modification"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Sucrose :: NA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: Ethylene diamine, VT750"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: Ethylene diamine, AminoSPARKâ„¢680"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: FITC, succinimidyl iodoacetate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: rhodamine, protamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amphiphilic polymer â€“ PEG :: NH2"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Cy5.5, protamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Tat peptide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: D-arg7-COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: FITC, Glutamic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Cy3.5"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: FITC, COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: L-arg8-COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Carboxymethyldextran :: NA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: NH2"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: Ethylene diamine, VT680"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: FITC, COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Cy7"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Cy5"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: L-arg7-COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: biotin"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amphiphilic polymer :: COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: FITC"@en ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_3a/Nanoparticle/Size> ;
    skos:narrower npo:NPO_1548,
        npo:NPO_1550 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_3a/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "20-74" ;
            sbd:lower_limit "20" ;
            sbd:upper_limit "74" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_3b/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a npo:NPO_296 ;
            rdfs:label "Cellular uptake of extracellular material"@en ;
            rdfs:comment "measured as log(pM) /cell"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Cellular uptake is expressed as decadic logarithm of the concentration (pM) of NP per cell"@en ;
    skos:narrower "Pancreatic human cancer cells (PaCa2)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_3b/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower pubchem:78218 ],
        [ a npo:NPO_1962 ;
            skos:narrower "4-Methyldihydro-2Hpyran-2,6(3H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "3-Phenyldihydro-2Hpyran-2,6(3H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:17386 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78232 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8926 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8102 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7719 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:75498 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12443 ],
        [ a npo:NPO_1962 ;
            skos:narrower "4 3,3-Dimethyldihydrofuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:74960 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6811 ],
        [ a npo:NPO_1962 ;
            skos:narrower "{Bis[2-(2,6-dioxomorpholin-4-yl)ethyl]amino}acetic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1,4,5, 8-Naphthalenetetracarboxylic acidanhydride"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7940 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:428 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:866 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:15659773 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7922 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:681 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69339 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:220977 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:85689 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:230976 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:70728 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12475 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5,6-Dihydro-1Hcyclopenta[c]furan-1,3(4H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:96580 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:602 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:994 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:68986 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69527 ],
        [ a npo:NPO_1962 ;
            skos:narrower "7 3,4-Dimethylfuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:19990 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:21631 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:239163 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:2733254 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8359 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:16402 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12801 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:876 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5603 ],
        [ a npo:NPO_1962 ;
            skos:narrower "6-Bromo-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6558 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:70334 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:3301 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:102679 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12012 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69545 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8265 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:76247 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:232 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:88069 ],
        [ a npo:NPO_1962 ;
            skos:narrower "6-Nitro-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:72794 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:750 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:513918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:9845 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:76074 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78479 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:75737 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:2794246 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78480 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-ammonio-3-(4-hydroxyphenyl)propanoate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8111 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:97914 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6385 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:25160 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8060 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12019 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:65729 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:98484 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:67742 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:513917 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:611 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:424 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1182 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:587821 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Amino-3-(1Himidazol-4-yl)propanoic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10946 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:95411 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8326 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5610 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:86625 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5-Nitro-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:25332 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:617 ],
        [ a npo:NPO_1962 ;
            skos:narrower "N-(2-Aminoethyl)-N'-(3-aminopropyl)butane-1,4-diamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:866 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:738 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:11089 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:79882 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:74918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1148 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6810 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Tetrahydrofuro[3',4':3,4]cyclobuta[1,2-c]furan-1,3,4,6-tetrone"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:16217 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:79743 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1045 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5-amino-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "3-Methylidenedihydrofuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7894 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7923 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7908 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:20051 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:205 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:587821 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:96196 ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_3b/Nanoparticle/Size> ;
    skos:narrower npo:NPO_729 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_3b/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "38" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_40a/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as -log(LC50)"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Determined the cytotoxicity of the metal oxide nanoparticles in terms of EC50 (concentration which cytotoxicity reduces bacteria viability up to 50%) based on the curve fitting least squares procedure."@en ;
    skos:narrower mesh:D004926 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_40a/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_40a/Nanoparticle/Size> ;
    skos:narrower npo:NPO_1373,
        npo:NPO_1486,
        npo:NPO_1542,
        npo:NPO_1550,
        enm:ENM_0000118,
        obo:CHEBI_30187,
        pubchem:14776,
        pubchem:14794,
        pubchem:14805,
        pubchem:14829,
        pubchem:150906,
        pubchem:157925,
        pubchem:159375,
        pubchem:166955,
        pubchem:29131,
        pubchem:518712,
        pubchem:62762 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_40a/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "15-90" ;
            sbd:lower_limit "15" ;
            sbd:upper_limit "90" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_40b/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as log(LC50)"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Cell viability was measured using the CytoTox-Glo Cytotoxicity Assay from Promega (Madison, WI). LC50 values for all MeOx were extrapolated using the third order polynomial equation of the log transformed data with the least squares fit in GraphPad (GraphPad Software, Inc., La Jolla, CA)"@en ;
    skos:narrower mesh:D000084282 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_40b/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_40b/Nanoparticle/Size> ;
    skos:narrower npo:NPO_1373,
        npo:NPO_1486,
        npo:NPO_1542,
        npo:NPO_1550,
        enm:ENM_0000118,
        obo:CHEBI_30187,
        pubchem:14776,
        pubchem:14794,
        pubchem:14805,
        pubchem:14811,
        pubchem:14824,
        pubchem:150906,
        pubchem:157925,
        pubchem:159375,
        pubchem:166955,
        pubchem:29131,
        pubchem:518712,
        pubchem:62762 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_40b/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "15-150" ;
            sbd:lower_limit "15" ;
            sbd:upper_limit "150" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_41/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as -log(LC50)"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "The samples in Pyrex and quartz test tubes were exposed to sunlight for 30 min with agitation in a water bath at 150 r.p.m. Similarly, corresponding samples were exposed under dark conditions, by wrapping the test samples in the test tubes with aluminium foils (solar irradiation outdoors: irradiance: UVA range = 3.979â€“4.652 mW/cm2; UVB range = 3.1â€“3.7 MED/h, where an MED is defined as the minimum erythemal dose or the amount of UV radiation to produce barely perceptible erythema; 1 MED/h = 0.05833 W/m2). The dark cytotoxicity and photo-induced cytotoxicity are examined as an united endpoint"@en ;
    skos:narrower mesh:D004926 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_41/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_41/Nanoparticle/Size> ;
    skos:narrower npo:NPO_1373,
        npo:NPO_1486,
        npo:NPO_1542,
        npo:NPO_1550,
        enm:ENM_0000118,
        obo:CHEBI_30187,
        pubchem:14776,
        pubchem:14794,
        pubchem:14805,
        pubchem:14829,
        pubchem:150906,
        pubchem:157925,
        pubchem:159375,
        pubchem:166955,
        pubchem:29131,
        pubchem:518712,
        pubchem:62762 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_41/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "15-90" ;
            sbd:lower_limit "15" ;
            sbd:upper_limit "90" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_42/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as Percentage of damaged cells by Propidium Iodide uptake of BEAS-2B"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "The numerical data on this endpoint related to four doses (50, 100, 150, and 200 Î¼g/mL) and seven exposure time (from 1 to 7 h) for all 24 nanometal-oxides are examined. In fact, the percentage of cells which have membrane damage is the measure of impact of nano-oxides (for defined dose and exposure time). The decimal logarithm of these values is examined as the endpoint. From 672 (24*4*7) data points, after four observation for CMD, were selected those with a dispersion of <10 %"@en ;
    skos:narrower "Human bronchial epithelial cells (BEAS-2B)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_42/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_42/Nanoparticle/Size> ;
    skos:narrower npo:NPO_1373,
        npo:NPO_1486,
        npo:NPO_1542,
        npo:NPO_1548,
        npo:NPO_1550,
        enm:ENM_0000118,
        enm:ENM_9000254,
        obo:CHEBI_30187,
        pubchem:10855842,
        pubchem:14794,
        pubchem:14805,
        pubchem:14811,
        pubchem:14829,
        pubchem:150906,
        pubchem:157925,
        pubchem:159375,
        pubchem:159385,
        pubchem:159423,
        pubchem:160959,
        pubchem:166955,
        pubchem:20597791,
        pubchem:29131,
        pubchem:62762,
        pubchem:73971 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_42/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "10-100" ;
            sbd:lower_limit "10" ;
            sbd:upper_limit "100" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_43/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a npo:NPO_296 ;
            rdfs:label "Cellular uptake of extracellular material"@en ;
            rdfs:comment "measured as log(pM) /cell"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Cellular uptake is expressed as decadic logarithm of the concentration (pM) of NP per cell"@en ;
    skos:narrower "Pancreatic human cancer cells (PaCa2)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_43/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower pubchem:78232 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:3301 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1,4,5, 8-Naphthalenetetracarboxylic acidanhydride"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:25160 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:994 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7719 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6811 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:681 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Amino-3-(1Himidazol-4-yl)propanoic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8111 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:205 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8265 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:65729 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8359 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:866 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1182 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5-Nitro-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7922 ],
        [ a npo:NPO_1962 ;
            skos:narrower "7 3,4-Dimethylfuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:16402 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12801 ],
        [ a npo:NPO_1962 ;
            skos:narrower "{Bis[2-(2,6-dioxomorpholin-4-yl)ethyl]amino}acetic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:68986 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6558 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:232 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8060 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8102 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:79743 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:21631 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5603 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:2733254 ],
        [ a npo:NPO_1962 ;
            skos:narrower "3-Methylidenedihydrofuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:15659773 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5-amino-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:16217 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:220977 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Tetrahydrofuro[3',4':3,4]cyclobuta[1,2-c]furan-1,3,4,6-tetrone"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:75737 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-ammonio-3-(4-hydroxyphenyl)propanoate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:513917 ],
        [ a npo:NPO_1962 ;
            skos:narrower "6-Bromo-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10946 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1148 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:602 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:74960 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:67742 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:76074 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:86625 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:88069 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:97914 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:11089 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:611 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:513918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78479 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:74918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7894 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:617 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:85689 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69545 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:2794246 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:9845 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78218 ],
        [ a npo:NPO_1962 ;
            skos:narrower "4 3,3-Dimethyldihydrofuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:75498 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12019 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6385 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:19990 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:98484 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:70728 ],
        [ a npo:NPO_1962 ;
            skos:narrower "3-Phenyldihydro-2Hpyran-2,6(3H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:750 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:738 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:587821 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:428 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1045 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:424 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12443 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69527 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6810 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7940 ],
        [ a npo:NPO_1962 ;
            skos:narrower "6-Nitro-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8926 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:587821 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78480 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12012 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:76247 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:876 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12475 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:230976 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:96580 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7908 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5,6-Dihydro-1Hcyclopenta[c]furan-1,3(4H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5610 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:96196 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69339 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:102679 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:25332 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:79882 ],
        [ a npo:NPO_1962 ;
            skos:narrower "4-Methyldihydro-2Hpyran-2,6(3H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:70334 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:866 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:20051 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8326 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:17386 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:72794 ],
        [ a npo:NPO_1962 ;
            skos:narrower "N-(2-Aminoethyl)-N'-(3-aminopropyl)butane-1,4-diamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:239163 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7923 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:95411 ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_43/Nanoparticle/Size> ;
    skos:narrower npo:NPO_729 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_43/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "38" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_44a/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "log2 transformed (Cell association [mL/Î¼g(Mg)] )" ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "The correlation of cell association of Au NPs (modified with different ionic/cationic surface ligands) with corona proteins and physicochemical properties was investigated via QSAR analysis of a recently published dataset (C. D. Walkey, et al. et al., 2015 already reported in this table). The ratio mcell/mwell divided by mcells quantified the total cell association, where mcell is the total atomic gold (or silver) content associated with cells, mwell is the total atomic gold (or silver) content in well (associated with cells and free in solution) and mcells is the total mass of magnesium per sample. The related net cell association data were log transformed (log2 transformation) prior to modelling. Cell association was chosen as a model biological interaction because of its relevance to inflammatory responses, biodistribution, and toxicity in vivo. A549 human lung epithelial carcinoma cells (ATCC) were maintained in RPMI1640 (Wisent, cat#: 350-000-CL) supplement with 10%(v/v) fetal bovine serum (FBS) (Gibco, cat#: 12483-020) and 1% (v/v) penicillin-streptomycin (P-S) (Gibco, cat#: 15140-122) in a sterile 5% CO2 atmin 175 cm2 tissue culture flasks (NEST, cat#: 709003)"@en ;
    skos:narrower mesh:D000072283 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_44a/Nanoparticle> a npo:NPO_1384,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-serine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ stearic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-phenylalanine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ 1,2-dioleoyl-3-trimethylammonium-propane"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5974 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5,5â€²-Dithiobis(2-nitrobenzoic acid)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10352850 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @benzyldimethylhexadecylammonium bromide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-glycine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:598 ],
        [ a npo:NPO_1962 ;
            skos:narrower "(11-Mercaptoundecyl)-N,N,Ntrimethylammonium"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "(11-Mercaptoundecyl)tetra(ethylene glycol)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6140 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CVVIT'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:329113 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ urea-modified poly(styrenecomaleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ Pluronic F-127"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated amino-poly(ethylene glycol) (methoxyterminated)(5kDa)*"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-asparagine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-threonine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Î±-Lipoic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1133 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(allylamine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5483 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:543502 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @hexadecyltrimethylammonium bromide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5281 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ ethylenediamine-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ (4'-aminoacetophenone)-modified poly(styrene-co-maleic nhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6514 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ ethanolamine-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (1kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-alanine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-methionine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(ethyleneimine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "TWEEN20"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ hexadecylamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ sodium dodecyl sulfate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:15793 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:31348 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(L-lysine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:3522585 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ octadecylamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10154203 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6268 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12841471 ],
        [ a npo:NPO_1962 ;
            skos:narrower "(low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Bis(p-sulfonatophenyl)phenylphosphine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12035 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-tryptophan"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ poly(vinyl alcohol)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Carboxymethyl-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amino-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ deoxycholic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated amino-poly(ethylene glycol) (3kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CALNN'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (20kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Carboxymethyl-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ aminopropanol-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8926 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CFGAILS'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Poly(vinylpyrrolidone)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:95738 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (20kDa) (low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:11199 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (2kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amino-poly(ethylene glycol)-thiol (5kDa) (low density)"@en ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_44a/Nanoparticle/Size> ;
    skos:narrower npo:NPO_401 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_44a/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "15",
                "30",
                "60" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_44b/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "log2 transformed (Cell association [mL/Î¼g(Mg)] )" ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "The correlation of cell association of Au NPs (modified with different ionic/cationic surface ligands) with corona proteins and physicochemical properties was investigated via QSAR analysis of a recently published dataset (C. D. Walkey, et al. et al., 2015 already reported in this table). The ratio mcell/mwell divided by mcells quantified the total cell association, where mcell is the total atomic gold (or silver) content associated with cells, mwell is the total atomic gold (or silver) content in well (associated with cells and free in solution) and mcells is the total mass of magnesium per sample. The related net cell association data were log transformed (log2 transformation) prior to modelling. Cell association was chosen as a model biological interaction because of its relevance to inflammatory responses, biodistribution, and toxicity in vivo. A549 human lung epithelial carcinoma cells (ATCC) were maintained in RPMI1640 (Wisent, cat#: 350-000-CL) supplement with 10%(v/v) fetal bovine serum (FBS) (Gibco, cat#: 12483-020) and 1% (v/v) penicillin-streptomycin (P-S) (Gibco, cat#: 15140-122) in a sterile 5% CO2 atmin 175 cm2 tissue culture flasks (NEST, cat#: 709003)"@en ;
    skos:narrower mesh:D000072283 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_44b/Nanoparticle> a npo:NPO_1384,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-methionine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6268 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @benzyldimethylhexadecylammonium bromide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ (4'-aminoacetophenone)-modified poly(styrene-co-maleic nhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(ethyleneimine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ urea-modified poly(styrenecomaleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:11199 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ deoxycholic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-phenylalanine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Î±-Lipoic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CVVIT'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:95738 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5,5â€²-Dithiobis(2-nitrobenzoic acid)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ poly(vinyl alcohol)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ stearic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ sodium dodecyl sulfate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:598 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-tryptophan"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated amino-poly(ethylene glycol) (3kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "TWEEN20"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10352850 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:543502 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (20kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-threonine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (1kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10154203 ],
        [ a npo:NPO_1962 ;
            skos:narrower "(11-Mercaptoundecyl)tetra(ethylene glycol)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:329113 ],
        [ a npo:NPO_1962 ;
            skos:narrower "(11-Mercaptoundecyl)-N,N,Ntrimethylammonium"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amino-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Carboxymethyl-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ hexadecylamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-serine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ aminopropanol-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12035 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amino-poly(ethylene glycol)-thiol (5kDa) (low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ 1,2-dioleoyl-3-trimethylammonium-propane"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5974 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Poly(vinylpyrrolidone)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(L-lysine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CFGAILS'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Carboxymethyl-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ ethylenediamine-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ Pluronic F-127"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6140 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated amino-poly(ethylene glycol) (methoxyterminated)(5kDa)*"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "(low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8926 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-alanine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ ethanolamine-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @hexadecyltrimethylammonium bromide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CALNN'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (2kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ octadecylamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6514 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:31348 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (20kDa) (low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-asparagine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5281 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5483 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Bis(p-sulfonatophenyl)phenylphosphine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:3522585 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(allylamine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12841471 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-glycine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:15793 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1133 ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_44b/Nanoparticle/Size> ;
    skos:narrower npo:NPO_401 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_44b/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "15",
                "30",
                "60" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_45/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a enm:ENM_0000042 ;
            rdfs:label "Mutagenicity"@en ;
            rdfs:comment "measured as the number of observed colonies"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "The mutagenecity of a substance is proportional to the number of colonies observed. The numerical data on mutagenic potential of MWCNTs taken from the literature (Wirnitzer et al., 2009). Mean mutant counts after incubation of Salmonella strains TA100 without and with metabolic activation (S9 mix) in the plate incorporation and in the preincubation (tube) part of the Salmonella microsome test. The numerical data on TA100 are converted into negative decimal logarithmic scale."@en ;
    skos:narrower "Salmonella typhimurium TA100" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_45/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_461 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_46/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a enm:ENM_0000042 ;
            rdfs:label "Mutagenicity"@en ;
            rdfs:comment "measured as the number of observed colonies"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "The mutagenecity of a substance is proportional to the number of colonies observed The numerical data on mutagenic potential of MWCNTs taken from the literature (Wirnitzer et al., 2009) and for fullerene (Shinohara et al., 2009). Mean mutant counts after incubation of Salmonella strains TA100 without and with metabolic activation (S9 mix) in the plate incorporation and in the preincubation (tube) part of the Salmonella microsome test. The numerical data on TA100 are converted into negative decimal logarithmic scale."@en ;
    skos:narrower "Salmonella typhimurium TA101" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_46/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower ""@en ],
        [ a npo:NPO_274 ;
            skos:narrower "fiber (mwcnt)"@en ],
        [ a npo:NPO_274 ;
            skos:narrower "spherical (c60)"@en ],
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_46/Nanoparticle/Size> ;
    skos:narrower npo:NPO_354,
        npo:NPO_730 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_46/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "<100.0" ;
            sbd:upper_limit "100.0" ] ;
    skos:narrower obo:PATO_0001334 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_47/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as LC50"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Cell viability was measured using the CytoTox-Glo Cytotoxicity Assay from Promega (Madison, WI). LC50 values for all MeOx were extrapolated using the third order polynomial equation of the log transformed data with the least squares fit in GraphPad (GraphPad Software, Inc., La Jolla, CA)"@en ;
    skos:narrower mesh:D000084282 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_47/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ],
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_47/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_47/Nanoparticle/Size_2> ;
    skos:narrower npo:NPO_1373,
        npo:NPO_1486,
        npo:NPO_1542,
        npo:NPO_1550,
        enm:ENM_0000118,
        obo:CHEBI_30187,
        pubchem:14776,
        pubchem:14794,
        pubchem:14805,
        pubchem:14811,
        pubchem:14824,
        pubchem:150906,
        pubchem:157925,
        pubchem:159375,
        pubchem:166955,
        pubchem:29131,
        pubchem:518712,
        pubchem:62762 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_47/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "15-210" ;
            sbd:lower_limit "15" ;
            sbd:upper_limit "210" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_47/Nanoparticle/Size_2> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "189-2029" ;
            sbd:lower_limit "189" ;
            sbd:upper_limit "2029" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_48/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a mesh:D005089 ;
            rdfs:label "Exocytosis"@en ;
            rdfs:comment "measured as percentage of observed NPs"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Undifferentiated (monocytes) or phorbol-12-myristate-13-acetate (PMA)-differentiated U937 cells (macrophages) were treated with each formulation of serum-coated GNPs for 6 h in serum-supplemented media at 37 ÂºC to saturate their endocytosis."@en ;
    skos:narrower "Human macrophage-like",
        "U937 cell" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_48/Nanoparticle> a npo:NPO_1384,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "Opsonisation by serum proteins"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Uncoated"@en ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_48/Nanoparticle/Size> ;
    skos:narrower npo:NPO_401 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_48/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "14-51" ;
            sbd:lower_limit "14" ;
            sbd:upper_limit "51" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_49a/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured by the the curve of dose-response and consensus Self-Organizing Map clustering on SPS and HTS assay"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Toxicological responses of twenty-four metal oxide NPs (over a concentration range of 0.39â€“100 mg L^(-1)) on RAW 264.7 and BEAS-2B cell lines, using both single parameter screening (SPS) assays (MTS, ATP and LDH) and multi-parameter high-throughput screening (HTS) assays (Mito, Fluo4, JC1, and PI over exposure time of 1â€“24 h) Toxicity class definition derived based on both doseâ€“response analysis and consensus Self-Organizing Map clustering."@en ;
    skos:narrower "Human bronchial epithelial cells (BEAS-2B)",
        "Rat alveolar macrophage cells (RAW264.7)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_49a/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_49a/Nanoparticle/Size> ;
    skos:narrower npo:NPO_1373,
        npo:NPO_1486,
        npo:NPO_1542,
        npo:NPO_1548,
        npo:NPO_1550,
        enm:ENM_0000118,
        enm:ENM_9000254,
        obo:CHEBI_30187,
        pubchem:10855842,
        pubchem:14794,
        pubchem:14805,
        pubchem:14811,
        pubchem:14824,
        pubchem:14829,
        pubchem:150906,
        pubchem:157925,
        pubchem:159375,
        pubchem:159385,
        pubchem:159423,
        pubchem:160959,
        pubchem:166955,
        pubchem:29131,
        pubchem:62762,
        pubchem:73971 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_49a/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "10-100" ;
            sbd:lower_limit "10" ;
            sbd:upper_limit "100" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_49b/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a npo:NPO_296 ;
            rdfs:label "Cellular uptake of extracellular material"@en ;
            rdfs:comment "measured as log(pM) /cell"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Cellular uptake is expressed as decadic logarithm of the concentration (pM) of NP per cell The cellular uptakes in PaCa2 for the 105 nanoparticles were ranged from 170 to 27 542 nanoparticles per cell. A total of 56 nanoparticles with cellular uptake of more than 5000 nanoparticles per cell were considered to have good/moderate (henceforth referred to as good for brevity) cellular uptake (positive class), while 49 nanoparticles with cellular uptake of less than 5000 nanoparticles per cell were considered to have poor cellular uptake (negative class)"@en ;
    skos:narrower "Pancreatic human cancer cells (PaCa2)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_49b/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower pubchem:75737 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:230976 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:239163 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:74918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8111 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:994 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:96196 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6385 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:15659773 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12019 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:19990 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6558 ],
        [ a npo:NPO_1962 ;
            skos:narrower "{Bis[2-(2,6-dioxomorpholin-4-yl)ethyl]amino}acetic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "3-Phenyldihydro-2Hpyran-2,6(3H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8102 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:750 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69339 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:25160 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Tetrahydrofuro[3',4':3,4]cyclobuta[1,2-c]furan-1,3,4,6-tetrone"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:86625 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5603 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7719 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10946 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:76074 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:513917 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:70728 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1045 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:74960 ],
        [ a npo:NPO_1962 ;
            skos:narrower "6-Bromo-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:97914 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:513918 ],
        [ a npo:NPO_1962 ;
            skos:narrower "N-(2-Aminoethyl)-N'-(3-aminopropyl)butane-1,4-diamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:3301 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:25332 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:9845 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69527 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12475 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7908 ],
        [ a npo:NPO_1962 ;
            skos:narrower "4-Methyldihydro-2Hpyran-2,6(3H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:98484 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:79882 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5610 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6810 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:611 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5-amino-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "3-Methylidenedihydrofuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:587821 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:68986 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:17386 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:232 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7940 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:866 ],
        [ a npo:NPO_1962 ;
            skos:narrower "6-Nitro-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:11089 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8926 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78480 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:681 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8060 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:88069 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-ammonio-3-(4-hydroxyphenyl)propanoate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8265 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:205 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:16217 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5-Nitro-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:21631 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:738 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7894 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12801 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5,6-Dihydro-1Hcyclopenta[c]furan-1,3(4H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:72794 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1,4,5, 8-Naphthalenetetracarboxylic acidanhydride"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7922 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:424 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:2733254 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:16402 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:587821 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:96580 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:79743 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:67742 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:602 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78218 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78232 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:85689 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:2794246 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69545 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:75498 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:428 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1148 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:102679 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:65729 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:76247 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:70334 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:617 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:220977 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7923 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12012 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:95411 ],
        [ a npo:NPO_1962 ;
            skos:narrower "7 3,4-Dimethylfuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:866 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8326 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:876 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12443 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Amino-3-(1Himidazol-4-yl)propanoic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1182 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8359 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6811 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:20051 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78479 ],
        [ a npo:NPO_1962 ;
            skos:narrower "4 3,3-Dimethyldihydrofuran-2,5-dione"@en ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_49b/Nanoparticle/Size> ;
    skos:narrower npo:NPO_729 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_49b/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "38" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_49c/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a npo:NPO_296 ;
            rdfs:label "Cellular uptake of extracellular material"@en ;
            rdfs:comment "measured as log(pM) /cell"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Cellular uptake is expressed as decadic logarithm of the concentration (pM) of NP per cell The cellular uptakes in PaCa2 for the 105 nanoparticles were ranged from 170 to 27 542 nanoparticles per cell. A total of 56 nanoparticles with cellular uptake of more than 5000 nanoparticles per cell were considered to have good/moderate (henceforth referred to as good for brevity) cellular uptake (positive class), while 49 nanoparticles with cellular uptake of less than 5000 nanoparticles per cell were considered to have poor cellular uptake (negative class)"@en ;
    skos:narrower "Pancreatic human cancer cells (PaCa2)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_49c/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower pubchem:75737 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5610 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12443 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:428 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Amino-3-(1Himidazol-4-yl)propanoic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:98484 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:72794 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:513918 ],
        [ a npo:NPO_1962 ;
            skos:narrower "N-(2-Aminoethyl)-N'-(3-aminopropyl)butane-1,4-diamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8102 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:239163 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:74960 ],
        [ a npo:NPO_1962 ;
            skos:narrower "{Bis[2-(2,6-dioxomorpholin-4-yl)ethyl]amino}acetic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8265 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8926 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:3301 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5-Nitro-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "3-Phenyldihydro-2Hpyran-2,6(3H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:68986 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-ammonio-3-(4-hydroxyphenyl)propanoate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:85689 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:25160 ],
        [ a npo:NPO_1962 ;
            skos:narrower "4 3,3-Dimethyldihydrofuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6810 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:96580 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8060 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:70334 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:75498 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1182 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5,6-Dihydro-1Hcyclopenta[c]furan-1,3(4H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7894 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:70728 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78218 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12019 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69527 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69545 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1045 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5603 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1,4,5, 8-Naphthalenetetracarboxylic acidanhydride"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7922 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:513917 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:611 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7940 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8111 ],
        [ a npo:NPO_1962 ;
            skos:narrower "6-Bromo-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:16402 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:617 ],
        [ a npo:NPO_1962 ;
            skos:narrower "4-Methyldihydro-2Hpyran-2,6(3H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:15659773 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:97914 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:20051 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8326 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:79743 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:65729 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1148 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:738 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7923 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:876 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:232 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:9845 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7719 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6385 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:994 ],
        [ a npo:NPO_1962 ;
            skos:narrower "7 3,4-Dimethylfuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12012 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:95411 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5-amino-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:86625 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:2733254 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:79882 ],
        [ a npo:NPO_1962 ;
            skos:narrower "3-Methylidenedihydrofuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:587821 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6558 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:17386 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6811 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:2794246 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:102679 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:587821 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:76074 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:866 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:19990 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:424 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78480 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78479 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:88069 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:25332 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:205 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:681 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:96196 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:16217 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Tetrahydrofuro[3',4':3,4]cyclobuta[1,2-c]furan-1,3,4,6-tetrone"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:750 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:866 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78232 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:74918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7908 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12475 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:67742 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8359 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:602 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12801 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69339 ],
        [ a npo:NPO_1962 ;
            skos:narrower "6-Nitro-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:220977 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:76247 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:11089 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:230976 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10946 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:21631 ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_49c/Nanoparticle/Size> ;
    skos:narrower npo:NPO_729 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_49c/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "38" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_49d/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as LC50"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Cell viability was measured using the CytoTox-Glo Cytotoxicity Assay from Promega (Madison, WI). LC50 values for all MeOx were extrapolated using the third order polynomial equation of the log transformed data with the least squares fit in GraphPad (GraphPad Software, Inc., La Jolla, CA) Since GPTree can only work with categorical endpoints, 18 NPs were divided into two homogenous clusters, e.g. low toxicity (nine NPs) and high toxicity (nine NPs), based on a threshold value of 2.4. Activity threshold was chosen based on the natural grouping of NPs with balanced distribution between toxic and non-toxic ENMs. There was no object falling near the decision boundary (between 2.32 and 2.48), hence, there was no need to exclude any compounds from the analysis. To ensure the validity of the data split, k-means clustering method was applied using XLSTAT statistic package (Fahmy, 1993). Results of k-means clustering were identical to the results of data split based on a threshold value of 2.4"@en ;
    skos:narrower mesh:D000084282 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_49d/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_49d/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_49d/Nanoparticle/Size_2> ;
    skos:narrower npo:NPO_1373,
        npo:NPO_1486,
        npo:NPO_1542,
        npo:NPO_1550,
        enm:ENM_0000118,
        obo:CHEBI_30187,
        pubchem:14776,
        pubchem:14794,
        pubchem:14805,
        pubchem:14811,
        pubchem:14824,
        pubchem:150906,
        pubchem:157925,
        pubchem:159375,
        pubchem:166955,
        pubchem:29131,
        pubchem:518712,
        pubchem:62762 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_49d/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "15-210" ;
            sbd:lower_limit "15" ;
            sbd:upper_limit "210" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_49d/Nanoparticle/Size_2> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "189-2029" ;
            sbd:lower_limit "189" ;
            sbd:upper_limit "2029" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_49e/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a mesh:D005089 ;
            rdfs:label "Exocytosis"@en ;
            rdfs:comment "measured as classification into low, medium or high exocytosis by count of NPs"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Undifferentiated (monocytes) or phorbol-12-myristate-13-acetate (PMA)-differentiated U937 cells (macrophages) were treated with each formulation of serum-coated Gold Nanoparticles (GNPs) for 6 h in serum-supplemented media at 37 ÂºC to saturate their endocytosis. The results of Oh & Park (2014) demonstrated that cationic GNPs exhibited the lowest rate of Exocytosis while PEGylated ones showed the highest rate. They also noted that the remaining ones, anionic and zwitterionic GNPs, exhibited medium Exocytosis rates. Based on these findings, we divided 12 GNPs into three homogenous clusters, e.g. low (three GNPs), medium (six GNPs) and high Exocytosis (three GNPs)."@en ;
    skos:narrower "Human macrophage-like",
        "U937 cell" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_49e/Nanoparticle> a npo:NPO_1384,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "Opsonisation by serum proteins"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Uncoated"@en ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_49e/Nanoparticle/Size> ;
    skos:narrower npo:NPO_401 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_49e/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "14-51" ;
            sbd:lower_limit "14" ;
            sbd:upper_limit "51" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_4a/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as percentage of dead E. Coli population"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "To determine the toxicity : E. coli, the culture was grown in nutrient brothmediumovernight at 30 â—¦C, 200 rpm. Nutrient broth was prepared in 100mM phosphate buffer with the pH under study and then diluted to a 5mM concentration. E. coli was diluted as described in Tables 1 and 2, and 1mL of the inoculum were added to 49mL of nutrient medium in 125mL Erlenmeyer flask containing ZVCN. The flasks (with ZVCN and E. Coli already prepared) were incubated for 30 min at different temperatures and aeration rate. Serial dilution and plating was carried out at the end of the experiment and agar plates incubated at 30 â—¦C for 24 h to determine the colony forming units (CFUs). The percent toxicity of nanoparticles was determined by comparing the number of CFU present in the media after the incubation as compared to the number of CFU at time zero."@en ;
    skos:narrower mesh:D004926 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_4a/Nanoparticle> a npo:NPO_1384,
        npo:NPO_707 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ],
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_4a/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_4a/Nanoparticle/Size_1> ;
    skos:narrower "ZVCN: zero valent cooper Cu nanoparticle" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_4a/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1800 ;
                    rdfs:label "Average" ] ;
            sio:SIO_000300 "25" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_4a/Nanoparticle/Size_1> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "2-60" ;
            sbd:lower_limit "2" ;
            sbd:upper_limit "60" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_4b/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as percentage of dead E. Coli population"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "To determine the toxicity : E. coli, the culture was grown in nutrient brothmediumovernight at 30 â—¦C, 200 rpm. Nutrient broth was prepared in 100mM phosphate buffer with the pH under study and then diluted to a 5mM concentration. E. coli was diluted as described in Tables 1 and 2, and 1mL of the inoculum were added to 49mL of nutrient medium in 125mL Erlenmeyer flask containing ZVCN. The flasks (with ZVCN and E. Coli already prepared) were incubated for 30 min at different temperatures and aeration rate. Serial dilution and plating was carried out at the end of the experiment and agar plates incubated at 30 â—¦C for 24 h to determine the colony forming units (CFUs). The percent toxicity of nanoparticles was determined by comparing the number of CFU present in the media after the incubation as compared to the number of CFU at time zero."@en ;
    skos:narrower mesh:D004926 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_4b/Nanoparticle> a npo:NPO_1384,
        npo:NPO_707 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ],
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_4b/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_4b/Nanoparticle/Size_1> ;
    skos:narrower "ZVCN: zero valent cooper Cu nanoparticle" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_4b/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1800 ;
                    rdfs:label "Average" ] ;
            sio:SIO_000300 "25" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_4b/Nanoparticle/Size_1> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "2-60" ;
            sbd:lower_limit "2" ;
            sbd:upper_limit "60" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_5/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a obo:CHEBI_70982 ;
            rdfs:label "ROS - reactive oxygen species"@en ] ;
    rdfs:comment "The model uses reactivity descriptors to build the energy band structure of oxide nanoparticles, assuming a particle diameter larger than 20â€“30 nm and no surface states in the band gap, and predicts their ability to induce an oxidative stress by comparing the redox potentials of relevant intracellular reactions with the oxidesâ€™ energy structure"@en ;
    skos:narrower "Intra- or extracellular redox reactions, creating an imbalance of oxidized levels in a cell" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_5/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_5/Nanoparticle/Size> ;
    skos:narrower mesh:C0053349,
        mesh:C0174148,
        mesh:C040225,
        mesh:C042120,
        npo:NPO_1150,
        npo:NPO_1373,
        npo:NPO_1486,
        npo:NPO_1542,
        npo:NPO_1548,
        npo:NPO_1550,
        enm:ENM_0000118,
        obo:CHEBI_30187,
        pubchem:10129883,
        pubchem:10197609,
        pubchem:10197697,
        pubchem:10855842,
        pubchem:134661,
        pubchem:139258,
        pubchem:14778,
        pubchem:14782,
        pubchem:14792,
        pubchem:14793,
        pubchem:14796,
        pubchem:14801,
        pubchem:14802,
        pubchem:14805,
        pubchem:14813,
        pubchem:14814,
        pubchem:14827,
        pubchem:14829,
        pubchem:14940,
        pubchem:14945,
        pubchem:150906,
        pubchem:157925,
        pubchem:159370,
        pubchem:159371,
        pubchem:159373,
        pubchem:159374,
        pubchem:159375,
        pubchem:159385,
        pubchem:159410,
        pubchem:159422,
        pubchem:159423,
        pubchem:159425,
        pubchem:159427,
        pubchem:160959,
        pubchem:166955,
        pubchem:166962,
        pubchem:16747781,
        pubchem:26042,
        pubchem:29131,
        pubchem:29936,
        pubchem:32051,
        pubchem:3788361,
        pubchem:518712,
        pubchem:62157,
        pubchem:62392,
        pubchem:62762,
        pubchem:6335517,
        pubchem:6850728,
        pubchem:73975,
        pubchem:82838,
        pubchem:82839,
        pubchem:82850,
        pubchem:84163,
        pubchem:9877337,
        pubchem:9905479,
        pubchem:9989219,
        "Wo3" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_5/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 ">20" ;
            sbd:lower_limit "20" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_50a/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as percentage of cellular viability"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Cellular viability decreased in a typical sigmoidal dose-response manner as the concentration of nanoparticles increased. The full numerical Cellular viability data are listed in Table S2 (Supporting Information of the publication)"@en ;
    skos:narrower "Human umbilical vein endothelial cells (HUVEC)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_50a/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "oleic acid (OA)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Uncoated"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "serum protein (from culture media)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:24261 ],
        [ a npo:NPO_1962 ;
            skos:narrower "PMMA: poly methyl methacrylate"@en ] ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_50b/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as percentage of cellular viability"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Cellular viability decreased in a typical sigmoidal dose-response manner as the concentration of nanoparticles increased. The full numerical Cellular viability data are listed in Table S2 (Supporting Information of the publication)"@en ;
    skos:narrower "Human umbilical vein endothelial cells (HUVEC)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_50b/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "PMMA: poly methyl methacrylate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Uncoated"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:24261 ],
        [ a npo:NPO_1962 ;
            skos:narrower "serum protein (from culture media)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "oleic acid (OA)"@en ] ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_50c/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "membrane damage measured as lactate dehydrogenase (LDH) release [units/L]"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "The amount of lactate dehydrogenase (LDH) released is proportional to the number of cells damaged or lysed and is a useful index for cytotoxicity based on the loss of membrane integrity. The full experimental data are summarized in Tables S3â€“S6 (Supporting Information of the publication)"@en ;
    skos:narrower "Human hepatocellular liver carcinoma cells (HepG2)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_50c/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "oleic acid (OA)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "serum protein (from culture media)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:24261 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Uncoated"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PMMA: poly methyl methacrylate"@en ] ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_50d/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "membrane damage measured as lactate dehydrogenase (LDH) release [units/L]"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "The amount of lactate dehydrogenase (LDH) released is proportional to the number of cells damaged or lysed and is a useful index for cytotoxicity based on the loss of membrane integrity. The full experimental data are summarized in Tables S3â€“S6 (Supporting Information of the publication)"@en ;
    skos:narrower "Human hepatocellular liver carcinoma cells (HepG2)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_50d/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "oleic acid (OA)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PMMA: poly methyl methacrylate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "serum protein (from culture media)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:24261 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Uncoated"@en ] ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_50e/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a obo:CHEBI_70982 ;
            rdfs:label "ROS - reactive oxygen species"@en ;
            rdfs:comment "measured as Luciferase fold increase"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Antioxidant-response element (ARE) reporter cells are one of the most reliable and sensitive in vitro methods to measure the oxidative stress response in cells. HepG2 cells and their transformed versions with luciferase reporter plasmid (HepG2-ARE) were used to assess oxidative stress. Luciferase assays, used as a read out of the response signal to oxidative stress, were reported as fold induction relative to values obtained from untreated control cells. The full experimental luciferase fold increase data is provided in Tables S7â€“S12 (Supporting Information of the publication)"@en ;
    skos:narrower "Human hepatocellular liver carcinoma cells (HepG2)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_50e/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "serum protein (from culture media)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "oleic acid (OA)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:24261 ],
        [ a npo:NPO_1962 ;
            skos:narrower "PMMA: poly methyl methacrylate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Uncoated"@en ] ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_50f/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a obo:CHEBI_70982 ;
            rdfs:label "ROS - reactive oxygen species"@en ;
            rdfs:comment "measured as Luciferase fold increase"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Antioxidant-response element (ARE) reporter cells are one of the most reliable and sensitive in vitro methods to measure the oxidative stress response in cells. HepG2 cells and their transformed versions with luciferase reporter plasmid (HepG2-ARE) were used to assess oxidative stress. Luciferase assays, used as a read out of the response signal to oxidative stress, were reported as fold induction relative to values obtained from untreated control cells. The full experimental luciferase fold increase data is provided in Tables S7â€“S12 (Supporting Information of the publication)"@en ;
    skos:narrower "Human hepatocellular liver carcinoma cells (HepG2)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_50f/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "Uncoated"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "oleic acid (OA)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:24261 ],
        [ a npo:NPO_1962 ;
            skos:narrower "serum protein (from culture media)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PMMA: poly methyl methacrylate"@en ] ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_51a/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "Protein binding of nanotube to carbonic anhydrase (CA) : F_0/F" ] ;
    rdfs:comment "F0 is the protein fluorescence intensity before CNT binding and F is the fluorescence intensity after CNT binding Steady-state fluorescence spectra were acquired on a Hitachi F-7000 spectrofluorometer (Hitachi Co. Ltd., Tokyo, Japan) at 22Â°C. Carbonic anhydrase (Sigma-Aldrich, St. Louis, MO) (50 Î¼g/mL) was titrated with f-MWNTs stock solutions (500 Î¼g/mL) at three different concentrations (0.0, 7.5 and 15.0 Î¼g/mL). The excitation wavelength was set at 280 nm. Emission fluorescence spectra were recorded between 300 and 400 nm. The scanning speed was 1200 nm/min and the excitation/emission slit was 5.0 nm. The fluorescence intensity of 340 nm was used for F_0/F calculation. For classification modelling: CNTs are labelled as â€˜â€˜0â€™â€™ (non-binder), if their CA bindings are smaller than 2.00 and â€˜â€˜1â€™â€™ (binder), if their CA bindings are greater than 2.00."@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_51a/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_part [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:243 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:21805890 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ] ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_461 ],
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_51a/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_51a/Nanoparticle/Size_2> ;
    skos:narrower npo:NPO_606 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_51a/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "30.0-50.0" ;
            sbd:lower_limit "30.0" ;
            sbd:upper_limit "50.0" ] ;
    skos:narrower obo:PATO_0001334 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_51a/Nanoparticle/Size_2> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "130.0-370.0" ;
            sbd:lower_limit "130.0" ;
            sbd:upper_limit "370.0" ] ;
    skos:narrower obo:PATO_0000122 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_51b/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as percentage of cellular viability"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "THP-1 (human monocyte) cell lines were cultivated in RPMI 1640 (Gibco) with 10% heat-inactivated fetal bovine serum, 2mM Lglutamine, 100 Î¼g/mL penicillin and 100 U/mL streptomycin and grown in a humidified incubator at 37Â°C (95% room air, 5% CO2). Cell differentiation into macrophages was triggered by adding Phorbol 12-myristate 13-acetate (PMA; Promega) at a concentration of 50 ng/mL and incubating for 48 h. Differentiated cells were characterized by allowing them to adhere to the plastic well surface in 96-well plates. The nonadherent monocytes were removed, and the adherent macrophages were washed twice in RPMI 1640. Cells were treated with f-MWNT suspensions (200 Î¼g/mL) in complete culture medium. After 24 h of incubation, a cell proliferation (WST-1) assay was used to determine the Cellular viability. For the whole set of 84 CNTs, the average of measurement variations is as low as 3.6% at (200 Î¼g/mL) and 3.8% at (50 Î¼g/mL). For classification modelling:CNTs are labelled as â€˜â€˜0â€™â€™ (non-toxic) if their associated Cellular viability is greater than 50% and â€˜â€˜1â€™â€™ (toxic) if their associated Cellular viability is smaller than 50%"@en ;
    skos:narrower "Human Macrophages" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_51b/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_part [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:21805890 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:243 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ],
        [ a npo:NPO_1962 ] ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_461 ],
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_51b/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_51b/Nanoparticle/Size_2> ;
    skos:narrower npo:NPO_606 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_51b/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "30.0-50.0" ;
            sbd:lower_limit "30.0" ;
            sbd:upper_limit "50.0" ] ;
    skos:narrower obo:PATO_0001334 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_51b/Nanoparticle/Size_2> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "130.0-370.0" ;
            sbd:lower_limit "130.0" ;
            sbd:upper_limit "370.0" ] ;
    skos:narrower obo:PATO_0000122 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_52a/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment """measured as percentage of cellular viability
  
  at a time of NP Size"""@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Mrc-5: Diploid human cell culture line composed of fibroblasts derived from lung tissue of an 14 week old aborted caucasian male fetus. 30 samples having different Chitosan (Cs) concentrations (i.e. 0.5-2.0 mg/mL) were prepared in 1% acetic acid solution (pH values 4.5-6.0). To dissolve the polymer, stirring time was set between 0.5 and 2.0 h and stir rate was fixed at 1000 rpm. Then, SK solution (0.1 mg/ml) was added to the solution drop wise and stirred. To determine size and zeta potential of nanoparticles, photon correlation spectroscopy (PCS, Zeta sizer Nano, Malvern, UK) was used at 25 Â°C MTT assay was performed and Cellular viability was obtained following the equation 1"@en ;
    skos:narrower "Mrc-5 cell line" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_52a/Nanoparticle> a npo:NPO_1375,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_52a/Nanoparticle/Size> ;
    skos:narrower "Streptokinase (SK) and Chitosan" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_52a/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "200-800" ;
            sbd:lower_limit "200" ;
            sbd:upper_limit "800" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_52b/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as percentage of cellular viability"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Mrc-5: Diploid human cell culture line composed of fibroblasts derived from lung tissue of an 14 week old aborted caucasian male fetus. 30 samples having different Chitosan (Cs) concentrations (i.e. 0.5-2.0 mg/mL) were prepared in 1% acetic acid solution (pH values 4.5-6.0). To dissolve the polymer, stirring time was set between 0.5 and 2.0 h and stir rate was fixed at 1000 rpm. Then, SK solution (0.1 mg/ml) was added to the solution drop wise and stirred. MTT assay was performed and Cellular viability was obtained following the equation 1"@en ;
    skos:narrower "Mrc-5 cell line" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_52b/Nanoparticle> a npo:NPO_1375,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_52b/Nanoparticle/Size> ;
    skos:narrower "Streptokinase (SK) and Chitosan" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_52b/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "200-800" ;
            sbd:lower_limit "200" ;
            sbd:upper_limit "800" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_52c/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as percentage of cellular viability"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Mrc-5: Diploid human cell culture line composed of fibroblasts derived from lung tissue of an 14 week old aborted caucasian male fetus. 30 samples having different Chitosan (Cs) concentrations (i.e. 0.5-2.0 mg/mL) were prepared in 1% acetic acid solution (pH values 4.5-6.0). To dissolve the polymer, stirring time was set between 0.5 and 2.0 h and stir rate was fixed at 1000 rpm. Then, SK solution (0.1 mg/ml) was added to the solution drop wise and stirred. MTT assay was performed and Cellular viability was obtained following the equation 1"@en ;
    skos:narrower "Mrc-5 cell line" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_52c/Nanoparticle> a npo:NPO_1375,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_52c/Nanoparticle/Size> ;
    skos:narrower "Streptokinase (SK) and Chitosan" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_52c/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "200-800" ;
            sbd:lower_limit "200" ;
            sbd:upper_limit "800" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53a/Endpoint> a sty:T001,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "Ecotoxicological endpoint" ;
            rdfs:comment "measured as LC50"@en ] ;
    bao:BAO_0095009 obo:OBI_0100026 ;
    rdfs:comment "400 ENMs from 90 publications or reports provided with experimental data on LC50. Units of the toxicity values were presented into mg/L. For classification models a threshold must to be set to label with Active or Inactive classes the different individuals into the data sets. In that case the threshold was set at 1.0 mg/L"@en ;
    skos:narrower mesh:D004926,
        "Brachionus Calyciflorus",
        "Brachionus plicatilis",
        "Caenorhabditis elegans",
        "Ceriodaphnia dubia",
        "Danio rerio (fish) - Zebrafish",
        "Daphnia magna (crustacean)",
        "Daphnia pulex",
        "Fathead Minnow",
        "Heterocypris incongruent",
        "Hypophthalmichthys molitrix",
        "Leptocheirus plumulosus",
        "Meloidogyn",
        "Moina macrocopa",
        "Nitrifying bacteria",
        "Oryzias latipes",
        "Paramecium caudatum",
        "Paramecium multimicronucleatum",
        "Physa acuta",
        "Pimephales promelas",
        "Pseudokirchneriella subcapitata (algae)",
        "Rainbow trout",
        "Thamnocephalus platyurus",
        "Zebrafish embryo" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53a/Nanoparticle> a npo:NPO_1384,
        npo:NPO_1541,
        npo:NPO_707 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53b/Endpoint> a sty:T001,
        sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "Ecotoxicological endpoint" ;
            rdfs:comment "measured as LC50"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285,
        obo:OBI_0100026 ;
    rdfs:comment "400 ENMs from 90 publications or reports provided with experimental data on LC50. Units of the toxicity values were presented into mg/L. For classification models a threshold must to be set to label with Active or Inactive classes the different individuals into the data sets. In that case the threshold was set at 1.0 mg/L"@en ;
    skos:narrower mesh:D004926,
        "Brachionus Calyciflorus",
        "Brachionus plicatilis",
        "Caenorhabditis elegans",
        "Ceriodaphnia dubia",
        "Danio rerio (fish) - Zebrafish",
        "Daphnia magna (crustacean)",
        "Daphnia pulex",
        "Fathead Minnow",
        "Heterocypris incongruent",
        "Hypophthalmichthys molitrix",
        "Leptocheirus plumulosus",
        "Meloidogyn",
        "Moina macrocopa",
        "Nitrifying bacteria",
        "Oryzias latipes",
        "Paramecium caudatum",
        "Paramecium multimicronucleatum",
        "Physa acuta",
        "Pimephales promelas",
        "Pseudokirchneriella subcapitata (algae)",
        "Rainbow trout",
        "Thamnocephalus platyurus",
        "Zebrafish embryo" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53b/Nanoparticle> a npo:NPO_1384,
        npo:NPO_1541,
        npo:NPO_707 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53c/Endpoint> a sty:T001,
        sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "Ecotoxicological endpoint" ;
            rdfs:comment "measured as LC50"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285,
        obo:OBI_0100026 ;
    rdfs:comment "400 ENMs from 90 publications or reports provided with experimental data on LC50. Units of the toxicity values were presented into mg/L. For classification models a threshold must to be set to label with Active or Inactive classes the different individuals into the data sets. In that case the threshold was set at 1.0 mg/L"@en ;
    skos:narrower mesh:D004926,
        "Brachionus Calyciflorus",
        "Brachionus plicatilis",
        "Caenorhabditis elegans",
        "Ceriodaphnia dubia",
        "Danio rerio (fish) - Zebrafish",
        "Daphnia magna (crustacean)",
        "Daphnia pulex",
        "Fathead Minnow",
        "Heterocypris incongruens",
        "Hypophthalmichthys molitrix",
        "Leptocheirus plumulosus",
        "Meloidogyn",
        "Moina macrocopa",
        "Nitrifying bacteria",
        "Oryzias latipes",
        "Paramecium caudatum",
        "Paramecium multimicronucleatum",
        "Physa acuta",
        "Pimephales promelas",
        "Pseudokirchneriella subcapitata (algae)",
        "Rainbow trout",
        "Thamnocephalus platyurus",
        "Zebrafish embryo" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53c/Nanoparticle> a npo:NPO_1384,
        npo:NPO_1541,
        npo:NPO_707 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53d/Endpoint> a sty:T001,
        sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "Ecotoxicological endpoint" ;
            rdfs:comment "measured as LC50"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285,
        obo:OBI_0100026 ;
    rdfs:comment "400 ENMs from 90 publications or reports provided with experimental data on LC50. Units of the toxicity values were presented into mg/L. For classification models a threshold must to be set to label with Active or Inactive classes the different individuals into the data sets. In that case the threshold was set at 1.0 mg/L"@en ;
    skos:narrower mesh:D004926,
        "Brachionus Calyciflorus",
        "Brachionus plicatilis",
        "Caenorhabditis elegans",
        "Ceriodaphnia dubia",
        "Danio rerio (fish) - Zebrafish",
        "Daphnia magna (crustacean)",
        "Daphnia pulex",
        "Fathead Minnow",
        "Heterocypris incongruens",
        "Hypophthalmichthys molitrix",
        "Leptocheirus plumulosus",
        "Meloidogyn",
        "Moina macrocopa",
        "Nitrifying bacteria",
        "Oryzias latipes",
        "Paramecium caudatum",
        "Paramecium multimicronucleatum",
        "Physa acuta",
        "Pimephales promelas",
        "Pseudokirchneriella subcapitata (algae)",
        "Rainbow trout",
        "Thamnocephalus platyurus",
        "Zebrafish embryo" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53d/Nanoparticle> a npo:NPO_1384,
        npo:NPO_1541,
        npo:NPO_707 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53e/Endpoint> a sty:T001,
        sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "Ecotoxicological endpoint" ;
            rdfs:comment "measured as EC50"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285,
        obo:OBI_0100026 ;
    rdfs:comment "450 ENM records from 79 publications or reports with quantitative information on EC50 values. Units of the toxicity values were presented into mg/L. For classification models a threshold must to be set to label with Active or Inactive classes the different individuals into the data sets. In that case the threshold was set at 10.0 mg/L"@en ;
    skos:narrower mesh:D004926,
        "Anabaena",
        "Bacillus licheniformis",
        "Bacillus subtilis",
        "Brachionus plicatilis",
        "Caenorhabditis elegans",
        "Ceriodaphnia dubia",
        "Chlamydomonas reinhardtii",
        "Chlorella",
        "Danio rerio (fish) - Zebrafish",
        "Daphnia magna (crustacean)",
        "Desmodesmus subspicatus",
        "Heterocypris incongruens",
        "Lemna minor",
        "Phaeodactylum tricornutum",
        "Pimephales promelas",
        "Pseudokirchneriella subcapitata (algae)",
        "Pseudomonas putida",
        "Raphidocelis subcapitata",
        "Saccharomyces cerevisiae",
        "Scenedesmus obliquus",
        "Tetrahymena thermophila",
        "Vibrio fischeri",
        "Xenopus laevis",
        "Zebrafish embryo" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53e/Nanoparticle> a npo:NPO_1384,
        npo:NPO_1541,
        npo:NPO_707 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53f/Endpoint> a sty:T001,
        sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "Ecotoxicological endpoint" ;
            rdfs:comment "measured as EC50"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285,
        obo:OBI_0100026 ;
    rdfs:comment "450 ENM records from 79 publications or reports with quantitative information on EC50 values. Units of the toxicity values were presented into mg/L. For classification models a threshold must to be set to label with Active or Inactive classes the different individuals into the data sets. In that case the threshold was set at 10.0 mg/L"@en ;
    skos:narrower mesh:D004926,
        "Anabaena",
        "Bacillus licheniformis",
        "Bacillus subtilis",
        "Brachionus plicatilis",
        "Caenorhabditis elegans",
        "Ceriodaphnia dubia",
        "Chlamydomonas reinhardtii",
        "Chlorella",
        "Danio rerio (fish) - Zebrafish",
        "Daphnia magna (crustacean)",
        "Desmodesmus subspicatus",
        "Heterocypris incongruens",
        "Lemna minor",
        "Phaeodactylum tricornutum",
        "Pimephales promelas",
        "Pseudokirchneriella subcapitata (algae)",
        "Pseudomonas putida",
        "Raphidocelis subcapitata",
        "Saccharomyces cerevisiae",
        "Scenedesmus obliquus",
        "Tetrahymena thermophila",
        "Vibrio fischeri",
        "Xenopus laevis",
        "Zebrafish embryo" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53f/Nanoparticle> a npo:NPO_1384,
        npo:NPO_1541,
        npo:NPO_707 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53g/Endpoint> a sty:T001,
        sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "Ecotoxicological endpoint" ;
            rdfs:comment "measured as EC50"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285,
        obo:OBI_0100026 ;
    rdfs:comment "450 ENM records from 79 publications or reports with quantitative information on EC50 values. Units of the toxicity values were presented into mg/L. For classification models a threshold must to be set to label with Active or Inactive classes the different individuals into the data sets. In that case the threshold was set at 10.0 mg/L"@en ;
    skos:narrower mesh:D004926,
        "Anabaena",
        "Bacillus licheniformis",
        "Bacillus subtilis",
        "Brachionus plicatilis",
        "Caenorhabditis elegans",
        "Ceriodaphnia dubia",
        "Chlamydomonas reinhardtii",
        "Chlorella",
        "Danio rerio (fish) - Zebrafish",
        "Daphnia magna (crustacean)",
        "Desmodesmus subspicatus",
        "Heterocypris incongruens",
        "Lemna minor",
        "Phaeodactylum tricornutum",
        "Pimephales promelas",
        "Pseudokirchneriella subcapitata (algae)",
        "Pseudomonas putida",
        "Raphidocelis subcapitata",
        "Saccharomyces cerevisiae",
        "Scenedesmus obliquus",
        "Tetrahymena thermophila",
        "Vibrio fischeri",
        "Xenopus laevis",
        "Zebrafish embryo" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53g/Nanoparticle> a npo:NPO_1384,
        npo:NPO_1541,
        npo:NPO_707 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53h/Endpoint> a sty:T001,
        sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "Ecotoxicological endpoint" ;
            rdfs:comment "measured as EC50"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285,
        obo:OBI_0100026 ;
    rdfs:comment "450 ENM records from 79 publications or reports with quantitative information on EC50 values. Units of the toxicity values were presented into mg/L. For classification models a threshold must to be set to label with Active or Inactive classes the different individuals into the data sets. In that case the threshold was set at 10.0 mg/L"@en ;
    skos:narrower mesh:D004926,
        "Anabaena",
        "Bacillus licheniformis",
        "Bacillus subtilis",
        "Brachionus plicatilis",
        "Caenorhabditis elegans",
        "Ceriodaphnia dubia",
        "Chlamydomonas reinhardtii",
        "Chlorella",
        "Danio rerio (fish) - Zebrafish",
        "Daphnia magna (crustacean)",
        "Desmodesmus subspicatus",
        "Heterocypris incongruens",
        "Lemna minor",
        "Phaeodactylum tricornutum",
        "Pimephales promelas",
        "Pseudokirchneriella subcapitata (algae)",
        "Pseudomonas putida",
        "Raphidocelis subcapitata",
        "Saccharomyces cerevisiae",
        "Scenedesmus obliquus",
        "Tetrahymena thermophila",
        "Vibrio fischeri",
        "Xenopus laevis",
        "Zebrafish embryo" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53h/Nanoparticle> a npo:NPO_1384,
        npo:NPO_1541,
        npo:NPO_707 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53i/Endpoint> a sty:T001,
        sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "Ecotoxicological endpoint" ;
            rdfs:comment "measured as MIC"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285,
        obo:OBI_0100026 ;
    rdfs:comment "166 ENMs obtained from 13 publications with experimental values of the MIC. MIC characterizes the antimicrobial properties of ENMs. Units of the toxicity values were presented into mg/L. For classification models a threshold must to be set to label with Active or Inactive classes the different individuals into the data sets. In that case the threshold was set at 10.0 mg/L"@en ;
    skos:narrower mesh:D004926,
        "Azotobacter vinelandii",
        "Enterococcus faecalis",
        "Klebsiella pneumoniae ESBL",
        "Neisseria gonorrhoeae",
        "Nitrosomonas europaea",
        "Pseudomonas aeruginosa",
        "Salmonella",
        "Staphylococcus aureus (bacteria)",
        "Staphylococcus epidermidis methicillinsusceptible" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53i/Nanoparticle> a npo:NPO_1384,
        npo:NPO_1541,
        npo:NPO_707 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53j/Endpoint> a sty:T001,
        sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "Ecotoxicological endpoint" ;
            rdfs:comment "measured as MIC"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285,
        obo:OBI_0100026 ;
    rdfs:comment "166 ENMs obtained from 13 publications with experimental values of the MIC. MIC characterizes the antimicrobial properties of ENMs. Units of the toxicity values were presented into mg/L. For classification models a threshold must to be set to label with Active or Inactive classes the different individuals into the data sets. In that case the threshold was set at 10.0 mg/L"@en ;
    skos:narrower mesh:D004926,
        "Azotobacter vinelandii",
        "Enterococcus faecalis",
        "Klebsiella pneumoniae ESBL",
        "Neisseria gonorrhoeae",
        "Nitrosomonas europaea",
        "Pseudomonas aeruginosa",
        "Salmonella",
        "Staphylococcus aureus (bacteria)",
        "Staphylococcus epidermidis methicillinsusceptible" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53j/Nanoparticle> a npo:NPO_1384,
        npo:NPO_1541,
        npo:NPO_707 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53k/Endpoint> a sty:T001,
        sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "Ecotoxicological endpoint" ;
            rdfs:comment "measured as MIC"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285,
        obo:OBI_0100026 ;
    rdfs:comment "166 ENMs obtained from 13 publications with experimental values of the MIC. MIC characterizes the antimicrobial properties of ENMs. Units of the toxicity values were presented into mg/L. For classification models a threshold must to be set to label with Active or Inactive classes the different individuals into the data sets. In that case the threshold was set at 10.0 mg/L"@en ;
    skos:narrower mesh:D004926,
        "Azotobacter vinelandii",
        "Enterococcus faecalis",
        "Klebsiella pneumoniae ESBL",
        "Neisseria gonorrhoeae",
        "Nitrosomonas europaea",
        "Pseudomonas aeruginosa",
        "Salmonella",
        "Staphylococcus aureus (bacteria)",
        "Staphylococcus epidermidis methicillinsusceptible" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53k/Nanoparticle> a npo:NPO_1384,
        npo:NPO_1541,
        npo:NPO_707 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53l/Endpoint> a sty:T001,
        sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "Ecotoxicological endpoint" ;
            rdfs:comment "measured as MIC"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285,
        obo:OBI_0100026 ;
    rdfs:comment "166 ENMs obtained from 13 publications with experimental values of the MIC. MIC characterizes the antimicrobial properties of ENMs. Units of the toxicity values were presented into mg/L. For classification models a threshold must to be set to label with Active or Inactive classes the different individuals into the data sets. In that case the threshold was set at 10.0 mg/L"@en ;
    skos:narrower mesh:D004926,
        "Azotobacter vinelandii",
        "Enterococcus faecalis",
        "Klebsiella pneumoniae ESBL",
        "Neisseria gonorrhoeae",
        "Nitrosomonas europaea",
        "Pseudomonas aeruginosa",
        "Salmonella",
        "Staphylococcus aureus (bacteria)",
        "Staphylococcus epidermidis methicillinsusceptible" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53l/Nanoparticle> a npo:NPO_1384,
        npo:NPO_1541,
        npo:NPO_707 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53m/Endpoint> a sty:T001,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "Ecotoxicological endpoint" ;
            rdfs:comment "measured as LC50"@en ] ;
    bao:BAO_0095009 obo:OBI_0100026 ;
    rdfs:comment "Danio rerio (94 records) cases were selected from dataset I. Units of the toxicity values were presented into mg/L. For classification models a threshold must to be set to label with Active or Inactive classes the different individuals into the data sets. In that case the threshold was set at 100.0 mg/L"@en ;
    skos:narrower "Danio rerio (fish) - Zebrafish" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53m/Nanoparticle> a npo:NPO_1384,
        npo:NPO_1541,
        npo:NPO_707 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53n/Endpoint> a sty:T001,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "Ecotoxicological endpoint" ;
            rdfs:comment "measured as LC50"@en ] ;
    bao:BAO_0095009 obo:OBI_0100026 ;
    rdfs:comment "Danio rerio (94 records) cases were selected from dataset I. Units of the toxicity values were presented into mg/L. For classification models a threshold must to be set to label with Active or Inactive classes the different individuals into the data sets. In that case the threshold was set at 100.0 mg/L"@en ;
    skos:narrower "Danio rerio (fish) - Zebrafish" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53n/Nanoparticle> a npo:NPO_1384,
        npo:NPO_1541,
        npo:NPO_707 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53o/Endpoint> a sty:T001,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "Ecotoxicological endpoint" ;
            rdfs:comment "measured as LC50"@en ] ;
    bao:BAO_0095009 obo:OBI_0100026 ;
    rdfs:comment "Daphnia magna (102 records) cases were selected from dataset I. Units of the toxicity values were presented into mg/L. For classification models a threshold must to be set to label with Active or Inactive classes the different individuals into the data sets. In that case the threshold was set at 1.0 mg/L"@en ;
    skos:narrower "Daphnia magna (crustacean)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53o/Nanoparticle> a npo:NPO_1384,
        npo:NPO_1541,
        npo:NPO_707 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53p/Endpoint> a sty:T001,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "Ecotoxicological endpoint" ;
            rdfs:comment "measured as LC50"@en ] ;
    bao:BAO_0095009 obo:OBI_0100026 ;
    rdfs:comment "Daphnia magna (102 records) cases were selected from dataset I. Units of the toxicity values were presented into mg/L. For classification models a threshold must to be set to label with Active or Inactive classes the different individuals into the data sets. In that case the threshold was set at 1.0 mg/L"@en ;
    skos:narrower "Daphnia magna (crustacean)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53p/Nanoparticle> a npo:NPO_1384,
        npo:NPO_1541,
        npo:NPO_707 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53q/Endpoint> a sty:T001,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "Ecotoxicological endpoint" ;
            rdfs:comment "measured as EC50"@en ] ;
    bao:BAO_0095009 obo:OBI_0100026 ;
    rdfs:comment "Pseudokirchneriella subcapitata (66 records) cases were selected from dataset II. Units of the toxicity values were presented into mg/L. For classification models a threshold must to be set to label with Active or Inactive classes the different individuals into the data sets. In that case the threshold was set at 1.0 mg/L"@en ;
    skos:narrower "Pseudokirchneriella subcapitata (algae)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53q/Nanoparticle> a npo:NPO_1384,
        npo:NPO_1541,
        npo:NPO_707 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53r/Endpoint> a sty:T001,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "Ecotoxicological endpoint" ;
            rdfs:comment "measured as EC50"@en ] ;
    bao:BAO_0095009 obo:OBI_0100026 ;
    rdfs:comment "Pseudokirchneriella subcapitata (66 records) cases were selected from dataset II. Units of the toxicity values were presented into mg/L. For classification models a threshold must to be set to label with Active or Inactive classes the different individuals into the data sets. In that case the threshold was set at 1.0 mg/L"@en ;
    skos:narrower "Pseudokirchneriella subcapitata (algae)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53r/Nanoparticle> a npo:NPO_1384,
        npo:NPO_1541,
        npo:NPO_707 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53s/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as MIC"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Staphylococcus aureus (39 records) cases were selected from dataset III. Units of the toxicity values were presented into mg/L. For classification models a threshold must to be set to label with Active or Inactive classes the different individuals into the data sets. In that case the threshold was set at 1.0 mg/L"@en ;
    skos:narrower "Staphylococcus aureus (bacteria)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_53s/Nanoparticle> a npo:NPO_1384,
        npo:NPO_1541,
        npo:NPO_707 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_54a/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as log(1/EC50)"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Combining two datasets, common 16 metal oxides were used to develop nano-QTTR models. As CuO has only cytotoxicity value for E. coli, and, WO3 and Mn2O3 had cytotoxicity values known for HaCaT cell line, we have used them as true external compounds for prediction of cytotoxicity value to HaCaT cell line and E. coli, respectively."@en ;
    skos:narrower mesh:D004926 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_54a/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_54a/Nanoparticle/Size> ;
    skos:narrower npo:NPO_1373,
        npo:NPO_1486,
        npo:NPO_1542,
        npo:NPO_1550,
        enm:ENM_0000118,
        obo:CHEBI_30187,
        pubchem:14776,
        pubchem:14794,
        pubchem:14805,
        pubchem:14829,
        pubchem:150906,
        pubchem:157925,
        pubchem:159375,
        pubchem:166955,
        pubchem:29131,
        pubchem:518712,
        pubchem:62762 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_54a/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "15-90" ;
            sbd:lower_limit "15" ;
            sbd:upper_limit "90" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_54b/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as log(1/EC50)"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Combining two datasets, common 16 metal oxides were used to develop nano-QTTR models. As CuO has only cytotoxicity value for E. coli, and, WO3 and Mn2O3 had cytotoxicity values known for HaCaT cell line, we have used them as true external compounds for prediction of cytotoxicity value to HaCaT cell line and E. coli, respectively."@en ;
    skos:narrower mesh:D000084282 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_54b/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_54b/Nanoparticle/Size> ;
    skos:narrower npo:NPO_1373,
        npo:NPO_1486,
        npo:NPO_1542,
        npo:NPO_1550,
        enm:ENM_0000118,
        obo:CHEBI_30187,
        pubchem:14776,
        pubchem:14794,
        pubchem:14805,
        pubchem:14811,
        pubchem:14824,
        pubchem:150906,
        pubchem:157925,
        pubchem:159375,
        pubchem:166955,
        pubchem:29131,
        pubchem:518712,
        pubchem:62762 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_54b/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "15-90" ;
            sbd:lower_limit "15" ;
            sbd:upper_limit "90" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_55a/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as log(1/EC50)"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Determined the cytotoxicity of the metal oxide nanoparticles in terms of EC50 (concentration which cytotoxicity reduces bacteria viability up to 50%) based on the curve fitting least squares procedure."@en ;
    skos:narrower mesh:D004926 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_55a/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_55a/Nanoparticle/Size> ;
    skos:narrower npo:NPO_1373,
        npo:NPO_1486,
        npo:NPO_1542,
        npo:NPO_1550,
        enm:ENM_0000118,
        obo:CHEBI_30187,
        pubchem:14776,
        pubchem:14794,
        pubchem:14805,
        pubchem:14829,
        pubchem:150906,
        pubchem:157925,
        pubchem:159375,
        pubchem:166955,
        pubchem:29131,
        pubchem:518712,
        pubchem:62762 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_55a/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "15-90" ;
            sbd:lower_limit "15" ;
            sbd:upper_limit "90" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_55b/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as log(1/EC50)"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Determined the cytotoxicity of the metal oxide nanoparticles in terms of EC50 (concentration which cytotoxicity reduces bacteria viability up to 50%) based on the curve fitting least squares procedure."@en ;
    skos:narrower mesh:D004926 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_55b/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_55b/Nanoparticle/Size> ;
    skos:narrower npo:NPO_1373,
        npo:NPO_1486,
        npo:NPO_1542,
        npo:NPO_1550,
        enm:ENM_0000118,
        obo:CHEBI_30187,
        pubchem:14776,
        pubchem:14794,
        pubchem:14805,
        pubchem:14829,
        pubchem:150906,
        pubchem:157925,
        pubchem:159375,
        pubchem:166955,
        pubchem:29131,
        pubchem:518712,
        pubchem:62762 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_55b/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "15-90" ;
            sbd:lower_limit "15" ;
            sbd:upper_limit "90" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_55c/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as log(1/LC50)"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Cell viability was measured using the CytoTox-Glo Cytotoxicity Assay from Promega (Madison, WI). LC50 values for all MeOx were extrapolated using the third order polynomial equation of the log transformed data with the least squares fit in GraphPad (GraphPad Software, Inc., La Jolla, CA)"@en ;
    skos:narrower mesh:D000084282 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_55c/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_55c/Nanoparticle/Size> ;
    skos:narrower npo:NPO_1373,
        npo:NPO_1486,
        npo:NPO_1542,
        npo:NPO_1550,
        enm:ENM_0000118,
        obo:CHEBI_30187,
        pubchem:14776,
        pubchem:14794,
        pubchem:14805,
        pubchem:14811,
        pubchem:14824,
        pubchem:150906,
        pubchem:157925,
        pubchem:159375,
        pubchem:166955,
        pubchem:29131,
        pubchem:518712,
        pubchem:62762 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_55c/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "15-150" ;
            sbd:lower_limit "15" ;
            sbd:upper_limit "150" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_55d/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as log(1/LC50)"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Cell viability was measured using the CytoTox-Glo Cytotoxicity Assay from Promega (Madison, WI). LC50 values for all MeOx were extrapolated using the third order polynomial equation of the log transformed data with the least squares fit in GraphPad (GraphPad Software, Inc., La Jolla, CA)"@en ;
    skos:narrower mesh:D000084282 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_55d/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_55d/Nanoparticle/Size> ;
    skos:narrower npo:NPO_1373,
        npo:NPO_1486,
        npo:NPO_1542,
        npo:NPO_1550,
        enm:ENM_0000118,
        obo:CHEBI_30187,
        pubchem:14776,
        pubchem:14794,
        pubchem:14805,
        pubchem:14811,
        pubchem:14824,
        pubchem:150906,
        pubchem:157925,
        pubchem:159375,
        pubchem:166955,
        pubchem:29131,
        pubchem:518712,
        pubchem:62762 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_55d/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "15-150" ;
            sbd:lower_limit "15" ;
            sbd:upper_limit "150" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_56/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as log(1/EC50)"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Determined the cytotoxicity of the metal oxide nanoparticles in terms of EC50 (concentration which cytotoxicity reduces bacteria viability up to 50%) based on the curve fitting least squares procedure."@en ;
    skos:narrower mesh:D000084282,
        mesh:D004926 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_56/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_56/Nanoparticle/Size> ;
    skos:narrower npo:NPO_1373,
        npo:NPO_1486,
        npo:NPO_1542,
        npo:NPO_1550,
        enm:ENM_0000118,
        obo:CHEBI_30187,
        pubchem:14776,
        pubchem:14794,
        pubchem:14805,
        pubchem:14829,
        pubchem:150906,
        pubchem:157925,
        pubchem:159375,
        pubchem:166955,
        pubchem:29131,
        pubchem:518712,
        pubchem:62762 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_56/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "15-90" ;
            sbd:lower_limit "15" ;
            sbd:upper_limit "90" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_57/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as pEC50"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Determined the cytotoxicity of the metal oxide nanoparticles in terms of EC50 (concentration which cytotoxicity reduces bacteria viability up to 50%) based on the curve fitting least squares procedure."@en ;
    skos:narrower mesh:D004926 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_57/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_57/Nanoparticle/Size> ;
    skos:narrower npo:NPO_1373,
        npo:NPO_1486,
        npo:NPO_1542,
        npo:NPO_1550,
        enm:ENM_0000118,
        obo:CHEBI_30187,
        pubchem:14776,
        pubchem:14794,
        pubchem:14805,
        pubchem:150906,
        pubchem:157925,
        pubchem:159375,
        pubchem:166955,
        pubchem:29131,
        pubchem:518712,
        pubchem:62762 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_57/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "15-90" ;
            sbd:lower_limit "15" ;
            sbd:upper_limit "90" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_58/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as biological response by H4"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "The dataset provided measurements of biological response for four cell types (Endothelial cells (human aorta), Vascular smooth muscle cells (human coronary artery), Hepatocytes (human HepG2 cells), and Murine RAW 264.7 leukemic monocyte/macrophage cell), exposed to the NPs at four concentrations (0.01, 0.03, 0.1, and 0.3 mg/mL Fe), determined based on four different assays (Apo: apoptosis, Mito: mitochondrial potential, Red: reducing equivalents, and ATP: ATP content) With a certainty above 95%, NP induced response that is above that of the control. In the present work, SNR(Signal-to-Noise ratio) > 1.645 was identified as a hit for a given NP. A 5% chance of miss-identifying a non-hit as â€œhitâ€ for a given NP, would be equivalent to a miss-identification of 3.2 out of the 64 measurements in its HTS profile. Therefore, even if 5% uncertainty would be acceptable it would be more practical to set the threshold to or above the next higher integer value, i.e., N hit â‰¥ 4."@en ;
    skos:narrower "Endothelial cells (human aorta)",
        "Hepatocytes (human HepG2 cells)",
        "Murine RAW 264.7 leukemic monocyte/macrophage cell",
        "Vascular smooth muscle cells (human coronary artery)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_58/Nanoparticle> a npo:NPO_1384,
        npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "PVA :: 15-mer peptide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: L-arg8-COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Alexa Fluor 488"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Cy5.5, tat"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Coating :: Surface modification"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: NA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: L-arg7-COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA, PEG :: NA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amphiphilic polymer :: COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: FITC, Glutamic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Arabino-galactan :: NA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: FITC, R-COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: VT680, protamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: FITC, COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Sucrose :: NA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: D-arg7-COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: rhodamine, protamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Alexa Fluor 750"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA, PEG :: Ethylene diamine, VT750"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: Ethylene diamine, AminoSPARKâ„¢680"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Cy5.5, protamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Cy7"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Tat peptide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: protamine, rhodamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA, PEG :: AngioSPARKâ„¢680- IVM"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: Ethylene diamine, VT750"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: NH2"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: Ethylene diamine, VT680"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: FITC, COOH"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: Ethylene diamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Cy5"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: biotin"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amphiphilic polymer â€“ PEG :: NH2"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Cy3.5"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: Cy5.5"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: FITC, succinimidyl iodoacetate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: VT680"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: FITC"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Cross-linked dextran :: glycine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: AminoSPARKâ„¢680"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Carboxymethyldextran :: NA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Dextran :: NA"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "PVA :: PEG Ethylene diamine, AminoSPARKâ„¢680"@en ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_58/Nanoparticle/Size> ;
    skos:narrower npo:NPO_1548,
        npo:NPO_1550 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_58/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "20-74" ;
            sbd:lower_limit "20" ;
            sbd:upper_limit "74" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_59a/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a npo:NPO_296 ;
            rdfs:label "Cellular uptake of extracellular material"@en ;
            rdfs:comment "measured as log(pM) /cell"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Cellular uptake is expressed as decadic logarithm of the concentration (pM) of NP per cell"@en ;
    skos:narrower "Pancreatic human cancer cells (PaCa2)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_59a/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower pubchem:10946 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:994 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:16402 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:239163 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:750 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5-amino-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:97914 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:232 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:95411 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:20051 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:230976 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7940 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1,4,5, 8-Naphthalenetetracarboxylic acidanhydride"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:602 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:98484 ],
        [ a npo:NPO_1962 ;
            skos:narrower "6-Nitro-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:587821 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12012 ],
        [ a npo:NPO_1962 ;
            skos:narrower "4 3,3-Dimethyldihydrofuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:85689 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7894 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8326 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:88069 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8265 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12475 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6558 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78480 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:16217 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1045 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5-Nitro-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:21631 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:9845 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:513918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:587821 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8359 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:2733254 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12801 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:65729 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:75498 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69339 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8060 ],
        [ a npo:NPO_1962 ;
            skos:narrower "3-Methylidenedihydrofuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7923 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:15659773 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:25160 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:220977 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5,6-Dihydro-1Hcyclopenta[c]furan-1,3(4H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:74918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:70334 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:96196 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8102 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7719 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12019 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:424 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:86625 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:866 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6810 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:876 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6811 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69527 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:866 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:513917 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12443 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:67742 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:70728 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69545 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:3301 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:102679 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:76247 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:96580 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78479 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:75737 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:617 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8926 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:11089 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78218 ],
        [ a npo:NPO_1962 ;
            skos:narrower "4-Methyldihydro-2Hpyran-2,6(3H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "N-(2-Aminoethyl)-N'-(3-aminopropyl)butane-1,4-diamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:611 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:68986 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78232 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5603 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:74960 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-ammonio-3-(4-hydroxyphenyl)propanoate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "6-Bromo-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:79882 ],
        [ a npo:NPO_1962 ;
            skos:narrower "7 3,4-Dimethylfuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Amino-3-(1Himidazol-4-yl)propanoic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6385 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:17386 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7908 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:19990 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:79743 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1182 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:738 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1148 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:681 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:76074 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:25332 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5610 ],
        [ a npo:NPO_1962 ;
            skos:narrower "3-Phenyldihydro-2Hpyran-2,6(3H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:205 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:72794 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7922 ],
        [ a npo:NPO_1962 ;
            skos:narrower "{Bis[2-(2,6-dioxomorpholin-4-yl)ethyl]amino}acetic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8111 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:2794246 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:428 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Tetrahydrofuro[3',4':3,4]cyclobuta[1,2-c]furan-1,3,4,6-tetrone"@en ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_59a/Nanoparticle/Size> ;
    skos:narrower npo:NPO_729 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_59a/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "38" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_59b/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a npo:NPO_296 ;
            rdfs:label "Cellular uptake of extracellular material"@en ;
            rdfs:comment "measured as log(pM) /cell"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Cellular uptake is expressed as decadic logarithm of the concentration (pM) of NP per cell"@en ;
    skos:narrower "Pancreatic human cancer cells (PaCa2)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_59b/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower pubchem:78480 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:16217 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5610 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:2794246 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-ammonio-3-(4-hydroxyphenyl)propanoate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:239163 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:230976 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:9845 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:16402 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:76074 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:21631 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:602 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:96196 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:74918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:68986 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:428 ],
        [ a npo:NPO_1962 ;
            skos:narrower "3-Phenyldihydro-2Hpyran-2,6(3H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:15659773 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12443 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Amino-3-(1Himidazol-4-yl)propanoic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:79882 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8060 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1182 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:232 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:85689 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:11089 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:65729 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12019 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:75498 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Tetrahydrofuro[3',4':3,4]cyclobuta[1,2-c]furan-1,3,4,6-tetrone"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:97914 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:19990 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:74960 ],
        [ a npo:NPO_1962 ;
            skos:narrower "4-Methyldihydro-2Hpyran-2,6(3H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8326 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6558 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6385 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:617 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6811 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8926 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:876 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7940 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:102679 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:17386 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:513917 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:76247 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:866 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:611 ],
        [ a npo:NPO_1962 ;
            skos:narrower "4 3,3-Dimethyldihydrofuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1148 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8265 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:79743 ],
        [ a npo:NPO_1962 ;
            skos:narrower "3-Methylidenedihydrofuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:86625 ],
        [ a npo:NPO_1962 ;
            skos:narrower "N-(2-Aminoethyl)-N'-(3-aminopropyl)butane-1,4-diamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:513918 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7923 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7894 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12801 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:866 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:88069 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7922 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:98484 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12475 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8359 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:70334 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69339 ],
        [ a npo:NPO_1962 ;
            skos:narrower "6-Bromo-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:3301 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6810 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8111 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69545 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:75737 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:220977 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:96580 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78479 ],
        [ a npo:NPO_1962 ;
            skos:narrower "7 3,4-Dimethylfuran-2,5-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:2733254 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10946 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78218 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:78232 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7908 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5-Nitro-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "6-Nitro-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:67742 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:20051 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:95411 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:750 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:424 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:25160 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:738 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7719 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5-amino-1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "5,6-Dihydro-1Hcyclopenta[c]furan-1,3(4H)-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:205 ],
        [ a npo:NPO_1962 ;
            skos:narrower "{Bis[2-(2,6-dioxomorpholin-4-yl)ethyl]amino}acetic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:72794 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:587821 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:69527 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:587821 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1,4,5, 8-Naphthalenetetracarboxylic acidanhydride"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12012 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5603 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8102 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:25332 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:681 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1045 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:70728 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1H,3Hbenzo[de]isochromene-1,3-dione"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:994 ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_59b/Nanoparticle/Size> ;
    skos:narrower npo:NPO_729 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_59b/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "38" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_6/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as Percentage of damaged cells by Propidium Iodide uptake of BEAS-2B"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "The cytotoxicity induced in BEAS-2B cells exposed to nanoparticle concentrated in the range of 0.375â€“200 mg*L^(âˆ’1) was assessed by measuring plasma-membrane leakage quantified by high throughput screening (HTS) of the Propidium Iodide (PI) uptake with the results quantified in terms of the percentage of membrane-damaged cells. The cytotoxicity-screening assay was carried out using a set of six 384 well plates containing both cells in a BEGM medium exposed to nanoparticles in a range of concentrations and unexposed cells . In order to improve the reliability of toxic response identify cation, replicate samples and controls were used within each plate to estimate experimental variability."@en ;
    skos:narrower "Transformed bronchial epithelial cells (BEAS-2B)" .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_6/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ],
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_6/Nanoparticle/Size> ;
    skos:narrower npo:NPO_1373,
        npo:NPO_1486,
        npo:NPO_1542,
        npo:NPO_1548,
        enm:ENM_9000254,
        obo:CHEBI_30187,
        pubchem:14811,
        pubchem:14829,
        pubchem:73971 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_6/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "44427" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_60/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a enm:ENM_9000082 ;
            rdfs:label "Solubility in organic solvents"@en ] ;
    rdfs:comment "Solubilities of C60 in different solvents (Table 1 in the publication , 134 different solvents) were taken from a previous reference. Solubilities are given in terms of logarithmic values of molar fractions (log S) because the log S values correspond to the free energy changes in the solvation process. For some solvents, zero solubility values were reported, hence log S is undeterminable. Then the authors used \"< -8\" notation in the Tables to face this issue."@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_60/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_61a/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a enm:ENM_9000082 ;
            rdfs:label "Solubility in organic solvents"@en ] ;
    rdfs:comment "The set of organic solvents used for this study included 96 compounds compiled from several sources. The solubility was expressed in units of (1 Ã— 104)(mole fraction of C60 in the saturated solution). To limit the range of the data, the base-ten logarithm was taken, and the new range extended from -3.00 (ethanol and propanone) to 2.12 log units (1-phenylnaphthalene). The identity of each compound and its experimental value for log solubility are presented in Table 1 in the publication. The data set consisted of a mixture of 45 alkanes, 36 benzene derivatives, 7 naphthalenes, 14 oxygen-containing compounds, 10 nitrogen-containing compounds, 21 chlorine-containing compounds, and 15 bromine- containing compounds. There is no groping, as in other papers."@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_61a/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_61b/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a enm:ENM_9000082 ;
            rdfs:label "Solubility in organic solvents"@en ] ;
    rdfs:comment "The set of organic solvents used for this study included 96 compounds compiled from several sources. The solubility was expressed in units of (1 Ã— 104)(mole fraction of C60 in the saturated solution). To limit the range of the data, the base-ten logarithm was taken, and the new range extended from -3.00 (ethanol and propanone) to 2.12 log units (1-phenylnaphthalene). The identity of each compound and its experimental value for log solubility are presented in Table 1 in the publication. The data set consisted of a mixture of 45 alkanes, 36 benzene derivatives, 7 naphthalenes, 14 oxygen-containing compounds, 10 nitrogen-containing compounds, 21 chlorine-containing compounds, and 15 bromine- containing compounds. There is no groping, as in other papers."@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_61b/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_61c/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a enm:ENM_9000082 ;
            rdfs:label "Solubility in organic solvents"@en ] ;
    rdfs:comment "The set of organic solvents used for this study included 96 compounds compiled from several sources. The solubility was expressed in units of (1 Ã— 104)(mole fraction of C60 in the saturated solution). To limit the range of the data, the base-ten logarithm was taken, and the new range extended from -3.00 (ethanol and propanone) to 2.12 log units (1-phenylnaphthalene). The identity of each compound and its experimental value for log solubility are presented in Table 1 in the publication. The data set consisted of a mixture of 45 alkanes, 36 benzene derivatives, 7 naphthalenes, 14 oxygen-containing compounds, 10 nitrogen-containing compounds, 21 chlorine-containing compounds, and 15 bromine- containing compounds. There is no groping, as in other papers."@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_61c/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_62a/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a enm:ENM_9000082 ;
            rdfs:label "Solubility in organic solvents"@en ] ;
    rdfs:comment "A dataset contining solubility of C60 in 75 diverse solvents is taken from pulication's bibliography (ref 1-3, Table 1). Solubility is given in terms of logarithmic values for molar fractions log(S) because the log(S) values correspond to the Gibbs free energy changes in the solvation process and also in mg/ml. Solubility data set was divided into subsets based on the chemical nature of the solvents. Some solvents are not taken into account either because of detection limits (e.g. acetone) or lack of replicates (e.g. acetonitrile). In this case subset A: alkanes"@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_62a/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_62b/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a enm:ENM_9000082 ;
            rdfs:label "Solubility in organic solvents"@en ] ;
    rdfs:comment "A dataset contining solubility of C60 in 75 diverse solvents is taken from pulication's bibliography (ref 1-3, Table 1). Solubility is given in terms of logarithmic values for molar fractions log(S) because the log(S) values correspond to the Gibbs free energy changes in the solvation process and also in mg/ml. Solubility data set was divided into subsets based on the chemical nature of the solvents. Some solvents are not taken into account either because of detection limits (e.g. acetone) or lack of replicates (e.g. acetonitrile). In this case subset B: alkyl halides"@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_62b/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_62c/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a enm:ENM_9000082 ;
            rdfs:label "Solubility in organic solvents"@en ] ;
    rdfs:comment "A dataset contining solubility of C60 in 75 diverse solvents is taken from pulication's bibliography (ref 1-3, Table 1). Solubility is given in terms of logarithmic values for molar fractions log(S) because the log(S) values correspond to the Gibbs free energy changes in the solvation process and also in mg/ml. Solubility data set was divided into subsets based on the chemical nature of the solvents. Some solvents are not taken into account either because of detection limits (e.g. acetone) or lack of replicates (e.g. acetonitrile). In this case subset C: alcohols"@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_62c/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_62d/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a enm:ENM_9000082 ;
            rdfs:label "Solubility in organic solvents"@en ] ;
    rdfs:comment "A dataset contining solubility of C60 in 75 diverse solvents is taken from pulication's bibliography (ref 1-3, Table 1). Solubility is given in terms of logarithmic values for molar fractions log(S) because the log(S) values correspond to the Gibbs free energy changes in the solvation process and also in mg/ml. Solubility data set was divided into subsets based on the chemical nature of the solvents. Some solvents are not taken into account either because of detection limits (e.g. acetone) or lack of replicates (e.g. acetonitrile). In this case subset D: cycloalkanes"@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_62d/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_62e/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a enm:ENM_9000082 ;
            rdfs:label "Solubility in organic solvents"@en ] ;
    rdfs:comment "A dataset contining solubility of C60 in 75 diverse solvents is taken from pulication's bibliography (ref 1-3, Table 1). Solubility is given in terms of logarithmic values for molar fractions log(S) because the log(S) values correspond to the Gibbs free energy changes in the solvation process and also in mg/ml. Solubility data set was divided into subsets based on the chemical nature of the solvents. Some solvents are not taken into account either because of detection limits (e.g. acetone) or lack of replicates (e.g. acetonitrile). In this case subset E: alkylbenzenes"@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_62e/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_62f/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a enm:ENM_9000082 ;
            rdfs:label "Solubility in organic solvents"@en ] ;
    rdfs:comment "A dataset contining solubility of C60 in 75 diverse solvents is taken from pulication's bibliography (ref 1-3, Table 1). Solubility is given in terms of logarithmic values for molar fractions log(S) because the log(S) values correspond to the Gibbs free energy changes in the solvation process and also in mg/ml. Solubility data set was divided into subsets based on the chemical nature of the solvents. Some solvents are not taken into account either because of detection limits (e.g. acetone) or lack of replicates (e.g. acetonitrile). In this case subset F: aryl halides"@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_62f/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_62g/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a enm:ENM_9000082 ;
            rdfs:label "Solubility in organic solvents"@en ] ;
    rdfs:comment "A dataset contining solubility of C60 in 75 diverse solvents is taken from pulication's bibliography (ref 1-3, Table 1). Solubility is given in terms of logarithmic values for molar fractions log(S) because the log(S) values correspond to the Gibbs free energy changes in the solvation process and also in mg/ml. Solubility data set was divided into subsets based on the chemical nature of the solvents. Some solvents are not taken into account either because of detection limits (e.g. acetone) or lack of replicates (e.g. acetonitrile). In this case subsets A+B: aliphatic (n=39)"@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_62g/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_62h/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a enm:ENM_9000082 ;
            rdfs:label "Solubility in organic solvents"@en ] ;
    rdfs:comment "A dataset contining solubility of C60 in 75 diverse solvents is taken from pulication's bibliography (ref 1-3, Table 1). Solubility is given in terms of logarithmic values for molar fractions log(S) because the log(S) values correspond to the Gibbs free energy changes in the solvation process and also in mg/ml. Solubility data set was divided into subsets based on the chemical nature of the solvents. Some solvents are not taken into account either because of detection limits (e.g. acetone) or lack of replicates (e.g. acetonitrile). In this case subsets A+B+C: aliphatic (n=45)"@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_62h/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_62i/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a enm:ENM_9000082 ;
            rdfs:label "Solubility in organic solvents"@en ] ;
    rdfs:comment "A dataset contining solubility of C60 in 75 diverse solvents is taken from pulication's bibliography (ref 1-3, Table 1). Solubility is given in terms of logarithmic values for molar fractions log(S) because the log(S) values correspond to the Gibbs free energy changes in the solvation process and also in mg/ml. Solubility data set was divided into subsets based on the chemical nature of the solvents. Some solvents are not taken into account either because of detection limits (e.g. acetone) or lack of replicates (e.g. acetonitrile). In this case subsets E+F: aromatics (n=25)"@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_62i/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_62j/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a enm:ENM_9000082 ;
            rdfs:label "Solubility in organic solvents"@en ] ;
    rdfs:comment "A dataset contining solubility of C60 in 75 diverse solvents is taken from pulication's bibliography (ref 1-3, Table 1). Solubility is given in terms of logarithmic values for molar fractions log(S) because the log(S) values correspond to the Gibbs free energy changes in the solvation process and also in mg/ml. Solubility data set was divided into subsets based on the chemical nature of the solvents. Some solvents are not taken into account either because of detection limits (e.g. acetone) or lack of replicates (e.g. acetonitrile). In this case subsets A+B+C: aliphatics (n=45)"@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_62j/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_63a/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a enm:ENM_9000082 ;
            rdfs:label "Solubility in organic solvents"@en ] ;
    rdfs:comment "Solubility data is used from previous references (source publications). Properties could be either measurable physical and chemical properties or ones computed by means of molecular mechanics or semiempirical quantum chemistry. 113 solubility data items (for 298 K, Table 1 in the publication) and 32 data items for 303 K (Table 2 in the publication), which could be employed with as many independents variables (solvent properties) as were deemed pertinent."@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_63a/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_63b/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a enm:ENM_9000082 ;
            rdfs:label "Solubility in organic solvents"@en ] ;
    rdfs:comment "Solubility data is used from previous references (source publications). Properties could be either measurable physical and chemical properties or ones computed by means of molecular mechanics or semiempirical quantum chemistry. 113 solubility data items (for 298 K, Table 1 in the publication) and 32 data items for 303 K (Table 2 in the publication), which could be employed with as many independents variables (solvent properties) as were deemed pertinent."@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_63b/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_63c/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a enm:ENM_9000082 ;
            rdfs:label "Solubility in organic solvents"@en ] ;
    rdfs:comment "Solubility data is used from previous references (source publications). Properties could be either measurable physical and chemical properties or ones computed by means of molecular mechanics or semiempirical quantum chemistry. 113 solubility data items (for 298 K, Table 1 in the publication) and 32 data items for 303 K (Table 2 in the publication), which could be employed with as many independents variables (solvent properties) as were deemed pertinent."@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_63c/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_64a/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a enm:ENM_9000082 ;
            rdfs:label "Solubility in organic solvents"@en ] ;
    rdfs:comment "Solubilities of 128 different solvents are compilled from the source publication which collected the data from previous studies. Solubilities are given in terms of logarithmic values of molar fractions (log S) because the log S values correspond to the free energy changes in the solvation process"@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_64a/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_64b/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a enm:ENM_9000082 ;
            rdfs:label "Solubility in organic solvents"@en ] ;
    rdfs:comment "Solubilities of 128 different solvents are compilled from a paper (originally from previous papers). Solubilities are given in terms of logarithmic values of molar fractions (log S) because the log S values correspond to the free energy changes in the solvation process"@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_64b/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_65/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a afr:AFR_0002583 ;
            rdfs:label "Young modulus"@en ] ;
    rdfs:comment "Young's modulus is the measure of the stiffness of an elastic material and is used to characterise materials"@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_65/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower "film"@en ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_66/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a enm:ENM_9000082 ;
            rdfs:label "Solubility in organic solvents"@en ] ;
    rdfs:comment "A series of benzene derivates have been selected. Modeling of solubility (10^4 molar fraction of C60 at T=298k) has been taken. These experimental values are taken from other literature sources."@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_66/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_67/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a enm:ENM_9000082 ;
            rdfs:label "Solubility in organic solvents"@en ] ;
    rdfs:comment "Experimental values of fullerene solubilities (log S) are taken from a previous reference (n=122)"@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_67/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_68a/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a npo:NPO_500 ;
            rdfs:label "Solubility in water"@en ] ;
    rdfs:comment "Data is taken for 16 CNT (with different components, i.e, n and m, of chiral vector). It is well known that toxicity depends on chemical solubility"@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_68a/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_461 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_68b/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "Octanol water partition coefficient" ] ;
    rdfs:comment "Data is taken for 16 CNT (with different components, i.e, n and m, of chiral vector). It is well known that toxicity depends on chemical solubility"@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_68b/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_461 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_69/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a enm:ENM_9000082 ;
            rdfs:label "Solubility in organic solvents"@en ] ;
    rdfs:comment "Experimental values of the C60 solubility as log S, where S is expressed in molar fraction."@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_69/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_7/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "log(k)    k: adsorption coefficient" ] ;
    rdfs:comment "The adsorption coefficient of a set of compounds with relevant biology activity on different nanomaterials was experimental measured. The data process for obtaining the nanodescriptors was briefly introduced using multiwalled carbon nanotubes (MWCNT) with diameters of 40 nm and carboxyl ( COOH) surface derivatives as an example."@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_7/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower pubchem:7416 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12167 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7809 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7505 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7165 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7150 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:996 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:11563 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:244 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7500 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:31242 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:9732 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7668 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7964 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7002 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7810 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7948 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7410 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7933 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6054 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:11476 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:931 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:33094 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7961 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7467 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:342 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:7473 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:11575 ] ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_461 ],
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_7/Nanoparticle/Size> ;
    skos:narrower npo:NPO_354 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_7/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "40" ] ;
    skos:narrower obo:PATO_0001334 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_70a/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a enm:ENM_9000082 ;
            rdfs:label "Solubility in organic solvents"@en ] ;
    rdfs:comment "A dataset contining solubility of C60 in 128 diverse solvents is taken from bibliography (ref 14-17). The same dataset has been used by other two authors earlier (ref 13 and ref11). This paper compares two new models with those generated in these references. Solubility is given in terms of logarithmic values for molar fractions log(S) because the log(S) values correspond to the Gibbs free energy changes in the solvation process."@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_70a/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_70b/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a enm:ENM_9000082 ;
            rdfs:label "Solubility in organic solvents"@en ] ;
    rdfs:comment "A dataset contining solubility of C60 in 128 diverse solvents is taken from bibliography (ref 14-17). The same dataset has been used by other two authors earlier (ref 13 and ref11). This paper compares two new models with those generated in these references. Solubility is given in terms of logarithmic values for molar fractions log(S) because the log(S) values correspond to the Gibbs free energy changes in the solvation process."@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_70b/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_71/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "Binding interaction between fullerenes and HIV-1 PR inhibitor (Human immunodeficiency virus type I aspartic protease)" ] ;
    rdfs:comment "Experimentally reported (Table 1 in publication) and computationally designed fullerene analogues (Table 2 in publication) and their activities (measured and calculated binding affinities) have been used. Since the experimental binding activities of most of the derivatives, used in this study are only reported as median effective concentration (EC50), these values are assumed to be equal with Ki in the calculations of the free binding energies. The logarithmic values of 1/EC50 (pEC50) were used in the 3D QSAR correlations, as they are related to changes in the free energy of binding."@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_71/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_72/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a enm:ENM_9000082 ;
            rdfs:label "Solubility in organic solvents"@en ] ;
    rdfs:comment "The endpoint is not described in the paper. It can be deduced from the text that solubility data is taken from a paper published by the same group A.A Toropov, B.F. Rasulev, D. Leszczynska, J. Leszczynski, Chem. Phys. Lett. 444, 209â€“214 (2007).. They just compare predicting ability of both models."@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_72/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_73/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a enm:ENM_9000082 ;
            rdfs:label "Solubility in organic solvents"@en ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_73/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_74/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a enm:ENM_9000082 ;
            rdfs:label "Solubility in organic solvents"@en ] ;
    rdfs:comment "Solubilities of 122 different solvents are compilled from Liu et al 2005 (published originally in Beck and Mandi 1977). Solubilities are given in terms of logarithmic values of molar fractions (log S) because the log S values correspond to the free energy changes in the solvation process"@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_74/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_75a/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a afr:AFR_0002583 ;
            rdfs:label "Young modulus"@en ] ;
    rdfs:comment "Youngâ€™s modulus (Y) is a measure of stiffness defined as the ratio of axial stress (Ïƒ) to axial strain (Îµ) over ranges of stress in which Hookeâ€™s law holds true."@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_75a/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_461 ],
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_75a/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_75a/Nanoparticle/Size_1> ;
    skos:narrower npo:NPO_606 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_75a/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "10" ] ;
    skos:narrower obo:PATO_0000122 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_75a/Nanoparticle/Size_1> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "0.2-2.1" ;
            sbd:lower_limit "0.2" ;
            sbd:upper_limit "2.1" ] ;
    skos:narrower obo:PATO_0002390 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_75b/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a opb:OPB_01022 ;
            rdfs:label "Poisson ratio"@en ] ;
    rdfs:comment "Poissonâ€™s ratio (PR) is the negative ratio of the lateral to longitudinal strain as an axial load is applied. For this study, values were calculated at an initial and final strain of 0% and 5%, respectively."@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_75b/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_461 ],
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_75b/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_75b/Nanoparticle/Size_1> ;
    skos:narrower npo:NPO_606 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_75b/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "10" ] ;
    skos:narrower obo:PATO_0000122 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_75b/Nanoparticle/Size_1> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "0.2-2.1" ;
            sbd:lower_limit "0.2" ;
            sbd:upper_limit "2.1" ] ;
    skos:narrower obo:PATO_0002390 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_75c/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a afr:AFR_0002583 ;
            rdfs:label "Young modulus"@en ] ;
    rdfs:comment "Youngâ€™s modulus (Y) is a measure of stiffness defined as the ratio of axial stress (Ïƒ) to axial strain (Îµ) over ranges of stress in which Hookeâ€™s law holds true."@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_75c/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "Methyl functionalization"@en ] ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_461 ],
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_75c/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_75c/Nanoparticle/Size_1> ;
    skos:narrower npo:NPO_606 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_75c/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "10" ] ;
    skos:narrower obo:PATO_0000122 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_75c/Nanoparticle/Size_1> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "0.2-2.1" ;
            sbd:lower_limit "0.2" ;
            sbd:upper_limit "2.1" ] ;
    skos:narrower obo:PATO_0002390 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_75d/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a opb:OPB_01022 ;
            rdfs:label "Poisson ratio"@en ] ;
    rdfs:comment "Poissonâ€™s ratio (PR) is the negative ratio of the lateral to longitudinal strain as an axial load is applied. For this study, values were calculated at an initial and final strain of 0% and 5%, respectively."@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_75d/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "Methyl functionalization"@en ] ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_461 ],
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_75d/Nanoparticle/Size_0>,
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_75d/Nanoparticle/Size_1> ;
    skos:narrower npo:NPO_606 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_75d/Nanoparticle/Size_0> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "10" ] ;
    skos:narrower obo:PATO_0000122 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_75d/Nanoparticle/Size_1> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "0.2-2.1" ;
            sbd:lower_limit "0.2" ;
            sbd:upper_limit "2.1" ] ;
    skos:narrower obo:PATO_0002390 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_76/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a enm:ENM_9000082 ;
            rdfs:label "Solubility in organic solvents"@en ] ;
    rdfs:comment "Solubilities of C60 in different solvents (Table 1 in the publication) were screened from a previous work (source reference) already reported in the table. From the whole set of solvents, only those ones which fit with the desired initial descriptors were selected for the study. Solubilities are given in terms of logarithmic values of molar fractions (log S) because the log S values correspond to the free energy changes in the solvation process."@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_76/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_77a/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a fix:FIX_0000608 ;
            rdfs:label "LC - Liquid Chromatography structure"@en ] ;
    rdfs:comment "Predicted the effect of different drugs on the complex phase behavior of lyotropic lipid-based LC (Liquied Crystal) nanoparticles Two experiments used phytantriol from different batches to assess effects of batch-to-batch variability; another used monoolein, and the last used Myverol, the commercial product containing monoolein. These amphiphilic materials were used to prepare inverse-bicontinuous cubic and inverse-hexagonal liquid-crystalline nanoparticles loaded with 10 commonly used drugs. These drugs had a wide range of structures and lipophilicities and were loaded at six concentrations (0, 1, 2, 5, 10, and 15 mol %) and at two temperatures (25 and 37 Â°C). The applied drugs for the training and testing were the following:levofloxacin, prednisolone, hydrocortisone, atropine, dexamethasone, diazepam, progesterone, indometacin, haloperidol, transretinol; and chlorambucil, cimetidine, Î²-estradiol, androsterone, flumequine, nifedipine, ibuprofen, curcumin, histamine, dopamine, calcein (Sigma-Aldrich)."@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_77a/Nanoparticle> a npo:NPO_1552,
        npo:NPO_707 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_77b/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a fix:FIX_0000608 ;
            rdfs:label "LC - Liquid Chromatography structure"@en ] ;
    rdfs:comment "Predicted the effect of different drugs on the complex phase behavior of lyotropic lipid-based LC (Liquied Crystal) nanoparticles Two experiments used phytantriol from different batches to assess effects of batch-to-batch variability; another used monoolein, and the last used Myverol, the commercial product containing monoolein. These amphiphilic materials were used to prepare inverse-bicontinuous cubic and inverse-hexagonal liquid-crystalline nanoparticles loaded with 10 commonly used drugs. These drugs had a wide range of structures and lipophilicities and were loaded at six concentrations (0, 1, 2, 5, 10, and 15 mol %) and at two temperatures (25 and 37 Â°C). The applied drugs for the training and testing were the following:levofloxacin, prednisolone, hydrocortisone, atropine, dexamethasone, diazepam, progesterone, indometacin, haloperidol, transretinol; and chlorambucil, cimetidine, Î²-estradiol, androsterone, flumequine, nifedipine, ibuprofen, curcumin, histamine, dopamine, calcein (Sigma-Aldrich)."@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_77b/Nanoparticle> a npo:NPO_1552,
        npo:NPO_707 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_77c/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a fix:FIX_0000608 ;
            rdfs:label "LC - Liquid Chromatography structure"@en ] ;
    rdfs:comment "Predicted the effect of different drugs on the complex phase behavior of lyotropic lipid-based LC (Liquied Crystal) nanoparticles Two experiments used phytantriol from different batches to assess effects of batch-to-batch variability; another used monoolein, and the last used Myverol, the commercial product containing monoolein. These amphiphilic materials were used to prepare inverse-bicontinuous cubic and inverse-hexagonal liquid-crystalline nanoparticles loaded with 10 commonly used drugs. These drugs had a wide range of structures and lipophilicities and were loaded at six concentrations (0, 1, 2, 5, 10, and 15 mol %) and at two temperatures (25 and 37 Â°C). The applied drugs for the training and testing were the following:levofloxacin, prednisolone, hydrocortisone, atropine, dexamethasone, diazepam, progesterone, indometacin, haloperidol, transretinol; and chlorambucil, cimetidine, Î²-estradiol, androsterone, flumequine, nifedipine, ibuprofen, curcumin, histamine, dopamine, calcein (Sigma-Aldrich)."@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_77c/Nanoparticle> a npo:NPO_1552,
        npo:NPO_707 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_77d/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a fix:FIX_0000608 ;
            rdfs:label "LC - Liquid Chromatography structure"@en ] ;
    rdfs:comment "Predicted the effect of different drugs on the complex phase behavior of lyotropic lipid-based LC (Liquied Crystal) nanoparticles Two experiments used phytantriol from different batches to assess effects of batch-to-batch variability; another used monoolein, and the last used Myverol, the commercial product containing monoolein. These amphiphilic materials were used to prepare inverse-bicontinuous cubic and inverse-hexagonal liquid-crystalline nanoparticles loaded with 10 commonly used drugs. These drugs had a wide range of structures and lipophilicities and were loaded at six concentrations (0, 1, 2, 5, 10, and 15 mol %) and at two temperatures (25 and 37 Â°C). The applied drugs for the training and testing were the following:levofloxacin, prednisolone, hydrocortisone, atropine, dexamethasone, diazepam, progesterone, indometacin, haloperidol, transretinol; and chlorambucil, cimetidine, Î²-estradiol, androsterone, flumequine, nifedipine, ibuprofen, curcumin, histamine, dopamine, calcein (Sigma-Aldrich)."@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_77d/Nanoparticle> a npo:NPO_1552,
        npo:NPO_707 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_78a/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a npo:NPO_1969 ;
            rdfs:label "Dispersion"@en ] ;
    rdfs:comment "Dispersion and solubilization are different phenomena but they are used interchangeably in the literature. Based on diameter and length of CNTs (Carbon Nanotubes) and their ability to form colloidal solutions, Geckeler and Premkumar recommended to use the dispersion term. The dispersion of CNTs in different organic solvents was determined measuring the dispersion absorbance as concentration (C_max) of SWNTs (Single-Walled Nanotubes) after sonication and mild centrifugation. Detailed description of the method reported as reference in the publication (Giordani et al. 2006; Bergin et al. 2008) The Log C_max was used as endpoint value in this model."@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_78a/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_461 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_78b/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a npo:NPO_1969 ;
            rdfs:label "Dispersion"@en ] ;
    rdfs:comment "Dispersion and solubilization are different phenomena but they are used interchangeably in the literature. Based on diameter and length of CNTs (Carbon Nanotubes) and their ability to form colloidal solutions, Geckeler and Premkumar recommended to use the dispersion term. The dispersion of CNTs in different organic solvents was determined measuring the dispersion absorbance as concentration (C_max) of SWNTs (Single-Walled Nanotubes) after sonication and mild centrifugation. Detailed description of the method reported as reference in the publication (Giordani et al. 2006; Bergin et al. 2008) The Log C_max was used as endpoint value in this model."@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_78b/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_461 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_79/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a npo:NPO_1969 ;
            rdfs:label "Dispersion"@en ] ;
    rdfs:comment "Dispersion and solubilization are different phenomena but they are used interchangeably in the literature. Based on diameter and length of CNTs (Carbon Nanotubes) and their ability to form colloidal solutions, Geckeler and Premkumar recommended to use the dispersion term. The dispersion of CNTs in different organic solvents was determined measuring the dispersion absorbance as concentration (C_max) of SWNTs (Single-Walled Nanotubes) after sonication and mild centrifugation. Detailed description of the method reported as reference in the publication (Giordani et al. 2006; Bergin et al. 2008) The Log C_max was used as endpoint value in this model."@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_79/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_461 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_8/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as percentage of cellular viability"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Different toxicity threshold (% of Cellular viability) were tested: accuracies of 86.6% for viability decrease threshold larger than 20%(>EC20), 87.1%for viability decrease threshold of 25% (>EC25), and 87.3% for viability decrease threshold of 30% (>EC30). No statistical significance between them was considered. Dose-response curves were examined employing 3-(4,5-dimethylthiazol- 2-Yl)-2,5-diphenyltetrazolium bromide test (MTT), neutral red (NR), and Alamar blue as end point assays following 48- and 72-h exposures. Because cobalt NPs undergoes dissolution in aqueous media, we determined the dose-response curves for Co-ions, employing cobalt chloride for the same end points."@en ;
    skos:narrower "Intestine (caco-2 TC7 cell line)",
        "Kidney (MDCK cell line)",
        "Liver (HepG2 cell line)",
        "Lung (A549 and NCIH441 cell lines)",
        "Primary mouse Dendritic Cells." .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_8/Nanoparticle> a npo:NPO_1384,
        npo:NPO_707 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_858 ],
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_8/Nanoparticle/Size> ;
    skos:narrower enm:ENM_9000248,
        obo:CHEBI_23336 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_8/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "10",
                "50." ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_80a/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a nci:C157206 ;
            rdfs:label "Adsorption"@en ] ;
    rdfs:comment "Methylene blue (MB) (chemical formula of C27H34N2O4S) adsorption was tested in CuO-NP-AC (Copper Oxide Nanoparticle loaded on Activated Carbon). The stock solution (100 mg L^-1) was prepared by dissolving 50.0 mg of MB in double distilled water and the test solutions were prepared by diluting stock solution to the desired concentrations daily. The pH was adjusted by addition of dilute HCl and/or KOH using pH/Ion meter model-686 and absorption studies were carried out using Jasco UV-Visible spectrophotometer model V-570. Chemicals with the highest purity available are purchased from Merck, Darmstadt, Germany. X-ray diffraction (XRD) patterns were recorded on a Bruker D8 advance X-ray diffractometer. Morphology and film thickness were measured by Philips XL-30 scanning electron microscopy. The dye adsorption capacity of adsorbent were determined at the time intervals in the range of 1â€“35 min for 15 and 20 mg L^-1 at room temperatures and it was found that equilibrium was established after 12 and 27 min for 15 and 20 mg L^-1. The ouput is normalized between 0 and 1 to avoid numerical overflows due to very large or very small weights."@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_80a/Nanoparticle> a npo:NPO_1384,
        npo:NPO_707 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower "coarse porous surface with irregular pores"@en ],
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_80a/Nanoparticle/Size> ;
    skos:narrower pubchem:14829 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_80a/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "45" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_80b/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a nci:C157206 ;
            rdfs:label "Adsorption"@en ] ;
    rdfs:comment "Methylene blue (MB) (chemical formula of C27H34N2O4S) adsorption was tested in CuO-NP-AC (Copper Oxide Nanoparticle loaded on Activated Carbon). The stock solution (100 mg L^-1) was prepared by dissolving 50.0 mg of MB in double distilled water and the test solutions were prepared by diluting stock solution to the desired concentrations daily. The pH was adjusted by addition of dilute HCl and/or KOH using pH/Ion meter model-686 and absorption studies were carried out using Jasco UV-Visible spectrophotometer model V-570. Chemicals with the highest purity available are purchased from Merck, Darmstadt, Germany. X-ray diffraction (XRD) patterns were recorded on a Bruker D8 advance X-ray diffractometer. Morphology and film thickness were measured by Philips XL-30 scanning electron microscopy. The dye adsorption capacity of adsorbent were determined at the time intervals in the range of 1â€“35 min for 15 and 20 mg L^-1 at room temperatures and it was found that equilibrium was established after 12 and 27 min for 15 and 20 mg L^-1. The ouput is normalized between 0 and 1 to avoid numerical overflows due to very large or very small weights."@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_80b/Nanoparticle> a npo:NPO_1384,
        npo:NPO_707 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower "coarse porous surface with irregular pores"@en ],
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_80b/Nanoparticle/Size> ;
    skos:narrower pubchem:14829 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_80b/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "45" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_81/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "log2 transformed (Cell association [mL/Î¼g(Mg)] )" ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "The ratio mcell/mwell divided by mcells quantified the total cell association, where mcell is the total atomic gold (or silver) content associated with cells, mwell is the total atomic gold (or silver) content in well (associated with cells and free in solution) and mcells is the total mass of magnesium per sample. The related net cell association data were log transformed (log2 transformation) prior to modelling. Cell association was chosen as a model biological interaction because of its relevance to inflammatory responses, biodistribution, and toxicity in vivo. A549 human lung epithelial carcinoma cells (ATCC) were maintained in RPMI1640 (Wisent, cat#: 350-000-CL) supplement with 10%(v/v) fetal bovine serum (FBS) (Gibco, cat#: 12483-020) and 1% (v/v) penicillin-streptomycin (P-S) (Gibco, cat#: 15140-122) in a sterile 5% CO2 atmin 175 cm2 tissue culture flasks (NEST, cat#: 709003)"@en ;
    skos:narrower mesh:D000072283 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_81/Nanoparticle> a npo:NPO_1384,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-tryptophan"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @benzyldimethylhexadecylammonium bromide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (20kDa) (low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(allylamine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Î±-Lipoic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6514 ],
        [ a npo:NPO_1962 ;
            skos:narrower "(low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:598 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Carboxymethyl-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Bis(p-sulfonatophenyl)phenylphosphine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amino-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ urea-modified poly(styrenecomaleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ 1,2-dioleoyl-3-trimethylammonium-propane"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12841471 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amino-poly(ethylene glycol)-thiol (5kDa) (low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-serine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-threonine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10352850 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ Pluronic F-127"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1133 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Carboxymethyl-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-phenylalanine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:3522585 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ ethanolamine-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CVVIT'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @hexadecyltrimethylammonium bromide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5483 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-glycine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "(11-Mercaptoundecyl)tetra(ethylene glycol)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10154203 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated amino-poly(ethylene glycol) (methoxyterminated)(5kDa)*"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:543502 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8926 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:95738 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5281 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated amino-poly(ethylene glycol) (3kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-asparagine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12035 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6140 ],
        [ a npo:NPO_1962 ;
            skos:narrower "TWEEN20"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (2kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ deoxycholic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (20kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:329113 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ sodium dodecyl sulfate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ hexadecylamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ aminopropanol-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CFGAILS'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ stearic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-alanine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6268 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5,5â€²-Dithiobis(2-nitrobenzoic acid)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ ethylenediamine-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (1kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CALNN'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:15793 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ octadecylamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-methionine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(ethyleneimine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:11199 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ poly(vinyl alcohol)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Poly(vinylpyrrolidone)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:31348 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5974 ],
        [ a npo:NPO_1962 ;
            skos:narrower "(11-Mercaptoundecyl)-N,N,Ntrimethylammonium"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(L-lysine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ (4'-aminoacetophenone)-modified poly(styrene-co-maleic nhydride)"@en ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_81/Nanoparticle/Size> ;
    skos:narrower npo:NPO_401 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_81/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "15",
                "30",
                "60" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_82/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a npo:NPO_1969 ;
            rdfs:label "Dispersion"@en ] ;
    rdfs:comment "Dispersion and solubilization are different phenomena but they are used interchangeably in the literature. Based on diameter and length of CNTs (Carbon Nanotubes) and their ability to form colloidal solutions, Geckeler and Premkumar recommended to use the dispersion term. The dispersion of CNTs in different organic solvents was determined measuring the dispersion absorbance as concentration (C_max) of SWNTs (Single-Walled Nanotubes) after sonication and mild centrifugation. Detailed description of the method reported as reference in the publication (Giordani et al. 2006; Bergin et al. 2008) The Log C_max was used as endpoint value in this model."@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_82/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_461 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_83/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "log2 transformed (Cell association [mL/Î¼g(Mg)] )" ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "The correlation of cell association of Au NPs (modified with different ionic/cationic surface ligands) with corona proteins and physicochemical properties was investigated via QSAR analysis of a recently published dataset (C. D. Walkey, et al. et al., 2015 already reported in this table). The ratio mcell/mwell divided by mcells quantified the total cell association, where mcell is the total atomic gold (or silver) content associated with cells, mwell is the total atomic gold (or silver) content in well (associated with cells and free in solution) and mcells is the total mass of magnesium per sample. The related net cell association data were log transformed (log2 transformation) prior to modelling. Cell association was chosen as a model biological interaction because of its relevance to inflammatory responses, biodistribution, and toxicity in vivo. A549 human lung epithelial carcinoma cells (ATCC) were maintained in RPMI1640 (Wisent, cat#: 350-000-CL) supplement with 10%(v/v) fetal bovine serum (FBS) (Gibco, cat#: 12483-020) and 1% (v/v) penicillin-streptomycin (P-S) (Gibco, cat#: 15140-122) in a sterile 5% CO2 atmin 175 cm2 tissue culture flasks (NEST, cat#: 709003)"@en ;
    skos:narrower mesh:D000072283 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_83/Nanoparticle> a npo:NPO_1384,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower pubchem:95738 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ urea-modified poly(styrenecomaleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ (4'-aminoacetophenone)-modified poly(styrene-co-maleic nhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @benzyldimethylhexadecylammonium bromide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ ethanolamine-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Poly(vinylpyrrolidone)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-serine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ octadecylamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "(low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amino-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-phenylalanine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-threonine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Bis(p-sulfonatophenyl)phenylphosphine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ Pluronic F-127"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-alanine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (2kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:15793 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10352850 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1133 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Î±-Lipoic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:598 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ deoxycholic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (20kDa) (low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ poly(vinyl alcohol)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(ethyleneimine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ stearic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "TWEEN20"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8926 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5,5â€²-Dithiobis(2-nitrobenzoic acid)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @hexadecyltrimethylammonium bromide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:31348 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Carboxymethyl-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6268 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ hexadecylamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12841471 ],
        [ a npo:NPO_1962 ;
            skos:narrower "(11-Mercaptoundecyl)-N,N,Ntrimethylammonium"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6140 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-methionine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (20kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CALNN'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (1kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:543502 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ sodium dodecyl sulfate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-glycine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-asparagine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ ethylenediamine-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "(11-Mercaptoundecyl)tetra(ethylene glycol)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5483 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CVVIT'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated amino-poly(ethylene glycol) (3kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ 1,2-dioleoyl-3-trimethylammonium-propane"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ aminopropanol-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:11199 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(L-lysine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CFGAILS'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12035 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(allylamine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5974 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10154203 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Carboxymethyl-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amino-poly(ethylene glycol)-thiol (5kDa) (low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:329113 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-tryptophan"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5281 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:3522585 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated amino-poly(ethylene glycol) (methoxyterminated)(5kDa)*"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6514 ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_83/Nanoparticle/Size> ;
    skos:narrower npo:NPO_401 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_83/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "15",
                "30",
                "60" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_84/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a enm:ENM_9000082 ;
            rdfs:label "Solubility in organic solvents"@en ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_84/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_85/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a npo:NPO_1302 ;
            rdfs:label "Zeta potential"@en ] ;
    rdfs:comment "The agglomeration phenomenon largely influences toxicity of nanoparticles. Such properties of nanoparticles that describe their behavior are known as extrinsic properties. The ease of formation of agglomerates strongly depends on the surface charge that stabilizes dispersed nanoparticles and prevents them from agglomeration. However, the available experimental techniques are unable to measure surface charge directly; its value can only be estimated by measuring zeta potential (Î¶) in a given medium. Dynamic light scattering (DLS) was used zeta potential (Î¶) in cell culture media (serum-free) was done using a Malvern Instruments zeta-sizer Nano-ZS instrument."@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_85/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ],
        <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_85/Nanoparticle/Size> ;
    skos:narrower npo:NPO_1373,
        npo:NPO_1486,
        npo:NPO_1542,
        npo:NPO_1550,
        enm:ENM_0000118,
        obo:CHEBI_30187,
        pubchem:14776,
        pubchem:14794,
        pubchem:14811,
        pubchem:150906,
        pubchem:157925,
        pubchem:159375,
        pubchem:29131,
        pubchem:518712,
        pubchem:62762 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_85/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "15-210" ;
            sbd:lower_limit "15" ;
            sbd:upper_limit "210" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_86/Endpoint> a bao:BAO_0000179 ;
    bao:BAO_0002662 [ a enm:ENM_9000082 ;
            rdfs:label "Solubility in organic solvents"@en ] ;
    rdfs:comment "Original solubility (mg/ml) was converted to molar (mmol/ml) and expressed as log(S) values. Molecular structures, solubility and data transformation are summarized in publication's Table 1."@en .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_86/Nanoparticle> a npo:NPO_707,
        npo:NPO_836 ;
    npo:has_quality [ a npo:NPO_274 ;
            skos:narrower npo:NPO_286 ] .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87a/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "log2 transformed (Cell association [mL/Î¼g(Mg)] )" ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "The correlation of cell association of Au NPs (modified with different ionic/cationic surface ligands) with corona proteins and physicochemical properties was investigated via QSAR analysis of a recently published dataset (C. D. Walkey, et al. et al., 2015 already reported in this table). The ratio mcell/mwell divided by mcells quantified the total cell association, where mcell is the total atomic gold (or silver) content associated with cells, mwell is the total atomic gold (or silver) content in well (associated with cells and free in solution) and mcells is the total mass of magnesium per sample. The related net cell association data were log transformed (log2 transformation) prior to modelling Cell association was chosen as a model biological interaction because of its relevance to inflammatory responses, biodistribution, and toxicity in vivo. A549 human lung epithelial carcinoma cells (ATCC) were maintained in RPMI1640 (Wisent, cat#: 350-000-CL) supplement with 10%(v/v) fetal bovine serum (FBS) (Gibco, cat#: 12483-020) and 1% (v/v) penicillin-streptomycin (P-S) (Gibco, cat#: 15140-122) in a sterile 5% CO2 atmin 175 cm2 tissue culture flasks (NEST, cat#: 709003)"@en ;
    skos:narrower mesh:D000072283 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87a/Nanoparticle> a npo:NPO_1384,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower pubchem:3522585 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8926 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:95738 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ 1,2-dioleoyl-3-trimethylammonium-propane"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated amino-poly(ethylene glycol) (methoxyterminated)(5kDa)*"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ ethylenediamine-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ sodium dodecyl sulfate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Carboxymethyl-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ hexadecylamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12035 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Î±-Lipoic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amino-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CFGAILS'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @benzyldimethylhexadecylammonium bromide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ octadecylamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-methionine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-tryptophan"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amino-poly(ethylene glycol)-thiol (5kDa) (low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-threonine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:31348 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10352850 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (1kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ Pluronic F-127"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:598 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (20kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "(11-Mercaptoundecyl)tetra(ethylene glycol)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-phenylalanine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-asparagine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated amino-poly(ethylene glycol) (3kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ urea-modified poly(styrenecomaleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Poly(vinylpyrrolidone)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (20kDa) (low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-glycine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CVVIT'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CALNN'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(L-lysine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ poly(vinyl alcohol)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1133 ],
        [ a npo:NPO_1962 ;
            skos:narrower "(11-Mercaptoundecyl)-N,N,Ntrimethylammonium"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ deoxycholic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ stearic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ aminopropanol-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-serine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Bis(p-sulfonatophenyl)phenylphosphine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:11199 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(allylamine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6514 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:15793 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ ethanolamine-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10154203 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5,5â€²-Dithiobis(2-nitrobenzoic acid)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(ethyleneimine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6268 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:543502 ],
        [ a npo:NPO_1962 ;
            skos:narrower "(low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5281 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12841471 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5974 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Carboxymethyl-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ (4'-aminoacetophenone)-modified poly(styrene-co-maleic nhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:329113 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5483 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (2kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "TWEEN20"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @hexadecyltrimethylammonium bromide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-alanine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6140 ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87a/Nanoparticle/Size> ;
    skos:narrower npo:NPO_401 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87a/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "15",
                "30",
                "60" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87b/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "log2 transformed (Cell association [mL/Î¼g(Mg)] )" ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "The correlation of cell association of Au NPs (modified with different ionic/cationic surface ligands) with corona proteins and physicochemical properties was investigated via QSAR analysis of a recently published dataset (C. D. Walkey, et al. et al., 2015 already reported in this table). The ratio mcell/mwell divided by mcells quantified the total cell association, where mcell is the total atomic gold (or silver) content associated with cells, mwell is the total atomic gold (or silver) content in well (associated with cells and free in solution) and mcells is the total mass of magnesium per sample. The related net cell association data were log transformed (log2 transformation) prior to modelling Cell association was chosen as a model biological interaction because of its relevance to inflammatory responses, biodistribution, and toxicity in vivo. A549 human lung epithelial carcinoma cells (ATCC) were maintained in RPMI1640 (Wisent, cat#: 350-000-CL) supplement with 10%(v/v) fetal bovine serum (FBS) (Gibco, cat#: 12483-020) and 1% (v/v) penicillin-streptomycin (P-S) (Gibco, cat#: 15140-122) in a sterile 5% CO2 atmin 175 cm2 tissue culture flasks (NEST, cat#: 709003)"@en ;
    skos:narrower mesh:D000072283 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87b/Nanoparticle> a npo:NPO_1384,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower pubchem:11199 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12841471 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ poly(vinyl alcohol)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:95738 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ (4'-aminoacetophenone)-modified poly(styrene-co-maleic nhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-phenylalanine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "(low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ Pluronic F-127"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated amino-poly(ethylene glycol) (methoxyterminated)(5kDa)*"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6268 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:543502 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-glycine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6140 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10154203 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5483 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-methionine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CVVIT'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Poly(vinylpyrrolidone)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:31348 ],
        [ a npo:NPO_1962 ;
            skos:narrower "(11-Mercaptoundecyl)-N,N,Ntrimethylammonium"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amino-poly(ethylene glycol)-thiol (5kDa) (low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Î±-Lipoic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated amino-poly(ethylene glycol) (3kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12035 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-threonine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(L-lysine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-asparagine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10352850 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-alanine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ sodium dodecyl sulfate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (20kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amino-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-serine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ 1,2-dioleoyl-3-trimethylammonium-propane"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-tryptophan"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1133 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:329113 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5281 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:3522585 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:598 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CALNN'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5974 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ ethylenediamine-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @hexadecyltrimethylammonium bromide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(allylamine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:15793 ],
        [ a npo:NPO_1962 ;
            skos:narrower "(11-Mercaptoundecyl)tetra(ethylene glycol)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ urea-modified poly(styrenecomaleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ deoxycholic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ hexadecylamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "TWEEN20"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Carboxymethyl-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Bis(p-sulfonatophenyl)phenylphosphine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6514 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (1kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8926 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ octadecylamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (2kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ stearic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "5,5â€²-Dithiobis(2-nitrobenzoic acid)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (20kDa) (low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @benzyldimethylhexadecylammonium bromide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(ethyleneimine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CFGAILS'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ aminopropanol-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Carboxymethyl-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ ethanolamine-modified poly(styrene-co-maleic anhydride)"@en ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87b/Nanoparticle/Size> ;
    skos:narrower npo:NPO_401 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87b/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "15",
                "30",
                "60" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87c/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "log2 transformed (Cell association [mL/Î¼g(Mg)] )" ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "The correlation of cell association of Au NPs (modified with different ionic/cationic surface ligands) with corona proteins and physicochemical properties was investigated via QSAR analysis of a recently published dataset (C. D. Walkey, et al. et al., 2015 already reported in this table). The ratio mcell/mwell divided by mcells quantified the total cell association, where mcell is the total atomic gold (or silver) content associated with cells, mwell is the total atomic gold (or silver) content in well (associated with cells and free in solution) and mcells is the total mass of magnesium per sample. The related net cell association data were log transformed (log2 transformation) prior to modelling Cell association was chosen as a model biological interaction because of its relevance to inflammatory responses, biodistribution, and toxicity in vivo. A549 human lung epithelial carcinoma cells (ATCC) were maintained in RPMI1640 (Wisent, cat#: 350-000-CL) supplement with 10%(v/v) fetal bovine serum (FBS) (Gibco, cat#: 12483-020) and 1% (v/v) penicillin-streptomycin (P-S) (Gibco, cat#: 15140-122) in a sterile 5% CO2 atmin 175 cm2 tissue culture flasks (NEST, cat#: 709003)"@en ;
    skos:narrower mesh:D000072283 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87c/Nanoparticle> a npo:NPO_1384,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "Carboxymethyl-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CFGAILS'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (20kDa) (low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8926 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5,5â€²-Dithiobis(2-nitrobenzoic acid)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "(low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-glycine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-threonine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "(11-Mercaptoundecyl)tetra(ethylene glycol)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ octadecylamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ sodium dodecyl sulfate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @benzyldimethylhexadecylammonium bromide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Carboxymethyl-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ (4'-aminoacetophenone)-modified poly(styrene-co-maleic nhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12841471 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ ethanolamine-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(ethyleneimine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ hexadecylamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(allylamine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ poly(vinyl alcohol)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ Pluronic F-127"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-methionine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-asparagine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (1kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated amino-poly(ethylene glycol) (methoxyterminated)(5kDa)*"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10352850 ],
        [ a npo:NPO_1962 ;
            skos:narrower "TWEEN20"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6268 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10154203 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (2kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-phenylalanine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:598 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12035 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1133 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-tryptophan"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:15793 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ ethylenediamine-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5281 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:11199 ],
        [ a npo:NPO_1962 ;
            skos:narrower "(11-Mercaptoundecyl)-N,N,Ntrimethylammonium"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @hexadecyltrimethylammonium bromide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amino-poly(ethylene glycol)-thiol (5kDa) (low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:543502 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:95738 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5974 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6140 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ aminopropanol-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Poly(vinylpyrrolidone)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-serine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5483 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (20kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(L-lysine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Î±-Lipoic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-alanine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CALNN'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ stearic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ deoxycholic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amino-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated amino-poly(ethylene glycol) (3kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Bis(p-sulfonatophenyl)phenylphosphine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ urea-modified poly(styrenecomaleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CVVIT'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:31348 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6514 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ 1,2-dioleoyl-3-trimethylammonium-propane"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:329113 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:3522585 ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87c/Nanoparticle/Size> ;
    skos:narrower npo:NPO_401 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87c/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "15",
                "30",
                "60" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87d/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "log2 transformed (Cell association [mL/Î¼g(Mg)] )" ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "The correlation of cell association of Au NPs (modified with different ionic/cationic surface ligands) with corona proteins and physicochemical properties was investigated via QSAR analysis of a recently published dataset (C. D. Walkey, et al. et al., 2015 already reported in this table). The ratio mcell/mwell divided by mcells quantified the total cell association, where mcell is the total atomic gold (or silver) content associated with cells, mwell is the total atomic gold (or silver) content in well (associated with cells and free in solution) and mcells is the total mass of magnesium per sample. The related net cell association data were log transformed (log2 transformation) prior to modelling Cell association was chosen as a model biological interaction because of its relevance to inflammatory responses, biodistribution, and toxicity in vivo. A549 human lung epithelial carcinoma cells (ATCC) were maintained in RPMI1640 (Wisent, cat#: 350-000-CL) supplement with 10%(v/v) fetal bovine serum (FBS) (Gibco, cat#: 12483-020) and 1% (v/v) penicillin-streptomycin (P-S) (Gibco, cat#: 15140-122) in a sterile 5% CO2 atmin 175 cm2 tissue culture flasks (NEST, cat#: 709003)"@en ;
    skos:narrower mesh:D000072283 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87d/Nanoparticle> a npo:NPO_1384,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower pubchem:5974 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-tryptophan"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6268 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amino-poly(ethylene glycol)-thiol (5kDa) (low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:15793 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Î±-Lipoic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-serine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-glycine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (20kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6514 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Bis(p-sulfonatophenyl)phenylphosphine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(ethyleneimine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ sodium dodecyl sulfate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ 1,2-dioleoyl-3-trimethylammonium-propane"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10154203 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (1kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:598 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1133 ],
        [ a npo:NPO_1962 ;
            skos:narrower "(low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-threonine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ ethanolamine-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12841471 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6140 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated amino-poly(ethylene glycol) (3kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12035 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:31348 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (2kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CFGAILS'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated amino-poly(ethylene glycol) (methoxyterminated)(5kDa)*"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "TWEEN20"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10352850 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-phenylalanine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:95738 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-methionine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @hexadecyltrimethylammonium bromide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(allylamine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:329113 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-alanine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CVVIT'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(L-lysine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ (4'-aminoacetophenone)-modified poly(styrene-co-maleic nhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ stearic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "5,5â€²-Dithiobis(2-nitrobenzoic acid)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Poly(vinylpyrrolidone)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ hexadecylamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CALNN'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ deoxycholic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ poly(vinyl alcohol)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Carboxymethyl-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ aminopropanol-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-asparagine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Carboxymethyl-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "(11-Mercaptoundecyl)-N,N,Ntrimethylammonium"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (20kDa) (low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:3522585 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5483 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ urea-modified poly(styrenecomaleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5281 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:11199 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ octadecylamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8926 ],
        [ a npo:NPO_1962 ;
            skos:narrower "(11-Mercaptoundecyl)tetra(ethylene glycol)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amino-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @benzyldimethylhexadecylammonium bromide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ Pluronic F-127"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ ethylenediamine-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:543502 ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87d/Nanoparticle/Size> ;
    skos:narrower npo:NPO_401 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87d/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "15",
                "30",
                "60" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87e/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "log2 transformed (Cell association [mL/Î¼g(Mg)] )" ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "The correlation of cell association of Au NPs (modified with different ionic/cationic surface ligands) with corona proteins and physicochemical properties was investigated via QSAR analysis of a recently published dataset (C. D. Walkey, et al. et al., 2015 already reported in this table). The ratio mcell/mwell divided by mcells quantified the total cell association, where mcell is the total atomic gold (or silver) content associated with cells, mwell is the total atomic gold (or silver) content in well (associated with cells and free in solution) and mcells is the total mass of magnesium per sample. The related net cell association data were log transformed (log2 transformation) prior to modelling Cell association was chosen as a model biological interaction because of its relevance to inflammatory responses, biodistribution, and toxicity in vivo. A549 human lung epithelial carcinoma cells (ATCC) were maintained in RPMI1640 (Wisent, cat#: 350-000-CL) supplement with 10%(v/v) fetal bovine serum (FBS) (Gibco, cat#: 12483-020) and 1% (v/v) penicillin-streptomycin (P-S) (Gibco, cat#: 15140-122) in a sterile 5% CO2 atmin 175 cm2 tissue culture flasks (NEST, cat#: 709003)"@en ;
    skos:narrower mesh:D000072283 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87e/Nanoparticle> a npo:NPO_1384,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ sodium dodecyl sulfate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:95738 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:31348 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:598 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:3522585 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (1kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ ethanolamine-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5974 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ Pluronic F-127"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (20kDa) (low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "(low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "5,5â€²-Dithiobis(2-nitrobenzoic acid)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ hexadecylamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Bis(p-sulfonatophenyl)phenylphosphine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:543502 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amino-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Carboxymethyl-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6140 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @hexadecyltrimethylammonium bromide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "TWEEN20"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ deoxycholic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-methionine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amino-poly(ethylene glycol)-thiol (5kDa) (low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (20kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:329113 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5483 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ aminopropanol-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-serine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5281 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:11199 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6514 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(L-lysine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "(11-Mercaptoundecyl)-N,N,Ntrimethylammonium"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-alanine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-tryptophan"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12841471 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(allylamine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Poly(vinylpyrrolidone)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CALNN'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10352850 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:15793 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12035 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ stearic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Carboxymethyl-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (2kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Î±-Lipoic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8926 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ octadecylamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-asparagine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CVVIT'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ 1,2-dioleoyl-3-trimethylammonium-propane"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated amino-poly(ethylene glycol) (methoxyterminated)(5kDa)*"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ poly(vinyl alcohol)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(ethyleneimine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-glycine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "(11-Mercaptoundecyl)tetra(ethylene glycol)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-threonine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1133 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @benzyldimethylhexadecylammonium bromide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10154203 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ ethylenediamine-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-phenylalanine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated amino-poly(ethylene glycol) (3kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6268 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ urea-modified poly(styrenecomaleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CFGAILS'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ (4'-aminoacetophenone)-modified poly(styrene-co-maleic nhydride)"@en ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87e/Nanoparticle/Size> ;
    skos:narrower npo:NPO_401 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87e/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "15",
                "30",
                "60" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87f/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "log2 transformed (Cell association [mL/Î¼g(Mg)] )" ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "The correlation of cell association of Au NPs (modified with different ionic/cationic surface ligands) with corona proteins and physicochemical properties was investigated via QSAR analysis of a recently published dataset (C. D. Walkey, et al. et al., 2015 already reported in this table). The ratio mcell/mwell divided by mcells quantified the total cell association, where mcell is the total atomic gold (or silver) content associated with cells, mwell is the total atomic gold (or silver) content in well (associated with cells and free in solution) and mcells is the total mass of magnesium per sample. The related net cell association data were log transformed (log2 transformation) prior to modelling Cell association was chosen as a model biological interaction because of its relevance to inflammatory responses, biodistribution, and toxicity in vivo. A549 human lung epithelial carcinoma cells (ATCC) were maintained in RPMI1640 (Wisent, cat#: 350-000-CL) supplement with 10%(v/v) fetal bovine serum (FBS) (Gibco, cat#: 12483-020) and 1% (v/v) penicillin-streptomycin (P-S) (Gibco, cat#: 15140-122) in a sterile 5% CO2 atmin 175 cm2 tissue culture flasks (NEST, cat#: 709003)"@en ;
    skos:narrower mesh:D000072283 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87f/Nanoparticle> a npo:NPO_1384,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "(11-Mercaptoundecyl)tetra(ethylene glycol)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Carboxymethyl-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @hexadecyltrimethylammonium bromide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ ethanolamine-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5974 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (2kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8926 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (20kDa) (low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-tryptophan"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "TWEEN20"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:3522585 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ ethylenediamine-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (1kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:11199 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12841471 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10154203 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6514 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amino-poly(ethylene glycol)-thiol (5kDa) (low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:15793 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CALNN'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:95738 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ 1,2-dioleoyl-3-trimethylammonium-propane"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:543502 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6268 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(allylamine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-methionine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-phenylalanine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12035 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5281 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(L-lysine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ sodium dodecyl sulfate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Poly(vinylpyrrolidone)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-glycine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1133 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:31348 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ octadecylamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5483 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-threonine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Carboxymethyl-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CFGAILS'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:329113 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:598 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-asparagine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6140 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ poly(vinyl alcohol)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ aminopropanol-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10352850 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ hexadecylamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Bis(p-sulfonatophenyl)phenylphosphine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (20kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @benzyldimethylhexadecylammonium bromide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ deoxycholic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(ethyleneimine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-serine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "(11-Mercaptoundecyl)-N,N,Ntrimethylammonium"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "(low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ (4'-aminoacetophenone)-modified poly(styrene-co-maleic nhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-alanine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ stearic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CVVIT'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated amino-poly(ethylene glycol) (3kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ Pluronic F-127"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated amino-poly(ethylene glycol) (methoxyterminated)(5kDa)*"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "5,5â€²-Dithiobis(2-nitrobenzoic acid)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Î±-Lipoic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ urea-modified poly(styrenecomaleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amino-poly(ethylene glycol)-thiol (5kDa)"@en ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87f/Nanoparticle/Size> ;
    skos:narrower npo:NPO_401 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87f/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "15",
                "30",
                "60" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87g/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "log2 transformed (Cell association [mL/Î¼g(Mg)] )" ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "The correlation of cell association of Au NPs (modified with different ionic/cationic surface ligands) with corona proteins and physicochemical properties was investigated via QSAR analysis of a recently published dataset (C. D. Walkey, et al. et al., 2015 already reported in this table). The ratio mcell/mwell divided by mcells quantified the total cell association, where mcell is the total atomic gold (or silver) content associated with cells, mwell is the total atomic gold (or silver) content in well (associated with cells and free in solution) and mcells is the total mass of magnesium per sample. The related net cell association data were log transformed (log2 transformation) prior to modelling Cell association was chosen as a model biological interaction because of its relevance to inflammatory responses, biodistribution, and toxicity in vivo. A549 human lung epithelial carcinoma cells (ATCC) were maintained in RPMI1640 (Wisent, cat#: 350-000-CL) supplement with 10%(v/v) fetal bovine serum (FBS) (Gibco, cat#: 12483-020) and 1% (v/v) penicillin-streptomycin (P-S) (Gibco, cat#: 15140-122) in a sterile 5% CO2 atmin 175 cm2 tissue culture flasks (NEST, cat#: 709003)"@en ;
    skos:narrower mesh:D000072283 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87g/Nanoparticle> a npo:NPO_1384,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (20kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ sodium dodecyl sulfate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ octadecylamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ Pluronic F-127"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @hexadecyltrimethylammonium bromide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5281 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-threonine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ deoxycholic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-serine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ ethylenediamine-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1133 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-phenylalanine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8926 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12841471 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:543502 ],
        [ a npo:NPO_1962 ;
            skos:narrower "(11-Mercaptoundecyl)tetra(ethylene glycol)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5974 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(L-lysine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12035 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (20kDa) (low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:95738 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ stearic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CFGAILS'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:11199 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ (4'-aminoacetophenone)-modified poly(styrene-co-maleic nhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:15793 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6140 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ ethanolamine-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ hexadecylamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (2kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:31348 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CVVIT'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated amino-poly(ethylene glycol) (methoxyterminated)(5kDa)*"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6268 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10154203 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10352850 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amino-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Carboxymethyl-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "5,5â€²-Dithiobis(2-nitrobenzoic acid)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "(low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ poly(vinyl alcohol)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-methionine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Carboxymethyl-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-asparagine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (1kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(ethyleneimine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:329113 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5483 ],
        [ a npo:NPO_1962 ;
            skos:narrower "TWEEN20"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Î±-Lipoic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:598 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated amino-poly(ethylene glycol) (3kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ 1,2-dioleoyl-3-trimethylammonium-propane"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "(11-Mercaptoundecyl)-N,N,Ntrimethylammonium"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-glycine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CALNN'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ aminopropanol-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amino-poly(ethylene glycol)-thiol (5kDa) (low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Poly(vinylpyrrolidone)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-tryptophan"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:3522585 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ urea-modified poly(styrenecomaleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Bis(p-sulfonatophenyl)phenylphosphine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @benzyldimethylhexadecylammonium bromide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6514 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(allylamine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-alanine"@en ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87g/Nanoparticle/Size> ;
    skos:narrower npo:NPO_401 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87g/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "15",
                "30",
                "60" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87h/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "log2 transformed (Cell association [mL/Î¼g(Mg)] )" ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "The correlation of cell association of Au NPs (modified with different ionic/cationic surface ligands) with corona proteins and physicochemical properties was investigated via QSAR analysis of a recently published dataset (C. D. Walkey, et al. et al., 2015 already reported in this table). The ratio mcell/mwell divided by mcells quantified the total cell association, where mcell is the total atomic gold (or silver) content associated with cells, mwell is the total atomic gold (or silver) content in well (associated with cells and free in solution) and mcells is the total mass of magnesium per sample. The related net cell association data were log transformed (log2 transformation) prior to modelling Cell association was chosen as a model biological interaction because of its relevance to inflammatory responses, biodistribution, and toxicity in vivo. A549 human lung epithelial carcinoma cells (ATCC) were maintained in RPMI1640 (Wisent, cat#: 350-000-CL) supplement with 10%(v/v) fetal bovine serum (FBS) (Gibco, cat#: 12483-020) and 1% (v/v) penicillin-streptomycin (P-S) (Gibco, cat#: 15140-122) in a sterile 5% CO2 atmin 175 cm2 tissue culture flasks (NEST, cat#: 709003)"@en ;
    skos:narrower mesh:D000072283 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87h/Nanoparticle> a npo:NPO_1384,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "(11-Mercaptoundecyl)-N,N,Ntrimethylammonium"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated amino-poly(ethylene glycol) (methoxyterminated)(5kDa)*"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-glycine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ deoxycholic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (2kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6140 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Carboxymethyl-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ poly(vinyl alcohol)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CVVIT'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amino-poly(ethylene glycol)-thiol (5kDa) (low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ urea-modified poly(styrenecomaleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:543502 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:31348 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12841471 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Bis(p-sulfonatophenyl)phenylphosphine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ hexadecylamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-asparagine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (20kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amino-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (20kDa) (low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5483 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:11199 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:3522585 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ stearic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10352850 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ aminopropanol-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-methionine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Carboxymethyl-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5974 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @benzyldimethylhexadecylammonium bromide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "(low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Î±-Lipoic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(allylamine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ 1,2-dioleoyl-3-trimethylammonium-propane"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "(11-Mercaptoundecyl)tetra(ethylene glycol)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CALNN'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @hexadecyltrimethylammonium bromide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:15793 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (1kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8926 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5,5â€²-Dithiobis(2-nitrobenzoic acid)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-phenylalanine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-serine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10154203 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CFGAILS'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ ethanolamine-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated amino-poly(ethylene glycol) (3kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-tryptophan"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ sodium dodecyl sulfate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(L-lysine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ Pluronic F-127"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ (4'-aminoacetophenone)-modified poly(styrene-co-maleic nhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6268 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6514 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-threonine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:95738 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5281 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1133 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(ethyleneimine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:598 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12035 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ octadecylamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ ethylenediamine-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Poly(vinylpyrrolidone)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:329113 ],
        [ a npo:NPO_1962 ;
            skos:narrower "TWEEN20"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-alanine"@en ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87h/Nanoparticle/Size> ;
    skos:narrower npo:NPO_401 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87h/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "15",
                "30",
                "60" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87i/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "log2 transformed (Cell association [mL/Î¼g(Mg)] )" ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "The correlation of cell association of Au NPs (modified with different ionic/cationic surface ligands) with corona proteins and physicochemical properties was investigated via QSAR analysis of a recently published dataset (C. D. Walkey, et al. et al., 2015 already reported in this table). The ratio mcell/mwell divided by mcells quantified the total cell association, where mcell is the total atomic gold (or silver) content associated with cells, mwell is the total atomic gold (or silver) content in well (associated with cells and free in solution) and mcells is the total mass of magnesium per sample. The related net cell association data were log transformed (log2 transformation) prior to modelling Cell association was chosen as a model biological interaction because of its relevance to inflammatory responses, biodistribution, and toxicity in vivo. A549 human lung epithelial carcinoma cells (ATCC) were maintained in RPMI1640 (Wisent, cat#: 350-000-CL) supplement with 10%(v/v) fetal bovine serum (FBS) (Gibco, cat#: 12483-020) and 1% (v/v) penicillin-streptomycin (P-S) (Gibco, cat#: 15140-122) in a sterile 5% CO2 atmin 175 cm2 tissue culture flasks (NEST, cat#: 709003)"@en ;
    skos:narrower mesh:D000072283 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87i/Nanoparticle> a npo:NPO_1384,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "Carboxymethyl-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Î±-Lipoic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6140 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ hexadecylamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5483 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CVVIT'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:598 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @hexadecyltrimethylammonium bromide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-methionine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-phenylalanine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:329113 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (2kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (1kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated amino-poly(ethylene glycol) (3kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-asparagine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5974 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-glycine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-tryptophan"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Bis(p-sulfonatophenyl)phenylphosphine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ aminopropanol-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amino-poly(ethylene glycol)-thiol (5kDa) (low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:543502 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-threonine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6268 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ Pluronic F-127"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "5,5â€²-Dithiobis(2-nitrobenzoic acid)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(ethyleneimine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "(11-Mercaptoundecyl)tetra(ethylene glycol)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:15793 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6514 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(L-lysine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ poly(vinyl alcohol)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8926 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10352850 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CFGAILS'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:31348 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ (4'-aminoacetophenone)-modified poly(styrene-co-maleic nhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ octadecylamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CALNN'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Poly(vinylpyrrolidone)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-serine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated amino-poly(ethylene glycol) (methoxyterminated)(5kDa)*"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amino-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:3522585 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ urea-modified poly(styrenecomaleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12841471 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @benzyldimethylhexadecylammonium bromide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ ethylenediamine-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "(low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5281 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(allylamine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ stearic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (20kDa) (low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (20kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "TWEEN20"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Carboxymethyl-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12035 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ ethanolamine-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ deoxycholic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-alanine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "(11-Mercaptoundecyl)-N,N,Ntrimethylammonium"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:11199 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ sodium dodecyl sulfate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ 1,2-dioleoyl-3-trimethylammonium-propane"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10154203 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:95738 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1133 ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87i/Nanoparticle/Size> ;
    skos:narrower npo:NPO_401 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87i/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "15",
                "30",
                "60" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87j/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "log2 transformed (Cell association [mL/Î¼g(Mg)] )" ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "The correlation of cell association of Au NPs (modified with different ionic/cationic surface ligands) with corona proteins and physicochemical properties was investigated via QSAR analysis of a recently published dataset (C. D. Walkey, et al. et al., 2015 already reported in this table). The ratio mcell/mwell divided by mcells quantified the total cell association, where mcell is the total atomic gold (or silver) content associated with cells, mwell is the total atomic gold (or silver) content in well (associated with cells and free in solution) and mcells is the total mass of magnesium per sample. The related net cell association data were log transformed (log2 transformation) prior to modelling Cell association was chosen as a model biological interaction because of its relevance to inflammatory responses, biodistribution, and toxicity in vivo. A549 human lung epithelial carcinoma cells (ATCC) were maintained in RPMI1640 (Wisent, cat#: 350-000-CL) supplement with 10%(v/v) fetal bovine serum (FBS) (Gibco, cat#: 12483-020) and 1% (v/v) penicillin-streptomycin (P-S) (Gibco, cat#: 15140-122) in a sterile 5% CO2 atmin 175 cm2 tissue culture flasks (NEST, cat#: 709003)"@en ;
    skos:narrower mesh:D000072283 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87j/Nanoparticle> a npo:NPO_1384,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ sodium dodecyl sulfate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5281 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-tryptophan"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Î±-Lipoic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated amino-poly(ethylene glycol) (3kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "5,5â€²-Dithiobis(2-nitrobenzoic acid)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:15793 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ stearic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Bis(p-sulfonatophenyl)phenylphosphine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:3522585 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CALNN'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "(11-Mercaptoundecyl)-N,N,Ntrimethylammonium"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12841471 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (20kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:11199 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-alanine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-asparagine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10154203 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ hexadecylamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ Pluronic F-127"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5483 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CVVIT'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1133 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6140 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-threonine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (2kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (20kDa) (low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10352850 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ ethylenediamine-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12035 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ aminopropanol-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Carboxymethyl-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (1kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "(low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ urea-modified poly(styrenecomaleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ octadecylamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:31348 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CFGAILS'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated amino-poly(ethylene glycol) (methoxyterminated)(5kDa)*"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:95738 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amino-poly(ethylene glycol)-thiol (5kDa) (low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amino-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-serine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "TWEEN20"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @benzyldimethylhexadecylammonium bromide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ ethanolamine-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:598 ],
        [ a npo:NPO_1962 ;
            skos:narrower "(11-Mercaptoundecyl)tetra(ethylene glycol)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-phenylalanine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(ethyleneimine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:329113 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8926 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-glycine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Poly(vinylpyrrolidone)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:543502 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @hexadecyltrimethylammonium bromide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ poly(vinyl alcohol)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6268 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6514 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ 1,2-dioleoyl-3-trimethylammonium-propane"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5974 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Carboxymethyl-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(L-lysine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ (4'-aminoacetophenone)-modified poly(styrene-co-maleic nhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-methionine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ deoxycholic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(allylamine)"@en ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87j/Nanoparticle/Size> ;
    skos:narrower npo:NPO_401 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87j/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "15",
                "30",
                "60" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87k/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "log2 transformed (Cell association [mL/Î¼g(Mg)] )" ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "The correlation of cell association of Au NPs (modified with different ionic/cationic surface ligands) with corona proteins and physicochemical properties was investigated via QSAR analysis of a recently published dataset (C. D. Walkey, et al. et al., 2015 already reported in this table). The ratio mcell/mwell divided by mcells quantified the total cell association, where mcell is the total atomic gold (or silver) content associated with cells, mwell is the total atomic gold (or silver) content in well (associated with cells and free in solution) and mcells is the total mass of magnesium per sample. The related net cell association data were log transformed (log2 transformation) prior to modelling Cell association was chosen as a model biological interaction because of its relevance to inflammatory responses, biodistribution, and toxicity in vivo. A549 human lung epithelial carcinoma cells (ATCC) were maintained in RPMI1640 (Wisent, cat#: 350-000-CL) supplement with 10%(v/v) fetal bovine serum (FBS) (Gibco, cat#: 12483-020) and 1% (v/v) penicillin-streptomycin (P-S) (Gibco, cat#: 15140-122) in a sterile 5% CO2 atmin 175 cm2 tissue culture flasks (NEST, cat#: 709003)"@en ;
    skos:narrower mesh:D000072283 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87k/Nanoparticle> a npo:NPO_1384,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower pubchem:6268 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:543502 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (20kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-glycine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(allylamine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6514 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5281 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:11199 ],
        [ a npo:NPO_1962 ;
            skos:narrower "5,5â€²-Dithiobis(2-nitrobenzoic acid)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ hexadecylamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated amino-poly(ethylene glycol) (methoxyterminated)(5kDa)*"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ sodium dodecyl sulfate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @benzyldimethylhexadecylammonium bromide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10154203 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1133 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:3522585 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12841471 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ poly(vinyl alcohol)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amino-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ Pluronic F-127"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ aminopropanol-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @hexadecyltrimethylammonium bromide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6140 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CALNN'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "(11-Mercaptoundecyl)-N,N,Ntrimethylammonium"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CFGAILS'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(L-lysine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:95738 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5974 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ deoxycholic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ (4'-aminoacetophenone)-modified poly(styrene-co-maleic nhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:15793 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (1kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-serine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10352850 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:598 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ ethanolamine-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8926 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-phenylalanine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Bis(p-sulfonatophenyl)phenylphosphine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-methionine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ 1,2-dioleoyl-3-trimethylammonium-propane"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amino-poly(ethylene glycol)-thiol (5kDa) (low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-threonine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Carboxymethyl-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-tryptophan"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-asparagine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "(low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(ethyleneimine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (2kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Carboxymethyl-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CVVIT'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ ethylenediamine-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:31348 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5483 ],
        [ a npo:NPO_1962 ;
            skos:narrower "(11-Mercaptoundecyl)tetra(ethylene glycol)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (20kDa) (low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated amino-poly(ethylene glycol) (3kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ stearic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Î±-Lipoic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "TWEEN20"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-alanine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ urea-modified poly(styrenecomaleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12035 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Poly(vinylpyrrolidone)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:329113 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ octadecylamine"@en ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87k/Nanoparticle/Size> ;
    skos:narrower npo:NPO_401 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87k/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "15",
                "30",
                "60" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87l/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a "log2 transformed (Cell association [mL/Î¼g(Mg)] )" ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "The correlation of cell association of Au NPs (modified with different ionic/cationic surface ligands) with corona proteins and physicochemical properties was investigated via QSAR analysis of a recently published dataset (C. D. Walkey, et al. et al., 2015 already reported in this table). The ratio mcell/mwell divided by mcells quantified the total cell association, where mcell is the total atomic gold (or silver) content associated with cells, mwell is the total atomic gold (or silver) content in well (associated with cells and free in solution) and mcells is the total mass of magnesium per sample. The related net cell association data were log transformed (log2 transformation) prior to modelling Cell association was chosen as a model biological interaction because of its relevance to inflammatory responses, biodistribution, and toxicity in vivo. A549 human lung epithelial carcinoma cells (ATCC) were maintained in RPMI1640 (Wisent, cat#: 350-000-CL) supplement with 10%(v/v) fetal bovine serum (FBS) (Gibco, cat#: 12483-020) and 1% (v/v) penicillin-streptomycin (P-S) (Gibco, cat#: 15140-122) in a sterile 5% CO2 atmin 175 cm2 tissue culture flasks (NEST, cat#: 709003)"@en ;
    skos:narrower mesh:D000072283 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87l/Nanoparticle> a npo:NPO_1384,
        npo:NPO_707 ;
    npo:has_part [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(L-lysine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6268 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5974 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5281 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:15793 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:11199 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ ethanolamine-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-phenylalanine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Î±-Lipoic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Bis(p-sulfonatophenyl)phenylphosphine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "(low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6514 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ aminopropanol-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ Pluronic F-127"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "5,5â€²-Dithiobis(2-nitrobenzoic acid)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-alanine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10352850 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ sodium dodecyl sulfate"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(ethyleneimine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ stearic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ deoxycholic acid"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:31348 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-methionine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ (4'-aminoacetophenone)-modified poly(styrene-co-maleic nhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:5483 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ ethylenediamine-modified poly(styrene-co-maleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (2kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:3522585 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CFGAILS'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:95738 ],
        [ a npo:NPO_1962 ;
            skos:narrower "(11-Mercaptoundecyl)tetra(ethylene glycol)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (20kDa) (low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @hexadecyltrimethylammonium bromide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CVVIT'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (20kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ hexadecylamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-tryptophan"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-threonine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ poly(vinyl alcohol)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Poly(vinylpyrrolidone)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-asparagine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "(11-Mercaptoundecyl)-N,N,Ntrimethylammonium"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amino-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated poly(allylamine)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:1133 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated amino-poly(ethylene glycol) (3kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-serine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Carboxymethyl-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @benzyldimethylhexadecylammonium bromide"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:10154203 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12035 ],
        [ a npo:NPO_1962 ;
            skos:narrower "2-Napthalenethiol @ urea-modified poly(styrenecomaleic anhydride)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated L-glycine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ 1,2-dioleoyl-3-trimethylammonium-propane"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Amino-poly(ethylene glycol)-thiol (5kDa) (low density)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Peptide sequence 'CALNN'"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:598 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:8926 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Carboxymethyl-poly(ethylene glycol)-thiol (5kDa)"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:543502 ],
        [ a npo:NPO_1962 ;
            skos:narrower "Thiolated amino-poly(ethylene glycol) (methoxyterminated)(5kDa)*"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "TWEEN20"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:6140 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:12841471 ],
        [ a npo:NPO_1962 ;
            skos:narrower pubchem:329113 ],
        [ a npo:NPO_1962 ;
            skos:narrower "1-Dodecanethiol @ octadecylamine"@en ],
        [ a npo:NPO_1962 ;
            skos:narrower "Methoxy-poly(ethylene glycol)-thiol (1kDa)"@en ] ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87l/Nanoparticle/Size> ;
    skos:narrower npo:NPO_401 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_87l/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a npo:NPO_1807 ;
                    rdfs:label "Size value" ] ;
            sio:SIO_000300 "15",
                "30",
                "60" ] ;
    skos:narrower npo:NPO_1694 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_9/Endpoint> a sty:T025,
        bao:BAO_0000179 ;
    bao:BAO_0002662 [ a bao:BAO_0002993 ;
            rdfs:label "Cytotoxicity assay"@en ;
            rdfs:comment "measured as log(1/EC50)"@en ] ;
    bao:BAO_0095009 obo:OBI_0001285 ;
    rdfs:comment "Determined the cytotoxicity of the metal oxide nanoparticles in terms of EC50 (concentration which cytotoxicity reduces bacteria viability up to 50%) based on the curve fitting least squares procedure. For experimental testing protocol see: Publication's supplementary information (Section 1)"@en ;
    skos:narrower mesh:D004926 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_9/Nanoparticle> a npo:NPO_1541,
        npo:NPO_707 ;
    npo:has_quality <https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_9/Nanoparticle/Size> ;
    skos:narrower npo:NPO_1373,
        npo:NPO_1486,
        npo:NPO_1542,
        npo:NPO_1550,
        enm:ENM_0000118,
        obo:CHEBI_30187,
        pubchem:14776,
        pubchem:14794,
        pubchem:14805,
        pubchem:14829,
        pubchem:150906,
        pubchem:157925,
        pubchem:159375,
        pubchem:166955,
        pubchem:29131,
        pubchem:518712,
        pubchem:62762 .

<https://h2020-sbd4nano.github.io/sbd-data-landscape/Model_9/Nanoparticle/Size> a obo:PATO_0000117 ;
    npo:has_unit_of_measure npo:NPO_1246 ;
    sio:SIO_000300 [ a [ a obo:STATO_0000035 ;
                    rdfs:label "Range" ] ;
            sio:SIO_000300 "15-90" ;
            sbd:lower_limit "15" ;
            sbd:upper_limit "90" ] ;
    skos:narrower npo:NPO_1694 .

pubchem:10129883 rdfs:label "dipotassium;oxygen(2-)" .

pubchem:10197609 rdfs:label "oxygen(2-);rubidium(1+)" .

pubchem:10197697 rdfs:label "manganese;oxygen(2-)" .

pubchem:11476 rdfs:label "(3-methylphenyl)methanol" .

pubchem:11563 rdfs:label "3-bromophenol" .

pubchem:11575 rdfs:label "iodobenzene" .

pubchem:12167 rdfs:label "1-chloro-4-methoxybenzene" .

pubchem:13010 rdfs:label "3,4-dimethylfuran-2,5-dione" .

pubchem:134661 rdfs:label "oxo(oxotitaniooxy)titanium" .

pubchem:139258 rdfs:label "oxygen(2-);scandium(3+)" .

pubchem:14778 rdfs:label "oxocalcium" .

pubchem:14782 rdfs:label "oxocadmium" .

pubchem:14792 rdfs:label "oxomagnesium" .

pubchem:14793 rdfs:label "dioxolead" .

pubchem:14796 rdfs:label "dioxogermane" .

pubchem:14801 rdfs:label "dioxomanganese" .

pubchem:14813 rdfs:label "(dioxo-lambda5-stibanyl)oxy-dioxo-lambda5-stibane" .

pubchem:14814 rdfs:label "dioxovanadiooxy(dioxo)vanadium" .

pubchem:14827 rdfs:label "oxolead" .

pubchem:14940 rdfs:label "trioxochromium" .

pubchem:14945 rdfs:label "oxomanganese" .

pubchem:159370 rdfs:label "digallium;oxygen(2-)" .

pubchem:159371 rdfs:label "dysprosium(3+);oxygen(2-)" .

pubchem:159373 rdfs:label "europium(3+);oxygen(2-)" .

pubchem:159374 rdfs:label "neodymium(3+);oxygen(2-)" .

pubchem:159410 rdfs:label "lutetium(3+);oxygen(2-)" .

pubchem:159422 rdfs:label "oxygen(2-);terbium(3+)" .

pubchem:159425 rdfs:label "holmium(3+);oxygen(2-)" .

pubchem:159427 rdfs:label "erbium(3+);oxygen(2-)" .

pubchem:166962 rdfs:label "dilithium;oxygen(2-)" .

pubchem:16747781 rdfs:label "lambda1-thallanyloxythallium" .

pubchem:20597791 rdfs:label "manganese;oxygen(2-)" .

pubchem:222 rdfs:label "azane" .

pubchem:23942 rdfs:label "platinum" .

pubchem:244 rdfs:label "phenylmethanol" .

pubchem:25087137 rdfs:label "zinc;iron(3+);oxygen(2-)" .

pubchem:26042 rdfs:label "oxovanadium" .

pubchem:29936 rdfs:label "dioxomolybdenum" .

pubchem:31242 rdfs:label "4-ethylphenol" .

pubchem:32051 rdfs:label "oxomercury" .

pubchem:33094 rdfs:label "methyl 2-methylbenzoate" .

pubchem:342 rdfs:label "3-methylphenol" .

pubchem:3788361 rdfs:label "oxo(oxothallanyloxy)thallane" .

pubchem:379 rdfs:label "octanoic acid" .

pubchem:4124403 rdfs:label "silicon(4+)" .

pubchem:4226345 rdfs:label "oxido(oxo)alumane" .

pubchem:439341 rdfs:label "(2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6S)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol" .

pubchem:445639 rdfs:label "(Z)-octadec-9-enoic acid" .

pubchem:6054 rdfs:label "2-phenylethanol" .

pubchem:6108 rdfs:label "4-nitrobenzoic acid" .

pubchem:62157 rdfs:label "oxotitanium" .

pubchem:6224 rdfs:label "trisodium;2-hydroxypropane-1,2,3-tricarboxylate" .

pubchem:62392 rdfs:label "oxygen(2-);tantalum(5+)" .

pubchem:6335514 rdfs:label "germanium" .

pubchem:6335517 rdfs:label "oxogermanium" .

pubchem:6850728 rdfs:label "cerium-144(3+);oxygen(2-)" .

pubchem:7002 rdfs:label "1-methylnaphthalene" .

pubchem:7150 rdfs:label "methyl benzoate" .

pubchem:7165 rdfs:label "ethyl benzoate" .

pubchem:73975 rdfs:label "disodium;oxygen(2-)" .

pubchem:7410 rdfs:label "1-phenylethanone" .

pubchem:7416 rdfs:label "nitrobenzene" .

pubchem:7467 rdfs:label "1-(4-chlorophenyl)ethanone" .

pubchem:7473 rdfs:label "1-methyl-4-nitrobenzene" .

pubchem:7500 rdfs:label "ethylbenzene" .

pubchem:7505 rdfs:label "benzonitrile" .

pubchem:7668 rdfs:label "propylbenzene" .

pubchem:7809 rdfs:label "1,4-xylene" .

pubchem:7810 rdfs:label "1-chloro-4-methylbenzene" .

pubchem:7933 rdfs:label "3-chlorophenol" .

pubchem:7948 rdfs:label "3,5-dimethylphenol" .

pubchem:7961 rdfs:label "bromobenzene" .

pubchem:7964 rdfs:label "chlorobenzene" .

pubchem:82838 rdfs:label "strontium;oxygen(2-)" .

pubchem:82839 rdfs:label "oxoniobium" .

pubchem:82850 rdfs:label "dioxoniobium" .

pubchem:84163 rdfs:label "dioxotungsten" .

pubchem:87067 rdfs:label "3,3-dimethyloxolane-2,5-dione" .

pubchem:91574 rdfs:label "tellanylidenecadmium" .

pubchem:931 rdfs:label "naphthalene" .

pubchem:9732 rdfs:label "4-fluorophenol" .

pubchem:9877337 rdfs:label "oxido(oxo)chromium" .

pubchem:9905479 rdfs:label "dicesium;oxygen(2-)" .

pubchem:996 rdfs:label "phenol" .

pubchem:9989219 rdfs:label "copper;copper(1+);oxygen(2-)" .

<https://www.researchgate.net/publication/282743802_Prediction_for_cellular_uptake_of_manufactured_nanoparticles_to_pancreatic_cancer_cells> a sio:SIO_000176 ;
    dcterms:issued 2015 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Wen Dai" ] ;
    dcterms:title "Prediction for cellular uptake of manufactured nanoparticles to pancreatic cancer cells" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "G. Y. He" ],
        [ a foaf:Person ;
            foaf:name "H. Q. Chen" ],
        [ a foaf:Person ;
            foaf:name "X. Y. Shan" ],
        [ a foaf:Person ;
            foaf:name "W. Dai" ] .

<http://doi.org/10.1007/s11051-013-2028-0> a sio:SIO_000176 ;
    dcterms:issued 2013 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "M. Salahinejad" ] ;
    dcterms:title "QSAR studies of the dispersion of SWNTs in different organic solvents" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "E. Zolfonoun" ],
        [ a foaf:Person ;
            foaf:name "M. Salahinejad" ] .

<http://doi.org/10.1016/j.compbiolchem.2007.02.002> a sio:SIO_000176 ;
    dcterms:issued 2007 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Andrey A. Toropov" ] ;
    dcterms:title "Predicting water solubility and octanol water partition coefficient for carbon nanotubes based on the chiral vector" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "J. Leszczynski" ],
        [ a foaf:Person ;
            foaf:name "A. A. Toropov" ],
        [ a foaf:Person ;
            foaf:name "D. Leszczynska" ] .

<http://doi.org/10.1016/j.ecoenv.2014.05.026> a sio:SIO_000176 ;
    dcterms:issued 2014 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Kunal Roy" ] ;
    dcterms:title "Periodic table-based descriptors to encode cytotoxicity profile of metal oxide nanoparticles: A mechanistic QSTR approach" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "A. Gajewicz" ],
        [ a foaf:Person ;
            foaf:name "J. Leszczynski" ],
        [ a foaf:Person ;
            foaf:name "S. Kar" ],
        [ a foaf:Person ;
            foaf:name "T. Puzyn" ],
        [ a foaf:Person ;
            foaf:name "K. Roy" ] .

<http://doi.org/10.1016/j.ecoenv.2015.12.033> a sio:SIO_000176 ;
    dcterms:issued 2016 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Tomasz Puzyn" ] ;
    dcterms:title "Extrapolating between toxicity endpoints of metal oxide nanoparticles: Predicting toxicity to Escherichia coli and human keratinocyte cell line (HaCaT) with Nano-QTTR" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "S. Kar" ],
        [ a foaf:Person ;
            foaf:name "T. Puzyn" ],
        [ a foaf:Person ;
            foaf:name "A. Gajewicz" ],
        [ a foaf:Person ;
            foaf:name "J. Leszczynski" ],
        [ a foaf:Person ;
            foaf:name "K. Roy" ] .

<http://doi.org/10.1016/j.jhazmat.2010.04.016> a sio:SIO_000176 ;
    dcterms:issued 2010 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Vishal Shah" ] ;
    dcterms:title "Understanding the toxicity of aggregated zero valent copper nanoparticles against Escherichia coli" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "S. Seal" ],
        [ a foaf:Person ;
            foaf:name "A. Angelov" ],
        [ a foaf:Person ;
            foaf:name "V. Shah" ],
        [ a foaf:Person ;
            foaf:name "A. Kumar" ],
        [ a foaf:Person ;
            foaf:name "D. Badia" ],
        [ a foaf:Person ;
            foaf:name "F. Rispoli" ] .

<http://doi.org/10.1016/j.jiec.2013.08.011> a sio:SIO_000176 ;
    dcterms:issued 2014 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "M. Ghaedi" ] ;
    dcterms:title "Least square-support vector (LS-SVM) method for modeling of methylene blue dye adsorption using copper oxide loaded on activated carbon: Kinetic and isotherm study" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "M. H. Habibi" ],
        [ a foaf:Person ;
            foaf:name "A. M. Ghaedi" ],
        [ a foaf:Person ;
            foaf:name "A. Ansari" ],
        [ a foaf:Person ;
            foaf:name "M. Hossainpour" ],
        [ a foaf:Person ;
            foaf:name "M. Ghaedi" ],
        [ a foaf:Person ;
            foaf:name "A. R. Asghari" ] .

<http://doi.org/10.1016/j.jphotobiol.2013.11.023> a sio:SIO_000176 ;
    dcterms:issued 2014 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "M.-J. Huang" ],
        [ a foaf:Person ;
            foaf:name "H.-M. Hwang" ] ;
    dcterms:title "Using experimental data of Escherichia coli to develop a QSAR model for predicting the photo-induced cytotoxicity of metal oxide nanoparticles" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "X. He" ],
        [ a foaf:Person ;
            foaf:name "J. D. Watts" ],
        [ a foaf:Person ;
            foaf:name "K. Pathakoti" ],
        [ a foaf:Person ;
            foaf:name "M.-J. Huang" ],
        [ a foaf:Person ;
            foaf:name "H.-M. Hwang" ] .

<http://doi.org/10.1016/j.scitotenv.2013.09.006> a sio:SIO_000176 ;
    dcterms:issued 2014 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Brajesh Dubey" ] ;
    dcterms:title "Particle size, surface charge and concentration dependent ecotoxicity of three organo-coated silver nanoparticles: Comparison between general linear model-predicted and observed toxicity" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "B. Dubey" ],
        [ a foaf:Person ;
            foaf:name "K. J. Maier" ],
        [ a foaf:Person ;
            foaf:name "X. Liu" ],
        [ a foaf:Person ;
            foaf:name "L. R. Pokhrel" ],
        [ a foaf:Person ;
            foaf:name "T. M. Tolaymat" ],
        [ a foaf:Person ;
            foaf:name "T. Silva" ] .

<http://doi.org/10.1021/ie3006947> a sio:SIO_000176 ;
    dcterms:issued 2012 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Mehdi Ghorbanzadeh" ] ;
    dcterms:title "Modeling the Cellular Uptake of Magnetofluorescent Nanoparticles in Pancreatic Cancer Cells: A Quantitative Structure Activity Relationship Study" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "M. Ghorbanzadeh" ],
        [ a foaf:Person ;
            foaf:name "M. Karimpour" ],
        [ a foaf:Person ;
            foaf:name "M. H. Fatemi" ] .

<http://doi.org/10.1021/jp052223n> a sio:SIO_000176 ;
    dcterms:issued 2005 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Huanxiang Liu" ] ;
    dcterms:title "Accurate Quantitative Structureâˆ’Property Relationship Model To Predict the Solubility of C60 in Various Solvents Based on a Novel Approach Using a Least-Squares Support Vector Machine" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "Z. Hu" ],
        [ a foaf:Person ;
            foaf:name "H. Liu" ],
        [ a foaf:Person ;
            foaf:name "M. Liu" ],
        [ a foaf:Person ;
            foaf:name "R. Zhang" ],
        [ a foaf:Person ;
            foaf:name "X. Yao" ],
        [ a foaf:Person ;
            foaf:name "B. Fan" ] .

<http://doi.org/10.1021/nn1013484> a sio:SIO_000176 ;
    dcterms:issued 2010 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Alexander Tropsha" ] ;
    dcterms:title "Quantitative Nanostructureâˆ’Activity Relationship Modeling" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "C. Tassa" ],
        [ a foaf:Person ;
            foaf:name "D. Fourches" ],
        [ a foaf:Person ;
            foaf:name "D. Pu" ],
        [ a foaf:Person ;
            foaf:name "A. Tropsha" ],
        [ a foaf:Person ;
            foaf:name "S. Y. Shaw" ],
        [ a foaf:Person ;
            foaf:name "R. Weissleder" ],
        [ a foaf:Person ;
            foaf:name "R. J. Mumper" ] .

<http://doi.org/10.1039/c4nr03487b> a sio:SIO_000176 ;
    dcterms:issued 2014 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Jerzy Leszczynski" ] ;
    dcterms:title "From basic physics to mechanisms of toxicity: the â€œliquid dropâ€ approach applied to develop predictive classification models for toxicity of metal oxide nanoparticles" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "V. Kuz'min" ],
        [ a foaf:Person ;
            foaf:name "J. Leszczynski" ],
        [ a foaf:Person ;
            foaf:name "T. Puzyn" ],
        [ a foaf:Person ;
            foaf:name "B. Rasulev" ],
        [ a foaf:Person ;
            foaf:name "A. Gajewicz" ],
        [ a foaf:Person ;
            foaf:name "N. Sizochenko" ] .

<http://doi.org/10.1039/c5nr01537e> a sio:SIO_000176 ;
    dcterms:issued 2015 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Yoram Cohen" ] ;
    dcterms:title "Prediction of nanoparticles-cell association based on corona proteins and physicochemical properties" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "W. C. W. Chan" ],
        [ a foaf:Person ;
            foaf:name "W. Jiang" ],
        [ a foaf:Person ;
            foaf:name "R. Liu" ],
        [ a foaf:Person ;
            foaf:name "Y. Cohen" ],
        [ a foaf:Person ;
            foaf:name "C. D. Walkey" ] .

<http://doi.org/10.1039/c5ra11399g> a sio:SIO_000176 ;
    dcterms:issued 2015 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Tomasz Puzyn" ] ;
    dcterms:title "Causal inference methods to assist in mechanistic interpretation of classification nano-SAR models" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "E. Mokshyna" ],
        [ a foaf:Person ;
            foaf:name "A. Gajewicz" ],
        [ a foaf:Person ;
            foaf:name "V. E. Kuz'min" ],
        [ a foaf:Person ;
            foaf:name "J. Leszczynski" ],
        [ a foaf:Person ;
            foaf:name "B. Rasulev" ],
        [ a foaf:Person ;
            foaf:name "T. Puzyn" ],
        [ a foaf:Person ;
            foaf:name "N. Sizochenko" ] .

<http://doi.org/10.1080/1062936X.2014.984327> a sio:SIO_000176 ;
    dcterms:issued 2015 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "A.A Toropov" ] ;
    dcterms:title "A quasi-QSPR modelling for the photocatalytic decolourization rate constants and cellular viability (CV%) of nanoparticles by CORAL" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "A. P. Toropova" ],
        [ a foaf:Person ;
            foaf:name "E. Benfenati" ],
        [ a foaf:Person ;
            foaf:name "A. A. Toropov" ] .

<http://doi.org/10.1080/15363830701779315> a sio:SIO_000176 ;
    dcterms:issued 2008 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Farhard Gharagheizi" ] ;
    dcterms:title "A Molecularâ€Based Model for Prediction of Solubility of C60 Fullerene in Various Solvents" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "F. Gharagheizi" ],
        [ a foaf:Person ;
            foaf:name "R. F. Alamdari" ] .

<http://doi.org/10.1088/0957-4484/26/1/015701> a sio:SIO_000176 ;
    dcterms:issued 2015 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Tomasz Puzyn" ] ;
    dcterms:title "Novel approach for efficient predictions properties of large pool of nanomaterials based on limited set of species: nano-read-across" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "M. T. Cronin" ],
        [ a foaf:Person ;
            foaf:name "A. Gajewicz" ],
        [ a foaf:Person ;
            foaf:name "T. Puzyn" ],
        [ a foaf:Person ;
            foaf:name "B. Rasulev" ],
        [ a foaf:Person ;
            foaf:name "J. Leszczynski" ] .

<http://doi.org/10.1111/j.1539-6924.2010.01438.x> a sio:SIO_000176 ;
    dcterms:issued 2010 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Christie Sayes" ] ;
    dcterms:title "Comparative Study of Predictive Computational Models for Nanoparticle-Induced Cytotoxicity" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "C. Sayes" ],
        [ a foaf:Person ;
            foaf:name "I. Ivanov" ] .

<http://doi.org/10.2147/IJN.S40742> a sio:SIO_000176 ;
    dcterms:issued 2013 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Xiong Liu" ] ;
    dcterms:title "Predictive modeling of nanomaterial exposure effects in biological systems" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "X. Liu" ],
        [ a foaf:Person ;
            foaf:name "B. Harper" ],
        [ a foaf:Person ;
            foaf:name "J. A. Steevens" ],
        [ a foaf:Person ;
            foaf:name "R. Xu" ],
        [ a foaf:Person ;
            foaf:name "S. Harper" ],
        [ a foaf:Person ;
            foaf:name "K. Tang" ] .

<http://doi.org/10.2174/1386207318666150306105525> a sio:SIO_000176 ;
    dcterms:issued 2015 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Yoram Cohen" ] ;
    dcterms:title "Quantitative Structure-Activity Relationships for Cellular Uptake of Surface-Modified Nanoparticles" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "R. Rallo" ],
        [ a foaf:Person ;
            foaf:name "R. Liu" ],
        [ a foaf:Person ;
            foaf:name "Y. Cohen" ],
        [ a foaf:Person ;
            foaf:name "M. Bilal" ] .

<http://doi.org/10.3109/17435390.2015.1073397> a sio:SIO_000176 ;
    dcterms:issued 2016 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Dr. Bing Yan" ],
        [ a foaf:Person ;
            foaf:name "Alexander Tropsha" ] ;
    dcterms:title "Computer-aided design of carbon nanotubes with the desired bioactivity and safety profiles" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "L. Li" ],
        [ a foaf:Person ;
            foaf:name "D. Fourches" ],
        [ a foaf:Person ;
            foaf:name "G. Su" ],
        [ a foaf:Person ;
            foaf:name "A. Tropsha" ],
        [ a foaf:Person ;
            foaf:name "D. Pu" ],
        [ a foaf:Person ;
            foaf:name "B. Yan" ],
        [ a foaf:Person ;
            foaf:name "Q. Mu" ],
        [ a foaf:Person ;
            foaf:name "H. Zhou" ] .

npo:NPO_103 rdfs:label "Al nanoparticle" .

npo:NPO_1967 rdfs:label "Aggregation"@en .

npo:NPO_354 rdfs:label "MWCNT40nm-COOH",
        "MWCNTs (Multi-walled carbon nanotubes)" .

npo:NPO_730 rdfs:label "Fullerene C60" .

npo:NPO_735 rdfs:label "Dendrimer"@en .

npo:NPO_850 rdfs:label "Elliptical" .

npo:NPO_852 rdfs:label "Needle" .

obo:CHEBI_33888 rdfs:label "Cobalt molecular entity" .

pubchem:112762823 rdfs:label "4-chloro-N-[1-oxo-1-[3-(trifluoromethyl)anilino]propan-2-yl]benzamide" .

pubchem:14802 rdfs:label "trioxomolybdenum" .

pubchem:21805890 rdfs:label "2-amino-3-(4-benzoyloxyphenyl)propanoic acid" .

pubchem:23926 rdfs:label "iron" .

pubchem:23980 rdfs:label "copper" .

pubchem:24101749 rdfs:label "N-[1-(cyclohexylamino)-1-oxopropan-2-yl]benzamide" .

pubchem:303942 rdfs:label "2-amino-N-phenylpropanamide" .

pubchem:3393128 rdfs:label "2-(benzenesulfonamido)-N-[3-(trifluoromethyl)phenyl]propanamide" .

pubchem:3496505 rdfs:label "2-amino-N-benzylpropanamide" .

pubchem:3618978 rdfs:label "2-(benzenesulfonamido)-N-phenylpropanamide" .

pubchem:4528484 rdfs:label "2-(benzenesulfonamido)-N-cyclohexylpropanamide" .

pubchem:46744931 rdfs:label "N-[1-(benzylamino)-1-oxopropan-2-yl]-4-chlorobenzamide" .

pubchem:47097636 rdfs:label "4-chloro-N-(1-oxo-1-pyrrolidin-1-ylpropan-2-yl)benzamide" .

pubchem:47099540 rdfs:label "N-[1-(butylamino)-1-oxopropan-2-yl]-4-chlorobenzamide" .

pubchem:51147965 rdfs:label "3-nitro-N-(1-oxo-1-pyrrolidin-1-ylpropan-2-yl)benzamide" .

pubchem:51148039 rdfs:label "N-[1-(cyclohexylamino)-1-oxopropan-2-yl]-3-nitrobenzamide" .

pubchem:51148259 rdfs:label "N-(1-anilino-1-oxopropan-2-yl)-3-nitrobenzamide" .

pubchem:51148276 rdfs:label "N-(1-anilino-1-oxopropan-2-yl)-4-chlorobenzamide" .

pubchem:5205930 rdfs:label "2-[(4-methylphenyl)sulfonylamino]-N-phenylpropanamide" .

pubchem:60407577 rdfs:label "ethyl 4-[2-[(4-chlorobenzoyl)amino]propanoylamino]benzoate" .

pubchem:934 rdfs:label "nickel(2+)" .

<http://doi.org/10.1016/j.nano.2015.09.002> a sio:SIO_000176 ;
    dcterms:issued 2016 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "A. Amani" ] ;
    dcterms:title "Cytotoxicity of chitosan/streptokinase nanoparticles as a function of size: An artificial neural networks study" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "H. Baharifar" ],
        [ a foaf:Person ;
            foaf:name "A. Amani" ] .

<http://doi.org/10.1021/ci000140s> a sio:SIO_000176 ;
    dcterms:issued 2001 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Peter C. Jurs" ] ;
    dcterms:title "Prediction of C60 Solubilities from Solvent Molecular Structures" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "S. M. Danauskas" ],
        [ a foaf:Person ;
            foaf:name "P. C. Jurs" ] .

<http://doi.org/10.1021/jp0023720> a sio:SIO_000176 ;
    dcterms:issued 2001 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Yizhak Marcus" ] ;
    dcterms:title "Solubility of C60 Fullerene" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "Y. Marcus" ],
        [ a foaf:Person ;
            foaf:name "A. L. Smith" ],
        [ a foaf:Person ;
            foaf:name "N. V. Avramenko" ],
        [ a foaf:Person ;
            foaf:name "E. B. Stukalin" ],
        [ a foaf:Person ;
            foaf:name "M. V. Korobov" ],
        [ a foaf:Person ;
            foaf:name "A. L. Mirakyan" ] .

pubchem:243 rdfs:label "benzoic acid" .

pubchem:6917 rdfs:label "1-ethenylpyrrolidin-2-one" .

<http://doi.org/10.1021/ci300482n> a sio:SIO_000176 ;
    dcterms:issued 2013 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Tammie L. Borders" ] ;
    dcterms:title "Developing Descriptors To Predict Mechanical Properties of Nanotubes" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "H. Zhang" ],
        [ a foaf:Person ;
            foaf:name "A. F. Fonseca" ],
        [ a foaf:Person ;
            foaf:name "A. Rusinko" ],
        [ a foaf:Person ;
            foaf:name "K. Cho" ],
        [ a foaf:Person ;
            foaf:name "T. L. Borders" ] .

<http://doi.org/10.1021/mp3006402> a sio:SIO_000176 ;
    dcterms:issued 2013 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "D.A. Winkler" ] ;
    dcterms:title "Predicting the Complex Phase Behavior of Self-Assembling Drug Delivery Nanoparticles" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "X. Mulet" ],
        [ a foaf:Person ;
            foaf:name "T. C. Le" ],
        [ a foaf:Person ;
            foaf:name "D. A. Winkler" ],
        [ a foaf:Person ;
            foaf:name "F. R. Burden" ] .

<http://doi.org/10.1021/nl303144k> a sio:SIO_000176 ;
    dcterms:issued 2012 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "D.A. Winkler" ] ;
    dcterms:title "Modeling Biological Activities of Nanoparticles" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "R. Weissleder" ],
        [ a foaf:Person ;
            foaf:name "F. R. Burden" ],
        [ a foaf:Person ;
            foaf:name "C. Tassa" ],
        [ a foaf:Person ;
            foaf:name "S. Shaw" ],
        [ a foaf:Person ;
            foaf:name "D. A. Winkler" ],
        [ a foaf:Person ;
            foaf:name "V. C. Epa" ] .

<http://doi.org/10.1039/c6ra01298a> a sio:SIO_000176 ;
    dcterms:issued 2016 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Yong Pan" ] ;
    dcterms:title "Nano-QSAR modeling for predicting the cytotoxicity of metal oxide nanoparticles using novel descriptors" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "J. Jiang" ],
        [ a foaf:Person ;
            foaf:name "J. I. Zink" ],
        [ a foaf:Person ;
            foaf:name "T. Li" ],
        [ a foaf:Person ;
            foaf:name "D. Telesca" ],
        [ a foaf:Person ;
            foaf:name "J. Cheng" ],
        [ a foaf:Person ;
            foaf:name "Y. Pan" ] .

<http://doi.org/10.3109/17435390.2016.1161857> a sio:SIO_000176 ;
    dcterms:issued 2016 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Xue Z. Wang" ] ;
    dcterms:title "Accurate and interpretable nanoSAR models from genetic programming-based decision tree construction approaches" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "C. Oksel" ],
        [ a foaf:Person ;
            foaf:name "X. Z. Wang" ],
        [ a foaf:Person ;
            foaf:name "T. Wilkins" ],
        [ a foaf:Person ;
            foaf:name "D. A. Winkler" ],
        [ a foaf:Person ;
            foaf:name "C. Y. Ma" ] .

npo:NPO_1552 rdfs:label "Lipid-based"@en .

npo:NPO_1892 rdfs:label "Ag nanoparticle" .

npo:NPO_858 rdfs:label "Hexagonal",
        "Polyhedral",
        "Pyramidal" .

obo:PATO_0002390 rdfs:label "Radius"@en .

<http://doi.org/10.1016/j.biomaterials.2015.03.042> a sio:SIO_000176 ;
    dcterms:issued 2015 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "K.M. Bratlie" ] ;
    dcterms:title "Altering inÂ vivo macrophage responses with modified polymer properties" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "H. C. Bygd" ],
        [ a foaf:Person ;
            foaf:name "K. D. Forsmark" ],
        [ a foaf:Person ;
            foaf:name "K. M. Bratlie" ] .

obo:CL_0000235 rdfs:label "Macrophage"@en .

pubchem:16773849 rdfs:label "3-amino-N'-hydroxybenzenecarboximidamide" .

pubchem:17749886 rdfs:label "2-methylsulfonylethanamine;hydrochloride" .

pubchem:3748064 rdfs:label "1,4-dioxan-2-ylmethanamine" .

pubchem:5355751 rdfs:label "(Z)-4-aminopent-3-en-2-one" .

pubchem:91550 rdfs:label "oxirane-2-carboxamide" .

<http://doi.org/10.1002/smll.201600597> a sio:SIO_000176 ;
    dcterms:issued 2016 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "D.A. Winkler" ],
        [ a foaf:Person ;
            foaf:name "Chunying Chen" ] ;
    dcterms:title "An Experimental and Computational Approach to the Development of ZnO Nanoparticles that are Safe by Design" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "Y. Chen" ],
        [ a foaf:Person ;
            foaf:name "D. A. Winkler" ],
        [ a foaf:Person ;
            foaf:name "H. Yin" ],
        [ a foaf:Person ;
            foaf:name "T. C. Le" ],
        [ a foaf:Person ;
            foaf:name "L. Zhao" ],
        [ a foaf:Person ;
            foaf:name "C. Chen" ],
        [ a foaf:Person ;
            foaf:name "R. Chen" ],
        [ a foaf:Person ;
            foaf:name "P. S. Casey" ] .

<http://doi.org/10.1039/c4ra01274g> a sio:SIO_000176 ;
    dcterms:issued 2014 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Kunwar P. Singh" ] ;
    dcterms:title "Nano-QSAR modeling for predicting biological activity of diverse nanomaterials" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "K. P. Singh" ],
        [ a foaf:Person ;
            foaf:name "S. Gupta" ] .

enm:ENM_9000254 rdfs:label "Co3O4 nanoparticle" .

pubchem:10855842 rdfs:label "nickel(3+);oxygen(2-)" .

pubchem:159423 rdfs:label "hafnium(4+);oxygen(2-)" .

<http://doi.org/10.1111/risa.12109> a sio:SIO_000176 ;
    dcterms:issued 2014 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Elisabeth A. Casman" ] ;
    dcterms:title "A Meta-Analysis of Carbon Nanotube Pulmonary Toxicity Studiesâ€”How Physical Dimensions and Impurities Affect the Toxicity of Carbon Nanotubes" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "E. A. Casman" ],
        [ a foaf:Person ;
            foaf:name "J. M. Gernand" ] .

mesh:D000084282 rdfs:label "Human keratinocyte cell line (HaCaT)"@en .

pubchem:24261 rdfs:label "dioxosilane",
        "zinc" .

pubchem:159385 rdfs:label "oxygen(2-);ytterbium(3+)" .

pubchem:160959 rdfs:label "gadolinium(3+);oxygen(2-)" .

pubchem:73971 rdfs:label "dioxocerium" .

<http://doi.org/10.1021/ci010003a> a sio:SIO_000176 ;
    dcterms:issued 2001 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "P.R. Vasudeva Rao" ] ;
    dcterms:title "QSPR Modeling for Solubility of Fullerene (C60) in Organic Solvents" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "P. R. Vasudeva Rao" ],
        [ a foaf:Person ;
            foaf:name "T. G. Srinivasan" ],
        [ a foaf:Person ;
            foaf:name "R. Natarajan" ],
        [ a foaf:Person ;
            foaf:name "N. Sivaraman" ] .

npo:NPO_1375 rdfs:label "Polymeric"@en .

<http://doi.org/10.1080/1062936X.2016.1197310> a sio:SIO_000176 ;
    dcterms:issued 2016 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Ester Papa" ] ;
    dcterms:title "Investigation of the influence of protein corona composition on gold nanoparticle bioactivity using machine learning approaches" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "J. P. Doucet" ],
        [ a foaf:Person ;
            foaf:name "E. Papa" ],
        [ a foaf:Person ;
            foaf:name "A. Sangion" ],
        [ a foaf:Person ;
            foaf:name "A. Doucet-Panaye" ] .

pubchem:14824 rdfs:label "oxo(oxomanganiooxy)manganese" .

npo:NPO_606 rdfs:label "CNT: Carbon nanotubes",
        "Single/Multiwalled nanotubes" .

<http://doi.org/10.1080/1062936X.2015.1080186> a sio:SIO_000176 ;
    dcterms:issued 2015 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Ester Papa" ] ;
    dcterms:title "Linear and non-linear modelling of the cytotoxicity of TiO2 and ZnO nanoparticles by empirical descriptors" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "J. P. Doucet" ],
        [ a foaf:Person ;
            foaf:name "A. Doucet-Panaye" ],
        [ a foaf:Person ;
            foaf:name "E. Papa" ] .

npo:NPO_729 rdfs:label "(Fe2O3)n(Fe3O4)m" .

obo:PATO_0000122 rdfs:label "Length"@en .

pubchem:10154203 rdfs:label "2-[2-(2-hydroxyethoxy)propoxy]ethanol" .

pubchem:102679 rdfs:label "4,10-dioxatetracyclo[5.5.2.02,6.08,12]tetradec-13-ene-3,5,9,11-tetrone" .

pubchem:10352850 rdfs:label "11-aminoundecane-1-thiol" .

pubchem:1045 rdfs:label "butane-1,4-diamine" .

pubchem:10946 rdfs:label "(2-chloroacetyl) 2-chloroacetate" .

pubchem:11089 rdfs:label "1,3-dioxo-2-benzofuran-5-carboxylic acid" .

pubchem:11199 rdfs:label "ethenol" .

pubchem:1148 rdfs:label "2-amino-3-(1H-indol-3-yl)propanoic acid" .

pubchem:1182 rdfs:label "2-amino-3-methylbutanoic acid" .

pubchem:12012 rdfs:label "3-methylfuran-2,5-dione" .

pubchem:12019 rdfs:label "pentan-3-amine" .

pubchem:12035 rdfs:label "(2R)-2-acetamido-3-sulfanylpropanoic acid" .

pubchem:12443 rdfs:label "4,5,6,7-tetrabromo-2-benzofuran-1,3-dione" .

pubchem:12475 rdfs:label "4,5,6,7-tetrahydro-2-benzofuran-1,3-dione" .

pubchem:12801 rdfs:label "4H-isochromene-1,3-dione" .

pubchem:12841471 rdfs:label "6-aminohexane-1-thiol" .

pubchem:14811 rdfs:label "trioxotungsten" .

pubchem:15659773 rdfs:label "3-amino-6-(hydroxymethyl)cyclohexane-1,2,4-triol" .

pubchem:15793 rdfs:label "octadecan-1-amine" .

pubchem:16217 rdfs:label "tetradecan-1-amine" .

pubchem:16402 rdfs:label "hexane-1,6-diamine" .

pubchem:17386 rdfs:label "pentadecan-1-amine" .

pubchem:19990 rdfs:label "N'-[2-[2-[2-(2-aminoethylamino)ethylamino]ethylamino]ethyl]ethane-1,2-diamine" .

pubchem:20051 rdfs:label "3-methyloxolane-2,5-dione" .

pubchem:205 rdfs:label "2-amino-3-hydroxybutanoic acid" .

pubchem:21631 rdfs:label "4-nitro-2-benzofuran-1,3-dione" .

pubchem:220977 rdfs:label "4-oxatricyclo[5.2.2.02,6]undec-8-ene-3,5-dione" .

pubchem:230976 rdfs:label "5-nitro-2-benzofuran-1,3-dione" .

pubchem:232 rdfs:label "2-amino-5-(diaminomethylideneamino)pentanoic acid" .

pubchem:239163 rdfs:label "2-(2,5-dioxooxolan-3-yl)acetic acid" .

pubchem:25160 rdfs:label "1-methyl-3,1-benzoxazine-2,4-dione" .

pubchem:25332 rdfs:label "adamantan-2-amine" .

pubchem:2733254 rdfs:label "(2-iodoacetyl) 2-iodoacetate" .

pubchem:2794246 rdfs:label "tricyclo[3.3.1.03,7]nonan-3-amine" .

pubchem:329113 rdfs:label "6-sulfanylhexanoic acid" .

pubchem:3301 rdfs:label "ethane-1,2-diamine" .

pubchem:3522585 rdfs:label "16-sulfanylhexadecanoic acid" .

pubchem:424 rdfs:label "2-aminobutanedioic acid" .

pubchem:428 rdfs:label "propane-1,3-diamine" .

pubchem:513917 rdfs:label "4-[2-(2,6-dioxomorpholin-4-yl)ethyl]morpholine-2,6-dione" .

pubchem:513918 rdfs:label "4,7-difluoro-2-benzofuran-1,3-dione" .

pubchem:5281 rdfs:label "octadecanoic acid" .

pubchem:5483 rdfs:label "2-(2-sulfanylpropanoylamino)acetic acid" .

pubchem:5603 rdfs:label "heptan-2-amine" .

pubchem:5610 rdfs:label "4-(2-aminoethyl)phenol" .

pubchem:598 rdfs:label "2-sulfanylethanesulfonic acid" .

pubchem:602 rdfs:label "2-aminopropanoic acid" .

pubchem:611 rdfs:label "2-aminopentanedioic acid" .

pubchem:6140 rdfs:label "(2S)-2-amino-3-phenylpropanoic acid" .

pubchem:617 rdfs:label "2-amino-3-hydroxypropanoic acid" .

pubchem:6268 rdfs:label "2-sulfanylbutanedioic acid" .

pubchem:6385 rdfs:label "2-methylpropan-2-amine" .

pubchem:6514 rdfs:label "3-sulfanylpropanoic acid" .

pubchem:6558 rdfs:label "2-methylpropan-1-amine" .

pubchem:65729 rdfs:label "1,1-dioxo-2,1lambda6-benzoxathiol-3-one" .

pubchem:67742 rdfs:label "2,2,3,3,3-pentafluoropropanoyl 2,2,3,3,3-pentafluoropropanoate" .

pubchem:681 rdfs:label "4-(2-aminoethyl)benzene-1,2-diol" .

pubchem:6810 rdfs:label "3a,4,7,7a-tetrahydro-2-benzofuran-1,3-dione" .

pubchem:6811 rdfs:label "2-benzofuran-1,3-dione" .

pubchem:68986 rdfs:label "2-methylbutan-2-amine" .

pubchem:69339 rdfs:label "hexadecanoyl hexadecanoate" .

pubchem:69527 rdfs:label "dodecanoyl dodecanoate" .

pubchem:69545 rdfs:label "4,5,6,7-tetrafluoro-2-benzofuran-1,3-dione" .

pubchem:70334 rdfs:label "5,6-dichloro-2-benzofuran-1,3-dione" .

pubchem:70728 rdfs:label "3,4-dichlorofuran-2,5-dione" .

pubchem:72794 rdfs:label "benzo[d][2]benzoxepine-5,7-dione" .

pubchem:738 rdfs:label "2,5-diamino-5-oxopentanoic acid" .

pubchem:74918 rdfs:label "hexanoyl hexanoate" .

pubchem:74960 rdfs:label "decanoyl decanoate" .

pubchem:750 rdfs:label "2-aminoacetic acid" .

pubchem:75498 rdfs:label "5-(1,3-dioxo-2-benzofuran-5-carbonyl)-2-benzofuran-1,3-dione" .

pubchem:75737 rdfs:label "methyl 2-amino-3-phenylpropanoate" .

pubchem:76074 rdfs:label "(2-chloro-2,2-difluoroacetyl) 2-chloro-2,2-difluoroacetate" .

pubchem:76247 rdfs:label "3,3-dimethyloxane-2,6-dione" .

pubchem:7719 rdfs:label "2-ethylhexan-1-amine" .

pubchem:78218 rdfs:label "4,7-dichloro-2-benzofuran-1,3-dione" .

pubchem:78232 rdfs:label "1,4-dioxane-2,6-dione" .

pubchem:78479 rdfs:label "N,N'-bis(2-aminoethyl)propane-1,3-diamine" .

pubchem:78480 rdfs:label "6-chloro-1H-3,1-benzoxazine-2,4-dione" .

pubchem:7894 rdfs:label "3-methylbutan-1-amine" .

pubchem:7908 rdfs:label "4-methylpentan-2-amine" .

pubchem:7918 rdfs:label "acetyl acetate" .

pubchem:7922 rdfs:label "oxolane-2,5-dione" .

pubchem:7923 rdfs:label "furan-2,5-dione" .

pubchem:7940 rdfs:label "oxane-2,6-dione" .

pubchem:79743 rdfs:label "8-oxaspiro[4.5]decane-7,9-dione" .

pubchem:79882 rdfs:label "2,2-dimethylpropan-1-amine" .

pubchem:8060 rdfs:label "pentan-1-amine" .

pubchem:8102 rdfs:label "hexan-1-amine" .

pubchem:8111 rdfs:label "N'-(2-aminoethyl)ethane-1,2-diamine" .

pubchem:8265 rdfs:label "1,7,8,9,10,10-hexachloro-4-oxatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione" .

pubchem:8326 rdfs:label "4,5,6,7-tetrachloro-2-benzofuran-1,3-dione" .

pubchem:8359 rdfs:label "1H-3,1-benzoxazine-2,4-dione" .

pubchem:85689 rdfs:label "3a,4,5,6,7,7a-hexahydro-2-benzofuran-1,3-dione" .

pubchem:86625 rdfs:label "1-adamantylmethanamine" .

pubchem:876 rdfs:label "2-amino-4-methylsulfanylbutanoic acid" .

pubchem:88069 rdfs:label "5-methyl-2-benzofuran-1,3-dione" .

pubchem:95411 rdfs:label "(4-acetyloxy-2,5-dioxooxolan-3-yl) acetate" .

pubchem:95738 rdfs:label "4-sulfanylbenzoic acid" .

pubchem:96196 rdfs:label "4-oxatricyclo[5.2.1.02,6]decane-3,5-dione" .

pubchem:96580 rdfs:label "4-hydroxy-2-benzofuran-1,3-dione" .

pubchem:97914 rdfs:label "S-(2,5-dioxooxolan-3-yl) ethanethioate" .

pubchem:9845 rdfs:label "(2,2,2-trifluoroacetyl) 2,2,2-trifluoroacetate" .

pubchem:98484 rdfs:label "4,10-dioxatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione" .

pubchem:994 rdfs:label "2-amino-3-phenylpropanoic acid" .

npo:NPO_1548 rdfs:label "Fe3O4" .

obo:PATO_0001334 rdfs:label "Diameter"@en .

pubchem:1133 rdfs:label "2-sulfanylacetic acid" .

pubchem:543502 rdfs:label "11-sulfanylundecanoic acid" .

pubchem:5974 rdfs:label "hexadecyl(trimethyl)azanium;bromide" .

mesh:D000072283 rdfs:label "An adenocarcinoma cell line (human lung epithelial cells)"@en .

rcd:X7A8D rdfs:label "Lung L2 (rat)"@en .

pubchem:31348 rdfs:label "2-hydroxypropane-1,2,3-tricarboxylate" .

<http://doi.org/10.1039/c6ra06159a> a sio:SIO_000176 ;
    dcterms:issued 2016 ;
    dcterms:mediator [ a foaf:Person ;
            foaf:name "Guangchao Chen" ] ;
    dcterms:title "Development of nanostructureâ€“activity relationships assisting the nanomaterial hazard categorization for risk assessment and regulatory decision-making" ;
    foaf:maker [ a foaf:Person ;
            foaf:name "G. Chen" ],
        [ a foaf:Person ;
            foaf:name "W. J. G. M. Peijnenburg" ],
        [ a foaf:Person ;
            foaf:name "V. Kovalishyn" ],
        [ a foaf:Person ;
            foaf:name "M. G. Vijver" ] .

npo:NPO_1846 rdfs:label "Phosphate Buffer Saline"@en .

obo:CHEBI_15377 rdfs:label "Water"@en .

npo:NPO_401 rdfs:label "Au nanopartice" .

pubchem:14776 rdfs:label "oxo(oxobismuthanyloxy)bismuthane" .

pubchem:518712 rdfs:label "oxo(oxovanadiooxy)vanadium" .

npo:NPO_461 rdfs:label "Fiber",
        "Rod" .

pubchem:14829 rdfs:label "oxocopper" .

pubchem:14794 rdfs:label "antimony(3+);oxygen(2-)" .

enm:ENM_0000118 rdfs:label "Cobalt (II) oxide nanoparticle" .

pubchem:150906 rdfs:label "indium(3+);oxygen(2-)" .

pubchem:166955 rdfs:label "chromium(3+);oxygen(2-)" .

pubchem:29131 rdfs:label "dioxotin" .

pubchem:62762 rdfs:label "dioxozirconium" .

mesh:D004926 rdfs:label "Bacteria Escherichia Coli (E. Coli)"@en .

pubchem:14805 rdfs:label "oxonickel" .

pubchem:159375 rdfs:label "oxygen(2-);yttrium(3+)" .

pubchem:157925 rdfs:label "lanthanum(3+);oxygen(2-)" .

pubchem:587821 rdfs:label "2-amino-2-(4-chlorophenyl)acetic acid" .

pubchem:866 rdfs:label "2,6-diaminohexanoic acid" .

pubchem:8926 rdfs:label "hexadecan-1-amine" .

sty:T001 rdfs:label "Organism"@en .

obo:CHEBI_30187 rdfs:label "Al2O3" .

npo:NPO_1373 rdfs:label "SiO2" .

obo:OBI_0100026 rdfs:label "In vivo" .

npo:NPO_1550 rdfs:label "Fe2O3" .

npo:NPO_1486 rdfs:label "R-TiO2",
        "TiO2" .

npo:NPO_1542 rdfs:label "ZnO" .

npo:NPO_286 rdfs:label "Pseudo-spherical",
        "Spherical" .

npo:NPO_836 rdfs:label "Carbon-based"@en .

npo:NPO_1384 rdfs:label "Metal"@en .

sio:SIO_000176 rdfs:label "Reference" .

npo:NPO_1541 rdfs:label "Metal Oxide"@en .

obo:OBI_0001285 rdfs:label "In vitro" .

sty:T025 rdfs:label "Cell"@en .

npo:NPO_1694 rdfs:label "Particle size"@en .

nci:C16275 rdfs:label "Algorithm"@en .

npo:NPO_707 rdfs:label "Nanoparticle"@en .

bao:BAO_0000179 rdfs:label "Endpoint"@en .

npo:NPO_1962 rdfs:label "Surface coating"@en .

@prefix dc:    <http://purl.org/dc/elements/1.1/> .
@prefix dct:   <http://purl.org/dc/terms/> .
@prefix foaf:  <http://xmlns.com/foaf/0.1/> .
@prefix rdfs:  <http://www.w3.org/2000/01/rdf-schema#> .
@prefix sbd:   <https://www.sbd4nano.eu/rdf/#> .
@prefix sbdbel:  <https://www.sbd4nano.eu/bel/#> .
@prefix xsd:   <http://www.w3.org/2001/XMLSchema#> .
@prefix void:    <http://rdfs.org/ns/void#> .

@prefix MOx: <http://purl.bioontology.org/ontology/npo#NPO_1541> .
@prefix Metal: <http://purl.bioontology.org/ontology/npo#NPO_1384> .
@prefix NP: <http://purl.bioontology.org/ontology/npo#NPO_707> .

<https://nanosolveit.eu/resources/tools-services/>
 a                    void:DatasetDescription ;
 dct:title            "NanoSolveIT Tools"@en ;
 dct:license          <http://creativecommons.org/publicdomain/zero/1.0/> ;
 dc:source            <https://nanosolveit.eu/resources/tools-services/> ;
 foaf:img             <https://nanosolveit.eu/wp-content/uploads/2019/06/NanoSolveIT-300x114-Transparent-Half.png> .

<http://enaloscloud.novamechanics.com/EnalosWebApps/ZetaPotential/> a sbd:Model ;
  dc:source <https://nanosolveit.eu/resources/tools-services/> ;
  rdfs:label "PhysChem: Zeta potential NanoXtract model" ;
  dc:description "A novel nanoinformatics predictive model using new computational descriptors from TEM images for the prediction of NMs properties, such as zeta potential."@en ;
  dct:license <http://example.com/unknown> ;
  foaf:page <http://enaloscloud.novamechanics.com/EnalosWebApps/ZetaPotential/> ;
  sbdbel:NP MOx:, Metal: .

<https://cellviability.cloud.nanosolveit.eu/> a sbd:Model ;
  dc:source <https://nanosolveit.eu/resources/tools-services/> ;
  rdfs:label "NanoSolveIT Cytotoxicity (Cell Viability) Prediction for Metal Oxide NPs"@en ;
  dc:description "A tool to predict the cytotoxicity of metal oxide nanomaterials to human bronchial epithelial (BEAS-2B) and murine myeloid (RAW 264.7) cell lines using single parameter (% cell viability) adenosine triphosphate (ATP) and lactate dehydrogenase (LDH) assays, based on selected physicochemical, atomistic and molecular descriptors."@en ;
  dct:license <http://example.com/unknown> ;
  foaf:page <https://cellviability.cloud.nanosolveit.eu/> ;
  sbdbel:NP MOx: .

<https://deepdaph.cloud.nanosolveit.eu/> a sbd:Model ;
  dc:source <https://nanosolveit.eu/resources/tools-services/> ;
  rdfs:label "DeepDaph"@en ;
  dc:description "A workflow applying two different deep learning architectures on microscopic images of Daphnia magna is proposed that can automatically detect possible malformations, such as effects on the length of the tail, and the overall size, and uncommon lipid concentrations and lipid deposit shapes, which are due to direct or parental exposure to ENMs."@en ;
  dct:license <http://example.com/unknown> ;
  foaf:page <https://deepdaph.cloud.nanosolveit.eu/> ;
  sbdbel:NP NP: .

<https://nanofase.cloud.nanosolveit.eu/> a sbd:Model ;
  dc:source <https://nanosolveit.eu/resources/tools-services/> ;
  rdfs:label "NanoFASE Soil-water-organism model"@en ;
  dct:license <http://example.com/unknown> ;
  foaf:page <https://nanofase.cloud.nanosolveit.eu/> .

<https://aerosol.cloud.nanosolveit.eu/> a sbd:Model ;
  dc:source <https://nanosolveit.eu/resources/tools-services/> ;
  rdfs:label "NanoSolveIT Tool for Assessment of Human Exposure to Nanomaterials"@en ;
  dct:license <http://example.com/unknown> ;
  foaf:page <https://aerosol.cloud.nanosolveit.eu/> ;
  sbdbel:NP NP: .

<https://funmappone.cloud.nanosolveit.eu/> a sbd:Model ;
  dc:source <https://nanosolveit.eu/resources/tools-services/> ;
  rdfs:label "FunMappOne"@en ;
  dc:description "FunMappOne is a R-shiny graphical tool that takes in input multiple lists of human or mouse genes, optionally along with their related modification magnitudes, computes the enriched annotations from Gene Ontology, Kyoto Encyclopedia of Genes and Genomes, or Reactome databases, and reports interactive maps of functional terms and pathways organized in rational groups. FunMappOne allows a fast and convenient comparison of multiple experiments and an easy way to interpret results."@en ;
  dct:license <http://example.com/unknown> ;
  foaf:page <https://funmappone.cloud.nanosolveit.eu/> .
@prefix dc:    <http://purl.org/dc/elements/1.1/> .
@prefix dct:   <http://purl.org/dc/terms/> .
@prefix foaf:  <http://xmlns.com/foaf/0.1/> .
@prefix rdfs:  <http://www.w3.org/2000/01/rdf-schema#> .
@prefix sbd:   <https://www.sbd4nano.eu/rdf/#> .
@prefix sbdbel:  <https://www.sbd4nano.eu/bel/#> .
@prefix xsd:   <http://www.w3.org/2001/XMLSchema#> .
@prefix void:    <http://rdfs.org/ns/void#> .

@prefix TiO2:  <http://purl.obolibrary.org/obo/CHEBI_51050> .
@prefix CBNP:  <http://purl.obolibrary.org/obo/CHEBI_133602> .
@prefix NM105: <http://purl.enanomapper.org/onto/ENM_9000204> .
@prefix NM110: <http://purl.enanomapper.org/onto/ENM_9000205> .
@prefix NM403: <http://purl.enanomapper.org/onto/ENM_9000230> .
@prefix ZnO:   <http://purl.bioontology.org/ontology/npo#NPO_1542> .
@prefix MOx:   <http://purl.bioontology.org/ontology/npo#NPO_1541> .
@prefix Fe2O3: <http://purl.bioontology.org/ontology/npo#NPO_1550> .
@prefix CNT:   <http://purl.bioontology.org/ontology/npo#NPO_606> .
@prefix SWCNT: <http://purl.bioontology.org/ontology/npo#NPO_943> .
@prefix MWCNT: <http://purl.bioontology.org/ontology/npo#NPO_354> .

<https://h2020-sbd4nano.github.io/sbd-data-smartnanotox/>
 a                    void:DatasetDescription ;
 dct:title            "SmartNanoTox Transcriptomics datasets"@en ;
 dc:source            <http://www.smartnanotox.eu/?page_id=131> ;
 foaf:img             <https://www.ucd.ie/sbi/t4media/SNT%20870x400.png> ;
 dct:license          <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/geo:GSE156457> a sbd:Dataset ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-smartnanotox/> ;
  foaf:page <https://identifiers.org/geo:GSE156457> ;
  dct:license <https://www.wikidata.org/entity/Q50423863> ;
  rdfs:label "Transcriptomic study of NR8383 rat macrophages cells following exposure to Printex90"@en ;
  sbdbel:NP CBNP: .

<https://identifiers.org/geo:GSE156458> a sbd:Dataset ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-smartnanotox/> ;
  foaf:page <https://identifiers.org/geo:GSE156458> ;
  dct:license <https://www.wikidata.org/entity/Q50423863> ;
  rdfs:label "Transcriptomic study of NR8383 rat macrophages cells in control condition (DMEM culture medium supplemented with 10% of fetal bovine serum)"@en .

<https://identifiers.org/geo:GSE156489> a sbd:Dataset ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-smartnanotox/> ;
  foaf:page <https://identifiers.org/geo:GSE156489> ;
  dct:license <https://www.wikidata.org/entity/Q50423863> ;
  rdfs:label "Transcriptomic study of NR8383 rat macrophages cells in control condition (water, H2O)"@en .

<https://identifiers.org/geo:GSE156493> a sbd:Dataset ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-smartnanotox/> ;
  foaf:page <https://identifiers.org/geo:GSE156493> ;
  dct:license <https://www.wikidata.org/entity/Q50423863> ;
  rdfs:label "Transcriptomic study of NR8383 rat macrophages cells in submerged condition (control)"@en .

<https://identifiers.org/geo:GSE156509> a sbd:Dataset ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-smartnanotox/> ;
  foaf:page <https://identifiers.org/geo:GSE156509> ;
  dct:license <https://www.wikidata.org/entity/Q50423863> ;
  rdfs:label "Transcriptomic study of NR8383 rat macrophages cells following exposure to TiO2 (NM105, p25 anatase/rutile)"@en ;
  sbdbel:NP NM105: .

<https://identifiers.org/geo:GSE156511> a sbd:Dataset ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-smartnanotox/> ;
  foaf:page <https://identifiers.org/geo:GSE156511> ;
  dct:license <https://www.wikidata.org/entity/Q50423863> ;
  rdfs:label "Transcriptomic study of NR8383 rat macrophages cells following exposure to NM403 carbon nanotubes"@en ;
  sbdbel:NP NM403: .

<https://identifiers.org/geo:GSE156564> a sbd:Dataset ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-smartnanotox/> ;
  foaf:page <https://identifiers.org/geo:GSE156564> ;
  dct:license <https://www.wikidata.org/entity/Q50423863> ;
  rdfs:label "Transcriptomic study of NR8383 rat macrophages cells following exposure to TiO2 (NRCWE001)"@en ;
  sbdbel:NP TiO2: .

<https://identifiers.org/geo:GSE156571> a sbd:Dataset ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-smartnanotox/> ;
  foaf:page <https://identifiers.org/geo:GSE156571> ;
  dct:license <https://www.wikidata.org/entity/Q50423863> ;
  rdfs:label "Transcriptomic study of NR8383 rat macrophages cells following exposure to multi-walled carbon nanotubes (NRCWE006)"@en ;
  sbdbel:NP MWCNT: .

<https://identifiers.org/geo:GSE156573> a sbd:Dataset ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-smartnanotox/> ;
  foaf:page <https://identifiers.org/geo:GSE156573> ;
  dct:license <https://www.wikidata.org/entity/Q50423863> ;
  rdfs:label "Transcriptomic study of NR8383 rat macrophages cells following exposure to NiZnFe2O4."@en .

<https://identifiers.org/geo:GSE156587> a sbd:Dataset ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-smartnanotox/> ;
  foaf:page <https://identifiers.org/geo:GSE156587> ;
  dct:license <https://www.wikidata.org/entity/Q50423863> ;
  rdfs:label "Transcriptomic study of NR8383 rat macrophages cells following exposure to Fe2O3 (NRCWE018)."@en ;
  sbdbel:NP Fe2O3: .

<https://identifiers.org/geo:GSE156659> a sbd:Dataset ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-smartnanotox/> ;
  foaf:page <https://identifiers.org/geo:GSE156659> ;
  dct:license <https://www.wikidata.org/entity/Q50423863> ;
  rdfs:label "Transcriptomic study of NR8383 rat macrophages cells following exposure to zinc iron oxide (ZnFe2O4, NRCWE021)"@en .

<https://identifiers.org/geo:GSE156660> a sbd:Dataset ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-smartnanotox/> ;
  foaf:page <https://identifiers.org/geo:GSE156660> ;
  dct:license <https://www.wikidata.org/entity/Q50423863> ;
  rdfs:label "Transcriptomic study of NR8383 rat macrophages cells following exposure to COOH-functionalized carbon nanotubes (NRCWE042)"@en ;
  sbdbel:NP CNT: .

<https://identifiers.org/geo:GSE156666> a sbd:Dataset ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-smartnanotox/> ;
  foaf:page <https://identifiers.org/geo:GSE156666> ;
  dct:license <https://www.wikidata.org/entity/Q50423863> ;
  rdfs:label "Transcriptomic study of NR8383 rat macrophages cells following exposure to NH2-functionalized carbon nanotubes (NRCWE049)"@en ;
  sbdbel:NP CNT: .

<https://identifiers.org/geo:GSE156691> a sbd:Dataset ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-smartnanotox/> ;
  foaf:page <https://identifiers.org/geo:GSE156691> ;
  dct:license <https://www.wikidata.org/entity/Q50423863> ;
  rdfs:label "Transcriptomic study of NR8383 rat macrophages cells following exposure to pristine single-walled carbon nanotubes (NRCWE055)"@en ;
  sbdbel:NP SWCNT: .

<https://identifiers.org/geo:GSE156694> a sbd:Dataset ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-smartnanotox/> ;
  foaf:page <https://identifiers.org/geo:GSE156694> ;
  dct:license <https://www.wikidata.org/entity/Q50423863> ;
  rdfs:label "Transcriptomic study of NR8383 rat macrophages cells following exposure to carbon black (Printex 90)"@en ;
  sbdbel:NP CBNP: .

<https://identifiers.org/geo:GSE156695> a sbd:Dataset ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-smartnanotox/> ;
  foaf:page <https://identifiers.org/geo:GSE156695> ;
  dct:license <https://www.wikidata.org/entity/Q50423863> ;
  rdfs:label "Transcriptomic study of NR8383 rat macrophages cells following exposure to ZnO 4 µg/mL and ZnO 16 µg/mL"@en ;
  sbdbel:NP ZnO: .

<https://identifiers.org/geo:GSE117487> a sbd:Dataset ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-smartnanotox/> ;
  foaf:page <https://identifiers.org/geo:GSE117487> ;
  dct:license <https://www.wikidata.org/entity/Q50423863> ;
  rdfs:label "Effect of cell passage number on gene expression in NR8383 macrophages"@en .

<https://identifiers.org/geo:GSE99997> a sbd:Dataset ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-smartnanotox/> ;
  foaf:page <https://identifiers.org/geo:GSE99997> ;
  dct:license <https://www.wikidata.org/entity/Q50423863> ;
  rdfs:label "TiO2-induced gene expression profiles in rat lung: a subacute inhalation study"@en ;
  sbdbel:NP TiO2: .

<https://identifiers.org/geo:GSE99435> a sbd:Dataset ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-smartnanotox/> ;
  foaf:page <https://identifiers.org/geo:GSE99435> ;
  dct:license <https://www.wikidata.org/entity/Q50423863> ;
  rdfs:label "Transcriptomic study of PMA-differentiated THP-1 cells following exposure to zinc oxide nanoparticles NM110"@en ;
  sbdbel:NP NM110: .

<https://identifiers.org/geo:GSE97852> a sbd:Dataset ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-smartnanotox/> ;
  foaf:page <https://identifiers.org/geo:GSE97852> ;
  dct:license <https://www.wikidata.org/entity/Q50423863> ;
  rdfs:label "Transcriptomic study of NR8383 cells following exposure to zinc oxide nanoparticles NM110"@en ;
  sbdbel:NP NM110: .
#402 triples detected in the JSON-LD
@prefix dc:    <http://purl.org/dc/elements/1.1/> .
@prefix dct:   <http://purl.org/dc/terms/> .
@prefix foaf:  <http://xmlns.com/foaf/0.1/> .
@prefix rdfs:  <http://www.w3.org/2000/01/rdf-schema#> .
@prefix sbd:   <https://www.sbd4nano.eu/rdf/#> .
@prefix xsd:   <http://www.w3.org/2001/XMLSchema#> .
@prefix void:  <http://rdfs.org/ns/void#> .

<https://search.data.enanomapper.net/>
 a                    void:DatasetDescription ;
 dc:source            <https://search.data.enanomapper.net/> ;
 dct:title            "Open datasets hosted at the Nanosafety Data Interface"@en ;
 foaf:img             <https://search.data.enanomapper.net/assets/img/logo.png> ;
 dct:license          <http://creativecommons.org/publicdomain/zero/1.0/> . # license of this metadata

<https://search.data.enanomapper.net/about/calibrate> a sbd:Database ;
  dc:source <https://search.data.enanomapper.net/> ;
  rdfs:label "calibrate - eNanoMapper database"@en ;
  dc:description "H2020 caLIBRAte project data: Performance testing, calibration and implementation of a next generation system-of-systems Risk Governance Framework for nanomaterials"@en ;
  dct:license <https://search.data.enanomapper.net/about/calibrate> ;
  foaf:page <https://search.data.enanomapper.net/projects/calibrate> .

<https://search.data.enanomapper.net/about/enanomapper> a sbd:Database ;
  dc:source <https://search.data.enanomapper.net/> ;
  rdfs:label "enanomapper - eNanoMapper database"@en ;
  dc:description "FP7 eNanoMapper project data: A Database and Ontology Framework for Nanomaterials Design and Safety Assessment"@en ;
  dct:license <https://search.data.enanomapper.net/about/enanomapper> ;
  foaf:page <https://search.data.enanomapper.net/projects/enanomapper> .

<https://search.data.enanomapper.net/about/gracious> a sbd:Database ;
  dc:source <https://search.data.enanomapper.net/> ;
  rdfs:label "gracious - eNanoMapper database"@en ;
  dc:description "H2020 GRACIOUS project data: Grouping materials for Risk Assessment"@en ;
  dct:license <https://search.data.enanomapper.net/about/gracious> ;
  foaf:page <https://search.data.enanomapper.net/projects/gracious> .

<https://search.data.enanomapper.net/about/nanoreg> a sbd:Database ;
  dc:source <https://search.data.enanomapper.net/> ;
  rdfs:label "nanoreg - eNanoMapper database"@en ;
  dc:description "FP7 NANoREG project data: A common European approach to the regulatory testing of nanomaterials"@en ;
  dct:license <https://search.data.enanomapper.net/about/nanoreg> ;
  foaf:page <https://search.data.enanomapper.net/projects/nanoreg> .

<https://search.data.enanomapper.net/about/nanoreg2> a sbd:Database ;
  dc:source <https://search.data.enanomapper.net/> ;
  rdfs:label "nanoreg2 - eNanoMapper database"@en ;
  dc:description "H2020 NanoReg2 project data: Development and implementation of Grouping and Safe-by-Design approaches within regulatory frameworks"@en ;
  dct:license <https://search.data.enanomapper.net/about/nanoreg2> ;
  foaf:page <https://search.data.enanomapper.net/projects/nanoreg2> .

#1732 triples detected in the JSON-LD
@prefix dc:    <http://purl.org/dc/elements/1.1/> .
@prefix dct:   <http://purl.org/dc/terms/> .
@prefix foaf:  <http://xmlns.com/foaf/0.1/> .
@prefix rdfs:  <http://www.w3.org/2000/01/rdf-schema#> .
@prefix sbd:   <https://www.sbd4nano.eu/rdf/#> .
@prefix xsd:   <http://www.w3.org/2001/XMLSchema#> .
@prefix void:  <http://rdfs.org/ns/void#> .

<https://search.data.enanomapper.net/closed/>
 a                    void:DatasetDescription ;
 dc:source            <https://search.data.enanomapper.net/> ;
 dct:title            "Closed datasets hosted at the Nanosafety Data Interface"@en ;
 foaf:img             <https://search.data.enanomapper.net/assets/img/logo.png> .

<https://search.data.enanomapper.net/about/aurora> a sbd:Database ;
  dc:source <https://search.data.enanomapper.net/closed/> ;
  rdfs:label "aurora - eNanoMapper database"@en ;
  dc:description "H2020 AURORA project data: AURORA - Developing an actionable European roadmap for early-life health risk assessment of micro- and nanoplastic (MNP) pollution"@en ;
  dct:license <https://search.data.enanomapper.net/about/aurora> ;
  foaf:page <https://search.data.enanomapper.net/projects/aurora> .

<https://search.data.enanomapper.net/about/biorima> a sbd:Database ;
  dc:source <https://search.data.enanomapper.net/closed/> ;
  rdfs:label "biorima - eNanoMapper database"@en ;
  dc:description "H2020 BIORIMA project data: Risk Management of Biomaterials"@en ;
  dct:license <https://search.data.enanomapper.net/about/biorima> ;
  foaf:page <https://search.data.enanomapper.net/projects/biorima> .

<https://search.data.enanomapper.net/about/charisma> a sbd:Database ;
  dc:source <https://search.data.enanomapper.net/closed/> ;
  rdfs:label "charisma - eNanoMapper database"@en ;
  dc:description "H2020 CHARISMA project data: Characterization and HARmonization for Industrial Standardisation of advanced MAterials"@en ;
  dct:license <https://search.data.enanomapper.net/about/charisma> ;
  foaf:page <https://search.data.enanomapper.net/projects/charisma> .

<https://search.data.enanomapper.net/about/cusp> a sbd:Database ;
  dc:source <https://search.data.enanomapper.net/closed/> ;
  rdfs:label "cusp - eNanoMapper database"@en ;
  dc:description "CUSP project data: CUSP – the European research cluster to understand the health impacts of micro- and nanoplastics (MNPs)"@en ;
  dct:license <https://search.data.enanomapper.net/about/cusp> ;
  foaf:page <https://search.data.enanomapper.net/projects/cusp> .

<https://search.data.enanomapper.net/about/gov4nano> a sbd:Database ;
  dc:source <https://search.data.enanomapper.net/closed/> ;
  rdfs:label "gov4nano - eNanoMapper database"@en ;
  dc:description "H2020 Gov4Nano project data: Implementation of Risk Governance: meeting the needs of nanotechnology"@en ;
  dct:license <https://search.data.enanomapper.net/about/gov4nano> ;
  foaf:page <https://search.data.enanomapper.net/projects/gov4nano> .

<https://search.data.enanomapper.net/about/harmless> a sbd:Database ;
  dc:source <https://search.data.enanomapper.net/closed/> ;
  rdfs:label "harmless - eNanoMapper database"@en ;
  dc:description "H2020 HARMLESS project data: Advanced High Aspect Ratio and Multicomponent materials: towards comprehensive intelLigent tEsting and Safe by design Strategies"@en ;
  dct:license <https://search.data.enanomapper.net/about/harmless> ;
  foaf:page <https://search.data.enanomapper.net/projects/harmless> .

<https://search.data.enanomapper.net/about/imptox> a sbd:Database ;
  dc:source <https://search.data.enanomapper.net/closed/> ;
  rdfs:label "imptox - eNanoMapper database"@en ;
  dc:description "H2020 IMPTOX project data: An innovative analytical platform to investigate the effect and toxicity of micro and nano plastics combined with environmental contaminants on the risk of allergic disease in preclinical and clinical models"@en ;
  dct:license <https://search.data.enanomapper.net/about/imptox> ;
  foaf:page <https://search.data.enanomapper.net/projects/imptox> .

<https://search.data.enanomapper.net/about/nanoinformatix> a sbd:Database ;
  dc:source <https://search.data.enanomapper.net/closed/> ;
  rdfs:label "nanoinformatix - eNanoMapper database"@en ;
  dc:description "H2020 NanoinformaTIX project data: Development and Implementation of a Sustainable Modelling Platform for NanoInformatics"@en ;
  dct:license <https://search.data.enanomapper.net/about/nanoinformatix> ;
  foaf:page <https://search.data.enanomapper.net/projects/nanoinformatix> .

<https://search.data.enanomapper.net/about/patrols> a sbd:Database ;
  dc:source <https://search.data.enanomapper.net/closed/> ;
  rdfs:label "patrols - eNanoMapper database"@en ;
  dc:description "H2020 PATROLS project data: PATROLS - Physiologically Anchored Tools for Realistic nanOmateriaL hazard aSsessment"@en ;
  dct:license <https://search.data.enanomapper.net/about/patrols> ;
  foaf:page <https://search.data.enanomapper.net/projects/patrols> .

<https://search.data.enanomapper.net/about/plasticfate> a sbd:Database ;
  dc:source <https://search.data.enanomapper.net/closed/> ;
  rdfs:label "plasticfate - eNanoMapper database"@en ;
  dc:description "H2020 PlasticFatE project data: Plastics fate and effects in the human body"@en ;
  dct:license <https://search.data.enanomapper.net/about/plasticfate> ;
  foaf:page <https://search.data.enanomapper.net/projects/plasticfate> .

<https://search.data.enanomapper.net/about/plasticheal> a sbd:Database ;
  dc:source <https://search.data.enanomapper.net/closed/> ;
  rdfs:label "plasticheal - eNanoMapper database"@en ;
  dc:description "H2020 PLASTICHEAL project data: Innovative tools to study the impact and mode of action of micro and nanoplastics on human health: towards a knowledge base for risk assessment"@en ;
  dct:license <https://search.data.enanomapper.net/about/plasticheal> ;
  foaf:page <https://search.data.enanomapper.net/projects/plasticheal> .

<https://search.data.enanomapper.net/about/polyrisk> a sbd:Database ;
  dc:source <https://search.data.enanomapper.net/closed/> ;
  rdfs:label "polyrisk - eNanoMapper database"@en ;
  dc:description "H2020 POLYRISK project data: POLYRISK - Understanding human exposure and health hazard of micro- and nanoplastic contaminants in our environment"@en ;
  dct:license <https://search.data.enanomapper.net/about/polyrisk> ;
  foaf:page <https://search.data.enanomapper.net/projects/polyrisk> .

<https://search.data.enanomapper.net/about/riskgone> a sbd:Database ;
  dc:source <https://search.data.enanomapper.net/closed/> ;
  rdfs:label "riskgone - eNanoMapper database"@en ;
  dc:description "H2020 RiskGone project data: Science-based Risk Governance of Nano-Technology"@en ;
  dct:license <https://search.data.enanomapper.net/about/riskgone> ;
  foaf:page <https://search.data.enanomapper.net/projects/riskgone> .

<https://search.data.enanomapper.net/about/sabydoma> a sbd:Database ;
  dc:source <https://search.data.enanomapper.net/closed/> ;
  rdfs:label "sabydoma - eNanoMapper database"@en ;
  dc:description "H2020 SABYDOMA project data: Safety BY Design Of nanoMaterials - From Lab Manufacture to Governance and Communication: Progressing Up the TRL Ladder"@en ;
  dct:license <https://search.data.enanomapper.net/about/sabydoma> ;
  foaf:page <https://search.data.enanomapper.net/projects/sabydoma> .

<https://search.data.enanomapper.net/about/sabyna> a sbd:Database ;
  dc:source <https://search.data.enanomapper.net/closed/> ;
  rdfs:label "sabyna - eNanoMapper database"@en ;
  dc:description "H2020 SAbyNA project data: SAbyNA - Simple, robust and cost-effective approaches to guide industry in the development of safer nanomaterials and nano-enabled products"@en ;
  dct:license <https://search.data.enanomapper.net/about/sabyna> ;
  foaf:page <https://search.data.enanomapper.net/projects/sabyna> .

<https://search.data.enanomapper.net/about/sbd4nano> a sbd:Database ;
  dc:source <https://search.data.enanomapper.net/closed/> ;
  rdfs:label "sbd4nano - eNanoMapper database"@en ;
  dc:description "H2020 SBD4Nano project data: Computing infrastructure for the definition, performance testing and implementation of safe-by-design approaches in nanotechnology supply chains"@en ;
  dct:license <https://search.data.enanomapper.net/about/sbd4nano> ;
  foaf:page <https://search.data.enanomapper.net/projects/sbd4nano> .

<https://search.data.enanomapper.net/about/sunshine> a sbd:Database ;
  dc:source <https://search.data.enanomapper.net/closed/> ;
  rdfs:label "sunshine - eNanoMapper database"@en ;
  dc:description "H2020 SUNSHINE project data: SUNSHINE - Safe and Sustainable Design for Advanced Materials"@en ;
  dct:license <https://search.data.enanomapper.net/about/sunshine> ;
  foaf:page <https://search.data.enanomapper.net/projects/sunshine> .

@prefix enm:    <http://purl.enanomapper.org/onto/> .
@prefix npo:    <http://purl.bioontology.org/ontology/npo#> .
@prefix obo:    <http://purl.obolibrary.org/obo/> .
@prefix owl:    <http://www.w3.org/2002/07/owl#> .
@prefix rdf:    <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix rdfs:   <http://www.w3.org/2000/01/rdf-schema#> .
@prefix sbdbel: <https://www.sbd4nano.eu/bel/#> .
@prefix xsd:    <http://www.w3.org/2001/XMLSchema#> .

<https://search.data.enanomapper.net/about/enpra>
        sbdbel:NP  obo:CHEBI_59999 , npo:NPO_1892 , npo:NPO_1542 , npo:NPO_354 , obo:CHEBI_51050 .

<https://search.data.enanomapper.net/about/nanotest>
        sbdbel:NP  npo:NPO_1559 , obo:CHEBI_51050 , npo:NPO_1373 , npo:NPO_1548 .

<https://search.data.enanomapper.net/about/calibrate>
        sbdbel:NP  obo:CHEBI_82297 , obo:CHEBI_59999 , npo:NPO_1544 , npo:NPO_1373 .

<https://search.data.enanomapper.net/projects/nanoreg2>
        sbdbel:NP  npo:NPO_199 , enm:ENM_9000005 , enm:ENM_9000006 , obo:CHEBI_133326 , npo:NPO_1892 , npo:NPO_354 , npo:NPO_1542 , npo:NPO_1373 , obo:CHEBI_51050 .

<https://search.data.enanomapper.net/projects/riskgone>
        sbdbel:NP  npo:NPO_354 , npo:NPO_1892 , npo:NPO_1544 , enm:ENM_9000257 , npo:NPO_401 , npo:NPO_1542 , obo:CHEBI_51050 .

<https://search.data.enanomapper.net/projects/gracious/>
        sbdbel:NP  npo:NPO_1542 , obo:CHEBI_46727 , npo:NPO_1550 , obo:CHEBI_133326 , npo:NPO_1892 , npo:NPO_126 , enm:ENM_9000006 , obo:CHEBI_51050 , npo:NPO_354 , obo:CHEBI_59999 , npo:NPO_589 , obo:CHEBI_133349 , obo:CHEBI_82297 , npo:NPO_1373 , npo:NPO_1544 , enm:ENM_9000073 , npo:NPO_1375 .

<https://search.data.enanomapper.net/about/nanoreg>
        sbdbel:NP  npo:NPO_1542 , npo:NPO_126 , obo:CHEBI_3311 , npo:NPO_1550 , enm:ENM_9000006 , enm:ENM_9000007 , npo:NPO_606 , obo:CHEBI_133337 , obo:CHEBI_133340 , npo:NPO_157 , npo:NPO_401 , obo:CHEBI_59999 , obo:CHEBI_133333 , obo:CHEBI_18246 , obo:CHEBI_51135 , obo:CHEBI_133349 , obo:CHEBI_33418 , npo:NPO_1373 , npo:NPO_1892 , obo:CHEBI_51050 , obo:CHEBI_133326 , npo:NPO_943 , npo:NPO_354 .

<https://search.data.enanomapper.net/projects/patrols/>
        sbdbel:NP  npo:NPO_1544 , enm:ENM_9000006 , obo:CHEBI_59999 , npo:NPO_1892 , npo:NPO_1542 , obo:CHEBI_51050 , obo:CHEBI_133326 , obo:CHEBI_46727 .

<https://search.data.enanomapper.net/projects/calibrate/>
        sbdbel:NP  obo:CHEBI_82297 , obo:CHEBI_59999 , npo:NPO_1544 , npo:NPO_1373 .

<https://search.data.enanomapper.net/projects/nanoinformatix>
        sbdbel:NP  npo:NPO_401 , npo:NPO_1542 , npo:NPO_1892 , npo:NPO_1544 , npo:NPO_1373 , enm:ENM_9000006 , obo:CHEBI_51050 , npo:NPO_354 .

<https://search.data.enanomapper.net/projects/omics/>
        sbdbel:NP  enm:ENM_9000239 , npo:NPO_401 , obo:CHEBI_33418 , npo:NPO_1373 , npo:NPO_1374 , obo:ENVO_00002008 , obo:CHEBI_46727 , npo:NPO_589 , npo:NPO_371 , obo:CHEBI_51050 , npo:NPO_965 , obo:CHEBI_132889 , npo:NPO_729 , npo:NPO_943 , npo:NPO_707 , npo:NPO_1544 , npo:NPO_354 , obo:CHEBI_131897 , enm:ENM_9000005 , npo:NPO_1542 , obo:CHEBI_50595 , enm:ENM_9000006 , obo:CHEBI_50596 , obo:ENVO_02000102 , npo:NPO_1892 , obo:CHEBI_82297 , obo:ENVO_00002985 , enm:ENM_9000008 , npo:NPO_122 , obo:ENVO_01000060 , obo:CHEBI_33416 , enm:ENM_9000254 , npo:NPO_126 , obo:CHEBI_46661 .

<https://search.data.enanomapper.net/projects/sbd4nano>
        sbdbel:NP  obo:CHEBI_59999 , obo:CHEBI_50814 , obo:CHEBI_132889 , npo:NPO_1373 .

<https://search.data.enanomapper.net/about/sanowork>
        sbdbel:NP  obo:CHEBI_82297 , obo:CHEBI_46666 , npo:NPO_1373 , npo:NPO_606 , enm:ENM_9000241 , npo:NPO_1892 , obo:CHEBI_51050 .

<https://search.data.enanomapper.net/about/marina>
        sbdbel:NP  obo:CHEBI_133326 , obo:CHEBI_59999 , obo:CHEBI_16412 , npo:NPO_1892 , npo:NPO_1542 , npo:NPO_354 , npo:NPO_1373 , obo:CHEBI_51050 .

<https://search.data.enanomapper.net/about/nanogenotox>
        sbdbel:NP  npo:NPO_1542 , npo:NPO_1373 , obo:CHEBI_51050 , obo:CHEBI_59999 , npo:NPO_354 .

@prefix void:    <http://rdfs.org/ns/void#> .
@prefix dcterms: <http://purl.org/dc/terms/> .
@prefix dct:     <http://purl.org/dc/> .
@prefix dc:      <http://purl.org/dc/elements/1.1/> .
@prefix npo:     <http://purl.bioontology.org/ontology/npo#> .
@prefix sbd:     <https://www.sbd4nano.eu/rdf/#> .
@prefix sbdbel:  <https://www.sbd4nano.eu/bel/#> .
@prefix rdfs:    <http://www.w3.org/2000/01/rdf-schema#> .
@prefix cito:    <http://purl.org/spar/cito/> .
@prefix zetaPotential:    <http://purl.bioontology.org/ontology/npo#NPO_1302> .
@prefix aggregation:      <http://purl.bioontology.org/ontology/npo#NPO_1967> .
@prefix pH:               <http://purl.bioontology.org/ontology/npo#NPO_1814> .
@prefix particleSize:     <http://purl.bioontology.org/ontology/npo#NPO_1694> .
@prefix particleType:     <http://127.0.0.1/mediawiki/index.php/Particle_Class> .
@prefix toxicity:         <http://127.0.0.1/mediawiki/index.php/Toxicity> .
@prefix cytotoxicity:     <http://127.0.0.1/mediawiki/index.php/Cytotoxicity> .
@prefix oxidationState:   <http://127.0.0.1/mediawiki/index.php/Oxidation_State_Concentration> .
@prefix surfaceModification: <http://127.0.0.1/mediawiki/index.php/Surface_Modification_Class> .
@prefix metalAtomCount:   <http://egonw.github.com/resource/NM_001002> .
@prefix ldhRelease:       <http://127.0.0.1/mediawiki/index.php/LDH_Release> .
@prefix exposureContentration: <http://127.0.0.1/mediawiki/index.php/Concentration_in_culture_medium> .
@prefix logEC50:          <http://127.0.0.1/mediawiki/index.php/Log_Reciprocal_EC50> .
@prefix ionizationEnthalpy: <http://egonw.github.com/resource/NM_001001> .
@prefix bioassayReading: <http://127.0.0.1/mediawiki/index.php/BioAssayProfile> .
@prefix foaf:  <http://xmlns.com/foaf/0.1/> .

<http://purl.bioontology.org/ontology/npo#NPO_1302> rdfs:label "zeta potential"@en .
<http://purl.bioontology.org/ontology/npo#NPO_1967> rdfs:label "aggregation"@en .
<http://purl.bioontology.org/ontology/npo#NPO_1814> rdfs:label "pH"@en .
<http://purl.bioontology.org/ontology/npo#NPO_1694> rdfs:label "particle size"@en .
<http://127.0.0.1/mediawiki/index.php/Particle_Class> rdfs:label "particle type"@en .
<http://127.0.0.1/mediawiki/index.php/Toxicity> rdfs:label "toxicity"@en .
<http://127.0.0.1/mediawiki/index.php/Cytotoxicity> rdfs:label "cytotoxicity"@en .
<http://127.0.0.1/mediawiki/index.php/Oxidation_State_Concentration> rdfs:label "oxditation state"@en .
<http://127.0.0.1/mediawiki/index.php/Surface_Modification_Class> rdfs:label "surface modification"@en .
<http://egonw.github.com/resource/NM_001002> rdfs:label "metal atom count"@en .
<http://127.0.0.1/mediawiki/index.php/LDH_Release> rdfs:label "LDH release"@en .
<http://127.0.0.1/mediawiki/index.php/Concentration_in_culture_medium> rdfs:label "exposure concentration"@en .
<http://127.0.0.1/mediawiki/index.php/Log_Reciprocal_EC50> rdfs:label "log 1/EC50"@en .
<http://egonw.github.com/resource/NM_001001> rdfs:label "bioassay reading"@en .
<http://127.0.0.1/mediawiki/index.php/BioAssayProfile> rdfs:label "bioassay profile"@en .

<https://h2020-sbd4nano.github.io/sbd-data-nanowiki/>
 a                    void:DatasetDescription ;
 dcterms:title        "NanoWiki v6 causal relationships"@en ;
 foaf:img             <https://search.data.enanomapper.net/assets/img/logo.png> ;
 dc:source <https://doi.org/10.6084/m9.figshare.11897205.v1> .

<http://127.0.0.1/mediawiki/index.php/Berg2009_R1> a sbdbel:CausalAssertion ;
   rdfs:label "Berg2009 R1"@en ;
   cito:containsAssertionFrom <https://doi.org/10.3109/17435390903276941> ;
   dc:source <https://h2020-sbd4nano.github.io/sbd-data-nanowiki/> ;
   dcterms:license <http://creativecommons.org/publicdomain/zero/1.0/> ;
   sbdbel:NP npo:NPO_1541 ;
   sbdbel:cause zetaPotential: ;
   sbdbel:relationship sbdbel:correlates ;
   sbdbel:outcome aggregation: ;
   sbdbel:quote "The isoelectric points (IEP) of the nanoparticles were near neutral with the exception of TiO2 (IEP = 5.19) and Fe2O3 (IEP = 4.24). Nanoparticle agglomerates were largest at the IEP. TiO2 and Fe2O3 increased in zeta potential and agglomerate size over time; while Al2O3 and ZnO displayed little change." .

npo:NPO_1541 rdfs:label "Metal Oxide"@en .
npo:NPO_707  rdfs:label "Nanomaterial"@en .

<http://127.0.0.1/mediawiki/index.php/Berg2009_R2> a sbdbel:CausalAssertion ;
   rdfs:label "Berg2009 R2"@en ;
   cito:containsAssertionFrom <https://doi.org/10.3109/17435390903276941> ;
   dc:source <https://h2020-sbd4nano.github.io/sbd-data-nanowiki/> ;
   dcterms:license <http://creativecommons.org/publicdomain/zero/1.0/> ;
   sbdbel:NP npo:NPO_1541 ;
   sbdbel:cause pH: ;
   sbdbel:relationship sbdbel:correlates ;
   sbdbel:outcome zetaPotential: ;
   sbdbel:quote "The isoelectric points (IEP) of the nanoparticles were near neutral with the exception of TiO2 (IEP = 5.19) and Fe2O3 (IEP = 4.24). Nanoparticle agglomerates were largest at the IEP. TiO2 and Fe2O3 increased in zeta potential and agglomerate size over time; while Al2O3 and ZnO displayed little change." .

<http://127.0.0.1/mediawiki/index.php/Deshpande2005_R1> a sbdbel:CausalAssertion ;
   rdfs:label "Deshpande2005 R1"@en ;
   cito:containsAssertionFrom <https://doi.org/10.1063/1.2061873> ;
   dc:source <https://h2020-sbd4nano.github.io/sbd-data-nanowiki/> ;
   dcterms:license <http://creativecommons.org/publicdomain/zero/1.0/> ;
   sbdbel:NP npo:NPO_1541 ;
   sbdbel:cause particleSize: ;
   sbdbel:relationship sbdbel:negativelyCorrelates ;
   sbdbel:outcome oxidationState: ;
   sbdbel:quote "A correlation between the particle size and the lattice parameter has been established in nanocerium oxide particles (3–30nm). The variation in the lattice parameter is attributed to the lattice strain induced by the introduction of Ce3+ due to the formation of oxygen vacancies. Lattice strain was observed to decrease with an increase in the particle size. Ce3+ ions concentration increased from 17% to 44% with the reduction in the particle size." .

<http://127.0.0.1/mediawiki/index.php/Hedberg2010_R1> a sbdbel:CausalAssertion ;
   rdfs:label "Hedberg2010 R1"@en ;
   cito:containsAssertionFrom <https://doi.org/10.1186/1743-8977-7-23> ;
   dc:source <https://h2020-sbd4nano.github.io/sbd-data-nanowiki/> ;
   dcterms:license <http://creativecommons.org/publicdomain/zero/1.0/> ;
   sbdbel:NP npo:NPO_707 ;
   sbdbel:cause particleSize: ;
   sbdbel:relationship sbdbel:correlates ;
   sbdbel:outcome toxicity: ;
   sbdbel:quote "It is evident that particle and alloy characteristics such as particle size and surface composition are important aspects to consider when assessing particle toxicity and metal release from alloy particles compared to pure metal particles." .

<http://127.0.0.1/mediawiki/index.php/Hedberg2010_R2> a sbdbel:CausalAssertion ;
   rdfs:label "Hedberg2010 R2"@en ;
   cito:containsAssertionFrom <https://doi.org/10.1186/1743-8977-7-23> ;
   dc:source <https://h2020-sbd4nano.github.io/sbd-data-nanowiki/> ;
   dcterms:license <http://creativecommons.org/publicdomain/zero/1.0/> ;
   sbdbel:NP npo:NPO_707 ;
   sbdbel:cause surfaceModification: ;
   sbdbel:relationship sbdbel:correlates ;
   sbdbel:outcome toxicity: ;
   sbdbel:quote "It is evident that particle and alloy characteristics such as particle size and surface composition are important aspects to consider when assessing particle toxicity and metal release from alloy particles compared to pure metal particles." .

<http://127.0.0.1/mediawiki/index.php/Prabhu2010_R1> a sbdbel:CausalAssertion ;
   rdfs:label "Prabhu2010 R1"@en ;
   cito:containsAssertionFrom <https://doi.org/10.3109/17435390903337693> ;
   dc:source <https://h2020-sbd4nano.github.io/sbd-data-nanowiki/> ;
   dcterms:license <http://creativecommons.org/publicdomain/zero/1.0/> ;
   sbdbel:NP npo:NPO_707 ;
   sbdbel:cause particleSize: ;
   sbdbel:relationship sbdbel:correlates ;
   sbdbel:outcome ldhRelease: ;
   sbdbel:quote "LDH and MTS assays revealed that exposure to copper nanoparticles had significant toxic effect with all the sizes tested when compared to unexposed control cultures. Further analysis of the results showed that copper nanoparticles of smaller size and higher concentration exerted the maximum toxic effects." .

<http://127.0.0.1/mediawiki/index.php/Prabhu2010_R2> a sbdbel:CausalAssertion ;
   rdfs:label "Prabhu2010 R2"@en ;
   cito:containsAssertionFrom <https://doi.org/10.3109/17435390903337693> ;
   dc:source <https://h2020-sbd4nano.github.io/sbd-data-nanowiki/> ;
   dcterms:license <http://creativecommons.org/publicdomain/zero/1.0/> ;
   sbdbel:NP npo:NPO_707 ;
   sbdbel:cause exposureContentration: ;
   sbdbel:relationship sbdbel:changes ;
   sbdbel:outcome ldhRelease: ;
   sbdbel:quote "LDH and MTS assays revealed that exposure to copper nanoparticles had significant toxic effect with all the sizes tested when compared to unexposed control cultures. Further analysis of the results showed that copper nanoparticles of smaller size and higher concentration exerted the maximum toxic effects." .

<http://127.0.0.1/mediawiki/index.php/Puzyn2011_R1> a sbdbel:CausalAssertion ;
   rdfs:label "Puzyn2011 R1"@en ;
   cito:containsAssertionFrom <https://doi.org/10.1038/nnano.2011.10> ;
   dc:source <https://h2020-sbd4nano.github.io/sbd-data-nanowiki/> ;
   dcterms:license <http://creativecommons.org/publicdomain/zero/1.0/> ;
   sbdbel:NP npo:NPO_1541 ;
   sbdbel:cause ionizationEnthalpy: ;
   sbdbel:relationship sbdbel:negativelyCorreclates ;
   sbdbel:outcome logEC50: ;
   sbdbel:quote "Our results indicate that DHMeþ can be utilized as an efficient descriptor of the chemical stability of metal oxides and, therefore, their cytotoxicity in E. coli in vitro tests. [..] In addition, DHMeþ is also related to the sum of the ionization potentials of a given metal, because the formation of Menþ cations requires sublimation followed by ionization reactions.".

<http://127.0.0.1/mediawiki/index.php/Shaw2008_R1> a sbdbel:CausalAssertion ;
   rdfs:label "Shaw2008 R1"@en ;
   cito:containsAssertionFrom <https://doi.org/10.1073/pnas.0802878105> ;
   dc:source <https://h2020-sbd4nano.github.io/sbd-data-nanowiki/> ;
   dcterms:license <http://creativecommons.org/publicdomain/zero/1.0/> ;
   sbdbel:NP npo:NPO_1541 ;
   sbdbel:cause surfaceModification: ;
   sbdbel:relationship sbdbel:correlates ;
   sbdbel:outcome bioassayReading: ;
   sbdbel:quote "We assessed nanoparticle effects in a multidimensional manner, using multiple cell types and multiple assays that reflect different aspects of cellular physiology. Hierarchical clustering of these data identifies nanomaterials with similar patterns of biologic activity across a broad sampling of cellular contexts, as opposed to extrapolating from results of a single in vitro assay." .

<http://127.0.0.1/mediawiki/index.php/Shaw2008_R2> a sbdbel:CausalAssertion ;
   rdfs:label "Shaw2008 R2"@en ;
   cito:containsAssertionFrom <https://doi.org/10.1073/pnas.0802878105> ;
   dc:source <https://h2020-sbd4nano.github.io/sbd-data-nanowiki/> ;
   dcterms:license <http://creativecommons.org/publicdomain/zero/1.0/> ;
   sbdbel:NP npo:NPO_1541 ;
   sbdbel:cause particleType: ;
   sbdbel:relationship sbdbel:correlates ;
   sbdbel:outcome bioassayReading: ;
   sbdbel:quote "We assessed nanoparticle effects in a multidimensional manner, using multiple cell types and multiple assays that reflect different aspects of cellular physiology. Hierarchical clustering of these data identifies nanomaterials with similar patterns of biologic activity across a broad sampling of cellular contexts, as opposed to extrapolating from results of a single in vitro assay." .

<http://127.0.0.1/mediawiki/index.php/Weissleder146_R1> a sbdbel:CausalAssertion ;
   rdfs:label "Weissleder146 R1"@en ;
   cito:containsAssertionFrom <https://doi.org/10.1073/pnas.0802878105> ;
   dc:source <https://h2020-sbd4nano.github.io/sbd-data-nanowiki/> ;
   dcterms:license <http://creativecommons.org/publicdomain/zero/1.0/> ;
   sbdbel:NP npo:NPO_707 ;
   sbdbel:cause surfaceModification: ;
   sbdbel:relationship sbdbel:correlates ;
   sbdbel:outcome bioassayReading: ;
   sbdbel:quote "We have applied a magnetofluorescent nanoparticle library decorated with small molecules to address four critical questions in biomedical nanomaterial research [..] Screening of this library identified a variety of nanomaterials that discriminate among different cell types as well as among different physiologic states of the same cell type." .
@prefix dc:    <http://purl.org/dc/elements/1.1/> .
@prefix dct:   <http://purl.org/dc/terms/> .
@prefix foaf:  <http://xmlns.com/foaf/0.1/> .
@prefix rdfs:  <http://www.w3.org/2000/01/rdf-schema#> .
@prefix sbd:   <https://www.sbd4nano.eu/rdf/#> .
@prefix sbdbel:  <https://www.sbd4nano.eu/bel/#> .
@prefix xsd:   <http://www.w3.org/2001/XMLSchema#> .
@prefix void:    <http://rdfs.org/ns/void#> .

@prefix TiO2: <http://purl.obolibrary.org/obo/CHEBI_51050> .
@prefix ZnO: <http://purl.bioontology.org/ontology/npo#NPO_1542> .
@prefix MOx: <http://purl.bioontology.org/ontology/npo#NPO_1541> .

<https://atena.urv.cat/model/>
 a                    void:DatasetDescription ;
 dc:source            <https://atena.urv.cat/model/> ;
 dct:title            "SbD4nano Nanocompound"@en ;
 dct:license          <http://example.com/unknown> ;
 foaf:img             <https://www.urv.cat/media/img/logo-urv-nav.png> .

<https://atena.urv.cat/model/#Papa2015-TiO2ZnO> a sbd:Model ;
  dc:source <https://atena.urv.cat/model/> ;
  rdfs:label "Nanocompound: LDH(TiO2+ZnO)" ;
  dc:description "This equation predicts the Lactate Dehydrogenase Release (LDH) of TiO2 and ZnO. It corresponds to Equation 1 in the following reference:E. Papa, J.P. Doucet & A. Doucet-Panaye (2015): Linear and non-linear modelling of the cytotoxicity of TiO2 and ZnO nanoparticles by empirical descriptors, SAR and QSAR in Environmental Research, DOI: 10.1080/1062936X.2015.1080186"@en ;
  dct:license <http://example.com/unknown> ;
  foaf:page <https://atena.urv.cat/model/> ;
  sbdbel:NP TiO2:, ZnO: .

<https://atena.urv.cat/model/#Papa2015-TiO2> a sbd:Model ;
  dc:source <https://atena.urv.cat/model/> ;
  rdfs:label "Nanocompound: LDH(TiO2)" ;
  dc:description "This equation predicts the Lactate Dehydrogenase Release (LDH) of TiO2 . It corresponds to Equation 2 in the following reference:E. Papa, J.P. Doucet & A. Doucet-Panaye (2015): Linear and non-linear modelling of the cytotoxicity of TiO2 and ZnO nanoparticles by empirical descriptors, SAR and QSAR in Environmental Research, DOI: 10.1080/1062936X.2015.1080186"@en ;
  dct:license <http://example.com/unknown> ;
  foaf:page <https://atena.urv.cat/model/> ;
  sbdbel:NP TiO2: .

<https://atena.urv.cat/model/#Papa2015-ZnO> a sbd:Model ;
  dc:source <https://atena.urv.cat/model/> ;
  rdfs:label "Nanocompound: LDH(TiO2+ZnO)" ;
  dc:description "This equation predicts the Lactate Dehydrogenase Release (LDH) of ZnO. It corresponds to Equation 3 in the following reference:E. Papa, J.P. Doucet & A. Doucet-Panaye (2015): Linear and non-linear modelling of the cytotoxicity of TiO2 and ZnO nanoparticles by empirical descriptors, SAR and QSAR in Environmental Research, DOI: 10.1080/1062936X.2015.1080186"@en ;
  dct:license <http://example.com/unknown> ;
  foaf:page <https://atena.urv.cat/model/> ;
  sbdbel:NP ZnO: .

<https://atena.urv.cat/model/#Anantha2021> a sbd:Model ;
  dc:source <https://atena.urv.cat/model/> ;
  rdfs:label "Nanocompound: Toxicity Metal-Oxide: Anantha 2021" ;
  dc:description "Prediction of toxicity of Metal-Ozide (binary output). It corresponds to the model presented in: NanoTox: Development of a Parsimonious In Silico Model for Toxicity Assessment of Metal-Oxide Nanoparticles Using Physicochemical Features, Nilesh Anantha Subramanian and Ashok Palaniappan, ACS Omega 2021 6 (17), 11729-11739, DOI: 10.1021/acsomega.1c01076"@en ;
  dct:license <http://example.com/unknown> ;
  foaf:page <https://atena.urv.cat/model/> ;
  sbdbel:NP MOx: .

<https://atena.urv.cat/model/#Puzyn2011> a sbd:Model ;
  dc:source <https://atena.urv.cat/model/> ;
  rdfs:label "Nanocompound: Toxicity Metal-Oxide: Puzyn 2011" ;
  dc:description "Prediction of toxicity of Metal-Ozide (log(1/EC50)). It corresponds to the model presented in: Using nano-QSAR to predict the cytotoxicity of metal oxide nanoparticles, Tomasz Puzyn, Bakhtiyor Rasulev, Agnieszka Gajewicz, Xiaoke Hu, Thabitha P Dasari, Andrea Michalkova, Huey-Min Hwang, Andrey Toropov, Danuta Leszczynska, Jerzy Leszczynski, Nature Nanotechnology, 2011 M6(3), DOI: 10.1038/nnano.2011.10"@en ;
  dct:license <http://example.com/unknown> ;
  foaf:page <https://atena.urv.cat/model/> ;
  sbdbel:NP MOx: .

<https://atena.urv.cat/model/#Gajewicz2015> a sbd:Model ;
  dc:source <https://atena.urv.cat/model/> ;
  rdfs:label "Nanocompound: Toxicity Metal-Oxide: Gajewicz 2015" ;
  dc:description "Prediction of toxicity of Metal-Ozide (log(1/EC50)). It corresponds to the model presented in: Agnieszka Gajewicz, Nicole Schaeublin, Bakhtiyor Rasulev, Saber Hussain, Danuta Leszczynska, Tomasz Puzyn & Jerzy Leszczynski (2015) Towards understanding mechanisms governing cytotoxicity of metal oxides nanoparticles: Hints from nano-QSAR studies, Nanotoxicology, 9:3, 313-325, DOI: 10.3109/17435390.2014.930195"@en ;
  dct:license <http://example.com/unknown> ;
  foaf:page <https://atena.urv.cat/model/> ;
  sbdbel:NP MOx: .

<https://atena.urv.cat/model/#Serratosa2022> a sbd:Model ;
  dc:source <https://atena.urv.cat/model/> ;
  rdfs:label "Nanocompound: Toxicity Metal-Oxide: Serratosa2022" ;
  dc:description "Prediction of toxicity of Metal-Ozide (binary output). It corresponds to the model presented in: F. Serratosa, S. Álvarez, L. Escorihuela and M. Calatayud, Subgraph NanoFingerprint for modelling metal oxide nanoparticles based on connected atoms exploration. NanoWeek & NanoCommons Final Conference 2022, Cyprus 2022."@en ;
  dct:license <http://example.com/unknown> ;
  foaf:page <https://atena.urv.cat/model/> ;
  sbdbel:NP MOx: .

<https://atena.urv.cat/model/#Serratosa2022> a sbd:Model ;
  dc:source <https://atena.urv.cat/model/> ;
  rdfs:label "Nanocompound: Toxicity Metal-Oxide: Serratosa2022" ;
  dc:description "Prediction of toxicity of Metal-Ozide (binary output). It corresponds to the model presented in: F. Serratosa, S. Álvarez, L. Escorihuela and M. Calatayud, Subgraph NanoFingerprint for modelling metal oxide nanoparticles based on connected atoms exploration. NanoWeek & NanoCommons Final Conference 2022, Cyprus 2022."@en ;
  dct:license <http://example.com/unknown> ;
  foaf:page <https://atena.urv.cat/model/> ;
  sbdbel:NP MOx: .

<https://atena.urv.cat/model/#Serratosa2022-TiO2ZnO> a sbd:Model ;
  dc:source <https://atena.urv.cat/model/> ;
  rdfs:label "Nanocompound: LDH(TiO2+ZnO): Serratosa2022" ;
  dc:description "Prediction of toxicity of Metal-Ozide (LDH). It corresponds to the model presented in: F. Serratosa, S. Álvarez, L. Escorihuela and M. Calatayud, Subgraph NanoFingerprint for modelling metal oxide nanoparticles based on connected atoms exploration. NanoWeek & NanoCommons Final Conference 2022, Cyprus 2022."@en ;
  dct:license <http://example.com/unknown> ;
  foaf:page <https://atena.urv.cat/model/> ;
  sbdbel:NP TiO2:, ZnO: .

<https://atena.urv.cat/model/#Serratosa2022-TiO2> a sbd:Model ;
  dc:source <https://atena.urv.cat/model/> ;
  rdfs:label "Nanocompound: LDH(TiO2): Serratosa2022" ;
  dc:description "Prediction of toxicity of Metal-Ozide (LDH). It corresponds to the model presented in: F. Serratosa, S. Álvarez, L. Escorihuela and M. Calatayud, Subgraph NanoFingerprint for modelling metal oxide nanoparticles based on connected atoms exploration. NanoWeek & NanoCommons Final Conference 2022, Cyprus 2022."@en ;
  dct:license <http://example.com/unknown> ;
  foaf:page <https://atena.urv.cat/model/> ;
  sbdbel:NP TiO2: .

<https://atena.urv.cat/model/#Serratosa2022-ZnO> a sbd:Model ;
  dc:source <https://atena.urv.cat/model/> ;
  rdfs:label "Nanocompound: LDH(ZnO): Serratosa2022" ;
  dc:description "Prediction of toxicity of Metal-Ozide (LDH). It corresponds to the model presented in: F. Serratosa, S. Álvarez, L. Escorihuela and M. Calatayud, Subgraph NanoFingerprint for modelling metal oxide nanoparticles based on connected atoms exploration. NanoWeek & NanoCommons Final Conference 2022, Cyprus 2022."@en ;
  dct:license <http://example.com/unknown> ;
  foaf:page <https://atena.urv.cat/model/> ;
  sbdbel:NP ZnO: .

@prefix sbd:     <https://www.sbd4nano.eu/rdf/#> .
@prefix sbdbel:  <https://www.sbd4nano.eu/bel/#> .
@prefix rdfs:    <http://www.w3.org/2000/01/rdf-schema#> .
@prefix dc:      <http://purl.org/dc/elements/1.1/> .
@prefix dcterms: <http://purl.org/dc/terms/> .
@prefix foaf:    <http://xmlns.com/foaf/0.1/> .
@prefix void:    <http://rdfs.org/ns/void#> .

<https://h2020-sbd4nano.github.io/sbd-data-aopwiki/>
 a                    void:DatasetDescription ;
 foaf:img             <https://aopwiki.rdf.bigcat-bioinformatics.org/assets/images/aopwiki-snorql-logo.png> ;
 dc:source            <https://aopwiki.rdf.bigcat-bioinformatics.org/> ;
 dcterms:title        "AOP-Wiki data"@en ;
 dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://h2020-sbd4nano.github.io/sbd-data-aopwiki/ao/>
   a sbd:Dataset ;
   dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/> ;
   rdfs:label "AOP-Wiki AOP-AO dataset"@en ;
   sbd:endpoint sbdbel:AdverseOutcome ;
   dcterms:license      <https://www.wikidata.org/entity/Q50423863> ;
   foaf:page <https://aopwiki.rdf.bigcat-bioinformatics.org/sparql?default-graph-uri=&query=SELECT+%3FAOP+%3FAOPTitle+%3FAO+%3FAOTitle+WHERE+%7B%0D%0A%3FAOP+a+aopo%3AAdverseOutcomePathway+%3B%0D%0Adc%3Atitle+%3FAOPTitle+%3B%0D%0Aaopo%3Ahas_adverse_outcome+%3FAO.%0D%0A%3FAO+dc%3Atitle+%3FAOTitle+.%7D&should-sponge=&format=text%2Fhtml&timeout=0&debug=on&run=+Run+Query+>.
   
<https://h2020-sbd4nano.github.io/sbd-data-aopwiki/ke/>
   a sbd:Dataset ;
   dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/> ;
   rdfs:label "AOP-Wiki AOP-KE dataset"@en ;
   sbd:endpoint sbdbel:KeyEvent ;
   dcterms:license      <https://www.wikidata.org/entity/Q50423863> ;
   foaf:page <https://aopwiki.rdf.bigcat-bioinformatics.org/sparql?default-graph-uri=&query=SELECT+%3FAOP+%3FAOPTitle+%3FKE+%3FKETitle+WHERE+%7B%0D%0A%3FAOP+a+aopo%3AAdverseOutcomePathway+%3B%0D%0Adc%3Atitle+%3FAOPTitle+%3B%0D%0Aaopo%3Ahas_key_event+%3FKE.%0D%0A%3FKE+dc%3Atitle+%3FKETitle+.%7D&should-sponge=&format=text%2Fhtml&timeout=0&debug=on&run=+Run+Query+> .

<https://h2020-sbd4nano.github.io/sbd-data-aopwiki/mie/>
   a sbd:Dataset ;
   dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/> ;
   rdfs:label "AOP-Wiki MIE-KE dataset"@en ;
   sbd:endpoint sbdbel:KeyEvent ;
   dcterms:license      <https://www.wikidata.org/entity/Q50423863> ;
   foaf:page <https://aopwiki.rdf.bigcat-bioinformatics.org/sparql?default-graph-uri=&query=SELECT+%3FMIE+%3FMolecularInitiatingEventName+%3FKE+%3FKeyEventName+WHERE+%7B%0D%0A%3FMIE+dc%3Atitle+%3FMolecularInitiatingEventName+.%0D%0A%3FAOP+a+aopo%3AAdverseOutcomePathway+%3B%0D%0Aaopo%3Ahas_molecular_initiating_event+%3FMIE%3B%0D%0Aaopo%3Ahas_key_event+%3FKE.%0D%0A%3FKE+dc%3Atitle+%3FKeyEventName+.%0D%0AFILTER+%28%3FMIE+%21%3D+%3FKE%29%7D&should-sponge=&format=text%2Fhtml&timeout=0&debug=on&run=+Run+Query+> .
@prefix dc:      <http://purl.org/dc/elements/1.1/> .
@prefix dcterms: <http://purl.org/dc/terms/> .
@prefix foaf:    <http://xmlns.com/foaf/0.1/> .
@prefix rdfs:    <http://www.w3.org/2000/01/rdf-schema#> .
@prefix sbd:     <https://www.sbd4nano.eu/rdf/#> .
@prefix xsd:     <http://www.w3.org/2001/XMLSchema#> .
@prefix void:    <http://rdfs.org/ns/void#> .
@prefix pav:     <http://purl.org/pav/> .

<https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/>
 a                    void:DatasetDescription ;
 foaf:img             <https://aopwiki.rdf.bigcat-bioinformatics.org/assets/images/aopwiki-snorql-logo.png> ;
 dc:source            <https://aopwiki.rdf.bigcat-bioinformatics.org/> ;
 dcterms:title        "AOP-Wiki AOPs"@en ;
 dcterms:description  "Models based on the AOP-Wiki AOPs that predict that even certain KEs happen, that the AO also happens"@en ;
 dcterms:publisher    <https://github.com/h2020-sbd4nano/sbd-data-aopwiki> ;
 pav:createdBy        <https://github.com/h2020-sbd4nano/sbd-data-aopwiki> ;
 dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop/10> a sbd:Model ;
  rdfs:label "Binding to the picrotoxin site of ionotropic GABA receptors leading to epileptic seizures in adult brain"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "As a neurotoxicity endpoint, information with regard to the seizure or epilepsy is often used by regulators such as EPA, FDA and DHS for human and environmental health assessment and regulation of chemicals, drugs and other materials. For instance, the Office of Pesticide Programs (OPP) in US EPA, regulates, monitors and investigates&nbsp;the use of all pesticides in accordance with the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) (https://www.epa.gov/laws-regulations/summary-federal-insecticide-fungicide-and-rodenticide-act).&nbsp;Many pesticides like fipronil target the iGABAR causing&nbsp;seizure and mortality. Another example is the regulatory actions of US FDA to ensure drug safety&nbsp;(see https://www.fda.gov/Drugs/DrugSafety/ucm436494.htm)."@en ;
  foaf:page <https://identifiers.org/aop/10> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/10> a sbd:Model ;
  rdfs:label "Binding to the picrotoxin site of ionotropic GABA receptors leading to epileptic seizures in adult brain"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Chemicals non-competitively bind at or near the central pore of the receptor complex (e.g., the picrotoxin site) and directly block chloride conductance through the ion channel (Kalueff 2007). It has been postulated that they fit a single &quot;big picrotoxin binding pocket&quot;&nbsp;in the chloride channel lumen lined by five TM2 segments (Kalueff 2007; Olsen 2006). This hypothesis was examined with the &beta;3 homopentamer by mutagenesis, pore structure studies, ligand binding, and molecular modeling (Chen et al. 2006). Results suggest that they fit the 2&#39; to 9&#39; pore region forming hydrogen bonds with the T6&#39; hydroxyl and hydrophobic interactions with A2&#39;, T6&#39;, and L9&#39; alkyl substituents, thereby blocking the channel. More computational evidence can be found in Sander et al. (2011), Carpenter et al. (2013) and Zheng et al. (2014)."@en ;
  foaf:page <https://identifiers.org/aop/10> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/10> a sbd:Model ;
  rdfs:label "Binding to the picrotoxin site of ionotropic GABA receptors leading to epileptic seizures in adult brain"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Ionotropic GABA receptors (iGABARs) are ligand-gated ion channels which play important functional roles in the nervous system. As the major player in inhibitory neurotransmission, iGABARs are widely distributed in&nbsp;both vertebrates and invertebrates (McGonigle&nbsp;and Lummis 2010; Garcia-Reyero et al. 2011). In vertebrates, the iGABAR includes two subclasses of fast-responding ion channels, GABAA receptor (GABAA-R) and GABAC receptor (GABAC-R). Invertebrate iGABARs do not readily fit the vertebrate GABAA/GABAC receptor categories (Sieghart 1995). The majority of insect iGABARs are distinguished from vertebrate GABAA receptors by their insensitivity to bicuculline and differ from GABAC-Rs in that they are subject to allosteric modulation, albeit weakly, by benzodiazepines and barbiturates (Hosie et al. 1997).  Chemical interactions with iGABARs can cause a variety of pharmacological and neurotoxicological effects depending on the location of the active or allosteric site affected. Three distinct types of interactions at binding sites on iGABARs can antagonize the postsynaptic inhibitory functions of GABA and lead to epileptic seizures and death. These three types of interactions correspond to three AOPs (Gong et al. 2015). One of the three types of&nbsp;interaction is non-competitive channel blocking at the picrotoxin convulsant site located inside of the iGABAR pore that spans neuronal cell membranes, which is the MIE described in the current AOP. The other two types of interactions are negative modulation at allosteric sites and competitive binding at the active orthosteric sites (MIEs to be developed in the future).  It is worth noting that there exist another class of GABA receptors called metabotropic G-protein-coupled receptors (mGABAR) or GABAB receptors. This AOP is not applicable to GABAB receptors because they mediate slow and sustained inhibitory responses to GABA and are involved in absence epilepsy (Han et al. 2012)."@en ;
  foaf:page <https://identifiers.org/aop/10> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/100> a sbd:Model ;
  rdfs:label "Cyclooxygenase inhibition leading to reproductive dysfunction via inhibition of female spawning behavior"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/100> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/100> a sbd:Model ;
  rdfs:label "Cyclooxygenase inhibition leading to reproductive dysfunction via inhibition of female spawning behavior"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Non-steroidal anti-inflammatory drugs have been specifically designed to inhibit cyclooxygenase active site of PTGS; these mechanisms of inhibition are well characterized (Simmons et al, 2004). NSAIDs interfere with COX site via multiple mechanisms including competitive inhibition (most NSAIDs compete for active site with arachidonic acid) and covalent modification (irreversible acetylation) of COX (e.g., aspirin) (Simmons et al., 2004; Willoughby et al., 2011). NSAIDs display different levels of selectivity for the COX-1 vs. COX-2 isoforms (Simmons et al., 2004). Majority of NSAIDs inhibit both isoforms (with variable levels of selectivity for COX-1 vs. COX-2), but several have been designed to preferentially inhibit COX-2 (Bacchi et al., 2012). Recently, COX-1 specific inhibitors have been developed and their therapeutic potential is being explored (Liedtke et al., 2012). Most extensive evidence regarding chemical initiation of this event comes from the mammalian literature and relates to NSAIDs. In addition to NSAIDs, common environmental contaminants of diverse chemical structures and uses (e.g., parabens, phthalates, benzophenones) have been postulated to inhibit prostaglandin synthesis via COX inhibition (Kristensen et al., 2011). U.S. EPA’s high throughput screening program (ACToR, epa.gov) indicated COX as a frequent contaminant target - 61% of 143 tested chemicals inhibited COX-1 and 59% of 106 inhibited COX-2 activity. Several chemicals were either similar in potency (e.g., monobutylphthalate) or more potent than NSAIDs (e.g., insecticide emamectin benzoate and industrial intermediary 1-Chloro-4-nitrobenzene were more potent inhibitors of COX2 than NSAID celecoxib, which was specifically designed to inhibit COX-2). Mechanisms of inhibition for these chemicals are not well elucidated."@en ;
  foaf:page <https://identifiers.org/aop/100> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/100> a sbd:Model ;
  rdfs:label "Cyclooxygenase inhibition leading to reproductive dysfunction via inhibition of female spawning behavior"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/100> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/100> a sbd:Model ;
  rdfs:label "Cyclooxygenase inhibition leading to reproductive dysfunction via inhibition of female spawning behavior"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Non-steroidal anti-inflammatory drugs have been specifically designed to inhibit cyclooxygenase active site of PTGS; these mechanisms of inhibition are well characterized (Simmons et al, 2004). NSAIDs interfere with COX site via multiple mechanisms including competitive inhibition (most NSAIDs compete for active site with arachidonic acid) and covalent modification (irreversible acetylation) of COX (e.g., aspirin) (Simmons et al., 2004; Willoughby et al., 2011). NSAIDs display different levels of selectivity for the COX-1 vs. COX-2 isoforms (Simmons et al., 2004). Majority of NSAIDs inhibit both isoforms (with variable levels of selectivity for COX-1 vs. COX-2), but several have been designed to preferentially inhibit COX-2 (Bacchi et al., 2012). Recently, COX-1 specific inhibitors have been developed and their therapeutic potential is being explored (Liedtke et al., 2012). Most extensive evidence regarding chemical initiation of this event comes from the mammalian literature and relates to NSAIDs. In addition to NSAIDs, common environmental contaminants of diverse chemical structures and uses (e.g., parabens, phthalates, benzophenones) have been postulated to inhibit prostaglandin synthesis via COX inhibition (Kristensen et al., 2011). U.S. EPA’s high throughput screening program (ACToR, epa.gov) indicated COX as a frequent contaminant target - 61% of 143 tested chemicals inhibited COX-1 and 59% of 106 inhibited COX-2 activity. Several chemicals were either similar in potency (e.g., monobutylphthalate) or more potent than NSAIDs (e.g., insecticide emamectin benzoate and industrial intermediary 1-Chloro-4-nitrobenzene were more potent inhibitors of COX2 than NSAID celecoxib, which was specifically designed to inhibit COX-2). Mechanisms of inhibition for these chemicals are not well elucidated."@en ;
  foaf:page <https://identifiers.org/aop/100> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/101> a sbd:Model ;
  rdfs:label "Cyclooxygenase inhibition leading to reproductive dysfunction via inhibition of pheromone release"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/101> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/101> a sbd:Model ;
  rdfs:label "Cyclooxygenase inhibition leading to reproductive dysfunction via inhibition of pheromone release"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Non-steroidal anti-inflammatory drugs have been specifically designed to inhibit cyclooxygenase active site of PTGS; these mechanisms of inhibition are well characterized (Simmons et al, 2004). NSAIDs interfere with COX site via multiple mechanisms including competitive inhibition (most NSAIDs compete for active site with arachidonic acid) and covalent modification (irreversible acetylation) of COX (e.g., aspirin) (Simmons et al., 2004; Willoughby et al., 2011). NSAIDs display different levels of selectivity for the COX-1 vs. COX-2 isoforms (Simmons et al., 2004). Majority of NSAIDs inhibit both isoforms (with variable levels of selectivity for COX-1 vs. COX-2), but several have been designed to preferentially inhibit COX-2 (Bacchi et al., 2012). Recently, COX-1 specific inhibitors have been developed and their therapeutic potential is being explored (Liedtke et al., 2012). Most extensive evidence regarding chemical initiation of this event comes from the mammalian literature and relates to NSAIDs. In addition to NSAIDs, common environmental contaminants of diverse chemical structures and uses (e.g., parabens, phthalates, benzophenones) have been postulated to inhibit prostaglandin synthesis via COX inhibition (Kristensen et al., 2011). U.S. EPA’s high throughput screening program (ACToR, epa.gov) indicated COX as a frequent contaminant target - 61% of 143 tested chemicals inhibited COX-1 and 59% of 106 inhibited COX-2 activity. Several chemicals were either similar in potency (e.g., monobutylphthalate) or more potent than NSAIDs (e.g., insecticide emamectin benzoate and industrial intermediary 1-Chloro-4-nitrobenzene were more potent inhibitors of COX2 than NSAID celecoxib, which was specifically designed to inhibit COX-2). Mechanisms of inhibition for these chemicals are not well elucidated."@en ;
  foaf:page <https://identifiers.org/aop/101> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/101> a sbd:Model ;
  rdfs:label "Cyclooxygenase inhibition leading to reproductive dysfunction via inhibition of pheromone release"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/101> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/101> a sbd:Model ;
  rdfs:label "Cyclooxygenase inhibition leading to reproductive dysfunction via inhibition of pheromone release"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Non-steroidal anti-inflammatory drugs have been specifically designed to inhibit cyclooxygenase active site of PTGS; these mechanisms of inhibition are well characterized (Simmons et al, 2004). NSAIDs interfere with COX site via multiple mechanisms including competitive inhibition (most NSAIDs compete for active site with arachidonic acid) and covalent modification (irreversible acetylation) of COX (e.g., aspirin) (Simmons et al., 2004; Willoughby et al., 2011). NSAIDs display different levels of selectivity for the COX-1 vs. COX-2 isoforms (Simmons et al., 2004). Majority of NSAIDs inhibit both isoforms (with variable levels of selectivity for COX-1 vs. COX-2), but several have been designed to preferentially inhibit COX-2 (Bacchi et al., 2012). Recently, COX-1 specific inhibitors have been developed and their therapeutic potential is being explored (Liedtke et al., 2012). Most extensive evidence regarding chemical initiation of this event comes from the mammalian literature and relates to NSAIDs. In addition to NSAIDs, common environmental contaminants of diverse chemical structures and uses (e.g., parabens, phthalates, benzophenones) have been postulated to inhibit prostaglandin synthesis via COX inhibition (Kristensen et al., 2011). U.S. EPA’s high throughput screening program (ACToR, epa.gov) indicated COX as a frequent contaminant target - 61% of 143 tested chemicals inhibited COX-1 and 59% of 106 inhibited COX-2 activity. Several chemicals were either similar in potency (e.g., monobutylphthalate) or more potent than NSAIDs (e.g., insecticide emamectin benzoate and industrial intermediary 1-Chloro-4-nitrobenzene were more potent inhibitors of COX2 than NSAID celecoxib, which was specifically designed to inhibit COX-2). Mechanisms of inhibition for these chemicals are not well elucidated."@en ;
  foaf:page <https://identifiers.org/aop/101> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/102> a sbd:Model ;
  rdfs:label "Cyclooxygenase inhibition leading to reproductive dysfunction via interference with meiotic prophase I /metaphase I transition"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/102> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/102> a sbd:Model ;
  rdfs:label "Cyclooxygenase inhibition leading to reproductive dysfunction via interference with meiotic prophase I /metaphase I transition"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Non-steroidal anti-inflammatory drugs have been specifically designed to inhibit cyclooxygenase active site of PTGS; these mechanisms of inhibition are well characterized (Simmons et al, 2004). NSAIDs interfere with COX site via multiple mechanisms including competitive inhibition (most NSAIDs compete for active site with arachidonic acid) and covalent modification (irreversible acetylation) of COX (e.g., aspirin) (Simmons et al., 2004; Willoughby et al., 2011). NSAIDs display different levels of selectivity for the COX-1 vs. COX-2 isoforms (Simmons et al., 2004). Majority of NSAIDs inhibit both isoforms (with variable levels of selectivity for COX-1 vs. COX-2), but several have been designed to preferentially inhibit COX-2 (Bacchi et al., 2012). Recently, COX-1 specific inhibitors have been developed and their therapeutic potential is being explored (Liedtke et al., 2012). Most extensive evidence regarding chemical initiation of this event comes from the mammalian literature and relates to NSAIDs. In addition to NSAIDs, common environmental contaminants of diverse chemical structures and uses (e.g., parabens, phthalates, benzophenones) have been postulated to inhibit prostaglandin synthesis via COX inhibition (Kristensen et al., 2011). U.S. EPA’s high throughput screening program (ACToR, epa.gov) indicated COX as a frequent contaminant target - 61% of 143 tested chemicals inhibited COX-1 and 59% of 106 inhibited COX-2 activity. Several chemicals were either similar in potency (e.g., monobutylphthalate) or more potent than NSAIDs (e.g., insecticide emamectin benzoate and industrial intermediary 1-Chloro-4-nitrobenzene were more potent inhibitors of COX2 than NSAID celecoxib, which was specifically designed to inhibit COX-2). Mechanisms of inhibition for these chemicals are not well elucidated."@en ;
  foaf:page <https://identifiers.org/aop/102> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/102> a sbd:Model ;
  rdfs:label "Cyclooxygenase inhibition leading to reproductive dysfunction via interference with meiotic prophase I /metaphase I transition"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/102> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/102> a sbd:Model ;
  rdfs:label "Cyclooxygenase inhibition leading to reproductive dysfunction via interference with meiotic prophase I /metaphase I transition"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Non-steroidal anti-inflammatory drugs have been specifically designed to inhibit cyclooxygenase active site of PTGS; these mechanisms of inhibition are well characterized (Simmons et al, 2004). NSAIDs interfere with COX site via multiple mechanisms including competitive inhibition (most NSAIDs compete for active site with arachidonic acid) and covalent modification (irreversible acetylation) of COX (e.g., aspirin) (Simmons et al., 2004; Willoughby et al., 2011). NSAIDs display different levels of selectivity for the COX-1 vs. COX-2 isoforms (Simmons et al., 2004). Majority of NSAIDs inhibit both isoforms (with variable levels of selectivity for COX-1 vs. COX-2), but several have been designed to preferentially inhibit COX-2 (Bacchi et al., 2012). Recently, COX-1 specific inhibitors have been developed and their therapeutic potential is being explored (Liedtke et al., 2012). Most extensive evidence regarding chemical initiation of this event comes from the mammalian literature and relates to NSAIDs. In addition to NSAIDs, common environmental contaminants of diverse chemical structures and uses (e.g., parabens, phthalates, benzophenones) have been postulated to inhibit prostaglandin synthesis via COX inhibition (Kristensen et al., 2011). U.S. EPA’s high throughput screening program (ACToR, epa.gov) indicated COX as a frequent contaminant target - 61% of 143 tested chemicals inhibited COX-1 and 59% of 106 inhibited COX-2 activity. Several chemicals were either similar in potency (e.g., monobutylphthalate) or more potent than NSAIDs (e.g., insecticide emamectin benzoate and industrial intermediary 1-Chloro-4-nitrobenzene were more potent inhibitors of COX2 than NSAID celecoxib, which was specifically designed to inhibit COX-2). Mechanisms of inhibition for these chemicals are not well elucidated."@en ;
  foaf:page <https://identifiers.org/aop/102> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/103> a sbd:Model ;
  rdfs:label "Cyclooxygenase inhibition leading to reproductive dysfunction via interference with spindle assembly checkpoint"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/103> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/103> a sbd:Model ;
  rdfs:label "Cyclooxygenase inhibition leading to reproductive dysfunction via interference with spindle assembly checkpoint"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Non-steroidal anti-inflammatory drugs have been specifically designed to inhibit cyclooxygenase active site of PTGS; these mechanisms of inhibition are well characterized (Simmons et al, 2004). NSAIDs interfere with COX site via multiple mechanisms including competitive inhibition (most NSAIDs compete for active site with arachidonic acid) and covalent modification (irreversible acetylation) of COX (e.g., aspirin) (Simmons et al., 2004; Willoughby et al., 2011). NSAIDs display different levels of selectivity for the COX-1 vs. COX-2 isoforms (Simmons et al., 2004). Majority of NSAIDs inhibit both isoforms (with variable levels of selectivity for COX-1 vs. COX-2), but several have been designed to preferentially inhibit COX-2 (Bacchi et al., 2012). Recently, COX-1 specific inhibitors have been developed and their therapeutic potential is being explored (Liedtke et al., 2012). Most extensive evidence regarding chemical initiation of this event comes from the mammalian literature and relates to NSAIDs. In addition to NSAIDs, common environmental contaminants of diverse chemical structures and uses (e.g., parabens, phthalates, benzophenones) have been postulated to inhibit prostaglandin synthesis via COX inhibition (Kristensen et al., 2011). U.S. EPA’s high throughput screening program (ACToR, epa.gov) indicated COX as a frequent contaminant target - 61% of 143 tested chemicals inhibited COX-1 and 59% of 106 inhibited COX-2 activity. Several chemicals were either similar in potency (e.g., monobutylphthalate) or more potent than NSAIDs (e.g., insecticide emamectin benzoate and industrial intermediary 1-Chloro-4-nitrobenzene were more potent inhibitors of COX2 than NSAID celecoxib, which was specifically designed to inhibit COX-2). Mechanisms of inhibition for these chemicals are not well elucidated."@en ;
  foaf:page <https://identifiers.org/aop/103> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/103> a sbd:Model ;
  rdfs:label "Cyclooxygenase inhibition leading to reproductive dysfunction via interference with spindle assembly checkpoint"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/103> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/103> a sbd:Model ;
  rdfs:label "Cyclooxygenase inhibition leading to reproductive dysfunction via interference with spindle assembly checkpoint"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Non-steroidal anti-inflammatory drugs have been specifically designed to inhibit cyclooxygenase active site of PTGS; these mechanisms of inhibition are well characterized (Simmons et al, 2004). NSAIDs interfere with COX site via multiple mechanisms including competitive inhibition (most NSAIDs compete for active site with arachidonic acid) and covalent modification (irreversible acetylation) of COX (e.g., aspirin) (Simmons et al., 2004; Willoughby et al., 2011). NSAIDs display different levels of selectivity for the COX-1 vs. COX-2 isoforms (Simmons et al., 2004). Majority of NSAIDs inhibit both isoforms (with variable levels of selectivity for COX-1 vs. COX-2), but several have been designed to preferentially inhibit COX-2 (Bacchi et al., 2012). Recently, COX-1 specific inhibitors have been developed and their therapeutic potential is being explored (Liedtke et al., 2012). Most extensive evidence regarding chemical initiation of this event comes from the mammalian literature and relates to NSAIDs. In addition to NSAIDs, common environmental contaminants of diverse chemical structures and uses (e.g., parabens, phthalates, benzophenones) have been postulated to inhibit prostaglandin synthesis via COX inhibition (Kristensen et al., 2011). U.S. EPA’s high throughput screening program (ACToR, epa.gov) indicated COX as a frequent contaminant target - 61% of 143 tested chemicals inhibited COX-1 and 59% of 106 inhibited COX-2 activity. Several chemicals were either similar in potency (e.g., monobutylphthalate) or more potent than NSAIDs (e.g., insecticide emamectin benzoate and industrial intermediary 1-Chloro-4-nitrobenzene were more potent inhibitors of COX2 than NSAID celecoxib, which was specifically designed to inhibit COX-2). Mechanisms of inhibition for these chemicals are not well elucidated."@en ;
  foaf:page <https://identifiers.org/aop/103> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/104> a sbd:Model ;
  rdfs:label "Altered ion channel activity leading impaired heart function"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Increased mortality is one of the most common regulatory assessment endpoints,&nbsp;along with reduced growth and reduced reproduction."@en ;
  foaf:page <https://identifiers.org/aop/104> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/106> a sbd:Model ;
  rdfs:label "Chemical binding to tubulin in oocytes leading to aneuploid offspring"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Various international regulatory agencies have established policies and practices for the assessment and management of heritable mutagenic hazards. Indeed, heritable effects are an important regulatory endpoint noted by agencies around the world [Yauk et al., 2015a].  The World Health Organization (WHO)/International Programme on Chemical Safety (IPCS) developed a harmonized scheme for mutagenicity testing. In this document the relationship between somatic cell mutagenicity and germ cell risk is summarized as: &ldquo;For substances that give positive results for mutagenic effects in somatic cells in vivo, their potential to affect germ cells should be considered. If there is toxicokinetic or toxicodynamic evidence that germ cells are actually exposed to the somatic mutagen or its bioactive metabolites, it is reasonable to assume that the substance may also pose a mutagenic hazard to germ cells and thus a risk to future generations.&rdquo; [Eastmond et al., 2009].  Thus, assessment of heritable mutagenic hazards such as aneuploidy, are an important regulatory endpoint. During drug and chemical development, agents that induce aneuploidy would not be developed further. There is currently not a specific example that can be referenced of a regulatory decision based on this adverse outcome. However, the UK Committee on Mutagenicity of Chemicals in Foods, Consumer Products and the Environment in its 2007 annual report (https://www.gov.uk/government/collections/com-guidance-statements) did recommend that the risk assessment of certain benzimidazoles be conducted solely on the aneugenic properties of these compounds.  The development of AOPs related to mutagenicity in germ cells [Yauk et al., 2015b; 2016] is expected to aid the identification of potential hazards to germ cell genomic integrity and support regulatory efforts to protect population health."@en ;
  foaf:page <https://identifiers.org/aop/106> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/106> a sbd:Model ;
  rdfs:label "Chemical binding to tubulin in oocytes leading to aneuploid offspring"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Colchicine is a prototypical spindle poison that has been extensively used to investigate binding to tubulin. The kinetics of colchicine binding are well established [Lambeir and Engelborghs, 1981; Engelborghs, 1998] and can be measured experimentally with high precision [Hamel and Lin, 1981]. Colchicine binds non-polymerized &alpha;/&beta; dimeric tubulin by a two-step process. The first step is rapid but weak, resulting in the formation of an initial pre-equilibrium complex, which involves a low affinity binding of colchicine that is reversible. This is followed by slow conformational changes in tubulin, which finally lead to the formation of an irreversible final state tubulin&ndash;colchicine complex that has high activation energy [Garland 1978]. The conformational change in tubulin heterodimers, followed by the addition of the complex at the ends of microtubules, is responsible for the suppressed polymerization at microtubule ends leading to their depolymerization [Ravelli et al., 2004]. The binding kinetics have been studied at different temperatures. The standard enthalpy change of the first step (&Delta;H&deg;1 = -33&plusmn;8 kJ &middot; mol&ndash;1) and the activation energy of the second step (&Delta;H&deg;2 = 100&plusmn;5 kJ &middot; mol&ndash;1) were determined based on the temperature dependence [Lambeir and Engelborghs, 1981]. Using eight different analogues to study the binding mechanisms of colchicine, it was demonstrated that the C-ring of colchicine is responsible for the first step of the binding mechanism, while the second step involves the rearrangement of the initial complex to interact with the A-ring [Engelborghs, 1998].  Other chemicals are also known to bind to tubulin [Marchetti et al., 2016]. These chemicals can be grouped in two general classes: colchicine domain binders and vinca domain binders.  Known colchicine domain binders:  1. Podophyllotoxin ((5R,5aR,8aR,9R)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one, POD) has a trimethoxybenzoic chemical structure similar to colchicine. It inhibits colchicine binding to the colchicine-binding domain of tubulin. However, although colchicine and podophyllotoxin bind in the same pocket on &beta;-tubulin, their binding sites are not completely overlapping [Desbene and Giorgi-Renault 2002].  2. 2-methoxyestradiol ((8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol, 2ME) binds to the colchicine domain of tubulin [D&#39;Amato et al. 1994].  3. Nocodazole (methyl (5-[2-thienylcarbonyl]-1H-benzimidazol-2-yl, NOC) belongs to the group of benzimidazole derivatives that were patented, as a class, for the treatment of cancer in conjunction with other pharmaceuticals. Nocodazole has been shown to bind in the colchicine domain [Xu et al. 2002].  4. Benomyl (methyl N-[1-(butylcarbamoyl)benzimidazol-2-yl]carbamate, BEN), another benzimidazole derivative, is the active compound in several agricultural fungicides. The benomyl-binding site is located in the core of &beta;-tubulin at a site distinct from the colchicine domain [Clement et al. 2008].  5. Carbendazim (methyl N-(1H-benzimidazol-2-yl)carbamate, MBC) is a fungicide commonly used in agriculture for the control of a wide range of fungal diseases. Carbendazim is the methylbenzimidazolcarbamate product of the spontaneous hydrolyzation process incurred by benomyl in aqueous solution (it is the major metabolite). Therefore, it is at least partially responsible for the benomyl effects observed in vivo. The affinity of carbendazim for mammalian tubulin is less than that of benomyl, most probably because it lacks the position 1 side chain of benomyl. Like benomyl, carbendazim does not compete with colchicine for binding to tubulin [Yenjerla et al., 2008].  6. Thiabendazole (4-(1H-benzimidazol-2-yl)-1,3-thiazole, TBZ) is a benzimidazole-derived anthelmintic and an agricultural fungicide, structurally related to NOC, benomyl and MBC. TBZ competitively inhibits MBC binding to fungal tubulin [Davidse and Flach, 1978].  7. ABT-751 (N-(2-((4-hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide) has a scaffold based on a benzsulfamide group. It was identified as a potent antiproliferative agent and was subsequently found to be an antitubulin agent by targeting the colchicine binding site [Yoshimatsu et al., 1997].  8. A compound base on m-ethoxyaniline group (2-(6-ethoxy-3-(3-ethoxyphenylamino)-1-methyl-1,4-dihydroindeno[1,2-c]pyrazol-7-yloxy)acetamide) showed noteworthy low nanomolar potency against cancer cell lines. In mechanistic studies, it inhibited tubulin polymerization and disorganized microtubule by binding to tubulin colchicine binding site [Liu et al., 2016].  Vinca domain binders:  The vinca alkaloids, a class of antimitotic compounds derived from the periwinkle plant, Catharanthus roseus [Cutts et al., 1960], bind near the GTP-binding site on the &beta;-subunit of tubulin at a site distinct from the colchicine-binding one [Rai and Wolff 1996]. Vinblastine and vincristine are ﬁrst-generation vinca alkaloids [Kingston, 2009]. At low concentrations, vincas bind to the plus ends of microtubules producing a conformational change of dimers from a straight &lsquo;&lsquo;growing&rsquo;&rsquo; vector to a curved &lsquo;&lsquo;peeling&rsquo;&rsquo; vector [Toso et al., 1993]. At higher concentrations, the vinca alkaloids have afﬁnity for free tubulin heterodimers, again potentially forming an altered, curved geometry of the dimeric biological vector [Warfield and Bouck, 1974]. Although vincas do not share structural similarity with colchicine and bind to a different site on tubulin, they similarly act by destabilizing microtubules [Stanton et al., 2011].  Vinca domain binders include:  1. Vinblastine (dimethyl (2&beta;,3&beta;,4&beta;,5&alpha;,12&beta;,19&alpha;)-15-[(5S,9S)-5-ethyl-5-hydroxy-9-(methoxycarbonyl)-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4b]indol-9-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3,4-dicarboxylate, VBL) is an anticancer drug that is used extensively. The crystal structure of vinblastine bound to tubulin has been determined [Gigant et al., 2005]. In contrast with the binding site for colchicine, which is mostly embedded in &beta;-tubulin subunit, the vinblastine binding site is shared equally between &alpha;/&beta;-heterodimer [Marchetti et al., 2016]. In the &beta;-subunit, vinblastine interacts through van der Waals contacts with residues Ser&beta;174-Asp&beta;179, Asn&beta;206-Asp&beta;211, Phe&beta;214 and Tyr&beta;224; while in the &alpha;-subunit, Phe&alpha;351, Lys&alpha;352, Val&alpha;353 and Ile&alpha;355 delimit the pocket occupied by VBL. Amino acids Pro&beta;222 and Asn&alpha;329 are also involved in hydrogen bond interactions with VBL [Marchetti et al., 2016]. Following a mechanism similar to colchicine, VBL binds to tubulin in two consecutive steps: formation of a rapid equilibrium complex followed by a slower rearrangement linked to changes in the structure of the heterodimer. A major effect of VBL is the formation of spiral-like tubulin aggregates [Weisenberg and Timasheff, 1970; Himes, 1991]. VBL binds to microtubule ends [Wilson et al., 1982] and at low concentrations suppresses the dynamic instability of plus ends [Toso et al., 1993]. When used at much higher concentrations, VBL depolymerizes microtubules, giving rise in particular to protofilament spirals and curls.  2. Vincristine (methyl (3aR,3a1R,4R,5S,5aR,10bR)-4-acetoxy-3a-ethyl-9-((5S,7S,9S)-5-ethyl-5-hydroxy-9-(methoxycarbonyl)1,4,5,6,7,8,9,10-octahydro-2H-3,7-methano[1]azacycloundecino[5,4-b]indol-9-yl)-6-formyl-5-hydroxy-8-methoxy-3a,3a1,4,5,5a,6,11,12-octahydro-1H-indolizino[8,1-cd]carbasole-5-carboxylate, VCR) is an anticancer drug that binds to tubulin in the vinca binding domain [Kingston, 2009].  3. Vinflunine (methyl (3aR,3a1R,4R,5S,5aR,10bR)-4-acetoxy-9-((4R,6R,8S)-4-(1,1-difluoroethyl)-8-(methoxycarbonyl)-1,3,4,5,6,7,8,9-octahydro-2,6-methanoazecino[4,3-b]indol-8-yl)-3a-ethyl-5-hydroxy-8-methoxy-6-methyl-3a,3a1,4,5,5a,6,11,12-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate) is a florinated Vinca alkaloid, like vinblastine and vincristine, and appears to interact at the Vinca binding domain [Kruczynski et al., 1998].  4. Vintafolide ((2R,5S,8S,11S,14S,19S)-19-(4-(((2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl)amino)benzamido)-5,8,14-tris(carboxymethyl)-2-(((2-((2-((3aR,3a1R,4R,5S,5aR,10bR)-3a-ethyl-9-((5S,7R,9S)-5-ethyl-5-hydroxy-9-(methoxycarbonyl)-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methano[1]azacycloundecino[5,4-b]indol-9-yl)-4,5-dihydroxy-8-methoxy-6-methyl-3a,3a1,4,5,5a,6,11,12-octahydro-1H-indolizino[8,1-cd]carbazole-5-carbonyl)hydrazine-1-carbonyl)oxy)ethyl)disulfanyl)methyl)-11-(3-guanidinopropyl)-4,7,10,13,16-pentaoxo-3,6,9,12,15-pentaazaicosanedioic acid) is a drug conjugate consisting of a small molecule targeting the folate receptor and vinblastine. Vintafolide is designed to deliver vinblastine selectively to cells over-expressing the folate receptor such as ovarian cancer cells [Vergote and Leamon, 2015]."@en ;
  foaf:page <https://identifiers.org/aop/106> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/106> a sbd:Model ;
  rdfs:label "Chemical binding to tubulin in oocytes leading to aneuploid offspring"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Aneuploidy is associated with serious human health effects. Approximately 10&ndash;30% of human zygotes, 50% of spontaneous abortions, and 0.3% of human newborns are aneuploid [Hassold et al., 2007; Nagaoka et al., 2012; Webster and Schuh, 2017]. Cytogenetic analyses of human oocytes and preimplantation embryos have reported frequencies of aneuploidy in excess of 50% [Magli et al., 2001; Munne, 2002; Kuliev et al., 2003]. In these studies, the overall aneuploidy frequency is estimated from the analysis of a subset of chromosomes, which may affect the accuracy of the estimate.  Aneuploidy can affect any chromosome [Nagaoka et al., 2012; Webster and Schuh, 2017], although there is evidence that acrocentric chromosomes may be more frequently involved in aneuploidy than metacentric chromosomes [Nicolaidis and Petersen, 1998; Hassold et al., 2007; Gianaroli et al., 2010]. In humans, only trisomies for a few autosomal chromosomes (13, 18 and 21) and aneuploidies of the sex chromosomes are compatible with life. These aneuploidies have important developmental, neurological and reproductive effects. Trisomy 21 or Down syndrome, with an occurrence of ~1/720 births, is the most common genetic abnormality in newborns [Hassold et al., 2007].  The etiology of human aneuploidy is still not well understood, although there is strong evidencesupporting a preferential occurrence during female meiosis I and a positive correlation with maternal age [Hunt and Hassold, 2002; Nagaoka et al., 2012]. The prevalence of chromosome segregation errors during female meiosis is clearly supported by the application of state-of-the-art genomic approaches, such as Comparative Genomic Hybridization (CGH), array-Comparative Genomic Hybridization (aCGH), SNP-arrays [Handyside, 2012; Nagaoka et al., 2012] and next generation sequencing (NGS) [Hou et al., 2013; Kung et al., 2015; Treff et al., 2016].   The present AOP focuses on chemical binding to tubulin that causes depolymerization of microtubules and generation of aneuploid cells. Although this molecular initiating event can occur in any cell, the adverse outcome is the generation of aneuploid conceptuses; therefore, this AOP is specific to germ cells, and in particular, to female germ cells.  &nbsp;  References  Gianaroli L, Magli MC, Cavallini G, Crippa A, Capoti A, Resta S, Robles F, Ferraretti AP. 2010. Predicting aneuploidy in human oocytes: key factors which affect the meiotic process. Hum Reprod 25:2374-2386.  Handyside AH. 2012. Molecular origin of female meiotic aneuploidies. Biochim Biophys Acta 1822:1913-1920.  Hassold T, Hall H, Hunt P. 2007. The origin of human aneuploidy: Where we have been, where we are going. Hum Mol Genet 16: R203&ndash;R208.  Hou Y, Fan W, Yan L, Li R, Lian Y, Huang J, Xu L, Tand F, Xiw XS, Qiao J. 2013. Genome analyses of single human oocytes. Cell 155:1492-1506.  Hunt PA, Hassold TJ. 2002. Sex matters in meiosis, Science 296:2181-2183.  Kuliev A, Cieslak J, Ilkevitch Y, Verlinsky Y. 2003. Chromosomal abnormalities in a series of 6,733 human oocytes in preimplantation diagnosis for age-related aneuploidies. Reprod Biomed Online 6:54-59.  Kung A, Munn&eacute; S, Bankowski B, Coates A, Wells D. 2015. Validation of next-generation sequencing for comprehensive chromosome screening of embryos. Reprod Biomed Online 31:760-769.  Magli MC, Gianaroli L, Ferraretti AP. 2001. Chromosomal abnormalities in embryos. Mol Cell Endocrinol 183:S29-34.  Munne S. 2002. Preimplantation genetic diagnosis of numerical and structural chromosome abnormalities. Reprod Biomed Online 4:183-196.  Nagaoka SI, Hassold TJ, Hunt PA. 2012. Human aneuploidy: Mechanisms and new insights into an age-old problem. Nat Rev Genet 13:493&ndash;504.  Nicolaidis P, Petersen MB. 1998. Origin and mechanisms of non-disjunction in human autosomal trisomies. Hum Reprod 13:313-319.  Treff NR, Kirsher RL, Tao X, Garnsey H, Boher C, Silva E, Landis J, Taylor D, Scott RT, Woodruff TK, Duncan FE. 2016. Next Generation Sequencing-based comprehensive chromosome screening in mouse polar bodies, oocytes, and embryos. Biol Reprod 94:76  Webster A, Schuh M. 2017. Mechanisms of aneuploidy in human eggs. Trends Cell Biol 27:55-68."@en ;
  foaf:page <https://identifiers.org/aop/106> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/107> a sbd:Model ;
  rdfs:label "Constitutive androstane receptor activation leading to hepatocellular adenomas and carcinomas in the mouse and the rat"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Stressors of CAR (i.e. chemicals that activate CAR) can be quite species-specific, due to the heterogeneity of the amino acid sequence of CAR, particularly in the ligand binding domain. TCPOBOP (1,4-bis-[2-(3,5-dichloropyridyloxy)]benzene, 3,3&prime;,5,5&prime;-tetrachloro-1,4-bis(pyridyloxy)benzene) is a very potent direct CAR activator in the mouse (Huang et al., 2005;&nbsp; Omiecinski et al., 2011b). In reporter assays for CAR from mouse, rat, human and dog, TCPOBOP was shown to be a strong activator of mouse CAR (28-fold), but it showed no activation of rat and dog CAR, and only a minimal activation of human CAR (3-fold) (Omiecinski et al., 2011b). Consistent with this potent activation in mice, &nbsp;studies in wild-type and CAR-null mice showed that absence of the CAR receptor effectively blocked CAR-mediated downstream effects including gene activation (Tojima et al., 2012), cell proliferation (Huang et al., 2005;&nbsp; Wei et al., 2000) and &nbsp;formation of liver tumors (Diwan et al., 1992;&nbsp; Huang et al., 2005).  Metofluthrin is a potent activator of CAR in rats, and produces liver tumors in chronic toxicity studies in male and female Wistar rats, but&nbsp;no liver tumors in male and female CD-1 mice&nbsp;(Yamada et al., 2009). In rats, metofluthrin produced significant increases in gene expression of CAR-responsive genes Cyp2b1/2 and Cyp3a1, increased cell proliferation and increased indirect markers of CAR activation such as CYP2B protein levels and hepatocellular hypertrophy. While metofluthrin was&nbsp;not tested in CAR-null rats, isolated rat hepatocyte cultures treated with metofluthrin and siRNA for CAR (a gene silencing technique) caused a knockdown of Car mRNA expression and resulting suppression of the response to metofluthrin in terms of Cyp2b1 mRNA and Car mRNA levels (Deguchi et al., 2009). This suppression indicates that metofluthrin produces its in vivo effects in rats via activation of CAR.  Phenobarbital is an indirect activator of CAR, in that it does not bind directly to the ligand binding domain, but instead binds to an&nbsp;EGF receptor to initiate a series of steps that eventually dephosphorylate a critical Threonine-38 residue in CAR, allowing it to migrate into the nucleus and alter gene expression (Mutoh et al., 2009;&nbsp; Mutoh et al., 2013;&nbsp; Swales and Negishi, 2004). Downstream events following CAR activation by phenobarbital have been shown to be essentially the same as with direct CAR activators, and include Cyp2b10 gene expression, cell proliferation and increases in mouse liver tumors (Huang et al., 2005), which are prevented by treatment of CAR-null mice lacking the CAR receptor (Huang et al., 2005;&nbsp; Wei et al., 2000;&nbsp; Yamamoto et al., 2004). Thus, lack of these downstream key events in CAR-null mice, including an initiation-promotion study, has been used to demonstrate that phenobarbital activates the CAR receptor in mice."@en ;
  foaf:page <https://identifiers.org/aop/107> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/107> a sbd:Model ;
  rdfs:label "Constitutive androstane receptor activation leading to hepatocellular adenomas and carcinomas in the mouse and the rat"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "In&nbsp;chronic carcinogenicity studies conducted in rats and mice as part of the registration process for drugs, agrochemicals and other xenobiotics, a frequent finding after high dose treatments is hepatocellular adenomas and carcinomas in the liver (Cohen, 2010; Gold et al., 2005). An AOP via activation of the CAR nuclear receptor is one well-understood mechanism by which these tumors can occur (Elcombe et al., 2014).&nbsp; An overall framework for describing a mode of action (Anderson et al., 2014; Meek et al., 2014) has established that a mode of action (or an AOP)&nbsp;can be described based on a series of Key Events (KEs), which are causal and required precursor steps to the AO.&nbsp;&nbsp;Studies comparing the postulated KEs in various species (e.g. rat, mouse, hamster, guinea pig, non-human primate) as well as in human hepatocytes or humans on&nbsp;chronic treatment with CAR activating drugs, have indicated large species differences in the susceptibility to 1) certain key events including KE2&nbsp;(cell proliferation) and 2) the ability of CAR activators to produce liver tumors. The main purpose of this AOP is to outline the measurable key events for an AOP via CAR activation that leads to liver tumors in rats and mice. However, by summarizing experimental results across a wider range of mammalian species, the AOP outlines species differences relating to the KEs and the AO. By this approach, it is intended that the AOP can help the wider scientific and regulatory community to recognize the measurable KEs that would indicate a xenobiotic produces liver effects via this AOP, and the methods typically employed to demonstrate the thresholds in dose-response, below which no KEs and no tumors have been shown to occur in rats and/or mice with model CAR activators.  Published summaries regarding the CAR mode of action (Elcombe et al., 2014; Peffer et al., 2018a; Peffer et al., 2018b; Lake, 2018) have identified a similar set of KEs, and they also identify associatve events, which are biological processes that are not necessary for the AOP, but can often be used as surrogate markers for a&nbsp;particular KE (Anderson et al., 2014).&nbsp; The associative events that follow CAR activation include:&nbsp; 1)&nbsp;Increased CYP2B, CYP3A enzyme activity and/or protein in hepatocytes; 2) increased hepatocellular hypertrophy; and 3) increased liver weight.&nbsp; Based on the guidance for writing AOPs, this current AOP on CAR activation leading to rodent hepatocellular tumors does not specifically include&nbsp;associative events within the graphical illustration (Figure 1),&nbsp;but instead identifies them within the&nbsp;context of &quot;How the KE is measured&quot; within each individual KE or KER.&nbsp;&nbsp;These associative events&nbsp;are readily measured in the course of many toxicology studies, and provide useful markers for the KEs that are part of the CAR AOP.&nbsp;&nbsp;  CAR (NR1I3) and PXR (pregnane X receptor; NR1I2)) are often cited together regarding potential mode(s) of action (MoA)&nbsp;for a specific chemical agent, because they are from the same family of nuclear receptors and exhibit extensive cross-talk in terms of the set of genes and response elements that they can activate (Stanley et al., 2006).&nbsp;In the published proceedings of a nuclear receptor workshop on the CAR / PXR MoA (Andersen et al., 2014; Elcombe et al., 2014), the authors could not identify a suitable nongenotoxic PXR activator for which carcinogenicity data were available, and hence a MoA was not developed for liver tumor formation by PXR&nbsp;activators. Some agents can activate both CAR and PXR in a particular species (Elcombe et al., 2014). In fact, PXR is activated by a large array of chemical substances, far more than those that activate CAR (Martin et al., 2010; Timsit and Negishi, 2007; Willson and Kliewer, 2002). PXR has been shown to increase liver weight after activation by a number of substrates, but suspected activators of PXR such as pregnenolone-16&alpha;-carbonitrile or dexamethasone have not consistently shown increases in assays for cell proliferation in rats and mice (Lake et al., 1998;&nbsp; Shizu et al., 2013; Thatcher and Caldwell, 1994). PXR activation is classically considered to selectively induce increased expression of CYP3A isoforms, with lesser induction of CYP2B isoforms, but again, cross-talk between PXR and CAR receptors upon activation of either nuclear receptor can be part of the altered expression of these Cyp isoforms in vivo. Given the lack of actual tumorigenic key events due to PXR activators alone, the rest of this current AOP will focus on the CAR&nbsp;mode of action&nbsp;by itself.  The&nbsp;AOP submitted here is limited to a definitive set of readily measurable endpoints that encompass the KEs that are critical to the progression from CAR activation to liver tumor formation, and differentiate an agent that works via CAR activation from one that operates by alternative modes of action. &nbsp;Therefore, not all of the possible biochemical steps discussed by Elcombe et al. (2014) or proposed in other publications are shown&nbsp;(Phillips and Goodman, 2008; Moennikes et al., 2000, Huang et al., 2005; Brauening et al., 2016).&nbsp;&nbsp;While suppression of apoptosis, changes in DNA methylation status or inhibition of gap junction intercellular communication (GJIC) have been shown to occur in rodent liver after treatment with CAR activators such as phenobarbital (Huang et al., 2005; Klaunig et al., 1990; Moennikes et al., 2000; Phillips and Goodman, 2008), these were viewed by Elcombe et al. (2014)&nbsp;as associative events, since clear demonstrations of essentiality and/or association with CAR activation have not been established. More importantly regarding the AOP for CAR activation, these possible associative events require specialized techniques to demonstrate them, such as micro-injection of individual hepatocytes with dye in the case of GJIC (Klaunig et al., 1990), or examination of apoptosis within altered foci at later time points in longer-term studies (Kolaja et al., 1996b). Considering the specialized methods needed and the fact that these&nbsp;associative events&nbsp;are not considered essential to demonstrating the overall AOP, they are not included in the set of KEs&nbsp;described in this AOP (Figure 1 and Table&nbsp;1).&nbsp; As with all of the AOPs on the AOPwiki site, this AOP for rodent liver tumors via CAR activation may be modified in the future to include additional or different KEs and experimental markers of those KEs&nbsp;as the understanding of these toxicological processes evolves.&nbsp;  Table 1 (see below)  In Table 1, the typical data that is generated to demonstrate a molecule produces a liver tumor response in mice or rats via CAR activation AOP is described. However, this should not be viewed as a set of required studies, as other techniques are available that can lead to the same endpoint of demonstrating the KEs in a CAR AOP, or markers for them. A more thorough description of current and emerging methods for identifying a CAR mode of action with a particular molecule is available in Peffer et al., 2018b."@en ;
  foaf:page <https://identifiers.org/aop/107> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/110> a sbd:Model ;
  rdfs:label "Inhibition of iodide pump activity leading to follicular cell adenomas and carcinomas (in rat and mouse)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Thyroid Disrupting Chemicals (TDCs) are defined as the xenobiotics that interfere with the thyroid axis with different outcomes for the organism. A very well-studied mechanism of action of the TDCs is the reduction of the circulating levels of THs by inhibiting hormone synthesis in the thyroid gland. For example, perchlorate is a very potent inhibitor of iodide uptake through the sodium/iodide symporter (Tonacchera et al., 2004). Perchlorate has been detected in human breast milk ranging from 1.4 to 92.2 mg &mu;l&ndash;1 (10.5 &mu;g l&ndash;1 mean) in 18 US states (Kirk et al. 2005), and 1.3 to 411 &mu;g l&ndash;1 (9.1 &mu;g l&ndash;1 median) in the Boston area, United States (Pearce et al. 2007). Perchlorate has also been detected in human colostrum of 46 women in the Boston area (from &lt; 0.05 to 187.2 &mu;mol l&ndash;1 (Leung et al. 2009)). The mechanism of perchlorate action is quite simple, as it is believed to be mediated only by the NIS inhibition (Dohan et al., 2007; Wolff, 1998). Additionally, thiocyanate and nitrate are two known inhibitors that have been found to reduce circulating TH levels (Blount et al., 2006; Steinhaus et al., 2007), but they are both less potent than perchlorate (Tonacchera et al., 2004). However, there are also contradictory results from other studies that showed no correlation between thyroid parameters and perchlorate levels in humans (Pearce et al., 2010; Amitai et al., 2007; Tellez et al., 2005).  Co-occurrence of perchlorate, nitrate, and thiocyanate can alter thyroid function in pregnant women. Horton et al. (2015) have shown positive associations between the weighted sum of urinary concentrations of these three analytes and increased TSH, with perchlorate showing the largest weight in the index. Interestingly, De Groef et al. 2006 showed that nitrate and thiocyanate, acquired through drinking water or food, account for a much larger proportion of iodine uptake inhibition than perchlorate, suggesting that NIS inhibition and any potential downstream effect by perchlorate are highly dependent on the presence of other environmental NIS inhibitors and iodine intake itself (Leung et al., 2010). In particular, Tonacchera et al. (2004) showed that the relative potency of perchlorate to inhibit radioactive I&minus; uptake by NIS is 15, 30 and 240 times that of thiocyanate, iodide, and nitrate respectively on a molar concentration basis. These data are in line with earlier studies in rats (Alexander and Wolff, 1996; Greer et al. 1966). Contradictory findings in these studies may therefore be a result of the confounding mixtures in the environment, masking the primary effect of perchlorate.  Decreased iodine intake can decrease TH production, and therefore exposure to perchlorate might be particularly detrimental in iodine-deficient individuals (Leung et al. 2010). Moreover, biologically based dose-response modeling of the relationships among iodide status (e.g., dietary iodine levels), perchlorate dose, and TH production in pregnant women has shown that iodide intake has a profound effect on the likelihood that exposure to goitrogens will produce hypothyroxinemia (Lewandowski et al. 2015).  During pregnancy TH requirements increase, particularly during the first trimester (Alexander et al. 2004; Leung et al. 2010), due to higher concentrations of thyroxine-binding globulin, placental T4 inner-ring deiodination leading to the inactive reverse T3 (rT3), and transfer of small amounts of T4 to the foetus (during the first trimester foetal thyroid function is absent). Moreover, glomerular filtration rate and clearance of proteins and other molecules are both increased during pregnancy, possibly causing increased renal iodide clearance and a decreased of circulating plasma iodine (Glinoer, 1997). Thus, even though the foetal thyroid can trap iodide by about 12 week of gestation (Fisher and Klein, 1981), high concentrations of maternal perchlorate may potentially decrease thyroidal iodine available to the foetus by inhibiting placental NIS (Leung et al. 2010).  Consequences of TH deficiency depend on the developmental timing of the deficiency (Zoeller and Rovet, 2004). For instance, if the TH deficiency occurs during early pregnancy, offspring show visual attention, visual processing and gross motor skills deficits, while if it occurs later, offspring may show subnormal visual and visuospatial skills, along with slower response speeds and motor deficits. If TH insufficiency occurs after birth, language and memory skills are most predominantly affected (Zoeller and Rovet, 2004).  Along this line, age and developmental stage are crucial in determining sensitivity to NIS inhibitors (e.g., perchlorate, thiocyanate, and nitrate). In this regard, McMullen et al. (2017) have shown that adolescent boys and girls, more than adults, represent vulnerable subpopulations to NIS symporter inhibitors. Altogether these studies indicate that age, gender, developmental stage, and dietary iodine levels can affect the impact of NIS inhibitors.  Finally, ten more small simple-structured molecules were identified in a large screening study (Lecat-Guillet et al., 2008b) that could block iodide uptake by specifically disrupting NIS in a dose-dependent manner. These molecules were named Iodide Transport Blockers (ITBs). There are few organic molecules that lead to NIS inhibition but no direct interaction with NIS has been determined (Gerard et al., 1994; Kaminsky et al., 1991). Up to date, only dysidenin, a toxin isolated from the marine sponge Dysidea herbacea, has been reported to specifically inhibit NIS (Van Sande et al., 2003). Finally, the aryltrifluoroborates were found to inhibit iodide uptake with an IC50 value of 0.4 &mu;M on rat-derived thyroid cells (Lecat-Guillet et al., 2008a). The biological activity is rationalized by the presence of the BF3&minus; ion as a minimal binding motif for substrate recognition at the iodide binding site.  It has been also shown that many anions, such as ClO3-, SCN-, NO3-, ReO4-, TcO4- and in a lower extent Br- and BF4-, are also acting as NIS substrates and they enter the cell by the same transporter mechanism (Van Sande et al., 2003). It has been also shown that ClO4- is transferred by NIS with high affinity and is considered as one of its most potent inhibitors (Dohan et al., 2007). Most recently, the aryltrifluoroborates were also shown to inhibit NIS function (Lecat-Guillet et al., 2008a). A library of 17,020 compounds was tested by a radioactive screening method with high specificity using transfected mammalian cells (Lecat-Guillet et al., 2008b; 2007) for NIS inhibition evaluation. Further studies with the most powerful inhibitors showed a high diversity in their structure and mode of action (Lindenthal et al., 2009)."@en ;
  foaf:page <https://identifiers.org/aop/110> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/113> a sbd:Model ;
  rdfs:label "Glutamate-gated chloride channel activation leading to acute mortality"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Increased mortality is one of the most common regulatory assessment endpoints,&nbsp;along with reduced growth and reduced reproduction."@en ;
  foaf:page <https://identifiers.org/aop/113> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/113> a sbd:Model ;
  rdfs:label "Glutamate-gated chloride channel activation leading to acute mortality"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Increased mortality is one of the most common regulatory assessment endpoints,&nbsp;along with reduced growth and reduced reproduction."@en ;
  foaf:page <https://identifiers.org/aop/113> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/119> a sbd:Model ;
  rdfs:label "Inhibition of thyroid peroxidase leading to follicular cell adenomas and carcinomas (in rat and mouse)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "There is a wealth of information on the inhibition of TPO by drugs such as MMI and PTU, as well as environmental xenobiotics. In the landmark paper on TH system&nbsp;disruption by environmental chemicals, Brucker-Davis (1998) identified environmental chemicals that depressed TH synthesis by inhibiting TPO. Hurley (1998) listed TPO as a major target for thyroid tumor inducing pesticides. More recent work has tested over 1000 chemicals using a high-throughput screening assay (Paul-Friedman et al., 2016)."@en ;
  foaf:page <https://identifiers.org/aop/119> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/12> a sbd:Model ;
  rdfs:label "Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development leads to neurodegeneration with impairment in learning and memory in aging"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Glu and glycine are endogenous agonists that bind to LBD of specific NMDA receptor subunits. In this binding site numerous competitive exogenous antagonists have been identified to cause closure of binding site and inhibition of NMDA receptor (reviewed in Traynelis et al., 2010). Here, are listed some known competitive antagonists for NMDA receptor, some of them are specific to NR1 subunit and some to NR2 subunit:  &alpha;-AA, &alpha;-aminoadipate;  5,7-DCKA, 5,7-dichlorokynurenic acid;  7-CKA, 7-chlorokynurenic acid;  ACEA-1011, 5-chloro-7-trifluoromethyl-1,4-dihydro-2,3-quinoxalinedione;  ACEA-1021, licostinel;  AP5, 2-amino-5-phosphonopentanoate;  AP7, 2-amino-7-phosphonopentanoate;  CGP-61594, (&plusmn;)-trans-4-[2-(4-azidophyenyl)acetylamino]-5,7-dichloro-1,2,3,4-tetrahydroquinoline-2-carboxylic acid;  CGP-40116, d-(E)-2-amino-4-methyl-5-phosphono-3-pentenoic acid;  CGP-43487, d-(E)-2-amino-4-methyl-5-phosphono-3-pentenoic acid methyl ester;  CGP-58411, 7-chloro-4-hydroxy-3-phenyl-1H-quinolin-2-one;  CGS-19755, (2R,4S)-4-(phosphonomethyl)piperidine-2-carboxylic acid;  CPP, 4-(3-phosphonopropyl) pizerazine-2-carboxylic acid;  GV150,526A, gavestinel;  GV196,771A, (E)-4,6-dichloro-3-[(2-oxo-1-phenyl-3-pyrrolidinylidene)methyl]-1H-indole-2-carboxylic acid;  L-689,560, 4-trans-2-carboxy-5,7-dichloro-4-phenylaminocarbonylamino-1,2,3,4-tetrahydroquinoline;  L-701,324, 7-chloro-4-hydroxy-3-(3-phenoxy)phenyl-2(1H)-quinolone;  MDL105,519, (E)-3-(2-phenyl-2-carboxyethenyl)-4, 6-dichloro-1H-indole-2-carboxylic acid;  PBPD, (2S,3R)-1-(biphenyl-4-carbonyl)piperazine-2,3-dicarboxylic acid;  PMPA, (R,S)-4-(phosphonomethyl)-piperazine-2-carboxylic acid;  PPDA, (2S,3R)-1-(phenanthren-2-carbonyl)piperazine-2,3-dicarboxylic acid  Besides competitive antagonists, noncompetitive antagonists have also been designed like phenylethanolamine ifenprodil that interacts with the NR2B extracellular amino-terminal domain. It has been suggested that they act by stabilizing an agonist-bound state in which the receptor has a low open probability. Other more potent derivatives of ifenprodil are: &alpha;-(4-hydroxyphenyl)-&beta;-methyl-4-(phenylmethyl)-1-piperidine propanol (Ro 25-6981), 1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol (Ro 63-1908), besonprodil (CI-1041), and traxoprodil mesylate (CP-101,606). Ethanol has been proposed to be a noncompetitive antagonist of NMDA receptors, binding to NR2 subunit (Nagy, 2008). Inhibition of NMDA receptor function by ethanol and interactions between ethanol and the noncompetitive NMDA receptor antagonist ifenprodil have been examined in neocortical neurons from rat and human embryonic kidney (HEK) 293 cells expressing recombinant NMDA receptors (Lovinger, 1995). Recently, a structural model has been suggested that predicts the presence of four sites of ethanol action on the NMDA receptor, each containing four pairs of positions in the NR1/NR2 subunits (reviewed in Chandrasekar, 2013). Some other antagonists can become trapped in the pore of the NMDA receptor after channel closure and these antagonists are called uncompetitive or trapping blockers. The most well studied NMDA receptor uncompetitive antagonists are Mg2+, polyamines, phencyclidine, ketamine, MK-801, memantine, amantadine, pentamidine, 9-tetrahydroaminoacridine, dextromethorphan, and its metabolite dextrorphan. MK-801 has been shown to prevent toluene-induced alterations in pattern-elicited visual-evoked potentials in vivo, suggesting the possibility that the binding site of toluene might be common with the one of MK-801 (Bale et al., 2007). However, another study suggests that toluene interference with the NMDA receptor might not be exclusively because of the binding to the channel pore (Smothers and Woodward, 2007) but it may involve some other binding sites. Lead (Pb2+) is considered a voltage independent antagonist of NMDA receptors and it is believed that possibly shares the same binding site with Zn2+ (reviewed in Neal and Guilarte, 2010; Traynelis et al., 2010). However, studies done in recombinant NR2A- and NR2B- containing NMDA receptors with mutated Zn2+ binding sites exhibit that additional structural elements, different from those important for Zn2+ binding are involved in Pb2+ binding site (reviewed in Neal and Guilarte, 2010). Similarly, there are contradicting experimental evidence and disagreement about Pb2+&#39;s role as competitive or non-competitive antagonist (Neal and Guilarte, 2010). Pb2+ -induced inhibition of NMDAR during synaptogenesis in hippocampal neurons altered synaptic NMDAR composition, resulting in a decrease in NR2A-containing NMDARs at the established synapses (Neal et al., 2011)."@en ;
  foaf:page <https://identifiers.org/aop/12> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/12> a sbd:Model ;
  rdfs:label "Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development leads to neurodegeneration with impairment in learning and memory in aging"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Currently the four available OECD Test Guidelines (TGs) for neurotoxicity testing are entirely based on in vivo neurotoxicity studies: (1)Delayed Neurotoxicity of Organophosphorus Substances Following Acute Exposure (TG 418); (2) Delayed Neurotoxicity of Organophosphorus Substances: 28-day Repeated Dose Study (TG 419); (3) Neurotoxicity Study in Rodents (TG 424) involves daily oral dosing of rats for acute, subchronic, or chronic assessments (28 days, 90 days, or one year or longer); (4) Developmental Neurotoxicity (DNT) Study (TG 426) evaluates in utero and early postnatal effects by daily dosing of at least 60 pregnant rats from implantation through lactation. One of the endpoints required by all four of these OECD TGs is evaluation of neurodegeneration that, so far, is performed through in vivo neuropathological and histological studies. Therefore, neurodegeneration described in this AOP as a key event, has a regulatory relevance and could be performed using in vitro assays that allow a reliable evaluation of neurodegeneration using a large range of existing assays, specific for apoptosis, necrosis and autophagy ( see also KE Cell injury/Cell death)."@en ;
  foaf:page <https://identifiers.org/aop/12> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/12> a sbd:Model ;
  rdfs:label "Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development leads to neurodegeneration with impairment in learning and memory in aging"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "A prime example of impairments in learning and memory as the adverse outcome for regulatory action is developmental lead exposure and IQ function in children (Bellinger, 2012). Most methods are well established in the published literature and many have been engaged to evaluate the effects of developmental thyroid disruption. The US EPA and OECD Developmental Neurotoxicity (DNT) Guidelines (OCSPP 870.6300 or OECD TG 426) as well as OECD TG 443 (OECD, 2018) both require testing of learning and memory (USEPA, 1998; OECD, 2007) advising to use the following tests passive avoidance, delayed-matching-to-position for the adult rat and for the infant rat, olfactory conditioning, Morris water maze, Biel or Cincinnati maze, radial arm maze, T-maze, and acquisition and retention of schedule-controlled behaviour.&nbsp; These DNT Guidelines have been deemed valid to identify developmental neurotoxicity and adverse neurodevelopmental outcomes (Makris et al., 2009).  Also, in the frame of the OECD GD 43 (2008) on reproductive toxicity, learning and memory testing may have potential to be applied in the context of developmental neurotoxicity studies. However, many of the learning and memory tasks used in guideline studies may not readily detect subtle impairments in cognitive function associated with modest degrees of developmental thyroid disruption (Gilbert et al., 2012)."@en ;
  foaf:page <https://identifiers.org/aop/12> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/12> a sbd:Model ;
  rdfs:label "Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development leads to neurodegeneration with impairment in learning and memory in aging"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Glu and glycine are endogenous agonists that bind to LBD of specific NMDA receptor subunits. In this binding site numerous competitive exogenous antagonists have been identified to cause closure of binding site and inhibition of NMDA receptor (reviewed in Traynelis et al., 2010). Here, are listed some known competitive antagonists for NMDA receptor, some of them are specific to NR1 subunit and some to NR2 subunit:  &alpha;-AA, &alpha;-aminoadipate;  5,7-DCKA, 5,7-dichlorokynurenic acid;  7-CKA, 7-chlorokynurenic acid;  ACEA-1011, 5-chloro-7-trifluoromethyl-1,4-dihydro-2,3-quinoxalinedione;  ACEA-1021, licostinel;  AP5, 2-amino-5-phosphonopentanoate;  AP7, 2-amino-7-phosphonopentanoate;  CGP-61594, (&plusmn;)-trans-4-[2-(4-azidophyenyl)acetylamino]-5,7-dichloro-1,2,3,4-tetrahydroquinoline-2-carboxylic acid;  CGP-40116, d-(E)-2-amino-4-methyl-5-phosphono-3-pentenoic acid;  CGP-43487, d-(E)-2-amino-4-methyl-5-phosphono-3-pentenoic acid methyl ester;  CGP-58411, 7-chloro-4-hydroxy-3-phenyl-1H-quinolin-2-one;  CGS-19755, (2R,4S)-4-(phosphonomethyl)piperidine-2-carboxylic acid;  CPP, 4-(3-phosphonopropyl) pizerazine-2-carboxylic acid;  GV150,526A, gavestinel;  GV196,771A, (E)-4,6-dichloro-3-[(2-oxo-1-phenyl-3-pyrrolidinylidene)methyl]-1H-indole-2-carboxylic acid;  L-689,560, 4-trans-2-carboxy-5,7-dichloro-4-phenylaminocarbonylamino-1,2,3,4-tetrahydroquinoline;  L-701,324, 7-chloro-4-hydroxy-3-(3-phenoxy)phenyl-2(1H)-quinolone;  MDL105,519, (E)-3-(2-phenyl-2-carboxyethenyl)-4, 6-dichloro-1H-indole-2-carboxylic acid;  PBPD, (2S,3R)-1-(biphenyl-4-carbonyl)piperazine-2,3-dicarboxylic acid;  PMPA, (R,S)-4-(phosphonomethyl)-piperazine-2-carboxylic acid;  PPDA, (2S,3R)-1-(phenanthren-2-carbonyl)piperazine-2,3-dicarboxylic acid  Besides competitive antagonists, noncompetitive antagonists have also been designed like phenylethanolamine ifenprodil that interacts with the NR2B extracellular amino-terminal domain. It has been suggested that they act by stabilizing an agonist-bound state in which the receptor has a low open probability. Other more potent derivatives of ifenprodil are: &alpha;-(4-hydroxyphenyl)-&beta;-methyl-4-(phenylmethyl)-1-piperidine propanol (Ro 25-6981), 1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol (Ro 63-1908), besonprodil (CI-1041), and traxoprodil mesylate (CP-101,606). Ethanol has been proposed to be a noncompetitive antagonist of NMDA receptors, binding to NR2 subunit (Nagy, 2008). Inhibition of NMDA receptor function by ethanol and interactions between ethanol and the noncompetitive NMDA receptor antagonist ifenprodil have been examined in neocortical neurons from rat and human embryonic kidney (HEK) 293 cells expressing recombinant NMDA receptors (Lovinger, 1995). Recently, a structural model has been suggested that predicts the presence of four sites of ethanol action on the NMDA receptor, each containing four pairs of positions in the NR1/NR2 subunits (reviewed in Chandrasekar, 2013). Some other antagonists can become trapped in the pore of the NMDA receptor after channel closure and these antagonists are called uncompetitive or trapping blockers. The most well studied NMDA receptor uncompetitive antagonists are Mg2+, polyamines, phencyclidine, ketamine, MK-801, memantine, amantadine, pentamidine, 9-tetrahydroaminoacridine, dextromethorphan, and its metabolite dextrorphan. MK-801 has been shown to prevent toluene-induced alterations in pattern-elicited visual-evoked potentials in vivo, suggesting the possibility that the binding site of toluene might be common with the one of MK-801 (Bale et al., 2007). However, another study suggests that toluene interference with the NMDA receptor might not be exclusively because of the binding to the channel pore (Smothers and Woodward, 2007) but it may involve some other binding sites. Lead (Pb2+) is considered a voltage independent antagonist of NMDA receptors and it is believed that possibly shares the same binding site with Zn2+ (reviewed in Neal and Guilarte, 2010; Traynelis et al., 2010). However, studies done in recombinant NR2A- and NR2B- containing NMDA receptors with mutated Zn2+ binding sites exhibit that additional structural elements, different from those important for Zn2+ binding are involved in Pb2+ binding site (reviewed in Neal and Guilarte, 2010). Similarly, there are contradicting experimental evidence and disagreement about Pb2+&#39;s role as competitive or non-competitive antagonist (Neal and Guilarte, 2010). Pb2+ -induced inhibition of NMDAR during synaptogenesis in hippocampal neurons altered synaptic NMDAR composition, resulting in a decrease in NR2A-containing NMDARs at the established synapses (Neal et al., 2011)."@en ;
  foaf:page <https://identifiers.org/aop/12> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/12> a sbd:Model ;
  rdfs:label "Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development leads to neurodegeneration with impairment in learning and memory in aging"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Currently the four available OECD Test Guidelines (TGs) for neurotoxicity testing are entirely based on in vivo neurotoxicity studies: (1)Delayed Neurotoxicity of Organophosphorus Substances Following Acute Exposure (TG 418); (2) Delayed Neurotoxicity of Organophosphorus Substances: 28-day Repeated Dose Study (TG 419); (3) Neurotoxicity Study in Rodents (TG 424) involves daily oral dosing of rats for acute, subchronic, or chronic assessments (28 days, 90 days, or one year or longer); (4) Developmental Neurotoxicity (DNT) Study (TG 426) evaluates in utero and early postnatal effects by daily dosing of at least 60 pregnant rats from implantation through lactation. One of the endpoints required by all four of these OECD TGs is evaluation of neurodegeneration that, so far, is performed through in vivo neuropathological and histological studies. Therefore, neurodegeneration described in this AOP as a key event, has a regulatory relevance and could be performed using in vitro assays that allow a reliable evaluation of neurodegeneration using a large range of existing assays, specific for apoptosis, necrosis and autophagy ( see also KE Cell injury/Cell death)."@en ;
  foaf:page <https://identifiers.org/aop/12> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/12> a sbd:Model ;
  rdfs:label "Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development leads to neurodegeneration with impairment in learning and memory in aging"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "A prime example of impairments in learning and memory as the adverse outcome for regulatory action is developmental lead exposure and IQ function in children (Bellinger, 2012). Most methods are well established in the published literature and many have been engaged to evaluate the effects of developmental thyroid disruption. The US EPA and OECD Developmental Neurotoxicity (DNT) Guidelines (OCSPP 870.6300 or OECD TG 426) as well as OECD TG 443 (OECD, 2018) both require testing of learning and memory (USEPA, 1998; OECD, 2007) advising to use the following tests passive avoidance, delayed-matching-to-position for the adult rat and for the infant rat, olfactory conditioning, Morris water maze, Biel or Cincinnati maze, radial arm maze, T-maze, and acquisition and retention of schedule-controlled behaviour.&nbsp; These DNT Guidelines have been deemed valid to identify developmental neurotoxicity and adverse neurodevelopmental outcomes (Makris et al., 2009).  Also, in the frame of the OECD GD 43 (2008) on reproductive toxicity, learning and memory testing may have potential to be applied in the context of developmental neurotoxicity studies. However, many of the learning and memory tasks used in guideline studies may not readily detect subtle impairments in cognitive function associated with modest degrees of developmental thyroid disruption (Gilbert et al., 2012)."@en ;
  foaf:page <https://identifiers.org/aop/12> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/122> a sbd:Model ;
  rdfs:label "Prolyl hydroxylase inhibition leading to reproductive dysfunction via increased HIF1 heterodimer formation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/122> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/122> a sbd:Model ;
  rdfs:label "Prolyl hydroxylase inhibition leading to reproductive dysfunction via increased HIF1 heterodimer formation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Cumulative fecundity is the most apical endpoint considered in the OECD 229 Fish Short Term Reproduction Assay. The OECD 229 assay serves as screening assay for endocrine disruption and associated reproductive impairment (OECD 2012). Fecundity is also an important apical endpoint in the Medaka Extended One Generation Reproduction Test (MEOGRT; OECD Test Guideline 240; OECD 2015).  A variety of fish life cycle tests also include cumulative fecundity as an endpoint (OECD 2008).  &nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/122> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/122> a sbd:Model ;
  rdfs:label "Prolyl hydroxylase inhibition leading to reproductive dysfunction via increased HIF1 heterodimer formation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/122> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/122> a sbd:Model ;
  rdfs:label "Prolyl hydroxylase inhibition leading to reproductive dysfunction via increased HIF1 heterodimer formation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Cumulative fecundity is the most apical endpoint considered in the OECD 229 Fish Short Term Reproduction Assay. The OECD 229 assay serves as screening assay for endocrine disruption and associated reproductive impairment (OECD 2012). Fecundity is also an important apical endpoint in the Medaka Extended One Generation Reproduction Test (MEOGRT; OECD Test Guideline 240; OECD 2015).  A variety of fish life cycle tests also include cumulative fecundity as an endpoint (OECD 2008).  &nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/122> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/123> a sbd:Model ;
  rdfs:label "Unknown MIE leading to reproductive dysfunction via increased HIF-1alpha transcription"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/123> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/123> a sbd:Model ;
  rdfs:label "Unknown MIE leading to reproductive dysfunction via increased HIF-1alpha transcription"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Cumulative fecundity is the most apical endpoint considered in the OECD 229 Fish Short Term Reproduction Assay. The OECD 229 assay serves as screening assay for endocrine disruption and associated reproductive impairment (OECD 2012). Fecundity is also an important apical endpoint in the Medaka Extended One Generation Reproduction Test (MEOGRT; OECD Test Guideline 240; OECD 2015).  A variety of fish life cycle tests also include cumulative fecundity as an endpoint (OECD 2008).  &nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/123> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/123> a sbd:Model ;
  rdfs:label "Unknown MIE leading to reproductive dysfunction via increased HIF-1alpha transcription"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/123> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/123> a sbd:Model ;
  rdfs:label "Unknown MIE leading to reproductive dysfunction via increased HIF-1alpha transcription"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Cumulative fecundity is the most apical endpoint considered in the OECD 229 Fish Short Term Reproduction Assay. The OECD 229 assay serves as screening assay for endocrine disruption and associated reproductive impairment (OECD 2012). Fecundity is also an important apical endpoint in the Medaka Extended One Generation Reproduction Test (MEOGRT; OECD Test Guideline 240; OECD 2015).  A variety of fish life cycle tests also include cumulative fecundity as an endpoint (OECD 2008).  &nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/123> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/13> a sbd:Model ;
  rdfs:label "Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development induces impairment of learning and memory abilities"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Glu and glycine are endogenous agonists that bind to LBD of specific NMDA receptor subunits. In this binding site numerous competitive exogenous antagonists have been identified to cause closure of binding site and inhibition of NMDA receptor (reviewed in Traynelis et al., 2010). Here, are listed some known competitive antagonists for NMDA receptor, some of them are specific to NR1 subunit and some to NR2 subunit:  &alpha;-AA, &alpha;-aminoadipate;  5,7-DCKA, 5,7-dichlorokynurenic acid;  7-CKA, 7-chlorokynurenic acid;  ACEA-1011, 5-chloro-7-trifluoromethyl-1,4-dihydro-2,3-quinoxalinedione;  ACEA-1021, licostinel;  AP5, 2-amino-5-phosphonopentanoate;  AP7, 2-amino-7-phosphonopentanoate;  CGP-61594, (&plusmn;)-trans-4-[2-(4-azidophyenyl)acetylamino]-5,7-dichloro-1,2,3,4-tetrahydroquinoline-2-carboxylic acid;  CGP-40116, d-(E)-2-amino-4-methyl-5-phosphono-3-pentenoic acid;  CGP-43487, d-(E)-2-amino-4-methyl-5-phosphono-3-pentenoic acid methyl ester;  CGP-58411, 7-chloro-4-hydroxy-3-phenyl-1H-quinolin-2-one;  CGS-19755, (2R,4S)-4-(phosphonomethyl)piperidine-2-carboxylic acid;  CPP, 4-(3-phosphonopropyl) pizerazine-2-carboxylic acid;  GV150,526A, gavestinel;  GV196,771A, (E)-4,6-dichloro-3-[(2-oxo-1-phenyl-3-pyrrolidinylidene)methyl]-1H-indole-2-carboxylic acid;  L-689,560, 4-trans-2-carboxy-5,7-dichloro-4-phenylaminocarbonylamino-1,2,3,4-tetrahydroquinoline;  L-701,324, 7-chloro-4-hydroxy-3-(3-phenoxy)phenyl-2(1H)-quinolone;  MDL105,519, (E)-3-(2-phenyl-2-carboxyethenyl)-4, 6-dichloro-1H-indole-2-carboxylic acid;  PBPD, (2S,3R)-1-(biphenyl-4-carbonyl)piperazine-2,3-dicarboxylic acid;  PMPA, (R,S)-4-(phosphonomethyl)-piperazine-2-carboxylic acid;  PPDA, (2S,3R)-1-(phenanthren-2-carbonyl)piperazine-2,3-dicarboxylic acid  Besides competitive antagonists, noncompetitive antagonists have also been designed like phenylethanolamine ifenprodil that interacts with the NR2B extracellular amino-terminal domain. It has been suggested that they act by stabilizing an agonist-bound state in which the receptor has a low open probability. Other more potent derivatives of ifenprodil are: &alpha;-(4-hydroxyphenyl)-&beta;-methyl-4-(phenylmethyl)-1-piperidine propanol (Ro 25-6981), 1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol (Ro 63-1908), besonprodil (CI-1041), and traxoprodil mesylate (CP-101,606). Ethanol has been proposed to be a noncompetitive antagonist of NMDA receptors, binding to NR2 subunit (Nagy, 2008). Inhibition of NMDA receptor function by ethanol and interactions between ethanol and the noncompetitive NMDA receptor antagonist ifenprodil have been examined in neocortical neurons from rat and human embryonic kidney (HEK) 293 cells expressing recombinant NMDA receptors (Lovinger, 1995). Recently, a structural model has been suggested that predicts the presence of four sites of ethanol action on the NMDA receptor, each containing four pairs of positions in the NR1/NR2 subunits (reviewed in Chandrasekar, 2013). Some other antagonists can become trapped in the pore of the NMDA receptor after channel closure and these antagonists are called uncompetitive or trapping blockers. The most well studied NMDA receptor uncompetitive antagonists are Mg2+, polyamines, phencyclidine, ketamine, MK-801, memantine, amantadine, pentamidine, 9-tetrahydroaminoacridine, dextromethorphan, and its metabolite dextrorphan. MK-801 has been shown to prevent toluene-induced alterations in pattern-elicited visual-evoked potentials in vivo, suggesting the possibility that the binding site of toluene might be common with the one of MK-801 (Bale et al., 2007). However, another study suggests that toluene interference with the NMDA receptor might not be exclusively because of the binding to the channel pore (Smothers and Woodward, 2007) but it may involve some other binding sites. Lead (Pb2+) is considered a voltage independent antagonist of NMDA receptors and it is believed that possibly shares the same binding site with Zn2+ (reviewed in Neal and Guilarte, 2010; Traynelis et al., 2010). However, studies done in recombinant NR2A- and NR2B- containing NMDA receptors with mutated Zn2+ binding sites exhibit that additional structural elements, different from those important for Zn2+ binding are involved in Pb2+ binding site (reviewed in Neal and Guilarte, 2010). Similarly, there are contradicting experimental evidence and disagreement about Pb2+&#39;s role as competitive or non-competitive antagonist (Neal and Guilarte, 2010). Pb2+ -induced inhibition of NMDAR during synaptogenesis in hippocampal neurons altered synaptic NMDAR composition, resulting in a decrease in NR2A-containing NMDARs at the established synapses (Neal et al., 2011)."@en ;
  foaf:page <https://identifiers.org/aop/13> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/13> a sbd:Model ;
  rdfs:label "Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development induces impairment of learning and memory abilities"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "A prime example of impairments in learning and memory as the adverse outcome for regulatory action is developmental lead exposure and IQ function in children (Bellinger, 2012). Most methods are well established in the published literature and many have been engaged to evaluate the effects of developmental thyroid disruption. The US EPA and OECD Developmental Neurotoxicity (DNT) Guidelines (OCSPP 870.6300 or OECD TG 426) as well as OECD TG 443 (OECD, 2018) both require testing of learning and memory (USEPA, 1998; OECD, 2007) advising to use the following tests passive avoidance, delayed-matching-to-position for the adult rat and for the infant rat, olfactory conditioning, Morris water maze, Biel or Cincinnati maze, radial arm maze, T-maze, and acquisition and retention of schedule-controlled behaviour.&nbsp; These DNT Guidelines have been deemed valid to identify developmental neurotoxicity and adverse neurodevelopmental outcomes (Makris et al., 2009).  Also, in the frame of the OECD GD 43 (2008) on reproductive toxicity, learning and memory testing may have potential to be applied in the context of developmental neurotoxicity studies. However, many of the learning and memory tasks used in guideline studies may not readily detect subtle impairments in cognitive function associated with modest degrees of developmental thyroid disruption (Gilbert et al., 2012)."@en ;
  foaf:page <https://identifiers.org/aop/13> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/131> a sbd:Model ;
  rdfs:label "Aryl hydrocarbon receptor activation leading to uroporphyria"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Uroporphyria is a disorder affecting multiple organs and can significantly decrease the quality of life in humans.&nbsp; The outbreak of porphyria in Turkish populations in the 1950&#39;s due to contaminated grain had significant, long-term health effects[9].&nbsp;  Uroporphyria has been detected in one wild animal population (Herring gulls in contaminated Great Lakes colonies[8]); although the disorder is characterized by hepatotoxicity, it has not been shown to lead to death, and therefore is not expected to cause population decline.&nbsp; Elevated porphyrins however are apparent long before overt signs of toxicity are manifested, making it a sensitive biomarker of chemical exposure; monitoring porphyrin levels in at-risk wild populations would identify the need for remediation of contaminated sights before the occurrence of overt adverse effects."@en ;
  foaf:page <https://identifiers.org/aop/131> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/131> a sbd:Model ;
  rdfs:label "Aryl hydrocarbon receptor activation leading to uroporphyria"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The AHR can be activated by several structurally diverse chemicals, but binds preferentially to planar halogenated aromatic hydrocarbons and polycyclic aromatic hydrocarbons. Dioxin-like compounds (DLCs), which include polychlorinated dibenzo-p-dioxins (PCDDs), polychlorinated dibenzofurans (PCDFs) and certain polychlorinated biphenyls (PCBs), are among the most potent AHR ligands[38]. Only a subset of PCDD, PCDF and PCB congeners has been shown to bind to the AHR and cause toxic effects to those elicited by TCDD. Until recently, TCDD was considered to be the most potent DLC in birds[39]; however, recent reports indicate that 2,3,4,7,8-pentachlorodibenzofuran (PeCDF) is more potent than TCDD in some species of birds.[40][13][41][21][42][43] When screened for their ability to induce aryl hydrocarbon hydroxylase (AHH) activity, dioxins with chlorine atoms at a minimum of three out of the four lateral ring positions, and with at least one non-chlorinated ring position are the most active[44]. Of the dioxin-like PCBs, non-ortho congeners are the most toxicologically active, while mono-ortho PCBs are generally less potent[45][9]. Chlorine substitution at ortho positions increases the energetic costs of assuming the coplanar conformation required for binding to the AHR [45]. Thus, a smaller proportion of mono-ortho PCB molecules are able to bind to the AHR and elicit toxic effects, resulting in reduced potency of these congeners. Other PCB congeners, such as di-ortho substituted PCBs, are very weak AHR agonists and do not likely contribute to dioxin-like effects [9].   	Contrary to studies of birds and mammals, even the most potent mono-ortho PCBs bind to AhRs of fishes with very low affinity, if at all (Abnet et al 1999; Doering et al 2014; 2015; Eisner et al 2016; Van den Berg et al 1998).   The role of the AHR in mediating the toxic effects of planar hydrophobic contaminants has been well studied, however the endogenous role of the AHR is less clear [1]. Some endogenous and natural substances, including prostaglandin PGG2 and the tryptophan derivatives indole-3-carbinol, 6-formylindolo[3,2-b]carbazole (FICZ) and kynurenic acid can bind to and activate the AHR. [6][46][47][48][49] The AHR is thought to have important endogenous roles in reproduction, liver and heart development, cardiovascular function, immune function and cell cycle regulation [50][38][51][52][53][54][46][55][56][57] and activation of the AHR by DLCs may therefore adversely affect these processes."@en ;
  foaf:page <https://identifiers.org/aop/131> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/131> a sbd:Model ;
  rdfs:label "Aryl hydrocarbon receptor activation leading to uroporphyria"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Heme is a cyclic tetrapyrrole cofactor containing Fe2+ porphyrin-containing ferroprotein that forms various hemoproteins such as hemoglobin, cytochromes and catalases [62]. Its biosynthesis mostly occurs in the liver and involves 8 separate steps. Porphyria is a disorder in which the disturbance of any of the steps of heme biosynthesis results in accumulation and excretion of porphyrins[2]. A variety of porphyrias exist depending on which enzyme in the pathway is deficient. This AOP describes a situation in which the 5th step of heme biosynthesis, uroporphyrinogen decarboxylase (UROD), which converts uroporphyrinogen to coproporphyrinogen, is inhibited.  Hepatic uroporphyria is viewed somewhat differently by clinicians and toxicologists. For the former it is mostly a sporadic disease (porphyria cutanea tarda; PCT) occurring sometimes in patients exposed to a variety of insults such as alcohol, estrogens, hepatitis viruses, HIV and on dialysis. Importantly, very early on it was found that lowering body iron stores by bleeding or now chelators causes remission [61]. In some northern European and US patients, carrying the hemochromatosis mutation is a risk factor but in other patients other iron susceptibility genes may contribute. Carrying a UROD mutation (lowering activity) is also a risk factor but still dependent on other susceptibility factors to see porphyria. To reproduce these findings experimentally has proved challenging but now possible. For toxicologists hepatic uroporphyria has mostly been seen as a toxic, but unique and curious endpoint of polychlorinated ligands of the AHR.&nbsp; Experimentally, TCDD in mice is the most potent agent consistent with AHR mode of action but is more difficult in rats and other organisms. Hexachlorobenzene (HCB) has been greatly studied for its porphyria-inducing abilities and a large incident of porphyria in some young people in Turkey 60 years ago was ascribed to susceptible individuals who had consumed HCB. It is controversial whether HCB is a weak AHR ligand. Evidence of porphyria in people exposed accidentally or occupationally to accepted AHR ligands such as TCDD and PCBs is thin. Importantly, iron status can profoundly modify experimental uroporphyria induced by these chemicals especially in mice. In fact iron overload alone of mice will eventually produce a strong hepatic uroporphyria which is markedly genetically determined and toxicity can be ameliorated by chelators resembling PCT. Thus hepatic porphyria could alternatively be viewed as an iron AOP. At an overall level hepatic uroporphyria in animals and patients is the outcome of complex genetic traits and external stimuli in which in some traditional toxicological circumstances binding of a chemical to the AHR may have a major contribution[67] but in others may not."@en ;
  foaf:page <https://identifiers.org/aop/131> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/134> a sbd:Model ;
  rdfs:label "Sodium Iodide Symporter (NIS) Inhibition and Subsequent Adverse Neurodevelopmental Outcomes in Mammals"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Thyroid Disrupting Chemicals (TDCs) are defined as the xenobiotics that interfere with the thyroid axis with different outcomes for the organism. A very well-studied mechanism of action of the TDCs is the reduction of the circulating levels of THs by inhibiting hormone synthesis in the thyroid gland. For example, perchlorate is a very potent inhibitor of iodide uptake through the sodium/iodide symporter (Tonacchera et al., 2004). Perchlorate has been detected in human breast milk ranging from 1.4 to 92.2 mg &mu;l&ndash;1 (10.5 &mu;g l&ndash;1 mean) in 18 US states (Kirk et al. 2005), and 1.3 to 411 &mu;g l&ndash;1 (9.1 &mu;g l&ndash;1 median) in the Boston area, United States (Pearce et al. 2007). Perchlorate has also been detected in human colostrum of 46 women in the Boston area (from &lt; 0.05 to 187.2 &mu;mol l&ndash;1 (Leung et al. 2009)). The mechanism of perchlorate action is quite simple, as it is believed to be mediated only by the NIS inhibition (Dohan et al., 2007; Wolff, 1998). Additionally, thiocyanate and nitrate are two known inhibitors that have been found to reduce circulating TH levels (Blount et al., 2006; Steinhaus et al., 2007), but they are both less potent than perchlorate (Tonacchera et al., 2004). However, there are also contradictory results from other studies that showed no correlation between thyroid parameters and perchlorate levels in humans (Pearce et al., 2010; Amitai et al., 2007; Tellez et al., 2005).  Co-occurrence of perchlorate, nitrate, and thiocyanate can alter thyroid function in pregnant women. Horton et al. (2015) have shown positive associations between the weighted sum of urinary concentrations of these three analytes and increased TSH, with perchlorate showing the largest weight in the index. Interestingly, De Groef et al. 2006 showed that nitrate and thiocyanate, acquired through drinking water or food, account for a much larger proportion of iodine uptake inhibition than perchlorate, suggesting that NIS inhibition and any potential downstream effect by perchlorate are highly dependent on the presence of other environmental NIS inhibitors and iodine intake itself (Leung et al., 2010). In particular, Tonacchera et al. (2004) showed that the relative potency of perchlorate to inhibit radioactive I&minus; uptake by NIS is 15, 30 and 240 times that of thiocyanate, iodide, and nitrate respectively on a molar concentration basis. These data are in line with earlier studies in rats (Alexander and Wolff, 1996; Greer et al. 1966). Contradictory findings in these studies may therefore be a result of the confounding mixtures in the environment, masking the primary effect of perchlorate.  Decreased iodine intake can decrease TH production, and therefore exposure to perchlorate might be particularly detrimental in iodine-deficient individuals (Leung et al. 2010). Moreover, biologically based dose-response modeling of the relationships among iodide status (e.g., dietary iodine levels), perchlorate dose, and TH production in pregnant women has shown that iodide intake has a profound effect on the likelihood that exposure to goitrogens will produce hypothyroxinemia (Lewandowski et al. 2015).  During pregnancy TH requirements increase, particularly during the first trimester (Alexander et al. 2004; Leung et al. 2010), due to higher concentrations of thyroxine-binding globulin, placental T4 inner-ring deiodination leading to the inactive reverse T3 (rT3), and transfer of small amounts of T4 to the foetus (during the first trimester foetal thyroid function is absent). Moreover, glomerular filtration rate and clearance of proteins and other molecules are both increased during pregnancy, possibly causing increased renal iodide clearance and a decreased of circulating plasma iodine (Glinoer, 1997). Thus, even though the foetal thyroid can trap iodide by about 12 week of gestation (Fisher and Klein, 1981), high concentrations of maternal perchlorate may potentially decrease thyroidal iodine available to the foetus by inhibiting placental NIS (Leung et al. 2010).  Consequences of TH deficiency depend on the developmental timing of the deficiency (Zoeller and Rovet, 2004). For instance, if the TH deficiency occurs during early pregnancy, offspring show visual attention, visual processing and gross motor skills deficits, while if it occurs later, offspring may show subnormal visual and visuospatial skills, along with slower response speeds and motor deficits. If TH insufficiency occurs after birth, language and memory skills are most predominantly affected (Zoeller and Rovet, 2004).  Along this line, age and developmental stage are crucial in determining sensitivity to NIS inhibitors (e.g., perchlorate, thiocyanate, and nitrate). In this regard, McMullen et al. (2017) have shown that adolescent boys and girls, more than adults, represent vulnerable subpopulations to NIS symporter inhibitors. Altogether these studies indicate that age, gender, developmental stage, and dietary iodine levels can affect the impact of NIS inhibitors.  Finally, ten more small simple-structured molecules were identified in a large screening study (Lecat-Guillet et al., 2008b) that could block iodide uptake by specifically disrupting NIS in a dose-dependent manner. These molecules were named Iodide Transport Blockers (ITBs). There are few organic molecules that lead to NIS inhibition but no direct interaction with NIS has been determined (Gerard et al., 1994; Kaminsky et al., 1991). Up to date, only dysidenin, a toxin isolated from the marine sponge Dysidea herbacea, has been reported to specifically inhibit NIS (Van Sande et al., 2003). Finally, the aryltrifluoroborates were found to inhibit iodide uptake with an IC50 value of 0.4 &mu;M on rat-derived thyroid cells (Lecat-Guillet et al., 2008a). The biological activity is rationalized by the presence of the BF3&minus; ion as a minimal binding motif for substrate recognition at the iodide binding site.  It has been also shown that many anions, such as ClO3-, SCN-, NO3-, ReO4-, TcO4- and in a lower extent Br- and BF4-, are also acting as NIS substrates and they enter the cell by the same transporter mechanism (Van Sande et al., 2003). It has been also shown that ClO4- is transferred by NIS with high affinity and is considered as one of its most potent inhibitors (Dohan et al., 2007). Most recently, the aryltrifluoroborates were also shown to inhibit NIS function (Lecat-Guillet et al., 2008a). A library of 17,020 compounds was tested by a radioactive screening method with high specificity using transfected mammalian cells (Lecat-Guillet et al., 2008b; 2007) for NIS inhibition evaluation. Further studies with the most powerful inhibitors showed a high diversity in their structure and mode of action (Lindenthal et al., 2009)."@en ;
  foaf:page <https://identifiers.org/aop/134> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/134> a sbd:Model ;
  rdfs:label "Sodium Iodide Symporter (NIS) Inhibition and Subsequent Adverse Neurodevelopmental Outcomes in Mammals"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "A prime example of impairments in cognitive function as the adverse outcome for regulatory action is developmental lead exposure and IQ function in children (Bellinger, 2012). In addition, testing for the impact of chemical expsoures on cognitive function, often including spatially-mediated behaviors, is an intergral part of both EPA and OECD developmental neurotoxicity guidelines (USEPA, 1998; OECD, 2007)."@en ;
  foaf:page <https://identifiers.org/aop/134> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/136> a sbd:Model ;
  rdfs:label "Intracellular Acidification Induced Olfactory Epithelial Injury Leading to Site of Contact Nasal Tumors"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Production of protons from metabolism of vinyl acetate, for example,  has been shown to reversibly acidify cells in culture [5], and nasal/buccal tissue explants[6]. Cleavage of any acetate ester will produce acetic acid, increases cellular proton loading. For example, [Q from Bogdanffy Tox Letters 2003] vinyl acetate is hydrolyzed to acetic acid and vinyl alcohol, which readily rearranges to acetaldehyde. This conversion has been shown to be dependent on carboxylesterase and is catalyzed by extracts of nasal respiratory and olfactory tissue, oral cavity mucosa, lung and liver [7]. Other related acetate esters, for example ethyl acetate, butyl acetate, and propyl acetate would produce protons upon ester cleavage by  releasing acetic acid."@en ;
  foaf:page <https://identifiers.org/aop/136> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/138> a sbd:Model ;
  rdfs:label "Organic anion transporter (OAT1) inhibition leading to renal failure and mortality"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/138> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/138> a sbd:Model ;
  rdfs:label "Organic anion transporter (OAT1) inhibition leading to renal failure and mortality"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Increased mortality is one of the most common regulatory assessment endpoints,&nbsp;along with reduced growth and reduced reproduction."@en ;
  foaf:page <https://identifiers.org/aop/138> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/138> a sbd:Model ;
  rdfs:label "Organic anion transporter (OAT1) inhibition leading to renal failure and mortality"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/138> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/138> a sbd:Model ;
  rdfs:label "Organic anion transporter (OAT1) inhibition leading to renal failure and mortality"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Increased mortality is one of the most common regulatory assessment endpoints,&nbsp;along with reduced growth and reduced reproduction."@en ;
  foaf:page <https://identifiers.org/aop/138> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/139> a sbd:Model ;
  rdfs:label "Alkylation of DNA leading to cancer 1"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Alkylating agents are prototypical DNA-reactive compounds and have been extensively studied for decades (reviewed in Beranek 1990). The chemicals can be direct-acting electrophiles, or can be converted from non-reactive substances to reactive metabolites via metabolism. A prototypical alkylating agent is N-ethyl-N-nitrosourea (chemical formula C3H7N3O2) (ENU). ENU is rapidly absorbed following oral exposure and intraperitoneal injections and distributed widely across the tissues. ENU is unstable and readily reacts with somatic and germ cell DNA in mice, rats, flies and hamsters, to alkylate DNA. Very generally, mono-functional (referring to the transfer of a single alkyl group) alkylating agents include: 1.	Alkyl sulfates: e.g., diethyl (DES) and dimethyl sulfate (DMS);  2.	Alkyl alkanesulfonates: e.g., methyl (MMS) and ethyl methanesulfonate (EMS);  3.	Nitrosamides: e.g., methyl (MNU) and ethyl nitrosourea (ENU), methyl- (MNNG) and ethyl-N'-nitro-N-nitrosoguanidine (ENNG), and the indirect-acting (i.e., requiring metabolic activation) dimethyl (DMN) and diethyl nitrosamines (DEN).  ENU is the most widely studied and understood alkylating agent and as such has been instrumental in contributing to the knowledgebase in this field. Immunohistochemistry studies clearly indicate the presence of alkylated DNA following exposure to ENU in both somatic cells and spermatogonia (Kamino et al. 1995; Seiler et al. 1997; van Zeeland et al. 1990)."@en ;
  foaf:page <https://identifiers.org/aop/139> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/141> a sbd:Model ;
  rdfs:label "Alkylation of DNA leading to cancer 2"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Alkylating agents are prototypical DNA-reactive compounds and have been extensively studied for decades (reviewed in Beranek 1990). The chemicals can be direct-acting electrophiles, or can be converted from non-reactive substances to reactive metabolites via metabolism. A prototypical alkylating agent is N-ethyl-N-nitrosourea (chemical formula C3H7N3O2) (ENU). ENU is rapidly absorbed following oral exposure and intraperitoneal injections and distributed widely across the tissues. ENU is unstable and readily reacts with somatic and germ cell DNA in mice, rats, flies and hamsters, to alkylate DNA. Very generally, mono-functional (referring to the transfer of a single alkyl group) alkylating agents include: 1.	Alkyl sulfates: e.g., diethyl (DES) and dimethyl sulfate (DMS);  2.	Alkyl alkanesulfonates: e.g., methyl (MMS) and ethyl methanesulfonate (EMS);  3.	Nitrosamides: e.g., methyl (MNU) and ethyl nitrosourea (ENU), methyl- (MNNG) and ethyl-N'-nitro-N-nitrosoguanidine (ENNG), and the indirect-acting (i.e., requiring metabolic activation) dimethyl (DMN) and diethyl nitrosamines (DEN).  ENU is the most widely studied and understood alkylating agent and as such has been instrumental in contributing to the knowledgebase in this field. Immunohistochemistry studies clearly indicate the presence of alkylated DNA following exposure to ENU in both somatic cells and spermatogonia (Kamino et al. 1995; Seiler et al. 1997; van Zeeland et al. 1990)."@en ;
  foaf:page <https://identifiers.org/aop/141> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/144> a sbd:Model ;
  rdfs:label "Endocytic lysosomal uptake leading to liver fibrosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "&nbsp;  Liver fibrosis is currently an important health problem potentially leading in its progressive form to cirrhosis and as such presents a significant economic burden (Lim and Kim, 2008). The only therapy for chronic liver failure is liver transplantation, with 5.500 liver transplantations in Europe on a yearly basis, costing up to &euro;100.000 (approximately US$110.000)&nbsp;the first year (Safadi and Friedman, 2002) and estimated mean cost of US$163.438 in United States (van der Hilst et al., 2008). There are constant research attempts for new therapeutic strategies, but so far without success. AOP concept presents an alternative approach which organizing mechanistic toxicological knowledge can lead to the prevention of liver fibrosis.  The use and possible applications of nanomaterials (NMs) are in constant increase, for example in food, food-related products or cosmetics. Therefore, the safety of NMs systemically taken up in the body needs to be ensured. The liver is known to be one of the main target organs for ingested NMs, but inhaled particles can also reach the liver upon clearance from the lung (Johnston et al., 2010; Cui et al., 2011; Geraets et al., 2012). In vivo experiments on gavaged or injected (intraperitoneal or intravenously) TiO2 suggest a wide range of adverse effects on the liver: an increase in general serum markers for liver damage such as Alanine Aminotransferase or Aspartate Aminotransferase (Liu et al., 2009; Duan et al., 2010), an increase in inflammatory markers such as pro-inflammatory cytokines and/or infiltration of inflammatory cells (Ma et al., 2009; Cui et al., 2011; Kermanizadeh, 2012), an increase of markers for oxidative stress (Liu et al., 2010; Soliman et al., 2013), apoptosis, necrosis and also fibrosis (Chen et al., 2009; Alarifi et al., 2013). Oral NM administration appeared to induce overall milder adverse effects than systemic administration, most likely due to the typically limited absorption of NMs in the GI tract. Thus, it is important to keep in mind that the route of exposure and the size of the NM, play an important role whether these reach the liver, and to which extent they&#39;re accumulated (Kermanizadeh, 2014).  Once a chemical is taken up by a cell, it is transported into the lysosome. In the lysosome, the acidic environment can enhance the solubility of a NM, or it remains in the initial nano form. &nbsp;Both situations can induce toxicity, causing lysosomal swelling, followed by lysosomal damage and the release of pro-apoptotic proteins (Wang et al., 2013; Cho et al., 2011; Cho et al., 2012). But not only NMs cause lysosomal damage: fluoroquinolones (Ouedraogo et al., 2000), lysosomotropic detergents such as o-methyl-serine dodecylamide hydrochloride (Villamil Giraldo et al., 2016), artesunate (Yang et al., 2014), chloroquine (Ashoor et al., 2013) can do the same, and Reactive Oxygen Species (ROS) such as H2O2 can amplify this effect (Repnik et al., 2012). &nbsp;The amount of lysosomal enzymes released into the cytosol regulates the cell death pathway: controlled increased permeability of lysosomal membrane, caused by limited level of stress, plays a vital role in the induction of apoptosis, whereas massive lysosomal rupture, caused by high-stress levels, leads to necrosis (Bursch, 2001; Guicciardi et al., 2004). Lysosomes are known to trigger mitochondrial-mediated cell death by the release of cathepsins into the cytosol (Repnik et al., 2012). At the same time, however, lysosomes themselves are a source of ROS, which can lead to damage of the mitochondrial membrane (Wang et al., 2013; Kubota et al., 2010). Cell death further leads to inflammation (Faouzi et al., 2001), which activates hepatic stellate cells and induce them to secrete collagen (Casini et al., 1997). It is established that collagen accumulation is a prephase&nbsp;of liver fibrosis (Bataller and Brenner, 2005; Lee and Friedman, 2011).  Overall, the connection between lysosomal and mitochondrial damage with liver inflammation and further on with fibrosis, is well known, regardless if triggered by chemicals, proteins or NMs (reviewed in Malhi and Gores, 2008; Kong et al., 2014). Therefore, due to its high importance, it is described extensively in the current AOP."@en ;
  foaf:page <https://identifiers.org/aop/144> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/144> a sbd:Model ;
  rdfs:label "Endocytic lysosomal uptake leading to liver fibrosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Several well-known drugs have lysosomotropic abilities including chloroquine, the antipsychotics chlorpromazine, thioridazine, aripiprazole, the antidepressants desipramine, imipramine, and clomipramine, as well as fluoroquinolone antibiotics; another substance group are lysosomotropic detergents (Villamil Giraldo et al., 2014; Ouedraogo et al., 2000).  Fluoroquinolones such as lomefloxacin, norfloxacin,&nbsp; BAYy 3118 and ciprofloxacin are lysosomotropic substances because of their Lewis acid&ndash;base properties characterized by pKa nearby neutrality (Ouedraogo et al. 2000). The anti-malarial and anti-inflammatory agent chloroquine is a basic lipophilic and therefore lysosomotropic compound that accumulates in lysosomes via pH partitioning (Ashoor et al. 2013). 3-aminopropanal has the structure of a weak lysosomotropic base, concentrates within the acidic vacuolar compartment and causes lysosomal rupture (Yu et al., 2003). Artesunate preferably accumulates in the lysosomes (Yang et al., 2014)  Most nanoscale macromolecules and molecular assemblies are internalized through endocytosis upon contact with the cell membrane. Intracellular trafficking of NPs following endocytosis has been reported to be mediated via the endosomal pathway through early endosomes, late endosomes and then lysosomes (Gilleron et al., 2013; Yang et al., 2013; Ng et al., 2015).&nbsp; Verma and Stellacci showed that 3.4-nm gold NPs were taken up into macrophages via pinocytosis and 24 h after internalization they were found in lysosomes. This endocytic fate has also been observed for iron oxide NPs and fullerenes (Verma and Stellacci, 2010).  Jin et al. investigated the cytotoxicity of Nanotitanium dioxide TiO2 (an industrial material used as an additive in cosmetics, pharmaceuticals, and food colorants and able to penetrate the skin) in mouse fibroblast (L929) cells. They saw that TiO2 NPs were phagocytosed and encapsulated in the lysosomes (Jin et al. 2008).  The rate and mechanism of NP uptake are dependent on physiochemical causes related to the properties of the NPs and the cells, but also the local microenvironment (Zhang, 2015). Nanomaterial shape and size contribute significantly to their interaction with cells (Verma and Stellacci, 2010; Oh, 2014). Several reports showing that NPs of 20&mdash;50nm are taken up more rapidly than smaller or larger particles (Lu et al., 2009; Iversen et al., 2011; Dykman and Khlebtsov, 2014).  Other variables that could influence the uptake of a NP cargo include orientation, density and steric freedom of targeting ligands and surface groups (Cleal et al., 2013). Most NPs are first coated with serum proteins before they reach cell plasma membranes; endocytosis patterns of aggregated or agglomerated NPs differ from the one of individual NPs (Oh and Park, 2014).  Harush-Frenkel et al. compared the endocytosis into HeLa cells of NPs exposing either a negative or positive charge on their surface and found that the exposed charge significantly affected their ability to internalize as well as the cellular endocytosis mechanism utilized. Negatively charged NPs showed an inferior rate of endocytosis and did not utilize the clathrin-mediated endocytosis pathway, while positively charged NPs internalize rapidly primarily via clathrin-mediated pathways as well as macropinocytosis. When the clathrin-mediated endocytosis pathway is blocked positively charged NPs activate a compensatory endocytosis pathway that results in enhanced accumulation of NPs (Harush-Frenkel et al., 2007). In contrast, a higher uptake of negatively charged quantum dot NPs has been reported in HEK cells by Zhang and Monteiro-Riviere (2009).  Schuetz et al. demonstrated that positively charged SiNPs enter cells largely via dynamin 2-dependent caveolar internalization rather than clathrin-mediated endocytosis and accumulate in lysosomes (Schuetz et al., 2016).  Ng et al. have shown that the uptake of 20 nm size AuNPs in MRC5 lung fibroblasts and Chang liver cells was dependent upon clathrin-mediated endocytosis (Ng et al., 2014). Yang et al. studied the cellular uptake of ultra-small fluorescent gold nanoclusters (AuNCs) by HeLa cells and found that this energy-dependent process involved multiple mechanisms, with clathrin-mediated endocytosis and macropinocytosis appearing to play a significant role, whereas the caveolin-mediated pathway contributing only to a lesser extent (Yang et al., 2013).&nbsp;  Gilleron et al. monitored the uptake of lipid NPs (LNPs) loaded with traceable siRNAs in different cell types in vitro and in mouse liver and found that LNPs enter cells by both constitutive and inducible pathways in a cell type-specific manner using clathrin-mediated endocytosis as well as macropinocytosis (Gilleron et al., 2013).  Saw et al. showed that the major uptake of confeito Au NP of 30 nm was both clathrin and caveolin mediated endocytosis, while for 60, 80 and 100 nm NP was via clathrin mediated pathway. Internalization by both clathrin and caveolin pathways explains higher cellular uptake of 30 nm Au NP compared to other ones (Saw et al., 2018). However, Brandenberger et al. showed that uptake of 30 nm citrate-cappedsphere Au NP was by a macroopinocytosis mechanism (Brandenberger et al., 2010).  It is obvious that not only size of NP, but also the surface property and shape are also important factors in the type of cellular uptake of NPs. As demonstrated earlier cationic NPs favor clathrin mediated endocytosis possibly due to electrostatic interaction with the cell surface receptors. However, not all the studies confirmed this preference of cationic NPs for clathrin mediated internalization. In contrast, caveolin mediated endocytosis occurs by interaction between hydrophobic group of NP with lipid raft on cell surface (Chakraborty and Jana, 2015). There is a connection between the endocytosis mechanism and the subcellular localization of the NPs. Clathrin mediated endocytosis leads to localization of NPs to the lysosome. Also, it has been found that if uptake of NPs occurs via both clathrin and lipid raft- mediated endocytosis, subcellular localization will also be mainly lysosomal. Caveolin mediated uptake of NPs is followed with formation of vesicles with neutral pH and transport to endoplasmic reticulum, Golgi apparatus or even nucleus (Rejman et al., 2005)"@en ;
  foaf:page <https://identifiers.org/aop/144> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/144> a sbd:Model ;
  rdfs:label "Endocytic lysosomal uptake leading to liver fibrosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "From the OECD - GUIDANCE DOCUMENT ON DEVELOPING AND ASSESSING ADVERSE OUTCOME PATHWAYS - Series on Testing and Assessment 18: &quot;...an adverse effect that is of regulatory interest (e.g. repeated dose liver fibrosis)&quot;"@en ;
  foaf:page <https://identifiers.org/aop/144> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/148> a sbd:Model ;
  rdfs:label "EGFR Activation Leading to Decreased Lung Function"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "EGFR activation in lung epithelial cells can be triggered by exposure to H2O2 (Goldkorn et al., 1998; Takeyama&nbsp;et al., 2000), naphthalene (Van Winkle et al., 1997), cigarette smoke (Takeyama&nbsp;et al., 2001; de Boer et al., 2006; Marinaş et al., 2011; Yu et al., 2011; Yu et al., 2015), acrolein (Deshmukh et al., 2008),&nbsp;and TCDD (Lee et al., 2011). Mechanistically, this process is dependent on ROS-mediated activation of metalloproteinases or ADAMs which cleave membrane-bound EGFR ligand precursors, making them locally available to bind to and transactivate EGFR in an autocrine manner (Deshmukh et al., 2009; Kim et al., 2004; Val et al., 2012; Yoshisue and Hasegawa, 2004). Furthermore, ligand binding to EGFR itself was shown to lead to H2O2 production, thereby facilitating receptor activation and downstream signaling (DeYulia et al., 2005; DeYulia&nbsp;and C&aacute;rcamo, 2005; Truong and Carroll, 2012)."@en ;
  foaf:page <https://identifiers.org/aop/148> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/148> a sbd:Model ;
  rdfs:label "EGFR Activation Leading to Decreased Lung Function"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Established regulatory guideline studies for inhalation toxicity focus on evident clinical signs of systemic toxicity, including death, or organ-specific toxicity following acute and (sub)chronic exposure respectively. In toxicological and safety pharmacological studies with airborne test items targeting the airways or the lungs as a whole, lung function is a relevant endpoint for the characterization of potential adverse events (OECD, 2018a; Hoymann, 2012). Hence, the AO &ldquo;decreased lung function&rdquo; is relevant for regulatory decision-making in the context of (sub)chronic exposure (OECD, 2018b; OECD, 2018c).  Regulatory relevance of the AO &ldquo;decreased lung function&rdquo; is evident when looking at the increased risk of diseases in humans following inhalation exposure, and because of its links to other comorbidities and mortality.  To aid diagnosis and monitoring of fibrosis, current recommendations include both the recording of potential environmental and occupational exposures as well as an assessment of lung function (Baumgartner et al., 2000). The latter typically confirms decreased lung function as demonstrated by a loss of lung volume. As the disease progresses, dyspnea and lung function worsen, and the prognosis is directly linked to the decline in FVC (Meltzer and Noble, 2008).   Chronic exposure to cigarette smoke and other combustion-derived particles results in the development of COPD. COPD is diagnosed on the basis of spirometry results as laid out in the ATS/ERS Task Force documents on the standardization of lung function tests and their interpretation (Pellegrino et al., 2005; Culver et al., 2017, Graham et al., 2019). Rapid rates of decline in the lung function parameter FEV1 are linked to higher risk of exacerbations, increased hospitalization and early death (Wise et al., 2006; Celli, 2010). Reduced FEV1 also poses a risk for serious cardiovascular events and mortality associated with cardiovascular disease (Sin et al., 2005; Lee et al., 2015).  &nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/148> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/148> a sbd:Model ;
  rdfs:label "EGFR Activation Leading to Decreased Lung Function"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "This AOP delineates a sequence of key events initiating with stressor-induced activation of EGFR and resulting in decreased lung function through increased production of mucins. Excessive mucin production and consequent mucus hypersecretion are characteristic features of chronic diseases such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, chronic bronchitis, and asthma, which pose a significant public health burden. Of note, exposure to cigarette smoke, occupational respiratory hazards, and air pollutants are clearly linked to the development of COPD, which is predicted to become the third leading cause of death worldwide by 2030 (Viegi et al., 2007, WHO, 2008). Mucus hypersecretion during the disease course can result in airway obstruction, decreased peak expiratory flow, respiratory muscle weakness, leading to decreased lung function (Kim and Criner, 2015, Yoshida and Tuder, 2007). Lung function decrease can have serious consequences and is associated with increased mortality (Panizza et al., 2006). This AOP is aimed to compile and organize the vast knowledge around molecular and cellular events and their relationships leading to lung function decrease with an overarching goal to facilitate the prediction and assessment of decreased pulmonary function. In vitro assays spanning from cell culture to organ system assays, with an aid of in silico methodology, all performed in human context, could be applied to measure each KE for inhaled toxicant assessments and adverse outcome predictions, and would contribute to eventual replacement of in-vivo tests in animals. This concept of hazard assessment and AO prediction aligns with integrated approach to testing and assessment (IATA) framework as a mechanistic support for regulatory decision-making (Clippinger et al., 2018).&nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/148> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/149> a sbd:Model ;
  rdfs:label "Peptide Oxidation Leading to Hypertension"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The motivation for the AOP development, a deeper explaination of the underlying biology, and KE/KER assessments can be found in Lowe et al. 2017.  Originally, &quot;oxidative stress&quot; was proposed as the MIE for this AOP.&nbsp; Upon discussion with EAGMST, it was suggested to use a term that is more representative of the mechanism of action, hence &quot;peptide oxidation&quot; is proposed instead.&nbsp; All references to &quot;oxidative stress&quot; within this&nbsp;wiki are made within the context that localised conditions conducive to oxidative damage within the vascular endothelium would trigger the revised MIE, and are limited to the peptide targets named within the AOP; namely GSH, GTPCH1, AKT and eNOS&nbsp;(although other redox sensitive peptides&nbsp;are undoubtedly affected also).  The mechanisms of potentially deleterious peptide oxidation by ROS/RNS are discussed&nbsp;by Berlett and Stadtman (1997) in the context of health effects.&nbsp; References to &quot;oxidative stress&quot; within this wiki are made with this context in mind.  &nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/149> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/15> a sbd:Model ;
  rdfs:label "Alkylation of DNA in male pre-meiotic germ cells leading to heritable mutations"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Alkylating agents are prototypical DNA-reactive compounds and have been extensively studied for decades (reviewed in Beranek 1990). The chemicals can be direct-acting electrophiles, or can be converted from non-reactive substances to reactive metabolites via metabolism. A prototypical alkylating agent is N-ethyl-N-nitrosourea (chemical formula C3H7N3O2) (ENU). ENU is rapidly absorbed following oral exposure and intraperitoneal injections and distributed widely across the tissues. ENU is unstable and readily reacts with somatic and germ cell DNA in mice, rats, flies and hamsters, to alkylate DNA. Very generally, mono-functional (referring to the transfer of a single alkyl group) alkylating agents include: 1.	Alkyl sulfates: e.g., diethyl (DES) and dimethyl sulfate (DMS);  2.	Alkyl alkanesulfonates: e.g., methyl (MMS) and ethyl methanesulfonate (EMS);  3.	Nitrosamides: e.g., methyl (MNU) and ethyl nitrosourea (ENU), methyl- (MNNG) and ethyl-N'-nitro-N-nitrosoguanidine (ENNG), and the indirect-acting (i.e., requiring metabolic activation) dimethyl (DMN) and diethyl nitrosamines (DEN).  ENU is the most widely studied and understood alkylating agent and as such has been instrumental in contributing to the knowledgebase in this field. Immunohistochemistry studies clearly indicate the presence of alkylated DNA following exposure to ENU in both somatic cells and spermatogonia (Kamino et al. 1995; Seiler et al. 1997; van Zeeland et al. 1990)."@en ;
  foaf:page <https://identifiers.org/aop/15> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/15> a sbd:Model ;
  rdfs:label "Alkylation of DNA in male pre-meiotic germ cells leading to heritable mutations"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "De novo germ cell mutations are changes in the DNA sequence of sperm or egg that can be inherited by offspring. De novo mutations contribute to a wide range of human disorders including cancer, infertility, autism, schizophrenia, intellectual disability, and epilepsy (Girirajan et al. 2010; Hoischen et al. 2010; Ku et al. 2012; Lupski 2010; Morrow 2010; Vissers et al. 2010). Each child inherits, on average, approximately one de novo mutation per 100 million nucleotides delivered via the parental egg and sperm (Conrad et al. 2011; Kong et al. 2012; O&#39;Roak et al. 2012; Roach et al. 2010). The precise locations and types of mutations in the genomic DNA sequence govern the outcome of these mutations (e.g., protein coding versus intergenic sequences, conserved versus non-conserved mutations, etc.). Although a large portion of human DNA is of unknown function, recent literature suggests that at least 80% of the genome is transcribed, and most DNA is expected to have a biological function (Bernstein et al. 2012). It has been estimated that the proportion of coding and splice-site base substitutions that result in truncating mutations is ~5% (Kryukov et al. 2007), and that as many as 30% of missense mutations are also likely to be highly deleterious due to loss of function (Boyko et al. 2008). When they occur in functional sites, de novo mutations can cause embryonic or fetal lethality, or if viable, can produce a broad spectrum of inherited genetic disorders. Recent estimates suggest that a human genome contains approximately 100 loss-of-function variants, with as many as 20 exhibiting complete loss of gene function (McLaughlin et al. 2010). Therefore, de novo mutations contribute to the overall population genetic disease burden. The present AOP focuses on DNA alkylation in spermatogonia that causes inherited mutation transmitted via sperm, arguably one of the most well characterized modes of action in genetic toxicology. Humans are exposed to alkylating agents from external (e.g., abiotic plant materials, tobacco smoke, combustion products, chemotherapeutic agents) and internal (e.g., byproducts of oxidative damage and cellular methyl donors) sources."@en ;
  foaf:page <https://identifiers.org/aop/15> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/15> a sbd:Model ;
  rdfs:label "Alkylation of DNA in male pre-meiotic germ cells leading to heritable mutations"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Heritable mutations are an important regulatory endpoint for most agencies around the world (reviewed in Yauk et al. 2015). Strategies and guidelines for regulatory toxicology testing in various national regulatory jurisdictions, including requirements for germ cell mutation assays, have been described extensively by Cimino (2006), and have not changed significantly. While no jurisdiction requires germ cell testing per se in an initial test battery, many regulatory authorities can request germ cell tests for follow-up studies, e.g. in the U.S.A (U.S. EPA), Canada (Health Canada), the United Kingdom (Committee on Mutagenicity: COM), and Europe (Registration, Evaluation, Authorization and Restriction of Chemicals, i.e. REACH). For example, within the REACH strategy a substance that is genotoxic in somatic cells is evaluated from the literature to see if it is a potential germ cell mutagen based on bioavailability to the germ cells and appropriate in vivo data. If such an evaluation shows that the literature is insufficient to determine whether the agent is or is not a potential germ cell mutagen, then that agent can be tested in a suitable germ cell genotoxicity assay. Although germ cell testing is not specifically required under the Canadian Environmental Protection Act (CEPA) New Substances Notification Regulations, germ cell mutation tests are requested and evaluated when necessary. For new chemical assessments under CEPA from 1994 to 2012, a total of 19 chemicals have been evaluated for germ cell mutagenicity (12 for which the test was submitted, plus 7 for which the test was referenced on the MSDS); importantly, this is comparable to the number for which testing in rodent cancer assays was evaluated (i.e. total of 20; 17 for which the test was submitted, plus 3 for which test was referenced on the MSDS) (Personal Communication, New Substances Assessment and Control Bureau, Health Canada).  These examples illustrates the regulatory importance of heritable mutations as an adverse outcome. For pharmaceuticals, the ICH Technical Requirements for Registration of Pharmaceuticals for Human Use does not require germ cell tests and assumes that in vivo somatic tests and carcinogenicity data will provide sufficient predictivity/protection for germ cell effects (ICH, 2011) The World Health Organization (WHO)/International Programme on Chemical Safety (IPCS) has developed a harmonized scheme for mutagenicity testing. In this document the relationship between somatic cell mutagenicity and germ cell risk is summarized in the following statement. “For substances that give positive results for mutagenic effects in somatic cells in vivo, their potential to affect germ cells should be considered. If there is toxicokinetic or toxicodynamic evidence that germ cells are actually exposed to the somatic mutagen or its bioactive metabolites, it is reasonable to assume that the substance may also pose a mutagenic hazard to germ cells and thus a risk to future generations.” (Eastmond et al. 2009). The Global Harmonization Scheme (GHS; UN, 2013) is a germ cell mutation classification system developed by the United Nations that identifies them according to the categories noted in the Table below. To date over 60 countries have implemented this programme, and are in the process of integrating it into their relevant regulations.  To date its implementation is focussed on product labelling legislation in the respective countries and regulatory jurisdictions. Categorization of mutagens by GHS Category	Description 1A	        Chemicals known to induce heritable mutations in germ cells of humans 1B	        Chemicals that should be regarded as if they induce heritable mutations in germ cells of humans 2	        Chemicals that cause concern for induction of heritable mutations in germ cells of humans Finally, we note that mouse data obtained with the specific locus test and other recessive mutation analyses played an important role in estimating radiation dose risk in the human population (BEIR VII 2006)."@en ;
  foaf:page <https://identifiers.org/aop/15> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/150> a sbd:Model ;
  rdfs:label "Aryl hydrocarbon receptor activation leading to early life stage mortality, via reduced VEGF"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "In 1957, millions of broiler chickens died due to a mysterious chick edema disease characterized by pericardial, subcutaneous and peritoneal edema (SCHMITTLE et al. 1958). This disease was later ascribed to the ingestion of feed contaminated with halogenated aromatic hydrocarbons (HAHs), including 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (Higginbotham et al. 1968; Metcalfe 1972). It has since become evident that TCDD is a prototypical agonist of the AHR: a transcription factor that modulates the expression of a vast array of genes involved in endogenous development and physiological responses to exogenous chemicals (Denison et al. 2011).&nbsp; A general study in the 1980&rsquo;s found that mothers exposed to herbicides during pregnancy had a 2.8-fold increase in risk of having a baby with congenital cardiovascular malformations (Loffredo et al. 2001). Epidemiological studies have correlated long-term TCDD exposure with ischemic heart disease (Bertazzi et al. 1998; Flesch-Janys et al. 1995); interestingly, and consistent with this AOP, sectioned and stained heart samples from patients with this disease lack epicardial cells (Di et al. 2010). Mammalian studies have confirmed that in utero exposure to TCDD increases susceptibility to cardiovascular dysfunction in adulthood (Aragon et al. 2008; Thackaberry et al. 2005b). The developing heart is highly dependent on oxygen saturation levels; somewhat counterintuitively, a state of hypoxia (relative to adult oxygen tension) drives normal formation and maturation. Deviation from this optimal oxygen level, either above or below normal, hinders myocardial and endothelial development, altering coronary artery connections, ventricle wall thickness and chamber formation (Patterson and Zhang 2010; Wikenheiser et al. 2009). Interestingly, AHR activation (by TCDD), inhibition, and knockdown significantly inhibited the formation of contractile cardiomyocyte nodes during spontaneous differentiation of embryonic stem cells into cardiomyocytes (in vitro) (Wang et al. 2013), indicating that AHR also has an optimal window of expression for normal cardiogenesis. TCDD significantly reduces the degree of myocardial hypoxia that normally occurs during myocyte proliferation and ventricular wall thickening in the developing embryo (Ivnitski-Steele et al. 2004; Lee et al. 2001). This reduction in hypoxia is associated with reduced expression of both HIF-1and the VEGF splice variant, VEGF166 mRNA, which is one of the primary VEGF variants required to mediate coronary vascularization (Ivnitski-Steele et al. 2004). Therefore, it is biologically plausible that sustained AHR activation sequesters ARNT from HIF-1&alpha; impairing hypoxia stimulated coronary angiogenesis."@en ;
  foaf:page <https://identifiers.org/aop/150> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/150> a sbd:Model ;
  rdfs:label "Aryl hydrocarbon receptor activation leading to early life stage mortality, via reduced VEGF"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The AHR can be activated by several structurally diverse chemicals, but binds preferentially to planar halogenated aromatic hydrocarbons and polycyclic aromatic hydrocarbons. Dioxin-like compounds (DLCs), which include polychlorinated dibenzo-p-dioxins (PCDDs), polychlorinated dibenzofurans (PCDFs) and certain polychlorinated biphenyls (PCBs), are among the most potent AHR ligands[38]. Only a subset of PCDD, PCDF and PCB congeners has been shown to bind to the AHR and cause toxic effects to those elicited by TCDD. Until recently, TCDD was considered to be the most potent DLC in birds[39]; however, recent reports indicate that 2,3,4,7,8-pentachlorodibenzofuran (PeCDF) is more potent than TCDD in some species of birds.[40][13][41][21][42][43] When screened for their ability to induce aryl hydrocarbon hydroxylase (AHH) activity, dioxins with chlorine atoms at a minimum of three out of the four lateral ring positions, and with at least one non-chlorinated ring position are the most active[44]. Of the dioxin-like PCBs, non-ortho congeners are the most toxicologically active, while mono-ortho PCBs are generally less potent[45][9]. Chlorine substitution at ortho positions increases the energetic costs of assuming the coplanar conformation required for binding to the AHR [45]. Thus, a smaller proportion of mono-ortho PCB molecules are able to bind to the AHR and elicit toxic effects, resulting in reduced potency of these congeners. Other PCB congeners, such as di-ortho substituted PCBs, are very weak AHR agonists and do not likely contribute to dioxin-like effects [9].   	Contrary to studies of birds and mammals, even the most potent mono-ortho PCBs bind to AhRs of fishes with very low affinity, if at all (Abnet et al 1999; Doering et al 2014; 2015; Eisner et al 2016; Van den Berg et al 1998).   The role of the AHR in mediating the toxic effects of planar hydrophobic contaminants has been well studied, however the endogenous role of the AHR is less clear [1]. Some endogenous and natural substances, including prostaglandin PGG2 and the tryptophan derivatives indole-3-carbinol, 6-formylindolo[3,2-b]carbazole (FICZ) and kynurenic acid can bind to and activate the AHR. [6][46][47][48][49] The AHR is thought to have important endogenous roles in reproduction, liver and heart development, cardiovascular function, immune function and cell cycle regulation [50][38][51][52][53][54][46][55][56][57] and activation of the AHR by DLCs may therefore adversely affect these processes."@en ;
  foaf:page <https://identifiers.org/aop/150> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/150> a sbd:Model ;
  rdfs:label "Aryl hydrocarbon receptor activation leading to early life stage mortality, via reduced VEGF"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Poor early life stage survival is an endpoint of major relevance to environmental regulators, as it is likely to lead to population decline.&nbsp; Early-life stage, acute and chronic test guidelines have been established by the Organisation for Economic Co-operation and Development (OECD), U.S. Environmental Protection Agency (EPA) and Environment and Climate Change Canada (ECCC), and are currently used in risk assessments to set limits for safe exposures.&nbsp; Aquatic test guidlines are most prevalent and include OECD210, OECD229, EPA850.1400 and ECCC&nbsp; EPS 1/RM/28 for fish and OECD241 for frogs."@en ;
  foaf:page <https://identifiers.org/aop/150> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/151> a sbd:Model ;
  rdfs:label "AhR activation leading to preeclampsia"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The AHR can be activated by several structurally diverse chemicals, but binds preferentially to planar halogenated aromatic hydrocarbons and polycyclic aromatic hydrocarbons. Dioxin-like compounds (DLCs), which include polychlorinated dibenzo-p-dioxins (PCDDs), polychlorinated dibenzofurans (PCDFs) and certain polychlorinated biphenyls (PCBs), are among the most potent AHR ligands[38]. Only a subset of PCDD, PCDF and PCB congeners has been shown to bind to the AHR and cause toxic effects to those elicited by TCDD. Until recently, TCDD was considered to be the most potent DLC in birds[39]; however, recent reports indicate that 2,3,4,7,8-pentachlorodibenzofuran (PeCDF) is more potent than TCDD in some species of birds.[40][13][41][21][42][43] When screened for their ability to induce aryl hydrocarbon hydroxylase (AHH) activity, dioxins with chlorine atoms at a minimum of three out of the four lateral ring positions, and with at least one non-chlorinated ring position are the most active[44]. Of the dioxin-like PCBs, non-ortho congeners are the most toxicologically active, while mono-ortho PCBs are generally less potent[45][9]. Chlorine substitution at ortho positions increases the energetic costs of assuming the coplanar conformation required for binding to the AHR [45]. Thus, a smaller proportion of mono-ortho PCB molecules are able to bind to the AHR and elicit toxic effects, resulting in reduced potency of these congeners. Other PCB congeners, such as di-ortho substituted PCBs, are very weak AHR agonists and do not likely contribute to dioxin-like effects [9].   	Contrary to studies of birds and mammals, even the most potent mono-ortho PCBs bind to AhRs of fishes with very low affinity, if at all (Abnet et al 1999; Doering et al 2014; 2015; Eisner et al 2016; Van den Berg et al 1998).   The role of the AHR in mediating the toxic effects of planar hydrophobic contaminants has been well studied, however the endogenous role of the AHR is less clear [1]. Some endogenous and natural substances, including prostaglandin PGG2 and the tryptophan derivatives indole-3-carbinol, 6-formylindolo[3,2-b]carbazole (FICZ) and kynurenic acid can bind to and activate the AHR. [6][46][47][48][49] The AHR is thought to have important endogenous roles in reproduction, liver and heart development, cardiovascular function, immune function and cell cycle regulation [50][38][51][52][53][54][46][55][56][57] and activation of the AHR by DLCs may therefore adversely affect these processes."@en ;
  foaf:page <https://identifiers.org/aop/151> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/152> a sbd:Model ;
  rdfs:label "Interference with thyroid serum binding protein transthyretin and subsequent adverse human neurodevelopmental toxicity "@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Rickenbacher et al (1986) provided initial direct evidence of competition for the T4 binding site using molecular modeling and binding assays using radiolabeled TH. Brouwer and van den Berg (1986) reported preferential binding of a metabolite of radiolabeled tetrachlorobiphenyl to TTR in rats (15 mg/kg, ip), using gel electrophoresis followed by HPLC analysis. Van den Berg (1990) used a competitive binding assay to assess the ability of hydroxylated chlorinated aromatic compounds to bind to radiolabeled T4. Van den Berg et al (1991) extended this work to 65 compounds from 12 different chemical groups in rats treated via a single ip dose and competitive binding assay. Chlorophenols were found to have higher affinity relative to other chlorinated aromatics, particular at higher levels of chlorination, and the combination and position of hydroxyl &amp; chlorine atoms. {insert Figure 2/Van den Berg 1990}  Lans et al (1993) described the ability of hydroxylated metabolites of PCBs, PCDDs and PCDFs to act as competetive ligands at the TTR-T4 binding site using an in vitro binding assay. Many of the hydroxylated PCBs examined were more potent ligands than T4, as opposed to those PCDFs and PCDDs that lacked chlorine atoms substituted adjacent to hydroxyl groups. When the hydroxyl group was in the meta or para positions, a 35- to 136-fold greater potency was found relative to ortho substitutions. These results were confirmed through later competitive binding work published by Cheek et al (1999) and Chauhan et al (2000).  Weiss et al (2009) first confirmed competitive binding of TTR with perfluorinated compounds (PFCs)"@en ;
  foaf:page <https://identifiers.org/aop/152> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/152> a sbd:Model ;
  rdfs:label "Interference with thyroid serum binding protein transthyretin and subsequent adverse human neurodevelopmental toxicity "@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Transthyretin is one of three ancient, highly conserved serum binding proteins&nbsp;that collectively act to transport thyroid hormone (TH) and thus help maintain normal homeostasis via modulation of the hypothalamic/pituitary/thyroid axis. In addition to TTR, albumin (ALB) and thyroxine-binding globulin (TBG) also serve to transport TH in serum and the relative contribution of each binding protein differs across species. In man, TBG has the greatest affinity for thyroxine (T4), followed by TTR and ALB shows the lowest affinity for T4 while prevalence in serum is the opposite, while in rat, TTR is the major serum transport protein (as rats lack TBG). Interference with TH serum binding proteins is one of several mechanisms through which xenobiotics and environmental contaminants can disrupt normal thyroid endocrine function (&quot;thyroid disruptors&quot;) and development of this AOP is expected to contribute towards a fuller understanding of the mechanism of TTR interference and how it may be measured in vitro as part of a larger screening battery for thyroid toxicants."@en ;
  foaf:page <https://identifiers.org/aop/152> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/152> a sbd:Model ;
  rdfs:label "Interference with thyroid serum binding protein transthyretin and subsequent adverse human neurodevelopmental toxicity "@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "A prime example of impairments in cognitive function as the adverse outcome for regulatory action is developmental lead exposure and IQ function in children (Bellinger, 2012). In addition, testing for the impact of chemical expsoures on cognitive function, often including spatially-mediated behaviors, is an intergral part of both EPA and OECD developmental neurotoxicity guidelines (USEPA, 1998; OECD, 2007)."@en ;
  foaf:page <https://identifiers.org/aop/152> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/154> a sbd:Model ;
  rdfs:label "Inhibition of Calcineurin Activity Leading to Impaired T-Cell Dependent Antibody Response"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "CN inhibitory activities (IC50) are shown in follows.  Tacrorimus:&nbsp; 0.4nM  Cyclosporin:&nbsp; 7nM  Pimecrolimus:&nbsp; 0.4 nM  Dodecylbenzene sulfonate&nbsp; 9.3 uM  Dibefurin:&nbsp; 44&nbsp;&nbsp;uM  Gossypol:&nbsp; 17 uM  Ascomycin:&nbsp; 0.7 nM  1,5-dibenzoyloxymethyl-norcantharidin:&nbsp; 7 uM  Kaempferol:&nbsp; 51.3 uM"@en ;
  foaf:page <https://identifiers.org/aop/154> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/154> a sbd:Model ;
  rdfs:label "Inhibition of Calcineurin Activity Leading to Impaired T-Cell Dependent Antibody Response"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Although there are other stressors that inhibit CN activity, this AOP is mainly based on an understanding of immunosuppression caused by the complex of FK506 and FKBP12 and cyclophilin and CsA,&nbsp;on which a significant body of scientific literature has been published.  We look forward to future amendments to this AOP with up-to-date information on other stressors, which will more clarify the linkage between inhibition of CN activity and impairment of TDAR."@en ;
  foaf:page <https://identifiers.org/aop/154> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/154> a sbd:Model ;
  rdfs:label "Inhibition of Calcineurin Activity Leading to Impaired T-Cell Dependent Antibody Response"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The ICH S8 guideline, which covers immunosuppression of small molecule drugs, determines the need for immunotoxicity studies by comprehensively evaluating the findings of pharmacology, changes in the immune system in repeated-dose toxicity studies, and other factors using a Weight of Evidence approach. If there is concern about immunotoxicity, the presence or absence of immunotoxicity should be determined using an in vivo test system capable of assessing the functional changes of predicted immunotoxic target cells. If immunotoxicity is observed, additional studies including in vitro assays or clinical evaluation should be considered to assess the risk of immunotoxicity in humans. Because TDAR involves many immune cell populations, including T cells, B cells, and antigen-presenting cells, evaluation of TDAR is recommended when there is concern about immunotoxicity but the immunotoxic target cells are unclear. The S8 guidelines list KLH, SRBC, and tetanus toxin as antigens for TDAR.  The draft FDA immunotoxicity testing guidance (2020) covers immunosuppressive and immunostimulatory drugs and biologics; evaluating immunosuppressive drugs in the draft FDA guidance is similar to that in the S8 guideline, with in vivo TDAR assays recommended when toxic target cells are unknown. The draft guidance states that TDAR assays using KLH as an antigen have been established in mice, rats, dogs, minipigs, and cynomolgus monkeys, but the use of SRBC and tetanus toxin as antigens is also acceptable.  For the assessment for pesticides, US EPA OPPTS 870.7800 immunotoxicity testing guideline recommends TDAR using SRBC. The REACH guideline does not provide for immunotoxicity testing, but it provides triggers for conducting immunotoxicity testing.  The WHO/IPSS Immunotoxicity Risk assessment Guidance (2012) describes a strategy for assessing five categories of immunotoxicity risks, including immunosuppression. For risk assessment of immunosuppression, it calls for identification of immunosuppression risks, prediction of pathogenesis that may occur, and consideration of safety margins based on the WoE approach from human findings, infection resistance tests, immune function tests, general immune system assays, histopathological findings and organ weights in general toxicity studies, and hematological data.  The evaluation of immunotoxicity in F1 animals in the OECD Guidelines for Extended First Generation Reproductive and Developmental Toxicity Studies (TG443) requires that PFC and ELSA assays to measure primary IgM antibody production by TDAR using T-cell dependent antigens (SRBC, KLH, etc.) be performed. Furthermore, if changes are observed, the significance of the changes should be examined by comprehensively evaluating other data.  The outcomes of immunosuppression are susceptibility to infection and tumorigenesis, and the FDA guidance requires that immunosuppressive drugs be evaluated for carcinogenic risk using WoE approach based on the results of carcinogenicity and immunotoxicity studies. Meanwhile, the ICH S1B(R1) Draft Step 2 Guidelines for Carcinogenicity Testing calls for evaluation of carcinogenicity by WoE approach instead of rat carcinogenicity testing, because rodent carcinogenicity test models are less capable of detecting carcinogenicity. On the other hand, it is difficult to define susceptibility to infection as a measurable AO with a clear mechanism, because immune responses vary among pathogens. In fact, many immunotoxicity guidelines require that the risk of immunotoxicity be identified and assessed by evaluating immune functions.  It was difficult to define susceptibility to infection as an AO, so TDAR, which is recommended as an indicator of immunosuppresoin in many guidelines, was used as an AO. It is expected that several AOPs with TDARs as AOs will be developed, and based on these AOPs, it may be possible to develop an IATA to assess the risk of immunotoxicity characterized by TDARs."@en ;
  foaf:page <https://identifiers.org/aop/154> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/155> a sbd:Model ;
  rdfs:label "Deiodinase 2 inhibition leading to increased mortality via reduced posterior swim bladder inflation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/155> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/155> a sbd:Model ;
  rdfs:label "Deiodinase 2 inhibition leading to increased mortality via reduced posterior swim bladder inflation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Olker et al. (2019) identified 20 DIO2-specific inhibitors using a human recombinant DIO2 enzyme (e.g., tetramethrin, elzasonan). Another typical inhibitor of DIO2 (and DIO1 and 3) is iopanoic acid (IOP), which acts as a substrate of all three DIO isoforms (Renko et al., 2015). In fact, many compounds inhibit all three DIO isoforms. Olker et al. (2019) identified 93 compounds that inhibit DIOs 1, 2 and 3."@en ;
  foaf:page <https://identifiers.org/aop/155> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/155> a sbd:Model ;
  rdfs:label "Deiodinase 2 inhibition leading to increased mortality via reduced posterior swim bladder inflation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Increased mortality is one of the most common regulatory assessment endpoints,&nbsp;along with reduced growth and reduced reproduction."@en ;
  foaf:page <https://identifiers.org/aop/155> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/155> a sbd:Model ;
  rdfs:label "Deiodinase 2 inhibition leading to increased mortality via reduced posterior swim bladder inflation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The larger AOP network describing the effect of deiodinase and thyroperoxidase inhibition on swim bladder inflation consists of 5 AOPs:   	Deiodinase 2 inhibition leading to increased mortality via reduced posterior swim bladder inflation: https://aopwiki.org/aops/155 	Deiodinase 2 inhibition leading to increased mortality via reduced anterior swim bladder inflation: https://aopwiki.org/aops/156 	Deiodinase 1 inhibition leading to increased mortality via reduced posterior swim bladder inflation : https://aopwiki.org/aops/157 	Deiodinase 1 inhibition leading to increased mortality via reduced anterior swim bladder inflation : https://aopwiki.org/aops/158 	Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflation: https://aopwiki.org/aops/159   The development of these AOPs was mainly based on a series of dedicated experiments (using a set of reference chemicals as prototypical stressors) in zebrafish and fathead minnow that form the core of the empirical evidence. Specific literature searches were used to add evidence from other studies, mainly in zebrafish and fathead minnow. No systematic review approach was applied."@en ;
  foaf:page <https://identifiers.org/aop/155> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/155> a sbd:Model ;
  rdfs:label "Deiodinase 2 inhibition leading to increased mortality via reduced posterior swim bladder inflation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/155> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/155> a sbd:Model ;
  rdfs:label "Deiodinase 2 inhibition leading to increased mortality via reduced posterior swim bladder inflation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Olker et al. (2019) identified 20 DIO2-specific inhibitors using a human recombinant DIO2 enzyme (e.g., tetramethrin, elzasonan). Another typical inhibitor of DIO2 (and DIO1 and 3) is iopanoic acid (IOP), which acts as a substrate of all three DIO isoforms (Renko et al., 2015). In fact, many compounds inhibit all three DIO isoforms. Olker et al. (2019) identified 93 compounds that inhibit DIOs 1, 2 and 3."@en ;
  foaf:page <https://identifiers.org/aop/155> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/155> a sbd:Model ;
  rdfs:label "Deiodinase 2 inhibition leading to increased mortality via reduced posterior swim bladder inflation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Increased mortality is one of the most common regulatory assessment endpoints,&nbsp;along with reduced growth and reduced reproduction."@en ;
  foaf:page <https://identifiers.org/aop/155> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/155> a sbd:Model ;
  rdfs:label "Deiodinase 2 inhibition leading to increased mortality via reduced posterior swim bladder inflation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The larger AOP network describing the effect of deiodinase and thyroperoxidase inhibition on swim bladder inflation consists of 5 AOPs:   	Deiodinase 2 inhibition leading to increased mortality via reduced posterior swim bladder inflation: https://aopwiki.org/aops/155 	Deiodinase 2 inhibition leading to increased mortality via reduced anterior swim bladder inflation: https://aopwiki.org/aops/156 	Deiodinase 1 inhibition leading to increased mortality via reduced posterior swim bladder inflation : https://aopwiki.org/aops/157 	Deiodinase 1 inhibition leading to increased mortality via reduced anterior swim bladder inflation : https://aopwiki.org/aops/158 	Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflation: https://aopwiki.org/aops/159   The development of these AOPs was mainly based on a series of dedicated experiments (using a set of reference chemicals as prototypical stressors) in zebrafish and fathead minnow that form the core of the empirical evidence. Specific literature searches were used to add evidence from other studies, mainly in zebrafish and fathead minnow. No systematic review approach was applied."@en ;
  foaf:page <https://identifiers.org/aop/155> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/156> a sbd:Model ;
  rdfs:label "Deiodinase 2 inhibition leading to increased mortality via reduced anterior swim bladder inflation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/156> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/156> a sbd:Model ;
  rdfs:label "Deiodinase 2 inhibition leading to increased mortality via reduced anterior swim bladder inflation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Olker et al. (2019) identified 20 DIO2-specific inhibitors using a human recombinant DIO2 enzyme (e.g., tetramethrin, elzasonan). Another typical inhibitor of DIO2 (and DIO1 and 3) is iopanoic acid (IOP), which acts as a substrate of all three DIO isoforms (Renko et al., 2015). In fact, many compounds inhibit all three DIO isoforms. Olker et al. (2019) identified 93 compounds that inhibit DIOs 1, 2 and 3."@en ;
  foaf:page <https://identifiers.org/aop/156> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/156> a sbd:Model ;
  rdfs:label "Deiodinase 2 inhibition leading to increased mortality via reduced anterior swim bladder inflation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Increased mortality is one of the most common regulatory assessment endpoints,&nbsp;along with reduced growth and reduced reproduction."@en ;
  foaf:page <https://identifiers.org/aop/156> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/156> a sbd:Model ;
  rdfs:label "Deiodinase 2 inhibition leading to increased mortality via reduced anterior swim bladder inflation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The larger AOP network describing the effect of deiodinase and thyroperoxidase inhibition on swim bladder inflation consists of 5 AOPs:   	Deiodinase 2 inhibition leading to increased mortality via reduced posterior swim bladder inflation: https://aopwiki.org/aops/155 	Deiodinase 2 inhibition leading to increased mortality via reduced anterior swim bladder inflation: https://aopwiki.org/aops/156 	Deiodinase 1 inhibition leading to increased mortality via reduced posterior swim bladder inflation : https://aopwiki.org/aops/157 	Deiodinase 1 inhibition leading to increased mortality via reduced anterior swim bladder inflation : https://aopwiki.org/aops/158 	Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflation: https://aopwiki.org/aops/159   The development of these AOPs was mainly based on a series of dedicated experiments (using a set of reference chemicals as prototypical stressors) in zebrafish and fathead minnow that form the core of the empirical evidence. Specific literature searches were used to add evidence from other studies, mainly in zebrafish and fathead minnow. No systematic review approach was applied."@en ;
  foaf:page <https://identifiers.org/aop/156> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/156> a sbd:Model ;
  rdfs:label "Deiodinase 2 inhibition leading to increased mortality via reduced anterior swim bladder inflation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/156> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/156> a sbd:Model ;
  rdfs:label "Deiodinase 2 inhibition leading to increased mortality via reduced anterior swim bladder inflation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Olker et al. (2019) identified 20 DIO2-specific inhibitors using a human recombinant DIO2 enzyme (e.g., tetramethrin, elzasonan). Another typical inhibitor of DIO2 (and DIO1 and 3) is iopanoic acid (IOP), which acts as a substrate of all three DIO isoforms (Renko et al., 2015). In fact, many compounds inhibit all three DIO isoforms. Olker et al. (2019) identified 93 compounds that inhibit DIOs 1, 2 and 3."@en ;
  foaf:page <https://identifiers.org/aop/156> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/156> a sbd:Model ;
  rdfs:label "Deiodinase 2 inhibition leading to increased mortality via reduced anterior swim bladder inflation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Increased mortality is one of the most common regulatory assessment endpoints,&nbsp;along with reduced growth and reduced reproduction."@en ;
  foaf:page <https://identifiers.org/aop/156> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/156> a sbd:Model ;
  rdfs:label "Deiodinase 2 inhibition leading to increased mortality via reduced anterior swim bladder inflation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The larger AOP network describing the effect of deiodinase and thyroperoxidase inhibition on swim bladder inflation consists of 5 AOPs:   	Deiodinase 2 inhibition leading to increased mortality via reduced posterior swim bladder inflation: https://aopwiki.org/aops/155 	Deiodinase 2 inhibition leading to increased mortality via reduced anterior swim bladder inflation: https://aopwiki.org/aops/156 	Deiodinase 1 inhibition leading to increased mortality via reduced posterior swim bladder inflation : https://aopwiki.org/aops/157 	Deiodinase 1 inhibition leading to increased mortality via reduced anterior swim bladder inflation : https://aopwiki.org/aops/158 	Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflation: https://aopwiki.org/aops/159   The development of these AOPs was mainly based on a series of dedicated experiments (using a set of reference chemicals as prototypical stressors) in zebrafish and fathead minnow that form the core of the empirical evidence. Specific literature searches were used to add evidence from other studies, mainly in zebrafish and fathead minnow. No systematic review approach was applied."@en ;
  foaf:page <https://identifiers.org/aop/156> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/157> a sbd:Model ;
  rdfs:label "Deiodinase 1 inhibition leading to increased mortality via reduced posterior swim bladder inflation "@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Propylthiouracil (PTU) is the prototypical DIO1 inhibitor in mammals, although teleostean and amphibian DIO1 enzymes are less sensitive to inhibition by PTU (Orozco et al., 2003; Kuiper et al., 2006). Olker et al. (2019) identified 22 DIO1-specific inhibitors using a human recombinant DIO1 enzyme (e.g., genistein, 6-methyl-2-thiouracil, sulfasalazine). Another well-known inhibitor of DIO1 (and DIO2 and 3) is iopanoic acid (IOP). Renko et al. (2003, 2015) pointed out that IOP is actually a substrate of DIO1 (and DIO2 and 3) which is in line with its action as a competitive inhibotor. In fact, many compounds inhibit all three DIO isoforms. Olker et al. (2019) identified 93 compounds that inhibit DIOs 1, 2 and 3."@en ;
  foaf:page <https://identifiers.org/aop/157> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/157> a sbd:Model ;
  rdfs:label "Deiodinase 1 inhibition leading to increased mortality via reduced posterior swim bladder inflation "@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/157> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/157> a sbd:Model ;
  rdfs:label "Deiodinase 1 inhibition leading to increased mortality via reduced posterior swim bladder inflation "@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Increased mortality is one of the most common regulatory assessment endpoints,&nbsp;along with reduced growth and reduced reproduction."@en ;
  foaf:page <https://identifiers.org/aop/157> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/157> a sbd:Model ;
  rdfs:label "Deiodinase 1 inhibition leading to increased mortality via reduced posterior swim bladder inflation "@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The larger AOP network describing the effect of deiodinase and thyroperoxidase inhibition on swim bladder inflation consists of 5 AOPs:   	Deiodinase 2 inhibition leading to increased mortality via reduced posterior swim bladder inflation: https://aopwiki.org/aops/155 	Deiodinase 2 inhibition leading to increased mortality via reduced anterior swim bladder inflation: https://aopwiki.org/aops/156 	Deiodinase 1 inhibition leading to increased mortality via reduced posterior swim bladder inflation : https://aopwiki.org/aops/157 	Deiodinase 1 inhibition leading to increased mortality via reduced anterior swim bladder inflation : https://aopwiki.org/aops/158 	Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflation: https://aopwiki.org/aops/159   The development of these AOPs was mainly based on a series of dedicated experiments (using a set of reference chemicals as prototypical stressors) in zebrafish and fathead minnow that form the core of the empirical evidence. Specific literature searches were used to add evidence from other studies, mainly in zebrafish and fathead minnow. No systematic review approach was applied."@en ;
  foaf:page <https://identifiers.org/aop/157> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/157> a sbd:Model ;
  rdfs:label "Deiodinase 1 inhibition leading to increased mortality via reduced posterior swim bladder inflation "@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Propylthiouracil (PTU) is the prototypical DIO1 inhibitor in mammals, although teleostean and amphibian DIO1 enzymes are less sensitive to inhibition by PTU (Orozco et al., 2003; Kuiper et al., 2006). Olker et al. (2019) identified 22 DIO1-specific inhibitors using a human recombinant DIO1 enzyme (e.g., genistein, 6-methyl-2-thiouracil, sulfasalazine). Another well-known inhibitor of DIO1 (and DIO2 and 3) is iopanoic acid (IOP). Renko et al. (2003, 2015) pointed out that IOP is actually a substrate of DIO1 (and DIO2 and 3) which is in line with its action as a competitive inhibotor. In fact, many compounds inhibit all three DIO isoforms. Olker et al. (2019) identified 93 compounds that inhibit DIOs 1, 2 and 3."@en ;
  foaf:page <https://identifiers.org/aop/157> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/157> a sbd:Model ;
  rdfs:label "Deiodinase 1 inhibition leading to increased mortality via reduced posterior swim bladder inflation "@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/157> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/157> a sbd:Model ;
  rdfs:label "Deiodinase 1 inhibition leading to increased mortality via reduced posterior swim bladder inflation "@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Increased mortality is one of the most common regulatory assessment endpoints,&nbsp;along with reduced growth and reduced reproduction."@en ;
  foaf:page <https://identifiers.org/aop/157> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/157> a sbd:Model ;
  rdfs:label "Deiodinase 1 inhibition leading to increased mortality via reduced posterior swim bladder inflation "@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The larger AOP network describing the effect of deiodinase and thyroperoxidase inhibition on swim bladder inflation consists of 5 AOPs:   	Deiodinase 2 inhibition leading to increased mortality via reduced posterior swim bladder inflation: https://aopwiki.org/aops/155 	Deiodinase 2 inhibition leading to increased mortality via reduced anterior swim bladder inflation: https://aopwiki.org/aops/156 	Deiodinase 1 inhibition leading to increased mortality via reduced posterior swim bladder inflation : https://aopwiki.org/aops/157 	Deiodinase 1 inhibition leading to increased mortality via reduced anterior swim bladder inflation : https://aopwiki.org/aops/158 	Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflation: https://aopwiki.org/aops/159   The development of these AOPs was mainly based on a series of dedicated experiments (using a set of reference chemicals as prototypical stressors) in zebrafish and fathead minnow that form the core of the empirical evidence. Specific literature searches were used to add evidence from other studies, mainly in zebrafish and fathead minnow. No systematic review approach was applied."@en ;
  foaf:page <https://identifiers.org/aop/157> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/158> a sbd:Model ;
  rdfs:label "Deiodinase 1 inhibition leading to increased mortality via reduced anterior swim bladder inflation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Propylthiouracil (PTU) is the prototypical DIO1 inhibitor in mammals, although teleostean and amphibian DIO1 enzymes are less sensitive to inhibition by PTU (Orozco et al., 2003; Kuiper et al., 2006). Olker et al. (2019) identified 22 DIO1-specific inhibitors using a human recombinant DIO1 enzyme (e.g., genistein, 6-methyl-2-thiouracil, sulfasalazine). Another well-known inhibitor of DIO1 (and DIO2 and 3) is iopanoic acid (IOP). Renko et al. (2003, 2015) pointed out that IOP is actually a substrate of DIO1 (and DIO2 and 3) which is in line with its action as a competitive inhibotor. In fact, many compounds inhibit all three DIO isoforms. Olker et al. (2019) identified 93 compounds that inhibit DIOs 1, 2 and 3."@en ;
  foaf:page <https://identifiers.org/aop/158> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/158> a sbd:Model ;
  rdfs:label "Deiodinase 1 inhibition leading to increased mortality via reduced anterior swim bladder inflation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/158> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/158> a sbd:Model ;
  rdfs:label "Deiodinase 1 inhibition leading to increased mortality via reduced anterior swim bladder inflation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Increased mortality is one of the most common regulatory assessment endpoints,&nbsp;along with reduced growth and reduced reproduction."@en ;
  foaf:page <https://identifiers.org/aop/158> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/158> a sbd:Model ;
  rdfs:label "Deiodinase 1 inhibition leading to increased mortality via reduced anterior swim bladder inflation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The larger AOP network describing the effect of deiodinase and thyroperoxidase inhibition on swim bladder inflation consists of 5 AOPs:   	Deiodinase 2 inhibition leading to increased mortality via reduced posterior swim bladder inflation: https://aopwiki.org/aops/155 	Deiodinase 2 inhibition leading to increased mortality via reduced anterior swim bladder inflation: https://aopwiki.org/aops/156 	Deiodinase 1 inhibition leading to increased mortality via reduced posterior swim bladder inflation : https://aopwiki.org/aops/157 	Deiodinase 1 inhibition leading to increased mortality via reduced anterior swim bladder inflation : https://aopwiki.org/aops/158 	Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflation: https://aopwiki.org/aops/159   The development of these AOPs was mainly based on a series of dedicated experiments (using a set of reference chemicals as prototypical stressors) in zebrafish and fathead minnow that form the core of the empirical evidence. Specific literature searches were used to add evidence from other studies, mainly in zebrafish and fathead minnow. No systematic review approach was applied."@en ;
  foaf:page <https://identifiers.org/aop/158> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/158> a sbd:Model ;
  rdfs:label "Deiodinase 1 inhibition leading to increased mortality via reduced anterior swim bladder inflation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Propylthiouracil (PTU) is the prototypical DIO1 inhibitor in mammals, although teleostean and amphibian DIO1 enzymes are less sensitive to inhibition by PTU (Orozco et al., 2003; Kuiper et al., 2006). Olker et al. (2019) identified 22 DIO1-specific inhibitors using a human recombinant DIO1 enzyme (e.g., genistein, 6-methyl-2-thiouracil, sulfasalazine). Another well-known inhibitor of DIO1 (and DIO2 and 3) is iopanoic acid (IOP). Renko et al. (2003, 2015) pointed out that IOP is actually a substrate of DIO1 (and DIO2 and 3) which is in line with its action as a competitive inhibotor. In fact, many compounds inhibit all three DIO isoforms. Olker et al. (2019) identified 93 compounds that inhibit DIOs 1, 2 and 3."@en ;
  foaf:page <https://identifiers.org/aop/158> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/158> a sbd:Model ;
  rdfs:label "Deiodinase 1 inhibition leading to increased mortality via reduced anterior swim bladder inflation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/158> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/158> a sbd:Model ;
  rdfs:label "Deiodinase 1 inhibition leading to increased mortality via reduced anterior swim bladder inflation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Increased mortality is one of the most common regulatory assessment endpoints,&nbsp;along with reduced growth and reduced reproduction."@en ;
  foaf:page <https://identifiers.org/aop/158> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/158> a sbd:Model ;
  rdfs:label "Deiodinase 1 inhibition leading to increased mortality via reduced anterior swim bladder inflation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The larger AOP network describing the effect of deiodinase and thyroperoxidase inhibition on swim bladder inflation consists of 5 AOPs:   	Deiodinase 2 inhibition leading to increased mortality via reduced posterior swim bladder inflation: https://aopwiki.org/aops/155 	Deiodinase 2 inhibition leading to increased mortality via reduced anterior swim bladder inflation: https://aopwiki.org/aops/156 	Deiodinase 1 inhibition leading to increased mortality via reduced posterior swim bladder inflation : https://aopwiki.org/aops/157 	Deiodinase 1 inhibition leading to increased mortality via reduced anterior swim bladder inflation : https://aopwiki.org/aops/158 	Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflation: https://aopwiki.org/aops/159   The development of these AOPs was mainly based on a series of dedicated experiments (using a set of reference chemicals as prototypical stressors) in zebrafish and fathead minnow that form the core of the empirical evidence. Specific literature searches were used to add evidence from other studies, mainly in zebrafish and fathead minnow. No systematic review approach was applied."@en ;
  foaf:page <https://identifiers.org/aop/158> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/159> a sbd:Model ;
  rdfs:label "Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/159> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/159> a sbd:Model ;
  rdfs:label "Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Increased mortality is one of the most common regulatory assessment endpoints,&nbsp;along with reduced growth and reduced reproduction."@en ;
  foaf:page <https://identifiers.org/aop/159> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/159> a sbd:Model ;
  rdfs:label "Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The larger AOP network describing the effect of deiodinase and thyroperoxidase inhibition on swim bladder inflation consists of 5 AOPs:   	Deiodinase 2 inhibition leading to increased mortality via reduced posterior swim bladder inflation: https://aopwiki.org/aops/155 	Deiodinase 2 inhibition leading to increased mortality via reduced anterior swim bladder inflation: https://aopwiki.org/aops/156 	Deiodinase 1 inhibition leading to increased mortality via reduced posterior swim bladder inflation : https://aopwiki.org/aops/157 	Deiodinase 1 inhibition leading to increased mortality via reduced anterior swim bladder inflation : https://aopwiki.org/aops/158 	Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflation: https://aopwiki.org/aops/159   The development of these AOPs was mainly based on a series of dedicated experiments (using a set of reference chemicals as prototypical stressors) in zebrafish and fathead minnow that form the core of the empirical evidence. Specific literature searches were used to add evidence from other studies, mainly in zebrafish and fathead minnow. No systematic review approach was applied."@en ;
  foaf:page <https://identifiers.org/aop/159> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/159> a sbd:Model ;
  rdfs:label "Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "There is a wealth of information on the inhibition of TPO by drugs such as MMI and PTU, as well as environmental xenobiotics. In the landmark paper on TH system&nbsp;disruption by environmental chemicals, Brucker-Davis (1998) identified environmental chemicals that depressed TH synthesis by inhibiting TPO. Hurley (1998) listed TPO as a major target for thyroid tumor inducing pesticides. More recent work has tested over 1000 chemicals using a high-throughput screening assay (Paul-Friedman et al., 2016)."@en ;
  foaf:page <https://identifiers.org/aop/159> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/159> a sbd:Model ;
  rdfs:label "Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/159> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/159> a sbd:Model ;
  rdfs:label "Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Increased mortality is one of the most common regulatory assessment endpoints,&nbsp;along with reduced growth and reduced reproduction."@en ;
  foaf:page <https://identifiers.org/aop/159> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/159> a sbd:Model ;
  rdfs:label "Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The larger AOP network describing the effect of deiodinase and thyroperoxidase inhibition on swim bladder inflation consists of 5 AOPs:   	Deiodinase 2 inhibition leading to increased mortality via reduced posterior swim bladder inflation: https://aopwiki.org/aops/155 	Deiodinase 2 inhibition leading to increased mortality via reduced anterior swim bladder inflation: https://aopwiki.org/aops/156 	Deiodinase 1 inhibition leading to increased mortality via reduced posterior swim bladder inflation : https://aopwiki.org/aops/157 	Deiodinase 1 inhibition leading to increased mortality via reduced anterior swim bladder inflation : https://aopwiki.org/aops/158 	Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflation: https://aopwiki.org/aops/159   The development of these AOPs was mainly based on a series of dedicated experiments (using a set of reference chemicals as prototypical stressors) in zebrafish and fathead minnow that form the core of the empirical evidence. Specific literature searches were used to add evidence from other studies, mainly in zebrafish and fathead minnow. No systematic review approach was applied."@en ;
  foaf:page <https://identifiers.org/aop/159> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/159> a sbd:Model ;
  rdfs:label "Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "There is a wealth of information on the inhibition of TPO by drugs such as MMI and PTU, as well as environmental xenobiotics. In the landmark paper on TH system&nbsp;disruption by environmental chemicals, Brucker-Davis (1998) identified environmental chemicals that depressed TH synthesis by inhibiting TPO. Hurley (1998) listed TPO as a major target for thyroid tumor inducing pesticides. More recent work has tested over 1000 chemicals using a high-throughput screening assay (Paul-Friedman et al., 2016)."@en ;
  foaf:page <https://identifiers.org/aop/159> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/16> a sbd:Model ;
  rdfs:label "Acetylcholinesterase inhibition leading to acute mortality"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Organophosphate and carbamate insecticides are prototypical AChE inhibitors. The OP and carbamate pesticides were synthesized specifically to act as inhibitors of AChE, with OPs developed from early nerve agents (e.g., sarin) and carbamate pesticides based on the natural plant alkaloid physostigmine (Ecobichon 2001). 	A positive and significant correlation between the log of the Eserine IC50 (in vitro) for AChE inhibition and the log Km value for the AChE in the fish and crustacea species has been reported, explaining 92% of the variation in enzyme inhibition (Monserrat and Bianchini, 2001). Similar success was found in relating the rate constants for inhibition of AChE in housefly and the pseudo first-order hydrolysis rate constant for active forms of OPs (Fukuto 1990).    	The open literature includes many studies on vertebrate and invertebrate species that demonstrate a clear dependence of AChE activity on the dose or concentration of the substance with increased concentrations leading to an increase in the inhibition of AChE (e.g., fish ( Karen et al., 2001), birds (Hudson et al., 1984 (see dimethoate and disulfoton), Grue and Shipley 1984; and Al-Zubaidy et al., 2011); cladocera (Barata et al., 2004); nematodes (Rajini et al., 2008); rodents (Roberts et al., 1988; and mollusk (Bianco et al., 2011)). 	The open literature includes many studies on vertebrate and invertebrate species that demonstrate a clear relationship between increasing AChE inhibition as duration of exposure increases (e.g., amphibians ( Venturino et al., 2001); fish (Rao 2008; Ferrari et al., 2004); insects (Rose and Sparks 1984); birds (Ludke 1985; Grue and Shipley 1984); annelids (Reddy and Rao 2008); cladocera (Barata et al., 2004)). 	Rao et al. 2008 exposed the estuarine fish Oreochromis mossambicus to a 24 h LC50 concentration of chlorpyrifos and reported that it took 6 hr to reach &gt;40% AChE inhibition and 24 hr to reach 90% AChE inhibition. It took &gt;100 days to recover to normal AChE levels when fish were placed in clean water. 	A time course study of earthworms (Eisenis foetida) exposed to the 48 hr LC50 of profenofos found a significant relationship (between increases in percent inhibition of AChE and increase in time of exposure from 8-48 hrs (Chakra Reddy and Rao 2008)."@en ;
  foaf:page <https://identifiers.org/aop/16> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/16> a sbd:Model ;
  rdfs:label "Acetylcholinesterase inhibition leading to acute mortality"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/16> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/16> a sbd:Model ;
  rdfs:label "Acetylcholinesterase inhibition leading to acute mortality"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Increased mortality is one of the most common regulatory assessment endpoints,&nbsp;along with reduced growth and reduced reproduction."@en ;
  foaf:page <https://identifiers.org/aop/16> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/16> a sbd:Model ;
  rdfs:label "Acetylcholinesterase inhibition leading to acute mortality"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Organophosphate and carbamate insecticides are prototypical AChE inhibitors. The OP and carbamate pesticides were synthesized specifically to act as inhibitors of AChE, with OPs developed from early nerve agents (e.g., sarin) and carbamate pesticides based on the natural plant alkaloid physostigmine (Ecobichon 2001). 	A positive and significant correlation between the log of the Eserine IC50 (in vitro) for AChE inhibition and the log Km value for the AChE in the fish and crustacea species has been reported, explaining 92% of the variation in enzyme inhibition (Monserrat and Bianchini, 2001). Similar success was found in relating the rate constants for inhibition of AChE in housefly and the pseudo first-order hydrolysis rate constant for active forms of OPs (Fukuto 1990).    	The open literature includes many studies on vertebrate and invertebrate species that demonstrate a clear dependence of AChE activity on the dose or concentration of the substance with increased concentrations leading to an increase in the inhibition of AChE (e.g., fish ( Karen et al., 2001), birds (Hudson et al., 1984 (see dimethoate and disulfoton), Grue and Shipley 1984; and Al-Zubaidy et al., 2011); cladocera (Barata et al., 2004); nematodes (Rajini et al., 2008); rodents (Roberts et al., 1988; and mollusk (Bianco et al., 2011)). 	The open literature includes many studies on vertebrate and invertebrate species that demonstrate a clear relationship between increasing AChE inhibition as duration of exposure increases (e.g., amphibians ( Venturino et al., 2001); fish (Rao 2008; Ferrari et al., 2004); insects (Rose and Sparks 1984); birds (Ludke 1985; Grue and Shipley 1984); annelids (Reddy and Rao 2008); cladocera (Barata et al., 2004)). 	Rao et al. 2008 exposed the estuarine fish Oreochromis mossambicus to a 24 h LC50 concentration of chlorpyrifos and reported that it took 6 hr to reach &gt;40% AChE inhibition and 24 hr to reach 90% AChE inhibition. It took &gt;100 days to recover to normal AChE levels when fish were placed in clean water. 	A time course study of earthworms (Eisenis foetida) exposed to the 48 hr LC50 of profenofos found a significant relationship (between increases in percent inhibition of AChE and increase in time of exposure from 8-48 hrs (Chakra Reddy and Rao 2008)."@en ;
  foaf:page <https://identifiers.org/aop/16> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/16> a sbd:Model ;
  rdfs:label "Acetylcholinesterase inhibition leading to acute mortality"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/16> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/16> a sbd:Model ;
  rdfs:label "Acetylcholinesterase inhibition leading to acute mortality"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Increased mortality is one of the most common regulatory assessment endpoints,&nbsp;along with reduced growth and reduced reproduction."@en ;
  foaf:page <https://identifiers.org/aop/16> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/160> a sbd:Model ;
  rdfs:label "Ionotropic gamma-aminobutyric acid receptor activation mediated neurotransmission inhibition leading to mortality"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Increased mortality is one of the most common regulatory assessment endpoints,&nbsp;along with reduced growth and reduced reproduction."@en ;
  foaf:page <https://identifiers.org/aop/160> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/161> a sbd:Model ;
  rdfs:label "Glutamate-gated chloride channel activation leading to neurotransmission inhibition associated mortality"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Increased mortality is one of the most common regulatory assessment endpoints,&nbsp;along with reduced growth and reduced reproduction."@en ;
  foaf:page <https://identifiers.org/aop/161> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/17> a sbd:Model ;
  rdfs:label "Binding of electrophilic chemicals to SH(thiol)-group of proteins and /or to seleno-proteins involved in protection against oxidative stress during brain development leads to impairment of learning and memory"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "This AOP was originally started in a workshop report entitled: Adverse Outcome Pathways (AOP) relevant to Neurotoxicity and published in Critical Review in Toxicol: Bal-Price, A., Crofton, K.M., Sachana, M., Shafer, T.J., Behl, M., Forsby, A., Hargreaves, A., Landesmann, B., Lein, P.J., Louisse, J., Monnet-Tschudi, F., Paini, A., Rolaki, A., Schrattenholz, A., Sunol, C., van Thriel, C., Whelan, M., Fritsche, E., 2015. Putative adverse outcome pathways relevant to neurotoxicity. Crit Rev Toxicol 45(1), 83-91.  The process of inflammation is common to many tissues and can be described by several KEs, as proposed in a dedicated workshop (Villeneuve et al., 2018). Brain inflammation called Neuroinflammation can be described by the two common KEs: Tissue resident cell, activation and pro-inflammatory mediators, increased. However, Neuroinflammation is a concept accepted by the regulators and is found in the whole literature describing brain inflammation. Therefore, in accord with the external reviewers, we decided to use the KE Neuroinflammation &nbsp;for building the KERs of this AOP, but we introduced in the list of the KEs the two KEs common to the inflammatory process, as proposed in Villeneuve et al., 2018."@en ;
  foaf:page <https://identifiers.org/aop/17> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/17> a sbd:Model ;
  rdfs:label "Binding of electrophilic chemicals to SH(thiol)-group of proteins and /or to seleno-proteins involved in protection against oxidative stress during brain development leads to impairment of learning and memory"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Mercury (Methylmercury, mercury chloride)  The binding of Methylmercury (MeHg) to redox sensitive thiol- or selenol-groups can disrupt the activity of enzymes or the biochemical role of non-enzymatic proteins. The stable or transitory interaction (binding) of MeHg with critical thiol and selenol groups in target enzymes can disrupt the biological function of different types of enzymes, particularly of the antioxidant selenoenzymes thioredoxin reductase (TrxR) and glutathione peroxidase isoforms. The dysregulation of cerebral glutathione (GSH and GSSG) and thioredoxin [Trx or Trx(SH)2] &nbsp;systems by MeHg (Farina et al. 2011; Branco et al. 2017) can impair the fine cellular redox balance via disruption of sensitive cysteinyl- or thiol-containing proteins (Go etal., 2013; Go et al. 2014; Jones 2015).   &nbsp;    Figure 1 &ndash; Hypothetical Binding of MeHg to different types of target proteins. The binding of MeHg to proteins can cause either a transitory inhibition of the protein fucntion (first line, the yellow protein was reactivated by interacting with LMM-SH or R-SH). The pink protein is an example of protein that after the binding of MeHg suffered a change in the structure in such a way that it cannot be reactivated by LMM-SH or R-SH.&nbsp; The third protein (blue) is an example of protein that was permanently denaturated after MeHg binding and even after the removal of MeHg the activity was not recovered. The same type of interactions can be applied to the selenol-containing proteins (i.e., the selenoproteins).  The affinity of Mercury chloride (Hg2+) for thiol and selenol groups is higher than that of MeHg (compare Table 2 with Table 1). The constants described in Table 1 and 2 indicate that MeHg and Hg2+ behave as&nbsp; strong soft electrophiles, i.e., theyhave much higher affinity for the soft nucleophiles centers of thiol- and selenol-containing molecules (Rabenstein 1978a; Arnold et al. 1986; Sugiura et al., 1976).Furthermore, the rate constant for the reaction of MeHg with thiol/thiolate (R-SH/R-S-) has been estimated to be about 6 x 108 M-1.sec-1,&nbsp; indicating that the reactions of electrophilic forms of Hg (EpHg+&nbsp;; here MeHg and Hg2+) with thiolate and selenolate groups are diffusion controlled reactions (Rabenstein&nbsp; and Fairhurst, 1975). The constant indicates that the binding of EpHg+ to thiolate (-S-) or selenolate (-Se-) groups will occurr almost instaneously, when an EpHg+ collides with &ndash;S- or -Se- groups.  The studies of Rabenstein and others have also pointed out that the affinity of MeHg for &ndash;SeH groups is higher than for&nbsp; &ndash;SH groups (Sugira et al. 1976; Arnold et al. 1986). Consequently, &ndash;SeH-containing molecules (i.e., selenoproteins) should be the preferential targets for MeHg (Farina et al. 2011). Accordingly, several studies have demonstrate that the selenoenzymes glutathione peroxidase (GPx) and thioredoxin reductase (TrxR) were inhibited after in vitro and in vivo exposure to MeHg&nbsp; or Hg2+ (Carvalho et al., 2008a; 2011, Farina et al.,&nbsp; 2009; Franco et al., 2009; Wagner et al., 2010; Branco et al., 2011; 2012; 2014, 2017; Dalla Corte et al., 2013; Meinerz et al., 2017).  As corollary, the occurrence of free MeHg and Hg2+ or bound to other ligands such as carboxylates, amines, chloride or hydroxyl anions in the physiological media of living cells is insignificant or nonexistent (George et al. 2008). The binding of MeHg to abundant low molecular mass thiols or LMM-SH (e.g., cysteine and reduced glutathione-GSH) and high molecular mass thiol-containing proteins or HMM-SH (e.g., albumin, hemoglobin, etc) is critical for the MeHg distribution from non-target to target organs and cells (Farina et al. 2017). The coordination of MeHg with one &ndash;S- group of a LMM-SH will determine MeHg distribution to its targets organs, including the brain. The coordination of Hg2+ with two &ndash;S- of LMM-SH molecules (particularly, cysteine or Cys) will determine the distribution of Hg2+ to kidney (which is its main target) and to non-classical targets organs, such as the brain (Oliveira et al. 2017). The entrance of Hg2+ into the brain is proportionally small, but recent literature data have indicated the neurotoxicity of very low and environmentally relevant doses of Hg2+ in rodents (Mello-Carpes et al. 2013&nbsp;), which confirms data obtained with toxic doses in rodents (Peixoto et al. 2007&nbsp;;&nbsp; Franciscato et al. 2009&nbsp;; Chehimi et al. 2012).  Table 1 - Affinity constants of methylmercury for important chemical groups found in biomolecules (adapted from aRabestein, 1978a, bRabestein and Bravo, 1987, using different thiol-containing molecules with the arylmercurialpara-mercurybenzenosulfonate,&nbsp; and from cArnold et al. 1986 taking into consideration that the calculated formation constant of &ndash;Se-MeHg conjugates was 0.1 to 1.2 order greater than that of &ndash;S-MeHg). The values represent the Log of the constants.   	 		 			 			Functional Group 			 			 			Occurrence 			 			 			Formation constant 			 		 		 			 			Thiol/thiolate (-SH/-S-) 			 			 			Cysteine, glutathione, proteins 			 			 			&asymp;14-18 a,b 			 		 		 			 			Selenol/selenolate (-SeH/Se-) 			 			 			Selenocysteinyl residues in selenoproteins 			 			 			&asymp; 16-18c 			 		 	   Table 2. Formation constants of Hg2+ with some representative nucleophilic centers from biomolecules.   	 		 			Functional group 			Hg2+ 		 		 			R-S-R 			&asymp; 6-12 		 		 			R-SH 			&asymp; 40-50 		 		 			R-SeH 			&asymp; 50-60 		 	   The approximate (&asymp;) Log of the constants. The values were adapted &nbsp;from Stricks and Kolthoff 1953; Mousavi 2011 and Liem-Nguyem et al. 2017.  We have to emphasize that what we call of binding to &ndash;SH or &ndash;SeH groups is, in fact, an exchange reaction of MeHg from MeHg-S conjugates (e.g., MeHg-cysteine or MeHg-Cys and MeHg-glutathione or MeHg-SG. conjugates) to&nbsp; a free thiol/thiolate- or selenol/selenolate-group from non-target or target proteins. Thus, the interaction of MeHg with its target proteins in the brain usually involves the exchange of MeHg from low-molecular mass conjugates (LMM-S-conjugates) to a thiol or selenol group in different types of proteins (Rabenstein 1978b; Rabenstein and Fairhurst, 1975; Reid and Rabenstein et al.; 1982; Rabenstein and Reid, 1984; Arnold et al. 1986; Farina et al. 2011, 2017; D&oacute;rea et al. 2013).     Figure 2 &ndash; Binding of MeHg (CH3Hg+) to target thiol- (HMM-SH) or selenol-containing proteins (HMM-SeH). Note that, in fact, the binding of MeHg to their high molecular mass target proteins is mediated by exchange reactions of MeHg from low molecular mass thiol (LMM-SH) molecules to HMM-SH (represented by Prot-SH) or HMM-SeH (represented by Prot-SeH). The scheme also demonstrated that MeHg conjugated with one LMM-SH (here represented by either Cys1-SHgCH3 or G1SHgCH3) can exchange with others LMM-SH (here represented by Cys2-SH or G2SH). After one exchange reaction, the conjugated Cys1-SHgCH3 and G1SHgCH3 release the free LMM-SH molecules Cys1-SH or G1SH.  &nbsp;  Table 3: References for the inhibition by MeHg and Hg2+ of SH-/seleno-proteins involved in protection against oxidative stress   	 		 			 			Protein activity inhibited by MeHg 			 			 			Exposure 			 			 			Functional group likely involved in the inhibition 			 			 			Organism-preparation 			 			 			&nbsp; 			 		 		 			 			Glutathione peroxidase (total GPx) 			 			 			in vivo 			 			 			-SeH 			 			 			Adult mice 			 			 			Glasser et al. 2013 			 		 		 			 			Total GPx 			 			 			in vivo 			 			 			-SeH 			 			 			Adult mice 			 			 			Glasser et al. 2010a 			 		 		 			 			Mitochondrial total GPx 			 			 			in vivo 			 			 			-SeH 			 			 			Adult mice 			 			 			Franco et al. 2009 			 		 		 			 			Total GPx 			 			 			in vitro 			 			 			-SeH 			 			 			SH-SY5Y cells 			 			 			Franco et al. 2009 			 		 		 			 			GPx1 and GPx4 			 			 			in vivo 			 			 			-SeH 			 			 			Adult mice 			 			 			Zemolin et al. 2012 			 		 		 			 			Total GPx 			 			 			in vivo 			 			 			-SeH 			 			 			Adult male mice 			 			 			Malagutti et al. 2009 			 		 		 			 			Total GPx 			 			 			in vitro 			 			 			-SeH 			 			 			PC12 cells 			 			 			Li et al. 2008 			 		 		 			 			Total GPx 			 			 			in vivo 			 			 			-SeH 			 			 			Mice gestational exposure 			 			 			Stringari et al. 2008 			 		 		 			 			Total GPx 			 			 			in vivo 			 			 			-SeH 			 			 			Adult rats 			 			 			Cheng et al. 2005 			 		 		 			 			Total GPx 			 			 			in vitro 			 			 			-SeH 			 			 			Fetal Telencepalic cells from rats 			 			 			Sorg et al. 1998 			 		 		 			 			Total GPx 			 			 			in vitro 			 			 			-SeH 			 			 			Mice neuroblastoma cells 			 			 			Kromidas et al. 1990 			 		 		 			 			Thioredoxin Reductase (TrxR) 			 			 			in vivo 			 			 			-SeH&nbsp; and &ndash;SH 			 			 			Adult mice 			 			 			Zemolin et al. 2012 			 		 		 			 			TrxR 			 			 			in vitro 			 			 			-SeH&nbsp; and &ndash;SH 			 			 			Adult mice 			 			 			Wagner et al. 2010 			 		 		 			 			TrxR 			 			 			in vivo 			 			 			-SeH-&nbsp; and &ndash;SH 			 			 			Adult rats 			 			 			Dalla Corte et al. 2013 			 		 		 			 			Mitochondrial total Gpx 			 			 			In vivo 			 			 			-SeH 			 			 			Adult rat 			 			 			Mori et al., 2007 			 		 		 			 			Mitochondrial total Gpx 			 			 			In vivo 			 			 			-SeH 			 			 			Adult Swiss male mice brain 			 			 			Franco et al., 2009 			 		 		 			&nbsp; 			&nbsp; 			&nbsp; 			&nbsp; 			&nbsp; 		 		 			 			Total brain TrxR 			 			 			In vivo 			 			 			-SeH and -SH 			 			 			Juvenile fish (zebra-seabreams) 			 			 			Branco et al. 2011  			Branco et al. 2012a,b 			 		 		 			&nbsp; 			&nbsp; 			&nbsp; 			&nbsp; 			&nbsp; 		 		 			 			Protein activity inhibited by Hg2+ 			 			 			&nbsp;  			exposure 			 			 			Functional group likely involved in the inhibition 			 			 			&nbsp;  			organism-preparation 			 			 			&nbsp; 			 		 		 			 			Total brain TrxR 			 			 			In vivo 			 			 			-SeH and -SH 			 			 			Juvenile fish (zebra-seabreams) 			 			 			Branco et al. 2012a,b 			 		 	   &nbsp;  Acrylamide   Acrylamide is an a,&beta;-unsaturated (conjugated) reactive molecule, which can react with thiol (-SH) and amino (-NH2) groups in proteins&nbsp; (LoPachin, 2004; LoPachin et al. 2007; 2009; 2011;&nbsp; Friedman, 2003; Bent et al. 2016; Martyniuk et al.2011; LoPachin and Gavin, 2014 ). However, the rate constant for the reaction between acrylamide with thiol/thiolate groups is much lower than that for MeHg.&nbsp; The rate of reaction of this compound with HMM-SH and LMM-SH is slow but can occur under physiological conditions (Tong et al. 2004; LoPachin, 2004). The inhibition of brain enzymes by acrylamide have been studied and the inhibition caused by acrylamide in some HMM-SH can be reversible&nbsp; (Howland et al. 1980). Despite of this, we can infer that some targets of MeHg and acrylamide can overlap, in particular GSH,where the rate constant for MeHg and acrylamide are &asymp;6.0 x 108 M-1.sec-1 and &asymp;0.15-2.1 x 10-2 M-1.sec-1, respectively (Yousef and Demerdash, 2006; Lapadula et al. 1989; Kopańska et al. 2015). Acrylamide can also be metabolized to an epoxide intermediate (glycidamide), which can also form adducts with cysteinyl residues in HMM-SH target proteins (Bergmark et al. 1991).  &nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/17> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/17> a sbd:Model ;
  rdfs:label "Binding of electrophilic chemicals to SH(thiol)-group of proteins and /or to seleno-proteins involved in protection against oxidative stress during brain development leads to impairment of learning and memory"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "A prime example of impairments in learning and memory as the adverse outcome for regulatory action is developmental lead exposure and IQ function in children (Bellinger, 2012). Most methods are well established in the published literature and many have been engaged to evaluate the effects of developmental thyroid disruption. The US EPA and OECD Developmental Neurotoxicity (DNT) Guidelines (OCSPP 870.6300 or OECD TG 426) as well as OECD TG 443 (OECD, 2018) both require testing of learning and memory (USEPA, 1998; OECD, 2007) advising to use the following tests passive avoidance, delayed-matching-to-position for the adult rat and for the infant rat, olfactory conditioning, Morris water maze, Biel or Cincinnati maze, radial arm maze, T-maze, and acquisition and retention of schedule-controlled behaviour.&nbsp; These DNT Guidelines have been deemed valid to identify developmental neurotoxicity and adverse neurodevelopmental outcomes (Makris et al., 2009).  Also, in the frame of the OECD GD 43 (2008) on reproductive toxicity, learning and memory testing may have potential to be applied in the context of developmental neurotoxicity studies. However, many of the learning and memory tasks used in guideline studies may not readily detect subtle impairments in cognitive function associated with modest degrees of developmental thyroid disruption (Gilbert et al., 2012)."@en ;
  foaf:page <https://identifiers.org/aop/17> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/173> a sbd:Model ;
  rdfs:label "Substance interaction with the pulmonary resident cell membrane components leading to pulmonary fibrosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "As stated earlier, there are many different ways by which pro-fibrotic stressors can interact with the components of cell membrane and often involve multiple interactions at the same time. Few studies investigate the exact interaction between the stressor and the cellular membrane components. Asbestos and silica crystals engage scavenger receptors present on the macrophages (Murthy et al., 2015). Bleomycin binds high affinity bleomycin binding sites present on rat alveolar macrophage surfaces, leading to macrophage activation (Denholm and Phan, 1990). However, the consequences of such interactions such as, the release of PRR agonists DAMPs (alarmins) from dying or injured cells, increased&nbsp; gene or protein synthesis downstream of receptor binding or in the case of NMs, their cellular uptake, are measured routinely as indicative of occurrence of such interactions (Nel et al., 2009; Cheng et al., 2013). Because of the phys-chem properties such as surface charge, NMs and asbestos like materials can bind to cellular macromolecules and cell surface/membrane components, which in turn, facilitate their uptake and intracellular sequestration by the cells (NIOSH, 2011a; Pascolo et al., 2013). Several DAMPs that can be effectively measured in biological samples and cultured cells include High Mobility Group Binding 1 (HMGB1) protein, Heat Shock proteins (HSPs), uric acid, annexins, and S100 proteins (Bianchi, 2007). Of all DAMPs, interleukin (IL)-1&alpha; is the most commonly measured alarmin. IL-1&alpha; is the principal pro-inflammatory moiety and is a designated &lsquo;alarmin&rsquo; in the cell that alerts the host to injury or damage (Di Paolo and Shayakhmetov, 2016). It is shown that administration of necrotic cells to mice results in neutrophilic inflammation that was entirely mediated by IL-1&alpha; released from the dying or necrosed cells and consequent activation of IL-1 Receptor 1 (IL-1R1) signalling (Suwara et al., 2014). IL-1&alpha; is released following exposure to MWCNTs (Nikota et al., 2017) and silica (Rabolli et al., 2014). Although IL1-b is not a designated alarmin, its secretion following exposure to stressors is routinely assessed and is linked to initiation of cell or tissue injury.  Other high aspect ratio fibres such as asbestos and CNTs induce frustrated phagocytosis and acute cell injury (Boyles et al., 2015; D&ouml;rger et al., 2001; Brown et al., 2007; Kim et al., 2010; Poland et al., 2008), leading to DAMP release (Nikota et al, 2017), inflammation and immune responses."@en ;
  foaf:page <https://identifiers.org/aop/173> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/173> a sbd:Model ;
  rdfs:label "Substance interaction with the pulmonary resident cell membrane components leading to pulmonary fibrosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "There is a high potential for inhalation exposure to toxicants in various occupational settings and polluted environments. Extensive investigation of pulmonary toxicity following inhalation of chemical and particulate stressors have demonstrated that these toxicants mount an exuberant inflammatory response early after exposure that, when unresolved, lays&nbsp;the foundation for later pathologies. Although inflammation is a normal immune reaction of the organism designed to effectively eliminate the invading threat, chronic and unresolved tissue inflammation is detrimental. Unresolved lung inflammation&nbsp;in humans plays a causative role in many debilitating and even lethal adverse health effects, such as decreased lung function, emphysema, fibrosis, and cancer. The various pathways, mechanisms, and biological processes associated with the pulmonary inflammatory process are well characterized in experimental animals and, to a great extent, in humans. Here, a mechanism underlying stressor-induced pulmonary&nbsp;fibrosis that involves a pro-inflammatory component is described.  Pulmonary fibrosis is a&nbsp;chronic lung pathology, which when not treated, results in&nbsp;lethality. It is&nbsp;characterized by the&nbsp;excessive&nbsp;extracellular matrix (collagen) deposition and&nbsp;restructuring. Numerous respiratory diseases, such as pneumoconiosis, silicosis, asbestosis, bronchiolitis obliterans (&lsquo;popcorn lung&rsquo;), and chronic beryllium disease have pulmonary fibrosis as a main or secondary symptom. In addition,&nbsp;exposure to pharmaceuticals and environmental contaminants such as bleomycin and arsenic via inhalation, oral or intravenous routes also induces the adverse outcome of pulmonary fibrosis.&nbsp;Idiopathic pulmonary fibrosis (IPF) is the most common type of pulmonary fibrosis in humans and involves alveolar regions of the lung consisting of type 2 alveolar epithelial cells (AEC2s), type 1 cells (AEC1s) and mesenchymal cells. AEC1s are responsible for gas exchange and AEC2s synthesise surfactant. The AEC2s are capable of self-renewal and differentiate to AEC1s regularly during normal tissue maintenance (Barkauskas &amp; Noble, 2014). In pro-fibrotic conditions, AEC2s fail to regenerate AEC1s lost by injury and do not respond normally to epithelial injury, undergoing hyperplasia. As a result, human patients suffering from IPF have dysregulated levels of surfactant proteins normally secreted by AEC2s (Barlo et al.,2009; Phelps et al., 2004).&nbsp;Genetic studies have associated mutations in genes encoding surfactant proteins and the development of a familial type of lung fibrosis. Furthermore, immunohistochemical staining of human IPF lung slices shows AEC death as well as proliferation adjacent to fibrotic foci (Uhal et al., 1998). AEC2s are hyperplastic and are located on top of the fibrotic lesions in the lung in human specimens (Katzenstein &amp; Myers, 1998).&nbsp;In animal models of bleomycin-induced pulmonary fibrosis, abnormal AEC2s are incapable of protecting the basement membrane&nbsp;destroyed by cell death, leading to aberrant repair and deposition of extracellular matrix (ECM),&nbsp;resulting in fibrosis (Rock et al., 2011). Targeted removal of AEC2s in mouse lungs results in full&nbsp;manifestion of the&nbsp;fibrotic disease (Sisson et al., 2010). In certain infectious conditions, epithelial cell stress and dysfunction leading to inefficient repair capacity or transcriptional reprogramming of epithelial cells to secrete pro-fibrotic and pro-inflammatory factors&nbsp;leads to lung fibrosis (Lawson et al., 2008; Lawson et al., 2011). Mesenchymal cells are the other main type of cell, which contribute to fibrosis development. The dysregulated proliferation of fibroblasts and myofibroblast differentiation leading to excessive ECM deposition in the fibrotic scar is the result of disrupted cross talk between epithelial and mesenchymal cells (Barkauskas 2014). Myofibroblasts exhibiting contractile properties of smooth muscle cells and expressing a-SMA and vimentin, are the types of mesenchymal cells that are most commonly associated with excessive collagen secretion in pro-fibrotic phenotypes (Todd et al., 2012). Myofibroblasts can arise mainly from differentiation of tissue resident fibroblasts, translocation of bone marrow derived fibrocytes into the lung, or from epithelial-to-mesenchymal transformation (EMT; a type of trans-differentiation) (Hung, 2020; Todd et al., 2012). These cells are critical to the normal process of wound healing, and are the main cells contributing to collagen deposition in both normal wear-and-tear repair processes and in disease promoting conditions. Following successful wound healing, myofibroblasts de-differentiate and disappear (Friedman, 2012). Myofibroblasts persistence is suggested to play a key role in progressive pulmonary fibrosis in humans. There is evidence for both EMT derived myofibroblasts and bone marrow derived fibrocytes in human pulmonary fibrotic conditions. Air epithelial biopsies from human patients suffering from bronchiolitis obliterans (BO) following lung transplant show significantly increased staining for mesenchymal markers (Vimentin and alpha-smooth muscle actin (a-SMA)), decreased staining for e-cadherin, and co-localization of epithelial and mesenchymal markers as compared to stable patients (Borthwick et al., 2009). With respect to bone marrow derived fibrocytes, these cells have been proposed as an indicator for poor prognosis in human IPF patients, and research has shown that the amount of fibrocytes in the human IPF lung correlates with the amount of fibroblastic foci (Andersson-Sj&ouml;land et al., 2008; Moeller et al., 2009). Additional cell types involved in fibrotic process include endothelial cells and immune cells such as macrophages, neutrophils, and T helper cells. Endothelial cells contribute to the fibrotic process through endothelial-to-mesenchymal transformation, as evidenced in bleomycin model systems in which endothelial cells in fibrotic conditions take on the characteristics of myofibroblasts (Kato et al., 2018). Macrophages present in the alveolar space as well as macrophages recruited to the lung during the fibrotic process also contribute to the inflammatory environment and potentiate the adverse outcome of pulmonary fibrosis. Direct interaction of fibrotic stressors, such as multi-walled carbon nanotubes (MWCNTs), silica, and asbestos, with the macrophage cell membrane can occur through scavenger receptors as well as through receptors such as Macrophage receptor with collagenous structure (MARCO) (Li &amp; Cao, 2018; Murphy et al., 2015). This can induce macrophage cell&nbsp;injury through frustrated or incomplete phagocytosis which leads to the production of alarmins such as Interleukin (IL) -1b&nbsp;and Reactive oxygen species (ROS), and profibrotic mediators such as Tumour&nbsp;necrosis factor alpha (TNF-a), Transforming growth factor (TGF-b), and Platelet derived growth factor (PDGF) (Dong &amp; Ma, 2016; Li &amp; Cao, 2018). The injured resident macrophages contribute to the initial acute phase pro-inflammatory response leading to recruitment&nbsp;of additional immune cells to the lung. Depending on the fibrotic stressor, different populations of immune cells can be initially recruited to the site of action. The recruitment of neutrophils into the lung space potentiates the inflammatory response and tissue damage. Furthermore, in conditions of acute lung injury, which can precede the development of a fibrotic phenotype, neutrophil&nbsp;recruitment to the lung through trans-epithelial migration can induce the formation of lesions in the epithelium and contribute to the loss of alveolar capillary membrane integrity (Zemans et al., 2009). Finally, T helper (Th) cells recruited to the lung potentiate the inflammatory environment, and through the induction of a Th type 2 (Th2)&nbsp;response, stimulate the proliferation of fibroblasts and differentiation of myofibroblasts driving the development of a fibrotic phenotype (Shao et al., 2008; Wynn, 2004).   Although this AOP is applicable to a broad group of stressors, the AOP was specifically assembled keeping in mind, a novel class of engineered materials (nanomaterials) exhibiting sophisticated properties that have been shown to induce lung fibrosis via this mechanism. Specifically, nanomaterial properties such as aspect ratio, tube/fiber rigidity, crystallinity and persistence are suggested to play a role in the induction of pulmonary fibrosis. Thus, it demonstrates the applicability of the AOP framework to nanotoxicology.  Given the fundamental role of inflammation in organ homeostasis, well characterized AOPs targeting the pathological outcomes of unregulated inflammatory responses are important and will guide the development of appropriate assays to measure the key events that are predictive of inflammation-mediated chronic health impacts, and aid in screening a large array of inhalation toxicants that are inflammogenic, for their potential to induce lung diseases."@en ;
  foaf:page <https://identifiers.org/aop/173> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/175> a sbd:Model ;
  rdfs:label "Thyroperoxidase inhibition leading to altered amphibian metamorphosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Altered metamorphosis is a critical&nbsp;apical endpoint evaluated as part of&nbsp;regulatory test guideline studies (OECD, 2009, 2015; US EPA 2009, 2015). Measurable effects on metamorphic rates can be&nbsp;an indication of endocrine disruption, and more specifically&nbsp;thyroid disruption, due to the requirement of thyroid hormone for amphibians to undergo metamorphosis. Although this outcome is evaluated at the level of the individual organism, delayed or arrested metamorphosis can have implications toward population-level effects; however, significant effects on metamorphic rates are typically considered in a weight-of-evidence evaluation to determine a chemical&#39;s potential to cause thyroid disruption.&nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/175> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/175> a sbd:Model ;
  rdfs:label "Thyroperoxidase inhibition leading to altered amphibian metamorphosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "There is a wealth of information on the inhibition of TPO by drugs such as MMI and PTU, as well as environmental xenobiotics. In the landmark paper on TH system&nbsp;disruption by environmental chemicals, Brucker-Davis (1998) identified environmental chemicals that depressed TH synthesis by inhibiting TPO. Hurley (1998) listed TPO as a major target for thyroid tumor inducing pesticides. More recent work has tested over 1000 chemicals using a high-throughput screening assay (Paul-Friedman et al., 2016)."@en ;
  foaf:page <https://identifiers.org/aop/175> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/176> a sbd:Model ;
  rdfs:label "Sodium Iodide Symporter (NIS) Inhibition leading to altered amphibian metamorphosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Altered metamorphosis is a critical&nbsp;apical endpoint evaluated as part of&nbsp;regulatory test guideline studies (OECD, 2009, 2015; US EPA 2009, 2015). Measurable effects on metamorphic rates can be&nbsp;an indication of endocrine disruption, and more specifically&nbsp;thyroid disruption, due to the requirement of thyroid hormone for amphibians to undergo metamorphosis. Although this outcome is evaluated at the level of the individual organism, delayed or arrested metamorphosis can have implications toward population-level effects; however, significant effects on metamorphic rates are typically considered in a weight-of-evidence evaluation to determine a chemical&#39;s potential to cause thyroid disruption.&nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/176> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/176> a sbd:Model ;
  rdfs:label "Sodium Iodide Symporter (NIS) Inhibition leading to altered amphibian metamorphosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Thyroid Disrupting Chemicals (TDCs) are defined as the xenobiotics that interfere with the thyroid axis with different outcomes for the organism. A very well-studied mechanism of action of the TDCs is the reduction of the circulating levels of THs by inhibiting hormone synthesis in the thyroid gland. For example, perchlorate is a very potent inhibitor of iodide uptake through the sodium/iodide symporter (Tonacchera et al., 2004). Perchlorate has been detected in human breast milk ranging from 1.4 to 92.2 mg &mu;l&ndash;1 (10.5 &mu;g l&ndash;1 mean) in 18 US states (Kirk et al. 2005), and 1.3 to 411 &mu;g l&ndash;1 (9.1 &mu;g l&ndash;1 median) in the Boston area, United States (Pearce et al. 2007). Perchlorate has also been detected in human colostrum of 46 women in the Boston area (from &lt; 0.05 to 187.2 &mu;mol l&ndash;1 (Leung et al. 2009)). The mechanism of perchlorate action is quite simple, as it is believed to be mediated only by the NIS inhibition (Dohan et al., 2007; Wolff, 1998). Additionally, thiocyanate and nitrate are two known inhibitors that have been found to reduce circulating TH levels (Blount et al., 2006; Steinhaus et al., 2007), but they are both less potent than perchlorate (Tonacchera et al., 2004). However, there are also contradictory results from other studies that showed no correlation between thyroid parameters and perchlorate levels in humans (Pearce et al., 2010; Amitai et al., 2007; Tellez et al., 2005).  Co-occurrence of perchlorate, nitrate, and thiocyanate can alter thyroid function in pregnant women. Horton et al. (2015) have shown positive associations between the weighted sum of urinary concentrations of these three analytes and increased TSH, with perchlorate showing the largest weight in the index. Interestingly, De Groef et al. 2006 showed that nitrate and thiocyanate, acquired through drinking water or food, account for a much larger proportion of iodine uptake inhibition than perchlorate, suggesting that NIS inhibition and any potential downstream effect by perchlorate are highly dependent on the presence of other environmental NIS inhibitors and iodine intake itself (Leung et al., 2010). In particular, Tonacchera et al. (2004) showed that the relative potency of perchlorate to inhibit radioactive I&minus; uptake by NIS is 15, 30 and 240 times that of thiocyanate, iodide, and nitrate respectively on a molar concentration basis. These data are in line with earlier studies in rats (Alexander and Wolff, 1996; Greer et al. 1966). Contradictory findings in these studies may therefore be a result of the confounding mixtures in the environment, masking the primary effect of perchlorate.  Decreased iodine intake can decrease TH production, and therefore exposure to perchlorate might be particularly detrimental in iodine-deficient individuals (Leung et al. 2010). Moreover, biologically based dose-response modeling of the relationships among iodide status (e.g., dietary iodine levels), perchlorate dose, and TH production in pregnant women has shown that iodide intake has a profound effect on the likelihood that exposure to goitrogens will produce hypothyroxinemia (Lewandowski et al. 2015).  During pregnancy TH requirements increase, particularly during the first trimester (Alexander et al. 2004; Leung et al. 2010), due to higher concentrations of thyroxine-binding globulin, placental T4 inner-ring deiodination leading to the inactive reverse T3 (rT3), and transfer of small amounts of T4 to the foetus (during the first trimester foetal thyroid function is absent). Moreover, glomerular filtration rate and clearance of proteins and other molecules are both increased during pregnancy, possibly causing increased renal iodide clearance and a decreased of circulating plasma iodine (Glinoer, 1997). Thus, even though the foetal thyroid can trap iodide by about 12 week of gestation (Fisher and Klein, 1981), high concentrations of maternal perchlorate may potentially decrease thyroidal iodine available to the foetus by inhibiting placental NIS (Leung et al. 2010).  Consequences of TH deficiency depend on the developmental timing of the deficiency (Zoeller and Rovet, 2004). For instance, if the TH deficiency occurs during early pregnancy, offspring show visual attention, visual processing and gross motor skills deficits, while if it occurs later, offspring may show subnormal visual and visuospatial skills, along with slower response speeds and motor deficits. If TH insufficiency occurs after birth, language and memory skills are most predominantly affected (Zoeller and Rovet, 2004).  Along this line, age and developmental stage are crucial in determining sensitivity to NIS inhibitors (e.g., perchlorate, thiocyanate, and nitrate). In this regard, McMullen et al. (2017) have shown that adolescent boys and girls, more than adults, represent vulnerable subpopulations to NIS symporter inhibitors. Altogether these studies indicate that age, gender, developmental stage, and dietary iodine levels can affect the impact of NIS inhibitors.  Finally, ten more small simple-structured molecules were identified in a large screening study (Lecat-Guillet et al., 2008b) that could block iodide uptake by specifically disrupting NIS in a dose-dependent manner. These molecules were named Iodide Transport Blockers (ITBs). There are few organic molecules that lead to NIS inhibition but no direct interaction with NIS has been determined (Gerard et al., 1994; Kaminsky et al., 1991). Up to date, only dysidenin, a toxin isolated from the marine sponge Dysidea herbacea, has been reported to specifically inhibit NIS (Van Sande et al., 2003). Finally, the aryltrifluoroborates were found to inhibit iodide uptake with an IC50 value of 0.4 &mu;M on rat-derived thyroid cells (Lecat-Guillet et al., 2008a). The biological activity is rationalized by the presence of the BF3&minus; ion as a minimal binding motif for substrate recognition at the iodide binding site.  It has been also shown that many anions, such as ClO3-, SCN-, NO3-, ReO4-, TcO4- and in a lower extent Br- and BF4-, are also acting as NIS substrates and they enter the cell by the same transporter mechanism (Van Sande et al., 2003). It has been also shown that ClO4- is transferred by NIS with high affinity and is considered as one of its most potent inhibitors (Dohan et al., 2007). Most recently, the aryltrifluoroborates were also shown to inhibit NIS function (Lecat-Guillet et al., 2008a). A library of 17,020 compounds was tested by a radioactive screening method with high specificity using transfected mammalian cells (Lecat-Guillet et al., 2008b; 2007) for NIS inhibition evaluation. Further studies with the most powerful inhibitors showed a high diversity in their structure and mode of action (Lindenthal et al., 2009)."@en ;
  foaf:page <https://identifiers.org/aop/176> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/177> a sbd:Model ;
  rdfs:label "Cyclooxygenase 1 (COX1) inhibition leading to renal failure and mortality"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/177> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/177> a sbd:Model ;
  rdfs:label "Cyclooxygenase 1 (COX1) inhibition leading to renal failure and mortality"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Increased mortality is one of the most common regulatory assessment endpoints,&nbsp;along with reduced growth and reduced reproduction."@en ;
  foaf:page <https://identifiers.org/aop/177> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/177> a sbd:Model ;
  rdfs:label "Cyclooxygenase 1 (COX1) inhibition leading to renal failure and mortality"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/177> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/177> a sbd:Model ;
  rdfs:label "Cyclooxygenase 1 (COX1) inhibition leading to renal failure and mortality"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Increased mortality is one of the most common regulatory assessment endpoints,&nbsp;along with reduced growth and reduced reproduction."@en ;
  foaf:page <https://identifiers.org/aop/177> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/178> a sbd:Model ;
  rdfs:label "Nicotinic acetylcholine receptor activation contributes to mitochondrial dysfunction and leads to colony loss/failure"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Text from LaLone et al. (2017) Weight of evidence evaluation of a network of adverse outcome pathways linking activaiton of the nicotinic acetylcholine receptor in honey bees to colony death. Science of the Total Environment 584-585, 751-775:  &quot;The nicotinoids and neonicotinoids are both agonists of the nAChR (Tomizawa and Casida, 2003); however, neonicotinoids are the primary chemicals considered in the AOPs relevant to bees. The potency of a nAChR agonist is dependent on the receptor subunit composition, structurally important amino acid residues at the binding site, and the ionization status of the chemical at physiological pH (Tomizawa and Casida, 2003; Dani and Bertrand, 2007). For example, nicotine is a classical vertebrate nAChR agonist; however, it has relatively low affinity (and insecticidal activity) for the invertebrate nAChR. Due to ionization, nicotine is poor at passing though the ion-impermeable barrier surrounding the insect central nervous system(CNS; Tomizawa and Casida, 2003). Conversely, non-ionizable neonicotinoids readily translocate into the insect CNS and have high affinity for the nAChR (e.g., Drosophila nAChR IC50 4.6 nM imidacloprid), with limited or no binding activity to vertebrate nAChR (Tomizawa and Casida, 2003). Various studies have demonstrated that similarities and differences in key amino acid residues in the ligand binding domain across species can lead to structural and binding site differences that dictate chemical interaction with the receptor (Dani and Bertrand, 2007; Matsuda et al., 2009; Tomizawa and Casida, 2009; Jones and Sattelle, 2010; LaLone et al., 2016). Due to the intended insecticidal action of neonicotinoids, a growing number of studies have been conducted to  evaluate potential adverse effects in non-target species such as honey bees exposed to neonicotinoids, particularly imidacloprid, clothianidin, and thiamethoxam. Some of the results of these studies are included in subsequent AOP descriptions.&quot;"@en ;
  foaf:page <https://identifiers.org/aop/178> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/18> a sbd:Model ;
  rdfs:label "PPARα activation in utero leading to impaired fertility in males"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Fibrates are ligands of PPAR&alpha; (Staels et al. 1998).  Phthalates  MHEP (CAS 4376-20-9) directly binds in vitro to PPAR&alpha; (Lapinskas et al. 2005) and activates this receptor in transactivation assays PPAR&alpha; (Lapinskas et al. 2005), (Maloney and Waxman 1999), (Hurst and Waxman 2003), (Bility et al. 2004), (Lampen, Zimnik, and Nau 2003), (Venkata et al. 2006) ]. DEHP (CAS 117-81-7) has not been found to bind and activate PPAR&alpha; (Lapinskas et al. 2005), (Maloney and Waxman 1999). However, the recent studies shown activation of PPAR&alpha; (ToxCastTM Data).  Notably, PPAR&alpha; are responsive to DEHP in vitro as they are translocated to the nucleus (in primary Sertoli cells) (Dufour et al. 2003), (Bhattacharya et al. 2005). Expression of PPAR&alpha; [mRNA and protein] has been reported to be also modulated by phthtalates: (to be up-regulated in vivo upon DEHP treatment (Xu et al. 2010) and down-regulated by Diisobutyl phthalate (DiBP) (Boberg et al. 2008)).   Perfluorooctanoic Acid (PFOA) is known to activate PPAR&alpha; (Vanden Heuvel et al. 2006).  Organotin  Tributyltin (TBT) activates all three heterodimers of PPAR with RXR, primarily through its interaction with RXR (le Maire et al. 2009)"@en ;
  foaf:page <https://identifiers.org/aop/18> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/18> a sbd:Model ;
  rdfs:label "PPARα activation in utero leading to impaired fertility in males"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Under REACH, information on reproductive toxicity is required for chemicals with an annual production/importation volume of 10 metric tonnes or more. Standard information requirements include a screening study on reproduction toxicity (OECD TG 421/422) at Annex VIII (10-100 t.p.a), a prenatal developmental toxicity study (OECD 414) on a first species at Annex IX (100-1000 t.p.a), and from March 2015 the OECD 443(Extended One-Generation Reproductive Toxicity Study) is reproductive toxicity requirement instead of the two generation reproductive toxicity study (OECD TG 416). If not conducted already at Annex IX, a prenatal developmental toxicity study on a second species at Annex X (&ge; 1000 t.p.a.).  Under the Biocidal Products Regulation (BPR), information is also required on reproductive toxicity for active substances as part of core data set and additional data set (EU 2012, ECHA 2013). As a core data set, prenatal developmental toxicity study (EU TM B.31) in rabbits as a first species and a two-generation reproduction toxicity study (EU TM B.31) are required. OECD TG 443 (Extended One-Generation Reproductive Toxicity Study) shall be considered as an alternative approach to the multi-generation study.) According to the Classification, Labelling and Packaging (CLP) regulation (EC, 200; Annex I: 3.7.1.1): a) &ldquo;reproductive toxicity&rdquo; includes adverse effects on sexual function and fertility in adult males and females, as well as developmental toxicity in the offspring; b) &ldquo;effects on fertility&rdquo; includes adverse effects on sexual function and fertility; and c) &ldquo;developmental toxicity&rdquo; includes adverse effects on development of the offspring."@en ;
  foaf:page <https://identifiers.org/aop/18> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/18> a sbd:Model ;
  rdfs:label "PPARα activation in utero leading to impaired fertility in males"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "In regulatory hazard identification and risk assessment of chemicals malformations of male genitalia are considered as a chemically induced adverse outcome that is used for risk assessment and management purposes. The prenatal developmental toxicity study (TG 414) is the method for examining embryo-foetal toxicity as a consequence of exposure during pregnancy. Parental and offspring growth, development and viability are the relevant endpoints in generation studies (OECD TG 415/416/443). These guidelines are implemented in a number of occasions where the reproductive /developmental toxicity have to be assessed in order to comply with relevant EU regulations.  Under REACH, information on reproductive toxicity is required for chemicals with an annual production/importation volume of 10 metric tonnes or more. Standard information requirements include a screening study on reproduction toxicity (OECD TG 421/422) at Annex VIII (10-100 t.p.a), a prenatal developmental toxicity study (OECD 414) on a first species at Annex IX (100-1000 t.p.a), and from March 2015 the OECD 443(Extended One-Generation Reproductive Toxicity Study) is reproductive toxicity requirement instead of the two generation reproductive toxicity study (OECD TG 416). If not conducted already at Annex IX, a prenatal developmental toxicity study on a second species at Annex X (&ge; 1000 t.p.a.).  Under the Biocidal Products Regulation (BPR), information is also required on reproductive toxicity for active substances as part of core data set and additional data set (EU 2012, ECHA 2013). As a core data set, prenatal developmental toxicity study (EU TM B.31) in rabbits as a first species and a two-generation reproduction toxicity study (EU TM B.31) are required. OECD TG 443 (Extended One-Generation Reproductive Toxicity Study) shall be considered as an alternative approach to the multi-generation study.  According to the Classification, Labelling and Packaging (CLP) regulation (EC, 200; Annex I: 3.7.1.1): a) &ldquo;reproductive toxicity&rdquo; includes adverse effects on sexual function and fertility in adult males and females, as well as developmental toxicity in the offspring; b) &ldquo;effects on fertility&rdquo; includes adverse effects on sexual function and fertility; and c) &ldquo;developmental toxicity&rdquo; includes adverse effects on development of the offspring.  AGD is a reproductive endpoint, assessment of AGD is mandatory in OECD TG 443, 415/416 (OECD 2012)."@en ;
  foaf:page <https://identifiers.org/aop/18> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/18> a sbd:Model ;
  rdfs:label "PPARα activation in utero leading to impaired fertility in males"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Fibrates are ligands of PPAR&alpha; (Staels et al. 1998).  Phthalates  MHEP (CAS 4376-20-9) directly binds in vitro to PPAR&alpha; (Lapinskas et al. 2005) and activates this receptor in transactivation assays PPAR&alpha; (Lapinskas et al. 2005), (Maloney and Waxman 1999), (Hurst and Waxman 2003), (Bility et al. 2004), (Lampen, Zimnik, and Nau 2003), (Venkata et al. 2006) ]. DEHP (CAS 117-81-7) has not been found to bind and activate PPAR&alpha; (Lapinskas et al. 2005), (Maloney and Waxman 1999). However, the recent studies shown activation of PPAR&alpha; (ToxCastTM Data).  Notably, PPAR&alpha; are responsive to DEHP in vitro as they are translocated to the nucleus (in primary Sertoli cells) (Dufour et al. 2003), (Bhattacharya et al. 2005). Expression of PPAR&alpha; [mRNA and protein] has been reported to be also modulated by phthtalates: (to be up-regulated in vivo upon DEHP treatment (Xu et al. 2010) and down-regulated by Diisobutyl phthalate (DiBP) (Boberg et al. 2008)).   Perfluorooctanoic Acid (PFOA) is known to activate PPAR&alpha; (Vanden Heuvel et al. 2006).  Organotin  Tributyltin (TBT) activates all three heterodimers of PPAR with RXR, primarily through its interaction with RXR (le Maire et al. 2009)"@en ;
  foaf:page <https://identifiers.org/aop/18> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/18> a sbd:Model ;
  rdfs:label "PPARα activation in utero leading to impaired fertility in males"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Under REACH, information on reproductive toxicity is required for chemicals with an annual production/importation volume of 10 metric tonnes or more. Standard information requirements include a screening study on reproduction toxicity (OECD TG 421/422) at Annex VIII (10-100 t.p.a), a prenatal developmental toxicity study (OECD 414) on a first species at Annex IX (100-1000 t.p.a), and from March 2015 the OECD 443(Extended One-Generation Reproductive Toxicity Study) is reproductive toxicity requirement instead of the two generation reproductive toxicity study (OECD TG 416). If not conducted already at Annex IX, a prenatal developmental toxicity study on a second species at Annex X (&ge; 1000 t.p.a.).  Under the Biocidal Products Regulation (BPR), information is also required on reproductive toxicity for active substances as part of core data set and additional data set (EU 2012, ECHA 2013). As a core data set, prenatal developmental toxicity study (EU TM B.31) in rabbits as a first species and a two-generation reproduction toxicity study (EU TM B.31) are required. OECD TG 443 (Extended One-Generation Reproductive Toxicity Study) shall be considered as an alternative approach to the multi-generation study.) According to the Classification, Labelling and Packaging (CLP) regulation (EC, 200; Annex I: 3.7.1.1): a) &ldquo;reproductive toxicity&rdquo; includes adverse effects on sexual function and fertility in adult males and females, as well as developmental toxicity in the offspring; b) &ldquo;effects on fertility&rdquo; includes adverse effects on sexual function and fertility; and c) &ldquo;developmental toxicity&rdquo; includes adverse effects on development of the offspring."@en ;
  foaf:page <https://identifiers.org/aop/18> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/18> a sbd:Model ;
  rdfs:label "PPARα activation in utero leading to impaired fertility in males"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "In regulatory hazard identification and risk assessment of chemicals malformations of male genitalia are considered as a chemically induced adverse outcome that is used for risk assessment and management purposes. The prenatal developmental toxicity study (TG 414) is the method for examining embryo-foetal toxicity as a consequence of exposure during pregnancy. Parental and offspring growth, development and viability are the relevant endpoints in generation studies (OECD TG 415/416/443). These guidelines are implemented in a number of occasions where the reproductive /developmental toxicity have to be assessed in order to comply with relevant EU regulations.  Under REACH, information on reproductive toxicity is required for chemicals with an annual production/importation volume of 10 metric tonnes or more. Standard information requirements include a screening study on reproduction toxicity (OECD TG 421/422) at Annex VIII (10-100 t.p.a), a prenatal developmental toxicity study (OECD 414) on a first species at Annex IX (100-1000 t.p.a), and from March 2015 the OECD 443(Extended One-Generation Reproductive Toxicity Study) is reproductive toxicity requirement instead of the two generation reproductive toxicity study (OECD TG 416). If not conducted already at Annex IX, a prenatal developmental toxicity study on a second species at Annex X (&ge; 1000 t.p.a.).  Under the Biocidal Products Regulation (BPR), information is also required on reproductive toxicity for active substances as part of core data set and additional data set (EU 2012, ECHA 2013). As a core data set, prenatal developmental toxicity study (EU TM B.31) in rabbits as a first species and a two-generation reproduction toxicity study (EU TM B.31) are required. OECD TG 443 (Extended One-Generation Reproductive Toxicity Study) shall be considered as an alternative approach to the multi-generation study.  According to the Classification, Labelling and Packaging (CLP) regulation (EC, 200; Annex I: 3.7.1.1): a) &ldquo;reproductive toxicity&rdquo; includes adverse effects on sexual function and fertility in adult males and females, as well as developmental toxicity in the offspring; b) &ldquo;effects on fertility&rdquo; includes adverse effects on sexual function and fertility; and c) &ldquo;developmental toxicity&rdquo; includes adverse effects on development of the offspring.  AGD is a reproductive endpoint, assessment of AGD is mandatory in OECD TG 443, 415/416 (OECD 2012)."@en ;
  foaf:page <https://identifiers.org/aop/18> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/186> a sbd:Model ;
  rdfs:label "unknown MIE leading to renal failure and mortality"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Increased mortality is one of the most common regulatory assessment endpoints,&nbsp;along with reduced growth and reduced reproduction."@en ;
  foaf:page <https://identifiers.org/aop/186> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/188> a sbd:Model ;
  rdfs:label "Iodotyrosine deiodinase (IYD) inhibition leading to altered amphibian metamorphosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Altered metamorphosis is a critical&nbsp;apical endpoint evaluated as part of&nbsp;regulatory test guideline studies (OECD, 2009, 2015; US EPA 2009, 2015). Measurable effects on metamorphic rates can be&nbsp;an indication of endocrine disruption, and more specifically&nbsp;thyroid disruption, due to the requirement of thyroid hormone for amphibians to undergo metamorphosis. Although this outcome is evaluated at the level of the individual organism, delayed or arrested metamorphosis can have implications toward population-level effects; however, significant effects on metamorphic rates are typically considered in a weight-of-evidence evaluation to determine a chemical&#39;s potential to cause thyroid disruption.&nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/188> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/189> a sbd:Model ;
  rdfs:label "Type I iodothyronine deiodinase (DIO1) inhibition leading to altered amphibian metamorphosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Propylthiouracil (PTU) is the prototypical DIO1 inhibitor in mammals, although teleostean and amphibian DIO1 enzymes are less sensitive to inhibition by PTU (Orozco et al., 2003; Kuiper et al., 2006). Olker et al. (2019) identified 22 DIO1-specific inhibitors using a human recombinant DIO1 enzyme (e.g., genistein, 6-methyl-2-thiouracil, sulfasalazine). Another well-known inhibitor of DIO1 (and DIO2 and 3) is iopanoic acid (IOP). Renko et al. (2003, 2015) pointed out that IOP is actually a substrate of DIO1 (and DIO2 and 3) which is in line with its action as a competitive inhibotor. In fact, many compounds inhibit all three DIO isoforms. Olker et al. (2019) identified 93 compounds that inhibit DIOs 1, 2 and 3."@en ;
  foaf:page <https://identifiers.org/aop/189> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/189> a sbd:Model ;
  rdfs:label "Type I iodothyronine deiodinase (DIO1) inhibition leading to altered amphibian metamorphosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Altered metamorphosis is a critical&nbsp;apical endpoint evaluated as part of&nbsp;regulatory test guideline studies (OECD, 2009, 2015; US EPA 2009, 2015). Measurable effects on metamorphic rates can be&nbsp;an indication of endocrine disruption, and more specifically&nbsp;thyroid disruption, due to the requirement of thyroid hormone for amphibians to undergo metamorphosis. Although this outcome is evaluated at the level of the individual organism, delayed or arrested metamorphosis can have implications toward population-level effects; however, significant effects on metamorphic rates are typically considered in a weight-of-evidence evaluation to determine a chemical&#39;s potential to cause thyroid disruption.&nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/189> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/190> a sbd:Model ;
  rdfs:label "Type II iodothyronine deiodinase (DIO2) inhibition leading to altered amphibian metamorphosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Olker et al. (2019) identified 20 DIO2-specific inhibitors using a human recombinant DIO2 enzyme (e.g., tetramethrin, elzasonan). Another typical inhibitor of DIO2 (and DIO1 and 3) is iopanoic acid (IOP), which acts as a substrate of all three DIO isoforms (Renko et al., 2015). In fact, many compounds inhibit all three DIO isoforms. Olker et al. (2019) identified 93 compounds that inhibit DIOs 1, 2 and 3."@en ;
  foaf:page <https://identifiers.org/aop/190> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/190> a sbd:Model ;
  rdfs:label "Type II iodothyronine deiodinase (DIO2) inhibition leading to altered amphibian metamorphosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Altered metamorphosis is a critical&nbsp;apical endpoint evaluated as part of&nbsp;regulatory test guideline studies (OECD, 2009, 2015; US EPA 2009, 2015). Measurable effects on metamorphic rates can be&nbsp;an indication of endocrine disruption, and more specifically&nbsp;thyroid disruption, due to the requirement of thyroid hormone for amphibians to undergo metamorphosis. Although this outcome is evaluated at the level of the individual organism, delayed or arrested metamorphosis can have implications toward population-level effects; however, significant effects on metamorphic rates are typically considered in a weight-of-evidence evaluation to determine a chemical&#39;s potential to cause thyroid disruption.&nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/190> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/191> a sbd:Model ;
  rdfs:label "Type III iodotyrosine deiodinase (DIO3) inhibition leading to altered amphibian metamorphosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Altered metamorphosis is a critical&nbsp;apical endpoint evaluated as part of&nbsp;regulatory test guideline studies (OECD, 2009, 2015; US EPA 2009, 2015). Measurable effects on metamorphic rates can be&nbsp;an indication of endocrine disruption, and more specifically&nbsp;thyroid disruption, due to the requirement of thyroid hormone for amphibians to undergo metamorphosis. Although this outcome is evaluated at the level of the individual organism, delayed or arrested metamorphosis can have implications toward population-level effects; however, significant effects on metamorphic rates are typically considered in a weight-of-evidence evaluation to determine a chemical&#39;s potential to cause thyroid disruption.&nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/191> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/192> a sbd:Model ;
  rdfs:label "Pendrin inhibition leading to altered amphibian metamorphosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Altered metamorphosis is a critical&nbsp;apical endpoint evaluated as part of&nbsp;regulatory test guideline studies (OECD, 2009, 2015; US EPA 2009, 2015). Measurable effects on metamorphic rates can be&nbsp;an indication of endocrine disruption, and more specifically&nbsp;thyroid disruption, due to the requirement of thyroid hormone for amphibians to undergo metamorphosis. Although this outcome is evaluated at the level of the individual organism, delayed or arrested metamorphosis can have implications toward population-level effects; however, significant effects on metamorphic rates are typically considered in a weight-of-evidence evaluation to determine a chemical&#39;s potential to cause thyroid disruption.&nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/192> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/193> a sbd:Model ;
  rdfs:label "Dual oxidase (DUOX) inhibition leading to altered amphibian metamorphosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Altered metamorphosis is a critical&nbsp;apical endpoint evaluated as part of&nbsp;regulatory test guideline studies (OECD, 2009, 2015; US EPA 2009, 2015). Measurable effects on metamorphic rates can be&nbsp;an indication of endocrine disruption, and more specifically&nbsp;thyroid disruption, due to the requirement of thyroid hormone for amphibians to undergo metamorphosis. Although this outcome is evaluated at the level of the individual organism, delayed or arrested metamorphosis can have implications toward population-level effects; however, significant effects on metamorphic rates are typically considered in a weight-of-evidence evaluation to determine a chemical&#39;s potential to cause thyroid disruption.&nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/193> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/194> a sbd:Model ;
  rdfs:label "Hepatic nuclear receptor activation leading to altered amphibian metamorphosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Altered metamorphosis is a critical&nbsp;apical endpoint evaluated as part of&nbsp;regulatory test guideline studies (OECD, 2009, 2015; US EPA 2009, 2015). Measurable effects on metamorphic rates can be&nbsp;an indication of endocrine disruption, and more specifically&nbsp;thyroid disruption, due to the requirement of thyroid hormone for amphibians to undergo metamorphosis. Although this outcome is evaluated at the level of the individual organism, delayed or arrested metamorphosis can have implications toward population-level effects; however, significant effects on metamorphic rates are typically considered in a weight-of-evidence evaluation to determine a chemical&#39;s potential to cause thyroid disruption.&nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/194> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/195> a sbd:Model ;
  rdfs:label "5-hydroxytryptamine transporter (5-HTT) inhibition leading to population increase"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "This AOP was developed, initially, as a case study in developing an AOP for species with known or suscpected chemical exposures, in &quot;Practical approaches to adverse outcome pathway (AOP) development and weight of evidence evaluation as illustrated by ecotoxicological case studies&quot; by Fay et al. 2017."@en ;
  foaf:page <https://identifiers.org/aop/195> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/196> a sbd:Model ;
  rdfs:label "Volatile Organic Chemicals Activate TRPA1 Receptor to Induce Sensory Pulmonary Irritation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Exposure to airborne pollutants can cause a number of harmful effects including irritation. Airborne pollutants are typically associated with industrial activities, cigarette smoke and automobile exhaust. However, inhalation exposure to irritant gases and vapors frequently occurs in occupational and ambient environments. Each year new and untested inhalable chemicals are added to the environment and the lack of appropriate toxic information may result in an underestimation of occupation risks due to exposure of airborne irritants. Assays or tests are needed to first determine and then characterize the potential irritant respiratory response of uncharacterized current and newly added volatile chemicals. To develop suitable assays it is necessary to understand the fundamental biochemical and physiology processes initiating the development and progression of irritation. The presented AOP is focused on the critical biochemical event, the activation of the TRP receptors, then describing the subsequent biochemical processes and pathways and how they interact with each other resulting in pulmonary irritation."@en ;
  foaf:page <https://identifiers.org/aop/196> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/196> a sbd:Model ;
  rdfs:label "Volatile Organic Chemicals Activate TRPA1 Receptor to Induce Sensory Pulmonary Irritation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Exposure to airborne pollutants can cause a number of harmful effects including irritation. Airborne pollutants are typically associated with industrial activities, cigarette smoke and automobile exhaust. However, inhalation exposure to irritant gases and vapors frequently occurs in occupational and ambient environments. Each year new and untested inhalable chemicals are added to the environment and the lack of appropriate toxic information may result in an underestimation of occupation risks due to exposure of airborne irritants. Assays or tests are needed to first determine and then characterize the potential irritant respiratory response of uncharacterized current and newly added volatile chemicals. To develop suitable assays it is necessary to understand the fundamental biochemical and physiology processes initiating the development and progression of irritation. The presented AOP is focused on the critical biochemical event, the activation of the TRP receptors, then describing the subsequent biochemical processes and pathways and how they interact with each other resulting in pulmonary irritation."@en ;
  foaf:page <https://identifiers.org/aop/196> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/196> a sbd:Model ;
  rdfs:label "Volatile Organic Chemicals Activate TRPA1 Receptor to Induce Sensory Pulmonary Irritation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Exposure to airborne pollutants can cause a number of harmful effects including irritation. Airborne pollutants are typically associated with industrial activities, cigarette smoke and automobile exhaust. However, inhalation exposure to irritant gases and vapors frequently occurs in occupational and ambient environments. Each year new and untested inhalable chemicals are added to the environment and the lack of appropriate toxic information may result in an underestimation of occupation risks due to exposure of airborne irritants. Assays or tests are needed to first determine and then characterize the potential irritant respiratory response of uncharacterized current and newly added volatile chemicals. To develop suitable assays it is necessary to understand the fundamental biochemical and physiology processes initiating the development and progression of irritation. The presented AOP is focused on the critical biochemical event, the activation of the TRP receptors, then describing the subsequent biochemical processes and pathways and how they interact with each other resulting in pulmonary irritation."@en ;
  foaf:page <https://identifiers.org/aop/196> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/200> a sbd:Model ;
  rdfs:label "Estrogen receptor activation leading to breast cancer  "@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Because of the long latency of mammary tumors, the two-year rodent carcinogenicity bioassay is the primary assay for this adverse outcome. The assay is included in the OECD Test No. 451 and 453 for carcinogenicity and combined toxicity and carcinogenicity (OECD 2009; OECD 2009), and is also used by the US National Toxicology program (Chhabra, Huff et al. 1990), and the FDA (FDA (Food and Drug Administration) 2007), and referenced by the EPA (EPA (Environmental Protection Agency) 2005) in guidelines for risk assessments. Other assays from short term (2-4 weeks) and subchronic (90 day) to chronic (1 year) toxicity also call for the documentation of mammary tumors (FDA (Food and Drug Administration) 2007; OECD (Organisation for Economic Cooperation and Development) 2018), so these assays could capture the early onset of tumors, and could be modified to report earlier key events like proliferation and inflammation.  Several characteristics of classic cancer bioassays limit the sensitivity of these assays to mammary gland carcinogens. First, no assays require prenatal or early post-natal exposures for carcinogenicity testing. The US NIH&rsquo;s National Toxicology Program assays start exposures at five to six weeks of age and OECD regulatory assay exposures suggest (but do not require) exposures beginning after weaning and before eight weeks of age. Assays initiating exposures at later ages have diminished sensitivity to agents that affect breast development and increase future susceptibility to cancer, such as estrogenic hormones, DDT and dioxins (EPA (Environmental Protection Agency) 2005; Rudel, Fenton et al. 2011). Agents with similar activity to ionizing radiation and DNA damaging chemicals may not be fully captured in some of these assays, since sensitivity appears to peak around or before week seven for these agents (around puberty) (Imaoka, Nishimura et al. 2013). Second, carcinogenicity assay guidelines do not require the best methods for detecting tumors in mammary gland: whole mount preparations of mammary gland coupled with longitudinal sections (dorsoventral sections parallel to the body) of mammary gland for histology (Tucker, Foley et al. 2017). Palpation and transverse sections of mammary gland can easily miss tumors or lesions of interest. Interestingly the NTP reproductive toxicity guidelines do specify these preferable methods for mammary gland analysis.  Two additional factors affect the sensitivity of standard carcinogenicity assays. First, benign tumors are not always considered to be an indicator of carcinogenicity, leading to a possible underestimation of risk. &nbsp;NTP and EPA guidance suggest that benign tumors provide additional weight of evidence if malignant tumors are also present or if studies suggest benign tumors can progress to carcinogenicity. In a short-term study, benign tumors may indicate a need for a longer-term study. However, benign mammary tumors (fibroadenomas) almost always coincide with carcinogenic tumors in mammary gland or other organs, and carcinomas sometimes grow from fibroadnomas (Rudel, Attfield et al. 2007; Russo 2015) suggesting that benign tumors may be an underutilized indicator of carcinogenicity.  Finally, the dose selection guidance in carcinogenicity testing typically calls for a high dose that is sufficiently toxic to suppress body weight (OECD 2009). However, body weight interacts with risk of breast cancer (Haseman, Young et al. 1997; Rudel, Attfield et al. 2007), reducing the sensitivity of the upper end of the dose range and the likelihood of a positive dose-response."@en ;
  foaf:page <https://identifiers.org/aop/200> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/202> a sbd:Model ;
  rdfs:label " Inhibitor binding to topoisomerase II leading to infant leukaemia"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Etoposide is one of the most well studied topoisomerase II targeted agents. It stabilizes covalent topoisomerase II-cleaved DNA complexes (ie cleavage complexes) by interacting at the enzyme-DNA interface in a noncovalent manner (Smith et al. 2014).  Etoposide ( and its derivatives) stimulate DNA cleavage mediated by yeast topoisomerase II.&nbsp;&nbsp;As a result of etoposide action, high levels of topoisomerase II-associated DNA breaks accumulate in treated cells (Hande et al. 1998; Ross et al 1984; Wistelrman et al.2007).  Etoposide quinone induces DNA cleavage via an enzyme-mediated mechanism. Control reactions were conducted in the absence of enzyme or drug (DNA Control), in the presence of 30 &mu;M etoposide quinone without enzyme (+EQ &minus;hTII&beta;), or in the presence of topoisomerase II&beta; without drug (&minus;EQ +hTII&beta;).&nbsp;The quinone induced &sim;4 times more enzyme-mediated DNA cleavage than did the parent drug. Furthermore, the potency of etoposide quinone was &sim;2 times greater against topoisomerase II&beta; than it was against topoisomerase II&alpha;, and the drug reacted &sim;2&ndash;4 times faster with the &beta; isoform. Etoposide quinone induced a higher ratio of double- to single-stranded breaks than etoposide, and its activity was less dependent on ATP (Smith et al. 2014).  TOP2 isoforms covalently bound to genomic DNA in&nbsp;&nbsp;hESC after 15 min treatment with etoposide 1-100uM (Rodriguez et al.2020).  &nbsp;  &nbsp;  &nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/202> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/202> a sbd:Model ;
  rdfs:label " Inhibitor binding to topoisomerase II leading to infant leukaemia"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Infant leukaemia (&lt;1 year old) is a rare disease of developmental origin distinct from adult and childhood leukaemias which fit the classical two-hit cancer model. Both genetic and haematological studies &nbsp;indicate an in utero origin at an early phase of foetal development. Investigation of identical twin pairs with infant leukaemia provided evidence of in-utero transfer of leukemic cells&nbsp;from one twin to the other (Ford AM, 1993), and the in-utero origin of this cancer was confirmed by retrospective analyses of neonatal blood spots from affected infants (Gale KB, 1997). The high concordance rate for leukaemia in monozygotic twins and the short latency of the disease suggest that MLL rearrangement in fetal hematopoietic stem cells causes infant leukaemia (Nanya M, 2015).&nbsp;Rearrangements of the mixed lineage leukemia (MLL) gene producing abnormal fusion protein are the most frequent genetic/molecular hallmarks in infant B-cell ALL. In small epidemiological studies, mother/foetus pesticide exposure has been associated with infant leukaemia; however, strength of evidence and power of these studies are weak at best. Despite recent advances in the pathogenesis of pediatric leukemia, surrogate models such as in vitro, ex vivo or animals in vivo do not reproduce the human disease sufficiently and they suffer from difficulties in interpretation and extrapolation of findings and from the intrinsic limitation in cancer bio-assay design to cover relevant window of exposure. This&nbsp;adverse outcome pathway (AOP) is based substantially on an analogous disease &ndash; secondary acute leukaemia caused by etoposide, a topoisomerase II (TopoII) poison &ndash;, and on cellular and animal models. The topo II inhibitor, Etoposide, induces DNA double-strand breaks between the S and the G2/M phases of the cell cycle and is related to the post treatment occurence of the acutemyeloid leukaemia, which is showing a similar pattern of genetic changes as observed in the Infant Leukaemia (IFL) disease.&nbsp;Indeeed, the hallmark of the IFL and acute myeloid leukaemia is the formation of MLL gene rearrangements (MLLr) via TopoII poisoning, leading to fusion genes and eventually acute leukaemia by global (epi)genetic dysregulation. Current knowledge&nbsp;supports&nbsp;the possibility that MLL-rearrangment in infant leukaemia is caused by transplacental exposure to topo2 poisons. Although it is considered unusual for a pregnant woman to be directly exposed to drugs such as etoposide, other compounds presents in the environment&nbsp;may exert &nbsp;similar effects, and this is considered toxicologically relevant for risk assessment (Nanya M, 2015).&nbsp;This&nbsp;AOP condenses molecular, pathological, regulatory, clinical and epidemiological knowledge in a pragmatic framework with the aspiration of focussing on human specific hazard in the risk assessment process. This&nbsp;AOP enables to identify important gaps of knowledge relevant to risk assessment, including the specific embryonic target cell during the short and spatially restricted period of susceptibility and the role of (epi)genetic features modifying initiation and progression of the disease. Furthermore, this&nbsp;AOP informs on a potential integrated approach to testing and assessment (IATA) to address the risk caused by environmental chemicals in the future and represents a transparent and weight of evidence based tool to define the plausible causative mechanism necessary for the interpretation and integration of epidemiological studies in the process of risk assessment.&nbsp;This AOP was first developed by the EFSA PPR Panel as part of a Scientific Opinion&nbsp;and published in the&nbsp;EFSA Journal 2017;15(3):4691DOI:&nbsp;10.2903/j.efsa.2017.4691.&nbsp;A copyright for figures and for most of the references included in this AOP was delt with in the EFSA Scientific Opinion. In addition, EFSA granted&nbsp;a research project&nbsp; for assessing&nbsp;in vitro and in vivo the potential genotoxic contribution of etoposide, Permethrin &nbsp;and Chlorpyrifos&nbsp;in human hematopoietic stem and progenitor cells (HSPCs) at different ontogeny stages, spanning from embryonic to adult HSPCs, with a special emphasis in their ability to induce MLL breaks/damage (Rodriguez et al. 2020)"@en ;
  foaf:page <https://identifiers.org/aop/202> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/202> a sbd:Model ;
  rdfs:label " Inhibitor binding to topoisomerase II leading to infant leukaemia"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Genotoxicity in general and carcinogenicity are apical endpoints in established regulatory guideline studies. TopoII poisoning has been listed as one of the potential mechanisms of genotoxicity and carcinogenicity in the ICH M7 guideline for human medicines. It is also known that some manifestations of genotoxicity in tests measuring chromosomal aberrations, micronuclei or DNA and chromosome damage (Comet assay) are partially due to double-strand breaks created by the disturbed action of TopoII enzymes.  &nbsp;The extended one generation test (OECD 443) includes a developmental immunotoxicity cohort. At present the cohort may identify post-natal effects of prenatal and neonatal exposures on the immune tissues and white blood cells population. However, each regulatory guideline study has potential limitations e.g. no specific parameters are in place to identify a pattern relevant to infant leukemia in humans in the extended one generation test, no treatment is occurring during the early in-utero development phase in the carcinogenicity studies&nbsp;and no considerations on the possible higher sensitivity of the HSC are in place for the genotoxicity assays.  Epidemiological evidence&nbsp; linking pesticide exposure to infant leukaemia, also suggests that pesticide exposure may have a greater impact on children than adults; though, almost all of the available evidence does&nbsp; not make a distinction between infant and childhood leukaemia.&nbsp;&nbsp; However, most epidemiological studies are limited because no specific pesticides have been directly associated with the risk of leukaemia, but rather the broad term &ldquo;pesticide exposure&rdquo; (Hernandez and Menendez 2016). In this perspective, this AOP would provide a regulatory relevant support for understanding the potential of a chemical to be involved in this toxicological pathway.&nbsp;It is however worth noting that IFL is not an animal disease &nbsp;and therefore the outcome of a chemically induced MLL translocation can likely only be tested at KE levels. In addition, MLL translocation is clearly a common node to alternative AOs not described in this AOP (chemotherapy induced leukaemia) and genotoxicity per se should be considered as adverse."@en ;
  foaf:page <https://identifiers.org/aop/202> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/203> a sbd:Model ;
  rdfs:label "5-hydroxytryptamine transporter inhibition leading to decreased reproductive success and population decline"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/203> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/203> a sbd:Model ;
  rdfs:label "5-hydroxytryptamine transporter inhibition leading to decreased reproductive success and population decline"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/203> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/205> a sbd:Model ;
  rdfs:label "AOP from chemical insult to cell death"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Evaluation of safety is a prerequisite prior introduction of new chemical entities onto the market. Historically, animal testing has formed the basis for such risk assessment exercises. Driven by scientific and ethical constraints, and initiated more than 3 decades ago, however, there is a clear tendency worldwide to increasingly address animal-free methods for this purpose. This has been reinforced by a number of legislative changes over the past few years in the European Union, imposing a ban on animal testing for particular groups of chemicals, in casu in the cosmetics field. This has been followed by other parts of the world, such as in Norway, Israel, India, New Zealand and the state of S&atilde;o Paulo in Brazil. In response to this ubiquitous matter, the scientific community has been urged to develop animal-free methods for evaluating the safety of chemicals, including in vitro and in silico assays, being a research area that is gaining momentum. Interestingly, this has triggered a paradigm shift from classical toxicology, focusing on apical endpoints for toxicity in animal models, to predictive toxicology, relying on information on mechanisms of toxic action.  A major tool adopted in predictive toxicology is the AOP framework, which refers to a conceptual construct that portrays existing knowledge concerning the linkage between a direct molecular initiating event (MIE) and an adverse outcome via a number of key events at a biological level of organization relevant to risk assessment. AOPs can serve several purposes pertinent to non-animal chemical risk assessment, such as read-across methods, integrated approaches to testing and assessment, quantitative structure-activity relationships or the elaboration of prioritization strategies. In fact, AOPs embody a number of proposed frameworks for the implementation of animal-free safety testing of chemicals. Such frameworks typically start with exposure assessment, physico-chemical profiling, read-across and biokinetic evaluation, all which dictate the subsequent selection of in vitro biomarkers and corresponding assays. For many new chemical entities, however, such pre-existing information may be scarce, which thus impedes targeted establishment of an in vitro testing battery. A strategy for setting up basal in vitro cytotoxicity testing of such data-poor chemicals is outlined could be based on the newly proposed generic AOP from chemical insult to cell death."@en ;
  foaf:page <https://identifiers.org/aop/205> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/205> a sbd:Model ;
  rdfs:label "AOP from chemical insult to cell death"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Evaluation of safety is a prerequisite prior introduction of new chemical entities onto the market. Historically, animal testing has formed the basis for such risk assessment exercises. Driven by scientific and ethical constraints, and initiated more than 3 decades ago, however, there is a clear tendency worldwide to increasingly address animal-free methods for this purpose. This has been reinforced by a number of legislative changes over the past few years in the European Union, imposing a ban on animal testing for particular groups of chemicals, in casu in the cosmetics field. This has been followed by other parts of the world, such as in Norway, Israel, India, New Zealand and the state of S&atilde;o Paulo in Brazil. In response to this ubiquitous matter, the scientific community has been urged to develop animal-free methods for evaluating the safety of chemicals, including in vitro and in silico assays, being a research area that is gaining momentum. Interestingly, this has triggered a paradigm shift from classical toxicology, focusing on apical endpoints for toxicity in animal models, to predictive toxicology, relying on information on mechanisms of toxic action.  A major tool adopted in predictive toxicology is the AOP framework, which refers to a conceptual construct that portrays existing knowledge concerning the linkage between a direct molecular initiating event (MIE) and an adverse outcome via a number of key events at a biological level of organization relevant to risk assessment. AOPs can serve several purposes pertinent to non-animal chemical risk assessment, such as read-across methods, integrated approaches to testing and assessment, quantitative structure-activity relationships or the elaboration of prioritization strategies. In fact, AOPs embody a number of proposed frameworks for the implementation of animal-free safety testing of chemicals. Such frameworks typically start with exposure assessment, physico-chemical profiling, read-across and biokinetic evaluation, all which dictate the subsequent selection of in vitro biomarkers and corresponding assays. For many new chemical entities, however, such pre-existing information may be scarce, which thus impedes targeted establishment of an in vitro testing battery. A strategy for setting up basal in vitro cytotoxicity testing of such data-poor chemicals is outlined could be based on the newly proposed generic AOP from chemical insult to cell death."@en ;
  foaf:page <https://identifiers.org/aop/205> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/212> a sbd:Model ;
  rdfs:label "Histone deacetylase inhibition leading to testicular atrophy"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The testicular atrophy&nbsp;assessment is important for assessing the side effects of the medicines such as anti-cancer drugs, as well as the hazard and risk of chemicals. The testicular atrophy including a decrease in testis weight and sperm count, fertility, decrease in morphology and function of the sperm, can become one of the main endpoints as the adverse effects of the therapeutics. The unexpected effects of the therapeutics may be predicted with this Adverse Outcome (AO). In terms of chemical risk assessment, the AO may be&nbsp;related to the health effects caused by the&nbsp;usage of pesticides or biocides."@en ;
  foaf:page <https://identifiers.org/aop/212> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/212> a sbd:Model ;
  rdfs:label "Histone deacetylase inhibition leading to testicular atrophy"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "HDIs are classified according to chemical nature and mode of mechanism: the short-chain fatty acids (e.g., butyrate, valproate), hydroxamic acids (e.g., suberoylanilide hydroxamic acid or SAHA, Trichostatin A or TSA), cyclic tetrapeptides (e.g., FK-228), benzamides (e.g., N-acetyldinaline and MS-275) and epoxides (depeudecin, trapoxin A) [Richon et al., 2003; Ropero and Esteller, 2007; Villar-Garea et al., 2004]. There is a report showing that TSA and butyrate competitively inhibit&nbsp;HDAC activity [Sekhavat et al., 2007]. HDIs inhibit preferentially HDACs with some selectiveness [Hu et al., 2003].&nbsp;TSA (Trichostatin A) inhibits class I and II of HDACs, while butyrate inhibits class I and IIa (HDACs 4, 5, 7, 9) of HDACs [Ooi et al., 2015; Park and Sohrabji, 2016; Wagner et al., 2015].&nbsp;&nbsp;TSA inhibits HDAC1, 2, and 3 [Damaskos et al., 2016], whereas MS-27-275 has an inhibitory effect for HDAC1 and HDAC3 (IC50 value of ~0.3 microM and ~8 microM, respectively), but no effect for HDAC8 (IC50 value &gt;100 microM) [Hu et al., 2003]."@en ;
  foaf:page <https://identifiers.org/aop/212> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/213> a sbd:Model ;
  rdfs:label "Inhibition of fatty acid beta oxidation leading to nonalcoholic steatohepatitis (NASH)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The precursor state to NASH&nbsp;(non-alcoholic steatohepatitis), steatosis, has been used in US EPA IRIS assessments as an adverse outcome.&nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/213> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/213> a sbd:Model ;
  rdfs:label "Inhibition of fatty acid beta oxidation leading to nonalcoholic steatohepatitis (NASH)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Steatosis is the condition where an abnormal amount of fat is being stored within the liver. The liver is the site where sugars and fats are converted for the purposes of supplying energy to the rest of the body. The liver will convert glucose to fatty acids and package them as triglycerides for distribution throughout the body via the bloodstream and storage in adipose tissue. The liver also takes in fatty acids and triglycerides, and oxidizes them back to glucose for distribution throughout the body. When the influx/efflux and metabolism of fatty acids is altered, leading to a net increase in cellular fatty acids, the result is steatosis. As steatosis progresses, these fatty acids may lead to oxidative stress that ultimately leads to oncotic necrosis (cell death) and inflammatory cell infiltration (inflammation). This is termed steatohepatitis.&nbsp;&nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/213> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/216> a sbd:Model ;
  rdfs:label "Deposition of energy leading to population decline via DNA strand breaks and follicular atresia"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/216> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/216> a sbd:Model ;
  rdfs:label "Deposition of energy leading to population decline via DNA strand breaks and follicular atresia"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Cumulative fecundity is the most apical endpoint considered in the OECD 229 Fish Short Term Reproduction Assay. The OECD 229 assay serves as screening assay for endocrine disruption and associated reproductive impairment (OECD 2012). Fecundity is also an important apical endpoint in the Medaka Extended One Generation Reproduction Test (MEOGRT; OECD Test Guideline 240; OECD 2015).  A variety of fish life cycle tests also include cumulative fecundity as an endpoint (OECD 2008).  &nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/216> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/216> a sbd:Model ;
  rdfs:label "Deposition of energy leading to population decline via DNA strand breaks and follicular atresia"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "It is well documented that ionizing radiation( (eg.&nbsp;X-rays, gamma, photons, alpha, beta, neutrons, heavy ions)&nbsp;leads to energy deposition on the atoms and molecules of the substrate. Many studies, have demonstrated that the type of radiation and distance from source has an impact on the pattern of energy deposition (Alloni, et al. 2014). High linear energy transfer (LET) radiation has been associated with higher-energy deposits (Liamsuwan et al., 2014) that are more densely-packed and cause more complex effects within the particle track (Hada and Georgakilas, 2008; Okayasu, 2012ab; Lorat et al., 2015; Nikitaki et al., 2016) in comparison to low LET radiation. Parameters such as mean lineal energy, dose mean lineal energy, frequency mean specific energy and dose mean specific energy can impact track structure of the traversed energy into a medium (Friedland et al., 2017). The detection of energy deposition by ionizing radiation can be demonstrated with the use of fluorescent nuclear track detectors (FNTDs). FNTDs used in conjunction with fluorescent microscopy, are able to visualize radiation tracks produced by ionizing radiation (Niklas et al., 2013; Kodaira et al., 2015; Sawakuchi and Akselrod, 2016). In addition, these FNTD chips can quantify the LET of primary and secondary radiation tracks up to 0.47 keV/um (Sawakuchi and Akselrod, 2016). This co-visualization of the radiation tracks and the cell markers enable the mapping of the radiation trajectory to specific cellular compartments, and the identification of accrued damage (Niklas et al., 2013; Kodaira et al., 2015). There are no known chemical initiators or prototypes that can mimic the MIE."@en ;
  foaf:page <https://identifiers.org/aop/216> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/216> a sbd:Model ;
  rdfs:label "Deposition of energy leading to population decline via DNA strand breaks and follicular atresia"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/216> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/216> a sbd:Model ;
  rdfs:label "Deposition of energy leading to population decline via DNA strand breaks and follicular atresia"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Cumulative fecundity is the most apical endpoint considered in the OECD 229 Fish Short Term Reproduction Assay. The OECD 229 assay serves as screening assay for endocrine disruption and associated reproductive impairment (OECD 2012). Fecundity is also an important apical endpoint in the Medaka Extended One Generation Reproduction Test (MEOGRT; OECD Test Guideline 240; OECD 2015).  A variety of fish life cycle tests also include cumulative fecundity as an endpoint (OECD 2008).  &nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/216> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/216> a sbd:Model ;
  rdfs:label "Deposition of energy leading to population decline via DNA strand breaks and follicular atresia"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "It is well documented that ionizing radiation( (eg.&nbsp;X-rays, gamma, photons, alpha, beta, neutrons, heavy ions)&nbsp;leads to energy deposition on the atoms and molecules of the substrate. Many studies, have demonstrated that the type of radiation and distance from source has an impact on the pattern of energy deposition (Alloni, et al. 2014). High linear energy transfer (LET) radiation has been associated with higher-energy deposits (Liamsuwan et al., 2014) that are more densely-packed and cause more complex effects within the particle track (Hada and Georgakilas, 2008; Okayasu, 2012ab; Lorat et al., 2015; Nikitaki et al., 2016) in comparison to low LET radiation. Parameters such as mean lineal energy, dose mean lineal energy, frequency mean specific energy and dose mean specific energy can impact track structure of the traversed energy into a medium (Friedland et al., 2017). The detection of energy deposition by ionizing radiation can be demonstrated with the use of fluorescent nuclear track detectors (FNTDs). FNTDs used in conjunction with fluorescent microscopy, are able to visualize radiation tracks produced by ionizing radiation (Niklas et al., 2013; Kodaira et al., 2015; Sawakuchi and Akselrod, 2016). In addition, these FNTD chips can quantify the LET of primary and secondary radiation tracks up to 0.47 keV/um (Sawakuchi and Akselrod, 2016). This co-visualization of the radiation tracks and the cell markers enable the mapping of the radiation trajectory to specific cellular compartments, and the identification of accrued damage (Niklas et al., 2013; Kodaira et al., 2015). There are no known chemical initiators or prototypes that can mimic the MIE."@en ;
  foaf:page <https://identifiers.org/aop/216> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/218> a sbd:Model ;
  rdfs:label "Inhibition of CYP7B activity leads to decreased reproductive success via decreased locomotor activity"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/218> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/218> a sbd:Model ;
  rdfs:label "Inhibition of CYP7B activity leads to decreased reproductive success via decreased locomotor activity"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The stressor&nbsp;identified for this AOP is&nbsp;used&nbsp;as fungicide both in the field for crop protection&nbsp;and in animal against fungus infection. Because it can inhibit various cytochrome P450 enzymes activity, a family of enzymes involved in a plethora of pathways including&nbsp;steroidogenesis, it has the potential to induce many different side effects for animal exposed indirectly through the environment or directly through medical treatment.&nbsp;This AOP targets one of these side effects.&nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/218> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/218> a sbd:Model ;
  rdfs:label "Inhibition of CYP7B activity leads to decreased reproductive success via decreased locomotor activity"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The binding of inhibitors to CYP7B is demonstrated in vitro with purified&nbsp;recombinant protein in presence of the inhibitor. Ligand-induced spectral changes is analyzed using spectrophotometric titration as a shift of the heme (Yantsevich et al., 2014).&nbsp;  Ketoconazole and other conazole are known to bind to CYPs preventing its enzymatic activity.     	CYP7B inhibitor (ketoconazole, 10-4 M) decreased the synthesis of 7&alpha;-hydroxypregnenolone 	CYP7B inhibitor (intracerebroventricular injection of ketoconazole) decreased the synthesis of 7&alpha;-hydroxypregnenolone in the male quail and newt brain, in vivo (Matsunaga et al., 2004; Rose et al., 1997; Tsutsui et al., 2008).&nbsp; 	The heme prosthetic group (catalytic site) of human recombinant CYP7B thightly bound&nbsp;to various imidazole- and triazole-based drugs in an in vitro spectrometric titration assay. The drugs with the highest affinities were the industrial pesticides tebuconazole (0.11&nbsp;&mu;m), propiconazole (0.13&nbsp;&mu;m) and the antifungal drugs tioconazole (0.15&nbsp;&mu;m) and miconazole (0.23&nbsp;&mu;m). Voriconazole and metyrapone (non-azole compound) also interacted&nbsp;with CYP7B&nbsp;(Yantsevich et al., 2014).&nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/218> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/219> a sbd:Model ;
  rdfs:label "Inhibition of CYP7B activity leads to decreased reproductive success via decreased sexual behavior"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/219> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/219> a sbd:Model ;
  rdfs:label "Inhibition of CYP7B activity leads to decreased reproductive success via decreased sexual behavior"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "This AOP shares most of its key events with AOP 218, with the exception of Locomotor activity, decreased (Event 1389). Due to&nbsp;this difference, the domain of applicability of the two&nbsp;AOPs differs and limits their compatibility. For that reason, two similar AOPs with different domain of applicability were created.&nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/219> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/219> a sbd:Model ;
  rdfs:label "Inhibition of CYP7B activity leads to decreased reproductive success via decreased sexual behavior"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The binding of inhibitors to CYP7B is demonstrated in vitro with purified&nbsp;recombinant protein in presence of the inhibitor. Ligand-induced spectral changes is analyzed using spectrophotometric titration as a shift of the heme (Yantsevich et al., 2014).&nbsp;  Ketoconazole and other conazole are known to bind to CYPs preventing its enzymatic activity.     	CYP7B inhibitor (ketoconazole, 10-4 M) decreased the synthesis of 7&alpha;-hydroxypregnenolone 	CYP7B inhibitor (intracerebroventricular injection of ketoconazole) decreased the synthesis of 7&alpha;-hydroxypregnenolone in the male quail and newt brain, in vivo (Matsunaga et al., 2004; Rose et al., 1997; Tsutsui et al., 2008).&nbsp; 	The heme prosthetic group (catalytic site) of human recombinant CYP7B thightly bound&nbsp;to various imidazole- and triazole-based drugs in an in vitro spectrometric titration assay. The drugs with the highest affinities were the industrial pesticides tebuconazole (0.11&nbsp;&mu;m), propiconazole (0.13&nbsp;&mu;m) and the antifungal drugs tioconazole (0.15&nbsp;&mu;m) and miconazole (0.23&nbsp;&mu;m). Voriconazole and metyrapone (non-azole compound) also interacted&nbsp;with CYP7B&nbsp;(Yantsevich et al., 2014).&nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/219> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/220> a sbd:Model ;
  rdfs:label "Cyp2E1 Activation Leading to Liver Cancer"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The subject of this AOP is xenobiotic metabolism by Cyp2E1 (MIE) during prolonged&nbsp;exposures, leading to liver cancer (AO). The intervening KEs are chronic oxidative stress, cytotoxicity, and regenerative proliferation. The setting for these events is the liver, which is the body&rsquo;s primary venue for chemical detoxification.  Xenobiotic metabolism typically occurs in three phases: (I) the chemical substrate is enzymatically bio-activated to its primary metabolite; (II) the metabolite(s) produced is (are) made less reactive through conjugation; and (III) the modified chemical(s) is (are) excreted. Cyp2E1 is a phase I P450 monooxygenase that bio-activates its substrates through the addition of an oxygen, thereby producing an electrophilic metabolite. Acting as an electrophile following metabolic activation is a key characteristic of a carcinogen (Smith, et al. 2015). While this reactive species often undergoes conjugation (phase II metabolism), sometimes it will react with cellular nucleophiles (e.g., proteins or DNA), which results in formation of adducts that produce cytotoxicity in extreme cases. Another feature of Cyp2E1 is that its catalytic cycle is prone to uncoupling, which leads to the production of reactive oxygen species (ROS). ROS are an important source of cytotoxicity (e.g., via lipid peroxidation) and are a source of oxidative lesions to DNA (which may be a source of cancer-causing mutations) (Caro and Cederbaum 2004). &nbsp;Redox-sensitive proteins are modified by oxidation; importantly, changes in gene expression are carried out by the redox-sensitive transcription factor Nrf2. Nrf2 increases the expression of genes that encode cyto-protective products, such as anti-oxidants and phase II conjugating enzymes (Furfaro, et al. 2016, Ma and He 2012, Sporn and Liby 2012, Tkachev, et al. 2011). At the same time, dying cells release pro-inflammatory signals and, together, these signals encourage regenerative proliferation of hepatocytes (Brenner, et al. 2013, Luedde, et al. 2014). However, when chronically activated, these molecular signals can produce dysregulated cellular proliferation in which the cytoprotective cellular mechanisms that are intended to promote tissue repair instead may lead to pre-malignant and malignant lesions.  This AOP explores these mechanisms in greater detail. Because exposure to Cyp2E1substrates is relatively common, this AOP will be an important tool for understanding the adverse health impacts of these potentially harmful substances. Cyp2E1 is well studied and is involved in the metabolism of a large number of substrates (Lieber 1997, Tanaka, et al. 2000), so it is impossible to summarize all of the evidence. &nbsp;Therefore, we report illustrative studies that support each KE and KER. In addition, because no single study has looked at each key event, supporting evidence is gathered from many studies that have used a variety of in vitro and in vivo systems, as well as a collection of Cyp2E1 substrates. We focus on evidence gathered from: furan (a group 2B carcinogen), ethanol (group 1), chloroform (group 2B), and carbon tetrachloride (group 2B). These compounds are established Cyp2E1 substrates that are known to be rodent carcinogens and are (group 1) or are suspected (group 2B) human carcinogens based on their International Agency for Research on Carcinogens (IARC) evaluations."@en ;
  foaf:page <https://identifiers.org/aop/220> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/220> a sbd:Model ;
  rdfs:label "Cyp2E1 Activation Leading to Liver Cancer"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "A variety of substrates have been described (Lieber 1997, Tanaka, et al. 2000). There are &gt;85 known Cyp2E1 substrates. They are low molecular weight compounds, including: molecular oxygen, acetone ADDIN RW.CITE{{839 Bondoc,F.Y. 1999}}(Bondoc, et al. 1999), acetaminophen ADDIN RW.CITE{{680 Lee,S.S. 1996; 835 Zaher,H. 1998}}(Lee, et al. 1996, Zaher, et al. 1998), carbon tetrachloride ADDIN RW.CITE{{838 Wong,F.W. 1998}}(Wong, et al. 1998), pyrazole, vinyl chloride, furan, chloroform, ethanol ADDIN RW.CITE{{848 Bardag-Gorce,F. 2000}}(Bardag-Gorce, et al. 2000), benzene ADDIN RW.CITE{{840 Powley,M.W. 2001}}(Powley and Carlson 2001), acrylonitrile (El Hadri, et al. 2005), trichloroethylene ADDIN RW.CITE{{844 Kim,D. 2006}}(Kim and Ghanayem 2006), aniline, N-nitrosodimethylamine, N-nitrosodiethylamine, diethylnitrosamine, thioacetamide ADDIN RW.CITE{{841 Chilakapati,J. 2007}}(Chilakapati, et al. 2007), urethane ADDIN RW.CITE{{847 Hoffler,U. 2003; 845 Hoffler,U. 2005}}(Hoffler, et al. 2003, Hoffler and Ghanayem 2005), and toluene."@en ;
  foaf:page <https://identifiers.org/aop/220> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/220> a sbd:Model ;
  rdfs:label "Cyp2E1 Activation Leading to Liver Cancer"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Any cancer endpoint is considered to be adverse from a regulatory perspective. Substances causing cancer are regulated such that the general population is not exposed to levels that exceed the carcinogenic dose. The standard assay for carcinogens is the two-year rodent bioassay, which is conducted by the National Toxicology Program in the U.S.A. (https://ntp.niehs.nih.gov/). The International Agency on Research on Cancer (IARC; https://www.iarc.fr/) categorizes substances based on available evidence pointing to their ability to cause cancer in humans and/or animals."@en ;
  foaf:page <https://identifiers.org/aop/220> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/223> a sbd:Model ;
  rdfs:label "Serotonin transporter activation to seizure"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Larry: The serotonin transporter may be repressed by SSRI, thus extracellular serotonin is increased and seizure is reduced. However, I did not add this &quot;SSRI inhibits serotonin transporter&quot; relationship into the AOP since SSRI inhibition does not contribute directly to the AOP (It modified the MIE &quot;the activation of serotonin transporter&quot;), but it certainly could be a modifier to prevent the adverse outcome."@en ;
  foaf:page <https://identifiers.org/aop/223> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/23> a sbd:Model ;
  rdfs:label "Androgen receptor agonism leading to reproductive dysfunction (in repeat-spawning fish)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/23> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/23> a sbd:Model ;
  rdfs:label "Androgen receptor agonism leading to reproductive dysfunction (in repeat-spawning fish)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Characterization of chemical properties: Androgen receptor binding chemicals can be grouped into two broad structural domains, steroidal and non-steroidal (Yin et al. 2003). Steroidal androgens consist primarily of testosterone and its derivatives (Yin et al. 2003). Many of the non-steroidal AR binding chemicals studied are derivatives of well known non-steroidal AR antagonists like bicalutamide, hydroxyflutamide, and nilutamide (Yin et al. 2003). Nonetheless, a number of QSARs and SARs that consider AR binding of both these pharmaceutical agents as well as environmental chemicals have been developed (Waller et al. 1996; Serafimova et al. 2002; Todorov et al. 2011; Hong et al. 2003; Bohl et al. 2004). However, it has been shown that very minor structural differences can dramatically impact function as either an agonist or antagonist (Yin et al. 2003; Bohl et al. 2004; Norris et al. 2009), making it difficult at present to predict agonist versus antagonist activity based on chemical structure alone.  In vivo considerations: A variety of steroidal androgens can be converted to estrogens in vitro through the action of cytochrome P450 19 (aromatase). Structures subject to aromatization may behave in vivo as estrogens despite exhibiting potent androgen receptor agonism in vitro."@en ;
  foaf:page <https://identifiers.org/aop/23> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/23> a sbd:Model ;
  rdfs:label "Androgen receptor agonism leading to reproductive dysfunction (in repeat-spawning fish)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "No additional background"@en ;
  foaf:page <https://identifiers.org/aop/23> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/237> a sbd:Model ;
  rdfs:label "Substance interaction with lung resident cell membrane components leading to atherosclerosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Cardiovascular disease (CVD) is the leading cause of death worldwide, being responsible for 31% of all deaths in 2012 (WHO: http://www.who.int). The term CVD covers all diseases of the cardiovascular system, including atherosclerosis, which is manifested as increased plaque deposition or build-up in the arteries. Atherosclerosis is normally asymptotic disease and is initiated by a biological, chemical or physical insult to the artery walls. This leads to the expression of cell adhesion molecules (selectins, VCAM-1 and ICAM-1) on the endothelial lining of the arteries, which facilitates the activation, recruitment, and migration of monocytes through the endothelial monolayer [1;2]. Inside the intima layer, the monocytes differentiate into macrophages and internalize fatty deposits (mainly oxidized low-density lipoprotein). This results in them transforming into foam cells, which is a major component of the atherosclerotic fatty streaks. The fatty streaks reduce the elasticity of the artery walls and the foam cells promote a pro-inflammatory environment by secretion of cytokines and ROS. In addition, foam cells also induce the recruitment of smooth muscle cells to the intima. Added together, these changes lead to the formation of plaques on the artery walls. A fibrous cap of collagen and vascular smooth muscle cells protects the necrotic core and stabilizes the plaque [3;4]. However, blood clots can be formed if the plaque ruptures. These may travel with the bloodstream and obstruct the blood flow of smaller vessels, eg. the coronary arteries, which ultimately can lead to myocardial infarction.   Inhalation of particulate matter, chemicals and pathogens have been related to increased pulmonary inflammation. Whereas a normal immune reaction is crucial for effective elimination of incoming threats, chronic and unresolved inflammation has been linked to both adverse pulmonary and adverse systemic effects in humans. In concordance with this, various retrospective and prospective epidemiological studies have linked pulmonary exposure to respirable air particulates with increased the risk of developing CVD [5-8]. Inhalation of particles has been proposed to affect the cardiovascular system in several different ways, including through disruption of vasomotor function and through acceleration of plaque progression in atherosclerosis [9;10]. We recently showed that a sustained pulmonary inflammatory response occurs concurrently with a persistent acute phase response (APR) in the lungs and in the plasma after exposure to particulate matter in mice [11-13]. Both responses were dose-dependent [14] and the most differentially expressed genes were the serum amyloid A (Saa) isoforms, with Saa3 showing the greatest fold changes [11;13-15]. The SAAs are characterized as APR proteins. Similar to the APR protein C-reactive protein (CRP), elevated plasma levels of SAA protein are a risk factor for CVD in human [16-19]. However, in contrast to CRP, increased plasma protein levels of SAA is still related to CVD after Mendelian randomization, suggesting a causal relationship [20;21]. Indeed, studies in rodents have shown that increased levels of SAA increase plaque progression in ApoE&minus;/&minus; mice [22;23]."@en ;
  foaf:page <https://identifiers.org/aop/237> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/237> a sbd:Model ;
  rdfs:label "Substance interaction with lung resident cell membrane components leading to atherosclerosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "As stated earlier, there are many different ways by which pro-fibrotic stressors can interact with the components of cell membrane and often involve multiple interactions at the same time. Few studies investigate the exact interaction between the stressor and the cellular membrane components. Asbestos and silica crystals engage scavenger receptors present on the macrophages (Murthy et al., 2015). Bleomycin binds high affinity bleomycin binding sites present on rat alveolar macrophage surfaces, leading to macrophage activation (Denholm and Phan, 1990). However, the consequences of such interactions such as, the release of PRR agonists DAMPs (alarmins) from dying or injured cells, increased&nbsp; gene or protein synthesis downstream of receptor binding or in the case of NMs, their cellular uptake, are measured routinely as indicative of occurrence of such interactions (Nel et al., 2009; Cheng et al., 2013). Because of the phys-chem properties such as surface charge, NMs and asbestos like materials can bind to cellular macromolecules and cell surface/membrane components, which in turn, facilitate their uptake and intracellular sequestration by the cells (NIOSH, 2011a; Pascolo et al., 2013). Several DAMPs that can be effectively measured in biological samples and cultured cells include High Mobility Group Binding 1 (HMGB1) protein, Heat Shock proteins (HSPs), uric acid, annexins, and S100 proteins (Bianchi, 2007). Of all DAMPs, interleukin (IL)-1&alpha; is the most commonly measured alarmin. IL-1&alpha; is the principal pro-inflammatory moiety and is a designated &lsquo;alarmin&rsquo; in the cell that alerts the host to injury or damage (Di Paolo and Shayakhmetov, 2016). It is shown that administration of necrotic cells to mice results in neutrophilic inflammation that was entirely mediated by IL-1&alpha; released from the dying or necrosed cells and consequent activation of IL-1 Receptor 1 (IL-1R1) signalling (Suwara et al., 2014). IL-1&alpha; is released following exposure to MWCNTs (Nikota et al., 2017) and silica (Rabolli et al., 2014). Although IL1-b is not a designated alarmin, its secretion following exposure to stressors is routinely assessed and is linked to initiation of cell or tissue injury.  Other high aspect ratio fibres such as asbestos and CNTs induce frustrated phagocytosis and acute cell injury (Boyles et al., 2015; D&ouml;rger et al., 2001; Brown et al., 2007; Kim et al., 2010; Poland et al., 2008), leading to DAMP release (Nikota et al, 2017), inflammation and immune responses."@en ;
  foaf:page <https://identifiers.org/aop/237> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/238> a sbd:Model ;
  rdfs:label "Deposition of energy leading to population decline via DNA strand breaks and oocyte apoptosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/238> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/238> a sbd:Model ;
  rdfs:label "Deposition of energy leading to population decline via DNA strand breaks and oocyte apoptosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Cumulative fecundity is the most apical endpoint considered in the OECD 229 Fish Short Term Reproduction Assay. The OECD 229 assay serves as screening assay for endocrine disruption and associated reproductive impairment (OECD 2012). Fecundity is also an important apical endpoint in the Medaka Extended One Generation Reproduction Test (MEOGRT; OECD Test Guideline 240; OECD 2015).  A variety of fish life cycle tests also include cumulative fecundity as an endpoint (OECD 2008).  &nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/238> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/238> a sbd:Model ;
  rdfs:label "Deposition of energy leading to population decline via DNA strand breaks and oocyte apoptosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "It is well documented that ionizing radiation( (eg.&nbsp;X-rays, gamma, photons, alpha, beta, neutrons, heavy ions)&nbsp;leads to energy deposition on the atoms and molecules of the substrate. Many studies, have demonstrated that the type of radiation and distance from source has an impact on the pattern of energy deposition (Alloni, et al. 2014). High linear energy transfer (LET) radiation has been associated with higher-energy deposits (Liamsuwan et al., 2014) that are more densely-packed and cause more complex effects within the particle track (Hada and Georgakilas, 2008; Okayasu, 2012ab; Lorat et al., 2015; Nikitaki et al., 2016) in comparison to low LET radiation. Parameters such as mean lineal energy, dose mean lineal energy, frequency mean specific energy and dose mean specific energy can impact track structure of the traversed energy into a medium (Friedland et al., 2017). The detection of energy deposition by ionizing radiation can be demonstrated with the use of fluorescent nuclear track detectors (FNTDs). FNTDs used in conjunction with fluorescent microscopy, are able to visualize radiation tracks produced by ionizing radiation (Niklas et al., 2013; Kodaira et al., 2015; Sawakuchi and Akselrod, 2016). In addition, these FNTD chips can quantify the LET of primary and secondary radiation tracks up to 0.47 keV/um (Sawakuchi and Akselrod, 2016). This co-visualization of the radiation tracks and the cell markers enable the mapping of the radiation trajectory to specific cellular compartments, and the identification of accrued damage (Niklas et al., 2013; Kodaira et al., 2015). There are no known chemical initiators or prototypes that can mimic the MIE."@en ;
  foaf:page <https://identifiers.org/aop/238> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/238> a sbd:Model ;
  rdfs:label "Deposition of energy leading to population decline via DNA strand breaks and oocyte apoptosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/238> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/238> a sbd:Model ;
  rdfs:label "Deposition of energy leading to population decline via DNA strand breaks and oocyte apoptosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Cumulative fecundity is the most apical endpoint considered in the OECD 229 Fish Short Term Reproduction Assay. The OECD 229 assay serves as screening assay for endocrine disruption and associated reproductive impairment (OECD 2012). Fecundity is also an important apical endpoint in the Medaka Extended One Generation Reproduction Test (MEOGRT; OECD Test Guideline 240; OECD 2015).  A variety of fish life cycle tests also include cumulative fecundity as an endpoint (OECD 2008).  &nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/238> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/238> a sbd:Model ;
  rdfs:label "Deposition of energy leading to population decline via DNA strand breaks and oocyte apoptosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "It is well documented that ionizing radiation( (eg.&nbsp;X-rays, gamma, photons, alpha, beta, neutrons, heavy ions)&nbsp;leads to energy deposition on the atoms and molecules of the substrate. Many studies, have demonstrated that the type of radiation and distance from source has an impact on the pattern of energy deposition (Alloni, et al. 2014). High linear energy transfer (LET) radiation has been associated with higher-energy deposits (Liamsuwan et al., 2014) that are more densely-packed and cause more complex effects within the particle track (Hada and Georgakilas, 2008; Okayasu, 2012ab; Lorat et al., 2015; Nikitaki et al., 2016) in comparison to low LET radiation. Parameters such as mean lineal energy, dose mean lineal energy, frequency mean specific energy and dose mean specific energy can impact track structure of the traversed energy into a medium (Friedland et al., 2017). The detection of energy deposition by ionizing radiation can be demonstrated with the use of fluorescent nuclear track detectors (FNTDs). FNTDs used in conjunction with fluorescent microscopy, are able to visualize radiation tracks produced by ionizing radiation (Niklas et al., 2013; Kodaira et al., 2015; Sawakuchi and Akselrod, 2016). In addition, these FNTD chips can quantify the LET of primary and secondary radiation tracks up to 0.47 keV/um (Sawakuchi and Akselrod, 2016). This co-visualization of the radiation tracks and the cell markers enable the mapping of the radiation trajectory to specific cellular compartments, and the identification of accrued damage (Niklas et al., 2013; Kodaira et al., 2015). There are no known chemical initiators or prototypes that can mimic the MIE."@en ;
  foaf:page <https://identifiers.org/aop/238> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/245> a sbd:Model ;
  rdfs:label "Reduction in photophosphorylation leading to growth inhibition in aquatic plants"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Growth is a regulatory relevant chronic toxicity endpoint for almost all organisms. Multiple OECD test guidelines have included growth either as a main endpoint of concern, or as an additional endpoint to be considered in the toxicity assessments. Relevant test guidelines include, but not only limited to:  &nbsp;  -Test No. 201: Freshwater Alga and Cyanobacteria, Growth Inhibition Test  -Test No. 208: Terrestrial Plant Test: Seedling Emergence and Seedling Growth Test  -Test No. 211: Daphnia magna Reproduction Test  -Test No. 212: Fish, Short-term Toxicity Test on Embryo and Sac-Fry Stages  -Test No. 215: Fish, Juvenile Growth Test  -Test No. 221: Lemna sp. Growth Inhibition Test  -Test No. 228: Determination of Developmental Toxicity to Dipteran Dung Flies (Scathophaga stercoraria L. (Scathophagidae), Musca autumnalis De Geer (Muscidae))  -Test No. 241: The Larval Amphibian Growth and Development Assay (LAGDA)  -Test No. 407: Repeated Dose 28-day Oral Toxicity Study in Rodents  -Test No. 408: Repeated Dose 90-Day Oral Toxicity Study in Rodents  -Test No. 416: Two-Generation Reproduction Toxicity  -Test No. 422: Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test  -Test No. 443: Extended One-Generation Reproductive Toxicity Study  -Test No. 453: Combined Chronic Toxicity/Carcinogenicity Studies"@en ;
  foaf:page <https://identifiers.org/aop/245> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/25> a sbd:Model ;
  rdfs:label "Aromatase inhibition leading to reproductive dysfunction"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/25> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/25> a sbd:Model ;
  rdfs:label "Aromatase inhibition leading to reproductive dysfunction"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Characterization of chemical properties: Chemicals are known to inhibit aromatase activity through two primary molecular mechanisms. Steroid-like structures can inhibit the enzyme at its active site, with structures having ∆4 positioned double bonds generally acting as stronger inhibitors than those with ∆5 positioned double bonds (Petkov et al. 2009). Non-steroidal aromatase inhibitors generally act by interfering with electron transfer via the cytochrome P450 heme group of the aromatase enzyme, with greater nucleophilicity of the heteroatom contributing to greater potency as an inhibitor (Petkov et al. 2009). Petkov et al. (Petkov et al. 2009) have provided a detailed analysis of structural categorization of chemicals as potential steroidal or non-steroidal aromatase inhibitors."@en ;
  foaf:page <https://identifiers.org/aop/25> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/258> a sbd:Model ;
  rdfs:label "Renal protein alkylation leading to kidney toxicity"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Two prototypical chemicals acting via protein alkylation are Allyl Alcohol  [12][13][6][14][15]  and Carbon Tetrachloride (CCl4)[11][16] [17]  [18] [19][20][21][22]   .                                                                                                        [23]  [24]                                                 .[25] [26] Covalent protein alkylation is a feature of many cytotoxic drugs but the overall extent of binding does not adequately distinguish toxic from non-toxic binding. [27] Interestingly, some chemicals significantly alkylate proteins without causing toxicity, which suggests that only alkylation of a specific protein subset critical subset contributes to injury. Indeed, Codreanu presented an inventory of proteins affected by electrophile-mediated alkylation in intact cells and suggested that non-toxic covalent binding largely affects cytoskeletal protein components, whereas toxic covalent binding induces lethal injury by targeting factors involved in protein synthesis and catabolism and possibly mitochondrial electron transport. [3] In vitro covalent binding studies to macromolecules have been used to elucidate the biochemical mechanisms of chemical-induced toxicity. Experimental work with kidney epithelial cells by Chen et al suggested that following alkylation of cellular macromolecules as initial cytotoxic event both sulfhydryl depletion and lipid peroxidation are components of the cytotoxic mechanism [28]  Dennehy et al have analyzed the protein targets in nuclear and cytoplasmic proteomes from human embryonic kidney cells (HEK293) treated in vitro with two biotin-tagged, thiol-reactive electrophiles and mapped the adducts. Certain protein families appeared particularly susceptible to alkylation. [29]  Shin et al have identified protein targets of two biotin-tagged model electrophiles in human liver microsomes through LC-MS-MS and showed that different target selectivities of the two electrophile probes correlated with different biological outcomes and that alkylation reactions of specific targets could be quantified. [30]"@en ;
  foaf:page <https://identifiers.org/aop/258> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/261> a sbd:Model ;
  rdfs:label "L-type calcium channel blockade leading to heart failure via decrease in cardiac contractility"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Cardiovascular safety liabilities remain a major cause of drug attrition during preclinical and clinical development. Drug-induced cardiovascular toxicity was identified as an area of potential interest for AOP development by a network of experts convened by the UK National Centre for the Replacement, Refinement, and Reduction of Animals in Research (NC3Rs) and the European Union Reference Laboratory for alternatives to animal testing (EURL-ECVAM) in 2015. The blockade of L-type calcium channels (LTCCs) was proposed as one of the priority molecular initiating events (MIE) that may benefit from the AOP vision.  From a toxicological perspective, the key importance of ion currents for drug safety came to light with the discovery that hERG potassium channel inhibition is the most common mechanism of drug-induced long QT syndrome and torsades de pointes arrhythmia [PMID:16322774]. However, a growing body of research has demonstrated that drugs can affect more cardiac currents than previously expected (e.g. calcium current). Thus, the integrated assessment of drug inhibitory activity for multiple ion currents may provide a more accurate prediction of the toxicological risk [PMID:16322774]. Considering the newly recognized complexity of the phenomenon, several authors called for dedicated inter-disciplinary efforts aimed at improving our understanding of the mechanistic basis of cardiovascular liabilities, beyond hERG current blockade [PMID: 21306581]. This AOP is intended to support those efforts by providing a detailed map of the multi-scale effects mediated by LTCCs-blockade."@en ;
  foaf:page <https://identifiers.org/aop/261> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/263> a sbd:Model ;
  rdfs:label "Uncoupling of oxidative phosphorylation leading to  growth inhibition via decreased cell proliferation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The mitochondrial OXPHOS machinery is a key physiological process responsible for producing the primary cellular energy, adenosine triphosphate (ATP). During OXPHOS, a series of redox reactions (oxidation) are mediated by protein complexes in an electron transport chain to create a protonmotive force (PMF) across the inner mitochondrial membrane (Liberman 1969). The PMF acts as a driving force of ATP synthesis through phosphorylation of adenosine diphosphate (ADP). Mitochondrial oxidation and phosphorylation are coupled to ensure continuous ATP supply for various physiological processes. A number of chemicals can bind to the inner mitochondrial membrane and dissipate the PMF, thus leading to uncoupling of OXPHOS and reduction in ATP synthetic efficiency. Classical &ldquo;uncouplers&rdquo; are normally protonophores with major characteristics of bulky hydrophobic moiety, an acid dissociable group and a strong electron-withdrawing group (Terada 1990). With the rapid development of in silico (Russom 1997; Schultz 1997; Naven 2012; Dreier 2019; Troger 2020) and in vitro (Escher 2002; Attene-Ramos 2013; Attene-Ramos 2015; Xia 2018) approaches, more and more uncouplers have been identified. However, their hazards to biota remain to be assessed. Uncoupling of OXPHOS can affect many ATP-dependent biological functions. In particular, cell proliferation as a major process to achieve organismal growth is positively correlated with the cellular ATP level and highly susceptible to energy depletion (Ramaiah 1964; Bonora 2012). Therefore, a link between uncoupling of OXPHOS and growth inhibition can be established with ATP depletion and reduced cell proliferation as the intermediate steps."@en ;
  foaf:page <https://identifiers.org/aop/263> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/263> a sbd:Model ;
  rdfs:label "Uncoupling of oxidative phosphorylation leading to  growth inhibition via decreased cell proliferation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Decreased coupling of oxidative phosphorylation can be directly triggered by &ldquo;uncouplers&rdquo; as a molecular initiating event.   	Most of the chemical uncouplers are protonophores, a type of proton binders that can translocate protons across membranes. These protonophores share several common structural characteristics, such as bulky hydrophobic moiety, an acid dissociable group and a strong electron-withdrawing group (Terada 1990). Weak acids such as phenols, benzimidazoles and salicylic acids are considered potential protonophores. 	Classical uncouplers, such as carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP), carbonyl cyanide m-chlorophenyl hydrazone (CCCP), 2,4-dinitrophenol (DNP), pentachlorophenol (PCP) and SF-6847 (Terada 1990). 	Newer uncouplers, such as triclosan&nbsp;(Shim 2016; Weatherly 2016), emodin (Sugiyama 2019), and hydroxylated polybrominated diphenyl ethers (PBDEs) (Legradi 2014) have been widely investigated in vertebrates. 	Computational predictions based on quantitative structure-activity relationships&nbsp;(Russom 1997; Schultz 1997; Naven 2012; Dreier 2019; Troger 2020) and in vitro high-throughput screening&nbsp;(Escher 2002; Attene-Ramos 2013; Attene-Ramos 2015; Xia 2018) have facilitated the identification and classification of potential uncouplers from a large&nbsp;list of chemicals. &nbsp;&nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/263> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/263> a sbd:Model ;
  rdfs:label "Uncoupling of oxidative phosphorylation leading to  growth inhibition via decreased cell proliferation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Growth is a regulatory relevant chronic toxicity endpoint for almost all organisms. Multiple OECD test guidelines have included growth either as a main endpoint of concern, or as an additional endpoint to be considered in the toxicity assessments. Relevant test guidelines include, but not only limited to:  &nbsp;  -Test No. 201: Freshwater Alga and Cyanobacteria, Growth Inhibition Test  -Test No. 208: Terrestrial Plant Test: Seedling Emergence and Seedling Growth Test  -Test No. 211: Daphnia magna Reproduction Test  -Test No. 212: Fish, Short-term Toxicity Test on Embryo and Sac-Fry Stages  -Test No. 215: Fish, Juvenile Growth Test  -Test No. 221: Lemna sp. Growth Inhibition Test  -Test No. 228: Determination of Developmental Toxicity to Dipteran Dung Flies (Scathophaga stercoraria L. (Scathophagidae), Musca autumnalis De Geer (Muscidae))  -Test No. 241: The Larval Amphibian Growth and Development Assay (LAGDA)  -Test No. 407: Repeated Dose 28-day Oral Toxicity Study in Rodents  -Test No. 408: Repeated Dose 90-Day Oral Toxicity Study in Rodents  -Test No. 416: Two-Generation Reproduction Toxicity  -Test No. 422: Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test  -Test No. 443: Extended One-Generation Reproductive Toxicity Study  -Test No. 453: Combined Chronic Toxicity/Carcinogenicity Studies"@en ;
  foaf:page <https://identifiers.org/aop/263> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/264> a sbd:Model ;
  rdfs:label "Uncoupling of oxidative phosphorylation leading to growth inhibition via ATP depletion associated cell death"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The mitochondrion is central for diverse types of physiological processes, such as energy production, cell cycle regulation, lipid metabolism and ion homeostasis. Mitochondrial dysfunction has frequently been reported as a common (eco)toxicological effect induced by a wide range of environmental stressors through direct or indirect modes of action (Meyer et al., 2013). Chemical mediated mitochondrial dysfunctions are tightly associated with various diseases in human, such as neurodegeneration, cardiovascular malfunction, diabetes and cancer, and multiple types of effects in wildlife, such as metabolic disorders, growth arrest, developmental abnormalities, reproduction failure, mortality and population decline (Meyer et al., 2013). Several mitochondrial dysfunction related MIEs have been well characterized, such as uncoupling of oxidative phosphorylation (OXPHOS) and inhibition of specific protein complexes in the mitochondrial electron transport chain. These MIEs commonly affect the mitochondrial membrane potential and ATP synthetic processes, induce reactive oxygen species (ROS) and oxidative damage to DNA, protein and lipid, modulate plasma membrane ion transporter activities and trigger programmed cell death."@en ;
  foaf:page <https://identifiers.org/aop/264> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/264> a sbd:Model ;
  rdfs:label "Uncoupling of oxidative phosphorylation leading to growth inhibition via ATP depletion associated cell death"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Decreased coupling of oxidative phosphorylation can be directly triggered by &ldquo;uncouplers&rdquo; as a molecular initiating event.   	Most of the chemical uncouplers are protonophores, a type of proton binders that can translocate protons across membranes. These protonophores share several common structural characteristics, such as bulky hydrophobic moiety, an acid dissociable group and a strong electron-withdrawing group (Terada 1990). Weak acids such as phenols, benzimidazoles and salicylic acids are considered potential protonophores. 	Classical uncouplers, such as carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP), carbonyl cyanide m-chlorophenyl hydrazone (CCCP), 2,4-dinitrophenol (DNP), pentachlorophenol (PCP) and SF-6847 (Terada 1990). 	Newer uncouplers, such as triclosan&nbsp;(Shim 2016; Weatherly 2016), emodin (Sugiyama 2019), and hydroxylated polybrominated diphenyl ethers (PBDEs) (Legradi 2014) have been widely investigated in vertebrates. 	Computational predictions based on quantitative structure-activity relationships&nbsp;(Russom 1997; Schultz 1997; Naven 2012; Dreier 2019; Troger 2020) and in vitro high-throughput screening&nbsp;(Escher 2002; Attene-Ramos 2013; Attene-Ramos 2015; Xia 2018) have facilitated the identification and classification of potential uncouplers from a large&nbsp;list of chemicals. &nbsp;&nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/264> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/264> a sbd:Model ;
  rdfs:label "Uncoupling of oxidative phosphorylation leading to growth inhibition via ATP depletion associated cell death"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Growth is a regulatory relevant chronic toxicity endpoint for almost all organisms. Multiple OECD test guidelines have included growth either as a main endpoint of concern, or as an additional endpoint to be considered in the toxicity assessments. Relevant test guidelines include, but not only limited to:  &nbsp;  -Test No. 201: Freshwater Alga and Cyanobacteria, Growth Inhibition Test  -Test No. 208: Terrestrial Plant Test: Seedling Emergence and Seedling Growth Test  -Test No. 211: Daphnia magna Reproduction Test  -Test No. 212: Fish, Short-term Toxicity Test on Embryo and Sac-Fry Stages  -Test No. 215: Fish, Juvenile Growth Test  -Test No. 221: Lemna sp. Growth Inhibition Test  -Test No. 228: Determination of Developmental Toxicity to Dipteran Dung Flies (Scathophaga stercoraria L. (Scathophagidae), Musca autumnalis De Geer (Muscidae))  -Test No. 241: The Larval Amphibian Growth and Development Assay (LAGDA)  -Test No. 407: Repeated Dose 28-day Oral Toxicity Study in Rodents  -Test No. 408: Repeated Dose 90-Day Oral Toxicity Study in Rodents  -Test No. 416: Two-Generation Reproduction Toxicity  -Test No. 422: Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test  -Test No. 443: Extended One-Generation Reproductive Toxicity Study  -Test No. 453: Combined Chronic Toxicity/Carcinogenicity Studies"@en ;
  foaf:page <https://identifiers.org/aop/264> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/265> a sbd:Model ;
  rdfs:label "Uncoupling of oxidative phosphorylation leading to growth inhibition via increased cytosolic calcium"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Decreased coupling of oxidative phosphorylation can be directly triggered by &ldquo;uncouplers&rdquo; as a molecular initiating event.   	Most of the chemical uncouplers are protonophores, a type of proton binders that can translocate protons across membranes. These protonophores share several common structural characteristics, such as bulky hydrophobic moiety, an acid dissociable group and a strong electron-withdrawing group (Terada 1990). Weak acids such as phenols, benzimidazoles and salicylic acids are considered potential protonophores. 	Classical uncouplers, such as carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP), carbonyl cyanide m-chlorophenyl hydrazone (CCCP), 2,4-dinitrophenol (DNP), pentachlorophenol (PCP) and SF-6847 (Terada 1990). 	Newer uncouplers, such as triclosan&nbsp;(Shim 2016; Weatherly 2016), emodin (Sugiyama 2019), and hydroxylated polybrominated diphenyl ethers (PBDEs) (Legradi 2014) have been widely investigated in vertebrates. 	Computational predictions based on quantitative structure-activity relationships&nbsp;(Russom 1997; Schultz 1997; Naven 2012; Dreier 2019; Troger 2020) and in vitro high-throughput screening&nbsp;(Escher 2002; Attene-Ramos 2013; Attene-Ramos 2015; Xia 2018) have facilitated the identification and classification of potential uncouplers from a large&nbsp;list of chemicals. &nbsp;&nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/265> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/265> a sbd:Model ;
  rdfs:label "Uncoupling of oxidative phosphorylation leading to growth inhibition via increased cytosolic calcium"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The mitochondrion is central for diverse types of physiological processes, such as energy production, cell cycle regulation, lipid metabolism and ion homeostasis. Mitochondrial dysfunction has frequently been reported as a common (eco)toxicological effect induced by a wide range of environmental stressors through direct or indirect modes of action (Meyer et al., 2013). Chemical mediated mitochondrial dysfunctions are tightly associated with various diseases in human, such as neurodegeneration, cardiovascular malfunction, diabetes and cancer, and multiple types of effects in wildlife, such as metabolic disorders, growth arrest, developmental abnormalities, reproduction failure, mortality and population decline (Meyer et al., 2013). Several mitochondrial dysfunction related MIEs have been well characterized, such as uncoupling of oxidative phosphorylation (OXPHOS) and inhibition of specific protein complexes in the mitochondrial electron transport chain. These MIEs commonly affect the mitochondrial membrane potential and ATP synthetic processes, inhibit protein and lipid sythetic processes, modulate plasma membrane ion transporter activities and trigger cell death."@en ;
  foaf:page <https://identifiers.org/aop/265> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/265> a sbd:Model ;
  rdfs:label "Uncoupling of oxidative phosphorylation leading to growth inhibition via increased cytosolic calcium"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Growth is a regulatory relevant chronic toxicity endpoint for almost all organisms. Multiple OECD test guidelines have included growth either as a main endpoint of concern, or as an additional endpoint to be considered in the toxicity assessments. Relevant test guidelines include, but not only limited to:  &nbsp;  -Test No. 201: Freshwater Alga and Cyanobacteria, Growth Inhibition Test  -Test No. 208: Terrestrial Plant Test: Seedling Emergence and Seedling Growth Test  -Test No. 211: Daphnia magna Reproduction Test  -Test No. 212: Fish, Short-term Toxicity Test on Embryo and Sac-Fry Stages  -Test No. 215: Fish, Juvenile Growth Test  -Test No. 221: Lemna sp. Growth Inhibition Test  -Test No. 228: Determination of Developmental Toxicity to Dipteran Dung Flies (Scathophaga stercoraria L. (Scathophagidae), Musca autumnalis De Geer (Muscidae))  -Test No. 241: The Larval Amphibian Growth and Development Assay (LAGDA)  -Test No. 407: Repeated Dose 28-day Oral Toxicity Study in Rodents  -Test No. 408: Repeated Dose 90-Day Oral Toxicity Study in Rodents  -Test No. 416: Two-Generation Reproduction Toxicity  -Test No. 422: Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test  -Test No. 443: Extended One-Generation Reproductive Toxicity Study  -Test No. 453: Combined Chronic Toxicity/Carcinogenicity Studies"@en ;
  foaf:page <https://identifiers.org/aop/265> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/266> a sbd:Model ;
  rdfs:label "Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased Na-K ATPase activity"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The mitochondrion is central for diverse types of physiological processes, such as energy production, cell cycle regulation, lipid metabolism and ion homeostasis. Mitochondrial dysfunction has frequently been reported as a common (eco)toxicological effect induced by a wide range of environmental stressors through direct or indirect modes of action (Meyer et al., 2013). Chemical mediated mitochondrial dysfunctions are tightly associated with various diseases in human, such as neurodegeneration, cardiovascular malfunction, diabetes and cancer, and multiple types of effects in wildlife, such as metabolic disorders, growth arrest, developmental abnormalities, reproduction failure, mortality and population decline (Meyer et al., 2013). Several mitochondrial dysfunction related MIEs have been well characterized, such as uncoupling of oxidative phosphorylation (OXPHOS) and inhibition of specific protein complexes in the mitochondrial electron transport chain. These MIEs commonly affect the mitochondrial membrane potential and ATP synthetic processes, induce reactive oxygen species (ROS) and oxidative damage to DNA, protein and lipid, modulate plasma membrane ion transporter activities and trigger programmed cell death."@en ;
  foaf:page <https://identifiers.org/aop/266> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/266> a sbd:Model ;
  rdfs:label "Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased Na-K ATPase activity"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Decreased coupling of oxidative phosphorylation can be directly triggered by &ldquo;uncouplers&rdquo; as a molecular initiating event.   	Most of the chemical uncouplers are protonophores, a type of proton binders that can translocate protons across membranes. These protonophores share several common structural characteristics, such as bulky hydrophobic moiety, an acid dissociable group and a strong electron-withdrawing group (Terada 1990). Weak acids such as phenols, benzimidazoles and salicylic acids are considered potential protonophores. 	Classical uncouplers, such as carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP), carbonyl cyanide m-chlorophenyl hydrazone (CCCP), 2,4-dinitrophenol (DNP), pentachlorophenol (PCP) and SF-6847 (Terada 1990). 	Newer uncouplers, such as triclosan&nbsp;(Shim 2016; Weatherly 2016), emodin (Sugiyama 2019), and hydroxylated polybrominated diphenyl ethers (PBDEs) (Legradi 2014) have been widely investigated in vertebrates. 	Computational predictions based on quantitative structure-activity relationships&nbsp;(Russom 1997; Schultz 1997; Naven 2012; Dreier 2019; Troger 2020) and in vitro high-throughput screening&nbsp;(Escher 2002; Attene-Ramos 2013; Attene-Ramos 2015; Xia 2018) have facilitated the identification and classification of potential uncouplers from a large&nbsp;list of chemicals. &nbsp;&nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/266> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/266> a sbd:Model ;
  rdfs:label "Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased Na-K ATPase activity"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Growth is a regulatory relevant chronic toxicity endpoint for almost all organisms. Multiple OECD test guidelines have included growth either as a main endpoint of concern, or as an additional endpoint to be considered in the toxicity assessments. Relevant test guidelines include, but not only limited to:  &nbsp;  -Test No. 201: Freshwater Alga and Cyanobacteria, Growth Inhibition Test  -Test No. 208: Terrestrial Plant Test: Seedling Emergence and Seedling Growth Test  -Test No. 211: Daphnia magna Reproduction Test  -Test No. 212: Fish, Short-term Toxicity Test on Embryo and Sac-Fry Stages  -Test No. 215: Fish, Juvenile Growth Test  -Test No. 221: Lemna sp. Growth Inhibition Test  -Test No. 228: Determination of Developmental Toxicity to Dipteran Dung Flies (Scathophaga stercoraria L. (Scathophagidae), Musca autumnalis De Geer (Muscidae))  -Test No. 241: The Larval Amphibian Growth and Development Assay (LAGDA)  -Test No. 407: Repeated Dose 28-day Oral Toxicity Study in Rodents  -Test No. 408: Repeated Dose 90-Day Oral Toxicity Study in Rodents  -Test No. 416: Two-Generation Reproduction Toxicity  -Test No. 422: Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test  -Test No. 443: Extended One-Generation Reproductive Toxicity Study  -Test No. 453: Combined Chronic Toxicity/Carcinogenicity Studies"@en ;
  foaf:page <https://identifiers.org/aop/266> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/267> a sbd:Model ;
  rdfs:label "Uncoupling of oxidative phosphorylation leading to growth inhibition via glucose depletion"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The mitochondrion is central for diverse types of physiological processes, such as energy production, cell cycle regulation, lipid metabolism and ion homeostasis. Mitochondrial dysfunction has frequently been reported as a common (eco)toxicological effect induced by a wide range of environmental stressors through direct or indirect modes of action (Meyer et al., 2013). Chemical mediated mitochondrial dysfunctions are tightly associated with various diseases in human, such as neurodegeneration, cardiovascular malfunction, diabetes and cancer, and multiple types of effects in wildlife, such as metabolic disorders, growth arrest, developmental abnormalities, reproduction failure, mortality and population decline (Meyer et al., 2013). Several mitochondrial dysfunction related MIEs have been well characterized, such as uncoupling of oxidative phosphorylation (OXPHOS) and inhibition of specific protein complexes in the mitochondrial electron transport chain. These MIEs commonly affect the mitochondrial membrane potential and ATP synthetic processes, induce reactive oxygen species (ROS) and oxidative damage to DNA, protein and lipid, modulate plasma membrane ion transporter activities and trigger programmed cell death."@en ;
  foaf:page <https://identifiers.org/aop/267> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/267> a sbd:Model ;
  rdfs:label "Uncoupling of oxidative phosphorylation leading to growth inhibition via glucose depletion"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Decreased coupling of oxidative phosphorylation can be directly triggered by &ldquo;uncouplers&rdquo; as a molecular initiating event.   	Most of the chemical uncouplers are protonophores, a type of proton binders that can translocate protons across membranes. These protonophores share several common structural characteristics, such as bulky hydrophobic moiety, an acid dissociable group and a strong electron-withdrawing group (Terada 1990). Weak acids such as phenols, benzimidazoles and salicylic acids are considered potential protonophores. 	Classical uncouplers, such as carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP), carbonyl cyanide m-chlorophenyl hydrazone (CCCP), 2,4-dinitrophenol (DNP), pentachlorophenol (PCP) and SF-6847 (Terada 1990). 	Newer uncouplers, such as triclosan&nbsp;(Shim 2016; Weatherly 2016), emodin (Sugiyama 2019), and hydroxylated polybrominated diphenyl ethers (PBDEs) (Legradi 2014) have been widely investigated in vertebrates. 	Computational predictions based on quantitative structure-activity relationships&nbsp;(Russom 1997; Schultz 1997; Naven 2012; Dreier 2019; Troger 2020) and in vitro high-throughput screening&nbsp;(Escher 2002; Attene-Ramos 2013; Attene-Ramos 2015; Xia 2018) have facilitated the identification and classification of potential uncouplers from a large&nbsp;list of chemicals. &nbsp;&nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/267> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/267> a sbd:Model ;
  rdfs:label "Uncoupling of oxidative phosphorylation leading to growth inhibition via glucose depletion"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Growth is a regulatory relevant chronic toxicity endpoint for almost all organisms. Multiple OECD test guidelines have included growth either as a main endpoint of concern, or as an additional endpoint to be considered in the toxicity assessments. Relevant test guidelines include, but not only limited to:  &nbsp;  -Test No. 201: Freshwater Alga and Cyanobacteria, Growth Inhibition Test  -Test No. 208: Terrestrial Plant Test: Seedling Emergence and Seedling Growth Test  -Test No. 211: Daphnia magna Reproduction Test  -Test No. 212: Fish, Short-term Toxicity Test on Embryo and Sac-Fry Stages  -Test No. 215: Fish, Juvenile Growth Test  -Test No. 221: Lemna sp. Growth Inhibition Test  -Test No. 228: Determination of Developmental Toxicity to Dipteran Dung Flies (Scathophaga stercoraria L. (Scathophagidae), Musca autumnalis De Geer (Muscidae))  -Test No. 241: The Larval Amphibian Growth and Development Assay (LAGDA)  -Test No. 407: Repeated Dose 28-day Oral Toxicity Study in Rodents  -Test No. 408: Repeated Dose 90-Day Oral Toxicity Study in Rodents  -Test No. 416: Two-Generation Reproduction Toxicity  -Test No. 422: Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test  -Test No. 443: Extended One-Generation Reproductive Toxicity Study  -Test No. 453: Combined Chronic Toxicity/Carcinogenicity Studies"@en ;
  foaf:page <https://identifiers.org/aop/267> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/268> a sbd:Model ;
  rdfs:label "Uncoupling of oxidative phosphorylation leading to growth inhibition via mitochondrial swelling"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The mitochondrion is central for diverse types of physiological processes, such as energy production, cell cycle regulation, lipid metabolism and ion homeostasis. Mitochondrial dysfunction has frequently been reported as a common (eco)toxicological effect induced by a wide range of environmental stressors through direct or indirect modes of action (Meyer et al., 2013). Chemical mediated mitochondrial dysfunctions are tightly associated with various diseases in human, such as neurodegeneration, cardiovascular malfunction, diabetes and cancer, and multiple types of effects in wildlife, such as metabolic disorders, growth arrest, developmental abnormalities, reproduction failure, mortality and population decline (Meyer et al., 2013). Several mitochondrial dysfunction related MIEs have been well characterized, such as uncoupling of oxidative phosphorylation (OXPHOS) and inhibition of specific protein complexes in the mitochondrial electron transport chain. These MIEs commonly affect the mitochondrial membrane potential and ATP synthetic processes, induce reactive oxygen species (ROS) and oxidative damage to DNA, protein and lipid, modulate plasma membrane ion transporter activities and trigger programmed cell death."@en ;
  foaf:page <https://identifiers.org/aop/268> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/268> a sbd:Model ;
  rdfs:label "Uncoupling of oxidative phosphorylation leading to growth inhibition via mitochondrial swelling"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Decreased coupling of oxidative phosphorylation can be directly triggered by &ldquo;uncouplers&rdquo; as a molecular initiating event.   	Most of the chemical uncouplers are protonophores, a type of proton binders that can translocate protons across membranes. These protonophores share several common structural characteristics, such as bulky hydrophobic moiety, an acid dissociable group and a strong electron-withdrawing group (Terada 1990). Weak acids such as phenols, benzimidazoles and salicylic acids are considered potential protonophores. 	Classical uncouplers, such as carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP), carbonyl cyanide m-chlorophenyl hydrazone (CCCP), 2,4-dinitrophenol (DNP), pentachlorophenol (PCP) and SF-6847 (Terada 1990). 	Newer uncouplers, such as triclosan&nbsp;(Shim 2016; Weatherly 2016), emodin (Sugiyama 2019), and hydroxylated polybrominated diphenyl ethers (PBDEs) (Legradi 2014) have been widely investigated in vertebrates. 	Computational predictions based on quantitative structure-activity relationships&nbsp;(Russom 1997; Schultz 1997; Naven 2012; Dreier 2019; Troger 2020) and in vitro high-throughput screening&nbsp;(Escher 2002; Attene-Ramos 2013; Attene-Ramos 2015; Xia 2018) have facilitated the identification and classification of potential uncouplers from a large&nbsp;list of chemicals. &nbsp;&nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/268> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/268> a sbd:Model ;
  rdfs:label "Uncoupling of oxidative phosphorylation leading to growth inhibition via mitochondrial swelling"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Growth is a regulatory relevant chronic toxicity endpoint for almost all organisms. Multiple OECD test guidelines have included growth either as a main endpoint of concern, or as an additional endpoint to be considered in the toxicity assessments. Relevant test guidelines include, but not only limited to:  &nbsp;  -Test No. 201: Freshwater Alga and Cyanobacteria, Growth Inhibition Test  -Test No. 208: Terrestrial Plant Test: Seedling Emergence and Seedling Growth Test  -Test No. 211: Daphnia magna Reproduction Test  -Test No. 212: Fish, Short-term Toxicity Test on Embryo and Sac-Fry Stages  -Test No. 215: Fish, Juvenile Growth Test  -Test No. 221: Lemna sp. Growth Inhibition Test  -Test No. 228: Determination of Developmental Toxicity to Dipteran Dung Flies (Scathophaga stercoraria L. (Scathophagidae), Musca autumnalis De Geer (Muscidae))  -Test No. 241: The Larval Amphibian Growth and Development Assay (LAGDA)  -Test No. 407: Repeated Dose 28-day Oral Toxicity Study in Rodents  -Test No. 408: Repeated Dose 90-Day Oral Toxicity Study in Rodents  -Test No. 416: Two-Generation Reproduction Toxicity  -Test No. 422: Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test  -Test No. 443: Extended One-Generation Reproductive Toxicity Study  -Test No. 453: Combined Chronic Toxicity/Carcinogenicity Studies"@en ;
  foaf:page <https://identifiers.org/aop/268> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/271> a sbd:Model ;
  rdfs:label "Inhibition of thyroid peroxidase leading to impaired fertility in fish"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Cumulative fecundity is the most apical endpoint considered in the OECD 229 Fish Short Term Reproduction Assay. The OECD 229 assay serves as screening assay for endocrine disruption and associated reproductive impairment (OECD 2012). Fecundity is also an important apical endpoint in the Medaka Extended One Generation Reproduction Test (MEOGRT; OECD Test Guideline 240; OECD 2015).  A variety of fish life cycle tests also include cumulative fecundity as an endpoint (OECD 2008).  &nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/271> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/271> a sbd:Model ;
  rdfs:label "Inhibition of thyroid peroxidase leading to impaired fertility in fish"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Acknowledgements: This research was supported by the National Research Council of Science &amp; Technology(NST) grant by the Korea&nbsp;government (MSIP) (No. CAP-17-01-KIST Europe)&nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/271> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/271> a sbd:Model ;
  rdfs:label "Inhibition of thyroid peroxidase leading to impaired fertility in fish"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "There is a wealth of information on the inhibition of TPO by drugs such as MMI and PTU, as well as environmental xenobiotics. In the landmark paper on TH system&nbsp;disruption by environmental chemicals, Brucker-Davis (1998) identified environmental chemicals that depressed TH synthesis by inhibiting TPO. Hurley (1998) listed TPO as a major target for thyroid tumor inducing pesticides. More recent work has tested over 1000 chemicals using a high-throughput screening assay (Paul-Friedman et al., 2016)."@en ;
  foaf:page <https://identifiers.org/aop/271> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/272> a sbd:Model ;
  rdfs:label "Deposition of energy leading to lung cancer"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "At present the AOP framework is not readily used to support regulatory decision-making in radiation protection practices.The goal of developing this AOP is to bring attention to the framework as an effective means to organize knowledge and identify gaps associated with the mechanistic understanding of low dose radiation exposures. We have used lung cancer as the case example due to its relevance to both radiation and chemical risk assessment. This AOP will help build the concept of an &ldquo;all hazards&rdquo; approach to risk assessment, as it will be the first &nbsp;with a molecular initiating event that is specific to a radiation insult. This in turn could serve to identify networks that are critical to both radiation and chemical exposure scenarios and contribute to prioritizing co-exposures of relevance to risk assessment. By developing this AOP, we will support the necessary efforts highlighted by the international and national radiation protection agencies such as, the United Nations Scientific Committee on the Effects of Atomic Radiation, International Commission of Radiological Protection, International Dose Effect Alliance and the Electric Power Research Institute Radiation Program to consolidate and enhance the knowledge in understanding the mechanisms of low dose radiation exposures from the cellular to organelle levels within the system."@en ;
  foaf:page <https://identifiers.org/aop/272> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/272> a sbd:Model ;
  rdfs:label "Deposition of energy leading to lung cancer"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "According to the World Cancer Research Fund, lung cancer is a disease that poses a significant healthcare burden world-wide. (https://www.wcrf.org/dietandcancer/cancer-trends/worldwide-cancer-data (https://www.wcrf.org/dietandcancer/cancer-trends/worldwide-cancer-data)). It is the most commonly diagnosed cancer with the highest incidence of occurrence on a global scale (excluding non-melanoma skin cancers). It is a multi-faceted disease exhibiting various genetic lesions and involving the accumulation of multiple molecular abnormalities over time. It is responsible for 1.5 million deaths annually. There is convincing evidence to show that smoking is an important risk modulating factor to lung cancer development.&nbsp; This risk is increased by age at which one starts, the total number of years&nbsp; and number of cigarettes smoked/day.&nbsp; Studies highlight smoking leads to the largest (relative) increases for small cell carcinoma and squamous cell carcinoma and (Sobue et al., 1999 and Janssen-Heijnen et al., 2001). Other risk factors include lack of physical activity, genetic mutations, dietary factors, asbestos, air pollution (de Groot et al., 2012). Although the link between smoking and lung cancer has been well-established, environmental and indoor radiation exposure are also significant contributors. Risk assessment measures for defining acceptable exposure levels of radiation exposure still remain uncertain; including the scientific research to support the justifications. This is partially due to the assumption of a non-threshold and linear model at low doses with no consideration that cellular/tissue effects of low dose radiation exposure remain poorly understood.   Efforts were focused on developing a simple, unidirectional AOP to lung cancer using predominantly available data from radiation studies. Decades of research suggest that energy in the form of ionizing radiation can break DNA molecules. In vitro mutagenicity studies suggest that alterations in genes in the form of mutations, chromosomal aberrations and micronuclei formation may be important for cancer cell differentiation/proliferation and eventually neoplastic transformation (Harris, 1987). The MIE was selected to be &ldquo;deposition of energy&rdquo; as it is the initial measurable interaction at the macro-molecular level within an organism that can lead to a perturbation that initiates the AOP. The term accurately defines the initiating phenomena that manifest from any type of radiation insult (e.g. alpha- and beta-particles, photons, neutrons and heavy ions) and is distinguishable from chemical-based initiation events.&nbsp; Although the &ldquo;deposition of energy&rdquo; is itself a physical phenomenon (not biological) it is essential to describe the causal relationship between radiation insults and the stochastic onset of associated downstream biological damage. Historically, this relationship has been empirically observed and reported in the form of dose-response data. In addition, this MIE encapsulates the known varieties of radiation and their differing physical properties while still adhering to the stressor agnostic principles of the AOP framework.   &nbsp;This AOP has brought together molecular and cellular based research in the radiation realm and defined a modular, simplistic path towards lung cancer. It has used data&ndash;rich key events to a classic targeted response onto a cell that is applicable to multiple radiation stressors (e.g. X-rays, gamma rays, alpha particles, beta particles, heavy ions, neutrons) and well supported thorough empirical evidence. The proposed&nbsp;AOP is not the only route to lung cancer it is likely to be one linear path in a network of multiple pathways that may include other critical events.&nbsp; This hypothetical AOP will be networked to AOP-296, AOP- 322, AOP-293, AOP-294 and AOP-303 forming a larger network of KEs related inflammation, apoptosis, and oxidative stress, providing a more complete path to lung cancer. This AOP is also a case example of how existing evidence from radiation stressors can stregthen empirical evidence surrounding key events that may be non-radiation specific and vice versa. By using a radiation centric molecular initiating event (MIE), networks can be developed for multiple adverse outcomes distinct to a radiation response. As different radiation stressors can trigger the MIE, the AOP will have wide applicability.   It is our goal, with the development of this AOP to motivate radiation researchers to use this framework for bringing together research data, exchanging knowledge, identifying priority areas and better co-ordinating research in the low-dose ionizing radiation field."@en ;
  foaf:page <https://identifiers.org/aop/272> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/272> a sbd:Model ;
  rdfs:label "Deposition of energy leading to lung cancer"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "It is well documented that ionizing radiation( (eg.&nbsp;X-rays, gamma, photons, alpha, beta, neutrons, heavy ions)&nbsp;leads to energy deposition on the atoms and molecules of the substrate. Many studies, have demonstrated that the type of radiation and distance from source has an impact on the pattern of energy deposition (Alloni, et al. 2014). High linear energy transfer (LET) radiation has been associated with higher-energy deposits (Liamsuwan et al., 2014) that are more densely-packed and cause more complex effects within the particle track (Hada and Georgakilas, 2008; Okayasu, 2012ab; Lorat et al., 2015; Nikitaki et al., 2016) in comparison to low LET radiation. Parameters such as mean lineal energy, dose mean lineal energy, frequency mean specific energy and dose mean specific energy can impact track structure of the traversed energy into a medium (Friedland et al., 2017). The detection of energy deposition by ionizing radiation can be demonstrated with the use of fluorescent nuclear track detectors (FNTDs). FNTDs used in conjunction with fluorescent microscopy, are able to visualize radiation tracks produced by ionizing radiation (Niklas et al., 2013; Kodaira et al., 2015; Sawakuchi and Akselrod, 2016). In addition, these FNTD chips can quantify the LET of primary and secondary radiation tracks up to 0.47 keV/um (Sawakuchi and Akselrod, 2016). This co-visualization of the radiation tracks and the cell markers enable the mapping of the radiation trajectory to specific cellular compartments, and the identification of accrued damage (Niklas et al., 2013; Kodaira et al., 2015). There are no known chemical initiators or prototypes that can mimic the MIE."@en ;
  foaf:page <https://identifiers.org/aop/272> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/273> a sbd:Model ;
  rdfs:label "Mitochondrial complex inhibition leading to liver injury"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Numerous hydrophobic, amphipathic compounds are known to inhibit the proton pumping NADH:ubiquinone oxidoreductase, also known as the ubiquinone reductase reaction of respiratory chain complex I (Fendel et al., 2008). However, the most studied examples of chemicals that inhibit CI are: rotenone and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Desplats et al., 2012; Lin et al., 2012; Sava et al., 2007). Both, rotenone (pesticide) and MPP+ (the active metabolite of MPTP) are well known to reproduce the anatomical, neurochemical, behavioural and neuropathological features of PD-like syndrome (Betarbet et al., 200; Greenamyre et al., 2001). Indeed, an overwhelming evidence has accumulated in the existing literature suggesting such a link and therefore these two inhibitors of CI will be discussed in the context of all KE identified in this AOP.  1. Rotenone affinity to complex I binding sites.  Rotenone (a flavonoid, extracted from the several plants e.g. Derris scandens)is one of the most powerful, an irreversible inhibitor of CI, binding with high affinity to CI and is typically used to define the specific activity of this complex. Rotenone is extremely lipophilic, it crosses biological membrane easily and it gets into brain very rapidly. Rotenone inhibits 20 kDa subunit of complex I (PSST) labeling without effect on 36 kDa subunit of complex I (ND1) (Schuler and Casida, 2001). The interaction of rotenone with active (&#39;pulsed&#39;) and thermally de-activated (&#39;resting&#39;) membrane-bound Complex I as revealed by inhibition of NADH-ubiquinone- and ubiquinol-NAD+ reductase activities was studied. Ki = 1 x 10(-9) M, k(on) = 5 x 10(7) M-1 min-1 and k(off) = 0.02 min-1 (inhibitory effect of rotenone on NADH oxidation) and Ki = 2 x 10(-8) M (inhibition of reverse electron transfer) were determined for pulsed enzyme. The equilibrium between de-activated and active enzyme is reached (K approximately 100) after the slow strongly temperature-dependent de-activation process has completed. Rotenone partially prevents and reverses the enzyme de-activation. About two order of magnitude difference in affinity of rotenone to the active and de-activated forms of the enzyme was demonstrated (Grivennikova et al., 1997). Dose-dependent relative affinities of rotenone to the inhibitory site of CI is shown in Fig. 3B (for more detail Grivennikova et al., 1997).  Most of the studies suggest that hydrophobic inhibitors like rotenone or Piericidin A most likely disrupt the electron transfer between the terminal Fe-S cluster N2 and ubiquinone (Fig. 3A).  &nbsp;    &nbsp;  Fig. 3A. Rotenone structure and a schematic representation of its binding site (and other Rotenone-like compounds) to CI. IMS: inter-membrane space (based on Lummen, 1998)  &nbsp;    &nbsp;  Fig. 3B. Fig. 2. Relative affinities of rotenone to the inhibitory site(s) of Complex I. Panel (A): activated submitochondrial particles (SMP) (2.8 mg/ml, approx. 0.4 microM Complex I) were incubated in the standard reaction mixture for 20 min at 25oC and residual initial rate of NADH oxidation was measured. 100% correspond to the specific activity of 1.0 micromol/min per mg of protein. Panel (B): curve 1 (o), SMP (48 microg/ml, approx. 8 nM Complex I) were activated in the assay cuvette and pre-incubated with rotenone in the presence of gramicidin and 10 mM malonate for 20 min at 25oC and the residual NADH oxidase activity was then measured; black circle: the same as (o), except that pre-incubation with rotenone was made in the presence of 10 mM succinate (no gramicidin and malonate), 10 mM malonate and gramicidin were added simultaneously with 100 microM NADH to measure the residual activity. Curve 2, presents the reverse electron transfer activity and curve 3, de-activated SMP were preincubated with rotenone as described for curve 1(o) (for further details see Grivennikova et al., 1997). Panel (C): The same as Panel B, curve 3, except for enzyme concentration was 0.5 mg/ml and rotenone concentration range which was increased to show interaction of the inhibitor with de-activated enzyme. The activity was measured after 200-fold dilution into the assay mixture. All the continues lines corresponds to the theoretical titration curves for the reversible single site inhibition with Ki values of 1 nM, 20 nM and 80 nM for the curves 1, 2 and 3, respectively (for further details see Grivennikova et al., 1997).   2. MPTP affinity to complex I binding sites. MPTP is not directly binding to CI and it is therefore non-toxic to DA neurons. MPTP exerts its toxicity after it is metabolized by mono-amino-oxidase, type B (MAO B), in astrocytes to 1-methyl-4-phenylpyridinium (MPP+). This metabolite binds to CI, and is toxic. MPP+ is a good substrate for dopamine transporters (DAT), expressed selectively by DA neurons (Greenamyre et al (2001). Due to both a positive charge and an amphoteric character, MPP+ specifically accumulates in mitochondria, where despite a lower affinity to the binding site of complex I than rotenone, it reaches high enough intra-mitochondrial concentrations to inhibit CI activity (Ramsay et al., 1991). The binding affinity of MPP+ is low (mM range), and it can be totally reversed by washing out.&nbsp; Competitive binding experiments with rotenone and MPP+ suggest that the two compounds bind to the same site of the CI (Ramasay et al., 1991). Schuler and Casida (2001) reported that MPP+ inhibits PSST and elevates ND1 labelling subunits of the mitochondrial complex I.  3. General characteristics of other complex I inhibitors. There is a variety of CI inhibitors, both naturally occurring besides rotenone such as Piericidin A (from Streptomyces mobaraensis), acetogenins (from various Annonaceae species) as well as their derivatives, and synthetically manufactured compounds like pyridaben and various piperazin derivatives (Ichimaru et al. 2008). They have been used to probe the catalytic activity of complex I especially in order to clarify its ubiquinone binding site and indeed, most of these compounds inhibit the electron transfer step from the Fe-S clusters to ubiquinone (Friedrich et al. 1994). Therefore, classification of CI inhibitors is based on their types of action. Type A inhibitors, like piericidin A, 2-decyl-4-quinazolinyl amine (DQA), annonin VI and rolliniastatin-1 and -2, are considered to be antagonists of the ubiquinone substrate. For piericidin A, it has been shown that it inhibits NADH:Q2 activity in a partially competitive manner. Contrary to type A, type B inhibitors, like the commonly used rotenone, have hydrogen-bonding acceptors only in the cyclic head of the molecule and are non-competitive towards UQ (ubiquinone), but are believed to displace the semiquinone intermediate during the catalysis (Fig. 2). Finally, inhibitors classified as type C, like stigmatellin and capsaicin, form a third group of hydrophobic CI inhibitors that are believed to act as antagonists of reduced ubiquinone (Degli Esposti 1998, Friedrich et al. 1994, Haefeli 2012) (Fig. 2). Competition studies with representatives of all three different types of inhibitors revealed that type A and B and type B and C, but not type A and C, compete with each other for binding. This led to a suggestion that all CI inhibitors acting at the ubiquinone binding pocket share a common binding domain with partially overlapping sites (Okun et al. 1999).  Some inhibitors bind to the outside of the ubiquinone reduction site and do not fit the preceding classification. Examples of such compounds are ADP-ribose, which competes for substrate binding at the NADH site (Zharova and Vinogradov, 1997), and diphenyleneiodonium (DPI) that covalently binds to reduced flavin mononucleotide (FMN) in the hydrophilic part of the enzyme blocking the electron transfer to the Fe-S clusters (Majander et al., 1994). There are also new, commercially available insecticides/acaricides with potential to inhibit mitochondrial respiration such as benzimidazole, bullatacin, 6-chlorobenzothiadiazole, cyhalothrin, Fenazaquin Fenpyroximate, Hoe 110779, Pyridaben, Pyrimidifen, Sandoz 547A, Tebufenpyrad and Thiangazole (Greenamyre et al., 2001). It is clear that they are capable of inhibiting the mammalian CI of mitochondrial respiratory chain, by binding to and blocking ubiquinone-dependent NADH oxidation with high efficacy (Lummen, 1998)."@en ;
  foaf:page <https://identifiers.org/aop/273> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/273> a sbd:Model ;
  rdfs:label "Mitochondrial complex inhibition leading to liver injury"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Numerous hydrophobic, amphipathic compounds are known to inhibit the proton pumping NADH:ubiquinone oxidoreductase, also known as the ubiquinone reductase reaction of respiratory chain complex I (Fendel et al., 2008). However, the most studied examples of chemicals that inhibit CI are: rotenone and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Desplats et al., 2012; Lin et al., 2012; Sava et al., 2007). Both, rotenone (pesticide) and MPP+ (the active metabolite of MPTP) are well known to reproduce the anatomical, neurochemical, behavioural and neuropathological features of PD-like syndrome (Betarbet et al., 200; Greenamyre et al., 2001). Indeed, an overwhelming evidence has accumulated in the existing literature suggesting such a link and therefore these two inhibitors of CI will be discussed in the context of all KE identified in this AOP.  1. Rotenone affinity to complex I binding sites.  Rotenone (a flavonoid, extracted from the several plants e.g. Derris scandens)is one of the most powerful, an irreversible inhibitor of CI, binding with high affinity to CI and is typically used to define the specific activity of this complex. Rotenone is extremely lipophilic, it crosses biological membrane easily and it gets into brain very rapidly. Rotenone inhibits 20 kDa subunit of complex I (PSST) labeling without effect on 36 kDa subunit of complex I (ND1) (Schuler and Casida, 2001). The interaction of rotenone with active (&#39;pulsed&#39;) and thermally de-activated (&#39;resting&#39;) membrane-bound Complex I as revealed by inhibition of NADH-ubiquinone- and ubiquinol-NAD+ reductase activities was studied. Ki = 1 x 10(-9) M, k(on) = 5 x 10(7) M-1 min-1 and k(off) = 0.02 min-1 (inhibitory effect of rotenone on NADH oxidation) and Ki = 2 x 10(-8) M (inhibition of reverse electron transfer) were determined for pulsed enzyme. The equilibrium between de-activated and active enzyme is reached (K approximately 100) after the slow strongly temperature-dependent de-activation process has completed. Rotenone partially prevents and reverses the enzyme de-activation. About two order of magnitude difference in affinity of rotenone to the active and de-activated forms of the enzyme was demonstrated (Grivennikova et al., 1997). Dose-dependent relative affinities of rotenone to the inhibitory site of CI is shown in Fig. 3B (for more detail Grivennikova et al., 1997).  Most of the studies suggest that hydrophobic inhibitors like rotenone or Piericidin A most likely disrupt the electron transfer between the terminal Fe-S cluster N2 and ubiquinone (Fig. 3A).  &nbsp;    &nbsp;  Fig. 3A. Rotenone structure and a schematic representation of its binding site (and other Rotenone-like compounds) to CI. IMS: inter-membrane space (based on Lummen, 1998)  &nbsp;    &nbsp;  Fig. 3B. Fig. 2. Relative affinities of rotenone to the inhibitory site(s) of Complex I. Panel (A): activated submitochondrial particles (SMP) (2.8 mg/ml, approx. 0.4 microM Complex I) were incubated in the standard reaction mixture for 20 min at 25oC and residual initial rate of NADH oxidation was measured. 100% correspond to the specific activity of 1.0 micromol/min per mg of protein. Panel (B): curve 1 (o), SMP (48 microg/ml, approx. 8 nM Complex I) were activated in the assay cuvette and pre-incubated with rotenone in the presence of gramicidin and 10 mM malonate for 20 min at 25oC and the residual NADH oxidase activity was then measured; black circle: the same as (o), except that pre-incubation with rotenone was made in the presence of 10 mM succinate (no gramicidin and malonate), 10 mM malonate and gramicidin were added simultaneously with 100 microM NADH to measure the residual activity. Curve 2, presents the reverse electron transfer activity and curve 3, de-activated SMP were preincubated with rotenone as described for curve 1(o) (for further details see Grivennikova et al., 1997). Panel (C): The same as Panel B, curve 3, except for enzyme concentration was 0.5 mg/ml and rotenone concentration range which was increased to show interaction of the inhibitor with de-activated enzyme. The activity was measured after 200-fold dilution into the assay mixture. All the continues lines corresponds to the theoretical titration curves for the reversible single site inhibition with Ki values of 1 nM, 20 nM and 80 nM for the curves 1, 2 and 3, respectively (for further details see Grivennikova et al., 1997).   2. MPTP affinity to complex I binding sites. MPTP is not directly binding to CI and it is therefore non-toxic to DA neurons. MPTP exerts its toxicity after it is metabolized by mono-amino-oxidase, type B (MAO B), in astrocytes to 1-methyl-4-phenylpyridinium (MPP+). This metabolite binds to CI, and is toxic. MPP+ is a good substrate for dopamine transporters (DAT), expressed selectively by DA neurons (Greenamyre et al (2001). Due to both a positive charge and an amphoteric character, MPP+ specifically accumulates in mitochondria, where despite a lower affinity to the binding site of complex I than rotenone, it reaches high enough intra-mitochondrial concentrations to inhibit CI activity (Ramsay et al., 1991). The binding affinity of MPP+ is low (mM range), and it can be totally reversed by washing out.&nbsp; Competitive binding experiments with rotenone and MPP+ suggest that the two compounds bind to the same site of the CI (Ramasay et al., 1991). Schuler and Casida (2001) reported that MPP+ inhibits PSST and elevates ND1 labelling subunits of the mitochondrial complex I.  3. General characteristics of other complex I inhibitors. There is a variety of CI inhibitors, both naturally occurring besides rotenone such as Piericidin A (from Streptomyces mobaraensis), acetogenins (from various Annonaceae species) as well as their derivatives, and synthetically manufactured compounds like pyridaben and various piperazin derivatives (Ichimaru et al. 2008). They have been used to probe the catalytic activity of complex I especially in order to clarify its ubiquinone binding site and indeed, most of these compounds inhibit the electron transfer step from the Fe-S clusters to ubiquinone (Friedrich et al. 1994). Therefore, classification of CI inhibitors is based on their types of action. Type A inhibitors, like piericidin A, 2-decyl-4-quinazolinyl amine (DQA), annonin VI and rolliniastatin-1 and -2, are considered to be antagonists of the ubiquinone substrate. For piericidin A, it has been shown that it inhibits NADH:Q2 activity in a partially competitive manner. Contrary to type A, type B inhibitors, like the commonly used rotenone, have hydrogen-bonding acceptors only in the cyclic head of the molecule and are non-competitive towards UQ (ubiquinone), but are believed to displace the semiquinone intermediate during the catalysis (Fig. 2). Finally, inhibitors classified as type C, like stigmatellin and capsaicin, form a third group of hydrophobic CI inhibitors that are believed to act as antagonists of reduced ubiquinone (Degli Esposti 1998, Friedrich et al. 1994, Haefeli 2012) (Fig. 2). Competition studies with representatives of all three different types of inhibitors revealed that type A and B and type B and C, but not type A and C, compete with each other for binding. This led to a suggestion that all CI inhibitors acting at the ubiquinone binding pocket share a common binding domain with partially overlapping sites (Okun et al. 1999).  Some inhibitors bind to the outside of the ubiquinone reduction site and do not fit the preceding classification. Examples of such compounds are ADP-ribose, which competes for substrate binding at the NADH site (Zharova and Vinogradov, 1997), and diphenyleneiodonium (DPI) that covalently binds to reduced flavin mononucleotide (FMN) in the hydrophilic part of the enzyme blocking the electron transfer to the Fe-S clusters (Majander et al., 1994). There are also new, commercially available insecticides/acaricides with potential to inhibit mitochondrial respiration such as benzimidazole, bullatacin, 6-chlorobenzothiadiazole, cyhalothrin, Fenazaquin Fenpyroximate, Hoe 110779, Pyridaben, Pyrimidifen, Sandoz 547A, Tebufenpyrad and Thiangazole (Greenamyre et al., 2001). It is clear that they are capable of inhibiting the mammalian CI of mitochondrial respiratory chain, by binding to and blocking ubiquinone-dependent NADH oxidation with high efficacy (Lummen, 1998)."@en ;
  foaf:page <https://identifiers.org/aop/273> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/274> a sbd:Model ;
  rdfs:label "Histone deacetylase inhibition leads to impeded craniofacial development"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "HDIs are classified according to chemical nature and mode of mechanism: the short-chain fatty acids (e.g., butyrate, valproate), hydroxamic acids (e.g., suberoylanilide hydroxamic acid or SAHA, Trichostatin A or TSA), cyclic tetrapeptides (e.g., FK-228), benzamides (e.g., N-acetyldinaline and MS-275) and epoxides (depeudecin, trapoxin A) [Richon et al., 2003; Ropero and Esteller, 2007; Villar-Garea et al., 2004]. There is a report showing that TSA and butyrate competitively inhibit&nbsp;HDAC activity [Sekhavat et al., 2007]. HDIs inhibit preferentially HDACs with some selectiveness [Hu et al., 2003].&nbsp;TSA (Trichostatin A) inhibits class I and II of HDACs, while butyrate inhibits class I and IIa (HDACs 4, 5, 7, 9) of HDACs [Ooi et al., 2015; Park and Sohrabji, 2016; Wagner et al., 2015].&nbsp;&nbsp;TSA inhibits HDAC1, 2, and 3 [Damaskos et al., 2016], whereas MS-27-275 has an inhibitory effect for HDAC1 and HDAC3 (IC50 value of ~0.3 microM and ~8 microM, respectively), but no effect for HDAC8 (IC50 value &gt;100 microM) [Hu et al., 2003]."@en ;
  foaf:page <https://identifiers.org/aop/274> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/275> a sbd:Model ;
  rdfs:label "Histone deacetylase inhibition leads to neural tube defects"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "HDIs are classified according to chemical nature and mode of mechanism: the short-chain fatty acids (e.g., butyrate, valproate), hydroxamic acids (e.g., suberoylanilide hydroxamic acid or SAHA, Trichostatin A or TSA), cyclic tetrapeptides (e.g., FK-228), benzamides (e.g., N-acetyldinaline and MS-275) and epoxides (depeudecin, trapoxin A) [Richon et al., 2003; Ropero and Esteller, 2007; Villar-Garea et al., 2004]. There is a report showing that TSA and butyrate competitively inhibit&nbsp;HDAC activity [Sekhavat et al., 2007]. HDIs inhibit preferentially HDACs with some selectiveness [Hu et al., 2003].&nbsp;TSA (Trichostatin A) inhibits class I and II of HDACs, while butyrate inhibits class I and IIa (HDACs 4, 5, 7, 9) of HDACs [Ooi et al., 2015; Park and Sohrabji, 2016; Wagner et al., 2015].&nbsp;&nbsp;TSA inhibits HDAC1, 2, and 3 [Damaskos et al., 2016], whereas MS-27-275 has an inhibitory effect for HDAC1 and HDAC3 (IC50 value of ~0.3 microM and ~8 microM, respectively), but no effect for HDAC8 (IC50 value &gt;100 microM) [Hu et al., 2003]."@en ;
  foaf:page <https://identifiers.org/aop/275> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/276> a sbd:Model ;
  rdfs:label "Inhibition of complex I of the electron transport chain leading to chemical induced Fanconi syndrome"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Numerous hydrophobic, amphipathic compounds are known to inhibit the proton pumping NADH:ubiquinone oxidoreductase, also known as the ubiquinone reductase reaction of respiratory chain complex I (Fendel et al., 2008). However, the most studied examples of chemicals that inhibit CI are: rotenone and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Desplats et al., 2012; Lin et al., 2012; Sava et al., 2007). Both, rotenone (pesticide) and MPP+ (the active metabolite of MPTP) are well known to reproduce the anatomical, neurochemical, behavioural and neuropathological features of PD-like syndrome (Betarbet et al., 200; Greenamyre et al., 2001). Indeed, an overwhelming evidence has accumulated in the existing literature suggesting such a link and therefore these two inhibitors of CI will be discussed in the context of all KE identified in this AOP.  1. Rotenone affinity to complex I binding sites.  Rotenone (a flavonoid, extracted from the several plants e.g. Derris scandens)is one of the most powerful, an irreversible inhibitor of CI, binding with high affinity to CI and is typically used to define the specific activity of this complex. Rotenone is extremely lipophilic, it crosses biological membrane easily and it gets into brain very rapidly. Rotenone inhibits 20 kDa subunit of complex I (PSST) labeling without effect on 36 kDa subunit of complex I (ND1) (Schuler and Casida, 2001). The interaction of rotenone with active (&#39;pulsed&#39;) and thermally de-activated (&#39;resting&#39;) membrane-bound Complex I as revealed by inhibition of NADH-ubiquinone- and ubiquinol-NAD+ reductase activities was studied. Ki = 1 x 10(-9) M, k(on) = 5 x 10(7) M-1 min-1 and k(off) = 0.02 min-1 (inhibitory effect of rotenone on NADH oxidation) and Ki = 2 x 10(-8) M (inhibition of reverse electron transfer) were determined for pulsed enzyme. The equilibrium between de-activated and active enzyme is reached (K approximately 100) after the slow strongly temperature-dependent de-activation process has completed. Rotenone partially prevents and reverses the enzyme de-activation. About two order of magnitude difference in affinity of rotenone to the active and de-activated forms of the enzyme was demonstrated (Grivennikova et al., 1997). Dose-dependent relative affinities of rotenone to the inhibitory site of CI is shown in Fig. 3B (for more detail Grivennikova et al., 1997).  Most of the studies suggest that hydrophobic inhibitors like rotenone or Piericidin A most likely disrupt the electron transfer between the terminal Fe-S cluster N2 and ubiquinone (Fig. 3A).  &nbsp;    &nbsp;  Fig. 3A. Rotenone structure and a schematic representation of its binding site (and other Rotenone-like compounds) to CI. IMS: inter-membrane space (based on Lummen, 1998)  &nbsp;    &nbsp;  Fig. 3B. Fig. 2. Relative affinities of rotenone to the inhibitory site(s) of Complex I. Panel (A): activated submitochondrial particles (SMP) (2.8 mg/ml, approx. 0.4 microM Complex I) were incubated in the standard reaction mixture for 20 min at 25oC and residual initial rate of NADH oxidation was measured. 100% correspond to the specific activity of 1.0 micromol/min per mg of protein. Panel (B): curve 1 (o), SMP (48 microg/ml, approx. 8 nM Complex I) were activated in the assay cuvette and pre-incubated with rotenone in the presence of gramicidin and 10 mM malonate for 20 min at 25oC and the residual NADH oxidase activity was then measured; black circle: the same as (o), except that pre-incubation with rotenone was made in the presence of 10 mM succinate (no gramicidin and malonate), 10 mM malonate and gramicidin were added simultaneously with 100 microM NADH to measure the residual activity. Curve 2, presents the reverse electron transfer activity and curve 3, de-activated SMP were preincubated with rotenone as described for curve 1(o) (for further details see Grivennikova et al., 1997). Panel (C): The same as Panel B, curve 3, except for enzyme concentration was 0.5 mg/ml and rotenone concentration range which was increased to show interaction of the inhibitor with de-activated enzyme. The activity was measured after 200-fold dilution into the assay mixture. All the continues lines corresponds to the theoretical titration curves for the reversible single site inhibition with Ki values of 1 nM, 20 nM and 80 nM for the curves 1, 2 and 3, respectively (for further details see Grivennikova et al., 1997).   2. MPTP affinity to complex I binding sites. MPTP is not directly binding to CI and it is therefore non-toxic to DA neurons. MPTP exerts its toxicity after it is metabolized by mono-amino-oxidase, type B (MAO B), in astrocytes to 1-methyl-4-phenylpyridinium (MPP+). This metabolite binds to CI, and is toxic. MPP+ is a good substrate for dopamine transporters (DAT), expressed selectively by DA neurons (Greenamyre et al (2001). Due to both a positive charge and an amphoteric character, MPP+ specifically accumulates in mitochondria, where despite a lower affinity to the binding site of complex I than rotenone, it reaches high enough intra-mitochondrial concentrations to inhibit CI activity (Ramsay et al., 1991). The binding affinity of MPP+ is low (mM range), and it can be totally reversed by washing out.&nbsp; Competitive binding experiments with rotenone and MPP+ suggest that the two compounds bind to the same site of the CI (Ramasay et al., 1991). Schuler and Casida (2001) reported that MPP+ inhibits PSST and elevates ND1 labelling subunits of the mitochondrial complex I.  3. General characteristics of other complex I inhibitors. There is a variety of CI inhibitors, both naturally occurring besides rotenone such as Piericidin A (from Streptomyces mobaraensis), acetogenins (from various Annonaceae species) as well as their derivatives, and synthetically manufactured compounds like pyridaben and various piperazin derivatives (Ichimaru et al. 2008). They have been used to probe the catalytic activity of complex I especially in order to clarify its ubiquinone binding site and indeed, most of these compounds inhibit the electron transfer step from the Fe-S clusters to ubiquinone (Friedrich et al. 1994). Therefore, classification of CI inhibitors is based on their types of action. Type A inhibitors, like piericidin A, 2-decyl-4-quinazolinyl amine (DQA), annonin VI and rolliniastatin-1 and -2, are considered to be antagonists of the ubiquinone substrate. For piericidin A, it has been shown that it inhibits NADH:Q2 activity in a partially competitive manner. Contrary to type A, type B inhibitors, like the commonly used rotenone, have hydrogen-bonding acceptors only in the cyclic head of the molecule and are non-competitive towards UQ (ubiquinone), but are believed to displace the semiquinone intermediate during the catalysis (Fig. 2). Finally, inhibitors classified as type C, like stigmatellin and capsaicin, form a third group of hydrophobic CI inhibitors that are believed to act as antagonists of reduced ubiquinone (Degli Esposti 1998, Friedrich et al. 1994, Haefeli 2012) (Fig. 2). Competition studies with representatives of all three different types of inhibitors revealed that type A and B and type B and C, but not type A and C, compete with each other for binding. This led to a suggestion that all CI inhibitors acting at the ubiquinone binding pocket share a common binding domain with partially overlapping sites (Okun et al. 1999).  Some inhibitors bind to the outside of the ubiquinone reduction site and do not fit the preceding classification. Examples of such compounds are ADP-ribose, which competes for substrate binding at the NADH site (Zharova and Vinogradov, 1997), and diphenyleneiodonium (DPI) that covalently binds to reduced flavin mononucleotide (FMN) in the hydrophilic part of the enzyme blocking the electron transfer to the Fe-S clusters (Majander et al., 1994). There are also new, commercially available insecticides/acaricides with potential to inhibit mitochondrial respiration such as benzimidazole, bullatacin, 6-chlorobenzothiadiazole, cyhalothrin, Fenazaquin Fenpyroximate, Hoe 110779, Pyridaben, Pyrimidifen, Sandoz 547A, Tebufenpyrad and Thiangazole (Greenamyre et al., 2001). It is clear that they are capable of inhibiting the mammalian CI of mitochondrial respiratory chain, by binding to and blocking ubiquinone-dependent NADH oxidation with high efficacy (Lummen, 1998)."@en ;
  foaf:page <https://identifiers.org/aop/276> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/277> a sbd:Model ;
  rdfs:label "Impaired IL-1R1 signaling leading to Impaired T-Cell Dependent Antibody Response"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Dex inhibits IL-1&beta; gene expression in LPS-stimulated RAW 264.7 cells by blocking NF-&kappa;B/Rel and AP-1 activation (Jeon et al., 2000).  Dex suppresses LPS-induced gene expression of IL-1&beta; in rat lung. (in vivo) (Qiu et al., 1997)  Dex inhibits the release of IL-1&beta; by human leukocyte stimulated with Streptococcus pneumoniae stimulation (van Furth et al., 1995).  Treatment of peripheral blood monocytes with 2 mg/ml LPS potently increased IL-1&beta; release (p= 0.001) and Dex (10 -7 M) significantly reduced both resting and stimulated IL-1&beta; release (p 0.009).) (Morand, Rickard and Goulding, 1993)  Dex effectively blocks the glutamine antagonist acivicin-induced expression of IL-1&beta; mRNA by HL-60 leukemia cells (Weinberg, Mason and Wortham, 1992).  &nbsp;  LPS treatment induced a significant upregulation of the mRNA and release of IL-1&beta; from retinal microglia. Minocycline inhibited its releases. Thus, minocycline might exert its anti-inflammatory effect on microglia by inhibiting the expression and release of IL-1&beta; (Wang et al., 2005).  &nbsp;  Caspase-1 inhibition reduced the release of IL-1&beta; in organotypic slices exposed to LPS+ATP. Administration of pralnacasan (intracerebroventricular, 50 &mu;g) or belnacasan (intraperitoneal, 25&ndash;200 mg/kg) to rats blocked seizure-induced production of IL-1&beta; in the hippocampus, and resulted in a twofold delay in seizure onset and 50% reduction in seizure duration (Ravizza et al., 2006).  Belnacasan, an orally active IL-1&beta; converting enzyme/caspase-1 inhibitor, blocked IL-1&beta; secretion with equal potency in LPS-stimulated cells from familial cold urticarial associated syndrome and control subjects (Stack et al., 2005).  &nbsp;  In LPS-induced acute lung injury (ALI) mice model, LPS induced inflammatory cytokines such as TNF-&alpha;, IL-6, IL-13 and IL-1&beta; were significantly decreased by cinnamaldehyde (CA) (Huang and Wang, 2017).  The suppressing capacities of six cinnamaldehyde-related compounds were evaluated and compared by using the LPS-primed and ATP-activated macrophages. At concentrations of 25~100 M, cinnamaldehyde and 2-methoxy cinnamaldehyde dose-dependently inhibited IL-1&beta; secretion (Ho, Chang and Chang, 2018).  In vitro, CA decreased the levels of pro-IL-1&beta; and IL-1&beta; in cell culture supernatants, as well as the expression of NLRP3 and IL-1&beta; mRNA in cells. In vivo, CA decreased IL-1&beta; production in serum. Furthermore, CA suppressed LPS-induced NLRP3, p20, Pro-IL-1&beta;, P2X7 receptor (P2X7R) and cathepsin B protein expression in lung, as well as the expression of NLRP3 and IL-1&beta; mRNA (Xu et al., 2017).  &nbsp;  IL-1 is known to mediates autoinflammatory syndrome, such as cryopyrin-associated periodic syndrome, neonatal-onset multisystem inflammatory disease and familial Mediterranean fever. Blocking of binding of IL-1 to IL-1R1 by anakinra, canakinumab, and rilonacept have been already used to treat these autoinflammatory syndrome associated with overactivation of IL-1 signaling (Quartier, 2011).   &nbsp;  Various inhibitors for NF‐&kappa;B, such as dimethyl fumarate, curcumin, iguratimod, epigalocathechin gallate (EGCG), and DHMEQ inhibits LPS-induced NF-&kappa;B activation and LPS-induced secretion of IL-1b (McGuire et al., 2016; Mucke, 2012; Peng et al., 2012; Suzuki and Umezawa, 2006; Wang et al., 2020; Wang et al., 2018; Wheeler et al., 2004).  &nbsp;  &nbsp;  Several chemicals that targe some of these molecules, an inhibitors of TLR4 such as TAK-242 (Matsunaga et al., 2011) and various IRAK4 inhibitors (Lee et al., 2017). IRAK4 has recently attracted attention as a therapeutic target for inflammation and tumor diseases.  IL-1Ra binds IL-1R but does not initiate IL-1 signal transduction (Dripps et al., 1991). Recombinant IL-1Ra (anakinra) is fully active in blocking the IL-1R1, and therefore, the biological activities of IL-1&alpha; and IL-1&beta;. The binding of IL-1&alpha; and IL-1&beta; to IL-1R1 can be suppressed by soluble IL-1R like rilonacept (Kapur and Bonk, 2009). The binding of IL-1&beta; to IL-1R1 can be inhibited by anti-IL-1&beta; antibody (canakinumab and gevokizumab) (Church and McDermott, 2009) (Roell et al., 2010).  &nbsp;  Various IRAK4 inhibitors are currently under the investigation on the possibility of clinical use for autoimmune disorders (Chaudhary, Robinson and Romero, 2015).  &nbsp;  &nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/277> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/277> a sbd:Model ;
  rdfs:label "Impaired IL-1R1 signaling leading to Impaired T-Cell Dependent Antibody Response"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The ICH S8 guideline, which covers immunosuppression of small molecule drugs, determines the need for immunotoxicity studies by comprehensively evaluating the findings of pharmacology, changes in the immune system in repeated-dose toxicity studies, and other factors using a Weight of Evidence approach. If there is concern about immunotoxicity, the presence or absence of immunotoxicity should be determined using an in vivo test system capable of assessing the functional changes of predicted immunotoxic target cells. If immunotoxicity is observed, additional studies including in vitro assays or clinical evaluation should be considered to assess the risk of immunotoxicity in humans. Because TDAR involves many immune cell populations, including T cells, B cells, and antigen-presenting cells, evaluation of TDAR is recommended when there is concern about immunotoxicity but the immunotoxic target cells are unclear. The S8 guidelines list KLH, SRBC, and tetanus toxin as antigens for TDAR.  &nbsp;  The draft FDA immunotoxicity testing guidance (2020) covers immunosuppressive and immunostimulatory drugs and biologics; evaluating immunosuppressive drugs in the draft FDA guidance is similar to that in the S8 guideline, with in vivo TDAR assays recommended when toxic target cells are unknown. The draft guidance states that TDAR assays using KLH as an antigen have been established in mice, rats, dogs, minipigs, and cynomolgus monkeys, but the use of SRBC and tetanus toxin as antigens is also acceptable.  &nbsp;  For the assessment for pesticides, US EPA OPPTS 870.7800 immunotoxicity testing guideline recommends TDAR using SRBC. The REACH guideline does not provide for immunotoxicity testing, but it provides triggers for conducting immunotoxicity testing.  &nbsp;  The WHO/IPSS Immunotoxicity Risk assessment Guidance (2012) describes a strategy for assessing five categories of immunotoxicity risks, including immunosuppression. For risk assessment of immunosuppression, it calls for identification of immunosuppression risks, prediction of pathogenesis that may occur, and consideration of safety margins based on the WoE approach from human findings, infection resistance tests, immune function tests, general immune system assays, histopathological findings and organ weights in general toxicity studies, and hematological data.  &nbsp;  The evaluation of immunotoxicity in F1 animals in the OECD Guidelines for Extended First Generation Reproductive and Developmental Toxicity Studies (TG443) requires that PFC and ELSA assays to measure primary IgM antibody production by TDAR using T-cell dependent antigens (SRBC, KLH, etc.) be performed. Furthermore, if changes are observed, the significance of the changes should be examined by comprehensively evaluating other data.  &nbsp;  The outcomes of immunosuppression are susceptibility to infection and tumorigenesis, and the FDA guidance requires that immunosuppressive drugs be evaluated for carcinogenic risk using WoE approach based on the results of carcinogenicity and immunotoxicity studies. Meanwhile, the ICH S1B(R1) Draft Step 2 Guidelines for Carcinogenicity Testing calls for evaluation of carcinogenicity by WoE approach instead of rat carcinogenicity testing, because rodent carcinogenicity test models are less capable of detecting carcinogenicity. On the other hand, it is difficult to define susceptibility to infection as a measurable AO with a clear mechanism, because immune responses vary among pathogens. In fact, many immunotoxicity guidelines require that the risk of immunotoxicity be identified and assessed by evaluating immune functions.  &nbsp;  In AOP277, it was difficult to define susceptibility to infection as an AO for the AOP154, so TDAR, which is recommended as an indicator of immunosuppresoin in many guidelines, was used as an AO. It is expected that several AOPs with TDARs as AOs will be developed, and based on these AOPs, it may be possible to develop an IATA to assess the risk of immunotoxicity characterized by TDARs."@en ;
  foaf:page <https://identifiers.org/aop/277> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/277> a sbd:Model ;
  rdfs:label "Impaired IL-1R1 signaling leading to Impaired T-Cell Dependent Antibody Response"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The pleiotropic cytokine IL-1 mediates its biological functions via association with the signaling receptor IL-1R1. These may include initiation of innate immunity and assistance of host defense, and sometimes, mediation of autoinflammatory, such as cryopyrin-associated periodic syndrome, neonatal-onset multisystem inflammatory disease and familial Mediterranean fever. The trimeric complex consists of IL-1, IL-1R1 and IL-1R3 (a coreceptor, formerly IL-1R accessory protein) allows for the approximation of the Toll-IL-1-Receptor (TIR) domains of each receptor chain. MyD88 then binds to the TIR domains. The binding of MyD88 triggers a cascade of kinases that produce a strong pro-inflammatory signal leading to activation of NF-&kappa;B and/or AP-1 and fundamental inflammatory responses such as the induction of cyclooxygenase type 2, production of multiple cytokines and chemokines, increased expression of adhesion molecules, or synthesis of nitric oxide. (Dinarello, 2018; Weber et al., 2010a, b; Jain et al., 2014).&nbsp;   &nbsp;  Molecules like nuclear or mitochondrial DNA, adenosine triphosphate (ATP), uridine triphosphate (UTP), uric acid and high mobility group box 1 (HMGB1) are classified as damage associated molecular patterns (DAMPs). DAMPs are secreted or produced upon cellular injury or death and induce sterile inflammation. On the other hand, bacterial products like lipopolysaccharide (LPS), peptidoglycans, lipoprotein flagellins, bacterial RNA and DNA are some of the well-characterized pathogen associated molecular patterns (PAMPs). These DAMPs and PAMPs with a few exceptions bind to pattern recognition receptors (PRRs) such as toll-like receptor (TLRs) and nucleotide oligomerization domain (NOD) like receptors (NLRs). Proinflammatory mediators such as DAMPs, PAMPs, and various inflammatory cytokines or mediators including IL-1&beta; itself activate innate immune mechanisms in the host leading to IL-1&beta; production (Handa et al., 2016; Newton and Dixit, 2012; Yang et al., 2017). Besides transcriptional regulation and posttranscriptional level by RNA-binding proteins, pro-IL-1&beta; protein requires proteolytic cleavage by active caspase-1 as the effector component of stimulation-induced multi-protein inflammasomes to acquire functional activity. Altogether, these different layers of regulation allow to fine tune IL-1&beta; production under different pathophysiological conditions (Bent et al., 2018).  &nbsp;  Therefore, the inhibition of various targets in different layers from the stimulation of PRRs or the receptors of proinflammatory cytokines, e.g., IL-1, IL-18, or TNFa, to the activation of NF-&kappa;B and/or AP-1 or the inhibition of posttranscriptional regulation of pro-IL-1&beta; cause impaired IL-1R1 signaling. In addition, since IL-1 also mediates autoinflammatory syndromes, such as cryopyrin-associated periodic syndrome, neonatal-onset multisystem inflammatory disease and familial Mediterranean fever, several inhibitors against IL-1R1 have been developed. They are IL-1 receptor antagonist（IL-1Ra）, anakinumab (anti-IL-1&beta; antibody) and rilonacept (soluble IL-1R). Several reports described that the administration of these drugs led to increased susceptibility to infection(De Benedetti et al., 2018; Fleischmann et al., 2003; Genovese et al., 2004; Imagawa et al., 2013; Kullenberg et al., 2016; Lachmann et al., 2009; Lequerre et al., 2008; Migkos et al., 2015; Schlesinger et al., 2012; Yokota et al., 2017). In addition to these human data, the experiments using knockout mice revealed that the lack of IL-1 signaling led to bacterial, tuberculosis or viral infection(Guler et al., 2011; Horino et al., 2009; Juffermans et al., 2000; Tian et al., 2017; Yamada et al., 2000)."@en ;
  foaf:page <https://identifiers.org/aop/277> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/28> a sbd:Model ;
  rdfs:label "Cyclooxygenase inhibition leading reproductive failure"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Non-steroidal anti-inflammatory drugs have been specifically designed to inhibit cyclooxygenase active site of PTGS; these mechanisms of inhibition are well characterized (Simmons et al, 2004). NSAIDs interfere with COX site via multiple mechanisms including competitive inhibition (most NSAIDs compete for active site with arachidonic acid) and covalent modification (irreversible acetylation) of COX (e.g., aspirin) (Simmons et al., 2004; Willoughby et al., 2011). NSAIDs display different levels of selectivity for the COX-1 vs. COX-2 isoforms (Simmons et al., 2004). Majority of NSAIDs inhibit both isoforms (with variable levels of selectivity for COX-1 vs. COX-2), but several have been designed to preferentially inhibit COX-2 (Bacchi et al., 2012). Recently, COX-1 specific inhibitors have been developed and their therapeutic potential is being explored (Liedtke et al., 2012). Most extensive evidence regarding chemical initiation of this event comes from the mammalian literature and relates to NSAIDs. In addition to NSAIDs, common environmental contaminants of diverse chemical structures and uses (e.g., parabens, phthalates, benzophenones) have been postulated to inhibit prostaglandin synthesis via COX inhibition (Kristensen et al., 2011). U.S. EPA’s high throughput screening program (ACToR, epa.gov) indicated COX as a frequent contaminant target - 61% of 143 tested chemicals inhibited COX-1 and 59% of 106 inhibited COX-2 activity. Several chemicals were either similar in potency (e.g., monobutylphthalate) or more potent than NSAIDs (e.g., insecticide emamectin benzoate and industrial intermediary 1-Chloro-4-nitrobenzene were more potent inhibitors of COX2 than NSAID celecoxib, which was specifically designed to inhibit COX-2). Mechanisms of inhibition for these chemicals are not well elucidated."@en ;
  foaf:page <https://identifiers.org/aop/28> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/281> a sbd:Model ;
  rdfs:label "Acetylcholinesterase Inhibition Leading to Neurodegeneration"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Organophosphate and carbamate insecticides are prototypical AChE inhibitors. The OP and carbamate pesticides were synthesized specifically to act as inhibitors of AChE, with OPs developed from early nerve agents (e.g., sarin) and carbamate pesticides based on the natural plant alkaloid physostigmine (Ecobichon 2001). 	A positive and significant correlation between the log of the Eserine IC50 (in vitro) for AChE inhibition and the log Km value for the AChE in the fish and crustacea species has been reported, explaining 92% of the variation in enzyme inhibition (Monserrat and Bianchini, 2001). Similar success was found in relating the rate constants for inhibition of AChE in housefly and the pseudo first-order hydrolysis rate constant for active forms of OPs (Fukuto 1990).    	The open literature includes many studies on vertebrate and invertebrate species that demonstrate a clear dependence of AChE activity on the dose or concentration of the substance with increased concentrations leading to an increase in the inhibition of AChE (e.g., fish ( Karen et al., 2001), birds (Hudson et al., 1984 (see dimethoate and disulfoton), Grue and Shipley 1984; and Al-Zubaidy et al., 2011); cladocera (Barata et al., 2004); nematodes (Rajini et al., 2008); rodents (Roberts et al., 1988; and mollusk (Bianco et al., 2011)). 	The open literature includes many studies on vertebrate and invertebrate species that demonstrate a clear relationship between increasing AChE inhibition as duration of exposure increases (e.g., amphibians ( Venturino et al., 2001); fish (Rao 2008; Ferrari et al., 2004); insects (Rose and Sparks 1984); birds (Ludke 1985; Grue and Shipley 1984); annelids (Reddy and Rao 2008); cladocera (Barata et al., 2004)). 	Rao et al. 2008 exposed the estuarine fish Oreochromis mossambicus to a 24 h LC50 concentration of chlorpyrifos and reported that it took 6 hr to reach &gt;40% AChE inhibition and 24 hr to reach 90% AChE inhibition. It took &gt;100 days to recover to normal AChE levels when fish were placed in clean water. 	A time course study of earthworms (Eisenis foetida) exposed to the 48 hr LC50 of profenofos found a significant relationship (between increases in percent inhibition of AChE and increase in time of exposure from 8-48 hrs (Chakra Reddy and Rao 2008)."@en ;
  foaf:page <https://identifiers.org/aop/281> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/281> a sbd:Model ;
  rdfs:label "Acetylcholinesterase Inhibition Leading to Neurodegeneration"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Currently the four available OECD Test Guidelines (TGs) for neurotoxicity testing are entirely based on in vivo neurotoxicity studies: (1)Delayed Neurotoxicity of Organophosphorus Substances Following Acute Exposure (TG 418); (2) Delayed Neurotoxicity of Organophosphorus Substances: 28-day Repeated Dose Study (TG 419); (3) Neurotoxicity Study in Rodents (TG 424) involves daily oral dosing of rats for acute, subchronic, or chronic assessments (28 days, 90 days, or one year or longer); (4) Developmental Neurotoxicity (DNT) Study (TG 426) evaluates in utero and early postnatal effects by daily dosing of at least 60 pregnant rats from implantation through lactation. One of the endpoints required by all four of these OECD TGs is evaluation of neurodegeneration that, so far, is performed through in vivo neuropathological and histological studies. Therefore, neurodegeneration described in this AOP as a key event, has a regulatory relevance and could be performed using in vitro assays that allow a reliable evaluation of neurodegeneration using a large range of existing assays, specific for apoptosis, necrosis and autophagy ( see also KE Cell injury/Cell death)."@en ;
  foaf:page <https://identifiers.org/aop/281> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/282> a sbd:Model ;
  rdfs:label "Adverse outcome pathway on photochemical toxicity initiated by light exposure"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Several classes of chemicals cause ROS generation under light exposure, and the ROS generation can be monitored by ROS assay (Onoue et al., 2014, Onoue et al., 2013, Onoue et al. , 2008, Seto et al. , 2013).&nbsp; The criteria of ROS assay&nbsp;for photosafety assessment of chemicals were defined  ADDIN EN.CITE  ADDIN EN.CITE.DATA   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 (Onoue et al., 2014, Onoue et al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en ;
  foaf:page <https://identifiers.org/aop/282> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/282> a sbd:Model ;
  rdfs:label "Adverse outcome pathway on photochemical toxicity initiated by light exposure"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Inflammatory events in light-exposed tissues are considered to be the endpoint of ROS-mediated chemical phototoxicity, especially photoirritant reactions (ICH, 2014, Onoue et al., 2009).&nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/282> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/282> a sbd:Model ;
  rdfs:label "Adverse outcome pathway on photochemical toxicity initiated by light exposure"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The primary event in any photosensitization process can be the absorption of photons of the appropriate wavelength, which allows chromophore to reach an excited state.&nbsp; The excitation energy is often transferred to oxygen molecules, followed by generation of ROS. &nbsp;These appear to be the principal intermediate species in the phototoxic response.&nbsp; In cells, this cascade gives rise to local oxidative stress and damage to genomic DNA, proteins, and lipids within cell membranes.&nbsp; From the standpoint of risk assessment, ROS generation from photoirradiated chemicals has been considered to be one of key determinants in recognizing their phototoxic potential.&nbsp; The ROS assay has been designed to assess photoreactivity of pharmaceuticals, of which the principle is to monitor types I and II photochemical reactions of the test chemicals when exposed to simulated sunlight.&nbsp; This simple analytical test could be used to screen potential chemical scaffolds, leads, and candidate drugs to identify and/or select away from those having phototoxic potential.&nbsp; The validation study for the ROS assay has been carried out by the Japan Pharmaceutical Manufacturers Association (JPMA), supervised by the Japanese Center for the Validation of Alternative Methods (JaCVAM).&nbsp; The validation study indicates satisfactory outcomes in terms of transferability, intra- and inter-laboratory variability, and predictive capacity.&nbsp; Thus, a negative result in this ROS assay would indicate a very low probability of phototoxicity, whereas a positive result would be a flag for follow-up assessment.&nbsp; ROS assay was successfully adopted as ICH S10 guideline (2014) and OECD test guideline 495 (2019)."@en ;
  foaf:page <https://identifiers.org/aop/282> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/284> a sbd:Model ;
  rdfs:label "Binding of electrophilic chemicals to SH(thiol)-group of proteins and /or to seleno-proteins involved in protection against oxidative stress leads to chronic kidney disease"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Mercury (Methylmercury, mercury chloride)  The binding of Methylmercury (MeHg) to redox sensitive thiol- or selenol-groups can disrupt the activity of enzymes or the biochemical role of non-enzymatic proteins. The stable or transitory interaction (binding) of MeHg with critical thiol and selenol groups in target enzymes can disrupt the biological function of different types of enzymes, particularly of the antioxidant selenoenzymes thioredoxin reductase (TrxR) and glutathione peroxidase isoforms. The dysregulation of cerebral glutathione (GSH and GSSG) and thioredoxin [Trx or Trx(SH)2] &nbsp;systems by MeHg (Farina et al. 2011; Branco et al. 2017) can impair the fine cellular redox balance via disruption of sensitive cysteinyl- or thiol-containing proteins (Go etal., 2013; Go et al. 2014; Jones 2015).   &nbsp;    Figure 1 &ndash; Hypothetical Binding of MeHg to different types of target proteins. The binding of MeHg to proteins can cause either a transitory inhibition of the protein fucntion (first line, the yellow protein was reactivated by interacting with LMM-SH or R-SH). The pink protein is an example of protein that after the binding of MeHg suffered a change in the structure in such a way that it cannot be reactivated by LMM-SH or R-SH.&nbsp; The third protein (blue) is an example of protein that was permanently denaturated after MeHg binding and even after the removal of MeHg the activity was not recovered. The same type of interactions can be applied to the selenol-containing proteins (i.e., the selenoproteins).  The affinity of Mercury chloride (Hg2+) for thiol and selenol groups is higher than that of MeHg (compare Table 2 with Table 1). The constants described in Table 1 and 2 indicate that MeHg and Hg2+ behave as&nbsp; strong soft electrophiles, i.e., theyhave much higher affinity for the soft nucleophiles centers of thiol- and selenol-containing molecules (Rabenstein 1978a; Arnold et al. 1986; Sugiura et al., 1976).Furthermore, the rate constant for the reaction of MeHg with thiol/thiolate (R-SH/R-S-) has been estimated to be about 6 x 108 M-1.sec-1,&nbsp; indicating that the reactions of electrophilic forms of Hg (EpHg+&nbsp;; here MeHg and Hg2+) with thiolate and selenolate groups are diffusion controlled reactions (Rabenstein&nbsp; and Fairhurst, 1975). The constant indicates that the binding of EpHg+ to thiolate (-S-) or selenolate (-Se-) groups will occurr almost instaneously, when an EpHg+ collides with &ndash;S- or -Se- groups.  The studies of Rabenstein and others have also pointed out that the affinity of MeHg for &ndash;SeH groups is higher than for&nbsp; &ndash;SH groups (Sugira et al. 1976; Arnold et al. 1986). Consequently, &ndash;SeH-containing molecules (i.e., selenoproteins) should be the preferential targets for MeHg (Farina et al. 2011). Accordingly, several studies have demonstrate that the selenoenzymes glutathione peroxidase (GPx) and thioredoxin reductase (TrxR) were inhibited after in vitro and in vivo exposure to MeHg&nbsp; or Hg2+ (Carvalho et al., 2008a; 2011, Farina et al.,&nbsp; 2009; Franco et al., 2009; Wagner et al., 2010; Branco et al., 2011; 2012; 2014, 2017; Dalla Corte et al., 2013; Meinerz et al., 2017).  As corollary, the occurrence of free MeHg and Hg2+ or bound to other ligands such as carboxylates, amines, chloride or hydroxyl anions in the physiological media of living cells is insignificant or nonexistent (George et al. 2008). The binding of MeHg to abundant low molecular mass thiols or LMM-SH (e.g., cysteine and reduced glutathione-GSH) and high molecular mass thiol-containing proteins or HMM-SH (e.g., albumin, hemoglobin, etc) is critical for the MeHg distribution from non-target to target organs and cells (Farina et al. 2017). The coordination of MeHg with one &ndash;S- group of a LMM-SH will determine MeHg distribution to its targets organs, including the brain. The coordination of Hg2+ with two &ndash;S- of LMM-SH molecules (particularly, cysteine or Cys) will determine the distribution of Hg2+ to kidney (which is its main target) and to non-classical targets organs, such as the brain (Oliveira et al. 2017). The entrance of Hg2+ into the brain is proportionally small, but recent literature data have indicated the neurotoxicity of very low and environmentally relevant doses of Hg2+ in rodents (Mello-Carpes et al. 2013&nbsp;), which confirms data obtained with toxic doses in rodents (Peixoto et al. 2007&nbsp;;&nbsp; Franciscato et al. 2009&nbsp;; Chehimi et al. 2012).  Table 1 - Affinity constants of methylmercury for important chemical groups found in biomolecules (adapted from aRabestein, 1978a, bRabestein and Bravo, 1987, using different thiol-containing molecules with the arylmercurialpara-mercurybenzenosulfonate,&nbsp; and from cArnold et al. 1986 taking into consideration that the calculated formation constant of &ndash;Se-MeHg conjugates was 0.1 to 1.2 order greater than that of &ndash;S-MeHg). The values represent the Log of the constants.   	 		 			 			Functional Group 			 			 			Occurrence 			 			 			Formation constant 			 		 		 			 			Thiol/thiolate (-SH/-S-) 			 			 			Cysteine, glutathione, proteins 			 			 			&asymp;14-18 a,b 			 		 		 			 			Selenol/selenolate (-SeH/Se-) 			 			 			Selenocysteinyl residues in selenoproteins 			 			 			&asymp; 16-18c 			 		 	   Table 2. Formation constants of Hg2+ with some representative nucleophilic centers from biomolecules.   	 		 			Functional group 			Hg2+ 		 		 			R-S-R 			&asymp; 6-12 		 		 			R-SH 			&asymp; 40-50 		 		 			R-SeH 			&asymp; 50-60 		 	   The approximate (&asymp;) Log of the constants. The values were adapted &nbsp;from Stricks and Kolthoff 1953; Mousavi 2011 and Liem-Nguyem et al. 2017.  We have to emphasize that what we call of binding to &ndash;SH or &ndash;SeH groups is, in fact, an exchange reaction of MeHg from MeHg-S conjugates (e.g., MeHg-cysteine or MeHg-Cys and MeHg-glutathione or MeHg-SG. conjugates) to&nbsp; a free thiol/thiolate- or selenol/selenolate-group from non-target or target proteins. Thus, the interaction of MeHg with its target proteins in the brain usually involves the exchange of MeHg from low-molecular mass conjugates (LMM-S-conjugates) to a thiol or selenol group in different types of proteins (Rabenstein 1978b; Rabenstein and Fairhurst, 1975; Reid and Rabenstein et al.; 1982; Rabenstein and Reid, 1984; Arnold et al. 1986; Farina et al. 2011, 2017; D&oacute;rea et al. 2013).     Figure 2 &ndash; Binding of MeHg (CH3Hg+) to target thiol- (HMM-SH) or selenol-containing proteins (HMM-SeH). Note that, in fact, the binding of MeHg to their high molecular mass target proteins is mediated by exchange reactions of MeHg from low molecular mass thiol (LMM-SH) molecules to HMM-SH (represented by Prot-SH) or HMM-SeH (represented by Prot-SeH). The scheme also demonstrated that MeHg conjugated with one LMM-SH (here represented by either Cys1-SHgCH3 or G1SHgCH3) can exchange with others LMM-SH (here represented by Cys2-SH or G2SH). After one exchange reaction, the conjugated Cys1-SHgCH3 and G1SHgCH3 release the free LMM-SH molecules Cys1-SH or G1SH.  &nbsp;  Table 3: References for the inhibition by MeHg and Hg2+ of SH-/seleno-proteins involved in protection against oxidative stress   	 		 			 			Protein activity inhibited by MeHg 			 			 			Exposure 			 			 			Functional group likely involved in the inhibition 			 			 			Organism-preparation 			 			 			&nbsp; 			 		 		 			 			Glutathione peroxidase (total GPx) 			 			 			in vivo 			 			 			-SeH 			 			 			Adult mice 			 			 			Glasser et al. 2013 			 		 		 			 			Total GPx 			 			 			in vivo 			 			 			-SeH 			 			 			Adult mice 			 			 			Glasser et al. 2010a 			 		 		 			 			Mitochondrial total GPx 			 			 			in vivo 			 			 			-SeH 			 			 			Adult mice 			 			 			Franco et al. 2009 			 		 		 			 			Total GPx 			 			 			in vitro 			 			 			-SeH 			 			 			SH-SY5Y cells 			 			 			Franco et al. 2009 			 		 		 			 			GPx1 and GPx4 			 			 			in vivo 			 			 			-SeH 			 			 			Adult mice 			 			 			Zemolin et al. 2012 			 		 		 			 			Total GPx 			 			 			in vivo 			 			 			-SeH 			 			 			Adult male mice 			 			 			Malagutti et al. 2009 			 		 		 			 			Total GPx 			 			 			in vitro 			 			 			-SeH 			 			 			PC12 cells 			 			 			Li et al. 2008 			 		 		 			 			Total GPx 			 			 			in vivo 			 			 			-SeH 			 			 			Mice gestational exposure 			 			 			Stringari et al. 2008 			 		 		 			 			Total GPx 			 			 			in vivo 			 			 			-SeH 			 			 			Adult rats 			 			 			Cheng et al. 2005 			 		 		 			 			Total GPx 			 			 			in vitro 			 			 			-SeH 			 			 			Fetal Telencepalic cells from rats 			 			 			Sorg et al. 1998 			 		 		 			 			Total GPx 			 			 			in vitro 			 			 			-SeH 			 			 			Mice neuroblastoma cells 			 			 			Kromidas et al. 1990 			 		 		 			 			Thioredoxin Reductase (TrxR) 			 			 			in vivo 			 			 			-SeH&nbsp; and &ndash;SH 			 			 			Adult mice 			 			 			Zemolin et al. 2012 			 		 		 			 			TrxR 			 			 			in vitro 			 			 			-SeH&nbsp; and &ndash;SH 			 			 			Adult mice 			 			 			Wagner et al. 2010 			 		 		 			 			TrxR 			 			 			in vivo 			 			 			-SeH-&nbsp; and &ndash;SH 			 			 			Adult rats 			 			 			Dalla Corte et al. 2013 			 		 		 			 			Mitochondrial total Gpx 			 			 			In vivo 			 			 			-SeH 			 			 			Adult rat 			 			 			Mori et al., 2007 			 		 		 			 			Mitochondrial total Gpx 			 			 			In vivo 			 			 			-SeH 			 			 			Adult Swiss male mice brain 			 			 			Franco et al., 2009 			 		 		 			&nbsp; 			&nbsp; 			&nbsp; 			&nbsp; 			&nbsp; 		 		 			 			Total brain TrxR 			 			 			In vivo 			 			 			-SeH and -SH 			 			 			Juvenile fish (zebra-seabreams) 			 			 			Branco et al. 2011  			Branco et al. 2012a,b 			 		 		 			&nbsp; 			&nbsp; 			&nbsp; 			&nbsp; 			&nbsp; 		 		 			 			Protein activity inhibited by Hg2+ 			 			 			&nbsp;  			exposure 			 			 			Functional group likely involved in the inhibition 			 			 			&nbsp;  			organism-preparation 			 			 			&nbsp; 			 		 		 			 			Total brain TrxR 			 			 			In vivo 			 			 			-SeH and -SH 			 			 			Juvenile fish (zebra-seabreams) 			 			 			Branco et al. 2012a,b 			 		 	   &nbsp;  Acrylamide   Acrylamide is an a,&beta;-unsaturated (conjugated) reactive molecule, which can react with thiol (-SH) and amino (-NH2) groups in proteins&nbsp; (LoPachin, 2004; LoPachin et al. 2007; 2009; 2011;&nbsp; Friedman, 2003; Bent et al. 2016; Martyniuk et al.2011; LoPachin and Gavin, 2014 ). However, the rate constant for the reaction between acrylamide with thiol/thiolate groups is much lower than that for MeHg.&nbsp; The rate of reaction of this compound with HMM-SH and LMM-SH is slow but can occur under physiological conditions (Tong et al. 2004; LoPachin, 2004). The inhibition of brain enzymes by acrylamide have been studied and the inhibition caused by acrylamide in some HMM-SH can be reversible&nbsp; (Howland et al. 1980). Despite of this, we can infer that some targets of MeHg and acrylamide can overlap, in particular GSH,where the rate constant for MeHg and acrylamide are &asymp;6.0 x 108 M-1.sec-1 and &asymp;0.15-2.1 x 10-2 M-1.sec-1, respectively (Yousef and Demerdash, 2006; Lapadula et al. 1989; Kopańska et al. 2015). Acrylamide can also be metabolized to an epoxide intermediate (glycidamide), which can also form adducts with cysteinyl residues in HMM-SH target proteins (Bergmark et al. 1991).  &nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/284> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/286> a sbd:Model ;
  rdfs:label "Mitochondrial complex III antagonism leading to growth inhibition (1)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Growth is a regulatory relevant chronic toxicity endpoint for almost all organisms. Multiple OECD test guidelines have included growth either as a main endpoint of concern, or as an additional endpoint to be considered in the toxicity assessments. Relevant test guidelines include, but not only limited to:  &nbsp;  -Test No. 201: Freshwater Alga and Cyanobacteria, Growth Inhibition Test  -Test No. 208: Terrestrial Plant Test: Seedling Emergence and Seedling Growth Test  -Test No. 211: Daphnia magna Reproduction Test  -Test No. 212: Fish, Short-term Toxicity Test on Embryo and Sac-Fry Stages  -Test No. 215: Fish, Juvenile Growth Test  -Test No. 221: Lemna sp. Growth Inhibition Test  -Test No. 228: Determination of Developmental Toxicity to Dipteran Dung Flies (Scathophaga stercoraria L. (Scathophagidae), Musca autumnalis De Geer (Muscidae))  -Test No. 241: The Larval Amphibian Growth and Development Assay (LAGDA)  -Test No. 407: Repeated Dose 28-day Oral Toxicity Study in Rodents  -Test No. 408: Repeated Dose 90-Day Oral Toxicity Study in Rodents  -Test No. 416: Two-Generation Reproduction Toxicity  -Test No. 422: Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test  -Test No. 443: Extended One-Generation Reproductive Toxicity Study  -Test No. 453: Combined Chronic Toxicity/Carcinogenicity Studies"@en ;
  foaf:page <https://identifiers.org/aop/286> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/287> a sbd:Model ;
  rdfs:label "Mitochondrial complex III antagonism leading to growth inhibition (2)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Growth is a regulatory relevant chronic toxicity endpoint for almost all organisms. Multiple OECD test guidelines have included growth either as a main endpoint of concern, or as an additional endpoint to be considered in the toxicity assessments. Relevant test guidelines include, but not only limited to:  &nbsp;  -Test No. 201: Freshwater Alga and Cyanobacteria, Growth Inhibition Test  -Test No. 208: Terrestrial Plant Test: Seedling Emergence and Seedling Growth Test  -Test No. 211: Daphnia magna Reproduction Test  -Test No. 212: Fish, Short-term Toxicity Test on Embryo and Sac-Fry Stages  -Test No. 215: Fish, Juvenile Growth Test  -Test No. 221: Lemna sp. Growth Inhibition Test  -Test No. 228: Determination of Developmental Toxicity to Dipteran Dung Flies (Scathophaga stercoraria L. (Scathophagidae), Musca autumnalis De Geer (Muscidae))  -Test No. 241: The Larval Amphibian Growth and Development Assay (LAGDA)  -Test No. 407: Repeated Dose 28-day Oral Toxicity Study in Rodents  -Test No. 408: Repeated Dose 90-Day Oral Toxicity Study in Rodents  -Test No. 416: Two-Generation Reproduction Toxicity  -Test No. 422: Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test  -Test No. 443: Extended One-Generation Reproductive Toxicity Study  -Test No. 453: Combined Chronic Toxicity/Carcinogenicity Studies"@en ;
  foaf:page <https://identifiers.org/aop/287> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/288> a sbd:Model ;
  rdfs:label "Inhibition of 17α-hydrolase/C 10,20-lyase (Cyp17A1) activity leads to birth reproductive defects (cryptorchidism) in male (mammals)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Abiraterone acetate used in androgen deprivation therapy4&nbsp;, antifungals from the conazoles family5&nbsp;(Ketonazole, Fadrozole, Imidazole, Prochloraz6&hellip;) etc."@en ;
  foaf:page <https://identifiers.org/aop/288> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/289> a sbd:Model ;
  rdfs:label "Inhibition of 5α-reductase leading to impaired fecundity in female fish"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/289> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/289> a sbd:Model ;
  rdfs:label "Inhibition of 5α-reductase leading to impaired fecundity in female fish"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The possible KE is the inhibition of 5&alpha;-reductase affects the level of the other endogenous substrate steroids such as androstenedione, progesterone, cortisol, and aldosterone. The physiological responses of the reduction of these steroids and the inhibition of 5&alpha;-reductase are not fully understood (Azzouni et al. 2012).&nbsp;  Acknowledgements:&nbsp;This research was supported by the National Research Council of Science &amp; Technology(NST) grant by the Korea&nbsp;government (MSIP) (No. CAP-17-01-KIST Europe)"@en ;
  foaf:page <https://identifiers.org/aop/289> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/29> a sbd:Model ;
  rdfs:label "Estrogen receptor agonism leading to reproductive dysfunction"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/29> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/29> a sbd:Model ;
  rdfs:label "Estrogen receptor agonism leading to reproductive dysfunction"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/29> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/29> a sbd:Model ;
  rdfs:label "Estrogen receptor agonism leading to reproductive dysfunction"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/29> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/29> a sbd:Model ;
  rdfs:label "Estrogen receptor agonism leading to reproductive dysfunction"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/29> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/290> a sbd:Model ;
  rdfs:label "Mitochondrial ATP synthase antagonism leading to growth inhibition (1)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Growth is a regulatory relevant chronic toxicity endpoint for almost all organisms. Multiple OECD test guidelines have included growth either as a main endpoint of concern, or as an additional endpoint to be considered in the toxicity assessments. Relevant test guidelines include, but not only limited to:  &nbsp;  -Test No. 201: Freshwater Alga and Cyanobacteria, Growth Inhibition Test  -Test No. 208: Terrestrial Plant Test: Seedling Emergence and Seedling Growth Test  -Test No. 211: Daphnia magna Reproduction Test  -Test No. 212: Fish, Short-term Toxicity Test on Embryo and Sac-Fry Stages  -Test No. 215: Fish, Juvenile Growth Test  -Test No. 221: Lemna sp. Growth Inhibition Test  -Test No. 228: Determination of Developmental Toxicity to Dipteran Dung Flies (Scathophaga stercoraria L. (Scathophagidae), Musca autumnalis De Geer (Muscidae))  -Test No. 241: The Larval Amphibian Growth and Development Assay (LAGDA)  -Test No. 407: Repeated Dose 28-day Oral Toxicity Study in Rodents  -Test No. 408: Repeated Dose 90-Day Oral Toxicity Study in Rodents  -Test No. 416: Two-Generation Reproduction Toxicity  -Test No. 422: Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test  -Test No. 443: Extended One-Generation Reproductive Toxicity Study  -Test No. 453: Combined Chronic Toxicity/Carcinogenicity Studies"@en ;
  foaf:page <https://identifiers.org/aop/290> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/291> a sbd:Model ;
  rdfs:label "Mitochondrial ATP synthase antagonism leading to growth inhibition (2)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Growth is a regulatory relevant chronic toxicity endpoint for almost all organisms. Multiple OECD test guidelines have included growth either as a main endpoint of concern, or as an additional endpoint to be considered in the toxicity assessments. Relevant test guidelines include, but not only limited to:  &nbsp;  -Test No. 201: Freshwater Alga and Cyanobacteria, Growth Inhibition Test  -Test No. 208: Terrestrial Plant Test: Seedling Emergence and Seedling Growth Test  -Test No. 211: Daphnia magna Reproduction Test  -Test No. 212: Fish, Short-term Toxicity Test on Embryo and Sac-Fry Stages  -Test No. 215: Fish, Juvenile Growth Test  -Test No. 221: Lemna sp. Growth Inhibition Test  -Test No. 228: Determination of Developmental Toxicity to Dipteran Dung Flies (Scathophaga stercoraria L. (Scathophagidae), Musca autumnalis De Geer (Muscidae))  -Test No. 241: The Larval Amphibian Growth and Development Assay (LAGDA)  -Test No. 407: Repeated Dose 28-day Oral Toxicity Study in Rodents  -Test No. 408: Repeated Dose 90-Day Oral Toxicity Study in Rodents  -Test No. 416: Two-Generation Reproduction Toxicity  -Test No. 422: Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test  -Test No. 443: Extended One-Generation Reproductive Toxicity Study  -Test No. 453: Combined Chronic Toxicity/Carcinogenicity Studies"@en ;
  foaf:page <https://identifiers.org/aop/291> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/292> a sbd:Model ;
  rdfs:label "Inhibition of tyrosinase leads to decreased population in fish"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/292> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/292> a sbd:Model ;
  rdfs:label "Inhibition of tyrosinase leads to decreased population in fish"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The present AOP shows a tyrosinase (TYR) inhibition-mediated adverse outcome (AO) in fishes.&nbsp; TYR is the rate-limiting enzyme controlling the induction of melanogenesis in diverse colored patterns in aquatic organisms. The significant reactions of TYR can be&nbsp;considered that the tyrosinase inhibitor-induced depigmentation reduces the trajectory of fishes.&nbsp;  			Acknowledgements:&nbsp;This research was supported by the National Research Council of Science &amp; Technology(NST) grant by the Korea&nbsp;government (MSIP) (No. CAP-17-01-KIST Europe) 			 		 	   &nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/292> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/293> a sbd:Model ;
  rdfs:label "Increased DNA damage leading to increased risk of breast cancer"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Stressors include:  Ionizing radiation  Estrogen"@en ;
  foaf:page <https://identifiers.org/aop/293> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/293> a sbd:Model ;
  rdfs:label "Increased DNA damage leading to increased risk of breast cancer"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Because of the long latency of mammary tumors, the two-year rodent carcinogenicity bioassay is the primary assay for this adverse outcome. The assay is included in the OECD Test No. 451 and 453 for carcinogenicity and combined toxicity and carcinogenicity (OECD 2009; OECD 2009), and is also used by the US National Toxicology program (Chhabra, Huff et al. 1990), and the FDA (FDA (Food and Drug Administration) 2007), and referenced by the EPA (EPA (Environmental Protection Agency) 2005) in guidelines for risk assessments. Other assays from short term (2-4 weeks) and subchronic (90 day) to chronic (1 year) toxicity also call for the documentation of mammary tumors (FDA (Food and Drug Administration) 2007; OECD (Organisation for Economic Cooperation and Development) 2018), so these assays could capture the early onset of tumors, and could be modified to report earlier key events like proliferation and inflammation.  Several characteristics of classic cancer bioassays limit the sensitivity of these assays to mammary gland carcinogens. First, no assays require prenatal or early post-natal exposures for carcinogenicity testing. The US NIH&rsquo;s National Toxicology Program assays start exposures at five to six weeks of age and OECD regulatory assay exposures suggest (but do not require) exposures beginning after weaning and before eight weeks of age. Assays initiating exposures at later ages have diminished sensitivity to agents that affect breast development and increase future susceptibility to cancer, such as estrogenic hormones, DDT and dioxins (EPA (Environmental Protection Agency) 2005; Rudel, Fenton et al. 2011). Agents with similar activity to ionizing radiation and DNA damaging chemicals may not be fully captured in some of these assays, since sensitivity appears to peak around or before week seven for these agents (around puberty) (Imaoka, Nishimura et al. 2013). Second, carcinogenicity assay guidelines do not require the best methods for detecting tumors in mammary gland: whole mount preparations of mammary gland coupled with longitudinal sections (dorsoventral sections parallel to the body) of mammary gland for histology (Tucker, Foley et al. 2017). Palpation and transverse sections of mammary gland can easily miss tumors or lesions of interest. Interestingly the NTP reproductive toxicity guidelines do specify these preferable methods for mammary gland analysis.  Two additional factors affect the sensitivity of standard carcinogenicity assays. First, benign tumors are not always considered to be an indicator of carcinogenicity, leading to a possible underestimation of risk. &nbsp;NTP and EPA guidance suggest that benign tumors provide additional weight of evidence if malignant tumors are also present or if studies suggest benign tumors can progress to carcinogenicity. In a short-term study, benign tumors may indicate a need for a longer-term study. However, benign mammary tumors (fibroadenomas) almost always coincide with carcinogenic tumors in mammary gland or other organs, and carcinomas sometimes grow from fibroadnomas (Rudel, Attfield et al. 2007; Russo 2015) suggesting that benign tumors may be an underutilized indicator of carcinogenicity.  Finally, the dose selection guidance in carcinogenicity testing typically calls for a high dose that is sufficiently toxic to suppress body weight (OECD 2009). However, body weight interacts with risk of breast cancer (Haseman, Young et al. 1997; Rudel, Attfield et al. 2007), reducing the sensitivity of the upper end of the dose range and the likelihood of a positive dose-response."@en ;
  foaf:page <https://identifiers.org/aop/293> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/293> a sbd:Model ;
  rdfs:label "Increased DNA damage leading to increased risk of breast cancer"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Breast cancer imposes a significant burden on women worldwide and is an important target for prevention. It is the most common invasive cancer in women with the highest rates found in North America and Europe (Ervik, Lam et al. 2016), and incidence is increasing globally (Forouzanfar, Foreman et al. 2011). In the US, the National Cancer Institute estimates that the total number of new breast cancers will increase from 283,000 to 441,000 between 2011 and 2030 (Rosenberg, Barker et al. 2015). Twin studies suggest that heritable factors explain at most a third of breast cancers and around 60% of all cancers are related to avoidable factors (Ronckers, Erdmann et al. 2005; Colditz and Wei 2012; Moller, Mucci et al. 2016), leaving significant room for prevention efforts focused on environmental factors to reduce new cases. Well-documented risk factors include tobacco and alcohol use as well as obesity, physical activity, and exposure to carcinogens (Colditz and Wei 2012).  &nbsp;  Breast cancer incidence and risk varies with age, and hormonal and reproductive factors. Incidence increases with age, with rates among women increasing rapidly after age 30 and peaking around 75 years of age (NCI SEER 2016). Incidence is strongly influenced by the reproductive hormones estrogen and progesterone and by childbirth, which influence the proliferation and number of cells in the breast (Gertig, Stillman et al. 1999; Ronckers, Erdmann et al. 2005; Bijwaard, Brenner et al. 2010; Dall, Risbridger et al. 2017). Breast cancer risk increases with earlier puberty or later menopause (CGHFBC 2012; Bodicoat, Schoemaker et al. 2014), factors that increase cumulative estrogen and progesterone exposure and the number of proliferative menstrual cycles in the breast. Conversely, risk decreases in women with ovariectomies (Olson, Sellers et al. 2004; Press, Sullivan-Halley et al. 2011) and with menopause (CGHFBC 2012). Risk also decreases with number of pregnancies, breastfeeding, and increasing time since childbirth. This decrease in risk is thought to be related to the differentiation of stem cells in the breast during pregnancy and lactation and the decline in epithelial cell number after childbirth (Gertig, Stillman et al. 1999; Dall, Risbridger et al. 2017). Breast cancer incidence in men is less than 1% that of women, a difference attributed to low levels of estrogen and progesterone and few breast epithelial cells (Stang and Thomssen 2008).  &nbsp;  Bijwaard, H., A. Brenner, et al. (2010). &quot;Breast cancer risk from different mammography screening practices.&quot; Radiation research 174(3): 367-376.  Bodicoat, D. H., M. J. Schoemaker, et al. (2014). &quot;Timing of pubertal stages and breast cancer risk: the Breakthrough Generations Study.&quot; Breast cancer research : BCR 16(1): R18.  CGHFBC (Collaborative Group on Hormonal Factors in Breast Cancer) (2012). &quot;Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies.&quot; The Lancet. Oncology 13(11): 1141-1151.  Colditz, G. A. and E. K. Wei (2012). &quot;Preventability of cancer: the relative contributions of biologic and social and physical environmental determinants of cancer mortality.&quot; Annu Rev Public Health 33: 137-156.  Dall, G., G. Risbridger, et al. (2017). &quot;Mammary stem cells and parity-induced breast cancer protection- new insights.&quot; The Journal of steroid biochemistry and molecular biology 170: 54-60.  Ervik, M., F. Lam, et al. (2016). &quot;Cancer Today.&quot;&nbsp;&nbsp; Retrieved 03/23/2018, 2018, from http://gco.iarc.fr/today.  Forouzanfar, M. H., K. J. Foreman, et al. (2011). &quot;Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis.&quot; The Lancet 378(9801): 1461-1484.  Gertig, D. M., I. E. Stillman, et al. (1999). &quot;Association of age and reproductive factors with benign breast tissue composition.&quot; Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 8(10): 873-879.  Moller, S., L. A. Mucci, et al. (2016). &quot;The Heritability of Breast Cancer among Women in the Nordic Twin Study of Cancer.&quot; Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 25(1): 145-150.  NCI SEER (National Cancer Institute Surveillance, E., and End Results Program), (2016). Cancer of the Breast (Invasive): SEER Incidence and U.S. Death Rates, Age-Adjusted and Age-Specific Rates, by Race and Sex. SEER Cancer Statistics Review (1975-2014), National Cancer Institute: Table 4-11.  Olson, J. E., T. A. Sellers, et al. (2004). &quot;Bilateral oophorectomy and breast cancer risk reduction among women with a family history.&quot; Cancer detection and prevention 28(5): 357-360.  Press, D. J., J. Sullivan-Halley, et al. (2011). &quot;Breast cancer risk and ovariectomy, hysterectomy, and tubal sterilization in the women&#39;s contraceptive and reproductive experiences study.&quot; American journal of epidemiology 173(1): 38-47.  Ronckers, C. M., C. A. Erdmann, et al. (2005). &quot;Radiation and breast cancer: a review of current evidence.&quot; Breast cancer research : BCR 7(1): 21-32.  Rosenberg, P. S., K. A. Barker, et al. (2015). &quot;Estrogen Receptor Status and the Future Burden of Invasive and In Situ Breast Cancers in the United States.&quot; Journal of the National Cancer Institute 107(9).  Stang, A. and C. Thomssen (2008). &quot;Decline in breast cancer incidence in the United States: what about male breast cancer?&quot; Breast cancer research and treatment 112(3): 595-596"@en ;
  foaf:page <https://identifiers.org/aop/293> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/293> a sbd:Model ;
  rdfs:label "Increased DNA damage leading to increased risk of breast cancer"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Stressors include:  Ionizing radiation  Estrogen"@en ;
  foaf:page <https://identifiers.org/aop/293> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/293> a sbd:Model ;
  rdfs:label "Increased DNA damage leading to increased risk of breast cancer"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Because of the long latency of mammary tumors, the two-year rodent carcinogenicity bioassay is the primary assay for this adverse outcome. The assay is included in the OECD Test No. 451 and 453 for carcinogenicity and combined toxicity and carcinogenicity (OECD 2009; OECD 2009), and is also used by the US National Toxicology program (Chhabra, Huff et al. 1990), and the FDA (FDA (Food and Drug Administration) 2007), and referenced by the EPA (EPA (Environmental Protection Agency) 2005) in guidelines for risk assessments. Other assays from short term (2-4 weeks) and subchronic (90 day) to chronic (1 year) toxicity also call for the documentation of mammary tumors (FDA (Food and Drug Administration) 2007; OECD (Organisation for Economic Cooperation and Development) 2018), so these assays could capture the early onset of tumors, and could be modified to report earlier key events like proliferation and inflammation.  Several characteristics of classic cancer bioassays limit the sensitivity of these assays to mammary gland carcinogens. First, no assays require prenatal or early post-natal exposures for carcinogenicity testing. The US NIH&rsquo;s National Toxicology Program assays start exposures at five to six weeks of age and OECD regulatory assay exposures suggest (but do not require) exposures beginning after weaning and before eight weeks of age. Assays initiating exposures at later ages have diminished sensitivity to agents that affect breast development and increase future susceptibility to cancer, such as estrogenic hormones, DDT and dioxins (EPA (Environmental Protection Agency) 2005; Rudel, Fenton et al. 2011). Agents with similar activity to ionizing radiation and DNA damaging chemicals may not be fully captured in some of these assays, since sensitivity appears to peak around or before week seven for these agents (around puberty) (Imaoka, Nishimura et al. 2013). Second, carcinogenicity assay guidelines do not require the best methods for detecting tumors in mammary gland: whole mount preparations of mammary gland coupled with longitudinal sections (dorsoventral sections parallel to the body) of mammary gland for histology (Tucker, Foley et al. 2017). Palpation and transverse sections of mammary gland can easily miss tumors or lesions of interest. Interestingly the NTP reproductive toxicity guidelines do specify these preferable methods for mammary gland analysis.  Two additional factors affect the sensitivity of standard carcinogenicity assays. First, benign tumors are not always considered to be an indicator of carcinogenicity, leading to a possible underestimation of risk. &nbsp;NTP and EPA guidance suggest that benign tumors provide additional weight of evidence if malignant tumors are also present or if studies suggest benign tumors can progress to carcinogenicity. In a short-term study, benign tumors may indicate a need for a longer-term study. However, benign mammary tumors (fibroadenomas) almost always coincide with carcinogenic tumors in mammary gland or other organs, and carcinomas sometimes grow from fibroadnomas (Rudel, Attfield et al. 2007; Russo 2015) suggesting that benign tumors may be an underutilized indicator of carcinogenicity.  Finally, the dose selection guidance in carcinogenicity testing typically calls for a high dose that is sufficiently toxic to suppress body weight (OECD 2009). However, body weight interacts with risk of breast cancer (Haseman, Young et al. 1997; Rudel, Attfield et al. 2007), reducing the sensitivity of the upper end of the dose range and the likelihood of a positive dose-response."@en ;
  foaf:page <https://identifiers.org/aop/293> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/293> a sbd:Model ;
  rdfs:label "Increased DNA damage leading to increased risk of breast cancer"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Breast cancer imposes a significant burden on women worldwide and is an important target for prevention. It is the most common invasive cancer in women with the highest rates found in North America and Europe (Ervik, Lam et al. 2016), and incidence is increasing globally (Forouzanfar, Foreman et al. 2011). In the US, the National Cancer Institute estimates that the total number of new breast cancers will increase from 283,000 to 441,000 between 2011 and 2030 (Rosenberg, Barker et al. 2015). Twin studies suggest that heritable factors explain at most a third of breast cancers and around 60% of all cancers are related to avoidable factors (Ronckers, Erdmann et al. 2005; Colditz and Wei 2012; Moller, Mucci et al. 2016), leaving significant room for prevention efforts focused on environmental factors to reduce new cases. Well-documented risk factors include tobacco and alcohol use as well as obesity, physical activity, and exposure to carcinogens (Colditz and Wei 2012).  &nbsp;  Breast cancer incidence and risk varies with age, and hormonal and reproductive factors. Incidence increases with age, with rates among women increasing rapidly after age 30 and peaking around 75 years of age (NCI SEER 2016). Incidence is strongly influenced by the reproductive hormones estrogen and progesterone and by childbirth, which influence the proliferation and number of cells in the breast (Gertig, Stillman et al. 1999; Ronckers, Erdmann et al. 2005; Bijwaard, Brenner et al. 2010; Dall, Risbridger et al. 2017). Breast cancer risk increases with earlier puberty or later menopause (CGHFBC 2012; Bodicoat, Schoemaker et al. 2014), factors that increase cumulative estrogen and progesterone exposure and the number of proliferative menstrual cycles in the breast. Conversely, risk decreases in women with ovariectomies (Olson, Sellers et al. 2004; Press, Sullivan-Halley et al. 2011) and with menopause (CGHFBC 2012). Risk also decreases with number of pregnancies, breastfeeding, and increasing time since childbirth. This decrease in risk is thought to be related to the differentiation of stem cells in the breast during pregnancy and lactation and the decline in epithelial cell number after childbirth (Gertig, Stillman et al. 1999; Dall, Risbridger et al. 2017). Breast cancer incidence in men is less than 1% that of women, a difference attributed to low levels of estrogen and progesterone and few breast epithelial cells (Stang and Thomssen 2008).  &nbsp;  Bijwaard, H., A. Brenner, et al. (2010). &quot;Breast cancer risk from different mammography screening practices.&quot; Radiation research 174(3): 367-376.  Bodicoat, D. H., M. J. Schoemaker, et al. (2014). &quot;Timing of pubertal stages and breast cancer risk: the Breakthrough Generations Study.&quot; Breast cancer research : BCR 16(1): R18.  CGHFBC (Collaborative Group on Hormonal Factors in Breast Cancer) (2012). &quot;Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies.&quot; The Lancet. Oncology 13(11): 1141-1151.  Colditz, G. A. and E. K. Wei (2012). &quot;Preventability of cancer: the relative contributions of biologic and social and physical environmental determinants of cancer mortality.&quot; Annu Rev Public Health 33: 137-156.  Dall, G., G. Risbridger, et al. (2017). &quot;Mammary stem cells and parity-induced breast cancer protection- new insights.&quot; The Journal of steroid biochemistry and molecular biology 170: 54-60.  Ervik, M., F. Lam, et al. (2016). &quot;Cancer Today.&quot;&nbsp;&nbsp; Retrieved 03/23/2018, 2018, from http://gco.iarc.fr/today.  Forouzanfar, M. H., K. J. Foreman, et al. (2011). &quot;Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis.&quot; The Lancet 378(9801): 1461-1484.  Gertig, D. M., I. E. Stillman, et al. (1999). &quot;Association of age and reproductive factors with benign breast tissue composition.&quot; Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 8(10): 873-879.  Moller, S., L. A. Mucci, et al. (2016). &quot;The Heritability of Breast Cancer among Women in the Nordic Twin Study of Cancer.&quot; Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 25(1): 145-150.  NCI SEER (National Cancer Institute Surveillance, E., and End Results Program), (2016). Cancer of the Breast (Invasive): SEER Incidence and U.S. Death Rates, Age-Adjusted and Age-Specific Rates, by Race and Sex. SEER Cancer Statistics Review (1975-2014), National Cancer Institute: Table 4-11.  Olson, J. E., T. A. Sellers, et al. (2004). &quot;Bilateral oophorectomy and breast cancer risk reduction among women with a family history.&quot; Cancer detection and prevention 28(5): 357-360.  Press, D. J., J. Sullivan-Halley, et al. (2011). &quot;Breast cancer risk and ovariectomy, hysterectomy, and tubal sterilization in the women&#39;s contraceptive and reproductive experiences study.&quot; American journal of epidemiology 173(1): 38-47.  Ronckers, C. M., C. A. Erdmann, et al. (2005). &quot;Radiation and breast cancer: a review of current evidence.&quot; Breast cancer research : BCR 7(1): 21-32.  Rosenberg, P. S., K. A. Barker, et al. (2015). &quot;Estrogen Receptor Status and the Future Burden of Invasive and In Situ Breast Cancers in the United States.&quot; Journal of the National Cancer Institute 107(9).  Stang, A. and C. Thomssen (2008). &quot;Decline in breast cancer incidence in the United States: what about male breast cancer?&quot; Breast cancer research and treatment 112(3): 595-596"@en ;
  foaf:page <https://identifiers.org/aop/293> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/293> a sbd:Model ;
  rdfs:label "Increased DNA damage leading to increased risk of breast cancer"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Stressors include:  Ionizing radiation  Estrogen"@en ;
  foaf:page <https://identifiers.org/aop/293> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/293> a sbd:Model ;
  rdfs:label "Increased DNA damage leading to increased risk of breast cancer"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Because of the long latency of mammary tumors, the two-year rodent carcinogenicity bioassay is the primary assay for this adverse outcome. The assay is included in the OECD Test No. 451 and 453 for carcinogenicity and combined toxicity and carcinogenicity (OECD 2009; OECD 2009), and is also used by the US National Toxicology program (Chhabra, Huff et al. 1990), and the FDA (FDA (Food and Drug Administration) 2007), and referenced by the EPA (EPA (Environmental Protection Agency) 2005) in guidelines for risk assessments. Other assays from short term (2-4 weeks) and subchronic (90 day) to chronic (1 year) toxicity also call for the documentation of mammary tumors (FDA (Food and Drug Administration) 2007; OECD (Organisation for Economic Cooperation and Development) 2018), so these assays could capture the early onset of tumors, and could be modified to report earlier key events like proliferation and inflammation.  Several characteristics of classic cancer bioassays limit the sensitivity of these assays to mammary gland carcinogens. First, no assays require prenatal or early post-natal exposures for carcinogenicity testing. The US NIH&rsquo;s National Toxicology Program assays start exposures at five to six weeks of age and OECD regulatory assay exposures suggest (but do not require) exposures beginning after weaning and before eight weeks of age. Assays initiating exposures at later ages have diminished sensitivity to agents that affect breast development and increase future susceptibility to cancer, such as estrogenic hormones, DDT and dioxins (EPA (Environmental Protection Agency) 2005; Rudel, Fenton et al. 2011). Agents with similar activity to ionizing radiation and DNA damaging chemicals may not be fully captured in some of these assays, since sensitivity appears to peak around or before week seven for these agents (around puberty) (Imaoka, Nishimura et al. 2013). Second, carcinogenicity assay guidelines do not require the best methods for detecting tumors in mammary gland: whole mount preparations of mammary gland coupled with longitudinal sections (dorsoventral sections parallel to the body) of mammary gland for histology (Tucker, Foley et al. 2017). Palpation and transverse sections of mammary gland can easily miss tumors or lesions of interest. Interestingly the NTP reproductive toxicity guidelines do specify these preferable methods for mammary gland analysis.  Two additional factors affect the sensitivity of standard carcinogenicity assays. First, benign tumors are not always considered to be an indicator of carcinogenicity, leading to a possible underestimation of risk. &nbsp;NTP and EPA guidance suggest that benign tumors provide additional weight of evidence if malignant tumors are also present or if studies suggest benign tumors can progress to carcinogenicity. In a short-term study, benign tumors may indicate a need for a longer-term study. However, benign mammary tumors (fibroadenomas) almost always coincide with carcinogenic tumors in mammary gland or other organs, and carcinomas sometimes grow from fibroadnomas (Rudel, Attfield et al. 2007; Russo 2015) suggesting that benign tumors may be an underutilized indicator of carcinogenicity.  Finally, the dose selection guidance in carcinogenicity testing typically calls for a high dose that is sufficiently toxic to suppress body weight (OECD 2009). However, body weight interacts with risk of breast cancer (Haseman, Young et al. 1997; Rudel, Attfield et al. 2007), reducing the sensitivity of the upper end of the dose range and the likelihood of a positive dose-response."@en ;
  foaf:page <https://identifiers.org/aop/293> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/293> a sbd:Model ;
  rdfs:label "Increased DNA damage leading to increased risk of breast cancer"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Breast cancer imposes a significant burden on women worldwide and is an important target for prevention. It is the most common invasive cancer in women with the highest rates found in North America and Europe (Ervik, Lam et al. 2016), and incidence is increasing globally (Forouzanfar, Foreman et al. 2011). In the US, the National Cancer Institute estimates that the total number of new breast cancers will increase from 283,000 to 441,000 between 2011 and 2030 (Rosenberg, Barker et al. 2015). Twin studies suggest that heritable factors explain at most a third of breast cancers and around 60% of all cancers are related to avoidable factors (Ronckers, Erdmann et al. 2005; Colditz and Wei 2012; Moller, Mucci et al. 2016), leaving significant room for prevention efforts focused on environmental factors to reduce new cases. Well-documented risk factors include tobacco and alcohol use as well as obesity, physical activity, and exposure to carcinogens (Colditz and Wei 2012).  &nbsp;  Breast cancer incidence and risk varies with age, and hormonal and reproductive factors. Incidence increases with age, with rates among women increasing rapidly after age 30 and peaking around 75 years of age (NCI SEER 2016). Incidence is strongly influenced by the reproductive hormones estrogen and progesterone and by childbirth, which influence the proliferation and number of cells in the breast (Gertig, Stillman et al. 1999; Ronckers, Erdmann et al. 2005; Bijwaard, Brenner et al. 2010; Dall, Risbridger et al. 2017). Breast cancer risk increases with earlier puberty or later menopause (CGHFBC 2012; Bodicoat, Schoemaker et al. 2014), factors that increase cumulative estrogen and progesterone exposure and the number of proliferative menstrual cycles in the breast. Conversely, risk decreases in women with ovariectomies (Olson, Sellers et al. 2004; Press, Sullivan-Halley et al. 2011) and with menopause (CGHFBC 2012). Risk also decreases with number of pregnancies, breastfeeding, and increasing time since childbirth. This decrease in risk is thought to be related to the differentiation of stem cells in the breast during pregnancy and lactation and the decline in epithelial cell number after childbirth (Gertig, Stillman et al. 1999; Dall, Risbridger et al. 2017). Breast cancer incidence in men is less than 1% that of women, a difference attributed to low levels of estrogen and progesterone and few breast epithelial cells (Stang and Thomssen 2008).  &nbsp;  Bijwaard, H., A. Brenner, et al. (2010). &quot;Breast cancer risk from different mammography screening practices.&quot; Radiation research 174(3): 367-376.  Bodicoat, D. H., M. J. Schoemaker, et al. (2014). &quot;Timing of pubertal stages and breast cancer risk: the Breakthrough Generations Study.&quot; Breast cancer research : BCR 16(1): R18.  CGHFBC (Collaborative Group on Hormonal Factors in Breast Cancer) (2012). &quot;Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies.&quot; The Lancet. Oncology 13(11): 1141-1151.  Colditz, G. A. and E. K. Wei (2012). &quot;Preventability of cancer: the relative contributions of biologic and social and physical environmental determinants of cancer mortality.&quot; Annu Rev Public Health 33: 137-156.  Dall, G., G. Risbridger, et al. (2017). &quot;Mammary stem cells and parity-induced breast cancer protection- new insights.&quot; The Journal of steroid biochemistry and molecular biology 170: 54-60.  Ervik, M., F. Lam, et al. (2016). &quot;Cancer Today.&quot;&nbsp;&nbsp; Retrieved 03/23/2018, 2018, from http://gco.iarc.fr/today.  Forouzanfar, M. H., K. J. Foreman, et al. (2011). &quot;Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis.&quot; The Lancet 378(9801): 1461-1484.  Gertig, D. M., I. E. Stillman, et al. (1999). &quot;Association of age and reproductive factors with benign breast tissue composition.&quot; Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 8(10): 873-879.  Moller, S., L. A. Mucci, et al. (2016). &quot;The Heritability of Breast Cancer among Women in the Nordic Twin Study of Cancer.&quot; Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 25(1): 145-150.  NCI SEER (National Cancer Institute Surveillance, E., and End Results Program), (2016). Cancer of the Breast (Invasive): SEER Incidence and U.S. Death Rates, Age-Adjusted and Age-Specific Rates, by Race and Sex. SEER Cancer Statistics Review (1975-2014), National Cancer Institute: Table 4-11.  Olson, J. E., T. A. Sellers, et al. (2004). &quot;Bilateral oophorectomy and breast cancer risk reduction among women with a family history.&quot; Cancer detection and prevention 28(5): 357-360.  Press, D. J., J. Sullivan-Halley, et al. (2011). &quot;Breast cancer risk and ovariectomy, hysterectomy, and tubal sterilization in the women&#39;s contraceptive and reproductive experiences study.&quot; American journal of epidemiology 173(1): 38-47.  Ronckers, C. M., C. A. Erdmann, et al. (2005). &quot;Radiation and breast cancer: a review of current evidence.&quot; Breast cancer research : BCR 7(1): 21-32.  Rosenberg, P. S., K. A. Barker, et al. (2015). &quot;Estrogen Receptor Status and the Future Burden of Invasive and In Situ Breast Cancers in the United States.&quot; Journal of the National Cancer Institute 107(9).  Stang, A. and C. Thomssen (2008). &quot;Decline in breast cancer incidence in the United States: what about male breast cancer?&quot; Breast cancer research and treatment 112(3): 595-596"@en ;
  foaf:page <https://identifiers.org/aop/293> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/294> a sbd:Model ;
  rdfs:label "Increased reactive oxygen and nitrogen species (RONS) leading to increased risk of breast cancer"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "DNA damage increases the susceptibility to and probability of subsequent mutations, described in the key event &lsquo;Increase in Mutation&rsquo;. Mutations&nbsp;can impair the functional capacity of the cell and are an endpoint of regulator significance&nbsp;in their own right.  Multiple guideline toxicity tests exist for DNA damage. The OECD test guideline for DNA synthesis Test No. 486 (OECD 1997) detects nucleotide excision repair, so it will reflect the formation of bulky DNA adducts but not the majority of oxidative damage to nucleotides, which is typically repaired via the Base Excision Repair pathway. The OECD test guideline alkaline comet assay Test No. 489 (OECD 2016) detects single and double strand breaks, including those arising from repair as well as some (alkali sensitive) nucleotide lesions including some lesions from oxidative damage. OECD tests for chromosomal damage and micronuclei Test No. 473, 475, 483, and 487 measure longer term effects of DNA damage but these tests require the damaged cell to subsequently undergo replication (OECD 2016; OECD 2016; OECD 2016; OECD 2016).&nbsp; They can therefore reflect a wider range of sources of DNA damage including changes in mitosis."@en ;
  foaf:page <https://identifiers.org/aop/294> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/294> a sbd:Model ;
  rdfs:label "Increased reactive oxygen and nitrogen species (RONS) leading to increased risk of breast cancer"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Breast cancer imposes a significant burden on women worldwide and is an important target for prevention. It is the most common invasive cancer in women with the highest rates found in North America and Europe (Ervik, Lam et al. 2016), and incidence is increasing globally (Forouzanfar, Foreman et al. 2011). In the US, the National Cancer Institute estimates that the total number of new breast cancers will increase from 283,000 to 441,000 between 2011 and 2030 (Rosenberg, Barker et al. 2015). Twin studies suggest that heritable factors explain at most a third of breast cancers and around 60% of all cancers are related to avoidable factors (Ronckers, Erdmann et al. 2005; Colditz and Wei 2012; Moller, Mucci et al. 2016), leaving significant room for prevention efforts focused on environmental factors to reduce new cases. Well-documented risk factors include tobacco and alcohol use as well as obesity, physical activity, and exposure to carcinogens (Colditz and Wei 2012).  &nbsp;  Breast cancer incidence and risk varies with age, and hormonal and reproductive factors. Incidence increases with age, with rates among women increasing rapidly after age 30 and peaking around 75 years of age (NCI SEER 2016). Incidence is strongly influenced by the reproductive hormones estrogen and progesterone and by childbirth, which influence the proliferation and number of cells in the breast (Gertig, Stillman et al. 1999; Ronckers, Erdmann et al. 2005; Bijwaard, Brenner et al. 2010; Dall, Risbridger et al. 2017). Breast cancer risk increases with earlier puberty or later menopause (CGHFBC 2012; Bodicoat, Schoemaker et al. 2014), factors that increase cumulative estrogen and progesterone exposure and the number of proliferative menstrual cycles in the breast. Conversely, risk decreases in women with ovariectomies (Olson, Sellers et al. 2004; Press, Sullivan-Halley et al. 2011) and with menopause (CGHFBC 2012). Risk also decreases with number of pregnancies, breastfeeding, and increasing time since childbirth. This decrease in risk is thought to be related to the differentiation of stem cells in the breast during pregnancy and lactation and the decline in epithelial cell number after childbirth (Gertig, Stillman et al. 1999; Dall, Risbridger et al. 2017). Breast cancer incidence in men is less than 1% that of women, a difference attributed to low levels of estrogen and progesterone and few breast epithelial cells (Stang and Thomssen 2008).  &nbsp;  Bijwaard, H., A. Brenner, et al. (2010). &quot;Breast cancer risk from different mammography screening practices.&quot;&nbsp;Radiation research174(3): 367-376.  Bodicoat, D. H., M. J. Schoemaker, et al. (2014). &quot;Timing of pubertal stages and breast cancer risk: the Breakthrough Generations Study.&quot;&nbsp;Breast cancer research : BCR&nbsp;16(1): R18.  CGHFBC (Collaborative Group on Hormonal Factors in Breast Cancer) (2012). &quot;Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies.&quot;&nbsp;The Lancet. Oncology&nbsp;13(11): 1141-1151.  Colditz, G. A. and E. K. Wei (2012). &quot;Preventability of cancer: the relative contributions of biologic and social and physical environmental determinants of cancer mortality.&quot;&nbsp;Annu Rev Public Health&nbsp;33: 137-156.  Dall, G., G. Risbridger, et al. (2017). &quot;Mammary stem cells and parity-induced breast cancer protection- new insights.&quot;&nbsp;The Journal of steroid biochemistry and molecular biology&nbsp;170: 54-60.  Ervik, M., F. Lam, et al. (2016). &quot;Cancer Today.&quot;&nbsp;&nbsp; Retrieved 03/23/2018, 2018, from http://gco.iarc.fr/today.  Forouzanfar, M. H., K. J. Foreman, et al. (2011). &quot;Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis.&quot;&nbsp;The Lancet&nbsp;378(9801): 1461-1484.  Gertig, D. M., I. E. Stillman, et al. (1999). &quot;Association of age and reproductive factors with benign breast tissue composition.&quot;&nbsp;Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology&nbsp;8(10): 873-879.  Moller, S., L. A. Mucci, et al. (2016). &quot;The Heritability of Breast Cancer among Women in the Nordic Twin Study of Cancer.&quot;&nbsp;Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology&nbsp;25(1): 145-150.  NCI SEER (National Cancer Institute Surveillance, E., and End Results Program), (2016). Cancer of the Breast (Invasive): SEER Incidence and U.S. Death Rates, Age-Adjusted and Age-Specific Rates, by Race and Sex.&nbsp;SEER Cancer Statistics Review (1975-2014), National Cancer Institute: Table 4-11.  Olson, J. E., T. A. Sellers, et al. (2004). &quot;Bilateral oophorectomy and breast cancer risk reduction among women with a family history.&quot;&nbsp;Cancer detection and prevention&nbsp;28(5): 357-360.  Press, D. J., J. Sullivan-Halley, et al. (2011). &quot;Breast cancer risk and ovariectomy, hysterectomy, and tubal sterilization in the women&#39;s contraceptive and reproductive experiences study.&quot;&nbsp;American journal of epidemiology&nbsp;173(1): 38-47.  Ronckers, C. M., C. A. Erdmann, et al. (2005). &quot;Radiation and breast cancer: a review of current evidence.&quot;&nbsp;Breast cancer research : BCR&nbsp;7(1): 21-32.  Rosenberg, P. S., K. A. Barker, et al. (2015). &quot;Estrogen Receptor Status and the Future Burden of Invasive and In Situ Breast Cancers in the United States.&quot;&nbsp;Journal of the National Cancer Institute&nbsp;107(9).  Stang, A. and C. Thomssen (2008). &quot;Decline in breast cancer incidence in the United States: what about male breast cancer?&quot;&nbsp;Breast cancer research and treatment&nbsp;112(3): 595-596"@en ;
  foaf:page <https://identifiers.org/aop/294> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/294> a sbd:Model ;
  rdfs:label "Increased reactive oxygen and nitrogen species (RONS) leading to increased risk of breast cancer"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Because of the long latency of mammary tumors, the two-year rodent carcinogenicity bioassay is the primary assay for this adverse outcome. The assay is included in the OECD Test No. 451 and 453 for carcinogenicity and combined toxicity and carcinogenicity (OECD 2009; OECD 2009), and is also used by the US National Toxicology program (Chhabra, Huff et al. 1990), and the FDA (FDA (Food and Drug Administration) 2007), and referenced by the EPA (EPA (Environmental Protection Agency) 2005) in guidelines for risk assessments. Other assays from short term (2-4 weeks) and subchronic (90 day) to chronic (1 year) toxicity also call for the documentation of mammary tumors (FDA (Food and Drug Administration) 2007; OECD (Organisation for Economic Cooperation and Development) 2018), so these assays could capture the early onset of tumors, and could be modified to report earlier key events like proliferation and inflammation.  Several characteristics of classic cancer bioassays limit the sensitivity of these assays to mammary gland carcinogens. First, no assays require prenatal or early post-natal exposures for carcinogenicity testing. The US NIH&rsquo;s National Toxicology Program assays start exposures at five to six weeks of age and OECD regulatory assay exposures suggest (but do not require) exposures beginning after weaning and before eight weeks of age. Assays initiating exposures at later ages have diminished sensitivity to agents that affect breast development and increase future susceptibility to cancer, such as estrogenic hormones, DDT and dioxins (EPA (Environmental Protection Agency) 2005; Rudel, Fenton et al. 2011). Agents with similar activity to ionizing radiation and DNA damaging chemicals may not be fully captured in some of these assays, since sensitivity appears to peak around or before week seven for these agents (around puberty) (Imaoka, Nishimura et al. 2013). Second, carcinogenicity assay guidelines do not require the best methods for detecting tumors in mammary gland: whole mount preparations of mammary gland coupled with longitudinal sections (dorsoventral sections parallel to the body) of mammary gland for histology (Tucker, Foley et al. 2017). Palpation and transverse sections of mammary gland can easily miss tumors or lesions of interest. Interestingly the NTP reproductive toxicity guidelines do specify these preferable methods for mammary gland analysis.  Two additional factors affect the sensitivity of standard carcinogenicity assays. First, benign tumors are not always considered to be an indicator of carcinogenicity, leading to a possible underestimation of risk. &nbsp;NTP and EPA guidance suggest that benign tumors provide additional weight of evidence if malignant tumors are also present or if studies suggest benign tumors can progress to carcinogenicity. In a short-term study, benign tumors may indicate a need for a longer-term study. However, benign mammary tumors (fibroadenomas) almost always coincide with carcinogenic tumors in mammary gland or other organs, and carcinomas sometimes grow from fibroadnomas (Rudel, Attfield et al. 2007; Russo 2015) suggesting that benign tumors may be an underutilized indicator of carcinogenicity.  Finally, the dose selection guidance in carcinogenicity testing typically calls for a high dose that is sufficiently toxic to suppress body weight (OECD 2009). However, body weight interacts with risk of breast cancer (Haseman, Young et al. 1997; Rudel, Attfield et al. 2007), reducing the sensitivity of the upper end of the dose range and the likelihood of a positive dose-response."@en ;
  foaf:page <https://identifiers.org/aop/294> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/294> a sbd:Model ;
  rdfs:label "Increased reactive oxygen and nitrogen species (RONS) leading to increased risk of breast cancer"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The following stressors increase this key event: ionizing radiation."@en ;
  foaf:page <https://identifiers.org/aop/294> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/294> a sbd:Model ;
  rdfs:label "Increased reactive oxygen and nitrogen species (RONS) leading to increased risk of breast cancer"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "DNA damage increases the susceptibility to and probability of subsequent mutations, described in the key event &lsquo;Increase in Mutation&rsquo;. Mutations&nbsp;can impair the functional capacity of the cell and are an endpoint of regulator significance&nbsp;in their own right.  Multiple guideline toxicity tests exist for DNA damage. The OECD test guideline for DNA synthesis Test No. 486 (OECD 1997) detects nucleotide excision repair, so it will reflect the formation of bulky DNA adducts but not the majority of oxidative damage to nucleotides, which is typically repaired via the Base Excision Repair pathway. The OECD test guideline alkaline comet assay Test No. 489 (OECD 2016) detects single and double strand breaks, including those arising from repair as well as some (alkali sensitive) nucleotide lesions including some lesions from oxidative damage. OECD tests for chromosomal damage and micronuclei Test No. 473, 475, 483, and 487 measure longer term effects of DNA damage but these tests require the damaged cell to subsequently undergo replication (OECD 2016; OECD 2016; OECD 2016; OECD 2016).&nbsp; They can therefore reflect a wider range of sources of DNA damage including changes in mitosis."@en ;
  foaf:page <https://identifiers.org/aop/294> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/294> a sbd:Model ;
  rdfs:label "Increased reactive oxygen and nitrogen species (RONS) leading to increased risk of breast cancer"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Breast cancer imposes a significant burden on women worldwide and is an important target for prevention. It is the most common invasive cancer in women with the highest rates found in North America and Europe (Ervik, Lam et al. 2016), and incidence is increasing globally (Forouzanfar, Foreman et al. 2011). In the US, the National Cancer Institute estimates that the total number of new breast cancers will increase from 283,000 to 441,000 between 2011 and 2030 (Rosenberg, Barker et al. 2015). Twin studies suggest that heritable factors explain at most a third of breast cancers and around 60% of all cancers are related to avoidable factors (Ronckers, Erdmann et al. 2005; Colditz and Wei 2012; Moller, Mucci et al. 2016), leaving significant room for prevention efforts focused on environmental factors to reduce new cases. Well-documented risk factors include tobacco and alcohol use as well as obesity, physical activity, and exposure to carcinogens (Colditz and Wei 2012).  &nbsp;  Breast cancer incidence and risk varies with age, and hormonal and reproductive factors. Incidence increases with age, with rates among women increasing rapidly after age 30 and peaking around 75 years of age (NCI SEER 2016). Incidence is strongly influenced by the reproductive hormones estrogen and progesterone and by childbirth, which influence the proliferation and number of cells in the breast (Gertig, Stillman et al. 1999; Ronckers, Erdmann et al. 2005; Bijwaard, Brenner et al. 2010; Dall, Risbridger et al. 2017). Breast cancer risk increases with earlier puberty or later menopause (CGHFBC 2012; Bodicoat, Schoemaker et al. 2014), factors that increase cumulative estrogen and progesterone exposure and the number of proliferative menstrual cycles in the breast. Conversely, risk decreases in women with ovariectomies (Olson, Sellers et al. 2004; Press, Sullivan-Halley et al. 2011) and with menopause (CGHFBC 2012). Risk also decreases with number of pregnancies, breastfeeding, and increasing time since childbirth. This decrease in risk is thought to be related to the differentiation of stem cells in the breast during pregnancy and lactation and the decline in epithelial cell number after childbirth (Gertig, Stillman et al. 1999; Dall, Risbridger et al. 2017). Breast cancer incidence in men is less than 1% that of women, a difference attributed to low levels of estrogen and progesterone and few breast epithelial cells (Stang and Thomssen 2008).  &nbsp;  Bijwaard, H., A. Brenner, et al. (2010). &quot;Breast cancer risk from different mammography screening practices.&quot;&nbsp;Radiation research174(3): 367-376.  Bodicoat, D. H., M. J. Schoemaker, et al. (2014). &quot;Timing of pubertal stages and breast cancer risk: the Breakthrough Generations Study.&quot;&nbsp;Breast cancer research : BCR&nbsp;16(1): R18.  CGHFBC (Collaborative Group on Hormonal Factors in Breast Cancer) (2012). &quot;Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies.&quot;&nbsp;The Lancet. Oncology&nbsp;13(11): 1141-1151.  Colditz, G. A. and E. K. Wei (2012). &quot;Preventability of cancer: the relative contributions of biologic and social and physical environmental determinants of cancer mortality.&quot;&nbsp;Annu Rev Public Health&nbsp;33: 137-156.  Dall, G., G. Risbridger, et al. (2017). &quot;Mammary stem cells and parity-induced breast cancer protection- new insights.&quot;&nbsp;The Journal of steroid biochemistry and molecular biology&nbsp;170: 54-60.  Ervik, M., F. Lam, et al. (2016). &quot;Cancer Today.&quot;&nbsp;&nbsp; Retrieved 03/23/2018, 2018, from http://gco.iarc.fr/today.  Forouzanfar, M. H., K. J. Foreman, et al. (2011). &quot;Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis.&quot;&nbsp;The Lancet&nbsp;378(9801): 1461-1484.  Gertig, D. M., I. E. Stillman, et al. (1999). &quot;Association of age and reproductive factors with benign breast tissue composition.&quot;&nbsp;Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology&nbsp;8(10): 873-879.  Moller, S., L. A. Mucci, et al. (2016). &quot;The Heritability of Breast Cancer among Women in the Nordic Twin Study of Cancer.&quot;&nbsp;Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology&nbsp;25(1): 145-150.  NCI SEER (National Cancer Institute Surveillance, E., and End Results Program), (2016). Cancer of the Breast (Invasive): SEER Incidence and U.S. Death Rates, Age-Adjusted and Age-Specific Rates, by Race and Sex.&nbsp;SEER Cancer Statistics Review (1975-2014), National Cancer Institute: Table 4-11.  Olson, J. E., T. A. Sellers, et al. (2004). &quot;Bilateral oophorectomy and breast cancer risk reduction among women with a family history.&quot;&nbsp;Cancer detection and prevention&nbsp;28(5): 357-360.  Press, D. J., J. Sullivan-Halley, et al. (2011). &quot;Breast cancer risk and ovariectomy, hysterectomy, and tubal sterilization in the women&#39;s contraceptive and reproductive experiences study.&quot;&nbsp;American journal of epidemiology&nbsp;173(1): 38-47.  Ronckers, C. M., C. A. Erdmann, et al. (2005). &quot;Radiation and breast cancer: a review of current evidence.&quot;&nbsp;Breast cancer research : BCR&nbsp;7(1): 21-32.  Rosenberg, P. S., K. A. Barker, et al. (2015). &quot;Estrogen Receptor Status and the Future Burden of Invasive and In Situ Breast Cancers in the United States.&quot;&nbsp;Journal of the National Cancer Institute&nbsp;107(9).  Stang, A. and C. Thomssen (2008). &quot;Decline in breast cancer incidence in the United States: what about male breast cancer?&quot;&nbsp;Breast cancer research and treatment&nbsp;112(3): 595-596"@en ;
  foaf:page <https://identifiers.org/aop/294> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/294> a sbd:Model ;
  rdfs:label "Increased reactive oxygen and nitrogen species (RONS) leading to increased risk of breast cancer"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Because of the long latency of mammary tumors, the two-year rodent carcinogenicity bioassay is the primary assay for this adverse outcome. The assay is included in the OECD Test No. 451 and 453 for carcinogenicity and combined toxicity and carcinogenicity (OECD 2009; OECD 2009), and is also used by the US National Toxicology program (Chhabra, Huff et al. 1990), and the FDA (FDA (Food and Drug Administration) 2007), and referenced by the EPA (EPA (Environmental Protection Agency) 2005) in guidelines for risk assessments. Other assays from short term (2-4 weeks) and subchronic (90 day) to chronic (1 year) toxicity also call for the documentation of mammary tumors (FDA (Food and Drug Administration) 2007; OECD (Organisation for Economic Cooperation and Development) 2018), so these assays could capture the early onset of tumors, and could be modified to report earlier key events like proliferation and inflammation.  Several characteristics of classic cancer bioassays limit the sensitivity of these assays to mammary gland carcinogens. First, no assays require prenatal or early post-natal exposures for carcinogenicity testing. The US NIH&rsquo;s National Toxicology Program assays start exposures at five to six weeks of age and OECD regulatory assay exposures suggest (but do not require) exposures beginning after weaning and before eight weeks of age. Assays initiating exposures at later ages have diminished sensitivity to agents that affect breast development and increase future susceptibility to cancer, such as estrogenic hormones, DDT and dioxins (EPA (Environmental Protection Agency) 2005; Rudel, Fenton et al. 2011). Agents with similar activity to ionizing radiation and DNA damaging chemicals may not be fully captured in some of these assays, since sensitivity appears to peak around or before week seven for these agents (around puberty) (Imaoka, Nishimura et al. 2013). Second, carcinogenicity assay guidelines do not require the best methods for detecting tumors in mammary gland: whole mount preparations of mammary gland coupled with longitudinal sections (dorsoventral sections parallel to the body) of mammary gland for histology (Tucker, Foley et al. 2017). Palpation and transverse sections of mammary gland can easily miss tumors or lesions of interest. Interestingly the NTP reproductive toxicity guidelines do specify these preferable methods for mammary gland analysis.  Two additional factors affect the sensitivity of standard carcinogenicity assays. First, benign tumors are not always considered to be an indicator of carcinogenicity, leading to a possible underestimation of risk. &nbsp;NTP and EPA guidance suggest that benign tumors provide additional weight of evidence if malignant tumors are also present or if studies suggest benign tumors can progress to carcinogenicity. In a short-term study, benign tumors may indicate a need for a longer-term study. However, benign mammary tumors (fibroadenomas) almost always coincide with carcinogenic tumors in mammary gland or other organs, and carcinomas sometimes grow from fibroadnomas (Rudel, Attfield et al. 2007; Russo 2015) suggesting that benign tumors may be an underutilized indicator of carcinogenicity.  Finally, the dose selection guidance in carcinogenicity testing typically calls for a high dose that is sufficiently toxic to suppress body weight (OECD 2009). However, body weight interacts with risk of breast cancer (Haseman, Young et al. 1997; Rudel, Attfield et al. 2007), reducing the sensitivity of the upper end of the dose range and the likelihood of a positive dose-response."@en ;
  foaf:page <https://identifiers.org/aop/294> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/294> a sbd:Model ;
  rdfs:label "Increased reactive oxygen and nitrogen species (RONS) leading to increased risk of breast cancer"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The following stressors increase this key event: ionizing radiation."@en ;
  foaf:page <https://identifiers.org/aop/294> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/294> a sbd:Model ;
  rdfs:label "Increased reactive oxygen and nitrogen species (RONS) leading to increased risk of breast cancer"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "DNA damage increases the susceptibility to and probability of subsequent mutations, described in the key event &lsquo;Increase in Mutation&rsquo;. Mutations&nbsp;can impair the functional capacity of the cell and are an endpoint of regulator significance&nbsp;in their own right.  Multiple guideline toxicity tests exist for DNA damage. The OECD test guideline for DNA synthesis Test No. 486 (OECD 1997) detects nucleotide excision repair, so it will reflect the formation of bulky DNA adducts but not the majority of oxidative damage to nucleotides, which is typically repaired via the Base Excision Repair pathway. The OECD test guideline alkaline comet assay Test No. 489 (OECD 2016) detects single and double strand breaks, including those arising from repair as well as some (alkali sensitive) nucleotide lesions including some lesions from oxidative damage. OECD tests for chromosomal damage and micronuclei Test No. 473, 475, 483, and 487 measure longer term effects of DNA damage but these tests require the damaged cell to subsequently undergo replication (OECD 2016; OECD 2016; OECD 2016; OECD 2016).&nbsp; They can therefore reflect a wider range of sources of DNA damage including changes in mitosis."@en ;
  foaf:page <https://identifiers.org/aop/294> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/294> a sbd:Model ;
  rdfs:label "Increased reactive oxygen and nitrogen species (RONS) leading to increased risk of breast cancer"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Breast cancer imposes a significant burden on women worldwide and is an important target for prevention. It is the most common invasive cancer in women with the highest rates found in North America and Europe (Ervik, Lam et al. 2016), and incidence is increasing globally (Forouzanfar, Foreman et al. 2011). In the US, the National Cancer Institute estimates that the total number of new breast cancers will increase from 283,000 to 441,000 between 2011 and 2030 (Rosenberg, Barker et al. 2015). Twin studies suggest that heritable factors explain at most a third of breast cancers and around 60% of all cancers are related to avoidable factors (Ronckers, Erdmann et al. 2005; Colditz and Wei 2012; Moller, Mucci et al. 2016), leaving significant room for prevention efforts focused on environmental factors to reduce new cases. Well-documented risk factors include tobacco and alcohol use as well as obesity, physical activity, and exposure to carcinogens (Colditz and Wei 2012).  &nbsp;  Breast cancer incidence and risk varies with age, and hormonal and reproductive factors. Incidence increases with age, with rates among women increasing rapidly after age 30 and peaking around 75 years of age (NCI SEER 2016). Incidence is strongly influenced by the reproductive hormones estrogen and progesterone and by childbirth, which influence the proliferation and number of cells in the breast (Gertig, Stillman et al. 1999; Ronckers, Erdmann et al. 2005; Bijwaard, Brenner et al. 2010; Dall, Risbridger et al. 2017). Breast cancer risk increases with earlier puberty or later menopause (CGHFBC 2012; Bodicoat, Schoemaker et al. 2014), factors that increase cumulative estrogen and progesterone exposure and the number of proliferative menstrual cycles in the breast. Conversely, risk decreases in women with ovariectomies (Olson, Sellers et al. 2004; Press, Sullivan-Halley et al. 2011) and with menopause (CGHFBC 2012). Risk also decreases with number of pregnancies, breastfeeding, and increasing time since childbirth. This decrease in risk is thought to be related to the differentiation of stem cells in the breast during pregnancy and lactation and the decline in epithelial cell number after childbirth (Gertig, Stillman et al. 1999; Dall, Risbridger et al. 2017). Breast cancer incidence in men is less than 1% that of women, a difference attributed to low levels of estrogen and progesterone and few breast epithelial cells (Stang and Thomssen 2008).  &nbsp;  Bijwaard, H., A. Brenner, et al. (2010). &quot;Breast cancer risk from different mammography screening practices.&quot;&nbsp;Radiation research174(3): 367-376.  Bodicoat, D. H., M. J. Schoemaker, et al. (2014). &quot;Timing of pubertal stages and breast cancer risk: the Breakthrough Generations Study.&quot;&nbsp;Breast cancer research : BCR&nbsp;16(1): R18.  CGHFBC (Collaborative Group on Hormonal Factors in Breast Cancer) (2012). &quot;Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies.&quot;&nbsp;The Lancet. Oncology&nbsp;13(11): 1141-1151.  Colditz, G. A. and E. K. Wei (2012). &quot;Preventability of cancer: the relative contributions of biologic and social and physical environmental determinants of cancer mortality.&quot;&nbsp;Annu Rev Public Health&nbsp;33: 137-156.  Dall, G., G. Risbridger, et al. (2017). &quot;Mammary stem cells and parity-induced breast cancer protection- new insights.&quot;&nbsp;The Journal of steroid biochemistry and molecular biology&nbsp;170: 54-60.  Ervik, M., F. Lam, et al. (2016). &quot;Cancer Today.&quot;&nbsp;&nbsp; Retrieved 03/23/2018, 2018, from http://gco.iarc.fr/today.  Forouzanfar, M. H., K. J. Foreman, et al. (2011). &quot;Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis.&quot;&nbsp;The Lancet&nbsp;378(9801): 1461-1484.  Gertig, D. M., I. E. Stillman, et al. (1999). &quot;Association of age and reproductive factors with benign breast tissue composition.&quot;&nbsp;Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology&nbsp;8(10): 873-879.  Moller, S., L. A. Mucci, et al. (2016). &quot;The Heritability of Breast Cancer among Women in the Nordic Twin Study of Cancer.&quot;&nbsp;Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology&nbsp;25(1): 145-150.  NCI SEER (National Cancer Institute Surveillance, E., and End Results Program), (2016). Cancer of the Breast (Invasive): SEER Incidence and U.S. Death Rates, Age-Adjusted and Age-Specific Rates, by Race and Sex.&nbsp;SEER Cancer Statistics Review (1975-2014), National Cancer Institute: Table 4-11.  Olson, J. E., T. A. Sellers, et al. (2004). &quot;Bilateral oophorectomy and breast cancer risk reduction among women with a family history.&quot;&nbsp;Cancer detection and prevention&nbsp;28(5): 357-360.  Press, D. J., J. Sullivan-Halley, et al. (2011). &quot;Breast cancer risk and ovariectomy, hysterectomy, and tubal sterilization in the women&#39;s contraceptive and reproductive experiences study.&quot;&nbsp;American journal of epidemiology&nbsp;173(1): 38-47.  Ronckers, C. M., C. A. Erdmann, et al. (2005). &quot;Radiation and breast cancer: a review of current evidence.&quot;&nbsp;Breast cancer research : BCR&nbsp;7(1): 21-32.  Rosenberg, P. S., K. A. Barker, et al. (2015). &quot;Estrogen Receptor Status and the Future Burden of Invasive and In Situ Breast Cancers in the United States.&quot;&nbsp;Journal of the National Cancer Institute&nbsp;107(9).  Stang, A. and C. Thomssen (2008). &quot;Decline in breast cancer incidence in the United States: what about male breast cancer?&quot;&nbsp;Breast cancer research and treatment&nbsp;112(3): 595-596"@en ;
  foaf:page <https://identifiers.org/aop/294> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/294> a sbd:Model ;
  rdfs:label "Increased reactive oxygen and nitrogen species (RONS) leading to increased risk of breast cancer"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Because of the long latency of mammary tumors, the two-year rodent carcinogenicity bioassay is the primary assay for this adverse outcome. The assay is included in the OECD Test No. 451 and 453 for carcinogenicity and combined toxicity and carcinogenicity (OECD 2009; OECD 2009), and is also used by the US National Toxicology program (Chhabra, Huff et al. 1990), and the FDA (FDA (Food and Drug Administration) 2007), and referenced by the EPA (EPA (Environmental Protection Agency) 2005) in guidelines for risk assessments. Other assays from short term (2-4 weeks) and subchronic (90 day) to chronic (1 year) toxicity also call for the documentation of mammary tumors (FDA (Food and Drug Administration) 2007; OECD (Organisation for Economic Cooperation and Development) 2018), so these assays could capture the early onset of tumors, and could be modified to report earlier key events like proliferation and inflammation.  Several characteristics of classic cancer bioassays limit the sensitivity of these assays to mammary gland carcinogens. First, no assays require prenatal or early post-natal exposures for carcinogenicity testing. The US NIH&rsquo;s National Toxicology Program assays start exposures at five to six weeks of age and OECD regulatory assay exposures suggest (but do not require) exposures beginning after weaning and before eight weeks of age. Assays initiating exposures at later ages have diminished sensitivity to agents that affect breast development and increase future susceptibility to cancer, such as estrogenic hormones, DDT and dioxins (EPA (Environmental Protection Agency) 2005; Rudel, Fenton et al. 2011). Agents with similar activity to ionizing radiation and DNA damaging chemicals may not be fully captured in some of these assays, since sensitivity appears to peak around or before week seven for these agents (around puberty) (Imaoka, Nishimura et al. 2013). Second, carcinogenicity assay guidelines do not require the best methods for detecting tumors in mammary gland: whole mount preparations of mammary gland coupled with longitudinal sections (dorsoventral sections parallel to the body) of mammary gland for histology (Tucker, Foley et al. 2017). Palpation and transverse sections of mammary gland can easily miss tumors or lesions of interest. Interestingly the NTP reproductive toxicity guidelines do specify these preferable methods for mammary gland analysis.  Two additional factors affect the sensitivity of standard carcinogenicity assays. First, benign tumors are not always considered to be an indicator of carcinogenicity, leading to a possible underestimation of risk. &nbsp;NTP and EPA guidance suggest that benign tumors provide additional weight of evidence if malignant tumors are also present or if studies suggest benign tumors can progress to carcinogenicity. In a short-term study, benign tumors may indicate a need for a longer-term study. However, benign mammary tumors (fibroadenomas) almost always coincide with carcinogenic tumors in mammary gland or other organs, and carcinomas sometimes grow from fibroadnomas (Rudel, Attfield et al. 2007; Russo 2015) suggesting that benign tumors may be an underutilized indicator of carcinogenicity.  Finally, the dose selection guidance in carcinogenicity testing typically calls for a high dose that is sufficiently toxic to suppress body weight (OECD 2009). However, body weight interacts with risk of breast cancer (Haseman, Young et al. 1997; Rudel, Attfield et al. 2007), reducing the sensitivity of the upper end of the dose range and the likelihood of a positive dose-response."@en ;
  foaf:page <https://identifiers.org/aop/294> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/294> a sbd:Model ;
  rdfs:label "Increased reactive oxygen and nitrogen species (RONS) leading to increased risk of breast cancer"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The following stressors increase this key event: ionizing radiation."@en ;
  foaf:page <https://identifiers.org/aop/294> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/294> a sbd:Model ;
  rdfs:label "Increased reactive oxygen and nitrogen species (RONS) leading to increased risk of breast cancer"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "DNA damage increases the susceptibility to and probability of subsequent mutations, described in the key event &lsquo;Increase in Mutation&rsquo;. Mutations&nbsp;can impair the functional capacity of the cell and are an endpoint of regulator significance&nbsp;in their own right.  Multiple guideline toxicity tests exist for DNA damage. The OECD test guideline for DNA synthesis Test No. 486 (OECD 1997) detects nucleotide excision repair, so it will reflect the formation of bulky DNA adducts but not the majority of oxidative damage to nucleotides, which is typically repaired via the Base Excision Repair pathway. The OECD test guideline alkaline comet assay Test No. 489 (OECD 2016) detects single and double strand breaks, including those arising from repair as well as some (alkali sensitive) nucleotide lesions including some lesions from oxidative damage. OECD tests for chromosomal damage and micronuclei Test No. 473, 475, 483, and 487 measure longer term effects of DNA damage but these tests require the damaged cell to subsequently undergo replication (OECD 2016; OECD 2016; OECD 2016; OECD 2016).&nbsp; They can therefore reflect a wider range of sources of DNA damage including changes in mitosis."@en ;
  foaf:page <https://identifiers.org/aop/294> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/294> a sbd:Model ;
  rdfs:label "Increased reactive oxygen and nitrogen species (RONS) leading to increased risk of breast cancer"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Breast cancer imposes a significant burden on women worldwide and is an important target for prevention. It is the most common invasive cancer in women with the highest rates found in North America and Europe (Ervik, Lam et al. 2016), and incidence is increasing globally (Forouzanfar, Foreman et al. 2011). In the US, the National Cancer Institute estimates that the total number of new breast cancers will increase from 283,000 to 441,000 between 2011 and 2030 (Rosenberg, Barker et al. 2015). Twin studies suggest that heritable factors explain at most a third of breast cancers and around 60% of all cancers are related to avoidable factors (Ronckers, Erdmann et al. 2005; Colditz and Wei 2012; Moller, Mucci et al. 2016), leaving significant room for prevention efforts focused on environmental factors to reduce new cases. Well-documented risk factors include tobacco and alcohol use as well as obesity, physical activity, and exposure to carcinogens (Colditz and Wei 2012).  &nbsp;  Breast cancer incidence and risk varies with age, and hormonal and reproductive factors. Incidence increases with age, with rates among women increasing rapidly after age 30 and peaking around 75 years of age (NCI SEER 2016). Incidence is strongly influenced by the reproductive hormones estrogen and progesterone and by childbirth, which influence the proliferation and number of cells in the breast (Gertig, Stillman et al. 1999; Ronckers, Erdmann et al. 2005; Bijwaard, Brenner et al. 2010; Dall, Risbridger et al. 2017). Breast cancer risk increases with earlier puberty or later menopause (CGHFBC 2012; Bodicoat, Schoemaker et al. 2014), factors that increase cumulative estrogen and progesterone exposure and the number of proliferative menstrual cycles in the breast. Conversely, risk decreases in women with ovariectomies (Olson, Sellers et al. 2004; Press, Sullivan-Halley et al. 2011) and with menopause (CGHFBC 2012). Risk also decreases with number of pregnancies, breastfeeding, and increasing time since childbirth. This decrease in risk is thought to be related to the differentiation of stem cells in the breast during pregnancy and lactation and the decline in epithelial cell number after childbirth (Gertig, Stillman et al. 1999; Dall, Risbridger et al. 2017). Breast cancer incidence in men is less than 1% that of women, a difference attributed to low levels of estrogen and progesterone and few breast epithelial cells (Stang and Thomssen 2008).  &nbsp;  Bijwaard, H., A. Brenner, et al. (2010). &quot;Breast cancer risk from different mammography screening practices.&quot;&nbsp;Radiation research174(3): 367-376.  Bodicoat, D. H., M. J. Schoemaker, et al. (2014). &quot;Timing of pubertal stages and breast cancer risk: the Breakthrough Generations Study.&quot;&nbsp;Breast cancer research : BCR&nbsp;16(1): R18.  CGHFBC (Collaborative Group on Hormonal Factors in Breast Cancer) (2012). &quot;Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies.&quot;&nbsp;The Lancet. Oncology&nbsp;13(11): 1141-1151.  Colditz, G. A. and E. K. Wei (2012). &quot;Preventability of cancer: the relative contributions of biologic and social and physical environmental determinants of cancer mortality.&quot;&nbsp;Annu Rev Public Health&nbsp;33: 137-156.  Dall, G., G. Risbridger, et al. (2017). &quot;Mammary stem cells and parity-induced breast cancer protection- new insights.&quot;&nbsp;The Journal of steroid biochemistry and molecular biology&nbsp;170: 54-60.  Ervik, M., F. Lam, et al. (2016). &quot;Cancer Today.&quot;&nbsp;&nbsp; Retrieved 03/23/2018, 2018, from http://gco.iarc.fr/today.  Forouzanfar, M. H., K. J. Foreman, et al. (2011). &quot;Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis.&quot;&nbsp;The Lancet&nbsp;378(9801): 1461-1484.  Gertig, D. M., I. E. Stillman, et al. (1999). &quot;Association of age and reproductive factors with benign breast tissue composition.&quot;&nbsp;Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology&nbsp;8(10): 873-879.  Moller, S., L. A. Mucci, et al. (2016). &quot;The Heritability of Breast Cancer among Women in the Nordic Twin Study of Cancer.&quot;&nbsp;Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology&nbsp;25(1): 145-150.  NCI SEER (National Cancer Institute Surveillance, E., and End Results Program), (2016). Cancer of the Breast (Invasive): SEER Incidence and U.S. Death Rates, Age-Adjusted and Age-Specific Rates, by Race and Sex.&nbsp;SEER Cancer Statistics Review (1975-2014), National Cancer Institute: Table 4-11.  Olson, J. E., T. A. Sellers, et al. (2004). &quot;Bilateral oophorectomy and breast cancer risk reduction among women with a family history.&quot;&nbsp;Cancer detection and prevention&nbsp;28(5): 357-360.  Press, D. J., J. Sullivan-Halley, et al. (2011). &quot;Breast cancer risk and ovariectomy, hysterectomy, and tubal sterilization in the women&#39;s contraceptive and reproductive experiences study.&quot;&nbsp;American journal of epidemiology&nbsp;173(1): 38-47.  Ronckers, C. M., C. A. Erdmann, et al. (2005). &quot;Radiation and breast cancer: a review of current evidence.&quot;&nbsp;Breast cancer research : BCR&nbsp;7(1): 21-32.  Rosenberg, P. S., K. A. Barker, et al. (2015). &quot;Estrogen Receptor Status and the Future Burden of Invasive and In Situ Breast Cancers in the United States.&quot;&nbsp;Journal of the National Cancer Institute&nbsp;107(9).  Stang, A. and C. Thomssen (2008). &quot;Decline in breast cancer incidence in the United States: what about male breast cancer?&quot;&nbsp;Breast cancer research and treatment&nbsp;112(3): 595-596"@en ;
  foaf:page <https://identifiers.org/aop/294> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/294> a sbd:Model ;
  rdfs:label "Increased reactive oxygen and nitrogen species (RONS) leading to increased risk of breast cancer"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Because of the long latency of mammary tumors, the two-year rodent carcinogenicity bioassay is the primary assay for this adverse outcome. The assay is included in the OECD Test No. 451 and 453 for carcinogenicity and combined toxicity and carcinogenicity (OECD 2009; OECD 2009), and is also used by the US National Toxicology program (Chhabra, Huff et al. 1990), and the FDA (FDA (Food and Drug Administration) 2007), and referenced by the EPA (EPA (Environmental Protection Agency) 2005) in guidelines for risk assessments. Other assays from short term (2-4 weeks) and subchronic (90 day) to chronic (1 year) toxicity also call for the documentation of mammary tumors (FDA (Food and Drug Administration) 2007; OECD (Organisation for Economic Cooperation and Development) 2018), so these assays could capture the early onset of tumors, and could be modified to report earlier key events like proliferation and inflammation.  Several characteristics of classic cancer bioassays limit the sensitivity of these assays to mammary gland carcinogens. First, no assays require prenatal or early post-natal exposures for carcinogenicity testing. The US NIH&rsquo;s National Toxicology Program assays start exposures at five to six weeks of age and OECD regulatory assay exposures suggest (but do not require) exposures beginning after weaning and before eight weeks of age. Assays initiating exposures at later ages have diminished sensitivity to agents that affect breast development and increase future susceptibility to cancer, such as estrogenic hormones, DDT and dioxins (EPA (Environmental Protection Agency) 2005; Rudel, Fenton et al. 2011). Agents with similar activity to ionizing radiation and DNA damaging chemicals may not be fully captured in some of these assays, since sensitivity appears to peak around or before week seven for these agents (around puberty) (Imaoka, Nishimura et al. 2013). Second, carcinogenicity assay guidelines do not require the best methods for detecting tumors in mammary gland: whole mount preparations of mammary gland coupled with longitudinal sections (dorsoventral sections parallel to the body) of mammary gland for histology (Tucker, Foley et al. 2017). Palpation and transverse sections of mammary gland can easily miss tumors or lesions of interest. Interestingly the NTP reproductive toxicity guidelines do specify these preferable methods for mammary gland analysis.  Two additional factors affect the sensitivity of standard carcinogenicity assays. First, benign tumors are not always considered to be an indicator of carcinogenicity, leading to a possible underestimation of risk. &nbsp;NTP and EPA guidance suggest that benign tumors provide additional weight of evidence if malignant tumors are also present or if studies suggest benign tumors can progress to carcinogenicity. In a short-term study, benign tumors may indicate a need for a longer-term study. However, benign mammary tumors (fibroadenomas) almost always coincide with carcinogenic tumors in mammary gland or other organs, and carcinomas sometimes grow from fibroadnomas (Rudel, Attfield et al. 2007; Russo 2015) suggesting that benign tumors may be an underutilized indicator of carcinogenicity.  Finally, the dose selection guidance in carcinogenicity testing typically calls for a high dose that is sufficiently toxic to suppress body weight (OECD 2009). However, body weight interacts with risk of breast cancer (Haseman, Young et al. 1997; Rudel, Attfield et al. 2007), reducing the sensitivity of the upper end of the dose range and the likelihood of a positive dose-response."@en ;
  foaf:page <https://identifiers.org/aop/294> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/294> a sbd:Model ;
  rdfs:label "Increased reactive oxygen and nitrogen species (RONS) leading to increased risk of breast cancer"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The following stressors increase this key event: ionizing radiation."@en ;
  foaf:page <https://identifiers.org/aop/294> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/296> a sbd:Model ;
  rdfs:label "Oxidative DNA damage leading to chromosomal aberrations and mutations"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "H2O2 &nbsp;and KBrO3 &ndash; A concentration-dependent increase in oxidative lesions was observed in both Fpg- and hOGG1-modified comet assays of TK6 cells treated with increasing concentrations of glucose oxidase (an enzyme that generates H2O2) &nbsp;and potassium bromate for 4 hours (Platel et al., 2011)."@en ;
  foaf:page <https://identifiers.org/aop/296> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/296> a sbd:Model ;
  rdfs:label "Oxidative DNA damage leading to chromosomal aberrations and mutations"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "This AOP network describes oxidative damage to DNA (MIE) leading to mutations (AO1) and chromosomal aberrations (AO2). The AOP summarizes the evidence supporting&nbsp;how increases in oxidative DNA lesions can overwhelm DNA repair mechanisms, causing an accumulation of unrepaired lesions and/or repair intermediates. Failure to resolve oxidative DNA damage can lead to permanent alterations to&nbsp;the genome. Increases in reactive oxygen and nitrogen species (RONS)&nbsp;that can lead to oxidative DNA lesions is a broad characteristic&nbsp;of many xenobiotics and indeed, is noted as one of the &#39;key characteristics of carcinogens&#39; (Smith et al., 2016). Moreover,&nbsp;oxidative stress is often suspected to be the cause of DNA damage by substances whose mechanism of genotoxicity is uncertain [e.g., glyphosate (Kier and Kirkland, 2013; Benbrook, 2019), monosodium glutamate (Ataseven et al., 2016)]. Thus, this AOP network&nbsp;will serve as a key tool in mechanism-based genotoxic hazard identification and assessment.  Oxidative stress describes&nbsp;an imbalance of oxidants and antioxidants in the cell. Oxidative stress can occur when free radicals overwhelm the antioxidant capacity under certain physiological conditions, such as inflammation due to diseases, and also through exogenous stressors that are oxidants and/or induce ROS and other free radicals. Excess oxidants can occur following&nbsp;exposure to agents that: (a) generate free radicals and other RONS, (b) deplete cellular antioxidants, and/or (c)&nbsp;have oxidizing properties (Parke, 1982). Furthermore, there are substances that can induce&nbsp;inflammatory responses&nbsp;and in turn cause oxidative stress as a secondary effect (Gustafson et al., 2016).&nbsp;The effects of oxidative stress in the cell are broad; all biomolecules are susceptible to damage by oxidizing agents. Oxidative stress and associated damage to cellular components have been implicated in various diseases, including neurodegenerative diseases, cardiovascular diseases, diabetes, and different cancers (Liguori et al., 2018).&nbsp;  Free radicals and other RONS are continuously generated as by-products of endogenous redox reactions (e.g., oxidative phosphorylation in the mitochondria, NADPH oxidation to NADP+ by NADPH oxidase) at steady state. The steady state concentration of oxidants is essential for cellular functions (e.g., as secondary signalling molecules) and is tightly regulated by endogenous antioxidants such as glutathione, and antioxidant enzymes such as superoxide dismutase and catalase. There are many protective barriers against oxidative damage to the genome within the cell. Compartmentalization is one of the ways in which DNA is protected from exposure to ROS and other free radicals generated by various biological processes that occur in different parts of the cell. Examples include CYP450 enzyme activity in the cytoplasmic endoplasmic reticulum and oxidative phosphorylation in the mitochondria (Dan Dunn et al., 2015; Veith and Moorthy, 2019).  Exogenous sources such as ionizing radiation, ultraviolet (UV) radiation, and certain compounds can directly or indirectly generate reactive species, causing oxidative stress. Oxidizing compounds can also directly cause oxidative damage to cellular components (Liguori et al., 2018). The nitrogenous bases of the DNA are susceptible to oxidation by both endogenous and exogenous oxidants (Berquist and Wilson III, 2012). Oxidizing agents cause a wide range of oxidative DNA lesions. In addition to strand breaks due to direct RONS attack on the phosphate backbone, the nitrogenous bases can be modified in various ways by free radicals and other reactive species. If these lesions are left unrepaired or the attempt at repair fails, mutations and strand breaks can occur, permanently altering the DNA sequence. All nitrogenous bases are susceptible to oxidative damage, however, to different extents. A variety of DNA lesions caused by RONS are described within this AOP ADDIN RW.CITE{{342 Cooke,M. 2003}}(Cooke et al., 2003). Notably, guanine is most readily damaged by RONS and other oxidants due to its low reduction potential. Indeed,&nbsp;8-oxoG is the most abundant oxidative DNA lesion and has been extensively studied.&nbsp;Consequently,&nbsp;chromosomal regions containing a higher GC content are more susceptible to oxidative base modifications. For example, human telomeres, which are constituted by TTAGGG repeats and a single-stranded G-rich 3&#39; overhang, are known to be comparatively more sensitive to oxidative damage than other regions in the genome&nbsp;and accumulate 8-oxodG lesions that eventually lead to telomere shortening and genomic instability (Petersen et al., 1998; Bolzan, 2012;&nbsp;Fouquerel et al., 2019).&nbsp;The repair mechanisms and consequences of oxidative damage to&nbsp;telomeres&nbsp;are&nbsp;active areas of research.&nbsp;  Within this AOP network, we mainly focus on 8-oxo-dG as oxidative DNA damage representing the MIE, for practicality.&nbsp;The fate of guanine lesions has been most extensively researched and well understood ADDIN RW.CITE{{300 Whitaker,A. 2017; 370 Cadet,J. 2017; 318 Markkanen,E. 2017; 139 Roszkowski,K. 2011}}(Roszkowski et al., 2011; Whitaker et al., 2017; Cadet et al., 2017; Markkanen, 2017). Also,&nbsp;8-oxodG is an accepted biomarker of oxidative stress and oxidative damage to DNA both&nbsp;in vitro&nbsp;and in vivo&nbsp;(Cooke et al., 2008; Roszkowski et al., 2011; P. Li et al., 2014; Guo et al., 2017). Several different detection methods for 8-oxo-dG are commercially available and, thus, are easy to access (e.g., immunodetection, comet assay). We note that 8-oxo-dG is not a terminal product of oxidative damage; 8-oxo-dG can be further oxidized to additional mutagenic lesions such as spiroiminodihydantoin and guanidinohydantoin ADDIN RW.CITE{{488 Jena,N.R. 2012}}(Jena and Mishra, 2012). However, as with many other oxidative lesions on pyrimidines and adenine, these guanine lesions are estimated to be small fractions compared to 8-oxo-dG&nbsp;(Yu et al., 2005; Cooke et al., 2008).&nbsp;  The pathway to mutations (AO1) from oxidative DNA lesions&nbsp;can either proceed (a) directly to mutation through replication of unrepaired oxidized DNA bases (insertion of an incorrect nucleotide by a replicative or translesion polymerase), or (b) indirectly through the creation of strand breaks that can be misrepaired to introduce mutations ADDIN RW.CITE{{346 Rodgers,K. 2016; 323 Taggart,D. 2014}}(Taggart et al., 2014; Rodgers and McVey, 2016). Strand breaks can arise during attempted repair of oxidative DNA lesions. Oxidative base damage is predominantly repaired by base excision repair (BER), and&nbsp;by nucleotide excision repair (NER) to&nbsp;a lesser extent (Whitaker et al., 2017). In the excision repair pathways, single strand breaks (SSB) are transiently introduced as repair intermediates. With increasing oxidative lesions and more lesions in close proximity to each other, the quality and efficiency of repair may be compromised, resulting in&nbsp;persistent unrepaired lesions and repair intermediates. Accumulated repair intermediates such as&nbsp;SSBs,&nbsp;oxidized bases, and abasic sites can interfere with proximal excision repair and/or&nbsp;impede replication fork elongation, leading&nbsp;to double strand breaks (DSBs), which are more toxic and&nbsp;difficult to repair ADDIN RW.CITE{{261 Yang,N. 2006; 340 Ensminger,M. 2014; 450 Sedletska,Y. 2013}}(Yang et al., 2006; Sedletska et al., 2013; Ensminger et al., 2014). Furthermore, if a SSB is introduced nearby another SSB on the opposite strand prior to or&nbsp;during excision repair, these SSBs may be converted to DSBs. Some studies suggest&nbsp;that multiple DNA lesions within one or two helical turns can increase the rate of DSB formation (Cannan and Pederson, 2017). Insufficiently repaired DSBs (incorrect or lack of rejoining) can permanently alter the DNA sequence (e.g., insertion, deletion, translocations), and cause both mutations (AO1) and structural chromosomal aberrations (AO2) ADDIN RW.CITE{{346 Rodgers,K. 2016}}(Rodgers and McVey, 2016). These processes are described in more detail within the AOP. &nbsp;&nbsp;  Overall, we anticipate that this AOP network will provide a key sub-network that will be relevant to many future AOPs. However, we note that the AOs herein, increased mutations and chromosomal aberrations, are regulatory endpoints of concern in and of themselves. This AOP also provides a template for designing testing strategies for RONS-induced genetic effects. Despite the fact that this is a long-studied area in genetic toxicology, this work highlights notable gaps in the empirical evidence linking adjacent KEs. For example, the extent to which the levels of oxidative DNA damage must increase before DNA repair processes are overwhelmed&nbsp;leading to an&nbsp;AO is currently poorly understood, and may vary based on the test system. Hence, further data are needed to improve our ability to predict whether this pathway is relevant to a chemical&rsquo;s toxicological effects.."@en ;
  foaf:page <https://identifiers.org/aop/296> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/296> a sbd:Model ;
  rdfs:label "Oxidative DNA damage leading to chromosomal aberrations and mutations"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "H2O2 &nbsp;and KBrO3 &ndash; A concentration-dependent increase in oxidative lesions was observed in both Fpg- and hOGG1-modified comet assays of TK6 cells treated with increasing concentrations of glucose oxidase (an enzyme that generates H2O2) &nbsp;and potassium bromate for 4 hours (Platel et al., 2011)."@en ;
  foaf:page <https://identifiers.org/aop/296> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/296> a sbd:Model ;
  rdfs:label "Oxidative DNA damage leading to chromosomal aberrations and mutations"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "This AOP network describes oxidative damage to DNA (MIE) leading to mutations (AO1) and chromosomal aberrations (AO2). The AOP summarizes the evidence supporting&nbsp;how increases in oxidative DNA lesions can overwhelm DNA repair mechanisms, causing an accumulation of unrepaired lesions and/or repair intermediates. Failure to resolve oxidative DNA damage can lead to permanent alterations to&nbsp;the genome. Increases in reactive oxygen and nitrogen species (RONS)&nbsp;that can lead to oxidative DNA lesions is a broad characteristic&nbsp;of many xenobiotics and indeed, is noted as one of the &#39;key characteristics of carcinogens&#39; (Smith et al., 2016). Moreover,&nbsp;oxidative stress is often suspected to be the cause of DNA damage by substances whose mechanism of genotoxicity is uncertain [e.g., glyphosate (Kier and Kirkland, 2013; Benbrook, 2019), monosodium glutamate (Ataseven et al., 2016)]. Thus, this AOP network&nbsp;will serve as a key tool in mechanism-based genotoxic hazard identification and assessment.  Oxidative stress describes&nbsp;an imbalance of oxidants and antioxidants in the cell. Oxidative stress can occur when free radicals overwhelm the antioxidant capacity under certain physiological conditions, such as inflammation due to diseases, and also through exogenous stressors that are oxidants and/or induce ROS and other free radicals. Excess oxidants can occur following&nbsp;exposure to agents that: (a) generate free radicals and other RONS, (b) deplete cellular antioxidants, and/or (c)&nbsp;have oxidizing properties (Parke, 1982). Furthermore, there are substances that can induce&nbsp;inflammatory responses&nbsp;and in turn cause oxidative stress as a secondary effect (Gustafson et al., 2016).&nbsp;The effects of oxidative stress in the cell are broad; all biomolecules are susceptible to damage by oxidizing agents. Oxidative stress and associated damage to cellular components have been implicated in various diseases, including neurodegenerative diseases, cardiovascular diseases, diabetes, and different cancers (Liguori et al., 2018).&nbsp;  Free radicals and other RONS are continuously generated as by-products of endogenous redox reactions (e.g., oxidative phosphorylation in the mitochondria, NADPH oxidation to NADP+ by NADPH oxidase) at steady state. The steady state concentration of oxidants is essential for cellular functions (e.g., as secondary signalling molecules) and is tightly regulated by endogenous antioxidants such as glutathione, and antioxidant enzymes such as superoxide dismutase and catalase. There are many protective barriers against oxidative damage to the genome within the cell. Compartmentalization is one of the ways in which DNA is protected from exposure to ROS and other free radicals generated by various biological processes that occur in different parts of the cell. Examples include CYP450 enzyme activity in the cytoplasmic endoplasmic reticulum and oxidative phosphorylation in the mitochondria (Dan Dunn et al., 2015; Veith and Moorthy, 2019).  Exogenous sources such as ionizing radiation, ultraviolet (UV) radiation, and certain compounds can directly or indirectly generate reactive species, causing oxidative stress. Oxidizing compounds can also directly cause oxidative damage to cellular components (Liguori et al., 2018). The nitrogenous bases of the DNA are susceptible to oxidation by both endogenous and exogenous oxidants (Berquist and Wilson III, 2012). Oxidizing agents cause a wide range of oxidative DNA lesions. In addition to strand breaks due to direct RONS attack on the phosphate backbone, the nitrogenous bases can be modified in various ways by free radicals and other reactive species. If these lesions are left unrepaired or the attempt at repair fails, mutations and strand breaks can occur, permanently altering the DNA sequence. All nitrogenous bases are susceptible to oxidative damage, however, to different extents. A variety of DNA lesions caused by RONS are described within this AOP ADDIN RW.CITE{{342 Cooke,M. 2003}}(Cooke et al., 2003). Notably, guanine is most readily damaged by RONS and other oxidants due to its low reduction potential. Indeed,&nbsp;8-oxoG is the most abundant oxidative DNA lesion and has been extensively studied.&nbsp;Consequently,&nbsp;chromosomal regions containing a higher GC content are more susceptible to oxidative base modifications. For example, human telomeres, which are constituted by TTAGGG repeats and a single-stranded G-rich 3&#39; overhang, are known to be comparatively more sensitive to oxidative damage than other regions in the genome&nbsp;and accumulate 8-oxodG lesions that eventually lead to telomere shortening and genomic instability (Petersen et al., 1998; Bolzan, 2012;&nbsp;Fouquerel et al., 2019).&nbsp;The repair mechanisms and consequences of oxidative damage to&nbsp;telomeres&nbsp;are&nbsp;active areas of research.&nbsp;  Within this AOP network, we mainly focus on 8-oxo-dG as oxidative DNA damage representing the MIE, for practicality.&nbsp;The fate of guanine lesions has been most extensively researched and well understood ADDIN RW.CITE{{300 Whitaker,A. 2017; 370 Cadet,J. 2017; 318 Markkanen,E. 2017; 139 Roszkowski,K. 2011}}(Roszkowski et al., 2011; Whitaker et al., 2017; Cadet et al., 2017; Markkanen, 2017). Also,&nbsp;8-oxodG is an accepted biomarker of oxidative stress and oxidative damage to DNA both&nbsp;in vitro&nbsp;and in vivo&nbsp;(Cooke et al., 2008; Roszkowski et al., 2011; P. Li et al., 2014; Guo et al., 2017). Several different detection methods for 8-oxo-dG are commercially available and, thus, are easy to access (e.g., immunodetection, comet assay). We note that 8-oxo-dG is not a terminal product of oxidative damage; 8-oxo-dG can be further oxidized to additional mutagenic lesions such as spiroiminodihydantoin and guanidinohydantoin ADDIN RW.CITE{{488 Jena,N.R. 2012}}(Jena and Mishra, 2012). However, as with many other oxidative lesions on pyrimidines and adenine, these guanine lesions are estimated to be small fractions compared to 8-oxo-dG&nbsp;(Yu et al., 2005; Cooke et al., 2008).&nbsp;  The pathway to mutations (AO1) from oxidative DNA lesions&nbsp;can either proceed (a) directly to mutation through replication of unrepaired oxidized DNA bases (insertion of an incorrect nucleotide by a replicative or translesion polymerase), or (b) indirectly through the creation of strand breaks that can be misrepaired to introduce mutations ADDIN RW.CITE{{346 Rodgers,K. 2016; 323 Taggart,D. 2014}}(Taggart et al., 2014; Rodgers and McVey, 2016). Strand breaks can arise during attempted repair of oxidative DNA lesions. Oxidative base damage is predominantly repaired by base excision repair (BER), and&nbsp;by nucleotide excision repair (NER) to&nbsp;a lesser extent (Whitaker et al., 2017). In the excision repair pathways, single strand breaks (SSB) are transiently introduced as repair intermediates. With increasing oxidative lesions and more lesions in close proximity to each other, the quality and efficiency of repair may be compromised, resulting in&nbsp;persistent unrepaired lesions and repair intermediates. Accumulated repair intermediates such as&nbsp;SSBs,&nbsp;oxidized bases, and abasic sites can interfere with proximal excision repair and/or&nbsp;impede replication fork elongation, leading&nbsp;to double strand breaks (DSBs), which are more toxic and&nbsp;difficult to repair ADDIN RW.CITE{{261 Yang,N. 2006; 340 Ensminger,M. 2014; 450 Sedletska,Y. 2013}}(Yang et al., 2006; Sedletska et al., 2013; Ensminger et al., 2014). Furthermore, if a SSB is introduced nearby another SSB on the opposite strand prior to or&nbsp;during excision repair, these SSBs may be converted to DSBs. Some studies suggest&nbsp;that multiple DNA lesions within one or two helical turns can increase the rate of DSB formation (Cannan and Pederson, 2017). Insufficiently repaired DSBs (incorrect or lack of rejoining) can permanently alter the DNA sequence (e.g., insertion, deletion, translocations), and cause both mutations (AO1) and structural chromosomal aberrations (AO2) ADDIN RW.CITE{{346 Rodgers,K. 2016}}(Rodgers and McVey, 2016). These processes are described in more detail within the AOP. &nbsp;&nbsp;  Overall, we anticipate that this AOP network will provide a key sub-network that will be relevant to many future AOPs. However, we note that the AOs herein, increased mutations and chromosomal aberrations, are regulatory endpoints of concern in and of themselves. This AOP also provides a template for designing testing strategies for RONS-induced genetic effects. Despite the fact that this is a long-studied area in genetic toxicology, this work highlights notable gaps in the empirical evidence linking adjacent KEs. For example, the extent to which the levels of oxidative DNA damage must increase before DNA repair processes are overwhelmed&nbsp;leading to an&nbsp;AO is currently poorly understood, and may vary based on the test system. Hence, further data are needed to improve our ability to predict whether this pathway is relevant to a chemical&rsquo;s toxicological effects.."@en ;
  foaf:page <https://identifiers.org/aop/296> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/297> a sbd:Model ;
  rdfs:label "Inhibition of retinaldehyde dehydrogenase leads to population decline"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/297> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/297> a sbd:Model ;
  rdfs:label "Inhibition of retinaldehyde dehydrogenase leads to population decline"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "This adverse outcome pathway (AOP) represents the potential causative adverse outcomes (AOs) by inhibition of retinaldehyde dehydrogenase (RALDH), which is one of the crucial enzymes participating in retinol metabolism. The role of RALDH in retinol metabolism is to catalyze the chemical reaction converting retinal to retinoic acid (RA). The synthesized RA is associated with the cellular RA-binding protein (CRABP) and enters into the nucleus, and then bind to retinoic acid receptors (RARs) along with retinoid X receptors (RXRs) (Vilhais-Neto and Pourqui&eacute;, 2008). The activated RARs and RXRs can act as target gene transcription factors regulating embryonic development in fishes (Perz-Edwards et al., 2011). Inhibition of RALDH can be caused by chemical inhibitors such as Disulphiram, Citral, Paclobutrazol, Diethylaminobenzaldehyde, Nitrofen, 4-biphenyl carboxylic acid, Bisdiamine, SB-210661 and etc. (Marsh-Armstrong et al., 1994; Chawla et al., 2018; Wang et al., 2017; Le et al., 2012; Mey et al., 2003). RALDH inhibition, the molecular initiating event (MIE) for this AOP, leads to decreased RA synthesis blocking the reaction converting retinal to RA in embryonic cells (Hyatt and Dowling, 1997; Molotkov et al., 2002; Le et al., 2012; Duester, 2009). Since RA is an essential activator for the RARs and RXRs-mediated gene transcription, low level of plasma RA leads to abnormal development in embryonic cells. A number of previous studies well-elucidated the abnormal developments by RA inhibition including visual function and eye development (Duester et al., 2009; Hyatt and Dowling, 1997; Hyatt et al., 1996; Kam et al., 2012; Le et al., 2012; Luo et al., 2006; Marsh-Armstrong et al., 1994; Matt et al., 2005; Wang et al., 2017), intestinal development (Nadauld et al., 2005), brain patterning and neurogenesis (Begemann et al., 2004; Niederreither and Doll&eacute;, 2008; Samarut et al., 2015), and heart development (Niederreither and Doll&eacute;, 2008; Samarut et al., 2015). The development of early embryonic cells of fishes plays an essential role in the organism&rsquo;s young of year survival and adaptation in fluctuated environmental condition. The impact of the development of the optical elements of the eye by RALDH inhibition in fish population trajectory has not been clarified yet, although the importance of the visual function of fishes previously mentioned by previous studies (Fernald, 1984; Sandstr&ouml;m, 1999).  			Acknowledgements:&nbsp;This research was supported by the National Research Council of Science &amp; Technology(NST) grant by the Korea&nbsp;government (MSIP) (No. CAP-17-01-KIST Europe) 			 		 	   &nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/297> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/298> a sbd:Model ;
  rdfs:label "Increases in cellular reactive oxygen species and chronic reactive oxygen species leading to human treatment-resistant gastric cancer"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Reactive oxygen species (ROS) are&nbsp;generated through NADPH oxidases consisting of p47phox and p67phox. Arsenic produces ROS [Zhang et al., 2011].  Ionizing radiation induces ROS [Kruk et al., 2017].  Iron(III)-nitrilotriacetate induces reactive oxygen species production via the transfer of an electron to molecular oxygen to form ROS [Tsuchiya et al., 2005, Akai et al., 2004]."@en ;
  foaf:page <https://identifiers.org/aop/298> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/298> a sbd:Model ;
  rdfs:label "Increases in cellular reactive oxygen species and chronic reactive oxygen species leading to human treatment-resistant gastric cancer"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Drug resistance is very important in cancer treatment since cancer metastasis and recurrence are some of the main obstacles to treating cancer. Cancer stem cells that share&nbsp;the phenotype of EMT&nbsp;may be targeted in anti-cancer drug development.&nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/298> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/299> a sbd:Model ;
  rdfs:label "Deposition of energy leading to population decline via DNA oxidation and follicular atresia"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/299> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/299> a sbd:Model ;
  rdfs:label "Deposition of energy leading to population decline via DNA oxidation and follicular atresia"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Cumulative fecundity is the most apical endpoint considered in the OECD 229 Fish Short Term Reproduction Assay. The OECD 229 assay serves as screening assay for endocrine disruption and associated reproductive impairment (OECD 2012). Fecundity is also an important apical endpoint in the Medaka Extended One Generation Reproduction Test (MEOGRT; OECD Test Guideline 240; OECD 2015).  A variety of fish life cycle tests also include cumulative fecundity as an endpoint (OECD 2008).  &nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/299> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/299> a sbd:Model ;
  rdfs:label "Deposition of energy leading to population decline via DNA oxidation and follicular atresia"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "It is well documented that ionizing radiation( (eg.&nbsp;X-rays, gamma, photons, alpha, beta, neutrons, heavy ions)&nbsp;leads to energy deposition on the atoms and molecules of the substrate. Many studies, have demonstrated that the type of radiation and distance from source has an impact on the pattern of energy deposition (Alloni, et al. 2014). High linear energy transfer (LET) radiation has been associated with higher-energy deposits (Liamsuwan et al., 2014) that are more densely-packed and cause more complex effects within the particle track (Hada and Georgakilas, 2008; Okayasu, 2012ab; Lorat et al., 2015; Nikitaki et al., 2016) in comparison to low LET radiation. Parameters such as mean lineal energy, dose mean lineal energy, frequency mean specific energy and dose mean specific energy can impact track structure of the traversed energy into a medium (Friedland et al., 2017). The detection of energy deposition by ionizing radiation can be demonstrated with the use of fluorescent nuclear track detectors (FNTDs). FNTDs used in conjunction with fluorescent microscopy, are able to visualize radiation tracks produced by ionizing radiation (Niklas et al., 2013; Kodaira et al., 2015; Sawakuchi and Akselrod, 2016). In addition, these FNTD chips can quantify the LET of primary and secondary radiation tracks up to 0.47 keV/um (Sawakuchi and Akselrod, 2016). This co-visualization of the radiation tracks and the cell markers enable the mapping of the radiation trajectory to specific cellular compartments, and the identification of accrued damage (Niklas et al., 2013; Kodaira et al., 2015). There are no known chemical initiators or prototypes that can mimic the MIE."@en ;
  foaf:page <https://identifiers.org/aop/299> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/299> a sbd:Model ;
  rdfs:label "Deposition of energy leading to population decline via DNA oxidation and follicular atresia"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/299> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/299> a sbd:Model ;
  rdfs:label "Deposition of energy leading to population decline via DNA oxidation and follicular atresia"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Cumulative fecundity is the most apical endpoint considered in the OECD 229 Fish Short Term Reproduction Assay. The OECD 229 assay serves as screening assay for endocrine disruption and associated reproductive impairment (OECD 2012). Fecundity is also an important apical endpoint in the Medaka Extended One Generation Reproduction Test (MEOGRT; OECD Test Guideline 240; OECD 2015).  A variety of fish life cycle tests also include cumulative fecundity as an endpoint (OECD 2008).  &nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/299> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/299> a sbd:Model ;
  rdfs:label "Deposition of energy leading to population decline via DNA oxidation and follicular atresia"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "It is well documented that ionizing radiation( (eg.&nbsp;X-rays, gamma, photons, alpha, beta, neutrons, heavy ions)&nbsp;leads to energy deposition on the atoms and molecules of the substrate. Many studies, have demonstrated that the type of radiation and distance from source has an impact on the pattern of energy deposition (Alloni, et al. 2014). High linear energy transfer (LET) radiation has been associated with higher-energy deposits (Liamsuwan et al., 2014) that are more densely-packed and cause more complex effects within the particle track (Hada and Georgakilas, 2008; Okayasu, 2012ab; Lorat et al., 2015; Nikitaki et al., 2016) in comparison to low LET radiation. Parameters such as mean lineal energy, dose mean lineal energy, frequency mean specific energy and dose mean specific energy can impact track structure of the traversed energy into a medium (Friedland et al., 2017). The detection of energy deposition by ionizing radiation can be demonstrated with the use of fluorescent nuclear track detectors (FNTDs). FNTDs used in conjunction with fluorescent microscopy, are able to visualize radiation tracks produced by ionizing radiation (Niklas et al., 2013; Kodaira et al., 2015; Sawakuchi and Akselrod, 2016). In addition, these FNTD chips can quantify the LET of primary and secondary radiation tracks up to 0.47 keV/um (Sawakuchi and Akselrod, 2016). This co-visualization of the radiation tracks and the cell markers enable the mapping of the radiation trajectory to specific cellular compartments, and the identification of accrued damage (Niklas et al., 2013; Kodaira et al., 2015). There are no known chemical initiators or prototypes that can mimic the MIE."@en ;
  foaf:page <https://identifiers.org/aop/299> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/3> a sbd:Model ;
  rdfs:label "Inhibition of the mitochondrial complex I of nigro-striatal neurons leads to parkinsonian motor deficits"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Numerous hydrophobic, amphipathic compounds are known to inhibit the proton pumping NADH:ubiquinone oxidoreductase, also known as the ubiquinone reductase reaction of respiratory chain complex I (Fendel et al., 2008). However, the most studied examples of chemicals that inhibit CI are: rotenone and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Desplats et al., 2012; Lin et al., 2012; Sava et al., 2007). Both, rotenone (pesticide) and MPP+ (the active metabolite of MPTP) are well known to reproduce the anatomical, neurochemical, behavioural and neuropathological features of PD-like syndrome (Betarbet et al., 200; Greenamyre et al., 2001). Indeed, an overwhelming evidence has accumulated in the existing literature suggesting such a link and therefore these two inhibitors of CI will be discussed in the context of all KE identified in this AOP.  1. Rotenone affinity to complex I binding sites.  Rotenone (a flavonoid, extracted from the several plants e.g. Derris scandens)is one of the most powerful, an irreversible inhibitor of CI, binding with high affinity to CI and is typically used to define the specific activity of this complex. Rotenone is extremely lipophilic, it crosses biological membrane easily and it gets into brain very rapidly. Rotenone inhibits 20 kDa subunit of complex I (PSST) labeling without effect on 36 kDa subunit of complex I (ND1) (Schuler and Casida, 2001). The interaction of rotenone with active (&#39;pulsed&#39;) and thermally de-activated (&#39;resting&#39;) membrane-bound Complex I as revealed by inhibition of NADH-ubiquinone- and ubiquinol-NAD+ reductase activities was studied. Ki = 1 x 10(-9) M, k(on) = 5 x 10(7) M-1 min-1 and k(off) = 0.02 min-1 (inhibitory effect of rotenone on NADH oxidation) and Ki = 2 x 10(-8) M (inhibition of reverse electron transfer) were determined for pulsed enzyme. The equilibrium between de-activated and active enzyme is reached (K approximately 100) after the slow strongly temperature-dependent de-activation process has completed. Rotenone partially prevents and reverses the enzyme de-activation. About two order of magnitude difference in affinity of rotenone to the active and de-activated forms of the enzyme was demonstrated (Grivennikova et al., 1997). Dose-dependent relative affinities of rotenone to the inhibitory site of CI is shown in Fig. 3B (for more detail Grivennikova et al., 1997).  Most of the studies suggest that hydrophobic inhibitors like rotenone or Piericidin A most likely disrupt the electron transfer between the terminal Fe-S cluster N2 and ubiquinone (Fig. 3A).  &nbsp;    &nbsp;  Fig. 3A. Rotenone structure and a schematic representation of its binding site (and other Rotenone-like compounds) to CI. IMS: inter-membrane space (based on Lummen, 1998)  &nbsp;    &nbsp;  Fig. 3B. Fig. 2. Relative affinities of rotenone to the inhibitory site(s) of Complex I. Panel (A): activated submitochondrial particles (SMP) (2.8 mg/ml, approx. 0.4 microM Complex I) were incubated in the standard reaction mixture for 20 min at 25oC and residual initial rate of NADH oxidation was measured. 100% correspond to the specific activity of 1.0 micromol/min per mg of protein. Panel (B): curve 1 (o), SMP (48 microg/ml, approx. 8 nM Complex I) were activated in the assay cuvette and pre-incubated with rotenone in the presence of gramicidin and 10 mM malonate for 20 min at 25oC and the residual NADH oxidase activity was then measured; black circle: the same as (o), except that pre-incubation with rotenone was made in the presence of 10 mM succinate (no gramicidin and malonate), 10 mM malonate and gramicidin were added simultaneously with 100 microM NADH to measure the residual activity. Curve 2, presents the reverse electron transfer activity and curve 3, de-activated SMP were preincubated with rotenone as described for curve 1(o) (for further details see Grivennikova et al., 1997). Panel (C): The same as Panel B, curve 3, except for enzyme concentration was 0.5 mg/ml and rotenone concentration range which was increased to show interaction of the inhibitor with de-activated enzyme. The activity was measured after 200-fold dilution into the assay mixture. All the continues lines corresponds to the theoretical titration curves for the reversible single site inhibition with Ki values of 1 nM, 20 nM and 80 nM for the curves 1, 2 and 3, respectively (for further details see Grivennikova et al., 1997).   2. MPTP affinity to complex I binding sites. MPTP is not directly binding to CI and it is therefore non-toxic to DA neurons. MPTP exerts its toxicity after it is metabolized by mono-amino-oxidase, type B (MAO B), in astrocytes to 1-methyl-4-phenylpyridinium (MPP+). This metabolite binds to CI, and is toxic. MPP+ is a good substrate for dopamine transporters (DAT), expressed selectively by DA neurons (Greenamyre et al (2001). Due to both a positive charge and an amphoteric character, MPP+ specifically accumulates in mitochondria, where despite a lower affinity to the binding site of complex I than rotenone, it reaches high enough intra-mitochondrial concentrations to inhibit CI activity (Ramsay et al., 1991). The binding affinity of MPP+ is low (mM range), and it can be totally reversed by washing out.&nbsp; Competitive binding experiments with rotenone and MPP+ suggest that the two compounds bind to the same site of the CI (Ramasay et al., 1991). Schuler and Casida (2001) reported that MPP+ inhibits PSST and elevates ND1 labelling subunits of the mitochondrial complex I.  3. General characteristics of other complex I inhibitors. There is a variety of CI inhibitors, both naturally occurring besides rotenone such as Piericidin A (from Streptomyces mobaraensis), acetogenins (from various Annonaceae species) as well as their derivatives, and synthetically manufactured compounds like pyridaben and various piperazin derivatives (Ichimaru et al. 2008). They have been used to probe the catalytic activity of complex I especially in order to clarify its ubiquinone binding site and indeed, most of these compounds inhibit the electron transfer step from the Fe-S clusters to ubiquinone (Friedrich et al. 1994). Therefore, classification of CI inhibitors is based on their types of action. Type A inhibitors, like piericidin A, 2-decyl-4-quinazolinyl amine (DQA), annonin VI and rolliniastatin-1 and -2, are considered to be antagonists of the ubiquinone substrate. For piericidin A, it has been shown that it inhibits NADH:Q2 activity in a partially competitive manner. Contrary to type A, type B inhibitors, like the commonly used rotenone, have hydrogen-bonding acceptors only in the cyclic head of the molecule and are non-competitive towards UQ (ubiquinone), but are believed to displace the semiquinone intermediate during the catalysis (Fig. 2). Finally, inhibitors classified as type C, like stigmatellin and capsaicin, form a third group of hydrophobic CI inhibitors that are believed to act as antagonists of reduced ubiquinone (Degli Esposti 1998, Friedrich et al. 1994, Haefeli 2012) (Fig. 2). Competition studies with representatives of all three different types of inhibitors revealed that type A and B and type B and C, but not type A and C, compete with each other for binding. This led to a suggestion that all CI inhibitors acting at the ubiquinone binding pocket share a common binding domain with partially overlapping sites (Okun et al. 1999).  Some inhibitors bind to the outside of the ubiquinone reduction site and do not fit the preceding classification. Examples of such compounds are ADP-ribose, which competes for substrate binding at the NADH site (Zharova and Vinogradov, 1997), and diphenyleneiodonium (DPI) that covalently binds to reduced flavin mononucleotide (FMN) in the hydrophilic part of the enzyme blocking the electron transfer to the Fe-S clusters (Majander et al., 1994). There are also new, commercially available insecticides/acaricides with potential to inhibit mitochondrial respiration such as benzimidazole, bullatacin, 6-chlorobenzothiadiazole, cyhalothrin, Fenazaquin Fenpyroximate, Hoe 110779, Pyridaben, Pyrimidifen, Sandoz 547A, Tebufenpyrad and Thiangazole (Greenamyre et al., 2001). It is clear that they are capable of inhibiting the mammalian CI of mitochondrial respiratory chain, by binding to and blocking ubiquinone-dependent NADH oxidation with high efficacy (Lummen, 1998)."@en ;
  foaf:page <https://identifiers.org/aop/3> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/3> a sbd:Model ;
  rdfs:label "Inhibition of the mitochondrial complex I of nigro-striatal neurons leads to parkinsonian motor deficits"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Neurotoxic effects shall be carefully addressed and reported in routine required regulatory toxicological studies (acute toxicity studies,short-term toxicity studies, long term toxicity and carcinogenicity studies and reproductive toxicity studies). Regarding neurotoxicity in rodents, inclusion of neurotoxicity investigations in routine toxicology studies shall also be considered. For pesticide active substances the circumstances in which neurotoxicity studies should be performed are listed in Regulation (EU) No 283/2013:  Specific neurotoxicity studies in rodents shall be performed in case of one those following conditions:   	there is indication of neurotoxicity in routine toxicity studies carried out with the active substance; 	the active substance is a structurally related to known neurotoxic compound; 	the active substance has a neurotoxic mode of pesticidal action.   As a result, specific neurotoxicity studies are not routinely required for all pesticide active substances. Specific neurotoxicity testing becomes obligatory only if neurotoxicity has been observed during histopathological evaluation or in case of structural analogy with a known neurotoxic compound. Motor activity should be measured once in short-term repeated dose toxicity studies (OECD 407, 408 and 422) and several times in specific neurotoxicity studies (OECD 424, OECD 426 and cohort 2 of OECD 443). However, this is not a requirement in chronic toxicity studies unless neurotoxic effects have been reported in the shorter studies. The same test (measures horizontal and/or vertical movements in a test chamber) is implemented in both routine studies and neurotoxicity studies. Coordination and balance are evaluated by rotation or rotarod or pole tests, and gait abnormalities by forepaw stride length test. Those tests are not required by any repeated dose toxicity OECD guidelines and they can be optionally incorporated in the design of neurotoxicity studies OECD 424 and OECD 426.  Although motor deficits is the AO in this AOP, degeneration of DA neurons, is also considered an adverse effect in the regulatory framework, even in the absence of clear clinical symptoms or motor deficits. Morphological assessment of brain structures is a standard requirement in the regulatory toxicological studies supporting the risk assessment of chemical substances and it is a regulatory expectation that the anatomical structures belonging to the nigrostriatal pathway would be included and evaluated as part of the standard evaluation of the brain. Treatment related neuronal degeneration, when occurring as a consequence of the treatment, is generally dose-dependent in incidence and severity. However, if not accompanied by clinical signs or behavioral changes indicative of central nervous system pathology, minimal loss of DA neurons would likely remain undetected in the standard histological evaluation, due to the presence of non DA neurons or as a consequence of the subjectivity of non-quantifiable analysis, unless specific markers are used. As multiple forms of perturbation can affect the neurons, some changes are potentially still reversible (e.g. loss of TH or DA) and irreversibility should be confirmed as part of the assessment. It is then important to apply a sensitive and appropriate method (Switzer 2000) and evaluation of the phenotypic markers in the striatum and in the SNpc should be always performed as a minimum standard (Minnema et al.,&nbsp;2014) when investigating perturbation of the nigrostriatal pathway. It should additionally consider that rat is likely to be a poor model to capture this kind of hazard, as demonstrated by the poor sensitivity of rat to MPTP or related compounds and this should be taken into account for the design and interpretation of the studies.  Dissimilarities of chemical induced animal models to human disease are also important and should be carefully weighted when considering the duration and schedule of the study/treatment. Differently from the human disease, with the MPTP animal model, the damage occurs rapidly, is hardly progressive, is little age-dependent and formation of Lewy bodies is sometime not occurring (Efremova et al., 2015). Therefore, for different animals models, the standard 90 days toxicity study could not match with the chronic and progressive characteristics of the human disease and compensatory changes influencing DA metabolism and turnover and protein catabolism can occur during the treatment period with an impact on the time of onset of the lesion (Ossowska et al., 2005)."@en ;
  foaf:page <https://identifiers.org/aop/3> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/30> a sbd:Model ;
  rdfs:label "Estrogen receptor antagonism leading to reproductive dysfunction"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/30> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/300> a sbd:Model ;
  rdfs:label "Thyroid Receptor Antagonism and Subsequent Adverse Neurodevelopmental Outcomes in Mammals"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "A prime example of impairments in cognitive function as the adverse outcome for regulatory action is developmental lead exposure and IQ function in children (Bellinger, 2012). In addition, testing for the impact of chemical expsoures on cognitive function, often including spatially-mediated behaviors, is an intergral part of both EPA and OECD developmental neurotoxicity guidelines (USEPA, 1998; OECD, 2007)."@en ;
  foaf:page <https://identifiers.org/aop/300> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/301> a sbd:Model ;
  rdfs:label "Inhibition of Cystathionine Beta synthase leading to impaired the early development of anterior-posterior axis "@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Several observations indicate the involvement of hyperhomocysteinemia in neurodegeneration. Hcy levels may play a role in neuronal death via stimulation of glutamate receptors. Homocysteine is an agonist for metabotropic glutamate receptors as well as for NMDA (N-methyl-D-aspartate, as a partial antagonist) and AMPA (amino-3-hydroxy-5-methyl-4-isoxazolepropionate)/Kainate ionotropic glutamate receptors (Lazarewicz et al. 2003; Poddar and Paul 2009). Hcy further mediated subsequent Ca2+ efflux to biphasic activation of p38 &nbsp;mitogen-activated protein kinase&nbsp; (MAPK) (poddar and Paul 2013). Second possible mechanism of Hcy toxicity is free radical species production, and downregulation of antioxidant enzymes such as superoxide dismutase and peroxidase (Moat et al. 2000; Liu et al. 2013) &nbsp;Hcy has also been reported to modulate the expression of pro-inflammatory molecules, C-reactive protein in vascular smooth muscle cells (Pang et al. 2014). Moreover, Hcy is able to inhibit neurogenesis in the hippocampus and subventricular zone of the murine adult brain (Wang et al. 2012; Rabaneda et al. 2008). &nbsp;&nbsp; Hyperhomocysteinemia accelerates the dopaminergic cell death, probably due to the fact that hyperhomocysteinemia could cause a severe reduction in dopamine turnover in the striatum (De Lau et al. 2005).  			Acknowledgements:&nbsp;This research was supported by the National Research Council of Science &amp; Technology(NST) grant by the Korea&nbsp;government (MSIP) (No. CAP-17-01-KIST Europe) 			 		 	   &nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/301> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/302> a sbd:Model ;
  rdfs:label "Lung surfactant function inhibition leading to decreased lung function"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Established regulatory guideline studies for inhalation toxicity focus on evident clinical signs of systemic toxicity, including death, or organ-specific toxicity following acute and (sub)chronic exposure respectively. In toxicological and safety pharmacological studies with airborne test items targeting the airways or the lungs as a whole, lung function is a relevant endpoint for the characterization of potential adverse events (OECD, 2018a; Hoymann, 2012). Hence, the AO &ldquo;decreased lung function&rdquo; is relevant for regulatory decision-making in the context of (sub)chronic exposure (OECD, 2018b; OECD, 2018c).  Regulatory relevance of the AO &ldquo;decreased lung function&rdquo; is evident when looking at the increased risk of diseases in humans following inhalation exposure, and because of its links to other comorbidities and mortality.  To aid diagnosis and monitoring of fibrosis, current recommendations include both the recording of potential environmental and occupational exposures as well as an assessment of lung function (Baumgartner et al., 2000). The latter typically confirms decreased lung function as demonstrated by a loss of lung volume. As the disease progresses, dyspnea and lung function worsen, and the prognosis is directly linked to the decline in FVC (Meltzer and Noble, 2008).   Chronic exposure to cigarette smoke and other combustion-derived particles results in the development of COPD. COPD is diagnosed on the basis of spirometry results as laid out in the ATS/ERS Task Force documents on the standardization of lung function tests and their interpretation (Pellegrino et al., 2005; Culver et al., 2017, Graham et al., 2019). Rapid rates of decline in the lung function parameter FEV1 are linked to higher risk of exacerbations, increased hospitalization and early death (Wise et al., 2006; Celli, 2010). Reduced FEV1 also poses a risk for serious cardiovascular events and mortality associated with cardiovascular disease (Sin et al., 2005; Lee et al., 2015).  &nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/302> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/302> a sbd:Model ;
  rdfs:label "Lung surfactant function inhibition leading to decreased lung function"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Inhibition of lung surfactant function  &nbsp;  The constrained drop surfactometer has been applied to the exposure to a broad range of substances, including nanoparticles (Fan, Wang et al. 2011, Valle, Wu et al. 2015, Yang, Xu et al. 2018, Larsen, Da Silva et al. 2020, Wang, Liu et al. 2020), individual chemicals (Da Silva, Autilio et al. 2021), mixtures of chemicals (S&oslash;rli, Da Silva et al. 2016, S&oslash;rli, Huang et al. 2018, Da Silva, Hickey et al. 2021), excipients for drug formulation (S&oslash;rli, Balogh Sivars et al. 2018), per- and poly-fluoroalkyl substances (S&oslash;rli, L&aring;g et al. 2020), or plasma (Autilio, Echaide et al. 2021).  &nbsp;  The captive bubble surfactometer has been applied to investigation of industrial chemicals (Da Silva, Autilio et al. 2021), nanoparticles (Bakshi, Zhao et al. 2008), cholesterol (Gunasekara, Schurch et al. 2005, Gomez-Gil, Schurch et al. 2009, Lopez-Rodriguez, Ospina et al. 2012), meconium (Lopez-Rodriguez, Echaide et al. 2011, Lopez-Rodriguez, Ospina et al. 2012), plasma (Autilio, Echaide et al. 2021), serum (Lopez-Rodriguez, Ospina et al. 2012, Lopez-Rodriguez, Cruz et al. 2013, Lugones, Blanco et al. 2018), corticosteroids (Hidalgo, Salomone et al. 2017), or cyclodextrines on lung surfactant (Al-Saiedy, Gunasekara et al. 2018).  &nbsp;  The surfactant adsorpion test has been used to study how albumin at the air-liquid interface hinders adsorption of lamellar body like particles (Hobi, Siber et al. 2014).  &nbsp;  Interaction with lung surfactant  &nbsp;  Atomic force microscopy has been extensively used with nanoparticles (including gold nanoparticles, graphene oxide, carbon nanotubes) in order to characterize their presence within surfactant films, to identify interactions with surface-associated structures, and to study the retention at the interface upon film compression (Sachan, Harishchandra et al. 2012, Tatur and Badia 2012, Hu, Jiao et al. 2013, Valle, Wu et al. 2015, Yang, Xu et al. 2018). Atomic force microscopy has also been used to compare the molecular organization and lateral structure of surfactant models in the presence and absence of corticosteroids (Wang, Zhang et al. 2012).  &nbsp;  Langmuir-Blodgett films have been applied successfully to the study of changes induced by resin acids (Jagalski, Barker et al. 2016), nanoparticles (Wang, Liu et al. 2020), soot particles (Fang, Zhao et al. 2020), volatile organic substances (Zhao, Li et al. 2019), industrial chemicals (Da Silva, Autilio et al. 2021), tobacco smoke constituents (Stenger, Alonso et al. 2009), e-cigarette components (Przybyla, Wright et al. 2017), spray products (Larsen, Dallot et al. 2014), corticosteroids (Wang, Zhang et al. 2012), and biological components like cholesterol (Taeusch, Bernardino de la Serna et al. 2005, Zhang, Wang et al. 2012), or meconium (Lopez-Rodriguez, Echaide et al. 2011).  &nbsp;  Cryogenic transmission electron microscopy was applied to study the effects of industrial chemicals (Da Silva, Autilio et al. 2021), resin acids (Jagalski, Barker et al. 2016), meconium (Gross, Zmora et al. 2006, Autilio, Echaide et al. 2021), and nanoparticles (Fan, Wang et al. 2011) on native surfactant.  &nbsp;  Differential scanning calorimetry has been used to investigate the effects of meconium (Lopez-Rodriguez, Echaide et al. 2011), cholesterol (Roldan, Perez-Gil et al. 2017), industrial chemicals (Da Silva, Autilio et al. 2021), or resin acids (Jagalski, Barker et al. 2016) on various membrane models.  &nbsp;  A range of other methods allows to investigate the interaction of a substance with lung surfactant. Binding of lung surfactant components on nanoparticles was shown by proteomics and lipidomics analysis of the corona after incubation in vitro (Gasser, Rothen-Rutishauser et al. 2010) or after exposure of rodents and broncho-alveolar lavage fluid isolation (Kapralov, Feng et al. 2012). Molecular dynamics simulations in silico have been successfully used to investigate the interaction of atmosphere components with lung surfactant (Yuan, Liu et al. 2020), particularly single-wall carbon nanotubes (Xu, Luo et al. 2017), and hydrophilic (hydroxyapatite, silver) and hydrophobic (polystyrene) nanoparticles (Hu, Jiao et al. 2013, Hu, Bai et al. 2017)."@en ;
  foaf:page <https://identifiers.org/aop/302> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/303> a sbd:Model ;
  rdfs:label "Frustrated phagocytosis-induced lung cancer"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "High aspect ratio nanoparticles are not completely engulfed by macrophages due to their long shape (&gt; 10&micro;m) [8, 10].    Some studies analysed the effect of the length of nanoparticles (NPs) on the capacity of macrophages to phagocytose them.  The study of Sweeney et al 2015 demonstrated that treatment of primary human alveolar macrophages by multi-walled carbon nanotubes (MWCNT) similar in term of diameter, specific surface area and purity but differ by their length differentially alter phagocytosis [6]. Indeed, treatment by the longer CNT (median length 19.3 &micro;m) induced frustrated phagocytosis and receptor expression (MARCO) as well as decreased phagocytic ability and migratory capacity in a more extend manner than the shorter CNT (median length 1.1 &micro;m) [6]. Another study analysed the effect of particle morphology on the ability of human monocytic cell line THP-1 to engulf carbon nanotubes [9]. Cells were treated for 24h by two longs CNTs (men length 13 and 36 &micro;m, dimeter 84.89 and 165.02 nm), two tangled CNTs (length 1-5 and 5-20 &micro;m, dimeter 14.84 and 10.40 nm) and one short CNT (length 1-2 &micro;m, diameter 25.7 nm). The authors observed by light microscopy that only the two long CNTs are protruding from the cells. A study on THP-1 cells treated for 4h was conducted with silver nanowires that possess similar diameter but different length (average length: 3, 5, 10, 14 and 28 &micro;m) [8]. The authors observed by bright-field microscopy that the shorter NPs (3 and 5) were fully enclosed by macrophages, while the longer NPs (14 and 28) caused frustrated phagocytosis. In addition, injection of NPs in mouse pleural cavity followed by pleural lavage demonstrated that the shorter (3 and 5) were fully phagocytosed whereas the longer (10) caused frustrated phagocytosis. The authors observed differences between in vitro and in vivo studies in term of sensitivity for the determination of the length threshold that caused frustrated phagocytosis [8]. Finally, Padmore et al showed by time-lapse video microscopy that immortalized MH-S murine alveolar macrophages were able to internalized short glass fibres (mean length 7 &micro;m) whereas the longer fibres were not (mean length 39.3&nbsp;&micro;m) [7].    All together, these studies could suggest that the threshold for frustrated phagocytosis should be around 10 &micro;m, close to the suggestion formulated by Donaldson et al that fibres longer than 15 &micro;m cause this process [10]."@en ;
  foaf:page <https://identifiers.org/aop/303> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/305> a sbd:Model ;
  rdfs:label "5α-reductase inhibition leading to short anogenital distance (AGD) in male (mammalian) offspring"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "In regulatory toxicology, the AGD is mandatory inclusions in OECD test guidelines used to test for developmental and reproductive toxicity of chemicals. Guidelines include &lsquo;TG 443 extended one-generation study&rsquo;, &lsquo;TG 421/422 reproductive toxicity screening studies&rsquo; and &lsquo;TG 414 developmental toxicity study&rsquo;."@en ;
  foaf:page <https://identifiers.org/aop/305> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/306> a sbd:Model ;
  rdfs:label "Androgen receptor (AR) antagonism leading to short anogenital distance (AGD) in male (mammalian) offspring"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "A large number of drugs and chemicals have been shown to antagonise the AR using various AR reporter gene assays. The AR is specifically targeted in AR-sensitive cancers, for example the use of the anti-androgenic drug flutamide in treating prostate cancer (Alapi &amp; Fischer, 2006). Flutamide has also been used in several rodent in vivo studies showing anti-androgenic effects (feminization of male offspring) evident by e.g. short anogenital distance (AGD) in males (Foster &amp; Harris, 2005; Hass et al, 2007; Kita et al, 2016). QSAR models can predict AR antagonism for a wide range of chemicals, many of which have shown in vitro antagonistic potential (Vinggaard et al, 2008)."@en ;
  foaf:page <https://identifiers.org/aop/306> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/306> a sbd:Model ;
  rdfs:label "Androgen receptor (AR) antagonism leading to short anogenital distance (AGD) in male (mammalian) offspring"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "In regulatory toxicology, the AGD is mandatory inclusions in OECD test guidelines used to test for developmental and reproductive toxicity of chemicals. Guidelines include &lsquo;TG 443 extended one-generation study&rsquo;, &lsquo;TG 421/422 reproductive toxicity screening studies&rsquo; and &lsquo;TG 414 developmental toxicity study&rsquo;."@en ;
  foaf:page <https://identifiers.org/aop/306> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/307> a sbd:Model ;
  rdfs:label "Decreased testosterone synthesis leading to short anogenital distance (AGD) in male (mammalian) offspring"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "In regulatory toxicology, the AGD is mandatory inclusions in OECD test guidelines used to test for developmental and reproductive toxicity of chemicals. Guidelines include &lsquo;TG 443 extended one-generation study&rsquo;, &lsquo;TG 421/422 reproductive toxicity screening studies&rsquo; and &lsquo;TG 414 developmental toxicity study&rsquo;."@en ;
  foaf:page <https://identifiers.org/aop/307> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/309> a sbd:Model ;
  rdfs:label "Luteinizing hormone receptor antagonism leading to reproductive dysfunction"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "This AOP describes an adverse outcome that results from the Luteinizing hormone (LH) receptor antagonism leading to reproductive dysfunction in female fish. Luteinizing hormone (LH) is glycoprotein hormones, called gonadotropins, that control gonadal functions. Gonadotropins exert their action through gonadotropin receptors, the LH receptor. In many species, LHR is primarily expressed in reproductive organs and function coordinately to control steroidogenesis and ovulation. It is well known that in teleosts, LHR is expressed primarily in the theca and granulosa cells of preovulatory ovarian follicles. LH regulates the expression of a variety of genes essential for ovulation, such as genes that code for steroidogenic enzymes (CYP11A1) which convert from cholesterol to pregnelone resulting the synthesis of progesterone. It is well organized that the luteinizing hormone triggers ovulation through progesterone binding to the progesterone receptor. The nuclear progesterone receptor, which is a member of the nuclear receptor transcription factor superfamily, has been suggested as an essential factor for LH-dependent ovulation in fish. In conclusion, LHR inhibition leads to a reduction of the synthesis of Progesterone, which is indispensable for ovulation and fertility in fish.  Acknowledgements:&nbsp;This research was supported by the National Research Council of Science &amp; Technology(NST) grant by the Korea&nbsp;government (MSIP) (No. CAP-17-01-KIST Europe)"@en ;
  foaf:page <https://identifiers.org/aop/309> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/310> a sbd:Model ;
  rdfs:label "Embryonic Activation of the AHR leading to Reproductive failure, via epigenetic down-regulation of GnRHR"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/310> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/310> a sbd:Model ;
  rdfs:label "Embryonic Activation of the AHR leading to Reproductive failure, via epigenetic down-regulation of GnRHR"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The AHR can be activated by several structurally diverse chemicals, but binds preferentially to planar halogenated aromatic hydrocarbons and polycyclic aromatic hydrocarbons. Dioxin-like compounds (DLCs), which include polychlorinated dibenzo-p-dioxins (PCDDs), polychlorinated dibenzofurans (PCDFs) and certain polychlorinated biphenyls (PCBs), are among the most potent AHR ligands[38]. Only a subset of PCDD, PCDF and PCB congeners has been shown to bind to the AHR and cause toxic effects to those elicited by TCDD. Until recently, TCDD was considered to be the most potent DLC in birds[39]; however, recent reports indicate that 2,3,4,7,8-pentachlorodibenzofuran (PeCDF) is more potent than TCDD in some species of birds.[40][13][41][21][42][43] When screened for their ability to induce aryl hydrocarbon hydroxylase (AHH) activity, dioxins with chlorine atoms at a minimum of three out of the four lateral ring positions, and with at least one non-chlorinated ring position are the most active[44]. Of the dioxin-like PCBs, non-ortho congeners are the most toxicologically active, while mono-ortho PCBs are generally less potent[45][9]. Chlorine substitution at ortho positions increases the energetic costs of assuming the coplanar conformation required for binding to the AHR [45]. Thus, a smaller proportion of mono-ortho PCB molecules are able to bind to the AHR and elicit toxic effects, resulting in reduced potency of these congeners. Other PCB congeners, such as di-ortho substituted PCBs, are very weak AHR agonists and do not likely contribute to dioxin-like effects [9].   	Contrary to studies of birds and mammals, even the most potent mono-ortho PCBs bind to AhRs of fishes with very low affinity, if at all (Abnet et al 1999; Doering et al 2014; 2015; Eisner et al 2016; Van den Berg et al 1998).   The role of the AHR in mediating the toxic effects of planar hydrophobic contaminants has been well studied, however the endogenous role of the AHR is less clear [1]. Some endogenous and natural substances, including prostaglandin PGG2 and the tryptophan derivatives indole-3-carbinol, 6-formylindolo[3,2-b]carbazole (FICZ) and kynurenic acid can bind to and activate the AHR. [6][46][47][48][49] The AHR is thought to have important endogenous roles in reproduction, liver and heart development, cardiovascular function, immune function and cell cycle regulation [50][38][51][52][53][54][46][55][56][57] and activation of the AHR by DLCs may therefore adversely affect these processes."@en ;
  foaf:page <https://identifiers.org/aop/310> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/310> a sbd:Model ;
  rdfs:label "Embryonic Activation of the AHR leading to Reproductive failure, via epigenetic down-regulation of GnRHR"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Cumulative fecundity is the most apical endpoint considered in the OECD 229 Fish Short Term Reproduction Assay. The OECD 229 assay serves as screening assay for endocrine disruption and associated reproductive impairment (OECD 2012). Fecundity is also an important apical endpoint in the Medaka Extended One Generation Reproduction Test (MEOGRT; OECD Test Guideline 240; OECD 2015).  A variety of fish life cycle tests also include cumulative fecundity as an endpoint (OECD 2008).  &nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/310> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/310> a sbd:Model ;
  rdfs:label "Embryonic Activation of the AHR leading to Reproductive failure, via epigenetic down-regulation of GnRHR"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/310> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/310> a sbd:Model ;
  rdfs:label "Embryonic Activation of the AHR leading to Reproductive failure, via epigenetic down-regulation of GnRHR"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The AHR can be activated by several structurally diverse chemicals, but binds preferentially to planar halogenated aromatic hydrocarbons and polycyclic aromatic hydrocarbons. Dioxin-like compounds (DLCs), which include polychlorinated dibenzo-p-dioxins (PCDDs), polychlorinated dibenzofurans (PCDFs) and certain polychlorinated biphenyls (PCBs), are among the most potent AHR ligands[38]. Only a subset of PCDD, PCDF and PCB congeners has been shown to bind to the AHR and cause toxic effects to those elicited by TCDD. Until recently, TCDD was considered to be the most potent DLC in birds[39]; however, recent reports indicate that 2,3,4,7,8-pentachlorodibenzofuran (PeCDF) is more potent than TCDD in some species of birds.[40][13][41][21][42][43] When screened for their ability to induce aryl hydrocarbon hydroxylase (AHH) activity, dioxins with chlorine atoms at a minimum of three out of the four lateral ring positions, and with at least one non-chlorinated ring position are the most active[44]. Of the dioxin-like PCBs, non-ortho congeners are the most toxicologically active, while mono-ortho PCBs are generally less potent[45][9]. Chlorine substitution at ortho positions increases the energetic costs of assuming the coplanar conformation required for binding to the AHR [45]. Thus, a smaller proportion of mono-ortho PCB molecules are able to bind to the AHR and elicit toxic effects, resulting in reduced potency of these congeners. Other PCB congeners, such as di-ortho substituted PCBs, are very weak AHR agonists and do not likely contribute to dioxin-like effects [9].   	Contrary to studies of birds and mammals, even the most potent mono-ortho PCBs bind to AhRs of fishes with very low affinity, if at all (Abnet et al 1999; Doering et al 2014; 2015; Eisner et al 2016; Van den Berg et al 1998).   The role of the AHR in mediating the toxic effects of planar hydrophobic contaminants has been well studied, however the endogenous role of the AHR is less clear [1]. Some endogenous and natural substances, including prostaglandin PGG2 and the tryptophan derivatives indole-3-carbinol, 6-formylindolo[3,2-b]carbazole (FICZ) and kynurenic acid can bind to and activate the AHR. [6][46][47][48][49] The AHR is thought to have important endogenous roles in reproduction, liver and heart development, cardiovascular function, immune function and cell cycle regulation [50][38][51][52][53][54][46][55][56][57] and activation of the AHR by DLCs may therefore adversely affect these processes."@en ;
  foaf:page <https://identifiers.org/aop/310> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/310> a sbd:Model ;
  rdfs:label "Embryonic Activation of the AHR leading to Reproductive failure, via epigenetic down-regulation of GnRHR"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Cumulative fecundity is the most apical endpoint considered in the OECD 229 Fish Short Term Reproduction Assay. The OECD 229 assay serves as screening assay for endocrine disruption and associated reproductive impairment (OECD 2012). Fecundity is also an important apical endpoint in the Medaka Extended One Generation Reproduction Test (MEOGRT; OECD Test Guideline 240; OECD 2015).  A variety of fish life cycle tests also include cumulative fecundity as an endpoint (OECD 2008).  &nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/310> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/311> a sbd:Model ;
  rdfs:label "Deposition of energy leading to population decline via DNA oxidation and oocyte apoptosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/311> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/311> a sbd:Model ;
  rdfs:label "Deposition of energy leading to population decline via DNA oxidation and oocyte apoptosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Cumulative fecundity is the most apical endpoint considered in the OECD 229 Fish Short Term Reproduction Assay. The OECD 229 assay serves as screening assay for endocrine disruption and associated reproductive impairment (OECD 2012). Fecundity is also an important apical endpoint in the Medaka Extended One Generation Reproduction Test (MEOGRT; OECD Test Guideline 240; OECD 2015).  A variety of fish life cycle tests also include cumulative fecundity as an endpoint (OECD 2008).  &nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/311> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/311> a sbd:Model ;
  rdfs:label "Deposition of energy leading to population decline via DNA oxidation and oocyte apoptosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "It is well documented that ionizing radiation( (eg.&nbsp;X-rays, gamma, photons, alpha, beta, neutrons, heavy ions)&nbsp;leads to energy deposition on the atoms and molecules of the substrate. Many studies, have demonstrated that the type of radiation and distance from source has an impact on the pattern of energy deposition (Alloni, et al. 2014). High linear energy transfer (LET) radiation has been associated with higher-energy deposits (Liamsuwan et al., 2014) that are more densely-packed and cause more complex effects within the particle track (Hada and Georgakilas, 2008; Okayasu, 2012ab; Lorat et al., 2015; Nikitaki et al., 2016) in comparison to low LET radiation. Parameters such as mean lineal energy, dose mean lineal energy, frequency mean specific energy and dose mean specific energy can impact track structure of the traversed energy into a medium (Friedland et al., 2017). The detection of energy deposition by ionizing radiation can be demonstrated with the use of fluorescent nuclear track detectors (FNTDs). FNTDs used in conjunction with fluorescent microscopy, are able to visualize radiation tracks produced by ionizing radiation (Niklas et al., 2013; Kodaira et al., 2015; Sawakuchi and Akselrod, 2016). In addition, these FNTD chips can quantify the LET of primary and secondary radiation tracks up to 0.47 keV/um (Sawakuchi and Akselrod, 2016). This co-visualization of the radiation tracks and the cell markers enable the mapping of the radiation trajectory to specific cellular compartments, and the identification of accrued damage (Niklas et al., 2013; Kodaira et al., 2015). There are no known chemical initiators or prototypes that can mimic the MIE."@en ;
  foaf:page <https://identifiers.org/aop/311> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/311> a sbd:Model ;
  rdfs:label "Deposition of energy leading to population decline via DNA oxidation and oocyte apoptosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/311> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/311> a sbd:Model ;
  rdfs:label "Deposition of energy leading to population decline via DNA oxidation and oocyte apoptosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Cumulative fecundity is the most apical endpoint considered in the OECD 229 Fish Short Term Reproduction Assay. The OECD 229 assay serves as screening assay for endocrine disruption and associated reproductive impairment (OECD 2012). Fecundity is also an important apical endpoint in the Medaka Extended One Generation Reproduction Test (MEOGRT; OECD Test Guideline 240; OECD 2015).  A variety of fish life cycle tests also include cumulative fecundity as an endpoint (OECD 2008).  &nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/311> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/311> a sbd:Model ;
  rdfs:label "Deposition of energy leading to population decline via DNA oxidation and oocyte apoptosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "It is well documented that ionizing radiation( (eg.&nbsp;X-rays, gamma, photons, alpha, beta, neutrons, heavy ions)&nbsp;leads to energy deposition on the atoms and molecules of the substrate. Many studies, have demonstrated that the type of radiation and distance from source has an impact on the pattern of energy deposition (Alloni, et al. 2014). High linear energy transfer (LET) radiation has been associated with higher-energy deposits (Liamsuwan et al., 2014) that are more densely-packed and cause more complex effects within the particle track (Hada and Georgakilas, 2008; Okayasu, 2012ab; Lorat et al., 2015; Nikitaki et al., 2016) in comparison to low LET radiation. Parameters such as mean lineal energy, dose mean lineal energy, frequency mean specific energy and dose mean specific energy can impact track structure of the traversed energy into a medium (Friedland et al., 2017). The detection of energy deposition by ionizing radiation can be demonstrated with the use of fluorescent nuclear track detectors (FNTDs). FNTDs used in conjunction with fluorescent microscopy, are able to visualize radiation tracks produced by ionizing radiation (Niklas et al., 2013; Kodaira et al., 2015; Sawakuchi and Akselrod, 2016). In addition, these FNTD chips can quantify the LET of primary and secondary radiation tracks up to 0.47 keV/um (Sawakuchi and Akselrod, 2016). This co-visualization of the radiation tracks and the cell markers enable the mapping of the radiation trajectory to specific cellular compartments, and the identification of accrued damage (Niklas et al., 2013; Kodaira et al., 2015). There are no known chemical initiators or prototypes that can mimic the MIE."@en ;
  foaf:page <https://identifiers.org/aop/311> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/312> a sbd:Model ;
  rdfs:label "Acetylcholinesterase Inhibition leading to Acute Mortality via Impaired Coordination & Movement​"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Organophosphate and carbamate insecticides are prototypical AChE inhibitors. The OP and carbamate pesticides were synthesized specifically to act as inhibitors of AChE, with OPs developed from early nerve agents (e.g., sarin) and carbamate pesticides based on the natural plant alkaloid physostigmine (Ecobichon 2001). 	A positive and significant correlation between the log of the Eserine IC50 (in vitro) for AChE inhibition and the log Km value for the AChE in the fish and crustacea species has been reported, explaining 92% of the variation in enzyme inhibition (Monserrat and Bianchini, 2001). Similar success was found in relating the rate constants for inhibition of AChE in housefly and the pseudo first-order hydrolysis rate constant for active forms of OPs (Fukuto 1990).    	The open literature includes many studies on vertebrate and invertebrate species that demonstrate a clear dependence of AChE activity on the dose or concentration of the substance with increased concentrations leading to an increase in the inhibition of AChE (e.g., fish ( Karen et al., 2001), birds (Hudson et al., 1984 (see dimethoate and disulfoton), Grue and Shipley 1984; and Al-Zubaidy et al., 2011); cladocera (Barata et al., 2004); nematodes (Rajini et al., 2008); rodents (Roberts et al., 1988; and mollusk (Bianco et al., 2011)). 	The open literature includes many studies on vertebrate and invertebrate species that demonstrate a clear relationship between increasing AChE inhibition as duration of exposure increases (e.g., amphibians ( Venturino et al., 2001); fish (Rao 2008; Ferrari et al., 2004); insects (Rose and Sparks 1984); birds (Ludke 1985; Grue and Shipley 1984); annelids (Reddy and Rao 2008); cladocera (Barata et al., 2004)). 	Rao et al. 2008 exposed the estuarine fish Oreochromis mossambicus to a 24 h LC50 concentration of chlorpyrifos and reported that it took 6 hr to reach &gt;40% AChE inhibition and 24 hr to reach 90% AChE inhibition. It took &gt;100 days to recover to normal AChE levels when fish were placed in clean water. 	A time course study of earthworms (Eisenis foetida) exposed to the 48 hr LC50 of profenofos found a significant relationship (between increases in percent inhibition of AChE and increase in time of exposure from 8-48 hrs (Chakra Reddy and Rao 2008)."@en ;
  foaf:page <https://identifiers.org/aop/312> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/312> a sbd:Model ;
  rdfs:label "Acetylcholinesterase Inhibition leading to Acute Mortality via Impaired Coordination & Movement​"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/312> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/312> a sbd:Model ;
  rdfs:label "Acetylcholinesterase Inhibition leading to Acute Mortality via Impaired Coordination & Movement​"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Increased mortality is one of the most common regulatory assessment endpoints,&nbsp;along with reduced growth and reduced reproduction."@en ;
  foaf:page <https://identifiers.org/aop/312> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/312> a sbd:Model ;
  rdfs:label "Acetylcholinesterase Inhibition leading to Acute Mortality via Impaired Coordination & Movement​"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Organophosphate and carbamate insecticides are prototypical AChE inhibitors. The OP and carbamate pesticides were synthesized specifically to act as inhibitors of AChE, with OPs developed from early nerve agents (e.g., sarin) and carbamate pesticides based on the natural plant alkaloid physostigmine (Ecobichon 2001). 	A positive and significant correlation between the log of the Eserine IC50 (in vitro) for AChE inhibition and the log Km value for the AChE in the fish and crustacea species has been reported, explaining 92% of the variation in enzyme inhibition (Monserrat and Bianchini, 2001). Similar success was found in relating the rate constants for inhibition of AChE in housefly and the pseudo first-order hydrolysis rate constant for active forms of OPs (Fukuto 1990).    	The open literature includes many studies on vertebrate and invertebrate species that demonstrate a clear dependence of AChE activity on the dose or concentration of the substance with increased concentrations leading to an increase in the inhibition of AChE (e.g., fish ( Karen et al., 2001), birds (Hudson et al., 1984 (see dimethoate and disulfoton), Grue and Shipley 1984; and Al-Zubaidy et al., 2011); cladocera (Barata et al., 2004); nematodes (Rajini et al., 2008); rodents (Roberts et al., 1988; and mollusk (Bianco et al., 2011)). 	The open literature includes many studies on vertebrate and invertebrate species that demonstrate a clear relationship between increasing AChE inhibition as duration of exposure increases (e.g., amphibians ( Venturino et al., 2001); fish (Rao 2008; Ferrari et al., 2004); insects (Rose and Sparks 1984); birds (Ludke 1985; Grue and Shipley 1984); annelids (Reddy and Rao 2008); cladocera (Barata et al., 2004)). 	Rao et al. 2008 exposed the estuarine fish Oreochromis mossambicus to a 24 h LC50 concentration of chlorpyrifos and reported that it took 6 hr to reach &gt;40% AChE inhibition and 24 hr to reach 90% AChE inhibition. It took &gt;100 days to recover to normal AChE levels when fish were placed in clean water. 	A time course study of earthworms (Eisenis foetida) exposed to the 48 hr LC50 of profenofos found a significant relationship (between increases in percent inhibition of AChE and increase in time of exposure from 8-48 hrs (Chakra Reddy and Rao 2008)."@en ;
  foaf:page <https://identifiers.org/aop/312> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/312> a sbd:Model ;
  rdfs:label "Acetylcholinesterase Inhibition leading to Acute Mortality via Impaired Coordination & Movement​"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/312> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/312> a sbd:Model ;
  rdfs:label "Acetylcholinesterase Inhibition leading to Acute Mortality via Impaired Coordination & Movement​"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Increased mortality is one of the most common regulatory assessment endpoints,&nbsp;along with reduced growth and reduced reproduction."@en ;
  foaf:page <https://identifiers.org/aop/312> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/313> a sbd:Model ;
  rdfs:label "Stimulation of TLR7/8 in dendric cells leading to Psoriatic skin disease"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Psoriasis model mice have been developed as a tool for understanding the etiology of this disease and as a preclinical model. Five representative models are based on K14-amphiregulin, K5-Stat3C, K5-Tie2, K5-TGF-&beta;1, and imiquimod. There were statistically significant similarities between the gene expression patterns associated with epidermal development and keratinization in these models and the gene expression patterns in human psoriasis. Direct high-level activation of keratinocytes via autoclean growth factor (amphiregulin) has the ability to induce cytokine-related genetic circuits that closely resemble human psoriasis. Through transgenes, inward mutations (CARD14), injury, and exposure to specific T cell-producing cytokines, activated keratinocytes induce and lead to a chronic inflammatory response that is highly consistent with psoriasis. However, there were frequent differences in the expression of immune-related genes between the models. (Cook PW et al. 1997)  &nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/313> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/313> a sbd:Model ;
  rdfs:label "Stimulation of TLR7/8 in dendric cells leading to Psoriatic skin disease"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Psoriasis is an chronic autoimmune disease characterized &nbsp;by chronic epithelial inflammatory disease induced by environmental factors such as infection, stress, smoking or alcohol consumption as well as by genetic factors. The onset of psoriasis has been reported to be triggered by drugs and chemical substances use, including &nbsp;beta-blockers, chloroquine, lithium, ACE inhibitors, indomethacin, terbinafine, and interferon alpha. Diagnosis is based on the type and distribution of the lesions.  Psoriasis occurs when abnormal differentiation (keratosis) of keratinocytes leads to thickening of the epidermis. Patients often exhibit an erythema with a clear border and epidermal hyperplasia, stratum corneum hyperplasia, heterocytosis in the stratum corneum, mixed skin moist cells of neutrophilic granulocytes and T cells in the epidermis. Dendritic cells (DC) and macrophages are associated with silver-white plaque. Neutrophilic effusion (Munro microabscesses) are observed in the epidermis, and CD8+ T cells (Tc17) increase the expression of angiogenesis related genes.  The main therapeutic agents are mild topical treatments such as emollients, salicylic acid, coal tar preparations, anthralin, corticosteroids, vitamin D3 derivatives, retinoids, calcineurin inhibitors or tazarotene. UV therapy is also used for moderate or severe psoriasis. Widespread psoriasis is treated with systemic therapies such as immunomodulators methotrexate, cyclosporin, retinoids and other immunosuppressants used alone or in combination.  Although there are stressors that are well known to induce psoriasis-like skin inflammation in mice, this AOP is based primarily on an understanding of stimulation caused by imiquimod, resiquimod or LL37-selfRNA complexes, for which a significant body of scientific literature has been published.  As a test model for psoriasis, an Autoimmune skin disease, mouse tests that induce skin inflammation like psoriasis are frequently conducted using the imidazoquinoline derivative imiquimod. This AOP is primarily based on an understanding of stimuli caused by imiquimod, resiquimod, or LL37-selfRNA complexes.  Imiquimod is derived from imidazoquinoline and is often used to create mouse models. It is our hope that this AOP will contribute to greater knowledge about the development of psoriatic skin diseases that start from stimulation of TLR as well as the development of new treatment targets for psoriasis."@en ;
  foaf:page <https://identifiers.org/aop/313> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/314> a sbd:Model ;
  rdfs:label "Binding to estrogen receptor (ER)-α in immune cells leading to exacerbation of systemic lupus erythematosus (SLE)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "It is well recognized that allergic diseases and autoimmune diseases are markedly increased the last several decades.&nbsp; About the same time, increasing scientific and social attention had been paid to environmentally dispersed chemicals that can enter the body by ingestion or adsorption and that mimic the actions of estrogens.&nbsp; These chemicals are termed endocrine disruptors (EDs) or environmental estrogens and are found in plastics (bisphenol-A, phthalates), pesticides (DDT, hexachlorobenzene, and dieldrin) and the like.&nbsp; Some of these estrogenic chemicals have also been shown to influence the immune system.&nbsp; Endocrine disruptors mimic hormones, block or alter hormone binding to receptors, or alter the metabolism of natural estrogens.&nbsp; It has been widely noted that females have stronger immune capabilities than males, as evidenced by their better immune responses to a variety of self-antigens and non-self-antigens, or vaccination.&nbsp; Paradoxically, the stronger immune response comes at a steep price, which is the high incidence of autoimmune diseases in females.&nbsp; This phenomenon of gender-based immune capability is largely attributed to the effects of sex hormones.&nbsp; Estrogens regulate the level of serum and uterine IgM, IgA, and IgG, and they augment antibody production to several nonself- antigens and self-antigens. It is possible that endocrine disruptors that mimic estrogenic activity may be involved in the increased incidence of autoimmune diseases such as SLE (Yurino H. 2004, Vaishali RM. 2018)."@en ;
  foaf:page <https://identifiers.org/aop/314> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/314> a sbd:Model ;
  rdfs:label "Binding to estrogen receptor (ER)-α in immune cells leading to exacerbation of systemic lupus erythematosus (SLE)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "E2 activates ER&alpha; and ER&beta; with the same affinity although they share only 56% similarity in their ligand binding domains (Monroe DG. 2005, Papoutsi Z. 2009).&nbsp; Exposure E2 induced thymic atrophy, and changing T-cell phenotype (decreasing double positive (CD4+CD8+) T cell and increasing double negative (CD4-CD8-) T cell) in thymus (Okasha SA. 2001).  BPA binds to both ER&alpha; and ER&beta;, and ER&alpha; binding affinity of BPA is lower than that of ER&beta; (Takayanagi S. 2006).&nbsp; While these bindings are less than 2000‑fold affinity compared to the binding of estradiol to estrogen receptors (Krishnan AV. 1993).  Propylpyrazoletriol (PPT) is an ER&alpha;-selective agonist, which shows 410-fold selectivity for ER&alpha; as compared with ER&beta; (Kraichely DM. 2000, Li J. 2006). &nbsp;Li et al (2006) demonstrated that ovariectomized mice exposed PPT induced severe thymic atrophy, changing T-cell phenotype (CD4/CD8 phenotype profile) in thymus, and a reduction of mature B cell number in spleen.&nbsp; Since these effects by PPT were equal to or greater than E2, ER&alpha; plays the predominant role in the upregulation of immune responses."@en ;
  foaf:page <https://identifiers.org/aop/314> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/314> a sbd:Model ;
  rdfs:label "Binding to estrogen receptor (ER)-α in immune cells leading to exacerbation of systemic lupus erythematosus (SLE)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "There are concerns about the increase in autoimmune diseases caused by estrogen-like substances, and its accurate in vitro toxicity assessment system is required in international regulations.&nbsp; The OECD has published a revised version of the guidance document on standardized test guidelines for evaluating ED (OECD. 2019)."@en ;
  foaf:page <https://identifiers.org/aop/314> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/315> a sbd:Model ;
  rdfs:label "Inhibition of JAK3 leading to impairment of T-Cell Dependent Antibody Response"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "TDAR is considered to be the most important endpoint of immunotoxicity, because T cells, B cells, and antigen-presenting cells, such as dendritic cells, are involved in inducing and developing TDAR. Thus, changes in any of these immune cell populations can influence TDAR.  The ICH S8 immunotoxicity testing guideline on pharmaceuticals recommends that TDAR can be evaluated whenever the target cells of immunotoxicity are not clear based on pharmacology and findings in standard toxicity studies. For the assessment of pesticides, the United States Environmental Protection Agency Office of Prevention, Pesticides and Toxic Substances &nbsp;870.7800 immunotoxicity testing guideline recommends TDAR using SRBC.  Finally, the draft Food and Drug Administration guidance of nonclinical safety evaluation for immunotoxicology recommends the TDAR assay."@en ;
  foaf:page <https://identifiers.org/aop/315> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/315> a sbd:Model ;
  rdfs:label "Inhibition of JAK3 leading to impairment of T-Cell Dependent Antibody Response"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Although many stressors inhibit JAK3 activity, this AOP is based on immunosuppression caused by the recently developed and highly selective JAK3 inhibitors PF-06651600 and RB1. A significant body of scientific literature has been published concerning these two inhibitors. We look forward to future amendments to this AOP with up-to-date information on other stressors, which will clarify the link between inhibition of JAK activity and impairment of TDAR."@en ;
  foaf:page <https://identifiers.org/aop/315> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/316> a sbd:Model ;
  rdfs:label "Trypsin inhibition leading to pancreatic acinar cell tumors"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Raw soy flour and purified trypsin inhibitors (TI) cause pancreatic hypertrophy and hyperplasia in some mammalian species, and prolonged treatment with high levels of TI contained in raw soy induced pancreatic nodular hyperplasia and acinar cell adenoma [Rackis JJ, 1965; McGuinness EE et al, 1984; McGuinness EE et al, 1980; McGuinness EE et al, 1985; McGuinness EE and Wormsley KG, 1986; Gumbmann MR et al, 1986]. TI also promoted nodular hyperplasia and tumor formation in rats treated with low levels of pancreatic carcinogens such as azaserine [McGuinness EE et al, 1984; McGuinness EE et al, 1987; Lhoste EF et al, 1988]. These findings question the safety of TI-containing plant foods, and many different studies and reviews have been published to date. The important factors for TI-induced pancreatic acinar cell tumors seem to be a high level of CCK release and CCK-stimulated acinar cell proliferation. In the present AOP, the pathway progressing from trypsin inhibition to pancreatic acinar cell tumor formation is considered from the viewpoints of such key factors."@en ;
  foaf:page <https://identifiers.org/aop/316> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/316> a sbd:Model ;
  rdfs:label "Trypsin inhibition leading to pancreatic acinar cell tumors"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "TBD"@en ;
  foaf:page <https://identifiers.org/aop/316> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/318> a sbd:Model ;
  rdfs:label "Glucocorticoid Receptor activation leading to hepatic steatosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Steatosis is a regulatory endpoint and has been used as an endpoint in many US EPA assessments, including IRIS assessments."@en ;
  foaf:page <https://identifiers.org/aop/318> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/319> a sbd:Model ;
  rdfs:label "Binding to ACE2 leading to lung fibrosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "ACE2 is an essential enzyme of blood pressure regulation in the renin-angiotensin system. ACE2 is primarily expressed on type II alveolar epithelial cells within the respiratory system. Angiotensin-converting enzyme (ACE) synthesizes the dominant vasoconstriction, inflammatory and profibrotic angiotensin II (Ang II) through its carboxypeptidase function&nbsp;on the decapeptide angiotensin I. In the meantime, Angiotensin-converting enzyme 2&nbsp;(ACE2) is an&nbsp;exopeptidase&nbsp;that catalyzes the conversion of&nbsp;angiotensin Il&nbsp;to&nbsp;the conversion of&nbsp;angiotensin 1-7 function as vasodilation, anti-inflammation, and anti-fibrotic.&nbsp;&nbsp;This AOP describes the dysfunction of membrane ACE2, which results in a high level of angiotensin Ang II synthesized by ACE, which can further lead to pulmonary fibrosis by excessive collagen deposition&nbsp;as the most potent profibrotic factor.  &nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/319> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/320> a sbd:Model ;
  rdfs:label "Binding of SARS-CoV-2 to ACE2 receptor leading to acute respiratory distress associated mortality"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Increased mortality is one of the most common regulatory assessment endpoints,&nbsp;along with reduced growth and reduced reproduction."@en ;
  foaf:page <https://identifiers.org/aop/320> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/320> a sbd:Model ;
  rdfs:label "Binding of SARS-CoV-2 to ACE2 receptor leading to acute respiratory distress associated mortality"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Receptor recognition is an essential determinant of molecular level in this AOP. ACE2 was reported as an entry receptor for SARS-CoV-2. The viral entry process is mediated by the envelope-embedded surface-located spike (S) glycoprotein.&nbsp; Jun Lan and Walls, A.C et al (Nature 581, 215&ndash;220; Cell 180, 281&ndash;292) demonstrated a critical initial step of infection at the molecular level from the interaction of ACE2 and S protein. ACE2 has shown that receptor binding affinity to S protein is nM range. To elucidate the interaction between the SARS-CoV-2 RBD and ACE2 at a higher resolution, they also determined the structure of the SARS-CoV-2 RBD&ndash;ACE2 complex using X-ray crystallography. The expression and distribution of the ACE2 in human body may indicate the potential infection of SARS-CoV-2. Through the developed single-cell RNA sequencing (scRNA-Seq) technique and single-cell transcriptomes based on the public database, researchers analyzed the ACE2 RNA expression profile at single-cell resolution. High ACE2 expression was identified in type II alveolar cells (Zou, X. et al. Front. Med.2020)  SARS-CoV-2 belongs to the Coronaviridae family, which includes evolutionary related enveloped (+) strand RNA viruses of vertebrates, such as seasonal common coronaviruses, SARS-CoV and CoV-NL63, SARS-CoV (Kim Young Jun et al)   	 		 			 			Human viruses strains 			 			 			Genus 			 			 			Major cell receptor 			 			 			First report 			 			 			Animal reservoir 			 			 			Intermediate host 			 			 			Pathology 			 			 			Diagnostic test 			 			 			Evidence 			 		 		 			 			HCoV-NL63 			 			 			Alphacoronavirus 			 			 			ACE2 			 			 			2004 			 			 			Bat 			 			 			Unknown 			 			 			Mild respiratory tract illness 			 			 			RT-PCR, IF, ELISA, WB 			 			 			Strong 			 		 		 			 			SARS-CoV 			 			 			Betacoronavirus 			 			 			ACE2 			 			 			2003 			 			 			Bat 			 			 			Pangolin 			 			 			Severe acute respiratory syndrome 			 			 			RT-PCR, IF, ELISA, WB 			 			 			Strong 			 		 		 			 			SARS-CoV-2 			 			 			Betacoronavirus 			 			 			ACE2 			 			 			2020 			 			 			Bat 			 			 			Pangolin 			 			 			Severe acute respiratory syndrome 			 			 			RT-PCR, IF, ELISA, WB 			 			 			Strong"@en ;
  foaf:page <https://identifiers.org/aop/320> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/320> a sbd:Model ;
  rdfs:label "Binding of SARS-CoV-2 to ACE2 receptor leading to acute respiratory distress associated mortality"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The&nbsp;ACE2&nbsp;gene encodes the angiotensin-converting enzyme-2, which has been proved to be the receptor for both the SARS-coronavirus (SARS-CoV) and the human respiratory coronavirus. ACE2 is a key component of blood pressure regulation in the renin-angiotensin system. Angiotensin (Ang) converting enzyme 2 (ACE2) is a homolog of ACE. &nbsp;ACE2 negatively regulates the renin-angiotensin system (RAS) by converting Ang II to Ang-(1-7) and AngI to Ang(1-9). The higher levels of receptor expression achieved by the expression of recombinant ACE2 could be relevant for cell-cell fusion. The underlying mechanisms remain to be elucidated and could play a role in the entry of the cell-free virus into cells and finally increase the acute respiratory distress associated with mortality."@en ;
  foaf:page <https://identifiers.org/aop/320> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/322> a sbd:Model ;
  rdfs:label "Alkylation of DNA leading to reduced sperm count"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Alkylating agents are prototypical DNA-reactive compounds and have been extensively studied for decades (reviewed in Beranek 1990). The chemicals can be direct-acting electrophiles, or can be converted from non-reactive substances to reactive metabolites via metabolism. A prototypical alkylating agent is N-ethyl-N-nitrosourea (chemical formula C3H7N3O2) (ENU). ENU is rapidly absorbed following oral exposure and intraperitoneal injections and distributed widely across the tissues. ENU is unstable and readily reacts with somatic and germ cell DNA in mice, rats, flies and hamsters, to alkylate DNA. Very generally, mono-functional (referring to the transfer of a single alkyl group) alkylating agents include: 1.	Alkyl sulfates: e.g., diethyl (DES) and dimethyl sulfate (DMS);  2.	Alkyl alkanesulfonates: e.g., methyl (MMS) and ethyl methanesulfonate (EMS);  3.	Nitrosamides: e.g., methyl (MNU) and ethyl nitrosourea (ENU), methyl- (MNNG) and ethyl-N'-nitro-N-nitrosoguanidine (ENNG), and the indirect-acting (i.e., requiring metabolic activation) dimethyl (DMN) and diethyl nitrosamines (DEN).  ENU is the most widely studied and understood alkylating agent and as such has been instrumental in contributing to the knowledgebase in this field. Immunohistochemistry studies clearly indicate the presence of alkylated DNA following exposure to ENU in both somatic cells and spermatogonia (Kamino et al. 1995; Seiler et al. 1997; van Zeeland et al. 1990)."@en ;
  foaf:page <https://identifiers.org/aop/322> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/323> a sbd:Model ;
  rdfs:label "PPARalpha Agonism Impairs Fish Reproduction"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/323> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/323> a sbd:Model ;
  rdfs:label "PPARalpha Agonism Impairs Fish Reproduction"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Fibrates are ligands of PPAR&alpha; (Staels et al. 1998).  Phthalates  MHEP (CAS 4376-20-9) directly binds in vitro to PPAR&alpha; (Lapinskas et al. 2005) and activates this receptor in transactivation assays PPAR&alpha; (Lapinskas et al. 2005), (Maloney and Waxman 1999), (Hurst and Waxman 2003), (Bility et al. 2004), (Lampen, Zimnik, and Nau 2003), (Venkata et al. 2006) ]. DEHP (CAS 117-81-7) has not been found to bind and activate PPAR&alpha; (Lapinskas et al. 2005), (Maloney and Waxman 1999). However, the recent studies shown activation of PPAR&alpha; (ToxCastTM Data).  Notably, PPAR&alpha; are responsive to DEHP in vitro as they are translocated to the nucleus (in primary Sertoli cells) (Dufour et al. 2003), (Bhattacharya et al. 2005). Expression of PPAR&alpha; [mRNA and protein] has been reported to be also modulated by phthtalates: (to be up-regulated in vivo upon DEHP treatment (Xu et al. 2010) and down-regulated by Diisobutyl phthalate (DiBP) (Boberg et al. 2008)).   Perfluorooctanoic Acid (PFOA) is known to activate PPAR&alpha; (Vanden Heuvel et al. 2006).  Organotin  Tributyltin (TBT) activates all three heterodimers of PPAR with RXR, primarily through its interaction with RXR (le Maire et al. 2009)"@en ;
  foaf:page <https://identifiers.org/aop/323> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/323> a sbd:Model ;
  rdfs:label "PPARalpha Agonism Impairs Fish Reproduction"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/323> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/323> a sbd:Model ;
  rdfs:label "PPARalpha Agonism Impairs Fish Reproduction"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Fibrates are ligands of PPAR&alpha; (Staels et al. 1998).  Phthalates  MHEP (CAS 4376-20-9) directly binds in vitro to PPAR&alpha; (Lapinskas et al. 2005) and activates this receptor in transactivation assays PPAR&alpha; (Lapinskas et al. 2005), (Maloney and Waxman 1999), (Hurst and Waxman 2003), (Bility et al. 2004), (Lampen, Zimnik, and Nau 2003), (Venkata et al. 2006) ]. DEHP (CAS 117-81-7) has not been found to bind and activate PPAR&alpha; (Lapinskas et al. 2005), (Maloney and Waxman 1999). However, the recent studies shown activation of PPAR&alpha; (ToxCastTM Data).  Notably, PPAR&alpha; are responsive to DEHP in vitro as they are translocated to the nucleus (in primary Sertoli cells) (Dufour et al. 2003), (Bhattacharya et al. 2005). Expression of PPAR&alpha; [mRNA and protein] has been reported to be also modulated by phthtalates: (to be up-regulated in vivo upon DEHP treatment (Xu et al. 2010) and down-regulated by Diisobutyl phthalate (DiBP) (Boberg et al. 2008)).   Perfluorooctanoic Acid (PFOA) is known to activate PPAR&alpha; (Vanden Heuvel et al. 2006).  Organotin  Tributyltin (TBT) activates all three heterodimers of PPAR with RXR, primarily through its interaction with RXR (le Maire et al. 2009)"@en ;
  foaf:page <https://identifiers.org/aop/323> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/324> a sbd:Model ;
  rdfs:label "Thermal stress leading to population decline (1)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/324> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/324> a sbd:Model ;
  rdfs:label "Thermal stress leading to population decline (1)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/324> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/325> a sbd:Model ;
  rdfs:label "Thermal stress leading to population decline (2)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/325> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/325> a sbd:Model ;
  rdfs:label "Thermal stress leading to population decline (2)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/325> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/326> a sbd:Model ;
  rdfs:label "Thermal stress leading to population decline (3)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/326> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/326> a sbd:Model ;
  rdfs:label "Thermal stress leading to population decline (3)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/326> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/327> a sbd:Model ;
  rdfs:label "Excessive reactive oxygen species production leading to mortality (1)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The Adverse Outcome is highly significant from a regulatory point of view. It is employed as regulatory endpoint in most studies assessing the toxicity of stressors."@en ;
  foaf:page <https://identifiers.org/aop/327> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/328> a sbd:Model ;
  rdfs:label "Excessive reactive oxygen species production leading to mortality (2)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The Adverse Outcome is highly significant from a regulatory point of view. It is employed as regulatory endpoint in most studies assessing the toxicity of stressors."@en ;
  foaf:page <https://identifiers.org/aop/328> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/329> a sbd:Model ;
  rdfs:label "Excessive reactive oxygen species production leading to mortality (3)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The Adverse Outcome is highly significant from a regulatory point of view. It is employed as regulatory endpoint in most studies assessing the toxicity of stressors."@en ;
  foaf:page <https://identifiers.org/aop/329> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/330> a sbd:Model ;
  rdfs:label "Excessive reactive oxygen species production leading to mortality (4)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The Adverse Outcome is highly significant from a regulatory point of view. It is employed as regulatory endpoint in most studies assessing the toxicity of stressors."@en ;
  foaf:page <https://identifiers.org/aop/330> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/331> a sbd:Model ;
  rdfs:label "Formation of DNA photoproducts leading to growth inhibition (1)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The Adverse Outcome is highly significant from a regulatory point of view. It is employed as regulatory endpoint in most studies assessing the toxicity of stressors."@en ;
  foaf:page <https://identifiers.org/aop/331> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/334> a sbd:Model ;
  rdfs:label "Glucocorticoid Receptor Agonism Leading to Impaired Fin Regeneration"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/334> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/334> a sbd:Model ;
  rdfs:label "Glucocorticoid Receptor Agonism Leading to Impaired Fin Regeneration"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Pending"@en ;
  foaf:page <https://identifiers.org/aop/334> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/336> a sbd:Model ;
  rdfs:label "DNA methyltransferase inhibition leading to population decline (1)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/336> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/336> a sbd:Model ;
  rdfs:label "DNA methyltransferase inhibition leading to population decline (1)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/336> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/337> a sbd:Model ;
  rdfs:label "DNA methyltransferase inhibition leading to population decline (2)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/337> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/337> a sbd:Model ;
  rdfs:label "DNA methyltransferase inhibition leading to population decline (2)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/337> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/338> a sbd:Model ;
  rdfs:label "DNA methyltransferase inhibition leading to population decline (3)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/338> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/338> a sbd:Model ;
  rdfs:label "DNA methyltransferase inhibition leading to population decline (3)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/338> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/339> a sbd:Model ;
  rdfs:label "DNA methyltransferase inhibition leading to population decline (4)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/339> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/339> a sbd:Model ;
  rdfs:label "DNA methyltransferase inhibition leading to population decline (4)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/339> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/34> a sbd:Model ;
  rdfs:label "LXR activation leading to hepatic steatosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "1.1 Binding and activation of receptor  PPAR&gamma; ligands thiazolidinediones (Rosiglitazone, Pioglitazone, Troglitazone) (Lehmann et al. 1995), (Forman et al. 1995), (Willson et al. 2000).  Phthalates  MEHP (CAS 4376-20-9) directly binds to PPAR&gamma; (Lapinskas et al. 2005), (ToxCastTM Data)in vitro and in silico (Feige et al. 2007), (Rotman et al. 2008), (Kaya et al. 2006) and activates this receptor in transactivation assays (Maloney &amp; Waxman 1999), (Hurst &amp; Waxman 2003b), (Venkata et al. 2006), (ToxCastTM Data). In summary, there is experimental in vitro evidence for binding and transcriptional activation of PPAR&gamma;. DEHP (CAS 117-81-7) was not found to bind and activate PPAR&gamma; (Lapinskas et al. 2005), (Maloney &amp; Waxman 1999). However recent studies show activation of PPAR&gamma; by DEHP(ToxCastTM Data), (Pereira-Fernandes et al. 2013). DEHP was also found to increase the levels of PPAR&gamma; in vitro (Lin et al. 2011). Notably, PPAR&gamma; is responsive to DEHP in vitro and is translocated to the nucleus (in primary Sertoli cells) (Dufour et al. 2003), (Bhattacharya et al. 2005).  Parabens  Butylparaben was not found to bind to the PPAR&gamma; (ToxCastTM Data), but activated the human PPAR&gamma; (ToxCastTM Data), (Pereira-Fernandes et al. 2013) and mPPAR&gamma; in reporter gene assay (Taxvig et al., 2012).  Phenols  Bisphenol A was not found to bind to the PPAR&gamma; (ToxCastTM Data), but activated the human PPAR&gamma; (ToxCastTM Data), (Pereira-Fernandes et al. 2013) but not mouse PPAR&gamma; (Taxvig et al., 2012) in reporter gene assay. BPA was also reported to increase PPAR&gamma; (mRNA) in ovarian granulosa cell line and human luteinized granulosa cells (Kwintkiewicz, Nishi, Yanase, &amp; Giudice, 2010).  Organotin  Tributyltin (TBT) activates all three heterodimers of PPAR with RXR, primarily through its interaction with RXR (le Maire et al. 2009).   1.2 Activation of target genes  MEHP activation of endogenous PPAR&gamma; target genes was evidenced by the stimulation of PPAR&gamma;-dependent adipogenesis in the 3T3-L1 cell differentiation model (Hurst &amp; Waxman, 2003)."@en ;
  foaf:page <https://identifiers.org/aop/34> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/340> a sbd:Model ;
  rdfs:label "DNA methyltransferase inhibition leading to transgenerational effects (1)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/340> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/340> a sbd:Model ;
  rdfs:label "DNA methyltransferase inhibition leading to transgenerational effects (1)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/340> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/341> a sbd:Model ;
  rdfs:label "DNA methyltransferase inhibition leading to transgenerational effects (2)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/341> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/341> a sbd:Model ;
  rdfs:label "DNA methyltransferase inhibition leading to transgenerational effects (2)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/341> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/342> a sbd:Model ;
  rdfs:label "S-adenosylmethionine depletion leading to population decline (1)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Stressors known to competitively inhibit CHS1 are polyoxin B, polyoxin D and Nikkomycin Z (Cohen and Casida 1982; Cohen and Casida 1990; Zhang and Yan Zhu 2013). There may also be stressors that inhibit CHS-1 in a non-competitive manner which may become apparent in further characterization efforts of this MIE. There is also a study that reports inhibition of CHS-1 by the phthalimide fungicide captan (Cohen and Casida 1982). However, it remains elusive if the observed inhibition is due to specific interaction with the enzyme or due to unspecific protein binding which is the predominant mode of action of phthalimides (Lukens and Sisler 1958)."@en ;
  foaf:page <https://identifiers.org/aop/342> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/342> a sbd:Model ;
  rdfs:label "S-adenosylmethionine depletion leading to population decline (1)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The Adverse Outcome is highly significant from a regulatory point of view. It is employed as regulatory endpoint in most studies assessing the toxicity of stressors."@en ;
  foaf:page <https://identifiers.org/aop/342> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/343> a sbd:Model ;
  rdfs:label "S-adenosylmethionine depletion leading to population decline (2)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The Adverse Outcome is highly significant from a regulatory point of view. It is employed as regulatory endpoint in most studies assessing the toxicity of stressors."@en ;
  foaf:page <https://identifiers.org/aop/343> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/344> a sbd:Model ;
  rdfs:label "Androgen receptor (AR) antagonism leading to nipple retention (NR) in male (mammalian) offspring"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "A large number of drugs and chemicals have been shown to antagonise the AR using various AR reporter gene assays. The AR is specifically targeted in AR-sensitive cancers, for example the use of the anti-androgenic drug flutamide in treating prostate cancer (Alapi &amp; Fischer, 2006). Flutamide has also been used in several rodent in vivo studies showing anti-androgenic effects (feminization of male offspring) evident by e.g. short anogenital distance (AGD) in males (Foster &amp; Harris, 2005; Hass et al, 2007; Kita et al, 2016). QSAR models can predict AR antagonism for a wide range of chemicals, many of which have shown in vitro antagonistic potential (Vinggaard et al, 2008)."@en ;
  foaf:page <https://identifiers.org/aop/344> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/344> a sbd:Model ;
  rdfs:label "Androgen receptor (AR) antagonism leading to nipple retention (NR) in male (mammalian) offspring"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "NR is recognized by the OECD as a relevant measure for anti-androgenic effects and is mandatory in the test guidelines Extended One Generation Reproductive Toxicity Study, TG 443 (OECD, 2018) and the two screening studies for reproductive toxicity, TGs 421/422 (OECD, 2016a, 2016b). The endpoint is also described in the guidance documents 43 (OECD, 2008) and 151 (OECD, 2013). Furthermore, NR data can be used in chemical risk assessment for setting the No Observed Adverse Effect Level (NOAEL) as stated in the OECD guidance document 151 (OECD, 2013): &ldquo;A statistically significant change in nipple retention should be evaluated similarly to an effect on AGD as both endpoints indicate an adverse effect of exposure and should be considered in setting a NOAEL&rdquo;."@en ;
  foaf:page <https://identifiers.org/aop/344> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/345> a sbd:Model ;
  rdfs:label "Androgen receptor (AR) antagonism leading to decreased fertility in females"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "A large number of drugs and chemicals have been shown to antagonise the AR using various AR reporter gene assays. The AR is specifically targeted in AR-sensitive cancers, for example the use of the anti-androgenic drug flutamide in treating prostate cancer (Alapi &amp; Fischer, 2006). Flutamide has also been used in several rodent in vivo studies showing anti-androgenic effects (feminization of male offspring) evident by e.g. short anogenital distance (AGD) in males (Foster &amp; Harris, 2005; Hass et al, 2007; Kita et al, 2016). QSAR models can predict AR antagonism for a wide range of chemicals, many of which have shown in vitro antagonistic potential (Vinggaard et al, 2008)."@en ;
  foaf:page <https://identifiers.org/aop/345> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/346> a sbd:Model ;
  rdfs:label "Aromatase inhibition leads to male-biased sex ratio via impacts on gonad differentiation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/346> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/346> a sbd:Model ;
  rdfs:label "Aromatase inhibition leads to male-biased sex ratio via impacts on gonad differentiation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Characterization of chemical properties: Chemicals are known to inhibit aromatase activity through two primary molecular mechanisms. Steroid-like structures can inhibit the enzyme at its active site, with structures having ∆4 positioned double bonds generally acting as stronger inhibitors than those with ∆5 positioned double bonds (Petkov et al. 2009). Non-steroidal aromatase inhibitors generally act by interfering with electron transfer via the cytochrome P450 heme group of the aromatase enzyme, with greater nucleophilicity of the heteroatom contributing to greater potency as an inhibitor (Petkov et al. 2009). Petkov et al. (Petkov et al. 2009) have provided a detailed analysis of structural categorization of chemicals as potential steroidal or non-steroidal aromatase inhibitors."@en ;
  foaf:page <https://identifiers.org/aop/346> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/346> a sbd:Model ;
  rdfs:label "Aromatase inhibition leads to male-biased sex ratio via impacts on gonad differentiation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "In fish&nbsp;sexual differentiation occurs post hatch and can be influenced&nbsp;by exogenous factors such as chemicals, temperature, pH, population density, social cues and more. As a result, the gonadal sex phenotype in oviparous fish&nbsp;can be altered by environmental conditions experienced during development, particularly in conjunction with sexual differentiation (Scholz and Kl&uuml;ver, 2009). At this stage, the bipotential gonad can differentiate&nbsp;to either testes or ovaries&nbsp;depending both on genetic and environmental factors (Str&uuml;ssmann and Nakamura, 2002). Sex steroids are among the factors that influence sex differentiation in non-mammalian vertebrates; in many fish species exogenous androgens and estrogens act, respectively, to enhance the development of testes and ovaries in exposed animals (Nakamura 2010). In teleost fish, the relative balance between endogenous estrogens and androgens during sexual differentiation is critical to ensuring normal sex ratios and, ultimately, viable populations.&nbsp;Various homeostatic mechanisms ensure that steroid biosynthesis is appropriately controlled during development. A key biosynthetic enzyme is CYP19a1 (aromatase), which is responsible for the conversion of C19 androgens (e.g., T) to C18 estrogens (e.g., E2) in brain and gonadal tissues of vertebrates (Payne and Hales, 2004; Simpson et al. 1994).&nbsp; In fish, there are two CYP19a1 isoforms, with CYP19a1a mostly expressed in the gonads and CYP19a1b largely expressed in the brain (Callard et al. 2001).  Since the mid-90s, there has been concern about the potential impacts of endocrine disrupting chemicals (EDCs) in fish and wildlife. Many &nbsp;EDCs can exert effects in early life stages that can lead to potential impacts at the population level. For example, some chemicals have been shown to alter the sexual phenotype of fish by affecting steroidogenic enzymes such as aromatase. Inhibition&nbsp;of CYP19a1 expression or activity can alter the production &nbsp;of estrogens in &nbsp;developing gonads, affecting processes such as gonadal differentiation. In many fish species the &ldquo;default&rdquo; gonad type is testes, so when estrogen signaling is reduced there is&nbsp;a resultant bias toward male-biased sex ratios (Guiguen et al. 2010). &nbsp;&nbsp;When male biased sex ratios occur, the number of breeding females can decrease over time and have negative impacts on population growth and sustainability. The present AOP provides the evidence framework of the negative impacts of aromatase inhibition at early developmental stages of teleost fish &nbsp;during the critical period of sexual differentiation and how this could&nbsp;lead to &nbsp;population-level effects.   &nbsp;  &nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/346> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/348> a sbd:Model ;
  rdfs:label "Inhibition of 11β-Hydroxysteroid Dehydrogenase leading to decreased population trajectory "@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/348> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/348> a sbd:Model ;
  rdfs:label "Inhibition of 11β-Hydroxysteroid Dehydrogenase leading to decreased population trajectory "@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "In fish spermatogenesis,11-KT is the main androgen in teleosts, where it has functions in spermatogenesis and&nbsp;their main action of 11-beta dehydrogenase(11&beta;HSD Type 2) &nbsp;is generally regarded as the induction of sperm maturation. it has also its&nbsp;role is to protect these tissues from an excess of cortisol. Stress conditions or inhibition of 11bHSD dehydrogenase activities result in a cortisol excess in the Leydig cells. A surplus of glucocorticoids causes delayed genomic repression of 11KT&nbsp;production through GR or a rapid nongenomic decrease in 11 KT&nbsp;production. The rapid depression has been hypothesized to occur via the putative plasma membrane corticosteroid receptor11&beta;HSD2 is unidirectional with NAD+ as a cofactor. It is expressed not only in mineralocorticoid sensitive tissues such as testis.11&beta;HSD has enzyme activities, metabolizing cortisol to cortisone, and 11 beta -hydroxytestosterone to 11-ketotestosterone (11-KT) which is the main androgen functions spermatogenesis. Especially, spermatogenesis can induce by 11-ketotestosterone(11-KT), a significant androgen in teleost.&nbsp;However, excess circulating cortisol, which is produced by 11&beta;-hydroxylase&nbsp;and decline of&nbsp;11KT by&nbsp;11&beta;HSD inhibition,&nbsp;leads to inhibition of&nbsp;the DNA replication in spermatogonial mitosis, gonadal function, and spermatogonial proliferation in male fish.  Acknowledgements:&nbsp;This research was supported by the National Research Council of Science &amp; Technology(NST) grant by the Korea&nbsp;government (MSIP) (No. CAP-17-01-KIST Europe)"@en ;
  foaf:page <https://identifiers.org/aop/348> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/349> a sbd:Model ;
  rdfs:label "Inhibition of 11β-hydroxylase leading to decresed population trajectory "@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/349> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/349> a sbd:Model ;
  rdfs:label "Inhibition of 11β-hydroxylase leading to decresed population trajectory "@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "&nbsp;    	 		 			 			11&beta;-hydroxylase is prominently expressed in the Leydig cells of the testis in teleost.&nbsp;Ribas L, et al, 2017 reported that elevated cortisol, primary glucocorticoid, during the stress response might play a role in teleost&#39;s masculinization. Cortisol has also been cross talked to be involved in reproduction and sex differentiation at a proper level for the success of spawning, oocyte maturation, and the survival of progeny in teleosts. In females, the 11&beta;-hydroxylase knockout females showed less spawned eggs and the eggs were defective in germinal vesicle breakdown. Stress conditions or inhibition of 11&beta;-hydroxylase activities finally decreased 11KT and cortisol in the Leydig and Sertoli cells. Taken together, the inhibitors of 11&beta;-hydroxylase (i.e metyrapone, lysodren, eomidate and ketoconazole etc.) could result in decreased 11-KT and cortisol, subsequently, leading to impairment of spermatogenesis and oocyte maturation and ovulation. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  			Acknowledgements:&nbsp;This research was supported by the National Research Council of Science &amp; Technology(NST) grant by the Korea&nbsp;government (MSIP) (No. CAP-17-01-KIST Europe)&nbsp;&nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/349> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/358> a sbd:Model ;
  rdfs:label "Chitinase inhibition leading to mortality"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The Adverse Outcome is highly significant from a regulatory point of view. It is employed as regulatory endpoint in most studies assessing the toxicity of stressors."@en ;
  foaf:page <https://identifiers.org/aop/358> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/359> a sbd:Model ;
  rdfs:label "Chitobiase inhibition leading to mortality"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The Adverse Outcome is highly significant from a regulatory point of view. It is employed as regulatory endpoint in most studies assessing the toxicity of stressors."@en ;
  foaf:page <https://identifiers.org/aop/359> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/36> a sbd:Model ;
  rdfs:label "Peroxisomal Fatty Acid Beta-Oxidation Inhibition Leading to Steatosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Steatosis is a regulatory endpoint and has been used as an endpoint in many US EPA assessments, including IRIS assessments."@en ;
  foaf:page <https://identifiers.org/aop/36> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/360> a sbd:Model ;
  rdfs:label "Chitin synthase 1 inhibition leading to mortality"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Stressors known to competitively inhibit CHS1 are polyoxin B, polyoxin D and Nikkomycin Z (Cohen and Casida 1982; Cohen and Casida 1990; Zhang and Yan Zhu 2013). There may also be stressors that inhibit CHS-1 in a non-competitive manner which may become apparent in further characterization efforts of this MIE. There is also a study that reports inhibition of CHS-1 by the phthalimide fungicide captan (Cohen and Casida 1982). However, it remains elusive if the observed inhibition is due to specific interaction with the enzyme or due to unspecific protein binding which is the predominant mode of action of phthalimides (Lukens and Sisler 1958)."@en ;
  foaf:page <https://identifiers.org/aop/360> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/360> a sbd:Model ;
  rdfs:label "Chitin synthase 1 inhibition leading to mortality"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The Adverse Outcome is highly significant from a regulatory point of view. It is employed as regulatory endpoint in most studies assessing the toxicity of stressors."@en ;
  foaf:page <https://identifiers.org/aop/360> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/360> a sbd:Model ;
  rdfs:label "Chitin synthase 1 inhibition leading to mortality"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Arthropods (including insects, crustaceans and arachnids) need to shed their exoskeleton in order to grow and reproduce. This process, also called molting or ecdysis, is mediated by behavioural mechanisms which involve the skeletal muscles (Ayali 2009; Song et al. 2017a). In order to properly shed its cuticle, the organism needs to possess a newly synthesized cuticle that possesses a certain integrity to support this process. Since chitin is a major constituent of the cuticle, it contributes substantially to its integrity (Cohen 2001; Vincent and Wegst 2004). Chitin is synthesized from uridine diphosphate-N-Acetylglucosamine (UDP-GlcNAc) in a polymerization reaction by the transmembrane enzyme chitin synthase isoform 1 (CHS-1). CHS-1 is localized on the apical side in the cuticular epithelium. Since chitin and the process of chitin synthesis does not occur in vertebrates, it can and has been exploited for the design of pest controlling agents. Inhibitors of chitin synthesis may not only be of use for the control of unwanted arthropods and fungi, they may also pose a risk for beneficial arthropods such as insects and crustaceans. Disruption of chitin synthesis or the endocrine mechanisms controlling molting generally lead to a disruption of ecdysis (Merzendorfer et al. 2012; Song et al. 2017a; Song et al. 2017b). If the amount of chitin in the cuticle decreases, the affected organism may not be able to molt properly and will most probably die of starvation or suffocation (Camp et al. 2014; Song et al. 2017a). Alternatively, if molting is completed despite an immature cuticle, the organism may be deformed and die as a consequence of a weak cuticle. Therefore, the present AOP should build the basis of a mechanistic approach for the systematic evaluation and the risk assessment of chemicals interfering with chitin synthesis by directly inhibiting CHS-1."@en ;
  foaf:page <https://identifiers.org/aop/360> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/361> a sbd:Model ;
  rdfs:label "Sulfonylureareceptor binding leading to mortality"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The Adverse Outcome is highly significant from a regulatory point of view. It is employed as regulatory endpoint in most studies assessing the toxicity of stressors."@en ;
  foaf:page <https://identifiers.org/aop/361> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/363> a sbd:Model ;
  rdfs:label "Thyroperoxidase inhibition leading to altered visual function via altered retinal layer structure"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/363> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/363> a sbd:Model ;
  rdfs:label "Thyroperoxidase inhibition leading to altered visual function via altered retinal layer structure"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Increased mortality is one of the most common regulatory assessment endpoints,&nbsp;along with reduced growth and reduced reproduction."@en ;
  foaf:page <https://identifiers.org/aop/363> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/363> a sbd:Model ;
  rdfs:label "Thyroperoxidase inhibition leading to altered visual function via altered retinal layer structure"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "There is a wealth of information on the inhibition of TPO by drugs such as MMI and PTU, as well as environmental xenobiotics. In the landmark paper on TH system&nbsp;disruption by environmental chemicals, Brucker-Davis (1998) identified environmental chemicals that depressed TH synthesis by inhibiting TPO. Hurley (1998) listed TPO as a major target for thyroid tumor inducing pesticides. More recent work has tested over 1000 chemicals using a high-throughput screening assay (Paul-Friedman et al., 2016)."@en ;
  foaf:page <https://identifiers.org/aop/363> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/363> a sbd:Model ;
  rdfs:label "Thyroperoxidase inhibition leading to altered visual function via altered retinal layer structure"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "This AOP is based on data derived from several extensive literature searches. &nbsp;First, data was collected on different biological levels: Results at the molecular level, data on hormone levels, data on the tissue level and on the behavioural/physiological level. In a next step, KEs and KERs were identified and defined and a more detailed search was initiated. While initially an AOP network including several different effects on eye development&nbsp;was considered, in a next step AOP 363 was selected and further refined, and again an intensive and very detailed final literature search was conducted. The search for bibliographic data was conducted online in &quot;pubmed&quot;, &quot;sciencedirect/Scopus&quot; and &quot;Web of Science&quot;. The initial search terms were: &quot;(zebra-)fish&quot;, &quot;eye development&quot;, &quot;retina&quot;, &quot;thyroid/hormone disorders&quot;, &quot;visual behavio(u)r&quot;, &quot;photoreceptors&quot; and combinations of these terms. A very detailed manual search followed for the various KEs and KERs. Not only articles on chemical exposure of different animals were considered, but also more basic studies using other THSD induction techniques such as transgenic or mutant fish, microinjection, morpholino oligonucleotides, thyroidectomy, etc. The range of data that was assessed is wide, from gene expression and hormone levels to physiological and behavioural changes in different animals. In total, around 120 articles from this&nbsp;structured search&nbsp;were analysed in terms of experimental design and information on different biological levels. The majority of literature used fish, especially zebrafish (85%), which is why this AOP focuses on fish, but it can probably be applied to other vertebrate species as well."@en ;
  foaf:page <https://identifiers.org/aop/363> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/363> a sbd:Model ;
  rdfs:label "Thyroperoxidase inhibition leading to altered visual function via altered retinal layer structure"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/363> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/363> a sbd:Model ;
  rdfs:label "Thyroperoxidase inhibition leading to altered visual function via altered retinal layer structure"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Increased mortality is one of the most common regulatory assessment endpoints,&nbsp;along with reduced growth and reduced reproduction."@en ;
  foaf:page <https://identifiers.org/aop/363> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/363> a sbd:Model ;
  rdfs:label "Thyroperoxidase inhibition leading to altered visual function via altered retinal layer structure"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "There is a wealth of information on the inhibition of TPO by drugs such as MMI and PTU, as well as environmental xenobiotics. In the landmark paper on TH system&nbsp;disruption by environmental chemicals, Brucker-Davis (1998) identified environmental chemicals that depressed TH synthesis by inhibiting TPO. Hurley (1998) listed TPO as a major target for thyroid tumor inducing pesticides. More recent work has tested over 1000 chemicals using a high-throughput screening assay (Paul-Friedman et al., 2016)."@en ;
  foaf:page <https://identifiers.org/aop/363> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/363> a sbd:Model ;
  rdfs:label "Thyroperoxidase inhibition leading to altered visual function via altered retinal layer structure"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "This AOP is based on data derived from several extensive literature searches. &nbsp;First, data was collected on different biological levels: Results at the molecular level, data on hormone levels, data on the tissue level and on the behavioural/physiological level. In a next step, KEs and KERs were identified and defined and a more detailed search was initiated. While initially an AOP network including several different effects on eye development&nbsp;was considered, in a next step AOP 363 was selected and further refined, and again an intensive and very detailed final literature search was conducted. The search for bibliographic data was conducted online in &quot;pubmed&quot;, &quot;sciencedirect/Scopus&quot; and &quot;Web of Science&quot;. The initial search terms were: &quot;(zebra-)fish&quot;, &quot;eye development&quot;, &quot;retina&quot;, &quot;thyroid/hormone disorders&quot;, &quot;visual behavio(u)r&quot;, &quot;photoreceptors&quot; and combinations of these terms. A very detailed manual search followed for the various KEs and KERs. Not only articles on chemical exposure of different animals were considered, but also more basic studies using other THSD induction techniques such as transgenic or mutant fish, microinjection, morpholino oligonucleotides, thyroidectomy, etc. The range of data that was assessed is wide, from gene expression and hormone levels to physiological and behavioural changes in different animals. In total, around 120 articles from this&nbsp;structured search&nbsp;were analysed in terms of experimental design and information on different biological levels. The majority of literature used fish, especially zebrafish (85%), which is why this AOP focuses on fish, but it can probably be applied to other vertebrate species as well."@en ;
  foaf:page <https://identifiers.org/aop/363> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/364> a sbd:Model ;
  rdfs:label "Thyroperoxidase inhibition leading to altered visual function via decreased eye size"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/364> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/364> a sbd:Model ;
  rdfs:label "Thyroperoxidase inhibition leading to altered visual function via decreased eye size"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Increased mortality is one of the most common regulatory assessment endpoints,&nbsp;along with reduced growth and reduced reproduction."@en ;
  foaf:page <https://identifiers.org/aop/364> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/364> a sbd:Model ;
  rdfs:label "Thyroperoxidase inhibition leading to altered visual function via decreased eye size"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "There is a wealth of information on the inhibition of TPO by drugs such as MMI and PTU, as well as environmental xenobiotics. In the landmark paper on TH system&nbsp;disruption by environmental chemicals, Brucker-Davis (1998) identified environmental chemicals that depressed TH synthesis by inhibiting TPO. Hurley (1998) listed TPO as a major target for thyroid tumor inducing pesticides. More recent work has tested over 1000 chemicals using a high-throughput screening assay (Paul-Friedman et al., 2016)."@en ;
  foaf:page <https://identifiers.org/aop/364> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/364> a sbd:Model ;
  rdfs:label "Thyroperoxidase inhibition leading to altered visual function via decreased eye size"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/364> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/364> a sbd:Model ;
  rdfs:label "Thyroperoxidase inhibition leading to altered visual function via decreased eye size"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Increased mortality is one of the most common regulatory assessment endpoints,&nbsp;along with reduced growth and reduced reproduction."@en ;
  foaf:page <https://identifiers.org/aop/364> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/364> a sbd:Model ;
  rdfs:label "Thyroperoxidase inhibition leading to altered visual function via decreased eye size"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "There is a wealth of information on the inhibition of TPO by drugs such as MMI and PTU, as well as environmental xenobiotics. In the landmark paper on TH system&nbsp;disruption by environmental chemicals, Brucker-Davis (1998) identified environmental chemicals that depressed TH synthesis by inhibiting TPO. Hurley (1998) listed TPO as a major target for thyroid tumor inducing pesticides. More recent work has tested over 1000 chemicals using a high-throughput screening assay (Paul-Friedman et al., 2016)."@en ;
  foaf:page <https://identifiers.org/aop/364> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/365> a sbd:Model ;
  rdfs:label "Thyroperoxidase inhibition leading to altered visual function via altered photoreceptor patterning"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/365> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/365> a sbd:Model ;
  rdfs:label "Thyroperoxidase inhibition leading to altered visual function via altered photoreceptor patterning"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Increased mortality is one of the most common regulatory assessment endpoints,&nbsp;along with reduced growth and reduced reproduction."@en ;
  foaf:page <https://identifiers.org/aop/365> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/365> a sbd:Model ;
  rdfs:label "Thyroperoxidase inhibition leading to altered visual function via altered photoreceptor patterning"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "There is a wealth of information on the inhibition of TPO by drugs such as MMI and PTU, as well as environmental xenobiotics. In the landmark paper on TH system&nbsp;disruption by environmental chemicals, Brucker-Davis (1998) identified environmental chemicals that depressed TH synthesis by inhibiting TPO. Hurley (1998) listed TPO as a major target for thyroid tumor inducing pesticides. More recent work has tested over 1000 chemicals using a high-throughput screening assay (Paul-Friedman et al., 2016)."@en ;
  foaf:page <https://identifiers.org/aop/365> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/365> a sbd:Model ;
  rdfs:label "Thyroperoxidase inhibition leading to altered visual function via altered photoreceptor patterning"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/365> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/365> a sbd:Model ;
  rdfs:label "Thyroperoxidase inhibition leading to altered visual function via altered photoreceptor patterning"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Increased mortality is one of the most common regulatory assessment endpoints,&nbsp;along with reduced growth and reduced reproduction."@en ;
  foaf:page <https://identifiers.org/aop/365> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/365> a sbd:Model ;
  rdfs:label "Thyroperoxidase inhibition leading to altered visual function via altered photoreceptor patterning"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "There is a wealth of information on the inhibition of TPO by drugs such as MMI and PTU, as well as environmental xenobiotics. In the landmark paper on TH system&nbsp;disruption by environmental chemicals, Brucker-Davis (1998) identified environmental chemicals that depressed TH synthesis by inhibiting TPO. Hurley (1998) listed TPO as a major target for thyroid tumor inducing pesticides. More recent work has tested over 1000 chemicals using a high-throughput screening assay (Paul-Friedman et al., 2016)."@en ;
  foaf:page <https://identifiers.org/aop/365> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/366> a sbd:Model ;
  rdfs:label "Competitive binding to thyroid hormone carrier protein transthyretin (TTR) leading to altered amphibian metamorphosis "@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Rickenbacher et al (1986) provided initial direct evidence of competition for the T4 binding site using molecular modeling and binding assays using radiolabeled TH. Brouwer and van den Berg (1986) reported preferential binding of a metabolite of radiolabeled tetrachlorobiphenyl to TTR in rats (15 mg/kg, ip), using gel electrophoresis followed by HPLC analysis. Van den Berg (1990) used a competitive binding assay to assess the ability of hydroxylated chlorinated aromatic compounds to bind to radiolabeled T4. Van den Berg et al (1991) extended this work to 65 compounds from 12 different chemical groups in rats treated via a single ip dose and competitive binding assay. Chlorophenols were found to have higher affinity relative to other chlorinated aromatics, particular at higher levels of chlorination, and the combination and position of hydroxyl &amp; chlorine atoms. {insert Figure 2/Van den Berg 1990}  Lans et al (1993) described the ability of hydroxylated metabolites of PCBs, PCDDs and PCDFs to act as competetive ligands at the TTR-T4 binding site using an in vitro binding assay. Many of the hydroxylated PCBs examined were more potent ligands than T4, as opposed to those PCDFs and PCDDs that lacked chlorine atoms substituted adjacent to hydroxyl groups. When the hydroxyl group was in the meta or para positions, a 35- to 136-fold greater potency was found relative to ortho substitutions. These results were confirmed through later competitive binding work published by Cheek et al (1999) and Chauhan et al (2000).  Weiss et al (2009) first confirmed competitive binding of TTR with perfluorinated compounds (PFCs)"@en ;
  foaf:page <https://identifiers.org/aop/366> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/366> a sbd:Model ;
  rdfs:label "Competitive binding to thyroid hormone carrier protein transthyretin (TTR) leading to altered amphibian metamorphosis "@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Altered metamorphosis is a critical&nbsp;apical endpoint evaluated as part of&nbsp;regulatory test guideline studies (OECD, 2009, 2015; US EPA 2009, 2015). Measurable effects on metamorphic rates can be&nbsp;an indication of endocrine disruption, and more specifically&nbsp;thyroid disruption, due to the requirement of thyroid hormone for amphibians to undergo metamorphosis. Although this outcome is evaluated at the level of the individual organism, delayed or arrested metamorphosis can have implications toward population-level effects; however, significant effects on metamorphic rates are typically considered in a weight-of-evidence evaluation to determine a chemical&#39;s potential to cause thyroid disruption.&nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/366> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/367> a sbd:Model ;
  rdfs:label "Competitive binding to thyroid hormone carrier protein thyroid binding globulin (TBG) leading to altered amphibian metamorphosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Altered metamorphosis is a critical&nbsp;apical endpoint evaluated as part of&nbsp;regulatory test guideline studies (OECD, 2009, 2015; US EPA 2009, 2015). Measurable effects on metamorphic rates can be&nbsp;an indication of endocrine disruption, and more specifically&nbsp;thyroid disruption, due to the requirement of thyroid hormone for amphibians to undergo metamorphosis. Although this outcome is evaluated at the level of the individual organism, delayed or arrested metamorphosis can have implications toward population-level effects; however, significant effects on metamorphic rates are typically considered in a weight-of-evidence evaluation to determine a chemical&#39;s potential to cause thyroid disruption.&nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/367> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/368> a sbd:Model ;
  rdfs:label "Cytochrome oxidase inhibition leading to olfactory nasal lesions"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "This AOP was developed for the purpose of bringing mechanistic information as one input into the selection of a point of departure in chemical-specific exposure limit.&nbsp; Based on that purpose, key events were defined and organized into hypothesized AOPs based on previously published systematic reviews on a single chemical (hydrogen sulfide); follow-up literature searches were conducted to inform the WOE assessment to include additional chemical stressors that activate the MIE (potassium cyanide, sodium azide, beta amyloid peptides).&nbsp;&nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/368> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/37> a sbd:Model ;
  rdfs:label "PPARα activation leading to hepatocellular adenomas and carcinomas in rodents"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Fibrates are ligands of PPAR&alpha; (Staels et al. 1998).  Phthalates  MHEP (CAS 4376-20-9) directly binds in vitro to PPAR&alpha; (Lapinskas et al. 2005) and activates this receptor in transactivation assays PPAR&alpha; (Lapinskas et al. 2005), (Maloney and Waxman 1999), (Hurst and Waxman 2003), (Bility et al. 2004), (Lampen, Zimnik, and Nau 2003), (Venkata et al. 2006) ]. DEHP (CAS 117-81-7) has not been found to bind and activate PPAR&alpha; (Lapinskas et al. 2005), (Maloney and Waxman 1999). However, the recent studies shown activation of PPAR&alpha; (ToxCastTM Data).  Notably, PPAR&alpha; are responsive to DEHP in vitro as they are translocated to the nucleus (in primary Sertoli cells) (Dufour et al. 2003), (Bhattacharya et al. 2005). Expression of PPAR&alpha; [mRNA and protein] has been reported to be also modulated by phthtalates: (to be up-regulated in vivo upon DEHP treatment (Xu et al. 2010) and down-regulated by Diisobutyl phthalate (DiBP) (Boberg et al. 2008)).   Perfluorooctanoic Acid (PFOA) is known to activate PPAR&alpha; (Vanden Heuvel et al. 2006).  Organotin  Tributyltin (TBT) activates all three heterodimers of PPAR with RXR, primarily through its interaction with RXR (le Maire et al. 2009)"@en ;
  foaf:page <https://identifiers.org/aop/37> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/37> a sbd:Model ;
  rdfs:label "PPARα activation leading to hepatocellular adenomas and carcinomas in rodents"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "During the 1970s, an increased incidence of hepatocellular adenomas and carcinomas was observed in rodents treated with a variety of seemingly disparate chemicals. The common effect was an increase in&nbsp;the number and size of peroxisomes and these substances were labeled&nbsp;&lsquo;&lsquo;peroxisome proliferators&rsquo;&rsquo; (Rao &amp; Reddy, 1996). Peroxisomes are subcellular organelles involved in&nbsp;long chain fatty acid catabolism through the &beta;-oxidation cycle (de Duve, 1996). Peroxisomes&nbsp;increase in number and/or size following exposure to substances that perturb fatty acid homeostasis. These substances include marketed pharmaceutical agents and drug candidates,&nbsp;phthalate ester plasticizers or their metabolites,&nbsp;herbicides , solvents&nbsp; and perfluorinated chemicals (Klaunig et al., 2003).&nbsp;Hepatocellular hypertrophy and hyperplasia, changes in apoptosis rates, Kupffer cell activation, and oxidative stress were also observed following chronic exposure of rats and mice&nbsp;to peroxisome proliferators (Corton, 2010).   The peroxisome proliferator-activated receptor &alpha; (PPAR&alpha;) was identified after cloning&nbsp;from mouse DNA (Issemann &amp; Green, 1990). PPAR&alpha; along with the PPARb/d and PPARg subtypes are ligand-activated transcription factors with both&nbsp;DNA-binding and ligand-binding domain with&nbsp;variation in&nbsp;tissue distribution, expression during&nbsp;development, ligand specificity, and biological function. PPAR&alpha; is expressed in metabolically active tissues, including the liver, kidney, brown fat and heart, which exhibit pleiotropic responses to peroxisome proliferators. The biological functions and role in chemical effects of PPAR&alpha; has been facilitated by the PPAR&alpha;-null mouse&nbsp; the experimental use of which revealed that a&nbsp;functional PPAR&alpha; was required for the obseved phenotypic effects&nbsp;and led to the identification of the genes involved in lipid catabolism, lipid transport,&nbsp;peroxisome proliferation and hepatocellular adenomas and carcinomas (Corton, 2010; Lee et al., 1995).&nbsp;&nbsp;  Like other nuclear receptors,&nbsp;PPAR&alpha; forms a heterodimer before translocating to the nucleus.&nbsp;&nbsp;with another nuclear receptor family member, retinoid X receptor (RXR), the receptor for 9-cis-retinoic acid. The PPAR&alpha;-RXR heterodimer binds to peroxisome proliferator response elements (PPREs)&nbsp;usually found in the promoter or enhancer regions. The PPRE consensus sequence consists of the sequence 5&rsquo;-AACT AGGTCA A AGGTCA-3&rsquo;&nbsp;with PPAR&alpha; occupying the 5&rsquo; position. After agonist binding to PPAR&alpha;, co-repressors dissociate from the complex leading to de-acetylation, chromatin remodeling&nbsp; to enable transcription&nbsp;(Escher &amp; Wahli, 2000; G&ouml;ttlicher et al., 1992; Moreno et al. 2010).&nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/37> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/372> a sbd:Model ;
  rdfs:label "Androgen receptor antagonism leading to testicular cancer "@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "A large number of drugs and chemicals have been shown to antagonise the AR using various AR reporter gene assays. The AR is specifically targeted in AR-sensitive cancers, for example the use of the anti-androgenic drug flutamide in treating prostate cancer (Alapi &amp; Fischer, 2006). Flutamide has also been used in several rodent in vivo studies showing anti-androgenic effects (feminization of male offspring) evident by e.g. short anogenital distance (AGD) in males (Foster &amp; Harris, 2005; Hass et al, 2007; Kita et al, 2016). QSAR models can predict AR antagonism for a wide range of chemicals, many of which have shown in vitro antagonistic potential (Vinggaard et al, 2008)."@en ;
  foaf:page <https://identifiers.org/aop/372> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/374> a sbd:Model ;
  rdfs:label "Binding of Sars-CoV-2 spike protein to ACE 2 receptors expressed on brain cells (neuronal and non-neuronal) leads to neuroinflammation resulting in encephalitis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Two KEs of this AOP (i.e., neuroinflammation and neurodegeneration) have been described in other AOPs (i.e., neuroinflammation (in AOP 12, AOP 48, AOP 3, and AOP 17); neurodegeneration (in AOP 12, AOP 48, AOP 281); however, quantitative information of KERs is limited or non-existing."@en ;
  foaf:page <https://identifiers.org/aop/374> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/374> a sbd:Model ;
  rdfs:label "Binding of Sars-CoV-2 spike protein to ACE 2 receptors expressed on brain cells (neuronal and non-neuronal) leads to neuroinflammation resulting in encephalitis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Receptor recognition is an essential determinant of molecular level in this AOP. ACE2 was reported as an entry receptor for SARS-CoV-2. The viral entry process is mediated by the envelope-embedded surface-located spike (S) glycoprotein.&nbsp; Jun Lan and Walls, A.C et al (Nature 581, 215&ndash;220; Cell 180, 281&ndash;292) demonstrated a critical initial step of infection at the molecular level from the interaction of ACE2 and S protein. ACE2 has shown that receptor binding affinity to S protein is nM range. To elucidate the interaction between the SARS-CoV-2 RBD and ACE2 at a higher resolution, they also determined the structure of the SARS-CoV-2 RBD&ndash;ACE2 complex using X-ray crystallography. The expression and distribution of the ACE2 in human body may indicate the potential infection of SARS-CoV-2. Through the developed single-cell RNA sequencing (scRNA-Seq) technique and single-cell transcriptomes based on the public database, researchers analyzed the ACE2 RNA expression profile at single-cell resolution. High ACE2 expression was identified in type II alveolar cells (Zou, X. et al. Front. Med.2020)  SARS-CoV-2 belongs to the Coronaviridae family, which includes evolutionary related enveloped (+) strand RNA viruses of vertebrates, such as seasonal common coronaviruses, SARS-CoV and CoV-NL63, SARS-CoV (Kim Young Jun et al)   	 		 			 			Human viruses strains 			 			 			Genus 			 			 			Major cell receptor 			 			 			First report 			 			 			Animal reservoir 			 			 			Intermediate host 			 			 			Pathology 			 			 			Diagnostic test 			 			 			Evidence 			 		 		 			 			HCoV-NL63 			 			 			Alphacoronavirus 			 			 			ACE2 			 			 			2004 			 			 			Bat 			 			 			Unknown 			 			 			Mild respiratory tract illness 			 			 			RT-PCR, IF, ELISA, WB 			 			 			Strong 			 		 		 			 			SARS-CoV 			 			 			Betacoronavirus 			 			 			ACE2 			 			 			2003 			 			 			Bat 			 			 			Pangolin 			 			 			Severe acute respiratory syndrome 			 			 			RT-PCR, IF, ELISA, WB 			 			 			Strong 			 		 		 			 			SARS-CoV-2 			 			 			Betacoronavirus 			 			 			ACE2 			 			 			2020 			 			 			Bat 			 			 			Pangolin 			 			 			Severe acute respiratory syndrome 			 			 			RT-PCR, IF, ELISA, WB 			 			 			Strong"@en ;
  foaf:page <https://identifiers.org/aop/374> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/376> a sbd:Model ;
  rdfs:label "Androgen receptor agonism leading to male-biased sex ratio"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/376> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/376> a sbd:Model ;
  rdfs:label "Androgen receptor agonism leading to male-biased sex ratio"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Characterization of chemical properties: Androgen receptor binding chemicals can be grouped into two broad structural domains, steroidal and non-steroidal (Yin et al. 2003). Steroidal androgens consist primarily of testosterone and its derivatives (Yin et al. 2003). Many of the non-steroidal AR binding chemicals studied are derivatives of well known non-steroidal AR antagonists like bicalutamide, hydroxyflutamide, and nilutamide (Yin et al. 2003). Nonetheless, a number of QSARs and SARs that consider AR binding of both these pharmaceutical agents as well as environmental chemicals have been developed (Waller et al. 1996; Serafimova et al. 2002; Todorov et al. 2011; Hong et al. 2003; Bohl et al. 2004). However, it has been shown that very minor structural differences can dramatically impact function as either an agonist or antagonist (Yin et al. 2003; Bohl et al. 2004; Norris et al. 2009), making it difficult at present to predict agonist versus antagonist activity based on chemical structure alone.  In vivo considerations: A variety of steroidal androgens can be converted to estrogens in vitro through the action of cytochrome P450 19 (aromatase). Structures subject to aromatization may behave in vivo as estrogens despite exhibiting potent androgen receptor agonism in vitro."@en ;
  foaf:page <https://identifiers.org/aop/376> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/376> a sbd:Model ;
  rdfs:label "Androgen receptor agonism leading to male-biased sex ratio"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "This AOP shares multiple KEs and KERs with AOP 346 which links aromatase inhibition to male-biased sex ratios in vertebrates with environmental sex determination.&nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/376> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/377> a sbd:Model ;
  rdfs:label "Dysregulated prolonged Toll Like Receptor 9 (TLR9) activation leading to Multi Organ Failure involving Acute Respiratory Distress Syndrome (ARDS)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Increased mortality is one of the most common regulatory assessment endpoints,&nbsp;along with reduced growth and reduced reproduction."@en ;
  foaf:page <https://identifiers.org/aop/377> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/377> a sbd:Model ;
  rdfs:label "Dysregulated prolonged Toll Like Receptor 9 (TLR9) activation leading to Multi Organ Failure involving Acute Respiratory Distress Syndrome (ARDS)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Increased mortality is one of the most common regulatory assessment endpoints,&nbsp;along with reduced growth and reduced reproduction."@en ;
  foaf:page <https://identifiers.org/aop/377> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/379> a sbd:Model ;
  rdfs:label "Binding to ACE2 leading to thrombosis and disseminated intravascular coagulation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Thrombosis is one of the world&rsquo;s main concerns in terms of severe symptoms or adverse responses of the vaccine for COVID-19 which is caused by SARS-CoV-2. Excess thrombosis leads to DIC, which might be mortal. For safely developing the therapeutics and vaccines of COVID-19, it is regulatory significant to understand the cellular and molecular mechanisms in the pathogenesis of coronaviral infection, which may include thrombosis and DIC, AO1846."@en ;
  foaf:page <https://identifiers.org/aop/379> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/379> a sbd:Model ;
  rdfs:label "Binding to ACE2 leading to thrombosis and disseminated intravascular coagulation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Receptor recognition is an essential determinant of molecular level in this AOP. ACE2 was reported as an entry receptor for SARS-CoV-2. The viral entry process is mediated by the envelope-embedded surface-located spike (S) glycoprotein.&nbsp; Jun Lan and Walls, A.C et al (Nature 581, 215&ndash;220; Cell 180, 281&ndash;292) demonstrated a critical initial step of infection at the molecular level from the interaction of ACE2 and S protein. ACE2 has shown that receptor binding affinity to S protein is nM range. To elucidate the interaction between the SARS-CoV-2 RBD and ACE2 at a higher resolution, they also determined the structure of the SARS-CoV-2 RBD&ndash;ACE2 complex using X-ray crystallography. The expression and distribution of the ACE2 in human body may indicate the potential infection of SARS-CoV-2. Through the developed single-cell RNA sequencing (scRNA-Seq) technique and single-cell transcriptomes based on the public database, researchers analyzed the ACE2 RNA expression profile at single-cell resolution. High ACE2 expression was identified in type II alveolar cells (Zou, X. et al. Front. Med.2020)  SARS-CoV-2 belongs to the Coronaviridae family, which includes evolutionary related enveloped (+) strand RNA viruses of vertebrates, such as seasonal common coronaviruses, SARS-CoV and CoV-NL63, SARS-CoV (Kim Young Jun et al)   	 		 			 			Human viruses strains 			 			 			Genus 			 			 			Major cell receptor 			 			 			First report 			 			 			Animal reservoir 			 			 			Intermediate host 			 			 			Pathology 			 			 			Diagnostic test 			 			 			Evidence 			 		 		 			 			HCoV-NL63 			 			 			Alphacoronavirus 			 			 			ACE2 			 			 			2004 			 			 			Bat 			 			 			Unknown 			 			 			Mild respiratory tract illness 			 			 			RT-PCR, IF, ELISA, WB 			 			 			Strong 			 		 		 			 			SARS-CoV 			 			 			Betacoronavirus 			 			 			ACE2 			 			 			2003 			 			 			Bat 			 			 			Pangolin 			 			 			Severe acute respiratory syndrome 			 			 			RT-PCR, IF, ELISA, WB 			 			 			Strong 			 		 		 			 			SARS-CoV-2 			 			 			Betacoronavirus 			 			 			ACE2 			 			 			2020 			 			 			Bat 			 			 			Pangolin 			 			 			Severe acute respiratory syndrome 			 			 			RT-PCR, IF, ELISA, WB 			 			 			Strong"@en ;
  foaf:page <https://identifiers.org/aop/379> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/38> a sbd:Model ;
  rdfs:label "Protein Alkylation leading to Liver Fibrosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "From the OECD - GUIDANCE DOCUMENT ON DEVELOPING AND ASSESSING ADVERSE OUTCOME PATHWAYS - Series on Testing and Assessment 18: &quot;...an adverse effect that is of regulatory interest (e.g. repeated dose liver fibrosis)&quot;"@en ;
  foaf:page <https://identifiers.org/aop/38> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/38> a sbd:Model ;
  rdfs:label "Protein Alkylation leading to Liver Fibrosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Two prototypical chemicals acting via protein alkylation are Allyl Alcohol  [12][13][6][14][15]  and Carbon Tetrachloride (CCl4)[11][16] [17]  [18] [19][20][21][22]   .                                                                                                        [23]  [24]                                                 .[25] [26] Covalent protein alkylation is a feature of many cytotoxic drugs but the overall extent of binding does not adequately distinguish toxic from non-toxic binding. [27] Interestingly, some chemicals significantly alkylate proteins without causing toxicity, which suggests that only alkylation of a specific protein subset critical subset contributes to injury. Indeed, Codreanu presented an inventory of proteins affected by electrophile-mediated alkylation in intact cells and suggested that non-toxic covalent binding largely affects cytoskeletal protein components, whereas toxic covalent binding induces lethal injury by targeting factors involved in protein synthesis and catabolism and possibly mitochondrial electron transport. [3] In vitro covalent binding studies to macromolecules have been used to elucidate the biochemical mechanisms of chemical-induced toxicity. Experimental work with kidney epithelial cells by Chen et al suggested that following alkylation of cellular macromolecules as initial cytotoxic event both sulfhydryl depletion and lipid peroxidation are components of the cytotoxic mechanism [28]  Dennehy et al have analyzed the protein targets in nuclear and cytoplasmic proteomes from human embryonic kidney cells (HEK293) treated in vitro with two biotin-tagged, thiol-reactive electrophiles and mapped the adducts. Certain protein families appeared particularly susceptible to alkylation. [29]  Shin et al have identified protein targets of two biotin-tagged model electrophiles in human liver microsomes through LC-MS-MS and showed that different target selectivities of the two electrophile probes correlated with different biological outcomes and that alkylation reactions of specific targets could be quantified. [30]"@en ;
  foaf:page <https://identifiers.org/aop/38> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/381> a sbd:Model ;
  rdfs:label "Binding of viral S-glycoprotein to ACE2 receptor leading to dysgeusia"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Receptor recognition is an essential determinant of molecular level in this AOP. ACE2 was reported as an entry receptor for SARS-CoV-2. The viral entry process is mediated by the envelope-embedded surface-located spike (S) glycoprotein.&nbsp; Jun Lan and Walls, A.C et al (Nature 581, 215&ndash;220; Cell 180, 281&ndash;292) demonstrated a critical initial step of infection at the molecular level from the interaction of ACE2 and S protein. ACE2 has shown that receptor binding affinity to S protein is nM range. To elucidate the interaction between the SARS-CoV-2 RBD and ACE2 at a higher resolution, they also determined the structure of the SARS-CoV-2 RBD&ndash;ACE2 complex using X-ray crystallography. The expression and distribution of the ACE2 in human body may indicate the potential infection of SARS-CoV-2. Through the developed single-cell RNA sequencing (scRNA-Seq) technique and single-cell transcriptomes based on the public database, researchers analyzed the ACE2 RNA expression profile at single-cell resolution. High ACE2 expression was identified in type II alveolar cells (Zou, X. et al. Front. Med.2020)  SARS-CoV-2 belongs to the Coronaviridae family, which includes evolutionary related enveloped (+) strand RNA viruses of vertebrates, such as seasonal common coronaviruses, SARS-CoV and CoV-NL63, SARS-CoV (Kim Young Jun et al)   	 		 			 			Human viruses strains 			 			 			Genus 			 			 			Major cell receptor 			 			 			First report 			 			 			Animal reservoir 			 			 			Intermediate host 			 			 			Pathology 			 			 			Diagnostic test 			 			 			Evidence 			 		 		 			 			HCoV-NL63 			 			 			Alphacoronavirus 			 			 			ACE2 			 			 			2004 			 			 			Bat 			 			 			Unknown 			 			 			Mild respiratory tract illness 			 			 			RT-PCR, IF, ELISA, WB 			 			 			Strong 			 		 		 			 			SARS-CoV 			 			 			Betacoronavirus 			 			 			ACE2 			 			 			2003 			 			 			Bat 			 			 			Pangolin 			 			 			Severe acute respiratory syndrome 			 			 			RT-PCR, IF, ELISA, WB 			 			 			Strong 			 		 		 			 			SARS-CoV-2 			 			 			Betacoronavirus 			 			 			ACE2 			 			 			2020 			 			 			Bat 			 			 			Pangolin 			 			 			Severe acute respiratory syndrome 			 			 			RT-PCR, IF, ELISA, WB 			 			 			Strong"@en ;
  foaf:page <https://identifiers.org/aop/381> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/383> a sbd:Model ;
  rdfs:label "Inhibition of Angiotensin-converting enzyme 2 leading to liver fibrosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "From the OECD - GUIDANCE DOCUMENT ON DEVELOPING AND ASSESSING ADVERSE OUTCOME PATHWAYS - Series on Testing and Assessment 18: &quot;...an adverse effect that is of regulatory interest (e.g. repeated dose liver fibrosis)&quot;"@en ;
  foaf:page <https://identifiers.org/aop/383> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/39> a sbd:Model ;
  rdfs:label "Covalent Binding, Protein, leading to Increase, Allergic Respiratory Hypersensitivity Response"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Sensitization of the respiratory tract by chemicals is the first stage in the development of chemical respiratory allergy, an immune-mediated hypersensitivity reaction to an exogenous low-molecular-weight chemical, which can result in asthma and rhinitis on repeated exposure and is an important occupational health problem. (Mapp et al., 2005) Due to the severity and irreversibility of the adverse effect, identifying chemical respiratory allergens is of considerable regulatory, industrial, and socioeconomic importance. (Boverhof et al., 2008) Efforts to outline a framework for assessment of potential respiratory-sensitizing chemicals are underway. (North et al., 2016) Currently, however, there are no standardized, validated, and regulatory-accepted models for detecting these chemicals or discriminating them from skin sensitizers, potentially due to remaining gaps within the literature as to the exact mechanistic steps leading to respiratory allergy. (Kimber et al., 2011)  Another important issue in the development of predictive test methods is the route of exposure in the sensitization phase. Inhalation exposure is perhaps the most common exposure route of concern for many substances, but there is evidence that sensitization of the respiratory tract can be induced via skin exposure as well. (Tarlo and Malo, 2006, Heederik et al., 2012, Redlich and Herrick, 2008, Kimber and Dearman, 2002) This knowledge has implications for both the mechanistic understanding of the pathway and the potential test methods that may be used to detect respiratory sensitizers. Therefore, this AOP will include information from models using skin and lung exposure (in vivo) and with dermal and respiratory cells and tissues (in vitro/ex vivo).  The outlines of this pathway follow the already-published skin sensitization AOP 40. However, the divergent AOs of the two pathways reflect differences in the effector response (T helper 1 [Th1] vs. T helper 2 [Th2]) and other mechanistic details of at least some KEs;(Kimber et al., 2014) these differences are the focus of this effort. Therefore, the primary evidence relied on to build this AOP must relate directly to known low-molecular-weight organic chemicals to the exclusion of chemicals that act via other mechanisms and therefore require a separate AOP, for example, chloroplatinates.  In brief, the AOP can be summarized as beginning with covalent protein binding, potentially preferentially to lysine nucleophiles in the lung or skin after respiratory or dermal exposure to a low-molecular-weight organic chemical. This protein binding causes the activation of stress response pathways and cellular danger signals, including oxidative stress, cytokines, and chemokines released by epithelial and other cells, leading to dendritic cell (DC) maturation and migration to the draining lymph nodes (DLN). Haptens can also contribute to DC activation directly. Th2-skewed DCs in the DLN signal activation and maturation of T cells, which characterize the sensitization phase, resulting in chemical respiratory allergy. Consistent with regulatory practice, sensitization is considered the AO. (Vandebriel et al., 2011)"@en ;
  foaf:page <https://identifiers.org/aop/39> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/39> a sbd:Model ;
  rdfs:label "Covalent Binding, Protein, leading to Increase, Allergic Respiratory Hypersensitivity Response"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The in chemico, in vitro, and in vivo experimental evidence is logical and consistent with the mechanistic plausibility proposed by covalent reactions based on the protein binding theory ([1];[19];[20]). In selected cases, (e.g. 1-chloro-2,4-dinitrobenzene) where the same compound has been examined in a variety of assays (see Annex 1 of[21]), the coherence and consistency of the experimental data is excellent. Alternative mechanism that logically present themselves and the extent to which they may distract from the postulated AOP. It should be noted that alternative mechanisms of action, if supported, require a separate AOP. While covalent reactions with thiol groups and to lesser extent amino groups, are clearly supported by the proposed AOP, reactions targeting other nucleophiles may or may not be supported by the proposed AOP. Limited data on chemical reactivity shows that two competing reactions are possible, the faster reaction dominates. However, this has yet to be proven in vitro or in vivo.  Earlier work on the molecular basis of skin sensitisation was reviewed by Lepoittevin et al. (1998)[22], since then our knowledge of skin sensitisation has continued to expand. Recent reviews (see[3];[9];[20];[22];[23];[24];[25]) repeatedly stress the same key steps leading to sensitisation. These events include hapten formation (i.e., the ability of a chemical to react with skin proteins).  The binding behavior of diisocyanates in particular has been well studied. Wisnewski et al.29,30 demonstrate that hexamethylene diisocyanate (HDI) and 4,4&rsquo;-diphenylmethane diisocyanate (MDI) react with glutathione (GSH) across an in vitro physiologically relevant vapor/liquid-phase barrier to form conjugates, which may &lsquo;&lsquo;shuttle,&rsquo;&rsquo; via a carbamoylating reaction, the chemical to bind with serum albumin. Diisocyanates (MDI) react with GSH across an in vitro physiologically relevant vapor/liquid-phase barrier to form conjugates, which may &lsquo;&lsquo;shuttle,&rsquo;&rsquo; via a carbamoylating reaction, the chemical to bind with serum albumin.  In contrast to skin sensitization where cysteine and lysine are both key nucleophiles, experimental work has suggested that some respiratory sensitizers appear to preferentially bind to lysine; (Hettick et al., 2012, Lalko et al., 2012, Holsapple et al., 2006, Hopkins et al., 2005) however, an in chemico analysis of a larger set of respiratory sensitizers indicates lack of a simple division between the reactivity preferences of the two types of sensitizers, showing that certain classes displayed a lysine preference, for example, anhydrides, whereas others, such as diisocyanates, do not. (Dik et al., 2016)  While respiratory sensitizers and skin sensitizers can both bind to cellular and serum proteins in separate cultures, a study comparing the binding profiles of both classes in co-culture systems found that skin sensitizers preferentially bind cellular proteins, while respiratory sensitizers preferentially bind serum proteins. (Hopkins et al., 2005)"@en ;
  foaf:page <https://identifiers.org/aop/39> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/39> a sbd:Model ;
  rdfs:label "Covalent Binding, Protein, leading to Increase, Allergic Respiratory Hypersensitivity Response"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "This adverse outcome is of high regulatory interest and relevance, though no test guideline is available. Regulatory agencies and industrial producers are interested in preventing the first step--induction of immune response. Importantly, induction of respiratory sensitisation can be obtained via skin exposure, which is consequential for potential exposure restrictions."@en ;
  foaf:page <https://identifiers.org/aop/39> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/40> a sbd:Model ;
  rdfs:label "Covalent Protein binding leading to Skin Sensitisation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The in chemico, in vitro, and in vivo experimental evidence is logical and consistent with the mechanistic plausibility proposed by covalent reactions based on the protein binding theory ([1];[19];[20]). In selected cases, (e.g. 1-chloro-2,4-dinitrobenzene) where the same compound has been examined in a variety of assays (see Annex 1 of[21]), the coherence and consistency of the experimental data is excellent. Alternative mechanism that logically present themselves and the extent to which they may distract from the postulated AOP. It should be noted that alternative mechanisms of action, if supported, require a separate AOP. While covalent reactions with thiol groups and to lesser extent amino groups, are clearly supported by the proposed AOP, reactions targeting other nucleophiles may or may not be supported by the proposed AOP. Limited data on chemical reactivity shows that two competing reactions are possible, the faster reaction dominates. However, this has yet to be proven in vitro or in vivo.  Earlier work on the molecular basis of skin sensitisation was reviewed by Lepoittevin et al. (1998)[22], since then our knowledge of skin sensitisation has continued to expand. Recent reviews (see[3];[9];[20];[22];[23];[24];[25]) repeatedly stress the same key steps leading to sensitisation. These events include hapten formation (i.e., the ability of a chemical to react with skin proteins).  The binding behavior of diisocyanates in particular has been well studied. Wisnewski et al.29,30 demonstrate that hexamethylene diisocyanate (HDI) and 4,4&rsquo;-diphenylmethane diisocyanate (MDI) react with glutathione (GSH) across an in vitro physiologically relevant vapor/liquid-phase barrier to form conjugates, which may &lsquo;&lsquo;shuttle,&rsquo;&rsquo; via a carbamoylating reaction, the chemical to bind with serum albumin. Diisocyanates (MDI) react with GSH across an in vitro physiologically relevant vapor/liquid-phase barrier to form conjugates, which may &lsquo;&lsquo;shuttle,&rsquo;&rsquo; via a carbamoylating reaction, the chemical to bind with serum albumin.  In contrast to skin sensitization where cysteine and lysine are both key nucleophiles, experimental work has suggested that some respiratory sensitizers appear to preferentially bind to lysine; (Hettick et al., 2012, Lalko et al., 2012, Holsapple et al., 2006, Hopkins et al., 2005) however, an in chemico analysis of a larger set of respiratory sensitizers indicates lack of a simple division between the reactivity preferences of the two types of sensitizers, showing that certain classes displayed a lysine preference, for example, anhydrides, whereas others, such as diisocyanates, do not. (Dik et al., 2016)  While respiratory sensitizers and skin sensitizers can both bind to cellular and serum proteins in separate cultures, a study comparing the binding profiles of both classes in co-culture systems found that skin sensitizers preferentially bind cellular proteins, while respiratory sensitizers preferentially bind serum proteins. (Hopkins et al., 2005)"@en ;
  foaf:page <https://identifiers.org/aop/40> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/40> a sbd:Model ;
  rdfs:label "Covalent Protein binding leading to Skin Sensitisation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Skin sensitisation is an endpoint that needs to be assessed within: - CLP Regulation (EC) No1272/2008 for \"Classification, Labelling and Packaging of substances and Mixtures\", - REACH Regulation (EC) No1907/2006 concerning the Registration, Evaluation, Authorization and Restriction of Chemicals, - PPP Regulation (EC) No1107/2009 concerning the placing of plant protection products on the market, - Biocidal Products Regulation (BPR) (EU) No528/2012 concerning the making available on the market and use of biocidal products, - Cosmetics Regulation (EC) No1223/2009."@en ;
  foaf:page <https://identifiers.org/aop/40> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/41> a sbd:Model ;
  rdfs:label "Sustained AhR Activation leading to Rodent Liver Tumours"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "For many years, EPA used a cancer slope factor of 1.5 E+05 per mg/kg/d based on the Kociba et al. (1978) bioassay. Today, the toxicity critierion for TCDD and other persistent AHR ligands is based on purported reproductive and developmental effects in humans."@en ;
  foaf:page <https://identifiers.org/aop/41> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/42> a sbd:Model ;
  rdfs:label "Inhibition of Thyroperoxidase and Subsequent Adverse Neurodevelopmental Outcomes in Mammals"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "A prime example of impairments in cognitive function as the adverse outcome for regulatory action is developmental lead exposure and IQ function in children (Bellinger, 2012). In addition, testing for the impact of chemical expsoures on cognitive function, often including spatially-mediated behaviors, is an intergral part of both EPA and OECD developmental neurotoxicity guidelines (USEPA, 1998; OECD, 2007)."@en ;
  foaf:page <https://identifiers.org/aop/42> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/42> a sbd:Model ;
  rdfs:label "Inhibition of Thyroperoxidase and Subsequent Adverse Neurodevelopmental Outcomes in Mammals"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "This AOP was originally started on the Chemical Mode of Action WIKI sponsored by WHO/IPCS. The MOA was originally described and published by Zoeller and Crofton (Crit Rev Toxicol 2005). Thanks to the following contributors whose work on the MOA-WIKI fostered further development on the AOP wiki: Michelle Embry, Richard Judson, Vicki Dellarco, Chihae Yang, Kevin Crofton.  Zoeller RT, Crofton KM.&nbsp;&nbsp; Mode of action: developmental thyroid hormone insufficiency--neurological abnormalities resulting from exposure to propylthiouracil. Crit Rev Toxicol. 2005 Oct-Nov;35(8-9):771-81  &nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/42> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/42> a sbd:Model ;
  rdfs:label "Inhibition of Thyroperoxidase and Subsequent Adverse Neurodevelopmental Outcomes in Mammals"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "There is a wealth of information on the inhibition of TPO by drugs such as MMI and PTU, as well as environmental xenobiotics. In the landmark paper on TH system&nbsp;disruption by environmental chemicals, Brucker-Davis (1998) identified environmental chemicals that depressed TH synthesis by inhibiting TPO. Hurley (1998) listed TPO as a major target for thyroid tumor inducing pesticides. More recent work has tested over 1000 chemicals using a high-throughput screening assay (Paul-Friedman et al., 2016)."@en ;
  foaf:page <https://identifiers.org/aop/42> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/43> a sbd:Model ;
  rdfs:label "Disruption of VEGFR Signaling Leading to Developmental Defects"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "https://aopwiki.org/wiki/index.php/File:KleinstreuerKnudsenAOPVascularDisruption.jpg  Functionalization of the ToxCast pVDC predictive signature  The ToxCast putative Vascular Disrupting Chemicals (pVDC) signature will be described here and parts will be incorporated into the relevant Key Events sections.  The sectors of the ToxPI are color-represented by features from ToxCast HTS assays indicated by the target of the assays, the characteristics as follows.  Vascular cell adhesion molecule 1 (VCAM1): the pVDC signature aggregates assays from the BioMAP Systems Predictive Toxicology panel [Houck et al., 2009, Kunkel et al., 2004] focusing here on chemical disruption of endothelial VCAM1 expression following stimulation by cytokines-growth factors. This assay endpoint is an in vitro surrogate for inflammatory cell recruitment per endothelial dysfunction and has been probed across five different cell systems: 4H (HUVECs stimulated with IL-4 + histamine); 3C (HUVECs stimulated with IL-1&beta; + TNF&alpha; + IFN&upsih;); CASM3C (primary human coronary artery smooth muscle cells stimulated with IL-1&beta; + TNF&alpha; + IFN&upsih;); LPS (HUVECs co-cultured with monocytes and stimulated with bacterial endotoxin); and hDFCGF (human dermal fibroblasts stimulated with IL-1&beta; + TNF&alpha; + IFN&upsih; and EGF + bFGF + PDGF-BB)[Knudsen and Kleinstreuer, 2011, Kleinstreuer et al., 2014].  Angiogenic cytokines and chemokines: the pVDC signature aggregates features for LPS-induced TNF&alpha; protein expression (see BioMAP descriptor above), nuclear factor-kappa B (NFkB) mediated reporter gene activation (Attagene; cis- configuration), and caspase 8 enzymatic activity (NovaScreen; inhibition or activation). TNF&alpha; is a proinflammatory cytokine that can promote angiogenesis indirectly through NFkB-mediated expression of angiogenic growth factors, or inhibit angiogenesis by direct effects on endothelial proliferation and survival. The pVDC signature also aggregates features for signaling activity of the pro-angiogenic cytokines interleukin-1 alpha (IL1a, a macrophage-derived activator of TNF&alpha;) and interleukin 6 (IL6). These cytokines act through the G-protein coupled receptors (GPCRs) IL1R and IL6R, respectively. CXCL8 (chemokine (C-X-C motif) ligand 8), formerly known as interleukin 8 (IL8), is angiogenic through its cognate GPCRs (CXCR1, CXCR2). In contrast to CXCL8, the chemokines CXCL9 (alias MIG, monokine induced by IFN&upsih;) and CXCL10 (alias IP10, interferon-inducible cytokine IP-10) are considered anti-angiogenic through their cognate receptor, CXCR3.  Angiogenic growth factors: FGFs and VEGFs exert their effects on endothelial cell proliferation, migration, and differentiation via specific binding to receptor tyrosine kinases VEGFR and FGFR. The pVDC signature has features for liganding VEGFR1, VEGFR2, and VEGFR3 based on receptor kinase activity (RTK, inhibition or activation) from the NovaScreen biochemical profile [Sipes et al. 2013] and for down-regulation of VEGFR2 expression in the 4H BioMAP system (HUVECs stimulated with IL-4 + histamine, B). VEGFR1 is a non-signaling VEGF-A decoy receptor that can be cleaved from the cell surface; VEGFR2 is the most important VEGF-A receptor and a master switch for developmental angiogenesis; and VEGFR3 is a VEGF-C receptor up-regulated by Notch signals. The pVDC signature includes features for the basic helix-loop-helix transcription factors Aryl Hydrocarbon Receptor (AhR) and Hypoxia Inducible Factor-1 alpha (HIF1a) that are upstream regulators of VEGF gene expression during ischemia or hypoxia. HIF1a and AhR are measured in reporter assays (Attagene). In addition to HIF1a and AhR, the pVDC signature has features for the estrogen receptor alpha (ERa), also a trans-activator of VEGF expression. This included human ERa binding activity (NovaScreen), ERa reporter trans-activation (Attagene) and ERE (estrogen responsive element) reporter cis-activation (Attagene).  Angiogenic sprouting: the ephrins (EFNA1 and EFNB2 in particular) couple VEGF signaling to angiogenic sprouting during early development of the embryonic vasculature (vasculogenesis, angiogenesis). The ToxCast pVDC signature included features for EPH-receptor tyrosine kinase biochemical activity (increased or decreased) for receptors EPHA1, EPHA2, EPHB1 and EPHB2 via their cognate cell membrane-anchored ligands (EFNAs). In contrast to the ephrin system, a number of chemicals had activity on diverse assays for urokinase-type plasminogen activator (uPA). That system, consisting of uPA (4 features) and its GPI-anchored receptor, uPAR (8 features) - both assayed in the BioMAP System [Kleinstreuer et al. 2014], functions in VEGFR2-induced changes to focal adhesion and extracellular matrix (ECM) degradation at the leading edge of endothelial cells during angiogenic sprouting. Binding of uPA to uPAR results in serine-protease conversion of plasminogen to plasmin that initiates a proteolytic cascade leading to degradation of the basement membrane and angiogenic sprouting. The uPA proteolytic cascade is suppressed by the serine protease inhibitor, endothelial plasminogen activator inhibitor type 1 (PAI1). The PAI1/uPA/uPAR assays report chemical effects on the system (up or down) across diverse cellular platforms: 4H, 3C, CASM3C, and hDFCGF noted above; BE3C (human bronchial epithelial cells stimulated with IL-1&beta; + TNF&alpha; + IFN&upsih;); and KF3T (human keratinocytes + fibroblasts stimulated with IL-1&beta; + TNF&alpha; + IFN&upsih; + TGF-&beta;). The pVDC signature has features for thrombomodulin (THBD) and the thromboxane A2 (TBXA2) receptor that participate in the regulation of endothelial migration during angiogenic sprouting. THBD is a type I transmembrane glycoprotein that mediates regulator of uPA/uPAR and TBXA2 is an angiogenic eicosanoid generated by endothelial cyclooxygenase-2 (COX-2) following VEGF- or bFGF stimulation. THBD protein expression was monitored in the 3C and CASM3C BioMAP systems (up, down) and TBXA2 was assayed for ligand binding in the NovaScreen platform.  Endothelial cell migration and proliferation: the pVDC signature includes assays for human primary vascular cultures (endothelial and vascular smooth muscle cells). Assays for nuclear localization of beta-catenin (CTNB) are based on the principle that nuclear translocation activates pathways important for endothelial cell migration, proliferation and survival during capillary network formation in HUVEC cells [Muller et al. 2002; Masckauchan et al. 2005].  Vascular stabilization: The signature has features for transforming growth factor-beta 1 (TGF-b), which regulates vascular morphogenesis and integrity, and for Tie2 - a receptor tyrosine kinase activated by the angiopoietins (ANG1, ANG2) that function stabilize nascent vasculature. The pVDC signature has features for the anti-angiogenic phosphatases PTEN (phosphatase and tensin homolog), PTPN11 (tyrosine-protein phosphatase non-receptor type 11) and PTPN12, and endothelial-specific receptor tyrosine protein phosphatase beta (PTPRB). Matrix metalloproteinases (MMPs) 1/2/9 aggregate features on biochemical activity and cellular function of zinc-dependent endopeptidases MMP1, MMP2 and MMP9 that facilitate angiogenesis through ECM degradation by activated endothelial cells."@en ;
  foaf:page <https://identifiers.org/aop/43> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/43> a sbd:Model ;
  rdfs:label "Disruption of VEGFR Signaling Leading to Developmental Defects"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Chemical effects on VEGF-A binding to VEGFR2 has been demonstrated for 6 different inhibitors using recombinant VEGF-A(165) [Gustafsdottir et al. 2008]. Among the inhibitors were DNA/RNA aptamers, neutralizing antibodies directed against VEGF-A or VEGFR2, recombinant competitive protein, and a low molecular weight synthetic molecule. A pharmacological panel of small molecule inhibitors of VEGFR inhibitors is known, having varied activities on VEGFR2 and other members of the same receptor tyrosine kinase family as the VEGF receptors, including the platelet-derived growth factor receptor &beta; (PDGFR-&beta;). These compounds include Vatalanib (VEGFR2/PDGFR&beta;/c-kit inhibitor), Sunitinib (VEGFR1/VEGFR2/PDGFR inhibitor), and Semaxinib (VEGFR2 inhibitor).  Vatalanib, also known by the code name PTK787, is a potent vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor that inhibits VEGFR2/KDR and VEGFR1/Flt-1 with the half maximal inhibition concentration IC50 values of 0.037 &mu;M and 0.077 &mu;M, respectively [Wood et al. 2000]. It also inhibits to a lesser degree PDGFR-&beta;. Liganding VEGFR2 leads to receptor dimerization and autophosphorylation on tyrosine residues, which initiates signal transduction [Kendall et al. 1999]. Using a double antibody chemiluminescence assay, PTK787 was shown to block VEGF-induced auto-phosphorylation of VEGFR2 with an IC50 of 0.017 &mu;M in human endothelial cells (HUVECs) and concentration-dependent suppression of endothelial migration and tumorigenic formation of microvessels [Wood et al. 2000].  &nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/43> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/43> a sbd:Model ;
  rdfs:label "Disruption of VEGFR Signaling Leading to Developmental Defects"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Regulatory Significance of the Adverse Outcome: The International Conference on Harmonization regulatory guidelines for embryo-fetal developmental toxicity testing (ICH 2005) require studies in both a rodent and a non-rodent species, usually rat and rabbit. The current two-species testing paradigm was developed in response to the pandemic of phocomelia associated with maternal exposure to thalidomide during early pregnancy [Schardein 2000]. Dose ranges of thalidomide that were teratogenic in the rabbit induced embryo-fetal loss in the rat [Janer et al. 2008]. This observation is consistent with current knowledge that the specific manifestations of embryo-fetal toxicity may in general vary greatly between species, and even between strains within the same species [Hurtt et al. 2003; Janer et al. 2008; Theunissen et al. 2016]."@en ;
  foaf:page <https://identifiers.org/aop/43> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/46> a sbd:Model ;
  rdfs:label "AFB1: Mutagenic Mode-of-Action leading to Hepatocellular Carcinoma (HCC)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Although not specifically used EPA for regulatory determinations vis-à-vis AFB1, HCC has been used as an adverse endpoint in many hazard assessments that can be used as input to risk management decisions.  The U.S. EPA Integrated Risk Information System (IRIS database) contains 111 instances wherein HCC has been considered in hazard assessment of environmental contaminants.  For example, HCC in rats formed part of the weight of evidence in categorizing polychlorinated biphenyls as probable human carcinogens. These tumors, combined with other liver tumors, also formed the basis for quantitative dose-response assessment for cancer induced by polychlorinated biphenyls by the oral route.(USEPA, 2014). Given that AFB1 can be a contaminant in both human food and animal feed, FDA has established allowable limits. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/foodadvisorycommittee/ucm428947.pdf"@en ;
  foaf:page <https://identifiers.org/aop/46> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/46> a sbd:Model ;
  rdfs:label "AFB1: Mutagenic Mode-of-Action leading to Hepatocellular Carcinoma (HCC)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "An extensive database demonstrates the formation of AFB1-specific DNA adducts in many different systems and from several laboratories. In particular, Groopman&rsquo;s lab and Essigman&rsquo;s group, among others, have provided pivotal data to demonstrate the formation of these pro-mutagenic AFB1-induced DNA adducts (Croy and Wogan, 1981a,b; Croy et al., 1978; Groopman et al., 1992; Smela et al., 2002; Egner et al., 2006). Lutz (1987) summarized data from a thesis that measured tritiated DNA in liver following p.o. administration of tritiated AFB1 to male F344 rats over a range of doses, from 1 ng AFB1/kg bw to 104 ng AFB1/kg bw and the dose-response was reported to be linear; only limited experimental details are available for this dataset, which relied on less sophisticated and less specific analytical methods than are currently available."@en ;
  foaf:page <https://identifiers.org/aop/46> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/46> a sbd:Model ;
  rdfs:label "AFB1: Mutagenic Mode-of-Action leading to Hepatocellular Carcinoma (HCC)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "This AOP describes a mutagenic mode of action (MOA) for cancer, using Aflatoxin B1 (AFB1) as a case example. Mutagenic MOAs are distinguished from other MOAs for cancer in that the chemical induces mutations in genes that are involved in the etiology of the cancer. This MOA is distinguished from a non-mutagenic MOA for carcinogens that cause proliferation of cells with existing mutations, or that in some other way promote the growth of cancer gene mutant cells. The induction of mutation in the cancer critical gene is the key event (KE) that is unique to mutagenic MOA (Jarabek et al., 2009; Pottenger et al., 2014). In this AFB1 case example, mutation in critical genes is a consequence of formation of pro-mutagenic DNA adducts by metabolites of the chemical. It is important to note that all cancers involve an increase in cells containing mutations in cancer critical gene(s). Likewise, cell proliferation is an essential step in the formation of tumors. To establish that an agent has a mutagenic MOA, it is necessary to determine the key events, both in terms of temporality and of dose-response concordance, between the increase in the number of mutant cells, cell proliferation, the appearance of any pre-neoplastic lesions, and ultimately tumor occurrence. The types of data that can be used to investigate whether a chemical acts via a mutagenic MOA include information on the chemical&rsquo;s ability to cause mutations, the temporality of those induced mutations, and the type of mutations that the chemical induces. It is not sufficient to determine if the chemical can induce mutations in any one of a number of standard gene mutation assays. Furthermore, because the etiology of all tumors includes an increase in cells with cancer gene mutations, the presence of mutations in the tumor tissue does not provide definitive information on MOA. When there is a high frequency of tumors with specific mutations (as is the case for AFB1), this observation provides a hypothesis that can be further evaluated.  The most definitive level of proof that a chemical acts via a mutagenic MOA is the demonstration that the chemical can induce the specific cancer gene mutation(s) observed in a majority of the specific tumors, and that the formation of this mutation is an early KE in the AOP (Moore et al., 2008). In the absence of this information, the ability of the chemical to induce the type(s) of mutations seen in the majority of the specific tumors adds greatly to the weight of evidence. Such information on specific chemical-induced mutations in cancer critical genes is uncommon, and currently, no such information is available for AFB1. A newly developed method, allele specific competitive blocker-polymerase chain reaction (ACB-PCR) has proved useful in providing such information, and data on specific chemical-induced mutations are available for only a very small number of chemicals (Parsons et al., 2010).  Both in vitro and in vivo gene mutation assays can detect chemically induced mutations; by sequencing the DNA from mutants induced in these assays, the type(s) of mutations that a chemical induces can be determined. A match between the type(s) of mutations found in these surrogate gene mutation assays and the mutations seen in a majority of the tumors provides a high level of confidence that the chemical has a mutagenic MOA for the induction of those specific tumors. Fortunately this type of data is available for AFB1.  This AOP is written for AFB1, a data-rich chemical. It is clear that (1) AFB1 can induce mutations in gene mutation assays; (2) AFB1 induces hepatocellular carcinoma (HCC) in a variety of species, including humans; (3) there is a high frequency of a specific cancer gene mutation (codon 249 of p53) in the human HCCs found in people in regions with high AFB1 exposure; and (4) the type of mutation seen in the human tumor (codon 249 of p53) is the same type of mutation that is seen in the surrogate gene mutation assay. Thus there is a high level of confidence that AFB1 has a mutagenic MOA for HCC in humans.  The AOP for a mutagenic MOA for liver cancer induced by Aflatoxin B1 includes the following series of key events: &bull; pre-MIE: Hepatic metabolic activation &bull; MIE: Pro-mutagenic DNA adduct formation &bull; KE#1: Insufficient repair or mis-repair of pro-mutagenic DNA adducts &bull; KE#2: Induced mutation in critical genes &bull; KE#3: Cellular proliferation and clonal expansion of mutant cells (pre-neoplastic lesions) &bull; AO: Hepatocellular carcinoma (HCC)  This AOP describes the KE that are specific to a mutagenic MOA for AFB1 (e.g., [pre-Molecular Initiating Event or pre-MIE: metabolic activation,] MIE: pro-mutagenic AFB1 DNA adduct, KE#1: insufficient/mis-repair of DNA, KE#2: induced mutation in critical gene). In addition, this AOP includes all of the steps involved from the exposure to AFB1 through to the appearance of the HCC, the adverse outcome. KE#3, the occurrence and growth of altered hepatic foci and the subsequent development of HCC (as described below) are events that would be involved in the etiology of all HCC whether occurring through a mutagenic MOA or another, different MOA. Although AFB1-specific information is lacking for these later steps in the AOP, the accumulated scientific knowledge of the development of HCC includes the recognition that all AOPs leading to HCC have a number of general steps in common; thus, these general steps are included in this AOP and are identified as not being specific to AFB1-induced HCC."@en ;
  foaf:page <https://identifiers.org/aop/46> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/48> a sbd:Model ;
  rdfs:label "Binding of agonists to ionotropic glutamate receptors in adult brain causes excitotoxicity that mediates neuronal cell death, contributing to learning and memory impairment."@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Evidence for Chemical Initiation of this Molecular Initiating Event L-Glutamate and glycine (or D-serine) are endogenous agonists that bind to the LBD of specific NMDA receptor subunits. Here listed some known agonists for NMDA receptor, some of them are specific to the NR1 subunit and some others to the NR2 subunit (reviewed in Traynelis et al., 2010): Specific to NR1 Glycine, l-Serine, d-Serine, l-Alanine, d-Alanine, d-Cycloserine, HA 966, (+)-(1-hydroxy-3-aminopyrrolidine-2-one,) β-Cl-d-Alanine, β-F-dl-Alanine, tri-F-dl-Alanine, ACPC, 1-aminocyclopropane-1-carboxylic acid, ACBC, 1-aminocyclobutane-1-carboxylic acid, GLYX-13. Specific to NR2 l-Glutamate, d-Glutamate, l-Aspartate, d-Aspartate, N-Methyl-l-aspartate, N-Methyl-d-aspartate, SYM208,1 l-Homocysteinsulfinate, d-Homocysteinsulfinate, l-Homocysteate, d-Homocysteate, l-Cysteinesulfinate, l-Cysteate, d-Cysteate, Homoquinolinate, Ibotenate, (R,S)-(Tetrazol-5-yl)glycine, L-CCG-IV, (2S,3R,4S)-2-(carboxycyclopropyl)glycine, trans-ACBD, trans-1-aminocyclobutane-1,3-dicarboxylate, cis-ADA, cis-azetidine-2,4-dicarboxylic acid, trans-ADC, azetidine-2,4-dicarboxylic acid, cis-ACPD, (1R,3R)-aminocyclopentane-cis-dicarboxylate, cis-2,3-Piperidinedicarboxylic acid, (R)-NHP4G, 2-(N-hydroxylpyrazol-4-yl)glycine, (R,S)-Ethyl-NHP5G, 2-(N-hydroxypyrazol-5-yl)glycine, (R)-Propyl-NHP5G, 2-(N-hydroxypyrazol-5-yl)glycine. Domoic acid (DomA) is structurally similar to kainic acid (KA) and both of them are analogues of the excitatory neurotransmitter L-glutamate. DomA induces excitotoxicity by an integrative action on ionotropic glutamate receptors at pre- and post-synaptic sides. DomA directly activates KA/AMPARs receptors followed by indirect activation of the NMDARs. Indeed, indirect activation of NMDARs by DomA is linked to the fact that KA and AMPA receptors activated by DomA induce increased levels of intracellular Ca2+ and Na+ which, in turn, causes endogenous glutamate release that subsequently potentiates activation of NMDARs (Berman and Murray, 1997; Berman et al., 2002; Watanabe et al., 2011). DomA has been demonstrated through both in vitro and in vivo approaches to indirectly activate the NMDARs (reviewed in Pulido et al., 2008).  Glufosinate (GLF)((RS)-2-amino-4-(hydroxy(methyl)phosphonoyl)butanoic acid, phosphinothricin) is a phosphorus containing amino acid herbicide that is naturally occurring as a component of the bacteria-derived bactericidal and fungicidal tripeptides bialaphos and phosalacine (Lanz et al., 2014). There are studies suggesting that convulsive and amnesic effects of GLF are mediated through direct binding and activation of NMDAR (Lantz et al., 2014; Matsumura et al., 2001). GLF agonist action at the NMDAR is expected to occur through direct interaction with the glutamate binding site and requires binding of the glycine co-agonist as well as release of the magnesium block from the channel pore."@en ;
  foaf:page <https://identifiers.org/aop/48> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/48> a sbd:Model ;
  rdfs:label "Binding of agonists to ionotropic glutamate receptors in adult brain causes excitotoxicity that mediates neuronal cell death, contributing to learning and memory impairment."@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "A prime example of impairments in learning and memory as the adverse outcome for regulatory action is developmental lead exposure and IQ function in children (Bellinger, 2012). Most methods are well established in the published literature and many have been engaged to evaluate the effects of developmental thyroid disruption. The US EPA and OECD Developmental Neurotoxicity (DNT) Guidelines (OCSPP 870.6300 or OECD TG 426) as well as OECD TG 443 (OECD, 2018) both require testing of learning and memory (USEPA, 1998; OECD, 2007) advising to use the following tests passive avoidance, delayed-matching-to-position for the adult rat and for the infant rat, olfactory conditioning, Morris water maze, Biel or Cincinnati maze, radial arm maze, T-maze, and acquisition and retention of schedule-controlled behaviour.&nbsp; These DNT Guidelines have been deemed valid to identify developmental neurotoxicity and adverse neurodevelopmental outcomes (Makris et al., 2009).  Also, in the frame of the OECD GD 43 (2008) on reproductive toxicity, learning and memory testing may have potential to be applied in the context of developmental neurotoxicity studies. However, many of the learning and memory tasks used in guideline studies may not readily detect subtle impairments in cognitive function associated with modest degrees of developmental thyroid disruption (Gilbert et al., 2012)."@en ;
  foaf:page <https://identifiers.org/aop/48> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/51> a sbd:Model ;
  rdfs:label "PPARα activation leading to impaired fertility in adult male rodents "@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Fibrates are ligands of PPAR&alpha; (Staels et al. 1998).  Phthalates  MHEP (CAS 4376-20-9) directly binds in vitro to PPAR&alpha; (Lapinskas et al. 2005) and activates this receptor in transactivation assays PPAR&alpha; (Lapinskas et al. 2005), (Maloney and Waxman 1999), (Hurst and Waxman 2003), (Bility et al. 2004), (Lampen, Zimnik, and Nau 2003), (Venkata et al. 2006) ]. DEHP (CAS 117-81-7) has not been found to bind and activate PPAR&alpha; (Lapinskas et al. 2005), (Maloney and Waxman 1999). However, the recent studies shown activation of PPAR&alpha; (ToxCastTM Data).  Notably, PPAR&alpha; are responsive to DEHP in vitro as they are translocated to the nucleus (in primary Sertoli cells) (Dufour et al. 2003), (Bhattacharya et al. 2005). Expression of PPAR&alpha; [mRNA and protein] has been reported to be also modulated by phthtalates: (to be up-regulated in vivo upon DEHP treatment (Xu et al. 2010) and down-regulated by Diisobutyl phthalate (DiBP) (Boberg et al. 2008)).   Perfluorooctanoic Acid (PFOA) is known to activate PPAR&alpha; (Vanden Heuvel et al. 2006).  Organotin  Tributyltin (TBT) activates all three heterodimers of PPAR with RXR, primarily through its interaction with RXR (le Maire et al. 2009)"@en ;
  foaf:page <https://identifiers.org/aop/51> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/51> a sbd:Model ;
  rdfs:label "PPARα activation leading to impaired fertility in adult male rodents "@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Under REACH, information on reproductive toxicity is required for chemicals with an annual production/importation volume of 10 metric tonnes or more. Standard information requirements include a screening study on reproduction toxicity (OECD TG 421/422) at Annex VIII (10-100 t.p.a), a prenatal developmental toxicity study (OECD 414) on a first species at Annex IX (100-1000 t.p.a), and from March 2015 the OECD 443(Extended One-Generation Reproductive Toxicity Study) is reproductive toxicity requirement instead of the two generation reproductive toxicity study (OECD TG 416). If not conducted already at Annex IX, a prenatal developmental toxicity study on a second species at Annex X (&ge; 1000 t.p.a.).  Under the Biocidal Products Regulation (BPR), information is also required on reproductive toxicity for active substances as part of core data set and additional data set (EU 2012, ECHA 2013). As a core data set, prenatal developmental toxicity study (EU TM B.31) in rabbits as a first species and a two-generation reproduction toxicity study (EU TM B.31) are required. OECD TG 443 (Extended One-Generation Reproductive Toxicity Study) shall be considered as an alternative approach to the multi-generation study.) According to the Classification, Labelling and Packaging (CLP) regulation (EC, 200; Annex I: 3.7.1.1): a) &ldquo;reproductive toxicity&rdquo; includes adverse effects on sexual function and fertility in adult males and females, as well as developmental toxicity in the offspring; b) &ldquo;effects on fertility&rdquo; includes adverse effects on sexual function and fertility; and c) &ldquo;developmental toxicity&rdquo; includes adverse effects on development of the offspring."@en ;
  foaf:page <https://identifiers.org/aop/51> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/54> a sbd:Model ;
  rdfs:label "Inhibition of Na+/I- symporter (NIS) leads to learning and memory impairment "@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Thyroid Disrupting Chemicals (TDCs) are defined as the xenobiotics that interfere with the thyroid axis with different outcomes for the organism. A very well-studied mechanism of action of the TDCs is the reduction of the circulating levels of THs by inhibiting hormone synthesis in the thyroid gland. For example, perchlorate is a very potent inhibitor of iodide uptake through the sodium/iodide symporter (Tonacchera et al., 2004). Perchlorate has been detected in human breast milk ranging from 1.4 to 92.2 mg &mu;l&ndash;1 (10.5 &mu;g l&ndash;1 mean) in 18 US states (Kirk et al. 2005), and 1.3 to 411 &mu;g l&ndash;1 (9.1 &mu;g l&ndash;1 median) in the Boston area, United States (Pearce et al. 2007). Perchlorate has also been detected in human colostrum of 46 women in the Boston area (from &lt; 0.05 to 187.2 &mu;mol l&ndash;1 (Leung et al. 2009)). The mechanism of perchlorate action is quite simple, as it is believed to be mediated only by the NIS inhibition (Dohan et al., 2007; Wolff, 1998). Additionally, thiocyanate and nitrate are two known inhibitors that have been found to reduce circulating TH levels (Blount et al., 2006; Steinhaus et al., 2007), but they are both less potent than perchlorate (Tonacchera et al., 2004). However, there are also contradictory results from other studies that showed no correlation between thyroid parameters and perchlorate levels in humans (Pearce et al., 2010; Amitai et al., 2007; Tellez et al., 2005).  Co-occurrence of perchlorate, nitrate, and thiocyanate can alter thyroid function in pregnant women. Horton et al. (2015) have shown positive associations between the weighted sum of urinary concentrations of these three analytes and increased TSH, with perchlorate showing the largest weight in the index. Interestingly, De Groef et al. 2006 showed that nitrate and thiocyanate, acquired through drinking water or food, account for a much larger proportion of iodine uptake inhibition than perchlorate, suggesting that NIS inhibition and any potential downstream effect by perchlorate are highly dependent on the presence of other environmental NIS inhibitors and iodine intake itself (Leung et al., 2010). In particular, Tonacchera et al. (2004) showed that the relative potency of perchlorate to inhibit radioactive I&minus; uptake by NIS is 15, 30 and 240 times that of thiocyanate, iodide, and nitrate respectively on a molar concentration basis. These data are in line with earlier studies in rats (Alexander and Wolff, 1996; Greer et al. 1966). Contradictory findings in these studies may therefore be a result of the confounding mixtures in the environment, masking the primary effect of perchlorate.  Decreased iodine intake can decrease TH production, and therefore exposure to perchlorate might be particularly detrimental in iodine-deficient individuals (Leung et al. 2010). Moreover, biologically based dose-response modeling of the relationships among iodide status (e.g., dietary iodine levels), perchlorate dose, and TH production in pregnant women has shown that iodide intake has a profound effect on the likelihood that exposure to goitrogens will produce hypothyroxinemia (Lewandowski et al. 2015).  During pregnancy TH requirements increase, particularly during the first trimester (Alexander et al. 2004; Leung et al. 2010), due to higher concentrations of thyroxine-binding globulin, placental T4 inner-ring deiodination leading to the inactive reverse T3 (rT3), and transfer of small amounts of T4 to the foetus (during the first trimester foetal thyroid function is absent). Moreover, glomerular filtration rate and clearance of proteins and other molecules are both increased during pregnancy, possibly causing increased renal iodide clearance and a decreased of circulating plasma iodine (Glinoer, 1997). Thus, even though the foetal thyroid can trap iodide by about 12 week of gestation (Fisher and Klein, 1981), high concentrations of maternal perchlorate may potentially decrease thyroidal iodine available to the foetus by inhibiting placental NIS (Leung et al. 2010).  Consequences of TH deficiency depend on the developmental timing of the deficiency (Zoeller and Rovet, 2004). For instance, if the TH deficiency occurs during early pregnancy, offspring show visual attention, visual processing and gross motor skills deficits, while if it occurs later, offspring may show subnormal visual and visuospatial skills, along with slower response speeds and motor deficits. If TH insufficiency occurs after birth, language and memory skills are most predominantly affected (Zoeller and Rovet, 2004).  Along this line, age and developmental stage are crucial in determining sensitivity to NIS inhibitors (e.g., perchlorate, thiocyanate, and nitrate). In this regard, McMullen et al. (2017) have shown that adolescent boys and girls, more than adults, represent vulnerable subpopulations to NIS symporter inhibitors. Altogether these studies indicate that age, gender, developmental stage, and dietary iodine levels can affect the impact of NIS inhibitors.  Finally, ten more small simple-structured molecules were identified in a large screening study (Lecat-Guillet et al., 2008b) that could block iodide uptake by specifically disrupting NIS in a dose-dependent manner. These molecules were named Iodide Transport Blockers (ITBs). There are few organic molecules that lead to NIS inhibition but no direct interaction with NIS has been determined (Gerard et al., 1994; Kaminsky et al., 1991). Up to date, only dysidenin, a toxin isolated from the marine sponge Dysidea herbacea, has been reported to specifically inhibit NIS (Van Sande et al., 2003). Finally, the aryltrifluoroborates were found to inhibit iodide uptake with an IC50 value of 0.4 &mu;M on rat-derived thyroid cells (Lecat-Guillet et al., 2008a). The biological activity is rationalized by the presence of the BF3&minus; ion as a minimal binding motif for substrate recognition at the iodide binding site.  It has been also shown that many anions, such as ClO3-, SCN-, NO3-, ReO4-, TcO4- and in a lower extent Br- and BF4-, are also acting as NIS substrates and they enter the cell by the same transporter mechanism (Van Sande et al., 2003). It has been also shown that ClO4- is transferred by NIS with high affinity and is considered as one of its most potent inhibitors (Dohan et al., 2007). Most recently, the aryltrifluoroborates were also shown to inhibit NIS function (Lecat-Guillet et al., 2008a). A library of 17,020 compounds was tested by a radioactive screening method with high specificity using transfected mammalian cells (Lecat-Guillet et al., 2008b; 2007) for NIS inhibition evaluation. Further studies with the most powerful inhibitors showed a high diversity in their structure and mode of action (Lindenthal et al., 2009)."@en ;
  foaf:page <https://identifiers.org/aop/54> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/54> a sbd:Model ;
  rdfs:label "Inhibition of Na+/I- symporter (NIS) leads to learning and memory impairment "@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "A prime example of impairments in learning and memory as the adverse outcome for regulatory action is developmental lead exposure and IQ function in children (Bellinger, 2012). Most methods are well established in the published literature and many have been engaged to evaluate the effects of developmental thyroid disruption. The US EPA and OECD Developmental Neurotoxicity (DNT) Guidelines (OCSPP 870.6300 or OECD TG 426) as well as OECD TG 443 (OECD, 2018) both require testing of learning and memory (USEPA, 1998; OECD, 2007) advising to use the following tests passive avoidance, delayed-matching-to-position for the adult rat and for the infant rat, olfactory conditioning, Morris water maze, Biel or Cincinnati maze, radial arm maze, T-maze, and acquisition and retention of schedule-controlled behaviour.&nbsp; These DNT Guidelines have been deemed valid to identify developmental neurotoxicity and adverse neurodevelopmental outcomes (Makris et al., 2009).  Also, in the frame of the OECD GD 43 (2008) on reproductive toxicity, learning and memory testing may have potential to be applied in the context of developmental neurotoxicity studies. However, many of the learning and memory tasks used in guideline studies may not readily detect subtle impairments in cognitive function associated with modest degrees of developmental thyroid disruption (Gilbert et al., 2012)."@en ;
  foaf:page <https://identifiers.org/aop/54> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/57> a sbd:Model ;
  rdfs:label "AhR activation leading to hepatic steatosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The AHR can be activated by several structurally diverse chemicals, but binds preferentially to planar halogenated aromatic hydrocarbons and polycyclic aromatic hydrocarbons. Dioxin-like compounds (DLCs), which include polychlorinated dibenzo-p-dioxins (PCDDs), polychlorinated dibenzofurans (PCDFs) and certain polychlorinated biphenyls (PCBs), are among the most potent AHR ligands[38]. Only a subset of PCDD, PCDF and PCB congeners has been shown to bind to the AHR and cause toxic effects to those elicited by TCDD. Until recently, TCDD was considered to be the most potent DLC in birds[39]; however, recent reports indicate that 2,3,4,7,8-pentachlorodibenzofuran (PeCDF) is more potent than TCDD in some species of birds.[40][13][41][21][42][43] When screened for their ability to induce aryl hydrocarbon hydroxylase (AHH) activity, dioxins with chlorine atoms at a minimum of three out of the four lateral ring positions, and with at least one non-chlorinated ring position are the most active[44]. Of the dioxin-like PCBs, non-ortho congeners are the most toxicologically active, while mono-ortho PCBs are generally less potent[45][9]. Chlorine substitution at ortho positions increases the energetic costs of assuming the coplanar conformation required for binding to the AHR [45]. Thus, a smaller proportion of mono-ortho PCB molecules are able to bind to the AHR and elicit toxic effects, resulting in reduced potency of these congeners. Other PCB congeners, such as di-ortho substituted PCBs, are very weak AHR agonists and do not likely contribute to dioxin-like effects [9].   	Contrary to studies of birds and mammals, even the most potent mono-ortho PCBs bind to AhRs of fishes with very low affinity, if at all (Abnet et al 1999; Doering et al 2014; 2015; Eisner et al 2016; Van den Berg et al 1998).   The role of the AHR in mediating the toxic effects of planar hydrophobic contaminants has been well studied, however the endogenous role of the AHR is less clear [1]. Some endogenous and natural substances, including prostaglandin PGG2 and the tryptophan derivatives indole-3-carbinol, 6-formylindolo[3,2-b]carbazole (FICZ) and kynurenic acid can bind to and activate the AHR. [6][46][47][48][49] The AHR is thought to have important endogenous roles in reproduction, liver and heart development, cardiovascular function, immune function and cell cycle regulation [50][38][51][52][53][54][46][55][56][57] and activation of the AHR by DLCs may therefore adversely affect these processes."@en ;
  foaf:page <https://identifiers.org/aop/57> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/58> a sbd:Model ;
  rdfs:label "NR1I3 (CAR) suppression leading to hepatic steatosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Steatosis is a regulatory endpoint and has been used as an endpoint in many US EPA assessments, including IRIS assessments."@en ;
  foaf:page <https://identifiers.org/aop/58> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/58> a sbd:Model ;
  rdfs:label "NR1I3 (CAR) suppression leading to hepatic steatosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "1.1 Binding and activation of receptor  PPAR&gamma; ligands thiazolidinediones (Rosiglitazone, Pioglitazone, Troglitazone) (Lehmann et al. 1995), (Forman et al. 1995), (Willson et al. 2000).  Phthalates  MEHP (CAS 4376-20-9) directly binds to PPAR&gamma; (Lapinskas et al. 2005), (ToxCastTM Data)in vitro and in silico (Feige et al. 2007), (Rotman et al. 2008), (Kaya et al. 2006) and activates this receptor in transactivation assays (Maloney &amp; Waxman 1999), (Hurst &amp; Waxman 2003b), (Venkata et al. 2006), (ToxCastTM Data). In summary, there is experimental in vitro evidence for binding and transcriptional activation of PPAR&gamma;. DEHP (CAS 117-81-7) was not found to bind and activate PPAR&gamma; (Lapinskas et al. 2005), (Maloney &amp; Waxman 1999). However recent studies show activation of PPAR&gamma; by DEHP(ToxCastTM Data), (Pereira-Fernandes et al. 2013). DEHP was also found to increase the levels of PPAR&gamma; in vitro (Lin et al. 2011). Notably, PPAR&gamma; is responsive to DEHP in vitro and is translocated to the nucleus (in primary Sertoli cells) (Dufour et al. 2003), (Bhattacharya et al. 2005).  Parabens  Butylparaben was not found to bind to the PPAR&gamma; (ToxCastTM Data), but activated the human PPAR&gamma; (ToxCastTM Data), (Pereira-Fernandes et al. 2013) and mPPAR&gamma; in reporter gene assay (Taxvig et al., 2012).  Phenols  Bisphenol A was not found to bind to the PPAR&gamma; (ToxCastTM Data), but activated the human PPAR&gamma; (ToxCastTM Data), (Pereira-Fernandes et al. 2013) but not mouse PPAR&gamma; (Taxvig et al., 2012) in reporter gene assay. BPA was also reported to increase PPAR&gamma; (mRNA) in ovarian granulosa cell line and human luteinized granulosa cells (Kwintkiewicz, Nishi, Yanase, &amp; Giudice, 2010).  Organotin  Tributyltin (TBT) activates all three heterodimers of PPAR with RXR, primarily through its interaction with RXR (le Maire et al. 2009).   1.2 Activation of target genes  MEHP activation of endogenous PPAR&gamma; target genes was evidenced by the stimulation of PPAR&gamma;-dependent adipogenesis in the 3T3-L1 cell differentiation model (Hurst &amp; Waxman, 2003)."@en ;
  foaf:page <https://identifiers.org/aop/58> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/6> a sbd:Model ;
  rdfs:label "Antagonist binding to PPARα leading to body-weight loss"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "WWeight loss in wild populations has direct implications on fitness as demonstrated dynamic energy budget modeling (Nisbet et al 2000).&nbsp; Thus weight loss can be used as a metric for populations sustainability.&nbsp; For individuals, rapid weight loss of greater than 20% total body weight is considered indicative of a moribund condition in laboratory animals for many Institutional Animal Care and Use Committees as established by American Association for Laboratory Animal Science (https://www.aalas.org/iacuc#.ViZzMSvaFs)."@en ;
  foaf:page <https://identifiers.org/aop/6> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/6> a sbd:Model ;
  rdfs:label "Antagonist binding to PPARα leading to body-weight loss"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Antagonist binding of GW6471 causing increased stabilization of the co-repressors SMRT and N-CoR to the PPAR&alpha; ligand binding domain has been explicitly demonstrated through x-ray crystallography (Xu et al 2002).    &nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/6> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/60> a sbd:Model ;
  rdfs:label "NR1I2 (Pregnane X Receptor, PXR)  activation leading to hepatic steatosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Steatosis is a regulatory endpoint and has been used as an endpoint in many US EPA assessments, including IRIS assessments."@en ;
  foaf:page <https://identifiers.org/aop/60> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/61> a sbd:Model ;
  rdfs:label "NFE2L2/FXR activation leading to hepatic steatosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Steatosis is a regulatory endpoint and has been used as an endpoint in many US EPA assessments, including IRIS assessments."@en ;
  foaf:page <https://identifiers.org/aop/61> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/62> a sbd:Model ;
  rdfs:label "AKT2 activation leading to hepatic steatosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Steatosis is a regulatory endpoint and has been used as an endpoint in many US EPA assessments, including IRIS assessments."@en ;
  foaf:page <https://identifiers.org/aop/62> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/63> a sbd:Model ;
  rdfs:label "Cyclooxygenase inhibition leading to reproductive dysfunction"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/63> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/63> a sbd:Model ;
  rdfs:label "Cyclooxygenase inhibition leading to reproductive dysfunction"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Non-steroidal anti-inflammatory drugs have been specifically designed to inhibit cyclooxygenase active site of PTGS; these mechanisms of inhibition are well characterized (Simmons et al, 2004). NSAIDs interfere with COX site via multiple mechanisms including competitive inhibition (most NSAIDs compete for active site with arachidonic acid) and covalent modification (irreversible acetylation) of COX (e.g., aspirin) (Simmons et al., 2004; Willoughby et al., 2011). NSAIDs display different levels of selectivity for the COX-1 vs. COX-2 isoforms (Simmons et al., 2004). Majority of NSAIDs inhibit both isoforms (with variable levels of selectivity for COX-1 vs. COX-2), but several have been designed to preferentially inhibit COX-2 (Bacchi et al., 2012). Recently, COX-1 specific inhibitors have been developed and their therapeutic potential is being explored (Liedtke et al., 2012). Most extensive evidence regarding chemical initiation of this event comes from the mammalian literature and relates to NSAIDs. In addition to NSAIDs, common environmental contaminants of diverse chemical structures and uses (e.g., parabens, phthalates, benzophenones) have been postulated to inhibit prostaglandin synthesis via COX inhibition (Kristensen et al., 2011). U.S. EPA’s high throughput screening program (ACToR, epa.gov) indicated COX as a frequent contaminant target - 61% of 143 tested chemicals inhibited COX-1 and 59% of 106 inhibited COX-2 activity. Several chemicals were either similar in potency (e.g., monobutylphthalate) or more potent than NSAIDs (e.g., insecticide emamectin benzoate and industrial intermediary 1-Chloro-4-nitrobenzene were more potent inhibitors of COX2 than NSAID celecoxib, which was specifically designed to inhibit COX-2). Mechanisms of inhibition for these chemicals are not well elucidated."@en ;
  foaf:page <https://identifiers.org/aop/63> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/63> a sbd:Model ;
  rdfs:label "Cyclooxygenase inhibition leading to reproductive dysfunction"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/63> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/63> a sbd:Model ;
  rdfs:label "Cyclooxygenase inhibition leading to reproductive dysfunction"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Non-steroidal anti-inflammatory drugs have been specifically designed to inhibit cyclooxygenase active site of PTGS; these mechanisms of inhibition are well characterized (Simmons et al, 2004). NSAIDs interfere with COX site via multiple mechanisms including competitive inhibition (most NSAIDs compete for active site with arachidonic acid) and covalent modification (irreversible acetylation) of COX (e.g., aspirin) (Simmons et al., 2004; Willoughby et al., 2011). NSAIDs display different levels of selectivity for the COX-1 vs. COX-2 isoforms (Simmons et al., 2004). Majority of NSAIDs inhibit both isoforms (with variable levels of selectivity for COX-1 vs. COX-2), but several have been designed to preferentially inhibit COX-2 (Bacchi et al., 2012). Recently, COX-1 specific inhibitors have been developed and their therapeutic potential is being explored (Liedtke et al., 2012). Most extensive evidence regarding chemical initiation of this event comes from the mammalian literature and relates to NSAIDs. In addition to NSAIDs, common environmental contaminants of diverse chemical structures and uses (e.g., parabens, phthalates, benzophenones) have been postulated to inhibit prostaglandin synthesis via COX inhibition (Kristensen et al., 2011). U.S. EPA’s high throughput screening program (ACToR, epa.gov) indicated COX as a frequent contaminant target - 61% of 143 tested chemicals inhibited COX-1 and 59% of 106 inhibited COX-2 activity. Several chemicals were either similar in potency (e.g., monobutylphthalate) or more potent than NSAIDs (e.g., insecticide emamectin benzoate and industrial intermediary 1-Chloro-4-nitrobenzene were more potent inhibitors of COX2 than NSAID celecoxib, which was specifically designed to inhibit COX-2). Mechanisms of inhibition for these chemicals are not well elucidated."@en ;
  foaf:page <https://identifiers.org/aop/63> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/64> a sbd:Model ;
  rdfs:label "Glucocorticoid Receptor (GR) Mediated Adult Leydig Cell Dysfunction Leading to Decreased Male Fertility"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Under REACH, information on reproductive toxicity is required for chemicals with an annual production/importation volume of 10 metric tonnes or more. Standard information requirements include a screening study on reproduction toxicity (OECD TG 421/422) at Annex VIII (10-100 t.p.a), a prenatal developmental toxicity study (OECD 414) on a first species at Annex IX (100-1000 t.p.a), and from March 2015 the OECD 443(Extended One-Generation Reproductive Toxicity Study) is reproductive toxicity requirement instead of the two generation reproductive toxicity study (OECD TG 416). If not conducted already at Annex IX, a prenatal developmental toxicity study on a second species at Annex X (&ge; 1000 t.p.a.).  Under the Biocidal Products Regulation (BPR), information is also required on reproductive toxicity for active substances as part of core data set and additional data set (EU 2012, ECHA 2013). As a core data set, prenatal developmental toxicity study (EU TM B.31) in rabbits as a first species and a two-generation reproduction toxicity study (EU TM B.31) are required. OECD TG 443 (Extended One-Generation Reproductive Toxicity Study) shall be considered as an alternative approach to the multi-generation study.) According to the Classification, Labelling and Packaging (CLP) regulation (EC, 200; Annex I: 3.7.1.1): a) &ldquo;reproductive toxicity&rdquo; includes adverse effects on sexual function and fertility in adult males and females, as well as developmental toxicity in the offspring; b) &ldquo;effects on fertility&rdquo; includes adverse effects on sexual function and fertility; and c) &ldquo;developmental toxicity&rdquo; includes adverse effects on development of the offspring."@en ;
  foaf:page <https://identifiers.org/aop/64> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/65> a sbd:Model ;
  rdfs:label "XX Inhibition of Sodium Iodide Symporter and Subsequent Adverse Neurodevelopmental Outcomes in Mammals"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Thyroid Disrupting Chemicals (TDCs) are defined as the xenobiotics that interfere with the thyroid axis with different outcomes for the organism. A very well-studied mechanism of action of the TDCs is the reduction of the circulating levels of THs by inhibiting hormone synthesis in the thyroid gland. For example, perchlorate is a very potent inhibitor of iodide uptake through the sodium/iodide symporter (Tonacchera et al., 2004). Perchlorate has been detected in human breast milk ranging from 1.4 to 92.2 mg &mu;l&ndash;1 (10.5 &mu;g l&ndash;1 mean) in 18 US states (Kirk et al. 2005), and 1.3 to 411 &mu;g l&ndash;1 (9.1 &mu;g l&ndash;1 median) in the Boston area, United States (Pearce et al. 2007). Perchlorate has also been detected in human colostrum of 46 women in the Boston area (from &lt; 0.05 to 187.2 &mu;mol l&ndash;1 (Leung et al. 2009)). The mechanism of perchlorate action is quite simple, as it is believed to be mediated only by the NIS inhibition (Dohan et al., 2007; Wolff, 1998). Additionally, thiocyanate and nitrate are two known inhibitors that have been found to reduce circulating TH levels (Blount et al., 2006; Steinhaus et al., 2007), but they are both less potent than perchlorate (Tonacchera et al., 2004). However, there are also contradictory results from other studies that showed no correlation between thyroid parameters and perchlorate levels in humans (Pearce et al., 2010; Amitai et al., 2007; Tellez et al., 2005).  Co-occurrence of perchlorate, nitrate, and thiocyanate can alter thyroid function in pregnant women. Horton et al. (2015) have shown positive associations between the weighted sum of urinary concentrations of these three analytes and increased TSH, with perchlorate showing the largest weight in the index. Interestingly, De Groef et al. 2006 showed that nitrate and thiocyanate, acquired through drinking water or food, account for a much larger proportion of iodine uptake inhibition than perchlorate, suggesting that NIS inhibition and any potential downstream effect by perchlorate are highly dependent on the presence of other environmental NIS inhibitors and iodine intake itself (Leung et al., 2010). In particular, Tonacchera et al. (2004) showed that the relative potency of perchlorate to inhibit radioactive I&minus; uptake by NIS is 15, 30 and 240 times that of thiocyanate, iodide, and nitrate respectively on a molar concentration basis. These data are in line with earlier studies in rats (Alexander and Wolff, 1996; Greer et al. 1966). Contradictory findings in these studies may therefore be a result of the confounding mixtures in the environment, masking the primary effect of perchlorate.  Decreased iodine intake can decrease TH production, and therefore exposure to perchlorate might be particularly detrimental in iodine-deficient individuals (Leung et al. 2010). Moreover, biologically based dose-response modeling of the relationships among iodide status (e.g., dietary iodine levels), perchlorate dose, and TH production in pregnant women has shown that iodide intake has a profound effect on the likelihood that exposure to goitrogens will produce hypothyroxinemia (Lewandowski et al. 2015).  During pregnancy TH requirements increase, particularly during the first trimester (Alexander et al. 2004; Leung et al. 2010), due to higher concentrations of thyroxine-binding globulin, placental T4 inner-ring deiodination leading to the inactive reverse T3 (rT3), and transfer of small amounts of T4 to the foetus (during the first trimester foetal thyroid function is absent). Moreover, glomerular filtration rate and clearance of proteins and other molecules are both increased during pregnancy, possibly causing increased renal iodide clearance and a decreased of circulating plasma iodine (Glinoer, 1997). Thus, even though the foetal thyroid can trap iodide by about 12 week of gestation (Fisher and Klein, 1981), high concentrations of maternal perchlorate may potentially decrease thyroidal iodine available to the foetus by inhibiting placental NIS (Leung et al. 2010).  Consequences of TH deficiency depend on the developmental timing of the deficiency (Zoeller and Rovet, 2004). For instance, if the TH deficiency occurs during early pregnancy, offspring show visual attention, visual processing and gross motor skills deficits, while if it occurs later, offspring may show subnormal visual and visuospatial skills, along with slower response speeds and motor deficits. If TH insufficiency occurs after birth, language and memory skills are most predominantly affected (Zoeller and Rovet, 2004).  Along this line, age and developmental stage are crucial in determining sensitivity to NIS inhibitors (e.g., perchlorate, thiocyanate, and nitrate). In this regard, McMullen et al. (2017) have shown that adolescent boys and girls, more than adults, represent vulnerable subpopulations to NIS symporter inhibitors. Altogether these studies indicate that age, gender, developmental stage, and dietary iodine levels can affect the impact of NIS inhibitors.  Finally, ten more small simple-structured molecules were identified in a large screening study (Lecat-Guillet et al., 2008b) that could block iodide uptake by specifically disrupting NIS in a dose-dependent manner. These molecules were named Iodide Transport Blockers (ITBs). There are few organic molecules that lead to NIS inhibition but no direct interaction with NIS has been determined (Gerard et al., 1994; Kaminsky et al., 1991). Up to date, only dysidenin, a toxin isolated from the marine sponge Dysidea herbacea, has been reported to specifically inhibit NIS (Van Sande et al., 2003). Finally, the aryltrifluoroborates were found to inhibit iodide uptake with an IC50 value of 0.4 &mu;M on rat-derived thyroid cells (Lecat-Guillet et al., 2008a). The biological activity is rationalized by the presence of the BF3&minus; ion as a minimal binding motif for substrate recognition at the iodide binding site.  It has been also shown that many anions, such as ClO3-, SCN-, NO3-, ReO4-, TcO4- and in a lower extent Br- and BF4-, are also acting as NIS substrates and they enter the cell by the same transporter mechanism (Van Sande et al., 2003). It has been also shown that ClO4- is transferred by NIS with high affinity and is considered as one of its most potent inhibitors (Dohan et al., 2007). Most recently, the aryltrifluoroborates were also shown to inhibit NIS function (Lecat-Guillet et al., 2008a). A library of 17,020 compounds was tested by a radioactive screening method with high specificity using transfected mammalian cells (Lecat-Guillet et al., 2008b; 2007) for NIS inhibition evaluation. Further studies with the most powerful inhibitors showed a high diversity in their structure and mode of action (Lindenthal et al., 2009)."@en ;
  foaf:page <https://identifiers.org/aop/65> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/65> a sbd:Model ;
  rdfs:label "XX Inhibition of Sodium Iodide Symporter and Subsequent Adverse Neurodevelopmental Outcomes in Mammals"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "A prime example of impairments in cognitive function as the adverse outcome for regulatory action is developmental lead exposure and IQ function in children (Bellinger, 2012). In addition, testing for the impact of chemical expsoures on cognitive function, often including spatially-mediated behaviors, is an intergral part of both EPA and OECD developmental neurotoxicity guidelines (USEPA, 1998; OECD, 2007)."@en ;
  foaf:page <https://identifiers.org/aop/65> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/7> a sbd:Model ;
  rdfs:label "Aromatase (Cyp19a1) reduction leading to impaired fertility in adult female"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Under REACH, information on reproductive toxicity is required for chemicals with an annual production/importation volume of 10 metric tonnes or more. Standard information requirements include a screening study on reproduction toxicity (OECD TG 421/422) at Annex VIII (10-100 t.p.a), a prenatal developmental toxicity study (OECD 414) on a first species at Annex IX (100-1000 t.p.a), and from March 2015 the OECD 443(Extended One-Generation Reproductive Toxicity Study) is reproductive toxicity requirement instead of the two generation reproductive toxicity study (OECD TG 416). If not conducted already at Annex IX, a prenatal developmental toxicity study on a second species at Annex X (&ge; 1000 t.p.a.).  Under the Biocidal Products Regulation (BPR), information is also required on reproductive toxicity for active substances as part of core data set and additional data set (EU 2012, ECHA 2013). As a core data set, prenatal developmental toxicity study (EU TM B.31) in rabbits as a first species and a two-generation reproduction toxicity study (EU TM B.31) are required. OECD TG 443 (Extended One-Generation Reproductive Toxicity Study) shall be considered as an alternative approach to the multi-generation study.) According to the Classification, Labelling and Packaging (CLP) regulation (EC, 200; Annex I: 3.7.1.1): a) &ldquo;reproductive toxicity&rdquo; includes adverse effects on sexual function and fertility in adult males and females, as well as developmental toxicity in the offspring; b) &ldquo;effects on fertility&rdquo; includes adverse effects on sexual function and fertility; and c) &ldquo;developmental toxicity&rdquo; includes adverse effects on development of the offspring."@en ;
  foaf:page <https://identifiers.org/aop/7> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/7> a sbd:Model ;
  rdfs:label "Aromatase (Cyp19a1) reduction leading to impaired fertility in adult female"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Chemicals may be found to interfere with reproductive function in the female rat. This interference is commonly expressed as a change in normal morphology of the reproductive tract or a disturbance in the duration of particular phases of the estrous cycle. This key event lies within the scope of testing for endocrine disrupting activity of chemicals and therefore for testing of female reproductive and developmental toxicity. Monitoring of oestrus cyclicity is included in OECD test guidelines (Test No. 407: Repeated Dose 28-day Oral Toxicity Study in Rodents, 2008), (Test No. 416: Two-Generation Reproduction Toxicity, 2001) and (Test No. 443: Extended One-Generation Reproductive Toxicity Study, 2012) and in USA EPA OCSPP 890.1450. While an evaluation of the estrous cycle in laboratory rodents can be a useful measure of the integrity of the hypothalamic-pituitary-ovarian reproductive axis, it can also serve as a way of insuring that animals exhibiting abnormal cycling patterns are excluded from a study prior to exposure to a test compound. When incorporated as an adjunct to other endpoint measures, a determination of a female's cycling status can contribute important information about the nature of a toxicant insult to the reproductive system. In doing so, it can help to integrate the data into a more comprehensive mechanistic portrait of the effect, and in terms of risk assessment, may provide some indication of a toxicant's impact on human reproductive physiology. Significant evidence that the estrous cycle (or menstrual cycle in primates) has been disrupted should be considered an adverse effect (OECD, 2008). Included should be evidence of abnormal cycle length or pattern, ovulation failure, or abnormal menstruation."@en ;
  foaf:page <https://identifiers.org/aop/7> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/7> a sbd:Model ;
  rdfs:label "Aromatase (Cyp19a1) reduction leading to impaired fertility in adult female"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Under REACH, information on reproductive toxicity is required for chemicals with an annual production/importation volume of 10 metric tonnes or more. Standard information requirements include a screening study on reproduction toxicity (OECD TG 421/422) at Annex VIII (10-100 t.p.a), a prenatal developmental toxicity study (OECD 414) on a first species at Annex IX (100-1000 t.p.a), and from March 2015 the OECD 443(Extended One-Generation Reproductive Toxicity Study) is reproductive toxicity requirement instead of the two generation reproductive toxicity study (OECD TG 416). If not conducted already at Annex IX, a prenatal developmental toxicity study on a second species at Annex X (&ge; 1000 t.p.a.).  Under the Biocidal Products Regulation (BPR), information is also required on reproductive toxicity for active substances as part of core data set and additional data set (EU 2012, ECHA 2013). As a core data set, prenatal developmental toxicity study (EU TM B.31) in rabbits as a first species and a two-generation reproduction toxicity study (EU TM B.31) are required. OECD TG 443 (Extended One-Generation Reproductive Toxicity Study) shall be considered as an alternative approach to the multi-generation study.) According to the Classification, Labelling and Packaging (CLP) regulation (EC, 200; Annex I: 3.7.1.1): a) &ldquo;reproductive toxicity&rdquo; includes adverse effects on sexual function and fertility in adult males and females, as well as developmental toxicity in the offspring; b) &ldquo;effects on fertility&rdquo; includes adverse effects on sexual function and fertility; and c) &ldquo;developmental toxicity&rdquo; includes adverse effects on development of the offspring."@en ;
  foaf:page <https://identifiers.org/aop/7> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/7> a sbd:Model ;
  rdfs:label "Aromatase (Cyp19a1) reduction leading to impaired fertility in adult female"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Chemicals may be found to interfere with reproductive function in the female rat. This interference is commonly expressed as a change in normal morphology of the reproductive tract or a disturbance in the duration of particular phases of the estrous cycle. This key event lies within the scope of testing for endocrine disrupting activity of chemicals and therefore for testing of female reproductive and developmental toxicity. Monitoring of oestrus cyclicity is included in OECD test guidelines (Test No. 407: Repeated Dose 28-day Oral Toxicity Study in Rodents, 2008), (Test No. 416: Two-Generation Reproduction Toxicity, 2001) and (Test No. 443: Extended One-Generation Reproductive Toxicity Study, 2012) and in USA EPA OCSPP 890.1450. While an evaluation of the estrous cycle in laboratory rodents can be a useful measure of the integrity of the hypothalamic-pituitary-ovarian reproductive axis, it can also serve as a way of insuring that animals exhibiting abnormal cycling patterns are excluded from a study prior to exposure to a test compound. When incorporated as an adjunct to other endpoint measures, a determination of a female's cycling status can contribute important information about the nature of a toxicant insult to the reproductive system. In doing so, it can help to integrate the data into a more comprehensive mechanistic portrait of the effect, and in terms of risk assessment, may provide some indication of a toxicant's impact on human reproductive physiology. Significant evidence that the estrous cycle (or menstrual cycle in primates) has been disrupted should be considered an adverse effect (OECD, 2008). Included should be evidence of abnormal cycle length or pattern, ovulation failure, or abnormal menstruation."@en ;
  foaf:page <https://identifiers.org/aop/7> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/72> a sbd:Model ;
  rdfs:label "Epigenetic modification of PPARG leading to adipogenesis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "1.1 Binding and activation of receptor  PPAR&gamma; ligands thiazolidinediones (Rosiglitazone, Pioglitazone, Troglitazone) (Lehmann et al. 1995), (Forman et al. 1995), (Willson et al. 2000).  Phthalates  MEHP (CAS 4376-20-9) directly binds to PPAR&gamma; (Lapinskas et al. 2005), (ToxCastTM Data)in vitro and in silico (Feige et al. 2007), (Rotman et al. 2008), (Kaya et al. 2006) and activates this receptor in transactivation assays (Maloney &amp; Waxman 1999), (Hurst &amp; Waxman 2003b), (Venkata et al. 2006), (ToxCastTM Data). In summary, there is experimental in vitro evidence for binding and transcriptional activation of PPAR&gamma;. DEHP (CAS 117-81-7) was not found to bind and activate PPAR&gamma; (Lapinskas et al. 2005), (Maloney &amp; Waxman 1999). However recent studies show activation of PPAR&gamma; by DEHP(ToxCastTM Data), (Pereira-Fernandes et al. 2013). DEHP was also found to increase the levels of PPAR&gamma; in vitro (Lin et al. 2011). Notably, PPAR&gamma; is responsive to DEHP in vitro and is translocated to the nucleus (in primary Sertoli cells) (Dufour et al. 2003), (Bhattacharya et al. 2005).  Parabens  Butylparaben was not found to bind to the PPAR&gamma; (ToxCastTM Data), but activated the human PPAR&gamma; (ToxCastTM Data), (Pereira-Fernandes et al. 2013) and mPPAR&gamma; in reporter gene assay (Taxvig et al., 2012).  Phenols  Bisphenol A was not found to bind to the PPAR&gamma; (ToxCastTM Data), but activated the human PPAR&gamma; (ToxCastTM Data), (Pereira-Fernandes et al. 2013) but not mouse PPAR&gamma; (Taxvig et al., 2012) in reporter gene assay. BPA was also reported to increase PPAR&gamma; (mRNA) in ovarian granulosa cell line and human luteinized granulosa cells (Kwintkiewicz, Nishi, Yanase, &amp; Giudice, 2010).  Organotin  Tributyltin (TBT) activates all three heterodimers of PPAR with RXR, primarily through its interaction with RXR (le Maire et al. 2009).   1.2 Activation of target genes  MEHP activation of endogenous PPAR&gamma; target genes was evidenced by the stimulation of PPAR&gamma;-dependent adipogenesis in the 3T3-L1 cell differentiation model (Hurst &amp; Waxman, 2003)."@en ;
  foaf:page <https://identifiers.org/aop/72> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/77> a sbd:Model ;
  rdfs:label "Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony death/failure 1"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Text from LaLone et al. (2017) Weight of evidence evaluation of a network of adverse outcome pathways linking activaiton of the nicotinic acetylcholine receptor in honey bees to colony death. Science of the Total Environment 584-585, 751-775:  &quot;The nicotinoids and neonicotinoids are both agonists of the nAChR (Tomizawa and Casida, 2003); however, neonicotinoids are the primary chemicals considered in the AOPs relevant to bees. The potency of a nAChR agonist is dependent on the receptor subunit composition, structurally important amino acid residues at the binding site, and the ionization status of the chemical at physiological pH (Tomizawa and Casida, 2003; Dani and Bertrand, 2007). For example, nicotine is a classical vertebrate nAChR agonist; however, it has relatively low affinity (and insecticidal activity) for the invertebrate nAChR. Due to ionization, nicotine is poor at passing though the ion-impermeable barrier surrounding the insect central nervous system(CNS; Tomizawa and Casida, 2003). Conversely, non-ionizable neonicotinoids readily translocate into the insect CNS and have high affinity for the nAChR (e.g., Drosophila nAChR IC50 4.6 nM imidacloprid), with limited or no binding activity to vertebrate nAChR (Tomizawa and Casida, 2003). Various studies have demonstrated that similarities and differences in key amino acid residues in the ligand binding domain across species can lead to structural and binding site differences that dictate chemical interaction with the receptor (Dani and Bertrand, 2007; Matsuda et al., 2009; Tomizawa and Casida, 2009; Jones and Sattelle, 2010; LaLone et al., 2016). Due to the intended insecticidal action of neonicotinoids, a growing number of studies have been conducted to  evaluate potential adverse effects in non-target species such as honey bees exposed to neonicotinoids, particularly imidacloprid, clothianidin, and thiamethoxam. Some of the results of these studies are included in subsequent AOP descriptions.&quot;"@en ;
  foaf:page <https://identifiers.org/aop/77> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/78> a sbd:Model ;
  rdfs:label "Nicotinic acetylcholine receptor activation contributes to abnormal role change within the worker bee caste leading to colony death failure 1"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Text from LaLone et al. (2017) Weight of evidence evaluation of a network of adverse outcome pathways linking activaiton of the nicotinic acetylcholine receptor in honey bees to colony death. Science of the Total Environment 584-585, 751-775:  &quot;The nicotinoids and neonicotinoids are both agonists of the nAChR (Tomizawa and Casida, 2003); however, neonicotinoids are the primary chemicals considered in the AOPs relevant to bees. The potency of a nAChR agonist is dependent on the receptor subunit composition, structurally important amino acid residues at the binding site, and the ionization status of the chemical at physiological pH (Tomizawa and Casida, 2003; Dani and Bertrand, 2007). For example, nicotine is a classical vertebrate nAChR agonist; however, it has relatively low affinity (and insecticidal activity) for the invertebrate nAChR. Due to ionization, nicotine is poor at passing though the ion-impermeable barrier surrounding the insect central nervous system(CNS; Tomizawa and Casida, 2003). Conversely, non-ionizable neonicotinoids readily translocate into the insect CNS and have high affinity for the nAChR (e.g., Drosophila nAChR IC50 4.6 nM imidacloprid), with limited or no binding activity to vertebrate nAChR (Tomizawa and Casida, 2003). Various studies have demonstrated that similarities and differences in key amino acid residues in the ligand binding domain across species can lead to structural and binding site differences that dictate chemical interaction with the receptor (Dani and Bertrand, 2007; Matsuda et al., 2009; Tomizawa and Casida, 2009; Jones and Sattelle, 2010; LaLone et al., 2016). Due to the intended insecticidal action of neonicotinoids, a growing number of studies have been conducted to  evaluate potential adverse effects in non-target species such as honey bees exposed to neonicotinoids, particularly imidacloprid, clothianidin, and thiamethoxam. Some of the results of these studies are included in subsequent AOP descriptions.&quot;"@en ;
  foaf:page <https://identifiers.org/aop/78> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/78> a sbd:Model ;
  rdfs:label "Nicotinic acetylcholine receptor activation contributes to abnormal role change within the worker bee caste leading to colony death failure 1"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Text from LaLone et al. (2017) Weight of evidence evaluation of a network of adverse outcome pathways linking activaiton of the nicotinic acetylcholine receptor in honey bees to colony death. Science of the Total Environment 584-585, 751-775:  &quot;The nicotinoids and neonicotinoids are both agonists of the nAChR (Tomizawa and Casida, 2003); however, neonicotinoids are the primary chemicals considered in the AOPs relevant to bees. The potency of a nAChR agonist is dependent on the receptor subunit composition, structurally important amino acid residues at the binding site, and the ionization status of the chemical at physiological pH (Tomizawa and Casida, 2003; Dani and Bertrand, 2007). For example, nicotine is a classical vertebrate nAChR agonist; however, it has relatively low affinity (and insecticidal activity) for the invertebrate nAChR. Due to ionization, nicotine is poor at passing though the ion-impermeable barrier surrounding the insect central nervous system(CNS; Tomizawa and Casida, 2003). Conversely, non-ionizable neonicotinoids readily translocate into the insect CNS and have high affinity for the nAChR (e.g., Drosophila nAChR IC50 4.6 nM imidacloprid), with limited or no binding activity to vertebrate nAChR (Tomizawa and Casida, 2003). Various studies have demonstrated that similarities and differences in key amino acid residues in the ligand binding domain across species can lead to structural and binding site differences that dictate chemical interaction with the receptor (Dani and Bertrand, 2007; Matsuda et al., 2009; Tomizawa and Casida, 2009; Jones and Sattelle, 2010; LaLone et al., 2016). Due to the intended insecticidal action of neonicotinoids, a growing number of studies have been conducted to  evaluate potential adverse effects in non-target species such as honey bees exposed to neonicotinoids, particularly imidacloprid, clothianidin, and thiamethoxam. Some of the results of these studies are included in subsequent AOP descriptions.&quot;"@en ;
  foaf:page <https://identifiers.org/aop/78> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/79> a sbd:Model ;
  rdfs:label "Nicotinic acetylcholine receptor activation contributes to impaired hive thermoregulation and leads to colony loss/failure"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Text from LaLone et al. (2017) Weight of evidence evaluation of a network of adverse outcome pathways linking activaiton of the nicotinic acetylcholine receptor in honey bees to colony death. Science of the Total Environment 584-585, 751-775:  &quot;The nicotinoids and neonicotinoids are both agonists of the nAChR (Tomizawa and Casida, 2003); however, neonicotinoids are the primary chemicals considered in the AOPs relevant to bees. The potency of a nAChR agonist is dependent on the receptor subunit composition, structurally important amino acid residues at the binding site, and the ionization status of the chemical at physiological pH (Tomizawa and Casida, 2003; Dani and Bertrand, 2007). For example, nicotine is a classical vertebrate nAChR agonist; however, it has relatively low affinity (and insecticidal activity) for the invertebrate nAChR. Due to ionization, nicotine is poor at passing though the ion-impermeable barrier surrounding the insect central nervous system(CNS; Tomizawa and Casida, 2003). Conversely, non-ionizable neonicotinoids readily translocate into the insect CNS and have high affinity for the nAChR (e.g., Drosophila nAChR IC50 4.6 nM imidacloprid), with limited or no binding activity to vertebrate nAChR (Tomizawa and Casida, 2003). Various studies have demonstrated that similarities and differences in key amino acid residues in the ligand binding domain across species can lead to structural and binding site differences that dictate chemical interaction with the receptor (Dani and Bertrand, 2007; Matsuda et al., 2009; Tomizawa and Casida, 2009; Jones and Sattelle, 2010; LaLone et al., 2016). Due to the intended insecticidal action of neonicotinoids, a growing number of studies have been conducted to  evaluate potential adverse effects in non-target species such as honey bees exposed to neonicotinoids, particularly imidacloprid, clothianidin, and thiamethoxam. Some of the results of these studies are included in subsequent AOP descriptions.&quot;"@en ;
  foaf:page <https://identifiers.org/aop/79> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/8> a sbd:Model ;
  rdfs:label "Upregulation of Thyroid Hormone Catabolism via Activation of Hepatic Nuclear Receptors, and Subsequent Adverse Neurodevelopmental Outcomes in Mammals"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "This AOP is an update of the WHO/IPCS MOA developed in 2005 by Crofton and Zoeller (Crit Rev Toxicol 2005).  Crofton KM, Zoeller RT. Mode of action: neurotoxicity induced by thyroid hormone disruption during development--hearing loss resulting from exposure to PHAHs. Crit Rev Toxicol. 2005 Oct-Nov;35(8-9):757-69. PMID: 6417043"@en ;
  foaf:page <https://identifiers.org/aop/8> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/80> a sbd:Model ;
  rdfs:label "Nicotinic acetylcholine receptor activation contributes to accumulation of damaged mitochondrial DNA and leads to colony loss/failure"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Text from LaLone et al. (2017) Weight of evidence evaluation of a network of adverse outcome pathways linking activaiton of the nicotinic acetylcholine receptor in honey bees to colony death. Science of the Total Environment 584-585, 751-775:  &quot;The nicotinoids and neonicotinoids are both agonists of the nAChR (Tomizawa and Casida, 2003); however, neonicotinoids are the primary chemicals considered in the AOPs relevant to bees. The potency of a nAChR agonist is dependent on the receptor subunit composition, structurally important amino acid residues at the binding site, and the ionization status of the chemical at physiological pH (Tomizawa and Casida, 2003; Dani and Bertrand, 2007). For example, nicotine is a classical vertebrate nAChR agonist; however, it has relatively low affinity (and insecticidal activity) for the invertebrate nAChR. Due to ionization, nicotine is poor at passing though the ion-impermeable barrier surrounding the insect central nervous system(CNS; Tomizawa and Casida, 2003). Conversely, non-ionizable neonicotinoids readily translocate into the insect CNS and have high affinity for the nAChR (e.g., Drosophila nAChR IC50 4.6 nM imidacloprid), with limited or no binding activity to vertebrate nAChR (Tomizawa and Casida, 2003). Various studies have demonstrated that similarities and differences in key amino acid residues in the ligand binding domain across species can lead to structural and binding site differences that dictate chemical interaction with the receptor (Dani and Bertrand, 2007; Matsuda et al., 2009; Tomizawa and Casida, 2009; Jones and Sattelle, 2010; LaLone et al., 2016). Due to the intended insecticidal action of neonicotinoids, a growing number of studies have been conducted to  evaluate potential adverse effects in non-target species such as honey bees exposed to neonicotinoids, particularly imidacloprid, clothianidin, and thiamethoxam. Some of the results of these studies are included in subsequent AOP descriptions.&quot;"@en ;
  foaf:page <https://identifiers.org/aop/80> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/80> a sbd:Model ;
  rdfs:label "Nicotinic acetylcholine receptor activation contributes to accumulation of damaged mitochondrial DNA and leads to colony loss/failure"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Text from LaLone et al. (2017) Weight of evidence evaluation of a network of adverse outcome pathways linking activaiton of the nicotinic acetylcholine receptor in honey bees to colony death. Science of the Total Environment 584-585, 751-775:  &quot;The nicotinoids and neonicotinoids are both agonists of the nAChR (Tomizawa and Casida, 2003); however, neonicotinoids are the primary chemicals considered in the AOPs relevant to bees. The potency of a nAChR agonist is dependent on the receptor subunit composition, structurally important amino acid residues at the binding site, and the ionization status of the chemical at physiological pH (Tomizawa and Casida, 2003; Dani and Bertrand, 2007). For example, nicotine is a classical vertebrate nAChR agonist; however, it has relatively low affinity (and insecticidal activity) for the invertebrate nAChR. Due to ionization, nicotine is poor at passing though the ion-impermeable barrier surrounding the insect central nervous system(CNS; Tomizawa and Casida, 2003). Conversely, non-ionizable neonicotinoids readily translocate into the insect CNS and have high affinity for the nAChR (e.g., Drosophila nAChR IC50 4.6 nM imidacloprid), with limited or no binding activity to vertebrate nAChR (Tomizawa and Casida, 2003). Various studies have demonstrated that similarities and differences in key amino acid residues in the ligand binding domain across species can lead to structural and binding site differences that dictate chemical interaction with the receptor (Dani and Bertrand, 2007; Matsuda et al., 2009; Tomizawa and Casida, 2009; Jones and Sattelle, 2010; LaLone et al., 2016). Due to the intended insecticidal action of neonicotinoids, a growing number of studies have been conducted to  evaluate potential adverse effects in non-target species such as honey bees exposed to neonicotinoids, particularly imidacloprid, clothianidin, and thiamethoxam. Some of the results of these studies are included in subsequent AOP descriptions.&quot;"@en ;
  foaf:page <https://identifiers.org/aop/80> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/80> a sbd:Model ;
  rdfs:label "Nicotinic acetylcholine receptor activation contributes to accumulation of damaged mitochondrial DNA and leads to colony loss/failure"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Text from LaLone et al. (2017) Weight of evidence evaluation of a network of adverse outcome pathways linking activaiton of the nicotinic acetylcholine receptor in honey bees to colony death. Science of the Total Environment 584-585, 751-775:  &quot;The nicotinoids and neonicotinoids are both agonists of the nAChR (Tomizawa and Casida, 2003); however, neonicotinoids are the primary chemicals considered in the AOPs relevant to bees. The potency of a nAChR agonist is dependent on the receptor subunit composition, structurally important amino acid residues at the binding site, and the ionization status of the chemical at physiological pH (Tomizawa and Casida, 2003; Dani and Bertrand, 2007). For example, nicotine is a classical vertebrate nAChR agonist; however, it has relatively low affinity (and insecticidal activity) for the invertebrate nAChR. Due to ionization, nicotine is poor at passing though the ion-impermeable barrier surrounding the insect central nervous system(CNS; Tomizawa and Casida, 2003). Conversely, non-ionizable neonicotinoids readily translocate into the insect CNS and have high affinity for the nAChR (e.g., Drosophila nAChR IC50 4.6 nM imidacloprid), with limited or no binding activity to vertebrate nAChR (Tomizawa and Casida, 2003). Various studies have demonstrated that similarities and differences in key amino acid residues in the ligand binding domain across species can lead to structural and binding site differences that dictate chemical interaction with the receptor (Dani and Bertrand, 2007; Matsuda et al., 2009; Tomizawa and Casida, 2009; Jones and Sattelle, 2010; LaLone et al., 2016). Due to the intended insecticidal action of neonicotinoids, a growing number of studies have been conducted to  evaluate potential adverse effects in non-target species such as honey bees exposed to neonicotinoids, particularly imidacloprid, clothianidin, and thiamethoxam. Some of the results of these studies are included in subsequent AOP descriptions.&quot;"@en ;
  foaf:page <https://identifiers.org/aop/80> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/87> a sbd:Model ;
  rdfs:label "Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony loss/failure "@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Text from LaLone et al. (2017) Weight of evidence evaluation of a network of adverse outcome pathways linking activaiton of the nicotinic acetylcholine receptor in honey bees to colony death. Science of the Total Environment 584-585, 751-775:  &quot;The nicotinoids and neonicotinoids are both agonists of the nAChR (Tomizawa and Casida, 2003); however, neonicotinoids are the primary chemicals considered in the AOPs relevant to bees. The potency of a nAChR agonist is dependent on the receptor subunit composition, structurally important amino acid residues at the binding site, and the ionization status of the chemical at physiological pH (Tomizawa and Casida, 2003; Dani and Bertrand, 2007). For example, nicotine is a classical vertebrate nAChR agonist; however, it has relatively low affinity (and insecticidal activity) for the invertebrate nAChR. Due to ionization, nicotine is poor at passing though the ion-impermeable barrier surrounding the insect central nervous system(CNS; Tomizawa and Casida, 2003). Conversely, non-ionizable neonicotinoids readily translocate into the insect CNS and have high affinity for the nAChR (e.g., Drosophila nAChR IC50 4.6 nM imidacloprid), with limited or no binding activity to vertebrate nAChR (Tomizawa and Casida, 2003). Various studies have demonstrated that similarities and differences in key amino acid residues in the ligand binding domain across species can lead to structural and binding site differences that dictate chemical interaction with the receptor (Dani and Bertrand, 2007; Matsuda et al., 2009; Tomizawa and Casida, 2009; Jones and Sattelle, 2010; LaLone et al., 2016). Due to the intended insecticidal action of neonicotinoids, a growing number of studies have been conducted to  evaluate potential adverse effects in non-target species such as honey bees exposed to neonicotinoids, particularly imidacloprid, clothianidin, and thiamethoxam. Some of the results of these studies are included in subsequent AOP descriptions.&quot;"@en ;
  foaf:page <https://identifiers.org/aop/87> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/88> a sbd:Model ;
  rdfs:label "Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony loss/failure via abnormal role change within caste"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Text from LaLone et al. (2017) Weight of evidence evaluation of a network of adverse outcome pathways linking activaiton of the nicotinic acetylcholine receptor in honey bees to colony death. Science of the Total Environment 584-585, 751-775:  &quot;The nicotinoids and neonicotinoids are both agonists of the nAChR (Tomizawa and Casida, 2003); however, neonicotinoids are the primary chemicals considered in the AOPs relevant to bees. The potency of a nAChR agonist is dependent on the receptor subunit composition, structurally important amino acid residues at the binding site, and the ionization status of the chemical at physiological pH (Tomizawa and Casida, 2003; Dani and Bertrand, 2007). For example, nicotine is a classical vertebrate nAChR agonist; however, it has relatively low affinity (and insecticidal activity) for the invertebrate nAChR. Due to ionization, nicotine is poor at passing though the ion-impermeable barrier surrounding the insect central nervous system(CNS; Tomizawa and Casida, 2003). Conversely, non-ionizable neonicotinoids readily translocate into the insect CNS and have high affinity for the nAChR (e.g., Drosophila nAChR IC50 4.6 nM imidacloprid), with limited or no binding activity to vertebrate nAChR (Tomizawa and Casida, 2003). Various studies have demonstrated that similarities and differences in key amino acid residues in the ligand binding domain across species can lead to structural and binding site differences that dictate chemical interaction with the receptor (Dani and Bertrand, 2007; Matsuda et al., 2009; Tomizawa and Casida, 2009; Jones and Sattelle, 2010; LaLone et al., 2016). Due to the intended insecticidal action of neonicotinoids, a growing number of studies have been conducted to  evaluate potential adverse effects in non-target species such as honey bees exposed to neonicotinoids, particularly imidacloprid, clothianidin, and thiamethoxam. Some of the results of these studies are included in subsequent AOP descriptions.&quot;"@en ;
  foaf:page <https://identifiers.org/aop/88> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/89> a sbd:Model ;
  rdfs:label "Nicotinic acetylcholine receptor activation followed by desensitization contributes to abnormal foraging and directly leads to colony loss/failure"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Text from LaLone et al. (2017) Weight of evidence evaluation of a network of adverse outcome pathways linking activaiton of the nicotinic acetylcholine receptor in honey bees to colony death. Science of the Total Environment 584-585, 751-775:  &quot;The nicotinoids and neonicotinoids are both agonists of the nAChR (Tomizawa and Casida, 2003); however, neonicotinoids are the primary chemicals considered in the AOPs relevant to bees. The potency of a nAChR agonist is dependent on the receptor subunit composition, structurally important amino acid residues at the binding site, and the ionization status of the chemical at physiological pH (Tomizawa and Casida, 2003; Dani and Bertrand, 2007). For example, nicotine is a classical vertebrate nAChR agonist; however, it has relatively low affinity (and insecticidal activity) for the invertebrate nAChR. Due to ionization, nicotine is poor at passing though the ion-impermeable barrier surrounding the insect central nervous system(CNS; Tomizawa and Casida, 2003). Conversely, non-ionizable neonicotinoids readily translocate into the insect CNS and have high affinity for the nAChR (e.g., Drosophila nAChR IC50 4.6 nM imidacloprid), with limited or no binding activity to vertebrate nAChR (Tomizawa and Casida, 2003). Various studies have demonstrated that similarities and differences in key amino acid residues in the ligand binding domain across species can lead to structural and binding site differences that dictate chemical interaction with the receptor (Dani and Bertrand, 2007; Matsuda et al., 2009; Tomizawa and Casida, 2009; Jones and Sattelle, 2010; LaLone et al., 2016). Due to the intended insecticidal action of neonicotinoids, a growing number of studies have been conducted to  evaluate potential adverse effects in non-target species such as honey bees exposed to neonicotinoids, particularly imidacloprid, clothianidin, and thiamethoxam. Some of the results of these studies are included in subsequent AOP descriptions.&quot;"@en ;
  foaf:page <https://identifiers.org/aop/89> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/90> a sbd:Model ;
  rdfs:label "Nicotinic acetylcholine receptor activation contributes to abnormal roll change within the worker bee caste leading to colony loss/failure 2"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Text from LaLone et al. (2017) Weight of evidence evaluation of a network of adverse outcome pathways linking activaiton of the nicotinic acetylcholine receptor in honey bees to colony death. Science of the Total Environment 584-585, 751-775:  &quot;The nicotinoids and neonicotinoids are both agonists of the nAChR (Tomizawa and Casida, 2003); however, neonicotinoids are the primary chemicals considered in the AOPs relevant to bees. The potency of a nAChR agonist is dependent on the receptor subunit composition, structurally important amino acid residues at the binding site, and the ionization status of the chemical at physiological pH (Tomizawa and Casida, 2003; Dani and Bertrand, 2007). For example, nicotine is a classical vertebrate nAChR agonist; however, it has relatively low affinity (and insecticidal activity) for the invertebrate nAChR. Due to ionization, nicotine is poor at passing though the ion-impermeable barrier surrounding the insect central nervous system(CNS; Tomizawa and Casida, 2003). Conversely, non-ionizable neonicotinoids readily translocate into the insect CNS and have high affinity for the nAChR (e.g., Drosophila nAChR IC50 4.6 nM imidacloprid), with limited or no binding activity to vertebrate nAChR (Tomizawa and Casida, 2003). Various studies have demonstrated that similarities and differences in key amino acid residues in the ligand binding domain across species can lead to structural and binding site differences that dictate chemical interaction with the receptor (Dani and Bertrand, 2007; Matsuda et al., 2009; Tomizawa and Casida, 2009; Jones and Sattelle, 2010; LaLone et al., 2016). Due to the intended insecticidal action of neonicotinoids, a growing number of studies have been conducted to  evaluate potential adverse effects in non-target species such as honey bees exposed to neonicotinoids, particularly imidacloprid, clothianidin, and thiamethoxam. Some of the results of these studies are included in subsequent AOP descriptions.&quot;"@en ;
  foaf:page <https://identifiers.org/aop/90> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/90> a sbd:Model ;
  rdfs:label "Nicotinic acetylcholine receptor activation contributes to abnormal roll change within the worker bee caste leading to colony loss/failure 2"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Text from LaLone et al. (2017) Weight of evidence evaluation of a network of adverse outcome pathways linking activaiton of the nicotinic acetylcholine receptor in honey bees to colony death. Science of the Total Environment 584-585, 751-775:  &quot;The nicotinoids and neonicotinoids are both agonists of the nAChR (Tomizawa and Casida, 2003); however, neonicotinoids are the primary chemicals considered in the AOPs relevant to bees. The potency of a nAChR agonist is dependent on the receptor subunit composition, structurally important amino acid residues at the binding site, and the ionization status of the chemical at physiological pH (Tomizawa and Casida, 2003; Dani and Bertrand, 2007). For example, nicotine is a classical vertebrate nAChR agonist; however, it has relatively low affinity (and insecticidal activity) for the invertebrate nAChR. Due to ionization, nicotine is poor at passing though the ion-impermeable barrier surrounding the insect central nervous system(CNS; Tomizawa and Casida, 2003). Conversely, non-ionizable neonicotinoids readily translocate into the insect CNS and have high affinity for the nAChR (e.g., Drosophila nAChR IC50 4.6 nM imidacloprid), with limited or no binding activity to vertebrate nAChR (Tomizawa and Casida, 2003). Various studies have demonstrated that similarities and differences in key amino acid residues in the ligand binding domain across species can lead to structural and binding site differences that dictate chemical interaction with the receptor (Dani and Bertrand, 2007; Matsuda et al., 2009; Tomizawa and Casida, 2009; Jones and Sattelle, 2010; LaLone et al., 2016). Due to the intended insecticidal action of neonicotinoids, a growing number of studies have been conducted to  evaluate potential adverse effects in non-target species such as honey bees exposed to neonicotinoids, particularly imidacloprid, clothianidin, and thiamethoxam. Some of the results of these studies are included in subsequent AOP descriptions.&quot;"@en ;
  foaf:page <https://identifiers.org/aop/90> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/96> a sbd:Model ;
  rdfs:label "Axonal sodium channel modulation leading to acute mortality"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Increased mortality is one of the most common regulatory assessment endpoints,&nbsp;along with reduced growth and reduced reproduction."@en ;
  foaf:page <https://identifiers.org/aop/96> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/97> a sbd:Model ;
  rdfs:label "5-hydroxytryptamine transporter (5-HTT; SERT) inhibition leading to population decline"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/97> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/97> a sbd:Model ;
  rdfs:label "5-hydroxytryptamine transporter (5-HTT; SERT) inhibition leading to population decline"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/97> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/476> a sbd:Model ;
  rdfs:label "Adverse Outcome Pathways diagram related to PBDEs associated male reproductive toxicity"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "In regulatory toxicology, the AGD is mandatory inclusions in OECD test guidelines used to test for developmental and reproductive toxicity of chemicals. Guidelines include &lsquo;TG 443 extended one-generation study&rsquo;, &lsquo;TG 421/422 reproductive toxicity screening studies&rsquo; and &lsquo;TG 414 developmental toxicity study&rsquo;."@en ;
  foaf:page <https://identifiers.org/aop/476> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/476> a sbd:Model ;
  rdfs:label "Adverse Outcome Pathways diagram related to PBDEs associated male reproductive toxicity"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "In regulatory toxicology, the AGD is mandatory inclusions in OECD test guidelines used to test for developmental and reproductive toxicity of chemicals. Guidelines include &lsquo;TG 443 extended one-generation study&rsquo;, &lsquo;TG 421/422 reproductive toxicity screening studies&rsquo; and &lsquo;TG 414 developmental toxicity study&rsquo;."@en ;
  foaf:page <https://identifiers.org/aop/476> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/476> a sbd:Model ;
  rdfs:label "Adverse Outcome Pathways diagram related to PBDEs associated male reproductive toxicity"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "In regulatory toxicology, the AGD is mandatory inclusions in OECD test guidelines used to test for developmental and reproductive toxicity of chemicals. Guidelines include &lsquo;TG 443 extended one-generation study&rsquo;, &lsquo;TG 421/422 reproductive toxicity screening studies&rsquo; and &lsquo;TG 414 developmental toxicity study&rsquo;."@en ;
  foaf:page <https://identifiers.org/aop/476> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/476> a sbd:Model ;
  rdfs:label "Adverse Outcome Pathways diagram related to PBDEs associated male reproductive toxicity"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "In regulatory toxicology, the AGD is mandatory inclusions in OECD test guidelines used to test for developmental and reproductive toxicity of chemicals. Guidelines include &lsquo;TG 443 extended one-generation study&rsquo;, &lsquo;TG 421/422 reproductive toxicity screening studies&rsquo; and &lsquo;TG 414 developmental toxicity study&rsquo;."@en ;
  foaf:page <https://identifiers.org/aop/476> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/485> a sbd:Model ;
  rdfs:label "Thyroid hormone antagonism leading to impaired oligodendrocyte maturation during development and subsequent decreased cognition"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "A prime example of impairments in cognitive function as the adverse outcome for regulatory action is developmental lead exposure and IQ function in children (Bellinger, 2012). In addition, testing for the impact of chemical expsoures on cognitive function, often including spatially-mediated behaviors, is an intergral part of both EPA and OECD developmental neurotoxicity guidelines (USEPA, 1998; OECD, 2007)."@en ;
  foaf:page <https://identifiers.org/aop/485> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/485> a sbd:Model ;
  rdfs:label "Thyroid hormone antagonism leading to impaired oligodendrocyte maturation during development and subsequent decreased cognition"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Included in OECD Work Plan -&nbsp;Project 1.82"@en ;
  foaf:page <https://identifiers.org/aop/485> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/486> a sbd:Model ;
  rdfs:label "Binding to the extracellular protein laminin leading to decreased cognitive function"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "A prime example of impairments in cognitive function as the adverse outcome for regulatory action is developmental lead exposure and IQ function in children (Bellinger, 2012). In addition, testing for the impact of chemical expsoures on cognitive function, often including spatially-mediated behaviors, is an intergral part of both EPA and OECD developmental neurotoxicity guidelines (USEPA, 1998; OECD, 2007)."@en ;
  foaf:page <https://identifiers.org/aop/486> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/486> a sbd:Model ;
  rdfs:label "Binding to the extracellular protein laminin leading to decreased cognitive function"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Included in OECD Work Plan -&nbsp;Project 1.83"@en ;
  foaf:page <https://identifiers.org/aop/486> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/487> a sbd:Model ;
  rdfs:label "Unknown MIE altering cholesterol metabolism leading to decreased cognition"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "A prime example of impairments in cognitive function as the adverse outcome for regulatory action is developmental lead exposure and IQ function in children (Bellinger, 2012). In addition, testing for the impact of chemical expsoures on cognitive function, often including spatially-mediated behaviors, is an intergral part of both EPA and OECD developmental neurotoxicity guidelines (USEPA, 1998; OECD, 2007)."@en ;
  foaf:page <https://identifiers.org/aop/487> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/488> a sbd:Model ;
  rdfs:label "Increased reactive oxygen species production leading to decreased cognitive function"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "A prime example of impairments in cognitive function as the adverse outcome for regulatory action is developmental lead exposure and IQ function in children (Bellinger, 2012). In addition, testing for the impact of chemical expsoures on cognitive function, often including spatially-mediated behaviors, is an intergral part of both EPA and OECD developmental neurotoxicity guidelines (USEPA, 1998; OECD, 2007)."@en ;
  foaf:page <https://identifiers.org/aop/488> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/489> a sbd:Model ;
  rdfs:label "Inhibition of voltage-gated sodium channels leading to decreased cognition"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "A prime example of impairments in cognitive function as the adverse outcome for regulatory action is developmental lead exposure and IQ function in children (Bellinger, 2012). In addition, testing for the impact of chemical expsoures on cognitive function, often including spatially-mediated behaviors, is an intergral part of both EPA and OECD developmental neurotoxicity guidelines (USEPA, 1998; OECD, 2007)."@en ;
  foaf:page <https://identifiers.org/aop/489> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/489> a sbd:Model ;
  rdfs:label "Inhibition of voltage-gated sodium channels leading to decreased cognition"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Due to their importance in neurons, sodium channels are known molecular targets of neurotoxins and neurotoxicants (Wakeling et al., 2012). There is strong evidence implicating the voltage-sensitive sodium channel as the principal site of insecticidal action of pyrethroids, which has led to extensive studies of the action of pyrethroids on mammalian sodium channels. Binding studies using radioactive pyrethroid demonstrated specific binding of the pyrethroid to rat brain VGSC &alpha; subunits (Trainer et al., 1997)."@en ;
  foaf:page <https://identifiers.org/aop/489> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/483> a sbd:Model ;
  rdfs:label "Deposition of Energy Leading to Learning and Memory Impairment"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "It is well documented that ionizing radiation( (eg.&nbsp;X-rays, gamma, photons, alpha, beta, neutrons, heavy ions)&nbsp;leads to energy deposition on the atoms and molecules of the substrate. Many studies, have demonstrated that the type of radiation and distance from source has an impact on the pattern of energy deposition (Alloni, et al. 2014). High linear energy transfer (LET) radiation has been associated with higher-energy deposits (Liamsuwan et al., 2014) that are more densely-packed and cause more complex effects within the particle track (Hada and Georgakilas, 2008; Okayasu, 2012ab; Lorat et al., 2015; Nikitaki et al., 2016) in comparison to low LET radiation. Parameters such as mean lineal energy, dose mean lineal energy, frequency mean specific energy and dose mean specific energy can impact track structure of the traversed energy into a medium (Friedland et al., 2017). The detection of energy deposition by ionizing radiation can be demonstrated with the use of fluorescent nuclear track detectors (FNTDs). FNTDs used in conjunction with fluorescent microscopy, are able to visualize radiation tracks produced by ionizing radiation (Niklas et al., 2013; Kodaira et al., 2015; Sawakuchi and Akselrod, 2016). In addition, these FNTD chips can quantify the LET of primary and secondary radiation tracks up to 0.47 keV/um (Sawakuchi and Akselrod, 2016). This co-visualization of the radiation tracks and the cell markers enable the mapping of the radiation trajectory to specific cellular compartments, and the identification of accrued damage (Niklas et al., 2013; Kodaira et al., 2015). There are no known chemical initiators or prototypes that can mimic the MIE."@en ;
  foaf:page <https://identifiers.org/aop/483> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/483> a sbd:Model ;
  rdfs:label "Deposition of Energy Leading to Learning and Memory Impairment"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "A prime example of impairments in learning and memory as the adverse outcome for regulatory action is developmental lead exposure and IQ function in children (Bellinger, 2012). Most methods are well established in the published literature and many have been engaged to evaluate the effects of developmental thyroid disruption. The US EPA and OECD Developmental Neurotoxicity (DNT) Guidelines (OCSPP 870.6300 or OECD TG 426) as well as OECD TG 443 (OECD, 2018) both require testing of learning and memory (USEPA, 1998; OECD, 2007) advising to use the following tests passive avoidance, delayed-matching-to-position for the adult rat and for the infant rat, olfactory conditioning, Morris water maze, Biel or Cincinnati maze, radial arm maze, T-maze, and acquisition and retention of schedule-controlled behaviour.&nbsp; These DNT Guidelines have been deemed valid to identify developmental neurotoxicity and adverse neurodevelopmental outcomes (Makris et al., 2009).  Also, in the frame of the OECD GD 43 (2008) on reproductive toxicity, learning and memory testing may have potential to be applied in the context of developmental neurotoxicity studies. However, many of the learning and memory tasks used in guideline studies may not readily detect subtle impairments in cognitive function associated with modest degrees of developmental thyroid disruption (Gilbert et al., 2012)."@en ;
  foaf:page <https://identifiers.org/aop/483> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/483> a sbd:Model ;
  rdfs:label "Deposition of Energy Leading to Learning and Memory Impairment"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Understanding the impact of ionizing radiation on the central nervous system is essential as there are many possibilities for humans to be exposed to ionizing radiation including from medical procedures, accidental or wartime exposures, and occupational exposures, such as industrial radiographers or astronaut crewmembers. Various studies have reported cognitive deficits after high-doses of radiation exposure from radiotherapy, though there is a reported individual variability in human cohorts (Greene-Schloesser et al., 2012; Katsura et al., 2021; Turnquist et al., 2020). In preclinical animal models, studies suggest that even low-to-moderate doses of ionizing radiation from heavy ions can cause structural and functional impairments to the central nervous system including reductions in neurogenesis, changes in dendritic properties, activation of glial cells, and neuronal remodeling (Cekanaviciute et al., 2018; Kiffer et al., 2019b). However, how key changes in structural and functional properties of the CNS from ionizing radiation exposure are related to changes in cognitive function have yet to be delineated. Furthermore, preclinical studies also suggest that ionizing radiation may impact two major cognitive processes: learning and memory. Learning is the ability to create new associative or non-associative relationships and memory is the ability to recall sensory, short-term or long-term information (Desai et al., 2022, Kiffer et al., 2019b). Both learning and memory involve multiple brain areas including the hippocampal region, as well as the amygdala, the prefrontal cortex and the basal ganglia (Cucinotta et al., 2014; Desai et al., 2022; NCRP Commentary, 2016). Thus far, direct pathways linking ionizing radiation to key cellular and molecular events leading to an AO of impaired learning and memory have not been established.&nbsp;&nbsp;&nbsp;  This AOP can serve as a foundational pathway for expansion to other cognitive disorders and CNS diseases from an MIE of deposition of energy. The strength of this AOP is in its rigorous and systematic collection and evaluation of evidence with moderate to high levels of qualitative evidence supporting the KERs."@en ;
  foaf:page <https://identifiers.org/aop/483> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/482> a sbd:Model ;
  rdfs:label "Deposition of energy leading to occurrence of bone loss"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "It is well documented that ionizing radiation( (eg.&nbsp;X-rays, gamma, photons, alpha, beta, neutrons, heavy ions)&nbsp;leads to energy deposition on the atoms and molecules of the substrate. Many studies, have demonstrated that the type of radiation and distance from source has an impact on the pattern of energy deposition (Alloni, et al. 2014). High linear energy transfer (LET) radiation has been associated with higher-energy deposits (Liamsuwan et al., 2014) that are more densely-packed and cause more complex effects within the particle track (Hada and Georgakilas, 2008; Okayasu, 2012ab; Lorat et al., 2015; Nikitaki et al., 2016) in comparison to low LET radiation. Parameters such as mean lineal energy, dose mean lineal energy, frequency mean specific energy and dose mean specific energy can impact track structure of the traversed energy into a medium (Friedland et al., 2017). The detection of energy deposition by ionizing radiation can be demonstrated with the use of fluorescent nuclear track detectors (FNTDs). FNTDs used in conjunction with fluorescent microscopy, are able to visualize radiation tracks produced by ionizing radiation (Niklas et al., 2013; Kodaira et al., 2015; Sawakuchi and Akselrod, 2016). In addition, these FNTD chips can quantify the LET of primary and secondary radiation tracks up to 0.47 keV/um (Sawakuchi and Akselrod, 2016). This co-visualization of the radiation tracks and the cell markers enable the mapping of the radiation trajectory to specific cellular compartments, and the identification of accrued damage (Niklas et al., 2013; Kodaira et al., 2015). There are no known chemical initiators or prototypes that can mimic the MIE."@en ;
  foaf:page <https://identifiers.org/aop/482> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/482> a sbd:Model ;
  rdfs:label "Deposition of energy leading to occurrence of bone loss"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Bone loss, as observed in a variety of conditions such as osteopenia and osteoporosis, is a skeletal disorder characterized by decreased bone density and quality resulting in porous, fracture-prone bones (Rachner, Khosla, and Hofbauer, 2011). In the United States, it has been estimated that 2 million fractures per year are due to osteoporosis, costing $57 billion per year from direct medical costs combined with productivity losses and informal caregiving (Lewiecki et al., 2019). Bone loss is more common in Caucasians, women, and older people (Sozen, Ozisik, and Basaran, 2017). Risk factors for fractures include low body mass index, previous fractures, glucocorticoid treatment, and other conditions like rheumatoid arthritis and type 1 diabetes mellitus (Sozen, Ozisik, and Basaran, 2017).&nbsp;&nbsp;  Growing evidence suggests that acute and chronic radiation exposure can contribute to the loss of bone mass (Donaubauer et al., 2020; Willey et al., 2011; Wissing, 2015). Clinical studies have shown that skeletal sites receiving high doses of ionizing radiation (25 Gy or higher) have increased fracture risk (Baxter et al., 2005; Oeffinger et al., 2006; Willey et al., 2011). For example, radiotherapy for pelvic malignancies causes an increased risk of hip fractures (Baxter et al., 2005; Williams and Davies, 2006). Similarly, radiotherapy for breast cancer or rectal carcinoma has been shown to increase the risk of fracture to the ribs or pelvis/femoral neck, respectively (Holm et al., 1996; Overgaard, 1988). Low to moderate doses of radiation as received during long-term spaceflight contribute to bone loss (Stavnichuk et al., 2020; Willey et al., 2011), but is the focus of fewer studies. Therefore, identifying essential early endpoints relevant to radiation-induced bone loss through the development of AOPs can inform mitigation strategies to reduce the risks from radiation exposures.&nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/482> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/480> a sbd:Model ;
  rdfs:label "Mitochondrial complexes inhibition leading to heart failure via decreased ATP production"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The Adverse Outcome is highly significant from a regulatory point of view. It is employed as regulatory endpoint in most studies assessing the toxicity of stressors."@en ;
  foaf:page <https://identifiers.org/aop/480> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/480> a sbd:Model ;
  rdfs:label "Mitochondrial complexes inhibition leading to heart failure via decreased ATP production"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The Adverse Outcome is highly significant from a regulatory point of view. It is employed as regulatory endpoint in most studies assessing the toxicity of stressors."@en ;
  foaf:page <https://identifiers.org/aop/480> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/479> a sbd:Model ;
  rdfs:label "Mitochondrial complexes inhibition leading to heart failure via increased myocardial oxidative stress"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The Adverse Outcome is highly significant from a regulatory point of view. It is employed as regulatory endpoint in most studies assessing the toxicity of stressors."@en ;
  foaf:page <https://identifiers.org/aop/479> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/479> a sbd:Model ;
  rdfs:label "Mitochondrial complexes inhibition leading to heart failure via increased myocardial oxidative stress"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The Adverse Outcome is highly significant from a regulatory point of view. It is employed as regulatory endpoint in most studies assessing the toxicity of stressors."@en ;
  foaf:page <https://identifiers.org/aop/479> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/478> a sbd:Model ;
  rdfs:label "Deposition of energy leading to occurrence of cataracts"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "It is well documented that ionizing radiation( (eg.&nbsp;X-rays, gamma, photons, alpha, beta, neutrons, heavy ions)&nbsp;leads to energy deposition on the atoms and molecules of the substrate. Many studies, have demonstrated that the type of radiation and distance from source has an impact on the pattern of energy deposition (Alloni, et al. 2014). High linear energy transfer (LET) radiation has been associated with higher-energy deposits (Liamsuwan et al., 2014) that are more densely-packed and cause more complex effects within the particle track (Hada and Georgakilas, 2008; Okayasu, 2012ab; Lorat et al., 2015; Nikitaki et al., 2016) in comparison to low LET radiation. Parameters such as mean lineal energy, dose mean lineal energy, frequency mean specific energy and dose mean specific energy can impact track structure of the traversed energy into a medium (Friedland et al., 2017). The detection of energy deposition by ionizing radiation can be demonstrated with the use of fluorescent nuclear track detectors (FNTDs). FNTDs used in conjunction with fluorescent microscopy, are able to visualize radiation tracks produced by ionizing radiation (Niklas et al., 2013; Kodaira et al., 2015; Sawakuchi and Akselrod, 2016). In addition, these FNTD chips can quantify the LET of primary and secondary radiation tracks up to 0.47 keV/um (Sawakuchi and Akselrod, 2016). This co-visualization of the radiation tracks and the cell markers enable the mapping of the radiation trajectory to specific cellular compartments, and the identification of accrued damage (Niklas et al., 2013; Kodaira et al., 2015). There are no known chemical initiators or prototypes that can mimic the MIE."@en ;
  foaf:page <https://identifiers.org/aop/478> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/478> a sbd:Model ;
  rdfs:label "Deposition of energy leading to occurrence of cataracts"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Cataracts, one of the leading causes of blindness, are a progressive condition in which the lens of the eye develops opacities and becomes cloudy, resulting in blurred vision as well as glare and haloes around lights (National Eye Institute, 2022). For the purposes of this AOP, cataracts are defined as over 5% of cells in the lens exhibiting opacities. Cataracts typically occur after the age of 50 in humans, as an age-related disease (Liu et al., 2017); however, progression of this disease can be initiated or accelerated after exposure to a variety of agents, one of which is radiation.&nbsp;&nbsp;  For radiation induced cataracts, most research shows that the anatomical location is within the posterior sub capsular region of the eye with limited occurrence in the cortical and nuclear region. Available epidemiological evidence confirms a positive statistically significant association between radiation exposure and cataracts (Nakashima et al., 2006; Worgul et al., 2007; Chylack et al., 2012; Little et al., 2018). The data comes from Chernobyl workers, radiologic technologists, and patients exposed to radiation through medical procedures, with the most compelling evidence derived from atomic bomb survivors. Although there is concern for the role of long duration space flight missions in cataract formation, there is limited data from astronauts.&nbsp;&nbsp;  In 2012, the International Commission on Radiological Protection (ICRP) recommended lowering the occupational eye lens dose limit from 150 mSv per year to an average of 20 mSv, with no single year exceeding 50 mSv. This revision was based on new evidence from both radiobiological studies and relevant epidemiological data. Assessment of the literature indicated a threshold dose for radiation induced cataracts of about 0.5 Gy (ICRP, 2012). This change in exposure limit has led to a need to further understand radiation-induced effects at lower doses and dose-rates.&nbsp;&nbsp;  This AOP provides a summary of the relevant studies and endpoints that can inform future research designed to understand the role of radiation in causing cataracts. Assays and study designs spanning biological levels of organization across relevant models were identified, with the end goal to improve testing strategies and understanding in risk from low dose low dose-rate exposures.&nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/478> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/477> a sbd:Model ;
  rdfs:label "Androgen receptor (AR) antagonism leading to hypospadias in male offspring"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "A large number of drugs and chemicals have been shown to antagonise the AR using various AR reporter gene assays. The AR is specifically targeted in AR-sensitive cancers, for example the use of the anti-androgenic drug flutamide in treating prostate cancer (Alapi &amp; Fischer, 2006). Flutamide has also been used in several rodent in vivo studies showing anti-androgenic effects (feminization of male offspring) evident by e.g. short anogenital distance (AGD) in males (Foster &amp; Harris, 2005; Hass et al, 2007; Kita et al, 2016). QSAR models can predict AR antagonism for a wide range of chemicals, many of which have shown in vitro antagonistic potential (Vinggaard et al, 2008)."@en ;
  foaf:page <https://identifiers.org/aop/477> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/475> a sbd:Model ;
  rdfs:label "Binding of chemicals to ionotropic glutamate receptors leads to impairment of learning and memory via loss of drebrin from dendritic spines of neurons"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Evidence for Chemical Initiation of this Molecular Initiating Event L-Glutamate and glycine (or D-serine) are endogenous agonists that bind to the LBD of specific NMDA receptor subunits. Here listed some known agonists for NMDA receptor, some of them are specific to the NR1 subunit and some others to the NR2 subunit (reviewed in Traynelis et al., 2010): Specific to NR1 Glycine, l-Serine, d-Serine, l-Alanine, d-Alanine, d-Cycloserine, HA 966, (+)-(1-hydroxy-3-aminopyrrolidine-2-one,) β-Cl-d-Alanine, β-F-dl-Alanine, tri-F-dl-Alanine, ACPC, 1-aminocyclopropane-1-carboxylic acid, ACBC, 1-aminocyclobutane-1-carboxylic acid, GLYX-13. Specific to NR2 l-Glutamate, d-Glutamate, l-Aspartate, d-Aspartate, N-Methyl-l-aspartate, N-Methyl-d-aspartate, SYM208,1 l-Homocysteinsulfinate, d-Homocysteinsulfinate, l-Homocysteate, d-Homocysteate, l-Cysteinesulfinate, l-Cysteate, d-Cysteate, Homoquinolinate, Ibotenate, (R,S)-(Tetrazol-5-yl)glycine, L-CCG-IV, (2S,3R,4S)-2-(carboxycyclopropyl)glycine, trans-ACBD, trans-1-aminocyclobutane-1,3-dicarboxylate, cis-ADA, cis-azetidine-2,4-dicarboxylic acid, trans-ADC, azetidine-2,4-dicarboxylic acid, cis-ACPD, (1R,3R)-aminocyclopentane-cis-dicarboxylate, cis-2,3-Piperidinedicarboxylic acid, (R)-NHP4G, 2-(N-hydroxylpyrazol-4-yl)glycine, (R,S)-Ethyl-NHP5G, 2-(N-hydroxypyrazol-5-yl)glycine, (R)-Propyl-NHP5G, 2-(N-hydroxypyrazol-5-yl)glycine. Domoic acid (DomA) is structurally similar to kainic acid (KA) and both of them are analogues of the excitatory neurotransmitter L-glutamate. DomA induces excitotoxicity by an integrative action on ionotropic glutamate receptors at pre- and post-synaptic sides. DomA directly activates KA/AMPARs receptors followed by indirect activation of the NMDARs. Indeed, indirect activation of NMDARs by DomA is linked to the fact that KA and AMPA receptors activated by DomA induce increased levels of intracellular Ca2+ and Na+ which, in turn, causes endogenous glutamate release that subsequently potentiates activation of NMDARs (Berman and Murray, 1997; Berman et al., 2002; Watanabe et al., 2011). DomA has been demonstrated through both in vitro and in vivo approaches to indirectly activate the NMDARs (reviewed in Pulido et al., 2008).  Glufosinate (GLF)((RS)-2-amino-4-(hydroxy(methyl)phosphonoyl)butanoic acid, phosphinothricin) is a phosphorus containing amino acid herbicide that is naturally occurring as a component of the bacteria-derived bactericidal and fungicidal tripeptides bialaphos and phosalacine (Lanz et al., 2014). There are studies suggesting that convulsive and amnesic effects of GLF are mediated through direct binding and activation of NMDAR (Lantz et al., 2014; Matsumura et al., 2001). GLF agonist action at the NMDAR is expected to occur through direct interaction with the glutamate binding site and requires binding of the glycine co-agonist as well as release of the magnesium block from the channel pore."@en ;
  foaf:page <https://identifiers.org/aop/475> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/475> a sbd:Model ;
  rdfs:label "Binding of chemicals to ionotropic glutamate receptors leads to impairment of learning and memory via loss of drebrin from dendritic spines of neurons"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "A prime example of impairments in learning and memory as the adverse outcome for regulatory action is developmental lead exposure and IQ function in children (Bellinger, 2012). Most methods are well established in the published literature and many have been engaged to evaluate the effects of developmental thyroid disruption. The US EPA and OECD Developmental Neurotoxicity (DNT) Guidelines (OCSPP 870.6300 or OECD TG 426) as well as OECD TG 443 (OECD, 2018) both require testing of learning and memory (USEPA, 1998; OECD, 2007) advising to use the following tests passive avoidance, delayed-matching-to-position for the adult rat and for the infant rat, olfactory conditioning, Morris water maze, Biel or Cincinnati maze, radial arm maze, T-maze, and acquisition and retention of schedule-controlled behaviour.&nbsp; These DNT Guidelines have been deemed valid to identify developmental neurotoxicity and adverse neurodevelopmental outcomes (Makris et al., 2009).  Also, in the frame of the OECD GD 43 (2008) on reproductive toxicity, learning and memory testing may have potential to be applied in the context of developmental neurotoxicity studies. However, many of the learning and memory tasks used in guideline studies may not readily detect subtle impairments in cognitive function associated with modest degrees of developmental thyroid disruption (Gilbert et al., 2012)."@en ;
  foaf:page <https://identifiers.org/aop/475> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/473> a sbd:Model ;
  rdfs:label "Energy deposition from internalized Ra-226 decay lower oxygen binding capacity of hemocyanin"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "It is well documented that ionizing radiation( (eg.&nbsp;X-rays, gamma, photons, alpha, beta, neutrons, heavy ions)&nbsp;leads to energy deposition on the atoms and molecules of the substrate. Many studies, have demonstrated that the type of radiation and distance from source has an impact on the pattern of energy deposition (Alloni, et al. 2014). High linear energy transfer (LET) radiation has been associated with higher-energy deposits (Liamsuwan et al., 2014) that are more densely-packed and cause more complex effects within the particle track (Hada and Georgakilas, 2008; Okayasu, 2012ab; Lorat et al., 2015; Nikitaki et al., 2016) in comparison to low LET radiation. Parameters such as mean lineal energy, dose mean lineal energy, frequency mean specific energy and dose mean specific energy can impact track structure of the traversed energy into a medium (Friedland et al., 2017). The detection of energy deposition by ionizing radiation can be demonstrated with the use of fluorescent nuclear track detectors (FNTDs). FNTDs used in conjunction with fluorescent microscopy, are able to visualize radiation tracks produced by ionizing radiation (Niklas et al., 2013; Kodaira et al., 2015; Sawakuchi and Akselrod, 2016). In addition, these FNTD chips can quantify the LET of primary and secondary radiation tracks up to 0.47 keV/um (Sawakuchi and Akselrod, 2016). This co-visualization of the radiation tracks and the cell markers enable the mapping of the radiation trajectory to specific cellular compartments, and the identification of accrued damage (Niklas et al., 2013; Kodaira et al., 2015). There are no known chemical initiators or prototypes that can mimic the MIE."@en ;
  foaf:page <https://identifiers.org/aop/473> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/473> a sbd:Model ;
  rdfs:label "Energy deposition from internalized Ra-226 decay lower oxygen binding capacity of hemocyanin"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Growth is a regulatory relevant chronic toxicity endpoint for almost all organisms. Multiple OECD test guidelines have included growth either as a main endpoint of concern, or as an additional endpoint to be considered in the toxicity assessments. Relevant test guidelines include, but not only limited to:  &nbsp;  -Test No. 201: Freshwater Alga and Cyanobacteria, Growth Inhibition Test  -Test No. 208: Terrestrial Plant Test: Seedling Emergence and Seedling Growth Test  -Test No. 211: Daphnia magna Reproduction Test  -Test No. 212: Fish, Short-term Toxicity Test on Embryo and Sac-Fry Stages  -Test No. 215: Fish, Juvenile Growth Test  -Test No. 221: Lemna sp. Growth Inhibition Test  -Test No. 228: Determination of Developmental Toxicity to Dipteran Dung Flies (Scathophaga stercoraria L. (Scathophagidae), Musca autumnalis De Geer (Muscidae))  -Test No. 241: The Larval Amphibian Growth and Development Assay (LAGDA)  -Test No. 407: Repeated Dose 28-day Oral Toxicity Study in Rodents  -Test No. 408: Repeated Dose 90-Day Oral Toxicity Study in Rodents  -Test No. 416: Two-Generation Reproduction Toxicity  -Test No. 422: Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test  -Test No. 443: Extended One-Generation Reproductive Toxicity Study  -Test No. 453: Combined Chronic Toxicity/Carcinogenicity Studies"@en ;
  foaf:page <https://identifiers.org/aop/473> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/473> a sbd:Model ;
  rdfs:label "Energy deposition from internalized Ra-226 decay lower oxygen binding capacity of hemocyanin"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "It is well documented that ionizing radiation( (eg.&nbsp;X-rays, gamma, photons, alpha, beta, neutrons, heavy ions)&nbsp;leads to energy deposition on the atoms and molecules of the substrate. Many studies, have demonstrated that the type of radiation and distance from source has an impact on the pattern of energy deposition (Alloni, et al. 2014). High linear energy transfer (LET) radiation has been associated with higher-energy deposits (Liamsuwan et al., 2014) that are more densely-packed and cause more complex effects within the particle track (Hada and Georgakilas, 2008; Okayasu, 2012ab; Lorat et al., 2015; Nikitaki et al., 2016) in comparison to low LET radiation. Parameters such as mean lineal energy, dose mean lineal energy, frequency mean specific energy and dose mean specific energy can impact track structure of the traversed energy into a medium (Friedland et al., 2017). The detection of energy deposition by ionizing radiation can be demonstrated with the use of fluorescent nuclear track detectors (FNTDs). FNTDs used in conjunction with fluorescent microscopy, are able to visualize radiation tracks produced by ionizing radiation (Niklas et al., 2013; Kodaira et al., 2015; Sawakuchi and Akselrod, 2016). In addition, these FNTD chips can quantify the LET of primary and secondary radiation tracks up to 0.47 keV/um (Sawakuchi and Akselrod, 2016). This co-visualization of the radiation tracks and the cell markers enable the mapping of the radiation trajectory to specific cellular compartments, and the identification of accrued damage (Niklas et al., 2013; Kodaira et al., 2015). There are no known chemical initiators or prototypes that can mimic the MIE."@en ;
  foaf:page <https://identifiers.org/aop/473> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/473> a sbd:Model ;
  rdfs:label "Energy deposition from internalized Ra-226 decay lower oxygen binding capacity of hemocyanin"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Growth is a regulatory relevant chronic toxicity endpoint for almost all organisms. Multiple OECD test guidelines have included growth either as a main endpoint of concern, or as an additional endpoint to be considered in the toxicity assessments. Relevant test guidelines include, but not only limited to:  &nbsp;  -Test No. 201: Freshwater Alga and Cyanobacteria, Growth Inhibition Test  -Test No. 208: Terrestrial Plant Test: Seedling Emergence and Seedling Growth Test  -Test No. 211: Daphnia magna Reproduction Test  -Test No. 212: Fish, Short-term Toxicity Test on Embryo and Sac-Fry Stages  -Test No. 215: Fish, Juvenile Growth Test  -Test No. 221: Lemna sp. Growth Inhibition Test  -Test No. 228: Determination of Developmental Toxicity to Dipteran Dung Flies (Scathophaga stercoraria L. (Scathophagidae), Musca autumnalis De Geer (Muscidae))  -Test No. 241: The Larval Amphibian Growth and Development Assay (LAGDA)  -Test No. 407: Repeated Dose 28-day Oral Toxicity Study in Rodents  -Test No. 408: Repeated Dose 90-Day Oral Toxicity Study in Rodents  -Test No. 416: Two-Generation Reproduction Toxicity  -Test No. 422: Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test  -Test No. 443: Extended One-Generation Reproductive Toxicity Study  -Test No. 453: Combined Chronic Toxicity/Carcinogenicity Studies"@en ;
  foaf:page <https://identifiers.org/aop/473> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/386> a sbd:Model ;
  rdfs:label "Deposition of ionizing energy leading to population decline via inhibition of photosynthesis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/386> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/386> a sbd:Model ;
  rdfs:label "Deposition of ionizing energy leading to population decline via inhibition of photosynthesis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "It is well documented that ionizing radiation( (eg.&nbsp;X-rays, gamma, photons, alpha, beta, neutrons, heavy ions)&nbsp;leads to energy deposition on the atoms and molecules of the substrate. Many studies, have demonstrated that the type of radiation and distance from source has an impact on the pattern of energy deposition (Alloni, et al. 2014). High linear energy transfer (LET) radiation has been associated with higher-energy deposits (Liamsuwan et al., 2014) that are more densely-packed and cause more complex effects within the particle track (Hada and Georgakilas, 2008; Okayasu, 2012ab; Lorat et al., 2015; Nikitaki et al., 2016) in comparison to low LET radiation. Parameters such as mean lineal energy, dose mean lineal energy, frequency mean specific energy and dose mean specific energy can impact track structure of the traversed energy into a medium (Friedland et al., 2017). The detection of energy deposition by ionizing radiation can be demonstrated with the use of fluorescent nuclear track detectors (FNTDs). FNTDs used in conjunction with fluorescent microscopy, are able to visualize radiation tracks produced by ionizing radiation (Niklas et al., 2013; Kodaira et al., 2015; Sawakuchi and Akselrod, 2016). In addition, these FNTD chips can quantify the LET of primary and secondary radiation tracks up to 0.47 keV/um (Sawakuchi and Akselrod, 2016). This co-visualization of the radiation tracks and the cell markers enable the mapping of the radiation trajectory to specific cellular compartments, and the identification of accrued damage (Niklas et al., 2013; Kodaira et al., 2015). There are no known chemical initiators or prototypes that can mimic the MIE."@en ;
  foaf:page <https://identifiers.org/aop/386> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/386> a sbd:Model ;
  rdfs:label "Deposition of ionizing energy leading to population decline via inhibition of photosynthesis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/386> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/386> a sbd:Model ;
  rdfs:label "Deposition of ionizing energy leading to population decline via inhibition of photosynthesis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "It is well documented that ionizing radiation( (eg.&nbsp;X-rays, gamma, photons, alpha, beta, neutrons, heavy ions)&nbsp;leads to energy deposition on the atoms and molecules of the substrate. Many studies, have demonstrated that the type of radiation and distance from source has an impact on the pattern of energy deposition (Alloni, et al. 2014). High linear energy transfer (LET) radiation has been associated with higher-energy deposits (Liamsuwan et al., 2014) that are more densely-packed and cause more complex effects within the particle track (Hada and Georgakilas, 2008; Okayasu, 2012ab; Lorat et al., 2015; Nikitaki et al., 2016) in comparison to low LET radiation. Parameters such as mean lineal energy, dose mean lineal energy, frequency mean specific energy and dose mean specific energy can impact track structure of the traversed energy into a medium (Friedland et al., 2017). The detection of energy deposition by ionizing radiation can be demonstrated with the use of fluorescent nuclear track detectors (FNTDs). FNTDs used in conjunction with fluorescent microscopy, are able to visualize radiation tracks produced by ionizing radiation (Niklas et al., 2013; Kodaira et al., 2015; Sawakuchi and Akselrod, 2016). In addition, these FNTD chips can quantify the LET of primary and secondary radiation tracks up to 0.47 keV/um (Sawakuchi and Akselrod, 2016). This co-visualization of the radiation tracks and the cell markers enable the mapping of the radiation trajectory to specific cellular compartments, and the identification of accrued damage (Niklas et al., 2013; Kodaira et al., 2015). There are no known chemical initiators or prototypes that can mimic the MIE."@en ;
  foaf:page <https://identifiers.org/aop/386> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/387> a sbd:Model ;
  rdfs:label "Deposition of ionising energy leading to population decline via mitochondrial dysfunction"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/387> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/387> a sbd:Model ;
  rdfs:label "Deposition of ionising energy leading to population decline via mitochondrial dysfunction"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "It is well documented that ionizing radiation( (eg.&nbsp;X-rays, gamma, photons, alpha, beta, neutrons, heavy ions)&nbsp;leads to energy deposition on the atoms and molecules of the substrate. Many studies, have demonstrated that the type of radiation and distance from source has an impact on the pattern of energy deposition (Alloni, et al. 2014). High linear energy transfer (LET) radiation has been associated with higher-energy deposits (Liamsuwan et al., 2014) that are more densely-packed and cause more complex effects within the particle track (Hada and Georgakilas, 2008; Okayasu, 2012ab; Lorat et al., 2015; Nikitaki et al., 2016) in comparison to low LET radiation. Parameters such as mean lineal energy, dose mean lineal energy, frequency mean specific energy and dose mean specific energy can impact track structure of the traversed energy into a medium (Friedland et al., 2017). The detection of energy deposition by ionizing radiation can be demonstrated with the use of fluorescent nuclear track detectors (FNTDs). FNTDs used in conjunction with fluorescent microscopy, are able to visualize radiation tracks produced by ionizing radiation (Niklas et al., 2013; Kodaira et al., 2015; Sawakuchi and Akselrod, 2016). In addition, these FNTD chips can quantify the LET of primary and secondary radiation tracks up to 0.47 keV/um (Sawakuchi and Akselrod, 2016). This co-visualization of the radiation tracks and the cell markers enable the mapping of the radiation trajectory to specific cellular compartments, and the identification of accrued damage (Niklas et al., 2013; Kodaira et al., 2015). There are no known chemical initiators or prototypes that can mimic the MIE."@en ;
  foaf:page <https://identifiers.org/aop/387> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/387> a sbd:Model ;
  rdfs:label "Deposition of ionising energy leading to population decline via mitochondrial dysfunction"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/387> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/387> a sbd:Model ;
  rdfs:label "Deposition of ionising energy leading to population decline via mitochondrial dysfunction"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "It is well documented that ionizing radiation( (eg.&nbsp;X-rays, gamma, photons, alpha, beta, neutrons, heavy ions)&nbsp;leads to energy deposition on the atoms and molecules of the substrate. Many studies, have demonstrated that the type of radiation and distance from source has an impact on the pattern of energy deposition (Alloni, et al. 2014). High linear energy transfer (LET) radiation has been associated with higher-energy deposits (Liamsuwan et al., 2014) that are more densely-packed and cause more complex effects within the particle track (Hada and Georgakilas, 2008; Okayasu, 2012ab; Lorat et al., 2015; Nikitaki et al., 2016) in comparison to low LET radiation. Parameters such as mean lineal energy, dose mean lineal energy, frequency mean specific energy and dose mean specific energy can impact track structure of the traversed energy into a medium (Friedland et al., 2017). The detection of energy deposition by ionizing radiation can be demonstrated with the use of fluorescent nuclear track detectors (FNTDs). FNTDs used in conjunction with fluorescent microscopy, are able to visualize radiation tracks produced by ionizing radiation (Niklas et al., 2013; Kodaira et al., 2015; Sawakuchi and Akselrod, 2016). In addition, these FNTD chips can quantify the LET of primary and secondary radiation tracks up to 0.47 keV/um (Sawakuchi and Akselrod, 2016). This co-visualization of the radiation tracks and the cell markers enable the mapping of the radiation trajectory to specific cellular compartments, and the identification of accrued damage (Niklas et al., 2013; Kodaira et al., 2015). There are no known chemical initiators or prototypes that can mimic the MIE."@en ;
  foaf:page <https://identifiers.org/aop/387> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/388> a sbd:Model ;
  rdfs:label "Deposition of ionising energy  leading to population decline via programmed cell death"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/388> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/388> a sbd:Model ;
  rdfs:label "Deposition of ionising energy  leading to population decline via programmed cell death"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "It is well documented that ionizing radiation( (eg.&nbsp;X-rays, gamma, photons, alpha, beta, neutrons, heavy ions)&nbsp;leads to energy deposition on the atoms and molecules of the substrate. Many studies, have demonstrated that the type of radiation and distance from source has an impact on the pattern of energy deposition (Alloni, et al. 2014). High linear energy transfer (LET) radiation has been associated with higher-energy deposits (Liamsuwan et al., 2014) that are more densely-packed and cause more complex effects within the particle track (Hada and Georgakilas, 2008; Okayasu, 2012ab; Lorat et al., 2015; Nikitaki et al., 2016) in comparison to low LET radiation. Parameters such as mean lineal energy, dose mean lineal energy, frequency mean specific energy and dose mean specific energy can impact track structure of the traversed energy into a medium (Friedland et al., 2017). The detection of energy deposition by ionizing radiation can be demonstrated with the use of fluorescent nuclear track detectors (FNTDs). FNTDs used in conjunction with fluorescent microscopy, are able to visualize radiation tracks produced by ionizing radiation (Niklas et al., 2013; Kodaira et al., 2015; Sawakuchi and Akselrod, 2016). In addition, these FNTD chips can quantify the LET of primary and secondary radiation tracks up to 0.47 keV/um (Sawakuchi and Akselrod, 2016). This co-visualization of the radiation tracks and the cell markers enable the mapping of the radiation trajectory to specific cellular compartments, and the identification of accrued damage (Niklas et al., 2013; Kodaira et al., 2015). There are no known chemical initiators or prototypes that can mimic the MIE."@en ;
  foaf:page <https://identifiers.org/aop/388> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/388> a sbd:Model ;
  rdfs:label "Deposition of ionising energy  leading to population decline via programmed cell death"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/388> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/388> a sbd:Model ;
  rdfs:label "Deposition of ionising energy  leading to population decline via programmed cell death"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "It is well documented that ionizing radiation( (eg.&nbsp;X-rays, gamma, photons, alpha, beta, neutrons, heavy ions)&nbsp;leads to energy deposition on the atoms and molecules of the substrate. Many studies, have demonstrated that the type of radiation and distance from source has an impact on the pattern of energy deposition (Alloni, et al. 2014). High linear energy transfer (LET) radiation has been associated with higher-energy deposits (Liamsuwan et al., 2014) that are more densely-packed and cause more complex effects within the particle track (Hada and Georgakilas, 2008; Okayasu, 2012ab; Lorat et al., 2015; Nikitaki et al., 2016) in comparison to low LET radiation. Parameters such as mean lineal energy, dose mean lineal energy, frequency mean specific energy and dose mean specific energy can impact track structure of the traversed energy into a medium (Friedland et al., 2017). The detection of energy deposition by ionizing radiation can be demonstrated with the use of fluorescent nuclear track detectors (FNTDs). FNTDs used in conjunction with fluorescent microscopy, are able to visualize radiation tracks produced by ionizing radiation (Niklas et al., 2013; Kodaira et al., 2015; Sawakuchi and Akselrod, 2016). In addition, these FNTD chips can quantify the LET of primary and secondary radiation tracks up to 0.47 keV/um (Sawakuchi and Akselrod, 2016). This co-visualization of the radiation tracks and the cell markers enable the mapping of the radiation trajectory to specific cellular compartments, and the identification of accrued damage (Niklas et al., 2013; Kodaira et al., 2015). There are no known chemical initiators or prototypes that can mimic the MIE."@en ;
  foaf:page <https://identifiers.org/aop/388> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/389> a sbd:Model ;
  rdfs:label " Oxygen-evolving complex damage leading to population decline via inhibition of photosynthesis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/389> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/389> a sbd:Model ;
  rdfs:label " Oxygen-evolving complex damage leading to population decline via inhibition of photosynthesis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/389> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/392> a sbd:Model ;
  rdfs:label "Decreased fibrinolysis and activated bradykinin system leading to hyperinflammation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "SARS-COV  SERPINE1 is inactivated causing an imbalance between fibrinolysis and coagulation (urokinase pathway). Also genes associated with the induction of a procoagulant state (thrombin, F7a, F11a, F12a, PLAU, PLAUR, tissue factor F2R) and other fibrinolysin pathway components were altered by infection  nanoparticles  Several proteins of the coagulation system, including fibrinogen, HMWK, kallikrein, F12, F11, and C1-INH bind to TiO2 NPs, and induce clot formation triggered specifically by F12, as well as release of pro-inflammatory cytokines and chemokines (IL-8 [CXCL8], MIP-1&alpha; [CCL3], MIP-1&beta; [CCL4] and MCP-1 [CCL2]).  SARS-COV-2  SERPING1 is downregulated in severe COVID-19 BAL samples lifting the suppression of F12"@en ;
  foaf:page <https://identifiers.org/aop/392> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/392> a sbd:Model ;
  rdfs:label "Decreased fibrinolysis and activated bradykinin system leading to hyperinflammation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "AOP 392 is developed as a part of the CIAO project,&nbsp;Modelling the Pathogenesis of&nbsp;COVID-19 Using the&nbsp;Adverse&nbsp;Outcome Pathway (AOP). The overall goal was to organize, consolidate, and understand the vast amount of data that is constantly evolving as a result of the COVID-19 pandemic and identify knowledge gaps that may be missing using&nbsp;the AOP framework. Many AOPs were developed as a part of the CIAO project, each AOP focusing on a specific element of the SARS-COV-2 virus responses in humans. AOP392 focuses on the inflammatory&nbsp;responses.  AOP 392 covers a set of events that act in concert towards perturbing inflammation. Hypo-fibrinolysis represents the first event (KE1866), in which interaction with SARS-COV-2 or nanomaterials causes decreased fibrinolytic response. The activation of the bradykinin system(KE1867) (MIE2), also instigated by SARS-COV-2 or nanomaterial stressors, can overactivate the bradykinin system and increases bradykinin production. As a result of hypo-fibrinolysis (KE1866), and bradykinin activation (KE1867), there is an increase in pro-inflammatory mediators secretion (KE1496), which signals the recruitment of pro-inflammatory cells into the lungs (KE1497). This KE process represents the changes occurring in inflammation. The increase in pro-inflammatory cells levels lead to a higher neutrophil to lymphocyte ratio, increased CRP, and high D-dimer and ferritin levels, all hallmarks of a hyperinflammatory state (KE1868). Hyperinflammation plays a critical role in driving the severity of the COVID-19 disease. Further exploration of the inflammation to hyperinflammation process is needed."@en ;
  foaf:page <https://identifiers.org/aop/392> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/392> a sbd:Model ;
  rdfs:label "Decreased fibrinolysis and activated bradykinin system leading to hyperinflammation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "SARS-CoV-2  Directly, the BK precursor kininogen as well as several kallikreins are up-regulated in COVID-19 patient bronchial alveolar lavage (BAL) samples.  Indirectly, SARS-COV-2 affects the Renin-angiotensin system by downregulating ACE2. With ACE2 unable to&nbsp; inactivates DABK and Lys-des-Arg9-BK enzymes, an activation of the bradykinin system would be triggered. SARS-COV-2 also highly downregulates the SERPING1 gene, which encodes for the C1-inhibitor, leading to increased bradykinin production.  &nbsp;  Nanomaterials  Ag, TiO2, and Fe2O3 nanoparticles directly interact with F12 and activate the bradykinin system."@en ;
  foaf:page <https://identifiers.org/aop/392> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/394> a sbd:Model ;
  rdfs:label "SARS-CoV-2 infection of olfactory epithelium leading to impaired olfactory function (short-term anosmia)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "AOP394 is developed as a part of the CIAO project, &quot;Modelling the Pathogenesis of&nbsp;COVID-19 Using the&nbsp;Adverse&nbsp;Outcome Pathway (AOP)&quot;. The overall goal is to organize and understand the vast amount of data that is constantly evolving as a result of the COVID-19 pandemic and identify uncertainties and knowledge gaps that may be missing using&nbsp;the AOP framework. Many AOPs were developed in the CIAO project, each AOP focusing on a specific element of the SARS-COV-2 virus responses in humans.  AOP394 focuses on the short-term olfactory disfunction (anosmia) following binding of SARS-CoV-2 to ACE2 receptors in the sustencular cells of the olfactory epithelium."@en ;
  foaf:page <https://identifiers.org/aop/394> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/394> a sbd:Model ;
  rdfs:label "SARS-CoV-2 infection of olfactory epithelium leading to impaired olfactory function (short-term anosmia)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Receptor recognition is an essential determinant of molecular level in this AOP. ACE2 was reported as an entry receptor for SARS-CoV-2. The viral entry process is mediated by the envelope-embedded surface-located spike (S) glycoprotein.&nbsp; Jun Lan and Walls, A.C et al (Nature 581, 215&ndash;220; Cell 180, 281&ndash;292) demonstrated a critical initial step of infection at the molecular level from the interaction of ACE2 and S protein. ACE2 has shown that receptor binding affinity to S protein is nM range. To elucidate the interaction between the SARS-CoV-2 RBD and ACE2 at a higher resolution, they also determined the structure of the SARS-CoV-2 RBD&ndash;ACE2 complex using X-ray crystallography. The expression and distribution of the ACE2 in human body may indicate the potential infection of SARS-CoV-2. Through the developed single-cell RNA sequencing (scRNA-Seq) technique and single-cell transcriptomes based on the public database, researchers analyzed the ACE2 RNA expression profile at single-cell resolution. High ACE2 expression was identified in type II alveolar cells (Zou, X. et al. Front. Med.2020)  SARS-CoV-2 belongs to the Coronaviridae family, which includes evolutionary related enveloped (+) strand RNA viruses of vertebrates, such as seasonal common coronaviruses, SARS-CoV and CoV-NL63, SARS-CoV (Kim Young Jun et al)   	 		 			 			Human viruses strains 			 			 			Genus 			 			 			Major cell receptor 			 			 			First report 			 			 			Animal reservoir 			 			 			Intermediate host 			 			 			Pathology 			 			 			Diagnostic test 			 			 			Evidence 			 		 		 			 			HCoV-NL63 			 			 			Alphacoronavirus 			 			 			ACE2 			 			 			2004 			 			 			Bat 			 			 			Unknown 			 			 			Mild respiratory tract illness 			 			 			RT-PCR, IF, ELISA, WB 			 			 			Strong 			 		 		 			 			SARS-CoV 			 			 			Betacoronavirus 			 			 			ACE2 			 			 			2003 			 			 			Bat 			 			 			Pangolin 			 			 			Severe acute respiratory syndrome 			 			 			RT-PCR, IF, ELISA, WB 			 			 			Strong 			 		 		 			 			SARS-CoV-2 			 			 			Betacoronavirus 			 			 			ACE2 			 			 			2020 			 			 			Bat 			 			 			Pangolin 			 			 			Severe acute respiratory syndrome 			 			 			RT-PCR, IF, ELISA, WB 			 			 			Strong"@en ;
  foaf:page <https://identifiers.org/aop/394> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/395> a sbd:Model ;
  rdfs:label "Binding of Sars-CoV-2 spike protein to ACE 2 receptors expressed on pericytes leads to disseminated intravascular coagulation resulting in cerebrovascular disease (stroke)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Receptor recognition is an essential determinant of molecular level in this AOP. ACE2 was reported as an entry receptor for SARS-CoV-2. The viral entry process is mediated by the envelope-embedded surface-located spike (S) glycoprotein.&nbsp; Jun Lan and Walls, A.C et al (Nature 581, 215&ndash;220; Cell 180, 281&ndash;292) demonstrated a critical initial step of infection at the molecular level from the interaction of ACE2 and S protein. ACE2 has shown that receptor binding affinity to S protein is nM range. To elucidate the interaction between the SARS-CoV-2 RBD and ACE2 at a higher resolution, they also determined the structure of the SARS-CoV-2 RBD&ndash;ACE2 complex using X-ray crystallography. The expression and distribution of the ACE2 in human body may indicate the potential infection of SARS-CoV-2. Through the developed single-cell RNA sequencing (scRNA-Seq) technique and single-cell transcriptomes based on the public database, researchers analyzed the ACE2 RNA expression profile at single-cell resolution. High ACE2 expression was identified in type II alveolar cells (Zou, X. et al. Front. Med.2020)  SARS-CoV-2 belongs to the Coronaviridae family, which includes evolutionary related enveloped (+) strand RNA viruses of vertebrates, such as seasonal common coronaviruses, SARS-CoV and CoV-NL63, SARS-CoV (Kim Young Jun et al)   	 		 			 			Human viruses strains 			 			 			Genus 			 			 			Major cell receptor 			 			 			First report 			 			 			Animal reservoir 			 			 			Intermediate host 			 			 			Pathology 			 			 			Diagnostic test 			 			 			Evidence 			 		 		 			 			HCoV-NL63 			 			 			Alphacoronavirus 			 			 			ACE2 			 			 			2004 			 			 			Bat 			 			 			Unknown 			 			 			Mild respiratory tract illness 			 			 			RT-PCR, IF, ELISA, WB 			 			 			Strong 			 		 		 			 			SARS-CoV 			 			 			Betacoronavirus 			 			 			ACE2 			 			 			2003 			 			 			Bat 			 			 			Pangolin 			 			 			Severe acute respiratory syndrome 			 			 			RT-PCR, IF, ELISA, WB 			 			 			Strong 			 		 		 			 			SARS-CoV-2 			 			 			Betacoronavirus 			 			 			ACE2 			 			 			2020 			 			 			Bat 			 			 			Pangolin 			 			 			Severe acute respiratory syndrome 			 			 			RT-PCR, IF, ELISA, WB 			 			 			Strong"@en ;
  foaf:page <https://identifiers.org/aop/395> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/397> a sbd:Model ;
  rdfs:label "Bulky DNA adducts leading to mutations"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "A variety of stressors can induce bulky adducts. The most well studied are Benzo(a)pyrene, Aflatoxin B1 and Aristolochic acid. These compounds have been demonstrated to induce bulky adducts in various in vivo and in vitro methods (). Many studies use 32-P post labelling and other methods to observe the presence of bulky adducts when different doses of a carcinogenic compound are administered. A dose-dependent increase of bulky adducts measured by 32P post-labelling and comet assay was observed by Long et al., 2018 and Lemieux et al., 2011 from Benzo(a)pyrene doses as low as 0.20 mg/kg BW/day in mammalian cells from various tissues in vivo. AFB1-induced adducts were observed by Woo et al. (year) by isotope dilution mass spectrometry (MS) in mice. A dose-dependent increase in Aristolochic Acid induced adducts have been demonstrated by 32-P post labelling in in rodent models (Mei et al., 2006 and McDaniel et al., 2012). The authors noted an increase in adducts from a dose as low as 0.1 mg/kg bodyweight (Li et al., 2020)."@en ;
  foaf:page <https://identifiers.org/aop/397> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/398> a sbd:Model ;
  rdfs:label "Inhibition of ALDH1A (RALDH) leading to impaired fertility via disrupted meiotic initiation of fetal oogonia of the ovary"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Under REACH, information on reproductive toxicity is required for chemicals with an annual production/importation volume of 10 metric tonnes or more. Standard information requirements include a screening study on reproduction toxicity (OECD TG 421/422) at Annex VIII (10-100 t.p.a), a prenatal developmental toxicity study (OECD 414) on a first species at Annex IX (100-1000 t.p.a), and from March 2015 the OECD 443(Extended One-Generation Reproductive Toxicity Study) is reproductive toxicity requirement instead of the two generation reproductive toxicity study (OECD TG 416). If not conducted already at Annex IX, a prenatal developmental toxicity study on a second species at Annex X (&ge; 1000 t.p.a.).  Under the Biocidal Products Regulation (BPR), information is also required on reproductive toxicity for active substances as part of core data set and additional data set (EU 2012, ECHA 2013). As a core data set, prenatal developmental toxicity study (EU TM B.31) in rabbits as a first species and a two-generation reproduction toxicity study (EU TM B.31) are required. OECD TG 443 (Extended One-Generation Reproductive Toxicity Study) shall be considered as an alternative approach to the multi-generation study.) According to the Classification, Labelling and Packaging (CLP) regulation (EC, 200; Annex I: 3.7.1.1): a) &ldquo;reproductive toxicity&rdquo; includes adverse effects on sexual function and fertility in adult males and females, as well as developmental toxicity in the offspring; b) &ldquo;effects on fertility&rdquo; includes adverse effects on sexual function and fertility; and c) &ldquo;developmental toxicity&rdquo; includes adverse effects on development of the offspring."@en ;
  foaf:page <https://identifiers.org/aop/398> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/398> a sbd:Model ;
  rdfs:label "Inhibition of ALDH1A (RALDH) leading to impaired fertility via disrupted meiotic initiation of fetal oogonia of the ovary"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "In mammals, the primordial germ cells are initially &lsquo;bipotential&rsquo;. They will develop into either oocytes or gonocytes in ovaries or testis, respectively, depending on cues from the somatic environment. Germ cells in the developing testis will enter a quiescent state and reactivate at the onset of puberty. In contrast, germ cells in the developing ovary will enter meiosis (prophase I) during fetal life. A key signaling event for this sexual dimorphic germ cell programming is retinoid signaling, with all-trans retinoic acid (atRA) acting as a meiosis-inducing factor (Spiller &amp; Bowles, 2019).   The source of atRA during ovary development differs to some degree between species. In mice, the adjacent mesonephros, which expresses two enzymes necessary for the final step in atRA production, ALDH1A2 and ALDH1A3, is likely the main source of atRA at early developmental stages (Bowles et al, 2018; Bowles et al, 2006; Koubova et al, 2006; Niederreither et al, 1999). There is also the capacity for atRA to be produced within the ovary itself, due to local expression of the atRA-synthesizing enzyme ALDH1A1 (Bowles et al, 2016; Mu et al, 2013).   In humans, ALDH1A enzymes (ALDH1A, -1B and -1C) are expressed in both testes and ovaries of the developing fetus, which suggest a capacity for de novo synthesis of atRA (Childs et al, 2011; J&oslash;rgensen &amp; Rajpert-De Meyts, 2014; le Bouffant et al, 2010), as is also the case in rabbits (D&iacute;az-Hern&aacute;ndez et al, 2019). One team studying human fetal ovaries reported a peak of ALDH1A1 expression at the onset of meiosis (le Bouffant et al, 2010), suggesting that meiotic onset in the human ovary depends on provision of atRA at the correct time.&nbsp; There seems to be conservation from rodent to human in terms of the requirement for atRA to induce the pre-meiotic factor STRA8. However, in mice atRA is produced by adjacent tissue and is present at high concentrations in the ovaries, whereas in human ovaries RA is present at only low levels and is then actively produced to induce meiosis in the ovary (Spiller &amp; Bowles, 2019)."@en ;
  foaf:page <https://identifiers.org/aop/398> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/399> a sbd:Model ;
  rdfs:label "Inhibition of Fyna leading to increased mortality via decreased eye size (Microphthalmos)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/399> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/399> a sbd:Model ;
  rdfs:label "Inhibition of Fyna leading to increased mortality via decreased eye size (Microphthalmos)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Increased mortality is one of the most common regulatory assessment endpoints,&nbsp;along with reduced growth and reduced reproduction."@en ;
  foaf:page <https://identifiers.org/aop/399> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/399> a sbd:Model ;
  rdfs:label "Inhibition of Fyna leading to increased mortality via decreased eye size (Microphthalmos)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Evidence for perturbation of Fyna is available for rosmarinic acid (Jelić et al., 2007), stauroporine (Kinoshita et al., 2006; Lamers et al., 2003) and&nbsp;AZD0530 (Green et al., 2009, Morisot et al., 2019).&nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/399> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/399> a sbd:Model ;
  rdfs:label "Inhibition of Fyna leading to increased mortality via decreased eye size (Microphthalmos)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The motivation behind building the AOP&nbsp;was methodological. Our team has recently developed molecular causal networks for developmental cardiotoxicity and neurotoxicity in zebrafish (doi.org/10.1021/acs.chemrestox.0c00095). These networks are highly curated, but rather large, going from adverse outcomes on the organ level upstream to wherever evidence takes us (many times finishing at what would be called MIEs). As there are many causal networks already present on the http://causalbionet.com/ (mostly for humans and for lung conditions), we were wondering how the rich knowledge available in causal pathways could be translated to AOPs. The AOP described in this document is one such example.&nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/399> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/399> a sbd:Model ;
  rdfs:label "Inhibition of Fyna leading to increased mortality via decreased eye size (Microphthalmos)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/399> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/399> a sbd:Model ;
  rdfs:label "Inhibition of Fyna leading to increased mortality via decreased eye size (Microphthalmos)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Increased mortality is one of the most common regulatory assessment endpoints,&nbsp;along with reduced growth and reduced reproduction."@en ;
  foaf:page <https://identifiers.org/aop/399> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/399> a sbd:Model ;
  rdfs:label "Inhibition of Fyna leading to increased mortality via decreased eye size (Microphthalmos)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Evidence for perturbation of Fyna is available for rosmarinic acid (Jelić et al., 2007), stauroporine (Kinoshita et al., 2006; Lamers et al., 2003) and&nbsp;AZD0530 (Green et al., 2009, Morisot et al., 2019).&nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/399> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/399> a sbd:Model ;
  rdfs:label "Inhibition of Fyna leading to increased mortality via decreased eye size (Microphthalmos)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The motivation behind building the AOP&nbsp;was methodological. Our team has recently developed molecular causal networks for developmental cardiotoxicity and neurotoxicity in zebrafish (doi.org/10.1021/acs.chemrestox.0c00095). These networks are highly curated, but rather large, going from adverse outcomes on the organ level upstream to wherever evidence takes us (many times finishing at what would be called MIEs). As there are many causal networks already present on the http://causalbionet.com/ (mostly for humans and for lung conditions), we were wondering how the rich knowledge available in causal pathways could be translated to AOPs. The AOP described in this document is one such example.&nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/399> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/401> a sbd:Model ;
  rdfs:label "G protein-coupled estrogen receptor 1 (GPER) signal pathway in the endocrine disrupting effect "@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The precursor state to NASH&nbsp;(non-alcoholic steatohepatitis), steatosis, has been used in US EPA IRIS assessments as an adverse outcome.&nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/401> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/401> a sbd:Model ;
  rdfs:label "G protein-coupled estrogen receptor 1 (GPER) signal pathway in the endocrine disrupting effect "@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Triphenyl phosphate (TPP) was appeared as an important candidate metabolism disruptors. TPP was one of the high production volume flame retardants, which has been used in various commercial mixtures, thus causing the frequent detection and high-dose exposure in both environmental media and biota. Toxicity studies had revealed that TPP could interact with essential regulators of lipids to induce lipid abnormalities and metabolic disorders. TPP could affect peroxisome proliferator-activated receptor &gamma; (PPAR&gamma;) and liver X receptors (LXRs) to induce lipid abnormalities . It also could modulate saturation of phospholipids (Hu et al., 2020) and increase the cholesterol or triglyceride concentrations in bloods. Under this circumstance, it is extraordinarily exigent to assess the health risk of TPP."@en ;
  foaf:page <https://identifiers.org/aop/401> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/402> a sbd:Model ;
  rdfs:label "Thyroid peroxidase (TPO) inhibition leads to periventricular heterotopia formation in the developing rat brain"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "There is a wealth of information on the inhibition of TPO by drugs such as MMI and PTU, as well as environmental xenobiotics. In the landmark paper on TH system&nbsp;disruption by environmental chemicals, Brucker-Davis (1998) identified environmental chemicals that depressed TH synthesis by inhibiting TPO. Hurley (1998) listed TPO as a major target for thyroid tumor inducing pesticides. More recent work has tested over 1000 chemicals using a high-throughput screening assay (Paul-Friedman et al., 2016)."@en ;
  foaf:page <https://identifiers.org/aop/402> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/402> a sbd:Model ;
  rdfs:label "Thyroid peroxidase (TPO) inhibition leads to periventricular heterotopia formation in the developing rat brain"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "There is a wealth of information on the inhibition of TPO by drugs such as MMI and PTU, as well as environmental xenobiotics. In the landmark paper on TH system&nbsp;disruption by environmental chemicals, Brucker-Davis (1998) identified environmental chemicals that depressed TH synthesis by inhibiting TPO. Hurley (1998) listed TPO as a major target for thyroid tumor inducing pesticides. More recent work has tested over 1000 chemicals using a high-throughput screening assay (Paul-Friedman et al., 2016)."@en ;
  foaf:page <https://identifiers.org/aop/402> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/405> a sbd:Model ;
  rdfs:label "Organo-Phosphate Chemicals induced inhibition of AChE  leading to impaired cognitive function"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Organophosphate and carbamate insecticides are prototypical AChE inhibitors. The OP and carbamate pesticides were synthesized specifically to act as inhibitors of AChE, with OPs developed from early nerve agents (e.g., sarin) and carbamate pesticides based on the natural plant alkaloid physostigmine (Ecobichon 2001). 	A positive and significant correlation between the log of the Eserine IC50 (in vitro) for AChE inhibition and the log Km value for the AChE in the fish and crustacea species has been reported, explaining 92% of the variation in enzyme inhibition (Monserrat and Bianchini, 2001). Similar success was found in relating the rate constants for inhibition of AChE in housefly and the pseudo first-order hydrolysis rate constant for active forms of OPs (Fukuto 1990).    	The open literature includes many studies on vertebrate and invertebrate species that demonstrate a clear dependence of AChE activity on the dose or concentration of the substance with increased concentrations leading to an increase in the inhibition of AChE (e.g., fish ( Karen et al., 2001), birds (Hudson et al., 1984 (see dimethoate and disulfoton), Grue and Shipley 1984; and Al-Zubaidy et al., 2011); cladocera (Barata et al., 2004); nematodes (Rajini et al., 2008); rodents (Roberts et al., 1988; and mollusk (Bianco et al., 2011)). 	The open literature includes many studies on vertebrate and invertebrate species that demonstrate a clear relationship between increasing AChE inhibition as duration of exposure increases (e.g., amphibians ( Venturino et al., 2001); fish (Rao 2008; Ferrari et al., 2004); insects (Rose and Sparks 1984); birds (Ludke 1985; Grue and Shipley 1984); annelids (Reddy and Rao 2008); cladocera (Barata et al., 2004)). 	Rao et al. 2008 exposed the estuarine fish Oreochromis mossambicus to a 24 h LC50 concentration of chlorpyrifos and reported that it took 6 hr to reach &gt;40% AChE inhibition and 24 hr to reach 90% AChE inhibition. It took &gt;100 days to recover to normal AChE levels when fish were placed in clean water. 	A time course study of earthworms (Eisenis foetida) exposed to the 48 hr LC50 of profenofos found a significant relationship (between increases in percent inhibition of AChE and increase in time of exposure from 8-48 hrs (Chakra Reddy and Rao 2008)."@en ;
  foaf:page <https://identifiers.org/aop/405> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/405> a sbd:Model ;
  rdfs:label "Organo-Phosphate Chemicals induced inhibition of AChE  leading to impaired cognitive function"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "A prime example of impairments in cognitive function as the adverse outcome for regulatory action is developmental lead exposure and IQ function in children (Bellinger, 2012). In addition, testing for the impact of chemical expsoures on cognitive function, often including spatially-mediated behaviors, is an intergral part of both EPA and OECD developmental neurotoxicity guidelines (USEPA, 1998; OECD, 2007)."@en ;
  foaf:page <https://identifiers.org/aop/405> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/406> a sbd:Model ;
  rdfs:label "SARS-CoV-2 infection leading to hyperinflammation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Attempts to understand molecular mechanisms of COVID-10 pathogenesis lead to several studies linking COVID-19 severity to oxidative stress in infected tissues (Bakadia, Boni et al. 2021, Mehri, Rahbar et al. 2021, Pincemail, Cavalier et al. 2021). In parallel, the antioxidant defensive mechanisms were lowered in COVID-19 patients (Pincemail, Cavalier et al. 2021). Reactive oxygen species (ROS) and oxidative stress are known to activate inflammasomes (Cruz, Rinna et al. 2007, Martinon 2010, Kauppinen, Niskanen et al. 2012, Abderrazak, Syrovets et al. 2015). &nbsp;Inflammasomes are critical components of innate immune system that induce secretion of pro-inflammatory cytokines such as IL1B and IL18 upon activation (Martinon, Burns et al. 2002, Kelley, Jeltema et al. 2019). In the study by Lage and colleagues, aberrant levels of oxidative stress hallmarks (such as mitochondrial superoxide and lipid peroxidation) with concomitant NLRP3 inflammasome activation and IL1B secretion were observed in monocytes of COVID-19 patients (Lage, Amaral et al. 2021). Since the outbreak of pandemics, several review articles postulated the involvement of oxidative stress and inflammasome activation in COVID-19 pathology (Beltr&aacute;n-Garc&iacute;a, Osca-Verdegal et al. 2020, Derouiche 2020, Shah 2020) however the causality of ROS in the inflammasome activation in the context of COVID-19 infection is not very clear."@en ;
  foaf:page <https://identifiers.org/aop/406> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/406> a sbd:Model ;
  rdfs:label "SARS-CoV-2 infection leading to hyperinflammation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Receptor recognition is an essential determinant of molecular level in this AOP. ACE2 was reported as an entry receptor for SARS-CoV-2. The viral entry process is mediated by the envelope-embedded surface-located spike (S) glycoprotein.&nbsp; Jun Lan and Walls, A.C et al (Nature 581, 215&ndash;220; Cell 180, 281&ndash;292) demonstrated a critical initial step of infection at the molecular level from the interaction of ACE2 and S protein. ACE2 has shown that receptor binding affinity to S protein is nM range. To elucidate the interaction between the SARS-CoV-2 RBD and ACE2 at a higher resolution, they also determined the structure of the SARS-CoV-2 RBD&ndash;ACE2 complex using X-ray crystallography. The expression and distribution of the ACE2 in human body may indicate the potential infection of SARS-CoV-2. Through the developed single-cell RNA sequencing (scRNA-Seq) technique and single-cell transcriptomes based on the public database, researchers analyzed the ACE2 RNA expression profile at single-cell resolution. High ACE2 expression was identified in type II alveolar cells (Zou, X. et al. Front. Med.2020)  SARS-CoV-2 belongs to the Coronaviridae family, which includes evolutionary related enveloped (+) strand RNA viruses of vertebrates, such as seasonal common coronaviruses, SARS-CoV and CoV-NL63, SARS-CoV (Kim Young Jun et al)   	 		 			 			Human viruses strains 			 			 			Genus 			 			 			Major cell receptor 			 			 			First report 			 			 			Animal reservoir 			 			 			Intermediate host 			 			 			Pathology 			 			 			Diagnostic test 			 			 			Evidence 			 		 		 			 			HCoV-NL63 			 			 			Alphacoronavirus 			 			 			ACE2 			 			 			2004 			 			 			Bat 			 			 			Unknown 			 			 			Mild respiratory tract illness 			 			 			RT-PCR, IF, ELISA, WB 			 			 			Strong 			 		 		 			 			SARS-CoV 			 			 			Betacoronavirus 			 			 			ACE2 			 			 			2003 			 			 			Bat 			 			 			Pangolin 			 			 			Severe acute respiratory syndrome 			 			 			RT-PCR, IF, ELISA, WB 			 			 			Strong 			 		 		 			 			SARS-CoV-2 			 			 			Betacoronavirus 			 			 			ACE2 			 			 			2020 			 			 			Bat 			 			 			Pangolin 			 			 			Severe acute respiratory syndrome 			 			 			RT-PCR, IF, ELISA, WB 			 			 			Strong"@en ;
  foaf:page <https://identifiers.org/aop/406> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/407> a sbd:Model ;
  rdfs:label "SARS-CoV-2 infection leading to pyroptosis"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Receptor recognition is an essential determinant of molecular level in this AOP. ACE2 was reported as an entry receptor for SARS-CoV-2. The viral entry process is mediated by the envelope-embedded surface-located spike (S) glycoprotein.&nbsp; Jun Lan and Walls, A.C et al (Nature 581, 215&ndash;220; Cell 180, 281&ndash;292) demonstrated a critical initial step of infection at the molecular level from the interaction of ACE2 and S protein. ACE2 has shown that receptor binding affinity to S protein is nM range. To elucidate the interaction between the SARS-CoV-2 RBD and ACE2 at a higher resolution, they also determined the structure of the SARS-CoV-2 RBD&ndash;ACE2 complex using X-ray crystallography. The expression and distribution of the ACE2 in human body may indicate the potential infection of SARS-CoV-2. Through the developed single-cell RNA sequencing (scRNA-Seq) technique and single-cell transcriptomes based on the public database, researchers analyzed the ACE2 RNA expression profile at single-cell resolution. High ACE2 expression was identified in type II alveolar cells (Zou, X. et al. Front. Med.2020)  SARS-CoV-2 belongs to the Coronaviridae family, which includes evolutionary related enveloped (+) strand RNA viruses of vertebrates, such as seasonal common coronaviruses, SARS-CoV and CoV-NL63, SARS-CoV (Kim Young Jun et al)   	 		 			 			Human viruses strains 			 			 			Genus 			 			 			Major cell receptor 			 			 			First report 			 			 			Animal reservoir 			 			 			Intermediate host 			 			 			Pathology 			 			 			Diagnostic test 			 			 			Evidence 			 		 		 			 			HCoV-NL63 			 			 			Alphacoronavirus 			 			 			ACE2 			 			 			2004 			 			 			Bat 			 			 			Unknown 			 			 			Mild respiratory tract illness 			 			 			RT-PCR, IF, ELISA, WB 			 			 			Strong 			 		 		 			 			SARS-CoV 			 			 			Betacoronavirus 			 			 			ACE2 			 			 			2003 			 			 			Bat 			 			 			Pangolin 			 			 			Severe acute respiratory syndrome 			 			 			RT-PCR, IF, ELISA, WB 			 			 			Strong 			 		 		 			 			SARS-CoV-2 			 			 			Betacoronavirus 			 			 			ACE2 			 			 			2020 			 			 			Bat 			 			 			Pangolin 			 			 			Severe acute respiratory syndrome 			 			 			RT-PCR, IF, ELISA, WB 			 			 			Strong"@en ;
  foaf:page <https://identifiers.org/aop/407> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/409> a sbd:Model ;
  rdfs:label "Frustrated phagocytosis leads to malignant mesothelioma"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "High aspect ratio nanoparticles are not completely engulfed by macrophages due to their long shape (&gt; 10&micro;m) [8, 10].    Some studies analysed the effect of the length of nanoparticles (NPs) on the capacity of macrophages to phagocytose them.  The study of Sweeney et al 2015 demonstrated that treatment of primary human alveolar macrophages by multi-walled carbon nanotubes (MWCNT) similar in term of diameter, specific surface area and purity but differ by their length differentially alter phagocytosis [6]. Indeed, treatment by the longer CNT (median length 19.3 &micro;m) induced frustrated phagocytosis and receptor expression (MARCO) as well as decreased phagocytic ability and migratory capacity in a more extend manner than the shorter CNT (median length 1.1 &micro;m) [6]. Another study analysed the effect of particle morphology on the ability of human monocytic cell line THP-1 to engulf carbon nanotubes [9]. Cells were treated for 24h by two longs CNTs (men length 13 and 36 &micro;m, dimeter 84.89 and 165.02 nm), two tangled CNTs (length 1-5 and 5-20 &micro;m, dimeter 14.84 and 10.40 nm) and one short CNT (length 1-2 &micro;m, diameter 25.7 nm). The authors observed by light microscopy that only the two long CNTs are protruding from the cells. A study on THP-1 cells treated for 4h was conducted with silver nanowires that possess similar diameter but different length (average length: 3, 5, 10, 14 and 28 &micro;m) [8]. The authors observed by bright-field microscopy that the shorter NPs (3 and 5) were fully enclosed by macrophages, while the longer NPs (14 and 28) caused frustrated phagocytosis. In addition, injection of NPs in mouse pleural cavity followed by pleural lavage demonstrated that the shorter (3 and 5) were fully phagocytosed whereas the longer (10) caused frustrated phagocytosis. The authors observed differences between in vitro and in vivo studies in term of sensitivity for the determination of the length threshold that caused frustrated phagocytosis [8]. Finally, Padmore et al showed by time-lapse video microscopy that immortalized MH-S murine alveolar macrophages were able to internalized short glass fibres (mean length 7 &micro;m) whereas the longer fibres were not (mean length 39.3&nbsp;&micro;m) [7].    All together, these studies could suggest that the threshold for frustrated phagocytosis should be around 10 &micro;m, close to the suggestion formulated by Donaldson et al that fibres longer than 15 &micro;m cause this process [10]."@en ;
  foaf:page <https://identifiers.org/aop/409> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/410> a sbd:Model ;
  rdfs:label "GSK3beta inactivation leading to increased mortality via defects in developing inner ear"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/410> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/410> a sbd:Model ;
  rdfs:label "GSK3beta inactivation leading to increased mortality via defects in developing inner ear"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Increased mortality is one of the most common regulatory assessment endpoints,&nbsp;along with reduced growth and reduced reproduction."@en ;
  foaf:page <https://identifiers.org/aop/410> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/410> a sbd:Model ;
  rdfs:label "GSK3beta inactivation leading to increased mortality via defects in developing inner ear"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The motivation behind building the AOP&nbsp;was methodological. Our team has recently developed molecular causal networks for developmental cardiotoxicity and neurotoxicity in zebrafish (doi.org/10.1021/acs.chemrestox.0c00095). These networks are highly curated, but rather large, going from adverse outcomes on the organ level upstream to wherever evidence takes us (many times finishing at what would be called MIEs). As there are many causal networks already present on the http://causalbionet.com/ (mostly for humans and for lung conditions), we were wondering how the rich knowledge available in causal pathways could be translated to AOPs. The AOP described in this document is one such example.&nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/410> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/410> a sbd:Model ;
  rdfs:label "GSK3beta inactivation leading to increased mortality via defects in developing inner ear"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/410> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/410> a sbd:Model ;
  rdfs:label "GSK3beta inactivation leading to increased mortality via defects in developing inner ear"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Increased mortality is one of the most common regulatory assessment endpoints,&nbsp;along with reduced growth and reduced reproduction."@en ;
  foaf:page <https://identifiers.org/aop/410> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/410> a sbd:Model ;
  rdfs:label "GSK3beta inactivation leading to increased mortality via defects in developing inner ear"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The motivation behind building the AOP&nbsp;was methodological. Our team has recently developed molecular causal networks for developmental cardiotoxicity and neurotoxicity in zebrafish (doi.org/10.1021/acs.chemrestox.0c00095). These networks are highly curated, but rather large, going from adverse outcomes on the organ level upstream to wherever evidence takes us (many times finishing at what would be called MIEs). As there are many causal networks already present on the http://causalbionet.com/ (mostly for humans and for lung conditions), we were wondering how the rich knowledge available in causal pathways could be translated to AOPs. The AOP described in this document is one such example.&nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/410> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/411> a sbd:Model ;
  rdfs:label "Oxidative stress Leading to Decreased Lung Function "@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "With a surface area of ~100 m2 and ventilated by 10,000 to 20,000 liters of air per day (National Research Council, 1988; Frohlich et al., 2016), the lungs are a major barrier that protect the body from a host of external factors that enter the respiratory system and may cause lung pathologies. Mucociliary clearance (MCC) is a key aspect of the innate immune&nbsp;defense against airborne pathogens and inhaled particles and is governed by the concerted action of its functional components, the cilia and the airway surface liquid (ASL), which comprises mucus and the periciliary layer (Bustamante-Marin and Ostrowski, 2017). In healthy subjects, &ge;10 mL&nbsp;airway secretions are continuously produced and transported daily by the mucociliary escalator. Disturbances in any of the processes regulating ASL volume, mucus production, mucus viscoelastic properties, or ciliary function can cause MCC dysfunction and are linked to airway diseases such as chronic obstructive pulmonary disease (COPD) or asthma, both of which bear a significant risk of increased morbidity and mortality. The mechanism by which exposure to inhaled toxicants might lead to mucus hypersecretion and thereby impact pulmonary function has already been mapped in AOP148 on decreased lung function.&nbsp;However, whether an exposure-related decline in lung function is solely related to excessive production of mucus is debatable, particularly in light of the close relationship between mucus, ciliary function, and efficient MCC. To date, no single event has been attributed to MCC impairment, and it is likely that events described in this AOP as well as in AOP148, AOP424, and AOP425 have to culminate to lead to&nbsp;decreased lung function."@en ;
  foaf:page <https://identifiers.org/aop/411> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/411> a sbd:Model ;
  rdfs:label "Oxidative stress Leading to Decreased Lung Function "@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Established regulatory guideline studies for inhalation toxicity focus on evident clinical signs of systemic toxicity, including death, or organ-specific toxicity following acute and (sub)chronic exposure respectively. In toxicological and safety pharmacological studies with airborne test items targeting the airways or the lungs as a whole, lung function is a relevant endpoint for the characterization of potential adverse events (OECD, 2018a; Hoymann, 2012). Hence, the AO &ldquo;decreased lung function&rdquo; is relevant for regulatory decision-making in the context of (sub)chronic exposure (OECD, 2018b; OECD, 2018c).  Regulatory relevance of the AO &ldquo;decreased lung function&rdquo; is evident when looking at the increased risk of diseases in humans following inhalation exposure, and because of its links to other comorbidities and mortality.  To aid diagnosis and monitoring of fibrosis, current recommendations include both the recording of potential environmental and occupational exposures as well as an assessment of lung function (Baumgartner et al., 2000). The latter typically confirms decreased lung function as demonstrated by a loss of lung volume. As the disease progresses, dyspnea and lung function worsen, and the prognosis is directly linked to the decline in FVC (Meltzer and Noble, 2008).   Chronic exposure to cigarette smoke and other combustion-derived particles results in the development of COPD. COPD is diagnosed on the basis of spirometry results as laid out in the ATS/ERS Task Force documents on the standardization of lung function tests and their interpretation (Pellegrino et al., 2005; Culver et al., 2017, Graham et al., 2019). Rapid rates of decline in the lung function parameter FEV1 are linked to higher risk of exacerbations, increased hospitalization and early death (Wise et al., 2006; Celli, 2010). Reduced FEV1 also poses a risk for serious cardiovascular events and mortality associated with cardiovascular disease (Sin et al., 2005; Lee et al., 2015).  &nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/411> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/413> a sbd:Model ;
  rdfs:label "Oxidation and antagonism of reduced glutathione leading to mortality via acute renal failure"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Increased mortality is one of the most common regulatory assessment endpoints,&nbsp;along with reduced growth and reduced reproduction."@en ;
  foaf:page <https://identifiers.org/aop/413> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/413> a sbd:Model ;
  rdfs:label "Oxidation and antagonism of reduced glutathione leading to mortality via acute renal failure"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The biology and chemistry of uranium effluent and its effects have&nbsp;been well explored, especially within fish species(Cooley et al. 2000; Kelly and Janz 2009; Goulet et al. 2011; Ma et al. 2020),&nbsp;however it has not been clearly presented.&nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/413> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/415> a sbd:Model ;
  rdfs:label "Aryl hydrocarbon receptor activation leading to lung fibrosis through IL-6 toxicity pathway"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The AHR can be activated by several structurally diverse chemicals, but binds preferentially to planar halogenated aromatic hydrocarbons and polycyclic aromatic hydrocarbons. Dioxin-like compounds (DLCs), which include polychlorinated dibenzo-p-dioxins (PCDDs), polychlorinated dibenzofurans (PCDFs) and certain polychlorinated biphenyls (PCBs), are among the most potent AHR ligands[38]. Only a subset of PCDD, PCDF and PCB congeners has been shown to bind to the AHR and cause toxic effects to those elicited by TCDD. Until recently, TCDD was considered to be the most potent DLC in birds[39]; however, recent reports indicate that 2,3,4,7,8-pentachlorodibenzofuran (PeCDF) is more potent than TCDD in some species of birds.[40][13][41][21][42][43] When screened for their ability to induce aryl hydrocarbon hydroxylase (AHH) activity, dioxins with chlorine atoms at a minimum of three out of the four lateral ring positions, and with at least one non-chlorinated ring position are the most active[44]. Of the dioxin-like PCBs, non-ortho congeners are the most toxicologically active, while mono-ortho PCBs are generally less potent[45][9]. Chlorine substitution at ortho positions increases the energetic costs of assuming the coplanar conformation required for binding to the AHR [45]. Thus, a smaller proportion of mono-ortho PCB molecules are able to bind to the AHR and elicit toxic effects, resulting in reduced potency of these congeners. Other PCB congeners, such as di-ortho substituted PCBs, are very weak AHR agonists and do not likely contribute to dioxin-like effects [9].   	Contrary to studies of birds and mammals, even the most potent mono-ortho PCBs bind to AhRs of fishes with very low affinity, if at all (Abnet et al 1999; Doering et al 2014; 2015; Eisner et al 2016; Van den Berg et al 1998).   The role of the AHR in mediating the toxic effects of planar hydrophobic contaminants has been well studied, however the endogenous role of the AHR is less clear [1]. Some endogenous and natural substances, including prostaglandin PGG2 and the tryptophan derivatives indole-3-carbinol, 6-formylindolo[3,2-b]carbazole (FICZ) and kynurenic acid can bind to and activate the AHR. [6][46][47][48][49] The AHR is thought to have important endogenous roles in reproduction, liver and heart development, cardiovascular function, immune function and cell cycle regulation [50][38][51][52][53][54][46][55][56][57] and activation of the AHR by DLCs may therefore adversely affect these processes."@en ;
  foaf:page <https://identifiers.org/aop/415> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/416> a sbd:Model ;
  rdfs:label "Aryl hydrocarbon receptor activation leading to lung cancer through IL-6 toxicity pathway"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The AHR can be activated by several structurally diverse chemicals, but binds preferentially to planar halogenated aromatic hydrocarbons and polycyclic aromatic hydrocarbons. Dioxin-like compounds (DLCs), which include polychlorinated dibenzo-p-dioxins (PCDDs), polychlorinated dibenzofurans (PCDFs) and certain polychlorinated biphenyls (PCBs), are among the most potent AHR ligands[38]. Only a subset of PCDD, PCDF and PCB congeners has been shown to bind to the AHR and cause toxic effects to those elicited by TCDD. Until recently, TCDD was considered to be the most potent DLC in birds[39]; however, recent reports indicate that 2,3,4,7,8-pentachlorodibenzofuran (PeCDF) is more potent than TCDD in some species of birds.[40][13][41][21][42][43] When screened for their ability to induce aryl hydrocarbon hydroxylase (AHH) activity, dioxins with chlorine atoms at a minimum of three out of the four lateral ring positions, and with at least one non-chlorinated ring position are the most active[44]. Of the dioxin-like PCBs, non-ortho congeners are the most toxicologically active, while mono-ortho PCBs are generally less potent[45][9]. Chlorine substitution at ortho positions increases the energetic costs of assuming the coplanar conformation required for binding to the AHR [45]. Thus, a smaller proportion of mono-ortho PCB molecules are able to bind to the AHR and elicit toxic effects, resulting in reduced potency of these congeners. Other PCB congeners, such as di-ortho substituted PCBs, are very weak AHR agonists and do not likely contribute to dioxin-like effects [9].   	Contrary to studies of birds and mammals, even the most potent mono-ortho PCBs bind to AhRs of fishes with very low affinity, if at all (Abnet et al 1999; Doering et al 2014; 2015; Eisner et al 2016; Van den Berg et al 1998).   The role of the AHR in mediating the toxic effects of planar hydrophobic contaminants has been well studied, however the endogenous role of the AHR is less clear [1]. Some endogenous and natural substances, including prostaglandin PGG2 and the tryptophan derivatives indole-3-carbinol, 6-formylindolo[3,2-b]carbazole (FICZ) and kynurenic acid can bind to and activate the AHR. [6][46][47][48][49] The AHR is thought to have important endogenous roles in reproduction, liver and heart development, cardiovascular function, immune function and cell cycle regulation [50][38][51][52][53][54][46][55][56][57] and activation of the AHR by DLCs may therefore adversely affect these processes."@en ;
  foaf:page <https://identifiers.org/aop/416> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/417> a sbd:Model ;
  rdfs:label "Aryl hydrocarbon receptor activation leading to lung cancer through AHR-ARNT toxicity pathway"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The AHR can be activated by several structurally diverse chemicals, but binds preferentially to planar halogenated aromatic hydrocarbons and polycyclic aromatic hydrocarbons. Dioxin-like compounds (DLCs), which include polychlorinated dibenzo-p-dioxins (PCDDs), polychlorinated dibenzofurans (PCDFs) and certain polychlorinated biphenyls (PCBs), are among the most potent AHR ligands[38]. Only a subset of PCDD, PCDF and PCB congeners has been shown to bind to the AHR and cause toxic effects to those elicited by TCDD. Until recently, TCDD was considered to be the most potent DLC in birds[39]; however, recent reports indicate that 2,3,4,7,8-pentachlorodibenzofuran (PeCDF) is more potent than TCDD in some species of birds.[40][13][41][21][42][43] When screened for their ability to induce aryl hydrocarbon hydroxylase (AHH) activity, dioxins with chlorine atoms at a minimum of three out of the four lateral ring positions, and with at least one non-chlorinated ring position are the most active[44]. Of the dioxin-like PCBs, non-ortho congeners are the most toxicologically active, while mono-ortho PCBs are generally less potent[45][9]. Chlorine substitution at ortho positions increases the energetic costs of assuming the coplanar conformation required for binding to the AHR [45]. Thus, a smaller proportion of mono-ortho PCB molecules are able to bind to the AHR and elicit toxic effects, resulting in reduced potency of these congeners. Other PCB congeners, such as di-ortho substituted PCBs, are very weak AHR agonists and do not likely contribute to dioxin-like effects [9].   	Contrary to studies of birds and mammals, even the most potent mono-ortho PCBs bind to AhRs of fishes with very low affinity, if at all (Abnet et al 1999; Doering et al 2014; 2015; Eisner et al 2016; Van den Berg et al 1998).   The role of the AHR in mediating the toxic effects of planar hydrophobic contaminants has been well studied, however the endogenous role of the AHR is less clear [1]. Some endogenous and natural substances, including prostaglandin PGG2 and the tryptophan derivatives indole-3-carbinol, 6-formylindolo[3,2-b]carbazole (FICZ) and kynurenic acid can bind to and activate the AHR. [6][46][47][48][49] The AHR is thought to have important endogenous roles in reproduction, liver and heart development, cardiovascular function, immune function and cell cycle regulation [50][38][51][52][53][54][46][55][56][57] and activation of the AHR by DLCs may therefore adversely affect these processes."@en ;
  foaf:page <https://identifiers.org/aop/417> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/419> a sbd:Model ;
  rdfs:label "Aryl hydrocarbon receptor activation leading to impaired lung function through P53 toxicity pathway"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Established regulatory guideline studies for inhalation toxicity focus on evident clinical signs of systemic toxicity, including death, or organ-specific toxicity following acute and (sub)chronic exposure respectively. In toxicological and safety pharmacological studies with airborne test items targeting the airways or the lungs as a whole, lung function is a relevant endpoint for the characterization of potential adverse events (OECD, 2018a; Hoymann, 2012). Hence, the AO &ldquo;decreased lung function&rdquo; is relevant for regulatory decision-making in the context of (sub)chronic exposure (OECD, 2018b; OECD, 2018c).  Regulatory relevance of the AO &ldquo;decreased lung function&rdquo; is evident when looking at the increased risk of diseases in humans following inhalation exposure, and because of its links to other comorbidities and mortality.  To aid diagnosis and monitoring of fibrosis, current recommendations include both the recording of potential environmental and occupational exposures as well as an assessment of lung function (Baumgartner et al., 2000). The latter typically confirms decreased lung function as demonstrated by a loss of lung volume. As the disease progresses, dyspnea and lung function worsen, and the prognosis is directly linked to the decline in FVC (Meltzer and Noble, 2008).   Chronic exposure to cigarette smoke and other combustion-derived particles results in the development of COPD. COPD is diagnosed on the basis of spirometry results as laid out in the ATS/ERS Task Force documents on the standardization of lung function tests and their interpretation (Pellegrino et al., 2005; Culver et al., 2017, Graham et al., 2019). Rapid rates of decline in the lung function parameter FEV1 are linked to higher risk of exacerbations, increased hospitalization and early death (Wise et al., 2006; Celli, 2010). Reduced FEV1 also poses a risk for serious cardiovascular events and mortality associated with cardiovascular disease (Sin et al., 2005; Lee et al., 2015).  &nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/419> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/423> a sbd:Model ;
  rdfs:label " Toxicological mechanisms of hepatocyte apoptosis through the PARP1 dependent cell death pathway "@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Triphenyl phosphate (TPP), as a typical aryl organophosphate ester, has drew much attention to its adverse effects (Du et al., 2016; Mendelsohn et al., 2016; Su et al., 2014; Zhang et al., 2016). It was also considered as a mitochondrial toxicant that could alter mitochondrial function and disorder mitochondria metabolism to exert severe cytotoxicity (Bowen et al., 2020). Further research is necessary to explore how TPP affects mitochondrial PARP1 activation in the early stage to cause cell death pathway."@en ;
  foaf:page <https://identifiers.org/aop/423> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/424> a sbd:Model ;
  rdfs:label "Oxidative stress Leading to Decreased Lung Function via CFTR dysfunction"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Established regulatory guideline studies for inhalation toxicity focus on evident clinical signs of systemic toxicity, including death, or organ-specific toxicity following acute and (sub)chronic exposure respectively. In toxicological and safety pharmacological studies with airborne test items targeting the airways or the lungs as a whole, lung function is a relevant endpoint for the characterization of potential adverse events (OECD, 2018a; Hoymann, 2012). Hence, the AO &ldquo;decreased lung function&rdquo; is relevant for regulatory decision-making in the context of (sub)chronic exposure (OECD, 2018b; OECD, 2018c).  Regulatory relevance of the AO &ldquo;decreased lung function&rdquo; is evident when looking at the increased risk of diseases in humans following inhalation exposure, and because of its links to other comorbidities and mortality.  To aid diagnosis and monitoring of fibrosis, current recommendations include both the recording of potential environmental and occupational exposures as well as an assessment of lung function (Baumgartner et al., 2000). The latter typically confirms decreased lung function as demonstrated by a loss of lung volume. As the disease progresses, dyspnea and lung function worsen, and the prognosis is directly linked to the decline in FVC (Meltzer and Noble, 2008).   Chronic exposure to cigarette smoke and other combustion-derived particles results in the development of COPD. COPD is diagnosed on the basis of spirometry results as laid out in the ATS/ERS Task Force documents on the standardization of lung function tests and their interpretation (Pellegrino et al., 2005; Culver et al., 2017, Graham et al., 2019). Rapid rates of decline in the lung function parameter FEV1 are linked to higher risk of exacerbations, increased hospitalization and early death (Wise et al., 2006; Celli, 2010). Reduced FEV1 also poses a risk for serious cardiovascular events and mortality associated with cardiovascular disease (Sin et al., 2005; Lee et al., 2015).  &nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/424> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/424> a sbd:Model ;
  rdfs:label "Oxidative stress Leading to Decreased Lung Function via CFTR dysfunction"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "With a surface area of ~100 m2 and ventilated by 10,000 to 20,000 liters of air per day (National Research Council, 1988; Frohlich et al., 2016), the lungs are a major barrier that protect the body from a host of external factors that enter the respiratory system and may cause lung pathologies. Mucociliary clearance (MCC) is a key aspect of the innate immune defense against airborne pathogens and inhaled particles and is governed by the concerted action of its functional components, the cilia and the airway surface liquid (ASL), which comprises mucus and the periciliary layer (Bustamante-Marin and Ostrowski, 2017). In healthy subjects, &ge;10 mL airway secretions are continuously produced and transported daily by the mucociliary escalator. Disturbances in any of the processes regulating ASL volume, mucus production, mucus viscoelastic properties, or ciliary function can cause MCC dysfunction and are linked to airway diseases such as chronic obstructive pulmonary disease (COPD) or asthma, both of which bear a significant risk of increased morbidity and mortality. The mechanism by which exposure to inhaled toxicants might lead to mucus hypersecretion and thereby impact pulmonary function has already been mapped in AOP148 on decreased lung function. However, whether an exposure-related decline in lung function is solely related to excessive production of mucus is debatable, particularly in light of the close relationship between mucus, ciliary function, and efficient MCC. To date, no single event has been attributed to MCC impairment, and it is likely that events described in this AOP as well as in AOPs 148, 411 and 425 have to culminate to lead to decreased lung function."@en ;
  foaf:page <https://identifiers.org/aop/424> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/425> a sbd:Model ;
  rdfs:label "Oxidative Stress Leading to Decreased Lung Function via Decreased FOXJ1"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "With a surface area of ~100 m2 and ventilated by 10,000 to 20,000 liters of air per day (National Research Council, 1988; Frohlich et al., 2016), the lungs are a major barrier that protect the body from a host of external factors that enter the respiratory system and may cause lung pathologies. Mucociliary clearance (MCC) is a key aspect of the innate immune defense against airborne pathogens and inhaled particles and is governed by the concerted action of its functional components, the cilia and the airway surface liquid (ASL), which comprises mucus and the periciliary layer (Bustamante-Marin and Ostrowski, 2017). In healthy subjects, &ge;10 mL airway secretions are continuously produced and transported daily by the mucociliary escalator. Disturbances in any of the processes regulating ASL volume, mucus production, mucus viscoelastic properties, or ciliary function can cause MCC dysfunction and are linked to airway diseases such as chronic obstructive pulmonary disease (COPD) or asthma, both of which bear a significant risk of increased morbidity and mortality. The mechanism by which exposure to inhaled toxicants might lead to mucus hypersecretion and thereby impact pulmonary function has already been mapped in AOP148 on decreased lung function. However, whether an exposure-related decline in lung function is solely related to excessive production of mucus is debatable, particularly in light of the close relationship between mucus, ciliary function, and efficient MCC. To date, no single event has been attributed to MCC impairment, and it is likely that events described in this AOP as well as in AOPs 148, 411 and 424 have to culminate to lead to decreased lung function."@en ;
  foaf:page <https://identifiers.org/aop/425> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/425> a sbd:Model ;
  rdfs:label "Oxidative Stress Leading to Decreased Lung Function via Decreased FOXJ1"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Established regulatory guideline studies for inhalation toxicity focus on evident clinical signs of systemic toxicity, including death, or organ-specific toxicity following acute and (sub)chronic exposure respectively. In toxicological and safety pharmacological studies with airborne test items targeting the airways or the lungs as a whole, lung function is a relevant endpoint for the characterization of potential adverse events (OECD, 2018a; Hoymann, 2012). Hence, the AO &ldquo;decreased lung function&rdquo; is relevant for regulatory decision-making in the context of (sub)chronic exposure (OECD, 2018b; OECD, 2018c).  Regulatory relevance of the AO &ldquo;decreased lung function&rdquo; is evident when looking at the increased risk of diseases in humans following inhalation exposure, and because of its links to other comorbidities and mortality.  To aid diagnosis and monitoring of fibrosis, current recommendations include both the recording of potential environmental and occupational exposures as well as an assessment of lung function (Baumgartner et al., 2000). The latter typically confirms decreased lung function as demonstrated by a loss of lung volume. As the disease progresses, dyspnea and lung function worsen, and the prognosis is directly linked to the decline in FVC (Meltzer and Noble, 2008).   Chronic exposure to cigarette smoke and other combustion-derived particles results in the development of COPD. COPD is diagnosed on the basis of spirometry results as laid out in the ATS/ERS Task Force documents on the standardization of lung function tests and their interpretation (Pellegrino et al., 2005; Culver et al., 2017, Graham et al., 2019). Rapid rates of decline in the lung function parameter FEV1 are linked to higher risk of exacerbations, increased hospitalization and early death (Wise et al., 2006; Celli, 2010). Reduced FEV1 also poses a risk for serious cardiovascular events and mortality associated with cardiovascular disease (Sin et al., 2005; Lee et al., 2015).  &nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/425> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/426> a sbd:Model ;
  rdfs:label "SARS-CoV-2 spike protein binding to ACE2 receptors expressed on pericytes leads to endothelial cell dysfunction, microvascular injury and myocardial infarction. "@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Receptor recognition is an essential determinant of molecular level in this AOP. ACE2 was reported as an entry receptor for SARS-CoV-2. The viral entry process is mediated by the envelope-embedded surface-located spike (S) glycoprotein.&nbsp; Jun Lan and Walls, A.C et al (Nature 581, 215&ndash;220; Cell 180, 281&ndash;292) demonstrated a critical initial step of infection at the molecular level from the interaction of ACE2 and S protein. ACE2 has shown that receptor binding affinity to S protein is nM range. To elucidate the interaction between the SARS-CoV-2 RBD and ACE2 at a higher resolution, they also determined the structure of the SARS-CoV-2 RBD&ndash;ACE2 complex using X-ray crystallography. The expression and distribution of the ACE2 in human body may indicate the potential infection of SARS-CoV-2. Through the developed single-cell RNA sequencing (scRNA-Seq) technique and single-cell transcriptomes based on the public database, researchers analyzed the ACE2 RNA expression profile at single-cell resolution. High ACE2 expression was identified in type II alveolar cells (Zou, X. et al. Front. Med.2020)  SARS-CoV-2 belongs to the Coronaviridae family, which includes evolutionary related enveloped (+) strand RNA viruses of vertebrates, such as seasonal common coronaviruses, SARS-CoV and CoV-NL63, SARS-CoV (Kim Young Jun et al)   	 		 			 			Human viruses strains 			 			 			Genus 			 			 			Major cell receptor 			 			 			First report 			 			 			Animal reservoir 			 			 			Intermediate host 			 			 			Pathology 			 			 			Diagnostic test 			 			 			Evidence 			 		 		 			 			HCoV-NL63 			 			 			Alphacoronavirus 			 			 			ACE2 			 			 			2004 			 			 			Bat 			 			 			Unknown 			 			 			Mild respiratory tract illness 			 			 			RT-PCR, IF, ELISA, WB 			 			 			Strong 			 		 		 			 			SARS-CoV 			 			 			Betacoronavirus 			 			 			ACE2 			 			 			2003 			 			 			Bat 			 			 			Pangolin 			 			 			Severe acute respiratory syndrome 			 			 			RT-PCR, IF, ELISA, WB 			 			 			Strong 			 		 		 			 			SARS-CoV-2 			 			 			Betacoronavirus 			 			 			ACE2 			 			 			2020 			 			 			Bat 			 			 			Pangolin 			 			 			Severe acute respiratory syndrome 			 			 			RT-PCR, IF, ELISA, WB 			 			 			Strong"@en ;
  foaf:page <https://identifiers.org/aop/426> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/427> a sbd:Model ;
  rdfs:label "ACE2 downregulation following SARS-CoV-2 infection triggers dysregulation of RAAS and can lead to heart failure."@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Receptor recognition is an essential determinant of molecular level in this AOP. ACE2 was reported as an entry receptor for SARS-CoV-2. The viral entry process is mediated by the envelope-embedded surface-located spike (S) glycoprotein.&nbsp; Jun Lan and Walls, A.C et al (Nature 581, 215&ndash;220; Cell 180, 281&ndash;292) demonstrated a critical initial step of infection at the molecular level from the interaction of ACE2 and S protein. ACE2 has shown that receptor binding affinity to S protein is nM range. To elucidate the interaction between the SARS-CoV-2 RBD and ACE2 at a higher resolution, they also determined the structure of the SARS-CoV-2 RBD&ndash;ACE2 complex using X-ray crystallography. The expression and distribution of the ACE2 in human body may indicate the potential infection of SARS-CoV-2. Through the developed single-cell RNA sequencing (scRNA-Seq) technique and single-cell transcriptomes based on the public database, researchers analyzed the ACE2 RNA expression profile at single-cell resolution. High ACE2 expression was identified in type II alveolar cells (Zou, X. et al. Front. Med.2020)  SARS-CoV-2 belongs to the Coronaviridae family, which includes evolutionary related enveloped (+) strand RNA viruses of vertebrates, such as seasonal common coronaviruses, SARS-CoV and CoV-NL63, SARS-CoV (Kim Young Jun et al)   	 		 			 			Human viruses strains 			 			 			Genus 			 			 			Major cell receptor 			 			 			First report 			 			 			Animal reservoir 			 			 			Intermediate host 			 			 			Pathology 			 			 			Diagnostic test 			 			 			Evidence 			 		 		 			 			HCoV-NL63 			 			 			Alphacoronavirus 			 			 			ACE2 			 			 			2004 			 			 			Bat 			 			 			Unknown 			 			 			Mild respiratory tract illness 			 			 			RT-PCR, IF, ELISA, WB 			 			 			Strong 			 		 		 			 			SARS-CoV 			 			 			Betacoronavirus 			 			 			ACE2 			 			 			2003 			 			 			Bat 			 			 			Pangolin 			 			 			Severe acute respiratory syndrome 			 			 			RT-PCR, IF, ELISA, WB 			 			 			Strong 			 		 		 			 			SARS-CoV-2 			 			 			Betacoronavirus 			 			 			ACE2 			 			 			2020 			 			 			Bat 			 			 			Pangolin 			 			 			Severe acute respiratory syndrome 			 			 			RT-PCR, IF, ELISA, WB 			 			 			Strong"@en ;
  foaf:page <https://identifiers.org/aop/427> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/430> a sbd:Model ;
  rdfs:label "Binding of SARS-CoV-2 to ACE2 leads to viral infection proliferation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Receptor recognition is an essential determinant of molecular level in this AOP. ACE2 was reported as an entry receptor for SARS-CoV-2. The viral entry process is mediated by the envelope-embedded surface-located spike (S) glycoprotein.&nbsp; Jun Lan and Walls, A.C et al (Nature 581, 215&ndash;220; Cell 180, 281&ndash;292) demonstrated a critical initial step of infection at the molecular level from the interaction of ACE2 and S protein. ACE2 has shown that receptor binding affinity to S protein is nM range. To elucidate the interaction between the SARS-CoV-2 RBD and ACE2 at a higher resolution, they also determined the structure of the SARS-CoV-2 RBD&ndash;ACE2 complex using X-ray crystallography. The expression and distribution of the ACE2 in human body may indicate the potential infection of SARS-CoV-2. Through the developed single-cell RNA sequencing (scRNA-Seq) technique and single-cell transcriptomes based on the public database, researchers analyzed the ACE2 RNA expression profile at single-cell resolution. High ACE2 expression was identified in type II alveolar cells (Zou, X. et al. Front. Med.2020)  SARS-CoV-2 belongs to the Coronaviridae family, which includes evolutionary related enveloped (+) strand RNA viruses of vertebrates, such as seasonal common coronaviruses, SARS-CoV and CoV-NL63, SARS-CoV (Kim Young Jun et al)   	 		 			 			Human viruses strains 			 			 			Genus 			 			 			Major cell receptor 			 			 			First report 			 			 			Animal reservoir 			 			 			Intermediate host 			 			 			Pathology 			 			 			Diagnostic test 			 			 			Evidence 			 		 		 			 			HCoV-NL63 			 			 			Alphacoronavirus 			 			 			ACE2 			 			 			2004 			 			 			Bat 			 			 			Unknown 			 			 			Mild respiratory tract illness 			 			 			RT-PCR, IF, ELISA, WB 			 			 			Strong 			 		 		 			 			SARS-CoV 			 			 			Betacoronavirus 			 			 			ACE2 			 			 			2003 			 			 			Bat 			 			 			Pangolin 			 			 			Severe acute respiratory syndrome 			 			 			RT-PCR, IF, ELISA, WB 			 			 			Strong 			 		 		 			 			SARS-CoV-2 			 			 			Betacoronavirus 			 			 			ACE2 			 			 			2020 			 			 			Bat 			 			 			Pangolin 			 			 			Severe acute respiratory syndrome 			 			 			RT-PCR, IF, ELISA, WB 			 			 			Strong"@en ;
  foaf:page <https://identifiers.org/aop/430> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/430> a sbd:Model ;
  rdfs:label "Binding of SARS-CoV-2 to ACE2 leads to viral infection proliferation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "This AOP was developed in the context of other COVID-19 AOPs through the work of a&nbsp;larger&nbsp;international effort to model the pathogenesis of COVID-19 using the AOP framework (the CIAO project,&nbsp;https://www.ciao-covid.net/about-us), initiated by the European Commission-Joint Research Centre (EC-JRC), and supported by the Society for the Advancement of Adverse Outcome Pathways (SAAOP). More than 80 scientists from 50 institutions contributed to the fifteen AOPs connected to the molecular initiating event (1739) SARS-CoV-2 binding to ACE2, and other COVID-19-related AOPs. AOP 430 serves as a hub of early key events leading to viral transmission (AO 1939) and the severe disease outcomes described in the networked COVID-19 AOPs."@en ;
  foaf:page <https://identifiers.org/aop/430> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/432> a sbd:Model ;
  rdfs:label "Deposition of Energy by Ionizing Radiation leading to Acute Myeloid Leukemia"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "It is well documented that ionizing radiation( (eg.&nbsp;X-rays, gamma, photons, alpha, beta, neutrons, heavy ions)&nbsp;leads to energy deposition on the atoms and molecules of the substrate. Many studies, have demonstrated that the type of radiation and distance from source has an impact on the pattern of energy deposition (Alloni, et al. 2014). High linear energy transfer (LET) radiation has been associated with higher-energy deposits (Liamsuwan et al., 2014) that are more densely-packed and cause more complex effects within the particle track (Hada and Georgakilas, 2008; Okayasu, 2012ab; Lorat et al., 2015; Nikitaki et al., 2016) in comparison to low LET radiation. Parameters such as mean lineal energy, dose mean lineal energy, frequency mean specific energy and dose mean specific energy can impact track structure of the traversed energy into a medium (Friedland et al., 2017). The detection of energy deposition by ionizing radiation can be demonstrated with the use of fluorescent nuclear track detectors (FNTDs). FNTDs used in conjunction with fluorescent microscopy, are able to visualize radiation tracks produced by ionizing radiation (Niklas et al., 2013; Kodaira et al., 2015; Sawakuchi and Akselrod, 2016). In addition, these FNTD chips can quantify the LET of primary and secondary radiation tracks up to 0.47 keV/um (Sawakuchi and Akselrod, 2016). This co-visualization of the radiation tracks and the cell markers enable the mapping of the radiation trajectory to specific cellular compartments, and the identification of accrued damage (Niklas et al., 2013; Kodaira et al., 2015). There are no known chemical initiators or prototypes that can mimic the MIE."@en ;
  foaf:page <https://identifiers.org/aop/432> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/435> a sbd:Model ;
  rdfs:label "Deposition of ionising energy leads to population decline via pollen abnormal"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "It is well documented that ionizing radiation( (eg.&nbsp;X-rays, gamma, photons, alpha, beta, neutrons, heavy ions)&nbsp;leads to energy deposition on the atoms and molecules of the substrate. Many studies, have demonstrated that the type of radiation and distance from source has an impact on the pattern of energy deposition (Alloni, et al. 2014). High linear energy transfer (LET) radiation has been associated with higher-energy deposits (Liamsuwan et al., 2014) that are more densely-packed and cause more complex effects within the particle track (Hada and Georgakilas, 2008; Okayasu, 2012ab; Lorat et al., 2015; Nikitaki et al., 2016) in comparison to low LET radiation. Parameters such as mean lineal energy, dose mean lineal energy, frequency mean specific energy and dose mean specific energy can impact track structure of the traversed energy into a medium (Friedland et al., 2017). The detection of energy deposition by ionizing radiation can be demonstrated with the use of fluorescent nuclear track detectors (FNTDs). FNTDs used in conjunction with fluorescent microscopy, are able to visualize radiation tracks produced by ionizing radiation (Niklas et al., 2013; Kodaira et al., 2015; Sawakuchi and Akselrod, 2016). In addition, these FNTD chips can quantify the LET of primary and secondary radiation tracks up to 0.47 keV/um (Sawakuchi and Akselrod, 2016). This co-visualization of the radiation tracks and the cell markers enable the mapping of the radiation trajectory to specific cellular compartments, and the identification of accrued damage (Niklas et al., 2013; Kodaira et al., 2015). There are no known chemical initiators or prototypes that can mimic the MIE."@en ;
  foaf:page <https://identifiers.org/aop/435> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/435> a sbd:Model ;
  rdfs:label "Deposition of ionising energy leads to population decline via pollen abnormal"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "It is well documented that ionizing radiation( (eg.&nbsp;X-rays, gamma, photons, alpha, beta, neutrons, heavy ions)&nbsp;leads to energy deposition on the atoms and molecules of the substrate. Many studies, have demonstrated that the type of radiation and distance from source has an impact on the pattern of energy deposition (Alloni, et al. 2014). High linear energy transfer (LET) radiation has been associated with higher-energy deposits (Liamsuwan et al., 2014) that are more densely-packed and cause more complex effects within the particle track (Hada and Georgakilas, 2008; Okayasu, 2012ab; Lorat et al., 2015; Nikitaki et al., 2016) in comparison to low LET radiation. Parameters such as mean lineal energy, dose mean lineal energy, frequency mean specific energy and dose mean specific energy can impact track structure of the traversed energy into a medium (Friedland et al., 2017). The detection of energy deposition by ionizing radiation can be demonstrated with the use of fluorescent nuclear track detectors (FNTDs). FNTDs used in conjunction with fluorescent microscopy, are able to visualize radiation tracks produced by ionizing radiation (Niklas et al., 2013; Kodaira et al., 2015; Sawakuchi and Akselrod, 2016). In addition, these FNTD chips can quantify the LET of primary and secondary radiation tracks up to 0.47 keV/um (Sawakuchi and Akselrod, 2016). This co-visualization of the radiation tracks and the cell markers enable the mapping of the radiation trajectory to specific cellular compartments, and the identification of accrued damage (Niklas et al., 2013; Kodaira et al., 2015). There are no known chemical initiators or prototypes that can mimic the MIE."@en ;
  foaf:page <https://identifiers.org/aop/435> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/436> a sbd:Model ;
  rdfs:label "Inhibition of RALDH2 causes reduced all-trans retinoic acid levels, leading to transposition of the great arteries"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Vertebrate embryo-fetal cardiovascular development involves multiple steps. The importance of all-trans retinoic acid (ATRA) in this process is well documented and has been the subject of multiple review papers (Brade et al., 2018; Duong &amp; Waxman, 2021; Nakajima, 2019; Perl &amp; Waxman, 2019; Stefanovic &amp; Zaffran, 2017; S. Wang &amp; Moise, 2019).   Cardiac progenitors  During early gastrulation at E6.5 in mice, the first cardiac progenitors are formed around the primitive streak and migrate anterior laterally to form the cardiac crescent to become the first heart field (FHF) at E7-7.5 (Stefanovic &amp; Zaffran, 2017). An evolutionary approach to cardiac development related to the vertebrate heart was reviewed by P&eacute;rez-Pomares et al. in 2009 (P&eacute;rez-Pomares et al., 2009).  To make the cardiac crescent and primary heart tube, weak or no ATRA signaling is sufficient (Nakajima, 2019). At this stage of cardiogenesis, ATRA controls the cardiac progenitor pool size (Keegan et al., 2005; S. Wang &amp; Moise, 2019). This early requirement of ATRA is conserved across species and restricts ventricular and atrial specification within the cardiac progenitor pool (Duong &amp; Waxman, 2021). Before the primitive heart tube is formed, ATRA signaling is symmetrical (Nakajima, 2019).  Tube formation and anterior/posterior heart segments before looping  The heart tube is derived from the FHF at E8 in mice or after three weeks in human development (Brade et al., 2018). As the cardiac crescent folds, it will form the primitive heart tube and consequently fusion and systemic circulation can emerge (S. Wang &amp; Moise, 2019). The FHF mainly will give rise to the left ventricle. The linear heart tube expands by cell proliferation and recruitment of additional cells that contribute to the arterial and venous poles of the heart tube and are derived from the second heart field (SHF) (Brade et al., 2018). The SHF mainly contributes to the outflow tract (OFT), the right ventricle, and part of the atria (Brade et al., 2018).   The posterior mesoderm and cardiac precursors produce ATRA, which at this stage is patterned in a caudo-rostral gradient determining the inflow-outflow poles of the heart tube (S. Wang &amp; Moise, 2019).   Specification Second Heart Field  The SHF is specified by ISL1 (Islet-1, transcription factor and SHF specifier) positive cells and contributes to the sub-pulmonary myocardium (S. Wang &amp; Moise, 2019).   Higher levels of ATRA promote posterior precursors of the FHF and SHF committing to the inflow tract (Hochgreb et al., 2003; Niederreither et al., 2001; Ryckebusch et al., 2008a; Sirbu et al., 2008; S. Wang &amp; Moise, 2019). Subsequently, ATRA restricts SHF boundaries and stimulates a SHF sublineage giving rise to the outflow tract (OFT) (P. Li et al., 2010; Ma et al., 2016; Nakajima, 2019; S. Wang &amp; Moise, 2019).   Heart tube looping / outflow tract development  As the heart tube grows, looping will occur at E9 in mice (S. Wang &amp; Moise, 2019). During this process the straight heart tube will be remodeled by forming a coiling loop to eventually form a multichambered heart.  ATRA receptors (RARs) have been shown to be essential for cardiac looping, left-right patterning, and inflow tract development (Perl &amp; Waxman, 2019). For proper OFT development in mice, Hox genes are necessary which are responsive to ATRA (Perl &amp; Waxman, 2019).   Chamber formation   Chamber septation emerges at E10 in mice (S. Wang &amp; Moise, 2019). Interaction of cardiomyocytes with epicardial, endocardial and cardiac neural crest cells (Brade et al., 2018).   ATRA is needed for the posterior heart segment to become the primitive atrium and sinus venosus (Nakajima, 2019). At later stages, ATRA stimulates growth and maturation of the ventriculi (Nakajima, 2019).  Proepicardium / Coronary vessel development  The proepicardial cells are formed between E9.5 and E11.5 in mice, migrate from a location near the sinus venosus to cover the primitive heart tube, and will form the epicardium which is the outer layer of the heart (Brade et al., 2018; S. Wang &amp; Moise, 2019).  Mesenchymal subepicardial cells and epicardial derived cells will merge and differentiate to the coronary plexus around E11.5 in mice and subsequently coronary vessels form around the ventricle until E13.5 (Brade et al., 2018).  Several lines of evidence indicate that precision in ATRA levels and timing is important in coronary vasculature development and are reviewed by Wang and Moise (S. Wang &amp; Moise, 2019). Coronary vasculature defects resulting from perturbed ATRA homeostasis usually concurs with myocardial expansion, vasculature development and fetal erythropoiesis (S. Wang &amp; Moise, 2019).  myocardial expansion (ventricular wall expansion)  The FHF contributes primarily to the myocardium (S. Wang &amp; Moise, 2019). ATRA signaling in epicardial(-derived) cells stimulates a signal promoting myocardium growth (Brade et al., 2011; S. Wang &amp; Moise, 2019). The embryonic liver is thought to contribute to myocardial expansion through erythropoietin (EPO) secretion, which is a direct target of ATRA in the liver, and in turn induces insulin growth factor 2 (IGF2) release from the epicardium (Brade et al., 2011; S. Wang &amp; Moise, 2019). Inactivation of EPO or its receptor resulted in ventricular hypoplasia (S. Wang &amp; Moise, 2019; Wu et al., 1999).   Cardiac neural crest orientation and positioning   Cardiac neural crest cells (cNCCs) mainly provide patterning signals that contribute to the aortic arteries, OFT/aortopulmonary development and septation, and formation of a functional myocardium (Brade et al., 2018; Stefanovic &amp; Zaffran, 2017; S. Wang &amp; Moise, 2019). Additionally, cNCCs contribute to the heart valves and parasympathetic innervation (Brade et al., 2018; Stefanovic &amp; Zaffran, 2017; S. Wang &amp; Moise, 2019). Furthermore, preotic cNCC derived precursors contribute to vascular smooth muscle cell formation and eventually to proximal coronary arteries (Stefanovic &amp; Zaffran, 2017). ATRA influences the cNCC migration and differentiation, which contribute to the aorticopulmonary septum / OFT (el Robrini et al., 2016; Ma et al., 2016; S. Wang &amp; Moise, 2019)."@en ;
  foaf:page <https://identifiers.org/aop/436> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/439> a sbd:Model ;
  rdfs:label "Activation of the AhR leading to breast cancer "@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The AHR can be activated by several structurally diverse chemicals, but binds preferentially to planar halogenated aromatic hydrocarbons and polycyclic aromatic hydrocarbons. Dioxin-like compounds (DLCs), which include polychlorinated dibenzo-p-dioxins (PCDDs), polychlorinated dibenzofurans (PCDFs) and certain polychlorinated biphenyls (PCBs), are among the most potent AHR ligands[38]. Only a subset of PCDD, PCDF and PCB congeners has been shown to bind to the AHR and cause toxic effects to those elicited by TCDD. Until recently, TCDD was considered to be the most potent DLC in birds[39]; however, recent reports indicate that 2,3,4,7,8-pentachlorodibenzofuran (PeCDF) is more potent than TCDD in some species of birds.[40][13][41][21][42][43] When screened for their ability to induce aryl hydrocarbon hydroxylase (AHH) activity, dioxins with chlorine atoms at a minimum of three out of the four lateral ring positions, and with at least one non-chlorinated ring position are the most active[44]. Of the dioxin-like PCBs, non-ortho congeners are the most toxicologically active, while mono-ortho PCBs are generally less potent[45][9]. Chlorine substitution at ortho positions increases the energetic costs of assuming the coplanar conformation required for binding to the AHR [45]. Thus, a smaller proportion of mono-ortho PCB molecules are able to bind to the AHR and elicit toxic effects, resulting in reduced potency of these congeners. Other PCB congeners, such as di-ortho substituted PCBs, are very weak AHR agonists and do not likely contribute to dioxin-like effects [9].   	Contrary to studies of birds and mammals, even the most potent mono-ortho PCBs bind to AhRs of fishes with very low affinity, if at all (Abnet et al 1999; Doering et al 2014; 2015; Eisner et al 2016; Van den Berg et al 1998).   The role of the AHR in mediating the toxic effects of planar hydrophobic contaminants has been well studied, however the endogenous role of the AHR is less clear [1]. Some endogenous and natural substances, including prostaglandin PGG2 and the tryptophan derivatives indole-3-carbinol, 6-formylindolo[3,2-b]carbazole (FICZ) and kynurenic acid can bind to and activate the AHR. [6][46][47][48][49] The AHR is thought to have important endogenous roles in reproduction, liver and heart development, cardiovascular function, immune function and cell cycle regulation [50][38][51][52][53][54][46][55][56][57] and activation of the AHR by DLCs may therefore adversely affect these processes."@en ;
  foaf:page <https://identifiers.org/aop/439> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/439> a sbd:Model ;
  rdfs:label "Activation of the AhR leading to breast cancer "@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Because of the long latency of mammary tumors, the two-year rodent carcinogenicity bioassay is the primary assay for this adverse outcome. The assay is included in the OECD Test No. 451 and 453 for carcinogenicity and combined toxicity and carcinogenicity (OECD 2009; OECD 2009), and is also used by the US National Toxicology program (Chhabra, Huff et al. 1990), and the FDA (FDA (Food and Drug Administration) 2007), and referenced by the EPA (EPA (Environmental Protection Agency) 2005) in guidelines for risk assessments. Other assays from short term (2-4 weeks) and subchronic (90 day) to chronic (1 year) toxicity also call for the documentation of mammary tumors (FDA (Food and Drug Administration) 2007; OECD (Organisation for Economic Cooperation and Development) 2018), so these assays could capture the early onset of tumors, and could be modified to report earlier key events like proliferation and inflammation.  Several characteristics of classic cancer bioassays limit the sensitivity of these assays to mammary gland carcinogens. First, no assays require prenatal or early post-natal exposures for carcinogenicity testing. The US NIH&rsquo;s National Toxicology Program assays start exposures at five to six weeks of age and OECD regulatory assay exposures suggest (but do not require) exposures beginning after weaning and before eight weeks of age. Assays initiating exposures at later ages have diminished sensitivity to agents that affect breast development and increase future susceptibility to cancer, such as estrogenic hormones, DDT and dioxins (EPA (Environmental Protection Agency) 2005; Rudel, Fenton et al. 2011). Agents with similar activity to ionizing radiation and DNA damaging chemicals may not be fully captured in some of these assays, since sensitivity appears to peak around or before week seven for these agents (around puberty) (Imaoka, Nishimura et al. 2013). Second, carcinogenicity assay guidelines do not require the best methods for detecting tumors in mammary gland: whole mount preparations of mammary gland coupled with longitudinal sections (dorsoventral sections parallel to the body) of mammary gland for histology (Tucker, Foley et al. 2017). Palpation and transverse sections of mammary gland can easily miss tumors or lesions of interest. Interestingly the NTP reproductive toxicity guidelines do specify these preferable methods for mammary gland analysis.  Two additional factors affect the sensitivity of standard carcinogenicity assays. First, benign tumors are not always considered to be an indicator of carcinogenicity, leading to a possible underestimation of risk. &nbsp;NTP and EPA guidance suggest that benign tumors provide additional weight of evidence if malignant tumors are also present or if studies suggest benign tumors can progress to carcinogenicity. In a short-term study, benign tumors may indicate a need for a longer-term study. However, benign mammary tumors (fibroadenomas) almost always coincide with carcinogenic tumors in mammary gland or other organs, and carcinomas sometimes grow from fibroadnomas (Rudel, Attfield et al. 2007; Russo 2015) suggesting that benign tumors may be an underutilized indicator of carcinogenicity.  Finally, the dose selection guidance in carcinogenicity testing typically calls for a high dose that is sufficiently toxic to suppress body weight (OECD 2009). However, body weight interacts with risk of breast cancer (Haseman, Young et al. 1997; Rudel, Attfield et al. 2007), reducing the sensitivity of the upper end of the dose range and the likelihood of a positive dose-response."@en ;
  foaf:page <https://identifiers.org/aop/439> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/439> a sbd:Model ;
  rdfs:label "Activation of the AhR leading to breast cancer "@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Breast cancer is a frequent disease, responsible of 2&nbsp;262 419 new cases and 684 996 deaths in 2020 in the world, making it the deadliest female cancer (Bray et al., 2018). In 70% of cases, the disease is localized, and the prognosis is favorable with a 5-year survival of 99%. However, once the disease spreads (lymph nodes, metastasis), survival is severely altered with a 5-year survival rate of 26% in case of metastasis (Henley et al., 2020). It is therefore of paramount importance to understand the mechanisms of metastasis in breast cancer.  Amongst risk factors clearly established, including obesity, genetic mutations and hormonal exposure, the importance of the role of the environment is currently emerging (Koual et al., 2020 Nov 17). In an epidemiologic study, we found a positive association between the concentrations of 2.3.7.8-TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxine) in the&nbsp;adipose tissue&nbsp;surrounding the tumors, and breast cancer metastasis in overweight and obese patients (Koual et al., 2019). Moreover, we have shown that, using both&nbsp;in vivo&nbsp;and&nbsp;in vitro&nbsp;models,&nbsp;TCDD&nbsp;exposure could promote an aggressive phenotype to breast cancer cells, thus favoring the formation of metastatic cells (Koual et al., 2021). TCDD is a potent ligand of the aryl hydrocarbon receptor (AhR), a transcriptional factor involved notably in the metabolism of&nbsp;xenobiotics&nbsp;(Larigot et al., 2022). Hence, the impact of the environment on breast cancer aggressiveness could be mediated by the activation of the AhR.  Interest is growing on the role of the AhR in breast cancer. First, the AhR is often overexpressed in different breast cancer cell lines (Zudaire et al., 2008,&nbsp;Kim et al., 2000 Nov 16,&nbsp;Li et al., 2014). Interestingly, the level of expression can be correlated to the stage or the molecular sub-type of the disease (Zudaire et al., 2008,&nbsp;Zhao et al., 2013). Second, the AhR pathway has been associated with different pro-metastatic features in breast cancer, such as resistance to apoptosis,&nbsp;invasiveness, modified cell cycle, migration and proliferation (Zudaire et al., 2008,&nbsp;Goode et al., 2013 Dec 15,&nbsp;Kanno et al., 2006). Triple negative cell lines, breast cancer cell lines with the worse prognosis (not over-expressing Her2 receptor or hormonal receptors), over-expressing the AhR seem to develop stem-like characteristics, favoring epithelial-mesenchymal transition (EMT) and thus metastasis (Stanford et al., 2016). Thirdly, the AhR could be involved in the resistance of breast cancer to treatments (Goode et al., 2013 Dec 15,&nbsp;Goode et al., 2014): after AhR knockout, Goode&nbsp;et al.&nbsp;found enhanced sensitivity of paclitaxel (a drug targeting cancer cells) in triple negative breast cancer, a cancer particularly difficult to treat (Goode et al., 2014). Breast cancer patients expressing estrogen receptors (ER-positive) in their cancer cells, can benefit from an efficient endocrine therapy, which greatly improves their survival. Activation of the AhR can lead to the loss of expression of the ER alpha and therefore to the loss of a potential therapeutic target (Safe et al., 2000 Jul).  The mechanisms linking the activation of the AhR to breast cancer aggressiveness are still unclear. Based on the AOP-wiki database (https://aopwiki.org/, last accessed March 2022), the central repository for AOPs, the AhR has already been proposed in several AOPs, but never in one characterized by the AO breast cancer metastasis. Likewise, an AOP linking an MIE to breast cancer aggressiveness has never been proposed. From our expertise and available knowledge, we hypothesize that the activation of the AhR could be a MIE leading to breast cancer related death (AO) through different KEs and KERs."@en ;
  foaf:page <https://identifiers.org/aop/439> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/440> a sbd:Model ;
  rdfs:label "Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Clomiphene citrate (a stressor) at 10-10 - 10-12 M concentrations exhibits approximately 30% of the estrogenic activity which is same from 17&beta;-estradiol (at 10-10 M) in ER&alpha;-expressing cells where as no activity in ER&beta; cells.   Clomiphene citrate at the concentration of &nbsp;10-10 M reveals weak estrogen agonist activity in the presence of 17 &beta; -estradiol (E2) at the concentration of 10-14 M in ER&alpha;-expressing cells, and no activity was found in ER&beta; cells.   Clomiphene citrate at lower doses (10-10 - 10-12 M), but not higher doses (10-6 - 10-8 M) showed estrogenic activity via ER&alpha;. However, clomiphene citrate at concentrations between 10-6 M and 10-12 M did not reveal any estrogenic activity via ER&beta;. In the presence of E2, clomiphene citrate worked as either as an agonist or an antagonist through ER&alpha; depending on the concentrations of E2. &nbsp;Clomiphene citrate worked as antagonistic when it is combined with the higher E2 concentrations and worked as agonistic with the lower E2 concentrations. On the other hand, via ER &beta;, clomiphene citrate acted as an estrogen antagonist irrespective of the concentration of E2. (Kurosawa et al., 2010).  &nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/440> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/440> a sbd:Model ;
  rdfs:label "Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Development and progression of certain types of cancer disease (e.g. ovarian cancer, breast cancer, prostate cancer etc.) is related with the hormonal levels in human. Lack of proper diagnosis at early stage of the disease increase the mortality rate of the cancer. Among many types of cancer ovarian cancer has the high mortality rate (~50%) due to the lack of proper diagnosis at early stage of the disease progression. Circulating levels of the steroidal sex hormones in conjunction with the gene expression is related with the progression of this disease. Some important sex hormones which are related with many cancer diseases include oestrogen, progesterone and testosterone. Oestrogen hormone mainly involved in female sex organ development, controlling of menstruation cycle etc. Progesterone also involved in controlling menstrual cycle, maintaining pregnancy and spermatogenesis. Testosterone hormone regulates sexual development, bone mass development, red blood cell production in male."@en ;
  foaf:page <https://identifiers.org/aop/440> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/440> a sbd:Model ;
  rdfs:label "Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Informations related with ovarian cancer will be helpful for the regulatory authorities to develop monographs, frame the rules of assesments and monitoring of the process."@en ;
  foaf:page <https://identifiers.org/aop/440> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/440> a sbd:Model ;
  rdfs:label "Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Clomiphene citrate (a stressor) at 10-10 - 10-12 M concentrations exhibits approximately 30% of the estrogenic activity which is same from 17&beta;-estradiol (at 10-10 M) in ER&alpha;-expressing cells where as no activity in ER&beta; cells.   Clomiphene citrate at the concentration of &nbsp;10-10 M reveals weak estrogen agonist activity in the presence of 17 &beta; -estradiol (E2) at the concentration of 10-14 M in ER&alpha;-expressing cells, and no activity was found in ER&beta; cells.   Clomiphene citrate at lower doses (10-10 - 10-12 M), but not higher doses (10-6 - 10-8 M) showed estrogenic activity via ER&alpha;. However, clomiphene citrate at concentrations between 10-6 M and 10-12 M did not reveal any estrogenic activity via ER&beta;. In the presence of E2, clomiphene citrate worked as either as an agonist or an antagonist through ER&alpha; depending on the concentrations of E2. &nbsp;Clomiphene citrate worked as antagonistic when it is combined with the higher E2 concentrations and worked as agonistic with the lower E2 concentrations. On the other hand, via ER &beta;, clomiphene citrate acted as an estrogen antagonist irrespective of the concentration of E2. (Kurosawa et al., 2010).  &nbsp;"@en ;
  foaf:page <https://identifiers.org/aop/440> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/440> a sbd:Model ;
  rdfs:label "Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Development and progression of certain types of cancer disease (e.g. ovarian cancer, breast cancer, prostate cancer etc.) is related with the hormonal levels in human. Lack of proper diagnosis at early stage of the disease increase the mortality rate of the cancer. Among many types of cancer ovarian cancer has the high mortality rate (~50%) due to the lack of proper diagnosis at early stage of the disease progression. Circulating levels of the steroidal sex hormones in conjunction with the gene expression is related with the progression of this disease. Some important sex hormones which are related with many cancer diseases include oestrogen, progesterone and testosterone. Oestrogen hormone mainly involved in female sex organ development, controlling of menstruation cycle etc. Progesterone also involved in controlling menstrual cycle, maintaining pregnancy and spermatogenesis. Testosterone hormone regulates sexual development, bone mass development, red blood cell production in male."@en ;
  foaf:page <https://identifiers.org/aop/440> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/440> a sbd:Model ;
  rdfs:label "Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Informations related with ovarian cancer will be helpful for the regulatory authorities to develop monographs, frame the rules of assesments and monitoring of the process."@en ;
  foaf:page <https://identifiers.org/aop/440> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/441> a sbd:Model ;
  rdfs:label "Ionizing radiation-induced DNA damage leads to microcephaly via apoptosis and premature cell differentiation"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "It is well documented that ionizing radiation( (eg.&nbsp;X-rays, gamma, photons, alpha, beta, neutrons, heavy ions)&nbsp;leads to energy deposition on the atoms and molecules of the substrate. Many studies, have demonstrated that the type of radiation and distance from source has an impact on the pattern of energy deposition (Alloni, et al. 2014). High linear energy transfer (LET) radiation has been associated with higher-energy deposits (Liamsuwan et al., 2014) that are more densely-packed and cause more complex effects within the particle track (Hada and Georgakilas, 2008; Okayasu, 2012ab; Lorat et al., 2015; Nikitaki et al., 2016) in comparison to low LET radiation. Parameters such as mean lineal energy, dose mean lineal energy, frequency mean specific energy and dose mean specific energy can impact track structure of the traversed energy into a medium (Friedland et al., 2017). The detection of energy deposition by ionizing radiation can be demonstrated with the use of fluorescent nuclear track detectors (FNTDs). FNTDs used in conjunction with fluorescent microscopy, are able to visualize radiation tracks produced by ionizing radiation (Niklas et al., 2013; Kodaira et al., 2015; Sawakuchi and Akselrod, 2016). In addition, these FNTD chips can quantify the LET of primary and secondary radiation tracks up to 0.47 keV/um (Sawakuchi and Akselrod, 2016). This co-visualization of the radiation tracks and the cell markers enable the mapping of the radiation trajectory to specific cellular compartments, and the identification of accrued damage (Niklas et al., 2013; Kodaira et al., 2015). There are no known chemical initiators or prototypes that can mimic the MIE."@en ;
  foaf:page <https://identifiers.org/aop/441> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/442> a sbd:Model ;
  rdfs:label "Inhibition of voltage gate sodium channels leading to impairment in learning and memory during development"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Due to their importance in neurons, sodium channels are known molecular targets of neurotoxins and neurotoxicants (Wakeling et al., 2012). There is strong evidence implicating the voltage-sensitive sodium channel as the principal site of insecticidal action of pyrethroids, which has led to extensive studies of the action of pyrethroids on mammalian sodium channels. Binding studies using radioactive pyrethroid demonstrated specific binding of the pyrethroid to rat brain VGSC &alpha; subunits (Trainer et al., 1997)."@en ;
  foaf:page <https://identifiers.org/aop/442> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/442> a sbd:Model ;
  rdfs:label "Inhibition of voltage gate sodium channels leading to impairment in learning and memory during development"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "A prime example of impairments in learning and memory as the adverse outcome for regulatory action is developmental lead exposure and IQ function in children (Bellinger, 2012). Most methods are well established in the published literature and many have been engaged to evaluate the effects of developmental thyroid disruption. The US EPA and OECD Developmental Neurotoxicity (DNT) Guidelines (OCSPP 870.6300 or OECD TG 426) as well as OECD TG 443 (OECD, 2018) both require testing of learning and memory (USEPA, 1998; OECD, 2007) advising to use the following tests passive avoidance, delayed-matching-to-position for the adult rat and for the infant rat, olfactory conditioning, Morris water maze, Biel or Cincinnati maze, radial arm maze, T-maze, and acquisition and retention of schedule-controlled behaviour.&nbsp; These DNT Guidelines have been deemed valid to identify developmental neurotoxicity and adverse neurodevelopmental outcomes (Makris et al., 2009).  Also, in the frame of the OECD GD 43 (2008) on reproductive toxicity, learning and memory testing may have potential to be applied in the context of developmental neurotoxicity studies. However, many of the learning and memory tasks used in guideline studies may not readily detect subtle impairments in cognitive function associated with modest degrees of developmental thyroid disruption (Gilbert et al., 2012)."@en ;
  foaf:page <https://identifiers.org/aop/442> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/443> a sbd:Model ;
  rdfs:label "Alcohol Induced DNA damage and mutations leading to Metastatic Breast Cancer"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Alcoholic beverages are classified by the International Agency for Research on Cancer(IARC) as Group 1 carcinogens. Studies have reported alcohol consumption to be a&nbsp; risk factor for breast cancer in women(Room R&nbsp;et al,&nbsp;2005). A woman drinking an average of two units of alcohol per day has an 8% higher risk of developing breast cancer than a woman who drinks an average of one unit of alcohol per day[2]. Alcohol is metabolized by alcohol dehydrogenase to acetaldehyde which is a mutagen. Various theories have been proposed which explain the mutagenicity of alcohol. Among them, the most relevant one for carcinoma of the breast has been proposed by Purohita et al, suggesting an alcohol-induced inactivation of the tumor suppressor gene BRCA1 and increased estrogen&nbsp;Responsiveness in breast tissues(Purohit V&nbsp;et al, 2005). Boffetta and Hashibe list plausible mechanisms of breast cancer as a result of the genotoxic effect of acetaldehyde-induced increased estrogen concentration(Boffetta P&nbsp;et al 2006).&nbsp;It has also been found that alcohol stimulates the epithelial-mesenchymal transition (EMT), because of which there is distant metastasis (Forsyth C. B.&nbsp;et al 2010). However, this mechanism needs to be elucidated in detail.  MicroRNAs (miRNAs) are non-coding, single-stranded RNA molecules that regulate target gene expression via post-transcriptional modifications [Mohr A. M&amp; Mott J. L 2015 and Lai&nbsp;E. C. 2002). Several studies indicated the promising role of miRNA in the diagnosis and outcome prediction in several cancers (Mirzaei H&nbsp;et al 2018 and Liu, S. Y&nbsp;et al 2017). miRNA-21 is upregulated and promotes metastasis in several cancers (Kunita, A&nbsp;et al 2018 and&nbsp;Liu Z&nbsp;et al 2015). A Chinese study by Kunita et al proved that plasma levels of miRNA&nbsp;were up-regulated in large B-cell lymphoma patients (Kunita, A&nbsp;et al 2018). A study&nbsp;by Wang et al also proved that plasma levels of miR&nbsp;were upregulated in large B-cell lymphoma patients in China (Chen et al 2014). Although miR-21 was indicated to play a crucial role in the metastasis of lung cancer, ovarian cancer, and head and neck cancer through several signaling pathways, the molecular mechanism of how miR-21 regulates the EMT process in breast cancer is not clear (Liu S. Y&nbsp;et al, Lopez-Santillan&nbsp;et al 2018, Panagal M.&nbsp;et al 2018, Zhou, B.et al 2018, Brabletz T&nbsp;et al and Ye, X.&nbsp;et al 2017).There are a number of miRNAs which regulate SIRT 1 expression.&nbsp;The epithelial-mesenchymal transition (EMT) is a process that which epithelial cells lose their cell polarity and cell adhesion ability, which will lead to cancer metastasis (Vaziri H&nbsp;et al 2001 and Luo, J&nbsp;et al 2001). Epithelial cells exhibit the property of regular cell-cell contacts, adhesion to the surrounding cellular fabric, preventing the detachment of individual cells. Whereas mesenchymal cells do not form intercellular contacts.&nbsp;   Sirtuins are nicotinamide adenine dinucleotide (NAD+)&ndash;dependent deacetylases that function as intracellular regulators of transcriptional activity (Blander G &amp; Guarente L 2004&nbsp;and Roth M &amp; Chen W 2014). It plays important roles in cell survival, signal transduction, and cell apoptosis by deacetylating key cell signaling molecules and apoptotic related proteins, such as NF-kB, p53, Ku70, and HIFs (Zhao, W&nbsp;et al 2008 and Chen W &amp; Bhatia R&nbsp;2013). Various studies have inconclusive reports&nbsp;on the role of SIRT1 in cancer, because of its opposite effects as both a tumor activator or suppressor in various human cancers, including breast cancer.&nbsp; Deng et al found that the expression of SIRT1 was lower in prostate cancer, bladder cancer, ovarian cancer, and glioblastoma when compared with normal tissues (Han, L&nbsp;et al 2013).On the contrary, it was found that, in leukemia and lung cancer, SIRT1 was significantly higher(Riggio M&nbsp;et al 2012 and Lee M S&nbsp;et al 2015).   This can be explained as follows: SIRT1-mediated deacetylation suppresses the functions of several tumor suppressors including p53, p73, and HIC1, it has been suggested that SIRT1 has a promoting function in tumor development and progression [Pinton G&nbsp;et al 2016, Pillai VB&nbsp;&nbsp;et al 2014, Wan G&nbsp;et al 2017 and Hwang B&nbsp;et al 2014].&nbsp;In contrast, SIRT1 may have a suppressive activity in tumor cell growth by suppressing NF-&kappa;B,&nbsp;a transcription factor playing a central role in the regulation of the innate and adaptive immune responses and carcinogenesis, the dysregulation of which leads to the onset of tumorigenesis and tumor malignancy(Yuan J&nbsp;et al 2009, Wang R H&nbsp;et al 2008, Chen L F&nbsp;et al 2004 and Greten F R &amp; Karin M 2004).&nbsp;Here, we aim to further explore the role of the SIRT1-NF kB signaling pathway in tumorigenesis&nbsp;of the breast as well as its associated mechanisms.  The nuclear factor-&kappa;B (NF- &kappa;B)/REL family of transcription factors is comprised of a RELA/p65,c-REL, RELB, p105/NF- &kappa;B1 and p100/NF- &kappa;B2 (Van Laere S J&nbsp;et al 2007). The p105 and p100 proteins can be processed by proteolytic cleavage into p50 and p52, respectively. Activation of the NF-&kappa;B signaling pathway leads to the induction of target genes that can inhibit apoptosis, interaction with cell cycle regulation, cell invasion, contribute to tumorigenesis and metastatic invasion (Shostak K &amp; Chariot 2011). Activation NF-&kappa;B in breast cancer is loss of Estrogen Receptor (ER) expression and Human Epidermal Growth Factor Receptor 2 (HER-2) overexpressed via epidermal growth factor receptor (EGFR) and Mitogen-Activated Protein Kinase (MAPK) pathway (Ali S &amp; Coombes R C&nbsp;2002). Indeed, the binding of epidermal growth factor (EGF) to its receptor (EGFR) also ultimately activates NF-&kappa;B and most likely contributes to the enhanced activity of this transcription factor in ER-negative breast cancer cells (Kalkhoven E&nbsp;et al 1996).   Loss of ER function has been associated with constitutive NFkB activity and hyperactive MAPK, because of constitutive secretion of cytokine and growth factors, which ultimately culminates in aggressive, metastatic, hormone-resistant cancers (Merkhofer E C&nbsp;et al 2010). Activation of the progesterone receptor can lead to inhibition of NF-&kappa;B driven gene expression (Sethi G&nbsp;et al 2008)&nbsp;reducing its DNA binding and transcriptional activity. HER-2 activates NF-&kappa;B through the canonical pathway which surprisingly, involves IKK&alpha; (Ito, T&nbsp;et al 2010). Activation of NF-&kappa;B promotes the survival of tumor cells. Several gene products that negatively regulate apoptosis in tumor cells are controlled by NF-&kappa;B activation (Lee J&nbsp;et al 2010). Estrogen plays an important role in breast cancer initiation and progression. Breast cancer over time acquires different mutations and the proportion of estrogen receptor-negative cells in tumors increases. This transformation confers aggressive biological characteristics to breast cancer such as rapid growth, poor differentiation, and poor response to hormone therapy. NF-&kappa;B pathway plays important role in this pathway (Lee J&nbsp;et al 2010).   Expression of SIRT1 is controlled at multiple levels by transcriptional, post-transcriptional, and post-translational mechanisms under physiological and pathological conditions. Emerging evidence indicates that miRs are important regulators of SIRT1 expression (Lovis P&nbsp;et al 2008,&nbsp;Ortega F J&nbsp;et al 2010, Zovoilis A&nbsp;et al 2011, Yamakuchi M&nbsp;et al 2008 and Mullany L E&nbsp;et al 2017). Studies have shown that miR-34a directly binds to the 3&prime; untranslated region (UTR) of SIRT1 mRNA and reduces its expression (Ortega F J&nbsp;et al 2010).   Study findings support the hypothesis that alcohol consumption is able to influence miRNA expression.&nbsp;Considerable evidence from rodent and human studies demonstrates that disruption of the hepatic SIRT1 signaling by ethanol plays a central role in the development of AFLD (Yin H&nbsp;et al 2014, Li M&nbsp;et al 2014).Ethanol down-regulates SIRT1 in hepatic cells and in the animal livers. The ethanol-mediated disruption of SIRT1 signaling leads to excess fat accumulation and inflammatory responses in the liver of animals and humans. Treatment with resveratrol, a known SIRT1 agonist, can alleviate liver steatosis . Accumulating evidence demonstrates that ethanol-mediated SIRT1 inhibition leads to the development of AFLD largely through disruption of a signaling network mediated by various transcriptional regulators and co-regulators, including nuclear transcription factor-&kappa;B (NF-&kappa;B)(Yin H&nbsp;et al 2014, Li M&nbsp;et al 2014)."@en ;
  foaf:page <https://identifiers.org/aop/443> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/444> a sbd:Model ;
  rdfs:label "Ionizing radiation leads to reduced reproduction in Eisenia fetida via reduced spermatogenesis and cocoon hatchability"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Maintenance of sustainable fish and wildlife populations (i.e., adequate to ensure long-term delivery of valued ecosystem services) is a widely accepted regulatory goal upon which risk assessments and risk management decisions are based."@en ;
  foaf:page <https://identifiers.org/aop/444> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/444> a sbd:Model ;
  rdfs:label "Ionizing radiation leads to reduced reproduction in Eisenia fetida via reduced spermatogenesis and cocoon hatchability"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Stressors include:  Ionizing radiation  Estrogen"@en ;
  foaf:page <https://identifiers.org/aop/444> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/444> a sbd:Model ;
  rdfs:label "Ionizing radiation leads to reduced reproduction in Eisenia fetida via reduced spermatogenesis and cocoon hatchability"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The following stressors increase this key event: ionizing radiation."@en ;
  foaf:page <https://identifiers.org/aop/444> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/444> a sbd:Model ;
  rdfs:label "Ionizing radiation leads to reduced reproduction in Eisenia fetida via reduced spermatogenesis and cocoon hatchability"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "It is well documented that ionizing radiation( (eg.&nbsp;X-rays, gamma, photons, alpha, beta, neutrons, heavy ions)&nbsp;leads to energy deposition on the atoms and molecules of the substrate. Many studies, have demonstrated that the type of radiation and distance from source has an impact on the pattern of energy deposition (Alloni, et al. 2014). High linear energy transfer (LET) radiation has been associated with higher-energy deposits (Liamsuwan et al., 2014) that are more densely-packed and cause more complex effects within the particle track (Hada and Georgakilas, 2008; Okayasu, 2012ab; Lorat et al., 2015; Nikitaki et al., 2016) in comparison to low LET radiation. Parameters such as mean lineal energy, dose mean lineal energy, frequency mean specific energy and dose mean specific energy can impact track structure of the traversed energy into a medium (Friedland et al., 2017). The detection of energy deposition by ionizing radiation can be demonstrated with the use of fluorescent nuclear track detectors (FNTDs). FNTDs used in conjunction with fluorescent microscopy, are able to visualize radiation tracks produced by ionizing radiation (Niklas et al., 2013; Kodaira et al., 2015; Sawakuchi and Akselrod, 2016). In addition, these FNTD chips can quantify the LET of primary and secondary radiation tracks up to 0.47 keV/um (Sawakuchi and Akselrod, 2016). This co-visualization of the radiation tracks and the cell markers enable the mapping of the radiation trajectory to specific cellular compartments, and the identification of accrued damage (Niklas et al., 2013; Kodaira et al., 2015). There are no known chemical initiators or prototypes that can mimic the MIE."@en ;
  foaf:page <https://identifiers.org/aop/444> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/450> a sbd:Model ;
  rdfs:label " Inhibition of AChE and activation of CYP2E1 leading to sensory axonal peripheral neuropathy and mortality"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Organophosphate and carbamate insecticides are prototypical AChE inhibitors. The OP and carbamate pesticides were synthesized specifically to act as inhibitors of AChE, with OPs developed from early nerve agents (e.g., sarin) and carbamate pesticides based on the natural plant alkaloid physostigmine (Ecobichon 2001). 	A positive and significant correlation between the log of the Eserine IC50 (in vitro) for AChE inhibition and the log Km value for the AChE in the fish and crustacea species has been reported, explaining 92% of the variation in enzyme inhibition (Monserrat and Bianchini, 2001). Similar success was found in relating the rate constants for inhibition of AChE in housefly and the pseudo first-order hydrolysis rate constant for active forms of OPs (Fukuto 1990).    	The open literature includes many studies on vertebrate and invertebrate species that demonstrate a clear dependence of AChE activity on the dose or concentration of the substance with increased concentrations leading to an increase in the inhibition of AChE (e.g., fish ( Karen et al., 2001), birds (Hudson et al., 1984 (see dimethoate and disulfoton), Grue and Shipley 1984; and Al-Zubaidy et al., 2011); cladocera (Barata et al., 2004); nematodes (Rajini et al., 2008); rodents (Roberts et al., 1988; and mollusk (Bianco et al., 2011)). 	The open literature includes many studies on vertebrate and invertebrate species that demonstrate a clear relationship between increasing AChE inhibition as duration of exposure increases (e.g., amphibians ( Venturino et al., 2001); fish (Rao 2008; Ferrari et al., 2004); insects (Rose and Sparks 1984); birds (Ludke 1985; Grue and Shipley 1984); annelids (Reddy and Rao 2008); cladocera (Barata et al., 2004)). 	Rao et al. 2008 exposed the estuarine fish Oreochromis mossambicus to a 24 h LC50 concentration of chlorpyrifos and reported that it took 6 hr to reach &gt;40% AChE inhibition and 24 hr to reach 90% AChE inhibition. It took &gt;100 days to recover to normal AChE levels when fish were placed in clean water. 	A time course study of earthworms (Eisenis foetida) exposed to the 48 hr LC50 of profenofos found a significant relationship (between increases in percent inhibition of AChE and increase in time of exposure from 8-48 hrs (Chakra Reddy and Rao 2008)."@en ;
  foaf:page <https://identifiers.org/aop/450> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/450> a sbd:Model ;
  rdfs:label " Inhibition of AChE and activation of CYP2E1 leading to sensory axonal peripheral neuropathy and mortality"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Increased mortality is one of the most common regulatory assessment endpoints,&nbsp;along with reduced growth and reduced reproduction."@en ;
  foaf:page <https://identifiers.org/aop/450> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/450> a sbd:Model ;
  rdfs:label " Inhibition of AChE and activation of CYP2E1 leading to sensory axonal peripheral neuropathy and mortality"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Organophosphate and carbamate insecticides are prototypical AChE inhibitors. The OP and carbamate pesticides were synthesized specifically to act as inhibitors of AChE, with OPs developed from early nerve agents (e.g., sarin) and carbamate pesticides based on the natural plant alkaloid physostigmine (Ecobichon 2001). 	A positive and significant correlation between the log of the Eserine IC50 (in vitro) for AChE inhibition and the log Km value for the AChE in the fish and crustacea species has been reported, explaining 92% of the variation in enzyme inhibition (Monserrat and Bianchini, 2001). Similar success was found in relating the rate constants for inhibition of AChE in housefly and the pseudo first-order hydrolysis rate constant for active forms of OPs (Fukuto 1990).    	The open literature includes many studies on vertebrate and invertebrate species that demonstrate a clear dependence of AChE activity on the dose or concentration of the substance with increased concentrations leading to an increase in the inhibition of AChE (e.g., fish ( Karen et al., 2001), birds (Hudson et al., 1984 (see dimethoate and disulfoton), Grue and Shipley 1984; and Al-Zubaidy et al., 2011); cladocera (Barata et al., 2004); nematodes (Rajini et al., 2008); rodents (Roberts et al., 1988; and mollusk (Bianco et al., 2011)). 	The open literature includes many studies on vertebrate and invertebrate species that demonstrate a clear relationship between increasing AChE inhibition as duration of exposure increases (e.g., amphibians ( Venturino et al., 2001); fish (Rao 2008; Ferrari et al., 2004); insects (Rose and Sparks 1984); birds (Ludke 1985; Grue and Shipley 1984); annelids (Reddy and Rao 2008); cladocera (Barata et al., 2004)). 	Rao et al. 2008 exposed the estuarine fish Oreochromis mossambicus to a 24 h LC50 concentration of chlorpyrifos and reported that it took 6 hr to reach &gt;40% AChE inhibition and 24 hr to reach 90% AChE inhibition. It took &gt;100 days to recover to normal AChE levels when fish were placed in clean water. 	A time course study of earthworms (Eisenis foetida) exposed to the 48 hr LC50 of profenofos found a significant relationship (between increases in percent inhibition of AChE and increase in time of exposure from 8-48 hrs (Chakra Reddy and Rao 2008)."@en ;
  foaf:page <https://identifiers.org/aop/450> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/450> a sbd:Model ;
  rdfs:label " Inhibition of AChE and activation of CYP2E1 leading to sensory axonal peripheral neuropathy and mortality"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Increased mortality is one of the most common regulatory assessment endpoints,&nbsp;along with reduced growth and reduced reproduction."@en ;
  foaf:page <https://identifiers.org/aop/450> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/451> a sbd:Model ;
  rdfs:label "Interaction with lung resident cell membrane components leads to lung cancer"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "As stated earlier, there are many different ways by which pro-fibrotic stressors can interact with the components of cell membrane and often involve multiple interactions at the same time. Few studies investigate the exact interaction between the stressor and the cellular membrane components. Asbestos and silica crystals engage scavenger receptors present on the macrophages (Murthy et al., 2015). Bleomycin binds high affinity bleomycin binding sites present on rat alveolar macrophage surfaces, leading to macrophage activation (Denholm and Phan, 1990). However, the consequences of such interactions such as, the release of PRR agonists DAMPs (alarmins) from dying or injured cells, increased&nbsp; gene or protein synthesis downstream of receptor binding or in the case of NMs, their cellular uptake, are measured routinely as indicative of occurrence of such interactions (Nel et al., 2009; Cheng et al., 2013). Because of the phys-chem properties such as surface charge, NMs and asbestos like materials can bind to cellular macromolecules and cell surface/membrane components, which in turn, facilitate their uptake and intracellular sequestration by the cells (NIOSH, 2011a; Pascolo et al., 2013). Several DAMPs that can be effectively measured in biological samples and cultured cells include High Mobility Group Binding 1 (HMGB1) protein, Heat Shock proteins (HSPs), uric acid, annexins, and S100 proteins (Bianchi, 2007). Of all DAMPs, interleukin (IL)-1&alpha; is the most commonly measured alarmin. IL-1&alpha; is the principal pro-inflammatory moiety and is a designated &lsquo;alarmin&rsquo; in the cell that alerts the host to injury or damage (Di Paolo and Shayakhmetov, 2016). It is shown that administration of necrotic cells to mice results in neutrophilic inflammation that was entirely mediated by IL-1&alpha; released from the dying or necrosed cells and consequent activation of IL-1 Receptor 1 (IL-1R1) signalling (Suwara et al., 2014). IL-1&alpha; is released following exposure to MWCNTs (Nikota et al., 2017) and silica (Rabolli et al., 2014). Although IL1-b is not a designated alarmin, its secretion following exposure to stressors is routinely assessed and is linked to initiation of cell or tissue injury.  Other high aspect ratio fibres such as asbestos and CNTs induce frustrated phagocytosis and acute cell injury (Boyles et al., 2015; D&ouml;rger et al., 2001; Brown et al., 2007; Kim et al., 2010; Poland et al., 2008), leading to DAMP release (Nikota et al, 2017), inflammation and immune responses."@en ;
  foaf:page <https://identifiers.org/aop/451> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/451> a sbd:Model ;
  rdfs:label "Interaction with lung resident cell membrane components leads to lung cancer"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Lung cancer, one of the most common and deadly forms of cancer, is in some cases associated with exposure to certain types of particles. With the rise of nanotechnology, there is concern that some engineered nanoparticles may be among such particles. In the absence of epidemiological evidence, assessment of nanoparticle carcinogenicity is currently performed on a time-consuming case-by-case basis, relying mainly on animal experiments. Non-animal alternatives exist, including a few validated cell-based methods accepted for regulatory risk assessment of nanoparticles. Furthermore, new approach methodologies (NAMs), focused on carcinogenic mechanisms and capable of handling the increasing numbers of nanoparticles, have been developed. However, such alternative methods are mainly applied as weight-of-evidence linked to generally required animal data, since challenges remain regarding interpretation of the results. These challenges may be more easily overcome by the novel Adverse Outcome Pathway (AOP) framework, which provides a basis for validation and uptake of alternative mechanism-focused methods in risk assessment. Here, we propose an AOP for lung cancer induced by nanosized foreign matter, anchored to a selection of 18 standardized methods and NAMs for&nbsp;in silico- and&nbsp;in vitro-based integrated assessment of lung carcinogenicity (Figure 1). The AOP&nbsp;provides a basis for development of AOP-aligned alternative methods-based integrated testing strategies for assessment of nanoparticle-induced lung cancer.  &nbsp;    Figure 1. A putative AOP for pulmonary deposition and retention of nanosized foreign matter leading to lung cancer, including anchored&nbsp;in silico&nbsp;and&nbsp;in vitro&nbsp;methods.&nbsp;(A)&nbsp;A putative AOP developed based on information and knowledge about the process-generated and engineered nanoparticles diesel exhaust, carbon black, and TiO2. Suggested relevant existing KEs in the AOP-Wiki, that could serve for informing development of the proposed AOP, are mentioned within parentheses.&nbsp;(B)&nbsp;The AOP supports integrated application of&nbsp;in silico- and&nbsp;in vitro-based standard OECD tests with new approach methodologies (NAMs), including models/approaches for prediction of deposited dose, detection of ROS generation, inflammation, DNA damage, mutations, and cell transformation. Examples of specific assays are provided at the bottom. MIE, molecular initiating event; KE, key event; AO, adverse outcome; AOP, adverse outcome pathway; IC-PMS, inductively coupled plasma mass spectrometry; AAS, atomic absorption spectroscopy; TEM, transmission electron microscopy; ROS, reactive oxygen species; DCFH-DA, 2&#39;-7&#39;dichlorofluorescin diacetate; GSH, glutathione; ELISA, enzyme-linked immunosorbent assay; HT, high-throughput; FPG, formamidopyrimidine DNA glycosylase; OECD, Organization for Economic Co-operation and Development; HPRT, hypoxanthine phosphorybosyl transferase; TK, thymidine kinase; FE1-MML, FE1-MutaMouse lung epithelial cells."@en ;
  foaf:page <https://identifiers.org/aop/451> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/455> a sbd:Model ;
  rdfs:label "Aryl hydrocarbon receptor activation leading to early life stage mortality via impeded craniofacial development"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The AHR can be activated by several structurally diverse chemicals, but binds preferentially to planar halogenated aromatic hydrocarbons and polycyclic aromatic hydrocarbons. Dioxin-like compounds (DLCs), which include polychlorinated dibenzo-p-dioxins (PCDDs), polychlorinated dibenzofurans (PCDFs) and certain polychlorinated biphenyls (PCBs), are among the most potent AHR ligands[38]. Only a subset of PCDD, PCDF and PCB congeners has been shown to bind to the AHR and cause toxic effects to those elicited by TCDD. Until recently, TCDD was considered to be the most potent DLC in birds[39]; however, recent reports indicate that 2,3,4,7,8-pentachlorodibenzofuran (PeCDF) is more potent than TCDD in some species of birds.[40][13][41][21][42][43] When screened for their ability to induce aryl hydrocarbon hydroxylase (AHH) activity, dioxins with chlorine atoms at a minimum of three out of the four lateral ring positions, and with at least one non-chlorinated ring position are the most active[44]. Of the dioxin-like PCBs, non-ortho congeners are the most toxicologically active, while mono-ortho PCBs are generally less potent[45][9]. Chlorine substitution at ortho positions increases the energetic costs of assuming the coplanar conformation required for binding to the AHR [45]. Thus, a smaller proportion of mono-ortho PCB molecules are able to bind to the AHR and elicit toxic effects, resulting in reduced potency of these congeners. Other PCB congeners, such as di-ortho substituted PCBs, are very weak AHR agonists and do not likely contribute to dioxin-like effects [9].   	Contrary to studies of birds and mammals, even the most potent mono-ortho PCBs bind to AhRs of fishes with very low affinity, if at all (Abnet et al 1999; Doering et al 2014; 2015; Eisner et al 2016; Van den Berg et al 1998).   The role of the AHR in mediating the toxic effects of planar hydrophobic contaminants has been well studied, however the endogenous role of the AHR is less clear [1]. Some endogenous and natural substances, including prostaglandin PGG2 and the tryptophan derivatives indole-3-carbinol, 6-formylindolo[3,2-b]carbazole (FICZ) and kynurenic acid can bind to and activate the AHR. [6][46][47][48][49] The AHR is thought to have important endogenous roles in reproduction, liver and heart development, cardiovascular function, immune function and cell cycle regulation [50][38][51][52][53][54][46][55][56][57] and activation of the AHR by DLCs may therefore adversely affect these processes."@en ;
  foaf:page <https://identifiers.org/aop/455> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/455> a sbd:Model ;
  rdfs:label "Aryl hydrocarbon receptor activation leading to early life stage mortality via impeded craniofacial development"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Poor early life stage survival is an endpoint of major relevance to environmental regulators, as it is likely to lead to population decline.&nbsp; Early-life stage, acute and chronic test guidelines have been established by the Organisation for Economic Co-operation and Development (OECD), U.S. Environmental Protection Agency (EPA) and Environment and Climate Change Canada (ECCC), and are currently used in risk assessments to set limits for safe exposures.&nbsp; Aquatic test guidlines are most prevalent and include OECD210, OECD229, EPA850.1400 and ECCC&nbsp; EPS 1/RM/28 for fish and OECD241 for frogs."@en ;
  foaf:page <https://identifiers.org/aop/455> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/455> a sbd:Model ;
  rdfs:label "Aryl hydrocarbon receptor activation leading to early life stage mortality via impeded craniofacial development"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "&lt;&lt;&lt;The key events (KEs) associated with AOPs 455 and 456 are predominantly similar, with the exception of KE4 in each AOP. KE4 in AOP 455 is Event 1559: &ldquo;Facial cartilage structures are reduced in size and morphologically distorted&rdquo;, and KE4 in AOP 456 is Event 317: &ldquo;Altered, Cardiovascular development/function.&rdquo; While AOP 456 may be of higher biologically relevance, both AOPs are ecologically important and contribute significantly to the growing network of AOPs beginning with the activation of the Aryl hydrocarbon receptor (Ahr). Since both AOPs have several overlapping KEs, some redundant text is to be expected in the individual AOP-Wiki pages.&gt;&gt;&gt;  The Aryl Hydrocarbon Receptor (Ahrs) are evolutionarily conserved ligand-dependent transcription factors that can be activated by a wide range of structurally diverse compounds (Denison and Nagy 2003; Hahn et al. 2017).   Ahr activation by environmental pollutants including halogenated aromatic hydrocarbons (HAHs), polycyclic aromatic hydrocarbons (PAHs), and polychlorinated biphenyls (PCBs) can lead to a variety of adverse health effects, such as dysfunction to the immune, reproductive, and cardiovascular systems (Hansen et al. 2014; Hernandez-Ochoa et al. 2009; Stevens et al. 2009; Zhang 2011), as well as improper development and neurobehavior (Garcia et al. 2018). Ahr activation is also associated with tumor promotion and carcinogenesis (Safe et al. 2013).   2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), a bioaccumulative and highly toxic HAH, is typically used as the prototypical molecular probe to investigate Ahr-related outcomes and is thus one of the most thoroughly investigated of the known Ahr agonists. Several studies in model organisms such as zebrafish and rodents have shown that Ahr-deficient animals in gene knock-out studies have either diminished or completely nonexistent harmful effects of both TCDD and several PAHs (Fernandez-Salguero et al. 1996; Garcia et al. 2018; Goodale et al. 2015; Harrill et al. 2016), highlighting the significance of the Ahrs in mediating toxicological outcomes of the Ahr-active chemicals.   Canonical Ahr signaling involves the conversion of the inactive Ahr, which is present in the cytoplasm, to its active form that can translocate to the nucleus and dimerize with the Ahr nuclear translocator (ARNT) (Wright et al. 2017). The Ahr-ARNT heterodimer can consequently regulate transcription of downstream genes either indirectly, or directly, which is the case for the cytochrome P450s (CYPs) that are induced via the direct binding of the heterodimer to the aryl hydrocarbon response elements (Ahres) (Lo and Matthews 2012).   Upon exposure to various Ahr activating chemicals, craniofacial malformations and cardiovascular toxicity have been identified under various exposure paradigms (Antkiewicz et al. 2005; Henry et al. 1997; Li et al. 2014). Importantly, developing zebrafish exposed to TCDD have severe heart and vasculature malformations, in addition to jaw structure impairments that occur secondarily to inhibited chondrogenesis (Carney et al. 2006). One of the genes whose expression is most reduced in the jaw upon TCDD exposure in zebrafish is sox9b, sry-box containing gene 9b (Xiong et al. 2008). This gene, one of two zebrafish paralogs of the SOX9 gene, is a critical transcription factor that has been implicated in several processes including chondrogenesis and cardiac development, in addition to skeletal development, male gonad genesis, and cancer progression (Lefebvre and Dvir-Ginzberg 2017; Panda et al. 2021). Based on current knowledge, primarily from developmental zebrafish studies, it is apparent that there are strong relationships between Ahr, SOX9, and craniofacial (AOP 455) or cardiovascular (AOP 456) malformations that can be causally linked in an AOP network. Evidence from studies conducted with other taxa provide further support and aid in evaluation of the domain of applicability as well as the breadth of the stressors that can cause the different relationships described in the two AOPs."@en ;
  foaf:page <https://identifiers.org/aop/455> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/456> a sbd:Model ;
  rdfs:label "Aryl hydrocarbon receptor activation leading to early life stage mortality via cardiovascular toxicity"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "The AHR can be activated by several structurally diverse chemicals, but binds preferentially to planar halogenated aromatic hydrocarbons and polycyclic aromatic hydrocarbons. Dioxin-like compounds (DLCs), which include polychlorinated dibenzo-p-dioxins (PCDDs), polychlorinated dibenzofurans (PCDFs) and certain polychlorinated biphenyls (PCBs), are among the most potent AHR ligands[38]. Only a subset of PCDD, PCDF and PCB congeners has been shown to bind to the AHR and cause toxic effects to those elicited by TCDD. Until recently, TCDD was considered to be the most potent DLC in birds[39]; however, recent reports indicate that 2,3,4,7,8-pentachlorodibenzofuran (PeCDF) is more potent than TCDD in some species of birds.[40][13][41][21][42][43] When screened for their ability to induce aryl hydrocarbon hydroxylase (AHH) activity, dioxins with chlorine atoms at a minimum of three out of the four lateral ring positions, and with at least one non-chlorinated ring position are the most active[44]. Of the dioxin-like PCBs, non-ortho congeners are the most toxicologically active, while mono-ortho PCBs are generally less potent[45][9]. Chlorine substitution at ortho positions increases the energetic costs of assuming the coplanar conformation required for binding to the AHR [45]. Thus, a smaller proportion of mono-ortho PCB molecules are able to bind to the AHR and elicit toxic effects, resulting in reduced potency of these congeners. Other PCB congeners, such as di-ortho substituted PCBs, are very weak AHR agonists and do not likely contribute to dioxin-like effects [9].   	Contrary to studies of birds and mammals, even the most potent mono-ortho PCBs bind to AhRs of fishes with very low affinity, if at all (Abnet et al 1999; Doering et al 2014; 2015; Eisner et al 2016; Van den Berg et al 1998).   The role of the AHR in mediating the toxic effects of planar hydrophobic contaminants has been well studied, however the endogenous role of the AHR is less clear [1]. Some endogenous and natural substances, including prostaglandin PGG2 and the tryptophan derivatives indole-3-carbinol, 6-formylindolo[3,2-b]carbazole (FICZ) and kynurenic acid can bind to and activate the AHR. [6][46][47][48][49] The AHR is thought to have important endogenous roles in reproduction, liver and heart development, cardiovascular function, immune function and cell cycle regulation [50][38][51][52][53][54][46][55][56][57] and activation of the AHR by DLCs may therefore adversely affect these processes."@en ;
  foaf:page <https://identifiers.org/aop/456> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/456> a sbd:Model ;
  rdfs:label "Aryl hydrocarbon receptor activation leading to early life stage mortality via cardiovascular toxicity"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Poor early life stage survival is an endpoint of major relevance to environmental regulators, as it is likely to lead to population decline.&nbsp; Early-life stage, acute and chronic test guidelines have been established by the Organisation for Economic Co-operation and Development (OECD), U.S. Environmental Protection Agency (EPA) and Environment and Climate Change Canada (ECCC), and are currently used in risk assessments to set limits for safe exposures.&nbsp; Aquatic test guidlines are most prevalent and include OECD210, OECD229, EPA850.1400 and ECCC&nbsp; EPS 1/RM/28 for fish and OECD241 for frogs."@en ;
  foaf:page <https://identifiers.org/aop/456> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/456> a sbd:Model ;
  rdfs:label "Aryl hydrocarbon receptor activation leading to early life stage mortality via cardiovascular toxicity"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "&lt;&lt;&lt;The key events (KEs) associated with AOPs 455 and 456 are predominantly similar, with the exception of KE4 in each AOP. KE4 in AOP 455 is Event 1559: &ldquo;Facial cartilage structures are reduced in size and morphologically distorted&rdquo;, and KE4 in AOP 456 is Event 317: &ldquo;Altered, Cardiovascular development/function.&rdquo; While AOP 456 may be of higher biologically relevance, both AOPs are ecologically important and contribute significantly to the growing network of AOPs beginning with the activation of the Aryl hydrocarbon receptor (Ahr). Since both AOPs have several overlapping KEs, some redundant text is to be expected in the individual AOP-Wiki pages.&gt;&gt;&gt;  The Aryl Hydrocarbon Receptor (Ahrs) are evolutionarily conserved ligand-dependent transcription factors that can be activated by a wide range of structurally diverse compounds (Denison and Nagy 2003; Hahn et al. 2017).   Ahr activation by environmental pollutants including halogenated aromatic hydrocarbons (HAHs), polycyclic aromatic hydrocarbons (PAHs), and polychlorinated biphenyls (PCBs) can lead to a variety of adverse health effects, such as dysfunction to the immune, reproductive, and cardiovascular systems (Hansen et al. 2014; Hernandez-Ochoa et al. 2009; Stevens et al. 2009; Zhang 2011), as well as improper development and neurobehavior (Garcia et al. 2018). Ahr activation is also associated with tumor promotion and carcinogenesis (Safe et al. 2013).   2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), a bioaccumulative and highly toxic HAH, is typically used as the prototypical molecular probe to investigate Ahr-related outcomes and is thus one of the most thoroughly investigated of the known Ahr agonists. Several studies in model organisms such as zebrafish and rodents have shown that Ahr-deficient animals in gene knock-out studies have either diminished or completely nonexistent harmful effects of both TCDD and several PAHs (Fernandez-Salguero et al. 1996; Garcia et al. 2018; Goodale et al. 2015; Harrill et al. 2016), highlighting the significance of the Ahrs in mediating toxicological outcomes of the Ahr-active chemicals.   Canonical Ahr signaling involves the conversion of the inactive Ahr, which is present in the cytoplasm, to its active form that can translocate to the nucleus and dimerize with the Ahr nuclear translocator (ARNT) (Wright et al. 2017). The Ahr-ARNT heterodimer can consequently regulate transcription of downstream genes either indirectly, or directly, which is the case for the cytochrome P450s (CYPs) that are induced via the direct binding of the heterodimer to the aryl hydrocarbon response elements (Ahres) (Lo and Matthews 2012).   Upon exposure to various Ahr activating chemicals, craniofacial malformations and cardiovascular toxicity have been identified under various exposure paradigms (Antkiewicz et al. 2005; Henry et al. 1997; Li et al. 2014). Importantly, developing zebrafish exposed to TCDD have severe heart and vasculature malformations, in addition to jaw structure impairments that occur secondarily to inhibited chondrogenesis (Carney et al. 2006). One of the genes whose expression is most reduced in the jaw upon TCDD exposure in zebrafish is sox9b, sry-box containing gene 9b (Xiong et al. 2008). This gene, one of two zebrafish paralogs of the SOX9 gene, is a critical transcription factor that has been implicated in several processes including chondrogenesis and cardiac development, in addition to skeletal development, male gonad genesis, and cancer progression (Lefebvre and Dvir-Ginzberg 2017; Panda et al. 2021). Based on current knowledge, primarily from developmental zebrafish studies, it is apparent that there are strong relationships between Ahr, SOX9, and craniofacial (AOP 455) or cardiovascular (AOP 456) malformations that can be causally linked in an AOP network. Evidence from studies conducted with other taxa provide further support and aid in evaluation of the domain of applicability as well as the breadth of the stressors that can cause the different relationships described in the two AOPs."@en ;
  foaf:page <https://identifiers.org/aop/456> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/460> a sbd:Model ;
  rdfs:label "Antagonism of Smoothened receptor leading to orofacial clefting"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "OFC is one of the most common birth defects occurring in approximately 1 in 700 live births. The etiology of OFC is poorly understood and is believed to be a combination of genetic and environmental factors. Understanding the genetic and environmental factors that can lead to OFC is the first step in preventing this birth defect."@en ;
  foaf:page <https://identifiers.org/aop/460> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/460> a sbd:Model ;
  rdfs:label "Antagonism of Smoothened receptor leading to orofacial clefting"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Orofacial clefts (OFCs), encompassing cleft lip with or without palate (CL/P), and cleft palate only (CPO) represent the second most common birth defect in humans with a prevalence of 1-2/1,000 births (Lidral, Moreno et al. 2008). The etiology of OFCs is complex with approximately 50% of CPO and 70% of CL/P considered non-syndromic (2011). SHH signaling is required for normal facial development and plays a critical role in the growth of the facial processes that form the upper palate and lip (Bush and Jiang 2012, Kurosaka 2015). The epithelial derived SHH drives orofacial development through an induced gradient in the underlying mesenchyme&nbsp; (Lan and Jiang 2009, Kurosaka 2015). This gradient of SHH induces cellular proliferation and outgrowth of the mesenchyme (Lan and Jiang 2009). The SHH pathway is sensitive to chemical disruption and can be disrupted at multiple places along the signaling cascade during critical windows for exposure and has been shown to cause OFCs (Lipinski and Bushman 2010, Heyne, Melberg et al. 2015). The targets of this disruption include ligand modification, ligand secretion, downstream sensing, and signal transduction (Jeong and McMahon 2002, Lauth, Bergstr&ouml;m et al. 2007, Petrova, Rios-Esteves et al. 2013). Chemical modulators of the SHH pathway have been identified including the natural alkaloid cyclopamine, both natural and synthetic pharmaceuticals, and a chemical commonly found in pesticides (Lipinski, Dengler et al. 2007, Lipinski, Song et al. 2010, Wang, Lu et al. 2012, Everson, Sun et al. 2019, Rivera-Gonz&aacute;lez, Beames et al. 2021)."@en ;
  foaf:page <https://identifiers.org/aop/460> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/464> a sbd:Model ;
  rdfs:label "Calcium overload in dopaminergic neurons of the substantia nigra leading to parkinsonian motor deficits"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Neurotoxic effects shall be carefully addressed and reported in routine required regulatory toxicological studies (acute toxicity studies,short-term toxicity studies, long term toxicity and carcinogenicity studies and reproductive toxicity studies). Regarding neurotoxicity in rodents, inclusion of neurotoxicity investigations in routine toxicology studies shall also be considered. For pesticide active substances the circumstances in which neurotoxicity studies should be performed are listed in Regulation (EU) No 283/2013:  Specific neurotoxicity studies in rodents shall be performed in case of one those following conditions:   	there is indication of neurotoxicity in routine toxicity studies carried out with the active substance; 	the active substance is a structurally related to known neurotoxic compound; 	the active substance has a neurotoxic mode of pesticidal action.   As a result, specific neurotoxicity studies are not routinely required for all pesticide active substances. Specific neurotoxicity testing becomes obligatory only if neurotoxicity has been observed during histopathological evaluation or in case of structural analogy with a known neurotoxic compound. Motor activity should be measured once in short-term repeated dose toxicity studies (OECD 407, 408 and 422) and several times in specific neurotoxicity studies (OECD 424, OECD 426 and cohort 2 of OECD 443). However, this is not a requirement in chronic toxicity studies unless neurotoxic effects have been reported in the shorter studies. The same test (measures horizontal and/or vertical movements in a test chamber) is implemented in both routine studies and neurotoxicity studies. Coordination and balance are evaluated by rotation or rotarod or pole tests, and gait abnormalities by forepaw stride length test. Those tests are not required by any repeated dose toxicity OECD guidelines and they can be optionally incorporated in the design of neurotoxicity studies OECD 424 and OECD 426.  Although motor deficits is the AO in this AOP, degeneration of DA neurons, is also considered an adverse effect in the regulatory framework, even in the absence of clear clinical symptoms or motor deficits. Morphological assessment of brain structures is a standard requirement in the regulatory toxicological studies supporting the risk assessment of chemical substances and it is a regulatory expectation that the anatomical structures belonging to the nigrostriatal pathway would be included and evaluated as part of the standard evaluation of the brain. Treatment related neuronal degeneration, when occurring as a consequence of the treatment, is generally dose-dependent in incidence and severity. However, if not accompanied by clinical signs or behavioral changes indicative of central nervous system pathology, minimal loss of DA neurons would likely remain undetected in the standard histological evaluation, due to the presence of non DA neurons or as a consequence of the subjectivity of non-quantifiable analysis, unless specific markers are used. As multiple forms of perturbation can affect the neurons, some changes are potentially still reversible (e.g. loss of TH or DA) and irreversibility should be confirmed as part of the assessment. It is then important to apply a sensitive and appropriate method (Switzer 2000) and evaluation of the phenotypic markers in the striatum and in the SNpc should be always performed as a minimum standard (Minnema et al.,&nbsp;2014) when investigating perturbation of the nigrostriatal pathway. It should additionally consider that rat is likely to be a poor model to capture this kind of hazard, as demonstrated by the poor sensitivity of rat to MPTP or related compounds and this should be taken into account for the design and interpretation of the studies.  Dissimilarities of chemical induced animal models to human disease are also important and should be carefully weighted when considering the duration and schedule of the study/treatment. Differently from the human disease, with the MPTP animal model, the damage occurs rapidly, is hardly progressive, is little age-dependent and formation of Lewy bodies is sometime not occurring (Efremova et al., 2015). Therefore, for different animals models, the standard 90 days toxicity study could not match with the chronic and progressive characteristics of the human disease and compensatory changes influencing DA metabolism and turnover and protein catabolism can occur during the treatment period with an impact on the time of onset of the lesion (Ossowska et al., 2005)."@en ;
  foaf:page <https://identifiers.org/aop/464> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/468> a sbd:Model ;
  rdfs:label "Binding of SARS-CoV-2 to ACE2 leads to hyperinflammation (via cell death)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Receptor recognition is an essential determinant of molecular level in this AOP. ACE2 was reported as an entry receptor for SARS-CoV-2. The viral entry process is mediated by the envelope-embedded surface-located spike (S) glycoprotein.&nbsp; Jun Lan and Walls, A.C et al (Nature 581, 215&ndash;220; Cell 180, 281&ndash;292) demonstrated a critical initial step of infection at the molecular level from the interaction of ACE2 and S protein. ACE2 has shown that receptor binding affinity to S protein is nM range. To elucidate the interaction between the SARS-CoV-2 RBD and ACE2 at a higher resolution, they also determined the structure of the SARS-CoV-2 RBD&ndash;ACE2 complex using X-ray crystallography. The expression and distribution of the ACE2 in human body may indicate the potential infection of SARS-CoV-2. Through the developed single-cell RNA sequencing (scRNA-Seq) technique and single-cell transcriptomes based on the public database, researchers analyzed the ACE2 RNA expression profile at single-cell resolution. High ACE2 expression was identified in type II alveolar cells (Zou, X. et al. Front. Med.2020)  SARS-CoV-2 belongs to the Coronaviridae family, which includes evolutionary related enveloped (+) strand RNA viruses of vertebrates, such as seasonal common coronaviruses, SARS-CoV and CoV-NL63, SARS-CoV (Kim Young Jun et al)   	 		 			 			Human viruses strains 			 			 			Genus 			 			 			Major cell receptor 			 			 			First report 			 			 			Animal reservoir 			 			 			Intermediate host 			 			 			Pathology 			 			 			Diagnostic test 			 			 			Evidence 			 		 		 			 			HCoV-NL63 			 			 			Alphacoronavirus 			 			 			ACE2 			 			 			2004 			 			 			Bat 			 			 			Unknown 			 			 			Mild respiratory tract illness 			 			 			RT-PCR, IF, ELISA, WB 			 			 			Strong 			 		 		 			 			SARS-CoV 			 			 			Betacoronavirus 			 			 			ACE2 			 			 			2003 			 			 			Bat 			 			 			Pangolin 			 			 			Severe acute respiratory syndrome 			 			 			RT-PCR, IF, ELISA, WB 			 			 			Strong 			 		 		 			 			SARS-CoV-2 			 			 			Betacoronavirus 			 			 			ACE2 			 			 			2020 			 			 			Bat 			 			 			Pangolin 			 			 			Severe acute respiratory syndrome 			 			 			RT-PCR, IF, ELISA, WB 			 			 			Strong"@en ;
  foaf:page <https://identifiers.org/aop/468> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/468> a sbd:Model ;
  rdfs:label "Binding of SARS-CoV-2 to ACE2 leads to hyperinflammation (via cell death)"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "This AOP is developed within the CIAO project, &quot;Modelling the Pathogenesis of&nbsp;COVID-19 Using the&nbsp;Adverse&nbsp;Outcome Pathway (AOP)&quot;. The overall goal is to organize and understand the vast amount of data that is constantly evolving as a result of the COVID-19 pandemic. This AOP-aligned systematic organisation of the knowledge allows to identify uncertainties and knowledge gaps. Many AOPs were developed in the CIAO project, each AOP focusing on a specific element of the SARS-COV-2 virus responses in humans.  This AOP focuses on the acute respiratory distress associated mortality following viral infection of pulmonary cells by SARS-CoV-2 leading to cell death and excessive inflammatory repsonse."@en ;
  foaf:page <https://identifiers.org/aop/468> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/470> a sbd:Model ;
  rdfs:label "Deposition of energy leads to vascular remodeling"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "It is well documented that ionizing radiation( (eg.&nbsp;X-rays, gamma, photons, alpha, beta, neutrons, heavy ions)&nbsp;leads to energy deposition on the atoms and molecules of the substrate. Many studies, have demonstrated that the type of radiation and distance from source has an impact on the pattern of energy deposition (Alloni, et al. 2014). High linear energy transfer (LET) radiation has been associated with higher-energy deposits (Liamsuwan et al., 2014) that are more densely-packed and cause more complex effects within the particle track (Hada and Georgakilas, 2008; Okayasu, 2012ab; Lorat et al., 2015; Nikitaki et al., 2016) in comparison to low LET radiation. Parameters such as mean lineal energy, dose mean lineal energy, frequency mean specific energy and dose mean specific energy can impact track structure of the traversed energy into a medium (Friedland et al., 2017). The detection of energy deposition by ionizing radiation can be demonstrated with the use of fluorescent nuclear track detectors (FNTDs). FNTDs used in conjunction with fluorescent microscopy, are able to visualize radiation tracks produced by ionizing radiation (Niklas et al., 2013; Kodaira et al., 2015; Sawakuchi and Akselrod, 2016). In addition, these FNTD chips can quantify the LET of primary and secondary radiation tracks up to 0.47 keV/um (Sawakuchi and Akselrod, 2016). This co-visualization of the radiation tracks and the cell markers enable the mapping of the radiation trajectory to specific cellular compartments, and the identification of accrued damage (Niklas et al., 2013; Kodaira et al., 2015). There are no known chemical initiators or prototypes that can mimic the MIE."@en ;
  foaf:page <https://identifiers.org/aop/470> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/470> a sbd:Model ;
  rdfs:label "Deposition of energy leads to vascular remodeling"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "Cardiovascular disease (CVD) includes any health condition affecting the heart and blood vessels. CVD is one of the leading causes of death worldwide, accounting for millions of deaths yearly and surpassed in some countries by only cancer (Bray et al., 2021; Tsao et al., 2022). This class of diseases includes congenital defects, as well as CVDs that can develop throughout life such as peripheral artery disease (PAD), atherosclerosis, coronary artery disease and myocardial infarction. While the progression to a CVD outcome can take significant time, many CVDs are often preceded by much earlier changes to vascular structure. Vascular remodeling entails various structural changes of existing vasculature arising from cell death, cell migration and changes to the endothelial cell membrane. It is important to note that changes to vascular structure are not inherently detrimental, and the cardiovascular system undergoes continuous adaptation to protect vascular health (Pries et al., 2001; Santamar&iacute;a et al., 2020; Zakrzewicz et al., 2002). However, certain remodeling can also serve as an important marker and risk factor for future adverse cardiovascular events (Cohn et al., 2004; Van Varik et al., 2012). Changes to vascular structure can be triggered through various perturbations such oxidative stress, inflammation, and alterations to various cellular signaling pathways. Adverse remodeling of the vasculature encompasses structural and functional changes to vessel wall intima-media, elevated stiffness, and decreased lumen diameter which are all predictive of the development of and mortality and morbidity from CVD (Heald et al., 2006; Hodis et al., 1998; Polak et al., 2011; Zieman et al., 2005).&nbsp;&nbsp;  The risk of CVD increases with several factors such as age. There is significant evidence suggesting that environmental factors such as radiation can contribute to the risk of development (Belzile-Dugas &amp; Eisenberg, 2021; Boerma et al., 2016; Francula-Zaninovic &amp; Nola, 2018; Wang et al., 2019). The deposition of energy from radiation exposure is a stochastic event and any part of the human body can be affected, with adverse effects emerging years or decades after the exposure (Boerma et al., 2016; D&ouml;rr, 2015; EPRI, 2020; Menezes et al., 2018). The effects of high-dose radiation on the cardiovascular system have been well-characterized while the effects of low-dose exposure are more contended. However, growing evidence suggests that lower doses than previously thought are linked to subsequent adverse cardiovascular outcomes (Boerma et al., 2016; EPRI, 2020; Little et al., 2021; UNSCEAR, 2008). Much of the high-dose data come from follow up studies in radiotherapy patient cohorts who are shown to be at elevated risk for adverse cardiovascular events (Zou et al., 2019). In addition to clinical exposure scenarios, epidemiological studies of occupational exposures and Japanese atomic bomb survivors have also been conducted. Cohort studies of atomic bomb survivors demonstrate various ways in which CVD risk is affected by exposure parameters, including factors such as age at exposure and estimated dose received (Ozasa et al., 2012; Preston et al., 2003; Shimizu et al., 2010; Takahashi et al., 2017). Long-term follow up of individuals exposed in the Chernobyl disaster region also identified statistically significant elevation in CVD risk (Ivanov et al., 2006; Kashcheev et al., 2017). Occupational exposure studies have also been conducted in various countries in an effort to understand the relationship between low-dose chronic exposure and cardiovascular health of nuclear workers (Azizova et al., 2018; Gillies et al., 2017; Zielinski et al., 2009). Occupational exposure studies suggest positive associations between received dose and excessive relative risk of circulatory diseases (Zielinski et al., 2009), CVD mortality (Gillies et al., 2017) and occurrence of ischemic and cerebrovascular disease involving the blood vessels (Azizova et al., 2018).&nbsp;&nbsp;  Beyond earth, space travel presents an additional radiation exposure scenario. With future missions planned beyond low Earth orbit and the protective shield of the magnetosphere, understanding the unique challenges of space radiation is crucial for protection of travelers. In space, radiation is present in the form of high linear energy transfer (LET) particles and high mass, high energy ions (HZE) which indiscriminately impacts the whole body at a low fluence rate (Baker et al., 2011; Durante &amp; Cucinotta, 2008; Norbury et al., 2016). While the present AOP includes an MIE focused on deposition of energy following radiation exposure, it is important to note that the space exposome contains multiple stressors to which space travelers will be exposed simultaneously. Particularly important, in the case of the cardiovascular system, is microgravity. The cardiovascular system is gravity sensitive, with the endothelial layer being responsive to changes in shear stress and blood pressure (Hughson et al., 2018; Maier et al., 2015; Versari et al., 2013). Variation to the pressure gradient throughout the body can also trigger regional adaptations to vascular structure (L. F. Zhang, 2013). While determining a mechanism for an MIE of microgravity has proven challenging, microgravity exposure has been shown to contribute to other KEs in the pathway and evidence from microgravity studies has been included in the weight of evidence (WOE)."@en ;
  foaf:page <https://identifiers.org/aop/470> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/490> a sbd:Model ;
  rdfs:label "Increased glutamate leads to economic burden through reduced IQ and non-cholinergic mechanisms"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "A prime example of impairments in learning and memory as the adverse outcome for regulatory action is developmental lead exposure and IQ function in children (Bellinger, 2012). Most methods are well established in the published literature and many have been engaged to evaluate the effects of developmental thyroid disruption. The US EPA and OECD Developmental Neurotoxicity (DNT) Guidelines (OCSPP 870.6300 or OECD TG 426) as well as OECD TG 443 (OECD, 2018) both require testing of learning and memory (USEPA, 1998; OECD, 2007) advising to use the following tests passive avoidance, delayed-matching-to-position for the adult rat and for the infant rat, olfactory conditioning, Morris water maze, Biel or Cincinnati maze, radial arm maze, T-maze, and acquisition and retention of schedule-controlled behaviour.&nbsp; These DNT Guidelines have been deemed valid to identify developmental neurotoxicity and adverse neurodevelopmental outcomes (Makris et al., 2009).  Also, in the frame of the OECD GD 43 (2008) on reproductive toxicity, learning and memory testing may have potential to be applied in the context of developmental neurotoxicity studies. However, many of the learning and memory tasks used in guideline studies may not readily detect subtle impairments in cognitive function associated with modest degrees of developmental thyroid disruption (Gilbert et al., 2012)."@en ;
  foaf:page <https://identifiers.org/aop/490> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

<https://identifiers.org/aop/491> a sbd:Model ;
  rdfs:label "Decrease, GLI1/2 target gene expression leads to orofacial clefting "@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/models/> ;
  dc:description "OFC is one of the most common birth defects occurring in approximately 1 in 700 live births. The etiology of OFC is poorly understood and is believed to be a combination of genetic and environmental factors. Understanding the genetic and environmental factors that can lead to OFC is the first step in preventing this birth defect."@en ;
  foaf:page <https://identifiers.org/aop/491> ;
  dcterms:license      <https://creativecommons.org/licenses/by/4.0/> .

@prefix sbd:   <https://www.sbd4nano.eu/rdf/#> .
@prefix foaf:  <http://xmlns.com/foaf/0.1/> .
@prefix rdfs:  <http://www.w3.org/2000/01/rdf-schema#> .
@prefix dc:    <http://purl.org/dc/elements/1.1/> .
@prefix void:  <http://rdfs.org/ns/void#> .
@prefix dcterms: <http://purl.org/dc/terms/> .
@prefix sbd:     <https://www.sbd4nano.eu/rdf/#> .
@prefix sbdbel:  <https://www.sbd4nano.eu/bel/#> .
@prefix xsd:     <http://www.w3.org/2001/XMLSchema#> .
@prefix pav:     <http://purl.org/pav/> .

<https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/>
 a                    void:DatasetDescription ;
 foaf:img             <https://aopwiki.rdf.bigcat-bioinformatics.org/assets/images/aopwiki-snorql-logo.png> ;
 dc:source            <https://aopwiki.rdf.bigcat-bioinformatics.org/> ;
 dcterms:title        "AOP-Wiki Key Event Relationships"@en ;
 dcterms:description  "Causal relationships based on AOP models describing the cause-effects captured by the KERs"@en ;
 dcterms:publisher    <https://github.com/h2020-sbd4nano/sbd-data-aopwiki> ;
 pav:createdBy        <https://github.com/h2020-sbd4nano/sbd-data-aopwiki> ;
 dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.relationships/2794> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2794"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2070> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2071> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2070> rdfs:label "Increase, Glycolysis"@en .
<https://identifiers.org/aop.events/2071> rdfs:label "Decrease, Glucose pool"@en .

<https://identifiers.org/aop.relationships/2795> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2795"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2071> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1821> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2071> rdfs:label "Decrease, Glucose pool"@en .
<https://identifiers.org/aop.events/1821> rdfs:label "Decrease, Cell proliferation"@en .

<https://identifiers.org/aop.relationships/2797> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2797"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2072> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/55> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2072> rdfs:label "Increase, Mitochondrial swelling"@en .
<https://identifiers.org/aop.events/55> rdfs:label "Cell injury/death"@en .

<https://identifiers.org/aop.relationships/2799> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2799"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2073> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2074> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2073> rdfs:label "increase oxidation of the di-copper moiety of the hemocyanin active site "@en .
<https://identifiers.org/aop.events/2074> rdfs:label "Decreased, oxygen binding capacity by hemocyanin"@en .

<https://identifiers.org/aop.relationships/2800> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2800"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2073> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2075> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2073> rdfs:label "increase oxidation of the di-copper moiety of the hemocyanin active site "@en .
<https://identifiers.org/aop.events/2075> rdfs:label "Cognitive, sensed as hypoxic/low oxygen environment"@en .

<https://identifiers.org/aop.relationships/2803> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2803"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2074> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2076> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2074> rdfs:label "Decreased, oxygen binding capacity by hemocyanin"@en .
<https://identifiers.org/aop.events/2076> rdfs:label "Increase, hemocyanin mRNA"@en .

<https://identifiers.org/aop.relationships/2801> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2801"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2075> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2077> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2075> rdfs:label "Cognitive, sensed as hypoxic/low oxygen environment"@en .
<https://identifiers.org/aop.events/2077> rdfs:label "Increase, pulmonate breathing"@en .

<https://identifiers.org/aop.relationships/2802> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2802"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2077> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1521> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2077> rdfs:label "Increase, pulmonate breathing"@en .
<https://identifiers.org/aop.events/1521> rdfs:label "Decrease, Growth"@en .

<https://identifiers.org/aop.relationships/2807> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2807"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2078> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1944> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2078> rdfs:label "Loss of drebrin"@en .
<https://identifiers.org/aop.events/1944> rdfs:label "Synaptic dysfunction"@en .

<https://identifiers.org/aop.relationships/2816> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2816"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2081> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2083> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2081> rdfs:label "Increased Modified Proteins"@en .
<https://identifiers.org/aop.events/2083> rdfs:label "Occurrence of Cataracts"@en .

<https://identifiers.org/aop.relationships/1024> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1024"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1000> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/858> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1000> rdfs:label "stabilization, PPAR alpha co-repressor"@en .
<https://identifiers.org/aop.events/858> rdfs:label "Decreased, PPARalpha transactivation of gene expression"@en .

<https://identifiers.org/aop.relationships/1026> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1026"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1002> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1003> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1002> rdfs:label "Inhibition, Deiodinase 2"@en .
<https://identifiers.org/aop.events/1003> rdfs:label "Decreased, Triiodothyronine (T3)"@en .

<https://identifiers.org/aop.relationships/1042> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1042"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1002> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1004> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1002> rdfs:label "Inhibition, Deiodinase 2"@en .
<https://identifiers.org/aop.events/1004> rdfs:label "Reduced, Posterior swim bladder inflation"@en .

<https://identifiers.org/aop.relationships/1199> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1199"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1002> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1116> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1002> rdfs:label "Inhibition, Deiodinase 2"@en .
<https://identifiers.org/aop.events/1116> rdfs:label "Decreased, Triiodothyronine (T3) in tissues"@en .

<https://identifiers.org/aop.relationships/1027> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1027"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1003> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1004> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1003> rdfs:label "Decreased, Triiodothyronine (T3)"@en .
<https://identifiers.org/aop.events/1004> rdfs:label "Reduced, Posterior swim bladder inflation"@en .

<https://identifiers.org/aop.relationships/1035> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1035"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1003> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1007> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1003> rdfs:label "Decreased, Triiodothyronine (T3)"@en .
<https://identifiers.org/aop.events/1007> rdfs:label "Reduced, Anterior swim bladder inflation"@en .

<https://identifiers.org/aop.relationships/2373> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2373"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1003> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1877> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1003> rdfs:label "Decreased, Triiodothyronine (T3)"@en .
<https://identifiers.org/aop.events/1877> rdfs:label "Altered, retinal layer structure"@en .

<https://identifiers.org/aop.relationships/2376> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2376"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1003> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1878> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1003> rdfs:label "Decreased, Triiodothyronine (T3)"@en .
<https://identifiers.org/aop.events/1878> rdfs:label "Decreased, Eye size"@en .

<https://identifiers.org/aop.relationships/2378> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2378"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1003> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1640> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1003> rdfs:label "Decreased, Triiodothyronine (T3)"@en .
<https://identifiers.org/aop.events/1640> rdfs:label "Altered, Photoreceptor patterning"@en .

<https://identifiers.org/aop.relationships/1037> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1037"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1009> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1003> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1009> rdfs:label "Inhibition, Deiodinase 1"@en .
<https://identifiers.org/aop.events/1003> rdfs:label "Decreased, Triiodothyronine (T3)"@en .

<https://identifiers.org/aop.relationships/1044> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1044"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1009> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1004> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1009> rdfs:label "Inhibition, Deiodinase 1"@en .
<https://identifiers.org/aop.events/1004> rdfs:label "Reduced, Posterior swim bladder inflation"@en .

<https://identifiers.org/aop.relationships/1198> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1198"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1009> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1116> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1009> rdfs:label "Inhibition, Deiodinase 1"@en .
<https://identifiers.org/aop.events/1116> rdfs:label "Decreased, Triiodothyronine (T3) in tissues"@en .

<https://identifiers.org/aop.relationships/125> a sbdbel:CausalAssertion ;
  rdfs:label "KER 125"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/110> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/298> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/110> rdfs:label "Impairment, Endothelial network"@en .
<https://identifiers.org/aop.events/298> rdfs:label "Insufficiency, Vascular"@en .

<https://identifiers.org/aop.relationships/976> a sbdbel:CausalAssertion ;
  rdfs:label "KER 976"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/110> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/317> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/110> rdfs:label "Impairment, Endothelial network"@en .
<https://identifiers.org/aop.events/317> rdfs:label "Altered, Cardiovascular development/function"@en .

<https://identifiers.org/aop.relationships/1151> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1151"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1108> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1107> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1108> rdfs:label "Abnormal, Role change within caste"@en .
<https://identifiers.org/aop.events/1107> rdfs:label "Weakened, Colony"@en .

<https://identifiers.org/aop.relationships/129> a sbdbel:CausalAssertion ;
  rdfs:label "KER 129"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/112> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/285> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/112> rdfs:label "Antagonism, Estrogen receptor"@en .
<https://identifiers.org/aop.events/285> rdfs:label "Reduction, Vitellogenin synthesis in liver"@en .

<https://identifiers.org/aop.relationships/2613> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2613"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/112> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1457> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/112> rdfs:label "Antagonism, Estrogen receptor"@en .
<https://identifiers.org/aop.events/1457> rdfs:label "Induction, Epithelial Mesenchymal Transition"@en .

<https://identifiers.org/aop.relationships/132> a sbdbel:CausalAssertion ;
  rdfs:label "KER 132"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/115> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/291> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/115> rdfs:label "Increase, FA Influx"@en .
<https://identifiers.org/aop.events/291> rdfs:label "Accumulation, Triglyceride"@en .

<https://identifiers.org/aop.relationships/133> a sbdbel:CausalAssertion ;
  rdfs:label "KER 133"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/116> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/89> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/116> rdfs:label "Activation, FAS"@en .
<https://identifiers.org/aop.events/89> rdfs:label "Synthesis, De Novo FA"@en .

<https://identifiers.org/aop.relationships/2612> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2612"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1172> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/112> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1172> rdfs:label "Increase activation, Nuclear factor kappa B (NF-kB)"@en .
<https://identifiers.org/aop.events/112> rdfs:label "Antagonism, Estrogen receptor"@en .

<https://identifiers.org/aop.relationships/2309> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2309"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1172> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1496> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1172> rdfs:label "Increase activation, Nuclear factor kappa B (NF-kB)"@en .
<https://identifiers.org/aop.events/1496> rdfs:label "Increased, secretion of proinflammatory mediators"@en .

<https://identifiers.org/aop.relationships/2431> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2431"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1172> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/87> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1172> rdfs:label "Increase activation, Nuclear factor kappa B (NF-kB)"@en .
<https://identifiers.org/aop.events/87> rdfs:label "Release, Cytokine"@en .

<https://identifiers.org/aop.relationships/2432> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2432"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1172> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1493> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1172> rdfs:label "Increase activation, Nuclear factor kappa B (NF-kB)"@en .
<https://identifiers.org/aop.events/1493> rdfs:label "Increased Pro-inflammatory mediators"@en .

<https://identifiers.org/aop.relationships/136> a sbdbel:CausalAssertion ;
  rdfs:label "KER 136"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/119> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/49> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/119> rdfs:label "N/A, Gap"@en .
<https://identifiers.org/aop.events/49> rdfs:label "Reduction, Ca and HCO3 transport to shell gland"@en .

<https://identifiers.org/aop.relationships/2007> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2007"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/12> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1703> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/12> rdfs:label "Acetylcholinesterase (AchE) Inhibition"@en .
<https://identifiers.org/aop.events/1703> rdfs:label "Dysregulation of heart rate and vascular tone"@en .

<https://identifiers.org/aop.relationships/450> a sbdbel:CausalAssertion ;
  rdfs:label "KER 450"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/12> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/445> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/12> rdfs:label "Acetylcholinesterase (AchE) Inhibition"@en .
<https://identifiers.org/aop.events/445> rdfs:label "Respiratory distress/arrest"@en .

<https://identifiers.org/aop.relationships/11> a sbdbel:CausalAssertion ;
  rdfs:label "KER 11"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/12> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/10> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/12> rdfs:label "Acetylcholinesterase (AchE) Inhibition"@en .
<https://identifiers.org/aop.events/10> rdfs:label "Acetylcholine accumulation in synapses"@en .

<https://identifiers.org/aop.relationships/2014> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2014"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/12> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1705> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/12> rdfs:label "Acetylcholinesterase (AchE) Inhibition"@en .
<https://identifiers.org/aop.events/1705> rdfs:label "Impaired coordination and movement"@en .

<https://identifiers.org/aop.relationships/2016> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2016"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/12> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/360> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/12> rdfs:label "Acetylcholinesterase (AchE) Inhibition"@en .
<https://identifiers.org/aop.events/360> rdfs:label "Decrease, Population growth rate"@en .

<https://identifiers.org/aop.relationships/451> a sbdbel:CausalAssertion ;
  rdfs:label "KER 451"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/12> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/39> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/12> rdfs:label "Acetylcholinesterase (AchE) Inhibition"@en .
<https://identifiers.org/aop.events/39> rdfs:label "Increased Cholinergic Signaling"@en .

<https://identifiers.org/aop.relationships/452> a sbdbel:CausalAssertion ;
  rdfs:label "KER 452"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/12> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/351> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/12> rdfs:label "Acetylcholinesterase (AchE) Inhibition"@en .
<https://identifiers.org/aop.events/351> rdfs:label "Increased Mortality"@en .

<https://identifiers.org/aop.relationships/2653> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2653"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/12> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1391> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/12> rdfs:label "Acetylcholinesterase (AchE) Inhibition"@en .
<https://identifiers.org/aop.events/1391> rdfs:label "Activation of Cyp2E1"@en .

<https://identifiers.org/aop.relationships/1510> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1510"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1202> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/984> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1202> rdfs:label "Suppression, IL-2 and IL-4 production"@en .
<https://identifiers.org/aop.events/984> rdfs:label "Impairment, T-cell dependent antibody response"@en .

<https://identifiers.org/aop.relationships/1269> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1269"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1214> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/716> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1214> rdfs:label "Altered gene expression specific to CAR activation, Hepatocytes"@en .
<https://identifiers.org/aop.events/716> rdfs:label "Increase, cell proliferation (hepatocytes)"@en .

<https://identifiers.org/aop.relationships/1310> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1310"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1243> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/341> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1243> rdfs:label "Altered, Ca2+-calmodulin activated signal transduction"@en .
<https://identifiers.org/aop.events/341> rdfs:label "Impairment, Learning and memory"@en .

<https://identifiers.org/aop.relationships/1331> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1331"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1253> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1254> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1253> rdfs:label " MLL chromosomal translocation"@en .
<https://identifiers.org/aop.events/1254> rdfs:label "Infant leukaemia"@en .

<https://identifiers.org/aop.relationships/1351> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1351"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1269> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/317> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1269> rdfs:label "Increase, COX-2 expression"@en .
<https://identifiers.org/aop.events/317> rdfs:label "Altered, Cardiovascular development/function"@en .

<https://identifiers.org/aop.relationships/996> a sbdbel:CausalAssertion ;
  rdfs:label "KER 996"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/139> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/854> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/139> rdfs:label "N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects"@en .
<https://identifiers.org/aop.events/854> rdfs:label "Alterations, Cellular proliferation / hyperplasia"@en .

<https://identifiers.org/aop.relationships/1512> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1512"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1391> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1392> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1391> rdfs:label "Activation of Cyp2E1"@en .
<https://identifiers.org/aop.events/1392> rdfs:label "Oxidative Stress "@en .

<https://identifiers.org/aop.relationships/1515> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1515"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1391> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1393> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1391> rdfs:label "Activation of Cyp2E1"@en .
<https://identifiers.org/aop.events/1393> rdfs:label "Hepatocytotoxicity"@en .

<https://identifiers.org/aop.relationships/2654> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2654"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1391> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1510> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1391> rdfs:label "Activation of Cyp2E1"@en .
<https://identifiers.org/aop.events/1510> rdfs:label "Oxidative Stress in Brain"@en .

<https://identifiers.org/aop.relationships/1810> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1810"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1477> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1562> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1477> rdfs:label "Decrease, Oxidative phosphorylation"@en .
<https://identifiers.org/aop.events/1562> rdfs:label "Decreased Na/K ATPase activity"@en .

<https://identifiers.org/aop.relationships/1669> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1669"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1477> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/40> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1477> rdfs:label "Decrease, Oxidative phosphorylation"@en .
<https://identifiers.org/aop.events/40> rdfs:label "Decrease, Mitochondrial ATP production"@en .

<https://identifiers.org/aop.relationships/2095> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2095"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1477> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1771> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1477> rdfs:label "Decrease, Oxidative phosphorylation"@en .
<https://identifiers.org/aop.events/1771> rdfs:label "Decrease, Adenosine triphosphate pool"@en .

<https://identifiers.org/aop.relationships/2713> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2713"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1477> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1392> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1477> rdfs:label "Decrease, Oxidative phosphorylation"@en .
<https://identifiers.org/aop.events/1392> rdfs:label "Oxidative Stress "@en .

<https://identifiers.org/aop.relationships/1778> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1778"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1494> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/265> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1494> rdfs:label "Leukocyte recruitment/activation"@en .
<https://identifiers.org/aop.events/265> rdfs:label "Activation, Stellate cells"@en .

<https://identifiers.org/aop.relationships/1905> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1905"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1494> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1632> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1494> rdfs:label "Leukocyte recruitment/activation"@en .
<https://identifiers.org/aop.events/1632> rdfs:label "Increase in reactive oxygen and nitrogen species (RONS)"@en .

<https://identifiers.org/aop.relationships/1705> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1705"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1498> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1499> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1498> rdfs:label "Loss of alveolar capillary membrane integrity"@en .
<https://identifiers.org/aop.events/1499> rdfs:label "Increased, activation of T (T) helper (h) type 2 cells"@en .

<https://identifiers.org/aop.relationships/2368> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2368"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1498> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1672> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1498> rdfs:label "Loss of alveolar capillary membrane integrity"@en .
<https://identifiers.org/aop.events/1672> rdfs:label "Inhibition of lung surfactant function"@en .

<https://identifiers.org/aop.relationships/2369> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2369"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1498> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1677> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1498> rdfs:label "Loss of alveolar capillary membrane integrity"@en .
<https://identifiers.org/aop.events/1677> rdfs:label "Reduced tidal volume "@en .

<https://identifiers.org/aop.relationships/2372> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2372"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1498> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1250> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1498> rdfs:label "Loss of alveolar capillary membrane integrity"@en .
<https://identifiers.org/aop.events/1250> rdfs:label "Decrease, Lung function"@en .

<https://identifiers.org/aop.relationships/1706> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1706"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1499> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1500> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1499> rdfs:label "Increased, activation of T (T) helper (h) type 2 cells"@en .
<https://identifiers.org/aop.events/1500> rdfs:label "Increased, fibroblast proliferation and myofibroblast differentiation"@en .

<https://identifiers.org/aop.relationships/2652> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2652"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1500> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/68> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1500> rdfs:label "Increased, fibroblast proliferation and myofibroblast differentiation"@en .
<https://identifiers.org/aop.events/68> rdfs:label "Accumulation, Collagen"@en .

<https://identifiers.org/aop.relationships/2325> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2325"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1501> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/344> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1501> rdfs:label "Increased, extracellular matrix deposition"@en .
<https://identifiers.org/aop.events/344> rdfs:label "N/A, Liver fibrosis"@en .

<https://identifiers.org/aop.relationships/1709> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1709"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1502> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1503> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1502> rdfs:label "Histone deacetylase inhibition"@en .
<https://identifiers.org/aop.events/1503> rdfs:label "Histone acetylation, increase"@en .

<https://identifiers.org/aop.relationships/1715> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1715"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1502> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1505> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1502> rdfs:label "Histone deacetylase inhibition"@en .
<https://identifiers.org/aop.events/1505> rdfs:label "Cell cycle, disrupted"@en .

<https://identifiers.org/aop.relationships/1716> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1716"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1502> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1262> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1502> rdfs:label "Histone deacetylase inhibition"@en .
<https://identifiers.org/aop.events/1262> rdfs:label "Apoptosis"@en .

<https://identifiers.org/aop.relationships/1717> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1717"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1502> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1506> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1502> rdfs:label "Histone deacetylase inhibition"@en .
<https://identifiers.org/aop.events/1506> rdfs:label "Testicular atrophy"@en .

<https://identifiers.org/aop.relationships/1802> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1802"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1502> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1557> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1502> rdfs:label "Histone deacetylase inhibition"@en .
<https://identifiers.org/aop.events/1557> rdfs:label "Neural crest cell migration, reduced"@en .

<https://identifiers.org/aop.relationships/1805> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1805"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1502> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1558> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1502> rdfs:label "Histone deacetylase inhibition"@en .
<https://identifiers.org/aop.events/1558> rdfs:label "Collagen production, reduced"@en .

<https://identifiers.org/aop.relationships/2010> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2010"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1502> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1515> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1502> rdfs:label "Histone deacetylase inhibition"@en .
<https://identifiers.org/aop.events/1515> rdfs:label "Spermatocyte depletion"@en .

<https://identifiers.org/aop.relationships/2699> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2699"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1502> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1561> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1502> rdfs:label "Histone deacetylase inhibition"@en .
<https://identifiers.org/aop.events/1561> rdfs:label "Neural tube defects"@en .

<https://identifiers.org/aop.relationships/1806> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1806"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1503> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1239> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1503> rdfs:label "Histone acetylation, increase"@en .
<https://identifiers.org/aop.events/1239> rdfs:label "Altered, Gene Expression"@en .

<https://identifiers.org/aop.relationships/1997> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1997"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1503> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1505> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1503> rdfs:label "Histone acetylation, increase"@en .
<https://identifiers.org/aop.events/1505> rdfs:label "Cell cycle, disrupted"@en .

<https://identifiers.org/aop.relationships/1726> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1726"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1508> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1510> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1508> rdfs:label "CYP2E1 Activation"@en .
<https://identifiers.org/aop.events/1510> rdfs:label "Oxidative Stress in Brain"@en .

<https://identifiers.org/aop.relationships/1727> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1727"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1510> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1511> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1510> rdfs:label "Oxidative Stress in Brain"@en .
<https://identifiers.org/aop.events/1511> rdfs:label "Lipid Peroxidation"@en .

<https://identifiers.org/aop.relationships/1730> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1730"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1510> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1512> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1510> rdfs:label "Oxidative Stress in Brain"@en .
<https://identifiers.org/aop.events/1512> rdfs:label "Unfolded Protein Response"@en .

<https://identifiers.org/aop.relationships/2655> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2655"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1510> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/352> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1510> rdfs:label "Oxidative Stress in Brain"@en .
<https://identifiers.org/aop.events/352> rdfs:label "N/A, Neurodegeneration"@en .

<https://identifiers.org/aop.relationships/1732> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1732"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1512> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1513> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1512> rdfs:label "Unfolded Protein Response"@en .
<https://identifiers.org/aop.events/1513> rdfs:label "General Apoptosis"@en .

<https://identifiers.org/aop.relationships/1866> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1866"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1512> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1262> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1512> rdfs:label "Unfolded Protein Response"@en .
<https://identifiers.org/aop.events/1262> rdfs:label "Apoptosis"@en .

<https://identifiers.org/aop.relationships/2712> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2712"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1512> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1825> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1512> rdfs:label "Unfolded Protein Response"@en .
<https://identifiers.org/aop.events/1825> rdfs:label "Increase, Cell death"@en .

<https://identifiers.org/aop.relationships/1733> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1733"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1513> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1514> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1513> rdfs:label "General Apoptosis"@en .
<https://identifiers.org/aop.events/1514> rdfs:label "Neurodegeneration"@en .

<https://identifiers.org/aop.relationships/1742> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1742"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1522> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1523> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1522> rdfs:label "Inhibition, Chitin synthase 1"@en .
<https://identifiers.org/aop.events/1523> rdfs:label "Decrease, Cuticular chitin content"@en .

<https://identifiers.org/aop.relationships/1749> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1749"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1528> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/861> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1528> rdfs:label "Fatty Acid Beta Oxidation, Decreased"@en .
<https://identifiers.org/aop.events/861> rdfs:label "Decreased, Ketogenesis (production of ketone bodies)"@en .

<https://identifiers.org/aop.relationships/1781> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1781"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1542> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1545> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1542> rdfs:label "Increase, Mitochondrial complex III antagonism"@en .
<https://identifiers.org/aop.events/1545> rdfs:label "Decrease in mitochondrial oxidative phosphorylation"@en .

<https://identifiers.org/aop.relationships/2230> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2230"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1542> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1771> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1542> rdfs:label "Increase, Mitochondrial complex III antagonism"@en .
<https://identifiers.org/aop.events/1771> rdfs:label "Decrease, Adenosine triphosphate pool"@en .

<https://identifiers.org/aop.relationships/1782> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1782"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1543> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1545> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1543> rdfs:label "Mitochondrial Complex IV inhibition"@en .
<https://identifiers.org/aop.events/1545> rdfs:label "Decrease in mitochondrial oxidative phosphorylation"@en .

<https://identifiers.org/aop.relationships/1783> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1783"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1544> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1545> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1544> rdfs:label "Mitochondrial Complex V inhibition"@en .
<https://identifiers.org/aop.events/1545> rdfs:label "Decrease in mitochondrial oxidative phosphorylation"@en .

<https://identifiers.org/aop.relationships/2817> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2817"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/155> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2083> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/155> rdfs:label "Inadequate DNA repair"@en .
<https://identifiers.org/aop.events/2083> rdfs:label "Occurrence of Cataracts"@en .

<https://identifiers.org/aop.relationships/164> a sbdbel:CausalAssertion ;
  rdfs:label "KER 164"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/155> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/185> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/155> rdfs:label "Inadequate DNA repair"@en .
<https://identifiers.org/aop.events/185> rdfs:label "Increase, Mutations"@en .

<https://identifiers.org/aop.relationships/1910> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1910"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/155> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1635> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/155> rdfs:label "Inadequate DNA repair"@en .
<https://identifiers.org/aop.events/1635> rdfs:label "Increase, DNA strand breaks"@en .

<https://identifiers.org/aop.relationships/1912> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1912"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/155> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1636> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/155> rdfs:label "Inadequate DNA repair"@en .
<https://identifiers.org/aop.events/1636> rdfs:label "Increase, Chromosomal aberrations"@en .

<https://identifiers.org/aop.relationships/1803> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1803"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1557> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1558> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1557> rdfs:label "Neural crest cell migration, reduced"@en .
<https://identifiers.org/aop.events/1558> rdfs:label "Collagen production, reduced"@en .

<https://identifiers.org/aop.relationships/2563> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2563"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1557> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1970> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1557> rdfs:label "Neural crest cell migration, reduced"@en .
<https://identifiers.org/aop.events/1970> rdfs:label "transposition of the great arteries"@en .

<https://identifiers.org/aop.relationships/1827> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1827"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1574> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/202> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1574> rdfs:label "Inhibition, IKK complex"@en .
<https://identifiers.org/aop.events/202> rdfs:label "Inhibition, Nuclear factor kappa B (NF-kB)"@en .

<https://identifiers.org/aop.relationships/1829> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1829"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1575> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/55> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1575> rdfs:label "Activation, Caspase 8 pathway"@en .
<https://identifiers.org/aop.events/55> rdfs:label "Cell injury/death"@en .

<https://identifiers.org/aop.relationships/1864> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1864"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1604> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1605> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1604> rdfs:label "Inhibition of N-linked glycosylation"@en .
<https://identifiers.org/aop.events/1605> rdfs:label "Accumulation of misfolded proteins"@en .

<https://identifiers.org/aop.relationships/2820> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2820"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1614> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1688> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1614> rdfs:label "Decrease, androgen receptors (AR) activation"@en .
<https://identifiers.org/aop.events/1688> rdfs:label "anogenital distance (AGD), decreased"@en .

<https://identifiers.org/aop.relationships/1937> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1937"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1614> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1615> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1614> rdfs:label "Decrease, androgen receptors (AR) activation"@en .
<https://identifiers.org/aop.events/1615> rdfs:label "Impaired inguinoscrotal testicular descent phase"@en .

<https://identifiers.org/aop.relationships/2124> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2124"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1614> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/286> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1614> rdfs:label "Decrease, androgen receptors (AR) activation"@en .
<https://identifiers.org/aop.events/286> rdfs:label "Altered, Transcription of genes by AR"@en .

<https://identifiers.org/aop.relationships/2128> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2128"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1614> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1687> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1614> rdfs:label "Decrease, androgen receptors (AR) activation"@en .
<https://identifiers.org/aop.events/1687> rdfs:label "decrease, transcription of genes by AR "@en .

<https://identifiers.org/aop.relationships/2828> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2828"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1614> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2082> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1614> rdfs:label "Decrease, androgen receptors (AR) activation"@en .
<https://identifiers.org/aop.events/2082> rdfs:label "Hypospadias, increased"@en .

<https://identifiers.org/aop.relationships/172> a sbdbel:CausalAssertion ;
  rdfs:label "KER 172"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/165> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/139> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/165> rdfs:label "Activation, Long term AHR receptor driven direct and indirect gene expression changes"@en .
<https://identifiers.org/aop.events/139> rdfs:label "N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects"@en .

<https://identifiers.org/aop.relationships/874> a sbdbel:CausalAssertion ;
  rdfs:label "KER 874"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/165> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/853> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/165> rdfs:label "Activation, Long term AHR receptor driven direct and indirect gene expression changes"@en .
<https://identifiers.org/aop.events/853> rdfs:label "Changes/Inhibition, Cellular Homeostasis and Apoptosis"@en .

<https://identifiers.org/aop.relationships/875> a sbdbel:CausalAssertion ;
  rdfs:label "KER 875"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/165> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/854> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/165> rdfs:label "Activation, Long term AHR receptor driven direct and indirect gene expression changes"@en .
<https://identifiers.org/aop.events/854> rdfs:label "Alterations, Cellular proliferation / hyperplasia"@en .

<https://identifiers.org/aop.relationships/876> a sbdbel:CausalAssertion ;
  rdfs:label "KER 876"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/165> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/856> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/165> rdfs:label "Activation, Long term AHR receptor driven direct and indirect gene expression changes"@en .
<https://identifiers.org/aop.events/856> rdfs:label "Formation, Hepatocellular and Bile duct tumors"@en .

<https://identifiers.org/aop.relationships/1929> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1929"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1650> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1651> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1650> rdfs:label "Epithelial-mesenchymal transition"@en .
<https://identifiers.org/aop.events/1651> rdfs:label "Treatment-resistant gastric cancer"@en .

<https://identifiers.org/aop.relationships/2677> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2677"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1650> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2013> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1650> rdfs:label "Epithelial-mesenchymal transition"@en .
<https://identifiers.org/aop.events/2013> rdfs:label "Airway remodeling"@en .

<https://identifiers.org/aop.relationships/1947> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1947"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1656> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/756> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1656> rdfs:label "Antagonism, Thyroid Receptor "@en .
<https://identifiers.org/aop.events/756> rdfs:label "Hippocampal gene expression, Altered "@en .

<https://identifiers.org/aop.relationships/1948> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1948"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1656> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/402> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1656> rdfs:label "Antagonism, Thyroid Receptor "@en .
<https://identifiers.org/aop.events/402> rdfs:label "Cognitive Function, Decreased "@en .

<https://identifiers.org/aop.relationships/173> a sbdbel:CausalAssertion ;
  rdfs:label "KER 173"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/167> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/54> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/167> rdfs:label "Activation, LXR"@en .
<https://identifiers.org/aop.events/54> rdfs:label "Up Regulation, CD36"@en .

<https://identifiers.org/aop.relationships/174> a sbdbel:CausalAssertion ;
  rdfs:label "KER 174"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/167> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/66> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/167> rdfs:label "Activation, LXR"@en .
<https://identifiers.org/aop.events/66> rdfs:label "Activation, ChREBP"@en .

<https://identifiers.org/aop.relationships/175> a sbdbel:CausalAssertion ;
  rdfs:label "KER 175"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/167> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/116> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/167> rdfs:label "Activation, LXR"@en .
<https://identifiers.org/aop.events/116> rdfs:label "Activation, FAS"@en .

<https://identifiers.org/aop.relationships/176> a sbdbel:CausalAssertion ;
  rdfs:label "KER 176"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/167> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/258> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/167> rdfs:label "Activation, LXR"@en .
<https://identifiers.org/aop.events/258> rdfs:label "Activation, SCD-1"@en .

<https://identifiers.org/aop.relationships/177> a sbdbel:CausalAssertion ;
  rdfs:label "KER 177"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/167> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/264> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/167> rdfs:label "Activation, LXR"@en .
<https://identifiers.org/aop.events/264> rdfs:label "Activation, SREBP-1c"@en .

<https://identifiers.org/aop.relationships/479> a sbdbel:CausalAssertion ;
  rdfs:label "KER 479"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/167> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/457> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/167> rdfs:label "Activation, LXR"@en .
<https://identifiers.org/aop.events/457> rdfs:label "Activation, SREBF1"@en .

<https://identifiers.org/aop.relationships/490> a sbdbel:CausalAssertion ;
  rdfs:label "KER 490"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/167> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/463> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/167> rdfs:label "Activation, LXR"@en .
<https://identifiers.org/aop.events/463> rdfs:label "Up Regulation, FAS"@en .

<https://identifiers.org/aop.relationships/491> a sbdbel:CausalAssertion ;
  rdfs:label "KER 491"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/167> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/462> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/167> rdfs:label "Activation, LXR"@en .
<https://identifiers.org/aop.events/462> rdfs:label "Up Regulation, SCD-1"@en .

<https://identifiers.org/aop.relationships/510> a sbdbel:CausalAssertion ;
  rdfs:label "KER 510"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/167> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/468> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/167> rdfs:label "Activation, LXR"@en .
<https://identifiers.org/aop.events/468> rdfs:label "Inhibition, PPAR alpha"@en .

<https://identifiers.org/aop.relationships/516> a sbdbel:CausalAssertion ;
  rdfs:label "KER 516"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/167> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/470> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/167> rdfs:label "Activation, LXR"@en .
<https://identifiers.org/aop.events/470> rdfs:label "Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)"@en .

<https://identifiers.org/aop.relationships/2002> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2002"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1700> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/202> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1700> rdfs:label "Impaired IL-1R1 signaling in T cell"@en .
<https://identifiers.org/aop.events/202> rdfs:label "Inhibition, Nuclear factor kappa B (NF-kB)"@en .

<https://identifiers.org/aop.relationships/2004> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2004"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1702> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/986> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1702> rdfs:label "Suppression of  T cell activation"@en .
<https://identifiers.org/aop.events/986> rdfs:label "Impairment of TDAR"@en .

<https://identifiers.org/aop.relationships/2017> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2017"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1706> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1707> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1706> rdfs:label "Stimulation, TLR7/8"@en .
<https://identifiers.org/aop.events/1707> rdfs:label "Increase, IL-23 from matured dendritic cells"@en .

<https://identifiers.org/aop.relationships/2018> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2018"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1707> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1708> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1707> rdfs:label "Increase, IL-23 from matured dendritic cells"@en .
<https://identifiers.org/aop.events/1708> rdfs:label "Th17 cell migration and inflammation induction"@en .

<https://identifiers.org/aop.relationships/2019> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2019"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1708> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1709> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1708> rdfs:label "Th17 cell migration and inflammation induction"@en .
<https://identifiers.org/aop.events/1709> rdfs:label "Psoriatic skin disease"@en .

<https://identifiers.org/aop.relationships/2020> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2020"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1710> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1711> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1710> rdfs:label "Binding to estrogen receptor (ER)-α in immune cells"@en .
<https://identifiers.org/aop.events/1711> rdfs:label "Induction of GATA3 expression"@en .

<https://identifiers.org/aop.relationships/2021> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2021"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1711> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1712> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1711> rdfs:label "Induction of GATA3 expression"@en .
<https://identifiers.org/aop.events/1712> rdfs:label "Increase of Th2 cells producing IL-4"@en .

<https://identifiers.org/aop.relationships/2022> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2022"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1712> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1713> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1712> rdfs:label "Increase of Th2 cells producing IL-4"@en .
<https://identifiers.org/aop.events/1713> rdfs:label "Increase of anti-DNA antibody from autoreactive B cell"@en .

<https://identifiers.org/aop.relationships/2023> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2023"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1713> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1714> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1713> rdfs:label "Increase of anti-DNA antibody from autoreactive B cell"@en .
<https://identifiers.org/aop.events/1714> rdfs:label "Exacerbation of systemic lupus erythematosus (SLE)"@en .

<https://identifiers.org/aop.relationships/2024> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2024"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1715> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1716> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1715> rdfs:label "Inhibition of JAK3"@en .
<https://identifiers.org/aop.events/1716> rdfs:label "Blockade of STAT5 phosphorylation"@en .

<https://identifiers.org/aop.relationships/2025> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2025"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1716> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1717> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1716> rdfs:label "Blockade of STAT5 phosphorylation"@en .
<https://identifiers.org/aop.events/1717> rdfs:label "Suppression of STAT5 binding to cytokine gene promoters"@en .

<https://identifiers.org/aop.relationships/2026> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2026"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1717> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1718> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1717> rdfs:label "Suppression of STAT5 binding to cytokine gene promoters"@en .
<https://identifiers.org/aop.events/1718> rdfs:label "Suppression of IL-4 production"@en .

<https://identifiers.org/aop.relationships/2027> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2027"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1718> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1719> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1718> rdfs:label "Suppression of IL-4 production"@en .
<https://identifiers.org/aop.events/1719> rdfs:label "Impairment of T-cell dependent antibody response"@en .

<https://identifiers.org/aop.relationships/2028> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2028"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1720> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1721> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1720> rdfs:label "Trypsin inhibition"@en .
<https://identifiers.org/aop.events/1721> rdfs:label "Increased intestinal monitor peptide level"@en .

<https://identifiers.org/aop.relationships/2029> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2029"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1721> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1722> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1721> rdfs:label "Increased intestinal monitor peptide level"@en .
<https://identifiers.org/aop.events/1722> rdfs:label "Increased blood CCK level"@en .

<https://identifiers.org/aop.relationships/2030> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2030"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1722> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1723> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1722> rdfs:label "Increased blood CCK level"@en .
<https://identifiers.org/aop.events/1723> rdfs:label "Increased exocrine secretion from pancreatic acinar cells"@en .

<https://identifiers.org/aop.relationships/2031> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2031"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1723> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1724> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1723> rdfs:label "Increased exocrine secretion from pancreatic acinar cells"@en .
<https://identifiers.org/aop.events/1724> rdfs:label "Acinar cell proliferation"@en .

<https://identifiers.org/aop.relationships/2032> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2032"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1724> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1725> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1724> rdfs:label "Acinar cell proliferation"@en .
<https://identifiers.org/aop.events/1725> rdfs:label "Pancreatic acinar cell tumors"@en .

<https://identifiers.org/aop.relationships/2286> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2286"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1739> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/188> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1739> rdfs:label "Binding to ACE2"@en .
<https://identifiers.org/aop.events/188> rdfs:label "Neuroinflammation"@en .

<https://identifiers.org/aop.relationships/2056> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2056"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1739> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1738> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1739> rdfs:label "Binding to ACE2"@en .
<https://identifiers.org/aop.events/1738> rdfs:label "SARS-CoV-2 cell entry "@en .

<https://identifiers.org/aop.relationships/2311> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2311"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1739> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1854> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1739> rdfs:label "Binding to ACE2"@en .
<https://identifiers.org/aop.events/1854> rdfs:label "Dysregulation, ACE2 expression and activity"@en .

<https://identifiers.org/aop.relationships/2312> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2312"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1739> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1787> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1739> rdfs:label "Binding to ACE2"@en .
<https://identifiers.org/aop.events/1787> rdfs:label "Downregulation, ACE2"@en .

<https://identifiers.org/aop.relationships/2070> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2070"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1754> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1755> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1754> rdfs:label "Porcupine-induced Wnt secretion and Wnt signaling activation"@en .
<https://identifiers.org/aop.events/1755> rdfs:label "beta-catenin activation"@en .

<https://identifiers.org/aop.relationships/2078> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2078"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1759> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1760> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1759> rdfs:label "Increase, Cripto-1 expression"@en .
<https://identifiers.org/aop.events/1760> rdfs:label "Inhibition, Activin signaling"@en .

<https://identifiers.org/aop.relationships/2082> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2082"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1759> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1761> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1759> rdfs:label "Increase, Cripto-1 expression"@en .
<https://identifiers.org/aop.events/1761> rdfs:label "Inhibition, Fin regeneration"@en .

<https://identifiers.org/aop.relationships/2079> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2079"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1760> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1761> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1760> rdfs:label "Inhibition, Activin signaling"@en .
<https://identifiers.org/aop.events/1761> rdfs:label "Inhibition, Fin regeneration"@en .

<https://identifiers.org/aop.relationships/869> a sbdbel:CausalAssertion ;
  rdfs:label "KER 869"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/18> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/850> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/18> rdfs:label "Activation, AhR"@en .
<https://identifiers.org/aop.events/850> rdfs:label "Induction, CYP1A2/CYP1A5"@en .

<https://identifiers.org/aop.relationships/972> a sbdbel:CausalAssertion ;
  rdfs:label "KER 972"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/18> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/944> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/18> rdfs:label "Activation, AhR"@en .
<https://identifiers.org/aop.events/944> rdfs:label "dimerization, AHR/ARNT"@en .

<https://identifiers.org/aop.relationships/984> a sbdbel:CausalAssertion ;
  rdfs:label "KER 984"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/18> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/947> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/18> rdfs:label "Activation, AhR"@en .
<https://identifiers.org/aop.events/947> rdfs:label "Increase, Early Life Stage Mortality"@en .

<https://identifiers.org/aop.relationships/1656> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1656"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/18> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/462> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/18> rdfs:label "Activation, AhR"@en .
<https://identifiers.org/aop.events/462> rdfs:label "Up Regulation, SCD-1"@en .

<https://identifiers.org/aop.relationships/19> a sbdbel:CausalAssertion ;
  rdfs:label "KER 19"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/18> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/80> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/18> rdfs:label "Activation, AhR"@en .
<https://identifiers.org/aop.events/80> rdfs:label "Up Regulation, CYP1A1"@en .

<https://identifiers.org/aop.relationships/473> a sbdbel:CausalAssertion ;
  rdfs:label "KER 473"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/18> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/451> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/18> rdfs:label "Activation, AhR"@en .
<https://identifiers.org/aop.events/451> rdfs:label "Inhibition, Mitochondrial fatty acid beta-oxidation"@en .

<https://identifiers.org/aop.relationships/495> a sbdbel:CausalAssertion ;
  rdfs:label "KER 495"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/18> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/54> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/18> rdfs:label "Activation, AhR"@en .
<https://identifiers.org/aop.events/54> rdfs:label "Up Regulation, CD36"@en .

<https://identifiers.org/aop.relationships/499> a sbdbel:CausalAssertion ;
  rdfs:label "KER 499"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/18> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/216> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/18> rdfs:label "Activation, AhR"@en .
<https://identifiers.org/aop.events/216> rdfs:label "Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway)"@en .

<https://identifiers.org/aop.relationships/506> a sbdbel:CausalAssertion ;
  rdfs:label "KER 506"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/18> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/466> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/18> rdfs:label "Activation, AhR"@en .
<https://identifiers.org/aop.events/466> rdfs:label "Up Regulation, LDLR (low density lipoprotein receptor)"@en .

<https://identifiers.org/aop.relationships/509> a sbdbel:CausalAssertion ;
  rdfs:label "KER 509"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/18> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/450> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/18> rdfs:label "Activation, AhR"@en .
<https://identifiers.org/aop.events/450> rdfs:label "Suppression, VLDL secretion"@en .

<https://identifiers.org/aop.relationships/2568> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2568"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/18> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/149> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/18> rdfs:label "Activation, AhR"@en .
<https://identifiers.org/aop.events/149> rdfs:label "Increase, Inflammation"@en .

<https://identifiers.org/aop.relationships/2569> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2569"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/18> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1262> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/18> rdfs:label "Activation, AhR"@en .
<https://identifiers.org/aop.events/1262> rdfs:label "Apoptosis"@en .

<https://identifiers.org/aop.relationships/2570> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2570"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/18> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1241> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/18> rdfs:label "Activation, AhR"@en .
<https://identifiers.org/aop.events/1241> rdfs:label "Increased, Motility"@en .

<https://identifiers.org/aop.relationships/2571> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2571"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/18> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1190> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/18> rdfs:label "Activation, AhR"@en .
<https://identifiers.org/aop.events/1190> rdfs:label "Increased, Migration (Endothelial Cells)"@en .

<https://identifiers.org/aop.relationships/2572> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2572"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/18> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1196> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/18> rdfs:label "Activation, AhR"@en .
<https://identifiers.org/aop.events/1196> rdfs:label "Increased, Invasion"@en .

<https://identifiers.org/aop.relationships/2688> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2688"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/18> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2020> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/18> rdfs:label "Activation, AhR"@en .
<https://identifiers.org/aop.events/2020> rdfs:label "Decrease, sox9 expression"@en .

<https://identifiers.org/aop.relationships/2689> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2689"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/18> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1559> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/18> rdfs:label "Activation, AhR"@en .
<https://identifiers.org/aop.events/1559> rdfs:label "Facial cartilage structures are reduced in size and morphologically distorted"@en .

<https://identifiers.org/aop.relationships/2765> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2765"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/18> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/317> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/18> rdfs:label "Activation, AhR"@en .
<https://identifiers.org/aop.events/317> rdfs:label "Altered, Cardiovascular development/function"@en .

<https://identifiers.org/aop.relationships/2303> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2303"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1848> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1496> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1848> rdfs:label "Toll Like Receptor (TLR) Dysregulation"@en .
<https://identifiers.org/aop.events/1496> rdfs:label "Increased, secretion of proinflammatory mediators"@en .

<https://identifiers.org/aop.relationships/203> a sbdbel:CausalAssertion ;
  rdfs:label "KER 203"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/186> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/192> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/186> rdfs:label "Altered, Neuroanatomy"@en .
<https://identifiers.org/aop.events/192> rdfs:label "Altered, Neurophysiology"@en .

<https://identifiers.org/aop.relationships/229> a sbdbel:CausalAssertion ;
  rdfs:label "KER 229"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/201> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/195> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/201> rdfs:label "Binding of antagonist, NMDA receptors"@en .
<https://identifiers.org/aop.events/195> rdfs:label "Inhibition, NMDARs"@en .

<https://identifiers.org/aop.relationships/284> a sbdbel:CausalAssertion ;
  rdfs:label "KER 284"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/258> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/89> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/258> rdfs:label "Activation, SCD-1"@en .
<https://identifiers.org/aop.events/89> rdfs:label "Synthesis, De Novo FA"@en .

<https://identifiers.org/aop.relationships/2201> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2201"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/26> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/286> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/26> rdfs:label "Antagonism, Androgen receptor"@en .
<https://identifiers.org/aop.events/286> rdfs:label "Altered, Transcription of genes by AR"@en .

<https://identifiers.org/aop.relationships/2123> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2123"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/26> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1688> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/26> rdfs:label "Antagonism, Androgen receptor"@en .
<https://identifiers.org/aop.events/1688> rdfs:label "anogenital distance (AGD), decreased"@en .

<https://identifiers.org/aop.relationships/2130> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2130"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/26> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1614> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/26> rdfs:label "Antagonism, Androgen receptor"@en .
<https://identifiers.org/aop.events/1614> rdfs:label "Decrease, androgen receptors (AR) activation"@en .

<https://identifiers.org/aop.relationships/2133> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2133"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/26> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1786> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/26> rdfs:label "Antagonism, Androgen receptor"@en .
<https://identifiers.org/aop.events/1786> rdfs:label "Nipple retention (NR), increased"@en .

<https://identifiers.org/aop.relationships/294> a sbdbel:CausalAssertion ;
  rdfs:label "KER 294"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/264> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/89> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/264> rdfs:label "Activation, SREBP-1c"@en .
<https://identifiers.org/aop.events/89> rdfs:label "Synthesis, De Novo FA"@en .

<https://identifiers.org/aop.relationships/1701> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1701"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/272> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/313> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/272> rdfs:label "Activation/Proliferation, T-cells"@en .
<https://identifiers.org/aop.events/313> rdfs:label "Increase, Allergic Respiratory Hypersensitivity Response"@en .

<https://identifiers.org/aop.relationships/835> a sbdbel:CausalAssertion ;
  rdfs:label "KER 835"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/272> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/827> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/272> rdfs:label "Activation/Proliferation, T-cells"@en .
<https://identifiers.org/aop.events/827> rdfs:label "sensitisation, skin"@en .

<https://identifiers.org/aop.relationships/1504> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1504"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/277> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/381> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/277> rdfs:label "Thyroid hormone synthesis, Decreased"@en .
<https://identifiers.org/aop.events/381> rdfs:label "Reduced levels of BDNF"@en .

<https://identifiers.org/aop.relationships/1505> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1505"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/277> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/851> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/277> rdfs:label "Thyroid hormone synthesis, Decreased"@en .
<https://identifiers.org/aop.events/851> rdfs:label "Decrease of GABAergic interneurons"@en .

<https://identifiers.org/aop.relationships/1506> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1506"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/277> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/341> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/277> rdfs:label "Thyroid hormone synthesis, Decreased"@en .
<https://identifiers.org/aop.events/341> rdfs:label "Impairment, Learning and memory"@en .

<https://identifiers.org/aop.relationships/305> a sbdbel:CausalAssertion ;
  rdfs:label "KER 305"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/277> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/281> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/277> rdfs:label "Thyroid hormone synthesis, Decreased"@en .
<https://identifiers.org/aop.events/281> rdfs:label " Thyroxine (T4) in serum, Decreased"@en .

<https://identifiers.org/aop.relationships/1768> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1768"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/277> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/219> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/277> rdfs:label "Thyroid hormone synthesis, Decreased"@en .
<https://identifiers.org/aop.events/219> rdfs:label "Reduction, Plasma 17beta-estradiol concentrations"@en .

<https://identifiers.org/aop.relationships/810> a sbdbel:CausalAssertion ;
  rdfs:label "KER 810"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/277> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/813> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/277> rdfs:label "Thyroid hormone synthesis, Decreased"@en .
<https://identifiers.org/aop.events/813> rdfs:label "Increased, Serum creatinine"@en .

<https://identifiers.org/aop.relationships/309> a sbdbel:CausalAssertion ;
  rdfs:label "KER 309"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/279> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/277> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/279> rdfs:label "Thyroperoxidase, Inhibition"@en .
<https://identifiers.org/aop.events/277> rdfs:label "Thyroid hormone synthesis, Decreased"@en .

<https://identifiers.org/aop.relationships/366> a sbdbel:CausalAssertion ;
  rdfs:label "KER 366"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/279> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/281> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/279> rdfs:label "Thyroperoxidase, Inhibition"@en .
<https://identifiers.org/aop.events/281> rdfs:label " Thyroxine (T4) in serum, Decreased"@en .

<https://identifiers.org/aop.relationships/36> a sbdbel:CausalAssertion ;
  rdfs:label "KER 36"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/28> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/110> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/28> rdfs:label "Reduction, Angiogenesis"@en .
<https://identifiers.org/aop.events/110> rdfs:label "Impairment, Endothelial network"@en .

<https://identifiers.org/aop.relationships/444> a sbdbel:CausalAssertion ;
  rdfs:label "KER 444"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/280> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/381> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/280> rdfs:label "Thyroxine (T4) in neuronal tissue, Decreased "@en .
<https://identifiers.org/aop.events/381> rdfs:label "Reduced levels of BDNF"@en .

<https://identifiers.org/aop.relationships/746> a sbdbel:CausalAssertion ;
  rdfs:label "KER 746"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/280> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/756> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/280> rdfs:label "Thyroxine (T4) in neuronal tissue, Decreased "@en .
<https://identifiers.org/aop.events/756> rdfs:label "Hippocampal gene expression, Altered "@en .

<https://identifiers.org/aop.relationships/1039> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1039"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/281> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1007> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/281> rdfs:label " Thyroxine (T4) in serum, Decreased"@en .
<https://identifiers.org/aop.events/1007> rdfs:label "Reduced, Anterior swim bladder inflation"@en .

<https://identifiers.org/aop.relationships/1387> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1387"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/281> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/756> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/281> rdfs:label " Thyroxine (T4) in serum, Decreased"@en .
<https://identifiers.org/aop.events/756> rdfs:label "Hippocampal gene expression, Altered "@en .

<https://identifiers.org/aop.relationships/1388> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1388"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/281> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/757> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/281> rdfs:label " Thyroxine (T4) in serum, Decreased"@en .
<https://identifiers.org/aop.events/757> rdfs:label "Hippocampal anatomy, Altered "@en .

<https://identifiers.org/aop.relationships/1389> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1389"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/281> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/758> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/281> rdfs:label " Thyroxine (T4) in serum, Decreased"@en .
<https://identifiers.org/aop.events/758> rdfs:label "Hippocampal Physiology, Altered"@en .

<https://identifiers.org/aop.relationships/2038> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2038"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/281> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1003> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/281> rdfs:label " Thyroxine (T4) in serum, Decreased"@en .
<https://identifiers.org/aop.events/1003> rdfs:label "Decreased, Triiodothyronine (T3)"@en .

<https://identifiers.org/aop.relationships/312> a sbdbel:CausalAssertion ;
  rdfs:label "KER 312"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/281> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/280> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/281> rdfs:label " Thyroxine (T4) in serum, Decreased"@en .
<https://identifiers.org/aop.events/280> rdfs:label "Thyroxine (T4) in neuronal tissue, Decreased "@en .

<https://identifiers.org/aop.relationships/403> a sbdbel:CausalAssertion ;
  rdfs:label "KER 403"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/281> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/402> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/281> rdfs:label " Thyroxine (T4) in serum, Decreased"@en .
<https://identifiers.org/aop.events/402> rdfs:label "Cognitive Function, Decreased "@en .

<https://identifiers.org/aop.relationships/2168> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2168"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/281> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1101> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/281> rdfs:label " Thyroxine (T4) in serum, Decreased"@en .
<https://identifiers.org/aop.events/1101> rdfs:label "Altered, Amphibian metamorphosis"@en .

<https://identifiers.org/aop.relationships/2422> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2422"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/281> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1023> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/281> rdfs:label " Thyroxine (T4) in serum, Decreased"@en .
<https://identifiers.org/aop.events/1023> rdfs:label "Increased, Thyroid-stimulating hormone (TSH)"@en .

<https://identifiers.org/aop.relationships/2473> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2473"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/281> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/818> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/281> rdfs:label " Thyroxine (T4) in serum, Decreased"@en .
<https://identifiers.org/aop.events/818> rdfs:label "Occurrence, Cytoplasmic vacuolization (Renal tubule)"@en .

<https://identifiers.org/aop.relationships/2474> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2474"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/281> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/823> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/281> rdfs:label " Thyroxine (T4) in serum, Decreased"@en .
<https://identifiers.org/aop.events/823> rdfs:label "Occurrence, Cystic dilatation (renal tubule)"@en .

<https://identifiers.org/aop.relationships/2475> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2475"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/281> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/824> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/281> rdfs:label " Thyroxine (T4) in serum, Decreased"@en .
<https://identifiers.org/aop.events/824> rdfs:label "Occurrence, Cytoplasmic vacuolization (podocyte)"@en .

<https://identifiers.org/aop.relationships/2273> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2273"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/286> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1800> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/286> rdfs:label "Altered, Transcription of genes by AR"@en .
<https://identifiers.org/aop.events/1800> rdfs:label "Granulosa cell proliferation of gonadotropin-independent follicles, Reduced"@en .

<https://identifiers.org/aop.relationships/2127> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2127"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/286> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1688> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/286> rdfs:label "Altered, Transcription of genes by AR"@en .
<https://identifiers.org/aop.events/1688> rdfs:label "anogenital distance (AGD), decreased"@en .

<https://identifiers.org/aop.relationships/2132> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2132"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/286> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1786> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/286> rdfs:label "Altered, Transcription of genes by AR"@en .
<https://identifiers.org/aop.events/1786> rdfs:label "Nipple retention (NR), increased"@en .

<https://identifiers.org/aop.relationships/316> a sbdbel:CausalAssertion ;
  rdfs:label "KER 316"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/286> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/240> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/286> rdfs:label "Altered, Transcription of genes by AR"@en .
<https://identifiers.org/aop.events/240> rdfs:label "Feminisation or incomplete development, Primary and accessory male sex organs"@en .

<https://identifiers.org/aop.relationships/317> a sbdbel:CausalAssertion ;
  rdfs:label "KER 317"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/286> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/310> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/286> rdfs:label "Altered, Transcription of genes by AR"@en .
<https://identifiers.org/aop.events/310> rdfs:label "Alteration, Wnt pathway"@en .

<https://identifiers.org/aop.relationships/1036> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1036"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/298> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1001> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/298> rdfs:label "Insufficiency, Vascular"@en .
<https://identifiers.org/aop.events/1001> rdfs:label "Increased, Developmental Defects"@en .

<https://identifiers.org/aop.relationships/335> a sbdbel:CausalAssertion ;
  rdfs:label "KER 335"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/305> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/28> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/305> rdfs:label "Inhibition, VegfR2"@en .
<https://identifiers.org/aop.events/28> rdfs:label "Reduction, Angiogenesis"@en .

<https://identifiers.org/aop.relationships/1069> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1069"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/352> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/341> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/352> rdfs:label "N/A, Neurodegeneration"@en .
<https://identifiers.org/aop.events/341> rdfs:label "Impairment, Learning and memory"@en .

<https://identifiers.org/aop.relationships/207> a sbdbel:CausalAssertion ;
  rdfs:label "KER 207"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/352> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/188> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/352> rdfs:label "N/A, Neurodegeneration"@en .
<https://identifiers.org/aop.events/188> rdfs:label "Neuroinflammation"@en .

<https://identifiers.org/aop.relationships/2287> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2287"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/352> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1841> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/352> rdfs:label "N/A, Neurodegeneration"@en .
<https://identifiers.org/aop.events/1841> rdfs:label "Encephalitis"@en .

<https://identifiers.org/aop.relationships/647> a sbdbel:CausalAssertion ;
  rdfs:label "KER 647"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/352> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/618> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/352> rdfs:label "N/A, Neurodegeneration"@en .
<https://identifiers.org/aop.events/618> rdfs:label "Decreased, Neuronal network function in adult brain"@en .

<https://identifiers.org/aop.relationships/2144> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2144"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/36> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1789> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/36> rdfs:label "Inhibition, Aromatase"@en .
<https://identifiers.org/aop.events/1789> rdfs:label "Reduction, 17beta-estradiol synthesis by the undifferentiated gonad "@en .

<https://identifiers.org/aop.relationships/2167> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2167"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/36> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1790> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/36> rdfs:label "Inhibition, Aromatase"@en .
<https://identifiers.org/aop.events/1790> rdfs:label "Increased, Differentiation to Testis "@en .

<https://identifiers.org/aop.relationships/45> a sbdbel:CausalAssertion ;
  rdfs:label "KER 45"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/36> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/3> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/36> rdfs:label "Inhibition, Aromatase"@en .
<https://identifiers.org/aop.events/3> rdfs:label "Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"@en .

<https://identifiers.org/aop.relationships/2350> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2350"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/36> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1791> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/36> rdfs:label "Inhibition, Aromatase"@en .
<https://identifiers.org/aop.events/1791> rdfs:label "Increased, Male Biased Sex Ratio"@en .

<https://identifiers.org/aop.relationships/1507> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1507"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/381> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/341> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/381> rdfs:label "Reduced levels of BDNF"@en .
<https://identifiers.org/aop.events/341> rdfs:label "Impairment, Learning and memory"@en .

<https://identifiers.org/aop.relationships/348> a sbdbel:CausalAssertion ;
  rdfs:label "KER 348"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/381> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/382> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/381> rdfs:label "Reduced levels of BDNF"@en .
<https://identifiers.org/aop.events/382> rdfs:label "Aberrant, Dendritic morphology"@en .

<https://identifiers.org/aop.relationships/353> a sbdbel:CausalAssertion ;
  rdfs:label "KER 353"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/381> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/55> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/381> rdfs:label "Reduced levels of BDNF"@en .
<https://identifiers.org/aop.events/55> rdfs:label "Cell injury/death"@en .

<https://identifiers.org/aop.relationships/354> a sbdbel:CausalAssertion ;
  rdfs:label "KER 354"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/381> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/383> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/381> rdfs:label "Reduced levels of BDNF"@en .
<https://identifiers.org/aop.events/383> rdfs:label "Reduced, Presynaptic release of glutamate"@en .

<https://identifiers.org/aop.relationships/448> a sbdbel:CausalAssertion ;
  rdfs:label "KER 448"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/381> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/385> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/381> rdfs:label "Reduced levels of BDNF"@en .
<https://identifiers.org/aop.events/385> rdfs:label "Decrease of synaptogenesis"@en .

<https://identifiers.org/aop.relationships/870> a sbdbel:CausalAssertion ;
  rdfs:label "KER 870"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/381> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/851> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/381> rdfs:label "Reduced levels of BDNF"@en .
<https://identifiers.org/aop.events/851> rdfs:label "Decrease of GABAergic interneurons"@en .

<https://identifiers.org/aop.relationships/358> a sbdbel:CausalAssertion ;
  rdfs:label "KER 358"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/385> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/386> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/385> rdfs:label "Decrease of synaptogenesis"@en .
<https://identifiers.org/aop.events/386> rdfs:label "Decrease of neuronal network function"@en .

<https://identifiers.org/aop.relationships/362> a sbdbel:CausalAssertion ;
  rdfs:label "KER 362"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/389> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/177> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/389> rdfs:label "Increased, Intracellular Calcium overload"@en .
<https://identifiers.org/aop.events/177> rdfs:label "N/A, Mitochondrial dysfunction 1"@en .

<https://identifiers.org/aop.relationships/1862> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1862"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/389> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/55> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/389> rdfs:label "Increased, Intracellular Calcium overload"@en .
<https://identifiers.org/aop.events/55> rdfs:label "Cell injury/death"@en .

<https://identifiers.org/aop.relationships/2704> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2704"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/389> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2038> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/389> rdfs:label "Increased, Intracellular Calcium overload"@en .
<https://identifiers.org/aop.events/2038> rdfs:label "Activation of calpain signalling"@en .

<https://identifiers.org/aop.relationships/2709> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2709"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/389> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1477> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/389> rdfs:label "Increased, Intracellular Calcium overload"@en .
<https://identifiers.org/aop.events/1477> rdfs:label "Decrease, Oxidative phosphorylation"@en .

<https://identifiers.org/aop.relationships/2710> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2710"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/389> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2017> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/389> rdfs:label "Increased, Intracellular Calcium overload"@en .
<https://identifiers.org/aop.events/2017> rdfs:label "Endoplasmic reticulum stress"@en .

<https://identifiers.org/aop.relationships/396> a sbdbel:CausalAssertion ;
  rdfs:label "KER 396"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/408> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/3> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/408> rdfs:label "reduction in ovarian granulosa cells, Aromatase (Cyp19a1)"@en .
<https://identifiers.org/aop.events/3> rdfs:label "Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"@en .

<https://identifiers.org/aop.relationships/927> a sbdbel:CausalAssertion ;
  rdfs:label "KER 927"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/41> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/214> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/41> rdfs:label "Inhibition, Bile Salt Export Pump (ABCB11)"@en .
<https://identifiers.org/aop.events/214> rdfs:label "Bile accumulation, Pathological condition"@en .

<https://identifiers.org/aop.relationships/1503> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1503"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/424> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/341> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/424> rdfs:label "Inhibition, Na+/I- symporter (NIS)"@en .
<https://identifiers.org/aop.events/341> rdfs:label "Impairment, Learning and memory"@en .

<https://identifiers.org/aop.relationships/442> a sbdbel:CausalAssertion ;
  rdfs:label "KER 442"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/424> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/425> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/424> rdfs:label "Inhibition, Na+/I- symporter (NIS)"@en .
<https://identifiers.org/aop.events/425> rdfs:label "Decrease of Thyroidal iodide"@en .

<https://identifiers.org/aop.relationships/2232> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2232"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/424> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/281> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/424> rdfs:label "Inhibition, Na+/I- symporter (NIS)"@en .
<https://identifiers.org/aop.events/281> rdfs:label " Thyroxine (T4) in serum, Decreased"@en .

<https://identifiers.org/aop.relationships/552> a sbdbel:CausalAssertion ;
  rdfs:label "KER 552"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/424> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/277> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/424> rdfs:label "Inhibition, Na+/I- symporter (NIS)"@en .
<https://identifiers.org/aop.events/277> rdfs:label "Thyroid hormone synthesis, Decreased"@en .

<https://identifiers.org/aop.relationships/872> a sbdbel:CausalAssertion ;
  rdfs:label "KER 872"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/425> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/277> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/425> rdfs:label "Decrease of Thyroidal iodide"@en .
<https://identifiers.org/aop.events/277> rdfs:label "Thyroid hormone synthesis, Decreased"@en .

<https://identifiers.org/aop.relationships/61> a sbdbel:CausalAssertion ;
  rdfs:label "KER 61"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/51> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/50> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/51> rdfs:label "Inhibition, Ca++ ATPase"@en .
<https://identifiers.org/aop.events/50> rdfs:label "Increase, Ca++ (intracellular)"@en .

<https://identifiers.org/aop.relationships/501> a sbdbel:CausalAssertion ;
  rdfs:label "KER 501"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/54> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/465> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/54> rdfs:label "Up Regulation, CD36"@en .
<https://identifiers.org/aop.events/465> rdfs:label "Increased, FA Influx"@en .

<https://identifiers.org/aop.relationships/66> a sbdbel:CausalAssertion ;
  rdfs:label "KER 66"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/54> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/115> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/54> rdfs:label "Up Regulation, CD36"@en .
<https://identifiers.org/aop.events/115> rdfs:label "Increase, FA Influx"@en .

<https://identifiers.org/aop.relationships/1242> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1242"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/584> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1176> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/584> rdfs:label "Inhibition, sodium channel"@en .
<https://identifiers.org/aop.events/1176> rdfs:label "Decreased, sodium conductance 2"@en .

<https://identifiers.org/aop.relationships/585> a sbdbel:CausalAssertion ;
  rdfs:label "KER 585"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/584> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/585> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/584> rdfs:label "Inhibition, sodium channel"@en .
<https://identifiers.org/aop.events/585> rdfs:label "Decreased, Sodium conductance 1"@en .

<https://identifiers.org/aop.relationships/1316> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1316"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/619> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/625> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/619> rdfs:label "Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)"@en .
<https://identifiers.org/aop.events/625> rdfs:label "Increased, muscular waves in foot"@en .

<https://identifiers.org/aop.relationships/1317> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1317"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/619> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1142> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/619> rdfs:label "Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)"@en .
<https://identifiers.org/aop.events/1142> rdfs:label "Increased, valve movement"@en .

<https://identifiers.org/aop.relationships/1318> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1318"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/619> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/621> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/619> rdfs:label "Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)"@en .
<https://identifiers.org/aop.events/621> rdfs:label "Increase, cilia movement"@en .

<https://identifiers.org/aop.relationships/1319> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1319"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/619> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1256> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/619> rdfs:label "Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)"@en .
<https://identifiers.org/aop.events/1256> rdfs:label "increased mantel display"@en .

<https://identifiers.org/aop.relationships/1337> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1337"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/619> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1161> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/619> rdfs:label "Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)"@en .
<https://identifiers.org/aop.events/1161> rdfs:label "Increased, oocyte maturation"@en .

<https://identifiers.org/aop.relationships/643> a sbdbel:CausalAssertion ;
  rdfs:label "KER 643"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/619> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/626> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/619> rdfs:label "Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)"@en .
<https://identifiers.org/aop.events/626> rdfs:label "Increased, serotonin (5-HT) "@en .

<https://identifiers.org/aop.relationships/483> a sbdbel:CausalAssertion ;
  rdfs:label "KER 483"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/66> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/458> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/66> rdfs:label "Activation, ChREBP"@en .
<https://identifiers.org/aop.events/458> rdfs:label "Increased, De Novo FA synthesis"@en .

<https://identifiers.org/aop.relationships/77> a sbdbel:CausalAssertion ;
  rdfs:label "KER 77"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/66> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/89> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/66> rdfs:label "Activation, ChREBP"@en .
<https://identifiers.org/aop.events/89> rdfs:label "Synthesis, De Novo FA"@en .

<https://identifiers.org/aop.relationships/1309> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1309"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/663> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1243> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/663> rdfs:label "Desensitization, Nicotinic acetylcholine receptor"@en .
<https://identifiers.org/aop.events/1243> rdfs:label "Altered, Ca2+-calmodulin activated signal transduction"@en .

<https://identifiers.org/aop.relationships/659> a sbdbel:CausalAssertion ;
  rdfs:label "KER 659"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/663> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/386> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/663> rdfs:label "Desensitization, Nicotinic acetylcholine receptor"@en .
<https://identifiers.org/aop.events/386> rdfs:label "Decrease of neuronal network function"@en .

<https://identifiers.org/aop.relationships/683> a sbdbel:CausalAssertion ;
  rdfs:label "KER 683"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/669> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/682> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/669> rdfs:label "Reduction, Neuronal synaptic inhibition"@en .
<https://identifiers.org/aop.events/682> rdfs:label "Generation, Amplified excitatory postsynaptic potential (EPSP)"@en .

<https://identifiers.org/aop.relationships/1268> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1268"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/715> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1214> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/715> rdfs:label "Activation, Constitutive androstane receptor"@en .
<https://identifiers.org/aop.events/1214> rdfs:label "Altered gene expression specific to CAR activation, Hepatocytes"@en .

<https://identifiers.org/aop.relationships/773> a sbdbel:CausalAssertion ;
  rdfs:label "KER 773"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/716> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/774> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/716> rdfs:label "Increase, cell proliferation (hepatocytes)"@en .
<https://identifiers.org/aop.events/774> rdfs:label "Increase, Preneoplastic foci (hepatocytes)"@en .

<https://identifiers.org/aop.relationships/1239> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1239"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/716> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1171> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/716> rdfs:label "Increase, cell proliferation (hepatocytes)"@en .
<https://identifiers.org/aop.events/1171> rdfs:label "Increase, Clonal Expansion of Altered Hepatic Foci"@en .

<https://identifiers.org/aop.relationships/2254> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2254"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/716> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/719> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/716> rdfs:label "Increase, cell proliferation (hepatocytes)"@en .
<https://identifiers.org/aop.events/719> rdfs:label "Increase, hepatocellular adenomas and carcinomas"@en .

<https://identifiers.org/aop.relationships/738> a sbdbel:CausalAssertion ;
  rdfs:label "KER 738"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/752> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/723> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/752> rdfs:label "Altered, Meiotic chromosome dynamics"@en .
<https://identifiers.org/aop.events/723> rdfs:label "Altered, Chromosome number"@en .

<https://identifiers.org/aop.relationships/2383> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2383"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/752> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1775> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/752> rdfs:label "Altered, Meiotic chromosome dynamics"@en .
<https://identifiers.org/aop.events/1775> rdfs:label "Increase, Oocyte apoptosis"@en .

<https://identifiers.org/aop.relationships/2384> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2384"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/752> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1798> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/752> rdfs:label "Altered, Meiotic chromosome dynamics"@en .
<https://identifiers.org/aop.events/1798> rdfs:label "Decreased spermatogenesis "@en .

<https://identifiers.org/aop.relationships/2554> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2554"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/752> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1965> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/752> rdfs:label "Altered, Meiotic chromosome dynamics"@en .
<https://identifiers.org/aop.events/1965> rdfs:label "Increase, Pollen abnormal"@en .

<https://identifiers.org/aop.relationships/670> a sbdbel:CausalAssertion ;
  rdfs:label "KER 670"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/79> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/672> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/79> rdfs:label "Inhibition, Cyclooxygenase activity"@en .
<https://identifiers.org/aop.events/672> rdfs:label "Reduced, Prostaglandin F2alpha synthesis, ovary  "@en .

<https://identifiers.org/aop.relationships/681> a sbdbel:CausalAssertion ;
  rdfs:label "KER 681"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/79> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/681> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/79> rdfs:label "Inhibition, Cyclooxygenase activity"@en .
<https://identifiers.org/aop.events/681> rdfs:label "Decreased, Prostaglandin F2alpha synthesis, ovary  "@en .

<https://identifiers.org/aop.relationships/686> a sbdbel:CausalAssertion ;
  rdfs:label "KER 686"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/79> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/685> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/79> rdfs:label "Inhibition, Cyclooxygenase activity"@en .
<https://identifiers.org/aop.events/685> rdfs:label "Reduced, Prostaglandins, ovary"@en .

<https://identifiers.org/aop.relationships/689> a sbdbel:CausalAssertion ;
  rdfs:label "KER 689"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/79> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/687> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/79> rdfs:label "Inhibition, Cyclooxygenase activity"@en .
<https://identifiers.org/aop.events/687> rdfs:label "Reduced, Prostaglandin E2 concentration, hypothalamus"@en .

<https://identifiers.org/aop.relationships/95> a sbdbel:CausalAssertion ;
  rdfs:label "KER 95"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/79> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/243> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/79> rdfs:label "Inhibition, Cyclooxygenase activity"@en .
<https://identifiers.org/aop.events/243> rdfs:label "Reduction, Prostaglandin E2 concentration"@en .

<https://identifiers.org/aop.relationships/834> a sbdbel:CausalAssertion ;
  rdfs:label "KER 834"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/826> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/398> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/826> rdfs:label "Activation, Keratinocytes"@en .
<https://identifiers.org/aop.events/398> rdfs:label "Activation, Dendritic Cells"@en .

<https://identifiers.org/aop.relationships/871> a sbdbel:CausalAssertion ;
  rdfs:label "KER 871"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/851> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/385> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/851> rdfs:label "Decrease of GABAergic interneurons"@en .
<https://identifiers.org/aop.events/385> rdfs:label "Decrease of synaptogenesis"@en .

<https://identifiers.org/aop.relationships/995> a sbdbel:CausalAssertion ;
  rdfs:label "KER 995"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/853> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/139> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/853> rdfs:label "Changes/Inhibition, Cellular Homeostasis and Apoptosis"@en .
<https://identifiers.org/aop.events/139> rdfs:label "N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects"@en .

<https://identifiers.org/aop.relationships/880> a sbdbel:CausalAssertion ;
  rdfs:label "KER 880"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/858> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/861> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/858> rdfs:label "Decreased, PPARalpha transactivation of gene expression"@en .
<https://identifiers.org/aop.events/861> rdfs:label "Decreased, Ketogenesis (production of ketone bodies)"@en .

<https://identifiers.org/aop.relationships/1748> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1748"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/858> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1528> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/858> rdfs:label "Decreased, PPARalpha transactivation of gene expression"@en .
<https://identifiers.org/aop.events/1528> rdfs:label "Fatty Acid Beta Oxidation, Decreased"@en .

<https://identifiers.org/aop.relationships/1131> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1131"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/877> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1096> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/877> rdfs:label "Inhibition, organic anion transporter 1 (OAT1)"@en .
<https://identifiers.org/aop.events/1096> rdfs:label "Increased, blood uric acid concentration"@en .

<https://identifiers.org/aop.relationships/1809> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1809"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/887> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1477> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/887> rdfs:label "Inhibition, NADH-ubiquinone oxidoreductase  (complex I)"@en .
<https://identifiers.org/aop.events/1477> rdfs:label "Decrease, Oxidative phosphorylation"@en .

<https://identifiers.org/aop.relationships/934> a sbdbel:CausalAssertion ;
  rdfs:label "KER 934"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/887> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/177> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/887> rdfs:label "Inhibition, NADH-ubiquinone oxidoreductase  (complex I)"@en .
<https://identifiers.org/aop.events/177> rdfs:label "N/A, Mitochondrial dysfunction 1"@en .

<https://identifiers.org/aop.relationships/1940> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1940"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/887> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1545> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/887> rdfs:label "Inhibition, NADH-ubiquinone oxidoreductase  (complex I)"@en .
<https://identifiers.org/aop.events/1545> rdfs:label "Decrease in mitochondrial oxidative phosphorylation"@en .

<https://identifiers.org/aop.relationships/933> a sbdbel:CausalAssertion ;
  rdfs:label "KER 933"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/888> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/887> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/888> rdfs:label "Binding of inhibitor, NADH-ubiquinone oxidoreductase (complex I)"@en .
<https://identifiers.org/aop.events/887> rdfs:label "Inhibition, NADH-ubiquinone oxidoreductase  (complex I)"@en .

<https://identifiers.org/aop.relationships/110> a sbdbel:CausalAssertion ;
  rdfs:label "KER 110"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/89> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/291> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/89> rdfs:label "Synthesis, De Novo FA"@en .
<https://identifiers.org/aop.events/291> rdfs:label "Accumulation, Triglyceride"@en .

<https://identifiers.org/aop.relationships/955> a sbdbel:CausalAssertion ;
  rdfs:label "KER 955"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/927> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/932> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/927> rdfs:label "KE1 : S-Glutathionylation, eNOS"@en .
<https://identifiers.org/aop.events/932> rdfs:label "KE4 : Uncoupling, eNOS"@en .

<https://identifiers.org/aop.relationships/952> a sbdbel:CausalAssertion ;
  rdfs:label "KER 952"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/935> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/934> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/935> rdfs:label "KE2 : Decrease, GTPCH-1"@en .
<https://identifiers.org/aop.events/934> rdfs:label "KE3 : Decrease, Tetrahydrobiopterin"@en .

<https://identifiers.org/aop.relationships/986> a sbdbel:CausalAssertion ;
  rdfs:label "KER 986"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/941> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/962> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/941> rdfs:label "Activation, EGFR"@en .
<https://identifiers.org/aop.events/962> rdfs:label "Increase, Mucin production"@en .

<https://identifiers.org/aop.relationships/2857> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2857"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/941> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2117> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/941> rdfs:label "Activation, EGFR"@en .
<https://identifiers.org/aop.events/2117> rdfs:label "Increase, goblet cell number"@en .

<https://identifiers.org/aop.relationships/1350> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1350"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/944> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1269> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/944> rdfs:label "dimerization, AHR/ARNT"@en .
<https://identifiers.org/aop.events/1269> rdfs:label "Increase, COX-2 expression"@en .

<https://identifiers.org/aop.relationships/973> a sbdbel:CausalAssertion ;
  rdfs:label "KER 973"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/944> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/945> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/944> rdfs:label "dimerization, AHR/ARNT"@en .
<https://identifiers.org/aop.events/945> rdfs:label "reduced dimerization, ARNT/HIF1-alpha"@en .

<https://identifiers.org/aop.relationships/1996> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1996"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/944> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1697> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/944> rdfs:label "dimerization, AHR/ARNT"@en .
<https://identifiers.org/aop.events/1697> rdfs:label "Increase, DNA methyltransferase expression"@en .

<https://identifiers.org/aop.relationships/2683> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2683"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/944> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2021> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/944> rdfs:label "dimerization, AHR/ARNT"@en .
<https://identifiers.org/aop.events/2021> rdfs:label "Increase, slincR expression"@en .

<https://identifiers.org/aop.relationships/975> a sbdbel:CausalAssertion ;
  rdfs:label "KER 975"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/948> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/110> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/948> rdfs:label "reduced production, VEGF"@en .
<https://identifiers.org/aop.events/110> rdfs:label "Impairment, Endothelial network"@en .

<https://identifiers.org/aop.relationships/2407> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2407"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/948> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1891> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/948> rdfs:label "reduced production, VEGF"@en .
<https://identifiers.org/aop.events/1891> rdfs:label "abnormal, placental labyrinth vasculature morphology"@en .

<https://identifiers.org/aop.relationships/2245> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2245"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/957> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/958> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/957> rdfs:label "Binding, Transthyretin in serum"@en .
<https://identifiers.org/aop.events/958> rdfs:label "Displacement, Serum thyroxine (T4) from transthyretin"@en .

<https://identifiers.org/aop.relationships/2248> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2248"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/957> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1830> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/957> rdfs:label "Binding, Transthyretin in serum"@en .
<https://identifiers.org/aop.events/1830> rdfs:label "Displacement, Serum thyroxine (T4) from carrier protein"@en .

<https://identifiers.org/aop.relationships/2246> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2246"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/958> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/959> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/958> rdfs:label "Displacement, Serum thyroxine (T4) from transthyretin"@en .
<https://identifiers.org/aop.events/959> rdfs:label "Increased, Free serum thyroxine (T4)"@en .

<https://identifiers.org/aop.relationships/2247> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2247"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/959> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1158> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/959> rdfs:label "Increased, Free serum thyroxine (T4)"@en .
<https://identifiers.org/aop.events/1158> rdfs:label "Increased, Hepatic thyroid hormone uptake/transport"@en .

<https://identifiers.org/aop.relationships/2272> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2272"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/959> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/961> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/959> rdfs:label "Increased, Free serum thyroxine (T4)"@en .
<https://identifiers.org/aop.events/961> rdfs:label "Increased, Clearance of thyroxine from serum"@en .

<https://identifiers.org/aop.relationships/2270> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2270"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/961> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/281> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/961> rdfs:label "Increased, Clearance of thyroxine from serum"@en .
<https://identifiers.org/aop.events/281> rdfs:label " Thyroxine (T4) in serum, Decreased"@en .

<https://identifiers.org/aop.relationships/2859> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2859"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/962> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1250> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/962> rdfs:label "Increase, Mucin production"@en .
<https://identifiers.org/aop.events/1250> rdfs:label "Decrease, Lung function"@en .

<https://identifiers.org/aop.relationships/988> a sbdbel:CausalAssertion ;
  rdfs:label "KER 988"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/973> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/933> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/973> rdfs:label "KE5 : Decrease, AKT/eNOS activity"@en .
<https://identifiers.org/aop.events/933> rdfs:label "KE6 : Depletion, Nitric Oxide"@en .

<https://identifiers.org/aop.relationships/1017> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1017"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/979> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/981> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/979> rdfs:label "Interference, nuclear localization of NFAT"@en .
<https://identifiers.org/aop.events/981> rdfs:label "Reduction, NFAT/AP-1 complex formation"@en .

<https://identifiers.org/aop.relationships/1508> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1508"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/980> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/979> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/980> rdfs:label "Inhibition, Calcineurin Activity"@en .
<https://identifiers.org/aop.events/979> rdfs:label "Interference, nuclear localization of NFAT"@en .

<https://identifiers.org/aop.relationships/1509> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1509"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/981> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1202> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/981> rdfs:label "Reduction, NFAT/AP-1 complex formation"@en .
<https://identifiers.org/aop.events/1202> rdfs:label "Suppression, IL-2 and IL-4 production"@en .

<https://identifiers.org/aop.relationships/1857> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1857"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/10> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1602> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/10> rdfs:label "Acetylcholine accumulation in synapses"@en .
<https://identifiers.org/aop.events/1602> rdfs:label "Activation, Muscarinic Acetylcholine Receptors"@en .

<https://identifiers.org/aop.relationships/456> a sbdbel:CausalAssertion ;
  rdfs:label "KER 456"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/10> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/39> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/10> rdfs:label "Acetylcholine accumulation in synapses"@en .
<https://identifiers.org/aop.events/39> rdfs:label "Increased Cholinergic Signaling"@en .

<https://identifiers.org/aop.relationships/2213> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2213"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1004> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/351> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1004> rdfs:label "Reduced, Posterior swim bladder inflation"@en .
<https://identifiers.org/aop.events/351> rdfs:label "Increased Mortality"@en .

<https://identifiers.org/aop.relationships/1028> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1028"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1004> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1005> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1004> rdfs:label "Reduced, Posterior swim bladder inflation"@en .
<https://identifiers.org/aop.events/1005> rdfs:label "Reduced, Swimming performance"@en .

<https://identifiers.org/aop.relationships/1641> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1641"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1005> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1467> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1005> rdfs:label "Reduced, Swimming performance"@en .
<https://identifiers.org/aop.events/1467> rdfs:label "Growth, reduction"@en .

<https://identifiers.org/aop.relationships/1642> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1642"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1005> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/636> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1005> rdfs:label "Reduced, Swimming performance"@en .
<https://identifiers.org/aop.events/636> rdfs:label "Decreased, survival"@en .

<https://identifiers.org/aop.relationships/2081> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2081"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1005> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/360> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1005> rdfs:label "Reduced, Swimming performance"@en .
<https://identifiers.org/aop.events/360> rdfs:label "Decrease, Population growth rate"@en .

<https://identifiers.org/aop.relationships/2212> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2212"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1005> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/351> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1005> rdfs:label "Reduced, Swimming performance"@en .
<https://identifiers.org/aop.events/351> rdfs:label "Increased Mortality"@en .

<https://identifiers.org/aop.relationships/1034> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1034"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1007> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1005> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1007> rdfs:label "Reduced, Anterior swim bladder inflation"@en .
<https://identifiers.org/aop.events/1005> rdfs:label "Reduced, Swimming performance"@en .

<https://identifiers.org/aop.relationships/1054> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1054"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1012> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1014> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1012> rdfs:label "Increased, Inhibitory postsynaptic potential"@en .
<https://identifiers.org/aop.events/1014> rdfs:label "Induction, Somatic muscle paralysis"@en .

<https://identifiers.org/aop.relationships/1058> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1058"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1012> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1019> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1012> rdfs:label "Increased, Inhibitory postsynaptic potential"@en .
<https://identifiers.org/aop.events/1019> rdfs:label "Induction, pharyngeal muscle paralysis"@en .

<https://identifiers.org/aop.relationships/1050> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1050"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1014> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/351> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1014> rdfs:label "Induction, Somatic muscle paralysis"@en .
<https://identifiers.org/aop.events/351> rdfs:label "Increased Mortality"@en .

<https://identifiers.org/aop.relationships/1055> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1055"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1014> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1016> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1014> rdfs:label "Induction, Somatic muscle paralysis"@en .
<https://identifiers.org/aop.events/1016> rdfs:label "Inhibition, Feeding"@en .

<https://identifiers.org/aop.relationships/1053> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1053"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1015> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1012> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1015> rdfs:label "Increased, Neuronal synaptic inhibition"@en .
<https://identifiers.org/aop.events/1012> rdfs:label "Increased, Inhibitory postsynaptic potential"@en .

<https://identifiers.org/aop.relationships/1056> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1056"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1016> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/351> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1016> rdfs:label "Inhibition, Feeding"@en .
<https://identifiers.org/aop.events/351> rdfs:label "Increased Mortality"@en .

<https://identifiers.org/aop.relationships/1057> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1057"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1018> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/761> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1018> rdfs:label "Activation, Glutamate-gated chloride channels"@en .
<https://identifiers.org/aop.events/761> rdfs:label "Increased, Chloride conductance"@en .

<https://identifiers.org/aop.relationships/1059> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1059"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1019> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1016> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1019> rdfs:label "Induction, pharyngeal muscle paralysis"@en .
<https://identifiers.org/aop.events/1016> rdfs:label "Inhibition, Feeding"@en .

<https://identifiers.org/aop.relationships/2240> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2240"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1023> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1828> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1023> rdfs:label "Increased, Thyroid-stimulating hormone (TSH)"@en .
<https://identifiers.org/aop.events/1828> rdfs:label "Increased, Thyroxine (T4) in serum"@en .

<https://identifiers.org/aop.relationships/2424> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2424"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1023> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/739> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1023> rdfs:label "Increased, Thyroid-stimulating hormone (TSH)"@en .
<https://identifiers.org/aop.events/739> rdfs:label "Increase, Hypertrophy and proliferation (follicular cell)"@en .

<https://identifiers.org/aop.relationships/1071> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1071"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1028> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1029> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1028> rdfs:label "Activation of specific nuclear receptors, PPAR-gamma activation"@en .
<https://identifiers.org/aop.events/1029> rdfs:label "Increased, adipogenesis"@en .

<https://identifiers.org/aop.relationships/1072> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1072"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1028> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1032> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1028> rdfs:label "Activation of specific nuclear receptors, PPAR-gamma activation"@en .
<https://identifiers.org/aop.events/1032> rdfs:label "Increased, secretion of local growth factors"@en .

<https://identifiers.org/aop.relationships/1609> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1609"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1028> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1449> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1028> rdfs:label "Activation of specific nuclear receptors, PPAR-gamma activation"@en .
<https://identifiers.org/aop.events/1449> rdfs:label "increased adipogenesis"@en .

<https://identifiers.org/aop.relationships/1073> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1073"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1029> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1032> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1029> rdfs:label "Increased, adipogenesis"@en .
<https://identifiers.org/aop.events/1032> rdfs:label "Increased, secretion of local growth factors"@en .

<https://identifiers.org/aop.relationships/1343> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1343"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/103> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1264> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/103> rdfs:label "Increase, Ecdysone receptor agonism"@en .
<https://identifiers.org/aop.events/1264> rdfs:label "Increase, Nuclear receptor E75b gene expression"@en .

<https://identifiers.org/aop.relationships/1074> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1074"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1032> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1033> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1032> rdfs:label "Increased, secretion of local growth factors"@en .
<https://identifiers.org/aop.events/1033> rdfs:label "Increased, proliferation of mesenchymal cells"@en .

<https://identifiers.org/aop.relationships/1075> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1075"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1032> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1034> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1032> rdfs:label "Increased, secretion of local growth factors"@en .
<https://identifiers.org/aop.events/1034> rdfs:label "Increased, IGF-1 (mouse)"@en .

<https://identifiers.org/aop.relationships/1129> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1129"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1032> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1089> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1032> rdfs:label "Increased, secretion of local growth factors"@en .
<https://identifiers.org/aop.events/1089> rdfs:label "Increased, Cell Proliferation (mesothelium)"@en .

<https://identifiers.org/aop.relationships/1076> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1076"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1033> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1035> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1033> rdfs:label "Increased, proliferation of mesenchymal cells"@en .
<https://identifiers.org/aop.events/1035> rdfs:label "Increased, Firbrosarcoma"@en .

<https://identifiers.org/aop.relationships/1077> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1077"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1033> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1036> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1033> rdfs:label "Increased, proliferation of mesenchymal cells"@en .
<https://identifiers.org/aop.events/1036> rdfs:label "Increased, liposarcoma"@en .

<https://identifiers.org/aop.relationships/1078> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1078"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1033> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1037> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1033> rdfs:label "Increased, proliferation of mesenchymal cells"@en .
<https://identifiers.org/aop.events/1037> rdfs:label "Increased, hemagiosarcoma"@en .

<https://identifiers.org/aop.relationships/1079> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1079"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1038> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1039> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1038> rdfs:label "Activation, beta-2 adrenergic receptor"@en .
<https://identifiers.org/aop.events/1039> rdfs:label "Increased activity, beta-2 adrenergic receptor"@en .

<https://identifiers.org/aop.relationships/1080> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1080"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1039> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1040> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1039> rdfs:label "Increased activity, beta-2 adrenergic receptor"@en .
<https://identifiers.org/aop.events/1040> rdfs:label "relaxation, smooth muscle"@en .

<https://identifiers.org/aop.relationships/1081> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1081"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1040> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1042> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1040> rdfs:label "relaxation, smooth muscle"@en .
<https://identifiers.org/aop.events/1042> rdfs:label "Proliferation/Clonal Expansion, smooth muscle"@en .

<https://identifiers.org/aop.relationships/1082> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1082"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1042> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1043> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1042> rdfs:label "Proliferation/Clonal Expansion, smooth muscle"@en .
<https://identifiers.org/aop.events/1043> rdfs:label "Hypertrophy/hyperplasia, smooth muscle"@en .

<https://identifiers.org/aop.relationships/1083> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1083"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1043> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1044> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1043> rdfs:label "Hypertrophy/hyperplasia, smooth muscle"@en .
<https://identifiers.org/aop.events/1044> rdfs:label "Promotion, mesovarian leiomyomas"@en .

<https://identifiers.org/aop.relationships/1085> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1085"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1045> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1056> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1045> rdfs:label "Decreased, Ovarian E2"@en .
<https://identifiers.org/aop.events/1056> rdfs:label "Decrease, E2 blood concentrations at hypothalamus"@en .

<https://identifiers.org/aop.relationships/1086> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1086"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1046> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1056> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1046> rdfs:label "Suppression, Estrogen receptor (ER) activity"@en .
<https://identifiers.org/aop.events/1056> rdfs:label "Decrease, E2 blood concentrations at hypothalamus"@en .

<https://identifiers.org/aop.relationships/2580> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2580"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1046> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1047> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1046> rdfs:label "Suppression, Estrogen receptor (ER) activity"@en .
<https://identifiers.org/aop.events/1047> rdfs:label "Increased, secretion of GnRH from hypothalamus"@en .

<https://identifiers.org/aop.relationships/1088> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1088"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1047> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1049> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1047> rdfs:label "Increased, secretion of GnRH from hypothalamus"@en .
<https://identifiers.org/aop.events/1049> rdfs:label "Increased, secrection of FSH from anterior pituitary"@en .

<https://identifiers.org/aop.relationships/1089> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1089"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1047> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1050> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1047> rdfs:label "Increased, secretion of GnRH from hypothalamus"@en .
<https://identifiers.org/aop.events/1050> rdfs:label "Increased, secretion of LH from anterior pituitary"@en .

<https://identifiers.org/aop.relationships/1090> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1090"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1049> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1051> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1049> rdfs:label "Increased, secrection of FSH from anterior pituitary"@en .
<https://identifiers.org/aop.events/1051> rdfs:label "Hyperplasia, ovarian stromal cells"@en .

<https://identifiers.org/aop.relationships/1091> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1091"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1049> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1052> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1049> rdfs:label "Increased, secrection of FSH from anterior pituitary"@en .
<https://identifiers.org/aop.events/1052> rdfs:label "Hyperplasia, ovarian epithelium"@en .

<https://identifiers.org/aop.relationships/1092> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1092"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1050> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1051> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1050> rdfs:label "Increased, secretion of LH from anterior pituitary"@en .
<https://identifiers.org/aop.events/1051> rdfs:label "Hyperplasia, ovarian stromal cells"@en .

<https://identifiers.org/aop.relationships/2581> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2581"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1050> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1972> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1050> rdfs:label "Increased, secretion of LH from anterior pituitary"@en .
<https://identifiers.org/aop.events/1972> rdfs:label "Increased, Steroidogenic acute regulatory protein (StAR) "@en .

<https://identifiers.org/aop.relationships/1094> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1094"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1051> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1054> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1051> rdfs:label "Hyperplasia, ovarian stromal cells"@en .
<https://identifiers.org/aop.events/1054> rdfs:label "Promotion, ovarian granular cell tumors"@en .

<https://identifiers.org/aop.relationships/1093> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1093"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1052> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1053> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1052> rdfs:label "Hyperplasia, ovarian epithelium"@en .
<https://identifiers.org/aop.events/1053> rdfs:label "Promotion, ovarian adenomas"@en .

<https://identifiers.org/aop.relationships/2829> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2829"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1053> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2092> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1053> rdfs:label "Promotion, ovarian adenomas"@en .
<https://identifiers.org/aop.events/2092> rdfs:label "Promotion, Ovarian Cancer "@en .

<https://identifiers.org/aop.relationships/1087> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1087"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1056> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1047> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1056> rdfs:label "Decrease, E2 blood concentrations at hypothalamus"@en .
<https://identifiers.org/aop.events/1047> rdfs:label "Increased, secretion of GnRH from hypothalamus"@en .

<https://identifiers.org/aop.relationships/1095> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1095"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1057> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1058> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1057> rdfs:label "Increased, PPAR-alpha activation"@en .
<https://identifiers.org/aop.events/1058> rdfs:label "Decreased, bile flow"@en .

<https://identifiers.org/aop.relationships/1096> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1096"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1057> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1059> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1057> rdfs:label "Increased, PPAR-alpha activation"@en .
<https://identifiers.org/aop.events/1059> rdfs:label "Increased, cholestasis"@en .

<https://identifiers.org/aop.relationships/1097> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1097"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1057> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1060> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1057> rdfs:label "Increased, PPAR-alpha activation"@en .
<https://identifiers.org/aop.events/1060> rdfs:label "Alteration, lipid metabolism"@en .

<https://identifiers.org/aop.relationships/1101> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1101"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1058> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1059> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1058> rdfs:label "Decreased, bile flow"@en .
<https://identifiers.org/aop.events/1059> rdfs:label "Increased, cholestasis"@en .

<https://identifiers.org/aop.relationships/1100> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1100"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1059> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1061> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1059> rdfs:label "Increased, cholestasis"@en .
<https://identifiers.org/aop.events/1061> rdfs:label "prolonged, elevation of serun CCK"@en .

<https://identifiers.org/aop.relationships/123> a sbdbel:CausalAssertion ;
  rdfs:label "KER 123"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/106> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/253> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/106> rdfs:label "Reduction, Eggshell thickness"@en .
<https://identifiers.org/aop.events/253> rdfs:label "N/A, Reproductive failure"@en .

<https://identifiers.org/aop.relationships/1098> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1098"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1061> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1062> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1061> rdfs:label "prolonged, elevation of serun CCK"@en .
<https://identifiers.org/aop.events/1062> rdfs:label "Increased, Cellular proliferation / hyperplasia of acinar cells"@en .

<https://identifiers.org/aop.relationships/1099> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1099"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1062> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1063> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1062> rdfs:label "Increased, Cellular proliferation / hyperplasia of acinar cells"@en .
<https://identifiers.org/aop.events/1063> rdfs:label "Increased, Pancreatic acinar tumors"@en .

<https://identifiers.org/aop.relationships/1102> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1102"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1064> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1065> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1064> rdfs:label "prepubertal increase, Estrogen receptor (ER) activity"@en .
<https://identifiers.org/aop.events/1065> rdfs:label "Activation, estrogen receptor alpha"@en .

<https://identifiers.org/aop.relationships/1103> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1103"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1065> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1066> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1065> rdfs:label "Activation, estrogen receptor alpha"@en .
<https://identifiers.org/aop.events/1066> rdfs:label "Promotion, SIX-1 postive basal-type progenitor cells"@en .

<https://identifiers.org/aop.relationships/2665> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2665"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1065> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1985> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1065> rdfs:label "Activation, estrogen receptor alpha"@en .
<https://identifiers.org/aop.events/1985> rdfs:label "Increased, Kisspeptin signalling"@en .

<https://identifiers.org/aop.relationships/2666> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2666"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1065> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1986> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1065> rdfs:label "Activation, estrogen receptor alpha"@en .
<https://identifiers.org/aop.events/1986> rdfs:label "Decreased, Gonadotropins"@en .

<https://identifiers.org/aop.relationships/2730> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2730"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1065> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1991> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1065> rdfs:label "Activation, estrogen receptor alpha"@en .
<https://identifiers.org/aop.events/1991> rdfs:label "Impaired, Reproduction"@en .

<https://identifiers.org/aop.relationships/1104> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1104"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1066> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1067> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1066> rdfs:label "Promotion, SIX-1 postive basal-type progenitor cells"@en .
<https://identifiers.org/aop.events/1067> rdfs:label "Proliferation/Clonal Expansion, aberrant basal cells"@en .

<https://identifiers.org/aop.relationships/1105> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1105"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1067> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1068> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1067> rdfs:label "Proliferation/Clonal Expansion, aberrant basal cells"@en .
<https://identifiers.org/aop.events/1068> rdfs:label "squamous metaplasia, aberrant basal cells"@en .

<https://identifiers.org/aop.relationships/1106> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1106"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1068> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1069> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1068> rdfs:label "squamous metaplasia, aberrant basal cells"@en .
<https://identifiers.org/aop.events/1069> rdfs:label "Increased, Hyperplasia (glandular epithelial cells of endometrium)"@en .

<https://identifiers.org/aop.relationships/1107> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1107"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1069> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1070> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1069> rdfs:label "Increased, Hyperplasia (glandular epithelial cells of endometrium)"@en .
<https://identifiers.org/aop.events/1070> rdfs:label "Increased, adenosquamous carcinomas of endometrium"@en .

<https://identifiers.org/aop.relationships/1108> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1108"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1071> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1072> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1071> rdfs:label "Decreased, GnRH pulsatility/release in hypothalamus"@en .
<https://identifiers.org/aop.events/1072> rdfs:label "Decreased, LH Surge from anterior pituitary"@en .

<https://identifiers.org/aop.relationships/1109> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1109"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1072> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1074> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1072> rdfs:label "Decreased, LH Surge from anterior pituitary"@en .
<https://identifiers.org/aop.events/1074> rdfs:label "interruption, Ovulation"@en .

<https://identifiers.org/aop.relationships/1110> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1110"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1072> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1075> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1072> rdfs:label "Decreased, LH Surge from anterior pituitary"@en .
<https://identifiers.org/aop.events/1075> rdfs:label "prolonged, estrus"@en .

<https://identifiers.org/aop.relationships/1118> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1118"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1074> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1076> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1074> rdfs:label "interruption, Ovulation"@en .
<https://identifiers.org/aop.events/1076> rdfs:label "Increased, circulating estrogen levels"@en .

<https://identifiers.org/aop.relationships/1111> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1111"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1075> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1076> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1075> rdfs:label "prolonged, estrus"@en .
<https://identifiers.org/aop.events/1076> rdfs:label "Increased, circulating estrogen levels"@en .

<https://identifiers.org/aop.relationships/1112> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1112"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1075> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1077> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1075> rdfs:label "prolonged, estrus"@en .
<https://identifiers.org/aop.events/1077> rdfs:label "Increased, prolactin exposure"@en .

<https://identifiers.org/aop.relationships/1113> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1113"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1076> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1078> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1076> rdfs:label "Increased, circulating estrogen levels"@en .
<https://identifiers.org/aop.events/1078> rdfs:label "Hyperplasia, Mammary gland"@en .

<https://identifiers.org/aop.relationships/1119> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1119"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1076> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1081> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1076> rdfs:label "Increased, circulating estrogen levels"@en .
<https://identifiers.org/aop.events/1081> rdfs:label "Increased, lactotroph hyperplasia and hypertrophy"@en .

<https://identifiers.org/aop.relationships/2585> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2585"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1076> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1052> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1076> rdfs:label "Increased, circulating estrogen levels"@en .
<https://identifiers.org/aop.events/1052> rdfs:label "Hyperplasia, ovarian epithelium"@en .

<https://identifiers.org/aop.relationships/1114> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1114"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1077> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1078> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1077> rdfs:label "Increased, prolactin exposure"@en .
<https://identifiers.org/aop.events/1078> rdfs:label "Hyperplasia, Mammary gland"@en .

<https://identifiers.org/aop.relationships/1115> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1115"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1078> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1080> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1078> rdfs:label "Hyperplasia, Mammary gland"@en .
<https://identifiers.org/aop.events/1080> rdfs:label "Increased, latency period"@en .

<https://identifiers.org/aop.relationships/1116> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1116"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1078> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1079> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1078> rdfs:label "Hyperplasia, Mammary gland"@en .
<https://identifiers.org/aop.events/1079> rdfs:label "Increased, Adenomas/carcinomas (mammary)"@en .

<https://identifiers.org/aop.relationships/1117> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1117"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1080> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1079> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1080> rdfs:label "Increased, latency period"@en .
<https://identifiers.org/aop.events/1079> rdfs:label "Increased, Adenomas/carcinomas (mammary)"@en .

<https://identifiers.org/aop.relationships/1120> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1120"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1081> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1082> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1081> rdfs:label "Increased, lactotroph hyperplasia and hypertrophy"@en .
<https://identifiers.org/aop.events/1082> rdfs:label "Increased, adenomas (pituitary)"@en .

<https://identifiers.org/aop.relationships/1121> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1121"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1083> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1084> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1083> rdfs:label "Decreased, Dopaminergic activity"@en .
<https://identifiers.org/aop.events/1084> rdfs:label "Increased, prolactin secretion"@en .

<https://identifiers.org/aop.relationships/1122> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1122"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1084> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1085> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1084> rdfs:label "Increased, prolactin secretion"@en .
<https://identifiers.org/aop.events/1085> rdfs:label "Increased, hyperplasia (mammary gland)"@en .

<https://identifiers.org/aop.relationships/1123> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1123"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1085> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1080> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1085> rdfs:label "Increased, hyperplasia (mammary gland)"@en .
<https://identifiers.org/aop.events/1080> rdfs:label "Increased, latency period"@en .

<https://identifiers.org/aop.relationships/1124> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1124"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1085> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1079> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1085> rdfs:label "Increased, hyperplasia (mammary gland)"@en .
<https://identifiers.org/aop.events/1079> rdfs:label "Increased, Adenomas/carcinomas (mammary)"@en .

<https://identifiers.org/aop.relationships/1125> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1125"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1086> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1087> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1086> rdfs:label "persistent, cytotoxicity (pleura or peritoneum)"@en .
<https://identifiers.org/aop.events/1087> rdfs:label "Increased, inflammation"@en .

<https://identifiers.org/aop.relationships/1126> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1126"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1086> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1088> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1086> rdfs:label "persistent, cytotoxicity (pleura or peritoneum)"@en .
<https://identifiers.org/aop.events/1088> rdfs:label "Increased, Oxidative Stress"@en .

<https://identifiers.org/aop.relationships/1127> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1127"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1087> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1032> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1087> rdfs:label "Increased, inflammation"@en .
<https://identifiers.org/aop.events/1032> rdfs:label "Increased, secretion of local growth factors"@en .

<https://identifiers.org/aop.relationships/1128> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1128"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1088> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1032> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1088> rdfs:label "Increased, Oxidative Stress"@en .
<https://identifiers.org/aop.events/1032> rdfs:label "Increased, secretion of local growth factors"@en .

<https://identifiers.org/aop.relationships/1160> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1160"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1088> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1097> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1088> rdfs:label "Increased, Oxidative Stress"@en .
<https://identifiers.org/aop.events/1097> rdfs:label "Occurrence, renal proximal tubular necrosis"@en .

<https://identifiers.org/aop.relationships/1300> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1300"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1088> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1194> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1088> rdfs:label "Increased, Oxidative Stress"@en .
<https://identifiers.org/aop.events/1194> rdfs:label "Increase, DNA damage"@en .

<https://identifiers.org/aop.relationships/2385> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2385"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1088> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1775> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1088> rdfs:label "Increased, Oxidative Stress"@en .
<https://identifiers.org/aop.events/1775> rdfs:label "Increase, Oocyte apoptosis"@en .

<https://identifiers.org/aop.relationships/2618> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2618"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1088> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1365> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1088> rdfs:label "Increased, Oxidative Stress"@en .
<https://identifiers.org/aop.events/1365> rdfs:label "Increase, Apoptosis"@en .

<https://identifiers.org/aop.relationships/1130> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1130"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1089> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1090> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1089> rdfs:label "Increased, Cell Proliferation (mesothelium)"@en .
<https://identifiers.org/aop.events/1090> rdfs:label "Increased, mesotheliomas"@en .

<https://identifiers.org/aop.relationships/1132> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1132"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1096> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1102> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1096> rdfs:label "Increased, blood uric acid concentration"@en .
<https://identifiers.org/aop.events/1102> rdfs:label "Occurrence, tophi (urate) deposition"@en .

<https://identifiers.org/aop.relationships/1158> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1158"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1096> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1088> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1096> rdfs:label "Increased, blood uric acid concentration"@en .
<https://identifiers.org/aop.events/1088> rdfs:label "Increased, Oxidative Stress"@en .

<https://identifiers.org/aop.relationships/1134> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1134"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1097> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1098> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1097> rdfs:label "Occurrence, renal proximal tubular necrosis"@en .
<https://identifiers.org/aop.events/1098> rdfs:label "Increased, blood potassium concentration"@en .

<https://identifiers.org/aop.relationships/1156> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1156"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1097> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1096> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1097> rdfs:label "Occurrence, renal proximal tubular necrosis"@en .
<https://identifiers.org/aop.events/1096> rdfs:label "Increased, blood uric acid concentration"@en .

<https://identifiers.org/aop.relationships/2647> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2647"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1097> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/814> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1097> rdfs:label "Occurrence, renal proximal tubular necrosis"@en .
<https://identifiers.org/aop.events/814> rdfs:label "Occurrence, Kidney toxicity"@en .

<https://identifiers.org/aop.relationships/1140> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1140"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1098> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1106> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1098> rdfs:label "Increased, blood potassium concentration"@en .
<https://identifiers.org/aop.events/1106> rdfs:label "Occurrence, cardiac arrhythmia"@en .

<https://identifiers.org/aop.relationships/1133> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1133"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1102> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1097> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1102> rdfs:label "Occurrence, tophi (urate) deposition"@en .
<https://identifiers.org/aop.events/1097> rdfs:label "Occurrence, renal proximal tubular necrosis"@en .

<https://identifiers.org/aop.relationships/1137> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1137"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1103> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1104> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1103> rdfs:label "Inhibition, Cyclooxygenase 1 activity"@en .
<https://identifiers.org/aop.events/1104> rdfs:label "Decreased, Prostaglandin F2alpha concentration, plasma "@en .

<https://identifiers.org/aop.relationships/1138> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1138"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1104> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1105> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1104> rdfs:label "Decreased, Prostaglandin F2alpha concentration, plasma "@en .
<https://identifiers.org/aop.events/1105> rdfs:label "Occurrence, renal ischemia"@en .

<https://identifiers.org/aop.relationships/1159> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1159"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1105> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1088> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1105> rdfs:label "Occurrence, renal ischemia"@en .
<https://identifiers.org/aop.events/1088> rdfs:label "Increased, Oxidative Stress"@en .

<https://identifiers.org/aop.relationships/1141> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1141"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1106> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/351> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1106> rdfs:label "Occurrence, cardiac arrhythmia"@en .
<https://identifiers.org/aop.events/351> rdfs:label "Increased Mortality"@en .

<https://identifiers.org/aop.relationships/1145> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1145"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1107> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/563> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1107> rdfs:label "Weakened, Colony"@en .
<https://identifiers.org/aop.events/563> rdfs:label "Death/Failure, Colony"@en .

<https://identifiers.org/aop.relationships/1155> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1155"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1109> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1107> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1109> rdfs:label "Increased, Deformed Wing Virus levels"@en .
<https://identifiers.org/aop.events/1107> rdfs:label "Weakened, Colony"@en .

<https://identifiers.org/aop.relationships/126> a sbdbel:CausalAssertion ;
  rdfs:label "KER 126"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/111> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/363> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/111> rdfs:label "Agonism, Estrogen receptor"@en .
<https://identifiers.org/aop.events/363> rdfs:label "Altered, Reproductive behaviour"@en .

<https://identifiers.org/aop.relationships/127> a sbdbel:CausalAssertion ;
  rdfs:label "KER 127"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/111> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/364> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/111> rdfs:label "Agonism, Estrogen receptor"@en .
<https://identifiers.org/aop.events/364> rdfs:label "Impaired development of, Reproductive organs"@en .

<https://identifiers.org/aop.relationships/128> a sbdbel:CausalAssertion ;
  rdfs:label "KER 128"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/111> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/307> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/111> rdfs:label "Agonism, Estrogen receptor"@en .
<https://identifiers.org/aop.events/307> rdfs:label "Increase, Vitellogenin synthesis in liver"@en .

<https://identifiers.org/aop.relationships/1157> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1157"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1110> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/560> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1110> rdfs:label "Increased, Energetic demands and therefore metabolic stress"@en .
<https://identifiers.org/aop.events/560> rdfs:label "Abnormal, Foraging activity and behavior"@en .

<https://identifiers.org/aop.relationships/1161> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1161"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1114> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1115> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1114> rdfs:label "Unknown, MIE"@en .
<https://identifiers.org/aop.events/1115> rdfs:label "Increased, Reactive oxygen species"@en .

<https://identifiers.org/aop.relationships/1162> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1162"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1115> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1088> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1115> rdfs:label "Increased, Reactive oxygen species"@en .
<https://identifiers.org/aop.events/1088> rdfs:label "Increased, Oxidative Stress"@en .

<https://identifiers.org/aop.relationships/1696> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1696"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1115> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1491> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1115> rdfs:label "Increased, Reactive oxygen species"@en .
<https://identifiers.org/aop.events/1491> rdfs:label "Increased, Oncotic Necrosis"@en .

<https://identifiers.org/aop.relationships/1965> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1965"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1115> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1669> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1115> rdfs:label "Increased, Reactive oxygen species"@en .
<https://identifiers.org/aop.events/1669> rdfs:label "Increased, DNA damage and mutation"@en .

<https://identifiers.org/aop.relationships/2320> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2320"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1115> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1172> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1115> rdfs:label "Increased, Reactive oxygen species"@en .
<https://identifiers.org/aop.events/1172> rdfs:label "Increase activation, Nuclear factor kappa B (NF-kB)"@en .

<https://identifiers.org/aop.relationships/2324> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2324"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1115> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1501> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1115> rdfs:label "Increased, Reactive oxygen species"@en .
<https://identifiers.org/aop.events/1501> rdfs:label "Increased, extracellular matrix deposition"@en .

<https://identifiers.org/aop.relationships/2328> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2328"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1115> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1855> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1115> rdfs:label "Increased, Reactive oxygen species"@en .
<https://identifiers.org/aop.events/1855> rdfs:label "Increased Sodium-sensitive hypertension"@en .

<https://identifiers.org/aop.relationships/2460> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2460"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1115> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1445> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1115> rdfs:label "Increased, Reactive oxygen species"@en .
<https://identifiers.org/aop.events/1445> rdfs:label "Increase, Lipid peroxidation"@en .

<https://identifiers.org/aop.relationships/2549> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2549"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1115> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1861> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1115> rdfs:label "Increased, Reactive oxygen species"@en .
<https://identifiers.org/aop.events/1861> rdfs:label "Increase, D1 protein deactivation"@en .

<https://identifiers.org/aop.relationships/2550> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2550"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1115> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1770> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1115> rdfs:label "Increased, Reactive oxygen species"@en .
<https://identifiers.org/aop.events/1770> rdfs:label "Decrease, Mitochondrial membrane potential"@en .

<https://identifiers.org/aop.relationships/2660> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2660"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1115> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2006> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1115> rdfs:label "Increased, Reactive oxygen species"@en .
<https://identifiers.org/aop.events/2006> rdfs:label "Secondary genotoxicity"@en .

<https://identifiers.org/aop.relationships/1164> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1164"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1116> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1101> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1116> rdfs:label "Decreased, Triiodothyronine (T3) in tissues"@en .
<https://identifiers.org/aop.events/1101> rdfs:label "Altered, Amphibian metamorphosis"@en .

<https://identifiers.org/aop.relationships/2238> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2238"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1116> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1023> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1116> rdfs:label "Decreased, Triiodothyronine (T3) in tissues"@en .
<https://identifiers.org/aop.events/1023> rdfs:label "Increased, Thyroid-stimulating hormone (TSH)"@en .

<https://identifiers.org/aop.relationships/2239> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2239"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1116> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1829> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1116> rdfs:label "Decreased, Triiodothyronine (T3) in tissues"@en .
<https://identifiers.org/aop.events/1829> rdfs:label "Altered, Thyroid hormone-dependent gene expression"@en .

<https://identifiers.org/aop.relationships/1168> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1168"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1122> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1130> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1122> rdfs:label "Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failure of secondary hemostasis  "@en .
<https://identifiers.org/aop.events/1130> rdfs:label "Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage)"@en .

<https://identifiers.org/aop.relationships/1169> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1169"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1130> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1132> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1130> rdfs:label "Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage)"@en .
<https://identifiers.org/aop.events/1132> rdfs:label "Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tissue, impaired carbon dioxide and waste product removal"@en .

<https://identifiers.org/aop.relationships/1165> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1165"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1131> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1133> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1131> rdfs:label "Failure in gamma-glutamyl carboxylation of  clotting factors II, VII, IX and X, Under carboxylation of clotting factors (e.g., des-gamma-carboxy prothrombin) "@en .
<https://identifiers.org/aop.events/1133> rdfs:label "Hemostasis, Depletion from blood of fully functional carboxylated clotting factors"@en .

<https://identifiers.org/aop.relationships/1170> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1170"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1132> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1135> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1132> rdfs:label "Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tissue, impaired carbon dioxide and waste product removal"@en .
<https://identifiers.org/aop.events/1135> rdfs:label "Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction"@en .

<https://identifiers.org/aop.relationships/1166> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1166"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1133> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1122> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1133> rdfs:label "Hemostasis, Depletion from blood of fully functional carboxylated clotting factors"@en .
<https://identifiers.org/aop.events/1122> rdfs:label "Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failure of secondary hemostasis  "@en .

<https://identifiers.org/aop.relationships/1167> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1167"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1134> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1131> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1134> rdfs:label "Irreversible inhibition of hepatic VKOR by binding of AR at tyrosine 139, Failure to cycle vitamin K epoxide to vitamin K to form vitamin K hydroquinone"@en .
<https://identifiers.org/aop.events/1131> rdfs:label "Failure in gamma-glutamyl carboxylation of  clotting factors II, VII, IX and X, Under carboxylation of clotting factors (e.g., des-gamma-carboxy prothrombin) "@en .

<https://identifiers.org/aop.relationships/1171> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1171"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1135> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1136> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1135> rdfs:label "Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction"@en .
<https://identifiers.org/aop.events/1136> rdfs:label "Impaired recruitment , Population trajectory"@en .

<https://identifiers.org/aop.relationships/1175> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1175"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1139> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/624> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1139> rdfs:label "Increased, water retention in foot"@en .
<https://identifiers.org/aop.events/624> rdfs:label "Increased, foot detachment"@en .

<https://identifiers.org/aop.relationships/1223> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1223"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1139> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1142> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1139> rdfs:label "Increased, water retention in foot"@en .
<https://identifiers.org/aop.events/1142> rdfs:label "Increased, valve movement"@en .

<https://identifiers.org/aop.relationships/2635> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2635"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1141> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/360> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1141> rdfs:label "Decreased, Reproductive Success"@en .
<https://identifiers.org/aop.events/360> rdfs:label "Decrease, Population growth rate"@en .

<https://identifiers.org/aop.relationships/1173> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1173"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1142> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1143> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1142> rdfs:label "Increased, valve movement"@en .
<https://identifiers.org/aop.events/1143> rdfs:label "Depletion, energy reserves"@en .

<https://identifiers.org/aop.relationships/1174> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1174"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1142> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1139> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1142> rdfs:label "Increased, valve movement"@en .
<https://identifiers.org/aop.events/1139> rdfs:label "Increased, water retention in foot"@en .

<https://identifiers.org/aop.relationships/1227> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1227"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1142> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/623> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1142> rdfs:label "Increased, valve movement"@en .
<https://identifiers.org/aop.events/623> rdfs:label "Increase, predation"@en .

<https://identifiers.org/aop.relationships/1320> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1320"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1142> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1255> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1142> rdfs:label "Increased, valve movement"@en .
<https://identifiers.org/aop.events/1255> rdfs:label "induced spawning"@en .

<https://identifiers.org/aop.relationships/1334> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1334"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1142> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1257> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1142> rdfs:label "Increased, valve movement"@en .
<https://identifiers.org/aop.events/1257> rdfs:label "Induced parturition"@en .

<https://identifiers.org/aop.relationships/1185> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1185"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1143> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/623> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1143> rdfs:label "Depletion, energy reserves"@en .
<https://identifiers.org/aop.events/623> rdfs:label "Increase, predation"@en .

<https://identifiers.org/aop.relationships/1197> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1197"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1152> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/425> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1152> rdfs:label "Inhibition, Iodotyrosine deiodinase (IYD)"@en .
<https://identifiers.org/aop.events/425> rdfs:label "Decrease of Thyroidal iodide"@en .

<https://identifiers.org/aop.relationships/2476> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2476"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1152> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/281> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1152> rdfs:label "Inhibition, Iodotyrosine deiodinase (IYD)"@en .
<https://identifiers.org/aop.events/281> rdfs:label " Thyroxine (T4) in serum, Decreased"@en .

<https://identifiers.org/aop.relationships/1200> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1200"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1153> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1154> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1153> rdfs:label "Inhibition, Deiodinase 3"@en .
<https://identifiers.org/aop.events/1154> rdfs:label "Increased, Triiodothyronine (T3) in tissues"@en .

<https://identifiers.org/aop.relationships/2243> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2243"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1154> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1829> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1154> rdfs:label "Increased, Triiodothyronine (T3) in tissues"@en .
<https://identifiers.org/aop.events/1829> rdfs:label "Altered, Thyroid hormone-dependent gene expression"@en .

<https://identifiers.org/aop.relationships/1202> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1202"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1155> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/277> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1155> rdfs:label "Inhibition, Pendrin"@en .
<https://identifiers.org/aop.events/277> rdfs:label "Thyroid hormone synthesis, Decreased"@en .

<https://identifiers.org/aop.relationships/1203> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1203"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1156> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/277> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1156> rdfs:label "Inhibition, Dual oxidase"@en .
<https://identifiers.org/aop.events/277> rdfs:label "Thyroid hormone synthesis, Decreased"@en .

<https://identifiers.org/aop.relationships/1204> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1204"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1157> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1158> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1157> rdfs:label "Activation, Hepatic nuclear receptor(s)"@en .
<https://identifiers.org/aop.events/1158> rdfs:label "Increased, Hepatic thyroid hormone uptake/transport"@en .

<https://identifiers.org/aop.relationships/1205> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1205"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1157> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/295> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1157> rdfs:label "Activation, Hepatic nuclear receptor(s)"@en .
<https://identifiers.org/aop.events/295> rdfs:label "Induction, Upregulation of glucuronyltransferase activity"@en .

<https://identifiers.org/aop.relationships/2237> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2237"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1158> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/281> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1158> rdfs:label "Increased, Hepatic thyroid hormone uptake/transport"@en .
<https://identifiers.org/aop.events/281> rdfs:label " Thyroxine (T4) in serum, Decreased"@en .

<https://identifiers.org/aop.relationships/2479> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2479"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1158> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/961> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1158> rdfs:label "Increased, Hepatic thyroid hormone uptake/transport"@en .
<https://identifiers.org/aop.events/961> rdfs:label "Increased, Clearance of thyroxine from serum"@en .

<https://identifiers.org/aop.relationships/1328> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1328"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1161> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1255> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1161> rdfs:label "Increased, oocyte maturation"@en .
<https://identifiers.org/aop.events/1255> rdfs:label "induced spawning"@en .

<https://identifiers.org/aop.relationships/1215> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1215"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1163> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1164> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1163> rdfs:label "Increased, Reproductive Success"@en .
<https://identifiers.org/aop.events/1164> rdfs:label "Increased, Population"@en .

<https://identifiers.org/aop.relationships/1230> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1230"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1170> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/716> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1170> rdfs:label "Increase, Phenotypic enzyme activity"@en .
<https://identifiers.org/aop.events/716> rdfs:label "Increase, cell proliferation (hepatocytes)"@en .

<https://identifiers.org/aop.relationships/1232> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1232"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1171> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/719> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1171> rdfs:label "Increase, Clonal Expansion of Altered Hepatic Foci"@en .
<https://identifiers.org/aop.events/719> rdfs:label "Increase, hepatocellular adenomas and carcinomas"@en .

<https://identifiers.org/aop.relationships/1360> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1360"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1174> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1278> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1174> rdfs:label "Activation, NADPH Oxidase"@en .
<https://identifiers.org/aop.events/1278> rdfs:label "ROS formation"@en .

<https://identifiers.org/aop.relationships/1244> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1244"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1176> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1179> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1176> rdfs:label "Decreased, sodium conductance 2"@en .
<https://identifiers.org/aop.events/1179> rdfs:label "Decreased, GABA release"@en .

<https://identifiers.org/aop.relationships/1246> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1246"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1181> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1187> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1181> rdfs:label "Activation, Estrogen receptor"@en .
<https://identifiers.org/aop.events/1187> rdfs:label "Increased, ER binding to DNA (classical pathway) "@en .

<https://identifiers.org/aop.relationships/1249> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1249"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1181> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1188> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1181> rdfs:label "Activation, Estrogen receptor"@en .
<https://identifiers.org/aop.events/1188> rdfs:label "Increased, ER binding to T.F. to DNA (non-classical pathway)"@en .

<https://identifiers.org/aop.relationships/1294> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1294"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1181> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1191> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1181> rdfs:label "Activation, Estrogen receptor"@en .
<https://identifiers.org/aop.events/1191> rdfs:label "Increased, Non-genomic signaling"@en .

<https://identifiers.org/aop.relationships/1307> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1307"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1181> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1242> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1181> rdfs:label "Activation, Estrogen receptor"@en .
<https://identifiers.org/aop.events/1242> rdfs:label "Increased, Second Messenger Production"@en .

<https://identifiers.org/aop.relationships/1247> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1247"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1182> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1192> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1182> rdfs:label "Increase, Cell Proliferation (Epithelial Cells)"@en .
<https://identifiers.org/aop.events/1192> rdfs:label "Increased, Ductal Hyperplasia "@en .

<https://identifiers.org/aop.relationships/1907> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1907"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1182> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/185> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1182> rdfs:label "Increase, Cell Proliferation (Epithelial Cells)"@en .
<https://identifiers.org/aop.events/185> rdfs:label "Increase, Mutations"@en .

<https://identifiers.org/aop.relationships/1248> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1248"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1183> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1192> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1183> rdfs:label "Decreased, Apoptosis (Epithelial Cells)"@en .
<https://identifiers.org/aop.events/1192> rdfs:label "Increased, Ductal Hyperplasia "@en .

<https://identifiers.org/aop.relationships/1250> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1250"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1187> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1182> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1187> rdfs:label "Increased, ER binding to DNA (classical pathway) "@en .
<https://identifiers.org/aop.events/1182> rdfs:label "Increase, Cell Proliferation (Epithelial Cells)"@en .

<https://identifiers.org/aop.relationships/1296> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1296"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1187> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1239> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1187> rdfs:label "Increased, ER binding to DNA (classical pathway) "@en .
<https://identifiers.org/aop.events/1239> rdfs:label "Altered, Gene Expression"@en .

<https://identifiers.org/aop.relationships/1251> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1251"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1188> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1182> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1188> rdfs:label "Increased, ER binding to T.F. to DNA (non-classical pathway)"@en .
<https://identifiers.org/aop.events/1182> rdfs:label "Increase, Cell Proliferation (Epithelial Cells)"@en .

<https://identifiers.org/aop.relationships/1297> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1297"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1188> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1239> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1188> rdfs:label "Increased, ER binding to T.F. to DNA (non-classical pathway)"@en .
<https://identifiers.org/aop.events/1239> rdfs:label "Altered, Gene Expression"@en .

<https://identifiers.org/aop.relationships/1266> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1266"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1189> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1213> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1189> rdfs:label "Increased, Proliferation (Endothelial cells) "@en .
<https://identifiers.org/aop.events/1213> rdfs:label "Increased, Angiogenesis"@en .

<https://identifiers.org/aop.relationships/1267> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1267"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1190> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1213> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1190> rdfs:label "Increased, Migration (Endothelial Cells)"@en .
<https://identifiers.org/aop.events/1213> rdfs:label "Increased, Angiogenesis"@en .

<https://identifiers.org/aop.relationships/2575> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2575"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1190> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1376> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1190> rdfs:label "Increased, Migration (Endothelial Cells)"@en .
<https://identifiers.org/aop.events/1376> rdfs:label "Increase, angiogenesis"@en .

<https://identifiers.org/aop.relationships/1295> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1295"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1191> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1188> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1191> rdfs:label "Increased, Non-genomic signaling"@en .
<https://identifiers.org/aop.events/1188> rdfs:label "Increased, ER binding to T.F. to DNA (non-classical pathway)"@en .

<https://identifiers.org/aop.relationships/1302> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1302"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1191> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1239> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1191> rdfs:label "Increased, Non-genomic signaling"@en .
<https://identifiers.org/aop.events/1239> rdfs:label "Altered, Gene Expression"@en .

<https://identifiers.org/aop.relationships/1252> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1252"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1192> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1193> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1192> rdfs:label "Increased, Ductal Hyperplasia "@en .
<https://identifiers.org/aop.events/1193> rdfs:label "N/A, Breast Cancer"@en .

<https://identifiers.org/aop.relationships/2790> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2790"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1194> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1505> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1194> rdfs:label "Increase, DNA damage"@en .
<https://identifiers.org/aop.events/1505> rdfs:label "Cell cycle, disrupted"@en .

<https://identifiers.org/aop.relationships/1897> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1897"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1194> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/185> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1194> rdfs:label "Increase, DNA damage"@en .
<https://identifiers.org/aop.events/185> rdfs:label "Increase, Mutations"@en .

<https://identifiers.org/aop.relationships/1301> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1301"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1194> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1239> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1194> rdfs:label "Increase, DNA damage"@en .
<https://identifiers.org/aop.events/1239> rdfs:label "Altered, Gene Expression"@en .

<https://identifiers.org/aop.relationships/1898> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1898"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1194> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1492> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1194> rdfs:label "Increase, DNA damage"@en .
<https://identifiers.org/aop.events/1492> rdfs:label "Tissue resident cell activation"@en .

<https://identifiers.org/aop.relationships/1468> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1468"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1194> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1365> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1194> rdfs:label "Increase, DNA damage"@en .
<https://identifiers.org/aop.events/1365> rdfs:label "Increase, Apoptosis"@en .

<https://identifiers.org/aop.relationships/2338> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2338"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1194> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1864> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1194> rdfs:label "Increase, DNA damage"@en .
<https://identifiers.org/aop.events/1864> rdfs:label "Increase, Programmed cell death"@en .

<https://identifiers.org/aop.relationships/2381> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2381"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1194> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/752> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1194> rdfs:label "Increase, DNA damage"@en .
<https://identifiers.org/aop.events/752> rdfs:label "Altered, Meiotic chromosome dynamics"@en .

<https://identifiers.org/aop.relationships/2382> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2382"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1194> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1775> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1194> rdfs:label "Increase, DNA damage"@en .
<https://identifiers.org/aop.events/1775> rdfs:label "Increase, Oocyte apoptosis"@en .

<https://identifiers.org/aop.relationships/2595> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2595"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1194> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1974> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1194> rdfs:label "Increase, DNA damage"@en .
<https://identifiers.org/aop.events/1974> rdfs:label "Activation of Tumor Protein 53"@en .

<https://identifiers.org/aop.relationships/2622> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2622"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1194> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1798> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1194> rdfs:label "Increase, DNA damage"@en .
<https://identifiers.org/aop.events/1798> rdfs:label "Decreased spermatogenesis "@en .

<https://identifiers.org/aop.relationships/2576> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2576"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1196> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1193> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1196> rdfs:label "Increased, Invasion"@en .
<https://identifiers.org/aop.events/1193> rdfs:label "N/A, Breast Cancer"@en .

<https://identifiers.org/aop.relationships/1261> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1261"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1205> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1206> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1205> rdfs:label "Activation, Juvenile hormone receptor"@en .
<https://identifiers.org/aop.events/1206> rdfs:label "Induction, Doublesex1 gene"@en .

<https://identifiers.org/aop.relationships/1262> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1262"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1206> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1209> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1206> rdfs:label "Induction, Doublesex1 gene"@en .
<https://identifiers.org/aop.events/1209> rdfs:label "Induction, Male reproductive tract"@en .

<https://identifiers.org/aop.relationships/1264> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1264"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1208> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/361> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1208> rdfs:label "Increased, Male offspring"@en .
<https://identifiers.org/aop.events/361> rdfs:label "Decline, Population"@en .

<https://identifiers.org/aop.relationships/1263> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1263"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1209> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1208> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1209> rdfs:label "Induction, Male reproductive tract"@en .
<https://identifiers.org/aop.events/1208> rdfs:label "Increased, Male offspring"@en .

<https://identifiers.org/aop.relationships/1271> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1271"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1215> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1218> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1215> rdfs:label "TRPA1 activation, TRPA1 Receptor"@en .
<https://identifiers.org/aop.events/1218> rdfs:label "Opening of calcium channel, Calcium influx"@en .

<https://identifiers.org/aop.relationships/1274> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1274"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1218> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1220> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1218> rdfs:label "Opening of calcium channel, Calcium influx"@en .
<https://identifiers.org/aop.events/1220> rdfs:label "Trigeminal nerve activation"@en .

<https://identifiers.org/aop.relationships/2077> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2077"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/122> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1759> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/122> rdfs:label "Activation, Glucocorticoid Receptor"@en .
<https://identifiers.org/aop.events/1759> rdfs:label "Increase, Cripto-1 expression"@en .

<https://identifiers.org/aop.relationships/1451> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1451"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/122> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1335> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/122> rdfs:label "Activation, Glucocorticoid Receptor"@en .
<https://identifiers.org/aop.events/1335> rdfs:label "Reduced, BDNF (Brain-derived neurotrophic factor)"@en .

<https://identifiers.org/aop.relationships/2266> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2266"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/122> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1834> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/122> rdfs:label "Activation, Glucocorticoid Receptor"@en .
<https://identifiers.org/aop.events/1834> rdfs:label "Decrease, Acyl-CoA dehydrogenases"@en .

<https://identifiers.org/aop.relationships/385> a sbdbel:CausalAssertion ;
  rdfs:label "KER 385"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/122> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/145> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/122> rdfs:label "Activation, Glucocorticoid Receptor"@en .
<https://identifiers.org/aop.events/145> rdfs:label "Induction, IKB inhibitory protein"@en .

<https://identifiers.org/aop.relationships/1575> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1575"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1220> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1222> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1220> rdfs:label "Trigeminal nerve activation"@en .
<https://identifiers.org/aop.events/1222> rdfs:label "SP (Substance P) release, Local increase of SP"@en .

<https://identifiers.org/aop.relationships/1578> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1578"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1220> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1433> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1220> rdfs:label "Trigeminal nerve activation"@en .
<https://identifiers.org/aop.events/1433> rdfs:label "Increased CGRP, neuronal release of CGRP"@en .

<https://identifiers.org/aop.relationships/1582> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1582"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1220> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1434> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1220> rdfs:label "Trigeminal nerve activation"@en .
<https://identifiers.org/aop.events/1434> rdfs:label "Irritation of nasal mucosa inducing sneeze reflex"@en .

<https://identifiers.org/aop.relationships/1583> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1583"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1220> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1435> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1220> rdfs:label "Trigeminal nerve activation"@en .
<https://identifiers.org/aop.events/1435> rdfs:label "Increased neurokinin A (NKA) by neuronal cells"@en .

<https://identifiers.org/aop.relationships/1772> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1772"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1222> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1226> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1222> rdfs:label "SP (Substance P) release, Local increase of SP"@en .
<https://identifiers.org/aop.events/1226> rdfs:label "Increased Respiratory irritability and Chronic Cough, "@en .

<https://identifiers.org/aop.relationships/1770> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1770"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1226> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1223> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1226> rdfs:label "Increased Respiratory irritability and Chronic Cough, "@en .
<https://identifiers.org/aop.events/1223> rdfs:label "Trigeminal and/or vagal nerve excitation causes Airway Hyper-responsiveness,Cough, Dyspnea"@en .

<https://identifiers.org/aop.relationships/1807> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1807"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1239> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1560> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1239> rdfs:label "Altered, Gene Expression"@en .
<https://identifiers.org/aop.events/1560> rdfs:label "Altered differentiation"@en .

<https://identifiers.org/aop.relationships/1298> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1298"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1239> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1240> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1239> rdfs:label "Altered, Gene Expression"@en .
<https://identifiers.org/aop.events/1240> rdfs:label "Altered, Protein Production"@en .

<https://identifiers.org/aop.relationships/1299> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1299"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1240> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1088> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1240> rdfs:label "Altered, Protein Production"@en .
<https://identifiers.org/aop.events/1088> rdfs:label "Increased, Oxidative Stress"@en .

<https://identifiers.org/aop.relationships/1303> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1303"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1240> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1189> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1240> rdfs:label "Altered, Protein Production"@en .
<https://identifiers.org/aop.events/1189> rdfs:label "Increased, Proliferation (Endothelial cells) "@en .

<https://identifiers.org/aop.relationships/1304> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1304"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1240> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1183> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1240> rdfs:label "Altered, Protein Production"@en .
<https://identifiers.org/aop.events/1183> rdfs:label "Decreased, Apoptosis (Epithelial Cells)"@en .

<https://identifiers.org/aop.relationships/1305> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1305"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1240> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1241> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1240> rdfs:label "Altered, Protein Production"@en .
<https://identifiers.org/aop.events/1241> rdfs:label "Increased, Motility"@en .

<https://identifiers.org/aop.relationships/1306> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1306"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1241> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1196> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1241> rdfs:label "Increased, Motility"@en .
<https://identifiers.org/aop.events/1196> rdfs:label "Increased, Invasion"@en .

<https://identifiers.org/aop.relationships/1308> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1308"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1242> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1191> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1242> rdfs:label "Increased, Second Messenger Production"@en .
<https://identifiers.org/aop.events/1191> rdfs:label "Increased, Non-genomic signaling"@en .

<https://identifiers.org/aop.relationships/1634> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1634"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1252> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1461> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1252> rdfs:label "Binding to (interferes with) topoisomerase II enzyme"@en .
<https://identifiers.org/aop.events/1461> rdfs:label "DNA double-strand break "@en .

<https://identifiers.org/aop.relationships/1325> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1325"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1255> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1163> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1255> rdfs:label "induced spawning"@en .
<https://identifiers.org/aop.events/1163> rdfs:label "Increased, Reproductive Success"@en .

<https://identifiers.org/aop.relationships/1322> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1322"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1256> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1257> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1256> rdfs:label "increased mantel display"@en .
<https://identifiers.org/aop.events/1257> rdfs:label "Induced parturition"@en .

<https://identifiers.org/aop.relationships/1323> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1323"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1257> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1141> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1257> rdfs:label "Induced parturition"@en .
<https://identifiers.org/aop.events/1141> rdfs:label "Decreased, Reproductive Success"@en .

<https://identifiers.org/aop.relationships/1326> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1326"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1257> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1163> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1257> rdfs:label "Induced parturition"@en .
<https://identifiers.org/aop.events/1163> rdfs:label "Increased, Reproductive Success"@en .

<https://identifiers.org/aop.relationships/1338> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1338"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1258> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1261> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1258> rdfs:label "Decompartmentalization"@en .
<https://identifiers.org/aop.events/1261> rdfs:label "Mitochondrial impairment"@en .

<https://identifiers.org/aop.relationships/1340> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1340"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1259> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1261> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1259> rdfs:label "narcosis"@en .
<https://identifiers.org/aop.events/1261> rdfs:label "Mitochondrial impairment"@en .

<https://identifiers.org/aop.relationships/1339> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1339"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1260> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1261> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1260> rdfs:label "Direct mitochondrial inhibition"@en .
<https://identifiers.org/aop.events/1261> rdfs:label "Mitochondrial impairment"@en .

<https://identifiers.org/aop.relationships/1341> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1341"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1261> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1262> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1261> rdfs:label "Mitochondrial impairment"@en .
<https://identifiers.org/aop.events/1262> rdfs:label "Apoptosis"@en .

<https://identifiers.org/aop.relationships/1342> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1342"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1261> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1263> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1261> rdfs:label "Mitochondrial impairment"@en .
<https://identifiers.org/aop.events/1263> rdfs:label "Necrosis"@en .

<https://identifiers.org/aop.relationships/2083> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2083"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1261> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1762> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1261> rdfs:label "Mitochondrial impairment"@en .
<https://identifiers.org/aop.events/1762> rdfs:label "Urothelial cell injury/death"@en .

<https://identifiers.org/aop.relationships/2792> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2792"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1262> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2041> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1262> rdfs:label "Apoptosis"@en .
<https://identifiers.org/aop.events/2041> rdfs:label "Decrease, palatal shelf outgrowth"@en .

<https://identifiers.org/aop.relationships/1735> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1735"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1262> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1515> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1262> rdfs:label "Apoptosis"@en .
<https://identifiers.org/aop.events/1515> rdfs:label "Spermatocyte depletion"@en .

<https://identifiers.org/aop.relationships/1368> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1368"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1262> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1277> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1262> rdfs:label "Apoptosis"@en .
<https://identifiers.org/aop.events/1277> rdfs:label "Reproductive failure"@en .

<https://identifiers.org/aop.relationships/1867> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1867"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1262> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1606> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1262> rdfs:label "Apoptosis"@en .
<https://identifiers.org/aop.events/1606> rdfs:label "Activation of hepatic stellate cells"@en .

<https://identifiers.org/aop.relationships/1869> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1869"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1262> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1549> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1262> rdfs:label "Apoptosis"@en .
<https://identifiers.org/aop.events/1549> rdfs:label "Liver Injury"@en .

<https://identifiers.org/aop.relationships/2577> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2577"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1262> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1971> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1262> rdfs:label "Apoptosis"@en .
<https://identifiers.org/aop.events/1971> rdfs:label "Increased, tumor growth"@en .

<https://identifiers.org/aop.relationships/2675> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2675"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1262> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2011> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1262> rdfs:label "Apoptosis"@en .
<https://identifiers.org/aop.events/2011> rdfs:label "Emphysema"@en .

<https://identifiers.org/aop.relationships/1344> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1344"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1264> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1265> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1264> rdfs:label "Increase, Nuclear receptor E75b gene expression"@en .
<https://identifiers.org/aop.events/1265> rdfs:label "Increase, Fushi tarazu factor-1 gene expression"@en .

<https://identifiers.org/aop.relationships/1345> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1345"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1265> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/988> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1265> rdfs:label "Increase, Fushi tarazu factor-1 gene expression"@en .
<https://identifiers.org/aop.events/988> rdfs:label "Decrease, Circulating ecdysis triggering hormone"@en .

<https://identifiers.org/aop.relationships/1347> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1347"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1266> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1267> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1266> rdfs:label "Decrease, Circulating crustacean cardioactive peptide"@en .
<https://identifiers.org/aop.events/1267> rdfs:label "Decrease, Ecdysis motoneuron bursts"@en .

<https://identifiers.org/aop.relationships/1348> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1348"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1267> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1268> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1267> rdfs:label "Decrease, Ecdysis motoneuron bursts"@en .
<https://identifiers.org/aop.events/1268> rdfs:label "Decrease, Excitatory postsynaptic potential"@en .

<https://identifiers.org/aop.relationships/1349> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1349"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1268> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/993> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1268> rdfs:label "Decrease, Excitatory postsynaptic potential"@en .
<https://identifiers.org/aop.events/993> rdfs:label "Decrease, Abdominal muscle contraction"@en .

<https://identifiers.org/aop.relationships/1353> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1353"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1270> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1271> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1270> rdfs:label "Inactivation of PPARγ"@en .
<https://identifiers.org/aop.events/1271> rdfs:label "Activation of TGF-β signaling"@en .

<https://identifiers.org/aop.relationships/2156> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2156"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1270> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1283> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1270> rdfs:label "Inactivation of PPARγ"@en .
<https://identifiers.org/aop.events/1283> rdfs:label "Activation, TGF-beta pathway"@en .

<https://identifiers.org/aop.relationships/1721> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1721"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1271> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/149> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1271> rdfs:label "Activation of TGF-β signaling"@en .
<https://identifiers.org/aop.events/149> rdfs:label "Increase, Inflammation"@en .

<https://identifiers.org/aop.relationships/1359> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1359"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1275> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1276> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1275> rdfs:label "Collagen Deposition"@en .
<https://identifiers.org/aop.events/1276> rdfs:label "Lung fibrosis"@en .

<https://identifiers.org/aop.relationships/1361> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1361"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1278> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1279> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1278> rdfs:label "ROS formation"@en .
<https://identifiers.org/aop.events/1279> rdfs:label "Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK"@en .

<https://identifiers.org/aop.relationships/1362> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1362"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1279> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1281> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1279> rdfs:label "Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK"@en .
<https://identifiers.org/aop.events/1281> rdfs:label "Increased, DNA Damage-Repair"@en .

<https://identifiers.org/aop.relationships/1363> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1363"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1279> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/176> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1279> rdfs:label "Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK"@en .
<https://identifiers.org/aop.events/176> rdfs:label "Damaging, Mitochondria"@en .

<https://identifiers.org/aop.relationships/1364> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1364"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1279> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1280> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1279> rdfs:label "Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK"@en .
<https://identifiers.org/aop.events/1280> rdfs:label "Activation, HIF-1"@en .

<https://identifiers.org/aop.relationships/1365> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1365"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1280> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1262> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1280> rdfs:label "Activation, HIF-1"@en .
<https://identifiers.org/aop.events/1262> rdfs:label "Apoptosis"@en .

<https://identifiers.org/aop.relationships/1366> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1366"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1281> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1262> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1281> rdfs:label "Increased, DNA Damage-Repair"@en .
<https://identifiers.org/aop.events/1262> rdfs:label "Apoptosis"@en .

<https://identifiers.org/aop.relationships/1369> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1369"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1282> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1283> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1282> rdfs:label "Activation, JAK/STAT pathway"@en .
<https://identifiers.org/aop.events/1283> rdfs:label "Activation, TGF-beta pathway"@en .

<https://identifiers.org/aop.relationships/1370> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1370"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1283> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1277> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1283> rdfs:label "Activation, TGF-beta pathway"@en .
<https://identifiers.org/aop.events/1277> rdfs:label "Reproductive failure"@en .

<https://identifiers.org/aop.relationships/2153> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2153"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1283> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1457> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1283> rdfs:label "Activation, TGF-beta pathway"@en .
<https://identifiers.org/aop.events/1457> rdfs:label "Induction, Epithelial Mesenchymal Transition"@en .

<https://identifiers.org/aop.relationships/1371> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1371"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1284> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1285> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1284> rdfs:label "Up Regulation, SREBF2"@en .
<https://identifiers.org/aop.events/1285> rdfs:label "Up Regulation, Unsaturated fatty acid"@en .

<https://identifiers.org/aop.relationships/1372> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1372"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1285> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1289> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1285> rdfs:label "Up Regulation, Unsaturated fatty acid"@en .
<https://identifiers.org/aop.events/1289> rdfs:label "Perturbation of cholesterol"@en .

<https://identifiers.org/aop.relationships/1373> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1373"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1286> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1287> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1286> rdfs:label "Down Regulation, GSS and GSTs gene"@en .
<https://identifiers.org/aop.events/1287> rdfs:label "Glutathione synthesis"@en .

<https://identifiers.org/aop.relationships/1376> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1376"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1286> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1290> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1286> rdfs:label "Down Regulation, GSS and GSTs gene"@en .
<https://identifiers.org/aop.events/1290> rdfs:label "Glutathione homeostasis"@en .

<https://identifiers.org/aop.relationships/1374> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1374"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1287> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1288> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1287> rdfs:label "Glutathione synthesis"@en .
<https://identifiers.org/aop.events/1288> rdfs:label "Activation, 3-hydroxy-3-methylglutaryl-CoA reductase gene"@en .

<https://identifiers.org/aop.relationships/1375> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1375"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1288> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1289> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1288> rdfs:label "Activation, 3-hydroxy-3-methylglutaryl-CoA reductase gene"@en .
<https://identifiers.org/aop.events/1289> rdfs:label "Perturbation of cholesterol"@en .

<https://identifiers.org/aop.relationships/1377> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1377"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1289> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1291> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1289> rdfs:label "Perturbation of cholesterol"@en .
<https://identifiers.org/aop.events/1291> rdfs:label "Hepatotoxicity"@en .

<https://identifiers.org/aop.relationships/143> a sbdbel:CausalAssertion ;
  rdfs:label "KER 143"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/129> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/274> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/129> rdfs:label "Reduction, Gonadotropins, circulating concentrations"@en .
<https://identifiers.org/aop.events/274> rdfs:label "Reduction, Testosterone synthesis by ovarian theca cells"@en .

<https://identifiers.org/aop.relationships/1378> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1378"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1290> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1291> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1290> rdfs:label "Glutathione homeostasis"@en .
<https://identifiers.org/aop.events/1291> rdfs:label "Hepatotoxicity"@en .

<https://identifiers.org/aop.relationships/1380> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1380"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1292> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1293> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1292> rdfs:label "Activation, JNK"@en .
<https://identifiers.org/aop.events/1293> rdfs:label "Activation, FOXO"@en .

<https://identifiers.org/aop.relationships/2149> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2149"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1292> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1793> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1292> rdfs:label "Activation, JNK"@en .
<https://identifiers.org/aop.events/1793> rdfs:label "Activator protein 1 activation"@en .

<https://identifiers.org/aop.relationships/2150> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2150"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1292> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1794> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1292> rdfs:label "Activation, JNK"@en .
<https://identifiers.org/aop.events/1794> rdfs:label "Pin-1 activation"@en .

<https://identifiers.org/aop.relationships/1381> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1381"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1293> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1294> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1293> rdfs:label "Activation, FOXO"@en .
<https://identifiers.org/aop.events/1294> rdfs:label "Inhibition, Wnt pathway"@en .

<https://identifiers.org/aop.relationships/1382> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1382"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1294> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1295> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1294> rdfs:label "Inhibition, Wnt pathway"@en .
<https://identifiers.org/aop.events/1295> rdfs:label "Defect of Embryogenesis"@en .

<https://identifiers.org/aop.relationships/1383> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1383"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1295> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1277> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1295> rdfs:label "Defect of Embryogenesis"@en .
<https://identifiers.org/aop.events/1277> rdfs:label "Reproductive failure"@en .

<https://identifiers.org/aop.relationships/1694> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1694"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1305> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/459> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1305> rdfs:label "Increase, cytosolic fatty acid"@en .
<https://identifiers.org/aop.events/459> rdfs:label "Increased, Liver Steatosis"@en .

<https://identifiers.org/aop.relationships/1426> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1426"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1317> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1321> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1317> rdfs:label "Decreased, serotonin transporter activity"@en .
<https://identifiers.org/aop.events/1321> rdfs:label "Increased, intracellular sodium (Na+)"@en .

<https://identifiers.org/aop.relationships/1427> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1427"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1317> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1322> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1317> rdfs:label "Decreased, serotonin transporter activity"@en .
<https://identifiers.org/aop.events/1322> rdfs:label "Increased, intracellular chloride (Cl-)"@en .

<https://identifiers.org/aop.relationships/1428> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1428"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1317> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1318> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1317> rdfs:label "Decreased, serotonin transporter activity"@en .
<https://identifiers.org/aop.events/1318> rdfs:label "Decreased, extracellular sodium (Na+) "@en .

<https://identifiers.org/aop.relationships/1429> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1429"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1317> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1319> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1317> rdfs:label "Decreased, serotonin transporter activity"@en .
<https://identifiers.org/aop.events/1319> rdfs:label "Decreased, extracellular chloride (Cl-)"@en .

<https://identifiers.org/aop.relationships/1430> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1430"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1317> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1320> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1317> rdfs:label "Decreased, serotonin transporter activity"@en .
<https://identifiers.org/aop.events/1320> rdfs:label "Increased, extracellular serotonin"@en .

<https://identifiers.org/aop.relationships/1431> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1431"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1317> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1323> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1317> rdfs:label "Decreased, serotonin transporter activity"@en .
<https://identifiers.org/aop.events/1323> rdfs:label "Decreased, intracellular serotonin"@en .

<https://identifiers.org/aop.relationships/1529> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1529"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1320> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1401> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1320> rdfs:label "Increased, extracellular serotonin"@en .
<https://identifiers.org/aop.events/1401> rdfs:label "Decreased, 5-HT3"@en .

<https://identifiers.org/aop.relationships/1531> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1531"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1320> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1336> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1320> rdfs:label "Increased, extracellular serotonin"@en .
<https://identifiers.org/aop.events/1336> rdfs:label "Activation, 5-HT2A (Serotonin 2A)"@en .

<https://identifiers.org/aop.relationships/1455> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1455"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1321> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1352> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1321> rdfs:label "Increased, intracellular sodium (Na+)"@en .
<https://identifiers.org/aop.events/1352> rdfs:label "Activated, voltage-gated sodium channel"@en .

<https://identifiers.org/aop.relationships/1465> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1465"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1322> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1356> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1322> rdfs:label "Increased, intracellular chloride (Cl-)"@en .
<https://identifiers.org/aop.events/1356> rdfs:label "Inactive, membrane depolarization"@en .

<https://identifiers.org/aop.relationships/1432> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1432"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1323> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1324> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1323> rdfs:label "Decreased, intracellular serotonin"@en .
<https://identifiers.org/aop.events/1324> rdfs:label "Decreased, packaged serotonin"@en .

<https://identifiers.org/aop.relationships/1433> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1433"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1324> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1325> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1324> rdfs:label "Decreased, packaged serotonin"@en .
<https://identifiers.org/aop.events/1325> rdfs:label "Decreased, synaptic release"@en .

<https://identifiers.org/aop.relationships/1434> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1434"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1325> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1347> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1325> rdfs:label "Decreased, synaptic release"@en .
<https://identifiers.org/aop.events/1347> rdfs:label "Decreased, extracellular serotonin"@en .

<https://identifiers.org/aop.relationships/1445> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1445"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1326> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1344> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1326> rdfs:label "Increased, 5-HT3 (5-hydroxytryptamine)"@en .
<https://identifiers.org/aop.events/1344> rdfs:label "Increased, seizure"@en .

<https://identifiers.org/aop.relationships/1446> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1446"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1328> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1329> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1328> rdfs:label "Inactivated, 5-HTR (serotonin receptors)"@en .
<https://identifiers.org/aop.events/1329> rdfs:label "Reduce expression, BDNF (Brain-derived neurotrophic factor)"@en .

<https://identifiers.org/aop.relationships/1511> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1511"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1328> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1335> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1328> rdfs:label "Inactivated, 5-HTR (serotonin receptors)"@en .
<https://identifiers.org/aop.events/1335> rdfs:label "Reduced, BDNF (Brain-derived neurotrophic factor)"@en .

<https://identifiers.org/aop.relationships/1447> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1447"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1329> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1330> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1329> rdfs:label "Reduce expression, BDNF (Brain-derived neurotrophic factor)"@en .
<https://identifiers.org/aop.events/1330> rdfs:label "Decreased, neuroplasticity"@en .

<https://identifiers.org/aop.relationships/1448> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1448"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1330> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1345> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1330> rdfs:label "Decreased, neuroplasticity"@en .
<https://identifiers.org/aop.events/1345> rdfs:label "Increased, agitation"@en .

<https://identifiers.org/aop.relationships/1449> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1449"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1330> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1346> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1330> rdfs:label "Decreased, neuroplasticity"@en .
<https://identifiers.org/aop.events/1346> rdfs:label "Increased, depression"@en .

<https://identifiers.org/aop.relationships/1450> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1450"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1334> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/122> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1334> rdfs:label "Increase, cortisone"@en .
<https://identifiers.org/aop.events/122> rdfs:label "Activation, Glucocorticoid Receptor"@en .

<https://identifiers.org/aop.relationships/1523> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1523"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1335> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1330> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1335> rdfs:label "Reduced, BDNF (Brain-derived neurotrophic factor)"@en .
<https://identifiers.org/aop.events/1330> rdfs:label "Decreased, neuroplasticity"@en .

<https://identifiers.org/aop.relationships/1438> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1438"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1336> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1337> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1336> rdfs:label "Activation, 5-HT2A (Serotonin 2A)"@en .
<https://identifiers.org/aop.events/1337> rdfs:label "Activate, PLC (Phospholipase C)"@en .

<https://identifiers.org/aop.relationships/1439> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1439"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1337> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1338> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1337> rdfs:label "Activate, PLC (Phospholipase C)"@en .
<https://identifiers.org/aop.events/1338> rdfs:label "Increase, inositol triphosphate"@en .

<https://identifiers.org/aop.relationships/1440> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1440"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1338> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1339> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1338> rdfs:label "Increase, inositol triphosphate"@en .
<https://identifiers.org/aop.events/1339> rdfs:label "Increase, intracellular calcium"@en .

<https://identifiers.org/aop.relationships/1441> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1441"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1339> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1340> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1339> rdfs:label "Increase, intracellular calcium"@en .
<https://identifiers.org/aop.events/1340> rdfs:label "Activate, calmodulin"@en .

<https://identifiers.org/aop.relationships/1442> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1442"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1340> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1341> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1340> rdfs:label "Activate, calmodulin"@en .
<https://identifiers.org/aop.events/1341> rdfs:label "Increase, myosin light chain phosphorylation"@en .

<https://identifiers.org/aop.relationships/1443> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1443"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1341> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1342> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1341> rdfs:label "Increase, myosin light chain phosphorylation"@en .
<https://identifiers.org/aop.events/1342> rdfs:label "Increase, vascular smooth muscle contraction"@en .

<https://identifiers.org/aop.relationships/1444> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1444"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1342> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1343> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1342> rdfs:label "Increase, vascular smooth muscle contraction"@en .
<https://identifiers.org/aop.events/1343> rdfs:label "Increase, hypertension"@en .

<https://identifiers.org/aop.relationships/1550> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1550"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1344> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1363> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1344> rdfs:label "Increased, seizure"@en .
<https://identifiers.org/aop.events/1363> rdfs:label "Increased, epilepsy"@en .

<https://identifiers.org/aop.relationships/1435> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1435"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1347> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1326> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1347> rdfs:label "Decreased, extracellular serotonin"@en .
<https://identifiers.org/aop.events/1326> rdfs:label "Increased, 5-HT3 (5-hydroxytryptamine)"@en .

<https://identifiers.org/aop.relationships/1436> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1436"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1347> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1328> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1347> rdfs:label "Decreased, extracellular serotonin"@en .
<https://identifiers.org/aop.events/1328> rdfs:label "Inactivated, 5-HTR (serotonin receptors)"@en .

<https://identifiers.org/aop.relationships/1437> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1437"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1347> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1336> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1347> rdfs:label "Decreased, extracellular serotonin"@en .
<https://identifiers.org/aop.events/1336> rdfs:label "Activation, 5-HT2A (Serotonin 2A)"@en .

<https://identifiers.org/aop.relationships/1460> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1460"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1348> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1363> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1348> rdfs:label "Increase, seizure"@en .
<https://identifiers.org/aop.events/1363> rdfs:label "Increased, epilepsy"@en .

<https://identifiers.org/aop.relationships/1452> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1452"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1349> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1350> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1349> rdfs:label "Activated, presynaptic neuron 1"@en .
<https://identifiers.org/aop.events/1350> rdfs:label "Increased, glutamate"@en .

<https://identifiers.org/aop.relationships/1859> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1859"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1350> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/388> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1350> rdfs:label "Increased, glutamate"@en .
<https://identifiers.org/aop.events/388> rdfs:label "Overactivation, NMDARs"@en .

<https://identifiers.org/aop.relationships/1453> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1453"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1350> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1351> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1350> rdfs:label "Increased, glutamate"@en .
<https://identifiers.org/aop.events/1351> rdfs:label "Activated, NMDA receptor"@en .

<https://identifiers.org/aop.relationships/1454> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1454"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1351> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1321> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1351> rdfs:label "Activated, NMDA receptor"@en .
<https://identifiers.org/aop.events/1321> rdfs:label "Increased, intracellular sodium (Na+)"@en .

<https://identifiers.org/aop.relationships/1457> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1457"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1352> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1355> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1352> rdfs:label "Activated, voltage-gated sodium channel"@en .
<https://identifiers.org/aop.events/1355> rdfs:label "Activated, membrane depolarization"@en .

<https://identifiers.org/aop.relationships/2605> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2605"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1353> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1977> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1353> rdfs:label "Inhibit, voltage-gated sodium channel"@en .
<https://identifiers.org/aop.events/1977> rdfs:label "Disruption of sodium channel gating kinetics"@en .

<https://identifiers.org/aop.relationships/1456> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1456"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1354> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1353> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1354> rdfs:label "Treat, carbamazepine"@en .
<https://identifiers.org/aop.events/1353> rdfs:label "Inhibit, voltage-gated sodium channel"@en .

<https://identifiers.org/aop.relationships/1458> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1458"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1355> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1362> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1355> rdfs:label "Activated, membrane depolarization"@en .
<https://identifiers.org/aop.events/1362> rdfs:label "Increased, hippocampal hyperdepolarization"@en .

<https://identifiers.org/aop.relationships/1463> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1463"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1357> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1359> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1357> rdfs:label "Increased, RDX dose"@en .
<https://identifiers.org/aop.events/1359> rdfs:label "Activate, GABA-A receptor"@en .

<https://identifiers.org/aop.relationships/1555> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1555"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1357> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1415> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1357> rdfs:label "Increased, RDX dose"@en .
<https://identifiers.org/aop.events/1415> rdfs:label "Reduced, GABA-A receptor activation"@en .

<https://identifiers.org/aop.relationships/1464> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1464"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1359> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1322> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1359> rdfs:label "Activate, GABA-A receptor"@en .
<https://identifiers.org/aop.events/1322> rdfs:label "Increased, intracellular chloride (Cl-)"@en .

<https://identifiers.org/aop.relationships/1461> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1461"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1360> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1361> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1360> rdfs:label "Activate, presynaptic neuron 2"@en .
<https://identifiers.org/aop.events/1361> rdfs:label "Increase, GABA"@en .

<https://identifiers.org/aop.relationships/1462> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1462"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1361> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1359> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1361> rdfs:label "Increase, GABA"@en .
<https://identifiers.org/aop.events/1359> rdfs:label "Activate, GABA-A receptor"@en .

<https://identifiers.org/aop.relationships/1459> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1459"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1362> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1348> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1362> rdfs:label "Increased, hippocampal hyperdepolarization"@en .
<https://identifiers.org/aop.events/1348> rdfs:label "Increase, seizure"@en .

<https://identifiers.org/aop.relationships/1549> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1549"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1362> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1344> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1362> rdfs:label "Increased, hippocampal hyperdepolarization"@en .
<https://identifiers.org/aop.events/1344> rdfs:label "Increased, seizure"@en .

<https://identifiers.org/aop.relationships/1876> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1876"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1364> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1608> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1364> rdfs:label "Increase, Reactive oxygen species"@en .
<https://identifiers.org/aop.events/1608> rdfs:label "Increase, Oxidative DNA damage"@en .

<https://identifiers.org/aop.relationships/2826> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2826"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1364> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1392> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1364> rdfs:label "Increase, Reactive oxygen species"@en .
<https://identifiers.org/aop.events/1392> rdfs:label "Oxidative Stress "@en .

<https://identifiers.org/aop.relationships/1469> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1469"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1365> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1366> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1365> rdfs:label "Increase, Apoptosis"@en .
<https://identifiers.org/aop.events/1366> rdfs:label "Decrease, Oogenesis"@en .

<https://identifiers.org/aop.relationships/1751> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1751"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1365> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/350> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1365> rdfs:label "Increase, Apoptosis"@en .
<https://identifiers.org/aop.events/350> rdfs:label "Increase, Mortality"@en .

<https://identifiers.org/aop.relationships/2075> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2075"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1365> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1757> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1365> rdfs:label "Increase, Apoptosis"@en .
<https://identifiers.org/aop.events/1757> rdfs:label "Reduce, Sperm count"@en .

<https://identifiers.org/aop.relationships/2602> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2602"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1365> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1978> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1365> rdfs:label "Increase, Apoptosis"@en .
<https://identifiers.org/aop.events/1978> rdfs:label "Increase risk, microcephaly"@en .

<https://identifiers.org/aop.relationships/2619> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2619"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1365> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1798> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1365> rdfs:label "Increase, Apoptosis"@en .
<https://identifiers.org/aop.events/1798> rdfs:label "Decreased spermatogenesis "@en .

<https://identifiers.org/aop.relationships/2645> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2645"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1365> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1097> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1365> rdfs:label "Increase, Apoptosis"@en .
<https://identifiers.org/aop.events/1097> rdfs:label "Occurrence, renal proximal tubular necrosis"@en .

<https://identifiers.org/aop.relationships/1752> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1752"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1366> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/328> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1366> rdfs:label "Decrease, Oogenesis"@en .
<https://identifiers.org/aop.events/328> rdfs:label "Decrease, Fecundity"@en .

<https://identifiers.org/aop.relationships/2588> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2588"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1366> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/78> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1366> rdfs:label "Decrease, Oogenesis"@en .
<https://identifiers.org/aop.events/78> rdfs:label "Reduction, Cumulative fecundity and spawning"@en .

<https://identifiers.org/aop.relationships/1480> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1480"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1369> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1375> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1369> rdfs:label "Activation, PTGS-1 (Prostaglandin-endoperoxide synthase 1)"@en .
<https://identifiers.org/aop.events/1375> rdfs:label "Increase, platelet aggregation"@en .

<https://identifiers.org/aop.relationships/1481> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1481"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1369> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1374> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1369> rdfs:label "Activation, PTGS-1 (Prostaglandin-endoperoxide synthase 1)"@en .
<https://identifiers.org/aop.events/1374> rdfs:label "Increase, mucosal blood flow"@en .

<https://identifiers.org/aop.relationships/1482> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1482"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1369> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1373> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1369> rdfs:label "Activation, PTGS-1 (Prostaglandin-endoperoxide synthase 1)"@en .
<https://identifiers.org/aop.events/1373> rdfs:label "Increase, mucous"@en .

<https://identifiers.org/aop.relationships/1483> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1483"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1369> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1372> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1369> rdfs:label "Activation, PTGS-1 (Prostaglandin-endoperoxide synthase 1)"@en .
<https://identifiers.org/aop.events/1372> rdfs:label "Increase, bicarbonate "@en .

<https://identifiers.org/aop.relationships/1478> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1478"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1370> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1377> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1370> rdfs:label "Activation, PTGS-2 (Prostaglandin-endoperoxide synthase 2)"@en .
<https://identifiers.org/aop.events/1377> rdfs:label "Decrease, leukocyte adherence"@en .

<https://identifiers.org/aop.relationships/1479> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1479"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1370> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1376> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1370> rdfs:label "Activation, PTGS-2 (Prostaglandin-endoperoxide synthase 2)"@en .
<https://identifiers.org/aop.events/1376> rdfs:label "Increase, angiogenesis"@en .

<https://identifiers.org/aop.relationships/1484> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1484"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1372> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1380> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1372> rdfs:label "Increase, bicarbonate "@en .
<https://identifiers.org/aop.events/1380> rdfs:label "Activate, mucosal defense"@en .

<https://identifiers.org/aop.relationships/1485> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1485"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1373> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1380> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1373> rdfs:label "Increase, mucous"@en .
<https://identifiers.org/aop.events/1380> rdfs:label "Activate, mucosal defense"@en .

<https://identifiers.org/aop.relationships/1486> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1486"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1374> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1380> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1374> rdfs:label "Increase, mucosal blood flow"@en .
<https://identifiers.org/aop.events/1380> rdfs:label "Activate, mucosal defense"@en .

<https://identifiers.org/aop.relationships/1474> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1474"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1375> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1367> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1375> rdfs:label "Increase, platelet aggregation"@en .
<https://identifiers.org/aop.events/1367> rdfs:label "Inhibit, gastric ulcer formation"@en .

<https://identifiers.org/aop.relationships/1473> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1473"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1376> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1367> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1376> rdfs:label "Increase, angiogenesis"@en .
<https://identifiers.org/aop.events/1367> rdfs:label "Inhibit, gastric ulcer formation"@en .

<https://identifiers.org/aop.relationships/2578> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2578"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1376> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1193> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1376> rdfs:label "Increase, angiogenesis"@en .
<https://identifiers.org/aop.events/1193> rdfs:label "N/A, Breast Cancer"@en .

<https://identifiers.org/aop.relationships/1477> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1477"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1378> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1379> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1378> rdfs:label "Increase, leukocyte adherence"@en .
<https://identifiers.org/aop.events/1379> rdfs:label "Activate, leukocyte "@en .

<https://identifiers.org/aop.relationships/1476> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1476"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1379> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1385> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1379> rdfs:label "Activate, leukocyte "@en .
<https://identifiers.org/aop.events/1385> rdfs:label "Activated, gastric ulcer formation"@en .

<https://identifiers.org/aop.relationships/1475> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1475"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1380> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1367> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1380> rdfs:label "Activate, mucosal defense"@en .
<https://identifiers.org/aop.events/1367> rdfs:label "Inhibit, gastric ulcer formation"@en .

<https://identifiers.org/aop.relationships/1489> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1489"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1381> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1380> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1381> rdfs:label "Increase, surfactant"@en .
<https://identifiers.org/aop.events/1380> rdfs:label "Activate, mucosal defense"@en .

<https://identifiers.org/aop.relationships/1547> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1547"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1382> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1405> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1382> rdfs:label "Decrease, surfactant"@en .
<https://identifiers.org/aop.events/1405> rdfs:label "Reduced, mucosal defense"@en .

<https://identifiers.org/aop.relationships/1488> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1488"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1383> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1382> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1383> rdfs:label "Activate, phospholipase"@en .
<https://identifiers.org/aop.events/1382> rdfs:label "Decrease, surfactant"@en .

<https://identifiers.org/aop.relationships/1487> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1487"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1384> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1382> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1384> rdfs:label "Increase, ammonium (NH4+)"@en .
<https://identifiers.org/aop.events/1382> rdfs:label "Decrease, surfactant"@en .

<https://identifiers.org/aop.relationships/1493> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1493"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1386> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1387> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1386> rdfs:label "CYP7B activity, inhibition"@en .
<https://identifiers.org/aop.events/1387> rdfs:label "7α-hydroxypregnenolone synthesis in the brain, decreased"@en .

<https://identifiers.org/aop.relationships/1494> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1494"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1386> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1389> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1386> rdfs:label "CYP7B activity, inhibition"@en .
<https://identifiers.org/aop.events/1389> rdfs:label "Locomotor activity, decreased"@en .

<https://identifiers.org/aop.relationships/1495> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1495"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1387> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1389> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1387> rdfs:label "7α-hydroxypregnenolone synthesis in the brain, decreased"@en .
<https://identifiers.org/aop.events/1389> rdfs:label "Locomotor activity, decreased"@en .

<https://identifiers.org/aop.relationships/1496> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1496"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1387> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1388> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1387> rdfs:label "7α-hydroxypregnenolone synthesis in the brain, decreased"@en .
<https://identifiers.org/aop.events/1388> rdfs:label "Dopamine release in the brain, decreased"@en .

<https://identifiers.org/aop.relationships/1498> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1498"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1387> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1390> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1387> rdfs:label "7α-hydroxypregnenolone synthesis in the brain, decreased"@en .
<https://identifiers.org/aop.events/1390> rdfs:label "Sexual behavior, decreased"@en .

<https://identifiers.org/aop.relationships/1497> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1497"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1388> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1389> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1388> rdfs:label "Dopamine release in the brain, decreased"@en .
<https://identifiers.org/aop.events/1389> rdfs:label "Locomotor activity, decreased"@en .

<https://identifiers.org/aop.relationships/1502> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1502"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1388> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1390> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1388> rdfs:label "Dopamine release in the brain, decreased"@en .
<https://identifiers.org/aop.events/1390> rdfs:label "Sexual behavior, decreased"@en .

<https://identifiers.org/aop.relationships/1500> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1500"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1389> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1141> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1389> rdfs:label "Locomotor activity, decreased"@en .
<https://identifiers.org/aop.events/1141> rdfs:label "Decreased, Reproductive Success"@en .

<https://identifiers.org/aop.relationships/1499> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1499"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1390> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1141> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1390> rdfs:label "Sexual behavior, decreased"@en .
<https://identifiers.org/aop.events/1141> rdfs:label "Decreased, Reproductive Success"@en .

<https://identifiers.org/aop.relationships/2810> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2810"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1392> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1634> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1392> rdfs:label "Oxidative Stress "@en .
<https://identifiers.org/aop.events/1634> rdfs:label "Increase, Oxidative damage to DNA"@en .

<https://identifiers.org/aop.relationships/2811> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2811"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1392> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1635> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1392> rdfs:label "Oxidative Stress "@en .
<https://identifiers.org/aop.events/1635> rdfs:label "Increase, DNA strand breaks"@en .

<https://identifiers.org/aop.relationships/2812> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2812"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1392> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2081> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1392> rdfs:label "Oxidative Stress "@en .
<https://identifiers.org/aop.events/2081> rdfs:label "Increased Modified Proteins"@en .

<https://identifiers.org/aop.relationships/2818> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2818"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1392> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2083> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1392> rdfs:label "Oxidative Stress "@en .
<https://identifiers.org/aop.events/2083> rdfs:label "Occurrence of Cataracts"@en .

<https://identifiers.org/aop.relationships/1513> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1513"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1392> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1393> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1392> rdfs:label "Oxidative Stress "@en .
<https://identifiers.org/aop.events/1393> rdfs:label "Hepatocytotoxicity"@en .

<https://identifiers.org/aop.relationships/1516> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1516"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1392> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1395> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1392> rdfs:label "Oxidative Stress "@en .
<https://identifiers.org/aop.events/1395> rdfs:label "Liver Cancer"@en .

<https://identifiers.org/aop.relationships/1685> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1685"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1392> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1488> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1392> rdfs:label "Oxidative Stress "@en .
<https://identifiers.org/aop.events/1488> rdfs:label "Glutamate dyshomeostasis"@en .

<https://identifiers.org/aop.relationships/1690> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1690"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1392> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/55> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1392> rdfs:label "Oxidative Stress "@en .
<https://identifiers.org/aop.events/55> rdfs:label "Cell injury/death"@en .

<https://identifiers.org/aop.relationships/2449> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2449"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1392> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1906> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1392> rdfs:label "Oxidative Stress "@en .
<https://identifiers.org/aop.events/1906> rdfs:label "Cystic Fibrosis Transmembrane Regulator Function, Decreased"@en .

<https://identifiers.org/aop.relationships/2450> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2450"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1392> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1911> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1392> rdfs:label "Oxidative Stress "@en .
<https://identifiers.org/aop.events/1911> rdfs:label "FOXJ1 Protein, Decreased"@en .

<https://identifiers.org/aop.relationships/2451> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2451"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1392> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1908> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1392> rdfs:label "Oxidative Stress "@en .
<https://identifiers.org/aop.events/1908> rdfs:label "Cilia Beat Frequency, Decreased"@en .

<https://identifiers.org/aop.relationships/2505> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2505"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1392> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1943> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1392> rdfs:label "Oxidative Stress "@en .
<https://identifiers.org/aop.events/1943> rdfs:label "Hyperphosphorylation of Tau"@en .

<https://identifiers.org/aop.relationships/2674> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2674"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1392> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2010> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1392> rdfs:label "Oxidative Stress "@en .
<https://identifiers.org/aop.events/2010> rdfs:label "Pulmonary inflammation"@en .

<https://identifiers.org/aop.relationships/2714> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2714"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1392> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1547> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1392> rdfs:label "Oxidative Stress "@en .
<https://identifiers.org/aop.events/1547> rdfs:label "Mitochondrial Injury"@en .

<https://identifiers.org/aop.relationships/2716> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2716"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1392> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1825> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1392> rdfs:label "Oxidative Stress "@en .
<https://identifiers.org/aop.events/1825> rdfs:label "Increase, Cell death"@en .

<https://identifiers.org/aop.relationships/2771> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2771"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1392> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2066> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1392> rdfs:label "Oxidative Stress "@en .
<https://identifiers.org/aop.events/2066> rdfs:label "Altered Signaling Pathways"@en .

<https://identifiers.org/aop.relationships/2772> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2772"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1392> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1493> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1392> rdfs:label "Oxidative Stress "@en .
<https://identifiers.org/aop.events/1493> rdfs:label "Increased Pro-inflammatory mediators"@en .

<https://identifiers.org/aop.relationships/2774> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2774"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1392> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2067> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1392> rdfs:label "Oxidative Stress "@en .
<https://identifiers.org/aop.events/2067> rdfs:label "Altered, Nitric Oxide Levels"@en .

<https://identifiers.org/aop.relationships/2776> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2776"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1392> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2068> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1392> rdfs:label "Oxidative Stress "@en .
<https://identifiers.org/aop.events/2068> rdfs:label "Increase, Endothelial Dysfunction"@en .

<https://identifiers.org/aop.relationships/2833> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2833"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1392> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1492> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1392> rdfs:label "Oxidative Stress "@en .
<https://identifiers.org/aop.events/1492> rdfs:label "Tissue resident cell activation"@en .

<https://identifiers.org/aop.relationships/2846> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2846"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1392> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2089> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1392> rdfs:label "Oxidative Stress "@en .
<https://identifiers.org/aop.events/2089> rdfs:label "Altered Bone Cell Homeostasis"@en .

<https://identifiers.org/aop.relationships/2827> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2827"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1392> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1816> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1392> rdfs:label "Oxidative Stress "@en .
<https://identifiers.org/aop.events/1816> rdfs:label "Mitochondrial dysfunction"@en .

<https://identifiers.org/aop.relationships/1514> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1514"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1393> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1394> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1393> rdfs:label "Hepatocytotoxicity"@en .
<https://identifiers.org/aop.events/1394> rdfs:label "Induction, persistent proliferation/sustained proliferation"@en .

<https://identifiers.org/aop.relationships/1517> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1517"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1393> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1395> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1393> rdfs:label "Hepatocytotoxicity"@en .
<https://identifiers.org/aop.events/1395> rdfs:label "Liver Cancer"@en .

<https://identifiers.org/aop.relationships/1518> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1518"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1394> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1395> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1394> rdfs:label "Induction, persistent proliferation/sustained proliferation"@en .
<https://identifiers.org/aop.events/1395> rdfs:label "Liver Cancer"@en .

<https://identifiers.org/aop.relationships/1522> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1522"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1396> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1335> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1396> rdfs:label "Increased, glucocorticoid receptor activity"@en .
<https://identifiers.org/aop.events/1335> rdfs:label "Reduced, BDNF (Brain-derived neurotrophic factor)"@en .

<https://identifiers.org/aop.relationships/1524> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1524"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1397> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1398> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1397> rdfs:label "Increased, serotonin transporter activity"@en .
<https://identifiers.org/aop.events/1398> rdfs:label "Increased, intracellular serotonin"@en .

<https://identifiers.org/aop.relationships/1528> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1528"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1397> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1347> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1397> rdfs:label "Increased, serotonin transporter activity"@en .
<https://identifiers.org/aop.events/1347> rdfs:label "Decreased, extracellular serotonin"@en .

<https://identifiers.org/aop.relationships/1525> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1525"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1398> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1399> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1398> rdfs:label "Increased, intracellular serotonin"@en .
<https://identifiers.org/aop.events/1399> rdfs:label "Increased, packaged serotonin"@en .

<https://identifiers.org/aop.relationships/1526> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1526"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1399> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1400> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1399> rdfs:label "Increased, packaged serotonin"@en .
<https://identifiers.org/aop.events/1400> rdfs:label "Increased, synaptic release"@en .

<https://identifiers.org/aop.relationships/154> a sbdbel:CausalAssertion ;
  rdfs:label "KER 154"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/140> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/8> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/140> rdfs:label "Decreased, HSD17B10 expression"@en .
<https://identifiers.org/aop.events/8> rdfs:label "Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity"@en .

<https://identifiers.org/aop.relationships/1527> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1527"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1400> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1320> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1400> rdfs:label "Increased, synaptic release"@en .
<https://identifiers.org/aop.events/1320> rdfs:label "Increased, extracellular serotonin"@en .

<https://identifiers.org/aop.relationships/1530> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1530"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1401> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1344> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1401> rdfs:label "Decreased, 5-HT3"@en .
<https://identifiers.org/aop.events/1344> rdfs:label "Increased, seizure"@en .

<https://identifiers.org/aop.relationships/1532> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1532"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1402> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1403> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1402> rdfs:label "Reduced, PTGS1 function"@en .
<https://identifiers.org/aop.events/1403> rdfs:label "Reduced, platelet aggregation"@en .

<https://identifiers.org/aop.relationships/1534> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1534"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1402> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1404> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1402> rdfs:label "Reduced, PTGS1 function"@en .
<https://identifiers.org/aop.events/1404> rdfs:label "Decreased, mucosal blood flow"@en .

<https://identifiers.org/aop.relationships/1537> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1537"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1402> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1406> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1402> rdfs:label "Reduced, PTGS1 function"@en .
<https://identifiers.org/aop.events/1406> rdfs:label "Decreased, mucous"@en .

<https://identifiers.org/aop.relationships/1539> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1539"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1402> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1407> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1402> rdfs:label "Reduced, PTGS1 function"@en .
<https://identifiers.org/aop.events/1407> rdfs:label "Decreased, bicarbonate"@en .

<https://identifiers.org/aop.relationships/1533> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1533"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1403> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1385> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1403> rdfs:label "Reduced, platelet aggregation"@en .
<https://identifiers.org/aop.events/1385> rdfs:label "Activated, gastric ulcer formation"@en .

<https://identifiers.org/aop.relationships/1535> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1535"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1404> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1405> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1404> rdfs:label "Decreased, mucosal blood flow"@en .
<https://identifiers.org/aop.events/1405> rdfs:label "Reduced, mucosal defense"@en .

<https://identifiers.org/aop.relationships/1536> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1536"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1405> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1385> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1405> rdfs:label "Reduced, mucosal defense"@en .
<https://identifiers.org/aop.events/1385> rdfs:label "Activated, gastric ulcer formation"@en .

<https://identifiers.org/aop.relationships/1538> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1538"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1406> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1405> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1406> rdfs:label "Decreased, mucous"@en .
<https://identifiers.org/aop.events/1405> rdfs:label "Reduced, mucosal defense"@en .

<https://identifiers.org/aop.relationships/1540> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1540"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1407> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1405> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1407> rdfs:label "Decreased, bicarbonate"@en .
<https://identifiers.org/aop.events/1405> rdfs:label "Reduced, mucosal defense"@en .

<https://identifiers.org/aop.relationships/1541> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1541"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1408> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1409> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1408> rdfs:label "Reduced, PTGS2 function"@en .
<https://identifiers.org/aop.events/1409> rdfs:label "Decreased, angiogenesis"@en .

<https://identifiers.org/aop.relationships/1543> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1543"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1408> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1410> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1408> rdfs:label "Reduced, PTGS2 function"@en .
<https://identifiers.org/aop.events/1410> rdfs:label "Increased, leukocyte adherence"@en .

<https://identifiers.org/aop.relationships/1542> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1542"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1409> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1385> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1409> rdfs:label "Decreased, angiogenesis"@en .
<https://identifiers.org/aop.events/1385> rdfs:label "Activated, gastric ulcer formation"@en .

<https://identifiers.org/aop.relationships/1544> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1544"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1410> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1411> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1410> rdfs:label "Increased, leukocyte adherence"@en .
<https://identifiers.org/aop.events/1411> rdfs:label "Increased, leukocyte activation"@en .

<https://identifiers.org/aop.relationships/1545> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1545"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1411> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1385> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1411> rdfs:label "Increased, leukocyte activation"@en .
<https://identifiers.org/aop.events/1385> rdfs:label "Activated, gastric ulcer formation"@en .

<https://identifiers.org/aop.relationships/1546> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1546"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1412> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1384> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1412> rdfs:label "Helicobacter pylori infection"@en .
<https://identifiers.org/aop.events/1384> rdfs:label "Increase, ammonium (NH4+)"@en .

<https://identifiers.org/aop.relationships/1551> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1551"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1413> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1414> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1413> rdfs:label "Reduced, presynaptic neuron 2 activity"@en .
<https://identifiers.org/aop.events/1414> rdfs:label "Decreased, GABA"@en .

<https://identifiers.org/aop.relationships/1552> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1552"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1414> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1415> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1414> rdfs:label "Decreased, GABA"@en .
<https://identifiers.org/aop.events/1415> rdfs:label "Reduced, GABA-A receptor activation"@en .

<https://identifiers.org/aop.relationships/1553> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1553"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1415> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1416> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1415> rdfs:label "Reduced, GABA-A receptor activation"@en .
<https://identifiers.org/aop.events/1416> rdfs:label "Decreased, intracellular chloride"@en .

<https://identifiers.org/aop.relationships/1554> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1554"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1416> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1355> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1416> rdfs:label "Decreased, intracellular chloride"@en .
<https://identifiers.org/aop.events/1355> rdfs:label "Activated, membrane depolarization"@en .

<https://identifiers.org/aop.relationships/1556> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1556"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1417> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1419> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1417> rdfs:label "NFE2/Nrf2 repression"@en .
<https://identifiers.org/aop.events/1419> rdfs:label "Reduced, FXR activity"@en .

<https://identifiers.org/aop.relationships/1557> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1557"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1419> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1420> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1419> rdfs:label "Reduced, FXR activity"@en .
<https://identifiers.org/aop.events/1420> rdfs:label "Reduced, SHP activity"@en .

<https://identifiers.org/aop.relationships/158> a sbdbel:CausalAssertion ;
  rdfs:label "KER 158"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/142> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/334> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/142> rdfs:label "Hyperplasia, Hyperplasia"@en .
<https://identifiers.org/aop.events/334> rdfs:label "Promotion, Hepatocelluar carcinoma"@en .

<https://identifiers.org/aop.relationships/1558> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1558"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1420> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1421> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1420> rdfs:label "Reduced, SHP activity"@en .
<https://identifiers.org/aop.events/1421> rdfs:label "Activated, LXR"@en .

<https://identifiers.org/aop.relationships/1559> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1559"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1421> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1422> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1421> rdfs:label "Activated, LXR"@en .
<https://identifiers.org/aop.events/1422> rdfs:label "Reduced, PPARalpha"@en .

<https://identifiers.org/aop.relationships/1560> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1560"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1422> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1423> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1422> rdfs:label "Reduced, PPARalpha"@en .
<https://identifiers.org/aop.events/1423> rdfs:label "Reduced, HSD17B4 activity"@en .

<https://identifiers.org/aop.relationships/1561> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1561"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1423> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1424> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1423> rdfs:label "Reduced, HSD17B4 activity"@en .
<https://identifiers.org/aop.events/1424> rdfs:label "Reduced, fatty acid beta oxidation"@en .

<https://identifiers.org/aop.relationships/1562> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1562"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1424> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1418> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1424> rdfs:label "Reduced, fatty acid beta oxidation"@en .
<https://identifiers.org/aop.events/1418> rdfs:label "Increased, steatosis"@en .

<https://identifiers.org/aop.relationships/1563> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1563"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1425> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1426> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1425> rdfs:label "Mu Opioid Receptor Agonism"@en .
<https://identifiers.org/aop.events/1426> rdfs:label "Release of G Proteins"@en .

<https://identifiers.org/aop.relationships/1564> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1564"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1426> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1427> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1426> rdfs:label "Release of G Proteins"@en .
<https://identifiers.org/aop.events/1427> rdfs:label "Opening of G protein gated inward rectifying K channels"@en .

<https://identifiers.org/aop.relationships/1568> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1568"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1426> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1429> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1426> rdfs:label "Release of G Proteins"@en .
<https://identifiers.org/aop.events/1429> rdfs:label "Inhibition of N-type Ca ion channels"@en .

<https://identifiers.org/aop.relationships/1565> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1565"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1427> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/763> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1427> rdfs:label "Opening of G protein gated inward rectifying K channels"@en .
<https://identifiers.org/aop.events/763> rdfs:label "hyperpolarisation, neuron"@en .

<https://identifiers.org/aop.relationships/1569> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1569"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1429> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1430> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1429> rdfs:label "Inhibition of N-type Ca ion channels"@en .
<https://identifiers.org/aop.events/1430> rdfs:label "Inhibition of neurotransmitter vesicle release"@en .

<https://identifiers.org/aop.relationships/1570> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1570"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1430> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1428> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1430> rdfs:label "Inhibition of neurotransmitter vesicle release"@en .
<https://identifiers.org/aop.events/1428> rdfs:label "Analgesia"@en .

<https://identifiers.org/aop.relationships/1573> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1573"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1430> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1432> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1430> rdfs:label "Inhibition of neurotransmitter vesicle release"@en .
<https://identifiers.org/aop.events/1432> rdfs:label "Anti-depressant Activity"@en .

<https://identifiers.org/aop.relationships/1571> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1571"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1431> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1426> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1431> rdfs:label "Serotonin 1A Receptor Agonism"@en .
<https://identifiers.org/aop.events/1426> rdfs:label "Release of G Proteins"@en .

<https://identifiers.org/aop.relationships/1587> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1587"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1433> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1226> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1433> rdfs:label "Increased CGRP, neuronal release of CGRP"@en .
<https://identifiers.org/aop.events/1226> rdfs:label "Increased Respiratory irritability and Chronic Cough, "@en .

<https://identifiers.org/aop.relationships/1773> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1773"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1435> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1226> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1435> rdfs:label "Increased neurokinin A (NKA) by neuronal cells"@en .
<https://identifiers.org/aop.events/1226> rdfs:label "Increased Respiratory irritability and Chronic Cough, "@en .

<https://identifiers.org/aop.relationships/1589> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1589"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1438> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1439> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1438> rdfs:label "Acute phase response proteins expression, Increased"@en .
<https://identifiers.org/aop.events/1439> rdfs:label "Systemic acute phase response"@en .

<https://identifiers.org/aop.relationships/2860> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2860"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1439> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1443> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1439> rdfs:label "Systemic acute phase response"@en .
<https://identifiers.org/aop.events/1443> rdfs:label "Atherosclerosis"@en .

<https://identifiers.org/aop.relationships/1597> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1597"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1444> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1366> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1444> rdfs:label "Increase, Follicular atresia"@en .
<https://identifiers.org/aop.events/1366> rdfs:label "Decrease, Oogenesis"@en .

<https://identifiers.org/aop.relationships/2097> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2097"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1445> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1772> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1445> rdfs:label "Increase, Lipid peroxidation"@en .
<https://identifiers.org/aop.events/1772> rdfs:label "Decrease, Neutral lipids"@en .

<https://identifiers.org/aop.relationships/2464> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2464"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1445> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1607> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1445> rdfs:label "Increase, Lipid peroxidation"@en .
<https://identifiers.org/aop.events/1607> rdfs:label "Increase, Necrosis"@en .

<https://identifiers.org/aop.relationships/2793> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2793"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1446> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2070> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1446> rdfs:label "Decrease, Coupling of oxidative phosphorylation"@en .
<https://identifiers.org/aop.events/2070> rdfs:label "Increase, Glycolysis"@en .

<https://identifiers.org/aop.relationships/2796> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2796"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1446> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2072> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1446> rdfs:label "Decrease, Coupling of oxidative phosphorylation"@en .
<https://identifiers.org/aop.events/2072> rdfs:label "Increase, Mitochondrial swelling"@en .

<https://identifiers.org/aop.relationships/2203> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2203"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1446> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1771> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1446> rdfs:label "Decrease, Coupling of oxidative phosphorylation"@en .
<https://identifiers.org/aop.events/1771> rdfs:label "Decrease, Adenosine triphosphate pool"@en .

<https://identifiers.org/aop.relationships/2763> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2763"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1446> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2064> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1446> rdfs:label "Decrease, Coupling of oxidative phosphorylation"@en .
<https://identifiers.org/aop.events/2064> rdfs:label "Increase, Cytosolic calcium"@en .

<https://identifiers.org/aop.relationships/1610> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1610"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1448> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1028> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1448> rdfs:label "activation of CCAAT/enhancer-binding protein alpha"@en .
<https://identifiers.org/aop.events/1028> rdfs:label "Activation of specific nuclear receptors, PPAR-gamma activation"@en .

<https://identifiers.org/aop.relationships/1611> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1611"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1448> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1449> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1448> rdfs:label "activation of CCAAT/enhancer-binding protein alpha"@en .
<https://identifiers.org/aop.events/1449> rdfs:label "increased adipogenesis"@en .

<https://identifiers.org/aop.relationships/1612> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1612"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1449> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1447> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1449> rdfs:label "increased adipogenesis"@en .
<https://identifiers.org/aop.events/1447> rdfs:label "obesity"@en .

<https://identifiers.org/aop.relationships/386> a sbdbel:CausalAssertion ;
  rdfs:label "KER 386"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/145> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/202> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/145> rdfs:label "Induction, IKB inhibitory protein"@en .
<https://identifiers.org/aop.events/202> rdfs:label "Inhibition, Nuclear factor kappa B (NF-kB)"@en .

<https://identifiers.org/aop.relationships/1614> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1614"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1450> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1451> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1450> rdfs:label "decreased dopamine"@en .
<https://identifiers.org/aop.events/1451> rdfs:label "decreased reward"@en .

<https://identifiers.org/aop.relationships/1615> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1615"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1451> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1452> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1451> rdfs:label "decreased reward"@en .
<https://identifiers.org/aop.events/1452> rdfs:label "decreased DNA methylation of tyrosine hydroxylase"@en .

<https://identifiers.org/aop.relationships/1616> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1616"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1451> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1453> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1451> rdfs:label "decreased reward"@en .
<https://identifiers.org/aop.events/1453> rdfs:label "decreased methylation of dopamine transporter promoter"@en .

<https://identifiers.org/aop.relationships/1617> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1617"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1451> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1450> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1451> rdfs:label "decreased reward"@en .
<https://identifiers.org/aop.events/1450> rdfs:label "decreased dopamine"@en .

<https://identifiers.org/aop.relationships/1618> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1618"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1452> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1447> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1452> rdfs:label "decreased DNA methylation of tyrosine hydroxylase"@en .
<https://identifiers.org/aop.events/1447> rdfs:label "obesity"@en .

<https://identifiers.org/aop.relationships/1620> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1620"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1452> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1450> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1452> rdfs:label "decreased DNA methylation of tyrosine hydroxylase"@en .
<https://identifiers.org/aop.events/1450> rdfs:label "decreased dopamine"@en .

<https://identifiers.org/aop.relationships/1619> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1619"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1453> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1447> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1453> rdfs:label "decreased methylation of dopamine transporter promoter"@en .
<https://identifiers.org/aop.events/1447> rdfs:label "obesity"@en .

<https://identifiers.org/aop.relationships/1621> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1621"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1453> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1450> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1453> rdfs:label "decreased methylation of dopamine transporter promoter"@en .
<https://identifiers.org/aop.events/1450> rdfs:label "decreased dopamine"@en .

<https://identifiers.org/aop.relationships/1613> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1613"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1454> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1450> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1454> rdfs:label "chronic high fat diet"@en .
<https://identifiers.org/aop.events/1450> rdfs:label "decreased dopamine"@en .

<https://identifiers.org/aop.relationships/1654> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1654"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1456> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/68> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1456> rdfs:label "Increase, Differentiation of fibroblasts"@en .
<https://identifiers.org/aop.events/68> rdfs:label "Accumulation, Collagen"@en .

<https://identifiers.org/aop.relationships/1655> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1655"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1457> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/68> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1457> rdfs:label "Induction, Epithelial Mesenchymal Transition"@en .
<https://identifiers.org/aop.events/68> rdfs:label "Accumulation, Collagen"@en .

<https://identifiers.org/aop.relationships/1779> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1779"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1457> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1275> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1457> rdfs:label "Induction, Epithelial Mesenchymal Transition"@en .
<https://identifiers.org/aop.events/1275> rdfs:label "Collagen Deposition"@en .

<https://identifiers.org/aop.relationships/1840> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1840"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1457> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1587> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1457> rdfs:label "Induction, Epithelial Mesenchymal Transition"@en .
<https://identifiers.org/aop.events/1587> rdfs:label "Fibroproliferative airway lesions"@en .

<https://identifiers.org/aop.relationships/2154> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2154"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1457> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1458> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1457> rdfs:label "Induction, Epithelial Mesenchymal Transition"@en .
<https://identifiers.org/aop.events/1458> rdfs:label "Pulmonary fibrosis"@en .

<https://identifiers.org/aop.relationships/2614> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2614"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1457> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1982> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1457> rdfs:label "Induction, Epithelial Mesenchymal Transition"@en .
<https://identifiers.org/aop.events/1982> rdfs:label "metastatic breast cancer"@en .

<https://identifiers.org/aop.relationships/1635> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1635"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1461> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1253> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1461> rdfs:label "DNA double-strand break "@en .
<https://identifiers.org/aop.events/1253> rdfs:label " MLL chromosomal translocation"@en .

<https://identifiers.org/aop.relationships/1636> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1636"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1462> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1463> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1462> rdfs:label "Thiol group of chemicals interact with sulfuhydryl groups of proteins to form thiol adducts"@en .
<https://identifiers.org/aop.events/1463> rdfs:label "Inhibition of lysyl oxidase"@en .

<https://identifiers.org/aop.relationships/1637> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1637"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1463> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1464> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1463> rdfs:label "Inhibition of lysyl oxidase"@en .
<https://identifiers.org/aop.events/1464> rdfs:label "Reduction of collagen crosslinking"@en .

<https://identifiers.org/aop.relationships/1638> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1638"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1464> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1465> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1464> rdfs:label "Reduction of collagen crosslinking"@en .
<https://identifiers.org/aop.events/1465> rdfs:label "Weak collagen matrix"@en .

<https://identifiers.org/aop.relationships/1639> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1639"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1465> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1466> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1465> rdfs:label "Weak collagen matrix"@en .
<https://identifiers.org/aop.events/1466> rdfs:label "Notochord distortion or malformations"@en .

<https://identifiers.org/aop.relationships/1640> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1640"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1466> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1005> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1466> rdfs:label "Notochord distortion or malformations"@en .
<https://identifiers.org/aop.events/1005> rdfs:label "Reduced, Swimming performance"@en .

<https://identifiers.org/aop.relationships/1651> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1651"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1468> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1469> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1468> rdfs:label "Activation, Latent Transforming Growth Factor Beta 1"@en .
<https://identifiers.org/aop.events/1469> rdfs:label "Activation, Transforming Growth Factor beta pathway"@en .

<https://identifiers.org/aop.relationships/1652> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1652"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1469> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1456> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1469> rdfs:label "Activation, Transforming Growth Factor beta pathway"@en .
<https://identifiers.org/aop.events/1456> rdfs:label "Increase, Differentiation of fibroblasts"@en .

<https://identifiers.org/aop.relationships/1653> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1653"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1469> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1457> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1469> rdfs:label "Activation, Transforming Growth Factor beta pathway"@en .
<https://identifiers.org/aop.events/1457> rdfs:label "Induction, Epithelial Mesenchymal Transition"@en .

<https://identifiers.org/aop.relationships/159> a sbdbel:CausalAssertion ;
  rdfs:label "KER 159"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/147> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/270> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/147> rdfs:label "Inhibition, Inducible Nitric Oxide Synthase by Metabolite CGA 265307"@en .
<https://identifiers.org/aop.events/270> rdfs:label "Induction, Sustained Hepatotoxicity"@en .

<https://identifiers.org/aop.relationships/1663> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1663"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1471> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1472> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1471> rdfs:label "Increase, Uncoupling of photophosphorylation"@en .
<https://identifiers.org/aop.events/1472> rdfs:label "Decrease, ATP production"@en .

<https://identifiers.org/aop.relationships/1664> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1664"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1472> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1473> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1472> rdfs:label "Decrease, ATP production"@en .
<https://identifiers.org/aop.events/1473> rdfs:label "Decrease, Chlorophyll synthesis"@en .

<https://identifiers.org/aop.relationships/2341> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2341"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1472> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1479> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1472> rdfs:label "Decrease, ATP production"@en .
<https://identifiers.org/aop.events/1479> rdfs:label "Decrease, Leaf development"@en .

<https://identifiers.org/aop.relationships/2547> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2547"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1472> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1863> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1472> rdfs:label "Decrease, ATP production"@en .
<https://identifiers.org/aop.events/1863> rdfs:label "Decrease, Reproduction"@en .

<https://identifiers.org/aop.relationships/1665> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1665"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1473> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1474> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1473> rdfs:label "Decrease, Chlorophyll synthesis"@en .
<https://identifiers.org/aop.events/1474> rdfs:label "Decrease, Light harvest capacity"@en .

<https://identifiers.org/aop.relationships/1666> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1666"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1474> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1475> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1474> rdfs:label "Decrease, Light harvest capacity"@en .
<https://identifiers.org/aop.events/1475> rdfs:label "Decrease, Photosynthesis"@en .

<https://identifiers.org/aop.relationships/1667> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1667"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1475> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1476> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1475> rdfs:label "Decrease, Photosynthesis"@en .
<https://identifiers.org/aop.events/1476> rdfs:label "Decrease, Glycolysis"@en .

<https://identifiers.org/aop.relationships/2334> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2334"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1475> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1472> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1475> rdfs:label "Decrease, Photosynthesis"@en .
<https://identifiers.org/aop.events/1472> rdfs:label "Decrease, ATP production"@en .

<https://identifiers.org/aop.relationships/1668> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1668"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1476> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1477> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1476> rdfs:label "Decrease, Glycolysis"@en .
<https://identifiers.org/aop.events/1477> rdfs:label "Decrease, Oxidative phosphorylation"@en .

<https://identifiers.org/aop.relationships/1671> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1671"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1478> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1479> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1478> rdfs:label "Decrease, Leaf cell mitosis"@en .
<https://identifiers.org/aop.events/1479> rdfs:label "Decrease, Leaf development"@en .

<https://identifiers.org/aop.relationships/2283> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2283"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1479> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1521> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1479> rdfs:label "Decrease, Leaf development"@en .
<https://identifiers.org/aop.events/1521> rdfs:label "Decrease, Growth"@en .

<https://identifiers.org/aop.relationships/2335> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2335"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1479> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1863> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1479> rdfs:label "Decrease, Leaf development"@en .
<https://identifiers.org/aop.events/1863> rdfs:label "Decrease, Reproduction"@en .

<https://identifiers.org/aop.relationships/1673> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1673"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1481> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1482> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1481> rdfs:label "Inhibition of mitochondrial DNA polymerase gamma (Pol gamma)"@en .
<https://identifiers.org/aop.events/1482> rdfs:label "Depletion, mtDNA "@en .

<https://identifiers.org/aop.relationships/1674> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1674"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1482> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1483> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1482> rdfs:label "Depletion, mtDNA "@en .
<https://identifiers.org/aop.events/1483> rdfs:label "Dysfunction, Mitochondria "@en .

<https://identifiers.org/aop.relationships/1675> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1675"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1483> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/709> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1483> rdfs:label "Dysfunction, Mitochondria "@en .
<https://identifiers.org/aop.events/709> rdfs:label "Increase, Cytotoxicity (renal tubular cell)"@en .

<https://identifiers.org/aop.relationships/1681> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1681"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1483> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/40> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1483> rdfs:label "Dysfunction, Mitochondria "@en .
<https://identifiers.org/aop.events/40> rdfs:label "Decrease, Mitochondrial ATP production"@en .

<https://identifiers.org/aop.relationships/1677> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1677"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1486> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/831> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1486> rdfs:label "Binding of substrate, endocytic receptor"@en .
<https://identifiers.org/aop.events/831> rdfs:label "Disturbance, Lysosomal function"@en .

<https://identifiers.org/aop.relationships/1765> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1765"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1487> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1538> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1487> rdfs:label "Binding, Thiol/seleno-proteins involved in protection against oxidative stress"@en .
<https://identifiers.org/aop.events/1538> rdfs:label "Decreased protection against oxidative stress"@en .

<https://identifiers.org/aop.relationships/1686> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1686"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1488> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/55> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1488> rdfs:label "Glutamate dyshomeostasis"@en .
<https://identifiers.org/aop.events/55> rdfs:label "Cell injury/death"@en .

<https://identifiers.org/aop.relationships/1724> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1724"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/149> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1457> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/149> rdfs:label "Increase, Inflammation"@en .
<https://identifiers.org/aop.events/1457> rdfs:label "Induction, Epithelial Mesenchymal Transition"@en .

<https://identifiers.org/aop.relationships/1839> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1839"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/149> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1587> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/149> rdfs:label "Increase, Inflammation"@en .
<https://identifiers.org/aop.events/1587> rdfs:label "Fibroproliferative airway lesions"@en .

<https://identifiers.org/aop.relationships/781> a sbdbel:CausalAssertion ;
  rdfs:label "KER 781"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/149> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/781> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/149> rdfs:label "Increase, Inflammation"@en .
<https://identifiers.org/aop.events/781> rdfs:label "Increase, Regenerative cell proliferation (forestomach epithelial cells)"@en .

<https://identifiers.org/aop.relationships/929> a sbdbel:CausalAssertion ;
  rdfs:label "KER 929"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/149> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/357> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/149> rdfs:label "Increase, Inflammation"@en .
<https://identifiers.org/aop.events/357> rdfs:label "Cholestasis, Pathology"@en .

<https://identifiers.org/aop.relationships/2573> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2573"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/149> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1196> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/149> rdfs:label "Increase, Inflammation"@en .
<https://identifiers.org/aop.events/1196> rdfs:label "Increased, Invasion"@en .

<https://identifiers.org/aop.relationships/2574> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2574"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/149> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1376> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/149> rdfs:label "Increase, Inflammation"@en .
<https://identifiers.org/aop.events/1376> rdfs:label "Increase, angiogenesis"@en .

<https://identifiers.org/aop.relationships/1692> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1692"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1490> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1305> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1490> rdfs:label "Inhibition, Fatty Acid Beta Oxidation"@en .
<https://identifiers.org/aop.events/1305> rdfs:label "Increase, cytosolic fatty acid"@en .

<https://identifiers.org/aop.relationships/1697> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1697"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1491> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1489> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1491> rdfs:label "Increased, Oncotic Necrosis"@en .
<https://identifiers.org/aop.events/1489> rdfs:label "N/A, Steatohepatisis"@en .

<https://identifiers.org/aop.relationships/1763> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1763"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1492> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1493> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1492> rdfs:label "Tissue resident cell activation"@en .
<https://identifiers.org/aop.events/1493> rdfs:label "Increased Pro-inflammatory mediators"@en .

<https://identifiers.org/aop.relationships/2834> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2834"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1492> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2097> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1492> rdfs:label "Tissue resident cell activation"@en .
<https://identifiers.org/aop.events/2097> rdfs:label "Increase, Pro-Inflammatory Mediators"@en .

<https://identifiers.org/aop.relationships/1719> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1719"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1493> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/55> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1493> rdfs:label "Increased Pro-inflammatory mediators"@en .
<https://identifiers.org/aop.events/55> rdfs:label "Cell injury/death"@en .

<https://identifiers.org/aop.relationships/1764> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1764"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1493> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/265> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1493> rdfs:label "Increased Pro-inflammatory mediators"@en .
<https://identifiers.org/aop.events/265> rdfs:label "Activation, Stellate cells"@en .

<https://identifiers.org/aop.relationships/1777> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1777"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1493> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1494> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1493> rdfs:label "Increased Pro-inflammatory mediators"@en .
<https://identifiers.org/aop.events/1494> rdfs:label "Leukocyte recruitment/activation"@en .

<https://identifiers.org/aop.relationships/1902> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1902"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1493> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1193> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1493> rdfs:label "Increased Pro-inflammatory mediators"@en .
<https://identifiers.org/aop.events/1193> rdfs:label "N/A, Breast Cancer"@en .

<https://identifiers.org/aop.relationships/1903> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1903"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1493> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1632> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1493> rdfs:label "Increased Pro-inflammatory mediators"@en .
<https://identifiers.org/aop.events/1632> rdfs:label "Increase in reactive oxygen and nitrogen species (RONS)"@en .

<https://identifiers.org/aop.relationships/1908> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1908"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1493> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1182> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1493> rdfs:label "Increased Pro-inflammatory mediators"@en .
<https://identifiers.org/aop.events/1182> rdfs:label "Increase, Cell Proliferation (Epithelial Cells)"@en .

<https://identifiers.org/aop.relationships/2777> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2777"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1493> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2068> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1493> rdfs:label "Increased Pro-inflammatory mediators"@en .
<https://identifiers.org/aop.events/2068> rdfs:label "Increase, Endothelial Dysfunction"@en .

<https://identifiers.org/aop.relationships/1702> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1702"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1495> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1496> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1495> rdfs:label "Substance interaction with the lung resident cell membrane components"@en .
<https://identifiers.org/aop.events/1496> rdfs:label "Increased, secretion of proinflammatory mediators"@en .

<https://identifiers.org/aop.relationships/2662> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2662"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1495> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1115> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1495> rdfs:label "Substance interaction with the lung resident cell membrane components"@en .
<https://identifiers.org/aop.events/1115> rdfs:label "Increased, Reactive oxygen species"@en .

<https://identifiers.org/aop.relationships/2663> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2663"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1495> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1669> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1495> rdfs:label "Substance interaction with the lung resident cell membrane components"@en .
<https://identifiers.org/aop.events/1669> rdfs:label "Increased, DNA damage and mutation"@en .

<https://identifiers.org/aop.relationships/1703> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1703"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1496> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1497> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1496> rdfs:label "Increased, secretion of proinflammatory mediators"@en .
<https://identifiers.org/aop.events/1497> rdfs:label "Increased, recruitment of inflammatory cells"@en .

<https://identifiers.org/aop.relationships/2061> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2061"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1496> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1750> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1496> rdfs:label "Increased, secretion of proinflammatory mediators"@en .
<https://identifiers.org/aop.events/1750> rdfs:label "Increased inflammatory immune responses"@en .

<https://identifiers.org/aop.relationships/2307> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2307"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1496> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/68> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1496> rdfs:label "Increased, secretion of proinflammatory mediators"@en .
<https://identifiers.org/aop.events/68> rdfs:label "Accumulation, Collagen"@en .

<https://identifiers.org/aop.relationships/2651> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2651"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1496> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/398> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1496> rdfs:label "Increased, secretion of proinflammatory mediators"@en .
<https://identifiers.org/aop.events/398> rdfs:label "Activation, Dendritic Cells"@en .

<https://identifiers.org/aop.relationships/2053> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2053"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1496> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1438> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1496> rdfs:label "Increased, secretion of proinflammatory mediators"@en .
<https://identifiers.org/aop.events/1438> rdfs:label "Acute phase response proteins expression, Increased"@en .

<https://identifiers.org/aop.relationships/1704> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1704"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1497> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1498> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1497> rdfs:label "Increased, recruitment of inflammatory cells"@en .
<https://identifiers.org/aop.events/1498> rdfs:label "Loss of alveolar capillary membrane integrity"@en .

<https://identifiers.org/aop.relationships/1964> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1964"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1497> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1115> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1497> rdfs:label "Increased, recruitment of inflammatory cells"@en .
<https://identifiers.org/aop.events/1115> rdfs:label "Increased, Reactive oxygen species"@en .

<https://identifiers.org/aop.relationships/2354> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2354"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1497> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1868> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1497> rdfs:label "Increased, recruitment of inflammatory cells"@en .
<https://identifiers.org/aop.events/1868> rdfs:label "Hyperinflammation"@en .

<https://identifiers.org/aop.relationships/2658> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2658"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1497> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/780> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1497> rdfs:label "Increased, recruitment of inflammatory cells"@en .
<https://identifiers.org/aop.events/780> rdfs:label "Increase, Cytotoxicity (epithelial cells)"@en .

<https://identifiers.org/aop.relationships/2761> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2761"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1497> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1496> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1497> rdfs:label "Increased, recruitment of inflammatory cells"@en .
<https://identifiers.org/aop.events/1496> rdfs:label "Increased, secretion of proinflammatory mediators"@en .

<https://identifiers.org/aop.relationships/2791> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2791"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1505> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/752> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1505> rdfs:label "Cell cycle, disrupted"@en .
<https://identifiers.org/aop.events/752> rdfs:label "Altered, Meiotic chromosome dynamics"@en .

<https://identifiers.org/aop.relationships/1712> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1712"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1505> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1262> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1505> rdfs:label "Cell cycle, disrupted"@en .
<https://identifiers.org/aop.events/1262> rdfs:label "Apoptosis"@en .

<https://identifiers.org/aop.relationships/1729> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1729"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1509> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1512> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1509> rdfs:label "Protein Adduct Formation"@en .
<https://identifiers.org/aop.events/1512> rdfs:label "Unfolded Protein Response"@en .

<https://identifiers.org/aop.relationships/1728> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1728"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1511> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1509> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1511> rdfs:label "Lipid Peroxidation"@en .
<https://identifiers.org/aop.events/1509> rdfs:label "Protein Adduct Formation"@en .

<https://identifiers.org/aop.relationships/1731> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1731"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1511> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1513> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1511> rdfs:label "Lipid Peroxidation"@en .
<https://identifiers.org/aop.events/1513> rdfs:label "General Apoptosis"@en .

<https://identifiers.org/aop.relationships/1734> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1734"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1515> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1506> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1515> rdfs:label "Spermatocyte depletion"@en .
<https://identifiers.org/aop.events/1506> rdfs:label "Testicular atrophy"@en .

<https://identifiers.org/aop.relationships/388> a sbdbel:CausalAssertion ;
  rdfs:label "KER 388"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/152> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/168> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/152> rdfs:label "Suppression, Inflammatory cytokines"@en .
<https://identifiers.org/aop.events/168> rdfs:label "Decreased, Lymphocytes"@en .

<https://identifiers.org/aop.relationships/2804> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2804"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1521> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1141> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1521> rdfs:label "Decrease, Growth"@en .
<https://identifiers.org/aop.events/1141> rdfs:label "Decreased, Reproductive Success"@en .

<https://identifiers.org/aop.relationships/1743> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1743"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1523> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1524> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1523> rdfs:label "Decrease, Cuticular chitin content"@en .
<https://identifiers.org/aop.events/1524> rdfs:label "Increase, Premature molting"@en .

<https://identifiers.org/aop.relationships/1744> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1744"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1524> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/350> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1524> rdfs:label "Increase, Premature molting"@en .
<https://identifiers.org/aop.events/350> rdfs:label "Increase, Mortality"@en .

<https://identifiers.org/aop.relationships/1745> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1745"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1525> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1527> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1525> rdfs:label "Increase, Sulfonylurea receptor binding"@en .
<https://identifiers.org/aop.events/1527> rdfs:label "Increase, Cell membrane depolarization"@en .

<https://identifiers.org/aop.relationships/1747> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1747"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1526> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1523> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1526> rdfs:label "Increase, Opening of voltage-dependent calcium channel"@en .
<https://identifiers.org/aop.events/1523> rdfs:label "Decrease, Cuticular chitin content"@en .

<https://identifiers.org/aop.relationships/2788> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2788"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1527> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/55> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1527> rdfs:label "Increase, Cell membrane depolarization"@en .
<https://identifiers.org/aop.events/55> rdfs:label "Cell injury/death"@en .

<https://identifiers.org/aop.relationships/1746> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1746"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1527> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1526> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1527> rdfs:label "Increase, Cell membrane depolarization"@en .
<https://identifiers.org/aop.events/1526> rdfs:label "Increase, Opening of voltage-dependent calcium channel"@en .

<https://identifiers.org/aop.relationships/2708> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2708"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1527> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/389> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1527> rdfs:label "Increase, Cell membrane depolarization"@en .
<https://identifiers.org/aop.events/389> rdfs:label "Increased, Intracellular Calcium overload"@en .

<https://identifiers.org/aop.relationships/1755> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1755"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1529> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1530> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1529> rdfs:label "Blockade, L-Type Calcium Channels "@en .
<https://identifiers.org/aop.events/1530> rdfs:label "Decrease, Calcium currents"@en .

<https://identifiers.org/aop.relationships/1756> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1756"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1530> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1531> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1530> rdfs:label "Decrease, Calcium currents"@en .
<https://identifiers.org/aop.events/1531> rdfs:label "Decrease, Calcium binding to Troponin C"@en .

<https://identifiers.org/aop.relationships/1760> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1760"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1530> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1536> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1530> rdfs:label "Decrease, Calcium currents"@en .
<https://identifiers.org/aop.events/1536> rdfs:label "Disruption, Intracellular calcium mobilization"@en .

<https://identifiers.org/aop.relationships/1757> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1757"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1531> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1532> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1531> rdfs:label "Decrease, Calcium binding to Troponin C"@en .
<https://identifiers.org/aop.events/1532> rdfs:label "Decrease, Cardiac contractility "@en .

<https://identifiers.org/aop.relationships/1758> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1758"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1532> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1533> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1532> rdfs:label "Decrease, Cardiac contractility "@en .
<https://identifiers.org/aop.events/1533> rdfs:label "Decrease, Cardiac ejection fraction "@en .

<https://identifiers.org/aop.relationships/2824> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2824"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1532> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1535> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1532> rdfs:label "Decrease, Cardiac contractility "@en .
<https://identifiers.org/aop.events/1535> rdfs:label "Heart failure "@en .

<https://identifiers.org/aop.relationships/1759> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1759"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1533> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1535> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1533> rdfs:label "Decrease, Cardiac ejection fraction "@en .
<https://identifiers.org/aop.events/1535> rdfs:label "Heart failure "@en .

<https://identifiers.org/aop.relationships/2825> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2825"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1535> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/350> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1535> rdfs:label "Heart failure "@en .
<https://identifiers.org/aop.events/350> rdfs:label "Increase, Mortality"@en .

<https://identifiers.org/aop.relationships/1761> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1761"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1536> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1537> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1536> rdfs:label "Disruption, Intracellular calcium mobilization"@en .
<https://identifiers.org/aop.events/1537> rdfs:label "Disruption, Sarcomere assembly"@en .

<https://identifiers.org/aop.relationships/1762> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1762"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1537> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1532> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1537> rdfs:label "Disruption, Sarcomere assembly"@en .
<https://identifiers.org/aop.events/1532> rdfs:label "Decrease, Cardiac contractility "@en .

<https://identifiers.org/aop.relationships/1766> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1766"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1538> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1392> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1538> rdfs:label "Decreased protection against oxidative stress"@en .
<https://identifiers.org/aop.events/1392> rdfs:label "Oxidative Stress "@en .

<https://identifiers.org/aop.relationships/1775> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1775"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1539> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/898> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1539> rdfs:label "Endocytotic lysosomal uptake"@en .
<https://identifiers.org/aop.events/898> rdfs:label "Disruption, Lysosome"@en .

<https://identifiers.org/aop.relationships/1956> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1956"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1545> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/177> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1545> rdfs:label "Decrease in mitochondrial oxidative phosphorylation"@en .
<https://identifiers.org/aop.events/177> rdfs:label "N/A, Mitochondrial dysfunction 1"@en .

<https://identifiers.org/aop.relationships/1957> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1957"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1546> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/177> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1546> rdfs:label "Increased reactive oxygen species (in the mitochondria)"@en .
<https://identifiers.org/aop.events/177> rdfs:label "N/A, Mitochondrial dysfunction 1"@en .

<https://identifiers.org/aop.relationships/2715> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2715"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1547> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1825> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1547> rdfs:label "Mitochondrial Injury"@en .
<https://identifiers.org/aop.events/1825> rdfs:label "Increase, Cell death"@en .

<https://identifiers.org/aop.relationships/1789> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1789"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1548> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1549> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1548> rdfs:label "Necrotic Tissue"@en .
<https://identifiers.org/aop.events/1549> rdfs:label "Liver Injury"@en .

<https://identifiers.org/aop.relationships/1804> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1804"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1558> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1559> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1558> rdfs:label "Collagen production, reduced"@en .
<https://identifiers.org/aop.events/1559> rdfs:label "Facial cartilage structures are reduced in size and morphologically distorted"@en .

<https://identifiers.org/aop.relationships/2686> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2686"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1559> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/947> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1559> rdfs:label "Facial cartilage structures are reduced in size and morphologically distorted"@en .
<https://identifiers.org/aop.events/947> rdfs:label "Increase, Early Life Stage Mortality"@en .

<https://identifiers.org/aop.relationships/1808> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1808"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1560> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1561> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1560> rdfs:label "Altered differentiation"@en .
<https://identifiers.org/aop.events/1561> rdfs:label "Neural tube defects"@en .

<https://identifiers.org/aop.relationships/2787> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2787"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1562> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1527> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1562> rdfs:label "Decreased Na/K ATPase activity"@en .
<https://identifiers.org/aop.events/1527> rdfs:label "Increase, Cell membrane depolarization"@en .

<https://identifiers.org/aop.relationships/1811> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1811"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1562> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1563> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1562> rdfs:label "Decreased Na/K ATPase activity"@en .
<https://identifiers.org/aop.events/1563> rdfs:label "Decreased proximal tubular vectorial transport"@en .

<https://identifiers.org/aop.relationships/1812> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1812"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1563> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1564> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1563> rdfs:label "Decreased proximal tubular vectorial transport"@en .
<https://identifiers.org/aop.events/1564> rdfs:label "Chemical induced Fanconi syndrome"@en .

<https://identifiers.org/aop.relationships/1832> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1832"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1576> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1579> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1576> rdfs:label "Activation, Tissue resident cells (Kuppfer cells)"@en .
<https://identifiers.org/aop.events/1579> rdfs:label "Increase, proinflammatory mediators (TNFalpha)"@en .

<https://identifiers.org/aop.relationships/1833> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1833"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1580> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1581> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1580> rdfs:label "Binding of microtubule stabilizing agents (MSA) to microtubules"@en .
<https://identifiers.org/aop.events/1581> rdfs:label "Disturbance in microtubule dynamic instability"@en .

<https://identifiers.org/aop.relationships/1834> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1834"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1581> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1582> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1581> rdfs:label "Disturbance in microtubule dynamic instability"@en .
<https://identifiers.org/aop.events/1582> rdfs:label "Impaired axonial transport"@en .

<https://identifiers.org/aop.relationships/1835> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1835"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1582> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1583> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1582> rdfs:label "Impaired axonial transport"@en .
<https://identifiers.org/aop.events/1583> rdfs:label "Sensory axonal peripheral neuropathy"@en .

<https://identifiers.org/aop.relationships/2506> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2506"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1582> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1944> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1582> rdfs:label "Impaired axonial transport"@en .
<https://identifiers.org/aop.events/1944> rdfs:label "Synaptic dysfunction"@en .

<https://identifiers.org/aop.relationships/2657> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2657"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1583> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/351> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1583> rdfs:label "Sensory axonal peripheral neuropathy"@en .
<https://identifiers.org/aop.events/351> rdfs:label "Increased Mortality"@en .

<https://identifiers.org/aop.relationships/1836> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1836"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1584> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1585> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1584> rdfs:label "Interaction of α-diketones with arginine residues"@en .
<https://identifiers.org/aop.events/1585> rdfs:label "Proteasomal dysfunction"@en .

<https://identifiers.org/aop.relationships/1837> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1837"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1585> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1586> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1585> rdfs:label "Proteasomal dysfunction"@en .
<https://identifiers.org/aop.events/1586> rdfs:label "Airway epithelial injury"@en .

<https://identifiers.org/aop.relationships/1838> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1838"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1586> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/149> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1586> rdfs:label "Airway epithelial injury"@en .
<https://identifiers.org/aop.events/149> rdfs:label "Increase, Inflammation"@en .

<https://identifiers.org/aop.relationships/1841> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1841"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1587> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1588> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1587> rdfs:label "Fibroproliferative airway lesions"@en .
<https://identifiers.org/aop.events/1588> rdfs:label "Bronchiolitis obliterans"@en .

<https://identifiers.org/aop.relationships/1845> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1845"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1592> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1594> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1592> rdfs:label "ROS generation from photoactivated chemicals"@en .
<https://identifiers.org/aop.events/1594> rdfs:label "Oxidation of membrane lipids"@en .

<https://identifiers.org/aop.relationships/1846> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1846"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1592> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1595> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1592> rdfs:label "ROS generation from photoactivated chemicals"@en .
<https://identifiers.org/aop.events/1595> rdfs:label "Oxidation/denatuation of membrane proteins"@en .

<https://identifiers.org/aop.relationships/1850> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1850"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1594> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1599> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1594> rdfs:label "Oxidation of membrane lipids"@en .
<https://identifiers.org/aop.events/1599> rdfs:label "Inflamatory events in light-exposed tissues"@en .

<https://identifiers.org/aop.relationships/1851> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1851"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1595> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1599> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1595> rdfs:label "Oxidation/denatuation of membrane proteins"@en .
<https://identifiers.org/aop.events/1599> rdfs:label "Inflamatory events in light-exposed tissues"@en .

<https://identifiers.org/aop.relationships/1889> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1889"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1602> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1623> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1602> rdfs:label "Activation, Muscarinic Acetylcholine Receptors"@en .
<https://identifiers.org/aop.events/1623> rdfs:label "Occurrence, Focal Seizure"@en .

<https://identifiers.org/aop.relationships/1865> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1865"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1605> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1512> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1605> rdfs:label "Accumulation of misfolded proteins"@en .
<https://identifiers.org/aop.events/1512> rdfs:label "Unfolded Protein Response"@en .

<https://identifiers.org/aop.relationships/1868> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1868"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1606> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1549> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1606> rdfs:label "Activation of hepatic stellate cells"@en .
<https://identifiers.org/aop.events/1549> rdfs:label "Liver Injury"@en .

<https://identifiers.org/aop.relationships/1877> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1877"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1608> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1365> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1608> rdfs:label "Increase, Oxidative DNA damage"@en .
<https://identifiers.org/aop.events/1365> rdfs:label "Increase, Apoptosis"@en .

<https://identifiers.org/aop.relationships/2100> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2100"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1608> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1766> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1608> rdfs:label "Increase, Oxidative DNA damage"@en .
<https://identifiers.org/aop.events/1766> rdfs:label "Increase, DNA double-strand break"@en .

<https://identifiers.org/aop.relationships/1878> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1878"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1609> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1610> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1609> rdfs:label "Inhibition, Cytochrome P450 enzyme (CYP17A1) activity"@en .
<https://identifiers.org/aop.events/1610> rdfs:label "Reduction, 17-OH-pregnenolone conversion in DHEA"@en .

<https://identifiers.org/aop.relationships/1879> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1879"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1609> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1611> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1609> rdfs:label "Inhibition, Cytochrome P450 enzyme (CYP17A1) activity"@en .
<https://identifiers.org/aop.events/1611> rdfs:label "Reduction, 17-OH-progesterone conversion in androstenedione"@en .

<https://identifiers.org/aop.relationships/169> a sbdbel:CausalAssertion ;
  rdfs:label "KER 169"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/161> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/173> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/161> rdfs:label "Increase, Liver and splenic hemosiderosis"@en .
<https://identifiers.org/aop.events/173> rdfs:label "N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number"@en .

<https://identifiers.org/aop.relationships/1932> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1932"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1610> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1612> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1610> rdfs:label "Reduction, 17-OH-pregnenolone conversion in DHEA"@en .
<https://identifiers.org/aop.events/1612> rdfs:label "Decrease, testosterone synthesis/level"@en .

<https://identifiers.org/aop.relationships/1933> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1933"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1611> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1612> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1611> rdfs:label "Reduction, 17-OH-progesterone conversion in androstenedione"@en .
<https://identifiers.org/aop.events/1612> rdfs:label "Decrease, testosterone synthesis/level"@en .

<https://identifiers.org/aop.relationships/1934> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1934"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1612> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1613> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1612> rdfs:label "Decrease, testosterone synthesis/level"@en .
<https://identifiers.org/aop.events/1613> rdfs:label "Decrease, dihydrotestosterone (DHT) level"@en .

<https://identifiers.org/aop.relationships/1936> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1936"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1612> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1614> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1612> rdfs:label "Decrease, testosterone synthesis/level"@en .
<https://identifiers.org/aop.events/1614> rdfs:label "Decrease, androgen receptors (AR) activation"@en .

<https://identifiers.org/aop.relationships/1935> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1935"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1613> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1614> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1613> rdfs:label "Decrease, dihydrotestosterone (DHT) level"@en .
<https://identifiers.org/aop.events/1614> rdfs:label "Decrease, androgen receptors (AR) activation"@en .

<https://identifiers.org/aop.relationships/1881> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1881"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1613> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/219> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1613> rdfs:label "Decrease, dihydrotestosterone (DHT) level"@en .
<https://identifiers.org/aop.events/219> rdfs:label "Reduction, Plasma 17beta-estradiol concentrations"@en .

<https://identifiers.org/aop.relationships/1938> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1938"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1615> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1616> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1615> rdfs:label "Impaired inguinoscrotal testicular descent phase"@en .
<https://identifiers.org/aop.events/1616> rdfs:label "Malformation, cryptorchidism - maldescended testis"@en .

<https://identifiers.org/aop.relationships/1880> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1880"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1617> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1613> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1617> rdfs:label "5α-reductase, inhibition"@en .
<https://identifiers.org/aop.events/1613> rdfs:label "Decrease, dihydrotestosterone (DHT) level"@en .

<https://identifiers.org/aop.relationships/2101> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2101"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1619> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1773> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1619> rdfs:label "Increase, DNA methyltransferase inhibition"@en .
<https://identifiers.org/aop.events/1773> rdfs:label "Decrease, Global DNA methylation"@en .

<https://identifiers.org/aop.relationships/2108> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2108"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1619> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1766> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1619> rdfs:label "Increase, DNA methyltransferase inhibition"@en .
<https://identifiers.org/aop.events/1766> rdfs:label "Increase, DNA double-strand break"@en .

<https://identifiers.org/aop.relationships/1890> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1890"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1623> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1350> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1623> rdfs:label "Occurrence, Focal Seizure"@en .
<https://identifiers.org/aop.events/1350> rdfs:label "Increased, glutamate"@en .

<https://identifiers.org/aop.relationships/1891> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1891"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1627> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1628> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1627> rdfs:label "Inhibition of tyrosinase "@en .
<https://identifiers.org/aop.events/1628> rdfs:label "Reduction of L-Dopaquinone"@en .

<https://identifiers.org/aop.relationships/1892> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1892"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1628> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1629> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1628> rdfs:label "Reduction of L-Dopaquinone"@en .
<https://identifiers.org/aop.events/1629> rdfs:label "Reduction in melanin level"@en .

<https://identifiers.org/aop.relationships/1893> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1893"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1629> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1630> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1629> rdfs:label "Reduction in melanin level"@en .
<https://identifiers.org/aop.events/1630> rdfs:label "Reduction of melanosome level"@en .

<https://identifiers.org/aop.relationships/1894> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1894"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1630> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1631> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1630> rdfs:label "Reduction of melanosome level"@en .
<https://identifiers.org/aop.events/1631> rdfs:label "Reduction fo Pigmentation pattern "@en .

<https://identifiers.org/aop.relationships/1895> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1895"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1631> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/360> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1631> rdfs:label "Reduction fo Pigmentation pattern "@en .
<https://identifiers.org/aop.events/360> rdfs:label "Decrease, Population growth rate"@en .

<https://identifiers.org/aop.relationships/2798> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2798"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1632> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2073> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1632> rdfs:label "Increase in reactive oxygen and nitrogen species (RONS)"@en .
<https://identifiers.org/aop.events/2073> rdfs:label "increase oxidation of the di-copper moiety of the hemocyanin active site "@en .

<https://identifiers.org/aop.relationships/1906> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1906"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1632> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1492> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1632> rdfs:label "Increase in reactive oxygen and nitrogen species (RONS)"@en .
<https://identifiers.org/aop.events/1492> rdfs:label "Tissue resident cell activation"@en .

<https://identifiers.org/aop.relationships/1904> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1904"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1632> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1194> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1632> rdfs:label "Increase in reactive oxygen and nitrogen species (RONS)"@en .
<https://identifiers.org/aop.events/1194> rdfs:label "Increase, DNA damage"@en .

<https://identifiers.org/aop.relationships/2617> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2617"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1632> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1088> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1632> rdfs:label "Increase in reactive oxygen and nitrogen species (RONS)"@en .
<https://identifiers.org/aop.events/1088> rdfs:label "Increased, Oxidative Stress"@en .

<https://identifiers.org/aop.relationships/2199> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2199"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1633> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1820> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1633> rdfs:label "Increase in inflammation"@en .
<https://identifiers.org/aop.events/1820> rdfs:label "Immune mediated hepatitis"@en .

<https://identifiers.org/aop.relationships/2646> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2646"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1633> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1097> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1633> rdfs:label "Increase in inflammation"@en .
<https://identifiers.org/aop.events/1097> rdfs:label "Occurrence, renal proximal tubular necrosis"@en .

<https://identifiers.org/aop.relationships/1909> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1909"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1634> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/155> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1634> rdfs:label "Increase, Oxidative damage to DNA"@en .
<https://identifiers.org/aop.events/155> rdfs:label "Inadequate DNA repair"@en .

<https://identifiers.org/aop.relationships/1913> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1913"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1634> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1635> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1634> rdfs:label "Increase, Oxidative damage to DNA"@en .
<https://identifiers.org/aop.events/1635> rdfs:label "Increase, DNA strand breaks"@en .

<https://identifiers.org/aop.relationships/1914> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1914"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1634> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/185> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1634> rdfs:label "Increase, Oxidative damage to DNA"@en .
<https://identifiers.org/aop.events/185> rdfs:label "Increase, Mutations"@en .

<https://identifiers.org/aop.relationships/2591> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2591"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1634> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1444> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1634> rdfs:label "Increase, Oxidative damage to DNA"@en .
<https://identifiers.org/aop.events/1444> rdfs:label "Increase, Follicular atresia"@en .

<https://identifiers.org/aop.relationships/2592> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2592"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1634> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1775> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1634> rdfs:label "Increase, Oxidative damage to DNA"@en .
<https://identifiers.org/aop.events/1775> rdfs:label "Increase, Oocyte apoptosis"@en .

<https://identifiers.org/aop.relationships/1911> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1911"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1635> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/155> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1635> rdfs:label "Increase, DNA strand breaks"@en .
<https://identifiers.org/aop.events/155> rdfs:label "Inadequate DNA repair"@en .

<https://identifiers.org/aop.relationships/1931> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1931"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1635> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/185> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1635> rdfs:label "Increase, DNA strand breaks"@en .
<https://identifiers.org/aop.events/185> rdfs:label "Increase, Mutations"@en .

<https://identifiers.org/aop.relationships/1939> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1939"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1635> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1636> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1635> rdfs:label "Increase, DNA strand breaks"@en .
<https://identifiers.org/aop.events/1636> rdfs:label "Increase, Chromosomal aberrations"@en .

<https://identifiers.org/aop.relationships/2074> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2074"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1635> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1365> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1635> rdfs:label "Increase, DNA strand breaks"@en .
<https://identifiers.org/aop.events/1365> rdfs:label "Increase, Apoptosis"@en .

<https://identifiers.org/aop.relationships/2587> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2587"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1635> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1444> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1635> rdfs:label "Increase, DNA strand breaks"@en .
<https://identifiers.org/aop.events/1444> rdfs:label "Increase, Follicular atresia"@en .

<https://identifiers.org/aop.relationships/2589> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2589"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1635> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1775> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1635> rdfs:label "Increase, DNA strand breaks"@en .
<https://identifiers.org/aop.events/1775> rdfs:label "Increase, Oocyte apoptosis"@en .

<https://identifiers.org/aop.relationships/2841> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2841"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1635> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2098> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1635> rdfs:label "Increase, DNA strand breaks"@en .
<https://identifiers.org/aop.events/2098> rdfs:label "Increase, Neural Remodeling"@en .

<https://identifiers.org/aop.relationships/2856> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2856"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1635> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2066> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1635> rdfs:label "Increase, DNA strand breaks"@en .
<https://identifiers.org/aop.events/2066> rdfs:label "Altered Signaling Pathways"@en .

<https://identifiers.org/aop.relationships/1979> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1979"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1636> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/870> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1636> rdfs:label "Increase, Chromosomal aberrations"@en .
<https://identifiers.org/aop.events/870> rdfs:label "Increase, Cell Proliferation"@en .

<https://identifiers.org/aop.relationships/1985> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1985"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1636> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1556> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1636> rdfs:label "Increase, Chromosomal aberrations"@en .
<https://identifiers.org/aop.events/1556> rdfs:label "Increase, lung cancer"@en .

<https://identifiers.org/aop.relationships/1915> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1915"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1637> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1641> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1637> rdfs:label "Retinaldehyde dehydrogenase inhibition"@en .
<https://identifiers.org/aop.events/1641> rdfs:label "Decreased retinoic acid (RA) synthesis"@en .

<https://identifiers.org/aop.relationships/170> a sbdbel:CausalAssertion ;
  rdfs:label "KER 170"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/164> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/147> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/164> rdfs:label "Induction, Liver “Dysfunctional” Changes by CGA 330050"@en .
<https://identifiers.org/aop.events/147> rdfs:label "Inhibition, Inducible Nitric Oxide Synthase by Metabolite CGA 265307"@en .

<https://identifiers.org/aop.relationships/1918> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1918"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1640> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1643> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1640> rdfs:label "Altered, Photoreceptor patterning"@en .
<https://identifiers.org/aop.events/1643> rdfs:label "Altered, Visual function"@en .

<https://identifiers.org/aop.relationships/1916> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1916"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1641> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1642> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1641> rdfs:label "Decreased retinoic acid (RA) synthesis"@en .
<https://identifiers.org/aop.events/1642> rdfs:label "Decreased plasma RA level"@en .

<https://identifiers.org/aop.relationships/1917> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1917"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1642> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1640> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1642> rdfs:label "Decreased plasma RA level"@en .
<https://identifiers.org/aop.events/1640> rdfs:label "Altered, Photoreceptor patterning"@en .

<https://identifiers.org/aop.relationships/2143> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2143"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1643> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/360> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1643> rdfs:label "Altered, Visual function"@en .
<https://identifiers.org/aop.events/360> rdfs:label "Decrease, Population growth rate"@en .

<https://identifiers.org/aop.relationships/2375> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2375"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1643> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/351> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1643> rdfs:label "Altered, Visual function"@en .
<https://identifiers.org/aop.events/351> rdfs:label "Increased Mortality"@en .

<https://identifiers.org/aop.relationships/1944> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1944"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1653> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1542> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1653> rdfs:label "Binding of inhibitor to mitochondrial complex III"@en .
<https://identifiers.org/aop.events/1542> rdfs:label "Increase, Mitochondrial complex III antagonism"@en .

<https://identifiers.org/aop.relationships/1945> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1945"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1654> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1543> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1654> rdfs:label "Binding of inhibitor to mitochondrial complex IV"@en .
<https://identifiers.org/aop.events/1543> rdfs:label "Mitochondrial Complex IV inhibition"@en .

<https://identifiers.org/aop.relationships/1946> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1946"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1655> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1544> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1655> rdfs:label "Binding of inhibitor to mitochondrial complex V"@en .
<https://identifiers.org/aop.events/1544> rdfs:label "Mitochondrial Complex V inhibition"@en .

<https://identifiers.org/aop.relationships/1949> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1949"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1657> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1661> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1657> rdfs:label "Inhibition of cystathionine beta-synthase"@en .
<https://identifiers.org/aop.events/1661> rdfs:label "Increased Homocysteine level "@en .

<https://identifiers.org/aop.relationships/1959> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1959"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1661> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1665> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1661> rdfs:label "Increased Homocysteine level "@en .
<https://identifiers.org/aop.events/1665> rdfs:label "Increased, Plasma HCY level"@en .

<https://identifiers.org/aop.relationships/1960> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1960"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1665> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1666> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1665> rdfs:label "Increased, Plasma HCY level"@en .
<https://identifiers.org/aop.events/1666> rdfs:label "Induced, dysfunction of microcirculation"@en .

<https://identifiers.org/aop.relationships/1961> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1961"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1666> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1667> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1666> rdfs:label "Induced, dysfunction of microcirculation"@en .
<https://identifiers.org/aop.events/1667> rdfs:label "Impaired,anterior-posterior axis development"@en .

<https://identifiers.org/aop.relationships/1962> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1962"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1668> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/87> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1668> rdfs:label "Frustrated phagocytosis"@en .
<https://identifiers.org/aop.events/87> rdfs:label "Release, Cytokine"@en .

<https://identifiers.org/aop.relationships/2415> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2415"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1668> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1496> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1668> rdfs:label "Frustrated phagocytosis"@en .
<https://identifiers.org/aop.events/1496> rdfs:label "Increased, secretion of proinflammatory mediators"@en .

<https://identifiers.org/aop.relationships/2416> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2416"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1668> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1115> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1668> rdfs:label "Frustrated phagocytosis"@en .
<https://identifiers.org/aop.events/1115> rdfs:label "Increased, Reactive oxygen species"@en .

<https://identifiers.org/aop.relationships/1966> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1966"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1669> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/870> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1669> rdfs:label "Increased, DNA damage and mutation"@en .
<https://identifiers.org/aop.events/870> rdfs:label "Increase, Cell Proliferation"@en .

<https://identifiers.org/aop.relationships/2608> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2608"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1669> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/155> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1669> rdfs:label "Increased, DNA damage and mutation"@en .
<https://identifiers.org/aop.events/155> rdfs:label "Inadequate DNA repair"@en .

<https://identifiers.org/aop.relationships/2417> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2417"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1669> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1896> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1669> rdfs:label "Increased, DNA damage and mutation"@en .
<https://identifiers.org/aop.events/1896> rdfs:label "Genomic instability"@en .

<https://identifiers.org/aop.relationships/2728> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2728"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1669> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1554> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1669> rdfs:label "Increased, DNA damage and mutation"@en .
<https://identifiers.org/aop.events/1554> rdfs:label "Increase Chromosomal Aberrations"@en .

<https://identifiers.org/aop.relationships/1969> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1969"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1672> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1673> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1672> rdfs:label "Inhibition of lung surfactant function"@en .
<https://identifiers.org/aop.events/1673> rdfs:label "Alveolar collapse"@en .

<https://identifiers.org/aop.relationships/2370> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2370"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1672> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1250> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1672> rdfs:label "Inhibition of lung surfactant function"@en .
<https://identifiers.org/aop.events/1250> rdfs:label "Decrease, Lung function"@en .

<https://identifiers.org/aop.relationships/1974> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1974"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1673> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1677> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1673> rdfs:label "Alveolar collapse"@en .
<https://identifiers.org/aop.events/1677> rdfs:label "Reduced tidal volume "@en .

<https://identifiers.org/aop.relationships/2284> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2284"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1673> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1498> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1673> rdfs:label "Alveolar collapse"@en .
<https://identifiers.org/aop.events/1498> rdfs:label "Loss of alveolar capillary membrane integrity"@en .

<https://identifiers.org/aop.relationships/2371> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2371"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1673> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1250> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1673> rdfs:label "Alveolar collapse"@en .
<https://identifiers.org/aop.events/1250> rdfs:label "Decrease, Lung function"@en .

<https://identifiers.org/aop.relationships/2367> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2367"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1677> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1250> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1677> rdfs:label "Reduced tidal volume "@en .
<https://identifiers.org/aop.events/1250> rdfs:label "Decrease, Lung function"@en .

<https://identifiers.org/aop.relationships/390> a sbdbel:CausalAssertion ;
  rdfs:label "KER 390"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/168> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/403> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/168> rdfs:label "Decreased, Lymphocytes"@en .
<https://identifiers.org/aop.events/403> rdfs:label "Suppression, Immune system"@en .

<https://identifiers.org/aop.relationships/2562> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2562"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1682> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1557> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1682> rdfs:label "Disruption, Progenitor cells of second heart field"@en .
<https://identifiers.org/aop.events/1557> rdfs:label "Neural crest cell migration, reduced"@en .

<https://identifiers.org/aop.relationships/2785> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2785"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1686> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2069> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1686> rdfs:label "Deposition of Energy"@en .
<https://identifiers.org/aop.events/2069> rdfs:label "Occurrence, Vascular Remodeling "@en .

<https://identifiers.org/aop.relationships/2809> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2809"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1686> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2081> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1686> rdfs:label "Deposition of Energy"@en .
<https://identifiers.org/aop.events/2081> rdfs:label "Increased Modified Proteins"@en .

<https://identifiers.org/aop.relationships/2813> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2813"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1686> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1634> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1686> rdfs:label "Deposition of Energy"@en .
<https://identifiers.org/aop.events/1634> rdfs:label "Increase, Oxidative damage to DNA"@en .

<https://identifiers.org/aop.relationships/2814> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2814"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1686> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/870> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1686> rdfs:label "Deposition of Energy"@en .
<https://identifiers.org/aop.events/870> rdfs:label "Increase, Cell Proliferation"@en .

<https://identifiers.org/aop.relationships/2815> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2815"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1686> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2083> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1686> rdfs:label "Deposition of Energy"@en .
<https://identifiers.org/aop.events/2083> rdfs:label "Occurrence of Cataracts"@en .

<https://identifiers.org/aop.relationships/1981> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1981"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1686> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/185> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1686> rdfs:label "Deposition of Energy"@en .
<https://identifiers.org/aop.events/185> rdfs:label "Increase, Mutations"@en .

<https://identifiers.org/aop.relationships/1982> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1982"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1686> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1636> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1686> rdfs:label "Deposition of Energy"@en .
<https://identifiers.org/aop.events/1636> rdfs:label "Increase, Chromosomal aberrations"@en .

<https://identifiers.org/aop.relationships/1983> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1983"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1686> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1556> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1686> rdfs:label "Deposition of Energy"@en .
<https://identifiers.org/aop.events/1556> rdfs:label "Increase, lung cancer"@en .

<https://identifiers.org/aop.relationships/1977> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1977"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1686> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1635> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1686> rdfs:label "Deposition of Energy"@en .
<https://identifiers.org/aop.events/1635> rdfs:label "Increase, DNA strand breaks"@en .

<https://identifiers.org/aop.relationships/2548> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2548"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1686> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1115> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1686> rdfs:label "Deposition of Energy"@en .
<https://identifiers.org/aop.events/1115> rdfs:label "Increased, Reactive oxygen species"@en .

<https://identifiers.org/aop.relationships/2552> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2552"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1686> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1194> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1686> rdfs:label "Deposition of Energy"@en .
<https://identifiers.org/aop.events/1194> rdfs:label "Increase, DNA damage"@en .

<https://identifiers.org/aop.relationships/2557> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2557"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1686> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/257> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1686> rdfs:label "Deposition of Energy"@en .
<https://identifiers.org/aop.events/257> rdfs:label "Increase, Reactive Oxygen Species production"@en .

<https://identifiers.org/aop.relationships/2604> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2604"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1686> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1978> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1686> rdfs:label "Deposition of Energy"@en .
<https://identifiers.org/aop.events/1978> rdfs:label "Increase risk, microcephaly"@en .

<https://identifiers.org/aop.relationships/2616> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2616"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1686> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1632> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1686> rdfs:label "Deposition of Energy"@en .
<https://identifiers.org/aop.events/1632> rdfs:label "Increase in reactive oxygen and nitrogen species (RONS)"@en .

<https://identifiers.org/aop.relationships/2769> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2769"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1686> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1392> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1686> rdfs:label "Deposition of Energy"@en .
<https://identifiers.org/aop.events/1392> rdfs:label "Oxidative Stress "@en .

<https://identifiers.org/aop.relationships/2779> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2779"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1686> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2067> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1686> rdfs:label "Deposition of Energy"@en .
<https://identifiers.org/aop.events/2067> rdfs:label "Altered, Nitric Oxide Levels"@en .

<https://identifiers.org/aop.relationships/2780> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2780"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1686> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2068> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1686> rdfs:label "Deposition of Energy"@en .
<https://identifiers.org/aop.events/2068> rdfs:label "Increase, Endothelial Dysfunction"@en .

<https://identifiers.org/aop.relationships/2832> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2832"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1686> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1492> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1686> rdfs:label "Deposition of Energy"@en .
<https://identifiers.org/aop.events/1492> rdfs:label "Tissue resident cell activation"@en .

<https://identifiers.org/aop.relationships/2837> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2837"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1686> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2098> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1686> rdfs:label "Deposition of Energy"@en .
<https://identifiers.org/aop.events/2098> rdfs:label "Increase, Neural Remodeling"@en .

<https://identifiers.org/aop.relationships/2838> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2838"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1686> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/341> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1686> rdfs:label "Deposition of Energy"@en .
<https://identifiers.org/aop.events/341> rdfs:label "Impairment, Learning and memory"@en .

<https://identifiers.org/aop.relationships/2847> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2847"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1686> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2089> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1686> rdfs:label "Deposition of Energy"@en .
<https://identifiers.org/aop.events/2089> rdfs:label "Altered Bone Cell Homeostasis"@en .

<https://identifiers.org/aop.relationships/2848> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2848"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1686> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2090> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1686> rdfs:label "Deposition of Energy"@en .
<https://identifiers.org/aop.events/2090> rdfs:label "Increase, Bone Remodeling"@en .

<https://identifiers.org/aop.relationships/2849> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2849"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1686> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2091> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1686> rdfs:label "Deposition of Energy"@en .
<https://identifiers.org/aop.events/2091> rdfs:label "Occurrence, Bone Loss"@en .

<https://identifiers.org/aop.relationships/2129> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2129"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1687> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1688> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1687> rdfs:label "decrease, transcription of genes by AR "@en .
<https://identifiers.org/aop.events/1688> rdfs:label "anogenital distance (AGD), decreased"@en .

<https://identifiers.org/aop.relationships/2126> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2126"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1690> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1613> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1690> rdfs:label "reduction, testosterone levels "@en .
<https://identifiers.org/aop.events/1613> rdfs:label "Decrease, dihydrotestosterone (DHT) level"@en .

<https://identifiers.org/aop.relationships/2131> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2131"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1690> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1614> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1690> rdfs:label "reduction, testosterone levels "@en .
<https://identifiers.org/aop.events/1614> rdfs:label "Decrease, androgen receptors (AR) activation"@en .

<https://identifiers.org/aop.relationships/1986> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1986"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1691> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1692> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1691> rdfs:label "Antagonism,LH receptor"@en .
<https://identifiers.org/aop.events/1692> rdfs:label "Reduction, Progesterone synthesis"@en .

<https://identifiers.org/aop.relationships/1987> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1987"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1692> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1693> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1692> rdfs:label "Reduction, Progesterone synthesis"@en .
<https://identifiers.org/aop.events/1693> rdfs:label "Reduction, Plasma progesterone concentration "@en .

<https://identifiers.org/aop.relationships/1988> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1988"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1693> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1694> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1693> rdfs:label "Reduction, Plasma progesterone concentration "@en .
<https://identifiers.org/aop.events/1694> rdfs:label "Reduction, progesterone uptake, decresed maturation "@en .

<https://identifiers.org/aop.relationships/1989> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1989"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1694> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1695> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1694> rdfs:label "Reduction, progesterone uptake, decresed maturation "@en .
<https://identifiers.org/aop.events/1695> rdfs:label "Impaired ovulation"@en .

<https://identifiers.org/aop.relationships/1990> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1990"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1695> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1696> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1695> rdfs:label "Impaired ovulation"@en .
<https://identifiers.org/aop.events/1696> rdfs:label "Decrease of egg production and cummulative fecundity"@en .

<https://identifiers.org/aop.relationships/1991> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1991"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1696> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/679> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1696> rdfs:label "Decrease of egg production and cummulative fecundity"@en .
<https://identifiers.org/aop.events/679> rdfs:label "Decline, Population trajectory"@en .

<https://identifiers.org/aop.relationships/2389> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2389"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1696> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/997> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1696> rdfs:label "Decrease of egg production and cummulative fecundity"@en .
<https://identifiers.org/aop.events/997> rdfs:label "Decreased, Population size"@en .

<https://identifiers.org/aop.relationships/1993> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1993"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1697> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1698> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1697> rdfs:label "Increase, DNA methyltransferase expression"@en .
<https://identifiers.org/aop.events/1698> rdfs:label "Increase, hypermethylation of the promotor region of gonadotropin releasing hormone receptor"@en .

<https://identifiers.org/aop.relationships/1994> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1994"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1698> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1699> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1698> rdfs:label "Increase, hypermethylation of the promotor region of gonadotropin releasing hormone receptor"@en .
<https://identifiers.org/aop.events/1699> rdfs:label "Decrease, expression of gonadotropin releasing hormone receptor"@en .

<https://identifiers.org/aop.relationships/1995> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1995"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1699> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/3> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1699> rdfs:label "Decrease, expression of gonadotropin releasing hormone receptor"@en .
<https://identifiers.org/aop.events/3> rdfs:label "Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"@en .

<https://identifiers.org/aop.relationships/2006> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2006"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1703> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/445> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1703> rdfs:label "Dysregulation of heart rate and vascular tone"@en .
<https://identifiers.org/aop.events/445> rdfs:label "Respiratory distress/arrest"@en .

<https://identifiers.org/aop.relationships/2012> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2012"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1705> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/351> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1705> rdfs:label "Impaired coordination and movement"@en .
<https://identifiers.org/aop.events/351> rdfs:label "Increased Mortality"@en .

<https://identifiers.org/aop.relationships/2015> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2015"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1705> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/360> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1705> rdfs:label "Impaired coordination and movement"@en .
<https://identifiers.org/aop.events/360> rdfs:label "Decrease, Population growth rate"@en .

<https://identifiers.org/aop.relationships/182> a sbdbel:CausalAssertion ;
  rdfs:label "KER 182"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/173> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/321> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/173> rdfs:label "N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number"@en .
<https://identifiers.org/aop.events/321> rdfs:label "N/A, Cyanosis occurs"@en .

<https://identifiers.org/aop.relationships/2310> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2310"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1738> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1847> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1738> rdfs:label "SARS-CoV-2 cell entry "@en .
<https://identifiers.org/aop.events/1847> rdfs:label "Increased SARS-CoV-2 production"@en .

<https://identifiers.org/aop.relationships/2496> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2496"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1738> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1901> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1738> rdfs:label "SARS-CoV-2 cell entry "@en .
<https://identifiers.org/aop.events/1901> rdfs:label "Interferon-I antiviral response, antagonized by SARS-CoV-2"@en .

<https://identifiers.org/aop.relationships/2065> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2065"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1740> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1752> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1740> rdfs:label "Induced dysregulation of ACE2 "@en .
<https://identifiers.org/aop.events/1752> rdfs:label "Increased Angiotensin II "@en .

<https://identifiers.org/aop.relationships/2434> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2434"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1740> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1743> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1740> rdfs:label "Induced dysregulation of ACE2 "@en .
<https://identifiers.org/aop.events/1743> rdfs:label "Increase plasma Ang II"@en .

<https://identifiers.org/aop.relationships/2435> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2435"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1743> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1852> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1743> rdfs:label "Increase plasma Ang II"@en .
<https://identifiers.org/aop.events/1852> rdfs:label "Increased Ang II type 1 receptor (AT1R)"@en .

<https://identifiers.org/aop.relationships/2135> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2135"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1748> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/351> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1748> rdfs:label "Increase, the risk of acute respiratory failure"@en .
<https://identifiers.org/aop.events/351> rdfs:label "Increased Mortality"@en .

<https://identifiers.org/aop.relationships/2062> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2062"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1750> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1748> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1750> rdfs:label "Increased inflammatory immune responses"@en .
<https://identifiers.org/aop.events/1748> rdfs:label "Increase, the risk of acute respiratory failure"@en .

<https://identifiers.org/aop.relationships/2317> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2317"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1752> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1856> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1752> rdfs:label "Increased Angiotensin II "@en .
<https://identifiers.org/aop.events/1856> rdfs:label "Imbalanced salty and sweet taste responses"@en .

<https://identifiers.org/aop.relationships/2327> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2327"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1752> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1852> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1752> rdfs:label "Increased Angiotensin II "@en .
<https://identifiers.org/aop.events/1852> rdfs:label "Increased Ang II type 1 receptor (AT1R)"@en .

<https://identifiers.org/aop.relationships/2593> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2593"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1752> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1851> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1752> rdfs:label "Increased Angiotensin II "@en .
<https://identifiers.org/aop.events/1851> rdfs:label "Binding of agonist, Angiotensin II receptor type 1 receptor (AT1R)"@en .

<https://identifiers.org/aop.relationships/2069> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2069"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1753> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1754> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1753> rdfs:label "Chronic reactive oxygen species"@en .
<https://identifiers.org/aop.events/1754> rdfs:label "Porcupine-induced Wnt secretion and Wnt signaling activation"@en .

<https://identifiers.org/aop.relationships/2071> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2071"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1755> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1650> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1755> rdfs:label "beta-catenin activation"@en .
<https://identifiers.org/aop.events/1650> rdfs:label "Epithelial-mesenchymal transition"@en .

<https://identifiers.org/aop.relationships/2076> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2076"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1756> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1758> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1756> rdfs:label "Decreased,  plasma 11-ketotestosterone level"@en .
<https://identifiers.org/aop.events/1758> rdfs:label "Impaired, Spermatogenesis"@en .

<https://identifiers.org/aop.relationships/2166> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2166"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1756> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1798> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1756> rdfs:label "Decreased,  plasma 11-ketotestosterone level"@en .
<https://identifiers.org/aop.events/1798> rdfs:label "Decreased spermatogenesis "@en .

<https://identifiers.org/aop.relationships/2274> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2274"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1758> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/406> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1758> rdfs:label "Impaired, Spermatogenesis"@en .
<https://identifiers.org/aop.events/406> rdfs:label "impaired, Fertility"@en .

<https://identifiers.org/aop.relationships/2692> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2692"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1758> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2032> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1758> rdfs:label "Impaired, Spermatogenesis"@en .
<https://identifiers.org/aop.events/2032> rdfs:label "Viable offspring, decreased"@en .

<https://identifiers.org/aop.relationships/1367> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1367"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/176> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1262> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/176> rdfs:label "Damaging, Mitochondria"@en .
<https://identifiers.org/aop.events/1262> rdfs:label "Apoptosis"@en .

<https://identifiers.org/aop.relationships/2080> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2080"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1761> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1005> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1761> rdfs:label "Inhibition, Fin regeneration"@en .
<https://identifiers.org/aop.events/1005> rdfs:label "Reduced, Swimming performance"@en .

<https://identifiers.org/aop.relationships/2084> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2084"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1762> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/795> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1762> rdfs:label "Urothelial cell injury/death"@en .
<https://identifiers.org/aop.events/795> rdfs:label "Increase, Regenerative cell proliferation (urothelial cells)"@en .

<https://identifiers.org/aop.relationships/2087> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2087"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1765> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1766> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1765> rdfs:label "Increase, Formation of DNA photoproducts"@en .
<https://identifiers.org/aop.events/1766> rdfs:label "Increase, DNA double-strand break"@en .

<https://identifiers.org/aop.relationships/2088> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2088"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1766> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1365> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1766> rdfs:label "Increase, DNA double-strand break"@en .
<https://identifiers.org/aop.events/1365> rdfs:label "Increase, Apoptosis"@en .

<https://identifiers.org/aop.relationships/2109> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2109"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1766> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1774> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1766> rdfs:label "Increase, DNA double-strand break"@en .
<https://identifiers.org/aop.events/1774> rdfs:label "Increase, Caspase transcription"@en .

<https://identifiers.org/aop.relationships/2090> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2090"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1767> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1768> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1767> rdfs:label "Increase, Protein oxidation"@en .
<https://identifiers.org/aop.events/1768> rdfs:label "Increase, Abnormal osmoregulation"@en .

<https://identifiers.org/aop.relationships/2091> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2091"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1768> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1769> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1768> rdfs:label "Increase, Abnormal osmoregulation"@en .
<https://identifiers.org/aop.events/1769> rdfs:label "Increase, Body fluid overload"@en .

<https://identifiers.org/aop.relationships/2092> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2092"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1769> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/350> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1769> rdfs:label "Increase, Body fluid overload"@en .
<https://identifiers.org/aop.events/350> rdfs:label "Increase, Mortality"@en .

<https://identifiers.org/aop.relationships/363> a sbdbel:CausalAssertion ;
  rdfs:label "KER 363"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/177> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/55> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/177> rdfs:label "N/A, Mitochondrial dysfunction 1"@en .
<https://identifiers.org/aop.events/55> rdfs:label "Cell injury/death"@en .

<https://identifiers.org/aop.relationships/904> a sbdbel:CausalAssertion ;
  rdfs:label "KER 904"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/177> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/889> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/177> rdfs:label "N/A, Mitochondrial dysfunction 1"@en .
<https://identifiers.org/aop.events/889> rdfs:label "Impaired, Proteostasis"@en .

<https://identifiers.org/aop.relationships/908> a sbdbel:CausalAssertion ;
  rdfs:label "KER 908"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/177> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/890> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/177> rdfs:label "N/A, Mitochondrial dysfunction 1"@en .
<https://identifiers.org/aop.events/890> rdfs:label "Degeneration of dopaminergic neurons of the nigrostriatal pathway"@en .

<https://identifiers.org/aop.relationships/1152> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1152"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/177> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/568> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/177> rdfs:label "N/A, Mitochondrial dysfunction 1"@en .
<https://identifiers.org/aop.events/568> rdfs:label "impaired, Hive thermoregulation"@en .

<https://identifiers.org/aop.relationships/1154> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1154"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/177> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1107> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/177> rdfs:label "N/A, Mitochondrial dysfunction 1"@en .
<https://identifiers.org/aop.events/1107> rdfs:label "Weakened, Colony"@en .

<https://identifiers.org/aop.relationships/1311> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1311"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/177> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1243> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/177> rdfs:label "N/A, Mitochondrial dysfunction 1"@en .
<https://identifiers.org/aop.events/1243> rdfs:label "Altered, Ca2+-calmodulin activated signal transduction"@en .

<https://identifiers.org/aop.relationships/1958> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1958"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/177> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1546> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/177> rdfs:label "N/A, Mitochondrial dysfunction 1"@en .
<https://identifiers.org/aop.events/1546> rdfs:label "Increased reactive oxygen species (in the mitochondria)"@en .

<https://identifiers.org/aop.relationships/2224> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2224"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/177> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/257> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/177> rdfs:label "N/A, Mitochondrial dysfunction 1"@en .
<https://identifiers.org/aop.events/257> rdfs:label "Increase, Reactive Oxygen Species production"@en .

<https://identifiers.org/aop.relationships/2227> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2227"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/177> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1364> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/177> rdfs:label "N/A, Mitochondrial dysfunction 1"@en .
<https://identifiers.org/aop.events/1364> rdfs:label "Increase, Reactive oxygen species"@en .

<https://identifiers.org/aop.relationships/2228> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2228"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/177> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1771> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/177> rdfs:label "N/A, Mitochondrial dysfunction 1"@en .
<https://identifiers.org/aop.events/1771> rdfs:label "Decrease, Adenosine triphosphate pool"@en .

<https://identifiers.org/aop.relationships/582> a sbdbel:CausalAssertion ;
  rdfs:label "KER 582"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/177> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/386> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/177> rdfs:label "N/A, Mitochondrial dysfunction 1"@en .
<https://identifiers.org/aop.events/386> rdfs:label "Decrease of neuronal network function"@en .

<https://identifiers.org/aop.relationships/660> a sbdbel:CausalAssertion ;
  rdfs:label "KER 660"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/177> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/664> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/177> rdfs:label "N/A, Mitochondrial dysfunction 1"@en .
<https://identifiers.org/aop.events/664> rdfs:label "Overwhelmed, Mitochondrial DNA repair mechanisms"@en .

<https://identifiers.org/aop.relationships/2822> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2822"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/177> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/40> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/177> rdfs:label "N/A, Mitochondrial dysfunction 1"@en .
<https://identifiers.org/aop.events/40> rdfs:label "Decrease, Mitochondrial ATP production"@en .

<https://identifiers.org/aop.relationships/2094> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2094"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1770> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1477> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1770> rdfs:label "Decrease, Mitochondrial membrane potential"@en .
<https://identifiers.org/aop.events/1477> rdfs:label "Decrease, Oxidative phosphorylation"@en .

<https://identifiers.org/aop.relationships/2637> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2637"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1770> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1968> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1770> rdfs:label "Decrease, Mitochondrial membrane potential"@en .
<https://identifiers.org/aop.events/1968> rdfs:label "Increase, Mitochondrial Dysfunction"@en .

<https://identifiers.org/aop.relationships/2786> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2786"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1771> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1562> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1771> rdfs:label "Decrease, Adenosine triphosphate pool"@en .
<https://identifiers.org/aop.events/1562> rdfs:label "Decreased Na/K ATPase activity"@en .

<https://identifiers.org/aop.relationships/2204> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2204"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1771> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1821> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1771> rdfs:label "Decrease, Adenosine triphosphate pool"@en .
<https://identifiers.org/aop.events/1821> rdfs:label "Decrease, Cell proliferation"@en .

<https://identifiers.org/aop.relationships/2096> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2096"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1771> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/350> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1771> rdfs:label "Decrease, Adenosine triphosphate pool"@en .
<https://identifiers.org/aop.events/350> rdfs:label "Increase, Mortality"@en .

<https://identifiers.org/aop.relationships/2209> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2209"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1771> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1366> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1771> rdfs:label "Decrease, Adenosine triphosphate pool"@en .
<https://identifiers.org/aop.events/1366> rdfs:label "Decrease, Oogenesis"@en .

<https://identifiers.org/aop.relationships/2214> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2214"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1771> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1825> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1771> rdfs:label "Decrease, Adenosine triphosphate pool"@en .
<https://identifiers.org/aop.events/1825> rdfs:label "Increase, Cell death"@en .

<https://identifiers.org/aop.relationships/2768> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2768"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1771> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/55> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1771> rdfs:label "Decrease, Adenosine triphosphate pool"@en .
<https://identifiers.org/aop.events/55> rdfs:label "Cell injury/death"@en .

<https://identifiers.org/aop.relationships/2098> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2098"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1772> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1771> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1772> rdfs:label "Decrease, Neutral lipids"@en .
<https://identifiers.org/aop.events/1771> rdfs:label "Decrease, Adenosine triphosphate pool"@en .

<https://identifiers.org/aop.relationships/2102> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2102"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1773> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1774> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1773> rdfs:label "Decrease, Global DNA methylation"@en .
<https://identifiers.org/aop.events/1774> rdfs:label "Increase, Caspase transcription"@en .

<https://identifiers.org/aop.relationships/2110> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2110"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1773> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1778> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1773> rdfs:label "Decrease, Global DNA methylation"@en .
<https://identifiers.org/aop.events/1778> rdfs:label "Decrease, Heritable DNA methylation (F3)"@en .

<https://identifiers.org/aop.relationships/2103> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2103"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1774> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1775> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1774> rdfs:label "Increase, Caspase transcription"@en .
<https://identifiers.org/aop.events/1775> rdfs:label "Increase, Oocyte apoptosis"@en .

<https://identifiers.org/aop.relationships/2105> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2105"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1774> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1776> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1774> rdfs:label "Increase, Caspase transcription"@en .
<https://identifiers.org/aop.events/1776> rdfs:label "Increase, Ovarian somatic cell apoptosis"@en .

<https://identifiers.org/aop.relationships/2104> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2104"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1775> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1366> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1775> rdfs:label "Increase, Oocyte apoptosis"@en .
<https://identifiers.org/aop.events/1366> rdfs:label "Decrease, Oogenesis"@en .

<https://identifiers.org/aop.relationships/2386> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2386"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1775> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/406> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1775> rdfs:label "Increase, Oocyte apoptosis"@en .
<https://identifiers.org/aop.events/406> rdfs:label "impaired, Fertility"@en .

<https://identifiers.org/aop.relationships/2400> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2400"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1775> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1696> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1775> rdfs:label "Increase, Oocyte apoptosis"@en .
<https://identifiers.org/aop.events/1696> rdfs:label "Decrease of egg production and cummulative fecundity"@en .

<https://identifiers.org/aop.relationships/2106> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2106"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1776> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1777> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1776> rdfs:label "Increase, Ovarian somatic cell apoptosis"@en .
<https://identifiers.org/aop.events/1777> rdfs:label "Increase, Ovarian follicle breakdown"@en .

<https://identifiers.org/aop.relationships/2107> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2107"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1777> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1366> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1777> rdfs:label "Increase, Ovarian follicle breakdown"@en .
<https://identifiers.org/aop.events/1366> rdfs:label "Decrease, Oogenesis"@en .

<https://identifiers.org/aop.relationships/2111> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2111"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1778> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1779> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1778> rdfs:label "Decrease, Heritable DNA methylation (F3)"@en .
<https://identifiers.org/aop.events/1779> rdfs:label "Increase, Caspase transcription (F3)"@en .

<https://identifiers.org/aop.relationships/2112> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2112"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1779> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1780> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1779> rdfs:label "Increase, Caspase transcription (F3)"@en .
<https://identifiers.org/aop.events/1780> rdfs:label "Increase, Oocyte apoptosis (F3)"@en .

<https://identifiers.org/aop.relationships/2116> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2116"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1779> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1783> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1779> rdfs:label "Increase, Caspase transcription (F3)"@en .
<https://identifiers.org/aop.events/1783> rdfs:label "Increase, Ovarian somatic cell apoptosis (F3)"@en .

<https://identifiers.org/aop.relationships/188> a sbdbel:CausalAssertion ;
  rdfs:label "KER 188"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/178> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/40> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/178> rdfs:label "Disruption, Mitochondrial electron transport chain"@en .
<https://identifiers.org/aop.events/40> rdfs:label "Decrease, Mitochondrial ATP production"@en .

<https://identifiers.org/aop.relationships/189> a sbdbel:CausalAssertion ;
  rdfs:label "KER 189"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/178> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/257> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/178> rdfs:label "Disruption, Mitochondrial electron transport chain"@en .
<https://identifiers.org/aop.events/257> rdfs:label "Increase, Reactive Oxygen Species production"@en .

<https://identifiers.org/aop.relationships/2113> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2113"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1780> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1782> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1780> rdfs:label "Increase, Oocyte apoptosis (F3)"@en .
<https://identifiers.org/aop.events/1782> rdfs:label "Decrease, Oogenesis (F3)"@en .

<https://identifiers.org/aop.relationships/2115> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2115"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1781> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/360> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1781> rdfs:label "Decrease, Fecundity (F3)"@en .
<https://identifiers.org/aop.events/360> rdfs:label "Decrease, Population growth rate"@en .

<https://identifiers.org/aop.relationships/2114> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2114"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1782> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1781> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1782> rdfs:label "Decrease, Oogenesis (F3)"@en .
<https://identifiers.org/aop.events/1781> rdfs:label "Decrease, Fecundity (F3)"@en .

<https://identifiers.org/aop.relationships/2117> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2117"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1783> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1784> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1783> rdfs:label "Increase, Ovarian somatic cell apoptosis (F3)"@en .
<https://identifiers.org/aop.events/1784> rdfs:label "Increase, Ovarian follicle breakdown (F3)"@en .

<https://identifiers.org/aop.relationships/2118> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2118"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1784> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1782> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1784> rdfs:label "Increase, Ovarian follicle breakdown (F3)"@en .
<https://identifiers.org/aop.events/1782> rdfs:label "Decrease, Oogenesis (F3)"@en .

<https://identifiers.org/aop.relationships/2229> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2229"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1785> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1771> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1785> rdfs:label "Increase, Mitochondrial ATP synthase antagonism"@en .
<https://identifiers.org/aop.events/1771> rdfs:label "Decrease, Adenosine triphosphate pool"@en .

<https://identifiers.org/aop.relationships/2137> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2137"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1787> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1752> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1787> rdfs:label "Downregulation, ACE2"@en .
<https://identifiers.org/aop.events/1752> rdfs:label "Increased Angiotensin II "@en .

<https://identifiers.org/aop.relationships/2782> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2782"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1788> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1350> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1788> rdfs:label "Status epilepticus"@en .
<https://identifiers.org/aop.events/1350> rdfs:label "Increased, glutamate"@en .

<https://identifiers.org/aop.relationships/2783> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2783"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1788> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/389> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1788> rdfs:label "Status epilepticus"@en .
<https://identifiers.org/aop.events/389> rdfs:label "Increased, Intracellular Calcium overload"@en .

<https://identifiers.org/aop.relationships/2145> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2145"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1789> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1790> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1789> rdfs:label "Reduction, 17beta-estradiol synthesis by the undifferentiated gonad "@en .
<https://identifiers.org/aop.events/1790> rdfs:label "Increased, Differentiation to Testis "@en .

<https://identifiers.org/aop.relationships/190> a sbdbel:CausalAssertion ;
  rdfs:label "KER 190"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/179> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/327> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/179> rdfs:label "Decreased, Mitochondrial fatty acid beta-oxidation"@en .
<https://identifiers.org/aop.events/327> rdfs:label "Accumulation, Fatty acid"@en .

<https://identifiers.org/aop.relationships/2146> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2146"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1790> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1791> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1790> rdfs:label "Increased, Differentiation to Testis "@en .
<https://identifiers.org/aop.events/1791> rdfs:label "Increased, Male Biased Sex Ratio"@en .

<https://identifiers.org/aop.relationships/2147> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2147"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1791> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/360> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1791> rdfs:label "Increased, Male Biased Sex Ratio"@en .
<https://identifiers.org/aop.events/360> rdfs:label "Decrease, Population growth rate"@en .

<https://identifiers.org/aop.relationships/2148> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2148"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1792> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1292> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1792> rdfs:label "Toll-like receptor 4 activation"@en .
<https://identifiers.org/aop.events/1292> rdfs:label "Activation, JNK"@en .

<https://identifiers.org/aop.relationships/2157> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2157"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1793> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1795> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1793> rdfs:label "Activator protein 1 activation"@en .
<https://identifiers.org/aop.events/1795> rdfs:label "Latent Transforming growth Factor beta expression"@en .

<https://identifiers.org/aop.relationships/2151> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2151"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1794> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1795> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1794> rdfs:label "Pin-1 activation"@en .
<https://identifiers.org/aop.events/1795> rdfs:label "Latent Transforming growth Factor beta expression"@en .

<https://identifiers.org/aop.relationships/2152> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2152"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1795> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1283> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1795> rdfs:label "Latent Transforming growth Factor beta expression"@en .
<https://identifiers.org/aop.events/1283> rdfs:label "Activation, TGF-beta pathway"@en .

<https://identifiers.org/aop.relationships/2275> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2275"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1796> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1835> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1796> rdfs:label "11β-hydroxylase inhibition"@en .
<https://identifiers.org/aop.events/1835> rdfs:label "Cortisol and 11β-(OH) testosterone decreased"@en .

<https://identifiers.org/aop.relationships/2161> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2161"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1798> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/406> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1798> rdfs:label "Decreased spermatogenesis "@en .
<https://identifiers.org/aop.events/406> rdfs:label "impaired, Fertility"@en .

<https://identifiers.org/aop.relationships/2388> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2388"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1798> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1696> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1798> rdfs:label "Decreased spermatogenesis "@en .
<https://identifiers.org/aop.events/1696> rdfs:label "Decrease of egg production and cummulative fecundity"@en .

<https://identifiers.org/aop.relationships/2620> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2620"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1798> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/328> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1798> rdfs:label "Decreased spermatogenesis "@en .
<https://identifiers.org/aop.events/328> rdfs:label "Decrease, Fecundity"@en .

<https://identifiers.org/aop.relationships/2623> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2623"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1798> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1863> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1798> rdfs:label "Decreased spermatogenesis "@en .
<https://identifiers.org/aop.events/1863> rdfs:label "Decrease, Reproduction"@en .

<https://identifiers.org/aop.relationships/2624> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2624"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1798> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/360> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1798> rdfs:label "Decreased spermatogenesis "@en .
<https://identifiers.org/aop.events/360> rdfs:label "Decrease, Population growth rate"@en .

<https://identifiers.org/aop.relationships/2162> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2162"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1799> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1756> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1799> rdfs:label "Inhibition of 11β-HSD "@en .
<https://identifiers.org/aop.events/1756> rdfs:label "Decreased,  plasma 11-ketotestosterone level"@en .

<https://identifiers.org/aop.relationships/2170> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2170"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1806> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/996> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1806> rdfs:label "Inhibition, Chitinase "@en .
<https://identifiers.org/aop.events/996> rdfs:label "Decrease, Digestion of old cuticle"@en .

<https://identifiers.org/aop.relationships/2172> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2172"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1807> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/996> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1807> rdfs:label "Inhibition, Chitobiase"@en .
<https://identifiers.org/aop.events/996> rdfs:label "Decrease, Digestion of old cuticle"@en .

<https://identifiers.org/aop.relationships/2192> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2192"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1814> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1816> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1814> rdfs:label "benzoquinone imine and acylglucuronide metabolites"@en .
<https://identifiers.org/aop.events/1816> rdfs:label "Mitochondrial dysfunction"@en .

<https://identifiers.org/aop.relationships/2194> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2194"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1814> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1818> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1814> rdfs:label "benzoquinone imine and acylglucuronide metabolites"@en .
<https://identifiers.org/aop.events/1818> rdfs:label "Immune cell activation"@en .

<https://identifiers.org/aop.relationships/2200> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2200"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1815> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1817> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1815> rdfs:label "Activation of ER stress"@en .
<https://identifiers.org/aop.events/1817> rdfs:label "Apoptotic cell death"@en .

<https://identifiers.org/aop.relationships/2643> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2643"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1815> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1365> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1815> rdfs:label "Activation of ER stress"@en .
<https://identifiers.org/aop.events/1365> rdfs:label "Increase, Apoptosis"@en .

<https://identifiers.org/aop.relationships/2193> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2193"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1816> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1817> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1816> rdfs:label "Mitochondrial dysfunction"@en .
<https://identifiers.org/aop.events/1817> rdfs:label "Apoptotic cell death"@en .

<https://identifiers.org/aop.relationships/2195> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2195"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1816> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1815> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1816> rdfs:label "Mitochondrial dysfunction"@en .
<https://identifiers.org/aop.events/1815> rdfs:label "Activation of ER stress"@en .

<https://identifiers.org/aop.relationships/2499> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2499"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1816> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1392> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1816> rdfs:label "Mitochondrial dysfunction"@en .
<https://identifiers.org/aop.events/1392> rdfs:label "Oxidative Stress "@en .

<https://identifiers.org/aop.relationships/2198> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2198"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1817> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1633> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1817> rdfs:label "Apoptotic cell death"@en .
<https://identifiers.org/aop.events/1633> rdfs:label "Increase in inflammation"@en .

<https://identifiers.org/aop.relationships/2196> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2196"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1818> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1819> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1818> rdfs:label "Immune cell activation"@en .
<https://identifiers.org/aop.events/1819> rdfs:label "IFNγ signaling"@en .

<https://identifiers.org/aop.relationships/2197> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2197"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1819> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1633> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1819> rdfs:label "IFNγ signaling"@en .
<https://identifiers.org/aop.events/1633> rdfs:label "Increase in inflammation"@en .

<https://identifiers.org/aop.relationships/2205> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2205"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1821> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1521> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1821> rdfs:label "Decrease, Cell proliferation"@en .
<https://identifiers.org/aop.events/1521> rdfs:label "Decrease, Growth"@en .

<https://identifiers.org/aop.relationships/2405> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2405"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1821> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1878> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1821> rdfs:label "Decrease, Cell proliferation"@en .
<https://identifiers.org/aop.events/1878> rdfs:label "Decreased, Eye size"@en .

<https://identifiers.org/aop.relationships/2724> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2724"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1821> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2041> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1821> rdfs:label "Decrease, Cell proliferation"@en .
<https://identifiers.org/aop.events/2041> rdfs:label "Decrease, palatal shelf outgrowth"@en .

<https://identifiers.org/aop.relationships/2215> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2215"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1825> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1521> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1825> rdfs:label "Increase, Cell death"@en .
<https://identifiers.org/aop.events/1521> rdfs:label "Decrease, Growth"@en .

<https://identifiers.org/aop.relationships/2467> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2467"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1825> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1930> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1825> rdfs:label "Increase, Cell death"@en .
<https://identifiers.org/aop.events/1930> rdfs:label "altered, inner ear development"@en .

<https://identifiers.org/aop.relationships/2706> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2706"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1825> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/896> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1825> rdfs:label "Increase, Cell death"@en .
<https://identifiers.org/aop.events/896> rdfs:label "Parkinsonian motor deficits"@en .

<https://identifiers.org/aop.relationships/2718> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2718"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1825> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/188> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1825> rdfs:label "Increase, Cell death"@en .
<https://identifiers.org/aop.events/188> rdfs:label "Neuroinflammation"@en .

<https://identifiers.org/aop.relationships/2760> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2760"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1825> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1496> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1825> rdfs:label "Increase, Cell death"@en .
<https://identifiers.org/aop.events/1496> rdfs:label "Increased, secretion of proinflammatory mediators"@en .

<https://identifiers.org/aop.relationships/2842> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2842"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1825> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2089> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1825> rdfs:label "Increase, Cell death"@en .
<https://identifiers.org/aop.events/2089> rdfs:label "Altered Bone Cell Homeostasis"@en .

<https://identifiers.org/aop.relationships/2226> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2226"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1827> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1365> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1827> rdfs:label "Increase, Global DNA methylation"@en .
<https://identifiers.org/aop.events/1365> rdfs:label "Increase, Apoptosis"@en .

<https://identifiers.org/aop.relationships/2241> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2241"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1828> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1101> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1828> rdfs:label "Increased, Thyroxine (T4) in serum"@en .
<https://identifiers.org/aop.events/1101> rdfs:label "Altered, Amphibian metamorphosis"@en .

<https://identifiers.org/aop.relationships/2242> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2242"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1828> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1829> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1828> rdfs:label "Increased, Thyroxine (T4) in serum"@en .
<https://identifiers.org/aop.events/1829> rdfs:label "Altered, Thyroid hormone-dependent gene expression"@en .

<https://identifiers.org/aop.relationships/2244> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2244"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1829> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1101> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1829> rdfs:label "Altered, Thyroid hormone-dependent gene expression"@en .
<https://identifiers.org/aop.events/1101> rdfs:label "Altered, Amphibian metamorphosis"@en .

<https://identifiers.org/aop.relationships/2249> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2249"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1830> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/959> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1830> rdfs:label "Displacement, Serum thyroxine (T4) from carrier protein"@en .
<https://identifiers.org/aop.events/959> rdfs:label "Increased, Free serum thyroxine (T4)"@en .

<https://identifiers.org/aop.relationships/2250> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2250"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1831> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1830> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1831> rdfs:label "Binding, Thyroid binding globulin in serum"@en .
<https://identifiers.org/aop.events/1830> rdfs:label "Displacement, Serum thyroxine (T4) from carrier protein"@en .

<https://identifiers.org/aop.relationships/2267> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2267"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1834> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/860> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1834> rdfs:label "Decrease, Acyl-CoA dehydrogenases"@en .
<https://identifiers.org/aop.events/860> rdfs:label "Decreased, Mitochondrial Fatty Acid Beta Oxidation"@en .

<https://identifiers.org/aop.relationships/2276> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2276"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1835> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1836> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1835> rdfs:label "Cortisol and 11β-(OH) testosterone decreased"@en .
<https://identifiers.org/aop.events/1836> rdfs:label "Decreased plasma Cortisol level"@en .

<https://identifiers.org/aop.relationships/2277> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2277"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1835> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1756> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1835> rdfs:label "Cortisol and 11β-(OH) testosterone decreased"@en .
<https://identifiers.org/aop.events/1756> rdfs:label "Decreased,  plasma 11-ketotestosterone level"@en .

<https://identifiers.org/aop.relationships/2278> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2278"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1836> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1837> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1836> rdfs:label "Decreased plasma Cortisol level"@en .
<https://identifiers.org/aop.events/1837> rdfs:label "decreased oocyte maturation"@en .

<https://identifiers.org/aop.relationships/2293> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2293"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1837> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/406> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1837> rdfs:label "decreased oocyte maturation"@en .
<https://identifiers.org/aop.events/406> rdfs:label "impaired, Fertility"@en .

<https://identifiers.org/aop.relationships/2429> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2429"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1842> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1897> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1842> rdfs:label "Prolonged TLR9 activation"@en .
<https://identifiers.org/aop.events/1897> rdfs:label "increased MyD88 activation"@en .

<https://identifiers.org/aop.relationships/2433> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2433"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1842> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1895> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1842> rdfs:label "Prolonged TLR9 activation"@en .
<https://identifiers.org/aop.events/1895> rdfs:label "NLRP3 inflammasome activity, increased"@en .

<https://identifiers.org/aop.relationships/2290> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2290"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1845> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1846> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1845> rdfs:label "Coagulation"@en .
<https://identifiers.org/aop.events/1846> rdfs:label "Thrombosis and Disseminated Intravascular Coagulation"@en .

<https://identifiers.org/aop.relationships/2360> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2360"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1845> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1869> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1845> rdfs:label "Coagulation"@en .
<https://identifiers.org/aop.events/1869> rdfs:label "Diminished protective oxidative stress response"@en .

<https://identifiers.org/aop.relationships/2351> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2351"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1847> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1848> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1847> rdfs:label "Increased SARS-CoV-2 production"@en .
<https://identifiers.org/aop.events/1848> rdfs:label "Toll Like Receptor (TLR) Dysregulation"@en .

<https://identifiers.org/aop.relationships/2358> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2358"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1847> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1869> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1847> rdfs:label "Increased SARS-CoV-2 production"@en .
<https://identifiers.org/aop.events/1869> rdfs:label "Diminished protective oxidative stress response"@en .

<https://identifiers.org/aop.relationships/2498> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2498"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1847> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1939> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1847> rdfs:label "Increased SARS-CoV-2 production"@en .
<https://identifiers.org/aop.events/1939> rdfs:label "Viral infection and host-to-host transmission, proliferated"@en .

<https://identifiers.org/aop.relationships/2545> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2545"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1847> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1870> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1847> rdfs:label "Increased SARS-CoV-2 production"@en .
<https://identifiers.org/aop.events/1870> rdfs:label "Sustentacular cells, decrease "@en .

<https://identifiers.org/aop.relationships/2546> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2546"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1847> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1931> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1847> rdfs:label "Increased SARS-CoV-2 production"@en .
<https://identifiers.org/aop.events/1931> rdfs:label "Intestinal barrier, disruption"@en .

<https://identifiers.org/aop.relationships/2488> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2488"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1847> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1825> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1847> rdfs:label "Increased SARS-CoV-2 production"@en .
<https://identifiers.org/aop.events/1825> rdfs:label "Increase, Cell death"@en .

<https://identifiers.org/aop.relationships/2296> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2296"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1849> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1850> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1849> rdfs:label "Impaired gustatory nerve"@en .
<https://identifiers.org/aop.events/1850> rdfs:label "dysgeusia"@en .

<https://identifiers.org/aop.relationships/1896> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1896"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/185> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1182> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/185> rdfs:label "Increase, Mutations"@en .
<https://identifiers.org/aop.events/1182> rdfs:label "Increase, Cell Proliferation (Epithelial Cells)"@en .

<https://identifiers.org/aop.relationships/1978> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1978"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/185> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/870> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/185> rdfs:label "Increase, Mutations"@en .
<https://identifiers.org/aop.events/870> rdfs:label "Increase, Cell Proliferation"@en .

<https://identifiers.org/aop.relationships/1984> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1984"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/185> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1556> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/185> rdfs:label "Increase, Mutations"@en .
<https://identifiers.org/aop.events/1556> rdfs:label "Increase, lung cancer"@en .

<https://identifiers.org/aop.relationships/202> a sbdbel:CausalAssertion ;
  rdfs:label "KER 202"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/185> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/336> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/185> rdfs:label "Increase, Mutations"@en .
<https://identifiers.org/aop.events/336> rdfs:label "Increase, Heritable mutations in offspring"@en .

<https://identifiers.org/aop.relationships/899> a sbdbel:CausalAssertion ;
  rdfs:label "KER 899"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/185> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/885> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/185> rdfs:label "Increase, Mutations"@en .
<https://identifiers.org/aop.events/885> rdfs:label "Increase, Cancer"@en .

<https://identifiers.org/aop.relationships/2609> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2609"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/185> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1980> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/185> rdfs:label "Increase, Mutations"@en .
<https://identifiers.org/aop.events/1980> rdfs:label "Increased micro RNA expression"@en .

<https://identifiers.org/aop.relationships/2319> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2319"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1851> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1115> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1851> rdfs:label "Binding of agonist, Angiotensin II receptor type 1 receptor (AT1R)"@en .
<https://identifiers.org/aop.events/1115> rdfs:label "Increased, Reactive oxygen species"@en .

<https://identifiers.org/aop.relationships/2323> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2323"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1852> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1115> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1852> rdfs:label "Increased Ang II type 1 receptor (AT1R)"@en .
<https://identifiers.org/aop.events/1115> rdfs:label "Increased, Reactive oxygen species"@en .

<https://identifiers.org/aop.relationships/2326> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2326"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1853> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1752> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1853> rdfs:label "Hyperactivation of ACE/Ang-II/AT1R axis"@en .
<https://identifiers.org/aop.events/1752> rdfs:label "Increased Angiotensin II "@en .

<https://identifiers.org/aop.relationships/2532> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2532"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1854> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1954> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1854> rdfs:label "Dysregulation, ACE2 expression and activity"@en .
<https://identifiers.org/aop.events/1954> rdfs:label "Gut microbiota, alteration"@en .

<https://identifiers.org/aop.relationships/2831> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2831"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1854> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2096> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1854> rdfs:label "Dysregulation, ACE2 expression and activity"@en .
<https://identifiers.org/aop.events/2096> rdfs:label "Occurrence, (Micro)vascular dysfunction"@en .

<https://identifiers.org/aop.relationships/1687> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1687"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/188> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/55> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/188> rdfs:label "Neuroinflammation"@en .
<https://identifiers.org/aop.events/55> rdfs:label "Cell injury/death"@en .

<https://identifiers.org/aop.relationships/208> a sbdbel:CausalAssertion ;
  rdfs:label "KER 208"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/188> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/352> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/188> rdfs:label "Neuroinflammation"@en .
<https://identifiers.org/aop.events/352> rdfs:label "N/A, Neurodegeneration"@en .

<https://identifiers.org/aop.relationships/2288> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2288"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/188> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1841> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/188> rdfs:label "Neuroinflammation"@en .
<https://identifiers.org/aop.events/1841> rdfs:label "Encephalitis"@en .

<https://identifiers.org/aop.relationships/906> a sbdbel:CausalAssertion ;
  rdfs:label "KER 906"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/188> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/890> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/188> rdfs:label "Neuroinflammation"@en .
<https://identifiers.org/aop.events/890> rdfs:label "Degeneration of dopaminergic neurons of the nigrostriatal pathway"@en .

<https://identifiers.org/aop.relationships/2500> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2500"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/188> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/386> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/188> rdfs:label "Neuroinflammation"@en .
<https://identifiers.org/aop.events/386> rdfs:label "Decrease of neuronal network function"@en .

<https://identifiers.org/aop.relationships/2717> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2717"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/188> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1825> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/188> rdfs:label "Neuroinflammation"@en .
<https://identifiers.org/aop.events/1825> rdfs:label "Increase, Cell death"@en .

<https://identifiers.org/aop.relationships/384> a sbdbel:CausalAssertion ;
  rdfs:label "KER 384"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/192> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/402> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/192> rdfs:label "Altered, Neurophysiology"@en .
<https://identifiers.org/aop.events/402> rdfs:label "Cognitive Function, Decreased "@en .

<https://identifiers.org/aop.relationships/212> a sbdbel:CausalAssertion ;
  rdfs:label "KER 212"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/193> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/166> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/193> rdfs:label "Decreased, Nitric Oxide"@en .
<https://identifiers.org/aop.events/166> rdfs:label "Decreased, Long-term potentiation (LTP)"@en .

<https://identifiers.org/aop.relationships/213> a sbdbel:CausalAssertion ;
  rdfs:label "KER 213"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/195> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/52> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/195> rdfs:label "Inhibition, NMDARs"@en .
<https://identifiers.org/aop.events/52> rdfs:label "Decreased, Calcium influx"@en .

<https://identifiers.org/aop.relationships/1828> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1828"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/202> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1575> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/202> rdfs:label "Inhibition, Nuclear factor kappa B (NF-kB)"@en .
<https://identifiers.org/aop.events/1575> rdfs:label "Activation, Caspase 8 pathway"@en .

<https://identifiers.org/aop.relationships/2003> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2003"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/202> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1702> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/202> rdfs:label "Inhibition, Nuclear factor kappa B (NF-kB)"@en .
<https://identifiers.org/aop.events/1702> rdfs:label "Suppression of  T cell activation"@en .

<https://identifiers.org/aop.relationships/387> a sbdbel:CausalAssertion ;
  rdfs:label "KER 387"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/202> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/152> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/202> rdfs:label "Inhibition, Nuclear factor kappa B (NF-kB)"@en .
<https://identifiers.org/aop.events/152> rdfs:label "Suppression, Inflammatory cytokines"@en .

<https://identifiers.org/aop.relationships/2644> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2644"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/202> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1633> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/202> rdfs:label "Inhibition, Nuclear factor kappa B (NF-kB)"@en .
<https://identifiers.org/aop.events/1633> rdfs:label "Increase in inflammation"@en .

<https://identifiers.org/aop.relationships/1698> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1698"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/209> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/927> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/209> rdfs:label "Peptide Oxidation"@en .
<https://identifiers.org/aop.events/927> rdfs:label "KE1 : S-Glutathionylation, eNOS"@en .

<https://identifiers.org/aop.relationships/980> a sbdbel:CausalAssertion ;
  rdfs:label "KER 980"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/209> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/935> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/209> rdfs:label "Peptide Oxidation"@en .
<https://identifiers.org/aop.events/935> rdfs:label "KE2 : Decrease, GTPCH-1"@en .

<https://identifiers.org/aop.relationships/992> a sbdbel:CausalAssertion ;
  rdfs:label "KER 992"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/209> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/973> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/209> rdfs:label "Peptide Oxidation"@en .
<https://identifiers.org/aop.events/973> rdfs:label "KE5 : Decrease, AKT/eNOS activity"@en .

<https://identifiers.org/aop.relationships/1379> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1379"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/209> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1292> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/209> rdfs:label "Peptide Oxidation"@en .
<https://identifiers.org/aop.events/1292> rdfs:label "Activation, JNK"@en .

<https://identifiers.org/aop.relationships/765> a sbdbel:CausalAssertion ;
  rdfs:label "KER 765"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/209> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/768> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/209> rdfs:label "Peptide Oxidation"@en .
<https://identifiers.org/aop.events/768> rdfs:label "Increase, Cytotoxicity"@en .

<https://identifiers.org/aop.relationships/932> a sbdbel:CausalAssertion ;
  rdfs:label "KER 932"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/209> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/357> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/209> rdfs:label "Peptide Oxidation"@en .
<https://identifiers.org/aop.events/357> rdfs:label "Cholestasis, Pathology"@en .

<https://identifiers.org/aop.relationships/240> a sbdbel:CausalAssertion ;
  rdfs:label "KER 240"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/211> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/131> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/211> rdfs:label "Propagation, Oxidative stress"@en .
<https://identifiers.org/aop.events/131> rdfs:label "Down Regulation, Gulcose-6-phosphate dehydrogenase"@en .

<https://identifiers.org/aop.relationships/241> a sbdbel:CausalAssertion ;
  rdfs:label "KER 241"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/211> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/250> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/211> rdfs:label "Propagation, Oxidative stress"@en .
<https://identifiers.org/aop.events/250> rdfs:label "Damaging, Red blood cells; hemolysis"@en .

<https://identifiers.org/aop.relationships/242> a sbdbel:CausalAssertion ;
  rdfs:label "KER 242"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/213> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/21> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/213> rdfs:label "N/A, Parent compound is converted to the reactive metabolite and forms free radicals leading to oxidation of heme iron(II) in hemoglobin to iron(III)"@en .
<https://identifiers.org/aop.events/21> rdfs:label "Altered regulation, Alpha hemoglobin"@en .

<https://identifiers.org/aop.relationships/243> a sbdbel:CausalAssertion ;
  rdfs:label "KER 243"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/213> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/118> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/213> rdfs:label "N/A, Parent compound is converted to the reactive metabolite and forms free radicals leading to oxidation of heme iron(II) in hemoglobin to iron(III)"@en .
<https://identifiers.org/aop.events/118> rdfs:label "Formation, Formation of hemoglobin adducts"@en .

<https://identifiers.org/aop.relationships/244> a sbdbel:CausalAssertion ;
  rdfs:label "KER 244"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/213> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/211> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/213> rdfs:label "N/A, Parent compound is converted to the reactive metabolite and forms free radicals leading to oxidation of heme iron(II) in hemoglobin to iron(III)"@en .
<https://identifiers.org/aop.events/211> rdfs:label "Propagation, Oxidative stress"@en .

<https://identifiers.org/aop.relationships/245> a sbdbel:CausalAssertion ;
  rdfs:label "KER 245"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/213> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/250> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/213> rdfs:label "N/A, Parent compound is converted to the reactive metabolite and forms free radicals leading to oxidation of heme iron(II) in hemoglobin to iron(III)"@en .
<https://identifiers.org/aop.events/250> rdfs:label "Damaging, Red blood cells; hemolysis"@en .

<https://identifiers.org/aop.relationships/248> a sbdbel:CausalAssertion ;
  rdfs:label "KER 248"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/214> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/288> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/214> rdfs:label "Bile accumulation, Pathological condition"@en .
<https://identifiers.org/aop.events/288> rdfs:label "Activation of specific nuclear receptors, Transcriptional change"@en .

<https://identifiers.org/aop.relationships/928> a sbdbel:CausalAssertion ;
  rdfs:label "KER 928"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/214> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/87> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/214> rdfs:label "Bile accumulation, Pathological condition"@en .
<https://identifiers.org/aop.events/87> rdfs:label "Release, Cytokine"@en .

<https://identifiers.org/aop.relationships/930> a sbdbel:CausalAssertion ;
  rdfs:label "KER 930"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/214> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/249> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/214> rdfs:label "Bile accumulation, Pathological condition"@en .
<https://identifiers.org/aop.events/249> rdfs:label "Production, Reactive oxygen species"@en .

<https://identifiers.org/aop.relationships/503> a sbdbel:CausalAssertion ;
  rdfs:label "KER 503"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/216> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/327> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/216> rdfs:label "Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway)"@en .
<https://identifiers.org/aop.events/327> rdfs:label "Accumulation, Fatty acid"@en .

<https://identifiers.org/aop.relationships/1386> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1386"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/219> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/221> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/219> rdfs:label "Reduction, Plasma 17beta-estradiol concentrations"@en .
<https://identifiers.org/aop.events/221> rdfs:label "Reduction, Plasma vitellogenin concentrations"@en .

<https://identifiers.org/aop.relationships/252> a sbdbel:CausalAssertion ;
  rdfs:label "KER 252"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/219> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/285> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/219> rdfs:label "Reduction, Plasma 17beta-estradiol concentrations"@en .
<https://identifiers.org/aop.events/285> rdfs:label "Reduction, Vitellogenin synthesis in liver"@en .

<https://identifiers.org/aop.relationships/392> a sbdbel:CausalAssertion ;
  rdfs:label "KER 392"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/219> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/405> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/219> rdfs:label "Reduction, Plasma 17beta-estradiol concentrations"@en .
<https://identifiers.org/aop.events/405> rdfs:label "irregularities, ovarian cycle"@en .

<https://identifiers.org/aop.relationships/254> a sbdbel:CausalAssertion ;
  rdfs:label "KER 254"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/220> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/252> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/220> rdfs:label "Increase, Plasma vitellogenin concentrations"@en .
<https://identifiers.org/aop.events/252> rdfs:label "Increase, Renal pathology due to VTG deposition"@en .

<https://identifiers.org/aop.relationships/1769> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1769"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/221> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/78> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/221> rdfs:label "Reduction, Plasma vitellogenin concentrations"@en .
<https://identifiers.org/aop.events/78> rdfs:label "Reduction, Cumulative fecundity and spawning"@en .

<https://identifiers.org/aop.relationships/255> a sbdbel:CausalAssertion ;
  rdfs:label "KER 255"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/221> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/309> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/221> rdfs:label "Reduction, Plasma vitellogenin concentrations"@en .
<https://identifiers.org/aop.events/309> rdfs:label "Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"@en .

<https://identifiers.org/aop.relationships/1229> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1229"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/227> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1170> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/227> rdfs:label "Activation, PPARα"@en .
<https://identifiers.org/aop.events/1170> rdfs:label "Increase, Phenotypic enzyme activity"@en .

<https://identifiers.org/aop.relationships/2073> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2073"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/227> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/807> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/227> rdfs:label "Activation, PPARα"@en .
<https://identifiers.org/aop.events/807> rdfs:label "Decreased, cholesterol"@en .

<https://identifiers.org/aop.relationships/369> a sbdbel:CausalAssertion ;
  rdfs:label "KER 369"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/227> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/266> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/227> rdfs:label "Activation, PPARα"@en .
<https://identifiers.org/aop.events/266> rdfs:label "Decrease, Steroidogenic acute regulatory protein (STAR)"@en .

<https://identifiers.org/aop.relationships/370> a sbdbel:CausalAssertion ;
  rdfs:label "KER 370"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/227> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/289> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/227> rdfs:label "Activation, PPARα"@en .
<https://identifiers.org/aop.events/289> rdfs:label "Decrease, Translocator protein (TSPO)"@en .

<https://identifiers.org/aop.relationships/2252> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2252"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/227> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/716> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/227> rdfs:label "Activation, PPARα"@en .
<https://identifiers.org/aop.events/716> rdfs:label "Increase, cell proliferation (hepatocytes)"@en .

<https://identifiers.org/aop.relationships/2253> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2253"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/227> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/719> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/227> rdfs:label "Activation, PPARα"@en .
<https://identifiers.org/aop.events/719> rdfs:label "Increase, hepatocellular adenomas and carcinomas"@en .

<https://identifiers.org/aop.relationships/535> a sbdbel:CausalAssertion ;
  rdfs:label "KER 535"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/227> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/483> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/227> rdfs:label "Activation, PPARα"@en .
<https://identifiers.org/aop.events/483> rdfs:label "Activation, LXR alpha"@en .

<https://identifiers.org/aop.relationships/411> a sbdbel:CausalAssertion ;
  rdfs:label "KER 411"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/228> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/54> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/228> rdfs:label "peroxisome proliferator activated receptor promoter demethylation"@en .
<https://identifiers.org/aop.events/54> rdfs:label "Up Regulation, CD36"@en .

<https://identifiers.org/aop.relationships/1608> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1608"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/228> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1028> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/228> rdfs:label "peroxisome proliferator activated receptor promoter demethylation"@en .
<https://identifiers.org/aop.events/1028> rdfs:label "Activation of specific nuclear receptors, PPAR-gamma activation"@en .

<https://identifiers.org/aop.relationships/1659> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1659"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/228> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/465> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/228> rdfs:label "peroxisome proliferator activated receptor promoter demethylation"@en .
<https://identifiers.org/aop.events/465> rdfs:label "Increased, FA Influx"@en .

<https://identifiers.org/aop.relationships/487> a sbdbel:CausalAssertion ;
  rdfs:label "KER 487"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/228> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/457> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/228> rdfs:label "peroxisome proliferator activated receptor promoter demethylation"@en .
<https://identifiers.org/aop.events/457> rdfs:label "Activation, SREBF1"@en .

<https://identifiers.org/aop.relationships/257> a sbdbel:CausalAssertion ;
  rdfs:label "KER 257"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/231> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/140> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/231> rdfs:label "Decreased, PPAR-alpha activation"@en .
<https://identifiers.org/aop.events/140> rdfs:label "Decreased, HSD17B10 expression"@en .

<https://identifiers.org/aop.relationships/259> a sbdbel:CausalAssertion ;
  rdfs:label "KER 259"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/232> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/140> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/232> rdfs:label "Decreased, PPAR-beta activation"@en .
<https://identifiers.org/aop.events/140> rdfs:label "Decreased, HSD17B10 expression"@en .

<https://identifiers.org/aop.relationships/260> a sbdbel:CausalAssertion ;
  rdfs:label "KER 260"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/233> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/140> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/233> rdfs:label "Decreased, PPAR-gamma activation"@en .
<https://identifiers.org/aop.events/140> rdfs:label "Decreased, HSD17B10 expression"@en .

<https://identifiers.org/aop.relationships/2482> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2482"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/239> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/295> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/239> rdfs:label "Activation, Pregnane-X receptor, NR1l2"@en .
<https://identifiers.org/aop.events/295> rdfs:label "Induction, Upregulation of glucuronyltransferase activity"@en .

<https://identifiers.org/aop.relationships/266> a sbdbel:CausalAssertion ;
  rdfs:label "KER 266"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/240> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/337> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/240> rdfs:label "Feminisation or incomplete development, Primary and accessory male sex organs"@en .
<https://identifiers.org/aop.events/337> rdfs:label "N/A, Impairment of reproductive capacity"@en .

<https://identifiers.org/aop.relationships/268> a sbdbel:CausalAssertion ;
  rdfs:label "KER 268"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/243> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/119> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/243> rdfs:label "Reduction, Prostaglandin E2 concentration"@en .
<https://identifiers.org/aop.events/119> rdfs:label "N/A, Gap"@en .

<https://identifiers.org/aop.relationships/269> a sbdbel:CausalAssertion ;
  rdfs:label "KER 269"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/244> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/55> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/244> rdfs:label "Alkylation, Protein"@en .
<https://identifiers.org/aop.events/55> rdfs:label "Cell injury/death"@en .

<https://identifiers.org/aop.relationships/1680> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1680"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/244> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1483> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/244> rdfs:label "Alkylation, Protein"@en .
<https://identifiers.org/aop.events/1483> rdfs:label "Dysfunction, Mitochondria "@en .

<https://identifiers.org/aop.relationships/518> a sbdbel:CausalAssertion ;
  rdfs:label "KER 518"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/245> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/471> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/245> rdfs:label "Activation, PXR/SXR"@en .
<https://identifiers.org/aop.events/471> rdfs:label "Inhibition, FoxA2"@en .

<https://identifiers.org/aop.relationships/526> a sbdbel:CausalAssertion ;
  rdfs:label "KER 526"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/245> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/462> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/245> rdfs:label "Activation, PXR/SXR"@en .
<https://identifiers.org/aop.events/462> rdfs:label "Up Regulation, SCD-1"@en .

<https://identifiers.org/aop.relationships/529> a sbdbel:CausalAssertion ;
  rdfs:label "KER 529"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/245> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/54> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/245> rdfs:label "Activation, PXR/SXR"@en .
<https://identifiers.org/aop.events/54> rdfs:label "Up Regulation, CD36"@en .

<https://identifiers.org/aop.relationships/272> a sbdbel:CausalAssertion ;
  rdfs:label "KER 272"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/246> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/173> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/246> rdfs:label "Increase, RBC congestion in liver"@en .
<https://identifiers.org/aop.events/173> rdfs:label "N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number"@en .

<https://identifiers.org/aop.relationships/276> a sbdbel:CausalAssertion ;
  rdfs:label "KER 276"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/249> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/209> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/249> rdfs:label "Production, Reactive oxygen species"@en .
<https://identifiers.org/aop.events/209> rdfs:label "Peptide Oxidation"@en .

<https://identifiers.org/aop.relationships/1384> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1384"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/25> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/3> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/25> rdfs:label "Agonism, Androgen receptor"@en .
<https://identifiers.org/aop.events/3> rdfs:label "Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"@en .

<https://identifiers.org/aop.relationships/1385> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1385"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/25> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/285> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/25> rdfs:label "Agonism, Androgen receptor"@en .
<https://identifiers.org/aop.events/285> rdfs:label "Reduction, Vitellogenin synthesis in liver"@en .

<https://identifiers.org/aop.relationships/31> a sbdbel:CausalAssertion ;
  rdfs:label "KER 31"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/25> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/129> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/25> rdfs:label "Agonism, Androgen receptor"@en .
<https://identifiers.org/aop.events/129> rdfs:label "Reduction, Gonadotropins, circulating concentrations"@en .

<https://identifiers.org/aop.relationships/32> a sbdbel:CausalAssertion ;
  rdfs:label "KER 32"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/25> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/274> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/25> rdfs:label "Agonism, Androgen receptor"@en .
<https://identifiers.org/aop.events/274> rdfs:label "Reduction, Testosterone synthesis by ovarian theca cells"@en .

<https://identifiers.org/aop.relationships/2260> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2260"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/25> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1790> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/25> rdfs:label "Agonism, Androgen receptor"@en .
<https://identifiers.org/aop.events/1790> rdfs:label "Increased, Differentiation to Testis "@en .

<https://identifiers.org/aop.relationships/2349> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2349"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/25> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1791> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/25> rdfs:label "Agonism, Androgen receptor"@en .
<https://identifiers.org/aop.events/1791> rdfs:label "Increased, Male Biased Sex Ratio"@en .

<https://identifiers.org/aop.relationships/277> a sbdbel:CausalAssertion ;
  rdfs:label "KER 277"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/250> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/161> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/250> rdfs:label "Damaging, Red blood cells; hemolysis"@en .
<https://identifiers.org/aop.events/161> rdfs:label "Increase, Liver and splenic hemosiderosis"@en .

<https://identifiers.org/aop.relationships/278> a sbdbel:CausalAssertion ;
  rdfs:label "KER 278"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/250> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/173> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/250> rdfs:label "Damaging, Red blood cells; hemolysis"@en .
<https://identifiers.org/aop.events/173> rdfs:label "N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number"@en .

<https://identifiers.org/aop.relationships/279> a sbdbel:CausalAssertion ;
  rdfs:label "KER 279"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/250> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/246> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/250> rdfs:label "Damaging, Red blood cells; hemolysis"@en .
<https://identifiers.org/aop.events/246> rdfs:label "Increase, RBC congestion in liver"@en .

<https://identifiers.org/aop.relationships/280> a sbdbel:CausalAssertion ;
  rdfs:label "KER 280"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/252> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/339> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/252> rdfs:label "Increase, Renal pathology due to VTG deposition"@en .
<https://identifiers.org/aop.events/339> rdfs:label "Altered, Larval development"@en .

<https://identifiers.org/aop.relationships/1603> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1603"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/257> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1445> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/257> rdfs:label "Increase, Reactive Oxygen Species production"@en .
<https://identifiers.org/aop.events/1445> rdfs:label "Increase, Lipid peroxidation"@en .

<https://identifiers.org/aop.relationships/2089> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2089"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/257> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1767> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/257> rdfs:label "Increase, Reactive Oxygen Species production"@en .
<https://identifiers.org/aop.events/1767> rdfs:label "Increase, Protein oxidation"@en .

<https://identifiers.org/aop.relationships/2093> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2093"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/257> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1770> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/257> rdfs:label "Increase, Reactive Oxygen Species production"@en .
<https://identifiers.org/aop.events/1770> rdfs:label "Decrease, Mitochondrial membrane potential"@en .

<https://identifiers.org/aop.relationships/2099> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2099"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/257> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1608> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/257> rdfs:label "Increase, Reactive Oxygen Species production"@en .
<https://identifiers.org/aop.events/1608> rdfs:label "Increase, Oxidative DNA damage"@en .

<https://identifiers.org/aop.relationships/2225> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2225"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/257> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1827> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/257> rdfs:label "Increase, Reactive Oxygen Species production"@en .
<https://identifiers.org/aop.events/1827> rdfs:label "Increase, Global DNA methylation"@en .

<https://identifiers.org/aop.relationships/282> a sbdbel:CausalAssertion ;
  rdfs:label "KER 282"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/257> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/193> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/257> rdfs:label "Increase, Reactive Oxygen Species production"@en .
<https://identifiers.org/aop.events/193> rdfs:label "Decreased, Nitric Oxide"@en .

<https://identifiers.org/aop.relationships/283> a sbdbel:CausalAssertion ;
  rdfs:label "KER 283"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/257> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/356> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/257> rdfs:label "Increase, Reactive Oxygen Species production"@en .
<https://identifiers.org/aop.events/356> rdfs:label "Increased, Oxidative damage"@en .

<https://identifiers.org/aop.relationships/2590> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2590"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/257> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1634> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/257> rdfs:label "Increase, Reactive Oxygen Species production"@en .
<https://identifiers.org/aop.events/1634> rdfs:label "Increase, Oxidative damage to DNA"@en .

<https://identifiers.org/aop.relationships/295> a sbdbel:CausalAssertion ;
  rdfs:label "KER 295"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/265> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/68> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/265> rdfs:label "Activation, Stellate cells"@en .
<https://identifiers.org/aop.events/68> rdfs:label "Accumulation, Collagen"@en .

<https://identifiers.org/aop.relationships/436> a sbdbel:CausalAssertion ;
  rdfs:label "KER 436"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/266> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/447> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/266> rdfs:label "Decrease, Steroidogenic acute regulatory protein (STAR)"@en .
<https://identifiers.org/aop.events/447> rdfs:label "Reduction, Cholesterol transport in mitochondria"@en .

<https://identifiers.org/aop.relationships/298> a sbdbel:CausalAssertion ;
  rdfs:label "KER 298"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/269> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/347> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/269> rdfs:label "Induction, Sustained Cell Proliferation"@en .
<https://identifiers.org/aop.events/347> rdfs:label "Formation, Liver tumor"@en .

<https://identifiers.org/aop.relationships/33> a sbdbel:CausalAssertion ;
  rdfs:label "KER 33"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/27> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/286> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/27> rdfs:label "N/A, Androgen receptor, Antagonism"@en .
<https://identifiers.org/aop.events/286> rdfs:label "Altered, Transcription of genes by AR"@en .

<https://identifiers.org/aop.relationships/35> a sbdbel:CausalAssertion ;
  rdfs:label "KER 35"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/27> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/310> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/27> rdfs:label "N/A, Androgen receptor, Antagonism"@en .
<https://identifiers.org/aop.events/310> rdfs:label "Alteration, Wnt pathway"@en .

<https://identifiers.org/aop.relationships/299> a sbdbel:CausalAssertion ;
  rdfs:label "KER 299"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/270> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/269> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/270> rdfs:label "Induction, Sustained Hepatotoxicity"@en .
<https://identifiers.org/aop.events/269> rdfs:label "Induction, Sustained Cell Proliferation"@en .

<https://identifiers.org/aop.relationships/302> a sbdbel:CausalAssertion ;
  rdfs:label "KER 302"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/274> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/3> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/274> rdfs:label "Reduction, Testosterone synthesis by ovarian theca cells"@en .
<https://identifiers.org/aop.events/3> rdfs:label "Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"@en .

<https://identifiers.org/aop.relationships/315> a sbdbel:CausalAssertion ;
  rdfs:label "KER 315"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/285> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/221> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/285> rdfs:label "Reduction, Vitellogenin synthesis in liver"@en .
<https://identifiers.org/aop.events/221> rdfs:label "Reduction, Plasma vitellogenin concentrations"@en .

<https://identifiers.org/aop.relationships/319> a sbdbel:CausalAssertion ;
  rdfs:label "KER 319"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/288> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/357> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/288> rdfs:label "Activation of specific nuclear receptors, Transcriptional change"@en .
<https://identifiers.org/aop.events/357> rdfs:label "Cholestasis, Pathology"@en .

<https://identifiers.org/aop.relationships/437> a sbdbel:CausalAssertion ;
  rdfs:label "KER 437"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/289> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/447> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/289> rdfs:label "Decrease, Translocator protein (TSPO)"@en .
<https://identifiers.org/aop.events/447> rdfs:label "Reduction, Cholesterol transport in mitochondria"@en .

<https://identifiers.org/aop.relationships/2265> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2265"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/291> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/459> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/291> rdfs:label "Accumulation, Triglyceride"@en .
<https://identifiers.org/aop.events/459> rdfs:label "Increased, Liver Steatosis"@en .

<https://identifiers.org/aop.relationships/321> a sbdbel:CausalAssertion ;
  rdfs:label "KER 321"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/291> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/176> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/291> rdfs:label "Accumulation, Triglyceride"@en .
<https://identifiers.org/aop.events/176> rdfs:label "Damaging, Mitochondria"@en .

<https://identifiers.org/aop.relationships/474> a sbdbel:CausalAssertion ;
  rdfs:label "KER 474"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/291> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/455> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/291> rdfs:label "Accumulation, Triglyceride"@en .
<https://identifiers.org/aop.events/455> rdfs:label "Accumulation, Liver lipid"@en .

<https://identifiers.org/aop.relationships/324> a sbdbel:CausalAssertion ;
  rdfs:label "KER 324"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/294> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/57> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/294> rdfs:label "N/A, Unknown"@en .
<https://identifiers.org/aop.events/57> rdfs:label "Proliferation, Cell proliferation in the absence of cytotoxicity"@en .

<https://identifiers.org/aop.relationships/751> a sbdbel:CausalAssertion ;
  rdfs:label "KER 751"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/294> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/759> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/294> rdfs:label "N/A, Unknown"@en .
<https://identifiers.org/aop.events/759> rdfs:label "Increased, Kidney Failure"@en .

<https://identifiers.org/aop.relationships/2478> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2478"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/295> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/961> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/295> rdfs:label "Induction, Upregulation of glucuronyltransferase activity"@en .
<https://identifiers.org/aop.events/961> rdfs:label "Increased, Clearance of thyroxine from serum"@en .

<https://identifiers.org/aop.relationships/5> a sbdbel:CausalAssertion ;
  rdfs:label "KER 5"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/3> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/219> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/3> rdfs:label "Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"@en .
<https://identifiers.org/aop.events/219> rdfs:label "Reduction, Plasma 17beta-estradiol concentrations"@en .

<https://identifiers.org/aop.relationships/336> a sbdbel:CausalAssertion ;
  rdfs:label "KER 336"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/307> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/220> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/307> rdfs:label "Increase, Vitellogenin synthesis in liver"@en .
<https://identifiers.org/aop.events/220> rdfs:label "Increase, Plasma vitellogenin concentrations"@en .

<https://identifiers.org/aop.relationships/337> a sbdbel:CausalAssertion ;
  rdfs:label "KER 337"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/309> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/78> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/309> rdfs:label "Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"@en .
<https://identifiers.org/aop.events/78> rdfs:label "Reduction, Cumulative fecundity and spawning"@en .

<https://identifiers.org/aop.relationships/338> a sbdbel:CausalAssertion ;
  rdfs:label "KER 338"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/310> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/240> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/310> rdfs:label "Alteration, Wnt pathway"@en .
<https://identifiers.org/aop.events/240> rdfs:label "Feminisation or incomplete development, Primary and accessory male sex organs"@en .

<https://identifiers.org/aop.relationships/1567> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1567"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/317> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/947> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/317> rdfs:label "Altered, Cardiovascular development/function"@en .
<https://identifiers.org/aop.events/947> rdfs:label "Increase, Early Life Stage Mortality"@en .

<https://identifiers.org/aop.relationships/502> a sbdbel:CausalAssertion ;
  rdfs:label "KER 502"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/327> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/455> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/327> rdfs:label "Accumulation, Fatty acid"@en .
<https://identifiers.org/aop.events/455> rdfs:label "Accumulation, Liver lipid"@en .

<https://identifiers.org/aop.relationships/514> a sbdbel:CausalAssertion ;
  rdfs:label "KER 514"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/327> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/454> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/327> rdfs:label "Accumulation, Fatty acid"@en .
<https://identifiers.org/aop.events/454> rdfs:label "Increased, Triglyceride formation"@en .

<https://identifiers.org/aop.relationships/515> a sbdbel:CausalAssertion ;
  rdfs:label "KER 515"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/327> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/459> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/327> rdfs:label "Accumulation, Fatty acid"@en .
<https://identifiers.org/aop.events/459> rdfs:label "Increased, Liver Steatosis"@en .

<https://identifiers.org/aop.relationships/1886> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1886"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/328> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/360> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/328> rdfs:label "Decrease, Fecundity"@en .
<https://identifiers.org/aop.events/360> rdfs:label "Decrease, Population growth rate"@en .

<https://identifiers.org/aop.relationships/2621> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2621"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/328> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1863> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/328> rdfs:label "Decrease, Fecundity"@en .
<https://identifiers.org/aop.events/1863> rdfs:label "Decrease, Reproduction"@en .

<https://identifiers.org/aop.relationships/1644> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1644"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/341> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/635> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/341> rdfs:label "Impairment, Learning and memory"@en .
<https://identifiers.org/aop.events/635> rdfs:label "Decreased, locomotion"@en .

<https://identifiers.org/aop.relationships/564> a sbdbel:CausalAssertion ;
  rdfs:label "KER 564"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/341> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/564> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/341> rdfs:label "Impairment, Learning and memory"@en .
<https://identifiers.org/aop.events/564> rdfs:label "Abnormal, Roll change within caste"@en .

<https://identifiers.org/aop.relationships/583> a sbdbel:CausalAssertion ;
  rdfs:label "KER 583"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/341> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/560> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/341> rdfs:label "Impairment, Learning and memory"@en .
<https://identifiers.org/aop.events/560> rdfs:label "Abnormal, Foraging activity and behavior"@en .

<https://identifiers.org/aop.relationships/405> a sbdbel:CausalAssertion ;
  rdfs:label "KER 405"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/348> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/406> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/348> rdfs:label "Malformation, Male reproductive tract"@en .
<https://identifiers.org/aop.events/406> rdfs:label "impaired, Fertility"@en .

<https://identifiers.org/aop.relationships/2013> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2013"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/351> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/360> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/351> rdfs:label "Increased Mortality"@en .
<https://identifiers.org/aop.events/360> rdfs:label "Decrease, Population growth rate"@en .

<https://identifiers.org/aop.relationships/756> a sbdbel:CausalAssertion ;
  rdfs:label "KER 756"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/351> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/765> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/351> rdfs:label "Increased Mortality"@en .
<https://identifiers.org/aop.events/765> rdfs:label "Decreased, population 1"@en .

<https://identifiers.org/aop.relationships/1265> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1265"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/361> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1210> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/361> rdfs:label "Decline, Population"@en .
<https://identifiers.org/aop.events/1210> rdfs:label "Alteration, Food-web structures"@en .

<https://identifiers.org/aop.relationships/345> a sbdbel:CausalAssertion ;
  rdfs:label "KER 345"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/373> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/378> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/373> rdfs:label "Formation, Pro-mutagenic DNA Adducts"@en .
<https://identifiers.org/aop.events/378> rdfs:label "Tumorigenesis, Hepatocellular carcinoma"@en .

<https://identifiers.org/aop.relationships/551> a sbdbel:CausalAssertion ;
  rdfs:label "KER 551"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/373> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/491> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/373> rdfs:label "Formation, Pro-mutagenic DNA Adducts"@en .
<https://identifiers.org/aop.events/491> rdfs:label "Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF)"@en .

<https://identifiers.org/aop.relationships/548> a sbdbel:CausalAssertion ;
  rdfs:label "KER 548"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/373> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/493> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/373> rdfs:label "Formation, Pro-mutagenic DNA Adducts"@en .
<https://identifiers.org/aop.events/493> rdfs:label "Increased, Insufficient repair or mis-repair of pro-mutagenic DNA adducts"@en .

<https://identifiers.org/aop.relationships/346> a sbdbel:CausalAssertion ;
  rdfs:label "KER 346"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/376> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/378> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/376> rdfs:label "Increased, Induced Mutations in Critical Genes"@en .
<https://identifiers.org/aop.events/378> rdfs:label "Tumorigenesis, Hepatocellular carcinoma"@en .

<https://identifiers.org/aop.relationships/549> a sbdbel:CausalAssertion ;
  rdfs:label "KER 549"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/376> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/491> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/376> rdfs:label "Increased, Induced Mutations in Critical Genes"@en .
<https://identifiers.org/aop.events/491> rdfs:label "Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF)"@en .

<https://identifiers.org/aop.relationships/356> a sbdbel:CausalAssertion ;
  rdfs:label "KER 356"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/382> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/385> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/382> rdfs:label "Aberrant, Dendritic morphology"@en .
<https://identifiers.org/aop.events/385> rdfs:label "Decrease of synaptogenesis"@en .

<https://identifiers.org/aop.relationships/357> a sbdbel:CausalAssertion ;
  rdfs:label "KER 357"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/383> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/385> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/383> rdfs:label "Reduced, Presynaptic release of glutamate"@en .
<https://identifiers.org/aop.events/385> rdfs:label "Decrease of synaptogenesis"@en .

<https://identifiers.org/aop.relationships/359> a sbdbel:CausalAssertion ;
  rdfs:label "KER 359"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/386> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/341> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/386> rdfs:label "Decrease of neuronal network function"@en .
<https://identifiers.org/aop.events/341> rdfs:label "Impairment, Learning and memory"@en .

<https://identifiers.org/aop.relationships/2411> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2411"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/386> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/402> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/386> rdfs:label "Decrease of neuronal network function"@en .
<https://identifiers.org/aop.events/402> rdfs:label "Cognitive Function, Decreased "@en .

<https://identifiers.org/aop.relationships/2501> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2501"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/386> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1941> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/386> rdfs:label "Decrease of neuronal network function"@en .
<https://identifiers.org/aop.events/1941> rdfs:label "Memory Loss"@en .

<https://identifiers.org/aop.relationships/2781> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2781"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/388> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1788> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/388> rdfs:label "Overactivation, NMDARs"@en .
<https://identifiers.org/aop.events/1788> rdfs:label "Status epilepticus"@en .

<https://identifiers.org/aop.relationships/2806> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2806"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/388> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2078> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/388> rdfs:label "Overactivation, NMDARs"@en .
<https://identifiers.org/aop.events/2078> rdfs:label "Loss of drebrin"@en .

<https://identifiers.org/aop.relationships/361> a sbdbel:CausalAssertion ;
  rdfs:label "KER 361"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/388> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/389> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/388> rdfs:label "Overactivation, NMDARs"@en .
<https://identifiers.org/aop.events/389> rdfs:label "Increased, Intracellular Calcium overload"@en .

<https://identifiers.org/aop.relationships/2005> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2005"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/39> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1703> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/39> rdfs:label "Increased Cholinergic Signaling"@en .
<https://identifiers.org/aop.events/1703> rdfs:label "Dysregulation of heart rate and vascular tone"@en .

<https://identifiers.org/aop.relationships/2011> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2011"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/39> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1705> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/39> rdfs:label "Increased Cholinergic Signaling"@en .
<https://identifiers.org/aop.events/1705> rdfs:label "Impaired coordination and movement"@en .

<https://identifiers.org/aop.relationships/457> a sbdbel:CausalAssertion ;
  rdfs:label "KER 457"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/39> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/445> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/39> rdfs:label "Increased Cholinergic Signaling"@en .
<https://identifiers.org/aop.events/445> rdfs:label "Respiratory distress/arrest"@en .

<https://identifiers.org/aop.relationships/2410> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2410"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/39> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/386> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/39> rdfs:label "Increased Cholinergic Signaling"@en .
<https://identifiers.org/aop.events/386> rdfs:label "Decrease of neuronal network function"@en .

<https://identifiers.org/aop.relationships/2412> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2412"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/39> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/402> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/39> rdfs:label "Increased Cholinergic Signaling"@en .
<https://identifiers.org/aop.events/402> rdfs:label "Cognitive Function, Decreased "@en .

<https://identifiers.org/aop.relationships/377> a sbdbel:CausalAssertion ;
  rdfs:label "KER 377"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/396> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/398> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/396> rdfs:label "Covalent Binding, Protein"@en .
<https://identifiers.org/aop.events/398> rdfs:label "Activation, Dendritic Cells"@en .

<https://identifiers.org/aop.relationships/833> a sbdbel:CausalAssertion ;
  rdfs:label "KER 833"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/396> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/826> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/396> rdfs:label "Covalent Binding, Protein"@en .
<https://identifiers.org/aop.events/826> rdfs:label "Activation, Keratinocytes"@en .

<https://identifiers.org/aop.relationships/2649> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2649"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/396> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1496> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/396> rdfs:label "Covalent Binding, Protein"@en .
<https://identifiers.org/aop.events/1496> rdfs:label "Increased, secretion of proinflammatory mediators"@en .

<https://identifiers.org/aop.relationships/2650> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2650"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/396> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/313> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/396> rdfs:label "Covalent Binding, Protein"@en .
<https://identifiers.org/aop.events/313> rdfs:label "Increase, Allergic Respiratory Hypersensitivity Response"@en .

<https://identifiers.org/aop.relationships/379> a sbdbel:CausalAssertion ;
  rdfs:label "KER 379"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/398> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/272> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/398> rdfs:label "Activation, Dendritic Cells"@en .
<https://identifiers.org/aop.events/272> rdfs:label "Activation/Proliferation, T-cells"@en .

<https://identifiers.org/aop.relationships/1670> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1670"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/40> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1478> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/40> rdfs:label "Decrease, Mitochondrial ATP production"@en .
<https://identifiers.org/aop.events/1478> rdfs:label "Decrease, Leaf cell mitosis"@en .

<https://identifiers.org/aop.relationships/1682> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1682"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/40> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/709> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/40> rdfs:label "Decrease, Mitochondrial ATP production"@en .
<https://identifiers.org/aop.events/709> rdfs:label "Increase, Cytotoxicity (renal tubular cell)"@en .

<https://identifiers.org/aop.relationships/2551> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2551"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/40> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1863> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/40> rdfs:label "Decrease, Mitochondrial ATP production"@en .
<https://identifiers.org/aop.events/1863> rdfs:label "Decrease, Reproduction"@en .

<https://identifiers.org/aop.relationships/2823> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2823"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/40> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1532> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/40> rdfs:label "Decrease, Mitochondrial ATP production"@en .
<https://identifiers.org/aop.events/1532> rdfs:label "Decrease, Cardiac contractility "@en .

<https://identifiers.org/aop.relationships/570> a sbdbel:CausalAssertion ;
  rdfs:label "KER 570"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/403> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/576> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/403> rdfs:label "Suppression, Immune system"@en .
<https://identifiers.org/aop.events/576> rdfs:label "Increased, Viral susceptibility"@en .

<https://identifiers.org/aop.relationships/394> a sbdbel:CausalAssertion ;
  rdfs:label "KER 394"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/405> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/406> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/405> rdfs:label "irregularities, ovarian cycle"@en .
<https://identifiers.org/aop.events/406> rdfs:label "impaired, Fertility"@en .

<https://identifiers.org/aop.relationships/2292> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2292"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/406> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/360> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/406> rdfs:label "impaired, Fertility"@en .
<https://identifiers.org/aop.events/360> rdfs:label "Decrease, Population growth rate"@en .

<https://identifiers.org/aop.relationships/2387> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2387"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/406> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1696> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/406> rdfs:label "impaired, Fertility"@en .
<https://identifiers.org/aop.events/1696> rdfs:label "Decrease of egg production and cummulative fecundity"@en .

<https://identifiers.org/aop.relationships/402> a sbdbel:CausalAssertion ;
  rdfs:label "KER 402"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/409> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/373> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/409> rdfs:label "Metabolism of AFB1, Production of Reactive Electrophiles"@en .
<https://identifiers.org/aop.events/373> rdfs:label "Formation, Pro-mutagenic DNA Adducts"@en .

<https://identifiers.org/aop.relationships/439> a sbdbel:CausalAssertion ;
  rdfs:label "KER 439"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/413> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/446> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/413> rdfs:label "Reduction, Testosterone synthesis in Leydig cells"@en .
<https://identifiers.org/aop.events/446> rdfs:label "Reduction, testosterone level"@en .

<https://identifiers.org/aop.relationships/2125> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2125"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/413> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1690> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/413> rdfs:label "Reduction, Testosterone synthesis in Leydig cells"@en .
<https://identifiers.org/aop.events/1690> rdfs:label "reduction, testosterone levels "@en .

<https://identifiers.org/aop.relationships/461> a sbdbel:CausalAssertion ;
  rdfs:label "KER 461"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/414> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/416> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/414> rdfs:label "Increase, Luteinizing hormone (LH) "@en .
<https://identifiers.org/aop.events/416> rdfs:label "Increase proliferation, Leydig cell "@en .

<https://identifiers.org/aop.relationships/462> a sbdbel:CausalAssertion ;
  rdfs:label "KER 462"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/415> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/406> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/415> rdfs:label "Hyperplasia, Leydig cell"@en .
<https://identifiers.org/aop.events/406> rdfs:label "impaired, Fertility"@en .

<https://identifiers.org/aop.relationships/398> a sbdbel:CausalAssertion ;
  rdfs:label "KER 398"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/416> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/415> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/416> rdfs:label "Increase proliferation, Leydig cell "@en .
<https://identifiers.org/aop.events/415> rdfs:label "Hyperplasia, Leydig cell"@en .

<https://identifiers.org/aop.relationships/591> a sbdbel:CausalAssertion ;
  rdfs:label "KER 591"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/444> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/445> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/444> rdfs:label "Increased, Atrioventricular block and bradycardia"@en .
<https://identifiers.org/aop.events/445> rdfs:label "Respiratory distress/arrest"@en .

<https://identifiers.org/aop.relationships/433> a sbdbel:CausalAssertion ;
  rdfs:label "KER 433"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/445> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/351> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/445> rdfs:label "Respiratory distress/arrest"@en .
<https://identifiers.org/aop.events/351> rdfs:label "Increased Mortality"@en .

<https://identifiers.org/aop.relationships/592> a sbdbel:CausalAssertion ;
  rdfs:label "KER 592"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/445> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/590> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/445> rdfs:label "Respiratory distress/arrest"@en .
<https://identifiers.org/aop.events/590> rdfs:label "N/A, hypoxia"@en .

<https://identifiers.org/aop.relationships/608> a sbdbel:CausalAssertion ;
  rdfs:label "KER 608"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/446> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/348> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/446> rdfs:label "Reduction, testosterone level"@en .
<https://identifiers.org/aop.events/348> rdfs:label "Malformation, Male reproductive tract"@en .

<https://identifiers.org/aop.relationships/1649> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1649"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/446> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/520> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/446> rdfs:label "Reduction, testosterone level"@en .
<https://identifiers.org/aop.events/520> rdfs:label "Decreased sperm quantity or quality in the adult, Decreased fertility "@en .

<https://identifiers.org/aop.relationships/460> a sbdbel:CausalAssertion ;
  rdfs:label "KER 460"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/446> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/414> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/446> rdfs:label "Reduction, testosterone level"@en .
<https://identifiers.org/aop.events/414> rdfs:label "Increase, Luteinizing hormone (LH) "@en .

<https://identifiers.org/aop.relationships/438> a sbdbel:CausalAssertion ;
  rdfs:label "KER 438"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/447> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/413> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/447> rdfs:label "Reduction, Cholesterol transport in mitochondria"@en .
<https://identifiers.org/aop.events/413> rdfs:label "Reduction, Testosterone synthesis in Leydig cells"@en .

<https://identifiers.org/aop.relationships/471> a sbdbel:CausalAssertion ;
  rdfs:label "KER 471"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/450> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/455> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/450> rdfs:label "Suppression, VLDL secretion"@en .
<https://identifiers.org/aop.events/455> rdfs:label "Accumulation, Liver lipid"@en .

<https://identifiers.org/aop.relationships/475> a sbdbel:CausalAssertion ;
  rdfs:label "KER 475"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/451> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/327> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/451> rdfs:label "Inhibition, Mitochondrial fatty acid beta-oxidation"@en .
<https://identifiers.org/aop.events/327> rdfs:label "Accumulation, Fatty acid"@en .

<https://identifiers.org/aop.relationships/538> a sbdbel:CausalAssertion ;
  rdfs:label "KER 538"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/451> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/459> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/451> rdfs:label "Inhibition, Mitochondrial fatty acid beta-oxidation"@en .
<https://identifiers.org/aop.events/459> rdfs:label "Increased, Liver Steatosis"@en .

<https://identifiers.org/aop.relationships/486> a sbdbel:CausalAssertion ;
  rdfs:label "KER 486"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/454> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/459> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/454> rdfs:label "Increased, Triglyceride formation"@en .
<https://identifiers.org/aop.events/459> rdfs:label "Increased, Liver Steatosis"@en .

<https://identifiers.org/aop.relationships/476> a sbdbel:CausalAssertion ;
  rdfs:label "KER 476"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/456> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/167> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/456> rdfs:label "Suppression, Constitutive androstane receptor, NR1l3"@en .
<https://identifiers.org/aop.events/167> rdfs:label "Activation, LXR"@en .

<https://identifiers.org/aop.relationships/477> a sbdbel:CausalAssertion ;
  rdfs:label "KER 477"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/456> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/228> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/456> rdfs:label "Suppression, Constitutive androstane receptor, NR1l3"@en .
<https://identifiers.org/aop.events/228> rdfs:label "peroxisome proliferator activated receptor promoter demethylation"@en .

<https://identifiers.org/aop.relationships/1662> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1662"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/457> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/459> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/457> rdfs:label "Activation, SREBF1"@en .
<https://identifiers.org/aop.events/459> rdfs:label "Increased, Liver Steatosis"@en .

<https://identifiers.org/aop.relationships/489> a sbdbel:CausalAssertion ;
  rdfs:label "KER 489"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/457> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/462> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/457> rdfs:label "Activation, SREBF1"@en .
<https://identifiers.org/aop.events/462> rdfs:label "Up Regulation, SCD-1"@en .

<https://identifiers.org/aop.relationships/1607> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1607"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/458> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/459> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/458> rdfs:label "Increased, De Novo FA synthesis"@en .
<https://identifiers.org/aop.events/459> rdfs:label "Increased, Liver Steatosis"@en .

<https://identifiers.org/aop.relationships/512> a sbdbel:CausalAssertion ;
  rdfs:label "KER 512"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/458> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/327> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/458> rdfs:label "Increased, De Novo FA synthesis"@en .
<https://identifiers.org/aop.events/327> rdfs:label "Accumulation, Fatty acid"@en .

<https://identifiers.org/aop.relationships/1695> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1695"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/459> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1115> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/459> rdfs:label "Increased, Liver Steatosis"@en .
<https://identifiers.org/aop.events/1115> rdfs:label "Increased, Reactive oxygen species"@en .

<https://identifiers.org/aop.relationships/1657> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1657"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/462> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/291> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/462> rdfs:label "Up Regulation, SCD-1"@en .
<https://identifiers.org/aop.events/291> rdfs:label "Accumulation, Triglyceride"@en .

<https://identifiers.org/aop.relationships/493> a sbdbel:CausalAssertion ;
  rdfs:label "KER 493"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/462> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/454> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/462> rdfs:label "Up Regulation, SCD-1"@en .
<https://identifiers.org/aop.events/454> rdfs:label "Increased, Triglyceride formation"@en .

<https://identifiers.org/aop.relationships/492> a sbdbel:CausalAssertion ;
  rdfs:label "KER 492"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/463> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/458> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/463> rdfs:label "Up Regulation, FAS"@en .
<https://identifiers.org/aop.events/458> rdfs:label "Increased, De Novo FA synthesis"@en .

<https://identifiers.org/aop.relationships/1658> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1658"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/465> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/454> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/465> rdfs:label "Increased, FA Influx"@en .
<https://identifiers.org/aop.events/454> rdfs:label "Increased, Triglyceride formation"@en .

<https://identifiers.org/aop.relationships/505> a sbdbel:CausalAssertion ;
  rdfs:label "KER 505"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/465> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/327> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/465> rdfs:label "Increased, FA Influx"@en .
<https://identifiers.org/aop.events/327> rdfs:label "Accumulation, Fatty acid"@en .

<https://identifiers.org/aop.relationships/507> a sbdbel:CausalAssertion ;
  rdfs:label "KER 507"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/466> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/467> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/466> rdfs:label "Up Regulation, LDLR (low density lipoprotein receptor)"@en .
<https://identifiers.org/aop.events/467> rdfs:label "Increased, LDL uptake"@en .

<https://identifiers.org/aop.relationships/508> a sbdbel:CausalAssertion ;
  rdfs:label "KER 508"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/467> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/327> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/467> rdfs:label "Increased, LDL uptake"@en .
<https://identifiers.org/aop.events/327> rdfs:label "Accumulation, Fatty acid"@en .

<https://identifiers.org/aop.relationships/511> a sbdbel:CausalAssertion ;
  rdfs:label "KER 511"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/468> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/451> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/468> rdfs:label "Inhibition, PPAR alpha"@en .
<https://identifiers.org/aop.events/451> rdfs:label "Inhibition, Mitochondrial fatty acid beta-oxidation"@en .

<https://identifiers.org/aop.relationships/517> a sbdbel:CausalAssertion ;
  rdfs:label "KER 517"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/470> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/458> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/470> rdfs:label "Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)"@en .
<https://identifiers.org/aop.events/458> rdfs:label "Increased, De Novo FA synthesis"@en .

<https://identifiers.org/aop.relationships/519> a sbdbel:CausalAssertion ;
  rdfs:label "KER 519"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/471> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/472> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/471> rdfs:label "Inhibition, FoxA2"@en .
<https://identifiers.org/aop.events/472> rdfs:label "Down Regulation, CPT1A"@en .

<https://identifiers.org/aop.relationships/523> a sbdbel:CausalAssertion ;
  rdfs:label "KER 523"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/471> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/474> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/471> rdfs:label "Inhibition, FoxA2"@en .
<https://identifiers.org/aop.events/474> rdfs:label "Down Regulation, HMGCS2"@en .

<https://identifiers.org/aop.relationships/520> a sbdbel:CausalAssertion ;
  rdfs:label "KER 520"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/472> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/179> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/472> rdfs:label "Down Regulation, CPT1A"@en .
<https://identifiers.org/aop.events/179> rdfs:label "Decreased, Mitochondrial fatty acid beta-oxidation"@en .

<https://identifiers.org/aop.relationships/524> a sbdbel:CausalAssertion ;
  rdfs:label "KER 524"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/474> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/477> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/474> rdfs:label "Down Regulation, HMGCS2"@en .
<https://identifiers.org/aop.events/477> rdfs:label "Decreased, Ketogenesis"@en .

<https://identifiers.org/aop.relationships/1660> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1660"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/477> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/327> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/477> rdfs:label "Decreased, Ketogenesis"@en .
<https://identifiers.org/aop.events/327> rdfs:label "Accumulation, Fatty acid"@en .

<https://identifiers.org/aop.relationships/532> a sbdbel:CausalAssertion ;
  rdfs:label "KER 532"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/478> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/479> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/478> rdfs:label "Activation, NRF2"@en .
<https://identifiers.org/aop.events/479> rdfs:label "Activation, NR1H4"@en .

<https://identifiers.org/aop.relationships/533> a sbdbel:CausalAssertion ;
  rdfs:label "KER 533"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/479> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/480> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/479> rdfs:label "Activation, NR1H4"@en .
<https://identifiers.org/aop.events/480> rdfs:label "Activation, SHP"@en .

<https://identifiers.org/aop.relationships/534> a sbdbel:CausalAssertion ;
  rdfs:label "KER 534"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/479> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/227> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/479> rdfs:label "Activation, NR1H4"@en .
<https://identifiers.org/aop.events/227> rdfs:label "Activation, PPARα"@en .

<https://identifiers.org/aop.relationships/896> a sbdbel:CausalAssertion ;
  rdfs:label "KER 896"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/480> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/878> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/480> rdfs:label "Activation, SHP"@en .
<https://identifiers.org/aop.events/878> rdfs:label "Inhibition, SREBP1c"@en .

<https://identifiers.org/aop.relationships/537> a sbdbel:CausalAssertion ;
  rdfs:label "KER 537"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/482> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/451> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/482> rdfs:label "Decreased, DHB4/HSD17B4"@en .
<https://identifiers.org/aop.events/451> rdfs:label "Inhibition, Mitochondrial fatty acid beta-oxidation"@en .

<https://identifiers.org/aop.relationships/1606> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1606"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/483> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/458> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/483> rdfs:label "Activation, LXR alpha"@en .
<https://identifiers.org/aop.events/458> rdfs:label "Increased, De Novo FA synthesis"@en .

<https://identifiers.org/aop.relationships/1661> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1661"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/484> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/457> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/484> rdfs:label "Activation, AKT2"@en .
<https://identifiers.org/aop.events/457> rdfs:label "Activation, SREBF1"@en .

<https://identifiers.org/aop.relationships/541> a sbdbel:CausalAssertion ;
  rdfs:label "KER 541"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/486> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/484> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/486> rdfs:label "systemic inflammation leading to hepatic steatosis"@en .
<https://identifiers.org/aop.events/484> rdfs:label "Activation, AKT2"@en .

<https://identifiers.org/aop.relationships/687> a sbdbel:CausalAssertion ;
  rdfs:label "KER 687"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/488> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/675> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/488> rdfs:label "Decrease, Ovulation"@en .
<https://identifiers.org/aop.events/675> rdfs:label "Reduced, Reproductive Success"@en .

<https://identifiers.org/aop.relationships/59> a sbdbel:CausalAssertion ;
  rdfs:label "KER 59"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/49> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/106> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/49> rdfs:label "Reduction, Ca and HCO3 transport to shell gland"@en .
<https://identifiers.org/aop.events/106> rdfs:label "Reduction, Eggshell thickness"@en .

<https://identifiers.org/aop.relationships/550> a sbdbel:CausalAssertion ;
  rdfs:label "KER 550"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/491> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/378> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/491> rdfs:label "Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF)"@en .
<https://identifiers.org/aop.events/378> rdfs:label "Tumorigenesis, Hepatocellular carcinoma"@en .

<https://identifiers.org/aop.relationships/547> a sbdbel:CausalAssertion ;
  rdfs:label "KER 547"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/493> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/376> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/493> rdfs:label "Increased, Insufficient repair or mis-repair of pro-mutagenic DNA adducts"@en .
<https://identifiers.org/aop.events/376> rdfs:label "Increased, Induced Mutations in Critical Genes"@en .

<https://identifiers.org/aop.relationships/1645> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1645"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/494> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/496> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/494> rdfs:label "Glucocorticoid Receptor Agonist, Activation"@en .
<https://identifiers.org/aop.events/496> rdfs:label "Increased apoptosis, decreased number of adult Leydig Cells "@en .

<https://identifiers.org/aop.relationships/1646> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1646"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/494> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/495> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/494> rdfs:label "Glucocorticoid Receptor Agonist, Activation"@en .
<https://identifiers.org/aop.events/495> rdfs:label "Repressed expression of steroidogenic enzymes "@en .

<https://identifiers.org/aop.relationships/1648> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1648"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/495> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/413> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/495> rdfs:label "Repressed expression of steroidogenic enzymes "@en .
<https://identifiers.org/aop.events/413> rdfs:label "Reduction, Testosterone synthesis in Leydig cells"@en .

<https://identifiers.org/aop.relationships/1647> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1647"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/496> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/413> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/496> rdfs:label "Increased apoptosis, decreased number of adult Leydig Cells "@en .
<https://identifiers.org/aop.events/413> rdfs:label "Reduction, Testosterone synthesis in Leydig cells"@en .

<https://identifiers.org/aop.relationships/60> a sbdbel:CausalAssertion ;
  rdfs:label "KER 60"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/50> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/178> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/50> rdfs:label "Increase, Ca++ (intracellular)"@en .
<https://identifiers.org/aop.events/178> rdfs:label "Disruption, Mitochondrial electron transport chain"@en .

<https://identifiers.org/aop.relationships/347> a sbdbel:CausalAssertion ;
  rdfs:label "KER 347"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/52> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/381> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/52> rdfs:label "Decreased, Calcium influx"@en .
<https://identifiers.org/aop.events/381> rdfs:label "Reduced levels of BDNF"@en .

<https://identifiers.org/aop.relationships/1650> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1650"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/520> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/406> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/520> rdfs:label "Decreased sperm quantity or quality in the adult, Decreased fertility "@en .
<https://identifiers.org/aop.events/406> rdfs:label "impaired, Fertility"@en .

<https://identifiers.org/aop.relationships/1688> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1688"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/55> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/386> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/55> rdfs:label "Cell injury/death"@en .
<https://identifiers.org/aop.events/386> rdfs:label "Decrease of neuronal network function"@en .

<https://identifiers.org/aop.relationships/1718> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1718"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/55> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1492> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/55> rdfs:label "Cell injury/death"@en .
<https://identifiers.org/aop.events/1492> rdfs:label "Tissue resident cell activation"@en .

<https://identifiers.org/aop.relationships/1776> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1776"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/55> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1493> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/55> rdfs:label "Cell injury/death"@en .
<https://identifiers.org/aop.events/1493> rdfs:label "Increased Pro-inflammatory mediators"@en .

<https://identifiers.org/aop.relationships/355> a sbdbel:CausalAssertion ;
  rdfs:label "KER 355"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/55> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/385> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/55> rdfs:label "Cell injury/death"@en .
<https://identifiers.org/aop.events/385> rdfs:label "Decrease of synaptogenesis"@en .

<https://identifiers.org/aop.relationships/364> a sbdbel:CausalAssertion ;
  rdfs:label "KER 364"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/55> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/352> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/55> rdfs:label "Cell injury/death"@en .
<https://identifiers.org/aop.events/352> rdfs:label "N/A, Neurodegeneration"@en .

<https://identifiers.org/aop.relationships/365> a sbdbel:CausalAssertion ;
  rdfs:label "KER 365"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/55> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/188> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/55> rdfs:label "Cell injury/death"@en .
<https://identifiers.org/aop.events/188> rdfs:label "Neuroinflammation"@en .

<https://identifiers.org/aop.relationships/68> a sbdbel:CausalAssertion ;
  rdfs:label "KER 68"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/55> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/265> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/55> rdfs:label "Cell injury/death"@en .
<https://identifiers.org/aop.events/265> rdfs:label "Activation, Stellate cells"@en .

<https://identifiers.org/aop.relationships/1830> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1830"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/55> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1548> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/55> rdfs:label "Cell injury/death"@en .
<https://identifiers.org/aop.events/1548> rdfs:label "Necrotic Tissue"@en .

<https://identifiers.org/aop.relationships/1831> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1831"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/55> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1576> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/55> rdfs:label "Cell injury/death"@en .
<https://identifiers.org/aop.events/1576> rdfs:label "Activation, Tissue resident cells (Kuppfer cells)"@en .

<https://identifiers.org/aop.relationships/2767> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2767"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/55> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1521> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/55> rdfs:label "Cell injury/death"@en .
<https://identifiers.org/aop.events/1521> rdfs:label "Decrease, Growth"@en .

<https://identifiers.org/aop.relationships/658> a sbdbel:CausalAssertion ;
  rdfs:label "KER 658"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/559> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/663> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/559> rdfs:label "Activation, Nicotinic acetylcholine receptor"@en .
<https://identifiers.org/aop.events/663> rdfs:label "Desensitization, Nicotinic acetylcholine receptor"@en .

<https://identifiers.org/aop.relationships/1146> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1146"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/559> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/341> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/559> rdfs:label "Activation, Nicotinic acetylcholine receptor"@en .
<https://identifiers.org/aop.events/341> rdfs:label "Impairment, Learning and memory"@en .

<https://identifiers.org/aop.relationships/581> a sbdbel:CausalAssertion ;
  rdfs:label "KER 581"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/559> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/177> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/559> rdfs:label "Activation, Nicotinic acetylcholine receptor"@en .
<https://identifiers.org/aop.events/177> rdfs:label "N/A, Mitochondrial dysfunction 1"@en .

<https://identifiers.org/aop.relationships/1144> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1144"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/560> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1107> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/560> rdfs:label "Abnormal, Foraging activity and behavior"@en .
<https://identifiers.org/aop.events/1107> rdfs:label "Weakened, Colony"@en .

<https://identifiers.org/aop.relationships/1150> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1150"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/560> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1108> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/560> rdfs:label "Abnormal, Foraging activity and behavior"@en .
<https://identifiers.org/aop.events/1108> rdfs:label "Abnormal, Role change within caste"@en .

<https://identifiers.org/aop.relationships/569> a sbdbel:CausalAssertion ;
  rdfs:label "KER 569"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/560> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/572> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/560> rdfs:label "Abnormal, Foraging activity and behavior"@en .
<https://identifiers.org/aop.events/572> rdfs:label "Decrease, Number of worker bees"@en .

<https://identifiers.org/aop.relationships/562> a sbdbel:CausalAssertion ;
  rdfs:label "KER 562"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/561> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/566> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/561> rdfs:label "Reduced, Food storage"@en .
<https://identifiers.org/aop.events/566> rdfs:label "impaired, Larval development"@en .

<https://identifiers.org/aop.relationships/565> a sbdbel:CausalAssertion ;
  rdfs:label "KER 565"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/564> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/565> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/564> rdfs:label "Abnormal, Roll change within caste"@en .
<https://identifiers.org/aop.events/565> rdfs:label "Reduced, Brood care"@en .

<https://identifiers.org/aop.relationships/579> a sbdbel:CausalAssertion ;
  rdfs:label "KER 579"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/564> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/561> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/564> rdfs:label "Abnormal, Roll change within caste"@en .
<https://identifiers.org/aop.events/561> rdfs:label "Reduced, Food storage"@en .

<https://identifiers.org/aop.relationships/566> a sbdbel:CausalAssertion ;
  rdfs:label "KER 566"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/565> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/566> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/565> rdfs:label "Reduced, Brood care"@en .
<https://identifiers.org/aop.events/566> rdfs:label "impaired, Larval development"@en .

<https://identifiers.org/aop.relationships/563> a sbdbel:CausalAssertion ;
  rdfs:label "KER 563"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/566> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/563> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/566> rdfs:label "impaired, Larval development"@en .
<https://identifiers.org/aop.events/563> rdfs:label "Death/Failure, Colony"@en .

<https://identifiers.org/aop.relationships/1153> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1153"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/568> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1107> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/568> rdfs:label "impaired, Hive thermoregulation"@en .
<https://identifiers.org/aop.events/1107> rdfs:label "Weakened, Colony"@en .

<https://identifiers.org/aop.relationships/574> a sbdbel:CausalAssertion ;
  rdfs:label "KER 574"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/568> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/563> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/568> rdfs:label "impaired, Hive thermoregulation"@en .
<https://identifiers.org/aop.events/563> rdfs:label "Death/Failure, Colony"@en .

<https://identifiers.org/aop.relationships/69> a sbdbel:CausalAssertion ;
  rdfs:label "KER 69"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/57> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/142> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/57> rdfs:label "Proliferation, Cell proliferation in the absence of cytotoxicity"@en .
<https://identifiers.org/aop.events/142> rdfs:label "Hyperplasia, Hyperplasia"@en .

<https://identifiers.org/aop.relationships/662> a sbdbel:CausalAssertion ;
  rdfs:label "KER 662"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/570> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/571> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/570> rdfs:label "Accumulation, Damaged mitochondrial DNA"@en .
<https://identifiers.org/aop.events/571> rdfs:label "Accelerated, Aging"@en .

<https://identifiers.org/aop.relationships/663> a sbdbel:CausalAssertion ;
  rdfs:label "KER 663"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/571> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/572> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/571> rdfs:label "Accelerated, Aging"@en .
<https://identifiers.org/aop.events/572> rdfs:label "Decrease, Number of worker bees"@en .

<https://identifiers.org/aop.relationships/559> a sbdbel:CausalAssertion ;
  rdfs:label "KER 559"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/572> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/563> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/572> rdfs:label "Decrease, Number of worker bees"@en .
<https://identifiers.org/aop.events/563> rdfs:label "Death/Failure, Colony"@en .

<https://identifiers.org/aop.relationships/573> a sbdbel:CausalAssertion ;
  rdfs:label "KER 573"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/572> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/568> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/572> rdfs:label "Decrease, Number of worker bees"@en .
<https://identifiers.org/aop.events/568> rdfs:label "impaired, Hive thermoregulation"@en .

<https://identifiers.org/aop.relationships/567> a sbdbel:CausalAssertion ;
  rdfs:label "KER 567"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/573> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/574> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/573> rdfs:label "Increase, Energetic demands and therefore metabolic stress"@en .
<https://identifiers.org/aop.events/574> rdfs:label "Increased, Appetite and hunger"@en .

<https://identifiers.org/aop.relationships/568> a sbdbel:CausalAssertion ;
  rdfs:label "KER 568"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/574> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/560> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/574> rdfs:label "Increased, Appetite and hunger"@en .
<https://identifiers.org/aop.events/560> rdfs:label "Abnormal, Foraging activity and behavior"@en .

<https://identifiers.org/aop.relationships/571> a sbdbel:CausalAssertion ;
  rdfs:label "KER 571"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/576> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/577> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/576> rdfs:label "Increased, Viral susceptibility"@en .
<https://identifiers.org/aop.events/577> rdfs:label "impaired, Development"@en .

<https://identifiers.org/aop.relationships/575> a sbdbel:CausalAssertion ;
  rdfs:label "KER 575"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/576> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/560> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/576> rdfs:label "Increased, Viral susceptibility"@en .
<https://identifiers.org/aop.events/560> rdfs:label "Abnormal, Foraging activity and behavior"@en .

<https://identifiers.org/aop.relationships/572> a sbdbel:CausalAssertion ;
  rdfs:label "KER 572"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/577> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/572> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/577> rdfs:label "impaired, Development"@en .
<https://identifiers.org/aop.events/572> rdfs:label "Decrease, Number of worker bees"@en .

<https://identifiers.org/aop.relationships/576> a sbdbel:CausalAssertion ;
  rdfs:label "KER 576"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/578> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/579> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/578> rdfs:label "Decreased, Glucose oxidase enzyme activity"@en .
<https://identifiers.org/aop.events/579> rdfs:label "Decreased, Hydrogen peroxide production"@en .

<https://identifiers.org/aop.relationships/577> a sbdbel:CausalAssertion ;
  rdfs:label "KER 577"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/579> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/580> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/579> rdfs:label "Decreased, Hydrogen peroxide production"@en .
<https://identifiers.org/aop.events/580> rdfs:label "Reduced, Antiseptic incorporated in food"@en .

<https://identifiers.org/aop.relationships/578> a sbdbel:CausalAssertion ;
  rdfs:label "KER 578"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/580> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/564> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/580> rdfs:label "Reduced, Antiseptic incorporated in food"@en .
<https://identifiers.org/aop.events/564> rdfs:label "Abnormal, Roll change within caste"@en .

<https://identifiers.org/aop.relationships/586> a sbdbel:CausalAssertion ;
  rdfs:label "KER 586"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/585> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/586> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/585> rdfs:label "Decreased, Sodium conductance 1"@en .
<https://identifiers.org/aop.events/586> rdfs:label "Reduced, swimming speed"@en .

<https://identifiers.org/aop.relationships/594> a sbdbel:CausalAssertion ;
  rdfs:label "KER 594"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/585> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/444> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/585> rdfs:label "Decreased, Sodium conductance 1"@en .
<https://identifiers.org/aop.events/444> rdfs:label "Increased, Atrioventricular block and bradycardia"@en .

<https://identifiers.org/aop.relationships/587> a sbdbel:CausalAssertion ;
  rdfs:label "KER 587"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/586> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/587> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/586> rdfs:label "Reduced, swimming speed"@en .
<https://identifiers.org/aop.events/587> rdfs:label "Reduced, feeding 1"@en .

<https://identifiers.org/aop.relationships/588> a sbdbel:CausalAssertion ;
  rdfs:label "KER 588"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/586> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/588> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/586> rdfs:label "Reduced, swimming speed"@en .
<https://identifiers.org/aop.events/588> rdfs:label "Increased, predation"@en .

<https://identifiers.org/aop.relationships/589> a sbdbel:CausalAssertion ;
  rdfs:label "KER 589"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/587> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/588> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/587> rdfs:label "Reduced, feeding 1"@en .
<https://identifiers.org/aop.events/588> rdfs:label "Increased, predation"@en .

<https://identifiers.org/aop.relationships/596> a sbdbel:CausalAssertion ;
  rdfs:label "KER 596"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/587> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/592> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/587> rdfs:label "Reduced, feeding 1"@en .
<https://identifiers.org/aop.events/592> rdfs:label "Reduced, survival"@en .

<https://identifiers.org/aop.relationships/595> a sbdbel:CausalAssertion ;
  rdfs:label "KER 595"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/588> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/592> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/588> rdfs:label "Increased, predation"@en .
<https://identifiers.org/aop.events/592> rdfs:label "Reduced, survival"@en .

<https://identifiers.org/aop.relationships/654> a sbdbel:CausalAssertion ;
  rdfs:label "KER 654"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/588> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/636> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/588> rdfs:label "Increased, predation"@en .
<https://identifiers.org/aop.events/636> rdfs:label "Decreased, survival"@en .

<https://identifiers.org/aop.relationships/593> a sbdbel:CausalAssertion ;
  rdfs:label "KER 593"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/590> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/591> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/590> rdfs:label "N/A, hypoxia"@en .
<https://identifiers.org/aop.events/591> rdfs:label "Increased, amputations"@en .

<https://identifiers.org/aop.relationships/597> a sbdbel:CausalAssertion ;
  rdfs:label "KER 597"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/593> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/585> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/593> rdfs:label "Inhibition, Ether-a-go-go (ERG) voltage-gated potassium channel "@en .
<https://identifiers.org/aop.events/585> rdfs:label "Decreased, Sodium conductance 1"@en .

<https://identifiers.org/aop.relationships/603> a sbdbel:CausalAssertion ;
  rdfs:label "KER 603"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/598> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/599> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/598> rdfs:label "modulation, sodium channel"@en .
<https://identifiers.org/aop.events/599> rdfs:label "prolonged, Depolarization of neuronal membrane"@en .

<https://identifiers.org/aop.relationships/604> a sbdbel:CausalAssertion ;
  rdfs:label "KER 604"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/599> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/600> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/599> rdfs:label "prolonged, Depolarization of neuronal membrane"@en .
<https://identifiers.org/aop.events/600> rdfs:label "Overactivation, Neuronotransmitter release"@en .

<https://identifiers.org/aop.relationships/605> a sbdbel:CausalAssertion ;
  rdfs:label "KER 605"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/600> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/601> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/600> rdfs:label "Overactivation, Neuronotransmitter release"@en .
<https://identifiers.org/aop.events/601> rdfs:label "Overactivation, muscle contraction"@en .

<https://identifiers.org/aop.relationships/606> a sbdbel:CausalAssertion ;
  rdfs:label "KER 606"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/601> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/602> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/601> rdfs:label "Overactivation, muscle contraction"@en .
<https://identifiers.org/aop.events/602> rdfs:label "Increased, Ataxia, paralysis, or hyperactivity"@en .

<https://identifiers.org/aop.relationships/607> a sbdbel:CausalAssertion ;
  rdfs:label "KER 607"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/602> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/351> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/602> rdfs:label "Increased, Ataxia, paralysis, or hyperactivity"@en .
<https://identifiers.org/aop.events/351> rdfs:label "Increased Mortality"@en .

<https://identifiers.org/aop.relationships/630> a sbdbel:CausalAssertion ;
  rdfs:label "KER 630"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/616> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/613> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/616> rdfs:label "Occurrence, A paroxysmal depolarizing shift"@en .
<https://identifiers.org/aop.events/613> rdfs:label "Occurrence, Epileptic seizure"@en .

<https://identifiers.org/aop.relationships/634> a sbdbel:CausalAssertion ;
  rdfs:label "KER 634"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/618> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/341> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/618> rdfs:label "Decreased, Neuronal network function in adult brain"@en .
<https://identifiers.org/aop.events/341> rdfs:label "Impairment, Learning and memory"@en .

<https://identifiers.org/aop.relationships/2656> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2656"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/618> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1583> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/618> rdfs:label "Decreased, Neuronal network function in adult brain"@en .
<https://identifiers.org/aop.events/1583> rdfs:label "Sensory axonal peripheral neuropathy"@en .

<https://identifiers.org/aop.relationships/1321> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1321"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/621> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1255> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/621> rdfs:label "Increase, cilia movement"@en .
<https://identifiers.org/aop.events/1255> rdfs:label "induced spawning"@en .

<https://identifiers.org/aop.relationships/1335> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1335"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/621> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1257> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/621> rdfs:label "Increase, cilia movement"@en .
<https://identifiers.org/aop.events/1257> rdfs:label "Induced parturition"@en .

<https://identifiers.org/aop.relationships/1177> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1177"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/622> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1143> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/622> rdfs:label "Increased, locomotion"@en .
<https://identifiers.org/aop.events/1143> rdfs:label "Depletion, energy reserves"@en .

<https://identifiers.org/aop.relationships/638> a sbdbel:CausalAssertion ;
  rdfs:label "KER 638"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/622> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/623> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/622> rdfs:label "Increased, locomotion"@en .
<https://identifiers.org/aop.events/623> rdfs:label "Increase, predation"@en .

<https://identifiers.org/aop.relationships/2634> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2634"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/623> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/360> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/623> rdfs:label "Increase, predation"@en .
<https://identifiers.org/aop.events/360> rdfs:label "Decrease, Population growth rate"@en .

<https://identifiers.org/aop.relationships/1176> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1176"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/624> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1143> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/624> rdfs:label "Increased, foot detachment"@en .
<https://identifiers.org/aop.events/1143> rdfs:label "Depletion, energy reserves"@en .

<https://identifiers.org/aop.relationships/641> a sbdbel:CausalAssertion ;
  rdfs:label "KER 641"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/625> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/622> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/625> rdfs:label "Increased, muscular waves in foot"@en .
<https://identifiers.org/aop.events/622> rdfs:label "Increased, locomotion"@en .

<https://identifiers.org/aop.relationships/642> a sbdbel:CausalAssertion ;
  rdfs:label "KER 642"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/625> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/624> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/625> rdfs:label "Increased, muscular waves in foot"@en .
<https://identifiers.org/aop.events/624> rdfs:label "Increased, foot detachment"@en .

<https://identifiers.org/aop.relationships/1212> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1212"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/626> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1161> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/626> rdfs:label "Increased, serotonin (5-HT) "@en .
<https://identifiers.org/aop.events/1161> rdfs:label "Increased, oocyte maturation"@en .

<https://identifiers.org/aop.relationships/1327> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1327"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/626> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1142> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/626> rdfs:label "Increased, serotonin (5-HT) "@en .
<https://identifiers.org/aop.events/1142> rdfs:label "Increased, valve movement"@en .

<https://identifiers.org/aop.relationships/1332> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1332"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/626> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/625> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/626> rdfs:label "Increased, serotonin (5-HT) "@en .
<https://identifiers.org/aop.events/625> rdfs:label "Increased, muscular waves in foot"@en .

<https://identifiers.org/aop.relationships/1333> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1333"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/626> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/621> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/626> rdfs:label "Increased, serotonin (5-HT) "@en .
<https://identifiers.org/aop.events/621> rdfs:label "Increase, cilia movement"@en .

<https://identifiers.org/aop.relationships/1336> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1336"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/626> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1256> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/626> rdfs:label "Increased, serotonin (5-HT) "@en .
<https://identifiers.org/aop.events/1256> rdfs:label "increased mantel display"@en .

<https://identifiers.org/aop.relationships/644> a sbdbel:CausalAssertion ;
  rdfs:label "KER 644"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/626> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/627> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/626> rdfs:label "Increased, serotonin (5-HT) "@en .
<https://identifiers.org/aop.events/627> rdfs:label "Decreased, anxiety"@en .

<https://identifiers.org/aop.relationships/645> a sbdbel:CausalAssertion ;
  rdfs:label "KER 645"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/627> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/629> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/627> rdfs:label "Decreased, anxiety"@en .
<https://identifiers.org/aop.events/629> rdfs:label "Decreased, sheltering"@en .

<https://identifiers.org/aop.relationships/646> a sbdbel:CausalAssertion ;
  rdfs:label "KER 646"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/629> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/588> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/629> rdfs:label "Decreased, sheltering"@en .
<https://identifiers.org/aop.events/588> rdfs:label "Increased, predation"@en .

<https://identifiers.org/aop.relationships/1643> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1643"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/633> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/341> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/633> rdfs:label "Decrease, histaminergic neuron excitation"@en .
<https://identifiers.org/aop.events/341> rdfs:label "Impairment, Learning and memory"@en .

<https://identifiers.org/aop.relationships/649> a sbdbel:CausalAssertion ;
  rdfs:label "KER 649"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/633> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/634> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/633> rdfs:label "Decrease, histaminergic neuron excitation"@en .
<https://identifiers.org/aop.events/634> rdfs:label "N/A, sedation"@en .

<https://identifiers.org/aop.relationships/650> a sbdbel:CausalAssertion ;
  rdfs:label "KER 650"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/634> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/635> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/634> rdfs:label "N/A, sedation"@en .
<https://identifiers.org/aop.events/635> rdfs:label "Decreased, locomotion"@en .

<https://identifiers.org/aop.relationships/651> a sbdbel:CausalAssertion ;
  rdfs:label "KER 651"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/635> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/588> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/635> rdfs:label "Decreased, locomotion"@en .
<https://identifiers.org/aop.events/588> rdfs:label "Increased, predation"@en .

<https://identifiers.org/aop.relationships/1061> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1061"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/638> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/633> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/638> rdfs:label "Antagonism, Histamine Receptor (H2)"@en .
<https://identifiers.org/aop.events/633> rdfs:label "Decrease, histaminergic neuron excitation"@en .

<https://identifiers.org/aop.relationships/667> a sbdbel:CausalAssertion ;
  rdfs:label "KER 667"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/64> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/669> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/64> rdfs:label "Reduction, Ionotropic GABA receptor chloride channel conductance"@en .
<https://identifiers.org/aop.events/669> rdfs:label "Reduction, Neuronal synaptic inhibition"@en .

<https://identifiers.org/aop.relationships/661> a sbdbel:CausalAssertion ;
  rdfs:label "KER 661"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/664> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/570> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/664> rdfs:label "Overwhelmed, Mitochondrial DNA repair mechanisms"@en .
<https://identifiers.org/aop.events/570> rdfs:label "Accumulation, Damaged mitochondrial DNA"@en .

<https://identifiers.org/aop.relationships/666> a sbdbel:CausalAssertion ;
  rdfs:label "KER 666"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/667> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/64> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/667> rdfs:label "Binding at picrotoxin site, iGABAR chloride channel"@en .
<https://identifiers.org/aop.events/64> rdfs:label "Reduction, Ionotropic GABA receptor chloride channel conductance"@en .

<https://identifiers.org/aop.relationships/672> a sbdbel:CausalAssertion ;
  rdfs:label "KER 672"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/671> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/673> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/671> rdfs:label "Reduced, Prostaglandin F2alpha concentration, plasma "@en .
<https://identifiers.org/aop.events/673> rdfs:label "Reduced, Spawning behavior"@en .

<https://identifiers.org/aop.relationships/678> a sbdbel:CausalAssertion ;
  rdfs:label "KER 678"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/671> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/678> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/671> rdfs:label "Reduced, Prostaglandin F2alpha concentration, plasma "@en .
<https://identifiers.org/aop.events/678> rdfs:label "Reduced, Pheromone release"@en .

<https://identifiers.org/aop.relationships/671> a sbdbel:CausalAssertion ;
  rdfs:label "KER 671"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/672> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/671> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/672> rdfs:label "Reduced, Prostaglandin F2alpha synthesis, ovary  "@en .
<https://identifiers.org/aop.events/671> rdfs:label "Reduced, Prostaglandin F2alpha concentration, plasma "@en .

<https://identifiers.org/aop.relationships/673> a sbdbel:CausalAssertion ;
  rdfs:label "KER 673"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/673> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/674> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/673> rdfs:label "Reduced, Spawning behavior"@en .
<https://identifiers.org/aop.events/674> rdfs:label "Reduced, Ability to attract spawning mates"@en .

<https://identifiers.org/aop.relationships/674> a sbdbel:CausalAssertion ;
  rdfs:label "KER 674"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/674> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/675> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/674> rdfs:label "Reduced, Ability to attract spawning mates"@en .
<https://identifiers.org/aop.events/675> rdfs:label "Reduced, Reproductive Success"@en .

<https://identifiers.org/aop.relationships/675> a sbdbel:CausalAssertion ;
  rdfs:label "KER 675"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/675> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/360> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/675> rdfs:label "Reduced, Reproductive Success"@en .
<https://identifiers.org/aop.events/360> rdfs:label "Decrease, Population growth rate"@en .

<https://identifiers.org/aop.relationships/679> a sbdbel:CausalAssertion ;
  rdfs:label "KER 679"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/678> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/674> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/678> rdfs:label "Reduced, Pheromone release"@en .
<https://identifiers.org/aop.events/674> rdfs:label "Reduced, Ability to attract spawning mates"@en .

<https://identifiers.org/aop.relationships/82> a sbdbel:CausalAssertion ;
  rdfs:label "KER 82"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/68> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/344> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/68> rdfs:label "Accumulation, Collagen"@en .
<https://identifiers.org/aop.events/344> rdfs:label "N/A, Liver fibrosis"@en .

<https://identifiers.org/aop.relationships/1629> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1629"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/68> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1458> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/68> rdfs:label "Accumulation, Collagen"@en .
<https://identifiers.org/aop.events/1458> rdfs:label "Pulmonary fibrosis"@en .

<https://identifiers.org/aop.relationships/2139> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2139"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/68> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1276> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/68> rdfs:label "Accumulation, Collagen"@en .
<https://identifiers.org/aop.events/1276> rdfs:label "Lung fibrosis"@en .

<https://identifiers.org/aop.relationships/682> a sbdbel:CausalAssertion ;
  rdfs:label "KER 682"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/681> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/671> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/681> rdfs:label "Decreased, Prostaglandin F2alpha synthesis, ovary  "@en .
<https://identifiers.org/aop.events/671> rdfs:label "Reduced, Prostaglandin F2alpha concentration, plasma "@en .

<https://identifiers.org/aop.relationships/684> a sbdbel:CausalAssertion ;
  rdfs:label "KER 684"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/682> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/616> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/682> rdfs:label "Generation, Amplified excitatory postsynaptic potential (EPSP)"@en .
<https://identifiers.org/aop.events/616> rdfs:label "Occurrence, A paroxysmal depolarizing shift"@en .

<https://identifiers.org/aop.relationships/685> a sbdbel:CausalAssertion ;
  rdfs:label "KER 685"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/685> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/488> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/685> rdfs:label "Reduced, Prostaglandins, ovary"@en .
<https://identifiers.org/aop.events/488> rdfs:label "Decrease, Ovulation"@en .

<https://identifiers.org/aop.relationships/690> a sbdbel:CausalAssertion ;
  rdfs:label "KER 690"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/687> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/689> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/687> rdfs:label "Reduced, Prostaglandin E2 concentration, hypothalamus"@en .
<https://identifiers.org/aop.events/689> rdfs:label "Reduced, Gonadotropin releasing hormone, hypothalamus"@en .

<https://identifiers.org/aop.relationships/691> a sbdbel:CausalAssertion ;
  rdfs:label "KER 691"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/689> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/690> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/689> rdfs:label "Reduced, Gonadotropin releasing hormone, hypothalamus"@en .
<https://identifiers.org/aop.events/690> rdfs:label "Reduced, Luteinizing hormone (LH), plasma "@en .

<https://identifiers.org/aop.relationships/692> a sbdbel:CausalAssertion ;
  rdfs:label "KER 692"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/690> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/691> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/690> rdfs:label "Reduced, Luteinizing hormone (LH), plasma "@en .
<https://identifiers.org/aop.events/691> rdfs:label "Reduced, Maturation inducing steroid, plasma"@en .

<https://identifiers.org/aop.relationships/693> a sbdbel:CausalAssertion ;
  rdfs:label "KER 693"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/691> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/692> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/691> rdfs:label "Reduced, Maturation inducing steroid, plasma"@en .
<https://identifiers.org/aop.events/692> rdfs:label "Reduced, Maturation inducing steroid receptor signalling, oocyte"@en .

<https://identifiers.org/aop.relationships/694> a sbdbel:CausalAssertion ;
  rdfs:label "KER 694"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/692> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/693> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/692> rdfs:label "Reduced, Maturation inducing steroid receptor signalling, oocyte"@en .
<https://identifiers.org/aop.events/693> rdfs:label "Increased, cyclic adenosine monophosphate"@en .

<https://identifiers.org/aop.relationships/698> a sbdbel:CausalAssertion ;
  rdfs:label "KER 698"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/692> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/695> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/692> rdfs:label "Reduced, Maturation inducing steroid receptor signalling, oocyte"@en .
<https://identifiers.org/aop.events/695> rdfs:label "Upregulated, Spindle assembly checkpoint protein Mad2-oocyte"@en .

<https://identifiers.org/aop.relationships/696> a sbdbel:CausalAssertion ;
  rdfs:label "KER 696"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/693> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/694> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/693> rdfs:label "Increased, cyclic adenosine monophosphate"@en .
<https://identifiers.org/aop.events/694> rdfs:label "Reduced, Meiotic prophase I/metaphase I transition, oocyte"@en .

<https://identifiers.org/aop.relationships/697> a sbdbel:CausalAssertion ;
  rdfs:label "KER 697"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/694> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/675> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/694> rdfs:label "Reduced, Meiotic prophase I/metaphase I transition, oocyte"@en .
<https://identifiers.org/aop.events/675> rdfs:label "Reduced, Reproductive Success"@en .

<https://identifiers.org/aop.relationships/699> a sbdbel:CausalAssertion ;
  rdfs:label "KER 699"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/695> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/696> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/695> rdfs:label "Upregulated, Spindle assembly checkpoint protein Mad2-oocyte"@en .
<https://identifiers.org/aop.events/696> rdfs:label "Increased, Chromosome misseggregation"@en .

<https://identifiers.org/aop.relationships/700> a sbdbel:CausalAssertion ;
  rdfs:label "KER 700"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/696> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/675> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/696> rdfs:label "Increased, Chromosome misseggregation"@en .
<https://identifiers.org/aop.events/675> rdfs:label "Reduced, Reproductive Success"@en .

<https://identifiers.org/aop.relationships/701> a sbdbel:CausalAssertion ;
  rdfs:label "KER 701"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/697> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/698> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/697> rdfs:label "impaired, ion channels"@en .
<https://identifiers.org/aop.events/698> rdfs:label "Altered, Action Potential"@en .

<https://identifiers.org/aop.relationships/702> a sbdbel:CausalAssertion ;
  rdfs:label "KER 702"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/698> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/699> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/698> rdfs:label "Altered, Action Potential"@en .
<https://identifiers.org/aop.events/699> rdfs:label "Increased, cardiac arrthymia"@en .

<https://identifiers.org/aop.relationships/703> a sbdbel:CausalAssertion ;
  rdfs:label "KER 703"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/699> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/351> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/699> rdfs:label "Increased, cardiac arrthymia"@en .
<https://identifiers.org/aop.events/351> rdfs:label "Increased Mortality"@en .

<https://identifiers.org/aop.relationships/707> a sbdbel:CausalAssertion ;
  rdfs:label "KER 707"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/708> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/709> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/708> rdfs:label "Increased, Accumulation of alpha2u microglobulin (proximal tubular epithelium)"@en .
<https://identifiers.org/aop.events/709> rdfs:label "Increase, Cytotoxicity (renal tubular cell)"@en .

<https://identifiers.org/aop.relationships/1676> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1676"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/709> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/814> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/709> rdfs:label "Increase, Cytotoxicity (renal tubular cell)"@en .
<https://identifiers.org/aop.events/814> rdfs:label "Occurrence, Kidney toxicity"@en .

<https://identifiers.org/aop.relationships/708> a sbdbel:CausalAssertion ;
  rdfs:label "KER 708"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/709> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/710> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/709> rdfs:label "Increase, Cytotoxicity (renal tubular cell)"@en .
<https://identifiers.org/aop.events/710> rdfs:label "Increase, Regenerative cell proliferation (tubular epithelial cells)"@en .

<https://identifiers.org/aop.relationships/760> a sbdbel:CausalAssertion ;
  rdfs:label "KER 760"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/710> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/767> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/710> rdfs:label "Increase, Regenerative cell proliferation (tubular epithelial cells)"@en .
<https://identifiers.org/aop.events/767> rdfs:label "Increase, Hyperplasia (renal tubular cells)"@en .

<https://identifiers.org/aop.relationships/785> a sbdbel:CausalAssertion ;
  rdfs:label "KER 785"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/710> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/784> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/710> rdfs:label "Increase, Regenerative cell proliferation (tubular epithelial cells)"@en .
<https://identifiers.org/aop.events/784> rdfs:label "Increase, Hyperplasia (tubular epithelial cells)"@en .

<https://identifiers.org/aop.relationships/706> a sbdbel:CausalAssertion ;
  rdfs:label "KER 706"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/714> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/708> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/714> rdfs:label "Increased, Binding of chemicals to 2u (serum)"@en .
<https://identifiers.org/aop.events/708> rdfs:label "Increased, Accumulation of alpha2u microglobulin (proximal tubular epithelium)"@en .

<https://identifiers.org/aop.relationships/714> a sbdbel:CausalAssertion ;
  rdfs:label "KER 714"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/718> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/720> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/718> rdfs:label "Binding, Tubulin"@en .
<https://identifiers.org/aop.events/720> rdfs:label "Disruption, Microtubule dynamics"@en .

<https://identifiers.org/aop.relationships/724> a sbdbel:CausalAssertion ;
  rdfs:label "KER 724"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/718> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/723> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/718> rdfs:label "Binding, Tubulin"@en .
<https://identifiers.org/aop.events/723> rdfs:label "Altered, Chromosome number"@en .

<https://identifiers.org/aop.relationships/715> a sbdbel:CausalAssertion ;
  rdfs:label "KER 715"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/720> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/721> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/720> rdfs:label "Disruption, Microtubule dynamics"@en .
<https://identifiers.org/aop.events/721> rdfs:label "Disorganization, Meiotic Spindle"@en .

<https://identifiers.org/aop.relationships/737> a sbdbel:CausalAssertion ;
  rdfs:label "KER 737"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/721> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/752> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/721> rdfs:label "Disorganization, Meiotic Spindle"@en .
<https://identifiers.org/aop.events/752> rdfs:label "Altered, Meiotic chromosome dynamics"@en .

<https://identifiers.org/aop.relationships/723> a sbdbel:CausalAssertion ;
  rdfs:label "KER 723"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/723> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/728> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/723> rdfs:label "Altered, Chromosome number"@en .
<https://identifiers.org/aop.events/728> rdfs:label "Increase, Aneuploid offspring"@en .

<https://identifiers.org/aop.relationships/716> a sbdbel:CausalAssertion ;
  rdfs:label "KER 716"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/724> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/726> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/724> rdfs:label "Inhibition, Pyruvate dehydrogenase kinase (PDK) enzyme"@en .
<https://identifiers.org/aop.events/726> rdfs:label "Increased, Induction of pyruvate dehydrogenase (PDH)"@en .

<https://identifiers.org/aop.relationships/762> a sbdbel:CausalAssertion ;
  rdfs:label "KER 762"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/726> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/769> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/726> rdfs:label "Increased, Induction of pyruvate dehydrogenase (PDH)"@en .
<https://identifiers.org/aop.events/769> rdfs:label "Increase, Oxidative metabolism"@en .

<https://identifiers.org/aop.relationships/726> a sbdbel:CausalAssertion ;
  rdfs:label "KER 726"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/733> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/734> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/733> rdfs:label "Increase, Necrosis (terminal bronchiolar cells)"@en .
<https://identifiers.org/aop.events/734> rdfs:label "Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells)"@en .

<https://identifiers.org/aop.relationships/727> a sbdbel:CausalAssertion ;
  rdfs:label "KER 727"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/734> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/735> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/734> rdfs:label "Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells)"@en .
<https://identifiers.org/aop.events/735> rdfs:label "Increase, Hyperplasia (terminal bronchiolar cells)"@en .

<https://identifiers.org/aop.relationships/728> a sbdbel:CausalAssertion ;
  rdfs:label "KER 728"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/735> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/736> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/735> rdfs:label "Increase, Hyperplasia (terminal bronchiolar cells)"@en .
<https://identifiers.org/aop.events/736> rdfs:label "Increase, Adenomas/carcinomas (bronchioloalveolar)"@en .

<https://identifiers.org/aop.relationships/742> a sbdbel:CausalAssertion ;
  rdfs:label "KER 742"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/739> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/740> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/739> rdfs:label "Increase, Hypertrophy and proliferation (follicular cell)"@en .
<https://identifiers.org/aop.events/740> rdfs:label "Increase, Hyperplasia (follicular cells)"@en .

<https://identifiers.org/aop.relationships/743> a sbdbel:CausalAssertion ;
  rdfs:label "KER 743"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/740> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/741> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/740> rdfs:label "Increase, Hyperplasia (follicular cells)"@en .
<https://identifiers.org/aop.events/741> rdfs:label "Increase, Adenomas/carcinomas (follicular cell)"@en .

<https://identifiers.org/aop.relationships/729> a sbdbel:CausalAssertion ;
  rdfs:label "KER 729"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/742> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/743> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/742> rdfs:label "Decreased, Androgen receptor activity"@en .
<https://identifiers.org/aop.events/743> rdfs:label "Decreased, Testosterone binding to androgen receptor (hypothalamus)"@en .

<https://identifiers.org/aop.relationships/744> a sbdbel:CausalAssertion ;
  rdfs:label "KER 744"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/743> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/754> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/743> rdfs:label "Decreased, Testosterone binding to androgen receptor (hypothalamus)"@en .
<https://identifiers.org/aop.events/754> rdfs:label "Increased, Luteinizing hormone (LH) "@en .

<https://identifiers.org/aop.relationships/731> a sbdbel:CausalAssertion ;
  rdfs:label "KER 731"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/744> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/745> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/744> rdfs:label "Increase, Hyperplasia (Leydig cells)"@en .
<https://identifiers.org/aop.events/745> rdfs:label "Increase, Leydig cell tumors"@en .

<https://identifiers.org/aop.relationships/732> a sbdbel:CausalAssertion ;
  rdfs:label "KER 732"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/746> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/747> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/746> rdfs:label "Increase, Dopaminergic activity"@en .
<https://identifiers.org/aop.events/747> rdfs:label "Decreased, Prolactin"@en .

<https://identifiers.org/aop.relationships/733> a sbdbel:CausalAssertion ;
  rdfs:label "KER 733"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/747> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/748> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/747> rdfs:label "Decreased, Prolactin"@en .
<https://identifiers.org/aop.events/748> rdfs:label "Increased, Estrogen receptor (ER) activity"@en .

<https://identifiers.org/aop.relationships/734> a sbdbel:CausalAssertion ;
  rdfs:label "KER 734"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/748> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/749> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/748> rdfs:label "Increased, Estrogen receptor (ER) activity"@en .
<https://identifiers.org/aop.events/749> rdfs:label "Decreased, Progesterone from corpus luteum"@en .

<https://identifiers.org/aop.relationships/2737> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2737"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/748> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2046> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/748> rdfs:label "Increased, Estrogen receptor (ER) activity"@en .
<https://identifiers.org/aop.events/2046> rdfs:label "Increase, Vitellogenin mRNA"@en .

<https://identifiers.org/aop.relationships/772> a sbdbel:CausalAssertion ;
  rdfs:label "KER 772"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/749> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/772> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/749> rdfs:label "Decreased, Progesterone from corpus luteum"@en .
<https://identifiers.org/aop.events/772> rdfs:label "Increase, Hyperplasia (glandular epithelial cells of endometrium)"@en .

<https://identifiers.org/aop.relationships/745> a sbdbel:CausalAssertion ;
  rdfs:label "KER 745"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/754> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/744> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/754> rdfs:label "Increased, Luteinizing hormone (LH) "@en .
<https://identifiers.org/aop.events/744> rdfs:label "Increase, Hyperplasia (Leydig cells)"@en .

<https://identifiers.org/aop.relationships/747> a sbdbel:CausalAssertion ;
  rdfs:label "KER 747"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/756> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/757> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/756> rdfs:label "Hippocampal gene expression, Altered "@en .
<https://identifiers.org/aop.events/757> rdfs:label "Hippocampal anatomy, Altered "@en .

<https://identifiers.org/aop.relationships/749> a sbdbel:CausalAssertion ;
  rdfs:label "KER 749"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/757> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/758> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/757> rdfs:label "Hippocampal anatomy, Altered "@en .
<https://identifiers.org/aop.events/758> rdfs:label "Hippocampal Physiology, Altered"@en .

<https://identifiers.org/aop.relationships/748> a sbdbel:CausalAssertion ;
  rdfs:label "KER 748"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/758> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/402> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/758> rdfs:label "Hippocampal Physiology, Altered"@en .
<https://identifiers.org/aop.events/402> rdfs:label "Cognitive Function, Decreased "@en .

<https://identifiers.org/aop.relationships/2484> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2484"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/758> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/319> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/758> rdfs:label "Hippocampal Physiology, Altered"@en .
<https://identifiers.org/aop.events/319> rdfs:label "Loss, Cochlear function"@en .

<https://identifiers.org/aop.relationships/2466> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2466"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/759> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/351> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/759> rdfs:label "Increased, Kidney Failure"@en .
<https://identifiers.org/aop.events/351> rdfs:label "Increased Mortality"@en .

<https://identifiers.org/aop.relationships/752> a sbdbel:CausalAssertion ;
  rdfs:label "KER 752"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/760> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/761> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/760> rdfs:label "Activation, Glutamate-gated chloride channel"@en .
<https://identifiers.org/aop.events/761> rdfs:label "Increased, Chloride conductance"@en .

<https://identifiers.org/aop.relationships/1052> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1052"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/761> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1015> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/761> rdfs:label "Increased, Chloride conductance"@en .
<https://identifiers.org/aop.events/1015> rdfs:label "Increased, Neuronal synaptic inhibition"@en .

<https://identifiers.org/aop.relationships/758> a sbdbel:CausalAssertion ;
  rdfs:label "KER 758"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/761> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/763> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/761> rdfs:label "Increased, Chloride conductance"@en .
<https://identifiers.org/aop.events/763> rdfs:label "hyperpolarisation, neuron"@en .

<https://identifiers.org/aop.relationships/1051> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1051"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/762> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/761> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/762> rdfs:label "Activation, ionotropic GABA Receptor chloride channel"@en .
<https://identifiers.org/aop.events/761> rdfs:label "Increased, Chloride conductance"@en .

<https://identifiers.org/aop.relationships/1566> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1566"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/763> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1428> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/763> rdfs:label "hyperpolarisation, neuron"@en .
<https://identifiers.org/aop.events/1428> rdfs:label "Analgesia"@en .

<https://identifiers.org/aop.relationships/1572> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1572"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/763> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1432> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/763> rdfs:label "hyperpolarisation, neuron"@en .
<https://identifiers.org/aop.events/1432> rdfs:label "Anti-depressant Activity"@en .

<https://identifiers.org/aop.relationships/755> a sbdbel:CausalAssertion ;
  rdfs:label "KER 755"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/763> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/764> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/763> rdfs:label "hyperpolarisation, neuron"@en .
<https://identifiers.org/aop.events/764> rdfs:label "N/A, Ataxia, paralysis, or hyperactivity"@en .

<https://identifiers.org/aop.relationships/757> a sbdbel:CausalAssertion ;
  rdfs:label "KER 757"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/764> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/351> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/764> rdfs:label "N/A, Ataxia, paralysis, or hyperactivity"@en .
<https://identifiers.org/aop.events/351> rdfs:label "Increased Mortality"@en .

<https://identifiers.org/aop.relationships/775> a sbdbel:CausalAssertion ;
  rdfs:label "KER 775"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/766> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/775> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/766> rdfs:label "Inhibition, 4-hydroxyphenyl-pyruvate dioxygenase (HPPD) enzyme"@en .
<https://identifiers.org/aop.events/775> rdfs:label "Increased, Plasma tyrosine"@en .

<https://identifiers.org/aop.relationships/761> a sbdbel:CausalAssertion ;
  rdfs:label "KER 761"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/767> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/713> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/767> rdfs:label "Increase, Hyperplasia (renal tubular cells)"@en .
<https://identifiers.org/aop.events/713> rdfs:label "Increase, Adenomas/carcinomas (renal tubular)"@en .

<https://identifiers.org/aop.relationships/766> a sbdbel:CausalAssertion ;
  rdfs:label "KER 766"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/768> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/719> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/768> rdfs:label "Increase, Cytotoxicity"@en .
<https://identifiers.org/aop.events/719> rdfs:label "Increase, hepatocellular adenomas and carcinomas"@en .

<https://identifiers.org/aop.relationships/887> a sbdbel:CausalAssertion ;
  rdfs:label "KER 887"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/768> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/868> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/768> rdfs:label "Increase, Cytotoxicity"@en .
<https://identifiers.org/aop.events/868> rdfs:label "Increase, Tissue Degeneration, Necrosis & Atrophy "@en .

<https://identifiers.org/aop.relationships/763> a sbdbel:CausalAssertion ;
  rdfs:label "KER 763"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/769> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/209> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/769> rdfs:label "Increase, Oxidative metabolism"@en .
<https://identifiers.org/aop.events/209> rdfs:label "Peptide Oxidation"@en .

<https://identifiers.org/aop.relationships/93> a sbdbel:CausalAssertion ;
  rdfs:label "KER 93"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/77> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/164> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/77> rdfs:label "Production, Critical Metabolites (CGA 330050 and CGA 265307)"@en .
<https://identifiers.org/aop.events/164> rdfs:label "Induction, Liver “Dysfunctional” Changes by CGA 330050"@en .

<https://identifiers.org/aop.relationships/767> a sbdbel:CausalAssertion ;
  rdfs:label "KER 767"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/770> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/733> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/770> rdfs:label "Increase, Cytotoxicity (club cells)"@en .
<https://identifiers.org/aop.events/733> rdfs:label "Increase, Necrosis (terminal bronchiolar cells)"@en .

<https://identifiers.org/aop.relationships/771> a sbdbel:CausalAssertion ;
  rdfs:label "KER 771"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/772> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/773> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/772> rdfs:label "Increase, Hyperplasia (glandular epithelial cells of endometrium)"@en .
<https://identifiers.org/aop.events/773> rdfs:label "Increase, Endometrial adenocarcinomas"@en .

<https://identifiers.org/aop.relationships/774> a sbdbel:CausalAssertion ;
  rdfs:label "KER 774"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/774> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/719> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/774> rdfs:label "Increase, Preneoplastic foci (hepatocytes)"@en .
<https://identifiers.org/aop.events/719> rdfs:label "Increase, hepatocellular adenomas and carcinomas"@en .

<https://identifiers.org/aop.relationships/776> a sbdbel:CausalAssertion ;
  rdfs:label "KER 776"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/775> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/776> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/775> rdfs:label "Increased, Plasma tyrosine"@en .
<https://identifiers.org/aop.events/776> rdfs:label "Increase, Cytotoxicity (corneal cells)"@en .

<https://identifiers.org/aop.relationships/777> a sbdbel:CausalAssertion ;
  rdfs:label "KER 777"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/776> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/777> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/776> rdfs:label "Increase, Cytotoxicity (corneal cells)"@en .
<https://identifiers.org/aop.events/777> rdfs:label "Increase, Inflammation (corneal cells)"@en .

<https://identifiers.org/aop.relationships/778> a sbdbel:CausalAssertion ;
  rdfs:label "KER 778"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/777> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/778> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/777> rdfs:label "Increase, Inflammation (corneal cells)"@en .
<https://identifiers.org/aop.events/778> rdfs:label "Increase, Regenerative cell proliferation (corneal cells)"@en .

<https://identifiers.org/aop.relationships/779> a sbdbel:CausalAssertion ;
  rdfs:label "KER 779"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/778> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/779> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/778> rdfs:label "Increase, Regenerative cell proliferation (corneal cells)"@en .
<https://identifiers.org/aop.events/779> rdfs:label "Increase, Papillomas/carcinomas (squamous cells)"@en .

<https://identifiers.org/aop.relationships/94> a sbdbel:CausalAssertion ;
  rdfs:label "KER 94"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/78> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/360> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/78> rdfs:label "Reduction, Cumulative fecundity and spawning"@en .
<https://identifiers.org/aop.events/360> rdfs:label "Decrease, Population growth rate"@en .

<https://identifiers.org/aop.relationships/780> a sbdbel:CausalAssertion ;
  rdfs:label "KER 780"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/780> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/149> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/780> rdfs:label "Increase, Cytotoxicity (epithelial cells)"@en .
<https://identifiers.org/aop.events/149> rdfs:label "Increase, Inflammation"@en .

<https://identifiers.org/aop.relationships/2659> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2659"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/780> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1115> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/780> rdfs:label "Increase, Cytotoxicity (epithelial cells)"@en .
<https://identifiers.org/aop.events/1115> rdfs:label "Increased, Reactive oxygen species"@en .

<https://identifiers.org/aop.relationships/2664> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2664"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/780> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2006> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/780> rdfs:label "Increase, Cytotoxicity (epithelial cells)"@en .
<https://identifiers.org/aop.events/2006> rdfs:label "Secondary genotoxicity"@en .

<https://identifiers.org/aop.relationships/782> a sbdbel:CausalAssertion ;
  rdfs:label "KER 782"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/781> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/782> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/781> rdfs:label "Increase, Regenerative cell proliferation (forestomach epithelial cells)"@en .
<https://identifiers.org/aop.events/782> rdfs:label "Increase, Hyperplasia (forestomach epithelial cells)"@en .

<https://identifiers.org/aop.relationships/783> a sbdbel:CausalAssertion ;
  rdfs:label "KER 783"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/782> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/779> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/782> rdfs:label "Increase, Hyperplasia (forestomach epithelial cells)"@en .
<https://identifiers.org/aop.events/779> rdfs:label "Increase, Papillomas/carcinomas (squamous cells)"@en .

<https://identifiers.org/aop.relationships/784> a sbdbel:CausalAssertion ;
  rdfs:label "KER 784"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/783> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/710> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/783> rdfs:label "Increase, Cytotoxicity (tubular epithelial cells)"@en .
<https://identifiers.org/aop.events/710> rdfs:label "Increase, Regenerative cell proliferation (tubular epithelial cells)"@en .

<https://identifiers.org/aop.relationships/786> a sbdbel:CausalAssertion ;
  rdfs:label "KER 786"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/784> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/713> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/784> rdfs:label "Increase, Hyperplasia (tubular epithelial cells)"@en .
<https://identifiers.org/aop.events/713> rdfs:label "Increase, Adenomas/carcinomas (renal tubular)"@en .

<https://identifiers.org/aop.relationships/787> a sbdbel:CausalAssertion ;
  rdfs:label "KER 787"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/785> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/716> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/785> rdfs:label "Activation, Androgen receptor"@en .
<https://identifiers.org/aop.events/716> rdfs:label "Increase, cell proliferation (hepatocytes)"@en .

<https://identifiers.org/aop.relationships/788> a sbdbel:CausalAssertion ;
  rdfs:label "KER 788"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/786> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/787> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/786> rdfs:label "Increase, Cytotoxicity (hepatocytes)"@en .
<https://identifiers.org/aop.events/787> rdfs:label "Increase, Regenerative cell proliferation (hepatocytes)"@en .

<https://identifiers.org/aop.relationships/789> a sbdbel:CausalAssertion ;
  rdfs:label "KER 789"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/787> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/774> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/787> rdfs:label "Increase, Regenerative cell proliferation (hepatocytes)"@en .
<https://identifiers.org/aop.events/774> rdfs:label "Increase, Preneoplastic foci (hepatocytes)"@en .

<https://identifiers.org/aop.relationships/792> a sbdbel:CausalAssertion ;
  rdfs:label "KER 792"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/790> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/792> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/790> rdfs:label "Inhibition, 5α-reductase activity"@en .
<https://identifiers.org/aop.events/792> rdfs:label "Decrease, Bioactivation of testosterone"@en .

<https://identifiers.org/aop.relationships/794> a sbdbel:CausalAssertion ;
  rdfs:label "KER 794"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/791> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/744> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/791> rdfs:label "Increased, Leutinizing hormone (LH)"@en .
<https://identifiers.org/aop.events/744> rdfs:label "Increase, Hyperplasia (Leydig cells)"@en .

<https://identifiers.org/aop.relationships/793> a sbdbel:CausalAssertion ;
  rdfs:label "KER 793"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/792> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/791> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/792> rdfs:label "Decrease, Bioactivation of testosterone"@en .
<https://identifiers.org/aop.events/791> rdfs:label "Increased, Leutinizing hormone (LH)"@en .

<https://identifiers.org/aop.relationships/795> a sbdbel:CausalAssertion ;
  rdfs:label "KER 795"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/793> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/794> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/793> rdfs:label "Increase, Urinary bladder calculi"@en .
<https://identifiers.org/aop.events/794> rdfs:label "Increase, Cytotoxicity (urothelial cells)"@en .

<https://identifiers.org/aop.relationships/796> a sbdbel:CausalAssertion ;
  rdfs:label "KER 796"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/794> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/795> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/794> rdfs:label "Increase, Cytotoxicity (urothelial cells)"@en .
<https://identifiers.org/aop.events/795> rdfs:label "Increase, Regenerative cell proliferation (urothelial cells)"@en .

<https://identifiers.org/aop.relationships/797> a sbdbel:CausalAssertion ;
  rdfs:label "KER 797"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/795> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/796> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/795> rdfs:label "Increase, Regenerative cell proliferation (urothelial cells)"@en .
<https://identifiers.org/aop.events/796> rdfs:label "Increase, Hyperplasia (urothelial)"@en .

<https://identifiers.org/aop.relationships/2085> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2085"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/796> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1763> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/796> rdfs:label "Increase, Hyperplasia (urothelial)"@en .
<https://identifiers.org/aop.events/1763> rdfs:label "Urothelial Tumor"@en .

<https://identifiers.org/aop.relationships/798> a sbdbel:CausalAssertion ;
  rdfs:label "KER 798"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/796> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/797> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/796> rdfs:label "Increase, Hyperplasia (urothelial)"@en .
<https://identifiers.org/aop.events/797> rdfs:label "Increase, Adenomas/carcinomas (urothelial)"@en .

<https://identifiers.org/aop.relationships/799> a sbdbel:CausalAssertion ;
  rdfs:label "KER 799"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/798> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/799> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/798> rdfs:label "Inhibition, Prolyl hydroxylases"@en .
<https://identifiers.org/aop.events/799> rdfs:label "Increased, HIF-1 heterodimer"@en .

<https://identifiers.org/aop.relationships/800> a sbdbel:CausalAssertion ;
  rdfs:label "KER 800"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/799> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/800> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/799> rdfs:label "Increased, HIF-1 heterodimer"@en .
<https://identifiers.org/aop.events/800> rdfs:label "Decreased, Aromatase (Cyp19a1) mRNA"@en .

<https://identifiers.org/aop.relationships/9> a sbdbel:CausalAssertion ;
  rdfs:label "KER 9"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/8> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/179> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/8> rdfs:label "Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity"@en .
<https://identifiers.org/aop.events/179> rdfs:label "Decreased, Mitochondrial fatty acid beta-oxidation"@en .

<https://identifiers.org/aop.relationships/801> a sbdbel:CausalAssertion ;
  rdfs:label "KER 801"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/800> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/3> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/800> rdfs:label "Decreased, Aromatase (Cyp19a1) mRNA"@en .
<https://identifiers.org/aop.events/3> rdfs:label "Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"@en .

<https://identifiers.org/aop.relationships/802> a sbdbel:CausalAssertion ;
  rdfs:label "KER 802"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/801> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/802> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/801> rdfs:label "modulation, Unknown"@en .
<https://identifiers.org/aop.events/802> rdfs:label "Increased, HIF-1 alpha transcription"@en .

<https://identifiers.org/aop.relationships/803> a sbdbel:CausalAssertion ;
  rdfs:label "KER 803"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/802> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/799> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/802> rdfs:label "Increased, HIF-1 alpha transcription"@en .
<https://identifiers.org/aop.events/799> rdfs:label "Increased, HIF-1 heterodimer"@en .

<https://identifiers.org/aop.relationships/804> a sbdbel:CausalAssertion ;
  rdfs:label "KER 804"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/804> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/805> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/804> rdfs:label "Inhibition, HMG-CoA reductase"@en .
<https://identifiers.org/aop.events/805> rdfs:label "Decreased, mevalonate"@en .

<https://identifiers.org/aop.relationships/805> a sbdbel:CausalAssertion ;
  rdfs:label "KER 805"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/805> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/807> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/805> rdfs:label "Decreased, mevalonate"@en .
<https://identifiers.org/aop.events/807> rdfs:label "Decreased, cholesterol"@en .

<https://identifiers.org/aop.relationships/2072> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2072"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/807> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1756> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/807> rdfs:label "Decreased, cholesterol"@en .
<https://identifiers.org/aop.events/1756> rdfs:label "Decreased,  plasma 11-ketotestosterone level"@en .

<https://identifiers.org/aop.relationships/806> a sbdbel:CausalAssertion ;
  rdfs:label "KER 806"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/807> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/808> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/807> rdfs:label "Decreased, cholesterol"@en .
<https://identifiers.org/aop.events/808> rdfs:label "Decreased, Testosterone"@en .

<https://identifiers.org/aop.relationships/807> a sbdbel:CausalAssertion ;
  rdfs:label "KER 807"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/808> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/809> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/808> rdfs:label "Decreased, Testosterone"@en .
<https://identifiers.org/aop.events/809> rdfs:label "malformed, Male reproductive tract"@en .

<https://identifiers.org/aop.relationships/808> a sbdbel:CausalAssertion ;
  rdfs:label "KER 808"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/809> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/330> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/809> rdfs:label "malformed, Male reproductive tract"@en .
<https://identifiers.org/aop.events/330> rdfs:label "Decrease, Fertility"@en .

<https://identifiers.org/aop.relationships/813> a sbdbel:CausalAssertion ;
  rdfs:label "KER 813"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/813> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/818> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/813> rdfs:label "Increased, Serum creatinine"@en .
<https://identifiers.org/aop.events/818> rdfs:label "Occurrence, Cytoplasmic vacuolization (Renal tubule)"@en .

<https://identifiers.org/aop.relationships/814> a sbdbel:CausalAssertion ;
  rdfs:label "KER 814"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/813> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/823> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/813> rdfs:label "Increased, Serum creatinine"@en .
<https://identifiers.org/aop.events/823> rdfs:label "Occurrence, Cystic dilatation (renal tubule)"@en .

<https://identifiers.org/aop.relationships/816> a sbdbel:CausalAssertion ;
  rdfs:label "KER 816"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/813> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/824> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/813> rdfs:label "Increased, Serum creatinine"@en .
<https://identifiers.org/aop.events/824> rdfs:label "Occurrence, Cytoplasmic vacuolization (podocyte)"@en .

<https://identifiers.org/aop.relationships/2648> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2648"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/814> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/759> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/814> rdfs:label "Occurrence, Kidney toxicity"@en .
<https://identifiers.org/aop.events/759> rdfs:label "Increased, Kidney Failure"@en .

<https://identifiers.org/aop.relationships/817> a sbdbel:CausalAssertion ;
  rdfs:label "KER 817"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/818> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/819> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/818> rdfs:label "Occurrence, Cytoplasmic vacuolization (Renal tubule)"@en .
<https://identifiers.org/aop.events/819> rdfs:label "Decreased, Glomerular filtration"@en .

<https://identifiers.org/aop.relationships/818> a sbdbel:CausalAssertion ;
  rdfs:label "KER 818"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/818> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/820> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/818> rdfs:label "Occurrence, Cytoplasmic vacuolization (Renal tubule)"@en .
<https://identifiers.org/aop.events/820> rdfs:label "Decreased, Renal plasma flow"@en .

<https://identifiers.org/aop.relationships/819> a sbdbel:CausalAssertion ;
  rdfs:label "KER 819"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/818> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/821> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/818> rdfs:label "Occurrence, Cytoplasmic vacuolization (Renal tubule)"@en .
<https://identifiers.org/aop.events/821> rdfs:label "Decreased, Sodium reabsorption"@en .

<https://identifiers.org/aop.relationships/820> a sbdbel:CausalAssertion ;
  rdfs:label "KER 820"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/818> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/825> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/818> rdfs:label "Occurrence, Cytoplasmic vacuolization (Renal tubule)"@en .
<https://identifiers.org/aop.events/825> rdfs:label "Decreased, Renal ability to dilute urine"@en .

<https://identifiers.org/aop.relationships/829> a sbdbel:CausalAssertion ;
  rdfs:label "KER 829"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/819> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/814> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/819> rdfs:label "Decreased, Glomerular filtration"@en .
<https://identifiers.org/aop.events/814> rdfs:label "Occurrence, Kidney toxicity"@en .

<https://identifiers.org/aop.relationships/830> a sbdbel:CausalAssertion ;
  rdfs:label "KER 830"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/820> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/814> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/820> rdfs:label "Decreased, Renal plasma flow"@en .
<https://identifiers.org/aop.events/814> rdfs:label "Occurrence, Kidney toxicity"@en .

<https://identifiers.org/aop.relationships/831> a sbdbel:CausalAssertion ;
  rdfs:label "KER 831"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/821> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/814> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/821> rdfs:label "Decreased, Sodium reabsorption"@en .
<https://identifiers.org/aop.events/814> rdfs:label "Occurrence, Kidney toxicity"@en .

<https://identifiers.org/aop.relationships/821> a sbdbel:CausalAssertion ;
  rdfs:label "KER 821"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/823> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/819> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/823> rdfs:label "Occurrence, Cystic dilatation (renal tubule)"@en .
<https://identifiers.org/aop.events/819> rdfs:label "Decreased, Glomerular filtration"@en .

<https://identifiers.org/aop.relationships/822> a sbdbel:CausalAssertion ;
  rdfs:label "KER 822"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/823> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/820> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/823> rdfs:label "Occurrence, Cystic dilatation (renal tubule)"@en .
<https://identifiers.org/aop.events/820> rdfs:label "Decreased, Renal plasma flow"@en .

<https://identifiers.org/aop.relationships/823> a sbdbel:CausalAssertion ;
  rdfs:label "KER 823"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/823> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/821> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/823> rdfs:label "Occurrence, Cystic dilatation (renal tubule)"@en .
<https://identifiers.org/aop.events/821> rdfs:label "Decreased, Sodium reabsorption"@en .

<https://identifiers.org/aop.relationships/824> a sbdbel:CausalAssertion ;
  rdfs:label "KER 824"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/823> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/825> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/823> rdfs:label "Occurrence, Cystic dilatation (renal tubule)"@en .
<https://identifiers.org/aop.events/825> rdfs:label "Decreased, Renal ability to dilute urine"@en .

<https://identifiers.org/aop.relationships/825> a sbdbel:CausalAssertion ;
  rdfs:label "KER 825"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/824> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/819> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/824> rdfs:label "Occurrence, Cytoplasmic vacuolization (podocyte)"@en .
<https://identifiers.org/aop.events/819> rdfs:label "Decreased, Glomerular filtration"@en .

<https://identifiers.org/aop.relationships/826> a sbdbel:CausalAssertion ;
  rdfs:label "KER 826"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/824> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/820> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/824> rdfs:label "Occurrence, Cytoplasmic vacuolization (podocyte)"@en .
<https://identifiers.org/aop.events/820> rdfs:label "Decreased, Renal plasma flow"@en .

<https://identifiers.org/aop.relationships/827> a sbdbel:CausalAssertion ;
  rdfs:label "KER 827"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/824> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/821> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/824> rdfs:label "Occurrence, Cytoplasmic vacuolization (podocyte)"@en .
<https://identifiers.org/aop.events/821> rdfs:label "Decreased, Sodium reabsorption"@en .

<https://identifiers.org/aop.relationships/828> a sbdbel:CausalAssertion ;
  rdfs:label "KER 828"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/824> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/825> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/824> rdfs:label "Occurrence, Cytoplasmic vacuolization (podocyte)"@en .
<https://identifiers.org/aop.events/825> rdfs:label "Decreased, Renal ability to dilute urine"@en .

<https://identifiers.org/aop.relationships/832> a sbdbel:CausalAssertion ;
  rdfs:label "KER 832"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/825> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/814> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/825> rdfs:label "Decreased, Renal ability to dilute urine"@en .
<https://identifiers.org/aop.events/814> rdfs:label "Occurrence, Kidney toxicity"@en .

<https://identifiers.org/aop.relationships/836> a sbdbel:CausalAssertion ;
  rdfs:label "KER 836"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/828> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/829> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/828> rdfs:label "Inhibition, Phospholipase A"@en .
<https://identifiers.org/aop.events/829> rdfs:label "Damage, Lipid bilayer"@en .

<https://identifiers.org/aop.relationships/837> a sbdbel:CausalAssertion ;
  rdfs:label "KER 837"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/828> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/831> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/828> rdfs:label "Inhibition, Phospholipase A"@en .
<https://identifiers.org/aop.events/831> rdfs:label "Disturbance, Lysosomal function"@en .

<https://identifiers.org/aop.relationships/838> a sbdbel:CausalAssertion ;
  rdfs:label "KER 838"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/828> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/832> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/828> rdfs:label "Inhibition, Phospholipase A"@en .
<https://identifiers.org/aop.events/832> rdfs:label "Injury, Mitochondria"@en .

<https://identifiers.org/aop.relationships/839> a sbdbel:CausalAssertion ;
  rdfs:label "KER 839"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/829> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/833> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/829> rdfs:label "Damage, Lipid bilayer"@en .
<https://identifiers.org/aop.events/833> rdfs:label "Occurrence, Cytoplasmic vacuolization (hepatocyte)"@en .

<https://identifiers.org/aop.relationships/840> a sbdbel:CausalAssertion ;
  rdfs:label "KER 840"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/829> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/835> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/829> rdfs:label "Damage, Lipid bilayer"@en .
<https://identifiers.org/aop.events/835> rdfs:label "Occurrence, Ballooning degeneration (hepatocyte)"@en .

<https://identifiers.org/aop.relationships/841> a sbdbel:CausalAssertion ;
  rdfs:label "KER 841"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/829> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/836> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/829> rdfs:label "Damage, Lipid bilayer"@en .
<https://identifiers.org/aop.events/836> rdfs:label "Occurrence, Cytoplasmic vacuolization (Bile duct cell)"@en .

<https://identifiers.org/aop.relationships/842> a sbdbel:CausalAssertion ;
  rdfs:label "KER 842"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/829> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/837> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/829> rdfs:label "Damage, Lipid bilayer"@en .
<https://identifiers.org/aop.events/837> rdfs:label "Occurrence, Cytoplasmic vacuolization (kupffer cell)"@en .

<https://identifiers.org/aop.relationships/1678> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1678"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/831> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/898> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/831> rdfs:label "Disturbance, Lysosomal function"@en .
<https://identifiers.org/aop.events/898> rdfs:label "Disruption, Lysosome"@en .

<https://identifiers.org/aop.relationships/843> a sbdbel:CausalAssertion ;
  rdfs:label "KER 843"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/831> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/833> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/831> rdfs:label "Disturbance, Lysosomal function"@en .
<https://identifiers.org/aop.events/833> rdfs:label "Occurrence, Cytoplasmic vacuolization (hepatocyte)"@en .

<https://identifiers.org/aop.relationships/844> a sbdbel:CausalAssertion ;
  rdfs:label "KER 844"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/831> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/835> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/831> rdfs:label "Disturbance, Lysosomal function"@en .
<https://identifiers.org/aop.events/835> rdfs:label "Occurrence, Ballooning degeneration (hepatocyte)"@en .

<https://identifiers.org/aop.relationships/845> a sbdbel:CausalAssertion ;
  rdfs:label "KER 845"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/831> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/836> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/831> rdfs:label "Disturbance, Lysosomal function"@en .
<https://identifiers.org/aop.events/836> rdfs:label "Occurrence, Cytoplasmic vacuolization (Bile duct cell)"@en .

<https://identifiers.org/aop.relationships/846> a sbdbel:CausalAssertion ;
  rdfs:label "KER 846"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/831> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/837> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/831> rdfs:label "Disturbance, Lysosomal function"@en .
<https://identifiers.org/aop.events/837> rdfs:label "Occurrence, Cytoplasmic vacuolization (kupffer cell)"@en .

<https://identifiers.org/aop.relationships/847> a sbdbel:CausalAssertion ;
  rdfs:label "KER 847"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/832> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/833> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/832> rdfs:label "Injury, Mitochondria"@en .
<https://identifiers.org/aop.events/833> rdfs:label "Occurrence, Cytoplasmic vacuolization (hepatocyte)"@en .

<https://identifiers.org/aop.relationships/848> a sbdbel:CausalAssertion ;
  rdfs:label "KER 848"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/832> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/835> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/832> rdfs:label "Injury, Mitochondria"@en .
<https://identifiers.org/aop.events/835> rdfs:label "Occurrence, Ballooning degeneration (hepatocyte)"@en .

<https://identifiers.org/aop.relationships/849> a sbdbel:CausalAssertion ;
  rdfs:label "KER 849"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/832> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/836> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/832> rdfs:label "Injury, Mitochondria"@en .
<https://identifiers.org/aop.events/836> rdfs:label "Occurrence, Cytoplasmic vacuolization (Bile duct cell)"@en .

<https://identifiers.org/aop.relationships/850> a sbdbel:CausalAssertion ;
  rdfs:label "KER 850"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/832> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/837> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/832> rdfs:label "Injury, Mitochondria"@en .
<https://identifiers.org/aop.events/837> rdfs:label "Occurrence, Cytoplasmic vacuolization (kupffer cell)"@en .

<https://identifiers.org/aop.relationships/851> a sbdbel:CausalAssertion ;
  rdfs:label "KER 851"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/833> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/838> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/833> rdfs:label "Occurrence, Cytoplasmic vacuolization (hepatocyte)"@en .
<https://identifiers.org/aop.events/838> rdfs:label "Induction, Microvesicular fat"@en .

<https://identifiers.org/aop.relationships/852> a sbdbel:CausalAssertion ;
  rdfs:label "KER 852"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/833> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/839> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/833> rdfs:label "Occurrence, Cytoplasmic vacuolization (hepatocyte)"@en .
<https://identifiers.org/aop.events/839> rdfs:label "Formation, Mallory body"@en .

<https://identifiers.org/aop.relationships/853> a sbdbel:CausalAssertion ;
  rdfs:label "KER 853"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/835> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/838> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/835> rdfs:label "Occurrence, Ballooning degeneration (hepatocyte)"@en .
<https://identifiers.org/aop.events/838> rdfs:label "Induction, Microvesicular fat"@en .

<https://identifiers.org/aop.relationships/854> a sbdbel:CausalAssertion ;
  rdfs:label "KER 854"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/835> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/839> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/835> rdfs:label "Occurrence, Ballooning degeneration (hepatocyte)"@en .
<https://identifiers.org/aop.events/839> rdfs:label "Formation, Mallory body"@en .

<https://identifiers.org/aop.relationships/855> a sbdbel:CausalAssertion ;
  rdfs:label "KER 855"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/836> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/838> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/836> rdfs:label "Occurrence, Cytoplasmic vacuolization (Bile duct cell)"@en .
<https://identifiers.org/aop.events/838> rdfs:label "Induction, Microvesicular fat"@en .

<https://identifiers.org/aop.relationships/856> a sbdbel:CausalAssertion ;
  rdfs:label "KER 856"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/836> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/839> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/836> rdfs:label "Occurrence, Cytoplasmic vacuolization (Bile duct cell)"@en .
<https://identifiers.org/aop.events/839> rdfs:label "Formation, Mallory body"@en .

<https://identifiers.org/aop.relationships/857> a sbdbel:CausalAssertion ;
  rdfs:label "KER 857"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/837> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/838> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/837> rdfs:label "Occurrence, Cytoplasmic vacuolization (kupffer cell)"@en .
<https://identifiers.org/aop.events/838> rdfs:label "Induction, Microvesicular fat"@en .

<https://identifiers.org/aop.relationships/858> a sbdbel:CausalAssertion ;
  rdfs:label "KER 858"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/837> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/839> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/837> rdfs:label "Occurrence, Cytoplasmic vacuolization (kupffer cell)"@en .
<https://identifiers.org/aop.events/839> rdfs:label "Formation, Mallory body"@en .

<https://identifiers.org/aop.relationships/859> a sbdbel:CausalAssertion ;
  rdfs:label "KER 859"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/838> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/840> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/838> rdfs:label "Induction, Microvesicular fat"@en .
<https://identifiers.org/aop.events/840> rdfs:label "Formation, Liver fibrosis"@en .

<https://identifiers.org/aop.relationships/860> a sbdbel:CausalAssertion ;
  rdfs:label "KER 860"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/839> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/840> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/839> rdfs:label "Formation, Mallory body"@en .
<https://identifiers.org/aop.events/840> rdfs:label "Formation, Liver fibrosis"@en .

<https://identifiers.org/aop.relationships/865> a sbdbel:CausalAssertion ;
  rdfs:label "KER 865"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/844> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/845> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/844> rdfs:label "Oxidation, Uroporphyrinogen"@en .
<https://identifiers.org/aop.events/845> rdfs:label "Inhibition, UROD"@en .

<https://identifiers.org/aop.relationships/1070> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1070"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/845> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/846> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/845> rdfs:label "Inhibition, UROD"@en .
<https://identifiers.org/aop.events/846> rdfs:label "Accumulation, Highly carboxylated porphyrins"@en .

<https://identifiers.org/aop.relationships/866> a sbdbel:CausalAssertion ;
  rdfs:label "KER 866"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/846> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/369> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/846> rdfs:label "Accumulation, Highly carboxylated porphyrins"@en .
<https://identifiers.org/aop.events/369> rdfs:label "Uroporphyria"@en .

<https://identifiers.org/aop.relationships/868> a sbdbel:CausalAssertion ;
  rdfs:label "KER 868"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/850> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/844> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/850> rdfs:label "Induction, CYP1A2/CYP1A5"@en .
<https://identifiers.org/aop.events/844> rdfs:label "Oxidation, Uroporphyrinogen"@en .

<https://identifiers.org/aop.relationships/997> a sbdbel:CausalAssertion ;
  rdfs:label "KER 997"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/854> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/856> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/854> rdfs:label "Alterations, Cellular proliferation / hyperplasia"@en .
<https://identifiers.org/aop.events/856> rdfs:label "Formation, Hepatocellular and Bile duct tumors"@en .

<https://identifiers.org/aop.relationships/2264> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2264"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/860> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/291> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/860> rdfs:label "Decreased, Mitochondrial Fatty Acid Beta Oxidation"@en .
<https://identifiers.org/aop.events/291> rdfs:label "Accumulation, Triglyceride"@en .

<https://identifiers.org/aop.relationships/883> a sbdbel:CausalAssertion ;
  rdfs:label "KER 883"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/861> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/862> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/861> rdfs:label "Decreased, Ketogenesis (production of ketone bodies)"@en .
<https://identifiers.org/aop.events/862> rdfs:label "Not Increased, Circulating Ketone Bodies"@en .

<https://identifiers.org/aop.relationships/884> a sbdbel:CausalAssertion ;
  rdfs:label "KER 884"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/862> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/863> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/862> rdfs:label "Not Increased, Circulating Ketone Bodies"@en .
<https://identifiers.org/aop.events/863> rdfs:label "Increased, Catabolism of Muscle Protein"@en .

<https://identifiers.org/aop.relationships/885> a sbdbel:CausalAssertion ;
  rdfs:label "KER 885"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/863> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/864> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/863> rdfs:label "Increased, Catabolism of Muscle Protein"@en .
<https://identifiers.org/aop.events/864> rdfs:label "Decreased, Body Weight"@en .

<https://identifiers.org/aop.relationships/886> a sbdbel:CausalAssertion ;
  rdfs:label "KER 886"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/867> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/768> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/867> rdfs:label "Decrease, Intracellular pH"@en .
<https://identifiers.org/aop.events/768> rdfs:label "Increase, Cytotoxicity"@en .

<https://identifiers.org/aop.relationships/888> a sbdbel:CausalAssertion ;
  rdfs:label "KER 888"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/868> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/869> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/868> rdfs:label "Increase, Tissue Degeneration, Necrosis & Atrophy "@en .
<https://identifiers.org/aop.events/869> rdfs:label "Increase, Respiratory or Squamous Metaplasia"@en .

<https://identifiers.org/aop.relationships/889> a sbdbel:CausalAssertion ;
  rdfs:label "KER 889"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/869> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/870> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/869> rdfs:label "Increase, Respiratory or Squamous Metaplasia"@en .
<https://identifiers.org/aop.events/870> rdfs:label "Increase, Cell Proliferation"@en .

<https://identifiers.org/aop.relationships/108> a sbdbel:CausalAssertion ;
  rdfs:label "KER 108"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/87> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/149> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/87> rdfs:label "Release, Cytokine"@en .
<https://identifiers.org/aop.events/149> rdfs:label "Increase, Inflammation"@en .

<https://identifiers.org/aop.relationships/1963> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1963"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/87> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1497> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/87> rdfs:label "Release, Cytokine"@en .
<https://identifiers.org/aop.events/1497> rdfs:label "Increased, recruitment of inflammatory cells"@en .

<https://identifiers.org/aop.relationships/2454> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2454"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/87> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1914> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/87> rdfs:label "Release, Cytokine"@en .
<https://identifiers.org/aop.events/1914> rdfs:label "Platelet activation, Increased"@en .

<https://identifiers.org/aop.relationships/2455> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2455"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/87> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1915> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/87> rdfs:label "Release, Cytokine"@en .
<https://identifiers.org/aop.events/1915> rdfs:label "Neutrophil activation, Increased "@en .

<https://identifiers.org/aop.relationships/2819> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2819"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/870> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2083> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/870> rdfs:label "Increase, Cell Proliferation"@en .
<https://identifiers.org/aop.events/2083> rdfs:label "Occurrence of Cataracts"@en .

<https://identifiers.org/aop.relationships/1980> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1980"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/870> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1556> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/870> rdfs:label "Increase, Cell Proliferation"@en .
<https://identifiers.org/aop.events/1556> rdfs:label "Increase, lung cancer"@en .

<https://identifiers.org/aop.relationships/1967> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1967"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/870> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1670> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/870> rdfs:label "Increase, Cell Proliferation"@en .
<https://identifiers.org/aop.events/1670> rdfs:label "Lung cancer"@en .

<https://identifiers.org/aop.relationships/893> a sbdbel:CausalAssertion ;
  rdfs:label "KER 893"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/870> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/876> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/870> rdfs:label "Increase, Cell Proliferation"@en .
<https://identifiers.org/aop.events/876> rdfs:label "Increase, Mutations in Critical Genes"@en .

<https://identifiers.org/aop.relationships/895> a sbdbel:CausalAssertion ;
  rdfs:label "KER 895"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/870> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/872> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/870> rdfs:label "Increase, Cell Proliferation"@en .
<https://identifiers.org/aop.events/872> rdfs:label "Increase, Site of Contact Nasal Tumors"@en .

<https://identifiers.org/aop.relationships/2419> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2419"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/870> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1090> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/870> rdfs:label "Increase, Cell Proliferation"@en .
<https://identifiers.org/aop.events/1090> rdfs:label "Increased, mesotheliomas"@en .

<https://identifiers.org/aop.relationships/919> a sbdbel:CausalAssertion ;
  rdfs:label "KER 919"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/875> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/388> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/875> rdfs:label "Binding of agonist, Ionotropic glutamate receptors"@en .
<https://identifiers.org/aop.events/388> rdfs:label "Overactivation, NMDARs"@en .

<https://identifiers.org/aop.relationships/894> a sbdbel:CausalAssertion ;
  rdfs:label "KER 894"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/876> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/872> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/876> rdfs:label "Increase, Mutations in Critical Genes"@en .
<https://identifiers.org/aop.events/872> rdfs:label "Increase, Site of Contact Nasal Tumors"@en .

<https://identifiers.org/aop.relationships/905> a sbdbel:CausalAssertion ;
  rdfs:label "KER 905"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/889> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/890> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/889> rdfs:label "Impaired, Proteostasis"@en .
<https://identifiers.org/aop.events/890> rdfs:label "Degeneration of dopaminergic neurons of the nigrostriatal pathway"@en .

<https://identifiers.org/aop.relationships/1943> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1943"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/889> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/55> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/889> rdfs:label "Impaired, Proteostasis"@en .
<https://identifiers.org/aop.events/55> rdfs:label "Cell injury/death"@en .

<https://identifiers.org/aop.relationships/907> a sbdbel:CausalAssertion ;
  rdfs:label "KER 907"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/890> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/188> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/890> rdfs:label "Degeneration of dopaminergic neurons of the nigrostriatal pathway"@en .
<https://identifiers.org/aop.events/188> rdfs:label "Neuroinflammation"@en .

<https://identifiers.org/aop.relationships/910> a sbdbel:CausalAssertion ;
  rdfs:label "KER 910"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/890> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/896> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/890> rdfs:label "Degeneration of dopaminergic neurons of the nigrostriatal pathway"@en .
<https://identifiers.org/aop.events/896> rdfs:label "Parkinsonian motor deficits"@en .

<https://identifiers.org/aop.relationships/993> a sbdbel:CausalAssertion ;
  rdfs:label "KER 993"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/898> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/177> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/898> rdfs:label "Disruption, Lysosome"@en .
<https://identifiers.org/aop.events/177> rdfs:label "N/A, Mitochondrial dysfunction 1"@en .

<https://identifiers.org/aop.relationships/1679> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1679"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/898> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/709> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/898> rdfs:label "Disruption, Lysosome"@en .
<https://identifiers.org/aop.events/709> rdfs:label "Increase, Cytotoxicity (renal tubular cell)"@en .

<https://identifiers.org/aop.relationships/750> a sbdbel:CausalAssertion ;
  rdfs:label "KER 750"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/9> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/294> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/9> rdfs:label "Activation, 5HT2c"@en .
<https://identifiers.org/aop.events/294> rdfs:label "N/A, Unknown"@en .

<https://identifiers.org/aop.relationships/2459> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2459"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/926> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1115> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/926> rdfs:label "Oxidation, Glutathione (To be considered with MIE)"@en .
<https://identifiers.org/aop.events/1115> rdfs:label "Increased, Reactive oxygen species"@en .

<https://identifiers.org/aop.relationships/956> a sbdbel:CausalAssertion ;
  rdfs:label "KER 956"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/932> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/933> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/932> rdfs:label "KE4 : Uncoupling, eNOS"@en .
<https://identifiers.org/aop.events/933> rdfs:label "KE6 : Depletion, Nitric Oxide"@en .

<https://identifiers.org/aop.relationships/958> a sbdbel:CausalAssertion ;
  rdfs:label "KER 958"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/933> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/937> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/933> rdfs:label "KE6 : Depletion, Nitric Oxide"@en .
<https://identifiers.org/aop.events/937> rdfs:label "KE7 : Impaired, Vasodilation"@en .

<https://identifiers.org/aop.relationships/953> a sbdbel:CausalAssertion ;
  rdfs:label "KER 953"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/934> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/932> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/934> rdfs:label "KE3 : Decrease, Tetrahydrobiopterin"@en .
<https://identifiers.org/aop.events/932> rdfs:label "KE4 : Uncoupling, eNOS"@en .

<https://identifiers.org/aop.relationships/982> a sbdbel:CausalAssertion ;
  rdfs:label "KER 982"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/937> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/951> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/937> rdfs:label "KE7 : Impaired, Vasodilation"@en .
<https://identifiers.org/aop.events/951> rdfs:label "KE8 : Increase, Vascular Resistance"@en .

<https://identifiers.org/aop.relationships/974> a sbdbel:CausalAssertion ;
  rdfs:label "KER 974"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/945> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/948> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/945> rdfs:label "reduced dimerization, ARNT/HIF1-alpha"@en .
<https://identifiers.org/aop.events/948> rdfs:label "reduced production, VEGF"@en .

<https://identifiers.org/aop.relationships/983> a sbdbel:CausalAssertion ;
  rdfs:label "KER 983"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/951> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/952> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/951> rdfs:label "KE8 : Increase, Vascular Resistance"@en .
<https://identifiers.org/aop.events/952> rdfs:label "Hypertension"@en .

<https://identifiers.org/aop.relationships/23> a sbdbel:CausalAssertion ;
  rdfs:label "KER 23"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/97> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/336> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/97> rdfs:label "Alkylation, DNA"@en .
<https://identifiers.org/aop.events/336> rdfs:label "Increase, Heritable mutations in offspring"@en .

<https://identifiers.org/aop.relationships/24> a sbdbel:CausalAssertion ;
  rdfs:label "KER 24"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/97> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/155> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/97> rdfs:label "Alkylation, DNA"@en .
<https://identifiers.org/aop.events/155> rdfs:label "Inadequate DNA repair"@en .

<https://identifiers.org/aop.relationships/25> a sbdbel:CausalAssertion ;
  rdfs:label "KER 25"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/97> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/185> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/97> rdfs:label "Alkylation, DNA"@en .
<https://identifiers.org/aop.events/185> rdfs:label "Increase, Mutations"@en .

<https://identifiers.org/aop.relationships/901> a sbdbel:CausalAssertion ;
  rdfs:label "KER 901"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/97> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/885> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/97> rdfs:label "Alkylation, DNA"@en .
<https://identifiers.org/aop.events/885> rdfs:label "Increase, Cancer"@en .

<https://identifiers.org/aop.relationships/1346> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1346"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/988> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1266> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/988> rdfs:label "Decrease, Circulating ecdysis triggering hormone"@en .
<https://identifiers.org/aop.events/1266> rdfs:label "Decrease, Circulating crustacean cardioactive peptide"@en .

<https://identifiers.org/aop.relationships/1002> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1002"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/990> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/350> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/990> rdfs:label "Increase, Incomplete ecdysis"@en .
<https://identifiers.org/aop.events/350> rdfs:label "Increase, Mortality"@en .

<https://identifiers.org/aop.relationships/2750> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2750"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/990> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2056> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/990> rdfs:label "Increase, Incomplete ecdysis"@en .
<https://identifiers.org/aop.events/2056> rdfs:label "Increase,  delay in oviposition"@en .

<https://identifiers.org/aop.relationships/2751> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2751"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/990> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2057> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/990> rdfs:label "Increase, Incomplete ecdysis"@en .
<https://identifiers.org/aop.events/2057> rdfs:label "Decrease,  hatching of egg"@en .

<https://identifiers.org/aop.relationships/2759> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2759"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/990> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2050> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/990> rdfs:label "Increase, Incomplete ecdysis"@en .
<https://identifiers.org/aop.events/2050> rdfs:label "Increase, developmental abnormalities"@en .

<https://identifiers.org/aop.relationships/1010> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1010"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/993> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/990> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/993> rdfs:label "Decrease, Abdominal muscle contraction"@en .
<https://identifiers.org/aop.events/990> rdfs:label "Increase, Incomplete ecdysis"@en .

<https://identifiers.org/aop.relationships/2171> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2171"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/996> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1524> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/996> rdfs:label "Decrease, Digestion of old cuticle"@en .
<https://identifiers.org/aop.events/1524> rdfs:label "Increase, Premature molting"@en .

<https://identifiers.org/aop.relationships/1023> a sbdbel:CausalAssertion ;
  rdfs:label "KER 1023"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/998> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1000> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/998> rdfs:label "Binding of antagonist, PPAR alpha"@en .
<https://identifiers.org/aop.events/1000> rdfs:label "stabilization, PPAR alpha co-repressor"@en .

<https://identifiers.org/aop.relationships/2414> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2414"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1895> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1868> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1895> rdfs:label "NLRP3 inflammasome activity, increased"@en .
<https://identifiers.org/aop.events/1868> rdfs:label "Hyperinflammation"@en .

<https://identifiers.org/aop.relationships/2553> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2553"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1864> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1863> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1864> rdfs:label "Increase, Programmed cell death"@en .
<https://identifiers.org/aop.events/1863> rdfs:label "Decrease, Reproduction"@en .

<https://identifiers.org/aop.relationships/2458> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2458"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1857> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1916> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1857> rdfs:label "Platelet-neutrophil interactions, Increased "@en .
<https://identifiers.org/aop.events/1916> rdfs:label "Thromboinflammation, Increased "@en .

<https://identifiers.org/aop.relationships/2356> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2356"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1866> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1496> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1866> rdfs:label "Fibrinolysis, decreased"@en .
<https://identifiers.org/aop.events/1496> rdfs:label "Increased, secretion of proinflammatory mediators"@en .

<https://identifiers.org/aop.relationships/2352> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2352"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1866> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1867> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1866> rdfs:label "Fibrinolysis, decreased"@en .
<https://identifiers.org/aop.events/1867> rdfs:label "Bradykinin system, hyperactivated"@en .

<https://identifiers.org/aop.relationships/2353> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2353"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1867> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1496> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1867> rdfs:label "Bradykinin system, hyperactivated"@en .
<https://identifiers.org/aop.events/1496> rdfs:label "Increased, secretion of proinflammatory mediators"@en .

<https://identifiers.org/aop.relationships/2355> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2355"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1867> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1866> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1867> rdfs:label "Bradykinin system, hyperactivated"@en .
<https://identifiers.org/aop.events/1866> rdfs:label "Fibrinolysis, decreased"@en .

<https://identifiers.org/aop.relationships/2357> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2357"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1867> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1868> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1867> rdfs:label "Bradykinin system, hyperactivated"@en .
<https://identifiers.org/aop.events/1868> rdfs:label "Hyperinflammation"@en .

<https://identifiers.org/aop.relationships/2359> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2359"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1869> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1845> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1869> rdfs:label "Diminished protective oxidative stress response"@en .
<https://identifiers.org/aop.events/1845> rdfs:label "Coagulation"@en .

<https://identifiers.org/aop.relationships/2413> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2413"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1869> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1895> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1869> rdfs:label "Diminished protective oxidative stress response"@en .
<https://identifiers.org/aop.events/1895> rdfs:label "NLRP3 inflammasome activity, increased"@en .

<https://identifiers.org/aop.relationships/2477> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2477"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1881> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1882> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1881> rdfs:label "Decreased, all-trans retinoic acid (atRA) concentration"@en .
<https://identifiers.org/aop.events/1882> rdfs:label "Disrupted meiotic initiation of fetal oogonia of the ovary"@en .

<https://identifiers.org/aop.relationships/2561> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2561"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1881> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1682> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1881> rdfs:label "Decreased, all-trans retinoic acid (atRA) concentration"@en .
<https://identifiers.org/aop.events/1682> rdfs:label "Disruption, Progenitor cells of second heart field"@en .

<https://identifiers.org/aop.relationships/2497> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2497"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1901> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1847> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1901> rdfs:label "Interferon-I antiviral response, antagonized by SARS-CoV-2"@en .
<https://identifiers.org/aop.events/1847> rdfs:label "Increased SARS-CoV-2 production"@en .

<https://identifiers.org/aop.relationships/2436> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2436"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1902> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1903> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1902> rdfs:label "Repression of Gbx2 expression"@en .
<https://identifiers.org/aop.events/1903> rdfs:label "foxi1 expression, increased"@en .

<https://identifiers.org/aop.relationships/2440> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2440"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1906> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1907> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1906> rdfs:label "Cystic Fibrosis Transmembrane Regulator Function, Decreased"@en .
<https://identifiers.org/aop.events/1907> rdfs:label "Airway Surface Liquid Height, Decreased "@en .

<https://identifiers.org/aop.relationships/2441> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2441"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1907> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1908> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1907> rdfs:label "Airway Surface Liquid Height, Decreased "@en .
<https://identifiers.org/aop.events/1908> rdfs:label "Cilia Beat Frequency, Decreased"@en .

<https://identifiers.org/aop.relationships/2442> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2442"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1908> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1909> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1908> rdfs:label "Cilia Beat Frequency, Decreased"@en .
<https://identifiers.org/aop.events/1909> rdfs:label "Mucociliary Clearance, Decreased"@en .

<https://identifiers.org/aop.relationships/2443> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2443"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1909> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1250> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1909> rdfs:label "Mucociliary Clearance, Decreased"@en .
<https://identifiers.org/aop.events/1250> rdfs:label "Decrease, Lung function"@en .

<https://identifiers.org/aop.relationships/2447> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2447"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1911> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1912> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1911> rdfs:label "FOXJ1 Protein, Decreased"@en .
<https://identifiers.org/aop.events/1912> rdfs:label "Motile Cilia Number/Length, Decreased"@en .

<https://identifiers.org/aop.relationships/2448> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2448"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1912> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1908> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1912> rdfs:label "Motile Cilia Number/Length, Decreased"@en .
<https://identifiers.org/aop.events/1908> rdfs:label "Cilia Beat Frequency, Decreased"@en .

<https://identifiers.org/aop.relationships/2611> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2611"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1981> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1172> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1981> rdfs:label "Decreased SIRT1 expression"@en .
<https://identifiers.org/aop.events/1172> rdfs:label "Increase activation, Nuclear factor kappa B (NF-kB)"@en .

<https://identifiers.org/aop.relationships/2231> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2231"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1008> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/351> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1008> rdfs:label "Reduced, Hearing"@en .
<https://identifiers.org/aop.events/351> rdfs:label "Increased Mortality"@en .

<https://identifiers.org/aop.relationships/2565> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2565"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/105> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1969> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/105> rdfs:label "Inhibition, Mitochondrial Electron Transport Chain Complexes"@en .
<https://identifiers.org/aop.events/1969> rdfs:label "Increase, Oxidative Stress"@en .

<https://identifiers.org/aop.relationships/2636> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2636"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/105> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1770> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/105> rdfs:label "Inhibition, Mitochondrial Electron Transport Chain Complexes"@en .
<https://identifiers.org/aop.events/1770> rdfs:label "Decrease, Mitochondrial membrane potential"@en .

<https://identifiers.org/aop.relationships/2821> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2821"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/105> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/177> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/105> rdfs:label "Inhibition, Mitochondrial Electron Transport Chain Complexes"@en .
<https://identifiers.org/aop.events/177> rdfs:label "N/A, Mitochondrial dysfunction 1"@en .

<https://identifiers.org/aop.relationships/2379> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2379"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1550> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1115> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1550> rdfs:label "Deposition of Ionizing Energy"@en .
<https://identifiers.org/aop.events/1115> rdfs:label "Increased, Reactive oxygen species"@en .

<https://identifiers.org/aop.relationships/2380> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2380"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1550> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1194> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1550> rdfs:label "Deposition of Ionizing Energy"@en .
<https://identifiers.org/aop.events/1194> rdfs:label "Increase, DNA damage"@en .

<https://identifiers.org/aop.relationships/2390> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2390"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1550> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1088> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1550> rdfs:label "Deposition of Ionizing Energy"@en .
<https://identifiers.org/aop.events/1088> rdfs:label "Increased, Oxidative Stress"@en .

<https://identifiers.org/aop.relationships/2392> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2392"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1550> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/752> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1550> rdfs:label "Deposition of Ionizing Energy"@en .
<https://identifiers.org/aop.events/752> rdfs:label "Altered, Meiotic chromosome dynamics"@en .

<https://identifiers.org/aop.relationships/2393> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2393"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1550> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1798> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1550> rdfs:label "Deposition of Ionizing Energy"@en .
<https://identifiers.org/aop.events/1798> rdfs:label "Decreased spermatogenesis "@en .

<https://identifiers.org/aop.relationships/2394> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2394"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1550> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/406> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1550> rdfs:label "Deposition of Ionizing Energy"@en .
<https://identifiers.org/aop.events/406> rdfs:label "impaired, Fertility"@en .

<https://identifiers.org/aop.relationships/2395> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2395"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1550> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1696> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1550> rdfs:label "Deposition of Ionizing Energy"@en .
<https://identifiers.org/aop.events/1696> rdfs:label "Decrease of egg production and cummulative fecundity"@en .

<https://identifiers.org/aop.relationships/2396> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2396"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1550> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/997> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1550> rdfs:label "Deposition of Ionizing Energy"@en .
<https://identifiers.org/aop.events/997> rdfs:label "Decreased, Population size"@en .

<https://identifiers.org/aop.relationships/2397> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2397"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1550> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1775> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1550> rdfs:label "Deposition of Ionizing Energy"@en .
<https://identifiers.org/aop.events/1775> rdfs:label "Increase, Oocyte apoptosis"@en .

<https://identifiers.org/aop.relationships/2465> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2465"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1607> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/759> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1607> rdfs:label "Increase, Necrosis"@en .
<https://identifiers.org/aop.events/759> rdfs:label "Increased, Kidney Failure"@en .

<https://identifiers.org/aop.relationships/2485> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2485"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1647> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1902> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1647> rdfs:label "GSK3beta inactivation"@en .
<https://identifiers.org/aop.events/1902> rdfs:label "Repression of Gbx2 expression"@en .

<https://identifiers.org/aop.relationships/2329> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2329"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1855> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1603> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1855> rdfs:label "Increased Sodium-sensitive hypertension"@en .
<https://identifiers.org/aop.events/1603> rdfs:label "Chronic kidney disease"@en .

<https://identifiers.org/aop.relationships/2318> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2318"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1856> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1849> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1856> rdfs:label "Imbalanced salty and sweet taste responses"@en .
<https://identifiers.org/aop.events/1849> rdfs:label "Impaired gustatory nerve"@en .

<https://identifiers.org/aop.relationships/2333> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2333"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1862> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1475> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1862> rdfs:label "Decrease, Photosystem II efficiency"@en .
<https://identifiers.org/aop.events/1475> rdfs:label "Decrease, Photosynthesis"@en .

<https://identifiers.org/aop.relationships/2336> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2336"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1863> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/360> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1863> rdfs:label "Decrease, Reproduction"@en .
<https://identifiers.org/aop.events/360> rdfs:label "Decrease, Population growth rate"@en .

<https://identifiers.org/aop.relationships/2556> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2556"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1863> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/442> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1863> rdfs:label "Decrease, Reproduction"@en .
<https://identifiers.org/aop.events/442> rdfs:label "Decreased, Population trajectory"@en .

<https://identifiers.org/aop.relationships/2340> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2340"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1865> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1862> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1865> rdfs:label "Increase, Oxygen-evolving complex damage"@en .
<https://identifiers.org/aop.events/1862> rdfs:label "Decrease, Photosystem II efficiency"@en .

<https://identifiers.org/aop.relationships/2362> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2362"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1870> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1871> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1870> rdfs:label "Sustentacular cells, decrease "@en .
<https://identifiers.org/aop.events/1871> rdfs:label "olfactory sensory neurons, decrease "@en .

<https://identifiers.org/aop.relationships/2365> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2365"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1870> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1873> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1870> rdfs:label "Sustentacular cells, decrease "@en .
<https://identifiers.org/aop.events/1873> rdfs:label "impaired olfactory function (anosmia) "@en .

<https://identifiers.org/aop.relationships/2363> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2363"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1871> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1872> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1871> rdfs:label "olfactory sensory neurons, decrease "@en .
<https://identifiers.org/aop.events/1872> rdfs:label "Olfactory epithelium degeneration"@en .

<https://identifiers.org/aop.relationships/2366> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2366"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1871> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1873> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1871> rdfs:label "olfactory sensory neurons, decrease "@en .
<https://identifiers.org/aop.events/1873> rdfs:label "impaired olfactory function (anosmia) "@en .

<https://identifiers.org/aop.relationships/2364> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2364"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1872> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1873> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1872> rdfs:label "Olfactory epithelium degeneration"@en .
<https://identifiers.org/aop.events/1873> rdfs:label "impaired olfactory function (anosmia) "@en .

<https://identifiers.org/aop.relationships/2374> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2374"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1877> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1643> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1877> rdfs:label "Altered, retinal layer structure"@en .
<https://identifiers.org/aop.events/1643> rdfs:label "Altered, Visual function"@en .

<https://identifiers.org/aop.relationships/2377> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2377"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1878> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1643> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1878> rdfs:label "Decreased, Eye size"@en .
<https://identifiers.org/aop.events/1643> rdfs:label "Altered, Visual function"@en .

<https://identifiers.org/aop.relationships/2399> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2399"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1879> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/185> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1879> rdfs:label "Bulky DNA adducts, increase"@en .
<https://identifiers.org/aop.events/185> rdfs:label "Increase, Mutations"@en .

<https://identifiers.org/aop.relationships/2398> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2398"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1879> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/155> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1879> rdfs:label "Bulky DNA adducts, increase"@en .
<https://identifiers.org/aop.events/155> rdfs:label "Inadequate DNA repair"@en .

<https://identifiers.org/aop.relationships/2401> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2401"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1880> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1881> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1880> rdfs:label "Inhibition of ALDH1A (RALDH)"@en .
<https://identifiers.org/aop.events/1881> rdfs:label "Decreased, all-trans retinoic acid (atRA) concentration"@en .

<https://identifiers.org/aop.relationships/2481> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2481"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1882> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1883> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1882> rdfs:label "Disrupted meiotic initiation of fetal oogonia of the ovary"@en .
<https://identifiers.org/aop.events/1883> rdfs:label "Reduced size of the ovarian follicle pool "@en .

<https://identifiers.org/aop.relationships/2525> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2525"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1883> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/405> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1883> rdfs:label "Reduced size of the ovarian follicle pool "@en .
<https://identifiers.org/aop.events/405> rdfs:label "irregularities, ovarian cycle"@en .

<https://identifiers.org/aop.relationships/2402> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2402"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1884> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1885> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1884> rdfs:label "Inhibition of Fyna"@en .
<https://identifiers.org/aop.events/1885> rdfs:label "Inhibition of Plxna2"@en .

<https://identifiers.org/aop.relationships/2403> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2403"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1885> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1886> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1885> rdfs:label "Inhibition of Plxna2"@en .
<https://identifiers.org/aop.events/1886> rdfs:label "Overexpression of rasl11b"@en .

<https://identifiers.org/aop.relationships/2404> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2404"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1886> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1821> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1886> rdfs:label "Overexpression of rasl11b"@en .
<https://identifiers.org/aop.events/1821> rdfs:label "Decrease, Cell proliferation"@en .

<https://identifiers.org/aop.relationships/2527> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2527"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1888> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1889> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1888> rdfs:label "Increased (ectopic) all-trans retinoic acid concentration"@en .
<https://identifiers.org/aop.events/1889> rdfs:label "Premature initiation of meiosis in fetal male germ cells"@en .

<https://identifiers.org/aop.relationships/2408> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2408"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1891> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1892> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1891> rdfs:label "abnormal, placental labyrinth vasculature morphology"@en .
<https://identifiers.org/aop.events/1892> rdfs:label "increase, placental insufficiency"@en .

<https://identifiers.org/aop.relationships/2409> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2409"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1892> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1893> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1892> rdfs:label "increase, placental insufficiency"@en .
<https://identifiers.org/aop.events/1893> rdfs:label "increase, Preeclampsia"@en .

<https://identifiers.org/aop.relationships/2418> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2418"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1896> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/870> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1896> rdfs:label "Genomic instability"@en .
<https://identifiers.org/aop.events/870> rdfs:label "Increase, Cell Proliferation"@en .

<https://identifiers.org/aop.relationships/2430> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2430"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1897> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1172> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1897> rdfs:label "increased MyD88 activation"@en .
<https://identifiers.org/aop.events/1172> rdfs:label "Increase activation, Nuclear factor kappa B (NF-kB)"@en .

<https://identifiers.org/aop.relationships/2437> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2437"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1903> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1904> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1903> rdfs:label "foxi1 expression, increased"@en .
<https://identifiers.org/aop.events/1904> rdfs:label "six1b expression, increased"@en .

<https://identifiers.org/aop.relationships/2438> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2438"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1904> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1905> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1904> rdfs:label "six1b expression, increased"@en .
<https://identifiers.org/aop.events/1905> rdfs:label "eya1 expression, inhibited"@en .

<https://identifiers.org/aop.relationships/2439> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2439"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1905> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1825> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1905> rdfs:label "eya1 expression, inhibited"@en .
<https://identifiers.org/aop.events/1825> rdfs:label "Increase, Cell death"@en .

<https://identifiers.org/aop.relationships/2453> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2453"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1913> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/87> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1913> rdfs:label "Endothelial cell dysfunction "@en .
<https://identifiers.org/aop.events/87> rdfs:label "Release, Cytokine"@en .

<https://identifiers.org/aop.relationships/2456> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2456"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1914> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1857> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1914> rdfs:label "Platelet activation, Increased"@en .
<https://identifiers.org/aop.events/1857> rdfs:label "Platelet-neutrophil interactions, Increased "@en .

<https://identifiers.org/aop.relationships/2457> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2457"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1915> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1857> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1915> rdfs:label "Neutrophil activation, Increased "@en .
<https://identifiers.org/aop.events/1857> rdfs:label "Platelet-neutrophil interactions, Increased "@en .

<https://identifiers.org/aop.relationships/2641> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2641"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1917> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1815> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1917> rdfs:label "Altered gene expression, NRF2 dependent antioxidant pathway"@en .
<https://identifiers.org/aop.events/1815> rdfs:label "Activation of ER stress"@en .

<https://identifiers.org/aop.relationships/2642> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2642"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1917> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1088> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1917> rdfs:label "Altered gene expression, NRF2 dependent antioxidant pathway"@en .
<https://identifiers.org/aop.events/1088> rdfs:label "Increased, Oxidative Stress"@en .

<https://identifiers.org/aop.relationships/2468> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2468"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1930> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1008> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1930> rdfs:label "altered, inner ear development"@en .
<https://identifiers.org/aop.events/1008> rdfs:label "Reduced, Hearing"@en .

<https://identifiers.org/aop.relationships/2526> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2526"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1940> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1754> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1940> rdfs:label "Increases in cellular reactive oxygen species"@en .
<https://identifiers.org/aop.events/1754> rdfs:label "Porcupine-induced Wnt secretion and Wnt signaling activation"@en .

<https://identifiers.org/aop.relationships/2503> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2503"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1942> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1582> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1942> rdfs:label "Accumulation, Cytosolic toxic Tau oligomers"@en .
<https://identifiers.org/aop.events/1582> rdfs:label "Impaired axonial transport"@en .

<https://identifiers.org/aop.relationships/2507> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2507"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1942> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/188> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1942> rdfs:label "Accumulation, Cytosolic toxic Tau oligomers"@en .
<https://identifiers.org/aop.events/188> rdfs:label "Neuroinflammation"@en .

<https://identifiers.org/aop.relationships/2808> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2808"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1944> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/341> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1944> rdfs:label "Synaptic dysfunction"@en .
<https://identifiers.org/aop.events/341> rdfs:label "Impairment, Learning and memory"@en .

<https://identifiers.org/aop.relationships/2504> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2504"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1944> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/386> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1944> rdfs:label "Synaptic dysfunction"@en .
<https://identifiers.org/aop.events/386> rdfs:label "Decrease of neuronal network function"@en .

<https://identifiers.org/aop.relationships/2502> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2502"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1945> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1942> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1945> rdfs:label "Dysfunctional Autophagy"@en .
<https://identifiers.org/aop.events/1942> rdfs:label "Accumulation, Cytosolic toxic Tau oligomers"@en .

<https://identifiers.org/aop.relationships/2676> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2676"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1945> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2011> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1945> rdfs:label "Dysfunctional Autophagy"@en .
<https://identifiers.org/aop.events/2011> rdfs:label "Emphysema"@en .

<https://identifiers.org/aop.relationships/2529> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2529"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1949> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1951> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1949> rdfs:label "Decrease, GLUT4"@en .
<https://identifiers.org/aop.events/1951> rdfs:label "Decrease, Glucose uptake"@en .

<https://identifiers.org/aop.relationships/2528> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2528"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1950> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1949> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1950> rdfs:label "Increase, TNF"@en .
<https://identifiers.org/aop.events/1949> rdfs:label "Decrease, GLUT4"@en .

<https://identifiers.org/aop.relationships/2530> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2530"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1951> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1952> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1951> rdfs:label "Decrease, Glucose uptake"@en .
<https://identifiers.org/aop.events/1952> rdfs:label "Abnormal, Glucose homeostasis"@en .

<https://identifiers.org/aop.relationships/2531> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2531"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1952> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1953> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1952> rdfs:label "Abnormal, Glucose homeostasis"@en .
<https://identifiers.org/aop.events/1953> rdfs:label "Gestational diabetes mellitus"@en .

<https://identifiers.org/aop.relationships/2540> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2540"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1961> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1962> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1961> rdfs:label "Prolongation of Action Potential Duration"@en .
<https://identifiers.org/aop.events/1962> rdfs:label "Prolongation of QT interval"@en .

<https://identifiers.org/aop.relationships/2541> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2541"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1962> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1963> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1962> rdfs:label "Prolongation of QT interval"@en .
<https://identifiers.org/aop.events/1963> rdfs:label "Torsades de Pointes"@en .

<https://identifiers.org/aop.relationships/2542> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2542"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1963> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1964> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1963> rdfs:label "Torsades de Pointes"@en .
<https://identifiers.org/aop.events/1964> rdfs:label "Sudden cardiac death"@en .

<https://identifiers.org/aop.relationships/2555> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2555"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1965> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1863> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1965> rdfs:label "Increase, Pollen abnormal"@en .
<https://identifiers.org/aop.events/1863> rdfs:label "Decrease, Reproduction"@en .

<https://identifiers.org/aop.relationships/2567> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2567"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1968> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/709> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1968> rdfs:label "Increase, Mitochondrial Dysfunction"@en .
<https://identifiers.org/aop.events/709> rdfs:label "Increase, Cytotoxicity (renal tubular cell)"@en .

<https://identifiers.org/aop.relationships/2638> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2638"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1968> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1917> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1968> rdfs:label "Increase, Mitochondrial Dysfunction"@en .
<https://identifiers.org/aop.events/1917> rdfs:label "Altered gene expression, NRF2 dependent antioxidant pathway"@en .

<https://identifiers.org/aop.relationships/2639> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2639"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1968> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/202> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1968> rdfs:label "Increase, Mitochondrial Dysfunction"@en .
<https://identifiers.org/aop.events/202> rdfs:label "Inhibition, Nuclear factor kappa B (NF-kB)"@en .

<https://identifiers.org/aop.relationships/2640> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2640"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1968> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1365> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1968> rdfs:label "Increase, Mitochondrial Dysfunction"@en .
<https://identifiers.org/aop.events/1365> rdfs:label "Increase, Apoptosis"@en .

<https://identifiers.org/aop.relationships/2566> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2566"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1969> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1968> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1969> rdfs:label "Increase, Oxidative Stress"@en .
<https://identifiers.org/aop.events/1968> rdfs:label "Increase, Mitochondrial Dysfunction"@en .

<https://identifiers.org/aop.relationships/2579> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2579"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1971> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1193> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1971> rdfs:label "Increased, tumor growth"@en .
<https://identifiers.org/aop.events/1193> rdfs:label "N/A, Breast Cancer"@en .

<https://identifiers.org/aop.relationships/2582> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2582"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1972> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1973> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1972> rdfs:label "Increased, Steroidogenic acute regulatory protein (StAR) "@en .
<https://identifiers.org/aop.events/1973> rdfs:label "Increased, estrogens "@en .

<https://identifiers.org/aop.relationships/2583> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2583"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1973> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1076> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1973> rdfs:label "Increased, estrogens "@en .
<https://identifiers.org/aop.events/1076> rdfs:label "Increased, circulating estrogen levels"@en .

<https://identifiers.org/aop.relationships/2600> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2600"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1974> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1365> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1974> rdfs:label "Activation of Tumor Protein 53"@en .
<https://identifiers.org/aop.events/1365> rdfs:label "Increase, Apoptosis"@en .

<https://identifiers.org/aop.relationships/2606> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2606"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1974> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1979> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1974> rdfs:label "Activation of Tumor Protein 53"@en .
<https://identifiers.org/aop.events/1979> rdfs:label "Premature cell differentiation"@en .

<https://identifiers.org/aop.relationships/2625> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2625"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1977> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1983> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1977> rdfs:label "Disruption of sodium channel gating kinetics"@en .
<https://identifiers.org/aop.events/1983> rdfs:label "Disruption, action potential"@en .

<https://identifiers.org/aop.relationships/2607> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2607"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1979> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1978> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1979> rdfs:label "Premature cell differentiation"@en .
<https://identifiers.org/aop.events/1978> rdfs:label "Increase risk, microcephaly"@en .

<https://identifiers.org/aop.relationships/2610> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2610"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1980> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1981> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1980> rdfs:label "Increased micro RNA expression"@en .
<https://identifiers.org/aop.events/1981> rdfs:label "Decreased SIRT1 expression"@en .

<https://identifiers.org/aop.relationships/2685> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2685"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2020> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1559> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2020> rdfs:label "Decrease, sox9 expression"@en .
<https://identifiers.org/aop.events/1559> rdfs:label "Facial cartilage structures are reduced in size and morphologically distorted"@en .

<https://identifiers.org/aop.relationships/2691> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2691"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2020> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/317> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2020> rdfs:label "Decrease, sox9 expression"@en .
<https://identifiers.org/aop.events/317> rdfs:label "Altered, Cardiovascular development/function"@en .

<https://identifiers.org/aop.relationships/2684> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2684"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2021> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2020> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2021> rdfs:label "Increase, slincR expression"@en .
<https://identifiers.org/aop.events/2020> rdfs:label "Decrease, sox9 expression"@en .

<https://identifiers.org/aop.relationships/2690> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2690"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2021> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1559> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2021> rdfs:label "Increase, slincR expression"@en .
<https://identifiers.org/aop.events/1559> rdfs:label "Facial cartilage structures are reduced in size and morphologically distorted"@en .

<https://identifiers.org/aop.relationships/2727> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2727"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2021> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/317> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2021> rdfs:label "Increase, slincR expression"@en .
<https://identifiers.org/aop.events/317> rdfs:label "Altered, Cardiovascular development/function"@en .

<https://identifiers.org/aop.relationships/2695> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2695"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2024> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2025> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2024> rdfs:label "Reduced complex sphingolipids"@en .
<https://identifiers.org/aop.events/2025> rdfs:label "Affected folate transporter"@en .

<https://identifiers.org/aop.relationships/2734> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2734"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2027> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2044> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2027> rdfs:label "Antagonism, Smoothened receptor"@en .
<https://identifiers.org/aop.events/2044> rdfs:label "Decrease, Smoothend relocation and activation "@en .

<https://identifiers.org/aop.relationships/2731> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2731"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2040> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2043> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2040> rdfs:label "Decrease, GLI1/2 target gene expression"@en .
<https://identifiers.org/aop.events/2043> rdfs:label "Decrease, Sonic Hedgehog second messenger production"@en .

<https://identifiers.org/aop.relationships/2732> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2732"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2043> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1821> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2043> rdfs:label "Decrease, Sonic Hedgehog second messenger production"@en .
<https://identifiers.org/aop.events/1821> rdfs:label "Decrease, Cell proliferation"@en .

<https://identifiers.org/aop.relationships/2735> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2735"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2044> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2028> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2044> rdfs:label "Decrease, Smoothend relocation and activation "@en .
<https://identifiers.org/aop.events/2028> rdfs:label "Decrease, GLI1/2 translocation to nucleus "@en .

<https://identifiers.org/aop.relationships/2729> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2729"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1554> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1980> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1554> rdfs:label "Increase Chromosomal Aberrations"@en .
<https://identifiers.org/aop.events/1980> rdfs:label "Increased micro RNA expression"@en .

<https://identifiers.org/aop.relationships/2627> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2627"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1985> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1986> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1985> rdfs:label "Increased, Kisspeptin signalling"@en .
<https://identifiers.org/aop.events/1986> rdfs:label "Decreased, Gonadotropins"@en .

<https://identifiers.org/aop.relationships/2629> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2629"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1986> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1987> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1986> rdfs:label "Decreased, Gonadotropins"@en .
<https://identifiers.org/aop.events/1987> rdfs:label "Decreased, Androgen and Progestin "@en .

<https://identifiers.org/aop.relationships/2630> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2630"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1987> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1988> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1987> rdfs:label "Decreased, Androgen and Progestin "@en .
<https://identifiers.org/aop.events/1988> rdfs:label "Decreased, Maturation Inducing Steroid Surge by Granulosa cells"@en .

<https://identifiers.org/aop.relationships/2631> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2631"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1988> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1989> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1988> rdfs:label "Decreased, Maturation Inducing Steroid Surge by Granulosa cells"@en .
<https://identifiers.org/aop.events/1989> rdfs:label "Impaired, Oocyte maturation and ovulation"@en .

<https://identifiers.org/aop.relationships/2632> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2632"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1989> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1990> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1989> rdfs:label "Impaired, Oocyte maturation and ovulation"@en .
<https://identifiers.org/aop.events/1990> rdfs:label "Increased, Oocyte Atresia"@en .

<https://identifiers.org/aop.relationships/2633> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2633"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/1990> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1991> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/1990> rdfs:label "Increased, Oocyte Atresia"@en .
<https://identifiers.org/aop.events/1991> rdfs:label "Impaired, Reproduction"@en .

<https://identifiers.org/aop.relationships/2661> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2661"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2006> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1669> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2006> rdfs:label "Secondary genotoxicity"@en .
<https://identifiers.org/aop.events/1669> rdfs:label "Increased, DNA damage and mutation"@en .

<https://identifiers.org/aop.relationships/2667> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2667"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2007> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2009> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2007> rdfs:label "Non-coding RNA expression profile alteration"@en .
<https://identifiers.org/aop.events/2009> rdfs:label "Activation of inflammation pathway"@en .

<https://identifiers.org/aop.relationships/2668> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2668"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2007> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1392> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2007> rdfs:label "Non-coding RNA expression profile alteration"@en .
<https://identifiers.org/aop.events/1392> rdfs:label "Oxidative Stress "@en .

<https://identifiers.org/aop.relationships/2669> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2669"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2007> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1650> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2007> rdfs:label "Non-coding RNA expression profile alteration"@en .
<https://identifiers.org/aop.events/1650> rdfs:label "Epithelial-mesenchymal transition"@en .

<https://identifiers.org/aop.relationships/2670> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2670"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2007> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2012> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2007> rdfs:label "Non-coding RNA expression profile alteration"@en .
<https://identifiers.org/aop.events/2012> rdfs:label "Fibroblast proliferation and differentiation"@en .

<https://identifiers.org/aop.relationships/2671> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2671"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2007> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1262> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2007> rdfs:label "Non-coding RNA expression profile alteration"@en .
<https://identifiers.org/aop.events/1262> rdfs:label "Apoptosis"@en .

<https://identifiers.org/aop.relationships/2672> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2672"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2007> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1945> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2007> rdfs:label "Non-coding RNA expression profile alteration"@en .
<https://identifiers.org/aop.events/1945> rdfs:label "Dysfunctional Autophagy"@en .

<https://identifiers.org/aop.relationships/2673> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2673"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2009> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2010> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2009> rdfs:label "Activation of inflammation pathway"@en .
<https://identifiers.org/aop.events/2010> rdfs:label "Pulmonary inflammation"@en .

<https://identifiers.org/aop.relationships/2679> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2679"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2010> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2008> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2010> rdfs:label "Pulmonary inflammation"@en .
<https://identifiers.org/aop.events/2008> rdfs:label "Chronic obstructive pulmonary disease"@en .

<https://identifiers.org/aop.relationships/2680> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2680"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2011> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2008> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2011> rdfs:label "Emphysema"@en .
<https://identifiers.org/aop.events/2008> rdfs:label "Chronic obstructive pulmonary disease"@en .

<https://identifiers.org/aop.relationships/2678> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2678"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2012> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2013> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2012> rdfs:label "Fibroblast proliferation and differentiation"@en .
<https://identifiers.org/aop.events/2013> rdfs:label "Airway remodeling"@en .

<https://identifiers.org/aop.relationships/2681> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2681"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2013> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2008> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2013> rdfs:label "Airway remodeling"@en .
<https://identifiers.org/aop.events/2008> rdfs:label "Chronic obstructive pulmonary disease"@en .

<https://identifiers.org/aop.relationships/2711> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2711"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2017> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1512> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2017> rdfs:label "Endoplasmic reticulum stress"@en .
<https://identifiers.org/aop.events/1512> rdfs:label "Unfolded Protein Response"@en .

<https://identifiers.org/aop.relationships/2694> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2694"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2023> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2024> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2023> rdfs:label "Inhibition of Ceramide Synthase "@en .
<https://identifiers.org/aop.events/2024> rdfs:label "Reduced complex sphingolipids"@en .

<https://identifiers.org/aop.relationships/2697> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2697"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2023> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2033> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2023> rdfs:label "Inhibition of Ceramide Synthase "@en .
<https://identifiers.org/aop.events/2033> rdfs:label "Increased sphingolipid-1-phosphate"@en .

<https://identifiers.org/aop.relationships/2696> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2696"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2025> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2026> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2025> rdfs:label "Affected folate transporter"@en .
<https://identifiers.org/aop.events/2026> rdfs:label "decreased folate uptake"@en .

<https://identifiers.org/aop.relationships/2700> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2700"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2026> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1561> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2026> rdfs:label "decreased folate uptake"@en .
<https://identifiers.org/aop.events/1561> rdfs:label "Neural tube defects"@en .

<https://identifiers.org/aop.relationships/2721> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2721"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2028> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2040> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2028> rdfs:label "Decrease, GLI1/2 translocation to nucleus "@en .
<https://identifiers.org/aop.events/2040> rdfs:label "Decrease, GLI1/2 target gene expression"@en .

<https://identifiers.org/aop.relationships/2719> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2719"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2030> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/177> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2030> rdfs:label "Activation, PARP1"@en .
<https://identifiers.org/aop.events/177> rdfs:label "N/A, Mitochondrial dysfunction 1"@en .

<https://identifiers.org/aop.relationships/2693> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2693"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2032> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/360> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2032> rdfs:label "Viable offspring, decreased"@en .
<https://identifiers.org/aop.events/360> rdfs:label "Decrease, Population growth rate"@en .

<https://identifiers.org/aop.relationships/2698> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2698"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2033> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1502> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2033> rdfs:label "Increased sphingolipid-1-phosphate"@en .
<https://identifiers.org/aop.events/1502> rdfs:label "Histone deacetylase inhibition"@en .

<https://identifiers.org/aop.relationships/2703> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2703"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2036> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2037> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2036> rdfs:label "Activation of metabotropic glutamate receptor"@en .
<https://identifiers.org/aop.events/2037> rdfs:label "Inositol triphosphate receptor activation"@en .

<https://identifiers.org/aop.relationships/2702> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2702"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2037> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/389> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2037> rdfs:label "Inositol triphosphate receptor activation"@en .
<https://identifiers.org/aop.events/389> rdfs:label "Increased, Intracellular Calcium overload"@en .

<https://identifiers.org/aop.relationships/2705> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2705"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2038> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1825> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2038> rdfs:label "Activation of calpain signalling"@en .
<https://identifiers.org/aop.events/1825> rdfs:label "Increase, Cell death"@en .

<https://identifiers.org/aop.relationships/2707> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2707"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2039> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1527> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2039> rdfs:label "Inhibition GABAA receptor"@en .
<https://identifiers.org/aop.events/1527> rdfs:label "Increase, Cell membrane depolarization"@en .

<https://identifiers.org/aop.relationships/2726> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2726"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2041> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2042> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2041> rdfs:label "Decrease, palatal shelf outgrowth"@en .
<https://identifiers.org/aop.events/2042> rdfs:label "Ororofacial clefting"@en .

<https://identifiers.org/aop.relationships/2736> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2736"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2045> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/748> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2045> rdfs:label "Increase, Alcohol dehydrogenase"@en .
<https://identifiers.org/aop.events/748> rdfs:label "Increased, Estrogen receptor (ER) activity"@en .

<https://identifiers.org/aop.relationships/2738> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2738"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2046> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2047> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2046> rdfs:label "Increase, Vitellogenin mRNA"@en .
<https://identifiers.org/aop.events/2047> rdfs:label "Delay, Ovarian maturation"@en .

<https://identifiers.org/aop.relationships/2739> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2739"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2047> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2048> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2047> rdfs:label "Delay, Ovarian maturation"@en .
<https://identifiers.org/aop.events/2048> rdfs:label "Increase, Body volume of female adults"@en .

<https://identifiers.org/aop.relationships/2740> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2740"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2047> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2049> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2047> rdfs:label "Delay, Ovarian maturation"@en .
<https://identifiers.org/aop.events/2049> rdfs:label "Increase, sex ratio (F/M)"@en .

<https://identifiers.org/aop.relationships/2741> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2741"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2048> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2050> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2048> rdfs:label "Increase, Body volume of female adults"@en .
<https://identifiers.org/aop.events/2050> rdfs:label "Increase, developmental abnormalities"@en .

<https://identifiers.org/aop.relationships/2742> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2742"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2049> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2050> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2049> rdfs:label "Increase, sex ratio (F/M)"@en .
<https://identifiers.org/aop.events/2050> rdfs:label "Increase, developmental abnormalities"@en .

<https://identifiers.org/aop.relationships/2743> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2743"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2050> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/350> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2050> rdfs:label "Increase, developmental abnormalities"@en .
<https://identifiers.org/aop.events/350> rdfs:label "Increase, Mortality"@en .

<https://identifiers.org/aop.relationships/2744> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2744"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2051> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2052> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2051> rdfs:label "Decrease, Tyrosine"@en .
<https://identifiers.org/aop.events/2052> rdfs:label "Decrease, dopa decarboxylase"@en .

<https://identifiers.org/aop.relationships/2745> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2745"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2052> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2053> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2052> rdfs:label "Decrease, dopa decarboxylase"@en .
<https://identifiers.org/aop.events/2053> rdfs:label "Increase, Defects in tanning of new cuticle"@en .

<https://identifiers.org/aop.relationships/2746> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2746"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2053> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2054> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2053> rdfs:label "Increase, Defects in tanning of new cuticle"@en .
<https://identifiers.org/aop.events/2054> rdfs:label "Increase,  impairment of cuticle sclerotization"@en .

<https://identifiers.org/aop.relationships/2747> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2747"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2053> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2055> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2053> rdfs:label "Increase, Defects in tanning of new cuticle"@en .
<https://identifiers.org/aop.events/2055> rdfs:label "Increase,  pigmentation"@en .

<https://identifiers.org/aop.relationships/2748> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2748"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2054> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/990> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2054> rdfs:label "Increase,  impairment of cuticle sclerotization"@en .
<https://identifiers.org/aop.events/990> rdfs:label "Increase, Incomplete ecdysis"@en .

<https://identifiers.org/aop.relationships/2749> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2749"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2055> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/990> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2055> rdfs:label "Increase,  pigmentation"@en .
<https://identifiers.org/aop.events/990> rdfs:label "Increase, Incomplete ecdysis"@en .

<https://identifiers.org/aop.relationships/2752> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2752"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2058> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2059> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2058> rdfs:label "Decrease, 20-hydroxyecdysone"@en .
<https://identifiers.org/aop.events/2059> rdfs:label "Decrease, knickkopf gene"@en .

<https://identifiers.org/aop.relationships/2753> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2753"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2059> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2060> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2059> rdfs:label "Decrease, knickkopf gene"@en .
<https://identifiers.org/aop.events/2060> rdfs:label "Decrease, Chitin laminar organization"@en .

<https://identifiers.org/aop.relationships/2754> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2754"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2059> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2061> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2059> rdfs:label "Decrease, knickkopf gene"@en .
<https://identifiers.org/aop.events/2061> rdfs:label "Decrease, Prevent chitin degradation by chitinases"@en .

<https://identifiers.org/aop.relationships/2755> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2755"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2060> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2062> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2060> rdfs:label "Decrease, Chitin laminar organization"@en .
<https://identifiers.org/aop.events/2062> rdfs:label "Weak, Procuticle protection"@en .

<https://identifiers.org/aop.relationships/2756> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2756"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2061> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2062> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2061> rdfs:label "Decrease, Prevent chitin degradation by chitinases"@en .
<https://identifiers.org/aop.events/2062> rdfs:label "Weak, Procuticle protection"@en .

<https://identifiers.org/aop.relationships/2757> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2757"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2062> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2063> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2062> rdfs:label "Weak, Procuticle protection"@en .
<https://identifiers.org/aop.events/2063> rdfs:label "Decrease, New cuticle secretion"@en .

<https://identifiers.org/aop.relationships/2758> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2758"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2063> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/990> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2063> rdfs:label "Decrease, New cuticle secretion"@en .
<https://identifiers.org/aop.events/990> rdfs:label "Increase, Incomplete ecdysis"@en .

<https://identifiers.org/aop.relationships/2766> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2766"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2064> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/55> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2064> rdfs:label "Increase, Cytosolic calcium"@en .
<https://identifiers.org/aop.events/55> rdfs:label "Cell injury/death"@en .

<https://identifiers.org/aop.relationships/2773> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2773"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2066> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2067> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2066> rdfs:label "Altered Signaling Pathways"@en .
<https://identifiers.org/aop.events/2067> rdfs:label "Altered, Nitric Oxide Levels"@en .

<https://identifiers.org/aop.relationships/2775> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2775"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2066> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2068> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2066> rdfs:label "Altered Signaling Pathways"@en .
<https://identifiers.org/aop.events/2068> rdfs:label "Increase, Endothelial Dysfunction"@en .

<https://identifiers.org/aop.relationships/2840> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2840"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2066> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2098> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2066> rdfs:label "Altered Signaling Pathways"@en .
<https://identifiers.org/aop.events/2098> rdfs:label "Increase, Neural Remodeling"@en .

<https://identifiers.org/aop.relationships/2843> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2843"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2066> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2089> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2066> rdfs:label "Altered Signaling Pathways"@en .
<https://identifiers.org/aop.events/2089> rdfs:label "Altered Bone Cell Homeostasis"@en .

<https://identifiers.org/aop.relationships/2789> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2789"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2067> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2068> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2067> rdfs:label "Altered, Nitric Oxide Levels"@en .
<https://identifiers.org/aop.events/2068> rdfs:label "Increase, Endothelial Dysfunction"@en .

<https://identifiers.org/aop.relationships/2784> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2784"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2068> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2069> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2068> rdfs:label "Increase, Endothelial Dysfunction"@en .
<https://identifiers.org/aop.events/2069> rdfs:label "Occurrence, Vascular Remodeling "@en .

<https://identifiers.org/aop.relationships/2844> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2844"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2089> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2090> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2089> rdfs:label "Altered Bone Cell Homeostasis"@en .
<https://identifiers.org/aop.events/2090> rdfs:label "Increase, Bone Remodeling"@en .

<https://identifiers.org/aop.relationships/2845> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2845"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2090> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2091> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2090> rdfs:label "Increase, Bone Remodeling"@en .
<https://identifiers.org/aop.events/2091> rdfs:label "Occurrence, Bone Loss"@en .

<https://identifiers.org/aop.relationships/2835> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2835"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2097> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2098> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2097> rdfs:label "Increase, Pro-Inflammatory Mediators"@en .
<https://identifiers.org/aop.events/2098> rdfs:label "Increase, Neural Remodeling"@en .

<https://identifiers.org/aop.relationships/2839> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2839"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2097> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/341> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2097> rdfs:label "Increase, Pro-Inflammatory Mediators"@en .
<https://identifiers.org/aop.events/341> rdfs:label "Impairment, Learning and memory"@en .

<https://identifiers.org/aop.relationships/2836> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2836"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2098> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/341> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2098> rdfs:label "Increase, Neural Remodeling"@en .
<https://identifiers.org/aop.events/341> rdfs:label "Impairment, Learning and memory"@en .

<https://identifiers.org/aop.relationships/2850> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2850"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2099> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/2100> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2099> rdfs:label "hERG channel blockade"@en .
<https://identifiers.org/aop.events/2100> rdfs:label "Inhibition of rapid delayed rectifying potassium current "@en .

<https://identifiers.org/aop.relationships/2851> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2851"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2100> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/1961> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2100> rdfs:label "Inhibition of rapid delayed rectifying potassium current "@en .
<https://identifiers.org/aop.events/1961> rdfs:label "Prolongation of Action Potential Duration"@en .

<https://identifiers.org/aop.relationships/2858> a sbdbel:CausalAssertion ;
  rdfs:label "KER 2858"@en ;
  dc:source <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:cause <https://identifiers.org/aop.events/2117> ;
  sbdbel:relationship <https://h2020-sbd4nano.github.io/sbd-data-aopwiki/relationships/> ;
  sbdbel:outcome <https://identifiers.org/aop.events/962> ;
  dcterms:license      <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://identifiers.org/aop.events/2117> rdfs:label "Increase, goblet cell number"@en .
<https://identifiers.org/aop.events/962> rdfs:label "Increase, Mucin production"@en .

#365 triples detected in the JSON-LD
@prefix dc:    <http://purl.org/dc/elements/1.1/> .
@prefix dct:   <http://purl.org/dc/terms/> .
@prefix foaf:  <http://xmlns.com/foaf/0.1/> .
@prefix rdfs:  <http://www.w3.org/2000/01/rdf-schema#> .
@prefix sbd:   <https://www.sbd4nano.eu/rdf/#> .
@prefix xsd:   <http://www.w3.org/2001/XMLSchema#> .
@prefix void:    <http://rdfs.org/ns/void#> .

<https://nanocommons.github.io/datasets/>
 a                    void:DatasetDescription ;
 dc:source            <https://nanocommons.github.io/datasets/> ;
 dct:title            "Overview of open datasets released by NanoSafety Cluster projects"@en ;
 foaf:img             <https://upload.wikimedia.org/wikipedia/commons/e/e1/NanoCommons-Logo-Large_-_White_Circle_01.png> ;
 dct:license          <http://creativecommons.org/publicdomain/zero/1.0/> .

<https://doi.org/10.5281/zenodo.3467015> a sbd:Dataset ;
  dc:source <https://nanocommons.github.io/datasets/> ;
  rdfs:label "NANoREG - eNanoMapper database"@en ;
  dc:description "In NANoREG over 85 institutional partners from EU member states, associated states, the Republic of Korea and Brazil collaborated in developing reliable, reproducible and relevant methods for testing and assessing the effects of nanomaterials on human health and environment in a regulatory context."@en ;
  dct:license <https://creativecommons.org/licenses/by-nc-sa/4.0/legalcode> ;
  foaf:page <https://doi.org/10.5281/zenodo.3467015> .

<https://doi.org/10.5281/zenodo.35493> a sbd:Dataset ;
  dc:source <https://nanocommons.github.io/datasets/> ;
  rdfs:label "All NanoPUZZLES ISA-TAB-Nano datasets"@en ;
  dc:description "This file is a ZIP archive which contains ALL publicly released ISA-TAB-Nano datasets developed within the NanoPUZZLES EU project [http://www.nanopuzzles.eu]. The (meta)data in these datasets were extracted from literature references."@en ;
  dct:license <https://creativecommons.org/licenses/by/4.0/legalcode> ;
  foaf:page <http://doi.org/10.5281/zenodo.35493> .

<https://doi.org/10.5281/zenodo.4146981> a sbd:Dataset ;
  dc:source <https://nanocommons.github.io/datasets/> ;
  rdfs:label "Toxicogenomic assessment of engineered nanomaterials"@en ;
  dc:description "Manually curated transcriptomics data collection for toxicogenomic assessment of engineered nanomaterials"@en ;
  dct:license <https://creativecommons.org/licenses/by/4.0/legalcode> ;
  foaf:page <https://doi.org/10.5281/zenodo.4146981> .

<https://doi.org/10.5281/zenodo.4421969> a sbd:Dataset ;
  dc:source <https://nanocommons.github.io/datasets/> ;
  rdfs:label "Status quo in data availability and predictive models of nano-mixture toxicity"@en ;
  dc:description "Supplementary materials for manuscript: Status quo in data availability and predictive models of nano-mixture toxicity. This table contains the list of 183 curated literature used in this study."@en ;
  dct:license <https://creativecommons.org/licenses/by/4.0/legalcode> ;
  foaf:page <https://doi.org/10.5281/zenodo.4421969> .

<https://doi.org/10.5281/zenodo.4609840> a sbd:Dataset ;
  dc:source <https://nanocommons.github.io/datasets/> ;
  rdfs:label "Raw data and metadata of SiO2 NP physicochemical characterisation, in vitro investigations and in silico predictions on protein corona formation"@en ;
  dc:description "Raw data and metadata of SiO2 NP physicochemical characterisation, in vitro investigations and in silico predictions on protein corona formation. Data repository for Hasenkopf I. et al., 2021"@en ;
  dct:license <https://creativecommons.org/licenses/by/4.0/legalcode> ;
  foaf:page <https://doi.org/10.5281/zenodo.4609840> .

<https://doi.org/10.5281/zenodo.4713745> a sbd:Dataset ;
  dc:source <https://nanocommons.github.io/datasets/> ;
  rdfs:label "NanoReg2 - eNanoMapper database"@en ;
  dc:description "H2020 NanoReg2 project data SQL dump for AMBIT chemical substance data management software."@en ;
  dct:license <https://creativecommons.org/licenses/by-nc/4.0/legalcode> ;
  foaf:page <https://doi.org/10.5281/zenodo.4713745> .

<https://doi.org/10.5281/zenodo.4986068> a sbd:Dataset ;
  dc:source <https://nanocommons.github.io/datasets/> ;
  rdfs:label "BAM reference data: XPS raw data of Al-coated titania nanoparticles (JRCNM62001a and JRCNM62002a)"@en ;
  dc:description "Data linked to Radnik, J. Kersting, R., Hagenhoff, B., Bennet, F., Ciornii, D.; Nymark, P., Grafström R. and Hodoroaba, V.-D. Nanomaterials 2021, 11, 639. https://doi.org/10.3390/nano11030639."@en ;
  dct:license <https://creativecommons.org/licenses/by/4.0/legalcode> ;
  foaf:page <https://doi.org/10.5281/zenodo.4986068> .

<https://doi.org/10.5281/zenodo.5743204> a sbd:Dataset ;
  dc:source <https://nanocommons.github.io/datasets/> ;
  rdfs:label "RDF version of the data from Choi, JS. et al. Towards a generalized toxicity prediction model for oxide nanomaterials using integrated data from different sources (2018)"@en ;
  dc:description "This is an RDFied version of the dataset published in Choi, JS., Ha, M.K., Trinh, T.X. et al. Towards a generalized toxicity prediction model for oxide nanomaterials using integrated data from different sources. Sci Rep 8, 6110 (2018). The original dataset publication DOI: https://doi.org/10.1038/s41598-018-24483-z. The Original publication authors: Jang-Sik Choi, My Kieu Ha, Tung Xuan Trinh, Tae Hyun Yoon & Hyung-Gi Byun"@en ;
  dct:license <https://creativecommons.org/licenses/by/4.0/legalcode> ;
  foaf:page <https://zenodo.org/record/5743204> .

<https://doi.org/10.5281/zenodo.5743788> a sbd:Dataset ;
  dc:source <https://nanocommons.github.io/datasets/> ;
  rdfs:label "RDF version of the data from Anastasios G. Papadiamantis et al. Predicting Cytotoxicity of Metal Oxide Nanoparticles Using Isalos Analytics Platform (2020)"@en ;
  dc:description "This is an RDFied version of the dataset published in Papadiamantis, A.G. et al. Predicting Cytotoxicity of Metal Oxide Nanoparticles Using Isalos Analytics Platform. Nanomaterials 2020, 10, 2017. The original dataset publication DOI: https://doi.org/10.3390/nano10102017. The Original publication authors: Papadiamantis, A.G.; Jänes, J.; Voyiatzis, E.; Sikk, L.; Burk, J.; Burk, P.; Tsoumanis, A.; Ha, M.K.; Yoon, T.H.; Valsami-Jones, E.; Lynch, I.; Melagraki, G.; Tämm, K.; Afantitis, A."@en ;
  dct:license <https://creativecommons.org/licenses/by/4.0/legalcode> ;
  foaf:page <https://zenodo.org/record/5743788> .

<https://doi.org/10.5281/zenodo.5744003> a sbd:Dataset ;
  dc:source <https://nanocommons.github.io/datasets/> ;
  rdfs:label "RDF version of the data from Saarimaki et al. Manually curated transcriptomics data collection for toxicogenomic assessment of engineered nanomaterials (Version 1.0.0) [Zenodo Dataset] (2020)"@en ;
  dc:description "This is an RDFied version of the dataset published by Saarimaki et al. Manually curated transcriptomics data collection for toxicogenomic assessment of engineered nanomaterials (Version 1.0.0) [Zenodo Dataset] (2020). The original dataset publication DOI: http://doi.org/10.5281/zenodo.4146981. The Original publication authors: Saarimaki, Laura Aliisa, Federico, Antonio, Lynch, Iseult, Papadiamantis, Anastasios G., Tsoumanis, Andreas, Melagraki, Georgia, Afantitis, Antreas, Serra, Angela, & Greco, Dario"@en ;
  dct:license <https://creativecommons.org/licenses/by/4.0/legalcode> ;
  foaf:page <https://zenodo.org/record/5744003> .

<https://doi.org/10.5281/zenodo.5744082> a sbd:Dataset ;
  dc:source <https://nanocommons.github.io/datasets/> ;
  rdfs:label "RDF version of the data from Anastasios G. et al. Computational enrichment of physicochemical data for the development of a zeta-potential read-across predictive model with Isalos Analytics Platform. NanoImpact (2021)"@en ;
  dc:description "This is an RDFied version of the dataset published by Anastasios G. et al. Computational enrichment of physicochemical data for the development of a zeta-potential read-across predictive model with Isalos Analytics Platform. NanoImpact (2021). The original dataset publication DOI: https://doi.org/10.1016/j.impact.2021.100308 The Original publication authors: Anastasios G. Papadiamantis, Antreas Afantitis, Andreas Tsoumanis, Eugenia Valsami-Jones, Iseult Lynch, Georgia Melagraki"@en ;
  dct:license <https://creativecommons.org/licenses/by/4.0/legalcode> ;
  foaf:page <https://doi.org/10.5281/zenodo.5744082> .

<https://doi.org/10.5281/zenodo.5744302> a sbd:Dataset ;
  dc:source <https://nanocommons.github.io/datasets/> ;
  rdfs:label "RDF version of the data from Hagar I. Labouta et al. Meta-Analysis of Nanoparticle Cytotoxicity via Data-Mining the Literature. NanoImpact (2019)"@en ;
  dc:description "This is an RDFied version of the dataset published by Hagar I. Labouta et al. Meta-Analysis of Nanoparticle Cytotoxicity via Data-Mining the Literature. NanoImpact (2019). The original dataset publication DOI: https://doi.org/10.1021/acsnano.8b07562 The Original publication authors: Hagar I. Labouta, Nasimeh Asgarian, Kristina Rinker, and David T. Cramb"@en ;
  dct:license <https://creativecommons.org/licenses/by/4.0/legalcode> ;
  foaf:page <https://doi.org/10.5281/zenodo.5744302> .

<https://doi.org/10.5281/zenodo.6473305> a sbd:Dataset ;
  dc:source <https://nanocommons.github.io/datasets/> ;
  rdfs:label "Raw data of in vitro investigations on immune activation by bare and surface-functionalized SiO2 NP-allergen conjugates using human monocyte-derived dendritic cells as model antigen-presenting cells. Data repository for Punz B. et al., 2022"@en ;
  dct:license <https://creativecommons.org/licenses/by/4.0/legalcode> ;
  foaf:page <https://zenodo.org/record/6473305> .

<https://doi.org/10.5281/zenodo.7335039> a sbd:Dataset ;
  dc:source <https://nanocommons.github.io/datasets/> ;
  rdfs:label "Extracting interpretable rules with Bayesian Networks. A case study of intrinsic human hazardous properties of silver nanoforms for the Safety Dimension of Safe and Sustainable by design paradigm"@en ;
  dct:license <https://creativecommons.org/licenses/by/4.0/legalcode> ;
  foaf:page <https://zenodo.org/record/7335039> .

<https://doi.org/10.5281/zenodo.7602354> a sbd:Dataset ;
  dc:source <https://nanocommons.github.io/datasets/> ;
  rdfs:label "RDF version of the supplementary data from Shin, Hyun Kil and Seo et al. Meta-analysis of Daphnia magna nanotoxicity experiments in accordance with test guidelines (2018)"@en ;
  dc:description "This is an RDF version of the dataset published by Shin, Hyun Kil and Seo et al. as a supplement of the study Meta-analysis of Daphnia magna nanotoxicity experiments in accordance with test guidelines. Environ. Sci.: Nano (2018). The original dataset is available online: https://ui.staging.kit.cloud.douglasconnect.com/dataexplorer?dataset=ab2bc1ee-99dc-4ddf-b1f9-9fdeb8a0f48c%3A1&q=%7B%7D. The original publication DOI: http://dx.doi.org/10.1039/C7EN01127J. GitHub repository of the datasets converted to RDF along with RML mappings: https://github.com/ammar257ammar/RDFied-datasets"@en ;
  dct:license <https://creativecommons.org/licenses/by/4.0/legalcode> ;
  foaf:page <https://zenodo.org/record/7602354> .

<https://doi.org/10.6084/m9.figshare.10071023.v1> a sbd:Dataset ;
  dc:source <https://nanocommons.github.io/datasets/> ;
  rdfs:label "MOESM1 of Role of chemical composition and redox modification of poorly soluble nanomaterials on their ability to enhance allergic airway sensitisation in mice"@en ;
  dc:description " Total and differential cell counts in bronchoalveolar lavage fluid."@en ;
  dct:license <https://springernature.figshare.com/articles/dataset/MOESM1_of_Role_of_chemical_composition_and_redox_modification_of_poorly_soluble_nanomaterials_on_their_ability_to_enhance_allergic_airway_sensitisation_in_mice/10071023> ;
  foaf:page <https://doi.org/10.6084/m9.figshare.10071023.v1> .

<https://doi.org/10.6084/m9.figshare.10071032.v1> a sbd:Dataset ;
  dc:source <https://nanocommons.github.io/datasets/> ;
  rdfs:label "MOESM2 of Role of chemical composition and redox modification of poorly soluble nanomaterials on their ability to enhance allergic airway sensitisation in mice"@en ;
  dc:description " Additional file 2. Cytokines in bronchoalveolar lavage fluid."@en ;
  dct:license <https://springernature.figshare.com/articles/dataset/MOESM1_of_Role_of_chemical_composition_and_redox_modification_of_poorly_soluble_nanomaterials_on_their_ability_to_enhance_allergic_airway_sensitisation_in_mice/10071032> ;
  foaf:page <https://doi.org/10.6084/m9.figshare.10071032.v1> .

<https://doi.org/10.6084/m9.figshare.11897205.v1> a sbd:Dataset ;
  dc:source <https://nanocommons.github.io/datasets/> ;
  rdfs:label "NanoWiki 6"@en ;
  dc:description "Data collection manually extracted from literature"@en ;
  dct:license <https://creativecommons.org/publicdomain/zero/1.0/> ;
  foaf:page <https://doi.org/10.6084/m9.figshare.11897205.v1> .

<https://doi.org/10.6084/m9.figshare.2056095.v1> a sbd:Dataset ;
  dc:source <https://nanocommons.github.io/datasets/> ;
  rdfs:label "NanoPUZZLES ISA-TAB-Nano dataset: Data extracted from NanoCare project final scientific report"@en ;
  dc:description "This file is a ZIP archive which contains three different copies of an ISA-TAB-Nano dataset developed within the NanoPUZZLES EU project (http://www.nanopuzzles.eu). The (meta)data in this dataset were primarily extracted from the following reference, with additional references consulted as indicated in the Investigation file: Data extracted from NanoCare project final scientific report: http://www.nanopartikel.info/files/projekte/NanoCare/NanoCare_Final_Report.pdf (last accessed 4th of June 2015)"@en ;
  dct:license <https://creativecommons.org/licenses/by/4.0/legalcode> ;
  foaf:page <https://doi.org/10.6084/m9.figshare.2056095.v1> .

<https://doi.org/10.6084/m9.figshare.7844594.v1> a sbd:Dataset ;
  dc:source <https://nanocommons.github.io/datasets/> ;
  rdfs:label "Heatmap of the overall HTS database"@en ;
  dc:description "High througput imaging DB of toxicological effect of Manufactured nanomaterials on HepaRGs."@en ;
  dct:license <https://creativecommons.org/share-your-work/public-domain/cc0> ;
  foaf:page <https://doi.org/10.6084/m9.figshare.7844594.v1> .

#185 triples detected in the JSON-LD
@prefix dc:    <http://purl.org/dc/elements/1.1/> .
@prefix dct:   <http://purl.org/dc/terms/> .
@prefix foaf:  <http://xmlns.com/foaf/0.1/> .
@prefix rdfs:  <http://www.w3.org/2000/01/rdf-schema#> .
@prefix sbd:   <https://www.sbd4nano.eu/rdf/#> .
@prefix xsd:   <http://www.w3.org/2001/XMLSchema#> .
@prefix void:  <http://rdfs.org/ns/void#> .

<https://vhp4safety.github.io/cloud/>
 a                    void:DatasetDescription ;
 dc:source            <https://cloud.vhp4safety.nl/> ;
 dct:title            "Cloud services provided by VHP4Safety"@en ;
 foaf:img             <https://images.nieuwsbrieven.rivm.nl/101500/0/5763/fe1e7915ce28f7a96ca25ed234631504.png> ;
 dct:license          <http://creativecommons.org/publicdomain/zero/1.0/> . # license of this metadata

<https://vhp4safety.github.io/cloud/service/aopwiki> a sbd:Resource ;
  dc:source <https://vhp4safety.github.io/cloud/> ;
  rdfs:label "AOP-Wiki Snorql UI"@en ;
  dc:description "Graphical interface to an AOP-Wiki SPARQL endpoint."@en ;
  foaf:page <https://aopwiki.cloud.vhp4safety.nl/> .

<https://vhp4safety.github.io/cloud/service/biomodels> a sbd:Resource ;
  dc:source <https://vhp4safety.github.io/cloud/> ;
  rdfs:label "BioModels"@en ;
  dc:description "BioModels is a repository of mathematical models of biological and biomedical systems."@en ;
  foaf:page <https://www.ebi.ac.uk/biomodels/> .

<https://vhp4safety.github.io/cloud/service/bridgedb> a sbd:Resource ;
  dc:source <https://vhp4safety.github.io/cloud/> ;
  rdfs:label "BridgeDb"@en ;
  dc:description "A framework to map identifiers between various biological databases and related sources."@en ;
  foaf:page <https://bridgedb.cloud.vhp4safety.nl/> .

<https://vhp4safety.github.io/cloud/service/cdkdepict> a sbd:Resource ;
  dc:source <https://vhp4safety.github.io/cloud/> ;
  rdfs:label "CDK Depict"@en ;
  dc:description "A webservice that converts a SMILES into 2D depictions (SVG or PNG)."@en ;
  foaf:page <https://cdkdepict.cloud.vhp4safety.nl/> .

<https://vhp4safety.github.io/cloud/service/celldesigner> a sbd:Resource ;
  dc:source <https://vhp4safety.github.io/cloud/> ;
  rdfs:label "CellDesigner"@en ;
  dc:description "A modeling tool of biochemical networks."@en ;
  foaf:page <https://www.celldesigner.org/> .

<https://vhp4safety.github.io/cloud/service/comptox> a sbd:Resource ;
  dc:source <https://vhp4safety.github.io/cloud/> ;
  rdfs:label "CompTox"@en ;
  dc:description "An online database to provide access to chemistry, toxicity, and exposure information for chemicals."@en ;
  foaf:page <https://comptox.epa.gov/dashboard/> .

<https://vhp4safety.github.io/cloud/service/copasi> a sbd:Resource ;
  dc:source <https://vhp4safety.github.io/cloud/> ;
  rdfs:label "COPASI"@en ;
  dc:description "Open-source software application for creating and solving mathematical models of biological processes such as metabolic networks, cell-signaling pathways, regulatory networks, infectious diseases, and many others."@en ;
  foaf:page <http://copasi.org/> .

<https://vhp4safety.github.io/cloud/service/decimer> a sbd:Resource ;
  dc:source <https://vhp4safety.github.io/cloud/> ;
  rdfs:label "DECIMER"@en ;
  dc:description "Online service to extract chemical structures from PDFs and images."@en ;
  foaf:page <https://decimer.ai/> .

<https://vhp4safety.github.io/cloud/service/flame> a sbd:Resource ;
  dc:source <https://vhp4safety.github.io/cloud/> ;
  rdfs:label "Flame"@en ;
  dc:description "An open source framework for model development, hosting, and usage in production environments."@en ;
  foaf:page <http://flame.cloud.vhp4safety.nl:8098/> .

<https://vhp4safety.github.io/cloud/service/jrc_data_catalogue> a sbd:Resource ;
  dc:source <https://vhp4safety.github.io/cloud/> ;
  rdfs:label "Joint Research Centre Data Catalogue"@en ;
  dc:description "A catalogue of metadata records about datasets."@en ;
  foaf:page <https://data.jrc.ec.europa.eu/> .

<https://vhp4safety.github.io/cloud/service/popgen> a sbd:Resource ;
  dc:source <https://vhp4safety.github.io/cloud/> ;
  rdfs:label "PopGen"@en ;
  dc:description "Service to generate online virtual human population."@en ;
  foaf:page <http://xnet.hsl.gov.uk/Popgen/> .

<https://vhp4safety.github.io/cloud/service/sombie> a sbd:Resource ;
  dc:source <https://vhp4safety.github.io/cloud/> ;
  rdfs:label "SOM Prediction"@en ;
  dc:description "A webservice for protein-structure and reactivity based (P450) site-of-metabolism prediction."@en ;
  foaf:page <https://sombie.cloud.vhp4safety.nl/> .

<https://vhp4safety.github.io/cloud/service/sysrev> a sbd:Resource ;
  dc:source <https://vhp4safety.github.io/cloud/> ;
  rdfs:label "SysRev"@en ;
  dc:description "Service to support literature research."@en ;
  foaf:page <https://sysrev.com/> .

<https://vhp4safety.github.io/cloud/service/txg_mapr> a sbd:Resource ;
  dc:source <https://vhp4safety.github.io/cloud/> ;
  rdfs:label "TXG-MAPr"@en ;
  dc:description "An R-Shiny-based implementation of weighted gene co-expression network analysis (WGCNA) obtained from the Primary Human Hepatocytes (PHH) TG-GATEs dataset."@en ;
  foaf:page <https://txg-mapr.eu/> .

<https://vhp4safety.github.io/cloud/service/wikibase> a sbd:Resource ;
  dc:source <https://vhp4safety.github.io/cloud/> ;
  rdfs:label "VHP4Safety Wikibase"@en ;
  dc:description "A Wikibase instance to hold information about compounds."@en ;
  foaf:page <https://compoundcloud.wikibase.cloud/> .

<https://vhp4safety.github.io/cloud/service/wikipathways_aop> a sbd:Resource ;
  dc:source <https://vhp4safety.github.io/cloud/> ;
  rdfs:label "WikiPathways - AOP Portal"@en ;
  dc:description "This Adverse Outcome Pathway (AOP) portal for WikiPathways to highlight the molecular basis of AOPs or events in AOPs."@en ;
  foaf:page <http://aop.wikipathways.org/> .

